<SEC-DOCUMENT>0001628280-23-015775.txt : 20230504
<SEC-HEADER>0001628280-23-015775.hdr.sgml : 20230504
<ACCEPTANCE-DATETIME>20230504162556
ACCESSION NUMBER:		0001628280-23-015775
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		79
CONFORMED PERIOD OF REPORT:	20230331
FILED AS OF DATE:		20230504
DATE AS OF CHANGE:		20230504

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CARDINAL HEALTH INC
		CENTRAL INDEX KEY:			0000721371
		STANDARD INDUSTRIAL CLASSIFICATION:	WHOLESALE-DRUGS PROPRIETARIES & DRUGGISTS' SUNDRIES [5122]
		IRS NUMBER:				310958666
		STATE OF INCORPORATION:			OH
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-11373
		FILM NUMBER:		23889180

	BUSINESS ADDRESS:	
		STREET 1:		7000 CARDINAL PLACE
		CITY:			DUBLIN
		STATE:			OH
		ZIP:			43017
		BUSINESS PHONE:		6147573033

	MAIL ADDRESS:	
		STREET 1:		7000 CARDINAL PLACE
		CITY:			DUBLIN
		STATE:			OH
		ZIP:			43017

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CARDINAL DISTRIBUTION INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>cah-20230331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:9ca698da-8642-4990-b842-4747c9f438b3,g:77ea8682-dcc2-43bc-841d-94551121f3ad,d:1d34fc4fc2424fbcb4837cc9f1c0665c--><html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:cah="http://www.cardinal.com/20230331" xmlns="http://www.w3.org/1999/xhtml" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:srt="http://fasb.org/srt/2023" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>cah-20230331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y180L2ZyYWc6MTZlNzFmOWMzZWZmNGIyN2I4ZThkZDJhMWIyNDYwYWQvdGFibGU6OTQxNjVmMjUwOGQ2NGE0NzkxZGUwMWQyOWExZmJmMTgvdGFibGVyYW5nZTo5NDE2NWYyNTA4ZDY0YTQ3OTFkZTAxZDI5YTFmYmYxOF8yLTEtMS0xLTI4Njk0NA_57d81c79-3cb9-4633-bbfb-20d61b0f1952">0000721371</ix:nonNumeric><ix:nonNumeric contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y180L2ZyYWc6MTZlNzFmOWMzZWZmNGIyN2I4ZThkZDJhMWIyNDYwYWQvdGFibGU6OTQxNjVmMjUwOGQ2NGE0NzkxZGUwMWQyOWExZmJmMTgvdGFibGVyYW5nZTo5NDE2NWYyNTA4ZDY0YTQ3OTFkZTAxZDI5YTFmYmYxOF8zLTEtMS0xLTI4Njk0NA_3b91be8e-71f5-447a-87ab-e2a9ec9ce050">--06-30</ix:nonNumeric><ix:nonNumeric contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y180L2ZyYWc6MTZlNzFmOWMzZWZmNGIyN2I4ZThkZDJhMWIyNDYwYWQvdGFibGU6OTQxNjVmMjUwOGQ2NGE0NzkxZGUwMWQyOWExZmJmMTgvdGFibGVyYW5nZTo5NDE2NWYyNTA4ZDY0YTQ3OTFkZTAxZDI5YTFmYmYxOF80LTEtMS0xLTI4Njk0NA_6da20d11-20e3-4d39-8e01-25521085be8c">2023</ix:nonNumeric><ix:nonNumeric contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y180L2ZyYWc6MTZlNzFmOWMzZWZmNGIyN2I4ZThkZDJhMWIyNDYwYWQvdGFibGU6OTQxNjVmMjUwOGQ2NGE0NzkxZGUwMWQyOWExZmJmMTgvdGFibGVyYW5nZTo5NDE2NWYyNTA4ZDY0YTQ3OTFkZTAxZDI5YTFmYmYxOF81LTEtMS0xLTI4Njk0NA_d7b5200d-6a48-43d6-ba27-1f5c2ca0dc87">Q3</ix:nonNumeric><ix:nonNumeric contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y180L2ZyYWc6MTZlNzFmOWMzZWZmNGIyN2I4ZThkZDJhMWIyNDYwYWQvdGFibGU6OTQxNjVmMjUwOGQ2NGE0NzkxZGUwMWQyOWExZmJmMTgvdGFibGVyYW5nZTo5NDE2NWYyNTA4ZDY0YTQ3OTFkZTAxZDI5YTFmYmYxOF82LTEtMS0xLTI4Njk0NA_92106f64-e077-4660-b2a5-0667ff38f2e1">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="cah-20230331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3e1bc5fa75b4fd38bbf74aaa66b04ed_I20230430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i7ad6d93eac9d48ab9fec302dd4e88915_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cah:A250MillionShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i1023e41d044c49ebb5274f9857d52b5f_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cah:A250MillionShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i00b750b6e2374500a1e8b10702e44d3a_D20221002-20230113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cah:A250MillionShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-02</xbrli:startDate><xbrli:endDate>2023-01-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i612fc934cf6040028ee1d4ea22c335da_D20230113-20230113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cah:A250MillionShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-13</xbrli:startDate><xbrli:endDate>2023-01-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic217743408d440409a59220a0bf14e4c_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56eab9e952334359a592f758a000f3a5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b46cf505d1d4c6286a2da8dfd32802a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e78bc722aef43c4ac908658f754bbe4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7fee7130363347368e48c8a5373ef212_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id91f4a6653dc429ab8550cb153ee63fe_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08aa4676fa1f412495f0dcda89ef5c61_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6743439f6d344529a1d9776e5a37b6af_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i691c4bcd6648489e9985b2ebac21c4c4_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5ce320f275240ee8f228b919198581e_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb01906f8808446da382eb7169a9c692_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3208791586fb4201860768dd298b3bb2_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69743694027f433b8def521fd90c10b1_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia191fa3eb5734906a8bf76c6f6496bc1_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf64830da37b4122b808db1a1819f451_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b78f3c4f51d4889980e7fc07edfec59_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13c78c23b94549919369f13eef7a33f8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib002348769da4f519bc0a52ddbe725a0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i869ddd309d65479f921f1950d72e9ae7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i400ae55f5bf646e1a4865cfff0502178_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31325593417c40aea09d306e481d5c1c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1da9880c72714008b4977c3a3f95890e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie41c2a5af47749b785d11deeee809585_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i418f71a8a1cc4ca49f486b30f467dcbc_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia19686236f7848079bbad68bd7c03742_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49e3f3cae16c423db19dc0526a881118_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9a10ddae3d841d29503e0ad7359eefa_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iafbe7b9485174b4e8c9f2d802e7dc231_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb5d714a0e8b461297b910f807c80a18_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9330ee3b45ee44a09dbcfeab14ffd40e_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f0673078b15401ba450a8f78e2cc590_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e1aae70a0da49d484500f615cb3fd5f_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9769f07affb42f58d537c7029824f72_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb1c4815be35411c8c429c87e4166d03_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79094c6b94cc48dc906e4841e8ebb7e7_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a2aef50edb6408382366ab58c0a5fe5_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ab713f43fd740a3981b34442abff7e2_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9f0457c7d4d49858c91362f01b0d1db_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iddb780ecd77a4a539d61e232d9c38a2a_D20220701-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5339f5e85f3b47c0aa0a7795a0147a83_D20220701-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iada78453d3a64782ab3851803455517a_D20220701-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e5c5ae766b74cf6a2409e8a66778fe4_D20220701-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icafe121606cd4112b5329a3ce5274e9d_D20220701-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4a2a8ced444402e984b4c3bc89c5c8d_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icfec14d9fb124cfe89c5bea933f8e5c2_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2aece4cef70c4e909ce54489503e648a_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i866c0616d4fa407cb18e678ede1cf44e_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ae8d288fa1c40efba1860f8c0297502_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75b88320c8d34867830cda3167c67779_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3eb749068f254e87ba6fe7696f1b7ae3_D20210701-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf631f27db6a4b97b407bf7c07872ada_D20210701-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i259a6ff3365f4c53ac0b2f2edbb89551_D20210701-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1adee5e79374a97893072820fddaa0e_D20210701-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0db8654b67c442ae83277edeaf53cedc_D20210701-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3c1b25895fb44c59c13bf46018fc577_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:CordisDivestitureAxis">cah:CordisDivestitureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice5ace5e97dc4e54b4c8d923f4a0967c_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba8dcdc7b0364befb6c48df592c69089_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i763ae6a550604d44b1d9024df65e87a4_D20220701-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i013227884afa401a8a0fac648dda0a66_D20220701-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie317acb3d5c44ca0bd1298978e77bb10_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i09619e867c3347d5b88ff001fdae470b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i043b921434d34afe9a3cdb74397ed704_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e6a4d2c754046f2bba40f47b73897d8_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69ad0b82db074919b5c03d2459c3d06b_D20220701-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6e92bcd32f84df9ab392ad9accbdacd_D20220701-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4007268cc1f496d86090b7230f7a94b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6cd27b73a20c437aa0e84891f2ea5dde_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic49dbe67bc04485785ead3e50d2ef7b5_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">cah:MedicalUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="rate"><xbrli:measure>utr:Rate</xbrli:measure></xbrli:unit><xbrli:context id="i984de195edf647df8b5c417d95fb895e_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c44423c33b44f2b91261015274103c9_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4173ed46aed24fea930a4ba9e851147e_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">cah:MedicalUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i6f07ddd2def943ba8d68405800839948_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">cah:MedicalUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8537355abc114656ba7b11fcb58c1278_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31378af16d0d40428cd5734ee81d07a0_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3002eff021944cff84e19dddc37565d6_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">cah:IPRDTrademarksandOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i476e8c3bb99545d29a40a868cf6b4eed_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief415993dc4a47a1a6841e6902c7341b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cah:TrademarksAndPatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i963e12db354a4503b026e3e3bb6ed1ae_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i173bc20d1a0d49e88d4984456dd1b3e0_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">cah:IPRDTrademarksandOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70d3a43084b1430ab3dd772e96aa6f88_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3d2fdf5757a41fc97c3a3a6ad11d72e_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cah:TrademarksAndPatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85178fe781b44231b4e7afb99223bc34_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70202e3eb1924e0fb801d98cddcbf880_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cah:A32NotesDue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c0fee9c3dfe482dbe67f839273b347f_D20210701-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cah:A2.616Notesdue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08f98bc525534cc2acbd1048c17f5b33_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i075adee0cf414c09a846d45f9d6a66c6_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9a5679304ee4538b6bbe0e34a4b5ed6_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">cah:ShortTermCreditFacilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cah:CommittedReceivablesSalesFacilityProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78f3cdc10c574a61aeee3a0d9409d753_D20220701-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">cah:CommittedReceivablesSalesFacilityProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i769da3763c9d46579b5dbf1f28eef5e3_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">cah:ShortTermCreditFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e20bef4bcbc46aa8704b4843abc61ed_D20140731-20140731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cah:CVSHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-07-31</xbrli:startDate><xbrli:endDate>2014-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a9e7f91ada745048021249c9ba3bf07_I20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:NewYorkOpioidStewardshipActMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6e1b925b14f48bdae321a2a92cddd99_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:NewYorkOpioidStewardshipActMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ba9cf1bead64efbbe00d2cffc0f7d5f_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:NewYorkOpioidStewardshipActMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i487c1d6cc123481ab174c77df6efc37c_D20220701-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:NewYorkOpioidStewardshipActMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3177191fb7864f68afd74d62ddd7feeb_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:NewYorkOpioidStewardshipActMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92600b80cf9f42e68ab2bb551fa5980c_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib507a23581594a42a6beb783c2499b40_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if44099e3d6fc462fbe010375b43d9efd_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:OK</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad6a19c0c20841d5b5851aaeb8d05e17_I20230131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="states"><xbrli:measure>cah:states</xbrli:measure></xbrli:unit><xbrli:unit id="numberofusterritories"><xbrli:measure>cah:numberOfUSTerritories</xbrli:measure></xbrli:unit><xbrli:context id="i92a2e3900c6e4547800cbb60799bcd60_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ef2614263ad48d9934f6cc996c22e16_D20220701-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd1c21d9101a4eba857ea787640fd22a_I20220731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WV</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i960566e19fe54aa890cd9defe241cee0_I20221031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cah:NativeAmericanTribesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f5e673a6ff2412f8e6ec60e722680b3_I20230428"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:PlaintiffTypeAxis">cah:PrivatePartiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="lawsuit"><xbrli:measure>cah:lawsuit</xbrli:measure></xbrli:unit><xbrli:context id="i584bd35326394834b21f8bff13805226_I20230428"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:LawsuitTypeAxis">cah:ClassActionLawsuitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cah:PlaintiffTypeAxis">cah:PrivatePartiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie21d9b2ab8b84826b773ef6884028072_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:GA</xbrldi:explicitMember><xbrldi:explicitMember dimension="cah:PlaintiffTypeAxis">cah:PrivatePartiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="plaintiff"><xbrli:measure>cah:plaintiff</xbrli:measure></xbrli:unit><xbrli:context id="i39d543d6d5bc4327b0cde155c825cad4_D20230701-20230701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:PlaintiffTypeAxis">cah:PrivatePartiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:AL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc7cc411a15e484b83110041666764e1_I20230428"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44256b1db02046efa5d29d670a7bcd5d_D20230428-20230428"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cah:AlamedaCountyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-28</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ab800634809483fba34f7f06e7a35fe_D20230430-20230430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cah:AgreementsAxis">cah:IVCApril2023AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cah:LawsuitTypeAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-30</xbrli:startDate><xbrli:endDate>2023-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i902b5ace502c4edbb1ba6a0998f22efa_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cah:AgreementsAxis">cah:IVCApril2023AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5afb309fb1ba4583a4deda7964b8c2cf_D20230501-20230930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cah:AgreementsAxis">cah:IVCApril2023AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80b8e7e7258b478b904b1818e9f2cc0c_D20210701-20230428"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cah:AgreementsAxis">cah:OtherAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cah:LawsuitTypeAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3e20dfd93ab46e4866c903c3dfc10cf_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i853c2433b9a24879ba53a4b6f202569b_D20220701-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ee8ab07c16a4a6c81486f97137b35dc_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cah:LawsuitTypeAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iacf755c31715440284f4942dd149ce26_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:ShareholderSecuritiesLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04e26b0d7e5d4849a52f150680f0c631_D20220701-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:ShareholderDerivativeLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie12745b4aa3e4e2f8127b2b3aa94621c_D20220701-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">cah:MedicalUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5694d08abff46ac90bbee9634d4edd3_D20220701-20230630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cah:GoodwillImpairmentAxis">cah:MedicalUnitGoodwillImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22d8ac48311042cebfc3c15dda5a16fa_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:GoodwillImpairmentAxis">cah:MedicalUnitGoodwillImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4fa6e3e07aa461e98a6b82df41d98ce_D20230401-20230630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cah:GoodwillImpairmentAxis">cah:MedicalUnitGoodwillImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0fb653442b8d46c4b1d69a67bca87b29_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifef254c9824a4dbcbe0e5996b5dcc160_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia83e033e96e343bda1abf45e39b6de85_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:TaxMatterAxis">cah:CareFusionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b473c3f43624d36b0c2c645e60d3c85_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:TaxMatterAxis">cah:CareFusionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0647080b68e4434fb69d13640e2185be_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22574d8c00bd4f13ae6ec2c4fcc2f017_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib308cbc504e54cfea2d4a2a0d5e67181_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic1d54b1779a94c778dcfd9c480a2851b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic019966f86814bbbafa5f64677ed3ae9_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3c2602782c94beab41f34560fbefd82_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic33b3236678d4dba9bb198c5653cc58f_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i590356452cf8465698d99ccf090749ee_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7058036db8747708418c4af8c5bbe90_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib40cb321ed7048c3a2302a1bf22f2f6f_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifafc390c5b574ce9a766400e79096086_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f91dc01d0934f62990f387aff42bfc0_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i324d3cb6fe534b2d935a46f13fe9d0d7_D20220701-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ad948cf8f05443b8e4818f18729c732_D20210701-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i580853edf11f49b9b0fd206b92df8e34_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2cb7ee6cde3b4b9ea40f39a43c463c3f_D20220701-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70283d29df464fa9bfe3ab000de0526c_D20230401-20240331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ce2d0d359a54a7d863e7717418b0884_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:MaturityDateAxis">cah:September2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="jpy"><xbrli:measure>iso4217:JPY</xbrli:measure></xbrli:unit><xbrli:context id="i7ca5414a08eb459f8e8d7a93077973ca_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cah:MaturityDateAxis">cah:June2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3218ae04c9b1466fb3401cfe9911661b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cah:MaturityDateAxis">cah:March2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:context id="ibc60a5f6f2fd4df2b6e365b67ce91912_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cah:MaturityDateAxis">cah:March2026Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1c240be19f544f5b489ee7fbc6ec77d_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cah:DateInitiatedAxis">cah:March2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie681b1f27879497aaac9197da201e94c_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cah:DateInitiatedAxis">cah:September2018Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05f897db0bb743d0b9331a8d46baf59a_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:DateInitiatedAxis">cah:March2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb235b08598c4a23bff0d5c8e268cb3b_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:DateInitiatedAxis">cah:September2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if773aecdfcdd4fa1af2b4a92af9fafff_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i286db9ed3e3a475e93934bbb8c001c46_D20220701-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i453169c026a64457a0140b1f759e3178_D20210701-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieaa5331918d94152a37d35bd4fbf59d1_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd36140f852d4fd491f55d7cbb74fc38_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12151c3f1a7a45f0a2e075e9b264e83b_D20220701-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6dc7675fbf84b8eabf826cb41d79193_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib43a93a1b1cb4e7f9c3a767d383622bd_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76064daaf24a4ffeb60544ffcf302fab_D20220701-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cah:A250MillionShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i461a6425bd69455b83513a1e59a9776f_D20230101-20230228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cah:A250MillionShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib66c40ad89944e97863448aacf257bd4_D20230228-20230228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cah:A250MillionShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-28</xbrli:startDate><xbrli:endDate>2023-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica007433189241b2959cc8d752b3303e_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cah:A1BillionShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib99db3d39b2a4d159a049760c79aa4ad_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cah:A1BillionShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7a9fd51d7b5402abd517b833b8aa389_D20220701-20221223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cah:A1BillionShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-12-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ea1c66ac32f47d58440504438bf12ae_D20221223-20221223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cah:A1BillionShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-23</xbrli:startDate><xbrli:endDate>2022-12-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i522fef760d964e82a180d92c34f911f9_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cah:A200MillionShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62909649d3db4353bc2ea5dbf602e573_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cah:A200MillionShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a09f6e3558145749952ae7fc79bd2af_D20220101-20220418"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cah:A200MillionShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i226477cc1ffc4f0d9d9f5dd33b1e9da1_D20220418-20220418"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cah:A200MillionShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-18</xbrli:startDate><xbrli:endDate>2022-04-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1867aca7ccf1480e9c1ee9dcad7d47ae_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cah:A300MillionShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9412268ef744658a8712d81ef405c17_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cah:A300MillionShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8be8904a0c5f40cbbebf2f710dcc62b3_D20211001-20220131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cah:A300MillionShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2552d9f48bd74eb3a693f3a9fead0a14_D20220131-20220131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cah:A300MillionShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-31</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie154fb452e1a418293380c4c4a39a5cd_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cah:A500MillionShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f140036aee94cfe9d2320e0cd2ce82a_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cah:A500MillionShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4db4d5927cda47f480368591c63e0175_D20210701-20211014"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cah:A500MillionShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-10-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1cda2ab21b97491cb2163653f2b875c8_D20211004-20211004"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cah:A500MillionShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-04</xbrli:startDate><xbrli:endDate>2021-10-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57bea63d714f4a0dafc21a5f5d7d9581_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6045190cc1424f8b979c1010722b563f_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i041bf7de7fa94db3b9bf9e7b272751da_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc6e3923d3894b44990b34501ac477b5_D20220701-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44c00bb3d01a45a9b2df0171c33fe41e_D20220701-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9df3ae431f2408093261364d8c57572_D20220701-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f9b2983d0ee4f86a50ac5496fc9091c_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f42aa5a93cc411195bf2bf78d59cde4_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d7f6b1c5d2b48eeba8549a518560256_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icbef955e1ad34a0db8f9c5e948d9cb27_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc51bd9677854ac6aaa9f7b93f52a94e_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63438b89f0184fe2bed728cdd44ae85b_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i515663cfb02c45c09a0fbc66b8fef70c_D20210701-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5450ec0270bb4ceaafa8ee587406b24e_D20210701-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i704ee587ce264884a099492815729252_D20210701-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ec1d9ad198a4e43b265abc3a0d32cb8_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id449ab0597f64cd29ac910cb2816b35b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6203134ce90347afaf3c8d39444a0a7d_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="reportable_segments"><xbrli:measure>cah:Reportable_Segments</xbrli:measure></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>cah:segment</xbrli:measure></xbrli:unit><xbrli:context id="idc26a4e700a342548208bd3adbce0cc3_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:PharmaceuticalDistributionandSpecialtyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3eeef5beb2e3457385d0a29a55055482_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:PharmaceuticalDistributionandSpecialtyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1f8c810883d4ff9a38b1a6311b7024a_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:NuclearPrecisionHealthSolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22582fc2d45245928c608e9b04993980_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:NuclearPrecisionHealthSolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16dc5579b6f94e7ca4452bbc7028e7c9_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45daaa94544f4353a00c894ddf85a502_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i496f651118df4ac294afe39b4aefdc23_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:MedicaldistributionandproductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieff878faa3b9482d85466ac9bdf16285_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:MedicaldistributionandproductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib56812ccf8264be98f8752c625e2e17a_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:CardinalHealthAtHomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i169b1a322c8c4e52985fff332cb28f47_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:CardinalHealthAtHomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1495b91ae50844b7bd8dee01339cb2ba_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc29744d3dd64b99ab33d733a31d8725_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7c59d976f4b491293536f66988a658a_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i569871ca4d47454f87c9b6023726a3aa_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia03b234276c04aa0af1cf1a16b60bc62_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b30b0809298478382f26a051e90bf8a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie54fd2c345514ac293e4ec5b948651d1_D20220701-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:PharmaceuticalDistributionandSpecialtyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d7a863829b14c7491f8ae6b2433a880_D20210701-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:PharmaceuticalDistributionandSpecialtyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92e95db7bd6246ed9c7bac5e8fb213ff_D20220701-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:NuclearPrecisionHealthSolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8bc9a61c2e44236ab69000fb26a2824_D20210701-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:NuclearPrecisionHealthSolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04924e9230e745fca992f99aa6ace85c_D20220701-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b399963940c4fcc875d6ee7b2e2a30c_D20210701-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id19b85c70c834e2788b7091044df235c_D20220701-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:MedicaldistributionandproductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i543467e6acd7440e976c6acaeebc9d47_D20210701-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:MedicaldistributionandproductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57cd785fabaf4688a3bbe54d4f0ca21d_D20220701-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:CardinalHealthAtHomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9e29a915c71426f8011dc3489ec5202_D20210701-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:CardinalHealthAtHomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44eddf7caae040f987146265a715a28d_D20220701-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie312826afe694135b31551dc50097180_D20210701-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09186e53513344a797c14f6874c9c782_D20220701-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i438495dce7084e9eb69ebe58bc06cd29_D20210701-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ed97f44ba534c3889ad982e9558682c_D20220701-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9dcc325ed5014b548d6c310c9974f048_D20210701-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73b99b7f00ef43c3b9264f23015dbdbc_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4bb3c35435cf4419a78f521a4ab0acc6_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i447a6c019d5146ccb318da808e4fb2f3_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4060ee92cb7e4a3a973a917c60eb75fc_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if67e0eb500ab42958354df8e59c31390_D20220701-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5273719c53784b1984b975c2b15073cf_D20210701-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib488e4c93b484184a8e52bee69885132_D20220701-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5f105aa532244e0885f2307bc2951ad_D20210701-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c0c3804d63c4f5fafbb13f1f87b1d95_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4a16787e42247d480a65342eeea298b_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib09896a0291b4dbd9d0deb987d93eb9c_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibee1c5b1f4f946f18b93d5abfb380e03_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f4869e77ac44a00a1348128c89edab9_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa15c30af25e4338b4b75b20fdd5cdfd_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61e443ff0bb041468d351efdad3a60ec_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a2edd19ded449568c634ce222c8bf11_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac5b45b6082b4c20bc77e15c6b0dfe4a_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6cb3c83f18544d88816e14ee29ce253f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7de355b6c9f244b0aecf4263ff24158b_D20220701-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4307df7bd4b4ddf85fe23923677a14f_D20210701-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9750f858065345b6b71dfdf94a3db05f_D20220701-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice80dc50332649f4a2e8211087c1473c_D20210701-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8acc2cf603d4cec94d38cdf7947bf8c_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia7a3dc6029084cef92896c48e8a19a01_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34b2dbad9e7648de967669561a47dd81_D20220701-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2fbe5a679b3841fcb8bbd7dfa64915ad_D20220701-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifab2ddff45a44bc58da3784419071ae5_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iace1106122bd40149cc5c5765c33fb32_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i1d34fc4fc2424fbcb4837cc9f1c0665c_1"></div><div style="min-height:40.5pt;width:100%"><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d34fc4fc2424fbcb4837cc9f1c0665c_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:100%">UNITED STATES</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:100%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Washington,&#160;D.C. 20549</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Form <ix:nonNumeric contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xL2ZyYWc6MjQ4ZTJhOWJlM2IxNDc1NjhhYTJjZGE1OWYwOGU4ZTYvdGV4dHJlZ2lvbjoyNDhlMmE5YmUzYjE0NzU2OGFhMmNkYTU5ZjA4ZThlNl84NA_4ed707b0-d504-44db-a741-d87f8f51983d">10-Q</ix:nonNumeric> </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.116%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.684%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xL2ZyYWc6MjQ4ZTJhOWJlM2IxNDc1NjhhYTJjZGE1OWYwOGU4ZTYvdGFibGU6YzBhZTVhMzc5MzZjNDUyNDhjM2FiMjIwMzI2N2RkNzAvdGFibGVyYW5nZTpjMGFlNWEzNzkzNmM0NTI0OGMzYWIyMjAzMjY3ZGQ3MF8wLTAtMS0xLTI4Njk0NA_4e7d8e1f-d8d5-4389-ada2-5317b0909db9">&#9745;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xL2ZyYWc6MjQ4ZTJhOWJlM2IxNDc1NjhhYTJjZGE1OWYwOGU4ZTYvdGV4dHJlZ2lvbjoyNDhlMmE5YmUzYjE0NzU2OGFhMmNkYTU5ZjA4ZThlNl8xMjE_fcb5b694-fbc5-4dff-b95f-5d1bfcd10631">March 31, 2023</ix:nonNumeric> </span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.116%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.684%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xL2ZyYWc6MjQ4ZTJhOWJlM2IxNDc1NjhhYTJjZGE1OWYwOGU4ZTYvdGFibGU6OGJlZjVkZTU5MDI2NGIyZDg0NThhM2ZjN2QyMzViMWYvdGFibGVyYW5nZTo4YmVmNWRlNTkwMjY0YjJkODQ1OGEzZmM3ZDIzNWIxZl8wLTAtMS0xLTI4Njk0NA_eefb2d1e-db24-448d-9eee-e1afae87f569">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the transition period from ________ to ________</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commission File Number:&#160;<ix:nonNumeric contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xL2ZyYWc6MjQ4ZTJhOWJlM2IxNDc1NjhhYTJjZGE1OWYwOGU4ZTYvdGV4dHJlZ2lvbjoyNDhlMmE5YmUzYjE0NzU2OGFhMmNkYTU5ZjA4ZThlNl8xOTA0_17181962-98cf-4e86-acf4-940b4d2dc704">1-11373</ix:nonNumeric> </span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xL2ZyYWc6MjQ4ZTJhOWJlM2IxNDc1NjhhYTJjZGE1OWYwOGU4ZTYvdGV4dHJlZ2lvbjoyNDhlMmE5YmUzYjE0NzU2OGFhMmNkYTU5ZjA4ZThlNl8xOTA1_35c8ee6f-d9ad-4229-8ade-ddcebcee4e99">Cardinal Health, Inc.</ix:nonNumeric> </span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.867%"><tr><td style="width:1.0%"></td><td style="width:24.860%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.860%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.306%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xL2ZyYWc6MjQ4ZTJhOWJlM2IxNDc1NjhhYTJjZGE1OWYwOGU4ZTYvdGFibGU6YWNjZjFhODcwNDM5NGQ5MTk1MjFiOTViZWI2YjUwOTYvdGFibGVyYW5nZTphY2NmMWE4NzA0Mzk0ZDkxOTUyMWI5NWJlYjZiNTA5Nl8wLTAtMS0xLTI4Njk0NA_eef7738c-09b3-47da-a9c7-4ef61d8485b0">Ohio</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xL2ZyYWc6MjQ4ZTJhOWJlM2IxNDc1NjhhYTJjZGE1OWYwOGU4ZTYvdGFibGU6YWNjZjFhODcwNDM5NGQ5MTk1MjFiOTViZWI2YjUwOTYvdGFibGVyYW5nZTphY2NmMWE4NzA0Mzk0ZDkxOTUyMWI5NWJlYjZiNTA5Nl8wLTYtMS0xLTI4Njk0NA_e9ce108b-ebe8-4fa6-8c5d-a764da3a24f2">31-0958666</ix:nonNumeric></span></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">(IRS Employer<br/>Identification No.)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xL2ZyYWc6MjQ4ZTJhOWJlM2IxNDc1NjhhYTJjZGE1OWYwOGU4ZTYvdGFibGU6YWNjZjFhODcwNDM5NGQ5MTk1MjFiOTViZWI2YjUwOTYvdGFibGVyYW5nZTphY2NmMWE4NzA0Mzk0ZDkxOTUyMWI5NWJlYjZiNTA5Nl8zLTAtMS0xLTI4Njk0NA_2a990dac-23c4-431a-9cc1-897a0dd504f2">7000 Cardinal Place</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">,</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xL2ZyYWc6MjQ4ZTJhOWJlM2IxNDc1NjhhYTJjZGE1OWYwOGU4ZTYvdGFibGU6YWNjZjFhODcwNDM5NGQ5MTk1MjFiOTViZWI2YjUwOTYvdGFibGVyYW5nZTphY2NmMWE4NzA0Mzk0ZDkxOTUyMWI5NWJlYjZiNTA5Nl8zLTItMS0xLTI4Njk0NA_de541535-5358-4016-bfe2-157512cff35f">Dublin</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">,</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xL2ZyYWc6MjQ4ZTJhOWJlM2IxNDc1NjhhYTJjZGE1OWYwOGU4ZTYvdGFibGU6YWNjZjFhODcwNDM5NGQ5MTk1MjFiOTViZWI2YjUwOTYvdGFibGVyYW5nZTphY2NmMWE4NzA0Mzk0ZDkxOTUyMWI5NWJlYjZiNTA5Nl8zLTQtMS0xLTI4Njk0NA_dd07a187-c5e2-4f15-a019-a287b31513a0">Ohio</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xL2ZyYWc6MjQ4ZTJhOWJlM2IxNDc1NjhhYTJjZGE1OWYwOGU4ZTYvdGFibGU6YWNjZjFhODcwNDM5NGQ5MTk1MjFiOTViZWI2YjUwOTYvdGFibGVyYW5nZTphY2NmMWE4NzA0Mzk0ZDkxOTUyMWI5NWJlYjZiNTA5Nl8zLTYtMS0xLTI4Njk0NA_61565e01-40e1-4f40-b424-6a27ddce795c">43017</ix:nonNumeric></span></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xL2ZyYWc6MjQ4ZTJhOWJlM2IxNDc1NjhhYTJjZGE1OWYwOGU4ZTYvdGV4dHJlZ2lvbjoyNDhlMmE5YmUzYjE0NzU2OGFhMmNkYTU5ZjA4ZThlNl8yOTY_482647f6-9ed5-4256-8184-6eb789cfaf0f">614</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xL2ZyYWc6MjQ4ZTJhOWJlM2IxNDc1NjhhYTJjZGE1OWYwOGU4ZTYvdGV4dHJlZ2lvbjoyNDhlMmE5YmUzYjE0NzU2OGFhMmNkYTU5ZjA4ZThlNl8xOTAw_fbcc873b-fb9f-4623-bf69-dcf62483ad6e">757-5000</ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.370%"><tr><td style="width:1.0%"></td><td style="width:35.931%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.836%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.933%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Securities registered pursuant to Section 12(b) of the Act:</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xL2ZyYWc6MjQ4ZTJhOWJlM2IxNDc1NjhhYTJjZGE1OWYwOGU4ZTYvdGFibGU6NDljYzdlNGUxOWVjNDdmNWE4MDQyNjIyZWZlZGRmMmYvdGFibGVyYW5nZTo0OWNjN2U0ZTE5ZWM0N2Y1YTgwNDI2MjJlZmVkZGYyZl8yLTAtMS0xLTI4Njk0NA_84efa336-b035-4826-aab0-03246dd8f2fb">Common shares (without par value)</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xL2ZyYWc6MjQ4ZTJhOWJlM2IxNDc1NjhhYTJjZGE1OWYwOGU4ZTYvdGFibGU6NDljYzdlNGUxOWVjNDdmNWE4MDQyNjIyZWZlZGRmMmYvdGFibGVyYW5nZTo0OWNjN2U0ZTE5ZWM0N2Y1YTgwNDI2MjJlZmVkZGYyZl8yLTEtMS0xLTI4Njk0NA_03707faf-8ed5-4f2f-9be7-71d8e134d631">CAH</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xL2ZyYWc6MjQ4ZTJhOWJlM2IxNDc1NjhhYTJjZGE1OWYwOGU4ZTYvdGFibGU6NDljYzdlNGUxOWVjNDdmNWE4MDQyNjIyZWZlZGRmMmYvdGFibGVyYW5nZTo0OWNjN2U0ZTE5ZWM0N2Y1YTgwNDI2MjJlZmVkZGYyZl8yLTItMS0xLTI4Njk0NA_eb756074-ffe8-451d-8474-03f9b9868aef">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xL2ZyYWc6MjQ4ZTJhOWJlM2IxNDc1NjhhYTJjZGE1OWYwOGU4ZTYvdGV4dHJlZ2lvbjoyNDhlMmE5YmUzYjE0NzU2OGFhMmNkYTU5ZjA4ZThlNl8xOTAx_2589a53e-c0f0-43c9-b8b3-0b6fa789f36b">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#254;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xL2ZyYWc6MjQ4ZTJhOWJlM2IxNDc1NjhhYTJjZGE1OWYwOGU4ZTYvdGV4dHJlZ2lvbjoyNDhlMmE5YmUzYjE0NzU2OGFhMmNkYTU5ZjA4ZThlNl8xOTAy_9d638c50-fc2c-4fb0-9233-bcbd9fc55ed7">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#254;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and "emerging growth company" in Rule&#160;12b-2 of the Exchange Act. </span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:17.550%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.471%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.550%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.471%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.813%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xL2ZyYWc6MjQ4ZTJhOWJlM2IxNDc1NjhhYTJjZGE1OWYwOGU4ZTYvdGFibGU6N2EzNzRjZTEyOWU3NGNjNWFhOTY4NDM1YWRhYzkyODIvdGFibGVyYW5nZTo3YTM3NGNlMTI5ZTc0Y2M1YWE5Njg0MzVhZGFjOTI4Ml8wLTAtMS0xLTI4Njk0NA_eee726ab-ead8-43d4-ad2f-9ecae828d6e4">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#9745;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xL2ZyYWc6MjQ4ZTJhOWJlM2IxNDc1NjhhYTJjZGE1OWYwOGU4ZTYvdGFibGU6N2EzNzRjZTEyOWU3NGNjNWFhOTY4NDM1YWRhYzkyODIvdGFibGVyYW5nZTo3YTM3NGNlMTI5ZTc0Y2M1YWE5Njg0MzVhZGFjOTI4Ml8xLTQtMS0xLTI4Njk0NA_69a91947-e711-4fc7-ada0-e8f6f11ea497">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xL2ZyYWc6MjQ4ZTJhOWJlM2IxNDc1NjhhYTJjZGE1OWYwOGU4ZTYvdGFibGU6N2EzNzRjZTEyOWU3NGNjNWFhOTY4NDM1YWRhYzkyODIvdGFibGVyYW5nZTo3YTM3NGNlMTI5ZTc0Y2M1YWE5Njg0MzVhZGFjOTI4Ml8yLTQtMS0xLTI4Njk0NA_f1f39869-0def-4d4b-adb9-f480f405fa03">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act   </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). &#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xL2ZyYWc6MjQ4ZTJhOWJlM2IxNDc1NjhhYTJjZGE1OWYwOGU4ZTYvdGV4dHJlZ2lvbjoyNDhlMmE5YmUzYjE0NzU2OGFhMmNkYTU5ZjA4ZThlNl8xOTAz_78c876aa-aa43-4561-b4ba-0b8679d79313">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#254;</span></div><div style="margin-bottom:1pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of the registrant&#8217;s common shares, without par value, outstanding as of April&#160;30, 2023, was the following: <ix:nonFraction unitRef="shares" contextRef="ia3e1bc5fa75b4fd38bbf74aaa66b04ed_I20230430" decimals="0" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xL2ZyYWc6MjQ4ZTJhOWJlM2IxNDc1NjhhYTJjZGE1OWYwOGU4ZTYvdGV4dHJlZ2lvbjoyNDhlMmE5YmUzYjE0NzU2OGFhMmNkYTU5ZjA4ZThlNl8xODk4_0a84d0bc-181f-439a-963a-2bb253278a92">254,600,182</ix:nonFraction>.</span></div><div style="height:22.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i1d34fc4fc2424fbcb4837cc9f1c0665c_7"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:22pt;font-weight:700;line-height:100%">Cardinal Health</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:100%"> </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:18pt;font-weight:700;line-height:100%"> </span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Q3 Fiscal 2023 Form 10-Q                                                                                                                                   </span></div></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Table of Contents</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.660%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.222%"><tr><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:91.080%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.720%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d34fc4fc2424fbcb4837cc9f1c0665c_13">Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i1d34fc4fc2424fbcb4837cc9f1c0665c_13">2</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d34fc4fc2424fbcb4837cc9f1c0665c_34">Explanation and Reconciliation of Non-GAAP Financial Measures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i1d34fc4fc2424fbcb4837cc9f1c0665c_34">16</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d34fc4fc2424fbcb4837cc9f1c0665c_43">Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i1d34fc4fc2424fbcb4837cc9f1c0665c_43">21</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d34fc4fc2424fbcb4837cc9f1c0665c_46">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i1d34fc4fc2424fbcb4837cc9f1c0665c_46">21</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d34fc4fc2424fbcb4837cc9f1c0665c_49">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i1d34fc4fc2424fbcb4837cc9f1c0665c_49">22</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d34fc4fc2424fbcb4837cc9f1c0665c_52">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i1d34fc4fc2424fbcb4837cc9f1c0665c_52">23</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d34fc4fc2424fbcb4837cc9f1c0665c_55">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i1d34fc4fc2424fbcb4837cc9f1c0665c_55">25</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d34fc4fc2424fbcb4837cc9f1c0665c_61">Financial Statemen</a>ts</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i1d34fc4fc2424fbcb4837cc9f1c0665c_61">26</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d34fc4fc2424fbcb4837cc9f1c0665c_124">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i1d34fc4fc2424fbcb4837cc9f1c0665c_124">44</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d34fc4fc2424fbcb4837cc9f1c0665c_127">Form 10-Q Cross Reference Index</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i1d34fc4fc2424fbcb4837cc9f1c0665c_127">45</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d34fc4fc2424fbcb4837cc9f1c0665c_130">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i1d34fc4fc2424fbcb4837cc9f1c0665c_130">46</a></span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%">About Cardinal Health</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cardinal Health, Inc., an Ohio corporation formed in 1979, is a globally integrated healthcare services and products company providing customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices and patients in the home. We provide pharmaceuticals and medical products and cost-effective solutions that enhance supply chain efficiency. We connect patients, providers, payers, pharmacists and manufacturers for integrated care coordination and better patient management. We manage our business and report our financial results in two segments: Pharmaceutical and Medical. As used in this report, &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us,&#8221; and similar pronouns refer to Cardinal Health, Inc. and its majority-owned and consolidated subsidiaries, unless the context requires otherwise. Our fiscal year ends on June 30. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References to fiscal 2023 and fiscal 2022 and to FY23 and FY22 are to the fiscal years ending or ended June&#160;30, 2023 and June 30, 2022, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Forward-Looking Statements</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q for the quarter ended March&#160;31, 2023 (this "Form 10-Q") (including information incorporated by reference) includes "forward-looking statements" addressing expectations, prospects, estimates and other matters that are dependent upon future events or developments. Many forward-looking statements appear in Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations ("MD&amp;A"), but there are others in this Form 10-Q, which may be identified by words such as "expect," "anticipate," "intend," "plan," "believe," "will," "should," "could," "would," "project," "continue," "likely," and similar expressions, and include statements reflecting future results or guidance, statements of outlook and expense accruals. These matters are subject to risks and uncertainties that could cause actual results to differ materially from those made, projected or implied. The most significant of these risks and uncertainties are described in this Form 10-Q, including Exhibit 99.1, and in "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended June 30, 2022 (our &#8220;2022 Form 10-K&#8221;). Forward-looking statements in this Form 10-Q speak only as of the date of this document. Except to the extent required by applicable law, we undertake no obligation to update or revise any forward-looking statement.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Non-GAAP Financial Measures</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the "Overview of Consolidated Results" section of MD&amp;A, we use financial measures that are derived from our consolidated financial data but are not presented in our condensed consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles ("GAAP"). These measures are considered "non-GAAP financial measures" under the United States Securities and Exchange Commission ("SEC") rules. The reasons we use these non-GAAP financial measures and the reconciliations to their most directly comparable GAAP financial measures are included in the &#8220;Explanation and Reconciliation of Non-GAAP Financial Measures&#8221; section following MD&amp;A in this Form 10-Q. </span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i1d34fc4fc2424fbcb4837cc9f1c0665c_13"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.820%"><tr><td style="width:1.0%"></td><td style="width:24.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Overview</span></div></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Management's Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discussion and analysis presented below is concerned with material changes in financial condition and results of operations, including amounts and certainty of cash flows from operations and from outside sources, between the periods specified in our condensed consolidated balance sheets at March&#160;31, 2023 and June&#160;30, 2022, and in our condensed consolidated statements of earnings/(loss) for the three and nine months ended March&#160;31, 2023 and 2022. All comparisons presented are with respect to the prior-year period, unless stated otherwise. This discussion and analysis should be read in conjunction with the MD&amp;A included in our 2022 Form 10-K.</span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i1d34fc4fc2424fbcb4837cc9f1c0665c_16"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Overview</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ff0000;font-family:'Arial Narrow',sans-serif;font-size:17pt;font-weight:700;line-height:120%">Overview of Consolidated Results</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended March&#160;31, 2023, revenue increased 13 percent to $50.5 billion and $151.6 billion, respectively, primarily due to branded and specialty pharmaceutical sales growth from existing customers. During the nine months ended March&#160;31, 2023, pharmaceutical sales growth from net new customers also contributed to increased revenue.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">GAAP and Non-GAAP Operating Earnings/(Loss)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:48.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.664%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">GAAP operating earnings/(loss)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">572</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(97)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">590</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(632)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Surgical gown recall costs/(income)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State opioid assessment related to prior fiscal years</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(6)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shareholder cooperation agreement costs</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring and employee severance</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">16</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">62</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization and other acquisition-related costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">74</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">216</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairments and (gain)/loss on disposal of assets, net</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">20</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">471&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">883</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,764&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation (recoveries)/charges, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(76)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(256)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-GAAP operating earnings</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">606</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">545&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,497</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,540&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(3)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The sum of the components and certain computations may reflect rounding adjustments.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had GAAP operating earnings of $572 million during the three months ended March&#160;31, 2023 and a GAAP operating loss of $97 million during the three months ended March 31, 2022, which reflects no goodwill impairment charge recognized during the three months ended March&#160;31, 2023 and the $474&#160;million pre-tax non-cash goodwill impairment charge related to the Medical segment recognized during the three months ended March 31, 2022. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had GAAP operating earnings of $590 million and a GAAP operating loss of $632 million during the nine months ended March&#160;31, 2023 and 2022, respectively, which included the $863 million and $1.8&#160;billion pre-tax non-cash goodwill impairment charges related to the Medical segment, respectively. See "Critical Accounting Policies and Sensitive Accounting Estimates" section of this MD&amp;A and </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1d34fc4fc2424fbcb4837cc9f1c0665c_88">Note 4</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for additional detail related to goodwill impairment.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GAAP operating earnings during the three and nine months ended March&#160;31, 2023 were favorably impacted by litigation recoveries. See "Results of Operations" section of this MD&amp;A and </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1d34fc4fc2424fbcb4837cc9f1c0665c_100">Note 6</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for additional detail related to litigation recoveries.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-GAAP operating earnings during the three months ended March&#160;31, 2023 increased 11 percent to $606 million primarily due to an increase in Pharmaceutical segment profit largely driven by the performance of our generics program and an increased contribution from branded and specialty pharmaceutical products. This increase was partially offset by a decrease in Medical segment profit largely resulting from lower volumes and unfavorable product sales mix within products and distribution.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-GAAP operating earnings during the nine months ended March&#160;31, 2023 decreased 3 percent to $1.5 billion primarily due to a decrease in Medical segment profit largely resulting from lower volumes and unfavorable product sales mix within products and distribution and net inflationary impacts. This decrease was partially offset by an increase in Pharmaceutical segment profit primarily driven by the performance of our generics program and an increased contribution from branded and specialty pharmaceutical products.</span></div><div style="margin-top:3pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Overview</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">GAAP and Non-GAAP Diluted EPS</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:48.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.664%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">($ per share)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">GAAP diluted EPS </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1.34</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.05)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1.23</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.82)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State opioid assessment related to prior fiscal years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.02</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shareholder cooperation agreement costs</span></div></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(0.02)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring and employee severance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.05</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.08&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.18</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization and other acquisition-related costs</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.21</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.21&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.61</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.63&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairments and (gain)/loss on disposal of assets, net </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.35</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.03&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2.82</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation (recoveries)/charges, net</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(0.21)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.18&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(0.60)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.33&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on early extinguishment of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.03&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-GAAP diluted EPS </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1.74</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.45&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">20</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4.24</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.01&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The sum of the components and certain computations may reflect rounding adjustments. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The reconciling items are presented within this table net of tax. See quantification of tax effect of each reconciling item in our GAAP to Non-GAAP Reconciliations in the "Explanation and Reconciliation of Non-GAAP Financial Measures."</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Diluted earnings/(loss) per share attributable to Cardinal Health, Inc. ("diluted EPS").</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">For the three and nine months ended March 31, 2022, GAAP diluted EPS and the EPS impact from the GAAP to non-GAAP per share reconciling items are calculated using a weighted average of 275 million and 281 million common shares, respectively, which excludes potentially dilutive securities from the denominator due to their anti-dilutive effects resulting from our GAAP net loss for the periods. For the three and nine months ended March 31, 2022, non-GAAP diluted EPS is calculated using a weighted average of 277 million and 282 million common shares, respectively, which includes potentially dilutive shares.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Impairments and (gain)/loss on disposal of assets, net included pre-tax goodwill impairment charges related to the Medical segment of $863 million recorded during the nine months ended March 31, 2023. For fiscal 2023, the estimated net tax benefit related to the impairments is $68 million and is included in the annual effective tax rate. As a result, the amount of tax expense recognized increased approximately by an incremental $74 million during the three months ended March 31, 2023. The incremental interim tax benefit recognized during the nine months ended March 31, 2023 was $66 million and will reverse in the fourth quarter of the fiscal year.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">During the three and nine months ended March 31, 2022, impairments and (gain)/loss on disposal of assets, net included pre-tax goodwill impairment charges of $474 million and $1.8 billion, respectively, related to the Medical segment. For fiscal 2022, the estimated net tax benefit related to the impairment was $126 million and was included in the annual effective tax rate. As a result, the amount of tax expense recognized during the three and nine months ended March 31, 2022 increased approximately by an incremental $1.2 billion and $180 million, respectively, and lowered the provision for income taxes during the fourth quarter of fiscal 2022 by approximately $180 million.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GAAP diluted EPS was adversely impacted by the goodwill impairment charges related to the Medical segment, which had a $(2.76) per share after tax impact during the nine months ended March&#160;31, 2023, and $(6.01) and $(6.67) per share after tax impact during the three and nine months ended March&#160;31, 2022, respectively. See "Critical Accounting Policies and Sensitive Accounting Estimates" section of this MD&amp;A, and </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1d34fc4fc2424fbcb4837cc9f1c0665c_88">Note 4</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1d34fc4fc2424fbcb4837cc9f1c0665c_103">Note 7</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for additional detail. GAAP EPS during the three and nine months ended March&#160;31, 2023 also includes the favorable impact of litigation recoveries as described further in the "Results of Operations" section of this MD&amp;A and </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1d34fc4fc2424fbcb4837cc9f1c0665c_100">Note 6</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of "Notes to Condensed Consolidated Financial Statements."</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023, non-GAAP diluted EPS increased 20 percent to $1.74 per share due to higher non-GAAP operating earnings and a lower share count.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended March&#160;31, 2023, non-GAAP diluted EPS increased 6 percent to $4.24 per share due to a lower share count and interest expense, partially offset by lower non-GAAP operating earnings.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Cash and Equivalents </span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash and equivalents balance was $4.0 billion at March&#160;31, 2023 compared to $4.7 billion at June&#160;30, 2022. During the nine months ended March&#160;31, 2023, net cash provided by operating activities was $2.0 billion, which includes the impact of our second annual payment of $372&#160;million related to the agreement to settle the vast majority of the opioid lawsuits filed by states and local governmental entities (the "Settlement Agreement"). In addition, during the nine months ended March&#160;31, 2023, we deployed $1.5 billion for share repurchases, $571 million for debt repayments, $399 million for cash dividends and $264 million for capital expenditures.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Overview</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#ff0000;font-family:'Arial Narrow',sans-serif;font-size:17pt;font-weight:700;line-height:120%">Significant Developments in Fiscal 2023 and Trends</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Inflationary Impacts </span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in fiscal 2022, Medical segment profit was negatively affected by incremental inflationary impacts, primarily related to transportation (including ocean and domestic freight), commodities and labor, and global supply chain constraints. Since that time, we have taken certain actions to mitigate these impacts, including implementing certain price increases and evolving our pricing and commercial contracting processes to provide us with greater pricing flexibility. In addition, certain decreases in some product-related costs are beginning to be recognized as the higher-cost inventory is moving through our supply chain. As a result, during the three months ended March&#160;31, 2023, these inflationary impacts, net of our mitigation actions, and global supply chain constraints had a slightly favorable impact on Medical segment profit on a year-over-year basis. During the nine months ended March&#160;31, 2023, these net inflationary impacts negatively affected Medical segment profit on a year-over-year basis.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect these net inflationary impacts to continue to affect Medical segment profit in fiscal 2023 and beyond, but to a lesser extent than in prior periods. These inflationary costs are difficult to predict and may be greater than we expect or continue longer than our current expectations. Any additional benefit to Medical segment profit from further decreases in these product-related costs will be delayed until the higher-cost inventory has moved through our supply chain. Our actions to increase prices and evolve our contracting strategies are subject to contingencies and uncertainties and it is possible that our results of operations will be adversely impacted to a greater extent than we currently anticipate or that we may not be able to mitigate the negative impact to the extent or on the timeline we anticipate.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To a lesser extent, inflationary impacts, primarily related to increased transportation and labor costs, also adversely affected Pharmaceutical segment profit during the three and nine months ended March&#160;31, 2023 and on a year-over-year basis during the nine months ended March&#160;31, 2023. During the three months ended March&#160;31, 2023, these inflationary impacts did not have a meaningful impact on Pharmaceutical segment profit on a year-over-year basis.</span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">PPE Demand and Pricing</span></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Personal protective equipment ("PPE") refers to protective clothing, medical gloves, face shields, face masks and other equipment designed to protect the wearer from injury or the spread of infection or illness. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PPE adversely impacted Medical segment revenue during the three and nine months ended March&#160;31, 2023 on a year-over-year basis, primarily due to declines in volumes and pricing.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical segment profit was favorably impacted during the three and nine months ended March&#160;31, 2023 and on a year-over-year basis by a net positive contribution from PPE, primarily driven by lower costs. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The demand and pricing for PPE is subject to risks and uncertainties, which may continue to impact Medical segment revenue, Medical segment profit and consolidated operating earnings during the remainder of fiscal 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Medical Goodwill</span></div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to changes in our long-term financial plan assumptions made during the three months ended March&#160;31, 2023, we performed interim goodwill impairment testing for the Medical operating segment (excluding our Cardinal Health at-Home Solutions division) (the &#8220;Medical Unit&#8221;) at March&#160;31, 2023. We concluded that there was no impairment of goodwill at March&#160;31, 2023, as the estimated fair value of the Medical Unit exceeded its carrying value.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We performed quantitative goodwill impairment testing for the Medical Unit at December 31, 2022 and September 30, 2022, which resulted in pre-tax goodwill impairment charges of $709 million and $154 million, respectively. The cumulative pre-tax goodwill impairment charges of $863 million were recognized in impairments and (gain)/loss on disposal of assets, net in our condensed consolidated statements of earnings/(loss) for the nine months ended March&#160;31, 2023. See "Critical Accounting Policies and Sensitive Accounting Estimates" section of this MD&amp;A and </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1d34fc4fc2424fbcb4837cc9f1c0665c_88">Note 4</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for additional detail.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adverse changes in key assumptions, including an increase in the discount rate, or a significant change in industry or economic trends during the remainder of fiscal 2023 and beyond could result in additional goodwill impairments.</span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Overview</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Shareholder Cooperation Agreement</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, we entered into a Cooperation Agreement (the "Cooperation Agreement") with Elliott Associates, L.P. and Elliott International, L.P. (together, "Elliott") under which our Board of Directors (the "Board"), among other things, (1) appointed four new independent directors, including a representative from Elliott, and (2) formed an advisory Business Review Committee of the Board, which is tasked with undertaking a comprehensive review of our strategy, portfolio, capital-allocation framework and operations. In May 2023, we extended the term of the Cooperation Agreement until the later of July 15, 2024 or until Elliott's representative ceases to serve on, or resigns from, the Board. In connection with this extension, the Board has extended the term of the Business Review Committee until July 15, 2024.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The evaluation and implementation of any actions recommended by the Business Review Committee and the Board may impact our financial position and results of operations during the remainder of fiscal 2023 and beyond. In addition, during the nine months ended March&#160;31, 2023, we incurred $8 million of expenses related to the negotiation and finalization of the Cooperation Agreement and other consulting expenses. We have incurred, and expect to continue to incur additional legal, consulting and other expenses related to the Cooperation Agreement and the activities of the Business Review Committee. See "Risk Factors" section for additional detail related to risks associated with the Cooperation Agreement.</span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Pharmaceutical Segment Generics Program</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The performance of our Pharmaceutical segment generics program positively impacted the year-over-year comparison of Pharmaceutical segment profit during the three and nine months ended March&#160;31, 2023. The Pharmaceutical segment generics program includes, among other things, the impact of generic pharmaceutical product launches, customer volumes, pricing changes, the Red Oak Sourcing, LLC venture ("Red Oak Sourcing") with CVS Health Corporation ("CVS Health") and generic pharmaceutical contract manufacturing and sourcing costs. During the nine months ended March 31, 2023, generic pharmaceutical contract manufacturing inventory-related charges adversely impacted the performance of our generics program. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The frequency, timing, magnitude and profit impact of generic pharmaceutical customer volumes, pricing changes, customer contract renewals, generic pharmaceutical manufacturer pricing changes and generic pharmaceutical contract manufacturing and sourcing costs all impact Pharmaceutical segment profit and are subject to risks and uncertainties. These risks and uncertainties may impact Pharmaceutical segment profit and consolidated operating earnings during the remainder of fiscal 2023.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i1d34fc4fc2424fbcb4837cc9f1c0665c_19"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.852%"><tr><td style="width:1.0%"></td><td style="width:24.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.450%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.797%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Results of Operations</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ff0000;font-family:'Arial Narrow',sans-serif;font-size:17pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><img src="cah-20230331_g1.jpg" alt="36" style="height:250px;margin-bottom:5pt;vertical-align:text-bottom;width:266px"/><img src="cah-20230331_g2.jpg" alt="37" style="height:250px;margin-bottom:5pt;vertical-align:text-bottom;width:266px"/></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">46,809</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40,957&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">14</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">140,310</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">122,154&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">15</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,684</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,884&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11,259</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,118&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">50,493</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,841&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">13</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">151,569</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">134,272&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">13</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">50,487</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,836&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">13</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">151,559</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">134,261&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">13</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pharmaceutical Segment </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical segment revenue increased during the three and nine months ended March&#160;31, 2023 due to branded and specialty pharmaceutical sales growth, which increased revenue by $5.8&#160;billion and $17.9&#160;billion, respectively, primarily from existing customers. During the nine months ended March&#160;31, 2023, pharmaceutical sales growth from net new customers also contributed to increased revenue.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Medical Segment</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical segment revenue decreased during the three months ended March&#160;31, 2023 primarily due to an adverse impact of PPE volumes and pricing within products and distribution. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical segment revenue decreased during the nine months ended March&#160;31, 2023 primarily due to lower sales within products and distribution, which includes an adverse impact from PPE volumes and pricing, and was partially offset by sales growth in at-Home Solutions.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Cost of Products Sold</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of products sold for the three and nine months ended March&#160;31, 2023 increased 13 percent to $48.7 billion and $146.5 billion, respectively, compared to the prior-year periods due to the factors affecting the changes in revenue and gross margin. </span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.852%"><tr><td style="width:1.0%"></td><td style="width:24.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.450%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.797%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Results of Operations</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Gross Margin</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><img src="cah-20230331_g3.jpg" alt="818" style="height:200px;margin-bottom:5pt;vertical-align:text-bottom;width:266px"/><img src="cah-20230331_g4.jpg" alt="819" style="height:200px;margin-bottom:5pt;vertical-align:text-bottom;width:266px"/></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross margin</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,785</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,682&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,062</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,940&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross margin increased during the three and nine months ended March&#160;31, 2023 primarily due to the Pharmaceutical segment, which included the performance of our generics program and a higher contribution from branded and specialty pharmaceutical products. The increase in gross margin due to the Pharmaceutical segment during the nine months ended March&#160;31, 2023 was partially offset by the performance of products and distribution within the Medical segment, primarily driven by lower volumes and unfavorable product sales mix.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross margin rate declined 21 basis points and 34 basis points during the three and nine months ended&#160;March&#160;31, 2023, respectively, mainly due to changes in overall product mix, primarily driven by increased pharmaceutical distribution branded sales, which have a dilutive impact on our overall gross margin rate.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Distribution, Selling, General and Administrative ("SG&amp;A") Expenses</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:11pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SG&amp;A expenses</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,179</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,137&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,567</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,402&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended March&#160;31, 2023, SG&amp;A expenses increased primarily due to inflationary impacts, primarily related to increased transportation and labor costs, and higher operating expenses (which were partially offset by the beneficial impact of enterprise-wide cost-savings measures). </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended March&#160;31, 2023, we incurred $8 million of expenses primarily related to the finalization of the Cooperation Agreement. See "Significant Developments in Fiscal 2023 and Trends" section in this MD&amp;A for additional detail related to the Cooperation Agreement.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended March&#160;31, 2023, we recorded $6 million of income to reduce our accrual for the assessment on prescription opioid medications that were sold or distributed in New York state in calendar year 2018 to the amount invoiced. See </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1d34fc4fc2424fbcb4837cc9f1c0665c_100">Note 6</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for additional information.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.852%"><tr><td style="width:1.0%"></td><td style="width:24.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.450%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.797%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Results of Operations</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Segment Profit</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate segment performance based on segment profit, among other measures. See </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1d34fc4fc2424fbcb4837cc9f1c0665c_118">Note 12</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for additional information on segment profit.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">     </span><img src="cah-20230331_g5.jpg" alt="3848290711240" style="height:250px;margin-bottom:5pt;vertical-align:text-bottom;width:266px"/><img src="cah-20230331_g6.jpg" alt="3848290711241" style="height:250px;margin-bottom:5pt;vertical-align:text-bottom;width:266px"/></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.195%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.450%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">600</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">487&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">23</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,495</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,319&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">13</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">20</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(66)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">29</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(88)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total segment profit</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">620</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">546&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">14</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,524</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,551&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(2)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(48)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(643)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(934)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,183)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total consolidated operating earnings/(loss)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">572</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(97)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">590</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(632)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td></tr></table></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pharmaceutical Segment Profit</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical segment profit increased during the three and nine months ended March&#160;31, 2023 primarily due to the performance of our generics program and an increased contribution from branded and specialty pharmaceutical products.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Medical Segment Profit</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical segment profit decreased during the three and nine months ended March&#160;31, 2023 primarily due to the performance of products and distribution, largely driven by lower volumes and unfavorable product sales mix. Medical segment profit during the nine months ended March&#160;31, 2023 was also unfavorably affected by net inflationary impacts.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Corporate</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in Corporate during the three and nine months ended&#160;March&#160;31, 2023&#160;were due to the factors discussed in the "Other Components of Consolidated Operating Earnings/(Loss)" section that follows. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.852%"><tr><td style="width:1.0%"></td><td style="width:24.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.450%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.797%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Results of Operations</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Other Components of Consolidated Operating Earnings/(Loss)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to revenue, gross margin and SG&amp;A expenses discussed previously, consolidated operating earnings/(loss) were impacted by the following:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.710%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.147%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring and employee severance</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">16</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">62</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization and other acquisition-related costs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">74</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">216</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairments and (gain)/loss on disposal of assets, net</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">20</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">471&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">883</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,764&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation (recoveries)/charges, net</span></td><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(76)</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(256)</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restructuring and Employee Severance</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring and employee severance costs during the three and nine months ended March&#160;31, 2023 were primarily related to the implementation of certain enterprise-wide cost-savings measures and the divestiture of the Cordis business. During the three and nine months ended March&#160;31, 2022, restructuring also included facility exit costs related to decreasing our overall office space.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amortization and Other Acquisition-Related Costs</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of acquisition-related intangible assets was $69 million and $78 million for the three months ended March 31, 2023 and 2022, respectively, and $211 million and $235 million for the nine months ended March&#160;31, 2023 and 2022, respectively.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impairments and (Gain)/Loss on Disposal of Assets, Net</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized $863 million of pre-tax non-cash goodwill impairment charges related to our Medical segment during the nine months ended March&#160;31, 2023, and $474&#160;million and $1.8 billion during the three and nine months ended March&#160;31, 2022, respectively, as discussed further in the "Critical Accounting Policies and Sensitive Accounting Estimates" section of this MD&amp;A and </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1d34fc4fc2424fbcb4837cc9f1c0665c_88">Note 4</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements." </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Litigation (Recoveries)/Charges, Net</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized income of $71 million and $95 million during the three and nine months ended March&#160;31, 2023, respectively, primarily related to a reduction of the reserve for the estimated settlement and defense costs for the Cordis OptEase and TrapEase inferior vena cava ("IVC") product liability due to the execution of certain settlement agreements. During the three and nine months ended March&#160;31, 2022, we recognized estimated losses and legal defense costs associated with the IVC filter product liability claims of $24 million and $63 million, respectively. See </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1d34fc4fc2424fbcb4837cc9f1c0665c_100">Note 6</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for additional information.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended March&#160;31, 2023, we recognized income of $93 million due to net proceeds from the settlement of a shareholder derivative litigation matter as described further in the "Legal Proceedings" section.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized income for net recoveries in class action antitrust lawsuits in which we were a class member or plaintiff of $66 million and $17&#160;million during the nine months ended March 31, 2023 and 2022, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended March&#160;31, 2022, we incurred a one-time contingent attorney fee of $18 million related to the finalization of the Settlement Agreement resulting in the settlement of the vast majority of opioid lawsuits filed by state and local governmental entities. Due to the unique nature and significance of the Settlement Agreement, and the one-time, contingent nature of the fee, this related fee was included in litigation (recoveries)/charges, net.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Earnings/(Loss) Before Income Taxes</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the items discussed above, earnings/(loss) before income taxes were impacted by the following:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income)/expense, net</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(5)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">28</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">78</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(32)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on early extinguishment of debt</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td></tr><tr><td colspan="3" style="border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Gain)/loss on sale of equity interest in naviHealth</span></td><td colspan="2" style="border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td><td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.852%"><tr><td style="width:1.0%"></td><td style="width:24.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.450%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.797%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Results of Operations</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Expense, Net</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended&#160;March&#160;31, 2023, interest expense decreased by 26 percent and 32 percent, respectively, primarily due to increased interest income from cash and equivalents.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Loss on Early Extinguishment of Debt</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended&#160;March 31, 2022, we recognized a $10 million loss in connection with the debt redemption as described further in</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"> </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1d34fc4fc2424fbcb4837cc9f1c0665c_97">Note 5</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the &#8220;Notes to Condensed Consolidated Financial Statements.&#8221;</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Provision for Income Taxes</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rate was&#160;36.3 percent and&#160;(916.5) percent during the three months ended&#160;March&#160;31, 2023 and 2022, respectively, and 36.7 percent and (44.4) percent during the nine months ended&#160;March&#160;31, 2023 and 2022, respectively. These tax rates reflect the impact of the tax effects of goodwill impairment charges recognized during the three and nine months ended March&#160;31, 2023 and 2022. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tax Effects of Goodwill Impairment Charges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended March&#160;31, 2023, we recognized cumulative pre-tax goodwill impairment charges of $863 million related to the Medical Unit. The net tax benefit related to these charges is $68 million for fiscal 2023. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless an item is considered discrete because it is unusual or infrequent, the tax impact of the item is included in our estimated annual effective tax rate. When items are recognized through our estimated annual effective tax rate, we apply our estimated annual effective tax rate to the earnings/(loss) before income taxes for the year-to-date period to compute our impact from income taxes for the current quarter and year-to-date period. The tax impacts of discrete items are recognized in their entirety in the period in which they occur.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax effect of the goodwill impairment charges recorded during the nine months ended March&#160;31, 2023 was included in our estimated annual effective tax rate because it was not considered unusual or infrequent, given that we recorded goodwill impairments in prior fiscal years. The impact of the non-deductible goodwill increased the estimated annual effective tax rate for fiscal 2023. Applying the higher tax rate to the pre-tax income for the nine months ended March&#160;31, 2023 resulted in recognizing an incremental interim tax expense of approximately $74&#160;million, which impacted the provision for income taxes in the condensed consolidated statements of earnings/(loss) during the three months ended March&#160;31, 2023 and prepaid expenses and other assets in the condensed consolidated balance sheet at March&#160;31, 2023. The incremental interim tax benefit recognized during the nine months ended March&#160;31, 2023 was $66 million and will reverse in the fourth quarter of fiscal 2023.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i1d34fc4fc2424fbcb4837cc9f1c0665c_22"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.262%"><tr><td style="width:1.0%"></td><td style="width:24.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.757%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.338%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liquidity and Capital Resources</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ff0000;font-family:'Arial Narrow',sans-serif;font-size:17pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently believe that, based on available capital resources (cash on hand and committed credit facilities) and projected operating cash flow, we have adequate capital resources to fund working capital needs; currently anticipated capital expenditures; currently anticipated business growth and expansion; contractual obligations and cash requirements; tax payments; current and projected debt service requirements, upcoming debt maturities, dividends and share repurchases; and known opioid litigation settlement payments. If we decide to engage in one or more acquisitions, depending on the size and timing of such transactions, we may need to access capital markets for additional financing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Cash and Equivalents</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash and equivalents balance was $4.0 billion at March&#160;31, 2023 compared to $4.7 billion at June&#160;30, 2022. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended March&#160;31, 2023, net cash provided by operating activities was $2.0 billion, which includes the impact of our second annual payment of $372&#160;million related to the Settlement Agreement. For additional information, see "Opioid Litigation Settlement Agreement" section below. In addition, we deployed cash of $1.5 billion for share repurchases, $571 million for debt repayments, $399 million for cash dividends and $264 million for capital expenditures. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2023, our cash and equivalents were held in cash depository accounts with major banks or invested in high quality, short-term liquid investments.</span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in working capital, which impact operating cash flow, can vary significantly depending on factors such as the timing of customer payments, inventory purchases, payments to vendors and tax payments in the regular course of business, as well as fluctuating working capital needs driven by customer and product mix. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cash and equivalents balance at March&#160;31, 2023 includes $689 million of cash held by subsidiaries outside of the United States. </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Other Financing Arrangements and Financial Instruments</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Credit Facilities and Commercial Paper</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to cash and equivalents and operating cash flow, other sources of liquidity at March&#160;31, 2023 include a $2.0 billion commercial paper program, backed by a $2.0 billion revolving credit facility. We also have a&#160;$1.0 billion&#160;committed receivables sales facility. During the nine months ended March&#160;31, 2023, under our commercial paper program and our committed receivables program, we had maximum combined total daily amounts outstanding of $445 million and average combined daily amount outstanding of $4 million. At&#160;March&#160;31, 2023, we had no amounts outstanding under our commercial paper program, revolving credit facility, or our committed receivables sales facility. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2023, we extended our revolving credit facility through February 25, 2028. In September 2022, we renewed our committed receivables sales facility program through Cardinal Health Funding, LLC ("CHF") through September 30, 2025. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revolving credit and committed receivables sales facilities require us to maintain a consolidated net leverage ratio of no more than 3.75-to-1. As of March&#160;31, 2023, we were in compliance with this financial covenant. </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Long-Term Debt and Other Short-Term Borrowings</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At&#160;March&#160;31, 2023 and June&#160;30, 2022, we had total long-term obligations, including the current portion and other short-term borrowings, of&#160;$4.7 billion and $5.3 billion, respectively. In March 2023, we repaid $550 million 3.2% Notes due 2023 at maturity with available cash.</span></div></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.262%"><tr><td style="width:1.0%"></td><td style="width:24.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.757%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.338%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liquidity and Capital Resources</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Capital Deployment</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Opioid Litigation Settlement Agreement</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had $5.85&#160;billion accrued at March&#160;31, 2023 related to certain opioid litigation, as further described within </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1d34fc4fc2424fbcb4837cc9f1c0665c_100">Note 6</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements." We expect the majority of the remaining payment amounts to be spread over the next 17 years. The effective date of the Settlement Agreement was April 2, 2022. During the nine months ended March&#160;31, 2023, we made our second annual payment of $372&#160;million under the Settlement Agreement. We expect to make subsequent annual payments under the Settlement Agreement every July for the remainder of the 18-year term of the Settlement Agreement. The amounts of these future payments may differ from the payments that we have already made.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Capital Expenditures</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capital expenditures during the nine months ended March&#160;31, 2023 and 2022 were $264 million and $223 million, respectively. </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Dividends</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On each of May 10, 2022, August 10, 2022, November 8, 2022 and February 10, 2023, our Board of Directors approved a quarterly dividend of $0.4957 per share, or $1.98 per share on an annualized basis, which were paid on July 15, 2022, October 17, 2022, January 15, 2023 and April 15, 2023 to shareholders of record on July 1, 2022, October 3, 2022, January 3, 2023 and April 3, 2023, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Share Repurchases</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended March&#160;31, 2023, we repurchased $1.5&#160;billion of our common shares, in the aggregate, under accelerated share repurchase ("ASR") programs. We funded the ASR programs with available cash. See </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1d34fc4fc2424fbcb4837cc9f1c0665c_112">Note 10</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for additional information.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 4, 2021, our Board of Directors approved a new $3.0&#160;billion share repurchase program, which will expire on December 31, 2024. As of March 31, 2023, we have $1.2 billion authorized for share repurchases remaining under this program.</span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i1d34fc4fc2424fbcb4837cc9f1c0665c_25"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"><tr><td style="width:1.0%"></td><td style="width:24.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.757%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.338%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Items</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#ff0000;font-family:'Arial Narrow',sans-serif;font-size:17pt;font-weight:700;line-height:120%">Other Items</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The MD&amp;A in our 2022 Form 10-K addresses our contractual obligations and cash requirements, as of and for the fiscal year ended June 30, 2022. There have been no subsequent material changes outside the ordinary course of business to those items.</span></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div id="i1d34fc4fc2424fbcb4837cc9f1c0665c_31"></div></div></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><span style="color:#ff0000;font-family:'Arial Narrow',sans-serif;font-size:17pt;font-weight:700;line-height:120%">Critical Accounting Policies and Sensitive Accounting Estimates</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discussion and analysis presented below is a supplemental disclosure to the critical accounting policies and sensitive accounting estimates specified in our consolidated balance sheet at June&#160;30, 2022. This discussion and analysis should be read in conjunction with the Critical Accounting Policies and Sensitive Accounting Estimates included in our 2022 Form 10-K and our Form 10-Q for the quarters ended September 30, 2022 and December 31, 2022.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Critical accounting policies are those accounting policies that (i) can have a significant impact on our financial condition and results of operations and (ii) require the use of complex and subjective estimates based upon past experience and management&#8217;s judgment. Other people applying reasonable judgment to the same facts and circumstances could develop different estimates. Because estimates are inherently uncertain, actual results may differ, including due to the risks discussed in "Risk Factors" and other risks discussed in our 2022 Form 10-K and our other filings with the SEC since June 30, 2022.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchased goodwill is tested for impairment annually or when indicators of impairment exist. Goodwill impairment testing involves a comparison of the estimated fair value of reporting units to the respective carrying amount, which may be performed utilizing either a qualitative or quantitative assessment. Qualitative factors are first assessed to determine if it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If it is determined that it is more likely than not that the fair value does not exceed the carrying amount, then a quantitative test is performed. The quantitative goodwill impairment test involves a comparison of the estimated fair value of the reporting unit to the respective carrying amount. A reporting unit is defined as an operating segment or one level below an operating segment (also known as a component).</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our reporting units are: Pharmaceutical operating segment (excluding our Nuclear and Precision Health Solutions division); Nuclear and Precision Health Solutions division; Medical operating segment (excluding our Cardinal Health at-Home Solutions division) (&#8220;Medical Unit&#8221;); and Cardinal Health at-Home Solutions division. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill impairment testing involves judgment, including the identification of reporting units, qualitative evaluation of events and circumstances to determine if it is more likely than not that an impairment exists, and, if necessary, the estimation of the fair value of the applicable reporting unit. Our qualitative evaluation considers the weight of evidence and significance of all identified events and circumstances and most relevant drivers of fair value, both positive and negative, in determining whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount.</span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Medical Unit Goodwill </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to changes in our long-term financial plan assumptions made during the three months ended March&#160;31, 2023, we elected to bypass the qualitative assessment and perform quantitative goodwill impairment testing for the Medical Unit. We concluded that there was no impairment of goodwill at March&#160;31, 2023, as the estimated fair value of the Medical Unit exceeded its carrying value by approximately 4 percent, primarily driven by a lower discount rate as described below.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We performed quantitative goodwill impairment testing for the Medical Unit at December 31, 2022 and September 30, 2022, which resulted in pre-tax goodwill impairment charges of $709 million and $154 million, respectively. The impairment charge recognized in the second quarter was driven by certain reductions in our long-term financial plan assumptions, and the impairment charge recognized in the first quarter was driven by an increase in the discount rate primarily due to an increase in the risk-free interest rate. The cumulative pre-tax goodwill impairment charges of $863 million were recognized in impairments and (gain)/loss on disposal of assets, net in our condensed consolidated statements of earnings/(loss) for the nine months ended March&#160;31, 2023. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our determinations of the estimated fair value of the Medical Unit at March&#160;31, 2023, December 31, 2022 and September 30, 2022 were based on a combination of the income-based approach (using a terminal growth rate of 2 percent), and the market-based approaches. For the income-based approach, we used discount rates of 10 percent, 10.5 percent and 10.5 percent for each quarter, respectively. Additionally, we assigned a weighting of 80 percent to the discounted cash flow method, 10 percent to the guideline public company method, and 10 percent to the guideline transaction method. The decrease in the discount rate for the interim testing performed at March&#160;31, 2023 was primarily due to a decrease in the risk-free interest rate.</span></div></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.820%"><tr><td style="width:1.0%"></td><td style="width:24.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Items</span></div></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we consider the assumptions used in our determination of the estimated fair value of the Medical Unit to be reasonable and appropriate, they are complex and subjective, and additional adverse changes in one key assumption or a combination of key assumptions during fiscal 2023 may significantly affect future estimates. These assumptions include, among other things, a failure to meet expected earnings or other financial plans, including the execution of key initiatives related to optimizing and growing sales of Cardinal Health branded medical products, increasing growth in certain strategic divisions within our Medical segment, and driving simplification efforts and cost optimization projects, or unanticipated events and circumstances, such as changes in assumptions about the duration and magnitude of increased supply chain and commodities costs and our efforts to mitigate such impact, including price increases or surcharges; further disruptions in the supply chain; manufacturing cost inefficiencies resulting from lower than anticipated sales volume; estimated demand and selling prices for PPE; an increase in the discount rate; a decrease in the terminal growth rate; increases in tax rates; or a significant change in industry or economic trends. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adverse changes in key assumptions may result in a decline in fair value below the carrying value in the future and therefore, an impairment of our Medical Unit goodwill in future periods, which could adversely affect our results of operations. For example, if we were to increase the discount rate by a hypothetical 0.5 percent to 10.5 percent or decrease the terminal growth rate by a hypothetical 1.7 percent to 0.3 percent, the carrying value would have exceeded the fair value of the Medical Unit by approximately 1 percent.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2022 and December 31, 2021, we performed quantitative goodwill impairment testing for the Medical Unit. This quantitative testing resulted in the carrying amount of the Medical Unit exceeding the fair value, resulting in pre-tax impairment charges of $474 million and $1.3 billion recorded during the three months ended March 31, 2022 and December 31, 2021, respectively. Refer to our 2022 Form 10-K for additional detail.</span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i1d34fc4fc2424fbcb4837cc9f1c0665c_34"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.076%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.754%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Explanation and Reconciliation of Non-GAAP Financial Measures</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#ff0000;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Explanation and Reconciliation of Non-GAAP Financial Measures</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The "Overview of Consolidated Results" section within MD&amp;A in this Form 10-Q contains financial measures that are not calculated in accordance with GAAP. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to analyzing our business based on financial information prepared in accordance with GAAP, we use these non-GAAP financial measures internally to evaluate our performance, engage in financial and operational planning, and determine incentive compensation because we believe that these measures provide additional perspective on and, in some circumstances are more closely correlated to, the performance of our underlying, ongoing business. We provide these non-GAAP financial measures to investors as supplemental metrics to assist readers in assessing the effects of items and events on our financial and operating results on a year-over-year basis and in comparing our performance to that of our competitors. However, the non-GAAP financial measures that we use may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies. The non-GAAP financial measures disclosed by us should not be considered a substitute for, or superior to, financial measures calculated in accordance with GAAP, and the financial results calculated in accordance with GAAP and reconciliations to those financial statements set forth below should be carefully evaluated. </span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Exclusions from Non-GAAP Financial Measures</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management believes it is useful to exclude the following items from the non-GAAP measures presented in this report for its own and for investors&#8217; assessment of the business for the reasons identified below:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt;text-decoration:underline">LIFO charges and credits</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are excluded because the factors that drive last-in first-out ("LIFO") inventory charges or credits, such as pharmaceutical manufacturer price appreciation or deflation and year-end inventory levels (which can be meaningfully influenced by customer buying behavior immediately preceding our fiscal year-end), are largely out of our control and cannot be accurately predicted. The exclusion of LIFO charges and credits from non-GAAP metrics facilitates comparison of our current financial results to our historical financial results and to our peer group companies&#8217; financial results. We did not recognize any LIFO charges or credits during the periods presented. </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt;text-decoration:underline">Surgical gown recall costs or income</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> includes inventory write-offs and certain remediation and supply disruption costs, net of related insurance recoveries, arising from the January 2020 recall of select Association for the Advancement of Medical Instrumentation ("AAMI") Level 3 surgical gowns and voluntary field actions (a recall of some packs and a corrective action allowing overlabeling of other packs) for Presource Procedure Packs containing affected gowns. Income from surgical gown recall costs represents insurance recoveries of these certain costs. We have excluded these costs from our non-GAAP metrics to allow investors to better understand the underlying operating results of the business and to facilitate comparison of our current financial results to our historical financial results and to our peer group companies&#8217; financial results.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt;text-decoration:underline">State opioid assessments related to prior fiscal years</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is the portion of state assessments for prescription opioid medications that were sold or distributed in periods prior to the period in which the expense is incurred. This portion is excluded from non-GAAP financial measures because it is retrospectively applied to sales in prior fiscal years and inclusion would obscure analysis of the current fiscal year results of our underlying, ongoing business. Additionally, while states' laws may require us to make payments on an ongoing basis, the portion of the assessment related to sales in prior periods are contemplated to be one-time, nonrecurring items. Income from state opioid assessments related to prior fiscal years represents reversals of accruals due to changes in estimates or when the underlying assessments were invalidated by a Court or reimbursed by manufacturers.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt;text-decoration:underline">Shareholder cooperation agreement costs</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> includes costs such as legal, consulting and other expenses incurred in relation to the agreement (the "Cooperation Agreement") entered into among Elliott Associates, L.P., Elliott International, L.P. (together, "Elliott") and Cardinal Health, including costs incurred to negotiate and finalize the Cooperation Agreement and costs incurred by the new Business Review Committee of the Board of Directors, which was formed under this Cooperation Agreement. We have excluded these costs from our non-GAAP metrics because they do not occur in or reflect the ordinary course of our ongoing business operations and may obscure analysis of trends and financial performance. </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt;text-decoration:underline">Restructuring and employee severance costs</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are excluded because they are not part of the ongoing operations of our underlying business. </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt;text-decoration:underline">Amortization and other acquisition-related costs</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which include transaction costs, integration costs, and changes in the fair value of contingent consideration obligations, are excluded because they are not part of the ongoing operations of our underlying business and to facilitate comparison of our current financial results to our historical financial results and to our peer group </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.076%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.754%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Explanation and Reconciliation of Non-GAAP Financial Measures</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">companies' financial results. Additionally, costs for amortization of acquisition-related intangible assets are non-cash amounts, which are variable in amount and frequency and are significantly impacted by the timing and size of acquisitions, so their exclusion facilitates comparison of historical, current and forecasted financial results. We also exclude other acquisition-related costs, which are directly related to an acquisition but do not meet the criteria to be recognized on the acquired entity&#8217;s initial balance sheet as part of the purchase price allocation. These costs are also significantly impacted by the timing, complexity and size of acquisitions. </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt;text-decoration:underline">Impairments and gain or loss on disposal of assets, net</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;are excluded because they do not occur in or reflect the ordinary course of our ongoing business operations and are inherently unpredictable in timing and amount, and in the case of impairments, are non-cash amounts, so their exclusion facilitates comparison of historical, current and forecasted financial results. </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.13pt;text-decoration:underline">Litigation recoveries or charges, net</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> are excluded because they often relate to events that may have occurred in prior or multiple periods, do not occur in or reflect the ordinary course of our business and are inherently unpredictable in timing and amount. During fiscal 2022, we incurred a one-time contingent attorneys' fee of $18 million related to the finalization of the settlement agreement (the &#8220;Settlement Agreement&#8221;) resulting in the settlement of the vast majority of opioid lawsuits filed by state and local governmental entities. Due to the unique nature and significance of the Settlement Agreement, and the one-time, contingent nature of the fee, this fee was included in litigation recoveries or charges, net. Additionally, during fiscal 2022 our Pharmaceutical segment profit was positively impacted by a $16 million judgment for lost profits. This judgment was the result of an ordinary course intellectual property rights claim and, therefore, is not adjusted in calculating the litigation recoveries or charges, net adjustment. During fiscal 2021, we incurred a tax benefit related to a carryback of a net operating loss. Some pre-tax amounts, which contributed to this loss, relate to litigation charges. As a result, we allocated substantially all of the tax benefit to litigation charges.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt;text-decoration:underline">Loss on early extinguishment of debt</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is excluded because it does not typically occur in the normal course of business and may obscure analysis of trends and financial performance. Additionally, the amount and frequency of this type of charge is not consistent and is significantly impacted by the timing and size of debt extinguishment transactions. </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt;text-decoration:underline">(Gain)/Loss on sale of equity interest in naviHealth</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was incurred in connection with the sale of our remaining equity interest in naviHealth in fiscal 2020. The equity interest was retained in connection with the initial sale of our majority interest in naviHealth during fiscal 2019. We exclude this significant gain because gains or losses on investments of this magnitude do not typically occur in the normal course of business and are similar in nature to a gain or loss from a divestiture of a majority interest, which we exclude from non-GAAP results. The gain on the initial sale of our majority interest in naviHealth in fiscal 2019 was also excluded from our non-GAAP measures.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax effect for each of the items listed above is determined using the tax rate and other tax attributes applicable to the item and the jurisdiction(s) in which the item is recorded. The gross, tax and net impact of each item are presented with our GAAP to non-GAAP reconciliations. </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Definitions</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Growth rate calculation:</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> growth rates in this report are determined by dividing the difference between current-period results and prior-period results by prior-period results. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-GAAP operating earnings</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: operating earnings/(loss) excluding (1) LIFO charges/(credits), (2) surgical gown recall costs/(income), (3) state opioid assessment related to prior fiscal years, (4) shareholder cooperation agreement costs, (5) restructuring and employee severance, (6) amortization and other acquisition-related costs, (7) impairments and (gain)/loss on disposal of assets, net and (8) litigation (recoveries)/charges, net. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-GAAP earnings before income taxes</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: earnings/(loss) before income taxes excluding (1) LIFO charges/(credits), (2) surgical gown recall costs/(income), (3) state opioid assessment related to prior fiscal years, (4) shareholder cooperation agreement costs, (5) restructuring and employee severance, (6) amortization and other acquisition-related costs, (7) impairments and (gain)/loss on disposal of assets, net, (8) litigation (recoveries)/charges, net, (9) loss on early extinguishment of debt and (10) (gain)/loss on sale of equity interest in naviHealth. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-GAAP net earnings attributable to Cardinal Health, Inc.</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: ne</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">t earnings/(loss)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> attributable to Cardinal Health, Inc. excluding (1) LIFO charges/(credits), (2) surgical gown recall costs/(income), (3) state opioid assessment related to prior fiscal years, (4) shareholder cooperation agreement costs, (5) restructuring and employee severance, (6) amortization and other acquisition-related costs, (7) impairments and (gain)/loss on disposal of assets, net, (8) litigation (recoveries)/charges, net, (9) loss on early extinguishment of debt and (10) (gain)/loss on sale of equity interest in naviHealth, each net of tax.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.076%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.754%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Explanation and Reconciliation of Non-GAAP Financial Measures</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-GAAP effective tax rate: </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">provision for income taxes adjusted for the tax impacts of (1) LIFO charges/(credits), (2) surgical gown recall costs/(income), (3) state opioid assessment related to prior fiscal years, (4) shareholder cooperation agreement costs, (5) restructuring and employee severance, (6) amortization and other acquisition-related costs, (7) impairments and (gain)/loss on disposal of assets, net, (8) litigation (recoveries)/charges, net, (9) loss on early extinguishment of debt and (10) (gain)/loss on sale of equity interest in naviHealth divided by (earnings before income taxes adjusted for the ten items above). </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-GAAP diluted earnings per share attributable to Cardinal Health, Inc.</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: non-GAAP net earnings attributable to Cardinal Health, Inc. divided by diluted weighted-average shares outstanding. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i1d34fc4fc2424fbcb4837cc9f1c0665c_37"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.076%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.754%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Explanation and Reconciliation of Non-GAAP Financial Measures</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">GAAP to Non-GAAP Reconciliation</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:6.638%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.679%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.019%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.042%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.679%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.298%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.452%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per common share amounts)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Earnings/(Loss)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Earnings Growth Rate</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Earnings/(Loss) Before Income Taxes</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Provision for Income Taxes</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Earnings/(Loss)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">1</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Earnings</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> Growth Rate</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Diluted EPS</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">1,2</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Diluted EPS</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> Growth Rate</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="24" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">GAAP</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">572</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">544</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">197</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">345</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1.34</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring and employee severance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.05&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization and other acquisition-related costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.21&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairments and (gain)/loss on disposal of assets, net </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">3</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(69)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation (recoveries)/charges, net </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.21)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-GAAP</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">606</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">578</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">129</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">447</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1.74</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">20</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="24" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended March 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GAAP</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(97)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N.M.</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(137)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,253&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,391)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N.M.</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.05)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N.M.</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring and employee severance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.08&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization and other acquisition-related costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.21&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairments and (gain)/loss on disposal of assets, net </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">3</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">471&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">471&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,189)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,660&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.03&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation (recoveries)/charges, net </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">4</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.18&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Gain)/Loss on sale of equity interest in naviHealth</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-GAAP</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">545&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">504&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">402&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.45&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="24" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">GAAP</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">590</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">517</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">189</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">325</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1.23</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State opioid assessment related to prior fiscal years</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.02&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shareholder cooperation agreement costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.02)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring and employee severance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization and other acquisition-related costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.61&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairments and (gain)/loss on disposal of assets, net </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">3</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">883&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">883&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">745&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation (recoveries)/charges, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(256)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(256)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(98)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(158)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.60)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-GAAP</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,497</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(3)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,424</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">299</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,122</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4.24</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="24" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended March 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GAAP</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(632)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N.M.</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(741)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,071)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N.M.</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.82)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N.M.</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Surgical gown recall costs/(income)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring and employee severance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.15&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization and other acquisition-related costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairments and (gain)/loss on disposal of assets, net </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">3</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,764&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,764&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(119)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,883&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.71&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation (recoveries)/charges, net </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">4,5</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on early extinguishment of debt</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.03&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Gain)/Loss on sale of equity interest in naviHealth</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-GAAP</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,540&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,438&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,131&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.01&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.076%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.754%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Explanation and Reconciliation of Non-GAAP Financial Measures</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">1&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Attributable to Cardinal Health, Inc.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">2&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the three and nine months ended March 31, 2022, GAAP diluted EPS and the EPS impact from the GAAP to non-GAAP per share reconciling items are calculated using a weighted average of 275 million and 281 million common shares, respectively, which excludes potentially dilutive securities from the denominator due to their anti-dilutive effects resulting from our GAAP net loss for the periods. For the three and nine months ended March 31, 2022, non-GAAP diluted EPS is calculated using a weighted average of 277 million and 282 million common shares, respectively, which includes potentially dilutive shares.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">3&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Impairments and (gain)/loss on disposal of assets, net included pre-tax goodwill impairment charges related to the Medical segment of $863 million recorded during the nine months ended March 31, 2023. For fiscal 2023, the estimated net tax benefit related to the impairments is $68 million and is included in the annual effective tax rate. As a result, the amount of tax expense recognized increased approximately by an incremental $74 million during the three months ended March 31, 2023. The incremental interim tax benefit recognized during the nine months ended March 31, 2023 was $66 million and will reverse in the fourth quarter of the fiscal year.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During the three and nine months ended March 31, 2022, impairments and (gain)/loss on disposal of assets, net included pre-tax goodwill impairment charges of $474 million and $1.8 billion, respectively, related to the Medical segment. For fiscal 2022, the estimated net tax benefit related to the impairment was $126 million and was included in the annual effective tax rate. As a result, the amount of tax expense recognized during the three and nine months ended March 31, 2022 increased approximately by an incremental $1.2 billion and $180 million, respectively, and lowered the provision for income taxes during the fourth quarter of fiscal 2022 by approximately $180 million.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">4&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Litigation (recoveries)/charges, net includes a one-time contingent attorney fee of $18 million recorded during the three and nine months ended March 31, 2022 related to the finalization of the settlement agreement (the "Settlement Agreement") resulting in the settlement of the vast majority of opioid lawsuits filed by state and local governmental entities. Due to the unique nature and significance of the Settlement Agreement, and the one-time, contingent nature of the fee, this related fee was included in litigation (recoveries)/charges, net. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">5&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Litigation (recoveries)/charges, net for the nine months ended March 31, 2022 does not include a $16 million judgement for lost profits related to an ordinary course intellectual property claim, which positively impacted Pharmaceutical segment profit.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The sum of the components and certain computations may reflect rounding adjustments.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We apply varying tax rates depending on the item's nature and tax jurisdiction where it is incurred.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i1d34fc4fc2424fbcb4837cc9f1c0665c_40"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:74.158%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="text-align:justify"><span><br/></span></div><div id="i1d34fc4fc2424fbcb4837cc9f1c0665c_43"></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes in the quantitative and qualitative market risk disclosures included in our&#160;2022&#160;Form 10-K since the end of fiscal&#160;2022&#160;through&#160;March&#160;31, 2023.</span></div><div id="i1d34fc4fc2424fbcb4837cc9f1c0665c_46"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Controls and Procedures</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluated, with the participation of our principal executive officer and principal financial officer, the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934 (the "Exchange Act")) as of March&#160;31, 2023. Based on this evaluation, our principal executive officer and principal financial officer have concluded that as of March&#160;31, 2023, our disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed in our reports under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC rules and forms and that such information is accumulated and communicated to management as appropriate to allow timely decisions regarding required disclosure. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting during the quarter ended March&#160;31, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i1d34fc4fc2424fbcb4837cc9f1c0665c_49"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.026%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.073%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.601%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#ff0000;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the proceeding described below, the legal proceedings described in </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1d34fc4fc2424fbcb4837cc9f1c0665c_100">Note 6</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" are incorporated in this "Legal Proceedings" section by reference.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Between June 2019 and January 2020, three purported shareholders filed actions on behalf of Cardinal Health, Inc. in the U.S. District Court for the Southern District of Ohio against certain current and former members of our Board of Directors alleging that the defendants breached their fiduciary duties by failing to effectively monitor Cardinal Health's distribution of controlled substances and approving certain payments of executive compensation. In January, 2020, the court consolidated these derivative cases under the caption In re Cardinal Health, Inc. Derivative Litigation and in March 2020, plaintiffs filed an amended complaint. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, the parties reached an agreement in principle to settle this matter and in October 2022, the court entered an order approving the settlement and dismissing the case. This settlement does not include any admission of liability. Under the settlement, in December 2022, Cardinal Health's director and officer liability insurance carriers, on behalf of the defendants, paid Cardinal Health $124 million, less approximately $31 million in attorneys' fees and expenses awarded by the court to plaintiffs' counsel. </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i1d34fc4fc2424fbcb4837cc9f1c0665c_52"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:74.158%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Risk Factors</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should carefully consider the information in this Form 10-Q, including the Risk Factors below, and the risk factors discussed in "Risk Factors" and other risks discussed in our 2022 Form 10-K, our Form 10-Q for the quarter ended December 31, 2022 and September 30, 2022, and our other filings with the SEC since June&#160;30, 2022. These risks could materially and adversely affect our results of operations, financial condition, liquidity, and cash flows. Our business also could be affected by risks that we are not presently aware of or that we currently consider immaterial to our operations.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our business could be affected by activist shareholders.</span></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, we entered into a Cooperation Agreement (the "Cooperation Agreement") with Elliott Associates, L.P. and Elliott International, L.P. (together, "Elliott") under which our Board of Directors, among other things, (1) appointed four new independent directors, including a representative from Elliott , and (2) formed an advisory Business Review Committee of the Board, which is tasked with undertaking a comprehensive review of our strategy, portfolio, capital-allocation framework and operations. In May 2023, we extended the term of the Cooperation Agreement until the later of July 15, 2024 or until Elliott's representative ceases to serve on, or resigns from, our Board of Directors. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Cooperation Agreement may create unintended consequences, such as creating uncertainty about our management, operations or future strategic direction, which could result in the loss of future business opportunities or negatively impact our ability to attract and retain qualified talent. Additionally, implementing any actions recommended by the Business Review Committee and the Board may be costly and time-consuming, may be disruptive to our ongoing business operations and may ultimately be unsuccessful. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that activist shareholders may, among other things, attempt to effect additional changes and exert influence over our Board of Directors and management or initiate a proxy contest, which may disrupt our operations by diverting the attention of management and the Board and be costly and time-consuming. Any such proxy contests, actions or requests, or the mere public presence of activist shareholders, may cause the market price for our shares to experience volatility, which could be significant.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We could be subject to adverse changes in the tax laws or additional challenges to our tax positions</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a large multinational corporation with operations in the United States and many foreign countries. As a result, we are subject to the tax laws of many jurisdictions.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, proposals are made in the United States and other jurisdictions in which we operate that could adversely affect our tax positions, effective tax rate or tax payments. Specific initiatives that may impact us include possible increases in U.S. or foreign corporate income tax rates or other changes in tax law to raise revenue, the repeal of the LIFO (last-in, first-out) method of inventory accounting for income tax purposes, the establishment or increase in taxation at the U.S. state level on the basis of gross revenues, recommendations of the base erosion and profit shifting project undertaken by the Organization for Economic Cooperation and Development and the European Commission&#8217;s investigation </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">into illegal state aid. In August 2022, the U.S. federal government enacted the Inflation Reduction Act, which imposed a 15 percent corporate minimum tax on certain large corporations and a 1 percent tax on share repurchases after December 31, 2022. These provisions may adversely impact our financial position and results of operations. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in connection with the accruals taken in connection with opioid-related lawsuits in fiscal years 2021 and 2020, we recorded net tax benefits of $228 million and $488 million, respectively, reflecting our current assessment of the estimated future deductibility of the amount that may be paid. We have made reasonable estimates and recorded amounts based on management's judgment and our current understanding of the U.S. Tax Cuts and Jobs Act ("Tax Act"); however, these estimates require significant judgment, and it is possible that they could be subject to challenges by the U.S. Internal Revenue Service ("IRS").</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. tax law governing deductibility was changed by the Tax Act. The taxing authorities could challenge our interpretation of the Tax Act or the estimates and assumptions used to assess the future deductibility of these benefits, or tax law could change again. We also regularly review these estimates and assumptions from time to time and adjust our accruals based on our review, resulting in changes in our tax provision/(benefit). The actual amount of tax benefit related to uncertain tax positions may differ materially from these estimates. See </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1d34fc4fc2424fbcb4837cc9f1c0665c_103">Note 7</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for more information regarding these matters. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In fiscal year 2021, our provision for income taxes reflected a $424 million benefit from the tax benefits of a self-insurance pre-tax net operating loss carryback under the Coronavirus Aid, Relief and Economic Security (&#8220;CARES&#8221;) Act. Also, as a result of this net operating loss carryback, we received a U.S. federal income tax refund of $966 million. In connection with this net operating loss carryback, certain industry participants, including us, received a letter from the U.S. House of Representatives&#8217; Committee on Oversight and Reform questioning, among other things, our plans to take tax deductions for opioid-related losses, including our use of the net operating loss carryback provisions under the CARES Act and deductibility under the Tax Act. We responded to the letter. It is possible that the IRS could challenge our tax position with respect to this self-insurance loss. If these initiatives are successful, our effective tax rate could be adversely impacted. Additionally, laws governing insurance coverage vary by state and </span></div></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:74.158%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">some state courts have interpreted laws and insurance policies in ways that may impact our self-insurance loss, which could negatively impact our financial position. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions and various foreign jurisdictions. Tax laws are complex and subject to varying interpretations. With few exceptions, we are subject to audit by taxing authorities for fiscal years 2015 through the current fiscal year. Proposed adjustments in ongoing audits may adversely affect our effective tax rate or tax payments.</span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">24</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i1d34fc4fc2424fbcb4837cc9f1c0665c_55"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:74.158%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Issuer Purchases of Equity Securities</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:14.822%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.691%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.370%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.691%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.694%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number<br/>of Shares<br/>Purchased&#160;(1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average Price Paid&#160;per Share (2,3)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number of Shares<br/>Purchased<br/>as Part of Publicly Announced Programs&#160;(2,3,4)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Approximate<br/>Dollar Value of<br/>Shares That May<br/>Yet be Purchased<br/>Under the Program&#160;(4)<br/>(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 2023</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">614,596&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81.40&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">614,248&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,493&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">February 2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,596,570&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77.03&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,596,391&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,293&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 2023</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">639,115&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78.25&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">638,930&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,243&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,850,281</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">77.93</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,849,569</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,243</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Reflects 348, 179 and 185 common shares purchased in January, February, and March 2023, respectively, through a rabbi trust as investments of participants in our Deferred Compensation Plan.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">On February 6, 2023, we entered into an accelerated share repurchase ("ASR") program to purchase common shares for an aggregate purchase price of $250&#160;million and received an initial delivery of 2.6&#160;million common shares using a reference price of $77.03. The ASR program concluded on February 28, 2023 at a volume weighted average price per common share of $77.27 resulting in a final delivery of 0.6 million common shares. See </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1d34fc4fc2424fbcb4837cc9f1c0665c_112">Note 10</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for additional information. </span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">On November 17, 2022, we entered into an ASR program to purchase common shares for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="i7ad6d93eac9d48ab9fec302dd4e88915_D20221001-20221231" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y181NS9mcmFnOjQ1ZjcxODJmYWJiMzRjZWVhMzI0ZTE0OGIxMTEwY2RlL3RleHRyZWdpb246NDVmNzE4MmZhYmIzNGNlZWEzMjRlMTQ4YjExMTBjZGVfNDI1_64d5790a-91d4-4a60-b5e4-f63e7f9964a6">250</ix:nonFraction> million and received an initial delivery of <ix:nonFraction unitRef="shares" contextRef="i1023e41d044c49ebb5274f9857d52b5f_D20221001-20221231" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y181NS9mcmFnOjQ1ZjcxODJmYWJiMzRjZWVhMzI0ZTE0OGIxMTEwY2RlL3RleHRyZWdpb246NDVmNzE4MmZhYmIzNGNlZWEzMjRlMTQ4YjExMTBjZGVfNDY0_befe0c17-5788-4e83-82ff-6be63c036597">2.6</ix:nonFraction> million common shares using a reference price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i1023e41d044c49ebb5274f9857d52b5f_D20221001-20221231" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y181NS9mcmFnOjQ1ZjcxODJmYWJiMzRjZWVhMzI0ZTE0OGIxMTEwY2RlL3RleHRyZWdpb246NDVmNzE4MmZhYmIzNGNlZWEzMjRlMTQ4YjExMTBjZGVfNTA4_3c4d1965-d6e1-4226-9f7d-b8f4af72583c">76.58</ix:nonFraction>. The ASR program concluded on January&#160;13, 2023 at a volume weighted average price per common share of $<ix:nonFraction unitRef="usdPerShare" contextRef="i00b750b6e2374500a1e8b10702e44d3a_D20221002-20230113" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y181NS9mcmFnOjQ1ZjcxODJmYWJiMzRjZWVhMzI0ZTE0OGIxMTEwY2RlL3RleHRyZWdpb246NDVmNzE4MmZhYmIzNGNlZWEzMjRlMTQ4YjExMTBjZGVfNTk1_740095a5-5465-4e5d-95dc-6a5c6f2536dc">77.50</ix:nonFraction> resulting in a final delivery of <ix:nonFraction unitRef="shares" contextRef="i612fc934cf6040028ee1d4ea22c335da_D20230113-20230113" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y181NS9mcmFnOjQ1ZjcxODJmYWJiMzRjZWVhMzI0ZTE0OGIxMTEwY2RlL3RleHRyZWdpb246NDVmNzE4MmZhYmIzNGNlZWEzMjRlMTQ4YjExMTBjZGVfNjMx_1499679e-59cb-421c-8dce-ef1d9f4cad63">0.6</ix:nonFraction> million common shares. See </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1d34fc4fc2424fbcb4837cc9f1c0665c_112">Note 10</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for additional information.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">On November 4, 2021, our Board of Directors approved a new $3.0&#160;billion share repurchase program, which will expire on December 31, 2024. As of March 31, 2023, we have $1.2 billion authorized for share repurchases remaining under this program.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">25</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i1d34fc4fc2424fbcb4837cc9f1c0665c_58"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span><br/></span></div><div id="i1d34fc4fc2424fbcb4837cc9f1c0665c_61"></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Earnings/(Loss)</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:51.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.226%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.226%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.226%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.228%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per common share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMi0xLTEtMS0yODY5NDQ_f465ea44-24cc-4426-a660-6685dfb42dc7">50,487</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMi0zLTEtMS0yODY5NDQ_2e44fb3d-23dd-43ab-bd72-5376ef3d46a2">44,836</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMi01LTEtMS0yODY5NDQ_732d42d3-1bbe-4bb4-900c-1a3a3afa04ff">151,559</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMi03LTEtMS0yODY5NDQ_6bdddb52-0254-4c48-bbf8-dcaae385fe82">134,261</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMy0xLTEtMS0yODY5NDQ_559878a9-3af6-47b0-ad2e-3b825471479a">48,702</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMy0zLTEtMS0yODY5NDQ_69c4c24e-981c-43d0-b3c8-56c3d6d99c7d">43,154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMy01LTEtMS0yODY5NDQ_6b9e8c90-71be-427c-836a-62ee4960b106">146,497</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMy03LTEtMS0yODY5NDQ_f373efa4-f8b6-4199-afdb-95a8ccc4fc17">129,321</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross margin</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331" decimals="-6" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfNC0xLTEtMS0yODY5NDQ_75abda9f-89cf-485a-87b1-df0915f53db9">1,785</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331" decimals="-6" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfNC0zLTEtMS0yODY5NDQ_5d1cd0ee-2360-43af-a9c1-b63c778b315c">1,682</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" decimals="-6" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfNC01LTEtMS0yODY5NDQ_90475e66-c866-47aa-b470-f18b2d3ed37c">5,062</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331" decimals="-6" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfNC03LTEtMS0yODY5NDQ_ee45a296-cff8-4301-b24f-1d38d36bd136">4,940</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distribution, selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfNy0xLTEtMS0yODY5NDQ_ef93991d-3809-475f-b415-4a3299f87b20">1,179</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfNy0zLTEtMS0yODY5NDQ_3135bffa-b981-43fe-949d-a433473ba3ad">1,137</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfNy01LTEtMS0yODY5NDQ_94860b56-81ab-46da-9889-211d2fa06fc5">3,567</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfNy03LTEtMS0yODY5NDQ_b57126be-9deb-46f3-b0c5-8fb2c7a6bb32">3,402</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring and employee severance</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfOC0xLTEtMS0yODY5NDQ_d5c2b286-8fb1-4eb0-89b8-00207baad552">16</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfOC0zLTEtMS0yODY5NDQ_41b347f7-8733-4c26-83af-c4b5a66c0427">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfOC01LTEtMS0yODY5NDQ_2d06f000-5905-41d7-aa40-697a0033ccb1">62</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfOC03LTEtMS0yODY5NDQ_76599c3e-f601-4d8a-933e-a34d34e66f22">56</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization and other acquisition-related costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331" decimals="-6" name="cah:Amortizationandotheracquisitionrelatedcosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfOS0xLTEtMS0yODY5NDQ_c93cd332-a210-4026-8201-cfe93c90e8e2">74</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331" decimals="-6" name="cah:Amortizationandotheracquisitionrelatedcosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfOS0zLTEtMS0yODY5NDQ_6d5862b4-d1af-4163-89d6-ecd177ab4404">79</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" decimals="-6" name="cah:Amortizationandotheracquisitionrelatedcosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfOS01LTEtMS0yODY5NDQ_13c4a2c4-fc81-4a3c-8afb-1c0ad1236ea0">216</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331" decimals="-6" name="cah:Amortizationandotheracquisitionrelatedcosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfOS03LTEtMS0yODY5NDQ_918989ad-a24e-4575-a046-9d7fc5c17974">237</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairments and (gain)/loss on disposal of assets, net</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMTAtMS0xLTEtMjg2OTQ0_5b5865e7-17d3-494e-a26f-248d7d4c877f">20</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMTAtMy0xLTEtMjg2OTQ0_d602e7d9-ddae-4a2f-ae35-be0d22fdb36f">471</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" decimals="-6" sign="-" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMTAtNS0xLTEtMjg2OTQ0_b33f54a0-e28f-4d84-800e-da7b3dec1734">883</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331" decimals="-6" sign="-" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMTAtNy0xLTEtMjg2OTQ0_115852db-d87a-4857-a6f4-da80ad813355">1,764</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation (recoveries)/charges, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331" decimals="-6" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMTEtMS0xLTEtMjg2OTQ0_019bf8f6-add2-4b47-b030-ee6d17785a08">76</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMTEtMy0xLTEtMjg2OTQ0_06686299-1d87-4c11-8514-99f879d80051">61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" decimals="-6" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMTEtNS0xLTEtMjg2OTQ0_9cd62cf1-3ded-4c41-b09b-5d7b1070f8bc">256</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331" decimals="-6" sign="-" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMTEtNy0xLTEtMjg2OTQ0_faed8f1e-bfda-4ff1-8541-a81dffabb212">113</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating earnings/(loss)</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMTItMS0xLTEtMjg2OTQ0_3c8574e7-93d5-4516-b2e3-1d847849dea4">572</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMTItMy0xLTEtMjg2OTQ0_d5ff7a68-59cb-4bc5-8017-f3d7ab6f4e4a">97</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMTItNS0xLTEtMjg2OTQ0_a9409bea-b445-4cef-ac64-8527bbb3e0de">590</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMTItNy0xLTEtMjg2OTQ0_b35c65f1-6696-4ba1-8b6a-ce08817e8643">632</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income)/expense, net</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMTQtMS0xLTEtMjg2OTQ0_4c48ffb9-7c94-4903-b4af-47e2175dc87e">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMTQtMy0xLTEtMjg2OTQ0_276abf10-8192-4820-b22a-5c4cae833c8a">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMTQtNS0xLTEtMjg2OTQ0_fd4f28f3-7e63-49eb-a96e-e967987215cf">5</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMTQtNy0xLTEtMjg2OTQ0_29d2400d-1efd-4f89-a27f-5d5e5c792188">14</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMTUtMS0xLTEtMjg2OTQ0_583bb06a-90d3-4669-b322-63969015ded9">28</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMTUtMy0xLTEtMjg2OTQ0_65e58008-4e8a-4681-b3bc-572e92de0d54">38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMTUtNS0xLTEtMjg2OTQ0_23a6c153-b429-4dfe-804f-6f0776104f45">78</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMTUtNy0xLTEtMjg2OTQ0_75b9d5a2-12e4-4069-a1ad-87d782d26564">115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on early extinguishment of debt</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331" decimals="-6" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMTYtMS0xLTEtMjg2OTQ0_1342af4a-6cce-495b-81ad-95ee7da25dec">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331" decimals="-6" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMTYtMy0xLTEtMjg2OTQ0_ca2de022-169c-44cd-b110-81331b60fbe4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" decimals="-6" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMTYtNS0xLTEtMjg2OTQ0_b6e8f42a-77ed-4f3d-8b4f-df7ae77d61d4">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMTYtNy0xLTEtMjg2OTQ0_3eaa9047-fdd3-4a78-876a-60283b9b9b80">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Gain)/loss on sale of equity interest in naviHealth</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331" decimals="-6" name="us-gaap:GainLossOnSaleOfInvestments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMTctMS0xLTEtMjg2OTQ0_822c0dea-eb78-48dc-b658-4f9f6d650ae9">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331" decimals="-6" name="us-gaap:GainLossOnSaleOfInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMTctMy0xLTEtMjg2OTQ0_3a4c8b31-5176-4102-bd53-9a5b4452de30">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" decimals="-6" name="us-gaap:GainLossOnSaleOfInvestments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMTctNS0xLTEtMjg2OTQ0_6aecc8bf-ad07-4d2c-b38f-28d882b4aa91">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331" decimals="-6" name="us-gaap:GainLossOnSaleOfInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMTctNy0xLTEtMjg2OTQ0_10e6c099-8ead-450c-be48-e060d5bb0ca9">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Earnings/(loss) before income taxes</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMTgtMS0xLTEtMjg2OTQ0_75e20552-653a-4797-a423-91d5dc0eb6c5">544</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMTgtMy0xLTEtMjg2OTQ0_e8c523ea-f03e-4895-8fa9-a9b9fe08933c">137</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMTgtNS0xLTEtMjg2OTQ0_fe8fdebe-8672-45fa-8454-9d4137a53b58">517</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMTgtNy0xLTEtMjg2OTQ0_ffb79ac7-b498-42de-9adc-3c136bf64fd4">741</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMjAtMS0xLTEtMjg2OTQ0_47770637-67e5-4674-941f-cf34aaa8eea4">197</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMjAtMy0xLTEtMjg2OTQ0_0a62327a-e528-490d-86e7-4bea388007cc">1,253</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMjAtNS0xLTEtMjg2OTQ0_94b38983-d6ad-4254-a700-6dc52e9f6c0a">189</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMjAtNy0xLTEtMjg2OTQ0_86c5f02d-c8cb-4037-9ccf-1c03608a9250">328</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net earnings/(loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMjEtMS0xLTEtMjg2OTQ0_9d0eb824-fb08-4da3-8055-d270278e2b2e">347</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMjEtMy0xLTEtMjg2OTQ0_ca70483e-b557-4fc0-b1d6-72d750181642">1,390</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMjEtNS0xLTEtMjg2OTQ0_806a14e6-3f77-4b43-8f95-1ae5f5f5aeb8">328</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331" decimals="-6" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMjEtNy0xLTEtMjg2OTQ0_8ae2cecf-d05e-4eb9-84a9-f936fc682e3f">1,069</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Net earnings attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMjYtMS0xLTEtMjg2OTQ0_22b80416-7d2b-4f13-929e-ccce0bd0ef8b">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMjYtMy0xLTEtMjg2OTQ0_23c2f111-3d3b-4511-8a37-77dee76f5632">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMjYtNS0xLTEtMjg2OTQ0_10db0e09-d28a-4fe9-a0a1-b2252a4d48d8">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMjYtNy0xLTEtMjg2OTQ0_980565b8-7d1c-4ecc-af97-4afcf721866e">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net earnings/(loss) attributable to Cardinal Health, Inc.</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMjctMS0xLTEtMjg2OTQ0_85a3bd11-1781-4e7e-b02c-a48a53700384">345</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMjctMy0xLTEtMjg2OTQ0_f85e46d8-d18a-43db-b7ff-b7d32571c7b4">1,391</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMjctNS0xLTEtMjg2OTQ0_a6206a32-8720-4c8e-a5b7-b7a1de917b87">325</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMjctNy0xLTEtMjg2OTQ0_78f36107-a51c-44b2-927c-4d7e4a73eb8b">1,071</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Earnings/(Loss) per common share attributable to Cardinal Health, Inc.:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMzAtMS0xLTEtMjg2OTQ0_6a4aa081-291b-4788-a75f-b67a5d60bc41">1.35</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMzAtMy0xLTEtMjg2OTQ0_b210b28b-f546-4d9a-8249-8b9031c1b6ba">5.05</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMzAtNS0xLTEtMjg2OTQ0_1ec068b3-cb30-472e-a418-a43c75ef71c3">1.24</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMzAtNy0xLTEtMjg2OTQ0_07256555-d1e3-4909-98b3-72c66a33e4dc">3.82</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMzEtMS0xLTEtMjg2OTQ0_7cb92158-3b17-4a29-9e1f-0e22fe3af87f">1.34</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMzEtMy0xLTEtMjg2OTQ0_bc232157-3b8b-4b85-84b0-1ad36ba5050c">5.05</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMzEtNS0xLTEtMjg2OTQ0_6bf92272-ea90-4218-865f-d9c61a5e20b7">1.23</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMzEtNy0xLTEtMjg2OTQ0_931a37a5-88c7-4484-93ad-5170026fc707">3.82</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average number of common shares outstanding:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMzQtMS0xLTEtMjg2OTQ0_d49e1e23-e255-4886-83b6-d8bad87a76b4">256</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMzQtMy0xLTEtMjg2OTQ0_b39e1c67-a14d-43d7-aea7-a867cda902fd">275</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMzQtNS0xLTEtMjg2OTQ0_69613f38-705f-4104-b2de-47efb2c75c34">263</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMzQtNy0xLTEtMjg2OTQ0_b3d42626-55b2-48d1-952d-37e0105ae49b">281</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMzUtMS0xLTEtMjg2OTQ0_8af8fe8f-8fa7-4117-a0b7-91f76a24d159">258</ix:nonFraction></span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMzUtMy0xLTEtMjg2OTQ0_5d2b4aac-50bd-4745-91b8-d9589fe9def2">275</ix:nonFraction></span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMzUtNS0xLTEtMjg2OTQ0_bb8d4d89-7271-493c-ab0c-969ecdf49c7f">264</ix:nonFraction></span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMzUtNy0xLTEtMjg2OTQ0_7bc2c11d-e84e-4869-acdf-64e755b5c78d">281</ix:nonFraction></span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash dividends declared per common share</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMzctMS0xLTEtMjg2OTQ0_9a6ce686-ceae-4c3e-83ba-9ed0faa34233">0.4957</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMzctMy0xLTEtMjg2OTQ0_9fe140d7-c2c1-49ed-be9c-36b16ae7cd23">0.4908</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" decimals="4" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMzctNS0xLTEtMjg2OTQ0_23031718-a597-4fbf-b542-c470fd5dba76">1.4871</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331" decimals="4" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMzctNy0xLTEtMjg2OTQ0_4f791a17-edec-4138-b918-e33f3a3e76fd">1.4724</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to condensed consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">26</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i1d34fc4fc2424fbcb4837cc9f1c0665c_64"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Comprehensive Income/(Loss)</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:51.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.226%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.226%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.226%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.228%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net earnings/(loss)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182NC9mcmFnOmI3N2Q3MTQ1NGU4NzRmNjBhZGRkMjU4ZTg4ZDRjMzUwL3RhYmxlOmY0ZWEyZDQ0NTM3NDRmYWJhYjU0MDgxYmIzMWYxYWEzL3RhYmxlcmFuZ2U6ZjRlYTJkNDQ1Mzc0NGZhYmFiNTQwODFiYjMxZjFhYTNfMi0xLTEtMS0yODY5NDQ_06a378ed-d846-4180-bfb7-1951ac1f382b">347</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182NC9mcmFnOmI3N2Q3MTQ1NGU4NzRmNjBhZGRkMjU4ZTg4ZDRjMzUwL3RhYmxlOmY0ZWEyZDQ0NTM3NDRmYWJhYjU0MDgxYmIzMWYxYWEzL3RhYmxlcmFuZ2U6ZjRlYTJkNDQ1Mzc0NGZhYmFiNTQwODFiYjMxZjFhYTNfMi0zLTEtMS0yODY5NDQ_e2c2de43-375c-4113-8c6f-d98f297b46c6">1,390</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182NC9mcmFnOmI3N2Q3MTQ1NGU4NzRmNjBhZGRkMjU4ZTg4ZDRjMzUwL3RhYmxlOmY0ZWEyZDQ0NTM3NDRmYWJhYjU0MDgxYmIzMWYxYWEzL3RhYmxlcmFuZ2U6ZjRlYTJkNDQ1Mzc0NGZhYmFiNTQwODFiYjMxZjFhYTNfMi01LTEtMS0yODY5NDQ_a3fd6002-e19a-44ec-8b5f-a0f611d880a4">328</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331" decimals="-6" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182NC9mcmFnOmI3N2Q3MTQ1NGU4NzRmNjBhZGRkMjU4ZTg4ZDRjMzUwL3RhYmxlOmY0ZWEyZDQ0NTM3NDRmYWJhYjU0MDgxYmIzMWYxYWEzL3RhYmxlcmFuZ2U6ZjRlYTJkNDQ1Mzc0NGZhYmFiNTQwODFiYjMxZjFhYTNfMi03LTEtMS0yODY5NDQ_01a5cad9-5c7e-4236-a962-2f26ea32aa16">1,069</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other comprehensive income/(loss):</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustments and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182NC9mcmFnOmI3N2Q3MTQ1NGU4NzRmNjBhZGRkMjU4ZTg4ZDRjMzUwL3RhYmxlOmY0ZWEyZDQ0NTM3NDRmYWJhYjU0MDgxYmIzMWYxYWEzL3RhYmxlcmFuZ2U6ZjRlYTJkNDQ1Mzc0NGZhYmFiNTQwODFiYjMxZjFhYTNfNS0xLTEtMS0yODY5NDQ_be11c938-63c5-4e03-939f-03219bd95bae">4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182NC9mcmFnOmI3N2Q3MTQ1NGU4NzRmNjBhZGRkMjU4ZTg4ZDRjMzUwL3RhYmxlOmY0ZWEyZDQ0NTM3NDRmYWJhYjU0MDgxYmIzMWYxYWEzL3RhYmxlcmFuZ2U6ZjRlYTJkNDQ1Mzc0NGZhYmFiNTQwODFiYjMxZjFhYTNfNS0zLTEtMS0yODY5NDQ_eef751ab-51a9-407a-8b7b-ff03ac4b9821">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182NC9mcmFnOmI3N2Q3MTQ1NGU4NzRmNjBhZGRkMjU4ZTg4ZDRjMzUwL3RhYmxlOmY0ZWEyZDQ0NTM3NDRmYWJhYjU0MDgxYmIzMWYxYWEzL3RhYmxlcmFuZ2U6ZjRlYTJkNDQ1Mzc0NGZhYmFiNTQwODFiYjMxZjFhYTNfNS01LTEtMS0yODY5NDQ_9259b86f-9aa1-4ed2-bf74-49954f7f1db6">34</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182NC9mcmFnOmI3N2Q3MTQ1NGU4NzRmNjBhZGRkMjU4ZTg4ZDRjMzUwL3RhYmxlOmY0ZWEyZDQ0NTM3NDRmYWJhYjU0MDgxYmIzMWYxYWEzL3RhYmxlcmFuZ2U6ZjRlYTJkNDQ1Mzc0NGZhYmFiNTQwODFiYjMxZjFhYTNfNS03LTEtMS0yODY5NDQ_78b7d4bf-5253-4e51-9c89-448473f129cf">47</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net unrealized gain on derivative instruments, net of tax</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182NC9mcmFnOmI3N2Q3MTQ1NGU4NzRmNjBhZGRkMjU4ZTg4ZDRjMzUwL3RhYmxlOmY0ZWEyZDQ0NTM3NDRmYWJhYjU0MDgxYmIzMWYxYWEzL3RhYmxlcmFuZ2U6ZjRlYTJkNDQ1Mzc0NGZhYmFiNTQwODFiYjMxZjFhYTNfNy0xLTEtMS0yODY5NDQ_fe43a41d-d24f-411b-ab86-1f5158aa9923">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182NC9mcmFnOmI3N2Q3MTQ1NGU4NzRmNjBhZGRkMjU4ZTg4ZDRjMzUwL3RhYmxlOmY0ZWEyZDQ0NTM3NDRmYWJhYjU0MDgxYmIzMWYxYWEzL3RhYmxlcmFuZ2U6ZjRlYTJkNDQ1Mzc0NGZhYmFiNTQwODFiYjMxZjFhYTNfNy0zLTEtMS0yODY5NDQ_bd201d47-3379-485b-a4f4-f6abb8fd23ef">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182NC9mcmFnOmI3N2Q3MTQ1NGU4NzRmNjBhZGRkMjU4ZTg4ZDRjMzUwL3RhYmxlOmY0ZWEyZDQ0NTM3NDRmYWJhYjU0MDgxYmIzMWYxYWEzL3RhYmxlcmFuZ2U6ZjRlYTJkNDQ1Mzc0NGZhYmFiNTQwODFiYjMxZjFhYTNfNy01LTEtMS0yODY5NDQ_b33d6ec3-3726-41ab-9ef4-38c5ccc084f1">6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182NC9mcmFnOmI3N2Q3MTQ1NGU4NzRmNjBhZGRkMjU4ZTg4ZDRjMzUwL3RhYmxlOmY0ZWEyZDQ0NTM3NDRmYWJhYjU0MDgxYmIzMWYxYWEzL3RhYmxlcmFuZ2U6ZjRlYTJkNDQ1Mzc0NGZhYmFiNTQwODFiYjMxZjFhYTNfNy03LTEtMS0yODY5NDQ_e940ca2b-c822-4aff-8666-d69a6aed4b37">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other comprehensive income/(loss), net of tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182NC9mcmFnOmI3N2Q3MTQ1NGU4NzRmNjBhZGRkMjU4ZTg4ZDRjMzUwL3RhYmxlOmY0ZWEyZDQ0NTM3NDRmYWJhYjU0MDgxYmIzMWYxYWEzL3RhYmxlcmFuZ2U6ZjRlYTJkNDQ1Mzc0NGZhYmFiNTQwODFiYjMxZjFhYTNfOC0xLTEtMS0yODY5NDQ_d1db4eed-bfb1-45d8-a96c-99e3cce96451">4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182NC9mcmFnOmI3N2Q3MTQ1NGU4NzRmNjBhZGRkMjU4ZTg4ZDRjMzUwL3RhYmxlOmY0ZWEyZDQ0NTM3NDRmYWJhYjU0MDgxYmIzMWYxYWEzL3RhYmxlcmFuZ2U6ZjRlYTJkNDQ1Mzc0NGZhYmFiNTQwODFiYjMxZjFhYTNfOC0zLTEtMS0yODY5NDQ_a0db2853-5646-44dd-83f2-a2a67bb7b6c4">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182NC9mcmFnOmI3N2Q3MTQ1NGU4NzRmNjBhZGRkMjU4ZTg4ZDRjMzUwL3RhYmxlOmY0ZWEyZDQ0NTM3NDRmYWJhYjU0MDgxYmIzMWYxYWEzL3RhYmxlcmFuZ2U6ZjRlYTJkNDQ1Mzc0NGZhYmFiNTQwODFiYjMxZjFhYTNfOC01LTEtMS0yODY5NDQ_9671a933-1e1e-47a7-a51a-1b49017372cf">28</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182NC9mcmFnOmI3N2Q3MTQ1NGU4NzRmNjBhZGRkMjU4ZTg4ZDRjMzUwL3RhYmxlOmY0ZWEyZDQ0NTM3NDRmYWJhYjU0MDgxYmIzMWYxYWEzL3RhYmxlcmFuZ2U6ZjRlYTJkNDQ1Mzc0NGZhYmFiNTQwODFiYjMxZjFhYTNfOC03LTEtMS0yODY5NDQ_092d6b93-a919-4d14-9fa9-72d7c26e2ed5">43</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total comprehensive income/(loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182NC9mcmFnOmI3N2Q3MTQ1NGU4NzRmNjBhZGRkMjU4ZTg4ZDRjMzUwL3RhYmxlOmY0ZWEyZDQ0NTM3NDRmYWJhYjU0MDgxYmIzMWYxYWEzL3RhYmxlcmFuZ2U6ZjRlYTJkNDQ1Mzc0NGZhYmFiNTQwODFiYjMxZjFhYTNfMTAtMS0xLTEtMjg2OTQ0_ba8bf834-6b82-4b4b-8164-1805e395ac38">351</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182NC9mcmFnOmI3N2Q3MTQ1NGU4NzRmNjBhZGRkMjU4ZTg4ZDRjMzUwL3RhYmxlOmY0ZWEyZDQ0NTM3NDRmYWJhYjU0MDgxYmIzMWYxYWEzL3RhYmxlcmFuZ2U6ZjRlYTJkNDQ1Mzc0NGZhYmFiNTQwODFiYjMxZjFhYTNfMTAtMy0xLTEtMjg2OTQ0_f9dec262-918c-41c2-87dd-0fcb7758573d">1,382</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182NC9mcmFnOmI3N2Q3MTQ1NGU4NzRmNjBhZGRkMjU4ZTg4ZDRjMzUwL3RhYmxlOmY0ZWEyZDQ0NTM3NDRmYWJhYjU0MDgxYmIzMWYxYWEzL3RhYmxlcmFuZ2U6ZjRlYTJkNDQ1Mzc0NGZhYmFiNTQwODFiYjMxZjFhYTNfMTAtNS0xLTEtMjg2OTQ0_054b75b3-cac1-4259-aba7-b0e2b9e3ad97">300</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182NC9mcmFnOmI3N2Q3MTQ1NGU4NzRmNjBhZGRkMjU4ZTg4ZDRjMzUwL3RhYmxlOmY0ZWEyZDQ0NTM3NDRmYWJhYjU0MDgxYmIzMWYxYWEzL3RhYmxlcmFuZ2U6ZjRlYTJkNDQ1Mzc0NGZhYmFiNTQwODFiYjMxZjFhYTNfMTAtNy0xLTEtMjg2OTQ0_6a45bc20-8f6a-4486-b400-a84df78442a8">1,112</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: comprehensive income attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182NC9mcmFnOmI3N2Q3MTQ1NGU4NzRmNjBhZGRkMjU4ZTg4ZDRjMzUwL3RhYmxlOmY0ZWEyZDQ0NTM3NDRmYWJhYjU0MDgxYmIzMWYxYWEzL3RhYmxlcmFuZ2U6ZjRlYTJkNDQ1Mzc0NGZhYmFiNTQwODFiYjMxZjFhYTNfMTItMS0xLTEtMjg2OTQ0_5445b090-435b-43bc-bcac-0cb461e99adf">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182NC9mcmFnOmI3N2Q3MTQ1NGU4NzRmNjBhZGRkMjU4ZTg4ZDRjMzUwL3RhYmxlOmY0ZWEyZDQ0NTM3NDRmYWJhYjU0MDgxYmIzMWYxYWEzL3RhYmxlcmFuZ2U6ZjRlYTJkNDQ1Mzc0NGZhYmFiNTQwODFiYjMxZjFhYTNfMTItMy0xLTEtMjg2OTQ0_0c52c2bb-68cd-4662-9e2d-5ba1c2dae13c">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182NC9mcmFnOmI3N2Q3MTQ1NGU4NzRmNjBhZGRkMjU4ZTg4ZDRjMzUwL3RhYmxlOmY0ZWEyZDQ0NTM3NDRmYWJhYjU0MDgxYmIzMWYxYWEzL3RhYmxlcmFuZ2U6ZjRlYTJkNDQ1Mzc0NGZhYmFiNTQwODFiYjMxZjFhYTNfMTItNS0xLTEtMjg2OTQ0_a3627142-27ee-4b07-8d8f-c6b12186164d">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182NC9mcmFnOmI3N2Q3MTQ1NGU4NzRmNjBhZGRkMjU4ZTg4ZDRjMzUwL3RhYmxlOmY0ZWEyZDQ0NTM3NDRmYWJhYjU0MDgxYmIzMWYxYWEzL3RhYmxlcmFuZ2U6ZjRlYTJkNDQ1Mzc0NGZhYmFiNTQwODFiYjMxZjFhYTNfMTItNy0xLTEtMjg2OTQ0_3a48471b-b3ca-4574-bd7b-64c7bd6d96f8">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total comprehensive income/(loss) attributable to Cardinal Health, Inc.</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182NC9mcmFnOmI3N2Q3MTQ1NGU4NzRmNjBhZGRkMjU4ZTg4ZDRjMzUwL3RhYmxlOmY0ZWEyZDQ0NTM3NDRmYWJhYjU0MDgxYmIzMWYxYWEzL3RhYmxlcmFuZ2U6ZjRlYTJkNDQ1Mzc0NGZhYmFiNTQwODFiYjMxZjFhYTNfMTQtMS0xLTEtMjg2OTQ0_ffd7aea6-ffe3-4457-b784-8f2c5391c571">349</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182NC9mcmFnOmI3N2Q3MTQ1NGU4NzRmNjBhZGRkMjU4ZTg4ZDRjMzUwL3RhYmxlOmY0ZWEyZDQ0NTM3NDRmYWJhYjU0MDgxYmIzMWYxYWEzL3RhYmxlcmFuZ2U6ZjRlYTJkNDQ1Mzc0NGZhYmFiNTQwODFiYjMxZjFhYTNfMTQtMy0xLTEtMjg2OTQ0_470f3c86-18c3-4e0c-9eb8-b357f8057627">1,383</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182NC9mcmFnOmI3N2Q3MTQ1NGU4NzRmNjBhZGRkMjU4ZTg4ZDRjMzUwL3RhYmxlOmY0ZWEyZDQ0NTM3NDRmYWJhYjU0MDgxYmIzMWYxYWEzL3RhYmxlcmFuZ2U6ZjRlYTJkNDQ1Mzc0NGZhYmFiNTQwODFiYjMxZjFhYTNfMTQtNS0xLTEtMjg2OTQ0_32735226-0588-4a6c-a85a-3cd633784c4c">297</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182NC9mcmFnOmI3N2Q3MTQ1NGU4NzRmNjBhZGRkMjU4ZTg4ZDRjMzUwL3RhYmxlOmY0ZWEyZDQ0NTM3NDRmYWJhYjU0MDgxYmIzMWYxYWEzL3RhYmxlcmFuZ2U6ZjRlYTJkNDQ1Mzc0NGZhYmFiNTQwODFiYjMxZjFhYTNfMTQtNy0xLTEtMjg2OTQ0_b7697901-33fc-452e-920a-220cd175174b">1,114</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to condensed consolidated financial statements.</span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">27</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i1d34fc4fc2424fbcb4837cc9f1c0665c_67"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.114%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.590%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.252%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and equivalents</span></td><td style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfNC0xLTEtMS0yODY5NDQ_6e351f3e-00a6-4af3-b25d-05c91de272f4">3,990</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic217743408d440409a59220a0bf14e4c_I20220630" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfNC0zLTEtMS0yODY5NDQ_1f463960-8f7f-40bc-8e11-ea2c104aff6f">4,717</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trade receivables, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331" decimals="-6" name="us-gaap:ReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfNS0xLTEtMS0yODY5NDQ_014c88d4-a563-45db-a5ee-ca83d90ac26f">10,992</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic217743408d440409a59220a0bf14e4c_I20220630" decimals="-6" name="us-gaap:ReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfNS0zLTEtMS0yODY5NDQ_6c677f3c-821f-45cf-98fe-ff85ffe6d3bc">10,561</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventories, net</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfNi0xLTEtMS0yODY5NDQ_91ace5b3-6f87-4b0b-bec8-c7e083d128a6">16,620</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic217743408d440409a59220a0bf14e4c_I20220630" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfNi0zLTEtMS0yODY5NDQ_8fe193ff-cfe6-4826-9e5a-ad718114b943">15,636</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331" decimals="-6" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfNy0xLTEtMS0yODY5NDQ_77f08de4-3862-45ed-a7df-4feff7ca43a4">1,895</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic217743408d440409a59220a0bf14e4c_I20220630" decimals="-6" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfNy0zLTEtMS0yODY5NDQ_9a1812a0-5b97-4d32-99d7-8da170040af1">2,021</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfOS0xLTEtMS0yODY5NDQ_bb9cec30-b89b-4ef5-bba1-3ad3b7a50395">33,497</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic217743408d440409a59220a0bf14e4c_I20220630" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfOS0zLTEtMS0yODY5NDQ_6e6a7dc8-ca32-473e-bce3-87e87e70223b">32,935</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfMTEtMS0xLTEtMjg2OTQ0_cd2f0509-0cd7-40b3-b4d6-339cb4ebb90a">2,362</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic217743408d440409a59220a0bf14e4c_I20220630" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfMTEtMy0xLTEtMjg2OTQ0_58cbbd24-c96f-428c-b2be-5c5ac68773d3">2,361</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill and other intangibles, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331" decimals="-6" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfMTItMS0xLTEtMjg2OTQ0_f25d438f-f233-4913-b7d6-b2f88bfac58a">6,567</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic217743408d440409a59220a0bf14e4c_I20220630" decimals="-6" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfMTItMy0xLTEtMjg2OTQ0_39d4722d-12f5-49e2-a217-9bd516a1d25e">7,629</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfMTQtMS0xLTEtMjg2OTQ0_66f8166a-ea93-4859-a333-a0bf328ad502">951</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic217743408d440409a59220a0bf14e4c_I20220630" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfMTQtMy0xLTEtMjg2OTQ0_d1dfb3b5-ba23-4633-b10f-9b9ed2e9871c">953</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfMTUtMS0xLTEtMjg2OTQ0_e7014d88-c357-4661-8f8a-7f059487a4a7">43,377</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic217743408d440409a59220a0bf14e4c_I20220630" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfMTUtMy0xLTEtMjg2OTQ0_3f8d0574-eacd-4464-82bc-ea8e16aa4df1">43,878</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cccccc;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities and Shareholders&#8217; Deficit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331" decimals="-6" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfMTktMS0xLTEtMjg2OTQ0_3692b8fb-b7a8-4494-9e1c-bbaf46eef2a8">29,601</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic217743408d440409a59220a0bf14e4c_I20220630" decimals="-6" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfMTktMy0xLTEtMjg2OTQ0_76462c68-2862-4ec8-946e-8f077912b8e9">27,128</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current portion of long-term obligations and other short-term borrowings</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331" decimals="-6" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfMjAtMS0xLTEtMjg2OTQ0_03544af3-782d-487d-9ff0-a59112c69621">26</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic217743408d440409a59220a0bf14e4c_I20220630" decimals="-6" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfMjAtMy0xLTEtMjg2OTQ0_f2361ca0-033f-450c-89d3-7b5d1da35b46">580</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331" decimals="-6" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfMjEtMS0xLTEtMjg2OTQ0_ef55d1cb-1918-478c-8216-29ab00a057b6">2,876</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic217743408d440409a59220a0bf14e4c_I20220630" decimals="-6" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfMjEtMy0xLTEtMjg2OTQ0_9ce1b767-7d35-4d26-ad50-1173c87d6f90">2,842</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfMjMtMS0xLTEtMjg2OTQ0_2f53c6de-3074-4b8b-a1fc-ebca777fb0e7">32,503</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic217743408d440409a59220a0bf14e4c_I20220630" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfMjMtMy0xLTEtMjg2OTQ0_71e70a41-4ae4-4fc3-be9a-240453518753">30,550</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term obligations, less current portion</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331" decimals="-6" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfMjUtMS0xLTEtMjg2OTQ0_4306d76e-2f22-4234-b1cf-47b69ff10ac5">4,708</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic217743408d440409a59220a0bf14e4c_I20220630" decimals="-6" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfMjUtMy0xLTEtMjg2OTQ0_95e902c8-8cc8-4096-8f2f-14b2354c0938">4,735</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred income taxes and other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331" decimals="-6" name="us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfMjYtMS0xLTEtMjg2OTQ0_ce5f08fe-7024-409b-a704-00ec0a01e196">8,384</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic217743408d440409a59220a0bf14e4c_I20220630" decimals="-6" name="us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfMjYtMy0xLTEtMjg2OTQ0_ab4344f9-fc72-440c-aa45-4ad27ccdc258">9,299</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shareholders&#8217; deficit:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Preferred shares, without par value:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Authorized&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331" decimals="-3" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfMzAtMC0xLTEtMjg2OTQ0L3RleHRyZWdpb246NmI5NjM4NWMzOGViNDVkNjhiZGYxYmYzNTcyZTViMWJfMTU_0036531e-a759-4501-a33f-feac3e115836"><ix:nonFraction unitRef="shares" contextRef="ic217743408d440409a59220a0bf14e4c_I20220630" decimals="-3" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfMzAtMC0xLTEtMjg2OTQ0L3RleHRyZWdpb246NmI5NjM4NWMzOGViNDVkNjhiZGYxYmYzNTcyZTViMWJfMTU_09dc6687-d72a-4920-9f65-4b0d322c600e">500</ix:nonFraction></ix:nonFraction> thousand</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> shares, Issued&#8212;<ix:nonFraction unitRef="shares" contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331" decimals="-3" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfMzAtMC0xLTEtMjg2OTQ0L3RleHRyZWdpb246NmI5NjM4NWMzOGViNDVkNjhiZGYxYmYzNTcyZTViMWJfMzM_9ab63c94-7f9e-4c1c-8f66-cdf2f558a7bf"><ix:nonFraction unitRef="shares" contextRef="ic217743408d440409a59220a0bf14e4c_I20220630" decimals="-3" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfMzAtMC0xLTEtMjg2OTQ0L3RleHRyZWdpb246NmI5NjM4NWMzOGViNDVkNjhiZGYxYmYzNTcyZTViMWJfMzM_f84bea32-08f7-4398-b0a5-f09a45102e02">none</ix:nonFraction></ix:nonFraction></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331" decimals="-6" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfMzAtMS0xLTEtMjg2OTQ0_9836a14e-a507-4b2a-bb68-430bddb75434">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic217743408d440409a59220a0bf14e4c_I20220630" decimals="-6" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfMzAtMy0xLTEtMjg2OTQ0_c068e564-2199-4079-a047-0c534efdf1bd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common shares, without par value:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Authorized&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331" decimals="-6" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfMzItMC0xLTEtMjg2OTQ0L3RleHRyZWdpb246YjhiNjVmY2NlMGRjNDQ2ZjhhNjczYmU2OTRlNGQ1N2NfMTY_8ff38525-bfda-4205-9a82-56d5199595b2"><ix:nonFraction unitRef="shares" contextRef="ic217743408d440409a59220a0bf14e4c_I20220630" decimals="-6" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfMzItMC0xLTEtMjg2OTQ0L3RleHRyZWdpb246YjhiNjVmY2NlMGRjNDQ2ZjhhNjczYmU2OTRlNGQ1N2NfMTY_c85f54c1-c7c7-458b-8892-23598f00e06a">755</ix:nonFraction></ix:nonFraction> million</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> shares, Issued&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331" decimals="-6" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfMzItMC0xLTEtMjg2OTQ0L3RleHRyZWdpb246YjhiNjVmY2NlMGRjNDQ2ZjhhNjczYmU2OTRlNGQ1N2NfMzQ_1384b21f-4d32-4e90-bb0c-526c7eca8a69"><ix:nonFraction unitRef="shares" contextRef="ic217743408d440409a59220a0bf14e4c_I20220630" decimals="-6" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfMzItMC0xLTEtMjg2OTQ0L3RleHRyZWdpb246YjhiNjVmY2NlMGRjNDQ2ZjhhNjczYmU2OTRlNGQ1N2NfMzQ_21585e76-3e4a-4f98-bf9a-ed8cc75e2861">327</ix:nonFraction></ix:nonFraction> million</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> shares at </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March&#160;31, 2023</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and June 30, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331" decimals="-6" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfMzItMS0xLTEtMjg2OTQ0_1a0cfbd8-e0ac-4c9a-a817-ad44920d47f4">2,818</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic217743408d440409a59220a0bf14e4c_I20220630" decimals="-6" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfMzItMy0xLTEtMjg2OTQ0_86dac88d-9c17-4bff-aaae-394cef2638c0">2,813</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331" decimals="-6" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfMzMtMS0xLTEtMjg2OTQ0_f89c4233-6763-45f8-bdeb-dc22a62224c9">342</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic217743408d440409a59220a0bf14e4c_I20220630" decimals="-6" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfMzMtMy0xLTEtMjg2OTQ0_c281251a-4ee3-437d-9829-6fc3339b03f5">280</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Common shares in treasury, at cost: </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331" decimals="-6" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfMzQtMC0xLTEtMjg2OTQ0L3RleHRyZWdpb246ZjFmZmQ1YzIxYWUwNGQ5Yzg1ZDliY2FkNzJhZDA1YzlfNDE_fff83e81-26b2-4d2f-926b-23f063692df7">72</ix:nonFraction> million </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">shares and <ix:nonFraction unitRef="shares" contextRef="ic217743408d440409a59220a0bf14e4c_I20220630" decimals="-6" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfMzQtMC0xLTEtMjg2OTQ0L3RleHRyZWdpb246ZjFmZmQ1YzIxYWUwNGQ5Yzg1ZDliY2FkNzJhZDA1YzlfNTU_268b9800-77cd-4538-9b3b-c3a130b2f6ec">54</ix:nonFraction> million shares at </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March&#160;31, 2023 </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">and June 30, 2022, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331" decimals="-6" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfMzQtMS0xLTEtMjg2OTQ0_b64bf472-2f6a-441d-b07f-3d8185fcb6ab">4,554</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic217743408d440409a59220a0bf14e4c_I20220630" decimals="-6" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfMzQtMy0xLTEtMjg2OTQ0_9e219953-e4e6-4e16-9dfd-42df1d6f32c1">3,128</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfMzUtMS0xLTEtMjg2OTQ0_f3718a10-f119-4c67-a927-fc9a0e6052ce">142</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic217743408d440409a59220a0bf14e4c_I20220630" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfMzUtMy0xLTEtMjg2OTQ0_5b28e671-32c1-4a96-8261-1ac1c47cf0ac">114</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Cardinal Health, Inc. shareholders' deficit</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfMzYtMS0xLTEtMjg2OTQ0_e7311ba6-3b73-41f9-96f1-0cd82ee747c6">2,220</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic217743408d440409a59220a0bf14e4c_I20220630" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfMzYtMy0xLTEtMjg2OTQ0_38075cd7-44d6-4081-8658-c9bf1743e4b3">709</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfMzctMS0xLTEtMjg2OTQ0_07f51885-85cd-4bc1-a5d3-1fd4b3897450">2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic217743408d440409a59220a0bf14e4c_I20220630" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfMzctMy0xLTEtMjg2OTQ0_5aa028e7-7278-49d2-8a84-efb223b2fbfd">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total shareholders&#8217; deficit</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfMzgtMS0xLTEtMjg2OTQ0_0fae8bbe-c363-4db3-9c8d-283de25315ee">2,218</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic217743408d440409a59220a0bf14e4c_I20220630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfMzgtMy0xLTEtMjg2OTQ0_4d8e6a9e-aad4-4de3-9b33-ab8159be9977">706</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total liabilities and shareholders&#8217; deficit</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfMzktMS0xLTEtMjg2OTQ0_946f38ca-ab6d-4f80-bbcf-c3bfebcb68fb">43,377</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic217743408d440409a59220a0bf14e4c_I20220630" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfMzktMy0xLTEtMjg2OTQ0_760364d8-85fd-45cf-83b4-bb34f1671520">43,878</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to condensed consolidated financial statements.</span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i1d34fc4fc2424fbcb4837cc9f1c0665c_70"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Shareholders' </span></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Equity/(Deficit)</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"></td><td style="width:30.140%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.213%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.070%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retained<br/>Earnings/ (Accumulated Deficit)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Treasury Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncontrolling Interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Shareholders&#8217; Equity/(Deficit)</span></td><td colspan="3" style="display:none"></td></tr><tr style="height:26pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares Issued</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2023</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i56eab9e952334359a592f758a000f3a5_I20221231" decimals="-6" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOmMwMDczMTdhZDBjNDRiNDRiZDAxNWI2MWUxYTcwZmUwL3RhYmxlcmFuZ2U6YzAwNzMxN2FkMGM0NGI0NGJkMDE1YjYxZTFhNzBmZTBfMy0xLTEtMS0yODY5NDQ_2c6cd24a-7906-4f7d-a896-e44d703040b3">327</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56eab9e952334359a592f758a000f3a5_I20221231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOmMwMDczMTdhZDBjNDRiNDRiZDAxNWI2MWUxYTcwZmUwL3RhYmxlcmFuZ2U6YzAwNzMxN2FkMGM0NGI0NGJkMDE1YjYxZTFhNzBmZTBfMy0zLTEtMS0yODY5NDQ_21362cb6-7acd-455b-9c94-390b9959ab1b">2,747</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8b46cf505d1d4c6286a2da8dfd32802a_I20221231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOmMwMDczMTdhZDBjNDRiNDRiZDAxNWI2MWUxYTcwZmUwL3RhYmxlcmFuZ2U6YzAwNzMxN2FkMGM0NGI0NGJkMDE1YjYxZTFhNzBmZTBfMy01LTEtMS0yODY5NDQ_b5030f87-de68-43c8-bd72-21e84307e378">560</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i0e78bc722aef43c4ac908658f754bbe4_I20221231" decimals="-6" sign="-" name="us-gaap:TreasuryStockCommonShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOmMwMDczMTdhZDBjNDRiNDRiZDAxNWI2MWUxYTcwZmUwL3RhYmxlcmFuZ2U6YzAwNzMxN2FkMGM0NGI0NGJkMDE1YjYxZTFhNzBmZTBfMy03LTEtMS0yODY5NDQ_b1445a7f-ec9f-42e4-8565-231840f8fbfd">68</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e78bc722aef43c4ac908658f754bbe4_I20221231" decimals="-6" sign="-" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOmMwMDczMTdhZDBjNDRiNDRiZDAxNWI2MWUxYTcwZmUwL3RhYmxlcmFuZ2U6YzAwNzMxN2FkMGM0NGI0NGJkMDE1YjYxZTFhNzBmZTBfMy05LTEtMS0yODY5NDQ_9a6e0956-cf46-452a-9bab-ad55f71cba9f">4,254</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7fee7130363347368e48c8a5373ef212_I20221231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOmMwMDczMTdhZDBjNDRiNDRiZDAxNWI2MWUxYTcwZmUwL3RhYmxlcmFuZ2U6YzAwNzMxN2FkMGM0NGI0NGJkMDE1YjYxZTFhNzBmZTBfMy0xMS0xLTEtMjg2OTQ0_ad2b4f3d-ee0b-437b-bb7d-972da9fee45f">146</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id91f4a6653dc429ab8550cb153ee63fe_I20221231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOmMwMDczMTdhZDBjNDRiNDRiZDAxNWI2MWUxYTcwZmUwL3RhYmxlcmFuZ2U6YzAwNzMxN2FkMGM0NGI0NGJkMDE1YjYxZTFhNzBmZTBfMy0xMy0xLTEtMjg2OTQ0_16ae91c5-79cd-496d-a079-83d37f58aa22">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i08aa4676fa1f412495f0dcda89ef5c61_I20221231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOmMwMDczMTdhZDBjNDRiNDRiZDAxNWI2MWUxYTcwZmUwL3RhYmxlcmFuZ2U6YzAwNzMxN2FkMGM0NGI0NGJkMDE1YjYxZTFhNzBmZTBfMy0xNS0xLTEtMjg2OTQ0_e0f35c1d-f094-49ff-829c-13548df128cc">2,212</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net earnings</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOmMwMDczMTdhZDBjNDRiNDRiZDAxNWI2MWUxYTcwZmUwL3RhYmxlcmFuZ2U6YzAwNzMxN2FkMGM0NGI0NGJkMDE1YjYxZTFhNzBmZTBfNC01LTEtMS0yODY5NDQ_85a3bd11-1781-4e7e-b02c-a48a53700384">345</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6743439f6d344529a1d9776e5a37b6af_D20230101-20230331" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOmMwMDczMTdhZDBjNDRiNDRiZDAxNWI2MWUxYTcwZmUwL3RhYmxlcmFuZ2U6YzAwNzMxN2FkMGM0NGI0NGJkMDE1YjYxZTFhNzBmZTBfNC0xMy0xLTEtMjg2OTQ0_7eb08e3f-5994-4f0b-9f98-42e5dbfd957a">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOmMwMDczMTdhZDBjNDRiNDRiZDAxNWI2MWUxYTcwZmUwL3RhYmxlcmFuZ2U6YzAwNzMxN2FkMGM0NGI0NGJkMDE1YjYxZTFhNzBmZTBfNC0xNS0xLTEtMjg2OTQ0_3d56888a-e7b9-42c4-95d1-85788506f609">347</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOmMwMDczMTdhZDBjNDRiNDRiZDAxNWI2MWUxYTcwZmUwL3RhYmxlcmFuZ2U6YzAwNzMxN2FkMGM0NGI0NGJkMDE1YjYxZTFhNzBmZTBfNS0xMS0xLTEtMjg2OTQ0_d1db4eed-bfb1-45d8-a96c-99e3cce96451">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOmMwMDczMTdhZDBjNDRiNDRiZDAxNWI2MWUxYTcwZmUwL3RhYmxlcmFuZ2U6YzAwNzMxN2FkMGM0NGI0NGJkMDE1YjYxZTFhNzBmZTBfNS0xNS0xLTEtMjg2OTQ0_8a0d8653-4e7f-4fdb-962f-5b8b3465559c">4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock plans activity, net of shares withheld for employee taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i691c4bcd6648489e9985b2ebac21c4c4_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOmMwMDczMTdhZDBjNDRiNDRiZDAxNWI2MWUxYTcwZmUwL3RhYmxlcmFuZ2U6YzAwNzMxN2FkMGM0NGI0NGJkMDE1YjYxZTFhNzBmZTBfNy0xLTEtMS0yODY5NDQ_5de2520d-5f25-4b3b-beb4-6d1564a2d8d7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i691c4bcd6648489e9985b2ebac21c4c4_D20230101-20230331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOmMwMDczMTdhZDBjNDRiNDRiZDAxNWI2MWUxYTcwZmUwL3RhYmxlcmFuZ2U6YzAwNzMxN2FkMGM0NGI0NGJkMDE1YjYxZTFhNzBmZTBfNy0zLTEtMS0yODY5NDQ_4b0759ec-c3be-4ca5-ad67-e4ca551e4899">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic5ce320f275240ee8f228b919198581e_D20230101-20230331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOmMwMDczMTdhZDBjNDRiNDRiZDAxNWI2MWUxYTcwZmUwL3RhYmxlcmFuZ2U6YzAwNzMxN2FkMGM0NGI0NGJkMDE1YjYxZTFhNzBmZTBfNy03LTEtMS0yODY5NDQ_7ea9dc69-58a2-4533-b115-7260e9bde01a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5ce320f275240ee8f228b919198581e_D20230101-20230331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOmMwMDczMTdhZDBjNDRiNDRiZDAxNWI2MWUxYTcwZmUwL3RhYmxlcmFuZ2U6YzAwNzMxN2FkMGM0NGI0NGJkMDE1YjYxZTFhNzBmZTBfNy05LTEtMS0yODY5NDQ_991c091b-d729-4f7d-9e6f-4c62f5a183a8">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOmMwMDczMTdhZDBjNDRiNDRiZDAxNWI2MWUxYTcwZmUwL3RhYmxlcmFuZ2U6YzAwNzMxN2FkMGM0NGI0NGJkMDE1YjYxZTFhNzBmZTBfNy0xNS0xLTEtMjg2OTQ0_8f528ffa-58af-4872-9fe0-61a7cfb14dc6">24</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share repurchase program activity</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i691c4bcd6648489e9985b2ebac21c4c4_D20230101-20230331" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOmMwMDczMTdhZDBjNDRiNDRiZDAxNWI2MWUxYTcwZmUwL3RhYmxlcmFuZ2U6YzAwNzMxN2FkMGM0NGI0NGJkMDE1YjYxZTFhNzBmZTBfOC0zLTEtMS0yODY5NDQ_d3a126af-81bc-4a92-9a23-4f5bf3522058">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ic5ce320f275240ee8f228b919198581e_D20230101-20230331" decimals="-6" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOmMwMDczMTdhZDBjNDRiNDRiZDAxNWI2MWUxYTcwZmUwL3RhYmxlcmFuZ2U6YzAwNzMxN2FkMGM0NGI0NGJkMDE1YjYxZTFhNzBmZTBfOC03LTEtMS0yODY5NDQ_05caf656-f200-428f-8839-3591d877af1c">4</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic5ce320f275240ee8f228b919198581e_D20230101-20230331" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOmMwMDczMTdhZDBjNDRiNDRiZDAxNWI2MWUxYTcwZmUwL3RhYmxlcmFuZ2U6YzAwNzMxN2FkMGM0NGI0NGJkMDE1YjYxZTFhNzBmZTBfOC05LTEtMS0yODY5NDQ_5fb2b130-7ee3-480a-b6d5-d7fffa22fdda">303</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOmMwMDczMTdhZDBjNDRiNDRiZDAxNWI2MWUxYTcwZmUwL3RhYmxlcmFuZ2U6YzAwNzMxN2FkMGM0NGI0NGJkMDE1YjYxZTFhNzBmZTBfOC0xNS0xLTEtMjg2OTQ0_719cb846-8c1a-4e8b-829c-6b7540b54506">253</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends declared</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibb01906f8808446da382eb7169a9c692_D20230101-20230331" decimals="-6" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOmMwMDczMTdhZDBjNDRiNDRiZDAxNWI2MWUxYTcwZmUwL3RhYmxlcmFuZ2U6YzAwNzMxN2FkMGM0NGI0NGJkMDE1YjYxZTFhNzBmZTBfOS01LTEtMS0yODY5NDQ_b8e02fcd-de0e-4afc-9900-d0a0256d2d6f">128</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331" decimals="-6" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOmMwMDczMTdhZDBjNDRiNDRiZDAxNWI2MWUxYTcwZmUwL3RhYmxlcmFuZ2U6YzAwNzMxN2FkMGM0NGI0NGJkMDE1YjYxZTFhNzBmZTBfOS0xNS0xLTEtMjg2OTQ0_2c5ea353-fd38-407e-a0d3-8fc03243f433">128</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i691c4bcd6648489e9985b2ebac21c4c4_D20230101-20230331" sign="-" xsi:nil="true" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOmMwMDczMTdhZDBjNDRiNDRiZDAxNWI2MWUxYTcwZmUwL3RhYmxlcmFuZ2U6YzAwNzMxN2FkMGM0NGI0NGJkMDE1YjYxZTFhNzBmZTBfMTAtMy0xLTEtMjg2OTQ0_539accdd-3b2d-494f-808d-5d4cb505808c"></ix:nonFraction></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb01906f8808446da382eb7169a9c692_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOmMwMDczMTdhZDBjNDRiNDRiZDAxNWI2MWUxYTcwZmUwL3RhYmxlcmFuZ2U6YzAwNzMxN2FkMGM0NGI0NGJkMDE1YjYxZTFhNzBmZTBfMTAtNS0xLTEtMjg2OTQ0_c99a582f-1b96-4c01-84d0-577e334b25fc">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"><ix:nonFraction unitRef="shares" contextRef="ic5ce320f275240ee8f228b919198581e_D20230101-20230331" sign="-" xsi:nil="true" name="us-gaap:StockholdersEquityOtherShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOmMwMDczMTdhZDBjNDRiNDRiZDAxNWI2MWUxYTcwZmUwL3RhYmxlcmFuZ2U6YzAwNzMxN2FkMGM0NGI0NGJkMDE1YjYxZTFhNzBmZTBfMTAtNy0xLTEtMjg2OTQ0_c5be152e-acaf-4eee-a176-3b0bfbab432c"></ix:nonFraction></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6743439f6d344529a1d9776e5a37b6af_D20230101-20230331" decimals="-6" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOmMwMDczMTdhZDBjNDRiNDRiZDAxNWI2MWUxYTcwZmUwL3RhYmxlcmFuZ2U6YzAwNzMxN2FkMGM0NGI0NGJkMDE1YjYxZTFhNzBmZTBfMTAtMTMtMS0xLTI4Njk0NA_ab889506-c96e-47c4-9c8b-91c152698ab8">1</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331" decimals="-6" name="us-gaap:StockholdersEquityOther" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOmMwMDczMTdhZDBjNDRiNDRiZDAxNWI2MWUxYTcwZmUwL3RhYmxlcmFuZ2U6YzAwNzMxN2FkMGM0NGI0NGJkMDE1YjYxZTFhNzBmZTBfMTAtMTUtMS0xLTI4Njk0NA_75c45fbf-a79c-4dc8-b5f7-b3625bda9542">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at March 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3208791586fb4201860768dd298b3bb2_I20230331" decimals="-6" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOmMwMDczMTdhZDBjNDRiNDRiZDAxNWI2MWUxYTcwZmUwL3RhYmxlcmFuZ2U6YzAwNzMxN2FkMGM0NGI0NGJkMDE1YjYxZTFhNzBmZTBfMTEtMS0xLTEtMjg2OTQ0_00c07c69-5f55-48da-a7d9-c5299285f4b4">327</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3208791586fb4201860768dd298b3bb2_I20230331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOmMwMDczMTdhZDBjNDRiNDRiZDAxNWI2MWUxYTcwZmUwL3RhYmxlcmFuZ2U6YzAwNzMxN2FkMGM0NGI0NGJkMDE1YjYxZTFhNzBmZTBfMTEtMy0xLTEtMjg2OTQ0_10d6aa23-2079-44a5-a8ee-bc8dc6a948a5">2,818</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69743694027f433b8def521fd90c10b1_I20230331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOmMwMDczMTdhZDBjNDRiNDRiZDAxNWI2MWUxYTcwZmUwL3RhYmxlcmFuZ2U6YzAwNzMxN2FkMGM0NGI0NGJkMDE1YjYxZTFhNzBmZTBfMTEtNS0xLTEtMjg2OTQ0_f80c1956-8afd-45c4-80a5-33afff861957">342</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ia191fa3eb5734906a8bf76c6f6496bc1_I20230331" decimals="-6" name="us-gaap:TreasuryStockCommonShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOmMwMDczMTdhZDBjNDRiNDRiZDAxNWI2MWUxYTcwZmUwL3RhYmxlcmFuZ2U6YzAwNzMxN2FkMGM0NGI0NGJkMDE1YjYxZTFhNzBmZTBfMTEtNy0xLTEtMjg2OTQ0_3aa1ca8a-b0fb-40ec-aac8-cd4c5839d9e0">72</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia191fa3eb5734906a8bf76c6f6496bc1_I20230331" decimals="-6" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOmMwMDczMTdhZDBjNDRiNDRiZDAxNWI2MWUxYTcwZmUwL3RhYmxlcmFuZ2U6YzAwNzMxN2FkMGM0NGI0NGJkMDE1YjYxZTFhNzBmZTBfMTEtOS0xLTEtMjg2OTQ0_345d968b-80ec-4498-812e-5be55e0dc95c">4,554</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idf64830da37b4122b808db1a1819f451_I20230331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOmMwMDczMTdhZDBjNDRiNDRiZDAxNWI2MWUxYTcwZmUwL3RhYmxlcmFuZ2U6YzAwNzMxN2FkMGM0NGI0NGJkMDE1YjYxZTFhNzBmZTBfMTEtMTEtMS0xLTI4Njk0NA_3a1ef906-5bf4-42e5-af17-12521f5e59b4">142</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b78f3c4f51d4889980e7fc07edfec59_I20230331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOmMwMDczMTdhZDBjNDRiNDRiZDAxNWI2MWUxYTcwZmUwL3RhYmxlcmFuZ2U6YzAwNzMxN2FkMGM0NGI0NGJkMDE1YjYxZTFhNzBmZTBfMTEtMTMtMS0xLTI4Njk0NA_5a043fd2-ab1c-4707-8bf1-26896ae2d596">2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOmMwMDczMTdhZDBjNDRiNDRiZDAxNWI2MWUxYTcwZmUwL3RhYmxlcmFuZ2U6YzAwNzMxN2FkMGM0NGI0NGJkMDE1YjYxZTFhNzBmZTBfMTEtMTUtMS0xLTI4Njk0NA_50de10f4-b95a-4ed7-bc5c-594c7dbdbd9e">2,218</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"></td><td style="width:30.140%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.213%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.070%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended March 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i13c78c23b94549919369f13eef7a33f8_I20211231" decimals="-6" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjE5MmJjMDFkYWYzNTQ0OTA5MDFiYjE1N2M4MTI2MGQ5L3RhYmxlcmFuZ2U6MTkyYmMwMWRhZjM1NDQ5MDkwMWJiMTU3YzgxMjYwZDlfMS0xLTEtMS0yODY5NDQ_e849fe56-aa03-40c1-9be3-0da901dc707c">327</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13c78c23b94549919369f13eef7a33f8_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjE5MmJjMDFkYWYzNTQ0OTA5MDFiYjE1N2M4MTI2MGQ5L3RhYmxlcmFuZ2U6MTkyYmMwMWRhZjM1NDQ5MDkwMWJiMTU3YzgxMjYwZDlfMS0zLTEtMS0yODY5NDQ_fabbfb60-d9c5-4932-95ac-2ac505c52d74">2,721</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib002348769da4f519bc0a52ddbe725a0_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjE5MmJjMDFkYWYzNTQ0OTA5MDFiYjE1N2M4MTI2MGQ5L3RhYmxlcmFuZ2U6MTkyYmMwMWRhZjM1NDQ5MDkwMWJiMTU3YzgxMjYwZDlfMS01LTEtMS0yODY5NDQ_14a89919-5dac-4bde-b626-9d6ea24d0d24">1,245</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i869ddd309d65479f921f1950d72e9ae7_I20211231" decimals="-6" name="us-gaap:TreasuryStockCommonShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjE5MmJjMDFkYWYzNTQ0OTA5MDFiYjE1N2M4MTI2MGQ5L3RhYmxlcmFuZ2U6MTkyYmMwMWRhZjM1NDQ5MDkwMWJiMTU3YzgxMjYwZDlfMS03LTEtMS0yODY5NDQ_f96cae7f-dcd0-4532-a747-d6eef74db78a">50</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i869ddd309d65479f921f1950d72e9ae7_I20211231" decimals="-6" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjE5MmJjMDFkYWYzNTQ0OTA5MDFiYjE1N2M4MTI2MGQ5L3RhYmxlcmFuZ2U6MTkyYmMwMWRhZjM1NDQ5MDkwMWJiMTU3YzgxMjYwZDlfMS05LTEtMS0yODY5NDQ_dbeca2a3-242b-416e-b296-63972bb893d3">2,883</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i400ae55f5bf646e1a4865cfff0502178_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjE5MmJjMDFkYWYzNTQ0OTA5MDFiYjE1N2M4MTI2MGQ5L3RhYmxlcmFuZ2U6MTkyYmMwMWRhZjM1NDQ5MDkwMWJiMTU3YzgxMjYwZDlfMS0xMS0xLTEtMjg2OTQ0_a70dc501-4eff-4de5-9e67-32673697a9a9">85</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31325593417c40aea09d306e481d5c1c_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjE5MmJjMDFkYWYzNTQ0OTA5MDFiYjE1N2M4MTI2MGQ5L3RhYmxlcmFuZ2U6MTkyYmMwMWRhZjM1NDQ5MDkwMWJiMTU3YzgxMjYwZDlfMS0xMy0xLTEtMjg2OTQ0_52695e7a-5090-41ea-9a65-0ad8cc3b1172">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1da9880c72714008b4977c3a3f95890e_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjE5MmJjMDFkYWYzNTQ0OTA5MDFiYjE1N2M4MTI2MGQ5L3RhYmxlcmFuZ2U6MTkyYmMwMWRhZjM1NDQ5MDkwMWJiMTU3YzgxMjYwZDlfMS0xNS0xLTEtMjg2OTQ0_3ccc7378-00f5-4f8d-a0cb-5a51c29c8275">1,002</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net earnings/(loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjE5MmJjMDFkYWYzNTQ0OTA5MDFiYjE1N2M4MTI2MGQ5L3RhYmxlcmFuZ2U6MTkyYmMwMWRhZjM1NDQ5MDkwMWJiMTU3YzgxMjYwZDlfMi01LTEtMS0yODY5NDQ_77ef8dfc-5b96-414c-8c86-ee9f14ac21ca">1,391</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie41c2a5af47749b785d11deeee809585_D20220101-20220331" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjE5MmJjMDFkYWYzNTQ0OTA5MDFiYjE1N2M4MTI2MGQ5L3RhYmxlcmFuZ2U6MTkyYmMwMWRhZjM1NDQ5MDkwMWJiMTU3YzgxMjYwZDlfMi0xMy0xLTEtMjg2OTQ0_6e5f5ce0-6ba9-4093-b17a-0e68742217d6">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjE5MmJjMDFkYWYzNTQ0OTA5MDFiYjE1N2M4MTI2MGQ5L3RhYmxlcmFuZ2U6MTkyYmMwMWRhZjM1NDQ5MDkwMWJiMTU3YzgxMjYwZDlfMi0xNS0xLTEtMjg2OTQ0_f16ab458-2fd9-4b77-a045-7e6e8511f1ad">1,390</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i418f71a8a1cc4ca49f486b30f467dcbc_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjE5MmJjMDFkYWYzNTQ0OTA5MDFiYjE1N2M4MTI2MGQ5L3RhYmxlcmFuZ2U6MTkyYmMwMWRhZjM1NDQ5MDkwMWJiMTU3YzgxMjYwZDlfMy0xMS0xLTEtMjg2OTQ0_2f7e362e-58f9-4dfb-ba92-cd57a2bf6348">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjE5MmJjMDFkYWYzNTQ0OTA5MDFiYjE1N2M4MTI2MGQ5L3RhYmxlcmFuZ2U6MTkyYmMwMWRhZjM1NDQ5MDkwMWJiMTU3YzgxMjYwZDlfMy0xNS0xLTEtMjg2OTQ0_f7c8fe36-b96b-49a6-bbd2-28104d343a1a">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock plans activity, net of shares withheld for employee taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia19686236f7848079bbad68bd7c03742_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjE5MmJjMDFkYWYzNTQ0OTA5MDFiYjE1N2M4MTI2MGQ5L3RhYmxlcmFuZ2U6MTkyYmMwMWRhZjM1NDQ5MDkwMWJiMTU3YzgxMjYwZDlfNS0xLTEtMS0yODY5NDQ_9c976a29-8670-4560-9a29-330a47d5b084">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia19686236f7848079bbad68bd7c03742_D20220101-20220331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjE5MmJjMDFkYWYzNTQ0OTA5MDFiYjE1N2M4MTI2MGQ5L3RhYmxlcmFuZ2U6MTkyYmMwMWRhZjM1NDQ5MDkwMWJiMTU3YzgxMjYwZDlfNS0zLTEtMS0yODY5NDQ_15ba2bb0-02bc-4200-8cae-b64cea40e3ce">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="shares" contextRef="i49e3f3cae16c423db19dc0526a881118_D20220101-20220331" xsi:nil="true" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjE5MmJjMDFkYWYzNTQ0OTA5MDFiYjE1N2M4MTI2MGQ5L3RhYmxlcmFuZ2U6MTkyYmMwMWRhZjM1NDQ5MDkwMWJiMTU3YzgxMjYwZDlfNS03LTEtMS0yODY5NDQ_76824acf-4888-4589-b0b2-e832607bb770"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49e3f3cae16c423db19dc0526a881118_D20220101-20220331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjE5MmJjMDFkYWYzNTQ0OTA5MDFiYjE1N2M4MTI2MGQ5L3RhYmxlcmFuZ2U6MTkyYmMwMWRhZjM1NDQ5MDkwMWJiMTU3YzgxMjYwZDlfNS05LTEtMS0yODY5NDQ_b88040db-1904-46be-a328-01f91101dd63">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjE5MmJjMDFkYWYzNTQ0OTA5MDFiYjE1N2M4MTI2MGQ5L3RhYmxlcmFuZ2U6MTkyYmMwMWRhZjM1NDQ5MDkwMWJiMTU3YzgxMjYwZDlfNS0xNS0xLTEtMjg2OTQ0_bfa19ac0-be77-468d-8a5c-e9978ae32c15">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share repurchase program activity</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia19686236f7848079bbad68bd7c03742_D20220101-20220331" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjE5MmJjMDFkYWYzNTQ0OTA5MDFiYjE1N2M4MTI2MGQ5L3RhYmxlcmFuZ2U6MTkyYmMwMWRhZjM1NDQ5MDkwMWJiMTU3YzgxMjYwZDlfNi0zLTEtMS0yODY5NDQ_9e964554-06fd-4247-933b-010ccecc5600">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i49e3f3cae16c423db19dc0526a881118_D20220101-20220331" decimals="-6" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjE5MmJjMDFkYWYzNTQ0OTA5MDFiYjE1N2M4MTI2MGQ5L3RhYmxlcmFuZ2U6MTkyYmMwMWRhZjM1NDQ5MDkwMWJiMTU3YzgxMjYwZDlfNi03LTEtMS0yODY5NDQ_f5c4c763-e9b3-4091-a9f8-128f6ef31e31">4</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i49e3f3cae16c423db19dc0526a881118_D20220101-20220331" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjE5MmJjMDFkYWYzNTQ0OTA5MDFiYjE1N2M4MTI2MGQ5L3RhYmxlcmFuZ2U6MTkyYmMwMWRhZjM1NDQ5MDkwMWJiMTU3YzgxMjYwZDlfNi05LTEtMS0yODY5NDQ_b7c4ce57-8621-40df-916d-3e30967ed089">220</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjE5MmJjMDFkYWYzNTQ0OTA5MDFiYjE1N2M4MTI2MGQ5L3RhYmxlcmFuZ2U6MTkyYmMwMWRhZjM1NDQ5MDkwMWJiMTU3YzgxMjYwZDlfNi0xNS0xLTEtMjg2OTQ0_3d393ee4-3c07-47f7-9d0b-97dbc87590d8">200</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends declared</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if9a10ddae3d841d29503e0ad7359eefa_D20220101-20220331" decimals="-6" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjE5MmJjMDFkYWYzNTQ0OTA5MDFiYjE1N2M4MTI2MGQ5L3RhYmxlcmFuZ2U6MTkyYmMwMWRhZjM1NDQ5MDkwMWJiMTU3YzgxMjYwZDlfNy01LTEtMS0yODY5NDQ_b6320e25-fe35-4b32-a0d9-1fe7341f9d10">135</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331" decimals="-6" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjE5MmJjMDFkYWYzNTQ0OTA5MDFiYjE1N2M4MTI2MGQ5L3RhYmxlcmFuZ2U6MTkyYmMwMWRhZjM1NDQ5MDkwMWJiMTU3YzgxMjYwZDlfNy0xNS0xLTEtMjg2OTQ0_d5c972a4-3df9-46af-b052-32d84bbaa9e4">135</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ia19686236f7848079bbad68bd7c03742_D20220101-20220331" sign="-" xsi:nil="true" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjE5MmJjMDFkYWYzNTQ0OTA5MDFiYjE1N2M4MTI2MGQ5L3RhYmxlcmFuZ2U6MTkyYmMwMWRhZjM1NDQ5MDkwMWJiMTU3YzgxMjYwZDlfOC0zLTEtMS0yODY5NDQ_df4e81ec-0f30-48f5-b0c5-73f6467b1473"></ix:nonFraction></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="if9a10ddae3d841d29503e0ad7359eefa_D20220101-20220331" sign="-" xsi:nil="true" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjE5MmJjMDFkYWYzNTQ0OTA5MDFiYjE1N2M4MTI2MGQ5L3RhYmxlcmFuZ2U6MTkyYmMwMWRhZjM1NDQ5MDkwMWJiMTU3YzgxMjYwZDlfOC01LTEtMS0yODY5NDQ_12d11af1-1ee3-4a7c-98c2-27eb762035db"></ix:nonFraction></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"><ix:nonFraction unitRef="shares" contextRef="i49e3f3cae16c423db19dc0526a881118_D20220101-20220331" sign="-" xsi:nil="true" name="us-gaap:StockholdersEquityOtherShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjE5MmJjMDFkYWYzNTQ0OTA5MDFiYjE1N2M4MTI2MGQ5L3RhYmxlcmFuZ2U6MTkyYmMwMWRhZjM1NDQ5MDkwMWJiMTU3YzgxMjYwZDlfOC03LTEtMS0yODY5NDQ_55c36e63-7d80-4b9c-b548-6d3ff5cfa109"></ix:nonFraction></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie41c2a5af47749b785d11deeee809585_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjE5MmJjMDFkYWYzNTQ0OTA5MDFiYjE1N2M4MTI2MGQ5L3RhYmxlcmFuZ2U6MTkyYmMwMWRhZjM1NDQ5MDkwMWJiMTU3YzgxMjYwZDlfOC0xMy0xLTEtMjg2OTQ0_88fa9e1e-6269-4856-a253-628ad00733d7">1</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjE5MmJjMDFkYWYzNTQ0OTA5MDFiYjE1N2M4MTI2MGQ5L3RhYmxlcmFuZ2U6MTkyYmMwMWRhZjM1NDQ5MDkwMWJiMTU3YzgxMjYwZDlfOC0xNS0xLTEtMjg2OTQ0_9f87e3a2-7713-4d70-8eac-921a8f596609">1</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iafbe7b9485174b4e8c9f2d802e7dc231_I20220331" decimals="-6" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjE5MmJjMDFkYWYzNTQ0OTA5MDFiYjE1N2M4MTI2MGQ5L3RhYmxlcmFuZ2U6MTkyYmMwMWRhZjM1NDQ5MDkwMWJiMTU3YzgxMjYwZDlfOS0xLTEtMS0yODY5NDQ_ef8bf1ad-3a64-45cd-84bd-fc8605f80d72">327</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafbe7b9485174b4e8c9f2d802e7dc231_I20220331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjE5MmJjMDFkYWYzNTQ0OTA5MDFiYjE1N2M4MTI2MGQ5L3RhYmxlcmFuZ2U6MTkyYmMwMWRhZjM1NDQ5MDkwMWJiMTU3YzgxMjYwZDlfOS0zLTEtMS0yODY5NDQ_4119fe99-3b60-43fd-a908-4399c51f0c03">2,761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifb5d714a0e8b461297b910f807c80a18_I20220331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjE5MmJjMDFkYWYzNTQ0OTA5MDFiYjE1N2M4MTI2MGQ5L3RhYmxlcmFuZ2U6MTkyYmMwMWRhZjM1NDQ5MDkwMWJiMTU3YzgxMjYwZDlfOS01LTEtMS0yODY5NDQ_7ca8bc5f-5b6e-4fc4-9008-7894763e1679">281</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i9330ee3b45ee44a09dbcfeab14ffd40e_I20220331" decimals="-6" name="us-gaap:TreasuryStockCommonShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjE5MmJjMDFkYWYzNTQ0OTA5MDFiYjE1N2M4MTI2MGQ5L3RhYmxlcmFuZ2U6MTkyYmMwMWRhZjM1NDQ5MDkwMWJiMTU3YzgxMjYwZDlfOS03LTEtMS0yODY5NDQ_478893bc-e2e1-43b8-a580-65c2b8fe9a96">54</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9330ee3b45ee44a09dbcfeab14ffd40e_I20220331" decimals="-6" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjE5MmJjMDFkYWYzNTQ0OTA5MDFiYjE1N2M4MTI2MGQ5L3RhYmxlcmFuZ2U6MTkyYmMwMWRhZjM1NDQ5MDkwMWJiMTU3YzgxMjYwZDlfOS05LTEtMS0yODY5NDQ_0b66ee18-5614-493e-be1d-4624a4f8785e">3,100</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f0673078b15401ba450a8f78e2cc590_I20220331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjE5MmJjMDFkYWYzNTQ0OTA5MDFiYjE1N2M4MTI2MGQ5L3RhYmxlcmFuZ2U6MTkyYmMwMWRhZjM1NDQ5MDkwMWJiMTU3YzgxMjYwZDlfOS0xMS0xLTEtMjg2OTQ0_bc21ccc9-0041-4fff-80c8-d02bd90fd33b">77</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e1aae70a0da49d484500f615cb3fd5f_I20220331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjE5MmJjMDFkYWYzNTQ0OTA5MDFiYjE1N2M4MTI2MGQ5L3RhYmxlcmFuZ2U6MTkyYmMwMWRhZjM1NDQ5MDkwMWJiMTU3YzgxMjYwZDlfOS0xMy0xLTEtMjg2OTQ0_1ba4b88a-d70a-4623-9268-3ee9c439f836">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if9769f07affb42f58d537c7029824f72_I20220331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjE5MmJjMDFkYWYzNTQ0OTA5MDFiYjE1N2M4MTI2MGQ5L3RhYmxlcmFuZ2U6MTkyYmMwMWRhZjM1NDQ5MDkwMWJiMTU3YzgxMjYwZDlfOS0xNS0xLTEtMjg2OTQ0_2bea77f7-0832-42d6-879c-8def1ccffd62">693</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"></td><td style="width:30.140%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.213%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.070%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2022</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idb1c4815be35411c8c429c87e4166d03_I20220630" decimals="-6" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjA5MmVmZGUxZjRmYjQzMjdiNGNlMzAxODU5NWZhY2ZiL3RhYmxlcmFuZ2U6MDkyZWZkZTFmNGZiNDMyN2I0Y2UzMDE4NTk1ZmFjZmJfMy0xLTEtMS0yODY5NDQ_6f941452-91f6-451d-a6d8-7b974e3e06a7">327</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb1c4815be35411c8c429c87e4166d03_I20220630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjA5MmVmZGUxZjRmYjQzMjdiNGNlMzAxODU5NWZhY2ZiL3RhYmxlcmFuZ2U6MDkyZWZkZTFmNGZiNDMyN2I0Y2UzMDE4NTk1ZmFjZmJfMy0zLTEtMS0yODY5NDQ_50fd0f9c-609d-48c1-8e79-5f07cb0e995b">2,813</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i79094c6b94cc48dc906e4841e8ebb7e7_I20220630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjA5MmVmZGUxZjRmYjQzMjdiNGNlMzAxODU5NWZhY2ZiL3RhYmxlcmFuZ2U6MDkyZWZkZTFmNGZiNDMyN2I0Y2UzMDE4NTk1ZmFjZmJfMy01LTEtMS0yODY5NDQ_386fe164-bf98-475c-8546-318dfed61135">280</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i7a2aef50edb6408382366ab58c0a5fe5_I20220630" decimals="-6" sign="-" name="us-gaap:TreasuryStockCommonShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjA5MmVmZGUxZjRmYjQzMjdiNGNlMzAxODU5NWZhY2ZiL3RhYmxlcmFuZ2U6MDkyZWZkZTFmNGZiNDMyN2I0Y2UzMDE4NTk1ZmFjZmJfMy03LTEtMS0yODY5NDQ_9a9c90d5-5328-42d7-9cfe-665f41e6c403">54</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7a2aef50edb6408382366ab58c0a5fe5_I20220630" decimals="-6" sign="-" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjA5MmVmZGUxZjRmYjQzMjdiNGNlMzAxODU5NWZhY2ZiL3RhYmxlcmFuZ2U6MDkyZWZkZTFmNGZiNDMyN2I0Y2UzMDE4NTk1ZmFjZmJfMy05LTEtMS0yODY5NDQ_5a2eae1b-1078-4343-ae88-07b42b7af21b">3,128</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ab713f43fd740a3981b34442abff7e2_I20220630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjA5MmVmZGUxZjRmYjQzMjdiNGNlMzAxODU5NWZhY2ZiL3RhYmxlcmFuZ2U6MDkyZWZkZTFmNGZiNDMyN2I0Y2UzMDE4NTk1ZmFjZmJfMy0xMS0xLTEtMjg2OTQ0_72ce8a44-1978-4a0f-b176-c591b2fcd266">114</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9f0457c7d4d49858c91362f01b0d1db_I20220630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjA5MmVmZGUxZjRmYjQzMjdiNGNlMzAxODU5NWZhY2ZiL3RhYmxlcmFuZ2U6MDkyZWZkZTFmNGZiNDMyN2I0Y2UzMDE4NTk1ZmFjZmJfMy0xMy0xLTEtMjg2OTQ0_25a7c9b5-9c5c-4f54-9771-0d6c683d4f5e">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic217743408d440409a59220a0bf14e4c_I20220630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjA5MmVmZGUxZjRmYjQzMjdiNGNlMzAxODU5NWZhY2ZiL3RhYmxlcmFuZ2U6MDkyZWZkZTFmNGZiNDMyN2I0Y2UzMDE4NTk1ZmFjZmJfMy0xNS0xLTEtMjg2OTQ0_b2cdd77d-e40f-4ebe-aebc-7b0365068896">706</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net earnings</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjA5MmVmZGUxZjRmYjQzMjdiNGNlMzAxODU5NWZhY2ZiL3RhYmxlcmFuZ2U6MDkyZWZkZTFmNGZiNDMyN2I0Y2UzMDE4NTk1ZmFjZmJfNC01LTEtMS0yODY5NDQ_556bbc86-ddaa-4d5a-9b50-d11a0ede17b2">325</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddb780ecd77a4a539d61e232d9c38a2a_D20220701-20230331" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjA5MmVmZGUxZjRmYjQzMjdiNGNlMzAxODU5NWZhY2ZiL3RhYmxlcmFuZ2U6MDkyZWZkZTFmNGZiNDMyN2I0Y2UzMDE4NTk1ZmFjZmJfNC0xMy0xLTEtMjg2OTQ0_dd3e2016-d336-4a92-bd24-74fc9196d4c5">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjA5MmVmZGUxZjRmYjQzMjdiNGNlMzAxODU5NWZhY2ZiL3RhYmxlcmFuZ2U6MDkyZWZkZTFmNGZiNDMyN2I0Y2UzMDE4NTk1ZmFjZmJfNC0xNS0xLTEtMjg2OTQ0_18993d5d-1e0e-4dd6-9c87-932d096119ed">328</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5339f5e85f3b47c0aa0a7795a0147a83_D20220701-20230331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjA5MmVmZGUxZjRmYjQzMjdiNGNlMzAxODU5NWZhY2ZiL3RhYmxlcmFuZ2U6MDkyZWZkZTFmNGZiNDMyN2I0Y2UzMDE4NTk1ZmFjZmJfNS0xMS0xLTEtMjg2OTQ0_94651b4b-4090-40c9-99cd-cfaddd4f7226">28</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjA5MmVmZGUxZjRmYjQzMjdiNGNlMzAxODU5NWZhY2ZiL3RhYmxlcmFuZ2U6MDkyZWZkZTFmNGZiNDMyN2I0Y2UzMDE4NTk1ZmFjZmJfNS0xNS0xLTEtMjg2OTQ0_8cb88a1c-749b-46bd-af99-855361768359">28</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase of noncontrolling interests</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iddb780ecd77a4a539d61e232d9c38a2a_D20220701-20230331" decimals="-6" sign="-" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjA5MmVmZGUxZjRmYjQzMjdiNGNlMzAxODU5NWZhY2ZiL3RhYmxlcmFuZ2U6MDkyZWZkZTFmNGZiNDMyN2I0Y2UzMDE4NTk1ZmFjZmJfNi0xMy0xLTEtMjg2OTQ0_1d846a4a-9071-4015-b220-933bc3214e93">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" decimals="-6" sign="-" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjA5MmVmZGUxZjRmYjQzMjdiNGNlMzAxODU5NWZhY2ZiL3RhYmxlcmFuZ2U6MDkyZWZkZTFmNGZiNDMyN2I0Y2UzMDE4NTk1ZmFjZmJfNi0xNS0xLTEtMjg2OTQ0_e01ee3c7-09c7-4799-8f6b-3dd3bb208400">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock plans activity, net of shares withheld for employee taxes</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"><ix:nonFraction unitRef="shares" contextRef="iada78453d3a64782ab3851803455517a_D20220701-20230331" xsi:nil="true" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjA5MmVmZGUxZjRmYjQzMjdiNGNlMzAxODU5NWZhY2ZiL3RhYmxlcmFuZ2U6MDkyZWZkZTFmNGZiNDMyN2I0Y2UzMDE4NTk1ZmFjZmJfNy0xLTEtMS0yODY5NDQ_43de3074-2b2b-4bf3-837c-b3fc7562df8e"></ix:nonFraction></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iada78453d3a64782ab3851803455517a_D20220701-20230331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjA5MmVmZGUxZjRmYjQzMjdiNGNlMzAxODU5NWZhY2ZiL3RhYmxlcmFuZ2U6MDkyZWZkZTFmNGZiNDMyN2I0Y2UzMDE4NTk1ZmFjZmJfNy0zLTEtMS0yODY5NDQ_fd11a5dd-fe2e-46f3-8d8b-006855404b01">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjA5MmVmZGUxZjRmYjQzMjdiNGNlMzAxODU5NWZhY2ZiL3RhYmxlcmFuZ2U6MDkyZWZkZTFmNGZiNDMyN2I0Y2UzMDE4NTk1ZmFjZmJfNy03LTEtMS0yODY5NDQ_e3c0b3c6-03a5-4bda-967e-3204b5fd7650">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e5c5ae766b74cf6a2409e8a66778fe4_D20220701-20230331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjA5MmVmZGUxZjRmYjQzMjdiNGNlMzAxODU5NWZhY2ZiL3RhYmxlcmFuZ2U6MDkyZWZkZTFmNGZiNDMyN2I0Y2UzMDE4NTk1ZmFjZmJfNy05LTEtMS0yODY5NDQ_eaa3e6cc-ce0d-46ba-b10a-afbc16be63bd">77</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjA5MmVmZGUxZjRmYjQzMjdiNGNlMzAxODU5NWZhY2ZiL3RhYmxlcmFuZ2U6MDkyZWZkZTFmNGZiNDMyN2I0Y2UzMDE4NTk1ZmFjZmJfNy0xNS0xLTEtMjg2OTQ0_5382aaec-85cd-4f91-840d-5f454db1c972">82</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share repurchase program activity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="iada78453d3a64782ab3851803455517a_D20220701-20230331" xsi:nil="true" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjA5MmVmZGUxZjRmYjQzMjdiNGNlMzAxODU5NWZhY2ZiL3RhYmxlcmFuZ2U6MDkyZWZkZTFmNGZiNDMyN2I0Y2UzMDE4NTk1ZmFjZmJfOC0zLTEtMS0yODY5NDQ_e0c67b81-97ca-4416-800b-b8a79fde309b"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i8e5c5ae766b74cf6a2409e8a66778fe4_D20220701-20230331" decimals="-6" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjA5MmVmZGUxZjRmYjQzMjdiNGNlMzAxODU5NWZhY2ZiL3RhYmxlcmFuZ2U6MDkyZWZkZTFmNGZiNDMyN2I0Y2UzMDE4NTk1ZmFjZmJfOC03LTEtMS0yODY5NDQ_4ef6f22f-2539-4b27-8b30-b8972393b105">20</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8e5c5ae766b74cf6a2409e8a66778fe4_D20220701-20230331" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjA5MmVmZGUxZjRmYjQzMjdiNGNlMzAxODU5NWZhY2ZiL3RhYmxlcmFuZ2U6MDkyZWZkZTFmNGZiNDMyN2I0Y2UzMDE4NTk1ZmFjZmJfOC05LTEtMS0yODY5NDQ_c5dae461-c117-44d4-85ae-1297337506da">1,503</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjA5MmVmZGUxZjRmYjQzMjdiNGNlMzAxODU5NWZhY2ZiL3RhYmxlcmFuZ2U6MDkyZWZkZTFmNGZiNDMyN2I0Y2UzMDE4NTk1ZmFjZmJfOC0xNS0xLTEtMjg2OTQ0_12e001a9-8222-4d41-b848-41551f164c69">1,503</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends declared</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icafe121606cd4112b5329a3ce5274e9d_D20220701-20230331" decimals="-6" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjA5MmVmZGUxZjRmYjQzMjdiNGNlMzAxODU5NWZhY2ZiL3RhYmxlcmFuZ2U6MDkyZWZkZTFmNGZiNDMyN2I0Y2UzMDE4NTk1ZmFjZmJfOS01LTEtMS0yODY5NDQ_ee0e48bd-2d8a-41c5-a7d4-2ef3ddff98a2">388</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" decimals="-6" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjA5MmVmZGUxZjRmYjQzMjdiNGNlMzAxODU5NWZhY2ZiL3RhYmxlcmFuZ2U6MDkyZWZkZTFmNGZiNDMyN2I0Y2UzMDE4NTk1ZmFjZmJfOS0xNS0xLTEtMjg2OTQ0_5596df0a-8031-40c4-9112-7c592beaf899">388</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icafe121606cd4112b5329a3ce5274e9d_D20220701-20230331" decimals="-6" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjA5MmVmZGUxZjRmYjQzMjdiNGNlMzAxODU5NWZhY2ZiL3RhYmxlcmFuZ2U6MDkyZWZkZTFmNGZiNDMyN2I0Y2UzMDE4NTk1ZmFjZmJfMTAtNS0xLTEtMjg2OTQ0_07e96f63-8a52-4f3b-a2ec-b5375468c314">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="shares" contextRef="i8e5c5ae766b74cf6a2409e8a66778fe4_D20220701-20230331" sign="-" xsi:nil="true" name="us-gaap:StockholdersEquityOtherShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjA5MmVmZGUxZjRmYjQzMjdiNGNlMzAxODU5NWZhY2ZiL3RhYmxlcmFuZ2U6MDkyZWZkZTFmNGZiNDMyN2I0Y2UzMDE4NTk1ZmFjZmJfMTAtNy0xLTEtMjg2OTQ0_f33e2617-cb11-42e1-ab22-d88cc3402fa3"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iddb780ecd77a4a539d61e232d9c38a2a_D20220701-20230331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjA5MmVmZGUxZjRmYjQzMjdiNGNlMzAxODU5NWZhY2ZiL3RhYmxlcmFuZ2U6MDkyZWZkZTFmNGZiNDMyN2I0Y2UzMDE4NTk1ZmFjZmJfMTAtMTMtMS0xLTI4Njk0NA_ef031a40-658b-437e-9ae8-a9cb8f58354c">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjA5MmVmZGUxZjRmYjQzMjdiNGNlMzAxODU5NWZhY2ZiL3RhYmxlcmFuZ2U6MDkyZWZkZTFmNGZiNDMyN2I0Y2UzMDE4NTk1ZmFjZmJfMTAtMTUtMS0xLTI4Njk0NA_cc93018f-4fa1-4c26-afa9-2ba91a039ecc">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at March 31, 2023</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3208791586fb4201860768dd298b3bb2_I20230331" decimals="-6" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjA5MmVmZGUxZjRmYjQzMjdiNGNlMzAxODU5NWZhY2ZiL3RhYmxlcmFuZ2U6MDkyZWZkZTFmNGZiNDMyN2I0Y2UzMDE4NTk1ZmFjZmJfMTEtMS0xLTEtMjg2OTQ0_0a31b62c-9f71-4744-adfe-df4dc0ee7c47">327</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3208791586fb4201860768dd298b3bb2_I20230331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjA5MmVmZGUxZjRmYjQzMjdiNGNlMzAxODU5NWZhY2ZiL3RhYmxlcmFuZ2U6MDkyZWZkZTFmNGZiNDMyN2I0Y2UzMDE4NTk1ZmFjZmJfMTEtMy0xLTEtMjg2OTQ0_492db031-98a2-4bb5-9909-8022bf59d9fa">2,818</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69743694027f433b8def521fd90c10b1_I20230331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjA5MmVmZGUxZjRmYjQzMjdiNGNlMzAxODU5NWZhY2ZiL3RhYmxlcmFuZ2U6MDkyZWZkZTFmNGZiNDMyN2I0Y2UzMDE4NTk1ZmFjZmJfMTEtNS0xLTEtMjg2OTQ0_c2718f4b-7b6e-45f6-a21b-f4f5fd3ab3f7">342</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ia191fa3eb5734906a8bf76c6f6496bc1_I20230331" decimals="-6" name="us-gaap:TreasuryStockCommonShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjA5MmVmZGUxZjRmYjQzMjdiNGNlMzAxODU5NWZhY2ZiL3RhYmxlcmFuZ2U6MDkyZWZkZTFmNGZiNDMyN2I0Y2UzMDE4NTk1ZmFjZmJfMTEtNy0xLTEtMjg2OTQ0_6ac4d55e-f1c2-44d3-8bf5-03b195520bca">72</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia191fa3eb5734906a8bf76c6f6496bc1_I20230331" decimals="-6" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjA5MmVmZGUxZjRmYjQzMjdiNGNlMzAxODU5NWZhY2ZiL3RhYmxlcmFuZ2U6MDkyZWZkZTFmNGZiNDMyN2I0Y2UzMDE4NTk1ZmFjZmJfMTEtOS0xLTEtMjg2OTQ0_9a23eed8-dbbd-43ea-895b-86483bf7f25a">4,554</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idf64830da37b4122b808db1a1819f451_I20230331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjA5MmVmZGUxZjRmYjQzMjdiNGNlMzAxODU5NWZhY2ZiL3RhYmxlcmFuZ2U6MDkyZWZkZTFmNGZiNDMyN2I0Y2UzMDE4NTk1ZmFjZmJfMTEtMTEtMS0xLTI4Njk0NA_79f83472-b662-46a3-a73d-25574720028d">142</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b78f3c4f51d4889980e7fc07edfec59_I20230331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjA5MmVmZGUxZjRmYjQzMjdiNGNlMzAxODU5NWZhY2ZiL3RhYmxlcmFuZ2U6MDkyZWZkZTFmNGZiNDMyN2I0Y2UzMDE4NTk1ZmFjZmJfMTEtMTMtMS0xLTI4Njk0NA_e279e930-895f-4ad0-ba7a-218cc94ab31a">2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjA5MmVmZGUxZjRmYjQzMjdiNGNlMzAxODU5NWZhY2ZiL3RhYmxlcmFuZ2U6MDkyZWZkZTFmNGZiNDMyN2I0Y2UzMDE4NTk1ZmFjZmJfMTEtMTUtMS0xLTI4Njk0NA_2cf09a2d-97f6-4e73-a64e-5def4554d7f7">2,218</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"></td><td style="width:30.140%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.213%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.070%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended March 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2021</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if4a2a8ced444402e984b4c3bc89c5c8d_I20210630" decimals="-6" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjM1ODMyMmU3ZDA0MTRjMzViZWI2NDkwNzNjMzI5NTgzL3RhYmxlcmFuZ2U6MzU4MzIyZTdkMDQxNGMzNWJlYjY0OTA3M2MzMjk1ODNfMS0xLTEtMS0yODY5NDQ_e4365db9-f24b-403e-8972-f28c8f5dfc39">327</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4a2a8ced444402e984b4c3bc89c5c8d_I20210630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjM1ODMyMmU3ZDA0MTRjMzViZWI2NDkwNzNjMzI5NTgzL3RhYmxlcmFuZ2U6MzU4MzIyZTdkMDQxNGMzNWJlYjY0OTA3M2MzMjk1ODNfMS0zLTEtMS0yODY5NDQ_2cbca1ea-85ad-4afc-849c-c3225cfee6aa">2,806</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfec14d9fb124cfe89c5bea933f8e5c2_I20210630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjM1ODMyMmU3ZDA0MTRjMzViZWI2NDkwNzNjMzI5NTgzL3RhYmxlcmFuZ2U6MzU4MzIyZTdkMDQxNGMzNWJlYjY0OTA3M2MzMjk1ODNfMS01LTEtMS0yODY5NDQ_b35942e5-a740-4eae-b356-efdfe94e6752">1,205</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i2aece4cef70c4e909ce54489503e648a_I20210630" decimals="-6" name="us-gaap:TreasuryStockCommonShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjM1ODMyMmU3ZDA0MTRjMzViZWI2NDkwNzNjMzI5NTgzL3RhYmxlcmFuZ2U6MzU4MzIyZTdkMDQxNGMzNWJlYjY0OTA3M2MzMjk1ODNfMS03LTEtMS0yODY5NDQ_72c6fd28-9e6d-4f1e-bc4d-8e0b566673a2">36</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2aece4cef70c4e909ce54489503e648a_I20210630" decimals="-6" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjM1ODMyMmU3ZDA0MTRjMzViZWI2NDkwNzNjMzI5NTgzL3RhYmxlcmFuZ2U6MzU4MzIyZTdkMDQxNGMzNWJlYjY0OTA3M2MzMjk1ODNfMS05LTEtMS0yODY5NDQ_d4209cf4-a513-4e97-9f98-5fc52f3e4b7c">2,186</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i866c0616d4fa407cb18e678ede1cf44e_I20210630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjM1ODMyMmU3ZDA0MTRjMzViZWI2NDkwNzNjMzI5NTgzL3RhYmxlcmFuZ2U6MzU4MzIyZTdkMDQxNGMzNWJlYjY0OTA3M2MzMjk1ODNfMS0xMS0xLTEtMjg2OTQ0_0893dd7f-9877-4d77-8bd6-058b5bc111b0">34</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ae8d288fa1c40efba1860f8c0297502_I20210630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjM1ODMyMmU3ZDA0MTRjMzViZWI2NDkwNzNjMzI5NTgzL3RhYmxlcmFuZ2U6MzU4MzIyZTdkMDQxNGMzNWJlYjY0OTA3M2MzMjk1ODNfMS0xMy0xLTEtMjg2OTQ0_1cb3be9e-8aa4-42a1-8052-3b100e585219">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75b88320c8d34867830cda3167c67779_I20210630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjM1ODMyMmU3ZDA0MTRjMzViZWI2NDkwNzNjMzI5NTgzL3RhYmxlcmFuZ2U6MzU4MzIyZTdkMDQxNGMzNWJlYjY0OTA3M2MzMjk1ODNfMS0xNS0xLTEtMjg2OTQ0_e6eb90ea-dcdd-474e-9bd4-bd8c645faad0">1,794</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net earnings/(loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjM1ODMyMmU3ZDA0MTRjMzViZWI2NDkwNzNjMzI5NTgzL3RhYmxlcmFuZ2U6MzU4MzIyZTdkMDQxNGMzNWJlYjY0OTA3M2MzMjk1ODNfMi01LTEtMS0yODY5NDQ_e4af5ca6-1f58-4572-9ff3-d6278df7c114">1,071</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3eb749068f254e87ba6fe7696f1b7ae3_D20210701-20220331" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjM1ODMyMmU3ZDA0MTRjMzViZWI2NDkwNzNjMzI5NTgzL3RhYmxlcmFuZ2U6MzU4MzIyZTdkMDQxNGMzNWJlYjY0OTA3M2MzMjk1ODNfMi0xMy0xLTEtMjg2OTQ0_c0bc6471-8b40-46d0-8269-1ebd5815f683">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331" decimals="-6" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjM1ODMyMmU3ZDA0MTRjMzViZWI2NDkwNzNjMzI5NTgzL3RhYmxlcmFuZ2U6MzU4MzIyZTdkMDQxNGMzNWJlYjY0OTA3M2MzMjk1ODNfMi0xNS0xLTEtMjg2OTQ0_5adecded-f796-45de-af41-d1f97bfa47a6">1,069</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibf631f27db6a4b97b407bf7c07872ada_D20210701-20220331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjM1ODMyMmU3ZDA0MTRjMzViZWI2NDkwNzNjMzI5NTgzL3RhYmxlcmFuZ2U6MzU4MzIyZTdkMDQxNGMzNWJlYjY0OTA3M2MzMjk1ODNfMy0xMS0xLTEtMjg2OTQ0_015d27b4-1b1e-478a-b659-0c7e25ca8e14">43</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjM1ODMyMmU3ZDA0MTRjMzViZWI2NDkwNzNjMzI5NTgzL3RhYmxlcmFuZ2U6MzU4MzIyZTdkMDQxNGMzNWJlYjY0OTA3M2MzMjk1ODNfMy0xNS0xLTEtMjg2OTQ0_658e0fab-e6ee-4827-a881-ecac3854f784">43</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock plans activity, net of shares withheld for employee taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i259a6ff3365f4c53ac0b2f2edbb89551_D20210701-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjM1ODMyMmU3ZDA0MTRjMzViZWI2NDkwNzNjMzI5NTgzL3RhYmxlcmFuZ2U6MzU4MzIyZTdkMDQxNGMzNWJlYjY0OTA3M2MzMjk1ODNfNS0xLTEtMS0yODY5NDQ_06ab98d5-3da2-4815-9cbb-966febd9370f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i259a6ff3365f4c53ac0b2f2edbb89551_D20210701-20220331" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjM1ODMyMmU3ZDA0MTRjMzViZWI2NDkwNzNjMzI5NTgzL3RhYmxlcmFuZ2U6MzU4MzIyZTdkMDQxNGMzNWJlYjY0OTA3M2MzMjk1ODNfNS0zLTEtMS0yODY5NDQ_e29d84b3-513d-43cd-a1d6-7a1dbc798f71">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib1adee5e79374a97893072820fddaa0e_D20210701-20220331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjM1ODMyMmU3ZDA0MTRjMzViZWI2NDkwNzNjMzI5NTgzL3RhYmxlcmFuZ2U6MzU4MzIyZTdkMDQxNGMzNWJlYjY0OTA3M2MzMjk1ODNfNS03LTEtMS0yODY5NDQ_d2997bc1-fded-4050-bef5-e7f7fb52c40e">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1adee5e79374a97893072820fddaa0e_D20210701-20220331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjM1ODMyMmU3ZDA0MTRjMzViZWI2NDkwNzNjMzI5NTgzL3RhYmxlcmFuZ2U6MzU4MzIyZTdkMDQxNGMzNWJlYjY0OTA3M2MzMjk1ODNfNS05LTEtMS0yODY5NDQ_57a2dd1d-b480-473b-9595-34744ee6e63c">46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjM1ODMyMmU3ZDA0MTRjMzViZWI2NDkwNzNjMzI5NTgzL3RhYmxlcmFuZ2U6MzU4MzIyZTdkMDQxNGMzNWJlYjY0OTA3M2MzMjk1ODNfNS0xNS0xLTEtMjg2OTQ0_936f353f-5f56-4787-8728-5be3b4c648ea">41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share repurchase program activity</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i259a6ff3365f4c53ac0b2f2edbb89551_D20210701-20220331" decimals="-6" sign="-" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjM1ODMyMmU3ZDA0MTRjMzViZWI2NDkwNzNjMzI5NTgzL3RhYmxlcmFuZ2U6MzU4MzIyZTdkMDQxNGMzNWJlYjY0OTA3M2MzMjk1ODNfNi0zLTEtMS0yODY5NDQ_2925d187-0757-422b-b16f-d25a6533b58d">40</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ib1adee5e79374a97893072820fddaa0e_D20210701-20220331" decimals="-6" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjM1ODMyMmU3ZDA0MTRjMzViZWI2NDkwNzNjMzI5NTgzL3RhYmxlcmFuZ2U6MzU4MzIyZTdkMDQxNGMzNWJlYjY0OTA3M2MzMjk1ODNfNi03LTEtMS0yODY5NDQ_bec5a1e1-5959-4f0c-9992-f636c87876fd">19</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib1adee5e79374a97893072820fddaa0e_D20210701-20220331" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjM1ODMyMmU3ZDA0MTRjMzViZWI2NDkwNzNjMzI5NTgzL3RhYmxlcmFuZ2U6MzU4MzIyZTdkMDQxNGMzNWJlYjY0OTA3M2MzMjk1ODNfNi05LTEtMS0yODY5NDQ_3f2f6548-7cca-4b33-bc3d-58515091b7ab">960</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjM1ODMyMmU3ZDA0MTRjMzViZWI2NDkwNzNjMzI5NTgzL3RhYmxlcmFuZ2U6MzU4MzIyZTdkMDQxNGMzNWJlYjY0OTA3M2MzMjk1ODNfNi0xNS0xLTEtMjg2OTQ0_e61c655b-a3b2-4728-b53a-b98d72fc5eea">1,000</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends declared</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0db8654b67c442ae83277edeaf53cedc_D20210701-20220331" decimals="-6" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjM1ODMyMmU3ZDA0MTRjMzViZWI2NDkwNzNjMzI5NTgzL3RhYmxlcmFuZ2U6MzU4MzIyZTdkMDQxNGMzNWJlYjY0OTA3M2MzMjk1ODNfNy01LTEtMS0yODY5NDQ_1a3625eb-0022-42cb-b10e-efaa803c4392">415</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331" decimals="-6" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjM1ODMyMmU3ZDA0MTRjMzViZWI2NDkwNzNjMzI5NTgzL3RhYmxlcmFuZ2U6MzU4MzIyZTdkMDQxNGMzNWJlYjY0OTA3M2MzMjk1ODNfNy0xNS0xLTEtMjg2OTQ0_45ec859a-c9ea-4ea2-a4f5-a7a33acbb03e">415</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i0db8654b67c442ae83277edeaf53cedc_D20210701-20220331" sign="-" xsi:nil="true" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjM1ODMyMmU3ZDA0MTRjMzViZWI2NDkwNzNjMzI5NTgzL3RhYmxlcmFuZ2U6MzU4MzIyZTdkMDQxNGMzNWJlYjY0OTA3M2MzMjk1ODNfOC01LTEtMS0yODY5NDQ_46475fb7-8028-4975-91a9-fd91da7717da"></ix:nonFraction></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"><ix:nonFraction unitRef="shares" contextRef="ib1adee5e79374a97893072820fddaa0e_D20210701-20220331" sign="-" xsi:nil="true" name="us-gaap:StockholdersEquityOtherShares" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjM1ODMyMmU3ZDA0MTRjMzViZWI2NDkwNzNjMzI5NTgzL3RhYmxlcmFuZ2U6MzU4MzIyZTdkMDQxNGMzNWJlYjY0OTA3M2MzMjk1ODNfOC03LTEtMS0yODY5NDQ_1d00571f-f3b2-4531-9944-9535d67af4de"></ix:nonFraction></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3eb749068f254e87ba6fe7696f1b7ae3_D20210701-20220331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjM1ODMyMmU3ZDA0MTRjMzViZWI2NDkwNzNjMzI5NTgzL3RhYmxlcmFuZ2U6MzU4MzIyZTdkMDQxNGMzNWJlYjY0OTA3M2MzMjk1ODNfOC0xMy0xLTEtMjg2OTQ0_7587a351-0390-4369-9670-003f4679110c">1</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjM1ODMyMmU3ZDA0MTRjMzViZWI2NDkwNzNjMzI5NTgzL3RhYmxlcmFuZ2U6MzU4MzIyZTdkMDQxNGMzNWJlYjY0OTA3M2MzMjk1ODNfOC0xNS0xLTEtMjg2OTQ0_8380e6f3-552d-4c15-ba67-1b6ca2c98f7d">1</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iafbe7b9485174b4e8c9f2d802e7dc231_I20220331" decimals="-6" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjM1ODMyMmU3ZDA0MTRjMzViZWI2NDkwNzNjMzI5NTgzL3RhYmxlcmFuZ2U6MzU4MzIyZTdkMDQxNGMzNWJlYjY0OTA3M2MzMjk1ODNfOS0xLTEtMS0yODY5NDQ_ff52e299-adbf-49ba-ad71-75a9c496d75b">327</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafbe7b9485174b4e8c9f2d802e7dc231_I20220331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjM1ODMyMmU3ZDA0MTRjMzViZWI2NDkwNzNjMzI5NTgzL3RhYmxlcmFuZ2U6MzU4MzIyZTdkMDQxNGMzNWJlYjY0OTA3M2MzMjk1ODNfOS0zLTEtMS0yODY5NDQ_b02832c9-a586-4602-9827-7f200df07600">2,761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifb5d714a0e8b461297b910f807c80a18_I20220331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjM1ODMyMmU3ZDA0MTRjMzViZWI2NDkwNzNjMzI5NTgzL3RhYmxlcmFuZ2U6MzU4MzIyZTdkMDQxNGMzNWJlYjY0OTA3M2MzMjk1ODNfOS01LTEtMS0yODY5NDQ_ad577e5c-7c24-419e-868c-ea539dc0759c">281</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i9330ee3b45ee44a09dbcfeab14ffd40e_I20220331" decimals="-6" name="us-gaap:TreasuryStockCommonShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjM1ODMyMmU3ZDA0MTRjMzViZWI2NDkwNzNjMzI5NTgzL3RhYmxlcmFuZ2U6MzU4MzIyZTdkMDQxNGMzNWJlYjY0OTA3M2MzMjk1ODNfOS03LTEtMS0yODY5NDQ_cec5b7f4-53da-4ff4-832d-9bce394e52d7">54</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9330ee3b45ee44a09dbcfeab14ffd40e_I20220331" decimals="-6" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjM1ODMyMmU3ZDA0MTRjMzViZWI2NDkwNzNjMzI5NTgzL3RhYmxlcmFuZ2U6MzU4MzIyZTdkMDQxNGMzNWJlYjY0OTA3M2MzMjk1ODNfOS05LTEtMS0yODY5NDQ_48819d01-1844-450b-96ce-c571de2a884a">3,100</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f0673078b15401ba450a8f78e2cc590_I20220331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjM1ODMyMmU3ZDA0MTRjMzViZWI2NDkwNzNjMzI5NTgzL3RhYmxlcmFuZ2U6MzU4MzIyZTdkMDQxNGMzNWJlYjY0OTA3M2MzMjk1ODNfOS0xMS0xLTEtMjg2OTQ0_31517a67-eff0-4500-b5f1-30cbf3154ea9">77</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e1aae70a0da49d484500f615cb3fd5f_I20220331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjM1ODMyMmU3ZDA0MTRjMzViZWI2NDkwNzNjMzI5NTgzL3RhYmxlcmFuZ2U6MzU4MzIyZTdkMDQxNGMzNWJlYjY0OTA3M2MzMjk1ODNfOS0xMy0xLTEtMjg2OTQ0_08f7bd88-a3b9-473f-b5fa-1f955043b2d9">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if9769f07affb42f58d537c7029824f72_I20220331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjM1ODMyMmU3ZDA0MTRjMzViZWI2NDkwNzNjMzI5NTgzL3RhYmxlcmFuZ2U6MzU4MzIyZTdkMDQxNGMzNWJlYjY0OTA3M2MzMjk1ODNfOS0xNS0xLTEtMjg2OTQ0_fa3ba32a-5269-4377-94ab-79eaa2aa3cc6">693</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to condensed consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">29</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i1d34fc4fc2424fbcb4837cc9f1c0665c_73"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.775%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.590%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.591%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net earnings/(loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfMy0xLTEtMS0yODY5NDQ_163febd8-dd9a-4c3d-bbbd-9124df675f7f">328</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331" decimals="-6" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfMy0zLTEtMS0yODY5NDQ_202d77f7-bddc-47c0-8de7-077a2fafdf3e">1,069</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments to reconcile net earnings/(loss) to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfNi0xLTEtMS0yODY5NDQ_6c9337b3-ab02-4a08-92be-44b1411a127f">516</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfNi0zLTEtMS0yODY5NDQ_b5d5a5a7-6766-4be2-be0d-a1feb2e5e05f">513</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairments and (gain)/loss on disposal of assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" decimals="-6" sign="-" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfNy0xLTEtMS0zNzAyMjc_bc7b2822-47d0-4aed-bfab-79f55bb76bea">883</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331" decimals="-6" sign="-" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfNy0zLTEtMS0zNzAyMjc_43f941d8-ff89-493b-8a3a-d74bdc532848">1,764</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairments and loss on sale of other investments</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" decimals="-6" name="us-gaap:GainLossOnSaleOfOtherInvestments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfNy0xLTEtMS0yODY5NDQ_de4c708d-5277-4a9c-9ea4-d80b083c8429">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331" decimals="-6" sign="-" name="us-gaap:GainLossOnSaleOfOtherInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfNy0zLTEtMS0yODY5NDQ_6dc3df36-2983-47a9-8582-a59e8a9a4c47">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Gain)/loss on sale of equity interest in naviHealth</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" decimals="-6" name="us-gaap:GainLossOnSaleOfInvestments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfOC0xLTEtMS0yODY5NDQ_81be80d2-2edf-4a5e-9242-12ba59d89dad">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331" decimals="-6" name="us-gaap:GainLossOnSaleOfInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfOC0zLTEtMS0yODY5NDQ_fca12224-74de-4744-877c-cc79a533e5f0">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on early extinguishment of debt</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" decimals="-6" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfMTAtMS0xLTEtMjg2OTQ0_30aa46e2-161f-4bcc-9204-9a9e39cbbf10">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfMTAtMy0xLTEtMjg2OTQ0_e63d7449-afd0-447c-b5b4-0f0c8cb0d7af">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfMTEtMS0xLTEtMjg2OTQ0_0223221d-a601-4c68-931a-7cab3537379f">69</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfMTEtMy0xLTEtMjg2OTQ0_fbd7e70a-57fe-4c30-b6ac-afb752d65ec4">65</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Provision for bad debts</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" decimals="-6" name="us-gaap:ProvisionForDoubtfulAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfMTMtMS0xLTEtMjg2OTQ0_aef6e029-9900-4324-bc6e-0b273dbc09c9">79</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331" decimals="-6" name="us-gaap:ProvisionForDoubtfulAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfMTMtMy0xLTEtMjg2OTQ0_7c18d82a-be15-4c38-9f92-c846ac8d79b9">46</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in operating assets and liabilities, net of effects from acquisitions and divestitures:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Increase in trade receivables</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" decimals="-6" name="us-gaap:IncreaseDecreaseInReceivables" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfMTUtMS0xLTEtMjg2OTQ0_865bb25f-6732-4b0a-92f4-0cf29a5c5388">510</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331" decimals="-6" name="us-gaap:IncreaseDecreaseInReceivables" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfMTUtMy0xLTEtMjg2OTQ0_7a389116-c6bd-44c2-9e73-24d0e8ec7a7e">1,193</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Increase in inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfMTYtMS0xLTEtMjg2OTQ0_aef1ba4e-3fe6-457f-abd8-5fce012ac3d9">1,012</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfMTYtMy0xLTEtMjg2OTQ0_4c97c433-70f9-4e75-9686-760fb2b13a5f">922</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Increase in accounts payable</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfMTctMS0xLTEtMjg2OTQ0_2afe8f8a-678c-4a83-b0d5-bc930fe1a37e">2,473</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfMTctMy0xLTEtMjg2OTQ0_7a04c180-e10f-4882-8711-d00313744646">1,121</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other accrued liabilities and operating items, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfMTgtMS0xLTEtMjg2OTQ0_8bd7f972-ce6f-488e-bb74-a47c40c2e5b5">845</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfMTgtMy0xLTEtMjg2OTQ0_0c234768-fee1-4e01-95a2-d122f85d3c76">206</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfMTktMS0xLTEtMjg2OTQ0_38d9bb09-c251-43f5-9df5-72e737ca4e98">1,981</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfMTktMy0xLTEtMjg2OTQ0_46bcc13b-3ebc-4b4b-8fde-cbaec4f116e7">130</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from divestitures, net of cash sold</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" decimals="-6" name="us-gaap:ProceedsFromDivestitureOfBusinesses" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfMjItMS0xLTEtMjg2OTQ0_36d60ceb-1451-47f1-8f25-045ec764d2f3">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331" decimals="-6" name="us-gaap:ProceedsFromDivestitureOfBusinesses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfMjItMy0xLTEtMjg2OTQ0_a4872ac6-a0a1-47a8-bc63-76b8cc2822cb">923</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisition of subsidiaries, net of cash acquired</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfMjMtMS0xLTEtMjg2OTQ0_c0f9137b-4df9-4170-aadc-22f173f9b4c8">10</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfMjMtMy0xLTEtMjg2OTQ0_f87eb946-50ed-4950-ac1c-71c4684a03fe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions to property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfMjQtMS0xLTEtMjg2OTQ0_d7b6283a-878b-47af-9029-e67433ad59ab">264</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfMjQtMy0xLTEtMjg2OTQ0_c867619d-45bb-4a4f-a2f5-8f3b78ee1488">223</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from disposal of property and equipment</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" decimals="-6" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfMjUtMS0xLTEtMjg2OTQ0_b34bcbca-96fb-4150-bc1b-1ca1e97addcc">2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331" decimals="-6" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfMjUtMy0xLTEtMjg2OTQ0_ff48f283-979a-47d7-bb9a-f41f1da6f300">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" decimals="-6" name="cah:Purchaseofavailableforsalesecuritiesandotherinvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfMjYtMS0xLTEtMjg2OTQ0_de8acc23-36ad-44fe-90e7-e8c65e35c858">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331" decimals="-6" name="cah:Purchaseofavailableforsalesecuritiesandotherinvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfMjYtMy0xLTEtMjg2OTQ0_251d6f36-5655-41a8-82e7-78009a587ce4">38</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from investments</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" decimals="-6" name="cah:Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfMjctMS0xLTEtMjg2OTQ0_1e804d15-e0f6-4ce0-8276-5489b348fd9f">1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331" decimals="-6" name="cah:Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfMjctMy0xLTEtMjg2OTQ0_9aa8e8db-c422-408e-921f-7d42a650dfa3">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from net investment hedge terminations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" decimals="-6" name="us-gaap:ProceedsFromHedgeInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfMjgtMS0xLTEtMjg2OTQ0_5f76ed65-6ea9-4ff3-a314-c03a081ebded">29</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331" decimals="-6" name="us-gaap:ProceedsFromHedgeInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfMjgtMy0xLTEtMjg2OTQ0_2993416f-1309-46c2-857e-4ec3fd0bad03">71</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by/(used in) investing activities</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfMjktMS0xLTEtMjg2OTQ0_720d3f56-e85e-4905-a97b-7a91d2a53965">248</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331" decimals="-6" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfMjktMy0xLTEtMjg2OTQ0_b6da81e9-b6ca-4d68-b993-148f558823a9">771</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reduction of long-term obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfMzQtMS0xLTEtMjg2OTQ0_c062f89a-93b4-4955-b87d-191df0163b74">571</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfMzQtMy0xLTEtMjg2OTQ0_0ca7978f-9066-406c-a075-67389e73493b">597</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net tax proceeds/(withholdings) from share-based compensation</span></div></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" decimals="-6" name="cah:Netproceedstaxwithholdingsfromsharebasedcompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfMzUtMS0xLTEtMjg2OTQ0_ff10d6bd-5a79-45e5-9c6b-6f3b0096e937">11</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331" decimals="-6" sign="-" name="cah:Netproceedstaxwithholdingsfromsharebasedcompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfMzUtMy0xLTEtMjg2OTQ0_af560d13-a106-4276-8754-d4ab98bd774e">26</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends on common shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" decimals="-6" name="us-gaap:PaymentsOfDividendsCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfMzctMS0xLTEtMjg2OTQ0_c3721e48-71f0-44c9-8248-3744716ceb89">399</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331" decimals="-6" name="us-gaap:PaymentsOfDividendsCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfMzctMy0xLTEtMjg2OTQ0_7ce1ebf9-592f-4566-90c7-02bcf090a647">425</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase of treasury shares</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfMzgtMS0xLTEtMjg2OTQ0_319511d2-e690-4bf0-8823-65bb881ced5e">1,500</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfMzgtMy0xLTEtMjg2OTQ0_c3a6682a-46a7-4d3a-98f6-266776247b9c">1,000</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash used in financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfMzktMS0xLTEtMjg2OTQ0_a1f5aa90-814a-453a-9ea7-0be03c030e0e">2,459</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfMzktMy0xLTEtMjg2OTQ0_822b3ad8-5b8a-489d-8df2-8afad2640a44">2,048</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" decimals="-6" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfNDEtMS0xLTEtMjg2OTQ0_36d00775-0ad3-4776-b4e9-b0690786b4e3">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331" decimals="-6" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfNDEtMy0xLTEtMjg2OTQ0_abbb1b4c-d1c0-4cf3-9783-e44bc0c333c2">13</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and equivalents reclassified from assets held for sale</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" decimals="-6" name="cah:CashReclassifiedToAssetHeldForSale" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfNDItMS0xLTEtMjg2OTQ0_3c32f349-a613-4866-a51f-4c5d1bbc4879">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331" decimals="-6" name="cah:CashReclassifiedToAssetHeldForSale" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfNDItMy0xLTEtMjg2OTQ0_a659b956-cdae-4cb9-a542-aabbb4e1f26a">109</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net decrease in cash and equivalents</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" decimals="-6" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfNDQtMS0xLTEtMjg2OTQ0_996eb76a-b073-4e72-9788-314a5466989b">727</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331" decimals="-6" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfNDQtMy0xLTEtMjg2OTQ0_59b54d3a-f02b-4fc8-bb64-7128a1c1a592">1,051</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and equivalents at beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic217743408d440409a59220a0bf14e4c_I20220630" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfNDUtMS0xLTEtMjg2OTQ0_43978c2e-b6d2-4479-8fc1-edd0eed2b085">4,717</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75b88320c8d34867830cda3167c67779_I20210630" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfNDUtMy0xLTEtMjg2OTQ0_6698bc56-c9d5-4c90-a56d-e028633c3c37">3,407</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash and equivalents at end of period</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfNDYtMS0xLTEtMjg2OTQ0_abfd1a24-db76-496f-b17b-06fa3e8b1b0e">3,990</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9769f07affb42f58d537c7029824f72_I20220331" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfNDYtMy0xLTEtMjg2OTQ0_0c64707d-8d15-4913-987c-e8a664f3716e">2,356</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to condensed consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">30</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i1d34fc4fc2424fbcb4837cc9f1c0665c_76"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div id="i1d34fc4fc2424fbcb4837cc9f1c0665c_79"></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><ix:nonNumeric contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183OS9mcmFnOmNiZjgzZWVmYjI4MDQ3NDA5ODE1ZjJhNjE3YjdjNzkzL3RleHRyZWdpb246Y2JmODNlZWZiMjgwNDc0MDk4MTVmMmE2MTdiN2M3OTNfMjgwNA_b08232ca-2175-4b37-90b5-47f2dbb87443" continuedAt="i06c5f628d9214252bdd625edb7dae4ec" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">1. Basis of Presentation and Summary of Significant Accounting Policies </span></div><ix:nonNumeric contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183OS9mcmFnOmNiZjgzZWVmYjI4MDQ3NDA5ODE1ZjJhNjE3YjdjNzkzL3RleHRyZWdpb246Y2JmODNlZWZiMjgwNDc0MDk4MTVmMmE2MTdiN2M3OTNfMjc5OQ_95f0f3ab-9e16-4684-80db-b82880ac9da9" continuedAt="i5ada70b567664f8485adc0ffc2687bb2" escape="true"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements include the accounts of all majority-owned or consolidated subsidiaries, and all significant intercompany transactions and amounts have been eliminated. The results of businesses acquired or disposed of are included in the condensed consolidated financial statements from the date of the acquisition or up to the date of disposal, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References to "we," "our," and similar pronouns in this Quarterly Report on Form 10-Q for the quarter ended March&#160;31, 2023 (this "Form 10-Q") refer to Cardinal Health, Inc. and its majority-owned or consolidated subsidiaries unless the context requires otherwise.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our fiscal year ends on June 30. References to fiscal 2023 and 2022 in these condensed consolidated financial statements are to the fiscal years ending or ended June&#160;30, 2023 and June&#160;30, 2022, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements have been prepared in accordance with the U.S. Securities and Exchange Commission ("SEC") instructions to Quarterly Reports on Form 10-Q and include the information and disclosures required by accounting principles generally accepted in the United States ("GAAP") for interim financial reporting. The preparation of financial statements in conformity with GAAP requires us to make estimates, judgments and assumptions that affect amounts reported in the condensed consolidated financial statements and accompanying notes. Actual amounts may differ from these estimated amounts. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our opinion, all adjustments necessary for a fair presentation of the condensed consolidated financial statements have been included. Except as disclosed elsewhere in this Form 10-Q, all such adjustments are of a normal and recurring nature.&#160;In addition, financial results presented for this fiscal 2023 interim period are not necessarily indicative of the results that may be expected for the full fiscal year ending June&#160;30, 2023. These condensed consolidated financial statements are unaudited and, accordingly, should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual Report on Form 10-K for the fiscal year ended June 30, 2022 (our "2022 Form 10-K").</span></div></ix:nonNumeric></ix:nonNumeric></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><ix:continuation id="i06c5f628d9214252bdd625edb7dae4ec"><ix:continuation id="i5ada70b567664f8485adc0ffc2687bb2"><ix:nonNumeric contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183OS9mcmFnOmNiZjgzZWVmYjI4MDQ3NDA5ODE1ZjJhNjE3YjdjNzkzL3RleHRyZWdpb246Y2JmODNlZWZiMjgwNDc0MDk4MTVmMmE2MTdiN2M3OTNfMjgwMw_8a01b5da-8dd3-4b25-baf1-030e3eb95ca5" escape="true"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Recently Issued Financial Accounting Standards</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Not Yet Adopted</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board ("FASB") on our condensed consolidated financial statements as well as material updates to previous assessments, if any, from our fiscal 2022 Form 10-K. There were no accounting standards issued in fiscal 2023 that will have a material impact on our condensed consolidated financial statements.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Recently Adopted Financial Accounting Standards</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new material accounting standards adopted during the nine months ended March 31, 2023.</span></div></ix:nonNumeric></ix:continuation></ix:continuation><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div id="i1d34fc4fc2424fbcb4837cc9f1c0665c_82"></div><ix:nonNumeric contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184Mi9mcmFnOmY0ZDBiYTMzM2M3YzRlZDJhYmIxMWRiY2FmZWQ4MDYzL3RleHRyZWdpb246ZjRkMGJhMzMzYzdjNGVkMmFiYjExZGJjYWZlZDgwNjNfNDgx_ef139275-cd19-425e-a3c7-c359195b1885" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">2. Divestitures</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, we sold the Cordis business to Hellman &amp; Friedman for proceeds of $<ix:nonFraction unitRef="usd" contextRef="if3c1b25895fb44c59c13bf46018fc577_D20210701-20210930" decimals="-6" name="us-gaap:ProceedsFromDivestitureOfBusinesses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184Mi9mcmFnOmY0ZDBiYTMzM2M3YzRlZDJhYmIxMWRiY2FmZWQ4MDYzL3RleHRyZWdpb246ZjRkMGJhMzMzYzdjNGVkMmFiYjExZGJjYWZlZDgwNjNfOTA_b642a1e9-0bbb-4063-b222-9a6cbd879b4f">923</ix:nonFraction> million, net of cash transferred, and we retained certain working capital accounts. Cardinal Health also retained product liability associated with lawsuits and claims related to the Cordis OptEase and TrapEase inferior vena cava ("IVC") filter products in the U.S. and Canada, as well as authority for these matters discussed in </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1d34fc4fc2424fbcb4837cc9f1c0665c_100">Note 6</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Cordis business operated within our Medical segment.</span></div></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">31</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i1d34fc4fc2424fbcb4837cc9f1c0665c_85"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><ix:nonNumeric contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184NS9mcmFnOjg5OTU5NGU4NGRlYjRlNjViNjQ4YzliODkyMzMxNWRlL3RleHRyZWdpb246ODk5NTk0ZTg0ZGViNGU2NWI2NDhjOWI4OTIzMzE1ZGVfMTA3OA_c29f514c-0ced-491c-a6e9-1333b14bfaf7" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">3. Restructuring and Employee Severance</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><ix:nonNumeric contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184NS9mcmFnOjg5OTU5NGU4NGRlYjRlNjViNjQ4YzliODkyMzMxNWRlL3RleHRyZWdpb246ODk5NTk0ZTg0ZGViNGU2NWI2NDhjOWI4OTIzMzE1ZGVfMTA3Mw_34921057-e925-4a4f-ae12-a23bdb145a1a" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes restructuring and employee severance:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.974%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.591%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.592%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee-related</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331" decimals="-6" name="us-gaap:SeveranceCosts1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184NS9mcmFnOjg5OTU5NGU4NGRlYjRlNjViNjQ4YzliODkyMzMxNWRlL3RhYmxlOmVjMWZjMDAzMzA2MTRlNDQ4ODU4MGM4MTczYjU4YWMxL3RhYmxlcmFuZ2U6ZWMxZmMwMDMzMDYxNGU0NDg4NTgwYzgxNzNiNThhYzFfMi0xLTEtMS0yODY5NDQ_18e2157c-b67d-47c0-9c43-2868962e89a4">3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331" decimals="-6" name="us-gaap:SeveranceCosts1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184NS9mcmFnOjg5OTU5NGU4NGRlYjRlNjViNjQ4YzliODkyMzMxNWRlL3RhYmxlOmVjMWZjMDAzMzA2MTRlNDQ4ODU4MGM4MTczYjU4YWMxL3RhYmxlcmFuZ2U6ZWMxZmMwMDMzMDYxNGU0NDg4NTgwYzgxNzNiNThhYzFfMi0zLTEtMS0yODY5NDQ_eff99c7a-654f-4ff1-957b-91db50579c54">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Facility exit and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331" decimals="-6" name="cah:FacilityExitAndOtherCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184NS9mcmFnOjg5OTU5NGU4NGRlYjRlNjViNjQ4YzliODkyMzMxNWRlL3RhYmxlOmVjMWZjMDAzMzA2MTRlNDQ4ODU4MGM4MTczYjU4YWMxL3RhYmxlcmFuZ2U6ZWMxZmMwMDMzMDYxNGU0NDg4NTgwYzgxNzNiNThhYzFfMy0xLTEtMS0yODY5NDQ_045bb275-ff7b-4552-9aca-1683a89e2a0a">13</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331" decimals="-6" name="cah:FacilityExitAndOtherCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184NS9mcmFnOjg5OTU5NGU4NGRlYjRlNjViNjQ4YzliODkyMzMxNWRlL3RhYmxlOmVjMWZjMDAzMzA2MTRlNDQ4ODU4MGM4MTczYjU4YWMxL3RhYmxlcmFuZ2U6ZWMxZmMwMDMzMDYxNGU0NDg4NTgwYzgxNzNiNThhYzFfMy0zLTEtMS0yODY5NDQ_451e5757-7153-41c7-948e-0df412a2bff9">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total restructuring and employee severance</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184NS9mcmFnOjg5OTU5NGU4NGRlYjRlNjViNjQ4YzliODkyMzMxNWRlL3RhYmxlOmVjMWZjMDAzMzA2MTRlNDQ4ODU4MGM4MTczYjU4YWMxL3RhYmxlcmFuZ2U6ZWMxZmMwMDMzMDYxNGU0NDg4NTgwYzgxNzNiNThhYzFfNC0xLTEtMS0yODY5NDQ_9691eb31-1666-491f-8980-b3fd30d429a0">16</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184NS9mcmFnOjg5OTU5NGU4NGRlYjRlNjViNjQ4YzliODkyMzMxNWRlL3RhYmxlOmVjMWZjMDAzMzA2MTRlNDQ4ODU4MGM4MTczYjU4YWMxL3RhYmxlcmFuZ2U6ZWMxZmMwMDMzMDYxNGU0NDg4NTgwYzgxNzNiNThhYzFfNC0zLTEtMS0yODY5NDQ_dde05ef6-20d9-41f6-8f00-4b8cf98e8344">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.974%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.591%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.592%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee-related</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" decimals="-6" name="us-gaap:SeveranceCosts1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184NS9mcmFnOjg5OTU5NGU4NGRlYjRlNjViNjQ4YzliODkyMzMxNWRlL3RhYmxlOjVhMTc0MTkxYzJkOTQ1OGViMjY1YjdjNDkyMGViMmNjL3RhYmxlcmFuZ2U6NWExNzQxOTFjMmQ5NDU4ZWIyNjViN2M0OTIwZWIyY2NfMi0xLTEtMS0yODY5NDQ_7681d990-8198-4dcf-9739-91d3124cc082">32</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331" decimals="-6" name="us-gaap:SeveranceCosts1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184NS9mcmFnOjg5OTU5NGU4NGRlYjRlNjViNjQ4YzliODkyMzMxNWRlL3RhYmxlOjVhMTc0MTkxYzJkOTQ1OGViMjY1YjdjNDkyMGViMmNjL3RhYmxlcmFuZ2U6NWExNzQxOTFjMmQ5NDU4ZWIyNjViN2M0OTIwZWIyY2NfMi0zLTEtMS0yODY5NDQ_d7552040-5862-4169-b249-e252cce958b5">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Facility exit and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" decimals="-6" name="cah:FacilityExitAndOtherCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184NS9mcmFnOjg5OTU5NGU4NGRlYjRlNjViNjQ4YzliODkyMzMxNWRlL3RhYmxlOjVhMTc0MTkxYzJkOTQ1OGViMjY1YjdjNDkyMGViMmNjL3RhYmxlcmFuZ2U6NWExNzQxOTFjMmQ5NDU4ZWIyNjViN2M0OTIwZWIyY2NfMy0xLTEtMS0yODY5NDQ_59c0807c-9b87-4934-b8d8-ae0901e04c89">30</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331" decimals="-6" name="cah:FacilityExitAndOtherCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184NS9mcmFnOjg5OTU5NGU4NGRlYjRlNjViNjQ4YzliODkyMzMxNWRlL3RhYmxlOjVhMTc0MTkxYzJkOTQ1OGViMjY1YjdjNDkyMGViMmNjL3RhYmxlcmFuZ2U6NWExNzQxOTFjMmQ5NDU4ZWIyNjViN2M0OTIwZWIyY2NfMy0zLTEtMS0yODY5NDQ_575e0655-23a5-4333-819a-907fd0bb7329">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total restructuring and employee severance</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184NS9mcmFnOjg5OTU5NGU4NGRlYjRlNjViNjQ4YzliODkyMzMxNWRlL3RhYmxlOjVhMTc0MTkxYzJkOTQ1OGViMjY1YjdjNDkyMGViMmNjL3RhYmxlcmFuZ2U6NWExNzQxOTFjMmQ5NDU4ZWIyNjViN2M0OTIwZWIyY2NfNC0xLTEtMS0yODY5NDQ_dc57b4d0-48ef-4098-831d-bb26000ff89f">62</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184NS9mcmFnOjg5OTU5NGU4NGRlYjRlNjViNjQ4YzliODkyMzMxNWRlL3RhYmxlOjVhMTc0MTkxYzJkOTQ1OGViMjY1YjdjNDkyMGViMmNjL3RhYmxlcmFuZ2U6NWExNzQxOTFjMmQ5NDU4ZWIyNjViN2M0OTIwZWIyY2NfNC0zLTEtMS0yODY5NDQ_d2c210a6-3e41-4759-97b3-99d1ffee5297">56</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee-related costs primarily consist of termination benefits provided to employees who have been involuntarily terminated, duplicate payroll costs and retention bonuses incurred during transition periods. Facility exit and other costs primarily consist of project consulting fees, accelerated depreciation, professional, project management and other service fees to support divestitures, costs associated with vacant facilities, and certain other divestiture-related costs.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring and employee severance costs during the three and nine months ended March&#160;31, 2023 and March 31, 2022 were primarily related to the implementation of certain enterprise-wide cost-savings measures and the divestiture of the Cordis business. During the three and nine months ended March 31, 2022, restructuring also included costs related to decreasing our overall office space. </span></div><ix:nonNumeric contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" name="us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184NS9mcmFnOjg5OTU5NGU4NGRlYjRlNjViNjQ4YzliODkyMzMxNWRlL3RleHRyZWdpb246ODk5NTk0ZTg0ZGViNGU2NWI2NDhjOWI4OTIzMzE1ZGVfMTA1OA_6b6c05e7-911e-4562-af9d-e68d19de534b" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes activity related to liabilities associated with restructuring and employee severance:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:43.791%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.237%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.237%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.241%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee-<br/>Related Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Facility Exit<br/>and Other Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2022</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice5ace5e97dc4e54b4c8d923f4a0967c_I20220630" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184NS9mcmFnOjg5OTU5NGU4NGRlYjRlNjViNjQ4YzliODkyMzMxNWRlL3RhYmxlOjA5YWJkOTk2MzkwMzQ3NzRhN2ExM2ViNzA4OTdkMjRlL3RhYmxlcmFuZ2U6MDlhYmQ5OTYzOTAzNDc3NGE3YTEzZWI3MDg5N2QyNGVfMS0xLTEtMS0yODY5NDQ_a1dc553b-823e-468c-b740-66e5dd2ad071">56</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba8dcdc7b0364befb6c48df592c69089_I20220630" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184NS9mcmFnOjg5OTU5NGU4NGRlYjRlNjViNjQ4YzliODkyMzMxNWRlL3RhYmxlOjA5YWJkOTk2MzkwMzQ3NzRhN2ExM2ViNzA4OTdkMjRlL3RhYmxlcmFuZ2U6MDlhYmQ5OTYzOTAzNDc3NGE3YTEzZWI3MDg5N2QyNGVfMS0zLTEtMS0yODY5NDQ_47508a1e-4eb5-43c0-b34d-2d50819a9013">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic217743408d440409a59220a0bf14e4c_I20220630" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184NS9mcmFnOjg5OTU5NGU4NGRlYjRlNjViNjQ4YzliODkyMzMxNWRlL3RhYmxlOjA5YWJkOTk2MzkwMzQ3NzRhN2ExM2ViNzA4OTdkMjRlL3RhYmxlcmFuZ2U6MDlhYmQ5OTYzOTAzNDc3NGE3YTEzZWI3MDg5N2QyNGVfMS01LTEtMS0yODY5NDQ_0c204b2c-b110-42ba-87e7-fa76456b9091">66</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i763ae6a550604d44b1d9024df65e87a4_D20220701-20230331" decimals="-6" name="us-gaap:RestructuringCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184NS9mcmFnOjg5OTU5NGU4NGRlYjRlNjViNjQ4YzliODkyMzMxNWRlL3RhYmxlOjA5YWJkOTk2MzkwMzQ3NzRhN2ExM2ViNzA4OTdkMjRlL3RhYmxlcmFuZ2U6MDlhYmQ5OTYzOTAzNDc3NGE3YTEzZWI3MDg5N2QyNGVfMi0xLTEtMS0yODY5NDQ_254100d5-aee2-4127-b31b-4d8fec0affe5">29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i013227884afa401a8a0fac648dda0a66_D20220701-20230331" decimals="-6" name="us-gaap:RestructuringCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184NS9mcmFnOjg5OTU5NGU4NGRlYjRlNjViNjQ4YzliODkyMzMxNWRlL3RhYmxlOjA5YWJkOTk2MzkwMzQ3NzRhN2ExM2ViNzA4OTdkMjRlL3RhYmxlcmFuZ2U6MDlhYmQ5OTYzOTAzNDc3NGE3YTEzZWI3MDg5N2QyNGVfMi0zLTEtMS0yODY5NDQ_ecc5ed7c-97f8-499e-bcdb-631cc2d5c7bb">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" decimals="-6" name="us-gaap:RestructuringCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184NS9mcmFnOjg5OTU5NGU4NGRlYjRlNjViNjQ4YzliODkyMzMxNWRlL3RhYmxlOjA5YWJkOTk2MzkwMzQ3NzRhN2ExM2ViNzA4OTdkMjRlL3RhYmxlcmFuZ2U6MDlhYmQ5OTYzOTAzNDc3NGE3YTEzZWI3MDg5N2QyNGVfMi01LTEtMS0yODY5NDQ_a6806b4c-9b1f-48dd-8e4c-11c621e00782">37</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments and other adjustments</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i763ae6a550604d44b1d9024df65e87a4_D20220701-20230331" decimals="-6" name="us-gaap:PaymentsForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184NS9mcmFnOjg5OTU5NGU4NGRlYjRlNjViNjQ4YzliODkyMzMxNWRlL3RhYmxlOjA5YWJkOTk2MzkwMzQ3NzRhN2ExM2ViNzA4OTdkMjRlL3RhYmxlcmFuZ2U6MDlhYmQ5OTYzOTAzNDc3NGE3YTEzZWI3MDg5N2QyNGVfMy0xLTEtMS0yODY5NDQ_892d3fa2-16b8-4d0e-8a33-05312dbbf586">36</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i013227884afa401a8a0fac648dda0a66_D20220701-20230331" decimals="-6" name="us-gaap:PaymentsForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184NS9mcmFnOjg5OTU5NGU4NGRlYjRlNjViNjQ4YzliODkyMzMxNWRlL3RhYmxlOjA5YWJkOTk2MzkwMzQ3NzRhN2ExM2ViNzA4OTdkMjRlL3RhYmxlcmFuZ2U6MDlhYmQ5OTYzOTAzNDc3NGE3YTEzZWI3MDg5N2QyNGVfMy0zLTEtMS0yODY5NDQ_c2f0d135-f07b-40fa-abc9-ced8f2537267">15</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" decimals="-6" name="us-gaap:PaymentsForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184NS9mcmFnOjg5OTU5NGU4NGRlYjRlNjViNjQ4YzliODkyMzMxNWRlL3RhYmxlOjA5YWJkOTk2MzkwMzQ3NzRhN2ExM2ViNzA4OTdkMjRlL3RhYmxlcmFuZ2U6MDlhYmQ5OTYzOTAzNDc3NGE3YTEzZWI3MDg5N2QyNGVfMy01LTEtMS0yODY5NDQ_38b23ca4-b8a8-4afb-ab06-43aefedf2e9b">51</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at March 31, 2023</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie317acb3d5c44ca0bd1298978e77bb10_I20230331" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184NS9mcmFnOjg5OTU5NGU4NGRlYjRlNjViNjQ4YzliODkyMzMxNWRlL3RhYmxlOjA5YWJkOTk2MzkwMzQ3NzRhN2ExM2ViNzA4OTdkMjRlL3RhYmxlcmFuZ2U6MDlhYmQ5OTYzOTAzNDc3NGE3YTEzZWI3MDg5N2QyNGVfNC0xLTEtMS0yODY5NDQ_e114c534-fe6c-4f8f-900d-01865fc91bdf">49</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09619e867c3347d5b88ff001fdae470b_I20230331" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184NS9mcmFnOjg5OTU5NGU4NGRlYjRlNjViNjQ4YzliODkyMzMxNWRlL3RhYmxlOjA5YWJkOTk2MzkwMzQ3NzRhN2ExM2ViNzA4OTdkMjRlL3RhYmxlcmFuZ2U6MDlhYmQ5OTYzOTAzNDc3NGE3YTEzZWI3MDg5N2QyNGVfNC0zLTEtMS0yODY5NDQ_cb4759c9-c21d-4afd-a4e7-54137b6bd7b0">3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184NS9mcmFnOjg5OTU5NGU4NGRlYjRlNjViNjQ4YzliODkyMzMxNWRlL3RhYmxlOjA5YWJkOTk2MzkwMzQ3NzRhN2ExM2ViNzA4OTdkMjRlL3RhYmxlcmFuZ2U6MDlhYmQ5OTYzOTAzNDc3NGE3YTEzZWI3MDg5N2QyNGVfNC01LTEtMS0yODY5NDQ_bc597167-ed45-41da-a222-49d1d64c3a1d">52</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div id="i1d34fc4fc2424fbcb4837cc9f1c0665c_88"></div><ix:nonNumeric contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RleHRyZWdpb246YjY4ZTgyNTRjMTc4NDc2ZWJmZmEzNTI5MzQ3MmQ3MzNfMjg2Nw_5bb01d82-5101-4690-a7f3-e285b813071c" continuedAt="ic75a58519d1b45878857b9612db7c3e6" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">4. Goodwill and Other Intangible Assets</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Goodwill</span></div><ix:nonNumeric contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RleHRyZWdpb246YjY4ZTgyNTRjMTc4NDc2ZWJmZmEzNTI5MzQ3MmQ3MzNfMjg4Mg_f0e5f4b1-3d3e-46c0-824e-63fd7dcaddeb" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the carrying amount of goodwill by segment and in total:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.801%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.517%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.640%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.556%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical (1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2022</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i043b921434d34afe9a3cdb74397ed704_I20220630" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmJlMWI4MDIzZTQ3YTRhNzZhZmRjNTM3ZDgwNzhmYmI3L3RhYmxlcmFuZ2U6YmUxYjgwMjNlNDdhNGE3NmFmZGM1MzdkODA3OGZiYjdfMS0xLTEtMS0yODY5NDQ_a6959a7d-50ff-4ed1-bc09-0b49e3a65012">2,673</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e6a4d2c754046f2bba40f47b73897d8_I20220630" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmJlMWI4MDIzZTQ3YTRhNzZhZmRjNTM3ZDgwNzhmYmI3L3RhYmxlcmFuZ2U6YmUxYjgwMjNlNDdhNGE3NmFmZGM1MzdkODA3OGZiYjdfMS0zLTEtMS0yODY5NDQ_09f29b43-d69e-48a0-b291-fade332deb67">3,182</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic217743408d440409a59220a0bf14e4c_I20220630" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmJlMWI4MDIzZTQ3YTRhNzZhZmRjNTM3ZDgwNzhmYmI3L3RhYmxlcmFuZ2U6YmUxYjgwMjNlNDdhNGE3NmFmZGM1MzdkODA3OGZiYjdfMS01LTEtMS0yODY5NDQ_efe90a12-045e-4904-9d53-25c66f7adfb5">5,855</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill acquired, net of purchase price adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69ad0b82db074919b5c03d2459c3d06b_D20220701-20230331" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmJlMWI4MDIzZTQ3YTRhNzZhZmRjNTM3ZDgwNzhmYmI3L3RhYmxlcmFuZ2U6YmUxYjgwMjNlNDdhNGE3NmFmZGM1MzdkODA3OGZiYjdfMi0xLTEtMS0yODY5NDQ_b253d0c7-0a85-4b88-a68f-b773094ff32c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6e92bcd32f84df9ab392ad9accbdacd_D20220701-20230331" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmJlMWI4MDIzZTQ3YTRhNzZhZmRjNTM3ZDgwNzhmYmI3L3RhYmxlcmFuZ2U6YmUxYjgwMjNlNDdhNGE3NmFmZGM1MzdkODA3OGZiYjdfMi0zLTEtMS0yODY5NDQ_aae65860-c638-4a32-872a-3f6ed0f96488">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmJlMWI4MDIzZTQ3YTRhNzZhZmRjNTM3ZDgwNzhmYmI3L3RhYmxlcmFuZ2U6YmUxYjgwMjNlNDdhNGE3NmFmZGM1MzdkODA3OGZiYjdfMi01LTEtMS0yODY5NDQ_e90ad1c2-8f36-4ac3-8b15-459c6801eb83">13</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustments and other</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69ad0b82db074919b5c03d2459c3d06b_D20220701-20230331" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmJlMWI4MDIzZTQ3YTRhNzZhZmRjNTM3ZDgwNzhmYmI3L3RhYmxlcmFuZ2U6YmUxYjgwMjNlNDdhNGE3NmFmZGM1MzdkODA3OGZiYjdfMy0xLTEtMS0yODY5NDQ_63c85d72-7674-4ebe-9c91-9468998a914f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia6e92bcd32f84df9ab392ad9accbdacd_D20220701-20230331" decimals="-6" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmJlMWI4MDIzZTQ3YTRhNzZhZmRjNTM3ZDgwNzhmYmI3L3RhYmxlcmFuZ2U6YmUxYjgwMjNlNDdhNGE3NmFmZGM1MzdkODA3OGZiYjdfMy0zLTEtMS0yODY5NDQ_a4107f1e-ea53-455c-8dce-ed277ea32ee2">5</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" decimals="-6" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmJlMWI4MDIzZTQ3YTRhNzZhZmRjNTM3ZDgwNzhmYmI3L3RhYmxlcmFuZ2U6YmUxYjgwMjNlNDdhNGE3NmFmZGM1MzdkODA3OGZiYjdfMy01LTEtMS0yODY5NDQ_7507ca6a-1678-4031-91dd-27f51c96ccd7">5</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill impairment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69ad0b82db074919b5c03d2459c3d06b_D20220701-20230331" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmJlMWI4MDIzZTQ3YTRhNzZhZmRjNTM3ZDgwNzhmYmI3L3RhYmxlcmFuZ2U6YmUxYjgwMjNlNDdhNGE3NmFmZGM1MzdkODA3OGZiYjdfNC0xLTEtMS0yODY5NDQ_4a206955-6791-4422-995e-a2ad4597d61f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia6e92bcd32f84df9ab392ad9accbdacd_D20220701-20230331" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmJlMWI4MDIzZTQ3YTRhNzZhZmRjNTM3ZDgwNzhmYmI3L3RhYmxlcmFuZ2U6YmUxYjgwMjNlNDdhNGE3NmFmZGM1MzdkODA3OGZiYjdfNC0zLTEtMS0yODY5NDQ_954d80c8-80ff-4960-bcb3-392797821886">863</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmJlMWI4MDIzZTQ3YTRhNzZhZmRjNTM3ZDgwNzhmYmI3L3RhYmxlcmFuZ2U6YmUxYjgwMjNlNDdhNGE3NmFmZGM1MzdkODA3OGZiYjdfNC01LTEtMS0yODY5NDQ_cdfd9d97-95a1-4b4c-a9a3-de161c9da387">863</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at March 31, 2023</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4007268cc1f496d86090b7230f7a94b_I20230331" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmJlMWI4MDIzZTQ3YTRhNzZhZmRjNTM3ZDgwNzhmYmI3L3RhYmxlcmFuZ2U6YmUxYjgwMjNlNDdhNGE3NmFmZGM1MzdkODA3OGZiYjdfNS0xLTEtMS0yODY5NDQ_7d688352-be3e-4cca-86af-de770f817998">2,673</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cd27b73a20c437aa0e84891f2ea5dde_I20230331" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmJlMWI4MDIzZTQ3YTRhNzZhZmRjNTM3ZDgwNzhmYmI3L3RhYmxlcmFuZ2U6YmUxYjgwMjNlNDdhNGE3NmFmZGM1MzdkODA3OGZiYjdfNS0zLTEtMS0yODY5NDQ_c29e5a86-6015-4245-9322-133a594cdb02">2,327</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmJlMWI4MDIzZTQ3YTRhNzZhZmRjNTM3ZDgwNzhmYmI3L3RhYmxlcmFuZ2U6YmUxYjgwMjNlNDdhNGE3NmFmZGM1MzdkODA3OGZiYjdfNS01LTEtMS0yODY5NDQ_0b047b90-1348-42dd-a2f2-0a1b9b46226c">5,000</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">At March 31, 2023 and June 30, 2022, the Medical segment accumulated goodwill impairment loss was $<ix:nonFraction unitRef="usd" contextRef="i6cd27b73a20c437aa0e84891f2ea5dde_I20230331" decimals="-6" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RleHRyZWdpb246YjY4ZTgyNTRjMTc4NDc2ZWJmZmEzNTI5MzQ3MmQ3MzNfMjI1_f187fac3-8b72-468e-9eed-58e33db084d8">4.4</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i8e6a4d2c754046f2bba40f47b73897d8_I20220630" decimals="-6" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RleHRyZWdpb246YjY4ZTgyNTRjMTc4NDc2ZWJmZmEzNTI5MzQ3MmQ3MzNfMjMy_67051717-e79c-4066-a95a-58ce74ffe812">3.5</ix:nonFraction>&#160;billion, respectively.</span></div></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to changes in our long-term financial plan assumptions made during the three months ended March&#160;31, 2023, we elected to bypass the qualitative assessment and perform quantitative goodwill impairment testing for the Medical Unit. The fair value of the reporting unit was estimated to be approximately <ix:nonFraction unitRef="rate" contextRef="ic49dbe67bc04485785ead3e50d2ef7b5_I20230331" decimals="2" name="us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RleHRyZWdpb246YjY4ZTgyNTRjMTc4NDc2ZWJmZmEzNTI5MzQ3MmQ3MzNfMzg0ODI5MDcwMzUxMw_f0df1588-ce64-47c4-a18f-620ae11d79ff">4</ix:nonFraction> percent in excess of its carrying value, primarily driven by a lower discount rate as described below.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We performed quantitative goodwill impairment testing for the Medical Unit at December 31, 2022 and September 30, 2022, which resulted in pre-tax goodwill impairment charges of $<ix:nonFraction unitRef="usd" contextRef="i984de195edf647df8b5c417d95fb895e_D20221001-20221231" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RleHRyZWdpb246YjY4ZTgyNTRjMTc4NDc2ZWJmZmEzNTI5MzQ3MmQ3MzNfMzg0ODI5MDcwMTY0MQ_4d080f98-4819-4e91-8994-33be604d9d4d">709</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i2c44423c33b44f2b91261015274103c9_D20220701-20220930" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RleHRyZWdpb246YjY4ZTgyNTRjMTc4NDc2ZWJmZmEzNTI5MzQ3MmQ3MzNfMzg0ODI5MDcwMTYyNA_9d3e5b1c-bd76-44dd-b501-ac57e2ab19c1">154</ix:nonFraction> million, respectively. The impairment charge recognized in the second quarter was driven by certain reductions in our long-term financial plan assumptions, and the impairment charge recognized in the first quarter was driven by an increase in the discount rate primarily due to an increase in the risk-free interest rate. The cumulative pre-tax goodwill impairment charges of $<ix:nonFraction unitRef="usd" contextRef="ia6e92bcd32f84df9ab392ad9accbdacd_D20220701-20230331" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RleHRyZWdpb246YjY4ZTgyNTRjMTc4NDc2ZWJmZmEzNTI5MzQ3MmQ3MzNfMTIzNA_954d80c8-80ff-4960-bcb3-392797821886">863</ix:nonFraction> million were recognized in impairments and (gain)/loss on disposal of assets, net in our condensed consolidated statements of earnings/(loss) for the nine months ended March&#160;31, 2023.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our determinations of the estimated fair value of the Medical Unit at March&#160;31, 2023, December 31, 2022 and September 30, 2022 were based on a combination of the income-based approach (using a terminal growth rate of <ix:nonFraction unitRef="number" contextRef="i4173ed46aed24fea930a4ba9e851147e_I20220930" decimals="3" name="cah:TerminalGrowthRateFairValueInput" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RleHRyZWdpb246YjY4ZTgyNTRjMTc4NDc2ZWJmZmEzNTI5MzQ3MmQ3MzNfMTYwMA_825b0ca2-657a-4c57-98b8-bbf70d081b93"><ix:nonFraction unitRef="number" contextRef="i6f07ddd2def943ba8d68405800839948_I20221231" decimals="2" name="cah:TerminalGrowthRateFairValueInput" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RleHRyZWdpb246YjY4ZTgyNTRjMTc4NDc2ZWJmZmEzNTI5MzQ3MmQ3MzNfMTYwMA_965b0571-5c62-490e-9082-0a0e4d265534"><ix:nonFraction unitRef="number" contextRef="ic49dbe67bc04485785ead3e50d2ef7b5_I20230331" decimals="2" name="cah:TerminalGrowthRateFairValueInput" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RleHRyZWdpb246YjY4ZTgyNTRjMTc4NDc2ZWJmZmEzNTI5MzQ3MmQ3MzNfMTYwMA_c350ead7-2c54-4dbe-b65d-a1ab174a68ee">2</ix:nonFraction></ix:nonFraction></ix:nonFraction> percent), and the market-based approaches. For the income-based approach, we used discount rates of <ix:nonFraction unitRef="number" contextRef="ic49dbe67bc04485785ead3e50d2ef7b5_I20230331" decimals="3" name="cah:DiscountRateFairValueInput" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RleHRyZWdpb246YjY4ZTgyNTRjMTc4NDc2ZWJmZmEzNTI5MzQ3MmQ3MzNfMTY0OTI2NzQ0NDk2NQ_672510ff-e347-48f2-aae6-c7b26175547b">10</ix:nonFraction> percent, <ix:nonFraction unitRef="number" contextRef="i4173ed46aed24fea930a4ba9e851147e_I20220930" decimals="3" name="cah:DiscountRateFairValueInput" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RleHRyZWdpb246YjY4ZTgyNTRjMTc4NDc2ZWJmZmEzNTI5MzQ3MmQ3MzNfMzg0ODI5MDcwMTY2NA_65c77e7e-f80d-49a9-8fd7-9c7945a9f896"><ix:nonFraction unitRef="number" contextRef="i6f07ddd2def943ba8d68405800839948_I20221231" decimals="3" name="cah:DiscountRateFairValueInput" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RleHRyZWdpb246YjY4ZTgyNTRjMTc4NDc2ZWJmZmEzNTI5MzQ3MmQ3MzNfMzg0ODI5MDcwMTY2NA_bd33a346-219b-4a72-aa1f-8a6272460e3e">10.5</ix:nonFraction></ix:nonFraction> percent and <ix:nonFraction unitRef="number" contextRef="i4173ed46aed24fea930a4ba9e851147e_I20220930" decimals="3" name="cah:DiscountRateFairValueInput" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RleHRyZWdpb246YjY4ZTgyNTRjMTc4NDc2ZWJmZmEzNTI5MzQ3MmQ3MzNfMTY5NQ_65c77e7e-f80d-49a9-8fd7-9c7945a9f896"><ix:nonFraction unitRef="number" contextRef="i6f07ddd2def943ba8d68405800839948_I20221231" decimals="3" name="cah:DiscountRateFairValueInput" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RleHRyZWdpb246YjY4ZTgyNTRjMTc4NDc2ZWJmZmEzNTI5MzQ3MmQ3MzNfMTY5NQ_bd33a346-219b-4a72-aa1f-8a6272460e3e">10.5</ix:nonFraction></ix:nonFraction> percent for each quarter, respectively. The decrease in the discount rate for the interim testing performed at March&#160;31, 2023 was primarily due to a decrease in the risk-free interest rate. Additionally, we assigned a weighting of 80 percent to the discounted cash flow method, 10 percent to the guideline public company method, and 10 percent to the guideline transaction method. Our fair value estimates utilize significant unobservable inputs and thus represent Level 3 fair value measurements.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2022 and December 31, 2021, we performed quantitative goodwill impairment testing for the Medical Unit. This quantitative testing resulted in the carrying </span></div></ix:nonNumeric></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">32</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><ix:continuation id="ic75a58519d1b45878857b9612db7c3e6" continuedAt="ia597c7624f004618ba8b31071c89ac37"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">amount of the Medical Unit exceeding the fair value, resulting in a pre-tax impairment charges of $<ix:nonFraction unitRef="usd" contextRef="i8537355abc114656ba7b11fcb58c1278_D20220101-20220331" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RleHRyZWdpb246YjY4ZTgyNTRjMTc4NDc2ZWJmZmEzNTI5MzQ3MmQ3MzNfMzg0ODI5MDcwMTc2Mw_8ea377a7-7ff4-4b82-864d-23af7420e03a">474</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i31378af16d0d40428cd5734ee81d07a0_D20211001-20211231" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RleHRyZWdpb246YjY4ZTgyNTRjMTc4NDc2ZWJmZmEzNTI5MzQ3MmQ3MzNfMzg0ODI5MDcwMTc3OA_43aa9ce7-6522-429c-9a4d-a15930c1009f">1.3</ix:nonFraction>&#160;billion recorded during the three months ended March 31, 2022 and December 31, 2021, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Other Intangible Assets</span></div><ix:nonNumeric contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RleHRyZWdpb246YjY4ZTgyNTRjMTc4NDc2ZWJmZmEzNTI5MzQ3MmQ3MzNfMjg5OA_d72be7e8-93de-44f0-b69a-0386dbd16b8c" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize other intangible assets by class at:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:24.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.070%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.714%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.070%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.409%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted- Average Remaining Amortization Period (Years)</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Indefinite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks and patents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3002eff021944cff84e19dddc37565d6_I20230331" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmQwMDc1ZDRjNzg0ZTQwZjA4Mjk1NTM0NzU1NjgzNmJmL3RhYmxlcmFuZ2U6ZDAwNzVkNGM3ODRlNDBmMDgyOTU1MzQ3NTU2ODM2YmZfMy0xLTEtMS0yODY5NDQ_7716ea35-8d6b-47e0-a0de-f745f89e5e4c">11</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3002eff021944cff84e19dddc37565d6_I20230331" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmQwMDc1ZDRjNzg0ZTQwZjA4Mjk1NTM0NzU1NjgzNmJmL3RhYmxlcmFuZ2U6ZDAwNzVkNGM3ODRlNDBmMDgyOTU1MzQ3NTU2ODM2YmZfMy01LTEtMS0yODY5NDQ_9258a8eb-3ee4-48f9-8faa-74be83df70df">11</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total indefinite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmQwMDc1ZDRjNzg0ZTQwZjA4Mjk1NTM0NzU1NjgzNmJmL3RhYmxlcmFuZ2U6ZDAwNzVkNGM3ODRlNDBmMDgyOTU1MzQ3NTU2ODM2YmZfNC0xLTEtMS0yODY5NDQ_97dc8a02-b28f-43f9-9e56-094ad981404a">11</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmQwMDc1ZDRjNzg0ZTQwZjA4Mjk1NTM0NzU1NjgzNmJmL3RhYmxlcmFuZ2U6ZDAwNzVkNGM3ODRlNDBmMDgyOTU1MzQ3NTU2ODM2YmZfNC01LTEtMS0yODY5NDQ_02dfac77-581d-4b5c-bb26-5bfca3b29725">11</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Definite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i476e8c3bb99545d29a40a868cf6b4eed_I20230331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmQwMDc1ZDRjNzg0ZTQwZjA4Mjk1NTM0NzU1NjgzNmJmL3RhYmxlcmFuZ2U6ZDAwNzVkNGM3ODRlNDBmMDgyOTU1MzQ3NTU2ODM2YmZfNy0xLTEtMS0yODY5NDQ_9e6658d8-ff12-45d7-ae79-b6ef97e66375">3,235</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i476e8c3bb99545d29a40a868cf6b4eed_I20230331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmQwMDc1ZDRjNzg0ZTQwZjA4Mjk1NTM0NzU1NjgzNmJmL3RhYmxlcmFuZ2U6ZDAwNzVkNGM3ODRlNDBmMDgyOTU1MzQ3NTU2ODM2YmZfNy0zLTEtMS0yODY5NDQ_0f94c53f-89d9-4f82-a17d-8f9597bb3526">2,267</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i476e8c3bb99545d29a40a868cf6b4eed_I20230331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmQwMDc1ZDRjNzg0ZTQwZjA4Mjk1NTM0NzU1NjgzNmJmL3RhYmxlcmFuZ2U6ZDAwNzVkNGM3ODRlNDBmMDgyOTU1MzQ3NTU2ODM2YmZfNy01LTEtMS0yODY5NDQ_f30875cd-7f32-49bc-82f7-d169aac21990">968</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i476e8c3bb99545d29a40a868cf6b4eed_I20230331" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmQwMDc1ZDRjNzg0ZTQwZjA4Mjk1NTM0NzU1NjgzNmJmL3RhYmxlcmFuZ2U6ZDAwNzVkNGM3ODRlNDBmMDgyOTU1MzQ3NTU2ODM2YmZfNy03LTEtMS0yODY5NDQ_9cda25e1-5fe5-4c7b-b245-1b0b725a1472">10</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks, trade names and patents</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief415993dc4a47a1a6841e6902c7341b_I20230331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmQwMDc1ZDRjNzg0ZTQwZjA4Mjk1NTM0NzU1NjgzNmJmL3RhYmxlcmFuZ2U6ZDAwNzVkNGM3ODRlNDBmMDgyOTU1MzQ3NTU2ODM2YmZfOC0xLTEtMS0yODY5NDQ_6d846297-ea20-4e53-9a4c-1dd6fbd5c8e0">550</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief415993dc4a47a1a6841e6902c7341b_I20230331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmQwMDc1ZDRjNzg0ZTQwZjA4Mjk1NTM0NzU1NjgzNmJmL3RhYmxlcmFuZ2U6ZDAwNzVkNGM3ODRlNDBmMDgyOTU1MzQ3NTU2ODM2YmZfOC0zLTEtMS0yODY5NDQ_8e262230-35b0-4e8f-94f3-2005734fd354">376</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief415993dc4a47a1a6841e6902c7341b_I20230331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmQwMDc1ZDRjNzg0ZTQwZjA4Mjk1NTM0NzU1NjgzNmJmL3RhYmxlcmFuZ2U6ZDAwNzVkNGM3ODRlNDBmMDgyOTU1MzQ3NTU2ODM2YmZfOC01LTEtMS0yODY5NDQ_689f8d5e-5bf8-42b8-9cfd-16aa2a04077b">174</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ief415993dc4a47a1a6841e6902c7341b_I20230331" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmQwMDc1ZDRjNzg0ZTQwZjA4Mjk1NTM0NzU1NjgzNmJmL3RhYmxlcmFuZ2U6ZDAwNzVkNGM3ODRlNDBmMDgyOTU1MzQ3NTU2ODM2YmZfOC03LTEtMS0yODY5NDQ_ac791765-c902-406e-aea5-8ba23edcdaff">9</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed technology and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i963e12db354a4503b026e3e3bb6ed1ae_I20230331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmQwMDc1ZDRjNzg0ZTQwZjA4Mjk1NTM0NzU1NjgzNmJmL3RhYmxlcmFuZ2U6ZDAwNzVkNGM3ODRlNDBmMDgyOTU1MzQ3NTU2ODM2YmZfOS0xLTEtMS0yODY5NDQ_59c464d6-f0ce-4b32-b0ae-3e3136dc8522">1,037</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i963e12db354a4503b026e3e3bb6ed1ae_I20230331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmQwMDc1ZDRjNzg0ZTQwZjA4Mjk1NTM0NzU1NjgzNmJmL3RhYmxlcmFuZ2U6ZDAwNzVkNGM3ODRlNDBmMDgyOTU1MzQ3NTU2ODM2YmZfOS0zLTEtMS0yODY5NDQ_320f1fcf-6c48-4acd-8abc-b9757474e814">623</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i963e12db354a4503b026e3e3bb6ed1ae_I20230331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmQwMDc1ZDRjNzg0ZTQwZjA4Mjk1NTM0NzU1NjgzNmJmL3RhYmxlcmFuZ2U6ZDAwNzVkNGM3ODRlNDBmMDgyOTU1MzQ3NTU2ODM2YmZfOS01LTEtMS0yODY5NDQ_e86e4999-480b-4a4f-ab4b-88ce09855733">414</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i963e12db354a4503b026e3e3bb6ed1ae_I20230331" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmQwMDc1ZDRjNzg0ZTQwZjA4Mjk1NTM0NzU1NjgzNmJmL3RhYmxlcmFuZ2U6ZDAwNzVkNGM3ODRlNDBmMDgyOTU1MzQ3NTU2ODM2YmZfOS03LTEtMS0yODY5NDQ_7178b5a2-015f-4b56-9421-78b81d63d48c">9</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total definite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmQwMDc1ZDRjNzg0ZTQwZjA4Mjk1NTM0NzU1NjgzNmJmL3RhYmxlcmFuZ2U6ZDAwNzVkNGM3ODRlNDBmMDgyOTU1MzQ3NTU2ODM2YmZfMTAtMS0xLTEtMjg2OTQ0_11f72dd1-be06-4eb0-b639-1c7543acc538">4,822</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmQwMDc1ZDRjNzg0ZTQwZjA4Mjk1NTM0NzU1NjgzNmJmL3RhYmxlcmFuZ2U6ZDAwNzVkNGM3ODRlNDBmMDgyOTU1MzQ3NTU2ODM2YmZfMTAtMy0xLTEtMjg2OTQ0_217e12e7-c44d-4829-b9ef-39b6a65573f9">3,266</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmQwMDc1ZDRjNzg0ZTQwZjA4Mjk1NTM0NzU1NjgzNmJmL3RhYmxlcmFuZ2U6ZDAwNzVkNGM3ODRlNDBmMDgyOTU1MzQ3NTU2ODM2YmZfMTAtNS0xLTEtMjg2OTQ0_f070d3f4-49ec-4438-ba36-bb5803bc46dd">1,556</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmQwMDc1ZDRjNzg0ZTQwZjA4Mjk1NTM0NzU1NjgzNmJmL3RhYmxlcmFuZ2U6ZDAwNzVkNGM3ODRlNDBmMDgyOTU1MzQ3NTU2ODM2YmZfMTAtNy0xLTEtMjg2OTQ0_49d4d494-0130-4919-8fda-e71116bafe12">10</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total other intangible assets</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331" decimals="-6" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmQwMDc1ZDRjNzg0ZTQwZjA4Mjk1NTM0NzU1NjgzNmJmL3RhYmxlcmFuZ2U6ZDAwNzVkNGM3ODRlNDBmMDgyOTU1MzQ3NTU2ODM2YmZfMTEtMS0xLTEtMjg2OTQ0_14ce0524-6080-43d0-b49c-6c8516a7d29f">4,833</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmQwMDc1ZDRjNzg0ZTQwZjA4Mjk1NTM0NzU1NjgzNmJmL3RhYmxlcmFuZ2U6ZDAwNzVkNGM3ODRlNDBmMDgyOTU1MzQ3NTU2ODM2YmZfMTEtMy0xLTEtMjg2OTQ0_0d457f52-64ad-45e7-b338-b890a7f2343b">3,266</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmQwMDc1ZDRjNzg0ZTQwZjA4Mjk1NTM0NzU1NjgzNmJmL3RhYmxlcmFuZ2U6ZDAwNzVkNGM3ODRlNDBmMDgyOTU1MzQ3NTU2ODM2YmZfMTEtNS0xLTEtMjg2OTQ0_391f2fa6-5b1b-4317-8edf-c96f9a0f6e2a">1,567</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:42.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.308%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.643%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.312%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net<br/>Intangible</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Indefinite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks and patents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i173bc20d1a0d49e88d4984456dd1b3e0_I20220630" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmNiNDA4NGY5M2VhMzQ0MTA5ODkxZTRhOWMxNTNhZmQ4L3RhYmxlcmFuZ2U6Y2I0MDg0ZjkzZWEzNDQxMDk4OTFlNGE5YzE1M2FmZDhfMy0xLTEtMS0yODY5NDQ_1febee8f-d5d8-4f3a-8c75-48ce2e2ff2fc">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i173bc20d1a0d49e88d4984456dd1b3e0_I20220630" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmNiNDA4NGY5M2VhMzQ0MTA5ODkxZTRhOWMxNTNhZmQ4L3RhYmxlcmFuZ2U6Y2I0MDg0ZjkzZWEzNDQxMDk4OTFlNGE5YzE1M2FmZDhfMy01LTEtMS0yODY5NDQ_931f9ac1-689c-4c43-8990-600d15496216">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total indefinite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic217743408d440409a59220a0bf14e4c_I20220630" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmNiNDA4NGY5M2VhMzQ0MTA5ODkxZTRhOWMxNTNhZmQ4L3RhYmxlcmFuZ2U6Y2I0MDg0ZjkzZWEzNDQxMDk4OTFlNGE5YzE1M2FmZDhfNC0xLTEtMS0yODY5NDQ_966b1f36-cc50-44af-b649-e653631e917f">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic217743408d440409a59220a0bf14e4c_I20220630" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmNiNDA4NGY5M2VhMzQ0MTA5ODkxZTRhOWMxNTNhZmQ4L3RhYmxlcmFuZ2U6Y2I0MDg0ZjkzZWEzNDQxMDk4OTFlNGE5YzE1M2FmZDhfNC01LTEtMS0yODY5NDQ_38736f52-2ea5-4eee-84d4-ecf812fb4e97">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Definite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70d3a43084b1430ab3dd772e96aa6f88_I20220630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmNiNDA4NGY5M2VhMzQ0MTA5ODkxZTRhOWMxNTNhZmQ4L3RhYmxlcmFuZ2U6Y2I0MDg0ZjkzZWEzNDQxMDk4OTFlNGE5YzE1M2FmZDhfNy0xLTEtMS0yODY5NDQ_d40ff0d7-b128-4f91-b700-4916c14683d7">3,272</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70d3a43084b1430ab3dd772e96aa6f88_I20220630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmNiNDA4NGY5M2VhMzQ0MTA5ODkxZTRhOWMxNTNhZmQ4L3RhYmxlcmFuZ2U6Y2I0MDg0ZjkzZWEzNDQxMDk4OTFlNGE5YzE1M2FmZDhfNy0zLTEtMS0yODY5NDQ_8b4ea995-7bee-449f-b763-cfcb8ccbea97">2,165</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70d3a43084b1430ab3dd772e96aa6f88_I20220630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmNiNDA4NGY5M2VhMzQ0MTA5ODkxZTRhOWMxNTNhZmQ4L3RhYmxlcmFuZ2U6Y2I0MDg0ZjkzZWEzNDQxMDk4OTFlNGE5YzE1M2FmZDhfNy01LTEtMS0yODY5NDQ_1d3b8697-bb25-44d3-a772-7c3e245af794">1,107</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks, trade names and patents</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3d2fdf5757a41fc97c3a3a6ad11d72e_I20220630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmNiNDA4NGY5M2VhMzQ0MTA5ODkxZTRhOWMxNTNhZmQ4L3RhYmxlcmFuZ2U6Y2I0MDg0ZjkzZWEzNDQxMDk4OTFlNGE5YzE1M2FmZDhfOC0xLTEtMS0yODY5NDQ_3a464291-d01b-4ad5-8e96-1f04676c5a5d">552</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3d2fdf5757a41fc97c3a3a6ad11d72e_I20220630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmNiNDA4NGY5M2VhMzQ0MTA5ODkxZTRhOWMxNTNhZmQ4L3RhYmxlcmFuZ2U6Y2I0MDg0ZjkzZWEzNDQxMDk4OTFlNGE5YzE1M2FmZDhfOC0zLTEtMS0yODY5NDQ_149a98c9-3210-4520-8961-8dd4cce08f39">360</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3d2fdf5757a41fc97c3a3a6ad11d72e_I20220630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmNiNDA4NGY5M2VhMzQ0MTA5ODkxZTRhOWMxNTNhZmQ4L3RhYmxlcmFuZ2U6Y2I0MDg0ZjkzZWEzNDQxMDk4OTFlNGE5YzE1M2FmZDhfOC01LTEtMS0yODY5NDQ_23d2c241-b3f3-4cc3-8b35-84a6c77591ac">192</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed technology and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85178fe781b44231b4e7afb99223bc34_I20220630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmNiNDA4NGY5M2VhMzQ0MTA5ODkxZTRhOWMxNTNhZmQ4L3RhYmxlcmFuZ2U6Y2I0MDg0ZjkzZWEzNDQxMDk4OTFlNGE5YzE1M2FmZDhfOS0xLTEtMS0yODY5NDQ_8b7b9789-82a5-4baa-aa8f-9d766b09303a">1,038</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85178fe781b44231b4e7afb99223bc34_I20220630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmNiNDA4NGY5M2VhMzQ0MTA5ODkxZTRhOWMxNTNhZmQ4L3RhYmxlcmFuZ2U6Y2I0MDg0ZjkzZWEzNDQxMDk4OTFlNGE5YzE1M2FmZDhfOS0zLTEtMS0yODY5NDQ_c49614ef-3561-4e0f-aed9-7517ebf1491f">574</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85178fe781b44231b4e7afb99223bc34_I20220630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmNiNDA4NGY5M2VhMzQ0MTA5ODkxZTRhOWMxNTNhZmQ4L3RhYmxlcmFuZ2U6Y2I0MDg0ZjkzZWEzNDQxMDk4OTFlNGE5YzE1M2FmZDhfOS01LTEtMS0yODY5NDQ_8eefb0fa-0558-401a-8b94-7c89800ff1e8">464</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total definite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic217743408d440409a59220a0bf14e4c_I20220630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmNiNDA4NGY5M2VhMzQ0MTA5ODkxZTRhOWMxNTNhZmQ4L3RhYmxlcmFuZ2U6Y2I0MDg0ZjkzZWEzNDQxMDk4OTFlNGE5YzE1M2FmZDhfMTAtMS0xLTEtMjg2OTQ0_ddbd384b-de48-460e-b968-a24b8f059542">4,862</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic217743408d440409a59220a0bf14e4c_I20220630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmNiNDA4NGY5M2VhMzQ0MTA5ODkxZTRhOWMxNTNhZmQ4L3RhYmxlcmFuZ2U6Y2I0MDg0ZjkzZWEzNDQxMDk4OTFlNGE5YzE1M2FmZDhfMTAtMy0xLTEtMjg2OTQ0_47d8ef9d-2cfd-4c2f-8705-372b2b7624ea">3,099</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic217743408d440409a59220a0bf14e4c_I20220630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmNiNDA4NGY5M2VhMzQ0MTA5ODkxZTRhOWMxNTNhZmQ4L3RhYmxlcmFuZ2U6Y2I0MDg0ZjkzZWEzNDQxMDk4OTFlNGE5YzE1M2FmZDhfMTAtNS0xLTEtMjg2OTQ0_ed4da037-e8cd-4533-b11c-537b95ef42d7">1,763</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total other intangible assets</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic217743408d440409a59220a0bf14e4c_I20220630" decimals="-6" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmNiNDA4NGY5M2VhMzQ0MTA5ODkxZTRhOWMxNTNhZmQ4L3RhYmxlcmFuZ2U6Y2I0MDg0ZjkzZWEzNDQxMDk4OTFlNGE5YzE1M2FmZDhfMTEtMS0xLTEtMjg2OTQ0_158ccc1f-f5cf-4aba-97f2-63f94f4899e0">4,873</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic217743408d440409a59220a0bf14e4c_I20220630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmNiNDA4NGY5M2VhMzQ0MTA5ODkxZTRhOWMxNTNhZmQ4L3RhYmxlcmFuZ2U6Y2I0MDg0ZjkzZWEzNDQxMDk4OTFlNGE5YzE1M2FmZDhfMTEtMy0xLTEtMjg2OTQ0_dd5a10a7-157e-41ea-99b8-83bd2ed74857">3,099</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic217743408d440409a59220a0bf14e4c_I20220630" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmNiNDA4NGY5M2VhMzQ0MTA5ODkxZTRhOWMxNTNhZmQ4L3RhYmxlcmFuZ2U6Y2I0MDg0ZjkzZWEzNDQxMDk4OTFlNGE5YzE1M2FmZDhfMTEtNS0xLTEtMjg2OTQ0_26f8ee57-dab8-4dd5-8423-cf78a6235a8f">1,774</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia597c7624f004618ba8b31071c89ac37">Total amortization of intangible assets was $<ix:nonFraction unitRef="usd" contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RleHRyZWdpb246YjY4ZTgyNTRjMTc4NDc2ZWJmZmEzNTI5MzQ3MmQ3MzNfMjYxOQ_eb13f8b7-190b-4fb8-9faa-555fc6e32859">69</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RleHRyZWdpb246YjY4ZTgyNTRjMTc4NDc2ZWJmZmEzNTI5MzQ3MmQ3MzNfMjYyNg_61bcdafb-2bb9-4765-959b-6761c053b19e">78</ix:nonFraction> million for the three months ended March 31, 2023 and 2022, respectively, and $<ix:nonFraction unitRef="usd" contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RleHRyZWdpb246YjY4ZTgyNTRjMTc4NDc2ZWJmZmEzNTI5MzQ3MmQ3MzNfMjY4NQ_08c01fea-f1ce-4c3e-8a6d-11087fa3a361">211</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RleHRyZWdpb246YjY4ZTgyNTRjMTc4NDc2ZWJmZmEzNTI5MzQ3MmQ3MzNfMjY5Mg_fd666ca8-f576-4dd2-a820-7f6a346edd45">235</ix:nonFraction> million for the nine months ended March&#160;31, 2023 and 2022, respectively. Estimated annual amortization of intangible assets for the remainder of fiscal 2023 through 2027 is as follows: $<ix:nonFraction unitRef="usd" contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RleHRyZWdpb246YjY4ZTgyNTRjMTc4NDc2ZWJmZmEzNTI5MzQ3MmQ3MzNfMjgzOQ_84269dcc-390c-4175-afd1-86c42d27c0d3">71</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RleHRyZWdpb246YjY4ZTgyNTRjMTc4NDc2ZWJmZmEzNTI5MzQ3MmQ3MzNfMjg0Mw_5f1c23c1-5ebc-402a-9ab0-128a533ffaef">261</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RleHRyZWdpb246YjY4ZTgyNTRjMTc4NDc2ZWJmZmEzNTI5MzQ3MmQ3MzNfMjg0Nw_95cc9da6-042f-4f28-bcee-1fe3b8b79845">236</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RleHRyZWdpb246YjY4ZTgyNTRjMTc4NDc2ZWJmZmEzNTI5MzQ3MmQ3MzNfMjg1MQ_52a838c3-dd6b-4d57-8449-154b624cf9ba">209</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RleHRyZWdpb246YjY4ZTgyNTRjMTc4NDc2ZWJmZmEzNTI5MzQ3MmQ3MzNfMjg1OQ_f5882ff8-2f3c-4481-97d2-7abddce20be3">177</ix:nonFraction> million.</ix:continuation></span></div><div id="i1d34fc4fc2424fbcb4837cc9f1c0665c_97"></div><ix:nonNumeric contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y185Ny9mcmFnOjYyZjA4MTU0NTMzYjQ1MWFhNjJjMmRiMGU3ZDhlMDFmL3RleHRyZWdpb246NjJmMDgxNTQ1MzNiNDUxYWE2MmMyZGIwZTdkOGUwMWZfMTk1NA_ef01f275-5cf6-4f26-9245-d12196798c8d" continuedAt="ia3220a1741e04119a2fc987ad5f784b4" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">5. Long-Term Obligations and Other Short-Term Borrowings</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Long-Term Debt</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had total long-term obligations, including the current portion and other short-term borrowings, of $<ix:nonFraction unitRef="usd" contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331" decimals="-6" name="cah:TotalLongTermandShortTermObligations" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y185Ny9mcmFnOjYyZjA4MTU0NTMzYjQ1MWFhNjJjMmRiMGU3ZDhlMDFmL3RleHRyZWdpb246NjJmMDgxNTQ1MzNiNDUxYWE2MmMyZGIwZTdkOGUwMWZfMTA5OTUxMTYzMDIzNA_a2d35407-fb43-475b-a638-20282e7b71e8">4.7</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="ic217743408d440409a59220a0bf14e4c_I20220630" decimals="-6" name="cah:TotalLongTermandShortTermObligations" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y185Ny9mcmFnOjYyZjA4MTU0NTMzYjQ1MWFhNjJjMmRiMGU3ZDhlMDFmL3RleHRyZWdpb246NjJmMDgxNTQ1MzNiNDUxYWE2MmMyZGIwZTdkOGUwMWZfMTY0OTI2NzQ0MzY4OA_c90e5006-0b70-477d-9eda-9531b322b3fb">5.3</ix:nonFraction> billion for March&#160;31, 2023 and June&#160;30, 2022, respectively. All the notes represent unsecured obligations of Cardinal Health, Inc. and rank equally in right of payment with all of our existing and future unsecured and unsubordinated indebtedness. Interest is paid pursuant to the terms of the obligations. These notes are effectively subordinated to the liabilities of our subsidiaries, including trade payables of $<ix:nonFraction unitRef="usd" contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331" decimals="-8" name="us-gaap:AccountsPayableCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y185Ny9mcmFnOjYyZjA4MTU0NTMzYjQ1MWFhNjJjMmRiMGU3ZDhlMDFmL3RleHRyZWdpb246NjJmMDgxNTQ1MzNiNDUxYWE2MmMyZGIwZTdkOGUwMWZfNTAy_02827bd0-2c88-4c2e-94ad-fe1a9ee7dfae">29.6</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="ic217743408d440409a59220a0bf14e4c_I20220630" decimals="-8" name="us-gaap:AccountsPayableCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y185Ny9mcmFnOjYyZjA4MTU0NTMzYjQ1MWFhNjJjMmRiMGU3ZDhlMDFmL3RleHRyZWdpb246NjJmMDgxNTQ1MzNiNDUxYWE2MmMyZGIwZTdkOGUwMWZfNTA5_ed33b5a3-81a0-4d8e-ae37-84918fc2ba96">27.1</ix:nonFraction> billion at March&#160;31, 2023 and June&#160;30, 2022, respectively.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023, we repaid the full principal of the $<ix:nonFraction unitRef="usd" contextRef="i70202e3eb1924e0fb801d98cddcbf880_D20230101-20230331" decimals="-6" name="us-gaap:RepaymentsOfNotesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y185Ny9mcmFnOjYyZjA4MTU0NTMzYjQ1MWFhNjJjMmRiMGU3ZDhlMDFmL3RleHRyZWdpb246NjJmMDgxNTQ1MzNiNDUxYWE2MmMyZGIwZTdkOGUwMWZfNTQ5NzU1ODE0MTY3MA_d5901d44-d14d-49d6-9731-18f354bc1367">550</ix:nonFraction>&#160;million 3.2% Notes due 2023 at maturity with available cash.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended March&#160;31, 2022, we redeemed all outstanding $<ix:nonFraction unitRef="usd" contextRef="i5c0fee9c3dfe482dbe67f839273b347f_D20210701-20220331" decimals="-6" name="cah:NotesPayableRepurchased" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y185Ny9mcmFnOjYyZjA4MTU0NTMzYjQ1MWFhNjJjMmRiMGU3ZDhlMDFmL3RleHRyZWdpb246NjJmMDgxNTQ1MzNiNDUxYWE2MmMyZGIwZTdkOGUwMWZfNTg2_67bd3202-c701-4a44-b716-0b1b368aca93">572</ix:nonFraction>&#160;million principal amount of 2.616% Notes due June 2022 at a redemption price equal to 100% of the principal amount and accrued but unpaid interest, plus the make-whole premium applicable to the notes. In connection with this redemption, we recorded a $<ix:nonFraction unitRef="usd" contextRef="i5c0fee9c3dfe482dbe67f839273b347f_D20210701-20220331" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y185Ny9mcmFnOjYyZjA4MTU0NTMzYjQ1MWFhNjJjMmRiMGU3ZDhlMDFmL3RleHRyZWdpb246NjJmMDgxNTQ1MzNiNDUxYWE2MmMyZGIwZTdkOGUwMWZfODMy_8f18e3ab-44c4-42f2-8287-8a821e17d6e7">10</ix:nonFraction>&#160;million loss on early extinguishment of debt. The early redemption was funded with available cash.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Other Financing Arrangements</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to cash and equivalents and operating cash flow, other sources of liquidity include a&#160;$<ix:nonFraction unitRef="usd" contextRef="i08f98bc525534cc2acbd1048c17f5b33_I20230331" decimals="-6" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y185Ny9mcmFnOjYyZjA4MTU0NTMzYjQ1MWFhNjJjMmRiMGU3ZDhlMDFmL3RleHRyZWdpb246NjJmMDgxNTQ1MzNiNDUxYWE2MmMyZGIwZTdkOGUwMWZfMTA1Mw_eaec01b1-03f1-4825-af29-f5be18c8d1f1">2.0</ix:nonFraction> billion&#160;commercial paper program backed by a $<ix:nonFraction unitRef="usd" contextRef="i075adee0cf414c09a846d45f9d6a66c6_I20230331" decimals="-6" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y185Ny9mcmFnOjYyZjA4MTU0NTMzYjQ1MWFhNjJjMmRiMGU3ZDhlMDFmL3RleHRyZWdpb246NjJmMDgxNTQ1MzNiNDUxYWE2MmMyZGIwZTdkOGUwMWZfMTA5Mw_6885719f-66cc-4f4c-b1b3-15689572c802">2.0</ix:nonFraction> billion&#160;revolving credit facility. We also have a&#160;$<ix:nonFraction unitRef="usd" contextRef="if9a5679304ee4538b6bbe0e34a4b5ed6_I20230331" decimals="-6" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y185Ny9mcmFnOjYyZjA4MTU0NTMzYjQ1MWFhNjJjMmRiMGU3ZDhlMDFmL3RleHRyZWdpb246NjJmMDgxNTQ1MzNiNDUxYWE2MmMyZGIwZTdkOGUwMWZfMTEzOA_8981b823-7b26-4fce-a336-c10f76796ef3">1.0</ix:nonFraction> billion&#160;committed receivables sales facility. During the nine months ended March&#160;31, 2023, under our commercial paper program and our committed receivables program, we had maximum combined total daily amounts outstanding of $<ix:nonFraction unitRef="usd" contextRef="i78f3cdc10c574a61aeee3a0d9409d753_D20220701-20230331" decimals="-6" name="us-gaap:LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y185Ny9mcmFnOjYyZjA4MTU0NTMzYjQ1MWFhNjJjMmRiMGU3ZDhlMDFmL3RleHRyZWdpb246NjJmMDgxNTQ1MzNiNDUxYWE2MmMyZGIwZTdkOGUwMWZfNTQ5NzU1ODE0MTcxMg_d8f0f0a4-c639-4493-8544-811d07f20665">445</ix:nonFraction>&#160;million and average combined daily amount outstanding of $<ix:nonFraction unitRef="usd" contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" decimals="-6" name="us-gaap:LineOfCreditFacilityAverageOutstandingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y185Ny9mcmFnOjYyZjA4MTU0NTMzYjQ1MWFhNjJjMmRiMGU3ZDhlMDFmL3RleHRyZWdpb246NjJmMDgxNTQ1MzNiNDUxYWE2MmMyZGIwZTdkOGUwMWZfNTQ5NzU1ODE0MTcyNg_52995717-1b44-46c5-a577-30096f11e2ca">4</ix:nonFraction>&#160;million. At March&#160;31, 2023, we had <ix:nonFraction unitRef="usd" contextRef="i769da3763c9d46579b5dbf1f28eef5e3_I20230331" decimals="-6" name="us-gaap:OtherShortTermBorrowings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y185Ny9mcmFnOjYyZjA4MTU0NTMzYjQ1MWFhNjJjMmRiMGU3ZDhlMDFmL3RleHRyZWdpb246NjJmMDgxNTQ1MzNiNDUxYWE2MmMyZGIwZTdkOGUwMWZfMTE5Mw_8355250f-2f5a-4bdd-b586-13d1bb0b43d1">no</ix:nonFraction> amounts outstanding under our commercial paper program, revolving credit facility or our committed receivables sales facility. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2023, we extended our $<ix:nonFraction unitRef="usd" contextRef="i075adee0cf414c09a846d45f9d6a66c6_I20230331" decimals="-6" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y185Ny9mcmFnOjYyZjA4MTU0NTMzYjQ1MWFhNjJjMmRiMGU3ZDhlMDFmL3RleHRyZWdpb246NjJmMDgxNTQ1MzNiNDUxYWE2MmMyZGIwZTdkOGUwMWZfMzg0ODI5MDY5OTYwMQ_6885719f-66cc-4f4c-b1b3-15689572c802">2.0</ix:nonFraction> billion revolving credit facility through February 25, 2028. In September 2022, we renewed our committed receivables sales facility program through Cardinal Health Funding, LLC (&#8220;CHF&#8221;) through September 30, 2025. CHF was organized for</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the sole purpose of buying receivables and selling undivided interests in those receivables to third-party purchasers. Although consolidated with Cardinal Health, </span></div></ix:nonNumeric></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">33</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia3220a1741e04119a2fc987ad5f784b4" continuedAt="i6b473a03aa6b4d2991a492c1a5a57c26">Inc. in accordance with GAAP, CHF is a separate legal entity from Cardinal Health, Inc. and from our subsidiary that sells receivables to CHF. CHF is designed to be a special purpose, bankruptcy-remote entity whose assets are available solely to satisfy the claims of its creditors. </ix:continuation></span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i6b473a03aa6b4d2991a492c1a5a57c26">Our revolving credit and committed receivables sales facilities require us to maintain a consolidated net leverage ratio of no more than 3.75-to-1. As of March&#160;31, 2023, we were in compliance with this financial covenant.</ix:continuation> </span></div><div id="i1d34fc4fc2424fbcb4837cc9f1c0665c_100"></div><ix:nonNumeric contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDAvZnJhZzo2NGI0MmYwYWIwNTM0MmVmODQyMWRhOGFmZmFiNjU2Mi90ZXh0cmVnaW9uOjY0YjQyZjBhYjA1MzQyZWY4NDIxZGE4YWZmYWI2NTYyXzE3OTUw_3aef8cba-8cf2-4dd0-b5ff-f7ab2f3f04b8" continuedAt="i5a61a0dc59b041d0bed20131bd7b6618" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">6. Commitments, Contingent Liabilities and Litigation</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commitments</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Generic Sourcing Venture with CVS Health Corporation ("CVS Health")</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2014, we established Red Oak Sourcing, LLC ("Red Oak Sourcing"), a U.S.-based generic pharmaceutical sourcing venture with CVS Health for an initial term of <ix:nonNumeric contextRef="i4e20bef4bcbc46aa8704b4843abc61ed_D20140731-20140731" name="us-gaap:LongtermPurchaseCommitmentPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDAvZnJhZzo2NGI0MmYwYWIwNTM0MmVmODQyMWRhOGFmZmFiNjU2Mi90ZXh0cmVnaW9uOjY0YjQyZjBhYjA1MzQyZWY4NDIxZGE4YWZmYWI2NTYyXzI1NA_48cabba9-a75f-46a2-aad0-42271aa122d1">10</ix:nonNumeric> years. Red Oak Sourcing negotiates generic pharmaceutical supply contracts on behalf of its participants. In August 2021, we amended our agreement to extend the term through June 2029. We are required to make quarterly payments to CVS Health for the term of the arrangement.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Contingencies</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New York Opioid Stewardship Act</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018, the State of New York passed a budget which included the Opioid Stewardship Act (the "OSA"). The OSA created an aggregate $<ix:nonFraction unitRef="usd" contextRef="i5a9e7f91ada745048021249c9ba3bf07_I20180430" decimals="-6" name="cah:AggregateAnnualAssessment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDAvZnJhZzo2NGI0MmYwYWIwNTM0MmVmODQyMWRhOGFmZmFiNjU2Mi90ZXh0cmVnaW9uOjY0YjQyZjBhYjA1MzQyZWY4NDIxZGE4YWZmYWI2NTYyXzcwOQ_91a331c3-46de-44ab-93f2-d6253cfa1aff">100</ix:nonFraction>&#160;million annual assessment on all manufacturers and distributors licensed to sell or distribute opioids in New York. Under the OSA, each licensed manufacturer and distributor would be required to pay a portion of the assessment based on its share of the total morphine milligram equivalents sold or distributed in New York during the applicable calendar year, beginning in 2017. Subsequently, New York passed a new statute that modified the assessment going forward and limited the OSA to two years (2017 and 2018).</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accrue contingencies if it is probable that a liability has been incurred and the amount can be estimated. In the second quarter of fiscal year 2022, we paid the State of New York $<ix:nonFraction unitRef="usd" contextRef="ie6e1b925b14f48bdae321a2a92cddd99_D20211001-20211231" decimals="-6" name="us-gaap:LossContingencyAccrualPayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDAvZnJhZzo2NGI0MmYwYWIwNTM0MmVmODQyMWRhOGFmZmFiNjU2Mi90ZXh0cmVnaW9uOjY0YjQyZjBhYjA1MzQyZWY4NDIxZGE4YWZmYWI2NTYyXzE0MDI_a491d424-4b5a-4e9a-9098-dd5d9062aeae">20</ix:nonFraction>&#160;million, our portion of the assessment for calendar year 2017. At June 30, 2022, we had an accrual of $<ix:nonFraction unitRef="usd" contextRef="i1ba9cf1bead64efbbe00d2cffc0f7d5f_I20220630" decimals="-6" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDAvZnJhZzo2NGI0MmYwYWIwNTM0MmVmODQyMWRhOGFmZmFiNjU2Mi90ZXh0cmVnaW9uOjY0YjQyZjBhYjA1MzQyZWY4NDIxZGE4YWZmYWI2NTYyXzE0OTk_6f41c80d-0e63-4a5c-a55d-047cc5bb7da0">20</ix:nonFraction>&#160;million, which represented our estimate of our portion of the assessment for calendar year 2018. Du</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ring the nine months ended March&#160;31, 2023, we recorded $<ix:nonFraction unitRef="usd" contextRef="i487c1d6cc123481ab174c77df6efc37c_D20220701-20230331" decimals="-3" sign="-" name="us-gaap:LossContingencyAccrualCarryingValuePeriodIncreaseDecrease" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDAvZnJhZzo2NGI0MmYwYWIwNTM0MmVmODQyMWRhOGFmZmFiNjU2Mi90ZXh0cmVnaW9uOjY0YjQyZjBhYjA1MzQyZWY4NDIxZGE4YWZmYWI2NTYyXzE2MzE_6c069275-baed-480f-97bb-a233164f0f7c">6</ix:nonFraction>&#160;million of income to reduce this accrual to the invoiced amount for the calendar year 2018 assessment and we paid $<ix:nonFraction unitRef="usd" contextRef="i487c1d6cc123481ab174c77df6efc37c_D20220701-20230331" decimals="-6" name="us-gaap:LossContingencyAccrualPayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDAvZnJhZzo2NGI0MmYwYWIwNTM0MmVmODQyMWRhOGFmZmFiNjU2Mi90ZXh0cmVnaW9uOjY0YjQyZjBhYjA1MzQyZWY4NDIxZGE4YWZmYWI2NTYyXzQzOTgwNDY1MzYyMTI_c963a491-184d-46fb-a8e4-916a1585fa2a">7</ix:nonFraction>&#160;million, resulting in an accrual of $<ix:nonFraction unitRef="usd" contextRef="i3177191fb7864f68afd74d62ddd7feeb_I20230331" decimals="-6" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDAvZnJhZzo2NGI0MmYwYWIwNTM0MmVmODQyMWRhOGFmZmFiNjU2Mi90ZXh0cmVnaW9uOjY0YjQyZjBhYjA1MzQyZWY4NDIxZGE4YWZmYWI2NTYyXzQzOTgwNDY1MzYyODk_defde614-171d-49f0-ae57-8d127332f4b9">7</ix:nonFraction>&#160;million at March 31, 2023.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We become involved from time to time in disputes, litigation and regulatory matters.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we determine that products we source, manufacture or market do not meet our specifications, regulatory requirements, or published standards. When we or a regulatory </span></div></ix:nonNumeric></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><ix:continuation id="i5a61a0dc59b041d0bed20131bd7b6618" continuedAt="ic61855f44943495092d01e00d64889c2"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">agency identify a potential quality or regulatory issue, we investigate and take appropriate corrective action. Such actions have led to product recalls, costs to repair or replace affected products, temporary interruptions in product sales, product liability claims and lawsuits and can lead to action by regulators. Even absent an identified regulatory or quality issue or product recall, we can become subject to product liability claims and lawsuits.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we become aware through employees, internal audits or other parties of possible compliance matters, such as complaints or concerns relating to accounting, internal accounting controls, financial reporting, auditing, or other ethical matters or relating to compliance with laws such as healthcare fraud and abuse, anti-corruption or anti-bribery laws. When we become aware of such possible compliance matters, we investigate internally and take appropriate corrective action. In addition, from time to time, we receive subpoenas or requests for information from various federal or state agencies relating to our business or to the business of a customer, supplier or other industry participants. Internal investigations, subpoenas or requests for information could directly or indirectly lead to the assertion of claims or the commencement of legal proceedings against us or result in sanctions.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have been named from time to time in qui tam actions initiated by private third parties. In such actions, the private parties purport to act on behalf of federal or state governments, allege that false claims have been submitted for payment by the government and may receive an award if their claims are successful. After a private party has filed a qui tam action, the government must investigate the private party's claim and determine whether to intervene in and take control over the litigation. These actions may remain under seal while the government makes this determination. If the government declines to intervene, the private party may nonetheless continue to pursue the litigation on his or her own purporting to act on behalf of the government.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accrue for contingencies related to disputes, litigation and regulatory matters if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Because these matters are inherently unpredictable and unfavorable developments or resolutions can occur, assessing contingencies is highly subjective and requires judgments about future events. We regularly review contingencies to determine whether our accruals and related disclosures are adequate. The amount of ultimate loss may differ from these estimates.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize income from the favorable outcome of litigation when we receive the associated cash or assets.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize estimated loss contingencies for certain litigation and regulatory matters and income from favorable resolution of litigation in litigation (recoveries)/charges, net in our condensed consolidated statements of earnings/(loss); however, losses and recoveries of lost profits from disputes that occur in the ordinary course of business are included within segment profit. For example, in the second quarter of fiscal year 2022, our </span></div></ix:continuation></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">34</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="width:100.000%"><ix:continuation id="ic61855f44943495092d01e00d64889c2" continuedAt="ic71ac4d727e64389910251b297c86002"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical segment profit was positively impacted by a $<ix:nonFraction unitRef="usd" contextRef="i92600b80cf9f42e68ab2bb551fa5980c_D20211001-20211231" decimals="-6" name="cah:JudgmentForLostProfits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDAvZnJhZzo2NGI0MmYwYWIwNTM0MmVmODQyMWRhOGFmZmFiNjU2Mi90ZXh0cmVnaW9uOjY0YjQyZjBhYjA1MzQyZWY4NDIxZGE4YWZmYWI2NTYyXzUzMTA_9c01752c-b170-4e27-820b-57bd6e842abd">16</ix:nonFraction>&#160;million judgment for lost profits related to an ordinary course intellectual property rights claim.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opioid Lawsuits and Investigations</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">States &amp; Political Subdivisions</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">National Settlement</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, in February 2022, we along with two other national distributors (collectively, the "Distributors") independently approved a settlement and settlement agreement (the "Settlement Agreement") to settle the vast majority of opioid lawsuits and claims brought by states and political subdivisions. This Settlement Agreement became effective on April 2, 2022. In May and June 2022, the Distributors reached agreements with the States of Washington and Oklahoma, respectively, to resolve the opioid-related claims of those states and their political subdivisions. Under these agreements, Cardinal Health agreed to pay approximately $<ix:nonFraction unitRef="usd" contextRef="ib507a23581594a42a6beb783c2499b40_I20220630" decimals="-6" name="us-gaap:LossContingencyEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDAvZnJhZzo2NGI0MmYwYWIwNTM0MmVmODQyMWRhOGFmZmFiNjU2Mi90ZXh0cmVnaW9uOjY0YjQyZjBhYjA1MzQyZWY4NDIxZGE4YWZmYWI2NTYyXzYxNDI_699338ae-c5fd-4973-b05f-1a01cf7b279c">160</ix:nonFraction>&#160;million to the State of Washington and its participating subdivisions and approximately $<ix:nonFraction unitRef="usd" contextRef="if44099e3d6fc462fbe010375b43d9efd_I20220630" decimals="-6" name="us-gaap:LossContingencyEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDAvZnJhZzo2NGI0MmYwYWIwNTM0MmVmODQyMWRhOGFmZmFiNjU2Mi90ZXh0cmVnaW9uOjY0YjQyZjBhYjA1MzQyZWY4NDIxZGE4YWZmYWI2NTYyXzYyMjU_89f94a4f-ab37-4bcc-8664-c363c02f177f">95</ix:nonFraction>&#160;million to the State of Oklahoma and its participating subdivisions. These amounts are consistent with the amounts that would have been allocated to Washington and Oklahoma under the Settlement Agreement. Each of Washington and Oklahoma is now subject to the Settlement Agreement.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the Distributors, parties to the Settlement Agreement include <ix:nonFraction unitRef="states" contextRef="iad6a19c0c20841d5b5851aaeb8d05e17_I20230131" decimals="0" name="cah:SettlingStates" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDAvZnJhZzo2NGI0MmYwYWIwNTM0MmVmODQyMWRhOGFmZmFiNjU2Mi90ZXh0cmVnaW9uOjY0YjQyZjBhYjA1MzQyZWY4NDIxZGE4YWZmYWI2NTYyXzE3OTQ0_4c687236-0675-4e18-906c-d6b76b57c38e">48</ix:nonFraction> states, the District of Columbia and <ix:nonFraction unitRef="numberofusterritories" contextRef="iad6a19c0c20841d5b5851aaeb8d05e17_I20230131" decimals="0" name="cah:SettlingUSTerritories" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDAvZnJhZzo2NGI0MmYwYWIwNTM0MmVmODQyMWRhOGFmZmFiNjU2Mi90ZXh0cmVnaW9uOjY0YjQyZjBhYjA1MzQyZWY4NDIxZGE4YWZmYWI2NTYyXzE3OTQ1_a6d9c3e5-1308-4603-adfd-6680fb8d8273">5</ix:nonFraction> U.S. territories. Over 99 percent of political subdivisions (by population as calculated under the Settlement Agreement) that had brought opioid-related suits against us have chosen to join the Settlement Agreement or have had their claims addressed by state legislation. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Settlement Agreement, we agreed to pay up to approximately $<ix:nonFraction unitRef="usd" contextRef="i92a2e3900c6e4547800cbb60799bcd60_I20230331" decimals="-6" name="us-gaap:LossContingencyEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDAvZnJhZzo2NGI0MmYwYWIwNTM0MmVmODQyMWRhOGFmZmFiNjU2Mi90ZXh0cmVnaW9uOjY0YjQyZjBhYjA1MzQyZWY4NDIxZGE4YWZmYWI2NTYyXzY5NjE_fecb7184-61c5-41a7-993e-5bfff8d1d876">6.3</ix:nonFraction>&#160;billion over 18 years. The Settlement Agreement also includes injunctive relief terms related to distributors&#8217; controlled substance anti-diversion programs. For more information on the terms of the Settlement Agreement, refer to our 2022 Form 10-K. As a result of the Settlement Agreement, most lawsuits brought against us by states and other political subdivisions have been dismissed. We continue to engage in resolution discussions with certain non-participating political subdivisions, including the Attorney General for the State of Alabama, and we intend to defend ourselves vigorously against all remaining lawsuits.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended March 31, 2023, we made our second annual payment of $<ix:nonFraction unitRef="usd" contextRef="i2ef2614263ad48d9934f6cc996c22e16_D20220701-20230331" decimals="-6" name="us-gaap:PaymentsForLegalSettlements" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDAvZnJhZzo2NGI0MmYwYWIwNTM0MmVmODQyMWRhOGFmZmFiNjU2Mi90ZXh0cmVnaW9uOjY0YjQyZjBhYjA1MzQyZWY4NDIxZGE4YWZmYWI2NTYyXzc3MjM_8306fb37-d460-4226-8df8-fa4b6c07eac0">372</ix:nonFraction>&#160;million under the Settlement Agreement. In total, we have $<ix:nonFraction unitRef="usd" contextRef="i92a2e3900c6e4547800cbb60799bcd60_I20230331" decimals="-7" name="us-gaap:LitigationReserve" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDAvZnJhZzo2NGI0MmYwYWIwNTM0MmVmODQyMWRhOGFmZmFiNjU2Mi90ZXh0cmVnaW9uOjY0YjQyZjBhYjA1MzQyZWY4NDIxZGE4YWZmYWI2NTYyXzc3NzY_f802714c-86a5-4962-9ac9-4a4590e4e901">5.85</ix:nonFraction>&#160;billion accrued at March&#160;31, 2023, of which $<ix:nonFraction unitRef="usd" contextRef="i92a2e3900c6e4547800cbb60799bcd60_I20230331" decimals="-6" name="us-gaap:LitigationReserveCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDAvZnJhZzo2NGI0MmYwYWIwNTM0MmVmODQyMWRhOGFmZmFiNjU2Mi90ZXh0cmVnaW9uOjY0YjQyZjBhYjA1MzQyZWY4NDIxZGE4YWZmYWI2NTYyXzc4MDM_71540c2f-2d5e-458a-8440-535a2c7d1e60">437</ix:nonFraction>&#160;million is included in other accrued liabilities and the remainder is included in deferred income taxes and other liabilities in our condensed consolidated balance sheets.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because loss contingencies are inherently unpredictable and unfavorable developments or resolutions can occur, the assessment is highly subjective and requires judgments about future events. We regularly review these opioid litigation matters to determine whether our accrual is adequate. The amount of </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ultimate loss may differ materially from this accrual, whether as a result of settlement discussions, a judicial decision or verdict or otherwise, but we are not able to estimate a range of reasonably possible additional losses for these matters. We continue to strongly dispute the allegations made in these lawsuits and none of these agreements is an admission of liability or wrongdoing.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other Settlements</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">West Virginia subdivisions and Native American tribes were not a part of the national settlement, and we had separate negotiations with these groups. A bench trial before a federal judge in West Virginia in a case brought by Cabell County and City of Huntington against the Distributors concluded in July 2021. In July 2022, a judgment in favor of the Distributors was entered. In July 2022, the Distributors reached an agreement to settle the opioid-related claims of the majority of the remaining West Virginia subdivisions. Under this agreement, we have agreed to pay eligible West Virginia subdivisions up to approximately $<ix:nonFraction unitRef="usd" contextRef="ibd1c21d9101a4eba857ea787640fd22a_I20220731" decimals="-6" name="us-gaap:LossContingencyEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDAvZnJhZzo2NGI0MmYwYWIwNTM0MmVmODQyMWRhOGFmZmFiNjU2Mi90ZXh0cmVnaW9uOjY0YjQyZjBhYjA1MzQyZWY4NDIxZGE4YWZmYWI2NTYyXzg2MTY_55dc2501-a25f-49d2-b101-f2ce17b97ddb">124</ix:nonFraction>&#160;million over an eleven-year period. This agreement became effective in October 2022 when all participating subdivisions dismissed their cases.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022, we executed a final settlement agreement with the Native American Tribes, pursuant to which we will pay up to approximately $<ix:nonFraction unitRef="usd" contextRef="i960566e19fe54aa890cd9defe241cee0_I20221031" decimals="-6" name="us-gaap:LossContingencyEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDAvZnJhZzo2NGI0MmYwYWIwNTM0MmVmODQyMWRhOGFmZmFiNjU2Mi90ZXh0cmVnaW9uOjY0YjQyZjBhYjA1MzQyZWY4NDIxZGE4YWZmYWI2NTYyXzkwMTU_8138b431-0fe9-40b4-a5a6-fa1e90146bf9">136</ix:nonFraction>&#160;million over five years. In connection with this settlement, the court entered dismissals for the Native American tribes' cases.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Department of Justice Investigations</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have received federal grand jury subpoenas issued in connection with investigations being conducted by the U.S. Attorney's Office for the Eastern District of New York and the Fraud Section of the U.S. Department of Justice ("DOJ"). We have also received civil requests for information from other DOJ offices. We believe that these investigations concern operation of our anti-diversion program, our anti-diversion policies and procedures, and distribution of certain controlled substances. We are cooperating with these investigations. We are unable to predict the outcome of any of these investigations. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Private Plaintiffs</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Settlement Agreement does not address claims by private parties, which includes unions and other health and welfare funds, hospital systems and other healthcare providers, businesses and individuals alleging personal injury. Private parties had brought approximately <ix:nonFraction unitRef="lawsuit" contextRef="i7f5e673a6ff2412f8e6ec60e722680b3_I20230428" decimals="0" name="cah:LossContingencyLawsuitsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDAvZnJhZzo2NGI0MmYwYWIwNTM0MmVmODQyMWRhOGFmZmFiNjU2Mi90ZXh0cmVnaW9uOjY0YjQyZjBhYjA1MzQyZWY4NDIxZGE4YWZmYWI2NTYyXzEwNzY5_389544b4-37c2-4247-aac6-395b50dd91fb">457</ix:nonFraction> lawsuits as of April 28, 2023. Of these, <ix:nonFraction unitRef="lawsuit" contextRef="i584bd35326394834b21f8bff13805226_I20230428" decimals="0" name="cah:LossContingencyLawsuitsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDAvZnJhZzo2NGI0MmYwYWIwNTM0MmVmODQyMWRhOGFmZmFiNjU2Mi90ZXh0cmVnaW9uOjY0YjQyZjBhYjA1MzQyZWY4NDIxZGE4YWZmYWI2NTYyXzEwODE1_d02fcf7b-855b-4af2-adab-907430b37fe4">107</ix:nonFraction> are purported class actions. The causes of action asserted by these plaintiffs are similar to those asserted by public plaintiffs. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A trial in a case involving <ix:nonFraction unitRef="plaintiff" contextRef="ie21d9b2ab8b84826b773ef6884028072_D20230101-20230331" decimals="0" name="us-gaap:LossContingencyNumberOfPlaintiffs" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDAvZnJhZzo2NGI0MmYwYWIwNTM0MmVmODQyMWRhOGFmZmFiNjU2Mi90ZXh0cmVnaW9uOjY0YjQyZjBhYjA1MzQyZWY4NDIxZGE4YWZmYWI2NTYyXzEwOTc4_472e4e88-d6ae-463a-be5e-ed3fc33cb380">21</ix:nonFraction> plaintiffs began in state court in Georgia in January 2023 and concluded in March 2023 with a verdict for the company and other defendants on all claims. The plaintiffs' motion for a new trial is pending. A trial involving <ix:nonFraction unitRef="plaintiff" contextRef="i39d543d6d5bc4327b0cde155c825cad4_D20230701-20230701" decimals="0" name="us-gaap:LossContingencyNumberOfPlaintiffs" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDAvZnJhZzo2NGI0MmYwYWIwNTM0MmVmODQyMWRhOGFmZmFiNjU2Mi90ZXh0cmVnaW9uOjY0YjQyZjBhYjA1MzQyZWY4NDIxZGE4YWZmYWI2NTYyXzExMTY3_a7f46e58-a2ca-495f-894f-9aad27bb0bea">eight</ix:nonFraction> hospital plaintiffs is scheduled to begin in Alabama in July 2023. We are vigorously defending ourselves in all of these matters; however, trials are inherently unpredictable and it is possible that an unfavorable outcome in these matters, individually or in the aggregate, could have a negative impact on our financial results.</span></div></div></ix:continuation></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">35</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="width:100.000%"><ix:continuation id="ic71ac4d727e64389910251b297c86002" continuedAt="i1136070a034f4fbfa42e562d596b1e52"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Insurance Litigation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in ongoing legal proceedings with insurers related their obligations to reimburse us for defense and indemnity costs in connection with the lawsuits described above. In the nine months ended March 31, 2023, we received approximately $<ix:nonFraction unitRef="usd" contextRef="i2ef2614263ad48d9934f6cc996c22e16_D20220701-20230331" decimals="-6" name="us-gaap:InsuranceRecoveries" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDAvZnJhZzo2NGI0MmYwYWIwNTM0MmVmODQyMWRhOGFmZmFiNjU2Mi90ZXh0cmVnaW9uOjY0YjQyZjBhYjA1MzQyZWY4NDIxZGE4YWZmYWI2NTYyXzExNzcz_de16c384-ca76-4f67-98cb-ea74971f17fb">10</ix:nonFraction>&#160;million in insurance recoveries related to these matters; however, we have not recorded a receivable for any additional recoveries as of March&#160;31, 2023.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cordis IVC Filter Matters </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Liability Lawsuits</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have been named as a defendant in approximately <ix:nonFraction unitRef="lawsuit" contextRef="icc7cc411a15e484b83110041666764e1_I20230428" decimals="0" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDAvZnJhZzo2NGI0MmYwYWIwNTM0MmVmODQyMWRhOGFmZmFiNjU2Mi90ZXh0cmVnaW9uOjY0YjQyZjBhYjA1MzQyZWY4NDIxZGE4YWZmYWI2NTYyXzEyMDMy_5ed521d7-147e-4f46-82b7-8aa8f955737d">453</ix:nonFraction> product liability lawsuits coordinated in Alameda County Superior Court in California involving claims by approximately <ix:nonFraction unitRef="plaintiff" contextRef="i44256b1db02046efa5d29d670a7bcd5d_D20230428-20230428" decimals="0" name="us-gaap:LossContingencyNumberOfPlaintiffs" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDAvZnJhZzo2NGI0MmYwYWIwNTM0MmVmODQyMWRhOGFmZmFiNjU2Mi90ZXh0cmVnaW9uOjY0YjQyZjBhYjA1MzQyZWY4NDIxZGE4YWZmYWI2NTYyXzEyMTU1_e273fff6-f50f-4bae-b3d4-80632d6c75bf">5,171</ix:nonFraction> plaintiffs that allege personal injuries associated with the use of IVC filter products. These lawsuits sought a variety of remedies, including unspecified monetary damages. The divestiture of the Cordis business did not include product liability related to the IVC filters in the U.S. and Canada, which we retained.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2023, we executed a settlement agreement that, if certain conditions are satisfied, will resolve approximately <ix:nonFraction unitRef="lawsuit" contextRef="i9ab800634809483fba34f7f06e7a35fe_D20230430-20230430" decimals="0" name="us-gaap:LossContingencyClaimsSettledNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDAvZnJhZzo2NGI0MmYwYWIwNTM0MmVmODQyMWRhOGFmZmFiNjU2Mi90ZXh0cmVnaW9uOjY0YjQyZjBhYjA1MzQyZWY4NDIxZGE4YWZmYWI2NTYyXzM4NDgyOTA3MjM2OTg_310cb90b-dae9-4932-bb06-a8e996fb9527">4,376</ix:nonFraction> claims for $<ix:nonFraction unitRef="usd" contextRef="i902b5ace502c4edbb1ba6a0998f22efa_I20230331" decimals="-6" name="us-gaap:LossContingencyEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDAvZnJhZzo2NGI0MmYwYWIwNTM0MmVmODQyMWRhOGFmZmFiNjU2Mi90ZXh0cmVnaW9uOjY0YjQyZjBhYjA1MzQyZWY4NDIxZGE4YWZmYWI2NTYyXzM4NDgyOTA3MjM3MzI_df08946b-57e7-4cd0-bf50-cd3dd387c3bb">275</ix:nonFraction>&#160;million. This settlement agreement is subject to certain conditions, including certain opt-in thresholds. Between May and September 2023, we will make settlement payments totaling $<ix:nonFraction unitRef="usd" contextRef="i5afb309fb1ba4583a4deda7964b8c2cf_D20230501-20230930" decimals="-6" name="us-gaap:PaymentsForLegalSettlements" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDAvZnJhZzo2NGI0MmYwYWIwNTM0MmVmODQyMWRhOGFmZmFiNjU2Mi90ZXh0cmVnaW9uOjY0YjQyZjBhYjA1MzQyZWY4NDIxZGE4YWZmYWI2NTYyXzU0OTc1NTgxNjU0Mzg_2c463f19-8ddd-44d7-8398-5cf9b99cdd53">275</ix:nonFraction>&#160;million into a qualified settlement fund, which will be disbursed to the plaintiffs if required conditions are satisfied. Since July 2021, we have also entered into other agreements to settle approximately <ix:nonFraction unitRef="lawsuit" contextRef="i80b8e7e7258b478b904b1818e9f2cc0c_D20210701-20230428" decimals="0" name="us-gaap:LossContingencyClaimsSettledNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDAvZnJhZzo2NGI0MmYwYWIwNTM0MmVmODQyMWRhOGFmZmFiNjU2Mi90ZXh0cmVnaW9uOjY0YjQyZjBhYjA1MzQyZWY4NDIxZGE4YWZmYWI2NTYyXzEyODM4_f3a862c7-d4c4-4c54-a81b-b872a6b6e8a9">2,881</ix:nonFraction> product liability claims. These settlements will not resolve all IVC filter product liability claims and we will continue to vigorously defend ourselves in the remaining lawsuits.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in August 2021, the Attorney General for the State of New Mexico filed an action against certain IVC filter manufacturers, including us, alleging claims under New Mexico's Unfair Practices Act, Medicaid Fraud Act and Fraud Against Taxpayers Act. The allegations are similar to those made in the product liability lawsuits.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized income of $<ix:nonFraction unitRef="usd" contextRef="ia3e20dfd93ab46e4866c903c3dfc10cf_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:ProductLiabilityAccrualPeriodExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDAvZnJhZzo2NGI0MmYwYWIwNTM0MmVmODQyMWRhOGFmZmFiNjU2Mi90ZXh0cmVnaW9uOjY0YjQyZjBhYjA1MzQyZWY4NDIxZGE4YWZmYWI2NTYyXzEzMTYz_17ed36e4-fe0a-487d-af99-7f19a8f3537b">71</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i853c2433b9a24879ba53a4b6f202569b_D20220701-20230331" decimals="-6" sign="-" name="us-gaap:ProductLiabilityAccrualPeriodExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDAvZnJhZzo2NGI0MmYwYWIwNTM0MmVmODQyMWRhOGFmZmFiNjU2Mi90ZXh0cmVnaW9uOjY0YjQyZjBhYjA1MzQyZWY4NDIxZGE4YWZmYWI2NTYyXzEzMTcw_c6b4c76a-f8c6-4e70-a660-a0ce4a505414">95</ix:nonFraction>&#160;million during the three and nine months ended March&#160;31, 2023, respectively, primarily related to a reduction of the reserve for the estimated settlement and defense costs for these matters due to the execution of the settlements noted above. At March&#160;31, 2023, we had a total of $<ix:nonFraction unitRef="usd" contextRef="i9ee8ab07c16a4a6c81486f97137b35dc_I20230331" decimals="-6" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDAvZnJhZzo2NGI0MmYwYWIwNTM0MmVmODQyMWRhOGFmZmFiNjU2Mi90ZXh0cmVnaW9uOjY0YjQyZjBhYjA1MzQyZWY4NDIxZGE4YWZmYWI2NTYyXzEzNDM1_7d4a35af-51c6-4a86-a76c-e71ab74216e5">385</ix:nonFraction>&#160;million accrued for losses and legal defense costs, related to the IVC filter product liability lawsuits in our condensed consolidated balance sheets. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shareholder Securities Litigation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, the Louisiana Sheriffs' Pension &amp; Relief Fund filed a purported class action complaint against Cardinal Health and certain current and former officers and employees in the United States District Court for the Southern District of Ohio purportedly on behalf of all purchasers of our common shares between March 2015 and May 2018. In June 2020, the court appointed 1199 SEIU Health Care Employees Pension Fund as lead plaintiff and a </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consolidated amended complaint was filed in September 2020. The amended complaint alleges that the defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 by making misrepresentations and omissions related to the acquisition and integration of the Cordis business and inventory and supply chain problems within the Cordis business, and seeks to recover unspecified damages and equitable relief for the alleged misstatements and omissions. The complaint also alleges that one of the individual defendants violated Section 20A of the Exchange Act because he sold shares of Cardinal Health stock during the time period. In February 2023, we reached an agreement in principle with the plaintiffs to settle this matter for $<ix:nonFraction unitRef="usd" contextRef="iacf755c31715440284f4942dd149ce26_D20230101-20230331" decimals="-6" name="us-gaap:GainLossRelatedToLitigationSettlement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDAvZnJhZzo2NGI0MmYwYWIwNTM0MmVmODQyMWRhOGFmZmFiNjU2Mi90ZXh0cmVnaW9uOjY0YjQyZjBhYjA1MzQyZWY4NDIxZGE4YWZmYWI2NTYyXzM4NDgyOTA3MjM3NDY_d0cd28e0-a8bf-4e07-a2c7-4001c586c96e">109</ix:nonFraction>&#160;million, subject to final approval by the court. The court granted its preliminary approval in April 2023 and will conduct a final hearing in September 2023. If the settlement is approved, our insurance carriers will pay $<ix:nonFraction unitRef="usd" contextRef="iacf755c31715440284f4942dd149ce26_D20230101-20230331" decimals="-6" name="us-gaap:InsuranceRecoveries" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDAvZnJhZzo2NGI0MmYwYWIwNTM0MmVmODQyMWRhOGFmZmFiNjU2Mi90ZXh0cmVnaW9uOjY0YjQyZjBhYjA1MzQyZWY4NDIxZGE4YWZmYWI2NTYyXzM4NDgyOTA3MjM3NjA_e2157eb6-716c-4cb2-8b38-5213a3548d25">109</ix:nonFraction>&#160;million to the plaintiffs. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Civil Litigation </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Generic Pharmaceutical Pricing Antitrust Litigation </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, pharmaceutical distributors including us were added as defendants in a civil class action lawsuit filed by indirect purchasers of generic drugs, such as hospitals and retail pharmacies. The indirect purchaser case is part of a multidistrict litigation consisting of multiple individual class action matters consolidated in the Eastern District of Pennsylvania. The indirect purchaser plaintiffs allege that pharmaceutical distributors encouraged manufacturers to increase prices, provided anti-competitive pricing information to manufacturers and improperly engaged in customer allocation. In May 2020, the court granted our motion to dismiss. In July 2022, the indirect purchasers filed an amended complaint and in August 2022, we filed a motion to dismiss the intended complaint. We are vigorously defending ourselves in this matter. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Antitrust Litigation Proceeds</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022, we received net cash proceeds resulting from the settlement of a lawsuit in which we were a class member or plaintiff of $<ix:nonFraction unitRef="usd" contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" decimals="-6" name="cah:IncomefromSettlementsofClassActionLawsuits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDAvZnJhZzo2NGI0MmYwYWIwNTM0MmVmODQyMWRhOGFmZmFiNjU2Mi90ZXh0cmVnaW9uOjY0YjQyZjBhYjA1MzQyZWY4NDIxZGE4YWZmYWI2NTYyXzE2NDY5_70ff50e8-4b2b-4c49-bc5b-e9133552e95b">66</ix:nonFraction>&#160;million, which was recognized in litigation (recoveries)/charges, net, during the nine months ended March 31, 2023. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shareholder Derivative Litigation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Between June 2019 and January 2020, three purported shareholders filed actions on behalf of Cardinal Health, Inc. in the U.S. District Court for the Southern District of Ohio against certain current and former members of our Board of Directors alleging that the defendants breached their fiduciary duties by failing to effectively monitor Cardinal Health's distribution of controlled substances and approving certain payments of executive compensation. In January 2020, the court consolidated these derivative cases under the caption In re Cardinal Health, Inc. Derivative Litigation and in March 2020, plaintiffs filed an amended complaint. </span></div></div></ix:continuation></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">36</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i1136070a034f4fbfa42e562d596b1e52">In October 2022, the court entered an order approving the settlement agreement reached between the parties and dismissing the case. The settlement does not include any admission of liability. Under this settlement, in December 2022, Cardinal Health's director and officer liability insurance carriers, on behalf of the defendants, paid Cardinal Health $<ix:nonFraction unitRef="usd" contextRef="i04e26b0d7e5d4849a52f150680f0c631_D20220701-20230331" decimals="-6" name="cah:GrossInsuranceSettlementBeforeAttorneyFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDAvZnJhZzo2NGI0MmYwYWIwNTM0MmVmODQyMWRhOGFmZmFiNjU2Mi90ZXh0cmVnaW9uOjY0YjQyZjBhYjA1MzQyZWY4NDIxZGE4YWZmYWI2NTYyXzE3NjU2_bd8c6a34-6f82-4a03-9891-edb4221df4d2">124</ix:nonFraction>&#160;million, less approximately $<ix:nonFraction unitRef="usd" contextRef="i04e26b0d7e5d4849a52f150680f0c631_D20220701-20230331" decimals="-6" name="us-gaap:LegalFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDAvZnJhZzo2NGI0MmYwYWIwNTM0MmVmODQyMWRhOGFmZmFiNjU2Mi90ZXh0cmVnaW9uOjY0YjQyZjBhYjA1MzQyZWY4NDIxZGE4YWZmYWI2NTYyXzE3Njc5_f47a8064-a5dc-40e1-af30-375cf6db8131">31</ix:nonFraction>&#160;million in attorneys' fees and expenses awarded by the court to plaintiffs' counsel. Cardinal Health received net cash proceeds resulting from this settlement of $<ix:nonFraction unitRef="usd" contextRef="i04e26b0d7e5d4849a52f150680f0c631_D20220701-20230331" decimals="-6" name="us-gaap:ProceedsFromInsuranceSettlementOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDAvZnJhZzo2NGI0MmYwYWIwNTM0MmVmODQyMWRhOGFmZmFiNjU2Mi90ZXh0cmVnaW9uOjY0YjQyZjBhYjA1MzQyZWY4NDIxZGE4YWZmYWI2NTYyXzE3ODI5_2629ac01-e949-44f6-80cd-0da1405253ff">93</ix:nonFraction>&#160;million, which was recognized in litigation (recoveries)/charges, net, during the nine months ended March 31, 2023.</ix:continuation> </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"></div></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div id="i1d34fc4fc2424fbcb4837cc9f1c0665c_103"></div><div style="width:100.000%"><ix:nonNumeric contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDMvZnJhZzphZGIwZjc3ODQ5Yzk0OGRiYWRkN2JkZGVlYTgwZDU3ZC90ZXh0cmVnaW9uOmFkYjBmNzc4NDljOTQ4ZGJhZGQ3YmRkZWVhODBkNTdkXzQzMTc_fc3f5a8b-af8f-4d57-956e-8479d3ef0ad8" continuedAt="ib29d80b221184bebba0e359550337750" escape="true"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">7. Income Taxes</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fluctuations in our provision for income taxes as a percentage of pre-tax earnings/(loss) (&#8220;effective tax rate&#8221;) are due to changes in international and U.S. state effective tax rates resulting from our business mix and discrete items. </span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Effective Tax Rate</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended&#160;March&#160;31, 2023, the effective tax rate was&#160;<ix:nonFraction unitRef="number" contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDMvZnJhZzphZGIwZjc3ODQ5Yzk0OGRiYWRkN2JkZGVlYTgwZDU3ZC90ZXh0cmVnaW9uOmFkYjBmNzc4NDljOTQ4ZGJhZGQ3YmRkZWVhODBkNTdkXzM0OQ_b908f30a-d1cb-48e0-832a-1944d6afb4a8">36.3</ix:nonFraction> percent and&#160;<ix:nonFraction unitRef="number" contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDMvZnJhZzphZGIwZjc3ODQ5Yzk0OGRiYWRkN2JkZGVlYTgwZDU3ZC90ZXh0cmVnaW9uOmFkYjBmNzc4NDljOTQ4ZGJhZGQ3YmRkZWVhODBkNTdkXzM1Ng_fd3419c9-554c-4638-b070-7eb64e713ce7">36.7</ix:nonFraction> percent, respectively, and reflects any impact of the tax effects of the goodwill impairment charges recognized during the three and nine months ended March&#160;31, 2023. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended&#160;March 31, 2022, the effective tax rate was (<ix:nonFraction unitRef="number" contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDMvZnJhZzphZGIwZjc3ODQ5Yzk0OGRiYWRkN2JkZGVlYTgwZDU3ZC90ZXh0cmVnaW9uOmFkYjBmNzc4NDljOTQ4ZGJhZGQ3YmRkZWVhODBkNTdkXzU2MQ_417c57df-6afc-4489-be95-94a586dee2a6">916.5</ix:nonFraction>) percent and (<ix:nonFraction unitRef="number" contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDMvZnJhZzphZGIwZjc3ODQ5Yzk0OGRiYWRkN2JkZGVlYTgwZDU3ZC90ZXh0cmVnaW9uOmFkYjBmNzc4NDljOTQ4ZGJhZGQ3YmRkZWVhODBkNTdkXzU2OA_45824f02-9c65-406e-b6b3-2af4f8ae07d1">44.4</ix:nonFraction>) percent, respectively, and reflects the impact of the tax effect of the goodwill impairment charges recognized during the three and nine months ended March 31, 2022.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tax Effects of Goodwill Impairment Charges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended March&#160;31, 2023, we recognized pre-tax goodwill impairment charges of $<ix:nonFraction unitRef="usd" contextRef="ie12745b4aa3e4e2f8127b2b3aa94621c_D20220701-20230331" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDMvZnJhZzphZGIwZjc3ODQ5Yzk0OGRiYWRkN2JkZGVlYTgwZDU3ZC90ZXh0cmVnaW9uOmFkYjBmNzc4NDljOTQ4ZGJhZGQ3YmRkZWVhODBkNTdkXzg0Mw_81d80d54-799e-4fdb-8938-1abf1e264da3">863</ix:nonFraction>&#160;million related to the Medical Unit. The net tax benefit related to these charges is $<ix:nonFraction unitRef="usd" contextRef="ie5694d08abff46ac90bbee9634d4edd3_D20220701-20230630" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDMvZnJhZzphZGIwZjc3ODQ5Yzk0OGRiYWRkN2JkZGVlYTgwZDU3ZC90ZXh0cmVnaW9uOmFkYjBmNzc4NDljOTQ4ZGJhZGQ3YmRkZWVhODBkNTdkXzkyMQ_e02dc733-d382-4589-8795-f28314e59f55">68</ix:nonFraction>&#160;million for fiscal 2023. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless an item is considered discrete because it is unusual or infrequent, the tax impact of the item is included in our estimated annual effective tax rate. When items are recognized through our estimated annual effective tax rate, we apply our estimated annual effective tax rate to the earnings/(loss) before income taxes for the year-to-date period to compute our impact from income taxes for the current quarter and year-to-date period. The tax impacts of discrete items are recognized in their entirety in the period in which they occur.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax effect of the goodwill impairment charges during the nine months ended March 31, 2023 was included in our estimated annual effective tax rate because it was not considered unusual or infrequent, given that we recorded goodwill impairments in prior fiscal years. The impact of the non-deductible goodwill increased the estimated annual effective tax rate for fiscal 2023. Applying the higher tax rate to the pre-tax income for the nine months ended March&#160;31, 2023 resulted in recognizing an incremental interim tax expense of approximately $<ix:nonFraction unitRef="usd" contextRef="i22d8ac48311042cebfc3c15dda5a16fa_D20230101-20230331" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDMvZnJhZzphZGIwZjc3ODQ5Yzk0OGRiYWRkN2JkZGVlYTgwZDU3ZC90ZXh0cmVnaW9uOmFkYjBmNzc4NDljOTQ4ZGJhZGQ3YmRkZWVhODBkNTdkXzIwMzQ_0c7ffd07-eeca-4a90-8f33-84570b7fb693">74</ix:nonFraction>&#160;million, which impacted the </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">provision for income taxes in the condensed consolidated statements of earnings/(loss) during the three months ended March&#160;31, 2023 and prepaid expenses and other assets in the condensed consolidated balance sheet at March&#160;31, 2023. The incremental interim tax benefit recognized during the nine months ended March&#160;31, 2023 was $<ix:nonFraction unitRef="usd" contextRef="ie4fa6e3e07aa461e98a6b82df41d98ce_D20230401-20230630" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDMvZnJhZzphZGIwZjc3ODQ5Yzk0OGRiYWRkN2JkZGVlYTgwZDU3ZC90ZXh0cmVnaW9uOmFkYjBmNzc4NDljOTQ4ZGJhZGQ3YmRkZWVhODBkNTdkXzU0OTc1NTgxNDM3Njc_41923bf4-257e-442d-815b-1dc425a99c0e">66</ix:nonFraction>&#160;million and will reverse in the fourth quarter of fiscal 2023.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unrecognized Tax Benefits</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had $<ix:nonFraction unitRef="usd" contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDMvZnJhZzphZGIwZjc3ODQ5Yzk0OGRiYWRkN2JkZGVlYTgwZDU3ZC90ZXh0cmVnaW9uOmFkYjBmNzc4NDljOTQ4ZGJhZGQ3YmRkZWVhODBkNTdkXzIzODU_0ae59b1a-c97b-42e6-ab9b-b817a2e67afc">1.1</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="ic217743408d440409a59220a0bf14e4c_I20220630" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDMvZnJhZzphZGIwZjc3ODQ5Yzk0OGRiYWRkN2JkZGVlYTgwZDU3ZC90ZXh0cmVnaW9uOmFkYjBmNzc4NDljOTQ4ZGJhZGQ3YmRkZWVhODBkNTdkXzIzOTI_cbc11d84-76e9-4eae-88a0-42b30d5657aa">943</ix:nonFraction> million of unrecognized tax benefits, at March&#160;31, 2023 and June&#160;30, 2022, respectively. The March&#160;31, 2023 and June&#160;30, 2022 balances include $<ix:nonFraction unitRef="usd" contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDMvZnJhZzphZGIwZjc3ODQ5Yzk0OGRiYWRkN2JkZGVlYTgwZDU3ZC90ZXh0cmVnaW9uOmFkYjBmNzc4NDljOTQ4ZGJhZGQ3YmRkZWVhODBkNTdkXzI0ODQ_f4e88101-5117-44da-a4b9-1b7279ea605d">897</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ic217743408d440409a59220a0bf14e4c_I20220630" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDMvZnJhZzphZGIwZjc3ODQ5Yzk0OGRiYWRkN2JkZGVlYTgwZDU3ZC90ZXh0cmVnaW9uOmFkYjBmNzc4NDljOTQ4ZGJhZGQ3YmRkZWVhODBkNTdkXzI0OTE_c0535ce1-5e47-49ba-9614-eb5cebff5e9a">858</ix:nonFraction> million of unrecognized tax benefits, respectively, that if recognized, would have an impact on the effective tax rate. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2023 and June&#160;30, 2022, we had $<ix:nonFraction unitRef="usd" contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDMvZnJhZzphZGIwZjc3ODQ5Yzk0OGRiYWRkN2JkZGVlYTgwZDU3ZC90ZXh0cmVnaW9uOmFkYjBmNzc4NDljOTQ4ZGJhZGQ3YmRkZWVhODBkNTdkXzI2Mjg_3da589e2-950b-4ad3-a7e9-e1201c3125f1">61</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ic217743408d440409a59220a0bf14e4c_I20220630" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDMvZnJhZzphZGIwZjc3ODQ5Yzk0OGRiYWRkN2JkZGVlYTgwZDU3ZC90ZXh0cmVnaW9uOmFkYjBmNzc4NDljOTQ4ZGJhZGQ3YmRkZWVhODBkNTdkXzI2MzU_0c297ded-eb53-40fc-aaef-518d9d41c01c">48</ix:nonFraction> million, respectively, accrued for the payment of interest and penalties related to unrecognized tax benefits, which we recognize in the provision for income taxes in the condensed consolidated statements of earnings/(loss). These balances are gross amounts before any tax benefits and are included in deferred income taxes and other liabilities in the condensed consolidated balance sheets. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is reasonably possible that there could be a change in the amount of unrecognized tax benefits within the next 12 months due to activities of the U.S. Internal Revenue Service ("IRS") or other taxing authorities, possible settlement of IRS and other audit issues, reassessment of existing unrecognized tax benefits or the expiration of statutes of limitations. We estimate that the range of the possible change in unrecognized tax benefits within the next 12 months is between <ix:nonFraction unitRef="usd" contextRef="i0fb653442b8d46c4b1d69a67bca87b29_I20230331" decimals="-6" name="us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDMvZnJhZzphZGIwZjc3ODQ5Yzk0OGRiYWRkN2JkZGVlYTgwZDU3ZC90ZXh0cmVnaW9uOmFkYjBmNzc4NDljOTQ4ZGJhZGQ3YmRkZWVhODBkNTdkXzM1MTg_4ee93fa3-1f67-4d18-b339-c902c028f19a">zero</ix:nonFraction> and a net decrease of up to $<ix:nonFraction unitRef="usd" contextRef="ifef254c9824a4dbcbe0e5996b5dcc160_I20230331" decimals="-6" name="us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDMvZnJhZzphZGIwZjc3ODQ5Yzk0OGRiYWRkN2JkZGVlYTgwZDU3ZC90ZXh0cmVnaW9uOmFkYjBmNzc4NDljOTQ4ZGJhZGQ3YmRkZWVhODBkNTdkXzM1NDk_5769d669-6139-4f47-abd0-39d6ab0faad2">125</ix:nonFraction> million, exclusive of penalties and interest.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Tax Matters</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions, and various foreign jurisdictions. With few exceptions, we are subject to audit by taxing authorities for fiscal years 2015 through the current fiscal year.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to a tax matters agreement with CareFusion Corporation ("CareFusion"), a subsidiary of Becton, Dickinson and Company. Under the tax matters agreement, CareFusion is obligated to indemnify us for certain tax exposures and transaction taxes prior to our fiscal 2010 spin-off of CareFusion. The indemnification receivable was $<ix:nonFraction unitRef="usd" contextRef="ia83e033e96e343bda1abf45e39b6de85_I20230331" decimals="-6" name="cah:IndemnificationReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDMvZnJhZzphZGIwZjc3ODQ5Yzk0OGRiYWRkN2JkZGVlYTgwZDU3ZC90ZXh0cmVnaW9uOmFkYjBmNzc4NDljOTQ4ZGJhZGQ3YmRkZWVhODBkNTdkXzQxOTg_0a75d12c-d0d5-4126-a309-f16fa26c0708">80</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i4b473c3f43624d36b0c2c645e60d3c85_I20220630" decimals="-6" name="cah:IndemnificationReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDMvZnJhZzphZGIwZjc3ODQ5Yzk0OGRiYWRkN2JkZGVlYTgwZDU3ZC90ZXh0cmVnaW9uOmFkYjBmNzc4NDljOTQ4ZGJhZGQ3YmRkZWVhODBkNTdkXzQyMDU_cda7e9b3-663f-435b-8af8-cdc7fe5f306d">75</ix:nonFraction>&#160;million at </span></div></div></ix:nonNumeric></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">37</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ib29d80b221184bebba0e359550337750">March&#160;31, 2023 and June&#160;30, 2022, respectively, and is included in other assets in the condensed consolidated balance sheets.</ix:continuation></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div id="i1d34fc4fc2424fbcb4837cc9f1c0665c_106"></div><ix:nonNumeric contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDYvZnJhZzo5ZDA4MzdmNjYxMjU0M2E0ODc0ZjM3OWFlZjc3MjY2Mi90ZXh0cmVnaW9uOjlkMDgzN2Y2NjEyNTQzYTQ4NzRmMzc5YWVmNzcyNjYyXzEyMjI_f775b671-2d7f-47be-a991-c89870c2d471" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">8. Fair Value Measurements</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><ix:nonNumeric contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDYvZnJhZzo5ZDA4MzdmNjYxMjU0M2E0ODc0ZjM3OWFlZjc3MjY2Mi90ZXh0cmVnaW9uOjlkMDgzN2Y2NjEyNTQzYTQ4NzRmMzc5YWVmNzcyNjYyXzEyMDg_d0511be6-05df-4080-9533-22cc8c02a236" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the fair values for assets and (liabilities) measured on a recurring basis at:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.938%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0647080b68e4434fb69d13640e2185be_I20230331" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDYvZnJhZzo5ZDA4MzdmNjYxMjU0M2E0ODc0ZjM3OWFlZjc3MjY2Mi90YWJsZTo2ZmI3Njg5ODc1NjE0MjJlYWYyZDdiMDFkNGEyNTc4Yy90YWJsZXJhbmdlOjZmYjc2ODk4NzU2MTQyMmVhZjJkN2IwMWQ0YTI1NzhjXzMtMS0xLTEtMjg2OTQ0_46b609ad-53f9-4e8e-9795-ecc0f1b40469">1,302</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22574d8c00bd4f13ae6ec2c4fcc2f017_I20230331" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDYvZnJhZzo5ZDA4MzdmNjYxMjU0M2E0ODc0ZjM3OWFlZjc3MjY2Mi90YWJsZTo2ZmI3Njg5ODc1NjE0MjJlYWYyZDdiMDFkNGEyNTc4Yy90YWJsZXJhbmdlOjZmYjc2ODk4NzU2MTQyMmVhZjJkN2IwMWQ0YTI1NzhjXzMtMy0xLTEtMjg2OTQ0_23784e5a-c381-460a-92f4-d1f9828c6a7a">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib308cbc504e54cfea2d4a2a0d5e67181_I20230331" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDYvZnJhZzo5ZDA4MzdmNjYxMjU0M2E0ODc0ZjM3OWFlZjc3MjY2Mi90YWJsZTo2ZmI3Njg5ODc1NjE0MjJlYWYyZDdiMDFkNGEyNTc4Yy90YWJsZXJhbmdlOjZmYjc2ODk4NzU2MTQyMmVhZjJkN2IwMWQ0YTI1NzhjXzMtNS0xLTEtMjg2OTQ0_4aad3254-e892-41e5-a30d-b4c738732194">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1d54b1779a94c778dcfd9c480a2851b_I20230331" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDYvZnJhZzo5ZDA4MzdmNjYxMjU0M2E0ODc0ZjM3OWFlZjc3MjY2Mi90YWJsZTo2ZmI3Njg5ODc1NjE0MjJlYWYyZDdiMDFkNGEyNTc4Yy90YWJsZXJhbmdlOjZmYjc2ODk4NzU2MTQyMmVhZjJkN2IwMWQ0YTI1NzhjXzMtNy0xLTEtMjg2OTQ0_4b720a6f-8b63-4194-a98b-500f700fd213">1,302</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other investments (1)</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0647080b68e4434fb69d13640e2185be_I20230331" decimals="-6" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDYvZnJhZzo5ZDA4MzdmNjYxMjU0M2E0ODc0ZjM3OWFlZjc3MjY2Mi90YWJsZTo2ZmI3Njg5ODc1NjE0MjJlYWYyZDdiMDFkNGEyNTc4Yy90YWJsZXJhbmdlOjZmYjc2ODk4NzU2MTQyMmVhZjJkN2IwMWQ0YTI1NzhjXzUtMS0xLTEtMjg2OTQ0_903f1b45-097c-474e-9d9b-7adc1172a4ab">95</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22574d8c00bd4f13ae6ec2c4fcc2f017_I20230331" decimals="-6" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDYvZnJhZzo5ZDA4MzdmNjYxMjU0M2E0ODc0ZjM3OWFlZjc3MjY2Mi90YWJsZTo2ZmI3Njg5ODc1NjE0MjJlYWYyZDdiMDFkNGEyNTc4Yy90YWJsZXJhbmdlOjZmYjc2ODk4NzU2MTQyMmVhZjJkN2IwMWQ0YTI1NzhjXzUtMy0xLTEtMjg2OTQ0_8d5d038b-90d6-4e82-b87e-a6bfb5a7836c">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib308cbc504e54cfea2d4a2a0d5e67181_I20230331" decimals="-6" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDYvZnJhZzo5ZDA4MzdmNjYxMjU0M2E0ODc0ZjM3OWFlZjc3MjY2Mi90YWJsZTo2ZmI3Njg5ODc1NjE0MjJlYWYyZDdiMDFkNGEyNTc4Yy90YWJsZXJhbmdlOjZmYjc2ODk4NzU2MTQyMmVhZjJkN2IwMWQ0YTI1NzhjXzUtNS0xLTEtMjg2OTQ0_1aeb4d69-2064-46b5-84b9-2b702aef6b7c">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1d54b1779a94c778dcfd9c480a2851b_I20230331" decimals="-6" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDYvZnJhZzo5ZDA4MzdmNjYxMjU0M2E0ODc0ZjM3OWFlZjc3MjY2Mi90YWJsZTo2ZmI3Njg5ODc1NjE0MjJlYWYyZDdiMDFkNGEyNTc4Yy90YWJsZXJhbmdlOjZmYjc2ODk4NzU2MTQyMmVhZjJkN2IwMWQ0YTI1NzhjXzUtNy0xLTEtMjg2OTQ0_4bebf854-25cb-485f-b965-672c302e7603">95</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contracts (2)</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0647080b68e4434fb69d13640e2185be_I20230331" decimals="-6" name="us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDYvZnJhZzo5ZDA4MzdmNjYxMjU0M2E0ODc0ZjM3OWFlZjc3MjY2Mi90YWJsZTo2ZmI3Njg5ODc1NjE0MjJlYWYyZDdiMDFkNGEyNTc4Yy90YWJsZXJhbmdlOjZmYjc2ODk4NzU2MTQyMmVhZjJkN2IwMWQ0YTI1NzhjXzgtMS0xLTEtMjg2OTQ0_39981380-d816-470a-8409-859dd01e63f1">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22574d8c00bd4f13ae6ec2c4fcc2f017_I20230331" decimals="-6" sign="-" name="us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDYvZnJhZzo5ZDA4MzdmNjYxMjU0M2E0ODc0ZjM3OWFlZjc3MjY2Mi90YWJsZTo2ZmI3Njg5ODc1NjE0MjJlYWYyZDdiMDFkNGEyNTc4Yy90YWJsZXJhbmdlOjZmYjc2ODk4NzU2MTQyMmVhZjJkN2IwMWQ0YTI1NzhjXzgtMy0xLTEtMjg2OTQ0_413970cf-feb1-4338-9a4b-1f23a460bdda">52</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib308cbc504e54cfea2d4a2a0d5e67181_I20230331" decimals="-6" name="us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDYvZnJhZzo5ZDA4MzdmNjYxMjU0M2E0ODc0ZjM3OWFlZjc3MjY2Mi90YWJsZTo2ZmI3Njg5ODc1NjE0MjJlYWYyZDdiMDFkNGEyNTc4Yy90YWJsZXJhbmdlOjZmYjc2ODk4NzU2MTQyMmVhZjJkN2IwMWQ0YTI1NzhjXzgtNS0xLTEtMjg2OTQ0_d40fd569-8641-46e0-a4e7-a7cbe3c0c646">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1d54b1779a94c778dcfd9c480a2851b_I20230331" decimals="-6" sign="-" name="us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDYvZnJhZzo5ZDA4MzdmNjYxMjU0M2E0ODc0ZjM3OWFlZjc3MjY2Mi90YWJsZTo2ZmI3Njg5ODc1NjE0MjJlYWYyZDdiMDFkNGEyNTc4Yy90YWJsZXJhbmdlOjZmYjc2ODk4NzU2MTQyMmVhZjJkN2IwMWQ0YTI1NzhjXzgtNy0xLTEtMjg2OTQ0_c66a4834-31b5-406d-ba46-3b67550246da">52</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.938%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic019966f86814bbbafa5f64677ed3ae9_I20220630" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDYvZnJhZzo5ZDA4MzdmNjYxMjU0M2E0ODc0ZjM3OWFlZjc3MjY2Mi90YWJsZTo3YzRmM2E4OWJmNDE0NTRhOGU1MGJkOTI0NDEyMjE5MC90YWJsZXJhbmdlOjdjNGYzYTg5YmY0MTQ1NGE4ZTUwYmQ5MjQ0MTIyMTkwXzMtMS0xLTEtMjg2OTQ0_c6638f5c-4ec4-4efd-aff8-a26ebb8bb74b">2,425</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3c2602782c94beab41f34560fbefd82_I20220630" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDYvZnJhZzo5ZDA4MzdmNjYxMjU0M2E0ODc0ZjM3OWFlZjc3MjY2Mi90YWJsZTo3YzRmM2E4OWJmNDE0NTRhOGU1MGJkOTI0NDEyMjE5MC90YWJsZXJhbmdlOjdjNGYzYTg5YmY0MTQ1NGE4ZTUwYmQ5MjQ0MTIyMTkwXzMtMy0xLTEtMjg2OTQ0_723b2f18-0db5-4b03-8788-1a2f23576222">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic33b3236678d4dba9bb198c5653cc58f_I20220630" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDYvZnJhZzo5ZDA4MzdmNjYxMjU0M2E0ODc0ZjM3OWFlZjc3MjY2Mi90YWJsZTo3YzRmM2E4OWJmNDE0NTRhOGU1MGJkOTI0NDEyMjE5MC90YWJsZXJhbmdlOjdjNGYzYTg5YmY0MTQ1NGE4ZTUwYmQ5MjQ0MTIyMTkwXzMtNS0xLTEtMjg2OTQ0_90ef35dc-08c9-412e-bc9d-72e2cb3f0266">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i590356452cf8465698d99ccf090749ee_I20220630" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDYvZnJhZzo5ZDA4MzdmNjYxMjU0M2E0ODc0ZjM3OWFlZjc3MjY2Mi90YWJsZTo3YzRmM2E4OWJmNDE0NTRhOGU1MGJkOTI0NDEyMjE5MC90YWJsZXJhbmdlOjdjNGYzYTg5YmY0MTQ1NGE4ZTUwYmQ5MjQ0MTIyMTkwXzMtNy0xLTEtMjg2OTQ0_ae7b7d13-1888-4c23-8b39-6146cdbba85d">2,425</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other investments (1)</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic019966f86814bbbafa5f64677ed3ae9_I20220630" decimals="-6" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDYvZnJhZzo5ZDA4MzdmNjYxMjU0M2E0ODc0ZjM3OWFlZjc3MjY2Mi90YWJsZTo3YzRmM2E4OWJmNDE0NTRhOGU1MGJkOTI0NDEyMjE5MC90YWJsZXJhbmdlOjdjNGYzYTg5YmY0MTQ1NGE4ZTUwYmQ5MjQ0MTIyMTkwXzUtMS0xLTEtMjg2OTQ0_5138fe7e-8832-4270-b89e-05f7a7bd0e3f">97</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3c2602782c94beab41f34560fbefd82_I20220630" decimals="-6" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDYvZnJhZzo5ZDA4MzdmNjYxMjU0M2E0ODc0ZjM3OWFlZjc3MjY2Mi90YWJsZTo3YzRmM2E4OWJmNDE0NTRhOGU1MGJkOTI0NDEyMjE5MC90YWJsZXJhbmdlOjdjNGYzYTg5YmY0MTQ1NGE4ZTUwYmQ5MjQ0MTIyMTkwXzUtMy0xLTEtMjg2OTQ0_4c7782c4-103f-44ef-85ec-adbea767618b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic33b3236678d4dba9bb198c5653cc58f_I20220630" decimals="-6" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDYvZnJhZzo5ZDA4MzdmNjYxMjU0M2E0ODc0ZjM3OWFlZjc3MjY2Mi90YWJsZTo3YzRmM2E4OWJmNDE0NTRhOGU1MGJkOTI0NDEyMjE5MC90YWJsZXJhbmdlOjdjNGYzYTg5YmY0MTQ1NGE4ZTUwYmQ5MjQ0MTIyMTkwXzUtNS0xLTEtMjg2OTQ0_13d410f3-962b-4dab-bb5f-9285b387cdd0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i590356452cf8465698d99ccf090749ee_I20220630" decimals="-6" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDYvZnJhZzo5ZDA4MzdmNjYxMjU0M2E0ODc0ZjM3OWFlZjc3MjY2Mi90YWJsZTo3YzRmM2E4OWJmNDE0NTRhOGU1MGJkOTI0NDEyMjE5MC90YWJsZXJhbmdlOjdjNGYzYTg5YmY0MTQ1NGE4ZTUwYmQ5MjQ0MTIyMTkwXzUtNy0xLTEtMjg2OTQ0_baef2075-b855-4ee8-b13d-7ebbc539deaa">97</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contracts (2)</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic019966f86814bbbafa5f64677ed3ae9_I20220630" decimals="-6" name="us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDYvZnJhZzo5ZDA4MzdmNjYxMjU0M2E0ODc0ZjM3OWFlZjc3MjY2Mi90YWJsZTo3YzRmM2E4OWJmNDE0NTRhOGU1MGJkOTI0NDEyMjE5MC90YWJsZXJhbmdlOjdjNGYzYTg5YmY0MTQ1NGE4ZTUwYmQ5MjQ0MTIyMTkwXzYtMS0xLTEtMjg2OTQ0_3afb4693-13b0-41aa-898d-674b43e2267a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3c2602782c94beab41f34560fbefd82_I20220630" decimals="-6" name="us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDYvZnJhZzo5ZDA4MzdmNjYxMjU0M2E0ODc0ZjM3OWFlZjc3MjY2Mi90YWJsZTo3YzRmM2E4OWJmNDE0NTRhOGU1MGJkOTI0NDEyMjE5MC90YWJsZXJhbmdlOjdjNGYzYTg5YmY0MTQ1NGE4ZTUwYmQ5MjQ0MTIyMTkwXzYtMy0xLTEtMjg2OTQ0_a1758862-1591-4abd-94f1-92eab4204df2">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic33b3236678d4dba9bb198c5653cc58f_I20220630" decimals="-6" name="us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDYvZnJhZzo5ZDA4MzdmNjYxMjU0M2E0ODc0ZjM3OWFlZjc3MjY2Mi90YWJsZTo3YzRmM2E4OWJmNDE0NTRhOGU1MGJkOTI0NDEyMjE5MC90YWJsZXJhbmdlOjdjNGYzYTg5YmY0MTQ1NGE4ZTUwYmQ5MjQ0MTIyMTkwXzYtNS0xLTEtMjg2OTQ0_419fbff5-a16e-4cc3-acfb-ebdaa9411a14">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i590356452cf8465698d99ccf090749ee_I20220630" decimals="-6" name="us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDYvZnJhZzo5ZDA4MzdmNjYxMjU0M2E0ODc0ZjM3OWFlZjc3MjY2Mi90YWJsZTo3YzRmM2E4OWJmNDE0NTRhOGU1MGJkOTI0NDEyMjE5MC90YWJsZXJhbmdlOjdjNGYzYTg5YmY0MTQ1NGE4ZTUwYmQ5MjQ0MTIyMTkwXzYtNy0xLTEtMjg2OTQ0_065b93fd-6604-4192-aacb-052a2e457c37">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">The other investments balance includes investments in mutual funds, which offset fluctuations in deferred compensation liabilities. These mutual funds invest in the equity securities of companies with both large and small market capitalization and high quality fixed income debt securities. The fair value of these investments is determined using quoted market prices.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">The fair value of interest rate swaps, foreign currency contracts, and net investment hedges is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in prepaid expenses and other, other assets, other accrued liabilities, and deferred income taxes and other liabilities within the condensed consolidated balance sheets.</span></div></ix:nonNumeric></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div id="i1d34fc4fc2424fbcb4837cc9f1c0665c_109"></div><ix:nonNumeric contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331" name="us-gaap:FinancialInstrumentsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDkvZnJhZzoyNWNlMTUzYjg0YzY0ZTc2OTNhY2U2MmNjZjgxYzk2MS90ZXh0cmVnaW9uOjI1Y2UxNTNiODRjNjRlNzY5M2FjZTYyY2NmODFjOTYxXzgwMTc_0b70712a-d0d9-490b-8fc5-8b7b7913fe60" continuedAt="idcf397c9e9ea408591ebee021a97ae73" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">9. Financial Instruments </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We utilize derivative financial instruments to manage exposure to certain risks related to our ongoing operations. The primary risks managed through the use of derivative instruments include interest rate risk, currency exchange risk and commodity price risk. We do not use derivative instruments for trading or speculative purposes. While the majority of our derivative instruments are designated as hedging instruments, we also enter into derivative instruments that are designed to hedge a risk but are not designated as hedging instruments. These derivative instruments are adjusted to current fair value through earnings at the end of each period. We are exposed to counterparty credit risk on all of our derivative instruments. Accordingly, we have established and maintain strict counterparty credit guidelines and only enter into derivative instruments with major financial institutions that are rated investment grade or better. We do not have significant exposure to </span></div></ix:nonNumeric></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><ix:continuation id="idcf397c9e9ea408591ebee021a97ae73" continuedAt="i680f67b422bb4f28925b48cfe0b0557e"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">any one counterparty and we believe the risk of loss is remote. Additionally, we do not require collateral under these agreements.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Interest Rate Risk Management</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the impact of interest rate changes. Our objective is to manage the impact of interest rate changes on cash flows and the market value of our borrowings. We utilize a mix of debt maturities on our fixed-rate debt to manage changes in interest rates. In addition, we enter into interest rate swaps to further manage our exposure to interest rate variations related to our borrowings and to lower our overall borrowing costs.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Currency Exchange Risk Management</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conduct business in several major international currencies and are subject to risks associated with changing foreign exchange rates. Our objective is to reduce earnings and cash flow volatility associated with foreign exchange rate changes to allow management to focus its attention on business operations. Accordingly, we enter into various contracts that change in value as foreign exchange rates change to protect the value of existing foreign currency assets and liabilities, commitments and anticipated foreign currency revenue and expenses.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commodity Price Risk Management</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to changes in the price of certain commodities. Our objective is to reduce earnings and cash flow volatility associated with forecasted purchases of these commodities to allow management to focus its attention on business operations. Accordingly, we enter into derivative contracts when possible to manage the price risk associated with certain forecasted purchases.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Fair Value Hedges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into pay-floating interest rate swaps to hedge the changes in the fair value of fixed-rate debt resulting from fluctuations in interest rates. These contracts are designated and qualify as fair value hedges. Accordingly, the gain or loss recorded on the pay-floating interest rate swaps is directly offset by the change in fair value of the underlying debt. Both the derivative instrument and the underlying debt are adjusted to market value at the end of each period with any resulting gain or loss recorded in interest expense, net in the condensed consolidated statements of earnings/(loss). For the three and nine months ended March&#160;31, 2023 and 2022, there was <ix:nonFraction unitRef="usd" contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331" decimals="-6" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDkvZnJhZzoyNWNlMTUzYjg0YzY0ZTc2OTNhY2U2MmNjZjgxYzk2MS90ZXh0cmVnaW9uOjI1Y2UxNTNiODRjNjRlNzY5M2FjZTYyY2NmODFjOTYxXzMyNTI_741382ce-00a8-4b5e-922c-2efaee48ddc8"><ix:nonFraction unitRef="usd" contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" decimals="-6" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDkvZnJhZzoyNWNlMTUzYjg0YzY0ZTc2OTNhY2U2MmNjZjgxYzk2MS90ZXh0cmVnaW9uOjI1Y2UxNTNiODRjNjRlNzY5M2FjZTYyY2NmODFjOTYxXzMyNTI_b0ee285c-f109-4110-8c84-5ce87cc00c2e"><ix:nonFraction unitRef="usd" contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331" decimals="-6" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDkvZnJhZzoyNWNlMTUzYjg0YzY0ZTc2OTNhY2U2MmNjZjgxYzk2MS90ZXh0cmVnaW9uOjI1Y2UxNTNiODRjNjRlNzY5M2FjZTYyY2NmODFjOTYxXzMyNTI_bb7d4d06-96e2-47d5-a0c7-2b97c4ad667b"><ix:nonFraction unitRef="usd" contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331" decimals="-6" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDkvZnJhZzoyNWNlMTUzYjg0YzY0ZTc2OTNhY2U2MmNjZjgxYzk2MS90ZXh0cmVnaW9uOjI1Y2UxNTNiODRjNjRlNzY5M2FjZTYyY2NmODFjOTYxXzMyNTI_d7de8f97-a1ff-490b-8d4f-95e66fa6f681">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> gain or loss recorded to interest expense as changes in the market value of our derivative instruments offset changes in the market value of the underlying debt.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended March 31, 2023 and 2022, we entered into pay-floating interest rate swaps with total notional amounts of $<ix:nonFraction unitRef="usd" contextRef="ie7058036db8747708418c4af8c5bbe90_I20230331" decimals="-6" name="us-gaap:DerivativeLiabilityNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDkvZnJhZzoyNWNlMTUzYjg0YzY0ZTc2OTNhY2U2MmNjZjgxYzk2MS90ZXh0cmVnaW9uOjI1Y2UxNTNiODRjNjRlNzY5M2FjZTYyY2NmODFjOTYxXzM1MjQ_f25d6a08-132f-4b6c-ae6c-d73772122590">200</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib40cb321ed7048c3a2302a1bf22f2f6f_I20220331" decimals="-6" name="us-gaap:DerivativeLiabilityNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDkvZnJhZzoyNWNlMTUzYjg0YzY0ZTc2OTNhY2U2MmNjZjgxYzk2MS90ZXh0cmVnaW9uOjI1Y2UxNTNiODRjNjRlNzY5M2FjZTYyY2NmODFjOTYxXzM1MzE_c2b09c12-44d7-49af-a768-8eb982ed8e97">300</ix:nonFraction> million, respectively. These swaps have been designated as fair value hedges of our fixed rate debt and are included in deferred income taxes and other liabilities in the condensed consolidated balance sheets.</span></div></ix:continuation><div><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">38</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><ix:continuation id="i680f67b422bb4f28925b48cfe0b0557e" continuedAt="ia963d63272d5420bb030840e3d575196"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Cash Flow Hedges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into derivative instruments to hedge our exposure to changes in cash flows attributable to interest rate, foreign currency and commodity price fluctuations associated with certain forecasted transactions. These derivative instruments are designated and qualify as cash flow hedges. Accordingly, the gain or loss on the derivative instrument is reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same line item associated with the forecasted transaction and in the same period during which the hedged transaction affects earnings.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-tax gains recognized in other comprehensive income/(loss) were $<ix:nonFraction unitRef="usd" contextRef="ifafc390c5b574ce9a766400e79096086_D20230101-20230331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDkvZnJhZzoyNWNlMTUzYjg0YzY0ZTc2OTNhY2U2MmNjZjgxYzk2MS90ZXh0cmVnaW9uOjI1Y2UxNTNiODRjNjRlNzY5M2FjZTYyY2NmODFjOTYxXzQ0MjU_699a51d2-141b-4825-8e57-3a240493974c">2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i9f91dc01d0934f62990f387aff42bfc0_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDkvZnJhZzoyNWNlMTUzYjg0YzY0ZTc2OTNhY2U2MmNjZjgxYzk2MS90ZXh0cmVnaW9uOjI1Y2UxNTNiODRjNjRlNzY5M2FjZTYyY2NmODFjOTYxXzQ0Mzk_3bd766d0-c83c-42cf-929a-481c89d600f4">1</ix:nonFraction>&#160;million for the three months ended March&#160;31, 2023 and 2022, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i324d3cb6fe534b2d935a46f13fe9d0d7_D20220701-20230331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDkvZnJhZzoyNWNlMTUzYjg0YzY0ZTc2OTNhY2U2MmNjZjgxYzk2MS90ZXh0cmVnaW9uOjI1Y2UxNTNiODRjNjRlNzY5M2FjZTYyY2NmODFjOTYxXzQ1MDc_6bbffcdc-7232-4ead-bb38-1d4a8a9217d5"><ix:nonFraction unitRef="usd" contextRef="i9ad948cf8f05443b8e4818f18729c732_D20210701-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDkvZnJhZzoyNWNlMTUzYjg0YzY0ZTc2OTNhY2U2MmNjZjgxYzk2MS90ZXh0cmVnaW9uOjI1Y2UxNTNiODRjNjRlNzY5M2FjZTYyY2NmODFjOTYxXzQ1MDc_d760d865-f292-49b7-b8fb-13372d758846">4</ix:nonFraction></ix:nonFraction>&#160;million for both the nine months ended March&#160;31, 2023 and 2022. Gains recognized in accumulated other comprehensive loss and reclassified into earnings were $<ix:nonFraction unitRef="usd" contextRef="i580853edf11f49b9b0fd206b92df8e34_D20230101-20230331" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDkvZnJhZzoyNWNlMTUzYjg0YzY0ZTc2OTNhY2U2MmNjZjgxYzk2MS90ZXh0cmVnaW9uOjI1Y2UxNTNiODRjNjRlNzY5M2FjZTYyY2NmODFjOTYxXzEwOTk1MTE2Mzg1MTU_6b1cd0a3-91f4-4599-b2ff-023a2512e360">4</ix:nonFraction>&#160;million and immaterial for the three months ended March&#160;31, 2023 and 2022, respectively, and were $<ix:nonFraction unitRef="usd" contextRef="i2cb7ee6cde3b4b9ea40f39a43c463c3f_D20220701-20230331" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDkvZnJhZzoyNWNlMTUzYjg0YzY0ZTc2OTNhY2U2MmNjZjgxYzk2MS90ZXh0cmVnaW9uOjI1Y2UxNTNiODRjNjRlNzY5M2FjZTYyY2NmODFjOTYxXzEwOTk1MTE2Mjg5MDEy_3c74551f-1770-4ad3-9f91-b457f6d0ac86">8</ix:nonFraction>&#160;million and immaterial for the nine months ended March&#160;31, 2023 and 2022, respectively. Gains currently included within accumulated other comprehensive loss associated with our cash flow hedges to be reclassified into net earnings within the next 12 months are $<ix:nonFraction unitRef="usd" contextRef="i70283d29df464fa9bfe3ab000de0526c_D20230401-20240331" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDkvZnJhZzoyNWNlMTUzYjg0YzY0ZTc2OTNhY2U2MmNjZjgxYzk2MS90ZXh0cmVnaW9uOjI1Y2UxNTNiODRjNjRlNzY5M2FjZTYyY2NmODFjOTYxXzEwOTk1MTE2Mzg3MjU_47f34235-70fa-4f08-90d4-4c7b4a51fce1">7</ix:nonFraction>&#160;million.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Net Investment Hedges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We hedge the foreign currency risk associated with certain net investment positions in foreign subsidiaries. To accomplish this, we enter into cross-currency swaps that are designated as hedges of net investments.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended&#160;March 31, 2023, we entered into &#165;<ix:nonFraction unitRef="jpy" contextRef="i7ce2d0d359a54a7d863e7717418b0884_I20230331" decimals="-6" name="us-gaap:DerivativeAssetNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDkvZnJhZzoyNWNlMTUzYjg0YzY0ZTc2OTNhY2U2MmNjZjgxYzk2MS90ZXh0cmVnaW9uOjI1Y2UxNTNiODRjNjRlNzY5M2FjZTYyY2NmODFjOTYxXzU0OTc1NTgxNTA1Njg_72bf928a-f5ac-4c3b-a1b2-f447a40a3f08">19</ix:nonFraction>&#160;billion ($<ix:nonFraction unitRef="usd" contextRef="i7ce2d0d359a54a7d863e7717418b0884_I20230331" decimals="-6" name="us-gaap:DerivativeAssetNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDkvZnJhZzoyNWNlMTUzYjg0YzY0ZTc2OTNhY2U2MmNjZjgxYzk2MS90ZXh0cmVnaW9uOjI1Y2UxNTNiODRjNjRlNzY5M2FjZTYyY2NmODFjOTYxXzU0OTc1NTgxNTA1ODE_21046e09-4f2f-4350-8935-3679a208374e">150</ix:nonFraction>&#160;million) cross-currency swaps maturing in September 2025, &#165;<ix:nonFraction unitRef="jpy" contextRef="i7ca5414a08eb459f8e8d7a93077973ca_I20230331" decimals="-6" name="us-gaap:DerivativeAssetNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDkvZnJhZzoyNWNlMTUzYjg0YzY0ZTc2OTNhY2U2MmNjZjgxYzk2MS90ZXh0cmVnaW9uOjI1Y2UxNTNiODRjNjRlNzY5M2FjZTYyY2NmODFjOTYxXzU0OTc1NTgxNTA1OTU_55456095-783b-4fb0-9563-9e9c758816ce">19</ix:nonFraction>&#160;billion ($<ix:nonFraction unitRef="usd" contextRef="i7ca5414a08eb459f8e8d7a93077973ca_I20230331" decimals="-6" name="us-gaap:DerivativeAssetNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDkvZnJhZzoyNWNlMTUzYjg0YzY0ZTc2OTNhY2U2MmNjZjgxYzk2MS90ZXh0cmVnaW9uOjI1Y2UxNTNiODRjNjRlNzY5M2FjZTYyY2NmODFjOTYxXzU0OTc1NTgxNTA2MDg_2c82e744-d162-43f6-aba4-0b65688cf4e2">150</ix:nonFraction>&#160;million) cross-currency swaps maturing in June 2027, &#8364;<ix:nonFraction unitRef="eur" contextRef="i3218ae04c9b1466fb3401cfe9911661b_I20230331" decimals="-6" name="us-gaap:DerivativeLiabilityNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDkvZnJhZzoyNWNlMTUzYjg0YzY0ZTc2OTNhY2U2MmNjZjgxYzk2MS90ZXh0cmVnaW9uOjI1Y2UxNTNiODRjNjRlNzY5M2FjZTYyY2NmODFjOTYxXzU0OTc1NTgxNTA2MjI_257c9f5b-1100-488f-86af-dd484ddd73e5">100</ix:nonFraction>&#160;million ($<ix:nonFraction unitRef="usd" contextRef="i3218ae04c9b1466fb3401cfe9911661b_I20230331" decimals="-6" name="us-gaap:DerivativeLiabilityNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDkvZnJhZzoyNWNlMTUzYjg0YzY0ZTc2OTNhY2U2MmNjZjgxYzk2MS90ZXh0cmVnaW9uOjI1Y2UxNTNiODRjNjRlNzY5M2FjZTYyY2NmODFjOTYxXzU0OTc1NTgxNTA2MzY_4fc748be-3aef-440c-b109-97e029ab11b1">107</ix:nonFraction>&#160;million) cross-currency swaps maturing in March 2025 and &#8364;<ix:nonFraction unitRef="eur" contextRef="ibc60a5f6f2fd4df2b6e365b67ce91912_I20230331" decimals="-6" name="us-gaap:DerivativeLiabilityNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDkvZnJhZzoyNWNlMTUzYjg0YzY0ZTc2OTNhY2U2MmNjZjgxYzk2MS90ZXh0cmVnaW9uOjI1Y2UxNTNiODRjNjRlNzY5M2FjZTYyY2NmODFjOTYxXzU0OTc1NTgxNTA2NTA_18f27b20-6ae8-4ebb-9433-1b72efb2ed45">100</ix:nonFraction>&#160;million ($<ix:nonFraction unitRef="usd" contextRef="ibc60a5f6f2fd4df2b6e365b67ce91912_I20230331" decimals="-6" name="us-gaap:DerivativeLiabilityNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDkvZnJhZzoyNWNlMTUzYjg0YzY0ZTc2OTNhY2U2MmNjZjgxYzk2MS90ZXh0cmVnaW9uOjI1Y2UxNTNiODRjNjRlNzY5M2FjZTYyY2NmODFjOTYxXzU0OTc1NTgxNTA2NjQ_776a1584-5b7d-4515-8f3a-fc73014b6fb5">107</ix:nonFraction>&#160;million) cross-currency swaps maturing in March 2026.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended&#160;March 31, 2023, we terminated the &#165;<ix:nonFraction unitRef="jpy" contextRef="ib1c240be19f544f5b489ee7fbc6ec77d_I20230331" decimals="-6" name="cah:DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDkvZnJhZzoyNWNlMTUzYjg0YzY0ZTc2OTNhY2U2MmNjZjgxYzk2MS90ZXh0cmVnaW9uOjI1Y2UxNTNiODRjNjRlNzY5M2FjZTYyY2NmODFjOTYxXzU0OTc1NTgxNTA2Nzg_8098993a-8bf0-488e-87e0-4eda24d4a471">48</ix:nonFraction>&#160;billion ($<ix:nonFraction unitRef="usd" contextRef="ib1c240be19f544f5b489ee7fbc6ec77d_I20230331" decimals="-6" name="cah:DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDkvZnJhZzoyNWNlMTUzYjg0YzY0ZTc2OTNhY2U2MmNjZjgxYzk2MS90ZXh0cmVnaW9uOjI1Y2UxNTNiODRjNjRlNzY5M2FjZTYyY2NmODFjOTYxXzU0OTc1NTgxNTA2OTE_c93ee9f4-72ce-4cf8-917a-b15835b2d8d2">400</ix:nonFraction>&#160;million) cross-currency swaps entered into in March 2022 and the &#8364;<ix:nonFraction unitRef="eur" contextRef="ie681b1f27879497aaac9197da201e94c_I20230331" decimals="-6" name="cah:DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDkvZnJhZzoyNWNlMTUzYjg0YzY0ZTc2OTNhY2U2MmNjZjgxYzk2MS90ZXh0cmVnaW9uOjI1Y2UxNTNiODRjNjRlNzY5M2FjZTYyY2NmODFjOTYxXzU0OTc1NTgxNTA3MDU_b41e1ae6-8b13-42ab-a3ab-dc6b43cf0372">200</ix:nonFraction>&#160;million ($<ix:nonFraction unitRef="usd" contextRef="ie681b1f27879497aaac9197da201e94c_I20230331" decimals="-6" name="cah:DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDkvZnJhZzoyNWNlMTUzYjg0YzY0ZTc2OTNhY2U2MmNjZjgxYzk2MS90ZXh0cmVnaW9uOjI1Y2UxNTNiODRjNjRlNzY5M2FjZTYyY2NmODFjOTYxXzU0OTc1NTgxNTA3MTk_5821ad9c-2531-4ddf-b09f-6c3fd923e4e6">233</ix:nonFraction>&#160;million) cross-currency swap entered into in September 2018 and received net settlements of $<ix:nonFraction unitRef="usd" contextRef="i05f897db0bb743d0b9331a8d46baf59a_D20230101-20230331" decimals="-6" name="us-gaap:ProceedsFromHedgeInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDkvZnJhZzoyNWNlMTUzYjg0YzY0ZTc2OTNhY2U2MmNjZjgxYzk2MS90ZXh0cmVnaW9uOjI1Y2UxNTNiODRjNjRlNzY5M2FjZTYyY2NmODFjOTYxXzU0OTc1NTgxNTA3MzM_22411494-d91d-44ca-aae3-233bfc73cf67">10</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="idb235b08598c4a23bff0d5c8e268cb3b_D20230101-20230331" decimals="-6" name="us-gaap:ProceedsFromHedgeInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDkvZnJhZzoyNWNlMTUzYjg0YzY0ZTc2OTNhY2U2MmNjZjgxYzk2MS90ZXh0cmVnaW9uOjI1Y2UxNTNiODRjNjRlNzY5M2FjZTYyY2NmODFjOTYxXzU0OTc1NTgxNTA3NDY_440975f3-daf1-4c29-a8e2-ebe51cef9318">19</ix:nonFraction>&#160;million in cash, respectively, recorded in proceeds from net investment hedge terminations in our condensed consolidated statements of cash flows.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cross-currency swaps designated as net investment hedges are marked to market using the current spot exchange rate as of the end of the period, with gains and losses included in the foreign currency translation component of accumulated other comprehensive loss until the sale or substantial liquidation of the underlying net investments. To the extent the cross-currency swaps designated as net investment hedges are not highly effective, changes in carrying value attributable to the change in spot rates are recorded in earnings.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-tax gain and loss from net investment hedges recorded in the foreign currency translation component of accumulated other </span></div></ix:continuation></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><ix:continuation id="ia963d63272d5420bb030840e3d575196"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">comprehensive loss was an immaterial loss and a $<ix:nonFraction unitRef="usd" contextRef="if773aecdfcdd4fa1af2b4a92af9fafff_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDkvZnJhZzoyNWNlMTUzYjg0YzY0ZTc2OTNhY2U2MmNjZjgxYzk2MS90ZXh0cmVnaW9uOjI1Y2UxNTNiODRjNjRlNzY5M2FjZTYyY2NmODFjOTYxXzU4NDY_f11402e0-30bf-4b16-8cc7-714b07db8531">22</ix:nonFraction>&#160;million gain during the three months ended March&#160;31, 2023 and 2022, respectively, and a $<ix:nonFraction unitRef="usd" contextRef="i286db9ed3e3a475e93934bbb8c001c46_D20220701-20230331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDkvZnJhZzoyNWNlMTUzYjg0YzY0ZTc2OTNhY2U2MmNjZjgxYzk2MS90ZXh0cmVnaW9uOjI1Y2UxNTNiODRjNjRlNzY5M2FjZTYyY2NmODFjOTYxXzU5MTU_85ee580a-4558-472e-97c1-0b8d2317bb16">21</ix:nonFraction>&#160;million loss and a $<ix:nonFraction unitRef="usd" contextRef="i453169c026a64457a0140b1f759e3178_D20210701-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDkvZnJhZzoyNWNlMTUzYjg0YzY0ZTc2OTNhY2U2MmNjZjgxYzk2MS90ZXh0cmVnaW9uOjI1Y2UxNTNiODRjNjRlNzY5M2FjZTYyY2NmODFjOTYxXzU5Mjk_5c0faee8-7ac7-4c2d-98ca-8beb12f026e9">44</ix:nonFraction>&#160;million gain during the nine months ended March&#160;31, 2023 and 2022, respectively. Gains recognized in interest expense, net in the condensed consolidated statements of earnings/(loss) for the portion of the net investment hedges excluded from the assessment of hedge effectiveness were $<ix:nonFraction unitRef="usd" contextRef="ieaa5331918d94152a37d35bd4fbf59d1_D20230101-20230331" decimals="-6" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDkvZnJhZzoyNWNlMTUzYjg0YzY0ZTc2OTNhY2U2MmNjZjgxYzk2MS90ZXh0cmVnaW9uOjI1Y2UxNTNiODRjNjRlNzY5M2FjZTYyY2NmODFjOTYxXzYxODA_11154d8b-ca1a-49ba-aa11-297dc4bfa5d6">4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="if773aecdfcdd4fa1af2b4a92af9fafff_D20220101-20220331" decimals="-6" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDkvZnJhZzoyNWNlMTUzYjg0YzY0ZTc2OTNhY2U2MmNjZjgxYzk2MS90ZXh0cmVnaW9uOjI1Y2UxNTNiODRjNjRlNzY5M2FjZTYyY2NmODFjOTYxXzYxODc_b1d7daf2-98b8-4a04-bce2-19619713a3a6">5</ix:nonFraction>&#160;million during the three months ended March&#160;31, 2023 and 2022, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i286db9ed3e3a475e93934bbb8c001c46_D20220701-20230331" decimals="-6" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDkvZnJhZzoyNWNlMTUzYjg0YzY0ZTc2OTNhY2U2MmNjZjgxYzk2MS90ZXh0cmVnaW9uOjI1Y2UxNTNiODRjNjRlNzY5M2FjZTYyY2NmODFjOTYxXzYyNDk_40dcb75e-1422-4a84-978c-c2623877f29e">12</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i453169c026a64457a0140b1f759e3178_D20210701-20220331" decimals="-6" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDkvZnJhZzoyNWNlMTUzYjg0YzY0ZTc2OTNhY2U2MmNjZjgxYzk2MS90ZXh0cmVnaW9uOjI1Y2UxNTNiODRjNjRlNzY5M2FjZTYyY2NmODFjOTYxXzYyNTY_e2eb69b3-d618-409e-a467-1b8720a2dc53">16</ix:nonFraction>&#160;million during the nine months ended March&#160;31, 2023 and 2022, respectively.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Economic (Non-Designated) Hedges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into foreign currency contracts to manage our foreign exchange exposure related to sales transactions, intercompany financing transactions and other balance sheet items subject to revaluation that do not meet the requirements for hedge accounting treatment. Accordingly, these derivative instruments are adjusted to current market value at the end of each period through earnings. The gain or loss recorded on these instruments is substantially offset by the remeasurement adjustment on the foreign currency denominated asset or liability. The settlement of the derivative instrument and the remeasurement adjustment on the foreign currency denominated asset or liability are both recorded in other (income)/expense, net. We recorded an immaterial loss and a $<ix:nonFraction unitRef="usd" contextRef="ifd36140f852d4fd491f55d7cbb74fc38_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDkvZnJhZzoyNWNlMTUzYjg0YzY0ZTc2OTNhY2U2MmNjZjgxYzk2MS90ZXh0cmVnaW9uOjI1Y2UxNTNiODRjNjRlNzY5M2FjZTYyY2NmODFjOTYxXzcwOTA_8c8c7958-3ddb-4997-9422-334f52054440">4</ix:nonFraction> million loss during the three months ended March 31, 2023 and 2022, respectively, and a $<ix:nonFraction unitRef="usd" contextRef="i12151c3f1a7a45f0a2e075e9b264e83b_D20220701-20230331" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDkvZnJhZzoyNWNlMTUzYjg0YzY0ZTc2OTNhY2U2MmNjZjgxYzk2MS90ZXh0cmVnaW9uOjI1Y2UxNTNiODRjNjRlNzY5M2FjZTYyY2NmODFjOTYxXzcxNTk_18f7fded-880c-41be-820d-85f55eac5587">3</ix:nonFraction> million loss and an immaterial loss during the nine months ended March&#160;31, 2023 and 2022, respectively. The principal currencies managed through foreign currency contracts are Canadian dollar, Euro, Chinese renminbi, Indian rupee and Thai baht.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of cash and equivalents, trade receivables, accounts payable and other accrued liabilities at March&#160;31, 2023 and June&#160;30, 2022 approximate fair value due to their short-term maturities.</span></div><ix:nonNumeric contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" name="us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDkvZnJhZzoyNWNlMTUzYjg0YzY0ZTc2OTNhY2U2MmNjZjgxYzk2MS90ZXh0cmVnaW9uOjI1Y2UxNTNiODRjNjRlNzY5M2FjZTYyY2NmODFjOTYxXzgwMTk_3bef790d-7150-468a-8d81-852636c7129c" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.109%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.986%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.062%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Estimated fair value</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6dc7675fbf84b8eabf826cb41d79193_I20230331" decimals="-6" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDkvZnJhZzoyNWNlMTUzYjg0YzY0ZTc2OTNhY2U2MmNjZjgxYzk2MS90YWJsZTo5ZjU5NDM0ZjUzNzE0YWM5OGRhNzMzYzEyZmU4Mzc4Yi90YWJsZXJhbmdlOjlmNTk0MzRmNTM3MTRhYzk4ZGE3MzNjMTJmZTgzNzhiXzEtMS0xLTEtMjg2OTQ0_205f7965-8d32-4479-a564-1e3d45a2b1c9">4,466</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib43a93a1b1cb4e7f9c3a767d383622bd_I20220630" decimals="-6" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDkvZnJhZzoyNWNlMTUzYjg0YzY0ZTc2OTNhY2U2MmNjZjgxYzk2MS90YWJsZTo5ZjU5NDM0ZjUzNzE0YWM5OGRhNzMzYzEyZmU4Mzc4Yi90YWJsZXJhbmdlOjlmNTk0MzRmNTM3MTRhYzk4ZGE3MzNjMTJmZTgzNzhiXzEtMy0xLTEtMjg2OTQ0_ce698e45-9605-4082-a493-5964318a08c7">5,049</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying amount</span></td><td colspan="2" style="border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331" decimals="-6" name="cah:CarryingAmountofLongTermandotherShortTermBorrowings" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDkvZnJhZzoyNWNlMTUzYjg0YzY0ZTc2OTNhY2U2MmNjZjgxYzk2MS90YWJsZTo5ZjU5NDM0ZjUzNzE0YWM5OGRhNzMzYzEyZmU4Mzc4Yi90YWJsZXJhbmdlOjlmNTk0MzRmNTM3MTRhYzk4ZGE3MzNjMTJmZTgzNzhiXzItMS0xLTEtMjg2OTQ0_383f8d54-f1b8-4c97-ae0d-bb15b5076ed3">4,734</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic217743408d440409a59220a0bf14e4c_I20220630" decimals="-6" name="cah:CarryingAmountofLongTermandotherShortTermBorrowings" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDkvZnJhZzoyNWNlMTUzYjg0YzY0ZTc2OTNhY2U2MmNjZjgxYzk2MS90YWJsZTo5ZjU5NDM0ZjUzNzE0YWM5OGRhNzMzYzEyZmU4Mzc4Yi90YWJsZXJhbmdlOjlmNTk0MzRmNTM3MTRhYzk4ZGE3MzNjMTJmZTgzNzhiXzItMy0xLTEtMjg2OTQ0_924ecb78-1414-4a2a-9d3d-3cad8500b204">5,315</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of our long-term obligations and other short-term borrowings is estimated based on either the quoted market prices for the same or similar issues or other inputs derived from available market information, which represents a Level 2 measurement.</span></div></ix:continuation><div id="i1d34fc4fc2424fbcb4837cc9f1c0665c_112"></div><ix:nonNumeric contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90ZXh0cmVnaW9uOjg3MTUwZDI5NjZmYTQ4OTk5ZWU5Yjg2MTk5NGFkM2ViXzU0OTc1NTgxNDMwNDU_cf439e00-4f7c-44c6-8ed1-e77d670f241f" continuedAt="i5e010a47d3ab4edfa0793c7d3d7e4aee" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">10. Shareholders' Equity/(Deficit)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We repurchased $<ix:nonFraction unitRef="usd" contextRef="i8e5c5ae766b74cf6a2409e8a66778fe4_D20220701-20230331" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90ZXh0cmVnaW9uOjg3MTUwZDI5NjZmYTQ4OTk5ZWU5Yjg2MTk5NGFkM2ViXzI0_38d6ffc2-2033-4ab3-b0f4-69839941e302">1.5</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="ib1adee5e79374a97893072820fddaa0e_D20210701-20220331" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90ZXh0cmVnaW9uOjg3MTUwZDI5NjZmYTQ4OTk5ZWU5Yjg2MTk5NGFkM2ViXzMx_9b10397b-fd0c-4182-b0b7-9ee740face84">1.0</ix:nonFraction> billion of our common shares, in the aggregate, through share repurchase programs during the nine months ended March&#160;31, 2023 and 2022, </span></div></ix:nonNumeric></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">39</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><ix:continuation id="i5e010a47d3ab4edfa0793c7d3d7e4aee" continuedAt="ia83a108a29724a298e8d041b190a8681"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">respectively. We funded the repurchases with available cash. The common shares repurchased are held in treasury to be used for general corporate purposes.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023, we entered into an accelerated share repurchase ("ASR") program to repurchase common shares for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="i7ad6d93eac9d48ab9fec302dd4e88915_D20221001-20221231" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90ZXh0cmVnaW9uOjg3MTUwZDI5NjZmYTQ4OTk5ZWU5Yjg2MTk5NGFkM2ViXzQ2NQ_64d5790a-91d4-4a60-b5e4-f63e7f9964a6">250</ix:nonFraction> million. We received an initial delivery of <ix:nonFraction unitRef="shares" contextRef="i76064daaf24a4ffeb60544ffcf302fab_D20220701-20230331" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90ZXh0cmVnaW9uOjg3MTUwZDI5NjZmYTQ4OTk5ZWU5Yjg2MTk5NGFkM2ViXzU0OTc1NTgxNDI4MTg_e02fd90b-740d-4c4f-9bcf-39c1eb57fe25">2.6</ix:nonFraction> million common shares using a reference price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i76064daaf24a4ffeb60544ffcf302fab_D20220701-20230331" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90ZXh0cmVnaW9uOjg3MTUwZDI5NjZmYTQ4OTk5ZWU5Yjg2MTk5NGFkM2ViXzE2NDkyNjc0NDQxNDI_b23205a1-a59d-4031-ba6e-3b0af8a1ae4b">77.03</ix:nonFraction>. The program concluded on February 28, 2023 at a volume weighted average price per common share of $<ix:nonFraction unitRef="usdPerShare" contextRef="i461a6425bd69455b83513a1e59a9776f_D20230101-20230228" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90ZXh0cmVnaW9uOjg3MTUwZDI5NjZmYTQ4OTk5ZWU5Yjg2MTk5NGFkM2ViXzE2NDkyNjc0NDQxMjU_84d25392-bfce-4928-a77d-65f7458b47d1">77.27</ix:nonFraction> resulting in a final delivery of <ix:nonFraction unitRef="shares" contextRef="ib66c40ad89944e97863448aacf257bd4_D20230228-20230228" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90ZXh0cmVnaW9uOjg3MTUwZDI5NjZmYTQ4OTk5ZWU5Yjg2MTk5NGFkM2ViXzE2NDkyNjc0NDQxMTk_2a344e0b-b753-43bb-9451-571b88ea656c">0.6</ix:nonFraction> million common shares.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended December&#160;31, 2022, we entered into an ASR program to repurchase common shares for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="i7ad6d93eac9d48ab9fec302dd4e88915_D20221001-20221231" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90ZXh0cmVnaW9uOjg3MTUwZDI5NjZmYTQ4OTk5ZWU5Yjg2MTk5NGFkM2ViXzU0OTc1NTgxNDI5MjI_f6df533e-b90c-46b6-bd4b-e9770d51cb91">250</ix:nonFraction>&#160;million. We received an initial delivery of <ix:nonFraction unitRef="shares" contextRef="i1023e41d044c49ebb5274f9857d52b5f_D20221001-20221231" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90ZXh0cmVnaW9uOjg3MTUwZDI5NjZmYTQ4OTk5ZWU5Yjg2MTk5NGFkM2ViXzE2NDkyNjc0NDQwOTk_befe0c17-5788-4e83-82ff-6be63c036597">2.6</ix:nonFraction> million common shares using a reference price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i1023e41d044c49ebb5274f9857d52b5f_D20221001-20221231" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90ZXh0cmVnaW9uOjg3MTUwZDI5NjZmYTQ4OTk5ZWU5Yjg2MTk5NGFkM2ViXzE2NDkyNjc0NDQxMDU_3c4d1965-d6e1-4226-9f7d-b8f4af72583c">76.58</ix:nonFraction>. The program concluded on January&#160;13, 2023 at a volume weighted average price per common share of $<ix:nonFraction unitRef="usdPerShare" contextRef="i00b750b6e2374500a1e8b10702e44d3a_D20221002-20230113" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90ZXh0cmVnaW9uOjg3MTUwZDI5NjZmYTQ4OTk5ZWU5Yjg2MTk5NGFkM2ViXzE2NDkyNjc0NDQxMDk_740095a5-5465-4e5d-95dc-6a5c6f2536dc">77.50</ix:nonFraction> resulting in a final delivery of <ix:nonFraction unitRef="shares" contextRef="i612fc934cf6040028ee1d4ea22c335da_D20230113-20230113" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90ZXh0cmVnaW9uOjg3MTUwZDI5NjZmYTQ4OTk5ZWU5Yjg2MTk5NGFkM2ViXzE2NDkyNjc0NDQxMTM_1499679e-59cb-421c-8dce-ef1d9f4cad63">0.6</ix:nonFraction> million common shares.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2022, we entered into an ASR program to repurchase common shares for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="ica007433189241b2959cc8d752b3303e_D20220701-20220930" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90ZXh0cmVnaW9uOjg3MTUwZDI5NjZmYTQ4OTk5ZWU5Yjg2MTk5NGFkM2ViXzgzMw_507388bd-1174-4743-a988-73cb172bbfb1">1.0</ix:nonFraction>&#160;billion. We received an initial delivery of <ix:nonFraction unitRef="shares" contextRef="ib99db3d39b2a4d159a049760c79aa4ad_D20220701-20220930" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90ZXh0cmVnaW9uOjg3MTUwZDI5NjZmYTQ4OTk5ZWU5Yjg2MTk5NGFkM2ViXzE2NDkyNjc0NDQxMzA_43d58a0c-5c47-4110-993c-286c1dea9c80">12.0</ix:nonFraction> million common shares using a reference price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ib99db3d39b2a4d159a049760c79aa4ad_D20220701-20220930" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90ZXh0cmVnaW9uOjg3MTUwZDI5NjZmYTQ4OTk5ZWU5Yjg2MTk5NGFkM2ViXzE2NDkyNjc0NDQ2ODc_aec13b63-df56-43bd-b48f-7699a0dcdd79">66.74</ix:nonFraction>. The program concluded on December 23, 2022 at a volume weighted average price per common share of $<ix:nonFraction unitRef="usdPerShare" contextRef="if7a9fd51d7b5402abd517b833b8aa389_D20220701-20221223" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90ZXh0cmVnaW9uOjg3MTUwZDI5NjZmYTQ4OTk5ZWU5Yjg2MTk5NGFkM2ViXzEwMTg_2aa58be1-c8e9-46e1-9780-9c739316afbe">73.36</ix:nonFraction> resulting in a final delivery of <ix:nonFraction unitRef="shares" contextRef="i3ea1c66ac32f47d58440504438bf12ae_D20221223-20221223" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90ZXh0cmVnaW9uOjg3MTUwZDI5NjZmYTQ4OTk5ZWU5Yjg2MTk5NGFkM2ViXzEwNTQ_68524cd8-c5c1-40eb-9da5-12c3e4080198">1.6</ix:nonFraction> million common shares.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2022, we entered into an ASR program to repurchase common shares for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="i522fef760d964e82a180d92c34f911f9_D20220101-20220331" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90ZXh0cmVnaW9uOjg3MTUwZDI5NjZmYTQ4OTk5ZWU5Yjg2MTk5NGFkM2ViXzEyMTU_3da53880-46c7-451b-87f0-f2fc4d368d7f">200</ix:nonFraction>&#160;million. We received an initial delivery of <ix:nonFraction unitRef="shares" contextRef="i62909649d3db4353bc2ea5dbf602e573_D20220101-20220331" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90ZXh0cmVnaW9uOjg3MTUwZDI5NjZmYTQ4OTk5ZWU5Yjg2MTk5NGFkM2ViXzEyNTQ_2efcda0d-d724-45b6-8397-d643862b4694">3.0</ix:nonFraction>&#160;million common shares using a reference price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i62909649d3db4353bc2ea5dbf602e573_D20220101-20220331" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90ZXh0cmVnaW9uOjg3MTUwZDI5NjZmYTQ4OTk5ZWU5Yjg2MTk5NGFkM2ViXzEyOTg_c03aae3b-8289-45a2-be8a-8bd90f94ee71">54.01</ix:nonFraction>. The program concluded on April 18, 2022 at a volume weighted average price per common share of $<ix:nonFraction unitRef="usdPerShare" contextRef="i6a09f6e3558145749952ae7fc79bd2af_D20220101-20220418" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90ZXh0cmVnaW9uOjg3MTUwZDI5NjZmYTQ4OTk5ZWU5Yjg2MTk5NGFkM2ViXzEzOTk_9b9043cb-26c8-4937-88b5-4207a77e6a0c">56.02</ix:nonFraction> resulting in a final delivery of <ix:nonFraction unitRef="shares" contextRef="i226477cc1ffc4f0d9d9f5dd33b1e9da1_D20220418-20220418" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90ZXh0cmVnaW9uOjg3MTUwZDI5NjZmYTQ4OTk5ZWU5Yjg2MTk5NGFkM2ViXzE0MzU_c8f6aa68-51a3-42c0-8224-c0953e6168da">0.6</ix:nonFraction>&#160;million common shares. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended December 31, 2021, we entered into an ASR program to repurchase common shares for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="i1867aca7ccf1480e9c1ee9dcad7d47ae_D20211001-20211231" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90ZXh0cmVnaW9uOjg3MTUwZDI5NjZmYTQ4OTk5ZWU5Yjg2MTk5NGFkM2ViXzU0OTc1NTgxNDI4MjM_e0f2cd57-58a2-4c61-897b-3fe786f483dd">300</ix:nonFraction>&#160;million. We received an initial delivery of <ix:nonFraction unitRef="shares" contextRef="ia9412268ef744658a8712d81ef405c17_D20211001-20211231" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90ZXh0cmVnaW9uOjg3MTUwZDI5NjZmYTQ4OTk5ZWU5Yjg2MTk5NGFkM2ViXzU0OTc1NTgxNDI4Mzc_51cec397-96aa-411c-b913-eedca43250f6">4.8</ix:nonFraction>&#160;million common shares using a reference price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ia9412268ef744658a8712d81ef405c17_D20211001-20211231" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90ZXh0cmVnaW9uOjg3MTUwZDI5NjZmYTQ4OTk5ZWU5Yjg2MTk5NGFkM2ViXzU0OTc1NTgxNDI4NTA_84942d60-7d09-48f2-b463-221159a1ed24">50.30</ix:nonFraction>. The program concluded on January 31, 2022 at a volume weighted average price per common share of $<ix:nonFraction unitRef="usdPerShare" contextRef="i8be8904a0c5f40cbbebf2f710dcc62b3_D20211001-20220131" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90ZXh0cmVnaW9uOjg3MTUwZDI5NjZmYTQ4OTk5ZWU5Yjg2MTk5NGFkM2ViXzU0OTc1NTgxNDI4NTg_151bc7cc-0c0c-440c-a0e3-88e9aaccdb7f">49.39</ix:nonFraction> resulting in a final delivery of <ix:nonFraction unitRef="shares" contextRef="i2552d9f48bd74eb3a693f3a9fead0a14_D20220131-20220131" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90ZXh0cmVnaW9uOjg3MTUwZDI5NjZmYTQ4OTk5ZWU5Yjg2MTk5NGFkM2ViXzU0OTc1NTgxNDI4NjY_feac5664-0757-4dc0-9013-debaa9b72235">1.3</ix:nonFraction>&#160;million common shares. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2021, we entered into an ASR program to repurchase common shares for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="ie154fb452e1a418293380c4c4a39a5cd_D20210701-20210930" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90ZXh0cmVnaW9uOjg3MTUwZDI5NjZmYTQ4OTk5ZWU5Yjg2MTk5NGFkM2ViXzU0OTc1NTgxNDI4Nzk_3b1908eb-476c-4b0b-8571-d1170d1d9f37">500</ix:nonFraction>&#160;million. We received an initial delivery of <ix:nonFraction unitRef="shares" contextRef="i4f140036aee94cfe9d2320e0cd2ce82a_D20210701-20210930" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90ZXh0cmVnaW9uOjg3MTUwZDI5NjZmYTQ4OTk5ZWU5Yjg2MTk5NGFkM2ViXzU0OTc1NTgxNDI4OTM_99837f95-8481-4e9d-8add-c25e154212b5">7.8</ix:nonFraction>&#160;million common shares using a reference price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i4f140036aee94cfe9d2320e0cd2ce82a_D20210701-20210930" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90ZXh0cmVnaW9uOjg3MTUwZDI5NjZmYTQ4OTk5ZWU5Yjg2MTk5NGFkM2ViXzU0OTc1NTgxNDI5MDY_83e51958-dcfc-4c8f-864b-9b45c0419d3b">51.53</ix:nonFraction>. The program concluded on October 4, 2021 at a volume weighted average price per common share of $<ix:nonFraction unitRef="usdPerShare" contextRef="i4db4d5927cda47f480368591c63e0175_D20210701-20211014" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90ZXh0cmVnaW9uOjg3MTUwZDI5NjZmYTQ4OTk5ZWU5Yjg2MTk5NGFkM2ViXzU0OTc1NTgxNDI5MTQ_f35b8c07-7962-4574-8baf-57c3194f3ac2">51.10</ix:nonFraction> resulting in a final delivery of <ix:nonFraction unitRef="shares" contextRef="i1cda2ab21b97491cb2163653f2b875c8_D20211004-20211004" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90ZXh0cmVnaW9uOjg3MTUwZDI5NjZmYTQ4OTk5ZWU5Yjg2MTk5NGFkM2ViXzU0OTc1NTgxNDI5MzY_7806d958-aeb3-468f-9cbc-15916af557e4">2.0</ix:nonFraction>&#160;million common shares.</span></div></ix:continuation></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><ix:continuation id="ia83a108a29724a298e8d041b190a8681"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive Loss</span></div><ix:nonNumeric contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90ZXh0cmVnaW9uOjg3MTUwZDI5NjZmYTQ4OTk5ZWU5Yjg2MTk5NGFkM2ViXzIwMTI_0981c231-505d-45a7-9b5e-0ecbf7c1139b" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the changes in the balance of accumulated other comprehensive loss by component and in total:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.097%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.492%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.875%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.050%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign<br/>Currency<br/>Translation<br/>Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized<br/>Gain/(Loss) on<br/>Derivatives,<br/>net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2022</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57bea63d714f4a0dafc21a5f5d7d9581_I20220630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90YWJsZTpiMGJhNTBmZTM5NjQ0ZGNlOWUwOWIzZmFmYTg1NWMxNy90YWJsZXJhbmdlOmIwYmE1MGZlMzk2NDRkY2U5ZTA5YjNmYWZhODU1YzE3XzEtMS0xLTEtMjg2OTQ0_84569150-46ee-47c3-bec5-3785720324a1">102</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6045190cc1424f8b979c1010722b563f_I20220630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90YWJsZTpiMGJhNTBmZTM5NjQ0ZGNlOWUwOWIzZmFmYTg1NWMxNy90YWJsZXJhbmdlOmIwYmE1MGZlMzk2NDRkY2U5ZTA5YjNmYWZhODU1YzE3XzEtMy0xLTEtMjg2OTQ0_f5ad6fb9-81d9-486c-a729-11c82e5ac578">12</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i041bf7de7fa94db3b9bf9e7b272751da_I20220630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90YWJsZTpiMGJhNTBmZTM5NjQ0ZGNlOWUwOWIzZmFmYTg1NWMxNy90YWJsZXJhbmdlOmIwYmE1MGZlMzk2NDRkY2U5ZTA5YjNmYWZhODU1YzE3XzEtNS0xLTEtMjg2OTQ0_bafaa009-5074-4dec-8558-4837632395bf">114</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss, before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc6e3923d3894b44990b34501ac477b5_D20220701-20230331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90YWJsZTpiMGJhNTBmZTM5NjQ0ZGNlOWUwOWIzZmFmYTg1NWMxNy90YWJsZXJhbmdlOmIwYmE1MGZlMzk2NDRkY2U5ZTA5YjNmYWZhODU1YzE3XzItMS0xLTEtMjg2OTQ0_560aab5d-0179-4157-8d7e-11f62fcd90f7">34</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44c00bb3d01a45a9b2df0171c33fe41e_D20220701-20230331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90YWJsZTpiMGJhNTBmZTM5NjQ0ZGNlOWUwOWIzZmFmYTg1NWMxNy90YWJsZXJhbmdlOmIwYmE1MGZlMzk2NDRkY2U5ZTA5YjNmYWZhODU1YzE3XzItMy0xLTEtMjg2OTQ0_f9905c2e-79f7-468e-a5c1-fbcf2efe81a0">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5339f5e85f3b47c0aa0a7795a0147a83_D20220701-20230331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90YWJsZTpiMGJhNTBmZTM5NjQ0ZGNlOWUwOWIzZmFmYTg1NWMxNy90YWJsZXJhbmdlOmIwYmE1MGZlMzk2NDRkY2U5ZTA5YjNmYWZhODU1YzE3XzItNS0xLTEtMjg2OTQ0_eac17f89-1e64-48bf-8353-6c22db66572f">19</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified to earnings</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc6e3923d3894b44990b34501ac477b5_D20220701-20230331" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90YWJsZTpiMGJhNTBmZTM5NjQ0ZGNlOWUwOWIzZmFmYTg1NWMxNy90YWJsZXJhbmdlOmIwYmE1MGZlMzk2NDRkY2U5ZTA5YjNmYWZhODU1YzE3XzMtMS0xLTEtMjg2OTQ0_720fa8b7-0034-49a1-b394-19b7b230816f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44c00bb3d01a45a9b2df0171c33fe41e_D20220701-20230331" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90YWJsZTpiMGJhNTBmZTM5NjQ0ZGNlOWUwOWIzZmFmYTg1NWMxNy90YWJsZXJhbmdlOmIwYmE1MGZlMzk2NDRkY2U5ZTA5YjNmYWZhODU1YzE3XzMtMy0xLTEtMjg2OTQ0_af710ddf-8f12-4f99-a523-fc0caecd973d">9</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5339f5e85f3b47c0aa0a7795a0147a83_D20220701-20230331" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90YWJsZTpiMGJhNTBmZTM5NjQ0ZGNlOWUwOWIzZmFmYTg1NWMxNy90YWJsZXJhbmdlOmIwYmE1MGZlMzk2NDRkY2U5ZTA5YjNmYWZhODU1YzE3XzMtNS0xLTEtMjg2OTQ0_847e4ea2-606b-438d-a1a8-d1f391b3088d">9</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other comprehensive loss attributable to Cardinal Health, Inc. net of tax benefit of $<ix:nonFraction unitRef="usd" contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90YWJsZTpiMGJhNTBmZTM5NjQ0ZGNlOWUwOWIzZmFmYTg1NWMxNy90YWJsZXJhbmdlOmIwYmE1MGZlMzk2NDRkY2U5ZTA5YjNmYWZhODU1YzE3XzQtMC0xLTEtMjg2OTQ0L3RleHRyZWdpb246NTRjZTM4ZjJkOTQwNDI4NGE1MGRlMGI2MDRhNjM3YWFfOTU_ae4bf9e3-7daf-4084-a1cb-147eed546e48">5</ix:nonFraction>&#160;million</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc6e3923d3894b44990b34501ac477b5_D20220701-20230331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90YWJsZTpiMGJhNTBmZTM5NjQ0ZGNlOWUwOWIzZmFmYTg1NWMxNy90YWJsZXJhbmdlOmIwYmE1MGZlMzk2NDRkY2U5ZTA5YjNmYWZhODU1YzE3XzQtMS0xLTEtMjg2OTQ0_94b1aa6c-efd5-4b0f-a050-829d431e55b3">34</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44c00bb3d01a45a9b2df0171c33fe41e_D20220701-20230331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90YWJsZTpiMGJhNTBmZTM5NjQ0ZGNlOWUwOWIzZmFmYTg1NWMxNy90YWJsZXJhbmdlOmIwYmE1MGZlMzk2NDRkY2U5ZTA5YjNmYWZhODU1YzE3XzQtMy0xLTEtMjg2OTQ0_16d8290d-8439-453f-8bde-5d82ca8d7e82">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9df3ae431f2408093261364d8c57572_D20220701-20230331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90YWJsZTpiMGJhNTBmZTM5NjQ0ZGNlOWUwOWIzZmFmYTg1NWMxNy90YWJsZXJhbmdlOmIwYmE1MGZlMzk2NDRkY2U5ZTA5YjNmYWZhODU1YzE3XzQtNS0xLTEtMjg2OTQ0_3b899454-1ebf-49fc-86e4-da7fed5f11f3">28</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at March 31, 2023</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5f9b2983d0ee4f86a50ac5496fc9091c_I20230331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90YWJsZTpiMGJhNTBmZTM5NjQ0ZGNlOWUwOWIzZmFmYTg1NWMxNy90YWJsZXJhbmdlOmIwYmE1MGZlMzk2NDRkY2U5ZTA5YjNmYWZhODU1YzE3XzUtMS0xLTEtMjg2OTQ0_bb22f156-6337-4f5c-8ad8-343456c915be">136</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7f42aa5a93cc411195bf2bf78d59cde4_I20230331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90YWJsZTpiMGJhNTBmZTM5NjQ0ZGNlOWUwOWIzZmFmYTg1NWMxNy90YWJsZXJhbmdlOmIwYmE1MGZlMzk2NDRkY2U5ZTA5YjNmYWZhODU1YzE3XzUtMy0xLTEtMjg2OTQ0_b2d092d0-d3a2-420f-998a-bd0ca8b199a1">6</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8d7f6b1c5d2b48eeba8549a518560256_I20230331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90YWJsZTpiMGJhNTBmZTM5NjQ0ZGNlOWUwOWIzZmFmYTg1NWMxNy90YWJsZXJhbmdlOmIwYmE1MGZlMzk2NDRkY2U5ZTA5YjNmYWZhODU1YzE3XzUtNS0xLTEtMjg2OTQ0_afeb4ec4-9031-47ae-a0e3-b136ab5b0a29">142</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.097%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.492%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.875%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.050%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign<br/>Currency<br/>Translation<br/>Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized<br/>Gain/(Loss) on<br/>Derivatives,<br/>net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2021</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icbef955e1ad34a0db8f9c5e948d9cb27_I20210630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90YWJsZToxYTc1NTQ5MjhkNGI0ZDI0YmQ3NjYwZWU4MDAxYjVkNS90YWJsZXJhbmdlOjFhNzU1NDkyOGQ0YjRkMjRiZDc2NjBlZTgwMDFiNWQ1XzEtMS0xLTEtMjg2OTQ0_cf118745-e6eb-429b-8ceb-0a52904029e3">46</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc51bd9677854ac6aaa9f7b93f52a94e_I20210630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90YWJsZToxYTc1NTQ5MjhkNGI0ZDI0YmQ3NjYwZWU4MDAxYjVkNS90YWJsZXJhbmdlOjFhNzU1NDkyOGQ0YjRkMjRiZDc2NjBlZTgwMDFiNWQ1XzEtMy0xLTEtMjg2OTQ0_3438fd5b-ce1f-4528-af93-2daea89e986d">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i63438b89f0184fe2bed728cdd44ae85b_I20210630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90YWJsZToxYTc1NTQ5MjhkNGI0ZDI0YmQ3NjYwZWU4MDAxYjVkNS90YWJsZXJhbmdlOjFhNzU1NDkyOGQ0YjRkMjRiZDc2NjBlZTgwMDFiNWQ1XzEtNS0xLTEtMjg2OTQ0_8dffc69d-43ec-4da4-b7e1-46dd964c6c29">34</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss, before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i515663cfb02c45c09a0fbc66b8fef70c_D20210701-20220331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90YWJsZToxYTc1NTQ5MjhkNGI0ZDI0YmQ3NjYwZWU4MDAxYjVkNS90YWJsZXJhbmdlOjFhNzU1NDkyOGQ0YjRkMjRiZDc2NjBlZTgwMDFiNWQ1XzItMS0xLTEtMjg2OTQ0_bdba8793-83cb-48a6-91de-0b669db3dbcc">47</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5450ec0270bb4ceaafa8ee587406b24e_D20210701-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90YWJsZToxYTc1NTQ5MjhkNGI0ZDI0YmQ3NjYwZWU4MDAxYjVkNS90YWJsZXJhbmdlOjFhNzU1NDkyOGQ0YjRkMjRiZDc2NjBlZTgwMDFiNWQ1XzItMy0xLTEtMjg2OTQ0_ea12aed6-ad98-45b5-88c8-7c822613c896">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibf631f27db6a4b97b407bf7c07872ada_D20210701-20220331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90YWJsZToxYTc1NTQ5MjhkNGI0ZDI0YmQ3NjYwZWU4MDAxYjVkNS90YWJsZXJhbmdlOjFhNzU1NDkyOGQ0YjRkMjRiZDc2NjBlZTgwMDFiNWQ1XzItNS0xLTEtMjg2OTQ0_3d2dd55a-9d64-4efc-82ae-56fa5e233e54">38</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified to earnings</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i515663cfb02c45c09a0fbc66b8fef70c_D20210701-20220331" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90YWJsZToxYTc1NTQ5MjhkNGI0ZDI0YmQ3NjYwZWU4MDAxYjVkNS90YWJsZXJhbmdlOjFhNzU1NDkyOGQ0YjRkMjRiZDc2NjBlZTgwMDFiNWQ1XzMtMS0xLTEtMjg2OTQ0_fc0a9d50-2f7b-4570-9af9-39a2abb2bc78">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5450ec0270bb4ceaafa8ee587406b24e_D20210701-20220331" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90YWJsZToxYTc1NTQ5MjhkNGI0ZDI0YmQ3NjYwZWU4MDAxYjVkNS90YWJsZXJhbmdlOjFhNzU1NDkyOGQ0YjRkMjRiZDc2NjBlZTgwMDFiNWQ1XzMtMy0xLTEtMjg2OTQ0_6169a393-c339-4dc9-9fb2-656d87490dfc">5</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibf631f27db6a4b97b407bf7c07872ada_D20210701-20220331" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90YWJsZToxYTc1NTQ5MjhkNGI0ZDI0YmQ3NjYwZWU4MDAxYjVkNS90YWJsZXJhbmdlOjFhNzU1NDkyOGQ0YjRkMjRiZDc2NjBlZTgwMDFiNWQ1XzMtNS0xLTEtMjg2OTQ0_e61a6747-f994-48b9-9ebd-57090e920c6f">5</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other comprehensive loss attributable to Cardinal Health, Inc. net of tax benefit of $<ix:nonFraction unitRef="usd" contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90YWJsZToxYTc1NTQ5MjhkNGI0ZDI0YmQ3NjYwZWU4MDAxYjVkNS90YWJsZXJhbmdlOjFhNzU1NDkyOGQ0YjRkMjRiZDc2NjBlZTgwMDFiNWQ1XzQtMC0xLTEtMjg2OTQ0L3RleHRyZWdpb246MTgxM2IzNjc4ODNkNGQ5MDljYmJkNmQ0NDc0ODZlYTBfOTU_017d1bce-4bee-4e97-beaa-77e892150cb1">6</ix:nonFraction>&#160;million</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i515663cfb02c45c09a0fbc66b8fef70c_D20210701-20220331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90YWJsZToxYTc1NTQ5MjhkNGI0ZDI0YmQ3NjYwZWU4MDAxYjVkNS90YWJsZXJhbmdlOjFhNzU1NDkyOGQ0YjRkMjRiZDc2NjBlZTgwMDFiNWQ1XzQtMS0xLTEtMjg2OTQ0_ce601dd9-c14b-4513-a39a-b9b05987ef8c">47</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5450ec0270bb4ceaafa8ee587406b24e_D20210701-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90YWJsZToxYTc1NTQ5MjhkNGI0ZDI0YmQ3NjYwZWU4MDAxYjVkNS90YWJsZXJhbmdlOjFhNzU1NDkyOGQ0YjRkMjRiZDc2NjBlZTgwMDFiNWQ1XzQtMy0xLTEtMjg2OTQ0_a8dfa241-1e7c-4fd3-8669-32a1032c7fce">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i704ee587ce264884a099492815729252_D20210701-20220331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90YWJsZToxYTc1NTQ5MjhkNGI0ZDI0YmQ3NjYwZWU4MDAxYjVkNS90YWJsZXJhbmdlOjFhNzU1NDkyOGQ0YjRkMjRiZDc2NjBlZTgwMDFiNWQ1XzQtNS0xLTEtMjg2OTQ0_7ece7d3d-aa81-4023-a0ef-3e5045169588">43</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at March 31, 2022</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8ec1d9ad198a4e43b265abc3a0d32cb8_I20220331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90YWJsZToxYTc1NTQ5MjhkNGI0ZDI0YmQ3NjYwZWU4MDAxYjVkNS90YWJsZXJhbmdlOjFhNzU1NDkyOGQ0YjRkMjRiZDc2NjBlZTgwMDFiNWQ1XzUtMS0xLTEtMjg2OTQ0_c45db010-9f6f-4d8c-89d9-3ccfc46c2d7a">93</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id449ab0597f64cd29ac910cb2816b35b_I20220331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90YWJsZToxYTc1NTQ5MjhkNGI0ZDI0YmQ3NjYwZWU4MDAxYjVkNS90YWJsZXJhbmdlOjFhNzU1NDkyOGQ0YjRkMjRiZDc2NjBlZTgwMDFiNWQ1XzUtMy0xLTEtMjg2OTQ0_7b4459ab-74ea-4a6a-975d-5a7b1d7a97b8">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6203134ce90347afaf3c8d39444a0a7d_I20220331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90YWJsZToxYTc1NTQ5MjhkNGI0ZDI0YmQ3NjYwZWU4MDAxYjVkNS90YWJsZXJhbmdlOjFhNzU1NDkyOGQ0YjRkMjRiZDc2NjBlZTgwMDFiNWQ1XzUtNS0xLTEtMjg2OTQ0_75d80f22-a7de-44c4-a821-86f1069889fc">77</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><span><br/></span></div><div id="i1d34fc4fc2424fbcb4837cc9f1c0665c_115"></div><ix:nonNumeric contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTUvZnJhZzoxYzYzZDA1YTlmYTk0MjhmODhkZjhiZjQ2NjI3ZjQ4Yi90ZXh0cmVnaW9uOjFjNjNkMDVhOWZhOTQyOGY4OGRmOGJmNDY2MjdmNDhiXzk0NQ_8ecacc64-8105-4fec-9c63-7d6e7256c2dd" continuedAt="i2e5e7161c3be421fa17e026c361d3a98" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">11. Earnings/(Loss) Per Share Attributable to Cardinal Health, Inc.</span></div><ix:nonNumeric contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" name="us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTUvZnJhZzoxYzYzZDA1YTlmYTk0MjhmODhkZjhiZjQ2NjI3ZjQ4Yi90ZXh0cmVnaW9uOjFjNjNkMDVhOWZhOTQyOGY4OGRmOGJmNDY2MjdmNDhiXzk0MQ_1839ceb7-68ab-45f6-8c52-af6f18f6f4be" continuedAt="i60230f3944b243748c883c3f08c5e08f" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the number of common shares used to compute basic and diluted earnings/(loss) per share attributable to Cardinal Health, Inc.:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.406%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.407%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average common shares&#8211;basic</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTUvZnJhZzoxYzYzZDA1YTlmYTk0MjhmODhkZjhiZjQ2NjI3ZjQ4Yi90YWJsZToxY2U3YmIxZjc4YTA0MjA0OTkzNzBkNjBkOWZhOGZmYi90YWJsZXJhbmdlOjFjZTdiYjFmNzhhMDQyMDQ5OTM3MGQ2MGQ5ZmE4ZmZiXzItMS0xLTEtMjg2OTQ0_4e89ed84-7b07-4285-b7af-8caf23941308">256</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTUvZnJhZzoxYzYzZDA1YTlmYTk0MjhmODhkZjhiZjQ2NjI3ZjQ4Yi90YWJsZToxY2U3YmIxZjc4YTA0MjA0OTkzNzBkNjBkOWZhOGZmYi90YWJsZXJhbmdlOjFjZTdiYjFmNzhhMDQyMDQ5OTM3MGQ2MGQ5ZmE4ZmZiXzItMy0xLTEtMjg2OTQ0_33456497-04e3-41c5-923b-7333742756f4">275</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock options, restricted share units and performance share units</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331" decimals="-6" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTUvZnJhZzoxYzYzZDA1YTlmYTk0MjhmODhkZjhiZjQ2NjI3ZjQ4Yi90YWJsZToxY2U3YmIxZjc4YTA0MjA0OTkzNzBkNjBkOWZhOGZmYi90YWJsZXJhbmdlOjFjZTdiYjFmNzhhMDQyMDQ5OTM3MGQ2MGQ5ZmE4ZmZiXzQtMS0xLTEtMjg2OTQ0_30547a20-c32b-437c-a7f0-6349cdbfb69e">2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331" decimals="-6" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTUvZnJhZzoxYzYzZDA1YTlmYTk0MjhmODhkZjhiZjQ2NjI3ZjQ4Yi90YWJsZToxY2U3YmIxZjc4YTA0MjA0OTkzNzBkNjBkOWZhOGZmYi90YWJsZXJhbmdlOjFjZTdiYjFmNzhhMDQyMDQ5OTM3MGQ2MGQ5ZmE4ZmZiXzQtMy0xLTEtMjg2OTQ0_cf43625e-87b4-48e4-b927-0810e5d49523">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average common shares&#8211;diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTUvZnJhZzoxYzYzZDA1YTlmYTk0MjhmODhkZjhiZjQ2NjI3ZjQ4Yi90YWJsZToxY2U3YmIxZjc4YTA0MjA0OTkzNzBkNjBkOWZhOGZmYi90YWJsZXJhbmdlOjFjZTdiYjFmNzhhMDQyMDQ5OTM3MGQ2MGQ5ZmE4ZmZiXzUtMS0xLTEtMjg2OTQ0_0fb08b0f-d988-4cfd-a95c-8f9077797303">258</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTUvZnJhZzoxYzYzZDA1YTlmYTk0MjhmODhkZjhiZjQ2NjI3ZjQ4Yi90YWJsZToxY2U3YmIxZjc4YTA0MjA0OTkzNzBkNjBkOWZhOGZmYi90YWJsZXJhbmdlOjFjZTdiYjFmNzhhMDQyMDQ5OTM3MGQ2MGQ5ZmE4ZmZiXzUtMy0xLTEtMjg2OTQ0_9b63ab52-7820-4abb-84c8-58e82a4a8eb7">275</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">40</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><ix:continuation id="i2e5e7161c3be421fa17e026c361d3a98"><div style="margin-bottom:6pt;text-align:center"><ix:continuation id="i60230f3944b243748c883c3f08c5e08f"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.406%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.407%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average common shares&#8211;basic</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTUvZnJhZzoxYzYzZDA1YTlmYTk0MjhmODhkZjhiZjQ2NjI3ZjQ4Yi90YWJsZTo0ZmNiMjk0ZTFhNGY0MTI4OWFkZjk0MjcxNTkwYmVhYy90YWJsZXJhbmdlOjRmY2IyOTRlMWE0ZjQxMjg5YWRmOTQyNzE1OTBiZWFjXzItMS0xLTEtMjg2OTQ0_c182c5ec-2d99-481d-b6a4-ee0246807c8e">263</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTUvZnJhZzoxYzYzZDA1YTlmYTk0MjhmODhkZjhiZjQ2NjI3ZjQ4Yi90YWJsZTo0ZmNiMjk0ZTFhNGY0MTI4OWFkZjk0MjcxNTkwYmVhYy90YWJsZXJhbmdlOjRmY2IyOTRlMWE0ZjQxMjg5YWRmOTQyNzE1OTBiZWFjXzItMy0xLTEtMjg2OTQ0_9ab39adf-7e77-4294-811b-f2a04dd9ec58">281</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock options, restricted share units and performance share units</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" decimals="-6" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTUvZnJhZzoxYzYzZDA1YTlmYTk0MjhmODhkZjhiZjQ2NjI3ZjQ4Yi90YWJsZTo0ZmNiMjk0ZTFhNGY0MTI4OWFkZjk0MjcxNTkwYmVhYy90YWJsZXJhbmdlOjRmY2IyOTRlMWE0ZjQxMjg5YWRmOTQyNzE1OTBiZWFjXzQtMS0xLTEtMjg2OTQ0_8001003d-5dfc-42a9-a03d-126197d95ea8">1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331" decimals="-6" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTUvZnJhZzoxYzYzZDA1YTlmYTk0MjhmODhkZjhiZjQ2NjI3ZjQ4Yi90YWJsZTo0ZmNiMjk0ZTFhNGY0MTI4OWFkZjk0MjcxNTkwYmVhYy90YWJsZXJhbmdlOjRmY2IyOTRlMWE0ZjQxMjg5YWRmOTQyNzE1OTBiZWFjXzQtMy0xLTEtMjg2OTQ0_9be59836-31a8-43e1-a6f6-e0550e52631a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average common shares&#8211;diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTUvZnJhZzoxYzYzZDA1YTlmYTk0MjhmODhkZjhiZjQ2NjI3ZjQ4Yi90YWJsZTo0ZmNiMjk0ZTFhNGY0MTI4OWFkZjk0MjcxNTkwYmVhYy90YWJsZXJhbmdlOjRmY2IyOTRlMWE0ZjQxMjg5YWRmOTQyNzE1OTBiZWFjXzUtMS0xLTEtMjg2OTQ0_ac51f02c-b540-40d3-b955-f463e153a4a6">264</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTUvZnJhZzoxYzYzZDA1YTlmYTk0MjhmODhkZjhiZjQ2NjI3ZjQ4Yi90YWJsZTo0ZmNiMjk0ZTFhNGY0MTI4OWFkZjk0MjcxNTkwYmVhYy90YWJsZXJhbmdlOjRmY2IyOTRlMWE0ZjQxMjg5YWRmOTQyNzE1OTBiZWFjXzUtMy0xLTEtMjg2OTQ0_3eb69860-b78a-4bcb-b7fa-5b647c2c8890">281</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The potentially dilutive employee stock options, restricted share units and performance share units that were antidilutive were <ix:nonFraction unitRef="shares" contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331" decimals="-6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTUvZnJhZzoxYzYzZDA1YTlmYTk0MjhmODhkZjhiZjQ2NjI3ZjQ4Yi90ZXh0cmVnaW9uOjFjNjNkMDVhOWZhOTQyOGY4OGRmOGJmNDY2MjdmNDhiXzU0OTc1NTgxNTI5Nw_26b0f308-7bfb-4736-8b93-14d21b640848"><ix:nonFraction unitRef="shares" contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" decimals="-6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTUvZnJhZzoxYzYzZDA1YTlmYTk0MjhmODhkZjhiZjQ2NjI3ZjQ4Yi90ZXh0cmVnaW9uOjFjNjNkMDVhOWZhOTQyOGY4OGRmOGJmNDY2MjdmNDhiXzU0OTc1NTgxNTI5Nw_de747c67-db71-4636-8c01-82188705a408">2</ix:nonFraction></ix:nonFraction> million for both the three and nine months ended March&#160;31, 2023.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The potentially dilutive employee stock options, restricted share units and performance share units that were antidilutive were <ix:nonFraction unitRef="shares" contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331" decimals="-6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTUvZnJhZzoxYzYzZDA1YTlmYTk0MjhmODhkZjhiZjQ2NjI3ZjQ4Yi90ZXh0cmVnaW9uOjFjNjNkMDVhOWZhOTQyOGY4OGRmOGJmNDY2MjdmNDhiXzU0OTc1NTgxNTQ3Mw_3c411e0b-70a8-4f9f-9846-e73041a01537"><ix:nonFraction unitRef="shares" contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331" decimals="-6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTUvZnJhZzoxYzYzZDA1YTlmYTk0MjhmODhkZjhiZjQ2NjI3ZjQ4Yi90ZXh0cmVnaW9uOjFjNjNkMDVhOWZhOTQyOGY4OGRmOGJmNDY2MjdmNDhiXzU0OTc1NTgxNTQ3Mw_ebf12571-0d30-41d0-9359-d21c865633e8">5</ix:nonFraction></ix:nonFraction> million for both the three and nine months ended March 31, 2022. For the three and nine months ended March 31, 2022, there were <ix:nonFraction unitRef="reportable_segments" contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331" decimals="-6" name="cah:SharesThatWouldBeAntidilutiveAsAResultOfNetLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTUvZnJhZzoxYzYzZDA1YTlmYTk0MjhmODhkZjhiZjQ2NjI3ZjQ4Yi90ZXh0cmVnaW9uOjFjNjNkMDVhOWZhOTQyOGY4OGRmOGJmNDY2MjdmNDhiXzU0OTc1NTgxNDA5ODc_2a4f7c9c-78f7-4d10-8d15-dc7b53a502d0">2</ix:nonFraction>&#160;million and <ix:nonFraction unitRef="reportable_segments" contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331" decimals="-6" name="cah:SharesThatWouldBeAntidilutiveAsAResultOfNetLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTUvZnJhZzoxYzYzZDA1YTlmYTk0MjhmODhkZjhiZjQ2NjI3ZjQ4Yi90ZXh0cmVnaW9uOjFjNjNkMDVhOWZhOTQyOGY4OGRmOGJmNDY2MjdmNDhiXzU0OTc1NTgxNDEwMDA_5e457c93-1140-47e1-b665-c7e098348e03">1</ix:nonFraction>&#160;million potentially dilutive employee stock options, restricted share units and performance share units not included in the computation of diluted loss per common share attributable to Cardinal Health, Inc. because their effect would have been antidilutive as a result of the net loss during those periods.</span></div></ix:continuation><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div id="i1d34fc4fc2424fbcb4837cc9f1c0665c_118"></div><ix:nonNumeric contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90ZXh0cmVnaW9uOjZmYzA0ZmQwYjc5NTQ1MTBiZDFkNWU0YTZmYzJlNGFiXzU3MTU_b3aab43d-a051-4088-b031-3e36f71fca1c" continuedAt="iedc2e9ed59454452bcb70f670a316485" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">12. Segment Information</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations are principally managed on a products and services basis and are comprised of <ix:nonFraction unitRef="segment" contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" decimals="0" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90ZXh0cmVnaW9uOjZmYzA0ZmQwYjc5NTQ1MTBiZDFkNWU0YTZmYzJlNGFiXzEwMQ_b6e3f197-a086-46d0-afe1-513b7b8c63cb"><ix:nonFraction unitRef="segment" contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" decimals="0" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90ZXh0cmVnaW9uOjZmYzA0ZmQwYjc5NTQ1MTBiZDFkNWU0YTZmYzJlNGFiXzEwMQ_f0d9d156-1de4-4b34-b1f0-32d65e4d3f4e">two</ix:nonFraction></ix:nonFraction> operating segments, which are the same as our reportable segments: Pharmaceutical and Medical. The factors for determining the reportable segments include the manner in which management evaluates performance for purposes of allocating resources and assessing performance combined with the nature of the individual business activities.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical and over-the-counter healthcare and consumer products in the United States. This segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; provides pharmacy management services to hospitals and operates a limited number of pharmacies, including pharmacies in community health centers; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; and connects pharmacists, payers and pharmaceutical companies and delivers health solutions for medication therapy management, digital patient engagement and telepharmacy; and repackages generic pharmaceuticals and over-the-counter healthcare products.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Medical segment manufactures, sources and distributes Cardinal Health branded medical, surgical and laboratory products, which are sold in the United States, Canada, Europe, Asia and other markets. In addition to distributing Cardinal Health branded products, this segment also distributes a broad range of medical, surgical and laboratory products known as national brand products and provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories and other healthcare providers in the United States and Canada. This </span></div></ix:nonNumeric></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><ix:continuation id="iedc2e9ed59454452bcb70f670a316485" continuedAt="i3b174f3b276041d7802ff8dd2ce036fa"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">segment also distributes medical products to patients' homes in the United States through our Cardinal Health at-Home Solutions division.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present revenue for each reportable segment and disaggregated revenue within our <ix:nonFraction unitRef="segment" contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" decimals="0" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90ZXh0cmVnaW9uOjZmYzA0ZmQwYjc5NTQ1MTBiZDFkNWU0YTZmYzJlNGFiXzIwNDA_b6e3f197-a086-46d0-afe1-513b7b8c63cb"><ix:nonFraction unitRef="segment" contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" decimals="0" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90ZXh0cmVnaW9uOjZmYzA0ZmQwYjc5NTQ1MTBiZDFkNWU0YTZmYzJlNGFiXzIwNDA_f0d9d156-1de4-4b34-b1f0-32d65e4d3f4e">two</ix:nonFraction></ix:nonFraction> reportable segments and Corporate:</span></div><ix:nonNumeric contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90ZXh0cmVnaW9uOjZmYzA0ZmQwYjc5NTQ1MTBiZDFkNWU0YTZmYzJlNGFiXzU3Mjk_696ea255-63ee-4be3-b9e7-2359a2b04497" escape="true"><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.591%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.593%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical Distribution and Specialty Solutions (1) (2)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc26a4e700a342548208bd3adbce0cc3_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpjN2M4NWJkM2U0ODY0MTdlYjM3OTU2YjI2MTE1MzFhMS90YWJsZXJhbmdlOmM3Yzg1YmQzZTQ4NjQxN2ViMzc5NTZiMjYxMTUzMWExXzItMS0xLTEtMjg2OTQ0_18574e7b-b7b3-4cea-ac91-249d6a9251a4">46,497</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3eeef5beb2e3457385d0a29a55055482_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpjN2M4NWJkM2U0ODY0MTdlYjM3OTU2YjI2MTE1MzFhMS90YWJsZXJhbmdlOmM3Yzg1YmQzZTQ4NjQxN2ViMzc5NTZiMjYxMTUzMWExXzItMy0xLTEtMjg2OTQ0_5914dadc-b40c-4e66-8c1e-1741344adec1">40,723</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nuclear and Precision Health Solutions (3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1f8c810883d4ff9a38b1a6311b7024a_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpjN2M4NWJkM2U0ODY0MTdlYjM3OTU2YjI2MTE1MzFhMS90YWJsZXJhbmdlOmM3Yzg1YmQzZTQ4NjQxN2ViMzc5NTZiMjYxMTUzMWExXzMtMS0xLTEtMjg2OTQ0_3e580059-56b4-449f-9a6a-d7e67005646b">312</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22582fc2d45245928c608e9b04993980_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpjN2M4NWJkM2U0ODY0MTdlYjM3OTU2YjI2MTE1MzFhMS90YWJsZXJhbmdlOmM3Yzg1YmQzZTQ4NjQxN2ViMzc5NTZiMjYxMTUzMWExXzMtMy0xLTEtMjg2OTQ0_897cf184-516e-4116-8690-80cd0b520895">234</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical segment revenue</span></div></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16dc5579b6f94e7ca4452bbc7028e7c9_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpjN2M4NWJkM2U0ODY0MTdlYjM3OTU2YjI2MTE1MzFhMS90YWJsZXJhbmdlOmM3Yzg1YmQzZTQ4NjQxN2ViMzc5NTZiMjYxMTUzMWExXzQtMS0xLTEtMjg2OTQ0_b41e1e5b-55ad-44bf-8c7c-bc08ac7c3a20">46,809</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45daaa94544f4353a00c894ddf85a502_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpjN2M4NWJkM2U0ODY0MTdlYjM3OTU2YjI2MTE1MzFhMS90YWJsZXJhbmdlOmM3Yzg1YmQzZTQ4NjQxN2ViMzc5NTZiMjYxMTUzMWExXzQtMy0xLTEtMjg2OTQ0_b63e13b4-8ba6-43ff-a74a-489fb80ff6e3">40,957</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical distribution and products (4)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i496f651118df4ac294afe39b4aefdc23_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpjN2M4NWJkM2U0ODY0MTdlYjM3OTU2YjI2MTE1MzFhMS90YWJsZXJhbmdlOmM3Yzg1YmQzZTQ4NjQxN2ViMzc5NTZiMjYxMTUzMWExXzUtMS0xLTEtMjg2OTQ0_d20863a7-0e7f-4bfd-9bf3-2459011a6a84">3,034</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieff878faa3b9482d85466ac9bdf16285_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpjN2M4NWJkM2U0ODY0MTdlYjM3OTU2YjI2MTE1MzFhMS90YWJsZXJhbmdlOmM3Yzg1YmQzZTQ4NjQxN2ViMzc5NTZiMjYxMTUzMWExXzUtMy0xLTEtMjg2OTQ0_5e8c9561-b8b3-4c80-b5b4-3dfa5863831d">3,283</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cardinal Health at-Home Solutions</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib56812ccf8264be98f8752c625e2e17a_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpjN2M4NWJkM2U0ODY0MTdlYjM3OTU2YjI2MTE1MzFhMS90YWJsZXJhbmdlOmM3Yzg1YmQzZTQ4NjQxN2ViMzc5NTZiMjYxMTUzMWExXzYtMS0xLTEtMjg2OTQ0_0c8e26ea-b2c6-45f6-846f-08d683f30fa3">650</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i169b1a322c8c4e52985fff332cb28f47_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpjN2M4NWJkM2U0ODY0MTdlYjM3OTU2YjI2MTE1MzFhMS90YWJsZXJhbmdlOmM3Yzg1YmQzZTQ4NjQxN2ViMzc5NTZiMjYxMTUzMWExXzYtMy0xLTEtMjg2OTQ0_1fee6fa9-25ba-4df3-8f3d-d81a21d15ac7">601</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical segment revenue</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1495b91ae50844b7bd8dee01339cb2ba_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpjN2M4NWJkM2U0ODY0MTdlYjM3OTU2YjI2MTE1MzFhMS90YWJsZXJhbmdlOmM3Yzg1YmQzZTQ4NjQxN2ViMzc5NTZiMjYxMTUzMWExXzctMS0xLTEtMjg2OTQ0_c3b8ed98-bfe4-4bdc-99b1-cfb2e399a961">3,684</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc29744d3dd64b99ab33d733a31d8725_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpjN2M4NWJkM2U0ODY0MTdlYjM3OTU2YjI2MTE1MzFhMS90YWJsZXJhbmdlOmM3Yzg1YmQzZTQ4NjQxN2ViMzc5NTZiMjYxMTUzMWExXzctMy0xLTEtMjg2OTQ0_1116a13d-fa6f-47a3-9cc3-7c843b04db92">3,884</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7c59d976f4b491293536f66988a658a_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpjN2M4NWJkM2U0ODY0MTdlYjM3OTU2YjI2MTE1MzFhMS90YWJsZXJhbmdlOmM3Yzg1YmQzZTQ4NjQxN2ViMzc5NTZiMjYxMTUzMWExXzgtMS0xLTEtMjg2OTQ0_d2d9aad5-eb2c-417d-88c2-57a417b9056c">50,493</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i569871ca4d47454f87c9b6023726a3aa_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpjN2M4NWJkM2U0ODY0MTdlYjM3OTU2YjI2MTE1MzFhMS90YWJsZXJhbmdlOmM3Yzg1YmQzZTQ4NjQxN2ViMzc5NTZiMjYxMTUzMWExXzgtMy0xLTEtMjg2OTQ0_de246105-4b53-4a16-939f-3efbf48e6a9e">44,841</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (5)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia03b234276c04aa0af1cf1a16b60bc62_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpjN2M4NWJkM2U0ODY0MTdlYjM3OTU2YjI2MTE1MzFhMS90YWJsZXJhbmdlOmM3Yzg1YmQzZTQ4NjQxN2ViMzc5NTZiMjYxMTUzMWExXzktMS0xLTEtMjg2OTQ0_cb27356b-ce76-4150-b31a-88fdd5513bc9">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0b30b0809298478382f26a051e90bf8a_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpjN2M4NWJkM2U0ODY0MTdlYjM3OTU2YjI2MTE1MzFhMS90YWJsZXJhbmdlOmM3Yzg1YmQzZTQ4NjQxN2ViMzc5NTZiMjYxMTUzMWExXzktMy0xLTEtMjg2OTQ0_fc273ded-b0f7-4cd7-b0a0-85e8566076e2">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpjN2M4NWJkM2U0ODY0MTdlYjM3OTU2YjI2MTE1MzFhMS90YWJsZXJhbmdlOmM3Yzg1YmQzZTQ4NjQxN2ViMzc5NTZiMjYxMTUzMWExXzEwLTEtMS0xLTI4Njk0NA_8b929348-2156-43a9-910b-a07b130945a8">50,487</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpjN2M4NWJkM2U0ODY0MTdlYjM3OTU2YjI2MTE1MzFhMS90YWJsZXJhbmdlOmM3Yzg1YmQzZTQ4NjQxN2ViMzc5NTZiMjYxMTUzMWExXzEwLTMtMS0xLTI4Njk0NA_7eb0407c-964b-4e7b-bf4d-02116ae17161">44,836</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.591%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.593%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical Distribution and Specialty Solutions (1) (2)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie54fd2c345514ac293e4ec5b948651d1_D20220701-20230331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpmNGJjYjczNDEwNTE0YjBmYjkyNzU4ZmY2OTViM2JkZS90YWJsZXJhbmdlOmY0YmNiNzM0MTA1MTRiMGZiOTI3NThmZjY5NWIzYmRlXzItMS0xLTEtMjg2OTQ0_e9c41963-12ca-4a16-8232-7bea86fba633">139,435</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d7a863829b14c7491f8ae6b2433a880_D20210701-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpmNGJjYjczNDEwNTE0YjBmYjkyNzU4ZmY2OTViM2JkZS90YWJsZXJhbmdlOmY0YmNiNzM0MTA1MTRiMGZiOTI3NThmZjY5NWIzYmRlXzItMy0xLTEtMjg2OTQ0_ee9b67c9-536c-47c5-aa9a-d1fdabb3ffb0">121,501</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nuclear and Precision Health Solutions (3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92e95db7bd6246ed9c7bac5e8fb213ff_D20220701-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpmNGJjYjczNDEwNTE0YjBmYjkyNzU4ZmY2OTViM2JkZS90YWJsZXJhbmdlOmY0YmNiNzM0MTA1MTRiMGZiOTI3NThmZjY5NWIzYmRlXzMtMS0xLTEtMjg2OTQ0_09d7a20d-753c-43ce-989c-037a3c1a9b9a">875</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8bc9a61c2e44236ab69000fb26a2824_D20210701-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpmNGJjYjczNDEwNTE0YjBmYjkyNzU4ZmY2OTViM2JkZS90YWJsZXJhbmdlOmY0YmNiNzM0MTA1MTRiMGZiOTI3NThmZjY5NWIzYmRlXzMtMy0xLTEtMjg2OTQ0_fc5fb015-74d4-4166-922d-34f45a0f23fd">653</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical segment revenue</span></div></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04924e9230e745fca992f99aa6ace85c_D20220701-20230331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpmNGJjYjczNDEwNTE0YjBmYjkyNzU4ZmY2OTViM2JkZS90YWJsZXJhbmdlOmY0YmNiNzM0MTA1MTRiMGZiOTI3NThmZjY5NWIzYmRlXzQtMS0xLTEtMjg2OTQ0_dcdce57e-dff8-4894-bb4d-0aec0f00a083">140,310</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b399963940c4fcc875d6ee7b2e2a30c_D20210701-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpmNGJjYjczNDEwNTE0YjBmYjkyNzU4ZmY2OTViM2JkZS90YWJsZXJhbmdlOmY0YmNiNzM0MTA1MTRiMGZiOTI3NThmZjY5NWIzYmRlXzQtMy0xLTEtMjg2OTQ0_d3b828b7-6385-48c2-afce-142fdd863bbd">122,154</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical distribution and products (4)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id19b85c70c834e2788b7091044df235c_D20220701-20230331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpmNGJjYjczNDEwNTE0YjBmYjkyNzU4ZmY2OTViM2JkZS90YWJsZXJhbmdlOmY0YmNiNzM0MTA1MTRiMGZiOTI3NThmZjY5NWIzYmRlXzUtMS0xLTEtMjg2OTQ0_9d834dc3-35be-4bd0-8ec4-f101000a2297">9,273</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i543467e6acd7440e976c6acaeebc9d47_D20210701-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpmNGJjYjczNDEwNTE0YjBmYjkyNzU4ZmY2OTViM2JkZS90YWJsZXJhbmdlOmY0YmNiNzM0MTA1MTRiMGZiOTI3NThmZjY5NWIzYmRlXzUtMy0xLTEtMjg2OTQ0_9e4c2a36-9aa8-40d7-a6df-5714319d9ec7">10,296</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cardinal Health at-Home Solutions</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57cd785fabaf4688a3bbe54d4f0ca21d_D20220701-20230331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpmNGJjYjczNDEwNTE0YjBmYjkyNzU4ZmY2OTViM2JkZS90YWJsZXJhbmdlOmY0YmNiNzM0MTA1MTRiMGZiOTI3NThmZjY5NWIzYmRlXzYtMS0xLTEtMjg2OTQ0_a8f25338-cc67-487a-89ab-1c0d94b96f66">1,986</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e29a915c71426f8011dc3489ec5202_D20210701-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpmNGJjYjczNDEwNTE0YjBmYjkyNzU4ZmY2OTViM2JkZS90YWJsZXJhbmdlOmY0YmNiNzM0MTA1MTRiMGZiOTI3NThmZjY5NWIzYmRlXzYtMy0xLTEtMjg2OTQ0_b2cdf083-f7b4-4081-ad34-985bb1821400">1,822</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical segment revenue</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44eddf7caae040f987146265a715a28d_D20220701-20230331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpmNGJjYjczNDEwNTE0YjBmYjkyNzU4ZmY2OTViM2JkZS90YWJsZXJhbmdlOmY0YmNiNzM0MTA1MTRiMGZiOTI3NThmZjY5NWIzYmRlXzctMS0xLTEtMjg2OTQ0_1cc16b83-49f9-49b8-bf03-5991099e3142">11,259</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie312826afe694135b31551dc50097180_D20210701-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpmNGJjYjczNDEwNTE0YjBmYjkyNzU4ZmY2OTViM2JkZS90YWJsZXJhbmdlOmY0YmNiNzM0MTA1MTRiMGZiOTI3NThmZjY5NWIzYmRlXzctMy0xLTEtMjg2OTQ0_e18328cb-be47-4830-add4-d6e34c0d4ce2">12,118</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09186e53513344a797c14f6874c9c782_D20220701-20230331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpmNGJjYjczNDEwNTE0YjBmYjkyNzU4ZmY2OTViM2JkZS90YWJsZXJhbmdlOmY0YmNiNzM0MTA1MTRiMGZiOTI3NThmZjY5NWIzYmRlXzgtMS0xLTEtMjg2OTQ0_cc9c9394-0622-44ef-b1fc-74d8a1b2e62e">151,569</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i438495dce7084e9eb69ebe58bc06cd29_D20210701-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpmNGJjYjczNDEwNTE0YjBmYjkyNzU4ZmY2OTViM2JkZS90YWJsZXJhbmdlOmY0YmNiNzM0MTA1MTRiMGZiOTI3NThmZjY5NWIzYmRlXzgtMy0xLTEtMjg2OTQ0_12ff11cf-26b5-4c28-adb8-120fb431c8bb">134,272</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (5)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ed97f44ba534c3889ad982e9558682c_D20220701-20230331" decimals="-6" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpmNGJjYjczNDEwNTE0YjBmYjkyNzU4ZmY2OTViM2JkZS90YWJsZXJhbmdlOmY0YmNiNzM0MTA1MTRiMGZiOTI3NThmZjY5NWIzYmRlXzktMS0xLTEtMjg2OTQ0_14de0a77-df94-4a52-a248-dfa383656e71">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9dcc325ed5014b548d6c310c9974f048_D20210701-20220331" decimals="-6" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpmNGJjYjczNDEwNTE0YjBmYjkyNzU4ZmY2OTViM2JkZS90YWJsZXJhbmdlOmY0YmNiNzM0MTA1MTRiMGZiOTI3NThmZjY5NWIzYmRlXzktMy0xLTEtMjg2OTQ0_70137c91-6127-4a86-b2ba-db9aced9c03f">11</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpmNGJjYjczNDEwNTE0YjBmYjkyNzU4ZmY2OTViM2JkZS90YWJsZXJhbmdlOmY0YmNiNzM0MTA1MTRiMGZiOTI3NThmZjY5NWIzYmRlXzEwLTEtMS0xLTI4Njk0NA_9083c730-0881-4afc-8694-a3402b330b4c">151,559</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpmNGJjYjczNDEwNTE0YjBmYjkyNzU4ZmY2OTViM2JkZS90YWJsZXJhbmdlOmY0YmNiNzM0MTA1MTRiMGZiOTI3NThmZjY5NWIzYmRlXzEwLTMtMS0xLTI4Njk0NA_6bdddb52-0254-4c48-bbf8-dcaae385fe82">134,261</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Products and services offered by our Specialty Solutions division are referred to as &#8220;specialty pharmaceutical products and services."</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Comprised of all Pharmaceutical segment businesses except for Nuclear and Precision Health Solutions division.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Increase from prior year relates to new product launches and changes in revenue recognition presentation from agent to principal for certain customer contracts.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Comprised of all Medical segment businesses except for Cardinal Health at-Home Solutions division.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.</span></div></ix:nonNumeric></ix:continuation></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">41</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="width:100.000%"><ix:continuation id="i3b174f3b276041d7802ff8dd2ce036fa" continuedAt="i1fe0f5aeec254f2489243abb4d84ea0a"><div style="display:inline-block;vertical-align:top;width:48.214%"><ix:nonNumeric contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" name="us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90ZXh0cmVnaW9uOjZmYzA0ZmQwYjc5NTQ1MTBiZDFkNWU0YTZmYzJlNGFiXzU3MjU_1a9a70cd-1827-4078-9328-3a2718650aa9" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present revenue by geographic area:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:43.482%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.215%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.217%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73b99b7f00ef43c3b9264f23015dbdbc_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpiODliZDJiMjMwYmE0ZjVmYTY1MjI2MGZkZDQ1ZDhiMS90YWJsZXJhbmdlOmI4OWJkMmIyMzBiYTRmNWZhNjUyMjYwZmRkNDVkOGIxXzItMS0xLTEtMjg2OTQ0_c4c43d26-e86b-41f7-9b7d-8b8f9d463921">49,326</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bb3c35435cf4419a78f521a4ab0acc6_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpiODliZDJiMjMwYmE0ZjVmYTY1MjI2MGZkZDQ1ZDhiMS90YWJsZXJhbmdlOmI4OWJkMmIyMzBiYTRmNWZhNjUyMjYwZmRkNDVkOGIxXzItMy0xLTEtMjg2OTQ0_fb436046-4834-4559-850e-fc0dbf1b0555">43,710</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i447a6c019d5146ccb318da808e4fb2f3_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpiODliZDJiMjMwYmE0ZjVmYTY1MjI2MGZkZDQ1ZDhiMS90YWJsZXJhbmdlOmI4OWJkMmIyMzBiYTRmNWZhNjUyMjYwZmRkNDVkOGIxXzMtMS0xLTEtMjg2OTQ0_fbd501e4-ce39-4618-99d5-15a5951751e8">1,167</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4060ee92cb7e4a3a973a917c60eb75fc_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpiODliZDJiMjMwYmE0ZjVmYTY1MjI2MGZkZDQ1ZDhiMS90YWJsZXJhbmdlOmI4OWJkMmIyMzBiYTRmNWZhNjUyMjYwZmRkNDVkOGIxXzMtMy0xLTEtMjg2OTQ0_bed4ec58-68ad-4960-ab1c-85607377cbc2">1,131</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7c59d976f4b491293536f66988a658a_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpiODliZDJiMjMwYmE0ZjVmYTY1MjI2MGZkZDQ1ZDhiMS90YWJsZXJhbmdlOmI4OWJkMmIyMzBiYTRmNWZhNjUyMjYwZmRkNDVkOGIxXzQtMS0xLTEtMjg2OTQ0_9b564c76-ea0a-4bfc-bfcc-5d5c1b93ffbf">50,493</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i569871ca4d47454f87c9b6023726a3aa_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpiODliZDJiMjMwYmE0ZjVmYTY1MjI2MGZkZDQ1ZDhiMS90YWJsZXJhbmdlOmI4OWJkMmIyMzBiYTRmNWZhNjUyMjYwZmRkNDVkOGIxXzQtMy0xLTEtMjg2OTQ0_80e65f17-72a6-4f3e-a46f-25b8d79360f4">44,841</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia03b234276c04aa0af1cf1a16b60bc62_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpiODliZDJiMjMwYmE0ZjVmYTY1MjI2MGZkZDQ1ZDhiMS90YWJsZXJhbmdlOmI4OWJkMmIyMzBiYTRmNWZhNjUyMjYwZmRkNDVkOGIxXzUtMS0xLTEtMjg2OTQ0_e9630610-0a44-4f33-a7b7-0e9e5a2e709a">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0b30b0809298478382f26a051e90bf8a_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpiODliZDJiMjMwYmE0ZjVmYTY1MjI2MGZkZDQ1ZDhiMS90YWJsZXJhbmdlOmI4OWJkMmIyMzBiYTRmNWZhNjUyMjYwZmRkNDVkOGIxXzUtMy0xLTEtMjg2OTQ0_caa74134-df1f-47fa-a962-0eb2d2d2ce88">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpiODliZDJiMjMwYmE0ZjVmYTY1MjI2MGZkZDQ1ZDhiMS90YWJsZXJhbmdlOmI4OWJkMmIyMzBiYTRmNWZhNjUyMjYwZmRkNDVkOGIxXzYtMS0xLTEtMjg2OTQ0_6f540ad5-6aed-4dcc-820c-4f9b0f8634d7">50,487</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpiODliZDJiMjMwYmE0ZjVmYTY1MjI2MGZkZDQ1ZDhiMS90YWJsZXJhbmdlOmI4OWJkMmIyMzBiYTRmNWZhNjUyMjYwZmRkNDVkOGIxXzYtMy0xLTEtMjg2OTQ0_3e60792d-f1e7-45f7-808c-f817028029fa">44,836</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:43.791%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.906%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.217%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if67e0eb500ab42958354df8e59c31390_D20220701-20230331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpkM2E4ODdlZTI2MDM0OGU0OWUwZDJlMGE2NTkxYzc2ZC90YWJsZXJhbmdlOmQzYTg4N2VlMjYwMzQ4ZTQ5ZTBkMmUwYTY1OTFjNzZkXzItMS0xLTEtMjg2OTQ0_9e3f9545-d67d-4a52-8221-3af7797830a9">148,136</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5273719c53784b1984b975c2b15073cf_D20210701-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpkM2E4ODdlZTI2MDM0OGU0OWUwZDJlMGE2NTkxYzc2ZC90YWJsZXJhbmdlOmQzYTg4N2VlMjYwMzQ4ZTQ5ZTBkMmUwYTY1OTFjNzZkXzItMy0xLTEtMjg2OTQ0_c5d7e4eb-fb8c-4f79-a0a9-90cdac7c1be2">130,933</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib488e4c93b484184a8e52bee69885132_D20220701-20230331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpkM2E4ODdlZTI2MDM0OGU0OWUwZDJlMGE2NTkxYzc2ZC90YWJsZXJhbmdlOmQzYTg4N2VlMjYwMzQ4ZTQ5ZTBkMmUwYTY1OTFjNzZkXzMtMS0xLTEtMjg2OTQ0_1b897c48-7407-4265-9a4e-9327756b0f8f">3,433</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5f105aa532244e0885f2307bc2951ad_D20210701-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpkM2E4ODdlZTI2MDM0OGU0OWUwZDJlMGE2NTkxYzc2ZC90YWJsZXJhbmdlOmQzYTg4N2VlMjYwMzQ4ZTQ5ZTBkMmUwYTY1OTFjNzZkXzMtMy0xLTEtMjg2OTQ0_6a0f9187-e9ba-436b-a8b1-641bf4c62b19">3,339</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09186e53513344a797c14f6874c9c782_D20220701-20230331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpkM2E4ODdlZTI2MDM0OGU0OWUwZDJlMGE2NTkxYzc2ZC90YWJsZXJhbmdlOmQzYTg4N2VlMjYwMzQ4ZTQ5ZTBkMmUwYTY1OTFjNzZkXzQtMS0xLTEtMjg2OTQ0_41b0adca-8c45-4ae6-82dc-c354f5a6bbef">151,569</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i438495dce7084e9eb69ebe58bc06cd29_D20210701-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpkM2E4ODdlZTI2MDM0OGU0OWUwZDJlMGE2NTkxYzc2ZC90YWJsZXJhbmdlOmQzYTg4N2VlMjYwMzQ4ZTQ5ZTBkMmUwYTY1OTFjNzZkXzQtMy0xLTEtMjg2OTQ0_40acc133-33ca-41b2-b433-626f9e108e0f">134,272</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ed97f44ba534c3889ad982e9558682c_D20220701-20230331" decimals="-6" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpkM2E4ODdlZTI2MDM0OGU0OWUwZDJlMGE2NTkxYzc2ZC90YWJsZXJhbmdlOmQzYTg4N2VlMjYwMzQ4ZTQ5ZTBkMmUwYTY1OTFjNzZkXzUtMS0xLTEtMjg2OTQ0_be44dea1-713b-4a9b-bc0c-2de176b8cd5b">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9dcc325ed5014b548d6c310c9974f048_D20210701-20220331" decimals="-6" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpkM2E4ODdlZTI2MDM0OGU0OWUwZDJlMGE2NTkxYzc2ZC90YWJsZXJhbmdlOmQzYTg4N2VlMjYwMzQ4ZTQ5ZTBkMmUwYTY1OTFjNzZkXzUtMy0xLTEtMjg2OTQ0_c4d9dd92-6635-4845-a8f1-22db78e63153">11</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpkM2E4ODdlZTI2MDM0OGU0OWUwZDJlMGE2NTkxYzc2ZC90YWJsZXJhbmdlOmQzYTg4N2VlMjYwMzQ4ZTQ5ZTBkMmUwYTY1OTFjNzZkXzYtMS0xLTEtMjg2OTQ0_1172e5fe-1d49-42ed-9caa-d6a7e7f5384d">151,559</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpkM2E4ODdlZTI2MDM0OGU0OWUwZDJlMGE2NTkxYzc2ZC90YWJsZXJhbmdlOmQzYTg4N2VlMjYwMzQ4ZTQ5ZTBkMmUwYTY1OTFjNzZkXzYtMy0xLTEtMjg2OTQ0_174ebb52-c628-44a3-8af0-f2d35b5ded97">134,261</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.</span></div></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Profit</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate segment performance based on segment profit, among other measures. Segment profit is segment revenue, less segment cost of products sold, less segment distribution, selling, general and administrative ("SG&amp;A") expenses. Segment SG&amp;A expenses include share-based compensation expense as well as allocated corporate expenses for shared functions, including corporate management, corporate finance, financial and customer care shared services, human resources, information technology and legal and compliance, including certain litigation defense costs. Corporate expenses are allocated to the segments based on headcount, level of benefit provided and other ratable allocation methodologies. The results attributable to noncontrolling interests are recorded within segment profit.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not allocate the following items to our segments: </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">last-in first-out, or ("LIFO"), inventory charges/(credits); </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">surgical gown recall costs/(income);</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">shareholder cooperation agreement costs;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">state opioid assessment related to prior fiscal years;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">restructuring and employee severance;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">amortization and other acquisition-related costs;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">impairments and (gain)/loss on disposal of assets, net; in connection with goodwill impairment testing for the Medical Unit as discussed further in </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1d34fc4fc2424fbcb4837cc9f1c0665c_88">Note 4</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we recognized cumulative goodwill impairment charges of $<ix:nonFraction unitRef="usd" contextRef="ie12745b4aa3e4e2f8127b2b3aa94621c_D20220701-20230331" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90ZXh0cmVnaW9uOjZmYzA0ZmQwYjc5NTQ1MTBiZDFkNWU0YTZmYzJlNGFiXzQyNDY_81d80d54-799e-4fdb-8938-1abf1e264da3">863</ix:nonFraction>&#160;million during the nine months ended March&#160;31, 2023;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">litigation (recoveries)/charges, net;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">other (income)/expense, net;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">interest expense, net;</span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">loss on early extinguishment of debt; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">(gain)/loss on sale of equity interest in naviHealth; or</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">provision for income taxes </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, certain investment spending, certain portions of enterprise-wide incentive compensation and other spending are not allocated to the segments. Investment spending generally includes the first-year spend for certain projects that require incremental investments in the form of additional operating expenses. Because approval for these projects is dependent on executive management, we retain these expenses at Corporate. Investment spending within Corporate was $<ix:nonFraction unitRef="usd" contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331" decimals="-6" name="cah:ProjectCostsOnInvestmentAndOtherSpending" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90ZXh0cmVnaW9uOjZmYzA0ZmQwYjc5NTQ1MTBiZDFkNWU0YTZmYzJlNGFiXzUwMDc_1abb8290-9c18-4627-b786-4ef0e436dea3">9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331" decimals="-6" name="cah:ProjectCostsOnInvestmentAndOtherSpending" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90ZXh0cmVnaW9uOjZmYzA0ZmQwYjc5NTQ1MTBiZDFkNWU0YTZmYzJlNGFiXzUwMTQ_cf2d9214-0581-45c5-9128-b29d743ff233">20</ix:nonFraction> million for the three months ended March&#160;31, 2023 and 2022, and $<ix:nonFraction unitRef="usd" contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" decimals="-6" name="cah:ProjectCostsOnInvestmentAndOtherSpending" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90ZXh0cmVnaW9uOjZmYzA0ZmQwYjc5NTQ1MTBiZDFkNWU0YTZmYzJlNGFiXzUwNTk_86d80263-64d1-4530-a47e-2520a5501922">20</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331" decimals="-6" name="cah:ProjectCostsOnInvestmentAndOtherSpending" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90ZXh0cmVnaW9uOjZmYzA0ZmQwYjc5NTQ1MTBiZDFkNWU0YTZmYzJlNGFiXzUwNjY_f62b9231-ea4c-412c-b1d5-607cd49011d2">38</ix:nonFraction> million for the nine months ended March&#160;31, 2023 and 2022, respectively.</span></div><ix:nonNumeric contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" name="us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90ZXh0cmVnaW9uOjZmYzA0ZmQwYjc5NTQ1MTBiZDFkNWU0YTZmYzJlNGFiXzU3MTk_d3ef53de-0f28-42e6-bbf7-574d732b0b97" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present segment profit by reportable segment and Corporate:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:50.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.429%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.122%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical (1)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16dc5579b6f94e7ca4452bbc7028e7c9_D20230101-20230331" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTo3MzQ0YzQwMTBhN2I0MzY4YmMwNWJiNzRlZDI3MjEzOC90YWJsZXJhbmdlOjczNDRjNDAxMGE3YjQzNjhiYzA1YmI3NGVkMjcyMTM4XzItMS0xLTEtMjg2OTQ0_b6bf9dbe-3728-47dd-a9cb-1e414f9b2fd7">600</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45daaa94544f4353a00c894ddf85a502_D20220101-20220331" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTo3MzQ0YzQwMTBhN2I0MzY4YmMwNWJiNzRlZDI3MjEzOC90YWJsZXJhbmdlOjczNDRjNDAxMGE3YjQzNjhiYzA1YmI3NGVkMjcyMTM4XzItMy0xLTEtMjg2OTQ0_29343a32-c189-439d-8c90-09094b594370">487</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1495b91ae50844b7bd8dee01339cb2ba_D20230101-20230331" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTo3MzQ0YzQwMTBhN2I0MzY4YmMwNWJiNzRlZDI3MjEzOC90YWJsZXJhbmdlOjczNDRjNDAxMGE3YjQzNjhiYzA1YmI3NGVkMjcyMTM4XzMtMS0xLTEtMjg2OTQ0_4976030d-c059-4f61-b535-8f2500c851cc">20</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc29744d3dd64b99ab33d733a31d8725_D20220101-20220331" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTo3MzQ0YzQwMTBhN2I0MzY4YmMwNWJiNzRlZDI3MjEzOC90YWJsZXJhbmdlOjczNDRjNDAxMGE3YjQzNjhiYzA1YmI3NGVkMjcyMTM4XzMtMy0xLTEtMjg2OTQ0_15591908-dccc-4757-b696-965913526fab">59</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total segment profit</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7c59d976f4b491293536f66988a658a_D20230101-20230331" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTo3MzQ0YzQwMTBhN2I0MzY4YmMwNWJiNzRlZDI3MjEzOC90YWJsZXJhbmdlOjczNDRjNDAxMGE3YjQzNjhiYzA1YmI3NGVkMjcyMTM4XzQtMS0xLTEtMjg2OTQ0_6fbeb105-4497-4ac1-841c-590f4872346d">620</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i569871ca4d47454f87c9b6023726a3aa_D20220101-20220331" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTo3MzQ0YzQwMTBhN2I0MzY4YmMwNWJiNzRlZDI3MjEzOC90YWJsZXJhbmdlOjczNDRjNDAxMGE3YjQzNjhiYzA1YmI3NGVkMjcyMTM4XzQtMy0xLTEtMjg2OTQ0_8d647f6c-3595-46d8-a227-a2bfde83fcf6">546</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia03b234276c04aa0af1cf1a16b60bc62_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTo3MzQ0YzQwMTBhN2I0MzY4YmMwNWJiNzRlZDI3MjEzOC90YWJsZXJhbmdlOjczNDRjNDAxMGE3YjQzNjhiYzA1YmI3NGVkMjcyMTM4XzUtMS0xLTEtMjg2OTQ0_73197045-9b70-40a5-8b08-5730ac7515db">48</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0b30b0809298478382f26a051e90bf8a_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTo3MzQ0YzQwMTBhN2I0MzY4YmMwNWJiNzRlZDI3MjEzOC90YWJsZXJhbmdlOjczNDRjNDAxMGE3YjQzNjhiYzA1YmI3NGVkMjcyMTM4XzUtMy0xLTEtMjg2OTQ0_d9285fb6-4716-4cbf-b505-432ec51eb304">643</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total operating earnings/(loss)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTo3MzQ0YzQwMTBhN2I0MzY4YmMwNWJiNzRlZDI3MjEzOC90YWJsZXJhbmdlOjczNDRjNDAxMGE3YjQzNjhiYzA1YmI3NGVkMjcyMTM4XzYtMS0xLTEtMjg2OTQ0_a2e83a9e-29d4-45ea-b36f-3bad389ed8d9">572</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTo3MzQ0YzQwMTBhN2I0MzY4YmMwNWJiNzRlZDI3MjEzOC90YWJsZXJhbmdlOjczNDRjNDAxMGE3YjQzNjhiYzA1YmI3NGVkMjcyMTM4XzYtMy0xLTEtMjg2OTQ0_d926b019-9a54-42ae-a59f-5990d6dd2541">97</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical (1)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04924e9230e745fca992f99aa6ace85c_D20220701-20230331" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpkNDEzNjgxYjM1ODE0ODA4ODU1NDYzZmJkNTA5NDM1YS90YWJsZXJhbmdlOmQ0MTM2ODFiMzU4MTQ4MDg4NTU0NjNmYmQ1MDk0MzVhXzItMS0xLTEtMjg2OTQ0_d5d35543-2aeb-4996-a0f3-cedaef97ad96">1,495</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b399963940c4fcc875d6ee7b2e2a30c_D20210701-20220331" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpkNDEzNjgxYjM1ODE0ODA4ODU1NDYzZmJkNTA5NDM1YS90YWJsZXJhbmdlOmQ0MTM2ODFiMzU4MTQ4MDg4NTU0NjNmYmQ1MDk0MzVhXzItMy0xLTEtMjg2OTQ0_abe19c98-e0d0-4919-8603-30326f5bbe96">1,319</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44eddf7caae040f987146265a715a28d_D20220701-20230331" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpkNDEzNjgxYjM1ODE0ODA4ODU1NDYzZmJkNTA5NDM1YS90YWJsZXJhbmdlOmQ0MTM2ODFiMzU4MTQ4MDg4NTU0NjNmYmQ1MDk0MzVhXzMtMS0xLTEtMjg2OTQ0_31267205-03ee-41f2-8a5b-8369a94e91e1">29</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie312826afe694135b31551dc50097180_D20210701-20220331" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpkNDEzNjgxYjM1ODE0ODA4ODU1NDYzZmJkNTA5NDM1YS90YWJsZXJhbmdlOmQ0MTM2ODFiMzU4MTQ4MDg4NTU0NjNmYmQ1MDk0MzVhXzMtMy0xLTEtMjg2OTQ0_8df6aacf-4ccb-425e-85a9-bd079e061d8e">232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total segment profit</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09186e53513344a797c14f6874c9c782_D20220701-20230331" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpkNDEzNjgxYjM1ODE0ODA4ODU1NDYzZmJkNTA5NDM1YS90YWJsZXJhbmdlOmQ0MTM2ODFiMzU4MTQ4MDg4NTU0NjNmYmQ1MDk0MzVhXzQtMS0xLTEtMjg2OTQ0_3c7454ac-5042-4040-9b44-e092717fc417">1,524</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i438495dce7084e9eb69ebe58bc06cd29_D20210701-20220331" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpkNDEzNjgxYjM1ODE0ODA4ODU1NDYzZmJkNTA5NDM1YS90YWJsZXJhbmdlOmQ0MTM2ODFiMzU4MTQ4MDg4NTU0NjNmYmQ1MDk0MzVhXzQtMy0xLTEtMjg2OTQ0_7c4dcd8c-4b99-45af-aa11-02e5d66ee63b">1,551</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ed97f44ba534c3889ad982e9558682c_D20220701-20230331" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpkNDEzNjgxYjM1ODE0ODA4ODU1NDYzZmJkNTA5NDM1YS90YWJsZXJhbmdlOmQ0MTM2ODFiMzU4MTQ4MDg4NTU0NjNmYmQ1MDk0MzVhXzUtMS0xLTEtMjg2OTQ0_f400714b-aa96-44fb-9dd8-00c5a5384089">934</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9dcc325ed5014b548d6c310c9974f048_D20210701-20220331" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpkNDEzNjgxYjM1ODE0ODA4ODU1NDYzZmJkNTA5NDM1YS90YWJsZXJhbmdlOmQ0MTM2ODFiMzU4MTQ4MDg4NTU0NjNmYmQ1MDk0MzVhXzUtMy0xLTEtMjg2OTQ0_d03fa483-101e-41f9-ae57-7e16a26f2df3">2,183</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total operating earnings/(loss)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpkNDEzNjgxYjM1ODE0ODA4ODU1NDYzZmJkNTA5NDM1YS90YWJsZXJhbmdlOmQ0MTM2ODFiMzU4MTQ4MDg4NTU0NjNmYmQ1MDk0MzVhXzYtMS0xLTEtMjg2OTQ0_9e4d5a53-e719-4579-b538-d44b8c048515">590</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpkNDEzNjgxYjM1ODE0ODA4ODU1NDYzZmJkNTA5NDM1YS90YWJsZXJhbmdlOmQ0MTM2ODFiMzU4MTQ4MDg4NTU0NjNmYmQ1MDk0MzVhXzYtMy0xLTEtMjg2OTQ0_3c0e7754-5ddf-40d3-b03d-479ff44a7e2d">632</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Pharmaceutical segment profit includes opioid-related litigation defense and compliance costs, but does not include a one-time contingent attorney fee of $<ix:nonFraction unitRef="usd" contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331" decimals="-6" name="cah:ContingentAttorneyFee" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90ZXh0cmVnaW9uOjZmYzA0ZmQwYjc5NTQ1MTBiZDFkNWU0YTZmYzJlNGFiXzU0OTc1NTgxNTU4NzE_d6b953ba-9cd8-4124-92dd-99302cbd903d"><ix:nonFraction unitRef="usd" contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331" decimals="-6" name="cah:ContingentAttorneyFee" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90ZXh0cmVnaW9uOjZmYzA0ZmQwYjc5NTQ1MTBiZDFkNWU0YTZmYzJlNGFiXzU0OTc1NTgxNTU4NzE_d7825190-f000-42b3-8df7-469b93990b70">18</ix:nonFraction></ix:nonFraction>&#160;million incurred during the three and nine months ended March 31, 2022 related to the finalization of the Settlement Agreement. Due to the unique nature and significance of the Settlement Agreement, and the one-time, contingent nature of the fee, this related fee was included in litigation (recoveries)/charges, net in the condensed consolidated statements of earnings/(loss). Additionally, pharmaceutical segment profit during the nine months ended March 31, 2022 was positively impacted by a $<ix:nonFraction unitRef="usd" contextRef="i92600b80cf9f42e68ab2bb551fa5980c_D20211001-20211231" decimals="-6" name="cah:JudgmentForLostProfits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90ZXh0cmVnaW9uOjZmYzA0ZmQwYjc5NTQ1MTBiZDFkNWU0YTZmYzJlNGFiXzUzMDc_9c01752c-b170-4e27-820b-57bd6e842abd">16</ix:nonFraction>&#160;million judgment for lost profits related to an ordinary course intellectual property rights claim.</span></div></ix:nonNumeric></div></ix:continuation></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">42</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><ix:continuation id="i1fe0f5aeec254f2489243abb4d84ea0a" continuedAt="i9843d85f034e47ed88e3d60b3084fd6e"><ix:nonNumeric contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" name="us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90ZXh0cmVnaW9uOjZmYzA0ZmQwYjc5NTQ1MTBiZDFkNWU0YTZmYzJlNGFiXzU3MTQ_99ef0df9-62b9-478f-a329-5ebf2848a695" continuedAt="ia18ec6dc3d804da2a280300d72592cc8" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents total assets for each reportable segment and Corporate at: </span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:52.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.503%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#d1d1d1;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c0c3804d63c4f5fafbb13f1f87b1d95_I20230331" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTphZWRkNjI1ZTM1M2I0NjA0ODNlMjU1OGMyYzA3OGVlNS90YWJsZXJhbmdlOmFlZGQ2MjVlMzUzYjQ2MDQ4M2UyNTU4YzJjMDc4ZWU1XzEtMS0xLTEtMjg2OTQ0_c4d9a72a-8e92-409c-bb33-f38c6c30935b">27,954</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"></td><td style="background-color:#d1d1d1;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a16787e42247d480a65342eeea298b_I20220630" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTphZWRkNjI1ZTM1M2I0NjA0ODNlMjU1OGMyYzA3OGVlNS90YWJsZXJhbmdlOmFlZGQ2MjVlMzUzYjQ2MDQ4M2UyNTU4YzJjMDc4ZWU1XzEtMy0xLTEtMjg2OTQ0_f154bb84-7a83-41ab-9f72-18de252c01eb">26,409</ix:nonFraction>&#160;</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib09896a0291b4dbd9d0deb987d93eb9c_I20230331" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTphZWRkNjI1ZTM1M2I0NjA0ODNlMjU1OGMyYzA3OGVlNS90YWJsZXJhbmdlOmFlZGQ2MjVlMzUzYjQ2MDQ4M2UyNTU4YzJjMDc4ZWU1XzItMS0xLTEtMjg2OTQ0_b9b760ca-2494-40a6-8068-932ec9d180f0">10,544</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibee1c5b1f4f946f18b93d5abfb380e03_I20220630" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTphZWRkNjI1ZTM1M2I0NjA0ODNlMjU1OGMyYzA3OGVlNS90YWJsZXJhbmdlOmFlZGQ2MjVlMzUzYjQ2MDQ4M2UyNTU4YzJjMDc4ZWU1XzItMy0xLTEtMjg2OTQ0_bbf9108c-5915-4be8-ab2b-3fa96d4eb2d1">11,632</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d1d1d1;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate </span></td><td colspan="2" style="background-color:#d1d1d1;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f4869e77ac44a00a1348128c89edab9_I20230331" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTphZWRkNjI1ZTM1M2I0NjA0ODNlMjU1OGMyYzA3OGVlNS90YWJsZXJhbmdlOmFlZGQ2MjVlMzUzYjQ2MDQ4M2UyNTU4YzJjMDc4ZWU1XzMtMS0xLTEtMjg2OTQ0_05e31436-d6aa-48a3-a329-f7e2e38d8804">4,879</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d1d1d1;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"></td><td colspan="2" style="background-color:#d1d1d1;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa15c30af25e4338b4b75b20fdd5cdfd_I20220630" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTphZWRkNjI1ZTM1M2I0NjA0ODNlMjU1OGMyYzA3OGVlNS90YWJsZXJhbmdlOmFlZGQ2MjVlMzUzYjQ2MDQ4M2UyNTU4YzJjMDc4ZWU1XzMtMy0xLTEtMjg2OTQ0_33f331f7-49bb-40b3-a3ee-18c572b972d1">5,837</ix:nonFraction>&#160;</span></td><td style="background-color:#d1d1d1;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total assets</span></td><td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTphZWRkNjI1ZTM1M2I0NjA0ODNlMjU1OGMyYzA3OGVlNS90YWJsZXJhbmdlOmFlZGQ2MjVlMzUzYjQ2MDQ4M2UyNTU4YzJjMDc4ZWU1XzQtMS0xLTEtMjg2OTQ0_18fde7c2-a807-448a-88a2-96c84665e885">43,377</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic217743408d440409a59220a0bf14e4c_I20220630" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTphZWRkNjI1ZTM1M2I0NjA0ODNlMjU1OGMyYzA3OGVlNS90YWJsZXJhbmdlOmFlZGQ2MjVlMzUzYjQ2MDQ4M2UyNTU4YzJjMDc4ZWU1XzQtMy0xLTEtMjg2OTQ0_16514b21-dc88-430c-97db-c7715d821b17">43,878</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:continuation id="i9843d85f034e47ed88e3d60b3084fd6e" continuedAt="id6632f9cab3748d6ab1ac43e7ba67c0c"><ix:continuation id="ia18ec6dc3d804da2a280300d72592cc8" continuedAt="i0bb426f00f9a43cfbe033723fd1adc82">(1)</ix:continuation></ix:continuation></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"><ix:continuation id="id6632f9cab3748d6ab1ac43e7ba67c0c"><ix:continuation id="i0bb426f00f9a43cfbe033723fd1adc82">Medical reflects cumulative $<ix:nonFraction unitRef="usd" contextRef="ie12745b4aa3e4e2f8127b2b3aa94621c_D20220701-20230331" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90ZXh0cmVnaW9uOjZmYzA0ZmQwYjc5NTQ1MTBiZDFkNWU0YTZmYzJlNGFiXzU1MjI_81d80d54-799e-4fdb-8938-1abf1e264da3">863</ix:nonFraction>&#160;million goodwill impairment charges recorded in connection with the interim goodwill impairment testing for the Medical Unit during the nine months ended March 31, 2023.</ix:continuation></ix:continuation> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div id="i1d34fc4fc2424fbcb4837cc9f1c0665c_121"></div><ix:nonNumeric contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMjEvZnJhZzo3NGQ2NzRmYTY0NTQ0YWQzYWVkMGE5MDM4ZTA3OTkwZS90ZXh0cmVnaW9uOjc0ZDY3NGZhNjQ1NDRhZDNhZWQwYTkwMzhlMDc5OTBlXzE4MDk_d2a19e3c-9f25-4a3f-a52c-7daca739fa8b" continuedAt="id5b7d1b416e7449c8e5b05f89392f8eb" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">13. Share-Based Compensation</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain stock incentive plans (collectively, the &#8220;Plans&#8221;) for the benefit of certain of our officers, directors and employees. </span></div><ix:nonNumeric contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMjEvZnJhZzo3NGQ2NzRmYTY0NTQ0YWQzYWVkMGE5MDM4ZTA3OTkwZS90ZXh0cmVnaW9uOjc0ZDY3NGZhNjQ1NDRhZDNhZWQwYTkwMzhlMDc5OTBlXzE4MTA_cb72ab6f-fbd2-4906-8ab2-becc502f7d02" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides total share-based compensation expense by type of award:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted share unit expense</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61e443ff0bb041468d351efdad3a60ec_D20230101-20230331" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMjEvZnJhZzo3NGQ2NzRmYTY0NTQ0YWQzYWVkMGE5MDM4ZTA3OTkwZS90YWJsZTpmM2M4OWNkZjUzNmU0YzVhODZiYzc2YmQ0OWE4OWJkNy90YWJsZXJhbmdlOmYzYzg5Y2RmNTM2ZTRjNWE4NmJjNzZiZDQ5YTg5YmQ3XzItMS0xLTEtMjg2OTQ0_3b999e5b-0090-42f6-a190-b8abd1c81a37">17</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a2edd19ded449568c634ce222c8bf11_D20220101-20220331" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMjEvZnJhZzo3NGQ2NzRmYTY0NTQ0YWQzYWVkMGE5MDM4ZTA3OTkwZS90YWJsZTpmM2M4OWNkZjUzNmU0YzVhODZiYzc2YmQ0OWE4OWJkNy90YWJsZXJhbmdlOmYzYzg5Y2RmNTM2ZTRjNWE4NmJjNzZiZDQ5YTg5YmQ3XzItMy0xLTEtMjg2OTQ0_f8aba577-1e92-4eb5-a9bd-775b3cc85534">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance share unit expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac5b45b6082b4c20bc77e15c6b0dfe4a_D20230101-20230331" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMjEvZnJhZzo3NGQ2NzRmYTY0NTQ0YWQzYWVkMGE5MDM4ZTA3OTkwZS90YWJsZTpmM2M4OWNkZjUzNmU0YzVhODZiYzc2YmQ0OWE4OWJkNy90YWJsZXJhbmdlOmYzYzg5Y2RmNTM2ZTRjNWE4NmJjNzZiZDQ5YTg5YmQ3XzQtMS0xLTEtMjg2OTQ0_4d81e1a7-f241-471e-b92a-f5aeff4634f5">4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cb3c83f18544d88816e14ee29ce253f_D20220101-20220331" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMjEvZnJhZzo3NGQ2NzRmYTY0NTQ0YWQzYWVkMGE5MDM4ZTA3OTkwZS90YWJsZTpmM2M4OWNkZjUzNmU0YzVhODZiYzc2YmQ0OWE4OWJkNy90YWJsZXJhbmdlOmYzYzg5Y2RmNTM2ZTRjNWE4NmJjNzZiZDQ5YTg5YmQ3XzQtMy0xLTEtMjg2OTQ0_e987d088-0fea-4b52-86f5-01b27d0c3808">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total share-based compensation</span></div></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMjEvZnJhZzo3NGQ2NzRmYTY0NTQ0YWQzYWVkMGE5MDM4ZTA3OTkwZS90YWJsZTpmM2M4OWNkZjUzNmU0YzVhODZiYzc2YmQ0OWE4OWJkNy90YWJsZXJhbmdlOmYzYzg5Y2RmNTM2ZTRjNWE4NmJjNzZiZDQ5YTg5YmQ3XzUtMS0xLTEtMjg2OTQ0_9fc700da-1ef8-4eb1-9b72-b879ce3c95f4">21</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMjEvZnJhZzo3NGQ2NzRmYTY0NTQ0YWQzYWVkMGE5MDM4ZTA3OTkwZS90YWJsZTpmM2M4OWNkZjUzNmU0YzVhODZiYzc2YmQ0OWE4OWJkNy90YWJsZXJhbmdlOmYzYzg5Y2RmNTM2ZTRjNWE4NmJjNzZiZDQ5YTg5YmQ3XzUtMy0xLTEtMjg2OTQ0_cd895d7f-bfce-488f-b254-38e3660445ea">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted share unit expense</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de355b6c9f244b0aecf4263ff24158b_D20220701-20230331" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMjEvZnJhZzo3NGQ2NzRmYTY0NTQ0YWQzYWVkMGE5MDM4ZTA3OTkwZS90YWJsZTpmNTM5NDI1N2ZiODg0MTM5OTk2ZmI5NjgwMzEzODQ3NS90YWJsZXJhbmdlOmY1Mzk0MjU3ZmI4ODQxMzk5OTZmYjk2ODAzMTM4NDc1XzItMS0xLTEtMjg2OTQ0_c524c61d-0a3d-4963-9929-7114bcaf54de">49</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4307df7bd4b4ddf85fe23923677a14f_D20210701-20220331" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMjEvZnJhZzo3NGQ2NzRmYTY0NTQ0YWQzYWVkMGE5MDM4ZTA3OTkwZS90YWJsZTpmNTM5NDI1N2ZiODg0MTM5OTk2ZmI5NjgwMzEzODQ3NS90YWJsZXJhbmdlOmY1Mzk0MjU3ZmI4ODQxMzk5OTZmYjk2ODAzMTM4NDc1XzItMy0xLTEtMjg2OTQ0_d0339608-531b-4c77-b049-636ef3456507">53</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance share unit expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9750f858065345b6b71dfdf94a3db05f_D20220701-20230331" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMjEvZnJhZzo3NGQ2NzRmYTY0NTQ0YWQzYWVkMGE5MDM4ZTA3OTkwZS90YWJsZTpmNTM5NDI1N2ZiODg0MTM5OTk2ZmI5NjgwMzEzODQ3NS90YWJsZXJhbmdlOmY1Mzk0MjU3ZmI4ODQxMzk5OTZmYjk2ODAzMTM4NDc1XzQtMS0xLTEtMjg2OTQ0_8b233a1f-6f1e-44e7-8166-90dee03165b8">20</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice80dc50332649f4a2e8211087c1473c_D20210701-20220331" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMjEvZnJhZzo3NGQ2NzRmYTY0NTQ0YWQzYWVkMGE5MDM4ZTA3OTkwZS90YWJsZTpmNTM5NDI1N2ZiODg0MTM5OTk2ZmI5NjgwMzEzODQ3NS90YWJsZXJhbmdlOmY1Mzk0MjU3ZmI4ODQxMzk5OTZmYjk2ODAzMTM4NDc1XzQtMy0xLTEtMjg2OTQ0_b968dbb1-1be9-4247-aa36-404385377148">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total share-based compensation</span></div></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMjEvZnJhZzo3NGQ2NzRmYTY0NTQ0YWQzYWVkMGE5MDM4ZTA3OTkwZS90YWJsZTpmNTM5NDI1N2ZiODg0MTM5OTk2ZmI5NjgwMzEzODQ3NS90YWJsZXJhbmdlOmY1Mzk0MjU3ZmI4ODQxMzk5OTZmYjk2ODAzMTM4NDc1XzUtMS0xLTEtMjg2OTQ0_52508af8-116c-484f-a219-b75d0ae07ff3">69</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMjEvZnJhZzo3NGQ2NzRmYTY0NTQ0YWQzYWVkMGE5MDM4ZTA3OTkwZS90YWJsZTpmNTM5NDI1N2ZiODg0MTM5OTk2ZmI5NjgwMzEzODQ3NS90YWJsZXJhbmdlOmY1Mzk0MjU3ZmI4ODQxMzk5OTZmYjk2ODAzMTM4NDc1XzUtMy0xLTEtMjg2OTQ0_b3e5fde3-f2bd-4836-bf88-726027c454a7">65</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total tax benefit related to share-based compensation was $<ix:nonFraction unitRef="usd" contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMjEvZnJhZzo3NGQ2NzRmYTY0NTQ0YWQzYWVkMGE5MDM4ZTA3OTkwZS90ZXh0cmVnaW9uOjc0ZDY3NGZhNjQ1NDRhZDNhZWQwYTkwMzhlMDc5OTBlXzI5Mw_33e36649-b168-43d6-b5f8-405db208cb44"><ix:nonFraction unitRef="usd" contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMjEvZnJhZzo3NGQ2NzRmYTY0NTQ0YWQzYWVkMGE5MDM4ZTA3OTkwZS90ZXh0cmVnaW9uOjc0ZDY3NGZhNjQ1NDRhZDNhZWQwYTkwMzhlMDc5OTBlXzI5Mw_67fe6db2-127d-4552-94c5-8f89698406ce">3</ix:nonFraction></ix:nonFraction> million for both the three months ended March&#160;31, 2023 and 2022, and $<ix:nonFraction unitRef="usd" contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMjEvZnJhZzo3NGQ2NzRmYTY0NTQ0YWQzYWVkMGE5MDM4ZTA3OTkwZS90ZXh0cmVnaW9uOjc0ZDY3NGZhNjQ1NDRhZDNhZWQwYTkwMzhlMDc5OTBlXzM1OQ_78c71c2a-ba1e-467c-8570-f2b42b745f52"><ix:nonFraction unitRef="usd" contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMjEvZnJhZzo3NGQ2NzRmYTY0NTQ0YWQzYWVkMGE5MDM4ZTA3OTkwZS90ZXh0cmVnaW9uOjc0ZDY3NGZhNjQ1NDRhZDNhZWQwYTkwMzhlMDc5OTBlXzM1OQ_8f0b4362-118f-4719-bf20-f6b89b7f4254">9</ix:nonFraction></ix:nonFraction> million for both the nine months ended March&#160;31, 2023 and 2022.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Restricted Share Units</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted share units granted under the Plans generally vest in equal annual installments over <ix:nonNumeric contextRef="i7de355b6c9f244b0aecf4263ff24158b_D20220701-20230331" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMjEvZnJhZzo3NGQ2NzRmYTY0NTQ0YWQzYWVkMGE5MDM4ZTA3OTkwZS90ZXh0cmVnaW9uOjc0ZDY3NGZhNjQ1NDRhZDNhZWQwYTkwMzhlMDc5OTBlXzUwOA_d49b26a3-a0d6-496f-ac57-e594a26b488f">three years</ix:nonNumeric>. Restricted share units accrue cash dividend equivalents that are payable upon vesting of the awards.</span></div><ix:nonNumeric contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMjEvZnJhZzo3NGQ2NzRmYTY0NTQ0YWQzYWVkMGE5MDM4ZTA3OTkwZS90ZXh0cmVnaW9uOjc0ZDY3NGZhNjQ1NDRhZDNhZWQwYTkwMzhlMDc5OTBlXzE4MDA_5fb509aa-de5a-4117-a655-eee3bf130a80" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes all transactions related to restricted share units under the Plans:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:51.221%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.714%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.218%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Share Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair<br/>Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nonvested at June 30, 2022</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia8acc2cf603d4cec94d38cdf7947bf8c_I20220630" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMjEvZnJhZzo3NGQ2NzRmYTY0NTQ0YWQzYWVkMGE5MDM4ZTA3OTkwZS90YWJsZTpjOTUzODQ1YTdhN2Y0ZDJkOTc1N2Q1NGQzOTU0ZDA4ZS90YWJsZXJhbmdlOmM5NTM4NDVhN2E3ZjRkMmQ5NzU3ZDU0ZDM5NTRkMDhlXzEtMS0xLTEtMjg2OTQ0_282d2bd2-fb8a-4052-92d7-3b6c3ba21fc2">2.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia8acc2cf603d4cec94d38cdf7947bf8c_I20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMjEvZnJhZzo3NGQ2NzRmYTY0NTQ0YWQzYWVkMGE5MDM4ZTA3OTkwZS90YWJsZTpjOTUzODQ1YTdhN2Y0ZDJkOTc1N2Q1NGQzOTU0ZDA4ZS90YWJsZXJhbmdlOmM5NTM4NDVhN2E3ZjRkMmQ5NzU3ZDU0ZDM5NTRkMDhlXzEtMy0xLTEtMjg2OTQ0_f17a48d7-48bc-4317-9e09-05b186819900">46.03</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7de355b6c9f244b0aecf4263ff24158b_D20220701-20230331" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMjEvZnJhZzo3NGQ2NzRmYTY0NTQ0YWQzYWVkMGE5MDM4ZTA3OTkwZS90YWJsZTpjOTUzODQ1YTdhN2Y0ZDJkOTc1N2Q1NGQzOTU0ZDA4ZS90YWJsZXJhbmdlOmM5NTM4NDVhN2E3ZjRkMmQ5NzU3ZDU0ZDM5NTRkMDhlXzItMS0xLTEtMjg2OTQ0_3b8e4c4f-d6b9-4c96-b126-78b34abbc19d">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7de355b6c9f244b0aecf4263ff24158b_D20220701-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMjEvZnJhZzo3NGQ2NzRmYTY0NTQ0YWQzYWVkMGE5MDM4ZTA3OTkwZS90YWJsZTpjOTUzODQ1YTdhN2Y0ZDJkOTc1N2Q1NGQzOTU0ZDA4ZS90YWJsZXJhbmdlOmM5NTM4NDVhN2E3ZjRkMmQ5NzU3ZDU0ZDM5NTRkMDhlXzItMy0xLTEtMjg2OTQ0_5278f09a-a808-4f0d-8621-4b9215a5c437">70.26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i7de355b6c9f244b0aecf4263ff24158b_D20220701-20230331" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMjEvZnJhZzo3NGQ2NzRmYTY0NTQ0YWQzYWVkMGE5MDM4ZTA3OTkwZS90YWJsZTpjOTUzODQ1YTdhN2Y0ZDJkOTc1N2Q1NGQzOTU0ZDA4ZS90YWJsZXJhbmdlOmM5NTM4NDVhN2E3ZjRkMmQ5NzU3ZDU0ZDM5NTRkMDhlXzMtMS0xLTEtMjg2OTQ0_2934a99b-0c8c-4688-9f6b-5fd56f2bbb90">1.3</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7de355b6c9f244b0aecf4263ff24158b_D20220701-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMjEvZnJhZzo3NGQ2NzRmYTY0NTQ0YWQzYWVkMGE5MDM4ZTA3OTkwZS90YWJsZTpjOTUzODQ1YTdhN2Y0ZDJkOTc1N2Q1NGQzOTU0ZDA4ZS90YWJsZXJhbmdlOmM5NTM4NDVhN2E3ZjRkMmQ5NzU3ZDU0ZDM5NTRkMDhlXzMtMy0xLTEtMjg2OTQ0_5893dbf6-e2c4-4535-893f-516a3ed091fb">50.03</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i7de355b6c9f244b0aecf4263ff24158b_D20220701-20230331" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMjEvZnJhZzo3NGQ2NzRmYTY0NTQ0YWQzYWVkMGE5MDM4ZTA3OTkwZS90YWJsZTpjOTUzODQ1YTdhN2Y0ZDJkOTc1N2Q1NGQzOTU0ZDA4ZS90YWJsZXJhbmdlOmM5NTM4NDVhN2E3ZjRkMmQ5NzU3ZDU0ZDM5NTRkMDhlXzQtMS0xLTEtMjg2OTQ0_de91d07d-05eb-4c76-83ac-cf4ea8296e70">0.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7de355b6c9f244b0aecf4263ff24158b_D20220701-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMjEvZnJhZzo3NGQ2NzRmYTY0NTQ0YWQzYWVkMGE5MDM4ZTA3OTkwZS90YWJsZTpjOTUzODQ1YTdhN2Y0ZDJkOTc1N2Q1NGQzOTU0ZDA4ZS90YWJsZXJhbmdlOmM5NTM4NDVhN2E3ZjRkMmQ5NzU3ZDU0ZDM5NTRkMDhlXzQtMy0xLTEtMjg2OTQ0_48fcf82a-384b-4a15-93e1-e2cbd3d2de23">58.30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nonvested at March 31, 2023</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia7a3dc6029084cef92896c48e8a19a01_I20230331" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMjEvZnJhZzo3NGQ2NzRmYTY0NTQ0YWQzYWVkMGE5MDM4ZTA3OTkwZS90YWJsZTpjOTUzODQ1YTdhN2Y0ZDJkOTc1N2Q1NGQzOTU0ZDA4ZS90YWJsZXJhbmdlOmM5NTM4NDVhN2E3ZjRkMmQ5NzU3ZDU0ZDM5NTRkMDhlXzUtMS0xLTEtMjg2OTQ0_06388dcd-5daa-4a25-88fc-3395cc2d34a5">2.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia7a3dc6029084cef92896c48e8a19a01_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMjEvZnJhZzo3NGQ2NzRmYTY0NTQ0YWQzYWVkMGE5MDM4ZTA3OTkwZS90YWJsZTpjOTUzODQ1YTdhN2Y0ZDJkOTc1N2Q1NGQzOTU0ZDA4ZS90YWJsZXJhbmdlOmM5NTM4NDVhN2E3ZjRkMmQ5NzU3ZDU0ZDM5NTRkMDhlXzUtMy0xLTEtMjg2OTQ0_c8a9e106-3b9a-45ed-b60b-c3259caaac87">57.14</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2023, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested restricted share units </span></div></ix:nonNumeric></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><ix:continuation id="id5b7d1b416e7449c8e5b05f89392f8eb"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">not yet recognized was $<ix:nonFraction unitRef="usd" contextRef="ia7a3dc6029084cef92896c48e8a19a01_I20230331" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMjEvZnJhZzo3NGQ2NzRmYTY0NTQ0YWQzYWVkMGE5MDM4ZTA3OTkwZS90ZXh0cmVnaW9uOjc0ZDY3NGZhNjQ1NDRhZDNhZWQwYTkwMzhlMDc5OTBlXzg1NQ_3bbc5362-f753-4829-9d4e-334f77146ff3">87</ix:nonFraction> million, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="i7de355b6c9f244b0aecf4263ff24158b_D20220701-20230331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMjEvZnJhZzo3NGQ2NzRmYTY0NTQ0YWQzYWVkMGE5MDM4ZTA3OTkwZS90ZXh0cmVnaW9uOjc0ZDY3NGZhNjQ1NDRhZDNhZWQwYTkwMzhlMDc5OTBlXzkyOA_deb70b92-5964-49b8-bc37-fe53b4a24fc1">two years</ix:nonNumeric>.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Performance Share Units</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance share units vest over a <ix:nonFraction unitRef="number" contextRef="i9750f858065345b6b71dfdf94a3db05f_D20220701-20230331" decimals="INF" name="cah:VestingPeriodinyearsforShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMjEvZnJhZzo3NGQ2NzRmYTY0NTQ0YWQzYWVkMGE5MDM4ZTA3OTkwZS90ZXh0cmVnaW9uOjc0ZDY3NGZhNjQ1NDRhZDNhZWQwYTkwMzhlMDc5OTBlXzk5Mg_822a0039-3f79-43e2-826d-259099b9c1c4">3</ix:nonFraction>-year performance period based on achievement of specific performance goals. Based on the extent to which the targets are achieved, vested shares may range from <ix:nonFraction unitRef="number" contextRef="i34b2dbad9e7648de967669561a47dd81_D20220701-20230331" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMjEvZnJhZzo3NGQ2NzRmYTY0NTQ0YWQzYWVkMGE5MDM4ZTA3OTkwZS90ZXh0cmVnaW9uOjc0ZDY3NGZhNjQ1NDRhZDNhZWQwYTkwMzhlMDc5OTBlXzEyMzE_32eb6414-bd07-4d9d-9354-e27e5a5ec693">zero</ix:nonFraction> to <ix:nonFraction unitRef="number" contextRef="i2fbe5a679b3841fcb8bbd7dfa64915ad_D20220701-20230331" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMjEvZnJhZzo3NGQ2NzRmYTY0NTQ0YWQzYWVkMGE5MDM4ZTA3OTkwZS90ZXh0cmVnaW9uOjc0ZDY3NGZhNjQ1NDRhZDNhZWQwYTkwMzhlMDc5OTBlXzEyMzc_7bd8b84a-9621-4e7b-80f4-a54d66c8cefc">234</ix:nonFraction> percent of the target award amount. Performance share units accrue cash dividend equivalents that are payable upon vesting of the awards.</span></div><ix:nonNumeric contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331" name="us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMjEvZnJhZzo3NGQ2NzRmYTY0NTQ0YWQzYWVkMGE5MDM4ZTA3OTkwZS90ZXh0cmVnaW9uOjc0ZDY3NGZhNjQ1NDRhZDNhZWQwYTkwMzhlMDc5OTBlXzE3ODM_f42fad25-93b8-4605-8afb-d107ec93a02c" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:49.983%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.023%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.147%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Performance<br/>Share Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair<br/>Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nonvested at June 30, 2022</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifab2ddff45a44bc58da3784419071ae5_I20220630" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMjEvZnJhZzo3NGQ2NzRmYTY0NTQ0YWQzYWVkMGE5MDM4ZTA3OTkwZS90YWJsZToxMWNlZjRhY2Q3YjE0M2VkOTdkMTRiYWU5NmVhYmYwMC90YWJsZXJhbmdlOjExY2VmNGFjZDdiMTQzZWQ5N2QxNGJhZTk2ZWFiZjAwXzEtMS0xLTEtMjg2OTQ0_1b3839bd-aaa4-4c00-b41e-a1de266a72c5">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifab2ddff45a44bc58da3784419071ae5_I20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMjEvZnJhZzo3NGQ2NzRmYTY0NTQ0YWQzYWVkMGE5MDM4ZTA3OTkwZS90YWJsZToxMWNlZjRhY2Q3YjE0M2VkOTdkMTRiYWU5NmVhYmYwMC90YWJsZXJhbmdlOjExY2VmNGFjZDdiMTQzZWQ5N2QxNGJhZTk2ZWFiZjAwXzEtMy0xLTEtMjg2OTQ0_4bcabfd9-2b64-43c8-b51d-5c4c6234b316">54.32</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9750f858065345b6b71dfdf94a3db05f_D20220701-20230331" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMjEvZnJhZzo3NGQ2NzRmYTY0NTQ0YWQzYWVkMGE5MDM4ZTA3OTkwZS90YWJsZToxMWNlZjRhY2Q3YjE0M2VkOTdkMTRiYWU5NmVhYmYwMC90YWJsZXJhbmdlOjExY2VmNGFjZDdiMTQzZWQ5N2QxNGJhZTk2ZWFiZjAwXzItMS0xLTEtMjg2OTQ0_b7dc104e-2976-46b5-b03b-4e0e55e270b6">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9750f858065345b6b71dfdf94a3db05f_D20220701-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMjEvZnJhZzo3NGQ2NzRmYTY0NTQ0YWQzYWVkMGE5MDM4ZTA3OTkwZS90YWJsZToxMWNlZjRhY2Q3YjE0M2VkOTdkMTRiYWU5NmVhYmYwMC90YWJsZXJhbmdlOjExY2VmNGFjZDdiMTQzZWQ5N2QxNGJhZTk2ZWFiZjAwXzItMy0xLTEtMjg2OTQ0_5cfc93ec-12b1-4ff6-bcd1-7dd7f640440b">70.52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i9750f858065345b6b71dfdf94a3db05f_D20220701-20230331" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMjEvZnJhZzo3NGQ2NzRmYTY0NTQ0YWQzYWVkMGE5MDM4ZTA3OTkwZS90YWJsZToxMWNlZjRhY2Q3YjE0M2VkOTdkMTRiYWU5NmVhYmYwMC90YWJsZXJhbmdlOjExY2VmNGFjZDdiMTQzZWQ5N2QxNGJhZTk2ZWFiZjAwXzMtMS0xLTEtMjg2OTQ0_76451eb2-b8dd-4c85-bcde-f6f3253c18ff">0.4</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9750f858065345b6b71dfdf94a3db05f_D20220701-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMjEvZnJhZzo3NGQ2NzRmYTY0NTQ0YWQzYWVkMGE5MDM4ZTA3OTkwZS90YWJsZToxMWNlZjRhY2Q3YjE0M2VkOTdkMTRiYWU5NmVhYmYwMC90YWJsZXJhbmdlOjExY2VmNGFjZDdiMTQzZWQ5N2QxNGJhZTk2ZWFiZjAwXzMtMy0xLTEtMjg2OTQ0_585db14e-8816-417d-ba3c-e3d0af852a0d">59.04</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i9750f858065345b6b71dfdf94a3db05f_D20220701-20230331" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMjEvZnJhZzo3NGQ2NzRmYTY0NTQ0YWQzYWVkMGE5MDM4ZTA3OTkwZS90YWJsZToxMWNlZjRhY2Q3YjE0M2VkOTdkMTRiYWU5NmVhYmYwMC90YWJsZXJhbmdlOjExY2VmNGFjZDdiMTQzZWQ5N2QxNGJhZTk2ZWFiZjAwXzQtMS0xLTEtMjg2OTQ0_4c02c5f8-3226-4995-8438-aa158ab18574">0.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9750f858065345b6b71dfdf94a3db05f_D20220701-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMjEvZnJhZzo3NGQ2NzRmYTY0NTQ0YWQzYWVkMGE5MDM4ZTA3OTkwZS90YWJsZToxMWNlZjRhY2Q3YjE0M2VkOTdkMTRiYWU5NmVhYmYwMC90YWJsZXJhbmdlOjExY2VmNGFjZDdiMTQzZWQ5N2QxNGJhZTk2ZWFiZjAwXzQtMy0xLTEtMjg2OTQ0_d3be355a-af53-4b09-ad6f-d39ef2ecbfb7">65.59</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nonvested at March 31, 2023</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iace1106122bd40149cc5c5765c33fb32_I20230331" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMjEvZnJhZzo3NGQ2NzRmYTY0NTQ0YWQzYWVkMGE5MDM4ZTA3OTkwZS90YWJsZToxMWNlZjRhY2Q3YjE0M2VkOTdkMTRiYWU5NmVhYmYwMC90YWJsZXJhbmdlOjExY2VmNGFjZDdiMTQzZWQ5N2QxNGJhZTk2ZWFiZjAwXzUtMS0xLTEtMjg2OTQ0_94673bf5-8918-4d4c-8fb8-9f121f7a07ac">1.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iace1106122bd40149cc5c5765c33fb32_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMjEvZnJhZzo3NGQ2NzRmYTY0NTQ0YWQzYWVkMGE5MDM4ZTA3OTkwZS90YWJsZToxMWNlZjRhY2Q3YjE0M2VkOTdkMTRiYWU5NmVhYmYwMC90YWJsZXJhbmdlOjExY2VmNGFjZDdiMTQzZWQ5N2QxNGJhZTk2ZWFiZjAwXzUtMy0xLTEtMjg2OTQ0_2e647015-3a7c-4644-9b2d-c478d35eaed7">76.24</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2023, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested performance share units not yet recognized was $<ix:nonFraction unitRef="usd" contextRef="iace1106122bd40149cc5c5765c33fb32_I20230331" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMjEvZnJhZzo3NGQ2NzRmYTY0NTQ0YWQzYWVkMGE5MDM4ZTA3OTkwZS90ZXh0cmVnaW9uOjc0ZDY3NGZhNjQ1NDRhZDNhZWQwYTkwMzhlMDc5OTBlXzE2NTU_a3c307af-980b-4fe7-993e-67f3dbaf9667">39</ix:nonFraction> million, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="i9750f858065345b6b71dfdf94a3db05f_D20220701-20230331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMjEvZnJhZzo3NGQ2NzRmYTY0NTQ0YWQzYWVkMGE5MDM4ZTA3OTkwZS90ZXh0cmVnaW9uOjc0ZDY3NGZhNjQ1NDRhZDNhZWQwYTkwMzhlMDc5OTBlXzE3Mjg_17baa54e-f600-4020-a4c4-1609a7d67302">two years</ix:nonNumeric> if performance goals are achieved.</span></div></ix:continuation></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">43</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i1d34fc4fc2424fbcb4837cc9f1c0665c_124"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="-sec-extract:summary;margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.757%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.338%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibits</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="-sec-extract:summary;margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Exhibits</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.353%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit<br/>Number</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/721371/000119312508230011/dex31.htm">Amended and Restated Articles of Incorporation of Cardinal Health, Inc., as amended (incorporated by reference to Exhibit 3.1 to Cardinal Health&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2008, File No. 1-11373)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/721371/000072137121000116/restatedcodeofregulationsn.htm">Cardinal Health, Inc. Restated Code of Regulations, as amended  (incorporated by reference to Exhibit 3.2 to Cardinal Health&#8217;s Quarterly Report on Form 10-Q filed on November 9, 2021, File No. 1-11373)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/721371/000072137123000014/a20230200-exhibit101.htm">Third Amended and Restated Five-Year Credit Agreement, dated as of February 27, 2023 (incorporated by reference to Exhibit 10.1 to Cardinal Health's Current Report on Form 8-K filed on March 2, 2023, File No. 1-11373)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="a23q3_10qx33123xexhibit311.htm">Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="a23q3_10qx33123xexhibit312.htm">Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="a23q3_10qx33123xexhibit321.htm">Certification of the Chief Executive Officer and the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="a23q3_10qx33123xexhibit991.htm">Statement Regarding Forward-Looking Information</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Definition Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cover Page Interactive Data File - formatted in Inline XBRL (included as Exhibit 101)</span></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#ff0000;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Cardinal Health Website</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cardinal Health&#160;uses its website as a channel of distribution for material company information. Important information, including news releases, financial information, earnings and analyst presentations, and information about upcoming presentations and events is routinely posted and accessible at ir.cardinalhealth.com. In addition, the website allows investors and other interested persons to sign up automatically to receive e-mail alerts when we post news releases,&#160;SEC filings and certain other information on its website.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="-sec-extract:summary;margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">44</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i1d34fc4fc2424fbcb4837cc9f1c0665c_127"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.115%"><tr><td style="width:1.0%"></td><td style="width:27.471%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.306%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Form 10-Q Cross Reference Index</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Form 10-Q Cross Reference Index</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.489%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.167%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part I. Financial Information</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d34fc4fc2424fbcb4837cc9f1c0665c_61">Financial Statements </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i1d34fc4fc2424fbcb4837cc9f1c0665c_61">26</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d34fc4fc2424fbcb4837cc9f1c0665c_13">Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i1d34fc4fc2424fbcb4837cc9f1c0665c_13">2</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d34fc4fc2424fbcb4837cc9f1c0665c_43">Quantitative and Qualitative Disclosures about Market Risk </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i1d34fc4fc2424fbcb4837cc9f1c0665c_43">21</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d34fc4fc2424fbcb4837cc9f1c0665c_46">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i1d34fc4fc2424fbcb4837cc9f1c0665c_46">21</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part II. Other Information</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d34fc4fc2424fbcb4837cc9f1c0665c_49">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i1d34fc4fc2424fbcb4837cc9f1c0665c_49">22</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d34fc4fc2424fbcb4837cc9f1c0665c_52">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i1d34fc4fc2424fbcb4837cc9f1c0665c_52">23</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d34fc4fc2424fbcb4837cc9f1c0665c_55">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i1d34fc4fc2424fbcb4837cc9f1c0665c_55">25</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Defaults Upon Senior Securities </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mine Safety Disclosures </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 5</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Information</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 6</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d34fc4fc2424fbcb4837cc9f1c0665c_124">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i1d34fc4fc2424fbcb4837cc9f1c0665c_124">44</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d34fc4fc2424fbcb4837cc9f1c0665c_130">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i1d34fc4fc2424fbcb4837cc9f1c0665c_130">46</a></span></div></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:3.221%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.739%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Not applicable</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">45</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i1d34fc4fc2424fbcb4837cc9f1c0665c_130"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:24.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.322%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.075%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additional Information</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Signatures</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.182%"><tr><td style="width:1.0%"></td><td style="width:4.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.300%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health, Inc.</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 4, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;JASON M. HOLLAR</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jason M. Hollar</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Executive Officer</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ AARON E. ALT</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aaron E. Alt</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Financial Officer</span></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">46</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>a23q3_10qx33123xexhibit311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i91d83f5a36d14841b6e4285582317368_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:31.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.282%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 31.1</font></td></tr></table></div><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Jason M. Hollar, certify that&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.16pt">I have reviewed this Form 10-Q of Cardinal Health, Inc.&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.16pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.16pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.16pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.46pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.16pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; May&#160;4, 2023 </font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:470.25pt"><tr><td style="width:1.0pt"></td><td style="width:147.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:319.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; JASON M. HOLLAR</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jason M. Hollar</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>a23q3_10qx33123xexhibit312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="id0de2430746f43c5b6e1989e36641815_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:31.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.282%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 31.2</font></td></tr></table></div><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Aaron E. Alt, certify that&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.16pt">I have reviewed this Form 10-Q of Cardinal Health, Inc.&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.16pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.16pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.16pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.46pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.16pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; May&#160;4, 2023 </font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:136.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:372.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; AARON E. ALT</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aaron E. Alt</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>a23q3_10qx33123xexhibit321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ib1520c100d1e4ba4a2e920d028d85700_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:31.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.282%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 32.1</font></td></tr></table></div><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Certification of the Chief Executive Officer and the Chief Financial Officer Pursuant to 18 U.S.C. Section&#160;1350, as Adopted </font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jason M. Hollar, Chief Executive Officer of Cardinal Health, Inc. (the &#8220;Company&#8221;) and Aaron E. Alt, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section&#160;1350, that&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26pt">the Periodic Report on Form 10-Q for the quarter ended March&#160;31, 2023 containing the financial statements of the Company (the &#8220;Periodic Report&#8221;), which this statement accompanies, fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d))&#59; and</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26pt">the information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated&#58; May&#160;4, 2023 </font></div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:69.031%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.769%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; JASON M. HOLLAR</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jason M. Hollar</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer </font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:69.031%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.769%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; AARON E. ALT</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aaron E. Alt</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>5
<FILENAME>a23q3_10qx33123xexhibit991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i26c7b1aab5244ec7a76b25628f02e09e_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:31.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.282%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 99.1</font></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Statement Regarding Forward-Looking Information </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As used in this exhibit, &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us&#8221; and similar pronouns refer to Cardinal Health, Inc. and its subsidiaries, unless the context requires otherwise. Our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the fiscal year ended June&#160;30, 2022 (the &#8220;2022 Form 10-K&#8221;), and our quarterly reports on Form 10-Q, including this one, and our current reports on Form 8-K (along with any exhibits and amendments to such reports), as well as our news releases or any other written or oral statements made by or on behalf of us, including materials posted on our website, may include, directly or by incorporation by reference, forward-looking statements that reflect our current view (as of the date the forward-looking statement is first made) about future events, prospects, projections or financial performance. The matters discussed in these forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied in or by such statements. These risks and uncertainties include&#58;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">competitive pressures in the markets in which we operate, including pricing pressures&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">uncertainties relating to the pricing of and demand for generic pharmaceuticals&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">significantly increased costs for commodities and other materials used in the Medical segment manufacturing, including various components, compounds, raw materials or energy such as oil-based resins, pulp, cotton, latex and other commodities and the possibility that we may not successfully offset or mitigate these increases&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">uncertainties relating to the timing, frequency and profitability of generic pharmaceutical launches or other components of our pharmaceutical generics program&#59;  </font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">changes in manufacturer approaches to pricing branded pharmaceutical products and risks related to our compensation under contractual arrangements with manufacturers being set as a percentage of the wholesale acquisition cost of branded pharmaceuticals and where a part of our compensation is based on branded pharmaceutical price appreciation, changes in the magnitude of such price appreciation&#59; </font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">changes in the timing or frequency of the introduction of branded pharmaceuticals&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">continuing risks associated with the resolution and defense of the lawsuits and investigations in which we have been or will be named relating to the distribution of prescription opioid pain medication, including the investigations by the Department of Justice which we believe concern our anti-diversion program, our anti-diversion policies and procedures and our distribution of certain controlled substances&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks associated with the national settlement agreement to resolve the vast majority of opioid-related claims brought by states and other governmental entities, including the risk that the implementation and maintenance of the required changes to distributors' controlled substance anti-diversion programs may result in unforeseen costs or operational challenges and the risk that if we fail to or are alleged to have failed to comply with the terms of the settlement agreement, we could incur monetary or other penalties or result in additional lawsuits being filed against us&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">potential damage to our reputation, adverse operational impacts or other effects that may result from the national opioid epidemic, the allegations that have been made about our role in such epidemic and the ongoing unfavorable publicity surrounding the lawsuits and investigations against us&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks associated with the tax benefit from our self-insurance loss claims, including risks associated with the letter certain industry participants, including us, received from the U.S. House of Representatives' Committee on Oversight and Reform questioning, among other things, our plans to take tax deductions for opioid-related losses, including the net operating loss carryback provisions under the CARES Act and deductibility under the Tax Act&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks associated with our Corporate Integrity Agreement with the Office of Inspector General of the Department of Health and Human Services, including the risk that failure to comply with the requirements set forth therein could result in monetary or other penalties&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">the possibility of additional adverse impacts to our financial results from enacted and proposed state taxes or other assessments on the sale or distribution of opioid medications&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">our high sales concentration with certain key customers, including CVS Health Corporation and OptumRx&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">our ability to maintain the benefits of our generic pharmaceutical sourcing venture with CVS Health Corporation&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">costs or claims resulting from quality issues, whether related to the manufacture of some of our sterile surgical gowns or pre-filled syringes, or other potential errors or defects in our manufacturing of medical devices or other products or in our compounding, repackaging, information systems or pharmacy management services that may injure persons or damage property or operations, including costs from recalls, remediation efforts, and related product liability claims and lawsuits, including class action lawsuits&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">actions of regulatory bodies and other governmental authorities, including the U.S. Drug Enforcement Administration, certain agencies within the U.S. Department of Health and Human Services (including the U.S. Food and Drug Administration, Centers for Medicare and Medicaid Services, the Office of Inspector General and the Office for Civil Rights), the U.S. Nuclear Regulatory Commission, the U.S. Federal Trade Commission, the U.S. Customs and Border Protection, various state boards of pharmacy, state controlled substance authorities, state health departments, state insurance departments, state Medicaid departments or comparable regulatory bodies or governmental authorities or foreign equivalents that, in each case, could delay, limit or suspend product development, manufacturing, distribution, importation or sales or result in warning letters, recalls, seizures, injunctions or monetary sanctions&#59;</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">any compromise of our information systems or of those of a third-party service provider, including unauthorized access to or use or disclosure of company or customer information, disruption of access and ancillary risks associated with our ability to effectively manage any issues arising from any such compromise or disruption&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">shortages in commodities, components, compounds, raw materials or energy used by our businesses, including supply disruptions of radioisotopes&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">the loss of, or default by, one or more key suppliers for which alternative suppliers may not be readily available&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">uncertainties related to our Medical segment's Cardinal Health Brand products, including our ability to manage cost, infrastructure and to retain margin or improve its performance&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks associated with the realignment of our Medical segment's supply chain and other businesses, including our ability to achieve the expected benefits from such realignment&#59; </font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">uncertainties with respect to our cost-savings initiatives or IT infrastructure activities, including the ability to achieve the expected benefits from such initiatives, the risk that we could incur unexpected charges, and the risk that we may fail to retain key personnel&#59; </font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">difficulties or delays in the development, production, manufacturing, sourcing and marketing of new or existing products and services, including difficulties or delays associated with obtaining or maintaining requisite regulatory consents, whether our own or third parties', or approvals associated with those activities&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">manufacturing disruptions, whether due to regulatory action, including regulatory action to reduce Ethylene Oxide emissions, production quality deviations, safety issues or raw material shortages or defects, or because a key product is manufactured at a single manufacturing facility with limited alternate facilities&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks associated with industry reliance on ethylene oxide (&#34;EtO&#34;) to sterilize certain medical products that we manufacture or distribute, including the possibility that regulatory actions to reduce EtO emissions could become more widespread, which may result in increased costs or supply shortages&#59; and risks that the lawsuits against us alleging personal injury resulting from EtO exposure could become more widespread&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">the possibility that we could be subject to adverse changes in the tax laws or challenges to our tax positions, including the possibility that the corporate tax rate in the U.S. could be increased&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks arising from possible violations of healthcare fraud and abuse laws&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks arising from possible violations of the U.S. Foreign Corrupt Practices Act and other similar anti-corruption laws in other jurisdictions and U.S. and foreign export control, trade embargo and customs laws&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks arising from our collecting, handling and maintaining patient-identifiable health information and other sensitive personal and financial information, which are subject to federal, state and foreign laws that regulate the use and disclosure of such information&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks arising from certain of our businesses being Medicare-certified suppliers or participating in other federal and state healthcare programs, such as state Medicaid programs and the federal 340B drug pricing program, which businesses are subject to accreditation and quality standards and other rules and regulations, including applicable reporting, billing, payment and record-keeping requirements&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks arising from pharmaceutical manufacturers' restriction of sales under the 340B drug pricing program to contract pharmacies, which may adversely impact our customers&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks arising from certain of our businesses manufacturing pharmaceutical and medical products or repackaging pharmaceuticals that are purchased or reimbursed through, or are otherwise governed by, federal or state healthcare programs, which businesses are subject to federal and state laws that establish eligibility for reimbursement by such programs and other applicable standards and regulations&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">changes in laws or changes in the interpretation or application of laws or regulations, as well as possible failures to comply with applicable laws or regulations, including as a result of possible misinterpretations or misapplications&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">material reductions in purchases, pricing changes, non-renewal, early termination, or delinquencies or defaults under contracts with key customers&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">unfavorable changes to the terms or with our ability to meet contractual obligations of key customer or supplier relationships, or changes in customer mix&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks arising from changes in U.S. or foreign tax laws and unfavorable challenges to our tax positions and payments to settle these challenges, which may adversely affect our effective tax rate or tax payments&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">uncertainties due to possible government healthcare reform, including proposals related to Medicare drug rebate arrangements, possible repeal or replacement of major parts of the Patient Protection and Affordable Care Act, proposals related to prescription drug pricing transparency and the possible adoption of Medicare-For-All&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">reductions or limitations on governmental funding at the state or federal level or efforts by healthcare insurance companies to limit payments for products and services&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">changes in manufacturers' pricing, selling, inventory, distribution or supply policies or practices&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">changes in legislation or regulations governing prescription drug pricing, healthcare services or mandated benefits&#59;</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">uncertainties arising as a result of the Supreme Court decision on Dobbs vs. Jackson, including uncertainties associated with states' proposed and adopted laws which may impact our ability to distribute or store certain pharmaceutical products and the risk that we could incur unforeseen costs to comply with these new laws in various jurisdictions&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">changes in hospital buying groups or hospital buying practices&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">changes in distribution or sourcing models for pharmaceutical and medical and surgical products, including an increase in direct and limited distribution&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">changes to the prescription drug reimbursement formula and related reporting requirements for generic pharmaceuticals under Medicaid&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">continuing consolidation in the healthcare industry, which could give the resulting enterprises greater bargaining power and may increase pressure on prices for our products and services or result in the loss of customers&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">disruption, damage or lack of access to, or failure of, our or our third-party service providers' information systems, our critical facilities, including our national logistics center, or our distribution networks&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks to our business and information and controls systems in the event that business process improvements, infrastructure modernizations or initiatives to use third-party service providers for key systems and processes are not effectively implemented&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">the risk that we may not effectively implement and maintain data governance structures across businesses to allow us to access and interpret our data, which could put us at a competitive disadvantage relative to our peers&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">the results, costs, effects or timing of any commercial disputes, government contract compliance matters, patent infringement claims, </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> actions, government investigations, shareholder lawsuits or other legal proceedings&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">the possibility that our business performance or internal control over financial reporting may be adversely impacted if we are not successful at attracting, retaining and developing talent&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">losses relating to product liability lawsuits and claims regarding products for which we cannot obtain product liability insurance or for which such insurance may not be adequate to cover our losses, including the product liability lawsuits we are currently defending relating to alleged personal injuries associated with the use of Cordis inferior vena cava filter products&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks associated with the importation of products or source materials used in products that we manufacture or distribute, including risks associated with our country-of-origin determinations and the possibility that we could experience supply disruptions as a result of the Uyghur Forced Labor Prevention Act&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">our ability to maintain adequate intellectual property protections&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">the costs, difficulties and uncertainties related to the integration of acquired businesses, including liabilities relating to the operations or activities of such businesses prior to their acquisition, and uncertainties relating to our ability to achieve the anticipated results from acquisitions&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks associated with the divestiture of the Cordis business, including the risk that the costs associated with exit or disposal activities could ultimately be greater than we currently expect or that we could incur greater stranded costs than expected&#59; </font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">our ability to manage and complete divestitures or other strategic business combination transactions, including our ability to find buyers or other strategic exit opportunities and risks associated with the possibility that we could experience greater dis-synergies than anticipated or otherwise fail to achieve our strategic objectives&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">bankruptcy, insolvency or other credit failure of a customer or supplier that owes us a substantial amount&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks associated with global operations, including the effect of local economic environments, inflation, recession, currency volatility and global competition, in addition to risks associated with compliance with U.S. and international laws relating to global operations&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">uncertainties with respect to U.S. or international trade policies, tariffs, excise or border taxes and their impact on our ability to source products or materials that we need to conduct our business&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks associated with our use of and reliance on the global capital and credit markets, including our ability to access credit and our cost of credit, which may adversely affect our ability to efficiently fund our operations or undertake certain expenditures&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">our ability to introduce and market new products and our ability to keep pace with advances in technology&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">significant charges to earnings if goodwill or intangible assets become impaired&#59; </font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">uncertainties relating to general political, business, industry, regulatory and market conditions&#59; </font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">certain risks arising from the ongoing COVID-19 pandemic&#59; and</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">other factors described in the &#8220;Risk Factors&#8221; section of the 2022 Form 10-K.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The words &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;believe,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;project,&#8221; &#8220;continue,&#8221; &#8220;likely,&#8221; and similar expressions generally identify &#8220;forward-looking statements,&#8221; which speak only as of the date the statements were made, and also include statements reflecting future results or guidance, statements of outlook and expense accruals. We undertake no obligation to update or revise any forward-looking statements, except to the extent required by applicable law.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>cah-20230331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:9ca698da-8642-4990-b842-4747c9f438b3,g:77ea8682-dcc2-43bc-841d-94551121f3ad-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:cah="http://www.cardinal.com/20230331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.cardinal.com/20230331">
  <xs:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/stpr/2023" schemaLocation="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cah-20230331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cah-20230331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cah-20230331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cah-20230331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.cardinal.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofEarnings" roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings">
        <link:definition>0000002 - Statement - Condensed Consolidated Statements of Earnings</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveIncome" roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome">
        <link:definition>0000003 - Statement - Condensed Consolidated Statements of Comprehensive Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>0000004 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.cardinal.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>0000005 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofShareholdersEquity" roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity">
        <link:definition>0000006 - Statement - Condensed Consolidated Statements of Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlows" roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows">
        <link:definition>0000007 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPolicies" roleURI="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies">
        <link:definition>0000008 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Divestitures" roleURI="http://www.cardinal.com/role/Divestitures">
        <link:definition>0000009 - Disclosure - Divestitures</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringandEmployeeSeverance" roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeverance">
        <link:definition>0000010 - Disclosure - Restructuring and Employee Severance</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssets" roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssets">
        <link:definition>0000011 - Disclosure - Goodwill and Other Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermObligationsandOtherShortTermBorrowings" roleURI="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowings">
        <link:definition>0000012 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsContingentLiabilitiesandLitigation" roleURI="http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigation">
        <link:definition>0000013 - Disclosure - Commitments, Contingent Liabilities and Litigation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.cardinal.com/role/IncomeTaxes">
        <link:definition>0000014 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.cardinal.com/role/FairValueMeasurements">
        <link:definition>0000015 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstruments" roleURI="http://www.cardinal.com/role/FinancialInstruments">
        <link:definition>0000016 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquity" roleURI="http://www.cardinal.com/role/ShareholdersEquity">
        <link:definition>0000017 - Disclosure - Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareAttributabletoCardinalHealthInc" roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthInc">
        <link:definition>0000018 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc.</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformation" roleURI="http://www.cardinal.com/role/SegmentInformation">
        <link:definition>0000019 - Disclosure - Segment Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensation" roleURI="http://www.cardinal.com/role/ShareBasedCompensation">
        <link:definition>0000020 - Disclosure - Share-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>0000021 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperationsandDisposalGroupsTables" roleURI="http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsTables">
        <link:definition>0000022 - Disclosure - Discontinued Operations and Disposal Groups (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringandEmployeeSeveranceTables" roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables">
        <link:definition>0000023 - Disclosure - Restructuring and Employee Severance (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssetsTables" roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables">
        <link:definition>0000024 - Disclosure - Goodwill and Other Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermObligationsandOtherShortTermBorrowingsTables" roleURI="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsTables">
        <link:definition>0000025 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.cardinal.com/role/FairValueMeasurementsTables">
        <link:definition>0000026 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsTables" roleURI="http://www.cardinal.com/role/FinancialInstrumentsTables">
        <link:definition>0000027 - Disclosure - Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityTables" roleURI="http://www.cardinal.com/role/ShareholdersEquityTables">
        <link:definition>0000028 - Disclosure - Shareholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareAttributabletoCardinalHealthIncTables" roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables">
        <link:definition>0000029 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationTables" roleURI="http://www.cardinal.com/role/SegmentInformationTables">
        <link:definition>0000030 - Disclosure - Segment Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationTables" roleURI="http://www.cardinal.com/role/ShareBasedCompensationTables">
        <link:definition>0000031 - Disclosure - Share-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeRecentFinancialAccountingStandardsDetails" roleURI="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeRecentFinancialAccountingStandardsDetails">
        <link:definition>0000032 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Narrative, Recent Financial Accounting Standards) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperationsandDisposalGroupsDetails" roleURI="http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails">
        <link:definition>0000033 - Disclosure - Discontinued Operations and Disposal Groups (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails" roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails">
        <link:definition>0000034 - Disclosure - Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails" roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails">
        <link:definition>0000035 - Disclosure - Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringandEmployeeSeveranceNarativeDetails" roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails">
        <link:definition>0000036 - Disclosure - Restructuring and Employee Severance Narative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails" roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails">
        <link:definition>0000037 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails">
        <link:definition>0000038 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssetsNarrativeDetails" roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails">
        <link:definition>0000039 - Disclosure - Goodwill and Other Intangible Assets (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermObligationsandOtherShortTermBorrowingsDetails" roleURI="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails">
        <link:definition>0000040 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails" roleURI="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails">
        <link:definition>0000041 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings Summary of Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsContingentLiabilitiesandLitigationDetails" roleURI="http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails">
        <link:definition>0000042 - Disclosure - Commitments, Contingent Liabilities and Litigation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://www.cardinal.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>0000043 - Disclosure - Income Taxes (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" roleURI="http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails">
        <link:definition>0000044 - Disclosure - Fair Value Measurements (Fair Value of Assets and Liabilities Measured on a Recurring Basis) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsNarrativeDetails" roleURI="http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails">
        <link:definition>0000045 - Disclosure - Financial Instruments (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails" roleURI="http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails">
        <link:definition>0000046 - Disclosure - Financial Instruments Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityNarrativeDetails" roleURI="http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails">
        <link:definition>0000047 - Disclosure - Shareholders' Equity (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" roleURI="http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails">
        <link:definition>0000048 - Disclosure - Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails" roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails">
        <link:definition>0000049 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails" roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails">
        <link:definition>0000050 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationNarrativeDetails" roleURI="http://www.cardinal.com/role/SegmentInformationNarrativeDetails">
        <link:definition>0000051 - Disclosure - Segment Information (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationRevenuebyReportableSegmentDetails" roleURI="http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails">
        <link:definition>0000052 - Disclosure - Segment Information (Revenue by Reportable Segment) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationSegmentProfitbyReportableSegmentDetails" roleURI="http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails">
        <link:definition>0000053 - Disclosure - Segment Information (Segment Profit by Reportable Segment) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails" roleURI="http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails">
        <link:definition>0000054 - Disclosure - Segment Information Revenue From External Customers By Geographic Areas (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationAssetsbyReportableSegmentDetails" roleURI="http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails">
        <link:definition>0000055 - Disclosure - Segment Information (Assets by Reportable Segment) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationNarrativeDetails" roleURI="http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails">
        <link:definition>0000056 - Disclosure - Share-Based Compensation (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails" roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails">
        <link:definition>0000057 - Disclosure - Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails" roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails">
        <link:definition>0000058 - Disclosure - Share-Based Compensation (Schedule of All Stock Option Transactions Under the Plans) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails" roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails">
        <link:definition>0000059 - Disclosure - Share-Based Compensation (Schedule of Additional Data Related to Stock Options) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails" roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails">
        <link:definition>0000060 - Disclosure - Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails" roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails">
        <link:definition>0000061 - Disclosure - Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="cah_MaturityDateDomain" abstract="true" name="MaturityDateDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cah_NuclearPrecisionHealthSolutionsMember" abstract="true" name="NuclearPrecisionHealthSolutionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cah_CVSHealthMember" abstract="true" name="CVSHealthMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cah_GrossInsuranceSettlementBeforeAttorneyFees" abstract="false" name="GrossInsuranceSettlementBeforeAttorneyFees" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_A200MillionShareRepurchaseProgramMember" abstract="true" name="A200MillionShareRepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cah_OpioidLitigationDomain" abstract="true" name="OpioidLitigationDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cah_MedicalUnitMember" abstract="true" name="MedicalUnitMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cah_AgreementsDomain" abstract="true" name="AgreementsDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cah_JudgmentForLostProfits" abstract="false" name="JudgmentForLostProfits" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_DateInitiatedDomain" abstract="true" name="DateInitiatedDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cah_TrademarksAndPatentsMember" abstract="true" name="TrademarksAndPatentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cah_A500MillionShareRepurchaseProgramMember" abstract="true" name="A500MillionShareRepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cah_CordisDivestitureAxis" abstract="true" name="CordisDivestitureAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cah_CARESActDomain" abstract="true" name="CARESActDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cah_LawsuitTypeDomain" abstract="true" name="LawsuitTypeDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cah_LossContingencyLawsuitsNumber" abstract="false" name="LossContingencyLawsuitsNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cah_PharmaceuticalMember" abstract="true" name="PharmaceuticalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cah_PharmaceuticalDistributionandSpecialtyMember" abstract="true" name="PharmaceuticalDistributionandSpecialtyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cah_OpioidLitigationAxis" abstract="true" name="OpioidLitigationAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems" abstract="true" name="SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cah_IVCApril2023AgreementMember" abstract="true" name="IVCApril2023AgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cah_IndemnificationReceivable" abstract="false" name="IndemnificationReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_SettlingStates" abstract="false" name="SettlingStates" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cah_PrivatePartiesMember" abstract="true" name="PrivatePartiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cah_CordisDivestitureMember" abstract="true" name="CordisDivestitureMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cah_CardinalHealthAtHomeMember" abstract="true" name="CardinalHealthAtHomeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cah_September2025Member" abstract="true" name="September2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cah_TerminalGrowthRateFairValueInput" abstract="false" name="TerminalGrowthRateFairValueInput" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="cah_ContingentAttorneyFee" abstract="false" name="ContingentAttorneyFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_PlaintiffTypeDomain" abstract="true" name="PlaintiffTypeDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cah_IPRDTrademarksandOtherMember" abstract="true" name="IPRDTrademarksandOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cah_GoodwillImpairmentDomain" abstract="true" name="GoodwillImpairmentDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cah_June2027Member" abstract="true" name="June2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cah_MaturityDateAxis" abstract="true" name="MaturityDateAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cah_ShareholderDerivativeLitigationMember" abstract="true" name="ShareholderDerivativeLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cah_Amortizationandotheracquisitionrelatedcosts" abstract="false" name="Amortizationandotheracquisitionrelatedcosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_March2025Member" abstract="true" name="March2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cah_CashReclassifiedToAssetHeldForSale" abstract="false" name="CashReclassifiedToAssetHeldForSale" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_A300MillionShareRepurchaseProgramMember" abstract="true" name="A300MillionShareRepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cah_VestingPeriodinyearsforShares" abstract="false" name="VestingPeriodinyearsforShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cah_TotalLongTermandShortTermObligations" abstract="false" name="TotalLongTermandShortTermObligations" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_CarryingAmountofLongTermandotherShortTermBorrowings" abstract="false" name="CarryingAmountofLongTermandotherShortTermBorrowings" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_NotesPayableRepurchased" abstract="false" name="NotesPayableRepurchased" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_March2026Member" abstract="true" name="March2026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cah_NewYorkOpioidStewardshipActMember" abstract="true" name="NewYorkOpioidStewardshipActMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cah_ProjectCostsOnInvestmentAndOtherSpending" abstract="false" name="ProjectCostsOnInvestmentAndOtherSpending" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_ShortTermCreditFacilitiesMember" abstract="true" name="ShortTermCreditFacilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cah_OtherAgreementsMember" abstract="true" name="OtherAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cah_IncomefromSettlementsofClassActionLawsuits" abstract="false" name="IncomefromSettlementsofClassActionLawsuits" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_March2022Member" abstract="true" name="March2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cah_ShareholderSecuritiesLitigationMember" abstract="true" name="ShareholderSecuritiesLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cah_A32NotesDue2023Member" abstract="true" name="A32NotesDue2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cah_LongTermObligationsandOtherShortTermBorrowingsAbstract" abstract="true" name="LongTermObligationsandOtherShortTermBorrowingsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cah_September2018Member" abstract="true" name="September2018Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cah_CordisDivestitureDomain" abstract="true" name="CordisDivestitureDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cah_TaxMattersAgreementAxis" abstract="true" name="TaxMattersAgreementAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cah_ClassActionLawsuitsMember" abstract="true" name="ClassActionLawsuitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cah_Netproceedstaxwithholdingsfromsharebasedcompensation" abstract="false" name="Netproceedstaxwithholdingsfromsharebasedcompensation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_ProductLiabilityLawsuitsMember" abstract="true" name="ProductLiabilityLawsuitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cah_SettlingUSTerritories" abstract="false" name="SettlingUSTerritories" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cah_Purchaseofavailableforsalesecuritiesandotherinvestments" abstract="false" name="Purchaseofavailableforsalesecuritiesandotherinvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_PlaintiffTypeAxis" abstract="true" name="PlaintiffTypeAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cah_NativeAmericanTribesMember" abstract="true" name="NativeAmericanTribesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cah_FacilityExitAndOtherCosts" abstract="false" name="FacilityExitAndOtherCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_TaxMatterAxis" abstract="true" name="TaxMatterAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cah_A250MillionShareRepurchaseProgramMember" abstract="true" name="A250MillionShareRepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cah_NarativeAbstract" abstract="true" name="NarativeAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cah_MedicalUnitGoodwillImpairmentMember" abstract="true" name="MedicalUnitGoodwillImpairmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cah_DiscountRateFairValueInput" abstract="false" name="DiscountRateFairValueInput" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="cah_TaxMattersAgreementDomain" abstract="true" name="TaxMattersAgreementDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cah_DateInitiatedAxis" abstract="true" name="DateInitiatedAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cah_NetOperatingLossCarrybackAxis" abstract="true" name="NetOperatingLossCarrybackAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments" abstract="false" name="Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_MedicaldistributionandproductsMember" abstract="true" name="MedicaldistributionandproductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable" abstract="true" name="SegmentRevenuefromExternalCustomersbyGeographicAreaTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="cah_TotalOpioidLitigationMember" abstract="true" name="TotalOpioidLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cah_LawsuitTypeAxis" abstract="true" name="LawsuitTypeAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cah_AgreementsAxis" abstract="true" name="AgreementsAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cah_A1BillionShareRepurchaseProgramMember" abstract="true" name="A1BillionShareRepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cah_DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount" abstract="false" name="DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_OpioidLawsuitsMember" abstract="true" name="OpioidLawsuitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cah_AlamedaCountyMember" abstract="true" name="AlamedaCountyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cah_CareFusionMember" abstract="true" name="CareFusionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cah_CommittedReceivablesSalesFacilityProgramMember" abstract="true" name="CommittedReceivablesSalesFacilityProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cah_SharesThatWouldBeAntidilutiveAsAResultOfNetLoss" abstract="false" name="SharesThatWouldBeAntidilutiveAsAResultOfNetLoss" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cah_AggregateAnnualAssessment" abstract="false" name="AggregateAnnualAssessment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_MedicalMember" abstract="true" name="MedicalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cah_GoodwillImpairmentAxis" abstract="true" name="GoodwillImpairmentAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cah_A2.616Notesdue2022Member" abstract="true" name="A2.616Notesdue2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cah_TaxMatterDomain" abstract="true" name="TaxMatterDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>cah-20230331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:9ca698da-8642-4990-b842-4747c9f438b3,g:77ea8682-dcc2-43bc-841d-94551121f3ad-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings" xlink:type="simple" xlink:href="cah-20230331.xsd#CondensedConsolidatedStatementsofEarnings"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_6ead2753-0ac4-4671-849f-91eb80737b7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c9d2707d-396f-4f74-9e68-7883e30c99a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_6ead2753-0ac4-4671-849f-91eb80737b7e" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c9d2707d-396f-4f74-9e68-7883e30c99a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_138ef301-e39a-42fe-8dc8-81c607b8a090" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_6ead2753-0ac4-4671-849f-91eb80737b7e" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_138ef301-e39a-42fe-8dc8-81c607b8a090" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6eee2f27-a890-46e6-9e02-e18d0498cf61" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_9c27ed36-c642-4136-a7a5-95a525a62c88" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_6eee2f27-a890-46e6-9e02-e18d0498cf61" xlink:to="loc_us-gaap_ProfitLoss_9c27ed36-c642-4136-a7a5-95a525a62c88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_2dd5b1fd-2f59-4446-9d77-028135f8ca94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_6eee2f27-a890-46e6-9e02-e18d0498cf61" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_2dd5b1fd-2f59-4446-9d77-028135f8ca94" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a3b0ca67-c416-4dde-aeeb-ca2fdebbefff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_1412ddb8-e379-46d9-bae9-00a11fff52f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a3b0ca67-c416-4dde-aeeb-ca2fdebbefff" xlink:to="loc_us-gaap_OperatingIncomeLoss_1412ddb8-e379-46d9-bae9-00a11fff52f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_ab3e99ad-1ff1-47f0-af0c-9512d04db39c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a3b0ca67-c416-4dde-aeeb-ca2fdebbefff" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_ab3e99ad-1ff1-47f0-af0c-9512d04db39c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_2f36eaaa-487a-400b-9977-afbbae965c02" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a3b0ca67-c416-4dde-aeeb-ca2fdebbefff" xlink:to="loc_us-gaap_InterestExpense_2f36eaaa-487a-400b-9977-afbbae965c02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_fd2255e2-e3e6-44cd-a36a-edf4ab3d0114" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a3b0ca67-c416-4dde-aeeb-ca2fdebbefff" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_fd2255e2-e3e6-44cd-a36a-edf4ab3d0114" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments_d3cba87a-8799-42b1-973c-791073884b1e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfInvestments"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a3b0ca67-c416-4dde-aeeb-ca2fdebbefff" xlink:to="loc_us-gaap_GainLossOnSaleOfInvestments_d3cba87a-8799-42b1-973c-791073884b1e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_1432dfee-f282-477d-92b5-2efed2b9925e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_af7666df-db66-42e9-9688-30de52f81b76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_1432dfee-f282-477d-92b5-2efed2b9925e" xlink:to="loc_us-gaap_GrossProfit_af7666df-db66-42e9-9688-30de52f81b76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_135f9c29-745d-47ea-bc9d-54c32e093c46" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_1432dfee-f282-477d-92b5-2efed2b9925e" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_135f9c29-745d-47ea-bc9d-54c32e093c46" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_84261c53-0af5-443a-8bc2-ea43316a7172" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_1432dfee-f282-477d-92b5-2efed2b9925e" xlink:to="loc_us-gaap_RestructuringCharges_84261c53-0af5-443a-8bc2-ea43316a7172" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Amortizationandotheracquisitionrelatedcosts_b231b4cc-ac11-4db2-a6b8-60df0c93a715" xlink:href="cah-20230331.xsd#cah_Amortizationandotheracquisitionrelatedcosts"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_1432dfee-f282-477d-92b5-2efed2b9925e" xlink:to="loc_cah_Amortizationandotheracquisitionrelatedcosts_b231b4cc-ac11-4db2-a6b8-60df0c93a715" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_0cc0e9cb-0be3-4f67-9e34-293cd8d5488f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_1432dfee-f282-477d-92b5-2efed2b9925e" xlink:to="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_0cc0e9cb-0be3-4f67-9e34-293cd8d5488f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_8582fe23-8703-4d93-907c-f9ec4e97edf4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_1432dfee-f282-477d-92b5-2efed2b9925e" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_8582fe23-8703-4d93-907c-f9ec4e97edf4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_474297af-3197-4870-858c-d320f79aff2b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_d0a25a53-09aa-4f33-996f-07b3d7d7d5d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_474297af-3197-4870-858c-d320f79aff2b" xlink:to="loc_us-gaap_Revenues_d0a25a53-09aa-4f33-996f-07b3d7d7d5d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_67bfc28f-59dc-4124-973c-274761c37924" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_474297af-3197-4870-858c-d320f79aff2b" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_67bfc28f-59dc-4124-973c-274761c37924" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="cah-20230331.xsd#CondensedConsolidatedStatementsofComprehensiveIncome"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_3fee7bd8-4015-43d6-9c65-e85a7b0b5341" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_3038e63e-ea14-47d6-8f57-1a00ecd9b83f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_3fee7bd8-4015-43d6-9c65-e85a7b0b5341" xlink:to="loc_us-gaap_ProfitLoss_3038e63e-ea14-47d6-8f57-1a00ecd9b83f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_441098c4-f862-4cce-b5c7-cb031e25fbe1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_3fee7bd8-4015-43d6-9c65-e85a7b0b5341" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_441098c4-f862-4cce-b5c7-cb031e25fbe1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_e21b808c-8d4d-48c4-8fbb-ef0a0916c067" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_d20e4e5d-233a-4442-af48-4cc586229612" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_e21b808c-8d4d-48c4-8fbb-ef0a0916c067" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_d20e4e5d-233a-4442-af48-4cc586229612" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_46c2199b-170d-452e-bab2-be88e727f859" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_e21b808c-8d4d-48c4-8fbb-ef0a0916c067" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_46c2199b-170d-452e-bab2-be88e727f859" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_b9681a2d-cfe0-4efe-8f7e-7a55fa67c16f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_dff567f1-41b1-4201-985e-8888ff4c1337" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_b9681a2d-cfe0-4efe-8f7e-7a55fa67c16f" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_dff567f1-41b1-4201-985e-8888ff4c1337" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_ed8a5cdc-b082-4842-bdb4-e1481c46fec8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_b9681a2d-cfe0-4efe-8f7e-7a55fa67c16f" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_ed8a5cdc-b082-4842-bdb4-e1481c46fec8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="cah-20230331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_15565c41-4c7f-4415-b185-801fe5ba4db3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_9d734f5b-eabf-4843-aa8d-6fd71473f1b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_15565c41-4c7f-4415-b185-801fe5ba4db3" xlink:to="loc_us-gaap_AssetsCurrent_9d734f5b-eabf-4843-aa8d-6fd71473f1b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_64501408-de8d-4af9-91fe-328b26c73c5b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_15565c41-4c7f-4415-b185-801fe5ba4db3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_64501408-de8d-4af9-91fe-328b26c73c5b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_45206201-a4cf-4464-94e8-73e4dd19068a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_15565c41-4c7f-4415-b185-801fe5ba4db3" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_45206201-a4cf-4464-94e8-73e4dd19068a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_bba69bb1-3434-4f32-98c0-e023efdd0931" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_15565c41-4c7f-4415-b185-801fe5ba4db3" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_bba69bb1-3434-4f32-98c0-e023efdd0931" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e1bb2482-5b4a-46b3-b58c-c3e4f13468bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_75d4d670-dc52-4072-a7c5-d5da68fc6df2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e1bb2482-5b4a-46b3-b58c-c3e4f13468bb" xlink:to="loc_us-gaap_CommonStockValue_75d4d670-dc52-4072-a7c5-d5da68fc6df2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_8510746e-acc1-4e42-a36f-fc1db82d0475" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e1bb2482-5b4a-46b3-b58c-c3e4f13468bb" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_8510746e-acc1-4e42-a36f-fc1db82d0475" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_7a8078c1-b956-43f7-a64d-21f666cfb305" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e1bb2482-5b4a-46b3-b58c-c3e4f13468bb" xlink:to="loc_us-gaap_TreasuryStockValue_7a8078c1-b956-43f7-a64d-21f666cfb305" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_a5f6b78b-c806-4c5f-aaad-4c0f1219d2e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e1bb2482-5b4a-46b3-b58c-c3e4f13468bb" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_a5f6b78b-c806-4c5f-aaad-4c0f1219d2e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_8c4d69ea-e18b-4f21-97d9-4399211f583b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e1bb2482-5b4a-46b3-b58c-c3e4f13468bb" xlink:to="loc_us-gaap_MinorityInterest_8c4d69ea-e18b-4f21-97d9-4399211f583b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_774038b7-65b3-460a-9a51-98724522e35f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_a055ec10-9650-43cd-9a77-ba8a9fdfa4fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_774038b7-65b3-460a-9a51-98724522e35f" xlink:to="loc_us-gaap_LiabilitiesCurrent_a055ec10-9650-43cd-9a77-ba8a9fdfa4fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_5fa3810e-d268-4884-9c29-0b6fbc99b494" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_774038b7-65b3-460a-9a51-98724522e35f" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_5fa3810e-d268-4884-9c29-0b6fbc99b494" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_1724e212-4eee-4d34-9108-147464a23e56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_774038b7-65b3-460a-9a51-98724522e35f" xlink:to="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_1724e212-4eee-4d34-9108-147464a23e56" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2ccba387-78a0-40fc-9969-5a95171de665" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_774038b7-65b3-460a-9a51-98724522e35f" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2ccba387-78a0-40fc-9969-5a95171de665" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_4141066d-bd9c-429c-981f-34deb57d0ae1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_dee75dba-a36c-4f7b-bf31-40df34de06d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4141066d-bd9c-429c-981f-34deb57d0ae1" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_dee75dba-a36c-4f7b-bf31-40df34de06d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_acdfe3de-b077-427a-9b0f-8bc5911347a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4141066d-bd9c-429c-981f-34deb57d0ae1" xlink:to="loc_us-gaap_ReceivablesNetCurrent_acdfe3de-b077-427a-9b0f-8bc5911347a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_e575f7ed-103d-40b1-8cf9-65831d9f3dd8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4141066d-bd9c-429c-981f-34deb57d0ae1" xlink:to="loc_us-gaap_InventoryNet_e575f7ed-103d-40b1-8cf9-65831d9f3dd8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_f5a0be27-3f22-4c77-8281-0d326072afa7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4141066d-bd9c-429c-981f-34deb57d0ae1" xlink:to="loc_us-gaap_OtherAssetsCurrent_f5a0be27-3f22-4c77-8281-0d326072afa7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a63f0a30-09b7-48e1-8ebd-1703e4e841ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_38e667ca-0b18-4a0e-b7d8-89183d17944c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a63f0a30-09b7-48e1-8ebd-1703e4e841ac" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_38e667ca-0b18-4a0e-b7d8-89183d17944c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_ed7d17ab-f31c-491f-a8d0-7b084e972d16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a63f0a30-09b7-48e1-8ebd-1703e4e841ac" xlink:to="loc_us-gaap_PreferredStockValue_ed7d17ab-f31c-491f-a8d0-7b084e972d16" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_53368725-90f8-4710-baaa-e96d02fcdbc5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a63f0a30-09b7-48e1-8ebd-1703e4e841ac" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_53368725-90f8-4710-baaa-e96d02fcdbc5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_352b66c5-cd3d-419f-b6cd-683ff7b15458" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a63f0a30-09b7-48e1-8ebd-1703e4e841ac" xlink:to="loc_us-gaap_CommonStockValue_352b66c5-cd3d-419f-b6cd-683ff7b15458" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_480ebc41-0290-4d26-9ab7-0b3748fd3143" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a63f0a30-09b7-48e1-8ebd-1703e4e841ac" xlink:to="loc_us-gaap_TreasuryStockValue_480ebc41-0290-4d26-9ab7-0b3748fd3143" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_b27e4e6b-f942-4e93-b3da-75bc81b32c73" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_c808ce2e-6970-44bd-ad41-75679039389b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b27e4e6b-f942-4e93-b3da-75bc81b32c73" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_c808ce2e-6970-44bd-ad41-75679039389b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_a50408b4-93b8-4323-8eab-16edc731a6a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b27e4e6b-f942-4e93-b3da-75bc81b32c73" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_a50408b4-93b8-4323-8eab-16edc731a6a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_fb010672-5827-4fa4-af61-960e98f9a434" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b27e4e6b-f942-4e93-b3da-75bc81b32c73" xlink:to="loc_us-gaap_AccountsPayableCurrent_fb010672-5827-4fa4-af61-960e98f9a434" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="cah-20230331.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c24d0e0c-b129-4403-acab-c469a61c9bdc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ac77fe05-432c-432d-95ec-269a8b011b6c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c24d0e0c-b129-4403-acab-c469a61c9bdc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ac77fe05-432c-432d-95ec-269a8b011b6c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6b25e015-56eb-4f63-a07d-c10e17ec262e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c24d0e0c-b129-4403-acab-c469a61c9bdc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6b25e015-56eb-4f63-a07d-c10e17ec262e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bedbe199-96cb-44a6-b134-41ab8651010c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c24d0e0c-b129-4403-acab-c469a61c9bdc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bedbe199-96cb-44a6-b134-41ab8651010c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_90e9d2f7-b71e-4d04-b0ab-f0e3cbbbffec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c24d0e0c-b129-4403-acab-c469a61c9bdc" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_90e9d2f7-b71e-4d04-b0ab-f0e3cbbbffec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CashReclassifiedToAssetHeldForSale_84b3c23f-0dd2-4d6a-8e72-e55c9cf8d30b" xlink:href="cah-20230331.xsd#cah_CashReclassifiedToAssetHeldForSale"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c24d0e0c-b129-4403-acab-c469a61c9bdc" xlink:to="loc_cah_CashReclassifiedToAssetHeldForSale_84b3c23f-0dd2-4d6a-8e72-e55c9cf8d30b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a30abb6d-1215-4e55-b22d-5c23f2f81d6d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_2db2877d-92fb-4de0-b1a6-a28326c9fbf6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a30abb6d-1215-4e55-b22d-5c23f2f81d6d" xlink:to="loc_us-gaap_ProfitLoss_2db2877d-92fb-4de0-b1a6-a28326c9fbf6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_cc3dd2bc-cf65-474f-a110-ca16b9587a0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a30abb6d-1215-4e55-b22d-5c23f2f81d6d" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_cc3dd2bc-cf65-474f-a110-ca16b9587a0a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_f9a22ba5-6427-4663-a13b-1ef6aaae04f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a30abb6d-1215-4e55-b22d-5c23f2f81d6d" xlink:to="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_f9a22ba5-6427-4663-a13b-1ef6aaae04f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments_f389cb8c-b8c8-4189-8db4-a33bee9b3943" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfInvestments"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a30abb6d-1215-4e55-b22d-5c23f2f81d6d" xlink:to="loc_us-gaap_GainLossOnSaleOfInvestments_f389cb8c-b8c8-4189-8db4-a33bee9b3943" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_eff9f0b0-8da5-454c-86d4-12995f00869e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a30abb6d-1215-4e55-b22d-5c23f2f81d6d" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_eff9f0b0-8da5-454c-86d4-12995f00869e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_f950558a-814c-4e0b-af04-680b50109ba7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a30abb6d-1215-4e55-b22d-5c23f2f81d6d" xlink:to="loc_us-gaap_ShareBasedCompensation_f950558a-814c-4e0b-af04-680b50109ba7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_5dd9d05b-ed43-4f10-a96f-873df65e806a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a30abb6d-1215-4e55-b22d-5c23f2f81d6d" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_5dd9d05b-ed43-4f10-a96f-873df65e806a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivables_5736ebe2-0114-4990-ba39-78a9840870b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a30abb6d-1215-4e55-b22d-5c23f2f81d6d" xlink:to="loc_us-gaap_IncreaseDecreaseInReceivables_5736ebe2-0114-4990-ba39-78a9840870b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_44241dbd-4e4b-4063-a1ec-ccddcd4e8061" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a30abb6d-1215-4e55-b22d-5c23f2f81d6d" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_44241dbd-4e4b-4063-a1ec-ccddcd4e8061" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_5b8f55f4-d969-45a0-b8c2-6e2a74637b8a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a30abb6d-1215-4e55-b22d-5c23f2f81d6d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_5b8f55f4-d969-45a0-b8c2-6e2a74637b8a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_d63a0b61-7ffd-4c92-8064-bfef233a313b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a30abb6d-1215-4e55-b22d-5c23f2f81d6d" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_d63a0b61-7ffd-4c92-8064-bfef233a313b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherInvestments_63c936b0-e34e-4cdd-a5e9-3f26060a7702" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfOtherInvestments"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a30abb6d-1215-4e55-b22d-5c23f2f81d6d" xlink:to="loc_us-gaap_GainLossOnSaleOfOtherInvestments_63c936b0-e34e-4cdd-a5e9-3f26060a7702" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9c1cebd8-8398-4652-9088-00d51e70899f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_f348a770-aaae-4020-8ab3-fcb03cc4ae98" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9c1cebd8-8398-4652-9088-00d51e70899f" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_f348a770-aaae-4020-8ab3-fcb03cc4ae98" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Netproceedstaxwithholdingsfromsharebasedcompensation_d6337045-71d2-4e58-9062-b1d884be3939" xlink:href="cah-20230331.xsd#cah_Netproceedstaxwithholdingsfromsharebasedcompensation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9c1cebd8-8398-4652-9088-00d51e70899f" xlink:to="loc_cah_Netproceedstaxwithholdingsfromsharebasedcompensation_d6337045-71d2-4e58-9062-b1d884be3939" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock_5fdc1b9b-7c36-4959-92e3-cb234250dcee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9c1cebd8-8398-4652-9088-00d51e70899f" xlink:to="loc_us-gaap_PaymentsOfDividendsCommonStock_5fdc1b9b-7c36-4959-92e3-cb234250dcee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_b29c3b88-89d4-433b-9cfb-220821c93ebc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9c1cebd8-8398-4652-9088-00d51e70899f" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_b29c3b88-89d4-433b-9cfb-220821c93ebc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fb59c96e-0a03-4c56-855e-249096f0fe32" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_399c8d72-8459-4009-b37d-7c8a44aae700" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fb59c96e-0a03-4c56-855e-249096f0fe32" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_399c8d72-8459-4009-b37d-7c8a44aae700" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Purchaseofavailableforsalesecuritiesandotherinvestments_995332e6-db79-4e7c-baec-0861ae73703a" xlink:href="cah-20230331.xsd#cah_Purchaseofavailableforsalesecuritiesandotherinvestments"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fb59c96e-0a03-4c56-855e-249096f0fe32" xlink:to="loc_cah_Purchaseofavailableforsalesecuritiesandotherinvestments_995332e6-db79-4e7c-baec-0861ae73703a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments_8505345f-55a7-46fb-86d7-a48c1391fca9" xlink:href="cah-20230331.xsd#cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fb59c96e-0a03-4c56-855e-249096f0fe32" xlink:to="loc_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments_8505345f-55a7-46fb-86d7-a48c1391fca9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_ef0bb583-ecd2-4954-9520-45c214d87b89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fb59c96e-0a03-4c56-855e-249096f0fe32" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_ef0bb583-ecd2-4954-9520-45c214d87b89" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_69b966cc-5e72-4b0d-bc2f-933280cf2a14" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fb59c96e-0a03-4c56-855e-249096f0fe32" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_69b966cc-5e72-4b0d-bc2f-933280cf2a14" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromHedgeInvestingActivities_57ef2f57-991e-4394-9dac-f783d92d320e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromHedgeInvestingActivities"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fb59c96e-0a03-4c56-855e-249096f0fe32" xlink:to="loc_us-gaap_ProceedsFromHedgeInvestingActivities_57ef2f57-991e-4394-9dac-f783d92d320e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_2d88d0b4-1f42-4975-906d-33f181a35828" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fb59c96e-0a03-4c56-855e-249096f0fe32" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_2d88d0b4-1f42-4975-906d-33f181a35828" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails" xlink:type="simple" xlink:href="cah-20230331.xsd#RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_1002ea57-b859-498b-9c40-632fc498044d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_f7818589-8f31-46f6-a685-be31ade64c29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeveranceCosts1"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestructuringCharges_1002ea57-b859-498b-9c40-632fc498044d" xlink:to="loc_us-gaap_SeveranceCosts1_f7818589-8f31-46f6-a685-be31ade64c29" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_FacilityExitAndOtherCosts_7cbb33b3-9c9d-49e7-a9bf-2d00521f1c94" xlink:href="cah-20230331.xsd#cah_FacilityExitAndOtherCosts"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestructuringCharges_1002ea57-b859-498b-9c40-632fc498044d" xlink:to="loc_cah_FacilityExitAndOtherCosts_7cbb33b3-9c9d-49e7-a9bf-2d00521f1c94" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="cah-20230331.xsd#ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_1891725d-5046-4ade-bc5a-65ef1e6f34a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_4fd68acf-5975-4b39-b81e-e7dc1673d3d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_1891725d-5046-4ade-bc5a-65ef1e6f34a9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_4fd68acf-5975-4b39-b81e-e7dc1673d3d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_eaa76977-db6c-4b5b-80af-3fc00c77bf8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_1891725d-5046-4ade-bc5a-65ef1e6f34a9" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_eaa76977-db6c-4b5b-80af-3fc00c77bf8b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails" xlink:type="simple" xlink:href="cah-20230331.xsd#EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3f1d66ae-632a-4fc5-83d4-cbf994b0d061" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e79e9d90-bfdd-487c-80e1-17bf2cfdc3ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3f1d66ae-632a-4fc5-83d4-cbf994b0d061" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e79e9d90-bfdd-487c-80e1-17bf2cfdc3ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_46083244-0d63-4fae-a73e-277f90e69980" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3f1d66ae-632a-4fc5-83d4-cbf994b0d061" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_46083244-0d63-4fae-a73e-277f90e69980" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>cah-20230331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:9ca698da-8642-4990-b842-4747c9f438b3,g:77ea8682-dcc2-43bc-841d-94551121f3ad-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity" xlink:type="simple" xlink:href="cah-20230331.xsd#CondensedConsolidatedStatementsofShareholdersEquity"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity" xlink:type="extended" id="i340376adc03040e2ae4e97a400eaf4fa_CondensedConsolidatedStatementsofShareholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_85556305-c28a-49e7-9c76-01e7c4587a51" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_eaf19a9e-17c4-4906-b552-5385178df5f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_85556305-c28a-49e7-9c76-01e7c4587a51" xlink:to="loc_us-gaap_CommonStockSharesIssued_eaf19a9e-17c4-4906-b552-5385178df5f8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7bb81574-766b-4181-bcd6-61a105dce3f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_85556305-c28a-49e7-9c76-01e7c4587a51" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7bb81574-766b-4181-bcd6-61a105dce3f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_5d3f65bb-2532-4ec3-8c38-bc76eff43602" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_85556305-c28a-49e7-9c76-01e7c4587a51" xlink:to="loc_us-gaap_TreasuryStockCommonShares_5d3f65bb-2532-4ec3-8c38-bc76eff43602" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_e9b24256-68fa-47ca-90f0-90ad1b6c4837" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_85556305-c28a-49e7-9c76-01e7c4587a51" xlink:to="loc_us-gaap_TreasuryStockValue_e9b24256-68fa-47ca-90f0-90ad1b6c4837" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_2eb0d1b1-14e4-497c-8c8a-aa37b35a5e08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_85556305-c28a-49e7-9c76-01e7c4587a51" xlink:to="loc_us-gaap_ProfitLoss_2eb0d1b1-14e4-497c-8c8a-aa37b35a5e08" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_db4733c9-8448-4b62-a7e6-8f503a083cf2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_85556305-c28a-49e7-9c76-01e7c4587a51" xlink:to="loc_us-gaap_NetIncomeLoss_db4733c9-8448-4b62-a7e6-8f503a083cf2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_f53609d6-9c27-4f56-b430-32bdfdf8b5e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_85556305-c28a-49e7-9c76-01e7c4587a51" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_f53609d6-9c27-4f56-b430-32bdfdf8b5e3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_1ab772de-b54d-4a7b-8ea1-03ad3879b2ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_85556305-c28a-49e7-9c76-01e7c4587a51" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_1ab772de-b54d-4a7b-8ea1-03ad3879b2ec" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_dd370e44-1d7b-4327-bdfd-429b455a73d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_85556305-c28a-49e7-9c76-01e7c4587a51" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_dd370e44-1d7b-4327-bdfd-429b455a73d8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_28f00124-d3c1-416b-9751-117e8bd05e59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_85556305-c28a-49e7-9c76-01e7c4587a51" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_28f00124-d3c1-416b-9751-117e8bd05e59" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_6f1f324c-ad89-4983-97cb-1a86c784bf89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_85556305-c28a-49e7-9c76-01e7c4587a51" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_6f1f324c-ad89-4983-97cb-1a86c784bf89" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_9f5753e9-8d0a-46d9-9881-612111f46c9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_85556305-c28a-49e7-9c76-01e7c4587a51" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_9f5753e9-8d0a-46d9-9881-612111f46c9e" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends_e8f4aac7-223d-4f8e-b437-c070199cde6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Dividends"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_85556305-c28a-49e7-9c76-01e7c4587a51" xlink:to="loc_us-gaap_Dividends_e8f4aac7-223d-4f8e-b437-c070199cde6f" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOtherShares_39335cd9-4f77-4371-8508-e237ea4f7c87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityOtherShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_85556305-c28a-49e7-9c76-01e7c4587a51" xlink:to="loc_us-gaap_StockholdersEquityOtherShares_39335cd9-4f77-4371-8508-e237ea4f7c87" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_58e218e9-de6b-430e-a8ca-544a94b87074" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_85556305-c28a-49e7-9c76-01e7c4587a51" xlink:to="loc_us-gaap_StockholdersEquityOther_58e218e9-de6b-430e-a8ca-544a94b87074" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_4f40daa6-c1bd-4dcb-99ab-6f2fe7a13f87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2f673f6a-ecce-4434-9aae-22626e1a53d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_f68a8b7c-3fa0-49d3-bd9d-3b6997b96472" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_8978bf67-8809-4b97-b9ca-fc56e9258d24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_ede57a60-b8b5-429f-81eb-6f3c59e84c55" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_85556305-c28a-49e7-9c76-01e7c4587a51" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_ede57a60-b8b5-429f-81eb-6f3c59e84c55" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_45db5373-bca2-4dcd-bf94-b88126d289f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_85556305-c28a-49e7-9c76-01e7c4587a51" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_45db5373-bca2-4dcd-bf94-b88126d289f4" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_4d616885-e130-4834-8c39-ab8c317a65fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_1f3b3b10-44b0-4af2-8f33-ea70c9552d0b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_85556305-c28a-49e7-9c76-01e7c4587a51" xlink:to="loc_us-gaap_StatementTable_1f3b3b10-44b0-4af2-8f33-ea70c9552d0b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1df7573c-8084-446a-9847-d0eddc3d5630" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1f3b3b10-44b0-4af2-8f33-ea70c9552d0b" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1df7573c-8084-446a-9847-d0eddc3d5630" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1df7573c-8084-446a-9847-d0eddc3d5630_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1df7573c-8084-446a-9847-d0eddc3d5630" xlink:to="loc_us-gaap_EquityComponentDomain_1df7573c-8084-446a-9847-d0eddc3d5630_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_0ca9dbc6-107f-46c3-8df4-ab51a8b9ced7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1df7573c-8084-446a-9847-d0eddc3d5630" xlink:to="loc_us-gaap_EquityComponentDomain_0ca9dbc6-107f-46c3-8df4-ab51a8b9ced7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_60b82a98-c546-42da-9713-8a5d2734426e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0ca9dbc6-107f-46c3-8df4-ab51a8b9ced7" xlink:to="loc_us-gaap_CommonStockMember_60b82a98-c546-42da-9713-8a5d2734426e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_1198105a-ec02-433a-ac9e-a8f33bd7fd71" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0ca9dbc6-107f-46c3-8df4-ab51a8b9ced7" xlink:to="loc_us-gaap_RetainedEarningsMember_1198105a-ec02-433a-ac9e-a8f33bd7fd71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_709b1959-394f-432f-9de1-f0335f0c527e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0ca9dbc6-107f-46c3-8df4-ab51a8b9ced7" xlink:to="loc_us-gaap_TreasuryStockCommonMember_709b1959-394f-432f-9de1-f0335f0c527e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_efbd5168-e067-4f7d-bdd6-6450151eb7da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0ca9dbc6-107f-46c3-8df4-ab51a8b9ced7" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_efbd5168-e067-4f7d-bdd6-6450151eb7da" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_d1b8ca76-f128-4bde-b07d-4394891edfee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0ca9dbc6-107f-46c3-8df4-ab51a8b9ced7" xlink:to="loc_us-gaap_NoncontrollingInterestMember_d1b8ca76-f128-4bde-b07d-4394891edfee" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_4cbdc49a-f80e-49c0-bae0-5884ee850428" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails" xlink:type="simple" xlink:href="cah-20230331.xsd#DiscontinuedOperationsandDisposalGroupsDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails" xlink:type="extended" id="i3745be15f5f84de2921f76fc71841d44_DiscontinuedOperationsandDisposalGroupsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_6de6b606-d69a-429e-9eeb-e328c8eaee26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_2dc80c83-be6b-4717-a2cb-dbb3d6e778e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_6de6b606-d69a-429e-9eeb-e328c8eaee26" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_2dc80c83-be6b-4717-a2cb-dbb3d6e778e3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_7693a2f2-27eb-44c8-965d-056cef251dac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_6de6b606-d69a-429e-9eeb-e328c8eaee26" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_7693a2f2-27eb-44c8-965d-056cef251dac" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_bc4ebc9b-b5e2-4c4c-8c57-e034a82e1a2e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_7693a2f2-27eb-44c8-965d-056cef251dac" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_bc4ebc9b-b5e2-4c4c-8c57-e034a82e1a2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_bc4ebc9b-b5e2-4c4c-8c57-e034a82e1a2e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_bc4ebc9b-b5e2-4c4c-8c57-e034a82e1a2e" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_bc4ebc9b-b5e2-4c4c-8c57-e034a82e1a2e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_f91c99ed-da7e-4b33-a8fd-4d3de2f94d08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_bc4ebc9b-b5e2-4c4c-8c57-e034a82e1a2e" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_f91c99ed-da7e-4b33-a8fd-4d3de2f94d08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureAxis_028d4e6b-a8c1-422a-bbe8-e40f4f5fa731" xlink:href="cah-20230331.xsd#cah_CordisDivestitureAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_7693a2f2-27eb-44c8-965d-056cef251dac" xlink:to="loc_cah_CordisDivestitureAxis_028d4e6b-a8c1-422a-bbe8-e40f4f5fa731" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureDomain_028d4e6b-a8c1-422a-bbe8-e40f4f5fa731_default" xlink:href="cah-20230331.xsd#cah_CordisDivestitureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_CordisDivestitureAxis_028d4e6b-a8c1-422a-bbe8-e40f4f5fa731" xlink:to="loc_cah_CordisDivestitureDomain_028d4e6b-a8c1-422a-bbe8-e40f4f5fa731_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureDomain_94ce987d-f47d-4fd8-83ac-70cccfca1a4e" xlink:href="cah-20230331.xsd#cah_CordisDivestitureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_CordisDivestitureAxis_028d4e6b-a8c1-422a-bbe8-e40f4f5fa731" xlink:to="loc_cah_CordisDivestitureDomain_94ce987d-f47d-4fd8-83ac-70cccfca1a4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureMember_679a9b4c-d600-4ed5-993d-83433c188e0a" xlink:href="cah-20230331.xsd#cah_CordisDivestitureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_CordisDivestitureDomain_94ce987d-f47d-4fd8-83ac-70cccfca1a4e" xlink:to="loc_cah_CordisDivestitureMember_679a9b4c-d600-4ed5-993d-83433c188e0a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails" xlink:type="simple" xlink:href="cah-20230331.xsd#RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails" xlink:type="extended" id="i09254080e4e6440d82534fbf490ecebb_RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_6ce9ad0d-7405-41c5-a956-289784c81585" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_e82cf884-c0a4-4765-9c7f-c34eecb7763f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_6ce9ad0d-7405-41c5-a956-289784c81585" xlink:to="loc_us-gaap_RestructuringReserveRollForward_e82cf884-c0a4-4765-9c7f-c34eecb7763f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_4b500795-ef11-42f2-bf4b-1075b7a56391" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_e82cf884-c0a4-4765-9c7f-c34eecb7763f" xlink:to="loc_us-gaap_RestructuringReserve_4b500795-ef11-42f2-bf4b-1075b7a56391" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCosts_a47ecb54-2fcd-4df1-ae47-0ad1fbda28f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_e82cf884-c0a4-4765-9c7f-c34eecb7763f" xlink:to="loc_us-gaap_RestructuringCosts_a47ecb54-2fcd-4df1-ae47-0ad1fbda28f0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_666373c6-e435-4818-9777-d1a4e3cd1890" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_e82cf884-c0a4-4765-9c7f-c34eecb7763f" xlink:to="loc_us-gaap_PaymentsForRestructuring_666373c6-e435-4818-9777-d1a4e3cd1890" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_f7e71c52-571d-4eab-b6b7-6ca60c180040" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserve"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_00406c67-8f82-4a41-b30a-8cbec6765d23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_6ce9ad0d-7405-41c5-a956-289784c81585" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_00406c67-8f82-4a41-b30a-8cbec6765d23" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_977342b7-3030-46d0-b078-1ab4e71d1c39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_00406c67-8f82-4a41-b30a-8cbec6765d23" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_977342b7-3030-46d0-b078-1ab4e71d1c39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_977342b7-3030-46d0-b078-1ab4e71d1c39_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_977342b7-3030-46d0-b078-1ab4e71d1c39" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_977342b7-3030-46d0-b078-1ab4e71d1c39_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_31c1e0b2-703a-4cc9-905c-2ce8d89b874c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_977342b7-3030-46d0-b078-1ab4e71d1c39" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_31c1e0b2-703a-4cc9-905c-2ce8d89b874c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_4079b5e8-35e1-4297-895b-535941c3ae45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_31c1e0b2-703a-4cc9-905c-2ce8d89b874c" xlink:to="loc_us-gaap_EmployeeSeveranceMember_4079b5e8-35e1-4297-895b-535941c3ae45" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FacilityClosingMember_7e8ec64c-2082-4a51-868a-6cba268af545" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FacilityClosingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_31c1e0b2-703a-4cc9-905c-2ce8d89b874c" xlink:to="loc_us-gaap_FacilityClosingMember_7e8ec64c-2082-4a51-868a-6cba268af545" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails" xlink:type="simple" xlink:href="cah-20230331.xsd#RestructuringandEmployeeSeveranceNarativeDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails" xlink:type="extended" id="i770caa68d73347109a74734819f04de6_RestructuringandEmployeeSeveranceNarativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_c480c69b-6fd0-4db8-b8b2-c408b2cc39cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_6939a014-429b-429a-b1da-a8a4d8437b6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeveranceCosts1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_c480c69b-6fd0-4db8-b8b2-c408b2cc39cf" xlink:to="loc_us-gaap_SeveranceCosts1_6939a014-429b-429a-b1da-a8a4d8437b6f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_FacilityExitAndOtherCosts_ef8698a4-8a40-4a33-aab6-f803b991dcac" xlink:href="cah-20230331.xsd#cah_FacilityExitAndOtherCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_c480c69b-6fd0-4db8-b8b2-c408b2cc39cf" xlink:to="loc_cah_FacilityExitAndOtherCosts_ef8698a4-8a40-4a33-aab6-f803b991dcac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_055e9581-d228-4afe-9b17-5c7dc0aac892" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_c480c69b-6fd0-4db8-b8b2-c408b2cc39cf" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_055e9581-d228-4afe-9b17-5c7dc0aac892" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_0290570a-4adc-47fa-a9a6-3dfed1323d4f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_055e9581-d228-4afe-9b17-5c7dc0aac892" xlink:to="loc_us-gaap_RestructuringPlanAxis_0290570a-4adc-47fa-a9a6-3dfed1323d4f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_0290570a-4adc-47fa-a9a6-3dfed1323d4f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_0290570a-4adc-47fa-a9a6-3dfed1323d4f" xlink:to="loc_us-gaap_RestructuringPlanDomain_0290570a-4adc-47fa-a9a6-3dfed1323d4f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_59cd91c0-a0e5-4ffb-bf41-505ac50b55d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_0290570a-4adc-47fa-a9a6-3dfed1323d4f" xlink:to="loc_us-gaap_RestructuringPlanDomain_59cd91c0-a0e5-4ffb-bf41-505ac50b55d8" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails" xlink:type="simple" xlink:href="cah-20230331.xsd#GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails" xlink:type="extended" id="i134202d1a00a4aab81db493231bfa4b7_GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_23db62c5-9f53-44c7-9665-dc97ca7b59c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_95a9b065-8fd9-4b21-a561-ccfba101e328" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_23db62c5-9f53-44c7-9665-dc97ca7b59c2" xlink:to="loc_us-gaap_GoodwillRollForward_95a9b065-8fd9-4b21-a561-ccfba101e328" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_38d0dcea-4c0d-4253-98f2-db72c6da0c6d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_95a9b065-8fd9-4b21-a561-ccfba101e328" xlink:to="loc_us-gaap_Goodwill_38d0dcea-4c0d-4253-98f2-db72c6da0c6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_2f88533f-6e23-489d-85fa-59325cf7d0bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_95a9b065-8fd9-4b21-a561-ccfba101e328" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_2f88533f-6e23-489d-85fa-59325cf7d0bd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_f3f05aba-ea14-491e-a022-6f676e2b298c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_95a9b065-8fd9-4b21-a561-ccfba101e328" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_f3f05aba-ea14-491e-a022-6f676e2b298c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_c77fe026-08ff-48e3-9d73-5ee46b4e910c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_95a9b065-8fd9-4b21-a561-ccfba101e328" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_c77fe026-08ff-48e3-9d73-5ee46b4e910c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_0ba7df1a-6346-49d0-b908-ee4ecfb08661" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_72c311b7-e012-4378-ade8-4dc65022805b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_23db62c5-9f53-44c7-9665-dc97ca7b59c2" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_72c311b7-e012-4378-ade8-4dc65022805b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_5f3e3457-da90-4d69-be38-04f7323b5e05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_23db62c5-9f53-44c7-9665-dc97ca7b59c2" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_5f3e3457-da90-4d69-be38-04f7323b5e05" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_5581b6f9-d12c-431b-a6d6-91db1995e1e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_5f3e3457-da90-4d69-be38-04f7323b5e05" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_5581b6f9-d12c-431b-a6d6-91db1995e1e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_5581b6f9-d12c-431b-a6d6-91db1995e1e7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_5581b6f9-d12c-431b-a6d6-91db1995e1e7" xlink:to="loc_us-gaap_SegmentDomain_5581b6f9-d12c-431b-a6d6-91db1995e1e7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_3b756d27-bb23-4fde-bfb4-cdbb726675b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_5581b6f9-d12c-431b-a6d6-91db1995e1e7" xlink:to="loc_us-gaap_SegmentDomain_3b756d27-bb23-4fde-bfb4-cdbb726675b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalMember_b749739d-4e70-4a69-b6d7-a1c06f83dca0" xlink:href="cah-20230331.xsd#cah_PharmaceuticalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_3b756d27-bb23-4fde-bfb4-cdbb726675b7" xlink:to="loc_cah_PharmaceuticalMember_b749739d-4e70-4a69-b6d7-a1c06f83dca0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember_459dd0a7-d6c7-44dd-ad61-07bc264d5330" xlink:href="cah-20230331.xsd#cah_MedicalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_3b756d27-bb23-4fde-bfb4-cdbb726675b7" xlink:to="loc_cah_MedicalMember_459dd0a7-d6c7-44dd-ad61-07bc264d5330" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureAxis_2f10b9f8-64c3-4050-a802-98080b40cb84" xlink:href="cah-20230331.xsd#cah_CordisDivestitureAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_5f3e3457-da90-4d69-be38-04f7323b5e05" xlink:to="loc_cah_CordisDivestitureAxis_2f10b9f8-64c3-4050-a802-98080b40cb84" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureDomain_2f10b9f8-64c3-4050-a802-98080b40cb84_default" xlink:href="cah-20230331.xsd#cah_CordisDivestitureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_CordisDivestitureAxis_2f10b9f8-64c3-4050-a802-98080b40cb84" xlink:to="loc_cah_CordisDivestitureDomain_2f10b9f8-64c3-4050-a802-98080b40cb84_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureDomain_89ce9886-797a-4647-863c-e095d16fda88" xlink:href="cah-20230331.xsd#cah_CordisDivestitureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_CordisDivestitureAxis_2f10b9f8-64c3-4050-a802-98080b40cb84" xlink:to="loc_cah_CordisDivestitureDomain_89ce9886-797a-4647-863c-e095d16fda88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureMember_a500759e-2861-463c-98a5-bd8ac4435933" xlink:href="cah-20230331.xsd#cah_CordisDivestitureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_CordisDivestitureDomain_89ce9886-797a-4647-863c-e095d16fda88" xlink:to="loc_cah_CordisDivestitureMember_a500759e-2861-463c-98a5-bd8ac4435933" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="cah-20230331.xsd#GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="extended" id="i204553896099450cb100ab88dd21bc75_GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_3db197f8-94c5-4e2e-a79d-621a25118318" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_6f25f955-388b-4f8c-bcd7-b16feedd72ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_3db197f8-94c5-4e2e-a79d-621a25118318" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_6f25f955-388b-4f8c-bcd7-b16feedd72ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_c22ffae9-594c-4f13-8a44-3567b6173bb1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_3db197f8-94c5-4e2e-a79d-621a25118318" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_c22ffae9-594c-4f13-8a44-3567b6173bb1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_f3372b8e-7050-4898-a12b-78eeac5e513c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_c22ffae9-594c-4f13-8a44-3567b6173bb1" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_f3372b8e-7050-4898-a12b-78eeac5e513c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_f3372b8e-7050-4898-a12b-78eeac5e513c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_f3372b8e-7050-4898-a12b-78eeac5e513c" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_f3372b8e-7050-4898-a12b-78eeac5e513c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_47875f57-183c-4f53-ba6b-8e0b7193934c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_f3372b8e-7050-4898-a12b-78eeac5e513c" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_47875f57-183c-4f53-ba6b-8e0b7193934c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_IPRDTrademarksandOtherMember_71be7658-a7bb-4a51-809a-2dbf99ec3bf4" xlink:href="cah-20230331.xsd#cah_IPRDTrademarksandOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_47875f57-183c-4f53-ba6b-8e0b7193934c" xlink:to="loc_cah_IPRDTrademarksandOtherMember_71be7658-a7bb-4a51-809a-2dbf99ec3bf4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e596331b-9a47-41a6-bef2-3a4c85e14bef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_ab6bd59b-658e-4ba3-8e5d-a6cd9eacf2ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e596331b-9a47-41a6-bef2-3a4c85e14bef" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_ab6bd59b-658e-4ba3-8e5d-a6cd9eacf2ae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_cb568245-fd04-4a4d-8c48-812e966055e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e596331b-9a47-41a6-bef2-3a4c85e14bef" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_cb568245-fd04-4a4d-8c48-812e966055e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_6fb1187e-392a-408e-9e2d-149071ecbdc5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e596331b-9a47-41a6-bef2-3a4c85e14bef" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_6fb1187e-392a-408e-9e2d-149071ecbdc5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_35791f35-75ef-4e17-ade3-a410fa139ab2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e596331b-9a47-41a6-bef2-3a4c85e14bef" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_35791f35-75ef-4e17-ade3-a410fa139ab2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_a10843bb-ac5e-4ccb-934c-5d049736f04e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e596331b-9a47-41a6-bef2-3a4c85e14bef" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_a10843bb-ac5e-4ccb-934c-5d049736f04e" xlink:type="arc" order="2" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0036e635-b7d2-4c58-a4a4-667903252a07" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_a10843bb-ac5e-4ccb-934c-5d049736f04e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0036e635-b7d2-4c58-a4a4-667903252a07" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0036e635-b7d2-4c58-a4a4-667903252a07_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0036e635-b7d2-4c58-a4a4-667903252a07" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0036e635-b7d2-4c58-a4a4-667903252a07_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c1dd52f2-d98b-4e6b-ace3-e19f6e47e6c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0036e635-b7d2-4c58-a4a4-667903252a07" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c1dd52f2-d98b-4e6b-ace3-e19f6e47e6c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_795a8df6-09b4-4877-b6dd-c7d889b24f6d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c1dd52f2-d98b-4e6b-ace3-e19f6e47e6c4" xlink:to="loc_us-gaap_CustomerRelationshipsMember_795a8df6-09b4-4877-b6dd-c7d889b24f6d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TrademarksAndPatentsMember_47b4b064-c4ff-445f-ad42-ec75eb4e0d73" xlink:href="cah-20230331.xsd#cah_TrademarksAndPatentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c1dd52f2-d98b-4e6b-ace3-e19f6e47e6c4" xlink:to="loc_cah_TrademarksAndPatentsMember_47b4b064-c4ff-445f-ad42-ec75eb4e0d73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_e4a453ee-d1a2-450f-8b67-fb85c9dcbb21" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c1dd52f2-d98b-4e6b-ace3-e19f6e47e6c4" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_e4a453ee-d1a2-450f-8b67-fb85c9dcbb21" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" xlink:type="simple" xlink:href="cah-20230331.xsd#GoodwillandOtherIntangibleAssetsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" xlink:type="extended" id="i78ee5437031048b6b7d526a8dd1c0100_GoodwillandOtherIntangibleAssetsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_238841ef-6c0e-49cf-b899-4bc46b90e2db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_ed20cf82-606c-4c19-833d-cbb66111f435" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_238841ef-6c0e-49cf-b899-4bc46b90e2db" xlink:to="loc_us-gaap_Goodwill_ed20cf82-606c-4c19-833d-cbb66111f435" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_74015f98-0576-4214-be76-8659bbc18236" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_238841ef-6c0e-49cf-b899-4bc46b90e2db" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_74015f98-0576-4214-be76-8659bbc18236" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_DiscountRateFairValueInput_9138c9b8-2ec1-4af7-b941-08cb663582ff" xlink:href="cah-20230331.xsd#cah_DiscountRateFairValueInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_238841ef-6c0e-49cf-b899-4bc46b90e2db" xlink:to="loc_cah_DiscountRateFairValueInput_9138c9b8-2ec1-4af7-b941-08cb663582ff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TerminalGrowthRateFairValueInput_58822e8b-3bae-4057-8008-fad20aed829a" xlink:href="cah-20230331.xsd#cah_TerminalGrowthRateFairValueInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_238841ef-6c0e-49cf-b899-4bc46b90e2db" xlink:to="loc_cah_TerminalGrowthRateFairValueInput_58822e8b-3bae-4057-8008-fad20aed829a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount_000bfecb-2268-41ae-8254-43e8d442e3f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_238841ef-6c0e-49cf-b899-4bc46b90e2db" xlink:to="loc_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount_000bfecb-2268-41ae-8254-43e8d442e3f1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_bc3665f2-6024-4bef-a332-ef3c1b1b09a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_238841ef-6c0e-49cf-b899-4bc46b90e2db" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_bc3665f2-6024-4bef-a332-ef3c1b1b09a4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis_f7e481a3-40ca-4912-bc87-2bd7dbb7a9f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReportingUnitAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_bc3665f2-6024-4bef-a332-ef3c1b1b09a4" xlink:to="loc_us-gaap_ReportingUnitAxis_f7e481a3-40ca-4912-bc87-2bd7dbb7a9f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_f7e481a3-40ca-4912-bc87-2bd7dbb7a9f3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReportingUnitDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReportingUnitAxis_f7e481a3-40ca-4912-bc87-2bd7dbb7a9f3" xlink:to="loc_us-gaap_ReportingUnitDomain_f7e481a3-40ca-4912-bc87-2bd7dbb7a9f3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_d32e811a-c67c-435f-9a66-bb3be278e3fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReportingUnitDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReportingUnitAxis_f7e481a3-40ca-4912-bc87-2bd7dbb7a9f3" xlink:to="loc_us-gaap_ReportingUnitDomain_d32e811a-c67c-435f-9a66-bb3be278e3fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalUnitMember_07a4122f-3fc1-441a-aa46-896cafba5edf" xlink:href="cah-20230331.xsd#cah_MedicalUnitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_d32e811a-c67c-435f-9a66-bb3be278e3fc" xlink:to="loc_cah_MedicalUnitMember_07a4122f-3fc1-441a-aa46-896cafba5edf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_fe480157-c365-4169-82d5-ab168da52348" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_bc3665f2-6024-4bef-a332-ef3c1b1b09a4" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_fe480157-c365-4169-82d5-ab168da52348" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_fe480157-c365-4169-82d5-ab168da52348_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_fe480157-c365-4169-82d5-ab168da52348" xlink:to="loc_us-gaap_SegmentDomain_fe480157-c365-4169-82d5-ab168da52348_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_1bfc2a90-c134-4080-a3e5-ecb13d036e01" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_fe480157-c365-4169-82d5-ab168da52348" xlink:to="loc_us-gaap_SegmentDomain_1bfc2a90-c134-4080-a3e5-ecb13d036e01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember_9d7108c2-b906-47da-a0f0-aaaf6d2e5c69" xlink:href="cah-20230331.xsd#cah_MedicalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_1bfc2a90-c134-4080-a3e5-ecb13d036e01" xlink:to="loc_cah_MedicalMember_9d7108c2-b906-47da-a0f0-aaaf6d2e5c69" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalUnitMember_745699c8-9328-4f9e-a7d6-2bc19928df27" xlink:href="cah-20230331.xsd#cah_MedicalUnitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_1bfc2a90-c134-4080-a3e5-ecb13d036e01" xlink:to="loc_cah_MedicalUnitMember_745699c8-9328-4f9e-a7d6-2bc19928df27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_GoodwillImpairmentAxis_da5677d6-689f-4ae2-bca2-d3d8a75a88cd" xlink:href="cah-20230331.xsd#cah_GoodwillImpairmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_bc3665f2-6024-4bef-a332-ef3c1b1b09a4" xlink:to="loc_cah_GoodwillImpairmentAxis_da5677d6-689f-4ae2-bca2-d3d8a75a88cd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_GoodwillImpairmentDomain_da5677d6-689f-4ae2-bca2-d3d8a75a88cd_default" xlink:href="cah-20230331.xsd#cah_GoodwillImpairmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_GoodwillImpairmentAxis_da5677d6-689f-4ae2-bca2-d3d8a75a88cd" xlink:to="loc_cah_GoodwillImpairmentDomain_da5677d6-689f-4ae2-bca2-d3d8a75a88cd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_GoodwillImpairmentDomain_a4d976ae-ff08-47a5-83b3-75376fec16fd" xlink:href="cah-20230331.xsd#cah_GoodwillImpairmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_GoodwillImpairmentAxis_da5677d6-689f-4ae2-bca2-d3d8a75a88cd" xlink:to="loc_cah_GoodwillImpairmentDomain_a4d976ae-ff08-47a5-83b3-75376fec16fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalUnitMember_191141dc-149b-42b3-996d-2f9e20b60824" xlink:href="cah-20230331.xsd#cah_MedicalUnitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_GoodwillImpairmentDomain_a4d976ae-ff08-47a5-83b3-75376fec16fd" xlink:to="loc_cah_MedicalUnitMember_191141dc-149b-42b3-996d-2f9e20b60824" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails" xlink:type="simple" xlink:href="cah-20230331.xsd#LongTermObligationsandOtherShortTermBorrowingsDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails" xlink:type="extended" id="ib19d0ed6d8ee4ef5bcd66ddc533191fc_LongTermObligationsandOtherShortTermBorrowingsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_48f5c042-5508-4b88-994d-a3bb762d4f03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalLongTermandShortTermObligations_c37d23a3-b99e-43cb-b2ef-f3ebd7711e4b" xlink:href="cah-20230331.xsd#cah_TotalLongTermandShortTermObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_48f5c042-5508-4b88-994d-a3bb762d4f03" xlink:to="loc_cah_TotalLongTermandShortTermObligations_c37d23a3-b99e-43cb-b2ef-f3ebd7711e4b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_7a30369c-3380-45f7-8559-501655ec169a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_48f5c042-5508-4b88-994d-a3bb762d4f03" xlink:to="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_7a30369c-3380-45f7-8559-501655ec169a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_32c93613-3241-4ea0-8d13-808f5439f228" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_48f5c042-5508-4b88-994d-a3bb762d4f03" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_32c93613-3241-4ea0-8d13-808f5439f228" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NotesPayableRepurchased_30da37cf-3ae9-465f-ac26-77253e140b7b" xlink:href="cah-20230331.xsd#cah_NotesPayableRepurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_48f5c042-5508-4b88-994d-a3bb762d4f03" xlink:to="loc_cah_NotesPayableRepurchased_30da37cf-3ae9-465f-ac26-77253e140b7b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_c81d5400-7b02-441d-b450-66428cdf15f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_48f5c042-5508-4b88-994d-a3bb762d4f03" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_c81d5400-7b02-441d-b450-66428cdf15f7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_986894b5-5802-41fc-8770-65502c557859" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_48f5c042-5508-4b88-994d-a3bb762d4f03" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_986894b5-5802-41fc-8770-65502c557859" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherShortTermBorrowings_04d8a791-47fc-4264-8b80-03ac1a51fa3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherShortTermBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_48f5c042-5508-4b88-994d-a3bb762d4f03" xlink:to="loc_us-gaap_OtherShortTermBorrowings_04d8a791-47fc-4264-8b80-03ac1a51fa3c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_9b0f6531-61e0-48a4-ad3b-c2cc73a003cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_48f5c042-5508-4b88-994d-a3bb762d4f03" xlink:to="loc_us-gaap_DebtInstrumentTable_9b0f6531-61e0-48a4-ad3b-c2cc73a003cd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_36e9c428-38b4-48e7-8efc-18ac3bf57ce1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_9b0f6531-61e0-48a4-ad3b-c2cc73a003cd" xlink:to="loc_us-gaap_DebtInstrumentAxis_36e9c428-38b4-48e7-8efc-18ac3bf57ce1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_36e9c428-38b4-48e7-8efc-18ac3bf57ce1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_36e9c428-38b4-48e7-8efc-18ac3bf57ce1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_36e9c428-38b4-48e7-8efc-18ac3bf57ce1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_82a3c607-0303-406a-9ebe-0560559b2e7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_36e9c428-38b4-48e7-8efc-18ac3bf57ce1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_82a3c607-0303-406a-9ebe-0560559b2e7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A2.616Notesdue2022Member_d558e194-b9b0-4739-a29c-6be5a836e20e" xlink:href="cah-20230331.xsd#cah_A2.616Notesdue2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_82a3c607-0303-406a-9ebe-0560559b2e7b" xlink:to="loc_cah_A2.616Notesdue2022Member_d558e194-b9b0-4739-a29c-6be5a836e20e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A32NotesDue2023Member_d8030c8f-c86f-427b-83cd-7bacfc5cb5b0" xlink:href="cah-20230331.xsd#cah_A32NotesDue2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_82a3c607-0303-406a-9ebe-0560559b2e7b" xlink:to="loc_cah_A32NotesDue2023Member_d8030c8f-c86f-427b-83cd-7bacfc5cb5b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CommittedReceivablesSalesFacilityProgramMember_8335bdd1-c861-487b-bcec-5d76bf1fab71" xlink:href="cah-20230331.xsd#cah_CommittedReceivablesSalesFacilityProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_82a3c607-0303-406a-9ebe-0560559b2e7b" xlink:to="loc_cah_CommittedReceivablesSalesFacilityProgramMember_8335bdd1-c861-487b-bcec-5d76bf1fab71" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_89cc09d6-0918-441f-9927-da48f7567bb0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_9b0f6531-61e0-48a4-ad3b-c2cc73a003cd" xlink:to="loc_us-gaap_CreditFacilityAxis_89cc09d6-0918-441f-9927-da48f7567bb0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_89cc09d6-0918-441f-9927-da48f7567bb0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_89cc09d6-0918-441f-9927-da48f7567bb0" xlink:to="loc_us-gaap_CreditFacilityDomain_89cc09d6-0918-441f-9927-da48f7567bb0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_409329d2-b852-4aba-b8f2-025e3d87e3af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_89cc09d6-0918-441f-9927-da48f7567bb0" xlink:to="loc_us-gaap_CreditFacilityDomain_409329d2-b852-4aba-b8f2-025e3d87e3af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_3432758d-014f-413e-b040-949d4fa83a6d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_409329d2-b852-4aba-b8f2-025e3d87e3af" xlink:to="loc_us-gaap_CommercialPaperMember_3432758d-014f-413e-b040-949d4fa83a6d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_7a51752b-595d-401b-a67a-c58f4936059d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_409329d2-b852-4aba-b8f2-025e3d87e3af" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_7a51752b-595d-401b-a67a-c58f4936059d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ShortTermCreditFacilitiesMember_7ec36e8c-083e-4a67-9ba7-9e7236ed1f72" xlink:href="cah-20230331.xsd#cah_ShortTermCreditFacilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_409329d2-b852-4aba-b8f2-025e3d87e3af" xlink:to="loc_cah_ShortTermCreditFacilitiesMember_7ec36e8c-083e-4a67-9ba7-9e7236ed1f72" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CommittedReceivablesSalesFacilityProgramMember_08df85f5-3ec9-454d-b48d-ec4a353b4008" xlink:href="cah-20230331.xsd#cah_CommittedReceivablesSalesFacilityProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_409329d2-b852-4aba-b8f2-025e3d87e3af" xlink:to="loc_cah_CommittedReceivablesSalesFacilityProgramMember_08df85f5-3ec9-454d-b48d-ec4a353b4008" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails" xlink:type="simple" xlink:href="cah-20230331.xsd#LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails" xlink:type="extended" id="i1ec6034edae84f02b41bb2e347d6ac0d_LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_033cbc8d-7048-4218-af87-7e5a923356f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalLongTermandShortTermObligations_f6aefb39-b449-4912-9210-62d44a9e8e17" xlink:href="cah-20230331.xsd#cah_TotalLongTermandShortTermObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_033cbc8d-7048-4218-af87-7e5a923356f0" xlink:to="loc_cah_TotalLongTermandShortTermObligations_f6aefb39-b449-4912-9210-62d44a9e8e17" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_4cf80141-3ad6-42a3-8216-247e65488d3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_033cbc8d-7048-4218-af87-7e5a923356f0" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_4cf80141-3ad6-42a3-8216-247e65488d3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_fb4c970e-55d1-4bfe-aa57-e7642b03324f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_033cbc8d-7048-4218-af87-7e5a923356f0" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_fb4c970e-55d1-4bfe-aa57-e7642b03324f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod_b8987862-74f7-41fb-b7bf-968a74456612" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_033cbc8d-7048-4218-af87-7e5a923356f0" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod_b8987862-74f7-41fb-b7bf-968a74456612" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAverageOutstandingAmount_3f04e94d-5869-45a7-b8cb-ea99b1b2baeb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityAverageOutstandingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_033cbc8d-7048-4218-af87-7e5a923356f0" xlink:to="loc_us-gaap_LineOfCreditFacilityAverageOutstandingAmount_3f04e94d-5869-45a7-b8cb-ea99b1b2baeb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_0a3b756e-3456-4982-9990-0eaf87e675a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_033cbc8d-7048-4218-af87-7e5a923356f0" xlink:to="loc_us-gaap_DebtInstrumentTable_0a3b756e-3456-4982-9990-0eaf87e675a0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_64a58b47-ec7f-46ec-b75c-93f3afaeffcd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_0a3b756e-3456-4982-9990-0eaf87e675a0" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_64a58b47-ec7f-46ec-b75c-93f3afaeffcd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_64a58b47-ec7f-46ec-b75c-93f3afaeffcd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_64a58b47-ec7f-46ec-b75c-93f3afaeffcd" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_64a58b47-ec7f-46ec-b75c-93f3afaeffcd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_a157cce5-9543-4585-b230-ffbccb97d263" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_64a58b47-ec7f-46ec-b75c-93f3afaeffcd" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_a157cce5-9543-4585-b230-ffbccb97d263" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_efbbee8c-9d7e-40ff-a18b-430fea46c303" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_0a3b756e-3456-4982-9990-0eaf87e675a0" xlink:to="loc_us-gaap_DebtInstrumentAxis_efbbee8c-9d7e-40ff-a18b-430fea46c303" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_efbbee8c-9d7e-40ff-a18b-430fea46c303_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_efbbee8c-9d7e-40ff-a18b-430fea46c303" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_efbbee8c-9d7e-40ff-a18b-430fea46c303_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b2e0c799-18b3-401a-a15c-a164bfbe78ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_efbbee8c-9d7e-40ff-a18b-430fea46c303" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b2e0c799-18b3-401a-a15c-a164bfbe78ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A2.616Notesdue2022Member_98d7eb97-cf86-4120-9164-1185a94f3d32" xlink:href="cah-20230331.xsd#cah_A2.616Notesdue2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b2e0c799-18b3-401a-a15c-a164bfbe78ac" xlink:to="loc_cah_A2.616Notesdue2022Member_98d7eb97-cf86-4120-9164-1185a94f3d32" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_844ff826-2260-4f78-b5ea-2bc43b37f5f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_0a3b756e-3456-4982-9990-0eaf87e675a0" xlink:to="loc_us-gaap_CreditFacilityAxis_844ff826-2260-4f78-b5ea-2bc43b37f5f2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_844ff826-2260-4f78-b5ea-2bc43b37f5f2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_844ff826-2260-4f78-b5ea-2bc43b37f5f2" xlink:to="loc_us-gaap_CreditFacilityDomain_844ff826-2260-4f78-b5ea-2bc43b37f5f2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_de2421cc-8d6d-41b3-9411-2d40dee83203" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_844ff826-2260-4f78-b5ea-2bc43b37f5f2" xlink:to="loc_us-gaap_CreditFacilityDomain_de2421cc-8d6d-41b3-9411-2d40dee83203" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CommittedReceivablesSalesFacilityProgramMember_6c75ae6c-6560-4be2-9b39-7116891506a1" xlink:href="cah-20230331.xsd#cah_CommittedReceivablesSalesFacilityProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_de2421cc-8d6d-41b3-9411-2d40dee83203" xlink:to="loc_cah_CommittedReceivablesSalesFacilityProgramMember_6c75ae6c-6560-4be2-9b39-7116891506a1" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" xlink:type="simple" xlink:href="cah-20230331.xsd#CommitmentsContingentLiabilitiesandLitigationDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" xlink:type="extended" id="ifaaa3f64b7254ad5bbfc4fefc5f922b0_CommitmentsContingentLiabilitiesandLitigationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_57001c87-7177-4af5-b7cd-2a45cee03b99" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermPurchaseCommitmentPeriod_ff57b10e-1f0b-4b6d-b8fb-dc230151935d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermPurchaseCommitmentPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_57001c87-7177-4af5-b7cd-2a45cee03b99" xlink:to="loc_us-gaap_LongtermPurchaseCommitmentPeriod_ff57b10e-1f0b-4b6d-b8fb-dc230151935d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_AggregateAnnualAssessment_d35f209f-53df-434d-913b-e37d52deeb70" xlink:href="cah-20230331.xsd#cah_AggregateAnnualAssessment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_57001c87-7177-4af5-b7cd-2a45cee03b99" xlink:to="loc_cah_AggregateAnnualAssessment_d35f209f-53df-434d-913b-e37d52deeb70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualPayments_bff6cb86-975c-4f76-aaf6-967c7756b1e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAccrualPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_57001c87-7177-4af5-b7cd-2a45cee03b99" xlink:to="loc_us-gaap_LossContingencyAccrualPayments_bff6cb86-975c-4f76-aaf6-967c7756b1e9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_e29e51e6-eb10-41df-924b-293a0e47dc32" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_57001c87-7177-4af5-b7cd-2a45cee03b99" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_e29e51e6-eb10-41df-924b-293a0e47dc32" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease_b7458ac3-be12-489d-a02d-77e8af012ea6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_57001c87-7177-4af5-b7cd-2a45cee03b99" xlink:to="loc_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease_b7458ac3-be12-489d-a02d-77e8af012ea6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_JudgmentForLostProfits_b403ee56-7861-46fc-a5ed-b9de161851e7" xlink:href="cah-20230331.xsd#cah_JudgmentForLostProfits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_57001c87-7177-4af5-b7cd-2a45cee03b99" xlink:to="loc_cah_JudgmentForLostProfits_b403ee56-7861-46fc-a5ed-b9de161851e7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_72a6e379-dc56-4b37-a657-64640e389fdb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_57001c87-7177-4af5-b7cd-2a45cee03b99" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_72a6e379-dc56-4b37-a657-64640e389fdb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SettlingStates_fb3f0ae2-839d-4d6b-804f-9ede73f863bc" xlink:href="cah-20230331.xsd#cah_SettlingStates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_57001c87-7177-4af5-b7cd-2a45cee03b99" xlink:to="loc_cah_SettlingStates_fb3f0ae2-839d-4d6b-804f-9ede73f863bc" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SettlingUSTerritories_60d7b355-f608-4065-94b2-570b35d0124d" xlink:href="cah-20230331.xsd#cah_SettlingUSTerritories"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_57001c87-7177-4af5-b7cd-2a45cee03b99" xlink:to="loc_cah_SettlingUSTerritories_60d7b355-f608-4065-94b2-570b35d0124d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_dca39be5-c023-4f96-80ae-6678c8bc9150" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_57001c87-7177-4af5-b7cd-2a45cee03b99" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_dca39be5-c023-4f96-80ae-6678c8bc9150" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserve_0d46bf59-a1cf-4a4d-b558-990599c60ba4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_57001c87-7177-4af5-b7cd-2a45cee03b99" xlink:to="loc_us-gaap_LitigationReserve_0d46bf59-a1cf-4a4d-b558-990599c60ba4" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent_0cd925c6-66ef-4c5f-9a07-8a041d82f5fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_57001c87-7177-4af5-b7cd-2a45cee03b99" xlink:to="loc_us-gaap_LitigationReserveCurrent_0cd925c6-66ef-4c5f-9a07-8a041d82f5fc" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LossContingencyLawsuitsNumber_79763e6b-6157-41db-91bf-9af556474aa0" xlink:href="cah-20230331.xsd#cah_LossContingencyLawsuitsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_57001c87-7177-4af5-b7cd-2a45cee03b99" xlink:to="loc_cah_LossContingencyLawsuitsNumber_79763e6b-6157-41db-91bf-9af556474aa0" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs_dfad94b5-63ad-4e83-90ce-34ac1af25859" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_57001c87-7177-4af5-b7cd-2a45cee03b99" xlink:to="loc_us-gaap_LossContingencyNumberOfPlaintiffs_dfad94b5-63ad-4e83-90ce-34ac1af25859" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceRecoveries_38c62994-a9dd-4921-b566-47ad29d449ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InsuranceRecoveries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_57001c87-7177-4af5-b7cd-2a45cee03b99" xlink:to="loc_us-gaap_InsuranceRecoveries_38c62994-a9dd-4921-b566-47ad29d449ef" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_23c836a6-f5e5-4c7a-b472-15f91b8655b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_57001c87-7177-4af5-b7cd-2a45cee03b99" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_23c836a6-f5e5-4c7a-b472-15f91b8655b6" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsSettledNumber_4a1d88a8-a3a6-4782-9813-fa8b4abe8a02" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyClaimsSettledNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_57001c87-7177-4af5-b7cd-2a45cee03b99" xlink:to="loc_us-gaap_LossContingencyClaimsSettledNumber_4a1d88a8-a3a6-4782-9813-fa8b4abe8a02" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductLiabilityAccrualPeriodExpense_b4996679-64ee-4f2f-8c82-9597281d54eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductLiabilityAccrualPeriodExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_57001c87-7177-4af5-b7cd-2a45cee03b99" xlink:to="loc_us-gaap_ProductLiabilityAccrualPeriodExpense_b4996679-64ee-4f2f-8c82-9597281d54eb" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_d63705cd-b6e4-4b2f-9794-0922d9702a6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_57001c87-7177-4af5-b7cd-2a45cee03b99" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_d63705cd-b6e4-4b2f-9794-0922d9702a6f" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_IncomefromSettlementsofClassActionLawsuits_cc70ded9-3531-4109-b1e0-0afac2e14644" xlink:href="cah-20230331.xsd#cah_IncomefromSettlementsofClassActionLawsuits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_57001c87-7177-4af5-b7cd-2a45cee03b99" xlink:to="loc_cah_IncomefromSettlementsofClassActionLawsuits_cc70ded9-3531-4109-b1e0-0afac2e14644" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_GrossInsuranceSettlementBeforeAttorneyFees_15c6977a-f302-4fcc-b9c1-8edd54a407aa" xlink:href="cah-20230331.xsd#cah_GrossInsuranceSettlementBeforeAttorneyFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_57001c87-7177-4af5-b7cd-2a45cee03b99" xlink:to="loc_cah_GrossInsuranceSettlementBeforeAttorneyFees_15c6977a-f302-4fcc-b9c1-8edd54a407aa" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalFees_5bd60eaa-7685-45d6-8ee6-60f1e8863d20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_57001c87-7177-4af5-b7cd-2a45cee03b99" xlink:to="loc_us-gaap_LegalFees_5bd60eaa-7685-45d6-8ee6-60f1e8863d20" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities_c5550fc2-d42e-417a-a914-b6509f8f076b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromInsuranceSettlementOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_57001c87-7177-4af5-b7cd-2a45cee03b99" xlink:to="loc_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities_c5550fc2-d42e-417a-a914-b6509f8f076b" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_0a560665-de10-476f-8897-04f38de8dfee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_57001c87-7177-4af5-b7cd-2a45cee03b99" xlink:to="loc_us-gaap_LossContingenciesTable_0a560665-de10-476f-8897-04f38de8dfee" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_6346ab1f-8331-4371-b5f2-0bf0dac74fe9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_0a560665-de10-476f-8897-04f38de8dfee" xlink:to="loc_srt_MajorCustomersAxis_6346ab1f-8331-4371-b5f2-0bf0dac74fe9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_6346ab1f-8331-4371-b5f2-0bf0dac74fe9_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_6346ab1f-8331-4371-b5f2-0bf0dac74fe9" xlink:to="loc_srt_NameOfMajorCustomerDomain_6346ab1f-8331-4371-b5f2-0bf0dac74fe9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_97ab586e-0211-4fe9-934d-947bccceb8b6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_6346ab1f-8331-4371-b5f2-0bf0dac74fe9" xlink:to="loc_srt_NameOfMajorCustomerDomain_97ab586e-0211-4fe9-934d-947bccceb8b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CVSHealthMember_4fa5249b-7141-4d23-8b30-6536b39916eb" xlink:href="cah-20230331.xsd#cah_CVSHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_97ab586e-0211-4fe9-934d-947bccceb8b6" xlink:to="loc_cah_CVSHealthMember_4fa5249b-7141-4d23-8b30-6536b39916eb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_0f6cae3c-6a38-44e3-95be-7930555157bb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_0a560665-de10-476f-8897-04f38de8dfee" xlink:to="loc_srt_LitigationCaseAxis_0f6cae3c-6a38-44e3-95be-7930555157bb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_0f6cae3c-6a38-44e3-95be-7930555157bb_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_0f6cae3c-6a38-44e3-95be-7930555157bb" xlink:to="loc_srt_LitigationCaseTypeDomain_0f6cae3c-6a38-44e3-95be-7930555157bb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_329d9136-c25b-43bf-ad93-6b48c5844aae" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_0f6cae3c-6a38-44e3-95be-7930555157bb" xlink:to="loc_srt_LitigationCaseTypeDomain_329d9136-c25b-43bf-ad93-6b48c5844aae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NewYorkOpioidStewardshipActMember_70b1a398-fb8c-4c72-922d-6ce2ebb8aa36" xlink:href="cah-20230331.xsd#cah_NewYorkOpioidStewardshipActMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_329d9136-c25b-43bf-ad93-6b48c5844aae" xlink:to="loc_cah_NewYorkOpioidStewardshipActMember_70b1a398-fb8c-4c72-922d-6ce2ebb8aa36" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLawsuitsMember_8082bee4-af78-41af-815f-d9dbdee73ac1" xlink:href="cah-20230331.xsd#cah_OpioidLawsuitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_329d9136-c25b-43bf-ad93-6b48c5844aae" xlink:to="loc_cah_OpioidLawsuitsMember_8082bee4-af78-41af-815f-d9dbdee73ac1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProductLiabilityLawsuitsMember_85c898b3-f951-4251-965e-753560c7efcb" xlink:href="cah-20230331.xsd#cah_ProductLiabilityLawsuitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_329d9136-c25b-43bf-ad93-6b48c5844aae" xlink:to="loc_cah_ProductLiabilityLawsuitsMember_85c898b3-f951-4251-965e-753560c7efcb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ShareholderDerivativeLitigationMember_af3581d0-c831-444d-bc1b-6fc08ae1c2b5" xlink:href="cah-20230331.xsd#cah_ShareholderDerivativeLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_329d9136-c25b-43bf-ad93-6b48c5844aae" xlink:to="loc_cah_ShareholderDerivativeLitigationMember_af3581d0-c831-444d-bc1b-6fc08ae1c2b5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ShareholderSecuritiesLitigationMember_9ed6c8e0-a1f8-478b-b481-23cca563a42b" xlink:href="cah-20230331.xsd#cah_ShareholderSecuritiesLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_329d9136-c25b-43bf-ad93-6b48c5844aae" xlink:to="loc_cah_ShareholderSecuritiesLitigationMember_9ed6c8e0-a1f8-478b-b481-23cca563a42b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationAxis_37328a44-d026-4b2f-a5a7-f1a5622b17d9" xlink:href="cah-20230331.xsd#cah_OpioidLitigationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_0a560665-de10-476f-8897-04f38de8dfee" xlink:to="loc_cah_OpioidLitigationAxis_37328a44-d026-4b2f-a5a7-f1a5622b17d9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationDomain_37328a44-d026-4b2f-a5a7-f1a5622b17d9_default" xlink:href="cah-20230331.xsd#cah_OpioidLitigationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_OpioidLitigationAxis_37328a44-d026-4b2f-a5a7-f1a5622b17d9" xlink:to="loc_cah_OpioidLitigationDomain_37328a44-d026-4b2f-a5a7-f1a5622b17d9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationDomain_6ba4ea65-8856-4db2-8243-0ab6790b92e8" xlink:href="cah-20230331.xsd#cah_OpioidLitigationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_OpioidLitigationAxis_37328a44-d026-4b2f-a5a7-f1a5622b17d9" xlink:to="loc_cah_OpioidLitigationDomain_6ba4ea65-8856-4db2-8243-0ab6790b92e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalOpioidLitigationMember_db8a53c4-1476-4c2b-907d-72c80a7a3b74" xlink:href="cah-20230331.xsd#cah_TotalOpioidLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_OpioidLitigationDomain_6ba4ea65-8856-4db2-8243-0ab6790b92e8" xlink:to="loc_cah_TotalOpioidLitigationMember_db8a53c4-1476-4c2b-907d-72c80a7a3b74" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LawsuitTypeAxis_1f285b23-0369-49a5-9c4f-490900121e54" xlink:href="cah-20230331.xsd#cah_LawsuitTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_0a560665-de10-476f-8897-04f38de8dfee" xlink:to="loc_cah_LawsuitTypeAxis_1f285b23-0369-49a5-9c4f-490900121e54" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LawsuitTypeDomain_1f285b23-0369-49a5-9c4f-490900121e54_default" xlink:href="cah-20230331.xsd#cah_LawsuitTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_LawsuitTypeAxis_1f285b23-0369-49a5-9c4f-490900121e54" xlink:to="loc_cah_LawsuitTypeDomain_1f285b23-0369-49a5-9c4f-490900121e54_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LawsuitTypeDomain_29898cf1-205e-4b7d-9077-3d675b2d7cd2" xlink:href="cah-20230331.xsd#cah_LawsuitTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_LawsuitTypeAxis_1f285b23-0369-49a5-9c4f-490900121e54" xlink:to="loc_cah_LawsuitTypeDomain_29898cf1-205e-4b7d-9077-3d675b2d7cd2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ClassActionLawsuitsMember_5450f433-ee83-47d6-a696-13288f9414ba" xlink:href="cah-20230331.xsd#cah_ClassActionLawsuitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_LawsuitTypeDomain_29898cf1-205e-4b7d-9077-3d675b2d7cd2" xlink:to="loc_cah_ClassActionLawsuitsMember_5450f433-ee83-47d6-a696-13288f9414ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProductLiabilityLawsuitsMember_c934a177-4c8d-4237-a407-8f106e9cf2d1" xlink:href="cah-20230331.xsd#cah_ProductLiabilityLawsuitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_LawsuitTypeDomain_29898cf1-205e-4b7d-9077-3d675b2d7cd2" xlink:to="loc_cah_ProductLiabilityLawsuitsMember_c934a177-4c8d-4237-a407-8f106e9cf2d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PlaintiffTypeAxis_8ae17632-4365-4c60-9a16-4aad7f83cdaf" xlink:href="cah-20230331.xsd#cah_PlaintiffTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_0a560665-de10-476f-8897-04f38de8dfee" xlink:to="loc_cah_PlaintiffTypeAxis_8ae17632-4365-4c60-9a16-4aad7f83cdaf" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PlaintiffTypeDomain_8ae17632-4365-4c60-9a16-4aad7f83cdaf_default" xlink:href="cah-20230331.xsd#cah_PlaintiffTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_PlaintiffTypeAxis_8ae17632-4365-4c60-9a16-4aad7f83cdaf" xlink:to="loc_cah_PlaintiffTypeDomain_8ae17632-4365-4c60-9a16-4aad7f83cdaf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PlaintiffTypeDomain_5de5e8ab-615c-4dea-a93a-364bfeaf9e05" xlink:href="cah-20230331.xsd#cah_PlaintiffTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_PlaintiffTypeAxis_8ae17632-4365-4c60-9a16-4aad7f83cdaf" xlink:to="loc_cah_PlaintiffTypeDomain_5de5e8ab-615c-4dea-a93a-364bfeaf9e05" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PrivatePartiesMember_d6e52a3a-51cc-429d-b53e-e28c4b9584f9" xlink:href="cah-20230331.xsd#cah_PrivatePartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_PlaintiffTypeDomain_5de5e8ab-615c-4dea-a93a-364bfeaf9e05" xlink:to="loc_cah_PrivatePartiesMember_d6e52a3a-51cc-429d-b53e-e28c4b9584f9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_665f3b56-3105-4788-af94-a694560f553b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_0a560665-de10-476f-8897-04f38de8dfee" xlink:to="loc_srt_StatementGeographicalAxis_665f3b56-3105-4788-af94-a694560f553b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_665f3b56-3105-4788-af94-a694560f553b_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_665f3b56-3105-4788-af94-a694560f553b" xlink:to="loc_srt_SegmentGeographicalDomain_665f3b56-3105-4788-af94-a694560f553b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_6ede8e74-296b-4b07-930e-86277c848883" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_665f3b56-3105-4788-af94-a694560f553b" xlink:to="loc_srt_SegmentGeographicalDomain_6ede8e74-296b-4b07-930e-86277c848883" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_GA_a3873865-100a-47c8-8ae4-0b2b5c3d1e45" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_GA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_6ede8e74-296b-4b07-930e-86277c848883" xlink:to="loc_stpr_GA_a3873865-100a-47c8-8ae4-0b2b5c3d1e45" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WV_781621f6-91ea-426c-adbd-586c0cbb3d44" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_WV"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_6ede8e74-296b-4b07-930e-86277c848883" xlink:to="loc_stpr_WV_781621f6-91ea-426c-adbd-586c0cbb3d44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WA_36fa3d6d-ea2d-4b27-8292-f21be9dba228" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_WA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_6ede8e74-296b-4b07-930e-86277c848883" xlink:to="loc_stpr_WA_36fa3d6d-ea2d-4b27-8292-f21be9dba228" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_AlamedaCountyMember_ed32da73-4b9e-428d-8c54-5813f4b26c43" xlink:href="cah-20230331.xsd#cah_AlamedaCountyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_6ede8e74-296b-4b07-930e-86277c848883" xlink:to="loc_cah_AlamedaCountyMember_ed32da73-4b9e-428d-8c54-5813f4b26c43" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_OK_213cd3e8-e44c-4dce-96ad-d1363ba36222" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_OK"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_6ede8e74-296b-4b07-930e-86277c848883" xlink:to="loc_stpr_OK_213cd3e8-e44c-4dce-96ad-d1363ba36222" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_AL_686552ae-875f-40af-af5c-3004abce534d" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_AL"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_6ede8e74-296b-4b07-930e-86277c848883" xlink:to="loc_stpr_AL_686552ae-875f-40af-af5c-3004abce534d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NativeAmericanTribesMember_e1a514d2-ce81-4f4a-8fcd-e79fe906f2b7" xlink:href="cah-20230331.xsd#cah_NativeAmericanTribesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_6ede8e74-296b-4b07-930e-86277c848883" xlink:to="loc_cah_NativeAmericanTribesMember_e1a514d2-ce81-4f4a-8fcd-e79fe906f2b7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c85a83d0-7d1f-4016-bda5-62210ebb960e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_0a560665-de10-476f-8897-04f38de8dfee" xlink:to="loc_srt_RangeAxis_c85a83d0-7d1f-4016-bda5-62210ebb960e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c85a83d0-7d1f-4016-bda5-62210ebb960e_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_c85a83d0-7d1f-4016-bda5-62210ebb960e" xlink:to="loc_srt_RangeMember_c85a83d0-7d1f-4016-bda5-62210ebb960e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5fa49202-9b62-42fa-bebd-c953ced328db" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_c85a83d0-7d1f-4016-bda5-62210ebb960e" xlink:to="loc_srt_RangeMember_5fa49202-9b62-42fa-bebd-c953ced328db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c21ce6d6-9893-4b44-8224-5e92123d4a3c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5fa49202-9b62-42fa-bebd-c953ced328db" xlink:to="loc_srt_MinimumMember_c21ce6d6-9893-4b44-8224-5e92123d4a3c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_514ecc41-edc0-44cf-9a05-8394647d271e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5fa49202-9b62-42fa-bebd-c953ced328db" xlink:to="loc_srt_MaximumMember_514ecc41-edc0-44cf-9a05-8394647d271e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_ab2bf2cc-78a2-4833-98de-4f9fa2749f38" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_0a560665-de10-476f-8897-04f38de8dfee" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_ab2bf2cc-78a2-4833-98de-4f9fa2749f38" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_ab2bf2cc-78a2-4833-98de-4f9fa2749f38_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_ab2bf2cc-78a2-4833-98de-4f9fa2749f38" xlink:to="loc_us-gaap_LossContingencyNatureDomain_ab2bf2cc-78a2-4833-98de-4f9fa2749f38_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_f9dd5b5b-9cac-4828-8d61-a5b7a67abe0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_ab2bf2cc-78a2-4833-98de-4f9fa2749f38" xlink:to="loc_us-gaap_LossContingencyNatureDomain_f9dd5b5b-9cac-4828-8d61-a5b7a67abe0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLawsuitsMember_47fe51d7-8abc-45a7-8894-99dbced94f25" xlink:href="cah-20230331.xsd#cah_OpioidLawsuitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_f9dd5b5b-9cac-4828-8d61-a5b7a67abe0a" xlink:to="loc_cah_OpioidLawsuitsMember_47fe51d7-8abc-45a7-8894-99dbced94f25" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProductLiabilityLawsuitsMember_42630b24-2494-4f0f-b408-743806e3968a" xlink:href="cah-20230331.xsd#cah_ProductLiabilityLawsuitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_f9dd5b5b-9cac-4828-8d61-a5b7a67abe0a" xlink:to="loc_cah_ProductLiabilityLawsuitsMember_42630b24-2494-4f0f-b408-743806e3968a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_75aa8c3d-127b-4f16-bd18-b670ad30117e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_0a560665-de10-476f-8897-04f38de8dfee" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_75aa8c3d-127b-4f16-bd18-b670ad30117e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_75aa8c3d-127b-4f16-bd18-b670ad30117e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_75aa8c3d-127b-4f16-bd18-b670ad30117e" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_75aa8c3d-127b-4f16-bd18-b670ad30117e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_a91c67f3-c981-49c9-b050-e2dc3a29950d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_75aa8c3d-127b-4f16-bd18-b670ad30117e" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_a91c67f3-c981-49c9-b050-e2dc3a29950d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_ecc2673e-36dc-4131-8284-78e85ce396e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_a91c67f3-c981-49c9-b050-e2dc3a29950d" xlink:to="loc_us-gaap_SubsequentEventMember_ecc2673e-36dc-4131-8284-78e85ce396e0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_c3d091b6-9a67-4e08-8e43-988ae34e6867" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_0a560665-de10-476f-8897-04f38de8dfee" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_c3d091b6-9a67-4e08-8e43-988ae34e6867" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_c3d091b6-9a67-4e08-8e43-988ae34e6867_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_c3d091b6-9a67-4e08-8e43-988ae34e6867" xlink:to="loc_us-gaap_SegmentDomain_c3d091b6-9a67-4e08-8e43-988ae34e6867_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_4cd4033a-e478-4b06-86f4-b78723272da0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_c3d091b6-9a67-4e08-8e43-988ae34e6867" xlink:to="loc_us-gaap_SegmentDomain_4cd4033a-e478-4b06-86f4-b78723272da0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalMember_47dcf6de-ebcf-4c0a-bb18-bb27bbc4f70f" xlink:href="cah-20230331.xsd#cah_PharmaceuticalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_4cd4033a-e478-4b06-86f4-b78723272da0" xlink:to="loc_cah_PharmaceuticalMember_47dcf6de-ebcf-4c0a-bb18-bb27bbc4f70f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_AgreementsAxis_5ba67e3f-33e7-4d03-8202-5c80156bbe23" xlink:href="cah-20230331.xsd#cah_AgreementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_0a560665-de10-476f-8897-04f38de8dfee" xlink:to="loc_cah_AgreementsAxis_5ba67e3f-33e7-4d03-8202-5c80156bbe23" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_AgreementsDomain_5ba67e3f-33e7-4d03-8202-5c80156bbe23_default" xlink:href="cah-20230331.xsd#cah_AgreementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_AgreementsAxis_5ba67e3f-33e7-4d03-8202-5c80156bbe23" xlink:to="loc_cah_AgreementsDomain_5ba67e3f-33e7-4d03-8202-5c80156bbe23_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_AgreementsDomain_fe4d9871-53de-4ac7-8715-9fc67d3de5b7" xlink:href="cah-20230331.xsd#cah_AgreementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_AgreementsAxis_5ba67e3f-33e7-4d03-8202-5c80156bbe23" xlink:to="loc_cah_AgreementsDomain_fe4d9871-53de-4ac7-8715-9fc67d3de5b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_IVCApril2023AgreementMember_424264c4-513c-47b8-9938-693c95e7f9ed" xlink:href="cah-20230331.xsd#cah_IVCApril2023AgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_AgreementsDomain_fe4d9871-53de-4ac7-8715-9fc67d3de5b7" xlink:to="loc_cah_IVCApril2023AgreementMember_424264c4-513c-47b8-9938-693c95e7f9ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OtherAgreementsMember_8b38fcd1-a49c-4e26-b6de-05d609394983" xlink:href="cah-20230331.xsd#cah_OtherAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_AgreementsDomain_fe4d9871-53de-4ac7-8715-9fc67d3de5b7" xlink:to="loc_cah_OtherAgreementsMember_8b38fcd1-a49c-4e26-b6de-05d609394983" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="cah-20230331.xsd#IncomeTaxesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended" id="ib9013687e37b4a9ea76c83b3a4805c86_IncomeTaxesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_940baa0e-2857-45a0-b8c4-adf73270640f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_68c75664-afd9-4484-b430-3993b72cdc8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_940baa0e-2857-45a0-b8c4-adf73270640f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_68c75664-afd9-4484-b430-3993b72cdc8e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_f3a5e538-31f4-4e74-8a3c-a6c242c8f7ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_940baa0e-2857-45a0-b8c4-adf73270640f" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_f3a5e538-31f4-4e74-8a3c-a6c242c8f7ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_08255c91-1ea6-4a7b-bfa8-cff9957aab80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_940baa0e-2857-45a0-b8c4-adf73270640f" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_08255c91-1ea6-4a7b-bfa8-cff9957aab80" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_160df928-b373-491b-a2e7-c1cac280ce20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_940baa0e-2857-45a0-b8c4-adf73270640f" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_160df928-b373-491b-a2e7-c1cac280ce20" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_e79fe5e6-5046-40e1-a489-dd06177ff6c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_940baa0e-2857-45a0-b8c4-adf73270640f" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_e79fe5e6-5046-40e1-a489-dd06177ff6c3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_f833e07b-8ff6-46d5-b830-8763c41274bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_940baa0e-2857-45a0-b8c4-adf73270640f" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_f833e07b-8ff6-46d5-b830-8763c41274bd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_20bf8dfd-ce78-45a4-a4c5-72be4fde3403" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_940baa0e-2857-45a0-b8c4-adf73270640f" xlink:to="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_20bf8dfd-ce78-45a4-a4c5-72be4fde3403" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_IndemnificationReceivable_2e8118df-0897-4c80-a8d3-907dcf18094b" xlink:href="cah-20230331.xsd#cah_IndemnificationReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_940baa0e-2857-45a0-b8c4-adf73270640f" xlink:to="loc_cah_IndemnificationReceivable_2e8118df-0897-4c80-a8d3-907dcf18094b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_b14d42bf-21c6-4886-a561-21dc88ad8e98" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_940baa0e-2857-45a0-b8c4-adf73270640f" xlink:to="loc_us-gaap_TaxCreditCarryforwardTable_b14d42bf-21c6-4886-a561-21dc88ad8e98" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationAxis_77790365-6646-45e4-836c-f7bdee114b78" xlink:href="cah-20230331.xsd#cah_OpioidLitigationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_b14d42bf-21c6-4886-a561-21dc88ad8e98" xlink:to="loc_cah_OpioidLitigationAxis_77790365-6646-45e4-836c-f7bdee114b78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationDomain_77790365-6646-45e4-836c-f7bdee114b78_default" xlink:href="cah-20230331.xsd#cah_OpioidLitigationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_OpioidLitigationAxis_77790365-6646-45e4-836c-f7bdee114b78" xlink:to="loc_cah_OpioidLitigationDomain_77790365-6646-45e4-836c-f7bdee114b78_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationDomain_da54776c-f2b0-46e8-8f02-bafb31b4fdad" xlink:href="cah-20230331.xsd#cah_OpioidLitigationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_OpioidLitigationAxis_77790365-6646-45e4-836c-f7bdee114b78" xlink:to="loc_cah_OpioidLitigationDomain_da54776c-f2b0-46e8-8f02-bafb31b4fdad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalOpioidLitigationMember_d124c39a-20b9-4757-b764-0e233dad1fcd" xlink:href="cah-20230331.xsd#cah_TotalOpioidLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_OpioidLitigationDomain_da54776c-f2b0-46e8-8f02-bafb31b4fdad" xlink:to="loc_cah_TotalOpioidLitigationMember_d124c39a-20b9-4757-b764-0e233dad1fcd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMatterAxis_9bb1d51e-e00d-4489-bfbd-54291f32dbb4" xlink:href="cah-20230331.xsd#cah_TaxMatterAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_b14d42bf-21c6-4886-a561-21dc88ad8e98" xlink:to="loc_cah_TaxMatterAxis_9bb1d51e-e00d-4489-bfbd-54291f32dbb4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMatterDomain_9bb1d51e-e00d-4489-bfbd-54291f32dbb4_default" xlink:href="cah-20230331.xsd#cah_TaxMatterDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_TaxMatterAxis_9bb1d51e-e00d-4489-bfbd-54291f32dbb4" xlink:to="loc_cah_TaxMatterDomain_9bb1d51e-e00d-4489-bfbd-54291f32dbb4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMatterDomain_cd188419-9a31-4e4f-a983-34decfc12b25" xlink:href="cah-20230331.xsd#cah_TaxMatterDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_TaxMatterAxis_9bb1d51e-e00d-4489-bfbd-54291f32dbb4" xlink:to="loc_cah_TaxMatterDomain_cd188419-9a31-4e4f-a983-34decfc12b25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CareFusionMember_77368f54-4571-44f3-bdf8-b4bc28381f57" xlink:href="cah-20230331.xsd#cah_CareFusionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_TaxMatterDomain_cd188419-9a31-4e4f-a983-34decfc12b25" xlink:to="loc_cah_CareFusionMember_77368f54-4571-44f3-bdf8-b4bc28381f57" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_dd53b2ec-ebe2-4e62-97f2-9f42050533d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_b14d42bf-21c6-4886-a561-21dc88ad8e98" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_dd53b2ec-ebe2-4e62-97f2-9f42050533d0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dd53b2ec-ebe2-4e62-97f2-9f42050533d0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_dd53b2ec-ebe2-4e62-97f2-9f42050533d0" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dd53b2ec-ebe2-4e62-97f2-9f42050533d0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1a03a749-7a53-4856-a264-878a6cf1c065" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_dd53b2ec-ebe2-4e62-97f2-9f42050533d0" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1a03a749-7a53-4856-a264-878a6cf1c065" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMattersAgreementAxis_ea9241b4-d4f2-4144-ac7a-7ee1d45db578" xlink:href="cah-20230331.xsd#cah_TaxMattersAgreementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_b14d42bf-21c6-4886-a561-21dc88ad8e98" xlink:to="loc_cah_TaxMattersAgreementAxis_ea9241b4-d4f2-4144-ac7a-7ee1d45db578" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMattersAgreementDomain_ea9241b4-d4f2-4144-ac7a-7ee1d45db578_default" xlink:href="cah-20230331.xsd#cah_TaxMattersAgreementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_TaxMattersAgreementAxis_ea9241b4-d4f2-4144-ac7a-7ee1d45db578" xlink:to="loc_cah_TaxMattersAgreementDomain_ea9241b4-d4f2-4144-ac7a-7ee1d45db578_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMattersAgreementDomain_0329aea4-288a-4a6c-953c-9ac9cb1454db" xlink:href="cah-20230331.xsd#cah_TaxMattersAgreementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_TaxMattersAgreementAxis_ea9241b4-d4f2-4144-ac7a-7ee1d45db578" xlink:to="loc_cah_TaxMattersAgreementDomain_0329aea4-288a-4a6c-953c-9ac9cb1454db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CareFusionMember_7c22d0ba-ccd1-49fd-a7eb-18e0322d7452" xlink:href="cah-20230331.xsd#cah_CareFusionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_TaxMattersAgreementDomain_0329aea4-288a-4a6c-953c-9ac9cb1454db" xlink:to="loc_cah_CareFusionMember_7c22d0ba-ccd1-49fd-a7eb-18e0322d7452" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a7c7992b-8363-46d8-afc9-252870dc8594" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_b14d42bf-21c6-4886-a561-21dc88ad8e98" xlink:to="loc_srt_RangeAxis_a7c7992b-8363-46d8-afc9-252870dc8594" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a7c7992b-8363-46d8-afc9-252870dc8594_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_a7c7992b-8363-46d8-afc9-252870dc8594" xlink:to="loc_srt_RangeMember_a7c7992b-8363-46d8-afc9-252870dc8594_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_766c5327-715f-4b1f-b460-f73bcb4b3afd" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_a7c7992b-8363-46d8-afc9-252870dc8594" xlink:to="loc_srt_RangeMember_766c5327-715f-4b1f-b460-f73bcb4b3afd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4a71940f-769c-4b15-95ff-4b0625692fc2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_766c5327-715f-4b1f-b460-f73bcb4b3afd" xlink:to="loc_srt_MinimumMember_4a71940f-769c-4b15-95ff-4b0625692fc2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e0428723-99ec-4616-98dd-9007235061c6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_766c5327-715f-4b1f-b460-f73bcb4b3afd" xlink:to="loc_srt_MaximumMember_e0428723-99ec-4616-98dd-9007235061c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NetOperatingLossCarrybackAxis_3bc57af6-bdd8-46fd-8942-4a2552262d03" xlink:href="cah-20230331.xsd#cah_NetOperatingLossCarrybackAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_b14d42bf-21c6-4886-a561-21dc88ad8e98" xlink:to="loc_cah_NetOperatingLossCarrybackAxis_3bc57af6-bdd8-46fd-8942-4a2552262d03" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CARESActDomain_3bc57af6-bdd8-46fd-8942-4a2552262d03_default" xlink:href="cah-20230331.xsd#cah_CARESActDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_NetOperatingLossCarrybackAxis_3bc57af6-bdd8-46fd-8942-4a2552262d03" xlink:to="loc_cah_CARESActDomain_3bc57af6-bdd8-46fd-8942-4a2552262d03_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CARESActDomain_23821944-5bc3-4d28-a384-7070ffd27bf5" xlink:href="cah-20230331.xsd#cah_CARESActDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_NetOperatingLossCarrybackAxis_3bc57af6-bdd8-46fd-8942-4a2552262d03" xlink:to="loc_cah_CARESActDomain_23821944-5bc3-4d28-a384-7070ffd27bf5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_55e83f63-3b2e-478d-a12e-14ae2afc93fb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_b14d42bf-21c6-4886-a561-21dc88ad8e98" xlink:to="loc_srt_StatementScenarioAxis_55e83f63-3b2e-478d-a12e-14ae2afc93fb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_55e83f63-3b2e-478d-a12e-14ae2afc93fb_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_55e83f63-3b2e-478d-a12e-14ae2afc93fb" xlink:to="loc_srt_ScenarioUnspecifiedDomain_55e83f63-3b2e-478d-a12e-14ae2afc93fb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_0f51d318-2a0a-40a0-961b-40d342f04313" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_55e83f63-3b2e-478d-a12e-14ae2afc93fb" xlink:to="loc_srt_ScenarioUnspecifiedDomain_0f51d318-2a0a-40a0-961b-40d342f04313" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_4d233b75-1460-4dc1-b15d-bc95413ecbe6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_0f51d318-2a0a-40a0-961b-40d342f04313" xlink:to="loc_srt_ScenarioForecastMember_4d233b75-1460-4dc1-b15d-bc95413ecbe6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_GoodwillImpairmentAxis_0966ed8b-7eaf-433c-a2d6-1acaeca09485" xlink:href="cah-20230331.xsd#cah_GoodwillImpairmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_b14d42bf-21c6-4886-a561-21dc88ad8e98" xlink:to="loc_cah_GoodwillImpairmentAxis_0966ed8b-7eaf-433c-a2d6-1acaeca09485" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_GoodwillImpairmentDomain_0966ed8b-7eaf-433c-a2d6-1acaeca09485_default" xlink:href="cah-20230331.xsd#cah_GoodwillImpairmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_GoodwillImpairmentAxis_0966ed8b-7eaf-433c-a2d6-1acaeca09485" xlink:to="loc_cah_GoodwillImpairmentDomain_0966ed8b-7eaf-433c-a2d6-1acaeca09485_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_GoodwillImpairmentDomain_7a6c388f-0701-4e15-9e42-6a461fbf5cf4" xlink:href="cah-20230331.xsd#cah_GoodwillImpairmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_GoodwillImpairmentAxis_0966ed8b-7eaf-433c-a2d6-1acaeca09485" xlink:to="loc_cah_GoodwillImpairmentDomain_7a6c388f-0701-4e15-9e42-6a461fbf5cf4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalUnitMember_02da21ad-24a0-4df1-8aa6-a73a383c2dc0" xlink:href="cah-20230331.xsd#cah_MedicalUnitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_GoodwillImpairmentDomain_7a6c388f-0701-4e15-9e42-6a461fbf5cf4" xlink:to="loc_cah_MedicalUnitMember_02da21ad-24a0-4df1-8aa6-a73a383c2dc0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalUnitGoodwillImpairmentMember_f19c8618-e23e-48b7-9a26-d40e89b268cf" xlink:href="cah-20230331.xsd#cah_MedicalUnitGoodwillImpairmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_GoodwillImpairmentDomain_7a6c388f-0701-4e15-9e42-6a461fbf5cf4" xlink:to="loc_cah_MedicalUnitGoodwillImpairmentMember_f19c8618-e23e-48b7-9a26-d40e89b268cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureAxis_a8dcc43f-ea3b-4d0e-9a0c-e71b891640b3" xlink:href="cah-20230331.xsd#cah_CordisDivestitureAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_b14d42bf-21c6-4886-a561-21dc88ad8e98" xlink:to="loc_cah_CordisDivestitureAxis_a8dcc43f-ea3b-4d0e-9a0c-e71b891640b3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureDomain_a8dcc43f-ea3b-4d0e-9a0c-e71b891640b3_default" xlink:href="cah-20230331.xsd#cah_CordisDivestitureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_CordisDivestitureAxis_a8dcc43f-ea3b-4d0e-9a0c-e71b891640b3" xlink:to="loc_cah_CordisDivestitureDomain_a8dcc43f-ea3b-4d0e-9a0c-e71b891640b3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureDomain_bce3e53f-5952-4c61-b275-e1482577ed2c" xlink:href="cah-20230331.xsd#cah_CordisDivestitureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_CordisDivestitureAxis_a8dcc43f-ea3b-4d0e-9a0c-e71b891640b3" xlink:to="loc_cah_CordisDivestitureDomain_bce3e53f-5952-4c61-b275-e1482577ed2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureMember_74b403e9-1b10-4061-82b1-50600e79c641" xlink:href="cah-20230331.xsd#cah_CordisDivestitureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_CordisDivestitureDomain_bce3e53f-5952-4c61-b275-e1482577ed2c" xlink:to="loc_cah_CordisDivestitureMember_74b403e9-1b10-4061-82b1-50600e79c641" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_92014054-fc2e-4cf8-894f-f01b517d4483" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_b14d42bf-21c6-4886-a561-21dc88ad8e98" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_92014054-fc2e-4cf8-894f-f01b517d4483" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_92014054-fc2e-4cf8-894f-f01b517d4483_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_92014054-fc2e-4cf8-894f-f01b517d4483" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_92014054-fc2e-4cf8-894f-f01b517d4483_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_2204b258-a2ff-4c3d-9b5b-af3ee08b12fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_92014054-fc2e-4cf8-894f-f01b517d4483" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_2204b258-a2ff-4c3d-9b5b-af3ee08b12fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_f44fa03d-5c13-418b-9017-2016199b34f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_2204b258-a2ff-4c3d-9b5b-af3ee08b12fa" xlink:to="loc_us-gaap_SubsequentEventMember_f44fa03d-5c13-418b-9017-2016199b34f0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis_3abbe6fa-dfc3-4db8-a835-d0f56bdad8db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReportingUnitAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_b14d42bf-21c6-4886-a561-21dc88ad8e98" xlink:to="loc_us-gaap_ReportingUnitAxis_3abbe6fa-dfc3-4db8-a835-d0f56bdad8db" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_3abbe6fa-dfc3-4db8-a835-d0f56bdad8db_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReportingUnitDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReportingUnitAxis_3abbe6fa-dfc3-4db8-a835-d0f56bdad8db" xlink:to="loc_us-gaap_ReportingUnitDomain_3abbe6fa-dfc3-4db8-a835-d0f56bdad8db_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_546f472a-e0d1-4a73-b9ab-ca880e18482c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReportingUnitDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReportingUnitAxis_3abbe6fa-dfc3-4db8-a835-d0f56bdad8db" xlink:to="loc_us-gaap_ReportingUnitDomain_546f472a-e0d1-4a73-b9ab-ca880e18482c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalUnitMember_07c6d55d-dbf6-4a55-949c-99963f0a2cae" xlink:href="cah-20230331.xsd#cah_MedicalUnitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_546f472a-e0d1-4a73-b9ab-ca880e18482c" xlink:to="loc_cah_MedicalUnitMember_07c6d55d-dbf6-4a55-949c-99963f0a2cae" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" xlink:type="simple" xlink:href="cah-20230331.xsd#FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" xlink:type="extended" id="i4aa2266394bc4685b7654842a3ccc205_FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cafcd035-e418-4e2c-889a-1381cbf9cc4a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_fc1fd1fb-af0a-4b8a-8c27-655ff5d9d7d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cafcd035-e418-4e2c-889a-1381cbf9cc4a" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_fc1fd1fb-af0a-4b8a-8c27-655ff5d9d7d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_f3049f28-c443-40f3-83e0-31ec44a787ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_fc1fd1fb-af0a-4b8a-8c27-655ff5d9d7d4" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_f3049f28-c443-40f3-83e0-31ec44a787ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_41c3c34b-6fe3-4bf9-8909-476a53a212ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_fc1fd1fb-af0a-4b8a-8c27-655ff5d9d7d4" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_41c3c34b-6fe3-4bf9-8909-476a53a212ea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet_94624656-e821-4129-aca7-12f13a15c138" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_fc1fd1fb-af0a-4b8a-8c27-655ff5d9d7d4" xlink:to="loc_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet_94624656-e821-4129-aca7-12f13a15c138" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_616d6584-b9e1-471e-9222-2fd14910f780" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cafcd035-e418-4e2c-889a-1381cbf9cc4a" xlink:to="loc_us-gaap_LiabilitiesAbstract_616d6584-b9e1-471e-9222-2fd14910f780" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet_ae3688ba-6328-4be0-a3e2-4889a1913ba2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_513c3b9a-e525-4961-8e6c-4aae527dae24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cafcd035-e418-4e2c-889a-1381cbf9cc4a" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_513c3b9a-e525-4961-8e6c-4aae527dae24" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_410d241e-396a-4854-88b5-a350eb042c7c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_513c3b9a-e525-4961-8e6c-4aae527dae24" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_410d241e-396a-4854-88b5-a350eb042c7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_410d241e-396a-4854-88b5-a350eb042c7c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_410d241e-396a-4854-88b5-a350eb042c7c" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_410d241e-396a-4854-88b5-a350eb042c7c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a160c88f-d100-4e00-9ef5-aca3b5634cc0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_410d241e-396a-4854-88b5-a350eb042c7c" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a160c88f-d100-4e00-9ef5-aca3b5634cc0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_1800160b-e27b-4f2c-83e5-46c0b1e42490" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a160c88f-d100-4e00-9ef5-aca3b5634cc0" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_1800160b-e27b-4f2c-83e5-46c0b1e42490" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_9349c799-755b-4c68-af62-af1cc8024f17" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a160c88f-d100-4e00-9ef5-aca3b5634cc0" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_9349c799-755b-4c68-af62-af1cc8024f17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_e0c1a5da-b0cf-4872-830c-8941a2537a3d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a160c88f-d100-4e00-9ef5-aca3b5634cc0" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_e0c1a5da-b0cf-4872-830c-8941a2537a3d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_86fe1960-1c0c-48aa-913d-5ca0c36656bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_513c3b9a-e525-4961-8e6c-4aae527dae24" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_86fe1960-1c0c-48aa-913d-5ca0c36656bd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_86fe1960-1c0c-48aa-913d-5ca0c36656bd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_86fe1960-1c0c-48aa-913d-5ca0c36656bd" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_86fe1960-1c0c-48aa-913d-5ca0c36656bd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_2dd92eae-b22a-4887-b1bc-86b7c83d9664" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_86fe1960-1c0c-48aa-913d-5ca0c36656bd" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_2dd92eae-b22a-4887-b1bc-86b7c83d9664" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_fdfdd0b4-9a6d-431b-bb0c-03dddfc64b1a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_2dd92eae-b22a-4887-b1bc-86b7c83d9664" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_fdfdd0b4-9a6d-431b-bb0c-03dddfc64b1a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="simple" xlink:href="cah-20230331.xsd#FinancialInstrumentsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="extended" id="i28f2f236414c4aa4920079d90454d528_FinancialInstrumentsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_1b1a616a-9f94-48d5-89de-593703303123" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_67118cef-6d79-42b9-9fde-4ab126451810" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_1b1a616a-9f94-48d5-89de-593703303123" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_67118cef-6d79-42b9-9fde-4ab126451810" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotionalAmount_ab9bf8c0-c094-4f56-954f-b3992e2dbb18" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilityNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_1b1a616a-9f94-48d5-89de-593703303123" xlink:to="loc_us-gaap_DerivativeLiabilityNotionalAmount_ab9bf8c0-c094-4f56-954f-b3992e2dbb18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotionalAmount_824f9fde-a182-42d7-a19e-3911a07df47f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssetNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_1b1a616a-9f94-48d5-89de-593703303123" xlink:to="loc_us-gaap_DerivativeAssetNotionalAmount_824f9fde-a182-42d7-a19e-3911a07df47f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_0f1e4001-e6bb-43db-be9c-adf7d995ee80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_1b1a616a-9f94-48d5-89de-593703303123" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_0f1e4001-e6bb-43db-be9c-adf7d995ee80" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_2a025b82-598c-41a5-a472-63f93858adc6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_1b1a616a-9f94-48d5-89de-593703303123" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_2a025b82-598c-41a5-a472-63f93858adc6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount_d0cf9099-a0b5-4acd-8798-68907a7f3429" xlink:href="cah-20230331.xsd#cah_DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_1b1a616a-9f94-48d5-89de-593703303123" xlink:to="loc_cah_DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount_d0cf9099-a0b5-4acd-8798-68907a7f3429" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromHedgeInvestingActivities_aa5c239a-f885-4a56-9c09-9dcdb4393673" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromHedgeInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_1b1a616a-9f94-48d5-89de-593703303123" xlink:to="loc_us-gaap_ProceedsFromHedgeInvestingActivities_aa5c239a-f885-4a56-9c09-9dcdb4393673" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_31a431e2-723d-4b49-a973-9d323f0bbab4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_1b1a616a-9f94-48d5-89de-593703303123" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_31a431e2-723d-4b49-a973-9d323f0bbab4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_87b11040-ab89-4ffc-81ad-cbca5da15a56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_1b1a616a-9f94-48d5-89de-593703303123" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_87b11040-ab89-4ffc-81ad-cbca5da15a56" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_963849d7-809f-41e3-9057-f92e0f5e5e8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_1b1a616a-9f94-48d5-89de-593703303123" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_963849d7-809f-41e3-9057-f92e0f5e5e8e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_b9d2e1be-10c4-47c5-8f43-cf3b810b04f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_1b1a616a-9f94-48d5-89de-593703303123" xlink:to="loc_us-gaap_DerivativeTable_b9d2e1be-10c4-47c5-8f43-cf3b810b04f8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_82d167c3-058f-4033-8d7b-445ed2078302" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_b9d2e1be-10c4-47c5-8f43-cf3b810b04f8" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_82d167c3-058f-4033-8d7b-445ed2078302" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_82d167c3-058f-4033-8d7b-445ed2078302_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_82d167c3-058f-4033-8d7b-445ed2078302" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_82d167c3-058f-4033-8d7b-445ed2078302_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_91373d04-faef-45de-bec4-1d863a2bbb4f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_82d167c3-058f-4033-8d7b-445ed2078302" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_91373d04-faef-45de-bec4-1d863a2bbb4f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_69ea0439-b0b5-424c-8b12-448b0bf67e20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_91373d04-faef-45de-bec4-1d863a2bbb4f" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_69ea0439-b0b5-424c-8b12-448b0bf67e20" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8d7637e7-7a6a-4732-91f1-46b3785bd76f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_b9d2e1be-10c4-47c5-8f43-cf3b810b04f8" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8d7637e7-7a6a-4732-91f1-46b3785bd76f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8d7637e7-7a6a-4732-91f1-46b3785bd76f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8d7637e7-7a6a-4732-91f1-46b3785bd76f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8d7637e7-7a6a-4732-91f1-46b3785bd76f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0ffca032-9362-4939-a04c-ab2376e7afb5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8d7637e7-7a6a-4732-91f1-46b3785bd76f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0ffca032-9362-4939-a04c-ab2376e7afb5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_ca024a99-ff53-4339-b8ef-e6b4a08f583c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0ffca032-9362-4939-a04c-ab2376e7afb5" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_ca024a99-ff53-4339-b8ef-e6b4a08f583c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_0deefe9d-d23f-4973-9a14-f4927fb2c8e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_b9d2e1be-10c4-47c5-8f43-cf3b810b04f8" xlink:to="loc_us-gaap_HedgingDesignationAxis_0deefe9d-d23f-4973-9a14-f4927fb2c8e3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_0deefe9d-d23f-4973-9a14-f4927fb2c8e3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_0deefe9d-d23f-4973-9a14-f4927fb2c8e3" xlink:to="loc_us-gaap_HedgingDesignationDomain_0deefe9d-d23f-4973-9a14-f4927fb2c8e3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_ef117b3e-6966-425e-bccc-18f38a249e83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_0deefe9d-d23f-4973-9a14-f4927fb2c8e3" xlink:to="loc_us-gaap_HedgingDesignationDomain_ef117b3e-6966-425e-bccc-18f38a249e83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_38dc4f01-9fbe-4db4-b916-0ce7a2b1e6cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_ef117b3e-6966-425e-bccc-18f38a249e83" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_38dc4f01-9fbe-4db4-b916-0ce7a2b1e6cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_e74d9dd3-fe41-42cd-b2c2-c114f30fb636" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_ef117b3e-6966-425e-bccc-18f38a249e83" xlink:to="loc_us-gaap_NondesignatedMember_e74d9dd3-fe41-42cd-b2c2-c114f30fb636" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_85c76ea0-690e-4c5d-81c2-f74c1e68dbb0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_b9d2e1be-10c4-47c5-8f43-cf3b810b04f8" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_85c76ea0-690e-4c5d-81c2-f74c1e68dbb0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_85c76ea0-690e-4c5d-81c2-f74c1e68dbb0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_85c76ea0-690e-4c5d-81c2-f74c1e68dbb0" xlink:to="loc_us-gaap_HedgingRelationshipDomain_85c76ea0-690e-4c5d-81c2-f74c1e68dbb0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_b5f757ed-7d21-46ec-8237-5fe558f5a6e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_85c76ea0-690e-4c5d-81c2-f74c1e68dbb0" xlink:to="loc_us-gaap_HedgingRelationshipDomain_b5f757ed-7d21-46ec-8237-5fe558f5a6e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_2407c9be-9fc5-4905-bd3e-a6226e06b814" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_b5f757ed-7d21-46ec-8237-5fe558f5a6e5" xlink:to="loc_us-gaap_FairValueHedgingMember_2407c9be-9fc5-4905-bd3e-a6226e06b814" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_4c8dcafa-39d9-4aa9-ae67-20232b67e46b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_b5f757ed-7d21-46ec-8237-5fe558f5a6e5" xlink:to="loc_us-gaap_CashFlowHedgingMember_4c8dcafa-39d9-4aa9-ae67-20232b67e46b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_f5e8bff6-74e0-4940-9ca0-706328ca73f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_b5f757ed-7d21-46ec-8237-5fe558f5a6e5" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_f5e8bff6-74e0-4940-9ca0-706328ca73f2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_71d7a26d-4f55-42ad-a2a4-3cc95186c946" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_b9d2e1be-10c4-47c5-8f43-cf3b810b04f8" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_71d7a26d-4f55-42ad-a2a4-3cc95186c946" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_71d7a26d-4f55-42ad-a2a4-3cc95186c946_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_71d7a26d-4f55-42ad-a2a4-3cc95186c946" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_71d7a26d-4f55-42ad-a2a4-3cc95186c946_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_30af096d-3d88-421d-a386-ddec48a6ca9f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_71d7a26d-4f55-42ad-a2a4-3cc95186c946" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_30af096d-3d88-421d-a386-ddec48a6ca9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_e3b8b512-0d9c-46da-93ac-9f6036992f06" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_30af096d-3d88-421d-a386-ddec48a6ca9f" xlink:to="loc_us-gaap_CashFlowHedgingMember_e3b8b512-0d9c-46da-93ac-9f6036992f06" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_68cbb5f6-4cf7-40b6-a693-34824eafb868" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_30af096d-3d88-421d-a386-ddec48a6ca9f" xlink:to="loc_us-gaap_ForeignExchangeContractMember_68cbb5f6-4cf7-40b6-a693-34824eafb868" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_3cc270b4-367e-4de3-b8ff-836a3f36d2d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_30af096d-3d88-421d-a386-ddec48a6ca9f" xlink:to="loc_us-gaap_InterestRateSwapMember_3cc270b4-367e-4de3-b8ff-836a3f36d2d8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_dcafaeba-7bc0-42da-9ffd-14efb0d4e50b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrencySwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_30af096d-3d88-421d-a386-ddec48a6ca9f" xlink:to="loc_us-gaap_CurrencySwapMember_dcafaeba-7bc0-42da-9ffd-14efb0d4e50b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MaturityDateAxis_3b51165a-3ad3-4069-9c66-9cc6f2d03267" xlink:href="cah-20230331.xsd#cah_MaturityDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_b9d2e1be-10c4-47c5-8f43-cf3b810b04f8" xlink:to="loc_cah_MaturityDateAxis_3b51165a-3ad3-4069-9c66-9cc6f2d03267" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MaturityDateDomain_3b51165a-3ad3-4069-9c66-9cc6f2d03267_default" xlink:href="cah-20230331.xsd#cah_MaturityDateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_MaturityDateAxis_3b51165a-3ad3-4069-9c66-9cc6f2d03267" xlink:to="loc_cah_MaturityDateDomain_3b51165a-3ad3-4069-9c66-9cc6f2d03267_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MaturityDateDomain_10d419ea-bbd4-48d3-b264-4192146f5ac2" xlink:href="cah-20230331.xsd#cah_MaturityDateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_MaturityDateAxis_3b51165a-3ad3-4069-9c66-9cc6f2d03267" xlink:to="loc_cah_MaturityDateDomain_10d419ea-bbd4-48d3-b264-4192146f5ac2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_September2025Member_d36cbaf8-aec9-4e12-9bbf-ea5b9e536266" xlink:href="cah-20230331.xsd#cah_September2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_MaturityDateDomain_10d419ea-bbd4-48d3-b264-4192146f5ac2" xlink:to="loc_cah_September2025Member_d36cbaf8-aec9-4e12-9bbf-ea5b9e536266" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_June2027Member_98be41dd-95f1-47b2-8596-52b02c2024b1" xlink:href="cah-20230331.xsd#cah_June2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_MaturityDateDomain_10d419ea-bbd4-48d3-b264-4192146f5ac2" xlink:to="loc_cah_June2027Member_98be41dd-95f1-47b2-8596-52b02c2024b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_March2025Member_dbd90a36-c1b7-430a-9f49-b20d44d97017" xlink:href="cah-20230331.xsd#cah_March2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_MaturityDateDomain_10d419ea-bbd4-48d3-b264-4192146f5ac2" xlink:to="loc_cah_March2025Member_dbd90a36-c1b7-430a-9f49-b20d44d97017" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_March2026Member_baa3e79d-010e-477f-a958-f70f7d0ea4fe" xlink:href="cah-20230331.xsd#cah_March2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_MaturityDateDomain_10d419ea-bbd4-48d3-b264-4192146f5ac2" xlink:to="loc_cah_March2026Member_baa3e79d-010e-477f-a958-f70f7d0ea4fe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_20c3940e-04c3-4bba-b837-af8a7af2e542" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_b9d2e1be-10c4-47c5-8f43-cf3b810b04f8" xlink:to="loc_srt_StatementScenarioAxis_20c3940e-04c3-4bba-b837-af8a7af2e542" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_20c3940e-04c3-4bba-b837-af8a7af2e542_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_20c3940e-04c3-4bba-b837-af8a7af2e542" xlink:to="loc_srt_ScenarioUnspecifiedDomain_20c3940e-04c3-4bba-b837-af8a7af2e542_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_3b48a2a7-60b4-4eb0-b5cc-837b201ad998" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_20c3940e-04c3-4bba-b837-af8a7af2e542" xlink:to="loc_srt_ScenarioUnspecifiedDomain_3b48a2a7-60b4-4eb0-b5cc-837b201ad998" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_bb8d9f50-8e63-4339-b4da-18ff47d3826a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_3b48a2a7-60b4-4eb0-b5cc-837b201ad998" xlink:to="loc_srt_ScenarioForecastMember_bb8d9f50-8e63-4339-b4da-18ff47d3826a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_8bade925-f639-4ca4-9e35-332cc6afdab6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_b9d2e1be-10c4-47c5-8f43-cf3b810b04f8" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_8bade925-f639-4ca4-9e35-332cc6afdab6" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_8bade925-f639-4ca4-9e35-332cc6afdab6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_8bade925-f639-4ca4-9e35-332cc6afdab6" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_8bade925-f639-4ca4-9e35-332cc6afdab6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_ee3411e0-42ce-4dd8-8a82-69da9a98a72d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_8bade925-f639-4ca4-9e35-332cc6afdab6" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_ee3411e0-42ce-4dd8-8a82-69da9a98a72d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_05ca4c67-b097-4e2e-ba1f-7e40bd1d7bab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_ee3411e0-42ce-4dd8-8a82-69da9a98a72d" xlink:to="loc_us-gaap_SubsequentEventMember_05ca4c67-b097-4e2e-ba1f-7e40bd1d7bab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_DateInitiatedAxis_4d373cc2-c8e9-4a42-b47b-65a2bf574e2e" xlink:href="cah-20230331.xsd#cah_DateInitiatedAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_b9d2e1be-10c4-47c5-8f43-cf3b810b04f8" xlink:to="loc_cah_DateInitiatedAxis_4d373cc2-c8e9-4a42-b47b-65a2bf574e2e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_DateInitiatedDomain_4d373cc2-c8e9-4a42-b47b-65a2bf574e2e_default" xlink:href="cah-20230331.xsd#cah_DateInitiatedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_DateInitiatedAxis_4d373cc2-c8e9-4a42-b47b-65a2bf574e2e" xlink:to="loc_cah_DateInitiatedDomain_4d373cc2-c8e9-4a42-b47b-65a2bf574e2e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_DateInitiatedDomain_099896b2-c063-4b9e-aed8-38bb642a64ff" xlink:href="cah-20230331.xsd#cah_DateInitiatedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_DateInitiatedAxis_4d373cc2-c8e9-4a42-b47b-65a2bf574e2e" xlink:to="loc_cah_DateInitiatedDomain_099896b2-c063-4b9e-aed8-38bb642a64ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_March2022Member_32c903ae-2934-415a-b8d6-2a1b3d0fb1d5" xlink:href="cah-20230331.xsd#cah_March2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_DateInitiatedDomain_099896b2-c063-4b9e-aed8-38bb642a64ff" xlink:to="loc_cah_March2022Member_32c903ae-2934-415a-b8d6-2a1b3d0fb1d5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_September2018Member_cd2b1a69-4d04-4d52-b785-e14206170cd7" xlink:href="cah-20230331.xsd#cah_September2018Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_DateInitiatedDomain_099896b2-c063-4b9e-aed8-38bb642a64ff" xlink:to="loc_cah_September2018Member_cd2b1a69-4d04-4d52-b785-e14206170cd7" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails" xlink:type="simple" xlink:href="cah-20230331.xsd#FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails" xlink:type="extended" id="i62c5956033ca49caa579ff910c4a9333_FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7bee449a-7292-4503-baa6-3c5ee3919061" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_bce96c52-e8a7-462d-b1e8-da4a3508b5ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7bee449a-7292-4503-baa6-3c5ee3919061" xlink:to="loc_us-gaap_DebtInstrumentFairValue_bce96c52-e8a7-462d-b1e8-da4a3508b5ee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CarryingAmountofLongTermandotherShortTermBorrowings_19aa7749-e6fa-474f-abda-42a082b65ec8" xlink:href="cah-20230331.xsd#cah_CarryingAmountofLongTermandotherShortTermBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7bee449a-7292-4503-baa6-3c5ee3919061" xlink:to="loc_cah_CarryingAmountofLongTermandotherShortTermBorrowings_19aa7749-e6fa-474f-abda-42a082b65ec8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4a06a8ef-8c71-4bd1-bf66-cb419ec9a950" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7bee449a-7292-4503-baa6-3c5ee3919061" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4a06a8ef-8c71-4bd1-bf66-cb419ec9a950" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2582d78a-2dea-4784-b96e-f70b80521aaa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4a06a8ef-8c71-4bd1-bf66-cb419ec9a950" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2582d78a-2dea-4784-b96e-f70b80521aaa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2582d78a-2dea-4784-b96e-f70b80521aaa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2582d78a-2dea-4784-b96e-f70b80521aaa" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2582d78a-2dea-4784-b96e-f70b80521aaa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9c4494bc-2b9b-4453-8585-43f04ad62742" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2582d78a-2dea-4784-b96e-f70b80521aaa" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9c4494bc-2b9b-4453-8585-43f04ad62742" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_5a560e9d-d01f-4c89-afbc-38b33e0fbb8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9c4494bc-2b9b-4453-8585-43f04ad62742" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_5a560e9d-d01f-4c89-afbc-38b33e0fbb8b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="cah-20230331.xsd#ShareholdersEquityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" xlink:type="extended" id="i77223c6c1df4465fbf0ad257d3d178f0_ShareholdersEquityNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_046c74d5-52ca-4d79-a38e-6482bfab791a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_f9cd2313-a8a6-47fa-b785-8a113c6ff37b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_046c74d5-52ca-4d79-a38e-6482bfab791a" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_f9cd2313-a8a6-47fa-b785-8a113c6ff37b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_6dda974a-5537-444b-871c-19573a8fadc5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_046c74d5-52ca-4d79-a38e-6482bfab791a" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_6dda974a-5537-444b-871c-19573a8fadc5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_2adccd76-9881-4f59-a21c-0c7b4fad09f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_046c74d5-52ca-4d79-a38e-6482bfab791a" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_2adccd76-9881-4f59-a21c-0c7b4fad09f8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_6eded314-592f-4b9a-815a-18bc161adc78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_046c74d5-52ca-4d79-a38e-6482bfab791a" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_6eded314-592f-4b9a-815a-18bc161adc78" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_8c316b2b-f212-42ba-a23a-d9ee01a2e954" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_6eded314-592f-4b9a-815a-18bc161adc78" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_8c316b2b-f212-42ba-a23a-d9ee01a2e954" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_8c316b2b-f212-42ba-a23a-d9ee01a2e954_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8c316b2b-f212-42ba-a23a-d9ee01a2e954" xlink:to="loc_us-gaap_EquityComponentDomain_8c316b2b-f212-42ba-a23a-d9ee01a2e954_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6dc58d56-34be-4fd9-9593-c89f95be7a3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8c316b2b-f212-42ba-a23a-d9ee01a2e954" xlink:to="loc_us-gaap_EquityComponentDomain_6dc58d56-34be-4fd9-9593-c89f95be7a3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_2efb182a-293a-4f98-ae5a-c8eae88c719e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6dc58d56-34be-4fd9-9593-c89f95be7a3c" xlink:to="loc_us-gaap_TreasuryStockCommonMember_2efb182a-293a-4f98-ae5a-c8eae88c719e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_204142b6-e711-49da-8eee-9b280f8c7a9a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_262df0e1-1a72-417a-99ab-7cd05d3a77e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_6eded314-592f-4b9a-815a-18bc161adc78" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_262df0e1-1a72-417a-99ab-7cd05d3a77e4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_262df0e1-1a72-417a-99ab-7cd05d3a77e4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_262df0e1-1a72-417a-99ab-7cd05d3a77e4" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_262df0e1-1a72-417a-99ab-7cd05d3a77e4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_09933b5c-0c04-40b1-8538-d739d22dd536" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_262df0e1-1a72-417a-99ab-7cd05d3a77e4" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_09933b5c-0c04-40b1-8538-d739d22dd536" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_922ede20-afb6-46d2-acd0-23532fc7710f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_09933b5c-0c04-40b1-8538-d739d22dd536" xlink:to="loc_us-gaap_SubsequentEventMember_922ede20-afb6-46d2-acd0-23532fc7710f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_b517b836-26c9-4a99-8ff6-607649a6552b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_6eded314-592f-4b9a-815a-18bc161adc78" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_b517b836-26c9-4a99-8ff6-607649a6552b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_b517b836-26c9-4a99-8ff6-607649a6552b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_b517b836-26c9-4a99-8ff6-607649a6552b" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_b517b836-26c9-4a99-8ff6-607649a6552b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_b0eb2d70-d053-45e1-92b8-210c6345bb57" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_b517b836-26c9-4a99-8ff6-607649a6552b" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_b0eb2d70-d053-45e1-92b8-210c6345bb57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A250MillionShareRepurchaseProgramMember_d03c64f3-6a4b-4720-9312-4cdb41fcfd0f" xlink:href="cah-20230331.xsd#cah_A250MillionShareRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_b0eb2d70-d053-45e1-92b8-210c6345bb57" xlink:to="loc_cah_A250MillionShareRepurchaseProgramMember_d03c64f3-6a4b-4720-9312-4cdb41fcfd0f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A1BillionShareRepurchaseProgramMember_a88fe11d-651f-468d-9a97-17f01936903f" xlink:href="cah-20230331.xsd#cah_A1BillionShareRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_b0eb2d70-d053-45e1-92b8-210c6345bb57" xlink:to="loc_cah_A1BillionShareRepurchaseProgramMember_a88fe11d-651f-468d-9a97-17f01936903f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A300MillionShareRepurchaseProgramMember_44775c6c-32d5-4474-84f8-58ce9135e10a" xlink:href="cah-20230331.xsd#cah_A300MillionShareRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_b0eb2d70-d053-45e1-92b8-210c6345bb57" xlink:to="loc_cah_A300MillionShareRepurchaseProgramMember_44775c6c-32d5-4474-84f8-58ce9135e10a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A500MillionShareRepurchaseProgramMember_e4d8d8eb-42bd-4584-8a09-c11da5e265b8" xlink:href="cah-20230331.xsd#cah_A500MillionShareRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_b0eb2d70-d053-45e1-92b8-210c6345bb57" xlink:to="loc_cah_A500MillionShareRepurchaseProgramMember_e4d8d8eb-42bd-4584-8a09-c11da5e265b8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A200MillionShareRepurchaseProgramMember_b69ef862-9997-4f0b-ba41-5a122e94683b" xlink:href="cah-20230331.xsd#cah_A200MillionShareRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_b0eb2d70-d053-45e1-92b8-210c6345bb57" xlink:to="loc_cah_A200MillionShareRepurchaseProgramMember_b69ef862-9997-4f0b-ba41-5a122e94683b" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="cah-20230331.xsd#ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended" id="iee0f21c2e53d4b44931a228688d67dfd_ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_5bed25ce-ec70-405f-9c0c-178165a31009" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_fdab17fb-43ec-4c6c-8904-35420e21548d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_5bed25ce-ec70-405f-9c0c-178165a31009" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_fdab17fb-43ec-4c6c-8904-35420e21548d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7427bd2f-0a57-4857-84f4-d95c50a7b802" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_fdab17fb-43ec-4c6c-8904-35420e21548d" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7427bd2f-0a57-4857-84f4-d95c50a7b802" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_490bf811-31fc-4d93-9d25-e68ac72dd068" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_fdab17fb-43ec-4c6c-8904-35420e21548d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_490bf811-31fc-4d93-9d25-e68ac72dd068" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_3a63b44a-6eb6-4d16-bf2e-9e689f532fdf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_fdab17fb-43ec-4c6c-8904-35420e21548d" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_3a63b44a-6eb6-4d16-bf2e-9e689f532fdf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_2d6f615e-1c56-49ca-b86f-a38bf0875025" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_fdab17fb-43ec-4c6c-8904-35420e21548d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTax_2d6f615e-1c56-49ca-b86f-a38bf0875025" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_4b70bfc4-60cf-4ddf-b2cc-8c3cc1a7d995" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_fdab17fb-43ec-4c6c-8904-35420e21548d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_4b70bfc4-60cf-4ddf-b2cc-8c3cc1a7d995" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_42916156-1ac0-42c8-a8a3-0f3597405af3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_0de2f9d9-2106-43e6-aba2-8d7e0f0d53fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_5bed25ce-ec70-405f-9c0c-178165a31009" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_0de2f9d9-2106-43e6-aba2-8d7e0f0d53fa" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2ad4f9fc-3cda-4afc-b083-e61901e24742" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_0de2f9d9-2106-43e6-aba2-8d7e0f0d53fa" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2ad4f9fc-3cda-4afc-b083-e61901e24742" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2ad4f9fc-3cda-4afc-b083-e61901e24742_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2ad4f9fc-3cda-4afc-b083-e61901e24742" xlink:to="loc_us-gaap_EquityComponentDomain_2ad4f9fc-3cda-4afc-b083-e61901e24742_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1e2c8b17-e736-402f-850e-80b84b7d56a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2ad4f9fc-3cda-4afc-b083-e61901e24742" xlink:to="loc_us-gaap_EquityComponentDomain_1e2c8b17-e736-402f-850e-80b84b7d56a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_fb27fc97-2ddf-4625-8997-7d3e8d348506" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1e2c8b17-e736-402f-850e-80b84b7d56a2" xlink:to="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_fb27fc97-2ddf-4625-8997-7d3e8d348506" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember_bfec6164-084d-4e42-8e88-d9c6564dac69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1e2c8b17-e736-402f-850e-80b84b7d56a2" xlink:to="loc_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember_bfec6164-084d-4e42-8e88-d9c6564dac69" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_b65403de-77d9-4c0a-842f-0df865833c14" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1e2c8b17-e736-402f-850e-80b84b7d56a2" xlink:to="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_b65403de-77d9-4c0a-842f-0df865833c14" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5fd541b5-e092-4d9a-b63e-202570fd8a2f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1e2c8b17-e736-402f-850e-80b84b7d56a2" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5fd541b5-e092-4d9a-b63e-202570fd8a2f" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationNarrativeDetails" xlink:type="simple" xlink:href="cah-20230331.xsd#SegmentInformationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/SegmentInformationNarrativeDetails" xlink:type="extended" id="i24c4db9150434a909e4a4caa25710997_SegmentInformationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_24532173-0c32-487d-8d31-bdd1a3c2374e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_00c0e20d-7126-4445-b583-26553587c71f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_24532173-0c32-487d-8d31-bdd1a3c2374e" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_00c0e20d-7126-4445-b583-26553587c71f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProjectCostsOnInvestmentAndOtherSpending_741ed225-0bd9-42b8-b260-ea5c86a88218" xlink:href="cah-20230331.xsd#cah_ProjectCostsOnInvestmentAndOtherSpending"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_24532173-0c32-487d-8d31-bdd1a3c2374e" xlink:to="loc_cah_ProjectCostsOnInvestmentAndOtherSpending_741ed225-0bd9-42b8-b260-ea5c86a88218" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_b9178b8e-72d3-4f21-95b9-7e0e9e8966b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_24532173-0c32-487d-8d31-bdd1a3c2374e" xlink:to="loc_us-gaap_NumberOfReportableSegments_b9178b8e-72d3-4f21-95b9-7e0e9e8966b2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_1f0fa068-06c7-4dee-abcf-2898b4b32d81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_24532173-0c32-487d-8d31-bdd1a3c2374e" xlink:to="loc_us-gaap_NumberOfOperatingSegments_1f0fa068-06c7-4dee-abcf-2898b4b32d81" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_8861233c-78ae-443d-8c5b-b297088f7ee8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_24532173-0c32-487d-8d31-bdd1a3c2374e" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_8861233c-78ae-443d-8c5b-b297088f7ee8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_46851951-b610-400b-a378-c415c538d67d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_24532173-0c32-487d-8d31-bdd1a3c2374e" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_46851951-b610-400b-a378-c415c538d67d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationAxis_fbfb82b9-0395-4f9e-9a3d-ff964a3c0327" xlink:href="cah-20230331.xsd#cah_OpioidLitigationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_46851951-b610-400b-a378-c415c538d67d" xlink:to="loc_cah_OpioidLitigationAxis_fbfb82b9-0395-4f9e-9a3d-ff964a3c0327" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationDomain_fbfb82b9-0395-4f9e-9a3d-ff964a3c0327_default" xlink:href="cah-20230331.xsd#cah_OpioidLitigationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_OpioidLitigationAxis_fbfb82b9-0395-4f9e-9a3d-ff964a3c0327" xlink:to="loc_cah_OpioidLitigationDomain_fbfb82b9-0395-4f9e-9a3d-ff964a3c0327_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationDomain_5a11e125-f84b-48ea-bfcd-dfc3c0691ef7" xlink:href="cah-20230331.xsd#cah_OpioidLitigationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_OpioidLitigationAxis_fbfb82b9-0395-4f9e-9a3d-ff964a3c0327" xlink:to="loc_cah_OpioidLitigationDomain_5a11e125-f84b-48ea-bfcd-dfc3c0691ef7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalOpioidLitigationMember_0b4d57fe-0640-4b19-bfe5-eec9ec2eb0c3" xlink:href="cah-20230331.xsd#cah_TotalOpioidLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_OpioidLitigationDomain_5a11e125-f84b-48ea-bfcd-dfc3c0691ef7" xlink:to="loc_cah_TotalOpioidLitigationMember_0b4d57fe-0640-4b19-bfe5-eec9ec2eb0c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_56ae9b17-690c-4eb8-9e2c-d060f9312b30" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_46851951-b610-400b-a378-c415c538d67d" xlink:to="loc_srt_LitigationCaseAxis_56ae9b17-690c-4eb8-9e2c-d060f9312b30" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_56ae9b17-690c-4eb8-9e2c-d060f9312b30_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_56ae9b17-690c-4eb8-9e2c-d060f9312b30" xlink:to="loc_srt_LitigationCaseTypeDomain_56ae9b17-690c-4eb8-9e2c-d060f9312b30_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_04b2bdac-15aa-4859-89ae-86d86db1bd85" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_56ae9b17-690c-4eb8-9e2c-d060f9312b30" xlink:to="loc_srt_LitigationCaseTypeDomain_04b2bdac-15aa-4859-89ae-86d86db1bd85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NewYorkOpioidStewardshipActMember_dd799755-680d-4583-ad89-f01563668f1f" xlink:href="cah-20230331.xsd#cah_NewYorkOpioidStewardshipActMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_04b2bdac-15aa-4859-89ae-86d86db1bd85" xlink:to="loc_cah_NewYorkOpioidStewardshipActMember_dd799755-680d-4583-ad89-f01563668f1f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureAxis_a1e55d8b-0e25-4795-a137-afd62b5b1f63" xlink:href="cah-20230331.xsd#cah_CordisDivestitureAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_46851951-b610-400b-a378-c415c538d67d" xlink:to="loc_cah_CordisDivestitureAxis_a1e55d8b-0e25-4795-a137-afd62b5b1f63" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureDomain_a1e55d8b-0e25-4795-a137-afd62b5b1f63_default" xlink:href="cah-20230331.xsd#cah_CordisDivestitureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_CordisDivestitureAxis_a1e55d8b-0e25-4795-a137-afd62b5b1f63" xlink:to="loc_cah_CordisDivestitureDomain_a1e55d8b-0e25-4795-a137-afd62b5b1f63_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureDomain_88a70068-140c-4a1a-b0af-71e32a64d307" xlink:href="cah-20230331.xsd#cah_CordisDivestitureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_CordisDivestitureAxis_a1e55d8b-0e25-4795-a137-afd62b5b1f63" xlink:to="loc_cah_CordisDivestitureDomain_88a70068-140c-4a1a-b0af-71e32a64d307" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureMember_a1b3be24-b7f0-4e65-b471-496d4f65ea58" xlink:href="cah-20230331.xsd#cah_CordisDivestitureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_CordisDivestitureDomain_88a70068-140c-4a1a-b0af-71e32a64d307" xlink:to="loc_cah_CordisDivestitureMember_a1b3be24-b7f0-4e65-b471-496d4f65ea58" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_46a3b41f-64d6-40bf-8c0d-7774a1226b60" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_46851951-b610-400b-a378-c415c538d67d" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_46a3b41f-64d6-40bf-8c0d-7774a1226b60" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_46a3b41f-64d6-40bf-8c0d-7774a1226b60_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_46a3b41f-64d6-40bf-8c0d-7774a1226b60" xlink:to="loc_us-gaap_SegmentDomain_46a3b41f-64d6-40bf-8c0d-7774a1226b60_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_1373d489-ee54-4b53-b6d2-5db25dfb0f97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_46a3b41f-64d6-40bf-8c0d-7774a1226b60" xlink:to="loc_us-gaap_SegmentDomain_1373d489-ee54-4b53-b6d2-5db25dfb0f97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember_4fb0d3c8-150e-435e-b2c5-efdca31d47d8" xlink:href="cah-20230331.xsd#cah_MedicalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_1373d489-ee54-4b53-b6d2-5db25dfb0f97" xlink:to="loc_cah_MedicalMember_4fb0d3c8-150e-435e-b2c5-efdca31d47d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis_36030064-fc4f-4caf-a452-bed2f1371b3e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReportingUnitAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_46851951-b610-400b-a378-c415c538d67d" xlink:to="loc_us-gaap_ReportingUnitAxis_36030064-fc4f-4caf-a452-bed2f1371b3e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_36030064-fc4f-4caf-a452-bed2f1371b3e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReportingUnitDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReportingUnitAxis_36030064-fc4f-4caf-a452-bed2f1371b3e" xlink:to="loc_us-gaap_ReportingUnitDomain_36030064-fc4f-4caf-a452-bed2f1371b3e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_d2b578ca-f993-4fce-884d-a24e50fef36a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReportingUnitDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReportingUnitAxis_36030064-fc4f-4caf-a452-bed2f1371b3e" xlink:to="loc_us-gaap_ReportingUnitDomain_d2b578ca-f993-4fce-884d-a24e50fef36a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalUnitMember_96830b82-5b8a-4e42-ae4d-b5a35414f956" xlink:href="cah-20230331.xsd#cah_MedicalUnitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_d2b578ca-f993-4fce-884d-a24e50fef36a" xlink:to="loc_cah_MedicalUnitMember_96830b82-5b8a-4e42-ae4d-b5a35414f956" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails" xlink:type="simple" xlink:href="cah-20230331.xsd#SegmentInformationRevenuebyReportableSegmentDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails" xlink:type="extended" id="i9aa1606b4cae42d3bb3ee8bcac5c0643_SegmentInformationRevenuebyReportableSegmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_39e0716d-84ae-4868-9408-fe1212ef79c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_c1287695-8b60-418c-ac4a-d46ac75beeb4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_39e0716d-84ae-4868-9408-fe1212ef79c8" xlink:to="loc_us-gaap_Revenues_c1287695-8b60-418c-ac4a-d46ac75beeb4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_b9cb6223-475e-4cc5-bd2a-4ad6399fa6c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_39e0716d-84ae-4868-9408-fe1212ef79c8" xlink:to="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_b9cb6223-475e-4cc5-bd2a-4ad6399fa6c0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis_615abe97-8573-4a93-9992-049624b3c43b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_b9cb6223-475e-4cc5-bd2a-4ad6399fa6c0" xlink:to="loc_us-gaap_SubsegmentsAxis_615abe97-8573-4a93-9992-049624b3c43b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_615abe97-8573-4a93-9992-049624b3c43b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsegmentsAxis_615abe97-8573-4a93-9992-049624b3c43b" xlink:to="loc_us-gaap_SubsegmentsDomain_615abe97-8573-4a93-9992-049624b3c43b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_6e0fb6bb-f234-4614-83f9-01610ea60891" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsegmentsAxis_615abe97-8573-4a93-9992-049624b3c43b" xlink:to="loc_us-gaap_SubsegmentsDomain_6e0fb6bb-f234-4614-83f9-01610ea60891" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalDistributionandSpecialtyMember_fa5829a6-0142-4bc2-af3e-64b106110d89" xlink:href="cah-20230331.xsd#cah_PharmaceuticalDistributionandSpecialtyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_6e0fb6bb-f234-4614-83f9-01610ea60891" xlink:to="loc_cah_PharmaceuticalDistributionandSpecialtyMember_fa5829a6-0142-4bc2-af3e-64b106110d89" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NuclearPrecisionHealthSolutionsMember_9cfe9f7d-3cb1-4a0b-a600-9c63e88400af" xlink:href="cah-20230331.xsd#cah_NuclearPrecisionHealthSolutionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_6e0fb6bb-f234-4614-83f9-01610ea60891" xlink:to="loc_cah_NuclearPrecisionHealthSolutionsMember_9cfe9f7d-3cb1-4a0b-a600-9c63e88400af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicaldistributionandproductsMember_3db2cd0a-e2ba-4a9a-acb4-077782130bde" xlink:href="cah-20230331.xsd#cah_MedicaldistributionandproductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_6e0fb6bb-f234-4614-83f9-01610ea60891" xlink:to="loc_cah_MedicaldistributionandproductsMember_3db2cd0a-e2ba-4a9a-acb4-077782130bde" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CardinalHealthAtHomeMember_e1a1ebcd-cd4e-4252-9177-053ecd04efbe" xlink:href="cah-20230331.xsd#cah_CardinalHealthAtHomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_6e0fb6bb-f234-4614-83f9-01610ea60891" xlink:to="loc_cah_CardinalHealthAtHomeMember_e1a1ebcd-cd4e-4252-9177-053ecd04efbe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_c7b20cfe-0b97-4c18-a7d6-e44e8fb4ee87" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_b9cb6223-475e-4cc5-bd2a-4ad6399fa6c0" xlink:to="loc_srt_ConsolidationItemsAxis_c7b20cfe-0b97-4c18-a7d6-e44e8fb4ee87" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_c7b20cfe-0b97-4c18-a7d6-e44e8fb4ee87_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_c7b20cfe-0b97-4c18-a7d6-e44e8fb4ee87" xlink:to="loc_srt_ConsolidationItemsDomain_c7b20cfe-0b97-4c18-a7d6-e44e8fb4ee87_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_70a187f7-adfb-4030-9d90-2df97d27265b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_c7b20cfe-0b97-4c18-a7d6-e44e8fb4ee87" xlink:to="loc_srt_ConsolidationItemsDomain_70a187f7-adfb-4030-9d90-2df97d27265b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_2be83122-27b2-4003-80ba-fd2bb667b2f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_70a187f7-adfb-4030-9d90-2df97d27265b" xlink:to="loc_us-gaap_OperatingSegmentsMember_2be83122-27b2-4003-80ba-fd2bb667b2f9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_7b611380-a9b9-48f4-b990-de2f652183f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_70a187f7-adfb-4030-9d90-2df97d27265b" xlink:to="loc_us-gaap_CorporateNonSegmentMember_7b611380-a9b9-48f4-b990-de2f652183f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_3d29f2e5-44a3-4fdf-b581-177bec4fd054" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_b9cb6223-475e-4cc5-bd2a-4ad6399fa6c0" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_3d29f2e5-44a3-4fdf-b581-177bec4fd054" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_3d29f2e5-44a3-4fdf-b581-177bec4fd054_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_3d29f2e5-44a3-4fdf-b581-177bec4fd054" xlink:to="loc_us-gaap_SegmentDomain_3d29f2e5-44a3-4fdf-b581-177bec4fd054_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_43bb60df-a81e-4707-bea6-cf162bd861ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_3d29f2e5-44a3-4fdf-b581-177bec4fd054" xlink:to="loc_us-gaap_SegmentDomain_43bb60df-a81e-4707-bea6-cf162bd861ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalMember_04e5a21f-2c66-4cee-8fd5-696512086226" xlink:href="cah-20230331.xsd#cah_PharmaceuticalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_43bb60df-a81e-4707-bea6-cf162bd861ed" xlink:to="loc_cah_PharmaceuticalMember_04e5a21f-2c66-4cee-8fd5-696512086226" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember_1b9739f9-b2f0-4d4e-8caf-88967c28d38c" xlink:href="cah-20230331.xsd#cah_MedicalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_43bb60df-a81e-4707-bea6-cf162bd861ed" xlink:to="loc_cah_MedicalMember_1b9739f9-b2f0-4d4e-8caf-88967c28d38c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails" xlink:type="simple" xlink:href="cah-20230331.xsd#SegmentInformationSegmentProfitbyReportableSegmentDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails" xlink:type="extended" id="i93ca77d4b0a448128ed4ace4aebcc2ef_SegmentInformationSegmentProfitbyReportableSegmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_9f26f21d-c4ff-42eb-a2ca-d8ab0773aeea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_aa45ceb4-e2a9-4993-b803-c73b6922121e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_9f26f21d-c4ff-42eb-a2ca-d8ab0773aeea" xlink:to="loc_us-gaap_OperatingIncomeLoss_aa45ceb4-e2a9-4993-b803-c73b6922121e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_JudgmentForLostProfits_ae7ad4d5-9fb9-47c7-8d83-70f842da8ff3" xlink:href="cah-20230331.xsd#cah_JudgmentForLostProfits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_9f26f21d-c4ff-42eb-a2ca-d8ab0773aeea" xlink:to="loc_cah_JudgmentForLostProfits_ae7ad4d5-9fb9-47c7-8d83-70f842da8ff3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ContingentAttorneyFee_2cf41e6e-c3c0-4328-98ff-0aa9e43da909" xlink:href="cah-20230331.xsd#cah_ContingentAttorneyFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_9f26f21d-c4ff-42eb-a2ca-d8ab0773aeea" xlink:to="loc_cah_ContingentAttorneyFee_2cf41e6e-c3c0-4328-98ff-0aa9e43da909" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_4de96dfb-ec50-437c-94e1-c24f836f6a17" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_9f26f21d-c4ff-42eb-a2ca-d8ab0773aeea" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_4de96dfb-ec50-437c-94e1-c24f836f6a17" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_53f98cf3-31e0-4815-98a3-1fab6c526383" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_4de96dfb-ec50-437c-94e1-c24f836f6a17" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_53f98cf3-31e0-4815-98a3-1fab6c526383" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_53f98cf3-31e0-4815-98a3-1fab6c526383_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_53f98cf3-31e0-4815-98a3-1fab6c526383" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_53f98cf3-31e0-4815-98a3-1fab6c526383_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_52eea8b9-d4a4-4ea5-85cc-e9c02b779cb9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_53f98cf3-31e0-4815-98a3-1fab6c526383" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_52eea8b9-d4a4-4ea5-85cc-e9c02b779cb9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_62baf2a5-e730-424f-bd2a-786806f8624b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_4de96dfb-ec50-437c-94e1-c24f836f6a17" xlink:to="loc_srt_ConsolidationItemsAxis_62baf2a5-e730-424f-bd2a-786806f8624b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_62baf2a5-e730-424f-bd2a-786806f8624b_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_62baf2a5-e730-424f-bd2a-786806f8624b" xlink:to="loc_srt_ConsolidationItemsDomain_62baf2a5-e730-424f-bd2a-786806f8624b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_9b779ac0-de5f-4b19-aab8-914f0827fa1f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_62baf2a5-e730-424f-bd2a-786806f8624b" xlink:to="loc_srt_ConsolidationItemsDomain_9b779ac0-de5f-4b19-aab8-914f0827fa1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_2c399be2-346a-411b-bcff-f66f87c01f23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_9b779ac0-de5f-4b19-aab8-914f0827fa1f" xlink:to="loc_us-gaap_OperatingSegmentsMember_2c399be2-346a-411b-bcff-f66f87c01f23" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_a477f636-ab73-485f-b615-0c51f7ac5424" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_9b779ac0-de5f-4b19-aab8-914f0827fa1f" xlink:to="loc_us-gaap_CorporateNonSegmentMember_a477f636-ab73-485f-b615-0c51f7ac5424" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_f6d22abb-dd63-4b0f-a106-9b1d5130587a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_4de96dfb-ec50-437c-94e1-c24f836f6a17" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_f6d22abb-dd63-4b0f-a106-9b1d5130587a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_f6d22abb-dd63-4b0f-a106-9b1d5130587a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_f6d22abb-dd63-4b0f-a106-9b1d5130587a" xlink:to="loc_us-gaap_SegmentDomain_f6d22abb-dd63-4b0f-a106-9b1d5130587a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_56568c0e-57a0-4891-b167-d5d842457f5f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_f6d22abb-dd63-4b0f-a106-9b1d5130587a" xlink:to="loc_us-gaap_SegmentDomain_56568c0e-57a0-4891-b167-d5d842457f5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalMember_66eebca3-eba2-48e5-b62e-da461c8729cf" xlink:href="cah-20230331.xsd#cah_PharmaceuticalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_56568c0e-57a0-4891-b167-d5d842457f5f" xlink:to="loc_cah_PharmaceuticalMember_66eebca3-eba2-48e5-b62e-da461c8729cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember_2576bc5e-b52b-480b-8227-020aa8f88dcd" xlink:href="cah-20230331.xsd#cah_MedicalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_56568c0e-57a0-4891-b167-d5d842457f5f" xlink:to="loc_cah_MedicalMember_2576bc5e-b52b-480b-8227-020aa8f88dcd" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails" xlink:type="simple" xlink:href="cah-20230331.xsd#SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails" xlink:type="extended" id="i5edb797ea88d412c9a374e37ea89bc7a_SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails">
    <link:loc xlink:type="locator" xlink:label="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems_a24a350e-cc6a-4826-822f-a9c8c3b0b8d8" xlink:href="cah-20230331.xsd#cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_07470280-491b-4425-9361-6ff45bff9e7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems_a24a350e-cc6a-4826-822f-a9c8c3b0b8d8" xlink:to="loc_us-gaap_Revenues_07470280-491b-4425-9361-6ff45bff9e7b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable_807bafa9-05fa-468a-80d3-4ba776040c3b" xlink:href="cah-20230331.xsd#cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems_a24a350e-cc6a-4826-822f-a9c8c3b0b8d8" xlink:to="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable_807bafa9-05fa-468a-80d3-4ba776040c3b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_94979fe0-5581-4a1f-ab57-f82e51b82976" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable_807bafa9-05fa-468a-80d3-4ba776040c3b" xlink:to="loc_srt_ConsolidationItemsAxis_94979fe0-5581-4a1f-ab57-f82e51b82976" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_94979fe0-5581-4a1f-ab57-f82e51b82976_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_94979fe0-5581-4a1f-ab57-f82e51b82976" xlink:to="loc_srt_ConsolidationItemsDomain_94979fe0-5581-4a1f-ab57-f82e51b82976_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_21ca1d30-3523-41ab-bcb1-3c9ac2de8ddc" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_94979fe0-5581-4a1f-ab57-f82e51b82976" xlink:to="loc_srt_ConsolidationItemsDomain_21ca1d30-3523-41ab-bcb1-3c9ac2de8ddc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_605cd8b5-11a8-4749-8677-3db7cdb3fdf2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_21ca1d30-3523-41ab-bcb1-3c9ac2de8ddc" xlink:to="loc_us-gaap_OperatingSegmentsMember_605cd8b5-11a8-4749-8677-3db7cdb3fdf2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_9248cdcb-0e95-4a3c-882e-189a05d0f286" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_21ca1d30-3523-41ab-bcb1-3c9ac2de8ddc" xlink:to="loc_us-gaap_CorporateNonSegmentMember_9248cdcb-0e95-4a3c-882e-189a05d0f286" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_a6d1e196-c4b3-4bd5-8183-56d3c71b3a14" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable_807bafa9-05fa-468a-80d3-4ba776040c3b" xlink:to="loc_srt_StatementGeographicalAxis_a6d1e196-c4b3-4bd5-8183-56d3c71b3a14" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_a6d1e196-c4b3-4bd5-8183-56d3c71b3a14_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_a6d1e196-c4b3-4bd5-8183-56d3c71b3a14" xlink:to="loc_srt_SegmentGeographicalDomain_a6d1e196-c4b3-4bd5-8183-56d3c71b3a14_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_b665e707-3945-4882-820e-d94e53a80463" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_a6d1e196-c4b3-4bd5-8183-56d3c71b3a14" xlink:to="loc_srt_SegmentGeographicalDomain_b665e707-3945-4882-820e-d94e53a80463" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_a8ae4d5e-5abc-4d85-bc89-340476d5d221" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_b665e707-3945-4882-820e-d94e53a80463" xlink:to="loc_country_US_a8ae4d5e-5abc-4d85-bc89-340476d5d221" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_20b326b3-91da-4968-ae79-f1ce6dd929ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_b665e707-3945-4882-820e-d94e53a80463" xlink:to="loc_us-gaap_NonUsMember_20b326b3-91da-4968-ae79-f1ce6dd929ab" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails" xlink:type="simple" xlink:href="cah-20230331.xsd#SegmentInformationAssetsbyReportableSegmentDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails" xlink:type="extended" id="i22fe500e30ec446da02c9014de392ca2_SegmentInformationAssetsbyReportableSegmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_d112117d-5cdc-4160-8ee3-3660cca3b5f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_f2bbeda2-5c70-4414-8bf7-4586c7f4c93e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d112117d-5cdc-4160-8ee3-3660cca3b5f9" xlink:to="loc_us-gaap_Assets_f2bbeda2-5c70-4414-8bf7-4586c7f4c93e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_03d83776-06c4-496e-a3de-74b86901c279" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d112117d-5cdc-4160-8ee3-3660cca3b5f9" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_03d83776-06c4-496e-a3de-74b86901c279" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_38872a4b-ae15-419a-91bb-efa1c1306193" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d112117d-5cdc-4160-8ee3-3660cca3b5f9" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_38872a4b-ae15-419a-91bb-efa1c1306193" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_72f64384-5240-46e7-b240-a44bfd73926a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_38872a4b-ae15-419a-91bb-efa1c1306193" xlink:to="loc_srt_ConsolidationItemsAxis_72f64384-5240-46e7-b240-a44bfd73926a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_72f64384-5240-46e7-b240-a44bfd73926a_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_72f64384-5240-46e7-b240-a44bfd73926a" xlink:to="loc_srt_ConsolidationItemsDomain_72f64384-5240-46e7-b240-a44bfd73926a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_ddf1d27f-eeab-4e3a-bca2-6bb6e218ac38" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_72f64384-5240-46e7-b240-a44bfd73926a" xlink:to="loc_srt_ConsolidationItemsDomain_ddf1d27f-eeab-4e3a-bca2-6bb6e218ac38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_9f61157a-b2bb-4765-9f69-38049be4cad1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_ddf1d27f-eeab-4e3a-bca2-6bb6e218ac38" xlink:to="loc_us-gaap_OperatingSegmentsMember_9f61157a-b2bb-4765-9f69-38049be4cad1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_b940e2a2-e092-45e1-9535-a851d9c7b7e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_ddf1d27f-eeab-4e3a-bca2-6bb6e218ac38" xlink:to="loc_us-gaap_CorporateNonSegmentMember_b940e2a2-e092-45e1-9535-a851d9c7b7e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_3f41eb45-dd6f-4ee2-ac11-fa205fb8c283" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_38872a4b-ae15-419a-91bb-efa1c1306193" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_3f41eb45-dd6f-4ee2-ac11-fa205fb8c283" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_3f41eb45-dd6f-4ee2-ac11-fa205fb8c283_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_3f41eb45-dd6f-4ee2-ac11-fa205fb8c283" xlink:to="loc_us-gaap_SegmentDomain_3f41eb45-dd6f-4ee2-ac11-fa205fb8c283_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_f2ae4835-5f21-4fc5-a04c-12426479f857" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_3f41eb45-dd6f-4ee2-ac11-fa205fb8c283" xlink:to="loc_us-gaap_SegmentDomain_f2ae4835-5f21-4fc5-a04c-12426479f857" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalMember_a8eb5a79-4039-4298-b16e-52c64abea262" xlink:href="cah-20230331.xsd#cah_PharmaceuticalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_f2ae4835-5f21-4fc5-a04c-12426479f857" xlink:to="loc_cah_PharmaceuticalMember_a8eb5a79-4039-4298-b16e-52c64abea262" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember_bb114528-dbba-45cd-81d1-a6b08e182366" xlink:href="cah-20230331.xsd#cah_MedicalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_f2ae4835-5f21-4fc5-a04c-12426479f857" xlink:to="loc_cah_MedicalMember_bb114528-dbba-45cd-81d1-a6b08e182366" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureAxis_abcdda7d-92d0-4efc-b73d-955b53abe3fd" xlink:href="cah-20230331.xsd#cah_CordisDivestitureAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_38872a4b-ae15-419a-91bb-efa1c1306193" xlink:to="loc_cah_CordisDivestitureAxis_abcdda7d-92d0-4efc-b73d-955b53abe3fd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureDomain_abcdda7d-92d0-4efc-b73d-955b53abe3fd_default" xlink:href="cah-20230331.xsd#cah_CordisDivestitureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_CordisDivestitureAxis_abcdda7d-92d0-4efc-b73d-955b53abe3fd" xlink:to="loc_cah_CordisDivestitureDomain_abcdda7d-92d0-4efc-b73d-955b53abe3fd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureDomain_c377990b-55ad-4d75-acbe-5b66df5fcbf3" xlink:href="cah-20230331.xsd#cah_CordisDivestitureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_CordisDivestitureAxis_abcdda7d-92d0-4efc-b73d-955b53abe3fd" xlink:to="loc_cah_CordisDivestitureDomain_c377990b-55ad-4d75-acbe-5b66df5fcbf3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureMember_a5e1e42f-42d0-4508-bd19-086ab57680c7" xlink:href="cah-20230331.xsd#cah_CordisDivestitureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_CordisDivestitureDomain_c377990b-55ad-4d75-acbe-5b66df5fcbf3" xlink:to="loc_cah_CordisDivestitureMember_a5e1e42f-42d0-4508-bd19-086ab57680c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis_4a0ac692-6c0f-468e-bad8-f87805493550" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReportingUnitAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_38872a4b-ae15-419a-91bb-efa1c1306193" xlink:to="loc_us-gaap_ReportingUnitAxis_4a0ac692-6c0f-468e-bad8-f87805493550" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_4a0ac692-6c0f-468e-bad8-f87805493550_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReportingUnitDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReportingUnitAxis_4a0ac692-6c0f-468e-bad8-f87805493550" xlink:to="loc_us-gaap_ReportingUnitDomain_4a0ac692-6c0f-468e-bad8-f87805493550_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_355ce2a3-5f6e-4cf5-8c01-81a0e1b9282d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReportingUnitDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReportingUnitAxis_4a0ac692-6c0f-468e-bad8-f87805493550" xlink:to="loc_us-gaap_ReportingUnitDomain_355ce2a3-5f6e-4cf5-8c01-81a0e1b9282d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalUnitMember_9007984c-405b-4339-bd78-60b9de42d155" xlink:href="cah-20230331.xsd#cah_MedicalUnitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_355ce2a3-5f6e-4cf5-8c01-81a0e1b9282d" xlink:to="loc_cah_MedicalUnitMember_9007984c-405b-4339-bd78-60b9de42d155" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="cah-20230331.xsd#ShareBasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails" xlink:type="extended" id="icb3937f647b3418e869ca8487ba7bf34_ShareBasedCompensationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_350740c4-9b75-4675-baf6-830da6c310b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_VestingPeriodinyearsforShares_06c1c929-8159-40ee-b069-a1670eee9671" xlink:href="cah-20230331.xsd#cah_VestingPeriodinyearsforShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_350740c4-9b75-4675-baf6-830da6c310b3" xlink:to="loc_cah_VestingPeriodinyearsforShares_06c1c929-8159-40ee-b069-a1670eee9671" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_61dfa077-01c6-42b8-b879-2b6c96b035b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_350740c4-9b75-4675-baf6-830da6c310b3" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_61dfa077-01c6-42b8-b879-2b6c96b035b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_bb7add85-3258-4549-8bf1-c56b636d978e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_350740c4-9b75-4675-baf6-830da6c310b3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_bb7add85-3258-4549-8bf1-c56b636d978e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_9d69f05e-1897-4944-bfcc-89a5baea1346" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_350740c4-9b75-4675-baf6-830da6c310b3" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_9d69f05e-1897-4944-bfcc-89a5baea1346" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_38d0ba70-0e4f-4931-9d3e-fe5ca0b121a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_350740c4-9b75-4675-baf6-830da6c310b3" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_38d0ba70-0e4f-4931-9d3e-fe5ca0b121a9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_2af988e5-0287-4bff-b76c-f3e7f016fea1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_350740c4-9b75-4675-baf6-830da6c310b3" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_2af988e5-0287-4bff-b76c-f3e7f016fea1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b5e8c14c-7063-42e0-b8be-6758649acaf4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_350740c4-9b75-4675-baf6-830da6c310b3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b5e8c14c-7063-42e0-b8be-6758649acaf4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b88787cf-07fe-40a2-b1c2-00deb7440808" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b5e8c14c-7063-42e0-b8be-6758649acaf4" xlink:to="loc_us-gaap_AwardTypeAxis_b88787cf-07fe-40a2-b1c2-00deb7440808" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b88787cf-07fe-40a2-b1c2-00deb7440808_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_b88787cf-07fe-40a2-b1c2-00deb7440808" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b88787cf-07fe-40a2-b1c2-00deb7440808_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1e55df24-37ef-4c87-aca4-800062c09d81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_b88787cf-07fe-40a2-b1c2-00deb7440808" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1e55df24-37ef-4c87-aca4-800062c09d81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_ca08e3e0-3b76-46ac-bf13-00d85fd9adf2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1e55df24-37ef-4c87-aca4-800062c09d81" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_ca08e3e0-3b76-46ac-bf13-00d85fd9adf2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_ed933725-22f8-4cf8-b00f-527bf4172ccb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1e55df24-37ef-4c87-aca4-800062c09d81" xlink:to="loc_us-gaap_PerformanceSharesMember_ed933725-22f8-4cf8-b00f-527bf4172ccb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7d7e8947-0b35-48eb-9256-3218f270d8ff" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b5e8c14c-7063-42e0-b8be-6758649acaf4" xlink:to="loc_srt_RangeAxis_7d7e8947-0b35-48eb-9256-3218f270d8ff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7d7e8947-0b35-48eb-9256-3218f270d8ff_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_7d7e8947-0b35-48eb-9256-3218f270d8ff" xlink:to="loc_srt_RangeMember_7d7e8947-0b35-48eb-9256-3218f270d8ff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_470f8606-d4be-4694-8004-2f7f65dd40eb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_7d7e8947-0b35-48eb-9256-3218f270d8ff" xlink:to="loc_srt_RangeMember_470f8606-d4be-4694-8004-2f7f65dd40eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_62287ca9-c539-40de-b6fe-136944802e65" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_470f8606-d4be-4694-8004-2f7f65dd40eb" xlink:to="loc_srt_MinimumMember_62287ca9-c539-40de-b6fe-136944802e65" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_941b48d2-231d-499d-ba36-1c27913a5a71" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_470f8606-d4be-4694-8004-2f7f65dd40eb" xlink:to="loc_srt_MaximumMember_941b48d2-231d-499d-ba36-1c27913a5a71" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails" xlink:type="simple" xlink:href="cah-20230331.xsd#ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails" xlink:type="extended" id="i7e9fbb6bbc044705a59e9003c4a3c6be_ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fd8eb61f-d8ee-4b1c-9e8e-bcdc24c62814" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_d5626726-82e2-40a3-bde4-d3299fa3b4e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fd8eb61f-d8ee-4b1c-9e8e-bcdc24c62814" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_d5626726-82e2-40a3-bde4-d3299fa3b4e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f1e8ae62-0d71-4db0-8f83-66658182c53b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fd8eb61f-d8ee-4b1c-9e8e-bcdc24c62814" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f1e8ae62-0d71-4db0-8f83-66658182c53b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_cc39b8d3-37cd-4285-9318-f6d61a9ae50d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f1e8ae62-0d71-4db0-8f83-66658182c53b" xlink:to="loc_us-gaap_AwardTypeAxis_cc39b8d3-37cd-4285-9318-f6d61a9ae50d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cc39b8d3-37cd-4285-9318-f6d61a9ae50d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_cc39b8d3-37cd-4285-9318-f6d61a9ae50d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cc39b8d3-37cd-4285-9318-f6d61a9ae50d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_39fd2f48-d51c-4c07-a5da-58fef30abc25" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_cc39b8d3-37cd-4285-9318-f6d61a9ae50d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_39fd2f48-d51c-4c07-a5da-58fef30abc25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_c386754e-e61f-4d4f-9ea3-eec7ae5e3b7a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_39fd2f48-d51c-4c07-a5da-58fef30abc25" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_c386754e-e61f-4d4f-9ea3-eec7ae5e3b7a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_c95c88db-e1b1-4dca-9bd8-a839420341dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_39fd2f48-d51c-4c07-a5da-58fef30abc25" xlink:to="loc_us-gaap_PerformanceSharesMember_c95c88db-e1b1-4dca-9bd8-a839420341dd" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails" xlink:type="simple" xlink:href="cah-20230331.xsd#ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails" xlink:type="extended" id="iaf1da3d705bc4cd99c96062181a22480_ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0d76841b-04e9-4dcc-ad48-6f55b836f5bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_a6de63d9-6b3c-4015-9795-73a469ce6b27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0d76841b-04e9-4dcc-ad48-6f55b836f5bb" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_a6de63d9-6b3c-4015-9795-73a469ce6b27" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7aec4ed5-c49d-4bee-8cbf-1888b7d1eedc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0d76841b-04e9-4dcc-ad48-6f55b836f5bb" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7aec4ed5-c49d-4bee-8cbf-1888b7d1eedc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_342a4943-263f-4307-93d1-d56529edcdf0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7aec4ed5-c49d-4bee-8cbf-1888b7d1eedc" xlink:to="loc_us-gaap_AwardTypeAxis_342a4943-263f-4307-93d1-d56529edcdf0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_342a4943-263f-4307-93d1-d56529edcdf0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_342a4943-263f-4307-93d1-d56529edcdf0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_342a4943-263f-4307-93d1-d56529edcdf0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_33bbe54e-f4ed-4041-aeb3-af962a2c86a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_342a4943-263f-4307-93d1-d56529edcdf0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_33bbe54e-f4ed-4041-aeb3-af962a2c86a6" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails" xlink:type="simple" xlink:href="cah-20230331.xsd#ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails" xlink:type="extended" id="i46c5fdae66cd41378443c13b3558491a_ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c5941236-c83d-48be-b7b4-e0fe3f26bcf4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_ec35163f-3915-494b-a8a9-c590bc5aaeb9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c5941236-c83d-48be-b7b4-e0fe3f26bcf4" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_ec35163f-3915-494b-a8a9-c590bc5aaeb9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_e730adc5-9cf6-4aa0-ae1b-570b7fceed45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c5941236-c83d-48be-b7b4-e0fe3f26bcf4" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_e730adc5-9cf6-4aa0-ae1b-570b7fceed45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2aa5fe4e-ed81-4453-9703-1abbc7b1eb29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c5941236-c83d-48be-b7b4-e0fe3f26bcf4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2aa5fe4e-ed81-4453-9703-1abbc7b1eb29" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_dfe3c38c-2645-4b94-a95b-39d43b84e204" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2aa5fe4e-ed81-4453-9703-1abbc7b1eb29" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_dfe3c38c-2645-4b94-a95b-39d43b84e204" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_365f303c-a019-478b-9aaf-6b45e0a119c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2aa5fe4e-ed81-4453-9703-1abbc7b1eb29" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_365f303c-a019-478b-9aaf-6b45e0a119c1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_9b08a353-6479-423c-9cd7-5b1577317132" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2aa5fe4e-ed81-4453-9703-1abbc7b1eb29" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_9b08a353-6479-423c-9cd7-5b1577317132" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_767eaa9f-6bde-47eb-80bb-c916836efd40" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2aa5fe4e-ed81-4453-9703-1abbc7b1eb29" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_767eaa9f-6bde-47eb-80bb-c916836efd40" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4f30094a-dd66-46c5-9137-da359dbcf3a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0bb0d089-5c52-47f1-9f90-62c12736a725" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c5941236-c83d-48be-b7b4-e0fe3f26bcf4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0bb0d089-5c52-47f1-9f90-62c12736a725" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7638a60c-520b-4c6f-ad8f-cc2a2614a00d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0bb0d089-5c52-47f1-9f90-62c12736a725" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7638a60c-520b-4c6f-ad8f-cc2a2614a00d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c08e04a5-3ca3-4216-85b5-229ceb9f4f02" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0bb0d089-5c52-47f1-9f90-62c12736a725" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c08e04a5-3ca3-4216-85b5-229ceb9f4f02" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_92b83949-8701-406b-8145-0407ada8db78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0bb0d089-5c52-47f1-9f90-62c12736a725" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_92b83949-8701-406b-8145-0407ada8db78" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_d5dea88f-c056-4e99-9599-4147d722da77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0bb0d089-5c52-47f1-9f90-62c12736a725" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_d5dea88f-c056-4e99-9599-4147d722da77" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c3fd9ca2-c315-4e7e-bee8-7fb85da4025b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fbb93dba-aec2-4384-9343-592b8f472691" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c5941236-c83d-48be-b7b4-e0fe3f26bcf4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fbb93dba-aec2-4384-9343-592b8f472691" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_1a0bc289-5fbd-4355-b9f9-2107d5d82174" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fbb93dba-aec2-4384-9343-592b8f472691" xlink:to="loc_us-gaap_AwardTypeAxis_1a0bc289-5fbd-4355-b9f9-2107d5d82174" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1a0bc289-5fbd-4355-b9f9-2107d5d82174_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1a0bc289-5fbd-4355-b9f9-2107d5d82174" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1a0bc289-5fbd-4355-b9f9-2107d5d82174_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d9b83166-7eda-42f6-a47a-bc46f01eb336" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1a0bc289-5fbd-4355-b9f9-2107d5d82174" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d9b83166-7eda-42f6-a47a-bc46f01eb336" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_a264840d-ca01-4832-9fbe-dfb1b0e80e05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d9b83166-7eda-42f6-a47a-bc46f01eb336" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_a264840d-ca01-4832-9fbe-dfb1b0e80e05" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails" xlink:type="simple" xlink:href="cah-20230331.xsd#ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails" xlink:type="extended" id="i2d7ac96f9a434dd2b2267415cab094c8_ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fb65c2d4-4ba1-4337-884f-c98da59c2283" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_ec02c8db-6df7-417d-9f1c-cd7ac7bb0d22" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fb65c2d4-4ba1-4337-884f-c98da59c2283" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_ec02c8db-6df7-417d-9f1c-cd7ac7bb0d22" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9d70a7ce-8df5-4988-aa30-d916036aaf5c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fb65c2d4-4ba1-4337-884f-c98da59c2283" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9d70a7ce-8df5-4988-aa30-d916036aaf5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_45502331-e74e-47fe-9f16-2e8e2d9557f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9d70a7ce-8df5-4988-aa30-d916036aaf5c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_45502331-e74e-47fe-9f16-2e8e2d9557f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3067d6ab-3ae0-44f0-a8c0-e560cc42683d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9d70a7ce-8df5-4988-aa30-d916036aaf5c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3067d6ab-3ae0-44f0-a8c0-e560cc42683d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_ac69b541-319b-46c2-82f6-68d0c20e3108" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9d70a7ce-8df5-4988-aa30-d916036aaf5c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_ac69b541-319b-46c2-82f6-68d0c20e3108" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_7fa40f2a-2320-4048-b80a-b2ef9796bd00" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9d70a7ce-8df5-4988-aa30-d916036aaf5c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_7fa40f2a-2320-4048-b80a-b2ef9796bd00" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9034d7d6-c1ae-4712-998a-4a53486e31ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_03f2b209-4535-48b1-abb4-5517a3e69398" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fb65c2d4-4ba1-4337-884f-c98da59c2283" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_03f2b209-4535-48b1-abb4-5517a3e69398" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f0762474-c201-4abf-af2e-26b8014e2552" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_03f2b209-4535-48b1-abb4-5517a3e69398" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f0762474-c201-4abf-af2e-26b8014e2552" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_12c811ad-6268-4f0d-9372-0dfd7e2426e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_03f2b209-4535-48b1-abb4-5517a3e69398" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_12c811ad-6268-4f0d-9372-0dfd7e2426e8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_7ee76213-1bb4-4d46-be5b-2a9dd7e7ac4b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_03f2b209-4535-48b1-abb4-5517a3e69398" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_7ee76213-1bb4-4d46-be5b-2a9dd7e7ac4b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_fb640b6e-adfe-49c0-a27e-cc8bb7624165" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_03f2b209-4535-48b1-abb4-5517a3e69398" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_fb640b6e-adfe-49c0-a27e-cc8bb7624165" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_bbcb07f8-01b2-4d44-9f69-defb57e89ec1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_8ce902e7-3f7e-4185-a115-61f13d1ba8c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fb65c2d4-4ba1-4337-884f-c98da59c2283" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_8ce902e7-3f7e-4185-a115-61f13d1ba8c5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_5a169603-d933-47d3-9c3b-42894d262277" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fb65c2d4-4ba1-4337-884f-c98da59c2283" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_5a169603-d933-47d3-9c3b-42894d262277" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_2b241d4a-1dac-492d-b256-b8c7eef85c3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fb65c2d4-4ba1-4337-884f-c98da59c2283" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_2b241d4a-1dac-492d-b256-b8c7eef85c3f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5d5aca59-3393-4b72-ae91-f32532a314a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fb65c2d4-4ba1-4337-884f-c98da59c2283" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5d5aca59-3393-4b72-ae91-f32532a314a2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9309c6bf-7772-4d36-9444-a8c54675e433" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5d5aca59-3393-4b72-ae91-f32532a314a2" xlink:to="loc_us-gaap_AwardTypeAxis_9309c6bf-7772-4d36-9444-a8c54675e433" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9309c6bf-7772-4d36-9444-a8c54675e433_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_9309c6bf-7772-4d36-9444-a8c54675e433" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9309c6bf-7772-4d36-9444-a8c54675e433_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2416afb4-686d-495b-9e15-f6e83aee6baf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_9309c6bf-7772-4d36-9444-a8c54675e433" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2416afb4-686d-495b-9e15-f6e83aee6baf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_91df620c-370b-4317-9c02-95c1c05d4d1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2416afb4-686d-495b-9e15-f6e83aee6baf" xlink:to="loc_us-gaap_PerformanceSharesMember_91df620c-370b-4317-9c02-95c1c05d4d1b" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>cah-20230331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:9ca698da-8642-4990-b842-4747c9f438b3,g:77ea8682-dcc2-43bc-841d-94551121f3ad-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_5210c588-afd1-4cb1-9a95-ba20f49756bd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Net earnings attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_4cb3fd46-df9c-4b28-aa08-347cc49b1a65_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityNotionalAmount_ea99a747-7630-4d3f-a1d7-83d0832dfd73_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Notional Amount</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilityNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityNotionalAmount" xlink:to="lab_us-gaap_DerivativeLiabilityNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_78dfea06-f76e-40e6-859b-e6f9f5ddc85a_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3818eae2-150e-4625-97ff-66b25848ac2b_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in operating assets and liabilities, net of effects from acquisitions and divestitures:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromHedgeInvestingActivities_2c44d30d-45fa-4f1c-8be3-48513246ce7b_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromHedgeInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from net investment hedge terminations</link:label>
    <link:label id="lab_us-gaap_ProceedsFromHedgeInvestingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromHedgeInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Hedge, Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromHedgeInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromHedgeInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromHedgeInvestingActivities" xlink:to="lab_us-gaap_ProceedsFromHedgeInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_28a0d5c3-9794-493e-97a7-2eb5922d73b4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_WA_310bc7bd-76a1-4a98-bbd3-010806c8df3d_terseLabel_en-US" xlink:label="lab_stpr_WA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WASHINGTON</link:label>
    <link:label id="lab_stpr_WA_label_en-US" xlink:label="lab_stpr_WA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WASHINGTON</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WA" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_WA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_WA" xlink:to="lab_stpr_WA" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ebf1df34-2d43-4f0b-86d5-f23a29feea90_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_39e69781-abd6-4f94-83fa-2cbc154c1ec1_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_4882f5ef-079d-46ed-94eb-ff04b50ec318_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Obligations and Other Short-Term Borrowings</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_e16a6560-47a9-4350-a3fd-d2771c68565e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_PharmaceuticalMember_dacff612-a5c7-4ca6-998c-11cd518ff30e_terseLabel_en-US" xlink:label="lab_cah_PharmaceuticalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical</link:label>
    <link:label id="lab_cah_PharmaceuticalMember_label_en-US" xlink:label="lab_cah_PharmaceuticalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical Member</link:label>
    <link:label id="lab_cah_PharmaceuticalMember_documentation_en-US" xlink:label="lab_cah_PharmaceuticalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalMember" xlink:href="cah-20230331.xsd#cah_PharmaceuticalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_PharmaceuticalMember" xlink:to="lab_cah_PharmaceuticalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_a8033676-bc53-4ca2-9201-335b0954a66a_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_566d6cdf-0ab0-4208-a2c0-655ef1404403_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable_2242c13b-a256-4093-9ac5-f898b87854fc_terseLabel_en-US" xlink:label="lab_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Revenue from External Customers by Geographic Area [Table]</link:label>
    <link:label id="lab_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable_label_en-US" xlink:label="lab_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Revenue from External Customers by Geographic Area [Table]</link:label>
    <link:label id="lab_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable_documentation_en-US" xlink:label="lab_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Revenue from External Customers by Geographic Area [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable" xlink:href="cah-20230331.xsd#cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable" xlink:to="lab_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_4cad7471-edc0-4131-aad7-6446aee99795_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Share Units</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_a06e85e5-3dd3-4558-ab2f-1c580d95f4cb_verboseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Share Unit</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_99817080-6c88-4149-aa2c-57ba1ee2b05f_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_768734c6-3327-4f61-a463-3895ef58d279_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_807bca7e-e7a3-48ef-baeb-8a2e815c0b2c_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Pending Claims, Number</link:label>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Pending Claims, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:to="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_VestingPeriodinyearsforShares_7a3bbc5d-1e7f-46de-9d85-298391d5337f_terseLabel_en-US" xlink:label="lab_cah_VestingPeriodinyearsforShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Period in years for Shares</link:label>
    <link:label id="lab_cah_VestingPeriodinyearsforShares_label_en-US" xlink:label="lab_cah_VestingPeriodinyearsforShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Period in years for Shares</link:label>
    <link:label id="lab_cah_VestingPeriodinyearsforShares_documentation_en-US" xlink:label="lab_cah_VestingPeriodinyearsforShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Period in years for Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_VestingPeriodinyearsforShares" xlink:href="cah-20230331.xsd#cah_VestingPeriodinyearsforShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_VestingPeriodinyearsforShares" xlink:to="lab_cah_VestingPeriodinyearsforShares" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_ProductLiabilityLawsuitsMember_48b77253-db09-4702-b267-ffa6902aa802_terseLabel_en-US" xlink:label="lab_cah_ProductLiabilityLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Liability Lawsuits</link:label>
    <link:label id="lab_cah_ProductLiabilityLawsuitsMember_label_en-US" xlink:label="lab_cah_ProductLiabilityLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Liability Lawsuits [Member]</link:label>
    <link:label id="lab_cah_ProductLiabilityLawsuitsMember_documentation_en-US" xlink:label="lab_cah_ProductLiabilityLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Liability Lawsuits [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProductLiabilityLawsuitsMember" xlink:href="cah-20230331.xsd#cah_ProductLiabilityLawsuitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_ProductLiabilityLawsuitsMember" xlink:to="lab_cah_ProductLiabilityLawsuitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1c27af60-fc35-4dfa-a8b6-d3184a4b4141_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardTable_ccf7478a-af5b-4c8d-98b6-d9f8755b2166_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardTable_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable" xlink:to="lab_us-gaap_TaxCreditCarryforwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_3ceb036a-4e87-40f0-9485-c03e2bf2788d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes and other liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax and Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_ClassActionLawsuitsMember_ab9be82d-bd9c-47c7-ae39-0ac650ab7235_terseLabel_en-US" xlink:label="lab_cah_ClassActionLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Action Lawsuits [Member]</link:label>
    <link:label id="lab_cah_ClassActionLawsuitsMember_label_en-US" xlink:label="lab_cah_ClassActionLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Action Lawsuits [Member]</link:label>
    <link:label id="lab_cah_ClassActionLawsuitsMember_documentation_en-US" xlink:label="lab_cah_ClassActionLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Action Lawsuits [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ClassActionLawsuitsMember" xlink:href="cah-20230331.xsd#cah_ClassActionLawsuitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_ClassActionLawsuitsMember" xlink:to="lab_cah_ClassActionLawsuitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_8e791e77-5fe9-4016-95ae-5a322b7d3e2c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_1ad31680-864a-4a84-8b6e-5769dce8024c_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_09f4d5d0-b697-4795-9147-d2b139cc05da_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_WV_938c2cb2-d898-4d95-bd31-94a3a6925446_terseLabel_en-US" xlink:label="lab_stpr_WV" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WEST VIRGINIA</link:label>
    <link:label id="lab_stpr_WV_label_en-US" xlink:label="lab_stpr_WV" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WEST VIRGINIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WV" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_WV"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_WV" xlink:to="lab_stpr_WV" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReportingUnitDomain_54039ef2-499a-471d-9929-d09ca0e90a1f_terseLabel_en-US" xlink:label="lab_us-gaap_ReportingUnitDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Domain]</link:label>
    <link:label id="lab_us-gaap_ReportingUnitDomain_label_en-US" xlink:label="lab_us-gaap_ReportingUnitDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReportingUnitDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReportingUnitDomain" xlink:to="lab_us-gaap_ReportingUnitDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_CordisDivestitureDomain_c69b410a-739f-49da-abbe-83c89c96a664_terseLabel_en-US" xlink:label="lab_cah_CordisDivestitureDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cordis Divestiture [Domain]</link:label>
    <link:label id="lab_cah_CordisDivestitureDomain_label_en-US" xlink:label="lab_cah_CordisDivestitureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cordis Divestiture [Domain]</link:label>
    <link:label id="lab_cah_CordisDivestitureDomain_documentation_en-US" xlink:label="lab_cah_CordisDivestitureDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cordis Divestiture [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureDomain" xlink:href="cah-20230331.xsd#cah_CordisDivestitureDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_CordisDivestitureDomain" xlink:to="lab_cah_CordisDivestitureDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_8446bfe9-c305-40d5-be6f-e5685ec17781_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_5c6d5673-346d-45ac-8a52-3b9730869aa0_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_73a35909-7578-4962-864b-00318697e6cb_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_bf4adabc-737b-4793-82dc-07d61df16371_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Authorized&#8212;500 thousand shares, Issued&#8212;none</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_82870651-f39a-4a84-80ea-fff14b929517_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Grant Date Fair Value per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_9531bca3-3f22-4274-bc8c-473102c19dd3_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Grant Date Fair Value per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_0f7f377d-3d59-484e-8dbb-5536e9c7db0f_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_9082f5b0-85d1-4ee8-b1e2-0892affbc1f5_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from divestitures, net of cash sold</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Divestiture of Businesses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:to="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_MaturityDateAxis_51caccf7-691c-41a0-be86-76a77018ce8f_terseLabel_en-US" xlink:label="lab_cah_MaturityDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity Date</link:label>
    <link:label id="lab_cah_MaturityDateAxis_label_en-US" xlink:label="lab_cah_MaturityDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity Date [Axis]</link:label>
    <link:label id="lab_cah_MaturityDateAxis_documentation_en-US" xlink:label="lab_cah_MaturityDateAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MaturityDateAxis" xlink:href="cah-20230331.xsd#cah_MaturityDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_MaturityDateAxis" xlink:to="lab_cah_MaturityDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5102cbf2-1278-41d8-807f-0ada7a88f67b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_124428c9-9330-430e-b500-e3963bea641f_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDividendsCommonStock_a4e179ee-3f43-48e0-9267-4c4bb0eff5da_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends on common shares</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDividendsCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Ordinary Dividends, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDividendsCommonStock" xlink:to="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_bcd88dc8-60d3-420f-a1f8-84f005edd89d_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_fb8489d6-f24a-4707-82e1-cfa857a97f39_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares in treasury, at cost: 72 million shares and 54 million shares at March&#160;31, 2023 and June 30, 2022, respectively</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_96901305-eb41-4b1e-b48d-bb53565f2132_negatedPeriodStartLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury, balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_ebd121c3-e5ec-478c-9c1c-d2ebd941ab5f_negatedPeriodEndLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury, balance at end of period</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_eadf37d9-5cdd-4bcc-903e-a0181af3cf86_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_06b5e9ff-71dc-452c-9a7a-e2680898a96b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_6e5b22e8-6858-4e98-bf18-c4fa7e383484_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares in treasury</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_a6eb2572-e857-42a8-b783-8892c6269060_negatedPeriodStartLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury, balance at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_abc522d5-3fe8-49c5-aa20-30601d03e086_negatedPeriodEndLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury, balance at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonShares" xlink:to="lab_us-gaap_TreasuryStockCommonShares" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_June2027Member_d5564ea7-e3f3-44ca-8f47-59190ece1d79_terseLabel_en-US" xlink:label="lab_cah_June2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">June 2027</link:label>
    <link:label id="lab_cah_June2027Member_label_en-US" xlink:label="lab_cah_June2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">June 2027 [Member]</link:label>
    <link:label id="lab_cah_June2027Member_documentation_en-US" xlink:label="lab_cah_June2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">June 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_June2027Member" xlink:href="cah-20230331.xsd#cah_June2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_June2027Member" xlink:to="lab_cah_June2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationReserve_e18c1a53-ac7d-4437-8743-4f16e81730c6_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationReserve" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Litigation Liability</link:label>
    <link:label id="lab_us-gaap_LitigationReserve_label_en-US" xlink:label="lab_us-gaap_LitigationReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Litigation Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationReserve" xlink:to="lab_us-gaap_LitigationReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_CashReclassifiedToAssetHeldForSale_087af13d-0aa2-4d96-b79c-3a11813c8f2d_terseLabel_en-US" xlink:label="lab_cah_CashReclassifiedToAssetHeldForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and equivalents reclassified from/(to) assets held for sale</link:label>
    <link:label id="lab_cah_CashReclassifiedToAssetHeldForSale_label_en-US" xlink:label="lab_cah_CashReclassifiedToAssetHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Reclassified to Asset Held for Sale</link:label>
    <link:label id="lab_cah_CashReclassifiedToAssetHeldForSale_documentation_en-US" xlink:label="lab_cah_CashReclassifiedToAssetHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Reclassified to Asset Held for Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CashReclassifiedToAssetHeldForSale" xlink:href="cah-20230331.xsd#cah_CashReclassifiedToAssetHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_CashReclassifiedToAssetHeldForSale" xlink:to="lab_cah_CashReclassifiedToAssetHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_27182cfd-3dcb-45ed-833c-3f17502059c9_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_9bfef78c-7a0b-42d5-9eda-1cfa1d3ff691_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_e9deeb5a-3fa8-4eaf-a81a-26b251a389ba_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanDomain" xlink:to="lab_us-gaap_RestructuringPlanDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_e3b2e854-24bc-4cde-ad5e-e113c85d67d9_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTax_a9a711ca-8317-48bf-836f-57428343f21d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_31a796ba-3128-4121-b2d1-871eb8bcaf2a_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net earnings/(loss) attributable to Cardinal Health, Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_5e3c52ff-a9fb-4ad3-9e88-04b0f082f531_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_7a5522b0-30e2-41ba-951a-ce7dc1973100_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_257b37be-26d8-42d6-9d88-b7f41c689ed0_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_d956d1d6-0134-4a86-ab64-4c6cd1ceef36_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_0a997eca-d5b2-49b7-93f5-68f4ee16cbb5_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_35ca846b-dfe7-467f-b08f-c3f18b4b3ada_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Intangible, Total other intangible assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5293c3aa-3666-4d59-8895-1d8496c527ce_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Shareholders&#8217; Deficit</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_CommittedReceivablesSalesFacilityProgramMember_9ac62a6a-8ed0-4374-bf59-cd1e1ea4766a_terseLabel_en-US" xlink:label="lab_cah_CommittedReceivablesSalesFacilityProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Committed Receivables Sales Facility Program [Member]</link:label>
    <link:label id="lab_cah_CommittedReceivablesSalesFacilityProgramMember_label_en-US" xlink:label="lab_cah_CommittedReceivablesSalesFacilityProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Committed Receivables Sales Facility Program [Member]</link:label>
    <link:label id="lab_cah_CommittedReceivablesSalesFacilityProgramMember_documentation_en-US" xlink:label="lab_cah_CommittedReceivablesSalesFacilityProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Committed receivables sales facility program that exists largely to provide liquidity by selling interests in trade receivables.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CommittedReceivablesSalesFacilityProgramMember" xlink:href="cah-20230331.xsd#cah_CommittedReceivablesSalesFacilityProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_CommittedReceivablesSalesFacilityProgramMember" xlink:to="lab_cah_CommittedReceivablesSalesFacilityProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_59939b08-665d-4bd5-9d70-71da7ce5de16_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_b5257386-8d93-4365-a668-6316b31cd803_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders&#8217; deficit:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_ProjectCostsOnInvestmentAndOtherSpending_438607e0-487e-4679-a6a1-761c9429155a_terseLabel_en-US" xlink:label="lab_cah_ProjectCostsOnInvestmentAndOtherSpending" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project costs on investment and other spending</link:label>
    <link:label id="lab_cah_ProjectCostsOnInvestmentAndOtherSpending_label_en-US" xlink:label="lab_cah_ProjectCostsOnInvestmentAndOtherSpending" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project Costs On Investment And Other Spending</link:label>
    <link:label id="lab_cah_ProjectCostsOnInvestmentAndOtherSpending_documentation_en-US" xlink:label="lab_cah_ProjectCostsOnInvestmentAndOtherSpending" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment spending at the Corporate level. Investment spending generally includes the first year spend for certain projects that require incremental investments in the form of additional operating expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProjectCostsOnInvestmentAndOtherSpending" xlink:href="cah-20230331.xsd#cah_ProjectCostsOnInvestmentAndOtherSpending"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_ProjectCostsOnInvestmentAndOtherSpending" xlink:to="lab_cah_ProjectCostsOnInvestmentAndOtherSpending" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_MedicalMember_550fcd71-3370-41b9-8852-da3a571276ad_terseLabel_en-US" xlink:label="lab_cah_MedicalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical</link:label>
    <link:label id="lab_cah_MedicalMember_label_en-US" xlink:label="lab_cah_MedicalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Member</link:label>
    <link:label id="lab_cah_MedicalMember_documentation_en-US" xlink:label="lab_cah_MedicalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember" xlink:href="cah-20230331.xsd#cah_MedicalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_MedicalMember" xlink:to="lab_cah_MedicalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_2bd61b00-05ac-4601-b0a5-fac55e347ec6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInReceivables_36e75e41-d741-4874-ad77-2057c9c885e4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInReceivables" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in trade receivables</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInReceivables_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInReceivables" xlink:to="lab_us-gaap_IncreaseDecreaseInReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_September2025Member_2fef6c55-fb5f-4ca5-ba68-b80d7b4e0868_terseLabel_en-US" xlink:label="lab_cah_September2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">September 2025</link:label>
    <link:label id="lab_cah_September2025Member_label_en-US" xlink:label="lab_cah_September2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">September 2025 [Member]</link:label>
    <link:label id="lab_cah_September2025Member_documentation_en-US" xlink:label="lab_cah_September2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">September 2025</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_September2025Member" xlink:href="cah-20230331.xsd#cah_September2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_September2025Member" xlink:to="lab_cah_September2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_f02850bf-f301-4245-9bbb-e4bee4d43425_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Loss [Rollforward]</link:label>
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_label_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:to="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_e722ef8b-b72f-4751-b2f1-1d6010786a6f_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of products sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_c2592023-d69c-4a6a-8ef9-241781e81869_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting period (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_91c2311e-c01e-4830-9668-9d55f502b6ff_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeContractMember" xlink:to="lab_us-gaap_ForeignExchangeContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_955b68c2-525b-4f78-acb9-8d2f214f6c52_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Common Shares Used to Compute Basic and Diluted Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Weighted Average Number of Shares [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_fecabb3a-ed47-47b5-b2a2-c752082bfe6d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Share Units</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0648150b-96bb-41a7-aae7-922d8f7fb653_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Share Units</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_IndemnificationReceivable_4d6d0f73-8339-4e75-89f5-183046675ffe_terseLabel_en-US" xlink:label="lab_cah_IndemnificationReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indemnification Receivable</link:label>
    <link:label id="lab_cah_IndemnificationReceivable_label_en-US" xlink:label="lab_cah_IndemnificationReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indemnification Receivable</link:label>
    <link:label id="lab_cah_IndemnificationReceivable_documentation_en-US" xlink:label="lab_cah_IndemnificationReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indemnification receivable from Patient recovery related to certain pre-acquisition tax exposures and transaction taxes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_IndemnificationReceivable" xlink:href="cah-20230331.xsd#cah_IndemnificationReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_IndemnificationReceivable" xlink:to="lab_cah_IndemnificationReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_5d4b96d8-d250-4646-a2e8-3199735688c1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_A1BillionShareRepurchaseProgramMember_9b4798db-f9aa-4eed-be8b-9cc8c5bb4294_terseLabel_en-US" xlink:label="lab_cah_A1BillionShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$1 billion share repurchase program</link:label>
    <link:label id="lab_cah_A1BillionShareRepurchaseProgramMember_label_en-US" xlink:label="lab_cah_A1BillionShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$1 billion share repurchase program [Member]</link:label>
    <link:label id="lab_cah_A1BillionShareRepurchaseProgramMember_documentation_en-US" xlink:label="lab_cah_A1BillionShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$1 billion share repurchase program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A1BillionShareRepurchaseProgramMember" xlink:href="cah-20230331.xsd#cah_A1BillionShareRepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_A1BillionShareRepurchaseProgramMember" xlink:to="lab_cah_A1BillionShareRepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_Netproceedstaxwithholdingsfromsharebasedcompensation_1ee8d187-f92e-47b1-80b4-23915fd87ceb_terseLabel_en-US" xlink:label="lab_cah_Netproceedstaxwithholdingsfromsharebasedcompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net tax proceeds/(withholdings) from share-based compensation</link:label>
    <link:label id="lab_cah_Netproceedstaxwithholdingsfromsharebasedcompensation_label_en-US" xlink:label="lab_cah_Netproceedstaxwithholdingsfromsharebasedcompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds/(tax withholdings) from share-based compensation</link:label>
    <link:label id="lab_cah_Netproceedstaxwithholdingsfromsharebasedcompensation_documentation_en-US" xlink:label="lab_cah_Netproceedstaxwithholdingsfromsharebasedcompensation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The net cash inflow/(outflow) associated with the amount received from holders exercising their stock options and paid by the company to satisfy an employee's income tax withholding obligation when shares are withheld from settlement of a share-based award to cover taxes. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Netproceedstaxwithholdingsfromsharebasedcompensation" xlink:href="cah-20230331.xsd#cah_Netproceedstaxwithholdingsfromsharebasedcompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_Netproceedstaxwithholdingsfromsharebasedcompensation" xlink:to="lab_cah_Netproceedstaxwithholdingsfromsharebasedcompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_e4041f00-99f2-48b9-8c79-df4d60be4135_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_a0a69959-d0e9-4839-9dee-65e06d3b2c0c_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_7889b148-226f-42e3-9893-94a0ba839d3a_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_deba977c-2975-4f78-94f6-9ffd9cdbb50a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_a967d929-bb58-4429-a834-cdf562fd71c0_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain" xlink:to="lab_us-gaap_HedgingRelationshipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_PlaintiffTypeDomain_a2fad334-2496-4c4b-b6fe-b33bac84d1af_terseLabel_en-US" xlink:label="lab_cah_PlaintiffTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plaintiff Type [Domain]</link:label>
    <link:label id="lab_cah_PlaintiffTypeDomain_label_en-US" xlink:label="lab_cah_PlaintiffTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plaintiff Type [Domain]</link:label>
    <link:label id="lab_cah_PlaintiffTypeDomain_documentation_en-US" xlink:label="lab_cah_PlaintiffTypeDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Plaintiff Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PlaintiffTypeDomain" xlink:href="cah-20230331.xsd#cah_PlaintiffTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_PlaintiffTypeDomain" xlink:to="lab_cah_PlaintiffTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet_1fc66fc5-057f-4a38-bf10-6acbf9045f15_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward Contract</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Assets (Liabilities), at Fair Value, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet" xlink:to="lab_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_554e603c-587b-4411-91bd-7005c31aafc7_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_01c3b793-933b-4d0a-8908-070a7c457cca_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated annual amortization of intangible assets - Year Four</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_bc85a190-4e87-4f06-8bec-96cf5388ab01_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_eaf7fe4c-d592-4f00-8e55-11289b0e551c_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_7b64f388-56ea-4b89-a9c3-6527ff783247_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash dividends declared per common share</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Declared</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:to="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_a319d93b-22bf-4d42-9eee-8d8c1ddbb5d4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_e53eec97-5cef-4c7a-b26b-4e4a1046aca4_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Share Units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_4c133a4e-5591-4d26-a37f-fd5a21ddd8bd_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Share Unit</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_SettlingUSTerritories_a9e56c2b-0d82-41cb-94f0-23db210652c3_terseLabel_en-US" xlink:label="lab_cah_SettlingUSTerritories" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settling U.S Territories</link:label>
    <link:label id="lab_cah_SettlingUSTerritories_label_en-US" xlink:label="lab_cah_SettlingUSTerritories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settling U.S Territories</link:label>
    <link:label id="lab_cah_SettlingUSTerritories_documentation_en-US" xlink:label="lab_cah_SettlingUSTerritories" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settling U.S Territories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SettlingUSTerritories" xlink:href="cah-20230331.xsd#cah_SettlingUSTerritories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_SettlingUSTerritories" xlink:to="lab_cah_SettlingUSTerritories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_1c60b627-0aa2-400b-a77c-20a5d245abf4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_8734c944-b5a7-4173-ba9c-58157eaaeefe_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_8ef49dea-c825-46ba-911f-fe5a2fdcd8b8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_bf85dac4-4472-4693-bc63-7b4fe825fd32_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and other intangibles, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Including Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_b43189b6-62c8-49ce-9e44-821a94e83069_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock options, restricted share units, and performance share units (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted, Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_CordisDivestitureMember_abd3a325-889c-48d0-a5c6-bef63b746d86_terseLabel_en-US" xlink:label="lab_cah_CordisDivestitureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cordis Divestiture</link:label>
    <link:label id="lab_cah_CordisDivestitureMember_label_en-US" xlink:label="lab_cah_CordisDivestitureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cordis Divestiture [Member]</link:label>
    <link:label id="lab_cah_CordisDivestitureMember_documentation_en-US" xlink:label="lab_cah_CordisDivestitureMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cordis Divestiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureMember" xlink:href="cah-20230331.xsd#cah_CordisDivestitureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_CordisDivestitureMember" xlink:to="lab_cah_CordisDivestitureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_A2.616Notesdue2022Member_4a5f83e2-625c-4420-9f07-e8f59f21f0d2_terseLabel_en-US" xlink:label="lab_cah_A2.616Notesdue2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.616% Notes due 2022 [Member]</link:label>
    <link:label id="lab_cah_A2.616Notesdue2022Member_label_en-US" xlink:label="lab_cah_A2.616Notesdue2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.616% Notes due 2022 [Member]</link:label>
    <link:label id="lab_cah_A2.616Notesdue2022Member_documentation_en-US" xlink:label="lab_cah_A2.616Notesdue2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.616% Notes due 2022</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A2.616Notesdue2022Member" xlink:href="cah-20230331.xsd#cah_A2.616Notesdue2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_A2.616Notesdue2022Member" xlink:to="lab_cah_A2.616Notesdue2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments_02b8a013-514e-4abf-8aa3-fa8311ee2fbf_terseLabel_en-US" xlink:label="lab_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from investments</link:label>
    <link:label id="lab_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments_label_en-US" xlink:label="lab_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of available-for-sale securities and other investments</link:label>
    <link:label id="lab_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments_documentation_en-US" xlink:label="lab_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The cash inflow from sales of available-for-sale securities and other investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments" xlink:href="cah-20230331.xsd#cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments" xlink:to="lab_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfInvestments_ad9e12db-9493-40df-b94e-dafb62b33df9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Gain)/loss on sale of equity interest in naviHealth</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfInvestments_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Sale of Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfInvestments" xlink:to="lab_us-gaap_GainLossOnSaleOfInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_e7d10c1b-64ec-47d0-8d74-1e4ad869b232_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_0097e32d-0fcf-4591-9e02-a716fefdc8a5_verboseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember_d6f79228-7fe3-4b5a-9247-444d9a6d1e0d_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain/(Loss) on Derivatives, net of tax</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Net Gain (Loss) from Cash Flow Hedges Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_49f9fb1d-a322-43eb-9fb5-99aa669202ed_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5e8d2be0-bc5b-4b5a-af1d-1f1592d05b29_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_a1c7d31a-f69a-4377-a5ec-438f59d611c8_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares, without par value:</link:label>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Number of Shares, Par Value and Other Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserve_9ea2f9dd-3629-4185-8f72-d19fc8e77f7d_periodStartLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_71b1f682-f08b-4db4-a25b-37b2a8c1723d_periodEndLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve" xlink:to="lab_us-gaap_RestructuringReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_a259d9c5-00b1-466a-bf20-2be0f147e186_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_47912f8b-a052-4e5c-aaad-815b2fd659b2_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potentially dilutive employee stock options, restricted share units and performance share units that were antidilutive (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_d0d8f18c-4c1c-4e54-a24b-ab9a9622bc4f_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4914bb8c-553a-4d38-8f7a-b00ce1ea919e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_feda20dd-f397-4d06-9d30-e325e8669c40_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_FacilityExitAndOtherCosts_a1272435-6b11-43ed-8fcb-3d3d1baa1df5_terseLabel_en-US" xlink:label="lab_cah_FacilityExitAndOtherCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Exit and Other Costs</link:label>
    <link:label id="lab_cah_FacilityExitAndOtherCosts_label_en-US" xlink:label="lab_cah_FacilityExitAndOtherCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Exit and Other Costs</link:label>
    <link:label id="lab_cah_FacilityExitAndOtherCosts_documentation_en-US" xlink:label="lab_cah_FacilityExitAndOtherCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility exit and other costs primarily consist of lease termination costs, accelerated depreciation, equipment relocation costs, project consulting fees and costs associated with restructuring our delivery of information technology infrastructure services.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_FacilityExitAndOtherCosts" xlink:href="cah-20230331.xsd#cah_FacilityExitAndOtherCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_FacilityExitAndOtherCosts" xlink:to="lab_cah_FacilityExitAndOtherCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_f4b50f94-49e9-4646-9e8f-b4863b2cc9b3_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense, net</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_15d1115a-dcd4-4d57-8d6a-7bb4c5087ca8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_6932a7e7-cadd-4120-87be-4cffba3b0edc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on early extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_d6eab3f9-5527-4bac-9d35-5a4e4de33cbe_negatedLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_a8f3eacf-8e88-469e-b0c4-bcd909eef0f3_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillLineItems_701673d6-d088-40f5-8de2-ad826422e18d_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems" xlink:to="lab_us-gaap_GoodwillLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_2ca7e03d-b004-4f02-a068-e9ad5efc5b58_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_3d39a5cf-8cad-4b69-b82f-312c971f0e0b_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated annual amortization of intangible assets - Remainder of Fiscal Year</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_e92fd9c3-e11f-4ee4-a237-9e1026a44882_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount_2447de61-4389-4d5b-a39c-74a49cf7dca0_terseLabel_en-US" xlink:label="lab_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit, Percentage of Fair Value in Excess of Carrying Amount</link:label>
    <link:label id="lab_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount_label_en-US" xlink:label="lab_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit, Percentage of Fair Value in Excess of Carrying Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" xlink:to="lab_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_7d01814d-b19c-450b-81ed-3b715202713b_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_65271f0d-dc04-462f-ade2-6c405e571391_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_2ac5d161-bb11-4f48-a72d-14c15f3c71bb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Transactions Related to Restricted Share Units Under the Plans</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrentAndNoncurrent_84e3fa82-cf25-4201-8656-21269cec1f38_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_6046b541-3ba3-4e05-b258-3f38a0f42f84_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_84f886c8-768f-4636-aea0-8fe4a05b8ca2_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_f391eade-77d7-4eb6-9930-362fcede7b32_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_bbf576ba-cae0-4258-a50e-07ccdf095966_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Intangible</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_dc1e0bb3-07c7-4690-8e7b-f9f6b0940bff_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Financial Accounting Standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_Amortizationandotheracquisitionrelatedcosts_d4073dbc-c5ac-4521-b55f-4388bd64f0a5_terseLabel_en-US" xlink:label="lab_cah_Amortizationandotheracquisitionrelatedcosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization and other acquisition-related costs</link:label>
    <link:label id="lab_cah_Amortizationandotheracquisitionrelatedcosts_label_en-US" xlink:label="lab_cah_Amortizationandotheracquisitionrelatedcosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization and other acquisition-related costs</link:label>
    <link:label id="lab_cah_Amortizationandotheracquisitionrelatedcosts_documentation_en-US" xlink:label="lab_cah_Amortizationandotheracquisitionrelatedcosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The aggregate expense charged against earnings to allocate the cost of acquired intangible assets and changes in the fair value of contingent consideration obligations. This also represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Amortizationandotheracquisitionrelatedcosts" xlink:href="cah-20230331.xsd#cah_Amortizationandotheracquisitionrelatedcosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_Amortizationandotheracquisitionrelatedcosts" xlink:to="lab_cah_Amortizationandotheracquisitionrelatedcosts" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_A32NotesDue2023Member_bfaf8291-0085-4748-a2da-defb7ccfe81d_terseLabel_en-US" xlink:label="lab_cah_A32NotesDue2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.2% Notes due 2023</link:label>
    <link:label id="lab_cah_A32NotesDue2023Member_label_en-US" xlink:label="lab_cah_A32NotesDue2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.2% Notes due 2023 [Member]</link:label>
    <link:label id="lab_cah_A32NotesDue2023Member_documentation_en-US" xlink:label="lab_cah_A32NotesDue2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.2% Notes due 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A32NotesDue2023Member" xlink:href="cah-20230331.xsd#cah_A32NotesDue2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_A32NotesDue2023Member" xlink:to="lab_cah_A32NotesDue2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_AgreementsAxis_47d57a90-3d38-4c2f-bcc8-f1c3956570e8_terseLabel_en-US" xlink:label="lab_cah_AgreementsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreements [Axis]</link:label>
    <link:label id="lab_cah_AgreementsAxis_label_en-US" xlink:label="lab_cah_AgreementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreements [Axis]</link:label>
    <link:label id="lab_cah_AgreementsAxis_documentation_en-US" xlink:label="lab_cah_AgreementsAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_AgreementsAxis" xlink:href="cah-20230331.xsd#cah_AgreementsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_AgreementsAxis" xlink:to="lab_cah_AgreementsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_364c729c-d136-4c79-8950-a557e1c3b3f2_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury shares acquired, average price per share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_label_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Acquired, Average Cost Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:to="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_GoodwillImpairmentAxis_48cd1f79-9aa7-4b22-9855-79854a8300c4_terseLabel_en-US" xlink:label="lab_cah_GoodwillImpairmentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill Impairment [Axis]</link:label>
    <link:label id="lab_cah_GoodwillImpairmentAxis_label_en-US" xlink:label="lab_cah_GoodwillImpairmentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill Impairment [Axis]</link:label>
    <link:label id="lab_cah_GoodwillImpairmentAxis_documentation_en-US" xlink:label="lab_cah_GoodwillImpairmentAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill Impairment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_GoodwillImpairmentAxis" xlink:href="cah-20230331.xsd#cah_GoodwillImpairmentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_GoodwillImpairmentAxis" xlink:to="lab_cah_GoodwillImpairmentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetNotionalAmount_576e30df-850c-4e42-b860-47911a35b991_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Notional Amount</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssetNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetNotionalAmount" xlink:to="lab_us-gaap_DerivativeAssetNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_36eb6596-fa70-46f1-9d11-81566b0c36f1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_21f5dbae-357a-465f-a46b-6fe142260a9b_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e0ba7885-e02a-438e-92cc-03a05a96b0f6_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_b525ef5b-2619-4981-9724-0caa7e4bbde0_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_95040021-a2c6-4610-b158-989d3b4d3857_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated fair value</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue" xlink:to="lab_us-gaap_DebtInstrumentFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_fde734fb-ad6a-49ab-8501-7da635ca2867_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average number of common shares outstanding:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_986e4fa9-0d1f-473d-86d4-14573e41282c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares, issued</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_3ac4a7a5-ab2b-4ea3-9429-4a6031c51f3a_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_8819cb99-27ae-4f2f-b090-ae2c61a5214d_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_8529ff2f-cbd1-4169-93bd-0b0b33235d43_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfit_f63875a7-e211-42a9-b4f5-a39e8f9cfe1c_totalLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross margin</link:label>
    <link:label id="lab_us-gaap_GrossProfit_label_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeveranceCosts1_71a40da0-a0e1-4f8a-9315-20e3e4487c8c_verboseLabel_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related costs</link:label>
    <link:label id="lab_us-gaap_SeveranceCosts1_label_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeveranceCosts1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeveranceCosts1" xlink:to="lab_us-gaap_SeveranceCosts1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_127bed44-9aca-44fc-92cb-da5ddef4901d_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term obligations and other short-term borrowings</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_bed2646d-4bee-443c-8cd2-062119b2f74e_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt and Lease Obligation, Current</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt and Lease Obligation, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_85284189-ab41-4b96-96ba-554abf5cc0e1_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_ee6e0994-3a56-4f5c-b625-fc3fffa1b230_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distribution, selling, general and administrative expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8ce16ffc-ba6c-4b37-bdcf-63a035724cb9_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_1c6fbbdf-2d2b-4cdf-942d-394345d443fb_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Target performance goal (as a percent)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_5286dd77-2cf2-4e8c-9de8-f5d5099d3681_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_bff01c3b-2bdc-4389-bfd7-ac94cffffe6e_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_efc4b993-7afb-451f-9309-ec416d8b42d3_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_b6fa762e-fe33-4146-b452-b5e2643e8c5f_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_f640c3f1-d462-4639-bf5b-90ca8fcc4b9a_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total comprehensive income attributable to Cardinal Health, Inc.</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_2c879720-3b8a-41bb-9ba6-85fc35972653_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Restructuring and Employee Severance</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_0bbe0247-c2f6-417f-be0c-a8ba11534c2f_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_d1ee61a8-807c-4728-a6c9-dc848f856109_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_TerminalGrowthRateFairValueInput_8bde5024-fd7f-4f54-a9ae-264f128b5cde_terseLabel_en-US" xlink:label="lab_cah_TerminalGrowthRateFairValueInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Terminal Growth Rate, Fair Value Input</link:label>
    <link:label id="lab_cah_TerminalGrowthRateFairValueInput_label_en-US" xlink:label="lab_cah_TerminalGrowthRateFairValueInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Terminal Growth Rate, Fair Value Input</link:label>
    <link:label id="lab_cah_TerminalGrowthRateFairValueInput_documentation_en-US" xlink:label="lab_cah_TerminalGrowthRateFairValueInput" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Terminal Growth Rate, Fair Value Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TerminalGrowthRateFairValueInput" xlink:href="cah-20230331.xsd#cah_TerminalGrowthRateFairValueInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_TerminalGrowthRateFairValueInput" xlink:to="lab_cah_TerminalGrowthRateFairValueInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_7a1253b5-15a9-4089-809a-86450c979e0a_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill acquired, net of purchase price adjustments</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_b5177462-420a-437e-8c6f-ab3b48377825_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Loss [Table]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAverageOutstandingAmount_3077b465-df17-4d65-a85c-97c91c7f2581_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAverageOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Average Outstanding Amount</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAverageOutstandingAmount_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAverageOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Average Outstanding Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAverageOutstandingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityAverageOutstandingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityAverageOutstandingAmount" xlink:to="lab_us-gaap_LineOfCreditFacilityAverageOutstandingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrencySwapMember_22d2559e-acf9-4b0e-a03d-11ae856e9d57_terseLabel_en-US" xlink:label="lab_us-gaap_CurrencySwapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency Swap [Member]</link:label>
    <link:label id="lab_us-gaap_CurrencySwapMember_label_en-US" xlink:label="lab_us-gaap_CurrencySwapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency Swap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrencySwapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrencySwapMember" xlink:to="lab_us-gaap_CurrencySwapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_6b878239-b911-4f45-a33b-3be319360c8d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_5389b514-a17e-478d-84d9-f34f3d79fd9a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_March2022Member_9ff6935d-01e1-4961-8abb-8814138ac0c9_terseLabel_en-US" xlink:label="lab_cah_March2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective March 2022</link:label>
    <link:label id="lab_cah_March2022Member_label_en-US" xlink:label="lab_cah_March2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 2022 [Member]</link:label>
    <link:label id="lab_cah_March2022Member_documentation_en-US" xlink:label="lab_cah_March2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 2022</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_March2022Member" xlink:href="cah-20230331.xsd#cah_March2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_March2022Member" xlink:to="lab_cah_March2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_18fa0440-1536-447f-9757-e7df5fb1635b_verboseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_4f8c1e6a-9558-4938-856b-ce4442090bd1_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_4c8e81f4-15a4-45fd-8ea4-ac67b3c924db_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_ShortTermCreditFacilitiesMember_d30d98f2-4b51-46af-ba73-a353e8dc6532_terseLabel_en-US" xlink:label="lab_cah_ShortTermCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short Term Credit Facilities Member</link:label>
    <link:label id="lab_cah_ShortTermCreditFacilitiesMember_label_en-US" xlink:label="lab_cah_ShortTermCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short Term Credit Facilities Member</link:label>
    <link:label id="lab_cah_ShortTermCreditFacilitiesMember_documentation_en-US" xlink:label="lab_cah_ShortTermCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other short-term credit facilities and an unsecured line of credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ShortTermCreditFacilitiesMember" xlink:href="cah-20230331.xsd#cah_ShortTermCreditFacilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_ShortTermCreditFacilitiesMember" xlink:to="lab_cah_ShortTermCreditFacilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_c53a7ff2-92c3-493e-80a3-76c6772e89ee_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_dc3fa525-0168-4fa9-95a0-da5d674b782d_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits, interest and penalties accrued</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTable_8bf20358-e55d-47f4-9415-5a34b258c189_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeTable_label_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTable" xlink:to="lab_us-gaap_DerivativeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_43c5562f-0c0d-476d-9d93-658c7520bbb7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_15ccea12-f6cc-42af-9fa4-1f5b9aaa02ec_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred shares, without par value:</link:label>
    <link:label id="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Number of Shares, Par Value and Other Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_4f47bf81-a781-4254-9887-aa61b7078a75_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_GrossInsuranceSettlementBeforeAttorneyFees_c7a1711e-4aec-46c5-8ae2-d83630b15bae_terseLabel_en-US" xlink:label="lab_cah_GrossInsuranceSettlementBeforeAttorneyFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Insurance Settlement Before Attorney Fees</link:label>
    <link:label id="lab_cah_GrossInsuranceSettlementBeforeAttorneyFees_label_en-US" xlink:label="lab_cah_GrossInsuranceSettlementBeforeAttorneyFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Insurance Settlement Before Attorney Fees</link:label>
    <link:label id="lab_cah_GrossInsuranceSettlementBeforeAttorneyFees_documentation_en-US" xlink:label="lab_cah_GrossInsuranceSettlementBeforeAttorneyFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Insurance Settlement Before Attorney Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_GrossInsuranceSettlementBeforeAttorneyFees" xlink:href="cah-20230331.xsd#cah_GrossInsuranceSettlementBeforeAttorneyFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_GrossInsuranceSettlementBeforeAttorneyFees" xlink:to="lab_cah_GrossInsuranceSettlementBeforeAttorneyFees" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_JudgmentForLostProfits_2b35d5fe-c394-4f33-85ac-a80761ee9c22_terseLabel_en-US" xlink:label="lab_cah_JudgmentForLostProfits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Judgment for lost profits</link:label>
    <link:label id="lab_cah_JudgmentForLostProfits_label_en-US" xlink:label="lab_cah_JudgmentForLostProfits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Judgment for lost profits</link:label>
    <link:label id="lab_cah_JudgmentForLostProfits_documentation_en-US" xlink:label="lab_cah_JudgmentForLostProfits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Judgment for lost profits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_JudgmentForLostProfits" xlink:href="cah-20230331.xsd#cah_JudgmentForLostProfits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_JudgmentForLostProfits" xlink:to="lab_cah_JudgmentForLostProfits" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_6c267466-8a7b-47b2-89e1-3b9e72f1e0a6_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_62177306-81a0-46b8-843c-9d0abbc333ee_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_LongTermObligationsandOtherShortTermBorrowingsAbstract_365c43f3-bf2b-4c55-a43d-c5b5f6f8ef71_terseLabel_en-US" xlink:label="lab_cah_LongTermObligationsandOtherShortTermBorrowingsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Obligations and Other Short-Term Borrowings [Abstract]</link:label>
    <link:label id="lab_cah_LongTermObligationsandOtherShortTermBorrowingsAbstract_label_en-US" xlink:label="lab_cah_LongTermObligationsandOtherShortTermBorrowingsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Obligations and Other Short-Term Borrowings [Abstract]</link:label>
    <link:label id="lab_cah_LongTermObligationsandOtherShortTermBorrowingsAbstract_documentation_en-US" xlink:label="lab_cah_LongTermObligationsandOtherShortTermBorrowingsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Obligations and Other Short-Term Borrowings [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LongTermObligationsandOtherShortTermBorrowingsAbstract" xlink:href="cah-20230331.xsd#cah_LongTermObligationsandOtherShortTermBorrowingsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_LongTermObligationsandOtherShortTermBorrowingsAbstract" xlink:to="lab_cah_LongTermObligationsandOtherShortTermBorrowingsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_5871f2f1-93eb-4002-8fac-17deb59fa95f_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_856c8b54-a82c-4430-995d-7757a1da480c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Activity Related to Liabilities Associated with Restructuring and Employee Severance</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_15f957d0-10d4-4e17-be96-560b44598eb1_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_label_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNatureDomain" xlink:to="lab_us-gaap_LossContingencyNatureDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityOtherShares_25b4190b-c909-4b42-b5e1-689fba121a1c_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityOtherShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Other Shares</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityOtherShares_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityOtherShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Other Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOtherShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityOtherShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityOtherShares" xlink:to="lab_us-gaap_StockholdersEquityOtherShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod_c8111f41-1966-4279-8c13-1b212105466d_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Amount Outstanding During Period</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Amount Outstanding During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_1f29e1f0-a518-469e-9b3a-91d0e7718c11_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Intangible</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_6b8647ed-62ef-40d4-abf6-893374a3701f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_label_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingSegmentsMember" xlink:to="lab_us-gaap_OperatingSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4f9ee0a4-1e3c-459c-a3f1-ef3104f94f39_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested at beginning of period (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_39ab0a1a-34f3-48ab-9acc-f62d9522d654_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested at end of period (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardLineItems_2c6e8315-a2a5-4974-ad4d-723f3f160911_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardLineItems_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems" xlink:to="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_c176b637-f790-470c-8040-ba96895a5e0e_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_16ed3ec5-98a3-41f9-9198-4ef5c853ea54_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_e6bd6c76-5850-40a2-bcb2-1cbe9fac7a1a_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_4686f698-af0d-451d-80d5-7d2806d22efd_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_TrademarksAndPatentsMember_016d8b3f-8e96-4d2f-a5dd-9b99f36053f1_terseLabel_en-US" xlink:label="lab_cah_TrademarksAndPatentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks, trade names and patents</link:label>
    <link:label id="lab_cah_TrademarksAndPatentsMember_label_en-US" xlink:label="lab_cah_TrademarksAndPatentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks And Patents Member</link:label>
    <link:label id="lab_cah_TrademarksAndPatentsMember_documentation_en-US" xlink:label="lab_cah_TrademarksAndPatentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, and the exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TrademarksAndPatentsMember" xlink:href="cah-20230331.xsd#cah_TrademarksAndPatentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_TrademarksAndPatentsMember" xlink:to="lab_cah_TrademarksAndPatentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_16c1fa84-d3c9-431f-8815-60673f31b658_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_26df459c-600e-4422-92da-1303ee633471_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:to="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_85343d5d-6bcb-454f-b5b0-40b044a29851_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_d10ef424-21d6-4c0e-aed7-2d05934e976b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustments and other</link:label>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:to="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_19781926-a045-493b-8313-061c14388ed7_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_TotalLongTermandShortTermObligations_7d62bd44-081d-4d2d-8f9f-4a24cb982a5c_terseLabel_en-US" xlink:label="lab_cah_TotalLongTermandShortTermObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Long-Term and Short-Term Obligations</link:label>
    <link:label id="lab_cah_TotalLongTermandShortTermObligations_label_en-US" xlink:label="lab_cah_TotalLongTermandShortTermObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Long-Term and Short-Term Obligations</link:label>
    <link:label id="lab_cah_TotalLongTermandShortTermObligations_documentation_en-US" xlink:label="lab_cah_TotalLongTermandShortTermObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Long-Term and Short-Term Obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalLongTermandShortTermObligations" xlink:href="cah-20230331.xsd#cah_TotalLongTermandShortTermObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_TotalLongTermandShortTermObligations" xlink:to="lab_cah_TotalLongTermandShortTermObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_e81ecf34-fc73-4c6d-ac52-0c07b4b78e56_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_CARESActDomain_1ec1690b-7bcf-474e-b431-c523d7dc229f_terseLabel_en-US" xlink:label="lab_cah_CARESActDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Operating Loss Carryback [Domain]</link:label>
    <link:label id="lab_cah_CARESActDomain_label_en-US" xlink:label="lab_cah_CARESActDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARES Act [Domain]</link:label>
    <link:label id="lab_cah_CARESActDomain_documentation_en-US" xlink:label="lab_cah_CARESActDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARES Act</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CARESActDomain" xlink:href="cah-20230331.xsd#cah_CARESActDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_CARESActDomain" xlink:to="lab_cah_CARESActDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InsuranceRecoveries_811d7a82-2d61-4580-8890-40cd5014c298_terseLabel_en-US" xlink:label="lab_us-gaap_InsuranceRecoveries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Recoveries</link:label>
    <link:label id="lab_us-gaap_InsuranceRecoveries_label_en-US" xlink:label="lab_us-gaap_InsuranceRecoveries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Recoveries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceRecoveries" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InsuranceRecoveries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InsuranceRecoveries" xlink:to="lab_us-gaap_InsuranceRecoveries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_36995f24-2e1e-450f-b621-42abbd76c10d_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_0559e23e-e140-4ad3-96cc-193d3a7b68bc_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_NotesPayableRepurchased_8fa3906e-e468-4c72-b051-46dbdbe89a5a_terseLabel_en-US" xlink:label="lab_cah_NotesPayableRepurchased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable Repurchased</link:label>
    <link:label id="lab_cah_NotesPayableRepurchased_label_en-US" xlink:label="lab_cah_NotesPayableRepurchased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable Repurchased</link:label>
    <link:label id="lab_cah_NotesPayableRepurchased_documentation_en-US" xlink:label="lab_cah_NotesPayableRepurchased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal Amount of Notes Payable Repurchased during the quarter</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NotesPayableRepurchased" xlink:href="cah-20230331.xsd#cah_NotesPayableRepurchased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_NotesPayableRepurchased" xlink:to="lab_cah_NotesPayableRepurchased" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_62467b23-5c98-44c2-874e-07ce26b87485_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of treasury shares</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_1e0bd5ae-29b2-453f-bfec-4d3232aa492e_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of treasury shares</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_7ae7867a-aeef-4c51-bf6e-ca758ba177e8_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_IPRDTrademarksandOtherMember_8828326b-1b9c-434e-8a87-9b1113ea0d58_terseLabel_en-US" xlink:label="lab_cah_IPRDTrademarksandOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks and patents</link:label>
    <link:label id="lab_cah_IPRDTrademarksandOtherMember_label_en-US" xlink:label="lab_cah_IPRDTrademarksandOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPR&amp;D,TrademarksandOther [Member]</link:label>
    <link:label id="lab_cah_IPRDTrademarksandOtherMember_documentation_en-US" xlink:label="lab_cah_IPRDTrademarksandOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Includes in process investigation of new knowledge useful in developing new product or service or new process or techniques or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for the improvements to existing product or process and rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_IPRDTrademarksandOtherMember" xlink:href="cah-20230331.xsd#cah_IPRDTrademarksandOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_IPRDTrademarksandOtherMember" xlink:to="lab_cah_IPRDTrademarksandOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_27fed0a9-691f-4bb7-8d44-b34c47714c2b_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_afe30c2a-e282-4422-8e37-e9eeb41f4bc7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_ccf53147-20fc-465b-8b30-a14be10356a5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_c35ef4d3-d0e0-4745-87f9-9cd1eb22323b_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_68ff84ce-339d-4559-b3f3-2202c050cb3d_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_fecc55c0-08ff-496a-a2a4-8bc3a3ca44e3_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_5aa91330-067f-4e22-ac00-ed8836b92eda_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation (recoveries)/charges, net</link:label>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_8f61785d-b311-4984-98b3-dae42e7ab4a3_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) Related to Litigation Settlement</link:label>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_a38a6715-4e72-4c76-82d3-147a24276741_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Related to Litigation Settlement</link:label>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_label_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) Related to Litigation Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossRelatedToLitigationSettlement" xlink:to="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_ShareholderSecuritiesLitigationMember_287caa0c-5936-4870-832e-1519bc8e0f27_terseLabel_en-US" xlink:label="lab_cah_ShareholderSecuritiesLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholder Securities Litigation [Member]</link:label>
    <link:label id="lab_cah_ShareholderSecuritiesLitigationMember_label_en-US" xlink:label="lab_cah_ShareholderSecuritiesLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholder Securities Litigation [Member]</link:label>
    <link:label id="lab_cah_ShareholderSecuritiesLitigationMember_documentation_en-US" xlink:label="lab_cah_ShareholderSecuritiesLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholder Securities Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ShareholderSecuritiesLitigationMember" xlink:href="cah-20230331.xsd#cah_ShareholderSecuritiesLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_ShareholderSecuritiesLitigationMember" xlink:to="lab_cah_ShareholderSecuritiesLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_NuclearPrecisionHealthSolutionsMember_8376ff1b-d9ad-45cc-aa21-4b4cd9164490_terseLabel_en-US" xlink:label="lab_cah_NuclearPrecisionHealthSolutionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nuclear Precision Health Services [Member]</link:label>
    <link:label id="lab_cah_NuclearPrecisionHealthSolutionsMember_label_en-US" xlink:label="lab_cah_NuclearPrecisionHealthSolutionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nuclear Precision Health Solutions [Member]</link:label>
    <link:label id="lab_cah_NuclearPrecisionHealthSolutionsMember_documentation_en-US" xlink:label="lab_cah_NuclearPrecisionHealthSolutionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nuclear Precision Health Solutions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NuclearPrecisionHealthSolutionsMember" xlink:href="cah-20230331.xsd#cah_NuclearPrecisionHealthSolutionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_NuclearPrecisionHealthSolutionsMember" xlink:to="lab_cah_NuclearPrecisionHealthSolutionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_0ffa5a16-aa6d-48f4-ad72-a3b858173fd6_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_403ab3dc-6b3f-45bf-ab89-272c935ef472_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_IncomefromSettlementsofClassActionLawsuits_7cbcb52e-e031-44e9-8efc-3afe13e0fc6c_terseLabel_en-US" xlink:label="lab_cah_IncomefromSettlementsofClassActionLawsuits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from Settlements of Class Action Lawsuits</link:label>
    <link:label id="lab_cah_IncomefromSettlementsofClassActionLawsuits_label_en-US" xlink:label="lab_cah_IncomefromSettlementsofClassActionLawsuits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from Settlements of Class Action Lawsuits</link:label>
    <link:label id="lab_cah_IncomefromSettlementsofClassActionLawsuits_documentation_en-US" xlink:label="lab_cah_IncomefromSettlementsofClassActionLawsuits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from Settlements of Class Action Lawsuits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_IncomefromSettlementsofClassActionLawsuits" xlink:href="cah-20230331.xsd#cah_IncomefromSettlementsofClassActionLawsuits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_IncomefromSettlementsofClassActionLawsuits" xlink:to="lab_cah_IncomefromSettlementsofClassActionLawsuits" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_5140ecf9-7c44-4f21-9b5a-554ccc662691_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_045a9c3c-2ce1-4ec0-9225-8beff0659b6b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings Compared to the Respective Carrying Amount</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_49e72ac8-73da-42d1-9f34-6758a598b5bc_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_35a47b7a-a9e3-486d-a7df-0b0370218b13_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_99b2162a-2fd7-4928-90b2-b01a17667710_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated annual amortization of intangible assets - Year One</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_MedicaldistributionandproductsMember_66c34cff-5ad6-4bbb-81db-9ad195b50841_terseLabel_en-US" xlink:label="lab_cah_MedicaldistributionandproductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical distribution and products [Member]</link:label>
    <link:label id="lab_cah_MedicaldistributionandproductsMember_label_en-US" xlink:label="lab_cah_MedicaldistributionandproductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical distribution and products [Member]</link:label>
    <link:label id="lab_cah_MedicaldistributionandproductsMember_documentation_en-US" xlink:label="lab_cah_MedicaldistributionandproductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical distribution and products [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicaldistributionandproductsMember" xlink:href="cah-20230331.xsd#cah_MedicaldistributionandproductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_MedicaldistributionandproductsMember" xlink:to="lab_cah_MedicaldistributionandproductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_232abd3b-c45c-4017-b540-70042967396f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Total Share-based Compensation Expense by Type of Award</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_TaxMatterDomain_ea84774a-6874-46cc-a616-0d8f107227c6_terseLabel_en-US" xlink:label="lab_cah_TaxMatterDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Matter [Domain]</link:label>
    <link:label id="lab_cah_TaxMatterDomain_label_en-US" xlink:label="lab_cah_TaxMatterDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Matter [Domain]</link:label>
    <link:label id="lab_cah_TaxMatterDomain_documentation_en-US" xlink:label="lab_cah_TaxMatterDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Tax Matter [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMatterDomain" xlink:href="cah-20230331.xsd#cah_TaxMatterDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_TaxMatterDomain" xlink:to="lab_cah_TaxMatterDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_96b198b1-08cb-4069-ad4b-4eeb67c8b8b2_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Dividends_ecdf8e2b-cbc6-439d-b48e-e68641b05b3e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_Dividends" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends</link:label>
    <link:label id="lab_us-gaap_Dividends_label_en-US" xlink:label="lab_us-gaap_Dividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Dividends"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Dividends" xlink:to="lab_us-gaap_Dividends" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_452a5baf-1c7e-4909-87e3-c05b6024819e_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings/(Loss) per common share attributable to Cardinal Health, Inc.:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_804ce5af-5425-41f5-b225-df429977e4ce_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Estimate of Possible Loss</link:label>
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_label_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Estimate of Possible Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:to="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityOther_a8ff68e8-ace3-4822-a3f7-e7590ca5f69a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityOther_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityOther" xlink:to="lab_us-gaap_StockholdersEquityOther" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_MedicalUnitGoodwillImpairmentMember_49e42de6-4cf1-4130-bf79-fecb42748060_terseLabel_en-US" xlink:label="lab_cah_MedicalUnitGoodwillImpairmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Unit Goodwill Impairment [Member]</link:label>
    <link:label id="lab_cah_MedicalUnitGoodwillImpairmentMember_label_en-US" xlink:label="lab_cah_MedicalUnitGoodwillImpairmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Unit Goodwill Impairment [Member]</link:label>
    <link:label id="lab_cah_MedicalUnitGoodwillImpairmentMember_documentation_en-US" xlink:label="lab_cah_MedicalUnitGoodwillImpairmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Unit Goodwill Impairment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalUnitGoodwillImpairmentMember" xlink:href="cah-20230331.xsd#cah_MedicalUnitGoodwillImpairmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_MedicalUnitGoodwillImpairmentMember" xlink:to="lab_cah_MedicalUnitGoodwillImpairmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_SettlingStates_8b1c5018-e5dd-47f8-8391-ff62c54cbbfa_terseLabel_en-US" xlink:label="lab_cah_SettlingStates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settling States</link:label>
    <link:label id="lab_cah_SettlingStates_label_en-US" xlink:label="lab_cah_SettlingStates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settling States</link:label>
    <link:label id="lab_cah_SettlingStates_documentation_en-US" xlink:label="lab_cah_SettlingStates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settling States</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SettlingStates" xlink:href="cah-20230331.xsd#cah_SettlingStates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_SettlingStates" xlink:to="lab_cah_SettlingStates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_d9b743c5-0dae-4313-bf7f-deb8bd81dcd7_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Net of Tax [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherShortTermBorrowings_fc182e5a-53a6-48e9-b3e6-ef3df5782d5a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Short-term Borrowings</link:label>
    <link:label id="lab_us-gaap_OtherShortTermBorrowings_label_en-US" xlink:label="lab_us-gaap_OtherShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Short-Term Borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherShortTermBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherShortTermBorrowings" xlink:to="lab_us-gaap_OtherShortTermBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationReserveCurrent_3479ac1f-dd98-43ce-8468-ce4be10611f7_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Litigation Liability, Current</link:label>
    <link:label id="lab_us-gaap_LitigationReserveCurrent_label_en-US" xlink:label="lab_us-gaap_LitigationReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Litigation Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationReserveCurrent" xlink:to="lab_us-gaap_LitigationReserveCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_b2a83981-826c-49c6-82ae-ca9153338577_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by/(used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_26fd6872-b427-475a-8287-c92f62d0e604_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_March2026Member_0adc7033-14c2-4366-9174-51c7b1ece614_terseLabel_en-US" xlink:label="lab_cah_March2026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 2026</link:label>
    <link:label id="lab_cah_March2026Member_label_en-US" xlink:label="lab_cah_March2026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 2026 [Member]</link:label>
    <link:label id="lab_cah_March2026Member_documentation_en-US" xlink:label="lab_cah_March2026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 2026</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_March2026Member" xlink:href="cah-20230331.xsd#cah_March2026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_March2026Member" xlink:to="lab_cah_March2026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyClaimsSettledNumber_80ca068d-73d8-4b06-8988-e1692cbe7ef6_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyClaimsSettledNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Claims Settled, Number</link:label>
    <link:label id="lab_us-gaap_LossContingencyClaimsSettledNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyClaimsSettledNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Claims Settled, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsSettledNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyClaimsSettledNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyClaimsSettledNumber" xlink:to="lab_us-gaap_LossContingencyClaimsSettledNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateSwapMember_e136e613-a787-4c4e-ac69-2c3b9a1dd1bb_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap</link:label>
    <link:label id="lab_us-gaap_InterestRateSwapMember_label_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestRateSwapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateSwapMember" xlink:to="lab_us-gaap_InterestRateSwapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_2defb0db-082e-42de-9600-a8f187d64bb9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_684993cd-e1ca-485f-a0d5-2c6691dc6b65_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_A300MillionShareRepurchaseProgramMember_8946b3b1-ddaa-482b-8cd5-92a98ecbf5dd_terseLabel_en-US" xlink:label="lab_cah_A300MillionShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$300 million share repurchase program</link:label>
    <link:label id="lab_cah_A300MillionShareRepurchaseProgramMember_label_en-US" xlink:label="lab_cah_A300MillionShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$300 million share repurchase program [Member]</link:label>
    <link:label id="lab_cah_A300MillionShareRepurchaseProgramMember_documentation_en-US" xlink:label="lab_cah_A300MillionShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$300 million share repurchase program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A300MillionShareRepurchaseProgramMember" xlink:href="cah-20230331.xsd#cah_A300MillionShareRepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_A300MillionShareRepurchaseProgramMember" xlink:to="lab_cah_A300MillionShareRepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_95b60891-4a01-4446-82db-c7f198957635_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c2b920ff-8207-4d46-8240-8cf2cfc901d4_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income/(Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6e64c550-1ea2-4b67-8d65-9512bb7b1365_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_3638dc04-18d4-4c64-9314-c400c4c6b72f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease_bd541ca2-444d-4dc2-8a5b-5633d34fda7f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual, Period Increase (Decrease)</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease" xlink:to="lab_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_CarryingAmountofLongTermandotherShortTermBorrowings_c2c63b68-84d7-4b7f-81f9-e861ee899117_terseLabel_en-US" xlink:label="lab_cah_CarryingAmountofLongTermandotherShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount of Long-Term and other Short-Term Borrowings</link:label>
    <link:label id="lab_cah_CarryingAmountofLongTermandotherShortTermBorrowings_label_en-US" xlink:label="lab_cah_CarryingAmountofLongTermandotherShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount of Long-Term and other Short-Term Borrowings</link:label>
    <link:label id="lab_cah_CarryingAmountofLongTermandotherShortTermBorrowings_documentation_en-US" xlink:label="lab_cah_CarryingAmountofLongTermandotherShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount of Long-Term and other Short-Term Borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CarryingAmountofLongTermandotherShortTermBorrowings" xlink:href="cah-20230331.xsd#cah_CarryingAmountofLongTermandotherShortTermBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_CarryingAmountofLongTermandotherShortTermBorrowings" xlink:to="lab_cah_CarryingAmountofLongTermandotherShortTermBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_LawsuitTypeDomain_1b2c5800-063d-4e44-bdff-30003aba2f63_terseLabel_en-US" xlink:label="lab_cah_LawsuitTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lawsuit Type [Domain]</link:label>
    <link:label id="lab_cah_LawsuitTypeDomain_label_en-US" xlink:label="lab_cah_LawsuitTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lawsuit Type [Domain]</link:label>
    <link:label id="lab_cah_LawsuitTypeDomain_documentation_en-US" xlink:label="lab_cah_LawsuitTypeDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Lawsuit Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LawsuitTypeDomain" xlink:href="cah-20230331.xsd#cah_LawsuitTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_LawsuitTypeDomain" xlink:to="lab_cah_LawsuitTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1ea916b9-5574-4757-b610-785f1bd49377_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Assets and Liabilities Held for Sale [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_OpioidLitigationDomain_bd201e6e-5417-43b0-8a81-d50eeb189e64_terseLabel_en-US" xlink:label="lab_cah_OpioidLitigationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid Litigation [Domain]</link:label>
    <link:label id="lab_cah_OpioidLitigationDomain_label_en-US" xlink:label="lab_cah_OpioidLitigationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid Litigation [Domain]</link:label>
    <link:label id="lab_cah_OpioidLitigationDomain_documentation_en-US" xlink:label="lab_cah_OpioidLitigationDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid Litigation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationDomain" xlink:href="cah-20230331.xsd#cah_OpioidLitigationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_OpioidLitigationDomain" xlink:to="lab_cah_OpioidLitigationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_March2025Member_e9f54bc2-d054-4477-87ae-8bd565e05a9d_terseLabel_en-US" xlink:label="lab_cah_March2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 2025</link:label>
    <link:label id="lab_cah_March2025Member_label_en-US" xlink:label="lab_cah_March2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 2025 [Member]</link:label>
    <link:label id="lab_cah_March2025Member_documentation_en-US" xlink:label="lab_cah_March2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 2025</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_March2025Member" xlink:href="cah-20230331.xsd#cah_March2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_March2025Member" xlink:to="lab_cah_March2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_AL_c96b0822-8d21-4a1a-b770-5bd8d80e56ae_terseLabel_en-US" xlink:label="lab_stpr_AL" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ALABAMA</link:label>
    <link:label id="lab_stpr_AL_label_en-US" xlink:label="lab_stpr_AL" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ALABAMA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_AL" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_AL"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_AL" xlink:to="lab_stpr_AL" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_3e910ed4-c366-49a2-b7ec-a334d1115d09_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_A500MillionShareRepurchaseProgramMember_6a3a365c-50e0-4d98-bbb0-f3a17a05c5ef_terseLabel_en-US" xlink:label="lab_cah_A500MillionShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$500 million share repurchase program [Domain]</link:label>
    <link:label id="lab_cah_A500MillionShareRepurchaseProgramMember_label_en-US" xlink:label="lab_cah_A500MillionShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$500 million share repurchase program [Member]</link:label>
    <link:label id="lab_cah_A500MillionShareRepurchaseProgramMember_documentation_en-US" xlink:label="lab_cah_A500MillionShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$500 million share repurchase program [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A500MillionShareRepurchaseProgramMember" xlink:href="cah-20230331.xsd#cah_A500MillionShareRepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_A500MillionShareRepurchaseProgramMember" xlink:to="lab_cah_A500MillionShareRepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_DateInitiatedDomain_800a1afd-e0c2-44ed-af62-51925093c24d_terseLabel_en-US" xlink:label="lab_cah_DateInitiatedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Date Initiated [Domain]</link:label>
    <link:label id="lab_cah_DateInitiatedDomain_label_en-US" xlink:label="lab_cah_DateInitiatedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Date Initiated [Domain]</link:label>
    <link:label id="lab_cah_DateInitiatedDomain_documentation_en-US" xlink:label="lab_cah_DateInitiatedDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Date Initiated [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_DateInitiatedDomain" xlink:href="cah-20230331.xsd#cah_DateInitiatedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_DateInitiatedDomain" xlink:to="lab_cah_DateInitiatedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_431390e9-48b8-4cf3-9edb-711c1afa6b59_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax benefit related to share-based compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense, Tax Benefit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_e688175b-040f-4ba0-bdc8-25568c7ad5f0_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_CareFusionMember_517d87ca-a26e-4e83-bca1-2c2522b48d43_terseLabel_en-US" xlink:label="lab_cah_CareFusionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CareFusion [Member]</link:label>
    <link:label id="lab_cah_CareFusionMember_label_en-US" xlink:label="lab_cah_CareFusionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CareFusion [Member]</link:label>
    <link:label id="lab_cah_CareFusionMember_documentation_en-US" xlink:label="lab_cah_CareFusionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CareFusion [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CareFusionMember" xlink:href="cah-20230331.xsd#cah_CareFusionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_CareFusionMember" xlink:to="lab_cah_CareFusionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_49812d91-d2ca-4a99-ab6b-e9bcfef6a6a3_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_GoodwillImpairmentDomain_8077543f-1150-4e7c-8a32-60922135007a_terseLabel_en-US" xlink:label="lab_cah_GoodwillImpairmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill Impairment [Domain]</link:label>
    <link:label id="lab_cah_GoodwillImpairmentDomain_label_en-US" xlink:label="lab_cah_GoodwillImpairmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill Impairment [Domain]</link:label>
    <link:label id="lab_cah_GoodwillImpairmentDomain_documentation_en-US" xlink:label="lab_cah_GoodwillImpairmentDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill Impairment [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_GoodwillImpairmentDomain" xlink:href="cah-20230331.xsd#cah_GoodwillImpairmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_GoodwillImpairmentDomain" xlink:to="lab_cah_GoodwillImpairmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_67e0f8b4-ec59-43ce-b927-7ec691d3d16f_terseLabel_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated range of decrease in unrecognized tax benefits within the next 12 months</link:label>
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_label_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in Unrecognized Tax Benefits is Reasonably Possible</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:to="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_bb65a986-308e-4004-bf2a-44f24cce1425_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Authorized&#8212;755 million shares, Issued&#8212;327 million shares at March&#160;31, 2023 and June 30, 2022</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_GA_5ded81be-9e0e-4268-b4ad-a85f0e8e7e1b_terseLabel_en-US" xlink:label="lab_stpr_GA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GEORGIA</link:label>
    <link:label id="lab_stpr_GA_label_en-US" xlink:label="lab_stpr_GA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GEORGIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_GA" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_GA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_GA" xlink:to="lab_stpr_GA" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_acbbfd31-2eaf-43e4-8ae6-19ae8b65a852_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_SharesThatWouldBeAntidilutiveAsAResultOfNetLoss_97e854a1-05fb-4be6-acbb-e4d7fcde6983_terseLabel_en-US" xlink:label="lab_cah_SharesThatWouldBeAntidilutiveAsAResultOfNetLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares that would be antidilutive as a result of net loss</link:label>
    <link:label id="lab_cah_SharesThatWouldBeAntidilutiveAsAResultOfNetLoss_label_en-US" xlink:label="lab_cah_SharesThatWouldBeAntidilutiveAsAResultOfNetLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares that would be antidilutive as a result of net loss</link:label>
    <link:label id="lab_cah_SharesThatWouldBeAntidilutiveAsAResultOfNetLoss_documentation_en-US" xlink:label="lab_cah_SharesThatWouldBeAntidilutiveAsAResultOfNetLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares that would be antidilutive as a result of net loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SharesThatWouldBeAntidilutiveAsAResultOfNetLoss" xlink:href="cah-20230331.xsd#cah_SharesThatWouldBeAntidilutiveAsAResultOfNetLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_SharesThatWouldBeAntidilutiveAsAResultOfNetLoss" xlink:to="lab_cah_SharesThatWouldBeAntidilutiveAsAResultOfNetLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_c15b29d4-35df-4f36-8f60-b653e871ff5e_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:to="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_aa61f887-d453-4dcb-a261-b36b3c78b66c_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_86a36057-e146-473a-af52-b9e6582a52fe_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (income)/expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_2886f910-e591-4a84-97c2-7acb8b4cf86a_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_18ee968a-bdfd-4cbf-9393-708e28ae971b_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_3a0a406c-5488-449a-864c-9b1cf8869a92_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsegmentsDomain_03524bca-fddb-4628-bc56-f97feffaf14b_terseLabel_en-US" xlink:label="lab_us-gaap_SubsegmentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsegmentsDomain_label_en-US" xlink:label="lab_us-gaap_SubsegmentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsegmentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsegmentsDomain" xlink:to="lab_us-gaap_SubsegmentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_ac71a9ab-1436-419f-bb5f-19106d708e51_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_MedicalUnitMember_0ff2e592-999e-4ac9-ad22-29952b382a15_terseLabel_en-US" xlink:label="lab_cah_MedicalUnitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Unit</link:label>
    <link:label id="lab_cah_MedicalUnitMember_label_en-US" xlink:label="lab_cah_MedicalUnitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Unit [Member]</link:label>
    <link:label id="lab_cah_MedicalUnitMember_documentation_en-US" xlink:label="lab_cah_MedicalUnitMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Unit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalUnitMember" xlink:href="cah-20230331.xsd#cah_MedicalUnitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_MedicalUnitMember" xlink:to="lab_cah_MedicalUnitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_f25036a8-4372-4855-8bd6-641006bdd8e4_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Other Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_d281266d-ee8c-4aa4-afdc-cea1b268c6cd_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments</link:label>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_label_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:to="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_18d24394-d21b-413c-a7e2-2ed0bee734a7_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_502dce14-cd1b-45c2-866b-1ffb3e8128d6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Changes in the Balance of Accumulated Other Comprehensive Loss by Component and in Total</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_26370b7c-933f-4dfd-a3b4-27de8329de71_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred shares, authorized</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_PharmaceuticalDistributionandSpecialtyMember_3a032951-5fa4-48a7-964d-e6cff67129e7_terseLabel_en-US" xlink:label="lab_cah_PharmaceuticalDistributionandSpecialtyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical Distribution and Specialty [Member]</link:label>
    <link:label id="lab_cah_PharmaceuticalDistributionandSpecialtyMember_label_en-US" xlink:label="lab_cah_PharmaceuticalDistributionandSpecialtyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical Distribution and Specialty [Member]</link:label>
    <link:label id="lab_cah_PharmaceuticalDistributionandSpecialtyMember_documentation_en-US" xlink:label="lab_cah_PharmaceuticalDistributionandSpecialtyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical Distribution and Specialty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalDistributionandSpecialtyMember" xlink:href="cah-20230331.xsd#cah_PharmaceuticalDistributionandSpecialtyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_PharmaceuticalDistributionandSpecialtyMember" xlink:to="lab_cah_PharmaceuticalDistributionandSpecialtyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f2e2693d-77cc-4eb9-97ca-ac6cc0e1612e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_8c596033-bf01-4ad5-a2eb-116fbc20c0fb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill by Reportable Segment</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermPurchaseCommitmentPeriod_69d4afb5-6f89-45ba-8c7d-827bcf1339dc_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermPurchaseCommitmentPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Purchase Commitment, Period</link:label>
    <link:label id="lab_us-gaap_LongtermPurchaseCommitmentPeriod_label_en-US" xlink:label="lab_us-gaap_LongtermPurchaseCommitmentPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Purchase Commitment, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermPurchaseCommitmentPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermPurchaseCommitmentPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermPurchaseCommitmentPeriod" xlink:to="lab_us-gaap_LongtermPurchaseCommitmentPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_284a08d4-f518-452c-aeab-5dce3a765839_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_MaturityDateDomain_fba8995d-6870-424b-b953-088cb1f7a7af_terseLabel_en-US" xlink:label="lab_cah_MaturityDateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity Date [Domain]</link:label>
    <link:label id="lab_cah_MaturityDateDomain_label_en-US" xlink:label="lab_cah_MaturityDateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity Date [Domain]</link:label>
    <link:label id="lab_cah_MaturityDateDomain_documentation_en-US" xlink:label="lab_cah_MaturityDateDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity Date [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MaturityDateDomain" xlink:href="cah-20230331.xsd#cah_MaturityDateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_MaturityDateDomain" xlink:to="lab_cah_MaturityDateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_ContingentAttorneyFee_71507861-2802-43cd-bee8-497c2a96e102_terseLabel_en-US" xlink:label="lab_cah_ContingentAttorneyFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Attorney Fee</link:label>
    <link:label id="lab_cah_ContingentAttorneyFee_label_en-US" xlink:label="lab_cah_ContingentAttorneyFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Attorney Fee</link:label>
    <link:label id="lab_cah_ContingentAttorneyFee_documentation_en-US" xlink:label="lab_cah_ContingentAttorneyFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Attorney Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ContingentAttorneyFee" xlink:href="cah-20230331.xsd#cah_ContingentAttorneyFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_ContingentAttorneyFee" xlink:to="lab_cah_ContingentAttorneyFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_6606824d-b367-45dc-aa0b-a5808e521b20_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_8ed8c61b-9cf5-4bcc-b00d-aa9abc95f0a8_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate</link:label>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_label_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate, Non-Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateNonSegmentMember" xlink:to="lab_us-gaap_CorporateNonSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_c5e6a9c5-289c-4e94-8082-da007864074b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued liabilities and operating items, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets and Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_91ab3c82-cafb-4104-9878-798f4ea708e9_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_b8984ad1-6e23-45db-a6d7-7bb5532f3926_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairments and (gain)/loss on disposal of assets, net</link:label>
    <link:label id="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Sale of Assets and Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:to="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_e412f2c6-ef1a-4507-8fa3-30fa8193286e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_CardinalHealthAtHomeMember_7822559b-33f7-4cae-b21c-6530da4cdc8c_terseLabel_en-US" xlink:label="lab_cah_CardinalHealthAtHomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardinal Health At Home [Member]</link:label>
    <link:label id="lab_cah_CardinalHealthAtHomeMember_label_en-US" xlink:label="lab_cah_CardinalHealthAtHomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardinal Health At Home [Member]</link:label>
    <link:label id="lab_cah_CardinalHealthAtHomeMember_documentation_en-US" xlink:label="lab_cah_CardinalHealthAtHomeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardinal Health At Home [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CardinalHealthAtHomeMember" xlink:href="cah-20230331.xsd#cah_CardinalHealthAtHomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_CardinalHealthAtHomeMember" xlink:to="lab_cah_CardinalHealthAtHomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_6505fe18-80e1-4934-9322-b43902659033_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Cardinal Health, Inc. shareholders' deficit</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_6c26b051-8e53-4868-853a-dc6a14f65c64_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_b80626cf-fe7d-49a8-925e-aa362ff2bacb_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_dc0dfc5a-3b93-4572-85a6-6f274b962e00_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits that would impact effective tax rate</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1093fb34-9105-4f05-ba61-bd0d564e8edf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_609b7d09-e784-4c4c-a466-62197c5a479d_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill impairment</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b54c81bb-8d89-45d7-9fcc-f8b0de6181de_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReportingUnitAxis_4d3f5eda-353d-454d-bd32-646a4d57ac37_terseLabel_en-US" xlink:label="lab_us-gaap_ReportingUnitAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Axis]</link:label>
    <link:label id="lab_us-gaap_ReportingUnitAxis_label_en-US" xlink:label="lab_us-gaap_ReportingUnitAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReportingUnitAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReportingUnitAxis" xlink:to="lab_us-gaap_ReportingUnitAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsegmentsAxis_e3171aa3-ce04-4110-bb01-aec203764cd3_terseLabel_en-US" xlink:label="lab_us-gaap_SubsegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsegmentsAxis_label_en-US" xlink:label="lab_us-gaap_SubsegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsegmentsAxis" xlink:to="lab_us-gaap_SubsegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_26246edd-393b-46a2-a3a2-08406a951ea8_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_22fd66e0-00e4-45e9-a5c4-c2220af65322_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustments and other</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_aeefb6a2-da22-48d6-bb8a-0001f6a6070a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_549bd959-8bd8-4179-b9b0-7722d729c634_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term obligations, less current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_05573cff-7d73-4edc-a97b-63ef343a1f42_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt and Lease Obligation</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt and Lease Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_548def1a-9f0d-4df9-b3a9-1c9c9710373e_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings/(loss) before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NondesignatedMember_8326c024-3a6a-494d-97c6-9981974a6e62_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NondesignatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember" xlink:to="lab_us-gaap_NondesignatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_41ebf0aa-a26c-44e5-bc26-101aa1d39fd8_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Employee Severance</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_36c57cec-c103-4e01-8a3b-00196e52e8c1_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred shares, issued</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_3daa1b40-3a00-4e70-abcb-9b9e0eed5d3c_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_960981a8-fd51-430a-b66a-e078e68a357d_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_80ff6e30-dba8-4dce-816f-081002db65d5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_DateInitiatedAxis_03328cd3-92e2-40d4-9919-cbc3dcf6606e_terseLabel_en-US" xlink:label="lab_cah_DateInitiatedAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Date [Axis]</link:label>
    <link:label id="lab_cah_DateInitiatedAxis_label_en-US" xlink:label="lab_cah_DateInitiatedAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Date Initiated [Axis]</link:label>
    <link:label id="lab_cah_DateInitiatedAxis_documentation_en-US" xlink:label="lab_cah_DateInitiatedAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Date Initiated</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_DateInitiatedAxis" xlink:href="cah-20230331.xsd#cah_DateInitiatedAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_DateInitiatedAxis" xlink:to="lab_cah_DateInitiatedAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_a51a062f-4cb0-430c-b3fb-4e5d7564c27b_terseLabel_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Investment Hedging [Member]</link:label>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_label_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Investment Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetInvestmentHedgingMember" xlink:to="lab_us-gaap_NetInvestmentHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_000d4bc2-7a61-434f-9db0-24499752e94b_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_6cc432ec-05b0-413b-bbd5-bb63fdd43da9_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Intangible, Total other intangible assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_TotalOpioidLitigationMember_e0e6f671-2023-4d31-9817-77cb2c60e04b_terseLabel_en-US" xlink:label="lab_cah_TotalOpioidLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Opioid Litigation [Member]</link:label>
    <link:label id="lab_cah_TotalOpioidLitigationMember_label_en-US" xlink:label="lab_cah_TotalOpioidLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Opioid Litigation [Member]</link:label>
    <link:label id="lab_cah_TotalOpioidLitigationMember_documentation_en-US" xlink:label="lab_cah_TotalOpioidLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Opioid Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalOpioidLitigationMember" xlink:href="cah-20230331.xsd#cah_TotalOpioidLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_TotalOpioidLitigationMember" xlink:to="lab_cah_TotalOpioidLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_072f1242-cc62-4c47-bfc2-635294eb9b87_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_c9647159-5ce1-441d-880e-fb816968a235_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_5806faf4-f6fc-4450-a5f3-11e7be03bc96_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Geographic Areas [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Geographic Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:to="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_61bc25a8-f6be-4774-a3f7-23c08359e944_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_LawsuitTypeAxis_a87dbe55-f603-4665-8f6c-22d538a5b2d0_terseLabel_en-US" xlink:label="lab_cah_LawsuitTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lawsuit Type [Axis]</link:label>
    <link:label id="lab_cah_LawsuitTypeAxis_label_en-US" xlink:label="lab_cah_LawsuitTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lawsuit Type [Axis]</link:label>
    <link:label id="lab_cah_LawsuitTypeAxis_documentation_en-US" xlink:label="lab_cah_LawsuitTypeAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lawsuit Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LawsuitTypeAxis" xlink:href="cah-20230331.xsd#cah_LawsuitTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_LawsuitTypeAxis" xlink:to="lab_cah_LawsuitTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_29b61b37-771b-42e2-8b2c-448f88d692fe_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_2fe3960b-cc2d-411d-adbc-3a12d98de7d4_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_dcc2d43d-784e-4440-a6fc-6b958bf468d6_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_b0ea07cc-cd1c-414a-976d-fdb086c56dbe_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_September2018Member_6ddffacc-06b0-4b66-9008-05f7090ccb7c_terseLabel_en-US" xlink:label="lab_cah_September2018Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective September 2018</link:label>
    <link:label id="lab_cah_September2018Member_label_en-US" xlink:label="lab_cah_September2018Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">September 2018 [Member]</link:label>
    <link:label id="lab_cah_September2018Member_documentation_en-US" xlink:label="lab_cah_September2018Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">September 2018</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_September2018Member" xlink:href="cah-20230331.xsd#cah_September2018Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_September2018Member" xlink:to="lab_cah_September2018Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_5750892e-7a80-4eed-8973-e016699be23b_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_e03a4ffd-64f2-41f4-80ac-cc7a10e6b74f_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c1ef5f67-38c2-4d2a-9404-e60e09608aa6_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total shareholders&#8217; deficit</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_066e24d1-ac60-44c0-996d-8cf8d2c1b78d_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_514aceef-c390-4642-ab89-804e233971e0_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductLiabilityAccrualPeriodExpense_b82a2189-c145-4e98-b71d-d0c77a0ec2e9_terseLabel_en-US" xlink:label="lab_us-gaap_ProductLiabilityAccrualPeriodExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Liability Accrual, Period Expense</link:label>
    <link:label id="lab_us-gaap_ProductLiabilityAccrualPeriodExpense_label_en-US" xlink:label="lab_us-gaap_ProductLiabilityAccrualPeriodExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Liability Accrual, Period Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductLiabilityAccrualPeriodExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductLiabilityAccrualPeriodExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductLiabilityAccrualPeriodExpense" xlink:to="lab_us-gaap_ProductLiabilityAccrualPeriodExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_f7397d47-3ca3-4ea3-8c42-c8feb6ad503d_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_1388d51c-27df-4512-8bd9-91536730db2e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_3796c253-a01e-4c08-97e8-16ab89b2300e_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_71e3747b-aca8-420d-aab8-0369e144150b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:to="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_ShareholderDerivativeLitigationMember_9ef5c1e2-7968-4b65-816b-c3d71d101070_terseLabel_en-US" xlink:label="lab_cah_ShareholderDerivativeLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholder Derivative Litigation [Member]</link:label>
    <link:label id="lab_cah_ShareholderDerivativeLitigationMember_label_en-US" xlink:label="lab_cah_ShareholderDerivativeLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholder Derivative Litigation [Member]</link:label>
    <link:label id="lab_cah_ShareholderDerivativeLitigationMember_documentation_en-US" xlink:label="lab_cah_ShareholderDerivativeLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholder Derivative Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ShareholderDerivativeLitigationMember" xlink:href="cah-20230331.xsd#cah_ShareholderDerivativeLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_ShareholderDerivativeLitigationMember" xlink:to="lab_cah_ShareholderDerivativeLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_d3473b7a-6ed1-42ac-9c3d-ce343d755f08_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade receivables, net</link:label>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesNetCurrent" xlink:to="lab_us-gaap_ReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a3684be2-018d-4152-8913-7dd880ed69c0_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_1f20fc1d-70da-4270-8acf-7d49b92f5168_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:to="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_152dd66c-afbb-44c2-a296-002f951d72ad_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other comprehensive income/(loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_47e641fe-1321-41eb-aa7c-cbaf7a7e431d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_00db5531-f46c-48a9-86c1-d2483aaf22b0_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_bf0b0270-98b5-4b65-852f-4c9e0c0ea060_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation Adjustments</link:label>
    <link:label id="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_cb27d4a5-b6b5-45a3-9eb8-aafcf7da4c35_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1f75405a-ee60-466b-9657-65d985364e2a_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_58dbaef9-f855-44b7-8c63-a054ee3d70a7_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="lab_us-gaap_LiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_15c9791e-eda4-4cd7-8405-87f1483aebec_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net earnings/(loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_0f785f4c-3614-43dd-8ffc-222475f996a3_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net earnings/(loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_d72983e0-2181-409d-9f6d-8d2e2805a47f_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_d70e37c3-2b06-4b40-a7ce-e036d85059f1_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_3e100046-984f-4463-aaa4-5f8289c20f8b_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments, Contingent Liabilities and Litigation</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_b47979f3-1691-4407-962d-25bf94a82dbd_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_9835ee61-8beb-4105-99eb-6f981cf9f81a_verboseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed technology and other</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_label_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:to="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_8ec571ce-88ab-4e54-8b98-ffaaaa2e8248_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_d1505e13-3409-4e21-ab91-6296cc795975_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Profit by Reportable Segment</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:to="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_d3271e3a-da79-4880-993b-aaf86237e7dc_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and shareholders&#8217; deficit</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_CordisDivestitureAxis_6f415007-771d-40fe-9252-aca9d079aef9_terseLabel_en-US" xlink:label="lab_cah_CordisDivestitureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cordis Divestiture [Axis]</link:label>
    <link:label id="lab_cah_CordisDivestitureAxis_label_en-US" xlink:label="lab_cah_CordisDivestitureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cordis Divestiture [Axis]</link:label>
    <link:label id="lab_cah_CordisDivestitureAxis_documentation_en-US" xlink:label="lab_cah_CordisDivestitureAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cordis Divestiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureAxis" xlink:href="cah-20230331.xsd#cah_CordisDivestitureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_CordisDivestitureAxis" xlink:to="lab_cah_CordisDivestitureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_cd4947a2-041f-4621-8f2a-f6c2b4ca31f1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_76492c02-f62a-428e-a7eb-f4dc7bedcc2c_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Remaining Amortization Period (Years)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Remaining Amortization Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_3e496299-a82a-4b62-92e4-37da71844627_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized gain on derivative instruments, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_6af2dec1-5968-4222-a6cd-419da41b8671_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_33101093-408a-43bd-9bf4-5bcbb0a96cf9_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCosts_b3f2bf47-d9bb-4abf-af69-07860c64afd0_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_us-gaap_RestructuringCosts_label_en-US" xlink:label="lab_us-gaap_RestructuringCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCosts" xlink:to="lab_us-gaap_RestructuringCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_5fd8e8fd-38dd-4877-a2c8-45fb05da584e_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_NetOperatingLossCarrybackAxis_5bc9507d-6c9d-4540-ba7b-1e53e0799730_terseLabel_en-US" xlink:label="lab_cah_NetOperatingLossCarrybackAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Operating Loss Carryback [Axis]</link:label>
    <link:label id="lab_cah_NetOperatingLossCarrybackAxis_label_en-US" xlink:label="lab_cah_NetOperatingLossCarrybackAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Operating Loss Carryback [Axis]</link:label>
    <link:label id="lab_cah_NetOperatingLossCarrybackAxis_documentation_en-US" xlink:label="lab_cah_NetOperatingLossCarrybackAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Operating Loss Carryback</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NetOperatingLossCarrybackAxis" xlink:href="cah-20230331.xsd#cah_NetOperatingLossCarrybackAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_NetOperatingLossCarrybackAxis" xlink:to="lab_cah_NetOperatingLossCarrybackAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_1889cc1d-9131-4669-b0de-4a30511728c3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_CVSHealthMember_5f96a40a-76d3-485d-8f69-ee09f9eaf8a1_terseLabel_en-US" xlink:label="lab_cah_CVSHealthMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CVS Health</link:label>
    <link:label id="lab_cah_CVSHealthMember_label_en-US" xlink:label="lab_cah_CVSHealthMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CVS Health [Member]</link:label>
    <link:label id="lab_cah_CVSHealthMember_documentation_en-US" xlink:label="lab_cah_CVSHealthMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CVS Health [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CVSHealthMember" xlink:href="cah-20230331.xsd#cah_CVSHealthMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_CVSHealthMember" xlink:to="lab_cah_CVSHealthMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_NewYorkOpioidStewardshipActMember_f68b8a36-28e4-4004-b2fe-16d3d9ac8226_terseLabel_en-US" xlink:label="lab_cah_NewYorkOpioidStewardshipActMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New York Opioid Stewardship Act [Member]</link:label>
    <link:label id="lab_cah_NewYorkOpioidStewardshipActMember_label_en-US" xlink:label="lab_cah_NewYorkOpioidStewardshipActMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New York Opioid Stewardship Act [Member]</link:label>
    <link:label id="lab_cah_NewYorkOpioidStewardshipActMember_documentation_en-US" xlink:label="lab_cah_NewYorkOpioidStewardshipActMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New York Opioid Stewardship Act</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NewYorkOpioidStewardshipActMember" xlink:href="cah-20230331.xsd#cah_NewYorkOpioidStewardshipActMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_NewYorkOpioidStewardshipActMember" xlink:to="lab_cah_NewYorkOpioidStewardshipActMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_2836acea-f5af-42db-8e7d-62b126329309_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and employee severance</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_f8d72862-9e4b-498a-a97b-4bfeee3db680_totalLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total restructuring and employee severance</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_a6e3a98d-c230-4d5a-b396-7ec0dbc23315_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromRedemptions_03c70160-ee14-46cd-9660-48a10c533a22_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury shares acquired, average price per share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromRedemptions_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:to="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_0cf4856b-2a5b-4996-9e6f-6427b6286242_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_dc1c34a9-817e-4608-9e47-4b89c505e0a7_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares, authorized</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_OtherAgreementsMember_684097ee-4de6-456f-9698-b8415212fcae_terseLabel_en-US" xlink:label="lab_cah_OtherAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Agreements [Member]</link:label>
    <link:label id="lab_cah_OtherAgreementsMember_label_en-US" xlink:label="lab_cah_OtherAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Agreements [Member]</link:label>
    <link:label id="lab_cah_OtherAgreementsMember_documentation_en-US" xlink:label="lab_cah_OtherAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OtherAgreementsMember" xlink:href="cah-20230331.xsd#cah_OtherAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_OtherAgreementsMember" xlink:to="lab_cah_OtherAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_94852411-0178-4322-8d62-6dc95eec35f1_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6b1d07ed-539d-46c5-8bcb-222aa1b70b76_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_OK_75a1a670-c82b-4df8-8c0c-511406d4885a_terseLabel_en-US" xlink:label="lab_stpr_OK" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OKLAHOMA</link:label>
    <link:label id="lab_stpr_OK_label_en-US" xlink:label="lab_stpr_OK" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OKLAHOMA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_OK" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_OK"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_OK" xlink:to="lab_stpr_OK" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_25beb7d5-537e-459b-b72b-480fd646aa2b_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_e25abf1c-d2a0-430e-a458-692c8891ec27_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_292a20a4-dcfb-43c4-8026-12a0fad271ea_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net earnings/(loss) to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLineItems_881b7967-633a-454b-9b2e-e41b46a4f28d_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLineItems" xlink:to="lab_us-gaap_DerivativeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_e2e88604-4bdf-4a08-a312-9383b5e9571d_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveRollForward" xlink:to="lab_us-gaap_RestructuringReserveRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock_03701b4c-4834-4dd2-91e7-3ec298d4c8c9_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets by Reportable Segment</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Assets from Segment to Consolidated [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:to="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_17c96a0c-2b32-4125-b623-725f04a8dfeb_terseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for bad debts</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_60c25445-1f1c-4868-a788-7d1e5f5f616c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled and forfeited (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_1a6c2b60-144f-436a-a4dc-a275462ac26c_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_33a1db3e-2379-4866-8d39-9679b4d8e80d_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanAxis" xlink:to="lab_us-gaap_RestructuringPlanAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_3a3856a2-5845-4103-b746-c767ae40b7d8_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_AgreementsDomain_0e9fc637-c62e-491e-8204-eb982dc73e24_terseLabel_en-US" xlink:label="lab_cah_AgreementsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreements [Domain]</link:label>
    <link:label id="lab_cah_AgreementsDomain_label_en-US" xlink:label="lab_cah_AgreementsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreements [Domain]</link:label>
    <link:label id="lab_cah_AgreementsDomain_documentation_en-US" xlink:label="lab_cah_AgreementsDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreements [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_AgreementsDomain" xlink:href="cah-20230331.xsd#cah_AgreementsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_AgreementsDomain" xlink:to="lab_cah_AgreementsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNumberOfPlaintiffs_6ddb0fb7-3da8-43b2-b5c0-d67434350a6d_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number of Plaintiffs</link:label>
    <link:label id="lab_us-gaap_LossContingencyNumberOfPlaintiffs_label_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number of Plaintiffs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:to="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_6ccea9a1-fee2-4dcf-8d6f-bf61313108a5_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated annual amortization of intangible assets - Year Three</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_f56ecc99-d88e-479b-82d4-b150ecfa71ed_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled and forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_de36eed7-c935-4896-a6e2-8894c6b66a7a_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_505fd116-b0cb-4533-9225-d6af869eb5d5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_PlaintiffTypeAxis_11ace342-e24a-403a-85e2-58796b1a0784_terseLabel_en-US" xlink:label="lab_cah_PlaintiffTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plaintiff Type [Axis]</link:label>
    <link:label id="lab_cah_PlaintiffTypeAxis_label_en-US" xlink:label="lab_cah_PlaintiffTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plaintiff Type [Axis]</link:label>
    <link:label id="lab_cah_PlaintiffTypeAxis_documentation_en-US" xlink:label="lab_cah_PlaintiffTypeAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plaintiff Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PlaintiffTypeAxis" xlink:href="cah-20230331.xsd#cah_PlaintiffTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_PlaintiffTypeAxis" xlink:to="lab_cah_PlaintiffTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_dac77a5b-2a0e-4ef5-ac21-86b6e76819a6_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LegalFees_5e6688e5-2a2a-49d4-9ded-db31426c238c_terseLabel_en-US" xlink:label="lab_us-gaap_LegalFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Fees</link:label>
    <link:label id="lab_us-gaap_LegalFees_label_en-US" xlink:label="lab_us-gaap_LegalFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalFees" xlink:to="lab_us-gaap_LegalFees" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_af8037a0-acab-4c54-8688-a49c4af8febf_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringChargesAbstract_30e940b0-9585-4b8e-82e2-716064f34a1d_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringChargesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges [Abstract]</link:label>
    <link:label id="lab_us-gaap_RestructuringChargesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringChargesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringChargesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringChargesAbstract" xlink:to="lab_us-gaap_RestructuringChargesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_41a49b68-6c49-4a5d-ac47-4f1a9e488e42_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated annual amortization of intangible assets - Year Two</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_NarativeAbstract_6625b189-a90f-4def-9077-8dde542bafb5_terseLabel_en-US" xlink:label="lab_cah_NarativeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Narative [Abstract]</link:label>
    <link:label id="lab_cah_NarativeAbstract_label_en-US" xlink:label="lab_cah_NarativeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Narative [Abstract]</link:label>
    <link:label id="lab_cah_NarativeAbstract_documentation_en-US" xlink:label="lab_cah_NarativeAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Narative [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NarativeAbstract" xlink:href="cah-20230331.xsd#cah_NarativeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_NarativeAbstract" xlink:to="lab_cah_NarativeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_67123595-0f6a-4641-8038-d0b38ce1c0d2_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from disposal of property and equipment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_96abbb15-0c5c-46cd-b082-f4fbb3460849_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee- Related Costs</link:label>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_label_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Severance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeSeveranceMember" xlink:to="lab_us-gaap_EmployeeSeveranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_1966c2bd-f8e0-4bca-8f28-5f2984f2618a_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_ba75c2ef-4e4f-40ba-a782-b221a76828cb_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments and other adjustments</link:label>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_label_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Restructuring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRestructuring" xlink:to="lab_us-gaap_PaymentsForRestructuring" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_dff8dd4a-0492-4bf9-8a1a-936547a50bd0_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_f084d18c-9e79-4dbf-9cfb-7a589ea5dafd_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_e9bbbaf4-cc81-4628-a4e0-e24f31bfc9e6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_234cf5d6-d500-4eca-9fdc-14255b0e4980_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Revenue from Segments to Consolidated [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:to="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_06fc8ad4-343f-4e86-bfe4-4f7bc4cff896_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction of long-term obligations</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_d6edc0b3-90b3-44fc-ac9d-07c7198dd714_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_4d1eeded-cfbf-411e-99c0-27e9494d2370_verboseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonMember" xlink:to="lab_us-gaap_TreasuryStockCommonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_bde2c8a8-2b92-4bd0-9435-b7af98fbcb38_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_NativeAmericanTribesMember_22810771-d5ff-4e7d-9141-cfdfb5b16505_terseLabel_en-US" xlink:label="lab_cah_NativeAmericanTribesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Native American tribes</link:label>
    <link:label id="lab_cah_NativeAmericanTribesMember_label_en-US" xlink:label="lab_cah_NativeAmericanTribesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Native American tribes [Member]</link:label>
    <link:label id="lab_cah_NativeAmericanTribesMember_documentation_en-US" xlink:label="lab_cah_NativeAmericanTribesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Native American tribes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NativeAmericanTribesMember" xlink:href="cah-20230331.xsd#cah_NativeAmericanTribesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_NativeAmericanTribesMember" xlink:to="lab_cah_NativeAmericanTribesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_8814f601-e21c-4a6f-8af3-2bd1ab68dc6c_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_5e31ad0f-57bc-44e9-9638-28dd0b753de5_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_91b4344c-cf93-4447-9ed6-480f8462bbd2_verboseLabel_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_7f971cdc-3d48-4c77-9671-a4bc25cba4f2_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total share-based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_fbe491e4-edaa-481d-9790-8479464bb3bd_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_label_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_b3fd4463-441b-480d-bee9-3032ec950caf_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Intangible</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_150f598d-04dd-40cb-a710-744b78f3e76e_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_fbb0f636-255b-47f8-bde9-cd24f5d1a13f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_a8a7f310-97c4-408a-801c-291c55d1d719_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_TaxMatterAxis_565c8c29-fd61-4dd8-9bad-a32ecdbeb8be_terseLabel_en-US" xlink:label="lab_cah_TaxMatterAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Matter [Axis]</link:label>
    <link:label id="lab_cah_TaxMatterAxis_label_en-US" xlink:label="lab_cah_TaxMatterAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Matter [Axis]</link:label>
    <link:label id="lab_cah_TaxMatterAxis_documentation_en-US" xlink:label="lab_cah_TaxMatterAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Matter [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMatterAxis" xlink:href="cah-20230331.xsd#cah_TaxMatterAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_TaxMatterAxis" xlink:to="lab_cah_TaxMatterAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_OpioidLawsuitsMember_72c91c9b-0d63-4e65-8e32-0d98b5c4ccb3_terseLabel_en-US" xlink:label="lab_cah_OpioidLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid Lawsuits [Member]</link:label>
    <link:label id="lab_cah_OpioidLawsuitsMember_label_en-US" xlink:label="lab_cah_OpioidLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid Lawsuits [Member]</link:label>
    <link:label id="lab_cah_OpioidLawsuitsMember_documentation_en-US" xlink:label="lab_cah_OpioidLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid Lawsuits [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLawsuitsMember" xlink:href="cah-20230331.xsd#cah_OpioidLawsuitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_OpioidLawsuitsMember" xlink:to="lab_cah_OpioidLawsuitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_f907bb07-39d2-4e55-956f-64e97aeea213_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_AlamedaCountyMember_50ed77f3-5871-4fdc-8200-6e99c998c276_terseLabel_en-US" xlink:label="lab_cah_AlamedaCountyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alameda County [Member]</link:label>
    <link:label id="lab_cah_AlamedaCountyMember_label_en-US" xlink:label="lab_cah_AlamedaCountyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alameda County [Member]</link:label>
    <link:label id="lab_cah_AlamedaCountyMember_documentation_en-US" xlink:label="lab_cah_AlamedaCountyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alameda County [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_AlamedaCountyMember" xlink:href="cah-20230331.xsd#cah_AlamedaCountyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_AlamedaCountyMember" xlink:to="lab_cah_AlamedaCountyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_PrivatePartiesMember_5be74b8e-63f2-4956-84c9-d8a39518d74a_terseLabel_en-US" xlink:label="lab_cah_PrivatePartiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Parties [Member]</link:label>
    <link:label id="lab_cah_PrivatePartiesMember_label_en-US" xlink:label="lab_cah_PrivatePartiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Parties [Member]</link:label>
    <link:label id="lab_cah_PrivatePartiesMember_documentation_en-US" xlink:label="lab_cah_PrivatePartiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Parties [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PrivatePartiesMember" xlink:href="cah-20230331.xsd#cah_PrivatePartiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_PrivatePartiesMember" xlink:to="lab_cah_PrivatePartiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_1dab0a82-13ca-49d0-b282-bed0ce63fda3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_20361244-39b5-4f80-b30e-4f275d8ebabb_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_288f45b9-0aaa-4ca0-9956-d04e9ee37f6c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfOtherInvestments_03413bd0-3c0f-46be-b9c4-5671f5a074bb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfOtherInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairments and loss on sale of other investments</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfOtherInvestments_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Sale of Other Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfOtherInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfOtherInvestments" xlink:to="lab_us-gaap_GainLossOnSaleOfOtherInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_cc46bc41-5667-4b7e-9c40-b90c771435e3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_3025ac71-333c-4a9c-a46f-9a70eaae12e3_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_416b4ab5-a1ae-47d0-a8f7-19c09f162a9d_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Legal Settlements</link:label>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_label_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Legal Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForLegalSettlements" xlink:to="lab_us-gaap_PaymentsForLegalSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_DiscountRateFairValueInput_e493c2eb-b3d0-4768-98fc-b425461a685b_terseLabel_en-US" xlink:label="lab_cah_DiscountRateFairValueInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount Rate, Fair Value Input</link:label>
    <link:label id="lab_cah_DiscountRateFairValueInput_label_en-US" xlink:label="lab_cah_DiscountRateFairValueInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount Rate, Fair Value Input</link:label>
    <link:label id="lab_cah_DiscountRateFairValueInput_documentation_en-US" xlink:label="lab_cah_DiscountRateFairValueInput" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount Rate, Fair Value Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_DiscountRateFairValueInput" xlink:href="cah-20230331.xsd#cah_DiscountRateFairValueInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_DiscountRateFairValueInput" xlink:to="lab_cah_DiscountRateFairValueInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_1e3c91c8-8d8f-4d1a-9ab0-b38e48f28344_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_da58f272-7644-4bdf-a684-a585d20d656c_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_72a4197b-c069-4da1-8d27-8d759d7d072b_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueHedgingMember_86e12970-2c61-40e2-884e-2915711071b8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hedging</link:label>
    <link:label id="lab_us-gaap_FairValueHedgingMember_label_en-US" xlink:label="lab_us-gaap_FairValueHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueHedgingMember" xlink:to="lab_us-gaap_FairValueHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_c41961f5-e708-48f7-ab4c-4554bd39e4e6_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_OpioidLitigationAxis_cc5fc491-40a6-477b-992a-fdb2409c6e9a_terseLabel_en-US" xlink:label="lab_cah_OpioidLitigationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid Litigation [Axis]</link:label>
    <link:label id="lab_cah_OpioidLitigationAxis_label_en-US" xlink:label="lab_cah_OpioidLitigationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid Litigation [Axis]</link:label>
    <link:label id="lab_cah_OpioidLitigationAxis_documentation_en-US" xlink:label="lab_cah_OpioidLitigationAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationAxis" xlink:href="cah-20230331.xsd#cah_OpioidLitigationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_OpioidLitigationAxis" xlink:to="lab_cah_OpioidLitigationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_5f883b36-58ff-4999-a6d6-322bfa297039_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Notes Payable</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfNotesPayable" xlink:to="lab_us-gaap_RepaymentsOfNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_18c8207a-1b6e-4223-8e3f-b728654056b5_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of subsidiaries, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_a1ebff19-a830-49e7-8417-27845380f383_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total comprehensive income/(loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_27ddf444-7e23-45c0-82ff-4d00ea693f55_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_e1f637a2-de41-4974-9fcc-1450ec75ce0e_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount_8259d65c-2fe8-433d-860a-9033e1db8fc8_terseLabel_en-US" xlink:label="lab_cah_DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Hedge Discontinuances, Termination of Hedging Instrument, Notional Amount</link:label>
    <link:label id="lab_cah_DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount_label_en-US" xlink:label="lab_cah_DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Hedge Discontinuances, Termination of Hedging Instrument, Notional Amount</link:label>
    <link:label id="lab_cah_DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount_documentation_en-US" xlink:label="lab_cah_DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Hedge Discontinuances, Termination of Hedging Instrument, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount" xlink:href="cah-20230331.xsd#cah_DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount" xlink:to="lab_cah_DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_AggregateAnnualAssessment_15ad1df5-67ae-4b2a-85f3-494f6550516c_terseLabel_en-US" xlink:label="lab_cah_AggregateAnnualAssessment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Annual Assessment</link:label>
    <link:label id="lab_cah_AggregateAnnualAssessment_label_en-US" xlink:label="lab_cah_AggregateAnnualAssessment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Annual Assessment</link:label>
    <link:label id="lab_cah_AggregateAnnualAssessment_documentation_en-US" xlink:label="lab_cah_AggregateAnnualAssessment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Annual Assessment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_AggregateAnnualAssessment" xlink:href="cah-20230331.xsd#cah_AggregateAnnualAssessment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_AggregateAnnualAssessment" xlink:to="lab_cah_AggregateAnnualAssessment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_d2afdf6e-69dd-4dbc-a68b-25f9c76f5853_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury shares acquired (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_c66a7db2-4ecf-410f-a1fc-92f0b875be59_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities_648e74f9-d08a-46a1-a1f3-dcf5e5e6fe35_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Insurance Settlement, Operating Activities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Insurance Settlement, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromInsuranceSettlementOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" xlink:to="lab_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_Purchaseofavailableforsalesecuritiesandotherinvestments_0c7fd630-623b-402c-84c6-569fa4075d85_negatedLabel_en-US" xlink:label="lab_cah_Purchaseofavailableforsalesecuritiesandotherinvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_cah_Purchaseofavailableforsalesecuritiesandotherinvestments_label_en-US" xlink:label="lab_cah_Purchaseofavailableforsalesecuritiesandotherinvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of available-for-sale securities and other investments</link:label>
    <link:label id="lab_cah_Purchaseofavailableforsalesecuritiesandotherinvestments_documentation_en-US" xlink:label="lab_cah_Purchaseofavailableforsalesecuritiesandotherinvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The cash outflow from purchases of available-for-sale securities and other investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Purchaseofavailableforsalesecuritiesandotherinvestments" xlink:href="cah-20230331.xsd#cah_Purchaseofavailableforsalesecuritiesandotherinvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_Purchaseofavailableforsalesecuritiesandotherinvestments" xlink:to="lab_cah_Purchaseofavailableforsalesecuritiesandotherinvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_77b3e7fb-c4eb-4088-9819-fbc4cba3f5a9_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8fc496aa-69cb-47bd-97dd-1434c5f58b46_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares&#8211;diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_A200MillionShareRepurchaseProgramMember_24915658-4341-43c2-9e0c-70d4326dfd3e_terseLabel_en-US" xlink:label="lab_cah_A200MillionShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$200 million</link:label>
    <link:label id="lab_cah_A200MillionShareRepurchaseProgramMember_label_en-US" xlink:label="lab_cah_A200MillionShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$200 million share repurchase program [Member]</link:label>
    <link:label id="lab_cah_A200MillionShareRepurchaseProgramMember_documentation_en-US" xlink:label="lab_cah_A200MillionShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$200 million share repurchase program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A200MillionShareRepurchaseProgramMember" xlink:href="cah-20230331.xsd#cah_A200MillionShareRepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_A200MillionShareRepurchaseProgramMember" xlink:to="lab_cah_A200MillionShareRepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_LossContingencyLawsuitsNumber_47e70ec7-7927-4a9d-90a4-c00b4e3cf6c6_verboseLabel_en-US" xlink:label="lab_cah_LossContingencyLawsuitsNumber" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Lawsuits, Number</link:label>
    <link:label id="lab_cah_LossContingencyLawsuitsNumber_label_en-US" xlink:label="lab_cah_LossContingencyLawsuitsNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Lawsuits, Number</link:label>
    <link:label id="lab_cah_LossContingencyLawsuitsNumber_documentation_en-US" xlink:label="lab_cah_LossContingencyLawsuitsNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Lawsuits, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LossContingencyLawsuitsNumber" xlink:href="cah-20230331.xsd#cah_LossContingencyLawsuitsNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_LossContingencyLawsuitsNumber" xlink:to="lab_cah_LossContingencyLawsuitsNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_9333aa01-321e-4f29-af74-559dc2836ba3_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income (Expense), Nonoperating, Net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income (Expense), Nonoperating, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_a0d6fce0-bf3f-4f23-a933-985b641def42_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1c910dc7-b4e4-422c-b4d0-6aedc8d665f8_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions to property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_65034cf2-3fdf-44b7-9a1e-c70bb8ff65b7_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of dilutive securities:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted, Adjustment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_547c189c-3ab3-453e-9b6b-2b99d97903b0_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_c2cf44b5-faaa-454e-a09a-81eab883411d_terseLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_cc2218cd-7dfb-49f6-aa35-f55ddb2e6316_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:to="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_9517ae2b-ff9a-40e3-89a2-82ad6d565095_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_42e2a916-6645-4042-9a8d-63ccf8cb73e8_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems_13f209b6-ff38-4974-9e2f-ff051781e564_terseLabel_en-US" xlink:label="lab_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Revenue from External Customers by Geographic Area [Line Items]</link:label>
    <link:label id="lab_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems_label_en-US" xlink:label="lab_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Revenue from External Customers by Geographic Area [Line Items]</link:label>
    <link:label id="lab_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems_documentation_en-US" xlink:label="lab_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Line Items] for Segment Revenue from External Customers by Geographic Area [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems" xlink:href="cah-20230331.xsd#cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems" xlink:to="lab_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_68417a29-4ceb-4ca5-8741-6640ed46a7e2_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_6e7a5884-508c-4497-ad41-de7895ff4c71_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_IVCApril2023AgreementMember_67afb830-5b1e-42ee-b66c-61f1f7f9595a_terseLabel_en-US" xlink:label="lab_cah_IVCApril2023AgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IVC April 2023 Agreement</link:label>
    <link:label id="lab_cah_IVCApril2023AgreementMember_label_en-US" xlink:label="lab_cah_IVCApril2023AgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IVC April 2023 Agreement [Member]</link:label>
    <link:label id="lab_cah_IVCApril2023AgreementMember_documentation_en-US" xlink:label="lab_cah_IVCApril2023AgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IVC April 2023 Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_IVCApril2023AgreementMember" xlink:href="cah-20230331.xsd#cah_IVCApril2023AgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_IVCApril2023AgreementMember" xlink:to="lab_cah_IVCApril2023AgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_25671813-3e75-4c15-bf43-23552f3aa902_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_82a8a4fe-2928-478f-a4ed-f2e50e3b7257_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense) [Member]</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_9dc75d9c-7a24-4c0e-97d1-04da3c4b5179_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_label_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowHedgingMember" xlink:to="lab_us-gaap_CashFlowHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualPayments_17c687e5-827d-4da5-83bd-c89b10ad5006_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual, Payments</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualPayments_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAccrualPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualPayments" xlink:to="lab_us-gaap_LossContingencyAccrualPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_7de0bb51-62d5-456f-8cb9-056edf7a7cd9_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e53fd2cd-8a91-4c9a-9349-4f36df416f06_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net decrease in cash and equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ad736871-e049-4c3b-a110-db28b3258ed4_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_be45e0e7-2243-4b02-86fd-77dcdccba7e1_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_fc5363b8-38ac-48fe-907d-295387c02a56_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_92c13f7e-e4da-4ca6-8606-c0ea2c2664c7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0b8b04a0-00cc-4984-bf81-cf9b71c18442_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f2479029-2e6d-42aa-9a57-7eaff5083ec0_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares&#8211;basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_109726f1-281f-4d45-9b66-185466878f67_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_b60fe9f2-9406-4d57-ae53-984a2c01a769_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating earnings/(loss)</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_f75bdebf-7e87-4031-8daa-d4eb35f0b198_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating earnings</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_3aea9b13-c303-4a90-8691-71e618b94386_terseLabel_en-US" xlink:label="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_72829f9a-0ec3-47a4-a68d-6a0aa2abc0e4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FacilityClosingMember_7886e328-5052-4b0f-bc22-276bf1e8c16b_terseLabel_en-US" xlink:label="lab_us-gaap_FacilityClosingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Exit and Other Costs</link:label>
    <link:label id="lab_us-gaap_FacilityClosingMember_label_en-US" xlink:label="lab_us-gaap_FacilityClosingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Closing [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FacilityClosingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FacilityClosingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FacilityClosingMember" xlink:to="lab_us-gaap_FacilityClosingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_A250MillionShareRepurchaseProgramMember_893068ff-fb0c-470e-8bd1-731b37fc6ea6_terseLabel_en-US" xlink:label="lab_cah_A250MillionShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$250 million share repurchase program [Member]</link:label>
    <link:label id="lab_cah_A250MillionShareRepurchaseProgramMember_label_en-US" xlink:label="lab_cah_A250MillionShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$250 million share repurchase program [Member]</link:label>
    <link:label id="lab_cah_A250MillionShareRepurchaseProgramMember_documentation_en-US" xlink:label="lab_cah_A250MillionShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$250 million share repurchase program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A250MillionShareRepurchaseProgramMember" xlink:href="cah-20230331.xsd#cah_A250MillionShareRepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_A250MillionShareRepurchaseProgramMember" xlink:to="lab_cah_A250MillionShareRepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_TaxMattersAgreementDomain_373211fc-516d-4fc4-b1aa-bfcca6070c6e_terseLabel_en-US" xlink:label="lab_cah_TaxMattersAgreementDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Matters Agreement [Domain]</link:label>
    <link:label id="lab_cah_TaxMattersAgreementDomain_label_en-US" xlink:label="lab_cah_TaxMattersAgreementDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Matters Agreement [Domain]</link:label>
    <link:label id="lab_cah_TaxMattersAgreementDomain_documentation_en-US" xlink:label="lab_cah_TaxMattersAgreementDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Tax Matters Agreement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMattersAgreementDomain" xlink:href="cah-20230331.xsd#cah_TaxMattersAgreementDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_TaxMattersAgreementDomain" xlink:to="lab_cah_TaxMattersAgreementDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_TaxMattersAgreementAxis_1f8e1b46-acb2-489c-a692-5efb3afa8f89_terseLabel_en-US" xlink:label="lab_cah_TaxMattersAgreementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Matters Agreement [Axis]</link:label>
    <link:label id="lab_cah_TaxMattersAgreementAxis_label_en-US" xlink:label="lab_cah_TaxMattersAgreementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Matters Agreement [Axis]</link:label>
    <link:label id="lab_cah_TaxMattersAgreementAxis_documentation_en-US" xlink:label="lab_cah_TaxMattersAgreementAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Matters Agreement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMattersAgreementAxis" xlink:href="cah-20230331.xsd#cah_TaxMattersAgreementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_TaxMattersAgreementAxis" xlink:to="lab_cah_TaxMattersAgreementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_552bdd0c-a442-4f96-82d1-639eefe65a29_verboseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating and Reportable Segment</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_e641c91e-6801-4618-96cc-4a60c4bd0745_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_02bcf234-ba05-418e-9de8-58d7903a2f24_verboseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_e01db804-7672-4fff-a5c1-2268b632f790_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income/(loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_fd9364ba-cf31-4063-9155-74fde7d99579_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Transactions Related to Performance Share Units Under the Plans</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Performance-Based Units Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_710a8a8f-93ed-41f5-8efd-41225073c548_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_2511aaef-fd40-49b2-aa5a-c5485ef2d197_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer relationships</link:label>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_label_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Relationships [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRelationshipsMember" xlink:to="lab_us-gaap_CustomerRelationshipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_4f169095-429c-4511-acaf-56d0a0cd128f_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_5227851a-0ab5-47a7-a429-690d533a3c91_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>cah-20230331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:9ca698da-8642-4990-b842-4747c9f438b3,g:77ea8682-dcc2-43bc-841d-94551121f3ad-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.cardinal.com/role/CoverPage" xlink:type="simple" xlink:href="cah-20230331.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_c55bf3a7-6925-4a78-a07a-7c1749bcb9b2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_718691eb-97c7-4dd6-9a52-334ff8c3b96a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c55bf3a7-6925-4a78-a07a-7c1749bcb9b2" xlink:to="loc_dei_DocumentType_718691eb-97c7-4dd6-9a52-334ff8c3b96a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_3db48735-13af-4243-9867-818b271e6972" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c55bf3a7-6925-4a78-a07a-7c1749bcb9b2" xlink:to="loc_dei_DocumentQuarterlyReport_3db48735-13af-4243-9867-818b271e6972" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_345d0dff-032e-4fbf-87fe-164bde496b98" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c55bf3a7-6925-4a78-a07a-7c1749bcb9b2" xlink:to="loc_dei_DocumentPeriodEndDate_345d0dff-032e-4fbf-87fe-164bde496b98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_63f18d90-f213-4797-8b61-df2b27a2a404" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c55bf3a7-6925-4a78-a07a-7c1749bcb9b2" xlink:to="loc_dei_DocumentTransitionReport_63f18d90-f213-4797-8b61-df2b27a2a404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_56698c95-86a9-419f-b276-ef8b99bb879f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c55bf3a7-6925-4a78-a07a-7c1749bcb9b2" xlink:to="loc_dei_EntityFileNumber_56698c95-86a9-419f-b276-ef8b99bb879f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_ce6fdd3c-66b4-4b70-8200-5ba2a6a9aa40" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c55bf3a7-6925-4a78-a07a-7c1749bcb9b2" xlink:to="loc_dei_EntityRegistrantName_ce6fdd3c-66b4-4b70-8200-5ba2a6a9aa40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_e6011955-6c32-4604-9925-4223b71f9be8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c55bf3a7-6925-4a78-a07a-7c1749bcb9b2" xlink:to="loc_dei_EntityCentralIndexKey_e6011955-6c32-4604-9925-4223b71f9be8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_7369b7a8-7808-4aff-aa9b-0da6a635b3dc" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c55bf3a7-6925-4a78-a07a-7c1749bcb9b2" xlink:to="loc_dei_CurrentFiscalYearEndDate_7369b7a8-7808-4aff-aa9b-0da6a635b3dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_dd423fb5-52bf-4a21-a22f-4cf86c56d23f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c55bf3a7-6925-4a78-a07a-7c1749bcb9b2" xlink:to="loc_dei_DocumentFiscalYearFocus_dd423fb5-52bf-4a21-a22f-4cf86c56d23f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_3b5e573c-ac74-4e9d-8748-1f644d8ecb96" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c55bf3a7-6925-4a78-a07a-7c1749bcb9b2" xlink:to="loc_dei_DocumentFiscalPeriodFocus_3b5e573c-ac74-4e9d-8748-1f644d8ecb96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_26d759bc-e6d9-4611-9f7c-7dc397ec2e68" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c55bf3a7-6925-4a78-a07a-7c1749bcb9b2" xlink:to="loc_dei_AmendmentFlag_26d759bc-e6d9-4611-9f7c-7dc397ec2e68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_3d3be19b-520f-4356-8a1c-7900c3a82cc0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c55bf3a7-6925-4a78-a07a-7c1749bcb9b2" xlink:to="loc_dei_EntityIncorporationStateCountryCode_3d3be19b-520f-4356-8a1c-7900c3a82cc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_9b3f502f-abf7-4dbf-a216-63d1c9720e93" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c55bf3a7-6925-4a78-a07a-7c1749bcb9b2" xlink:to="loc_dei_EntityTaxIdentificationNumber_9b3f502f-abf7-4dbf-a216-63d1c9720e93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_0d3a8670-9bb6-49f0-b800-332463acbe18" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c55bf3a7-6925-4a78-a07a-7c1749bcb9b2" xlink:to="loc_dei_EntityAddressAddressLine1_0d3a8670-9bb6-49f0-b800-332463acbe18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_f8ea733e-7e28-4236-a6f7-b5e9453211a9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c55bf3a7-6925-4a78-a07a-7c1749bcb9b2" xlink:to="loc_dei_EntityAddressCityOrTown_f8ea733e-7e28-4236-a6f7-b5e9453211a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_72d04bf3-baf3-4ab1-b77c-3a8b23c1e75a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c55bf3a7-6925-4a78-a07a-7c1749bcb9b2" xlink:to="loc_dei_EntityAddressStateOrProvince_72d04bf3-baf3-4ab1-b77c-3a8b23c1e75a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_d68b7bdb-eb9d-4fe9-80c8-0c30fc6011d6" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c55bf3a7-6925-4a78-a07a-7c1749bcb9b2" xlink:to="loc_dei_EntityAddressPostalZipCode_d68b7bdb-eb9d-4fe9-80c8-0c30fc6011d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_2dcdbec8-f23e-4137-b8be-8f15161e47ea" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c55bf3a7-6925-4a78-a07a-7c1749bcb9b2" xlink:to="loc_dei_CityAreaCode_2dcdbec8-f23e-4137-b8be-8f15161e47ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_3baadb77-5a5b-440a-aac6-bd1641e6a024" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c55bf3a7-6925-4a78-a07a-7c1749bcb9b2" xlink:to="loc_dei_LocalPhoneNumber_3baadb77-5a5b-440a-aac6-bd1641e6a024" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_5336be33-e483-486c-a53f-01b0996be255" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c55bf3a7-6925-4a78-a07a-7c1749bcb9b2" xlink:to="loc_dei_Security12bTitle_5336be33-e483-486c-a53f-01b0996be255" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_9fc5dfe6-7007-4e59-b1be-c9aff1ff73bb" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c55bf3a7-6925-4a78-a07a-7c1749bcb9b2" xlink:to="loc_dei_TradingSymbol_9fc5dfe6-7007-4e59-b1be-c9aff1ff73bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_a2d898ef-8bf7-4a15-8794-7a33c1b0e5b1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c55bf3a7-6925-4a78-a07a-7c1749bcb9b2" xlink:to="loc_dei_SecurityExchangeName_a2d898ef-8bf7-4a15-8794-7a33c1b0e5b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_a2a71dae-6998-400f-88af-aa70dbd63ba4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c55bf3a7-6925-4a78-a07a-7c1749bcb9b2" xlink:to="loc_dei_EntityCurrentReportingStatus_a2a71dae-6998-400f-88af-aa70dbd63ba4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_026b9a57-04d0-4d29-9f6e-7adfeaf62d13" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c55bf3a7-6925-4a78-a07a-7c1749bcb9b2" xlink:to="loc_dei_EntityInteractiveDataCurrent_026b9a57-04d0-4d29-9f6e-7adfeaf62d13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_e9c59dce-a5bb-4b55-9551-d3e050df98ea" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c55bf3a7-6925-4a78-a07a-7c1749bcb9b2" xlink:to="loc_dei_EntityFilerCategory_e9c59dce-a5bb-4b55-9551-d3e050df98ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_8d85da9b-ff40-4cd1-8797-d9498d193206" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c55bf3a7-6925-4a78-a07a-7c1749bcb9b2" xlink:to="loc_dei_EntitySmallBusiness_8d85da9b-ff40-4cd1-8797-d9498d193206" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_3b677ac5-66a2-46d1-96aa-d2240dd6eb4d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c55bf3a7-6925-4a78-a07a-7c1749bcb9b2" xlink:to="loc_dei_EntityEmergingGrowthCompany_3b677ac5-66a2-46d1-96aa-d2240dd6eb4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_ca2bd5f5-a61a-4c08-b689-86500485b750" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c55bf3a7-6925-4a78-a07a-7c1749bcb9b2" xlink:to="loc_dei_EntityShellCompany_ca2bd5f5-a61a-4c08-b689-86500485b750" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_d65467b8-7d55-4078-b37e-220f1cddd509" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c55bf3a7-6925-4a78-a07a-7c1749bcb9b2" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_d65467b8-7d55-4078-b37e-220f1cddd509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings" xlink:type="simple" xlink:href="cah-20230331.xsd#CondensedConsolidatedStatementsofEarnings"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_c82f6287-0d39-44dc-a04d-abfb653295a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_91a41ebe-e2bf-4119-9a1c-118047925a53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c82f6287-0d39-44dc-a04d-abfb653295a5" xlink:to="loc_us-gaap_Revenues_91a41ebe-e2bf-4119-9a1c-118047925a53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_11bdc081-899d-48de-ade1-e199a3e0203d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c82f6287-0d39-44dc-a04d-abfb653295a5" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_11bdc081-899d-48de-ade1-e199a3e0203d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_6d6428bf-6871-4471-a5d3-c6284fd71e44" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c82f6287-0d39-44dc-a04d-abfb653295a5" xlink:to="loc_us-gaap_GrossProfit_6d6428bf-6871-4471-a5d3-c6284fd71e44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_b705ad16-eefb-4e04-b005-3b2080927e5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c82f6287-0d39-44dc-a04d-abfb653295a5" xlink:to="loc_us-gaap_OperatingExpensesAbstract_b705ad16-eefb-4e04-b005-3b2080927e5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_190f96e2-9f8f-441b-8f7e-9ca8dfe9a99c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_b705ad16-eefb-4e04-b005-3b2080927e5a" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_190f96e2-9f8f-441b-8f7e-9ca8dfe9a99c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_d35694dc-d629-4120-be81-340a8f51c692" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_b705ad16-eefb-4e04-b005-3b2080927e5a" xlink:to="loc_us-gaap_RestructuringCharges_d35694dc-d629-4120-be81-340a8f51c692" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Amortizationandotheracquisitionrelatedcosts_3f903667-ecaf-4d6a-9548-71a416f47d84" xlink:href="cah-20230331.xsd#cah_Amortizationandotheracquisitionrelatedcosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_b705ad16-eefb-4e04-b005-3b2080927e5a" xlink:to="loc_cah_Amortizationandotheracquisitionrelatedcosts_3f903667-ecaf-4d6a-9548-71a416f47d84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_ec164186-024e-423f-a7f6-471760dc6c50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_b705ad16-eefb-4e04-b005-3b2080927e5a" xlink:to="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_ec164186-024e-423f-a7f6-471760dc6c50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_539b9a2f-b9b2-48df-bb55-55450669a0cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_b705ad16-eefb-4e04-b005-3b2080927e5a" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_539b9a2f-b9b2-48df-bb55-55450669a0cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_a7059458-adf5-49d4-a822-22462d92acef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c82f6287-0d39-44dc-a04d-abfb653295a5" xlink:to="loc_us-gaap_OperatingIncomeLoss_a7059458-adf5-49d4-a822-22462d92acef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_e5e8cac2-63ae-403f-bb74-3b0bfc45d247" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c82f6287-0d39-44dc-a04d-abfb653295a5" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_e5e8cac2-63ae-403f-bb74-3b0bfc45d247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_88da831a-4257-4af0-9f69-81ad89318888" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c82f6287-0d39-44dc-a04d-abfb653295a5" xlink:to="loc_us-gaap_InterestExpense_88da831a-4257-4af0-9f69-81ad89318888" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_024ec475-b958-4e77-9119-a82b2a2fa882" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c82f6287-0d39-44dc-a04d-abfb653295a5" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_024ec475-b958-4e77-9119-a82b2a2fa882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments_dca469a5-89a8-43a3-8c04-b5f95ef1b2ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfInvestments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c82f6287-0d39-44dc-a04d-abfb653295a5" xlink:to="loc_us-gaap_GainLossOnSaleOfInvestments_dca469a5-89a8-43a3-8c04-b5f95ef1b2ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6039fc81-f611-434d-9e1c-88455dc901b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c82f6287-0d39-44dc-a04d-abfb653295a5" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6039fc81-f611-434d-9e1c-88455dc901b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_e375a011-0d6b-4aa3-a159-821fdb2cfbdf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c82f6287-0d39-44dc-a04d-abfb653295a5" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_e375a011-0d6b-4aa3-a159-821fdb2cfbdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_53ad7ab9-4800-465f-8403-b846fe44f6a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c82f6287-0d39-44dc-a04d-abfb653295a5" xlink:to="loc_us-gaap_ProfitLoss_53ad7ab9-4800-465f-8403-b846fe44f6a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_d6c2ca59-8933-4c0d-8834-7ee499480d94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c82f6287-0d39-44dc-a04d-abfb653295a5" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_d6c2ca59-8933-4c0d-8834-7ee499480d94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8e438713-3784-4883-bec4-7db15f8b06e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c82f6287-0d39-44dc-a04d-abfb653295a5" xlink:to="loc_us-gaap_NetIncomeLoss_8e438713-3784-4883-bec4-7db15f8b06e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_0f29bcbb-435d-417d-9dd0-0c7dd773cc1a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c82f6287-0d39-44dc-a04d-abfb653295a5" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_0f29bcbb-435d-417d-9dd0-0c7dd773cc1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_094897ac-cba5-4497-8056-71d32d22a27c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_0f29bcbb-435d-417d-9dd0-0c7dd773cc1a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_094897ac-cba5-4497-8056-71d32d22a27c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_21b39dd2-31c6-4961-9c4d-43faede839c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_0f29bcbb-435d-417d-9dd0-0c7dd773cc1a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_21b39dd2-31c6-4961-9c4d-43faede839c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_1791a516-9597-47cc-a7b7-5402ce65d363" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c82f6287-0d39-44dc-a04d-abfb653295a5" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_1791a516-9597-47cc-a7b7-5402ce65d363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_d0988cb4-d24e-4da2-9e0a-01f02b4c0c11" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c82f6287-0d39-44dc-a04d-abfb653295a5" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_d0988cb4-d24e-4da2-9e0a-01f02b4c0c11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3c166ac3-8b4f-4d34-a7a6-c95724e1256c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_d0988cb4-d24e-4da2-9e0a-01f02b4c0c11" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3c166ac3-8b4f-4d34-a7a6-c95724e1256c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f268a6a0-1d81-486b-8caa-c024909901ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_d0988cb4-d24e-4da2-9e0a-01f02b4c0c11" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f268a6a0-1d81-486b-8caa-c024909901ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_c9612f1d-253d-4217-80f4-b41bacff7750" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c82f6287-0d39-44dc-a04d-abfb653295a5" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_c9612f1d-253d-4217-80f4-b41bacff7750" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="cah-20230331.xsd#CondensedConsolidatedStatementsofComprehensiveIncome"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_c5a3b573-41aa-4cc8-997d-dce6ad6d6275" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_bcf5a926-4fac-4ee1-abc6-397093fe2d19" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_c5a3b573-41aa-4cc8-997d-dce6ad6d6275" xlink:to="loc_us-gaap_ProfitLoss_bcf5a926-4fac-4ee1-abc6-397093fe2d19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_527c1aa5-c3cc-43f1-9723-bb89b37ba102" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_c5a3b573-41aa-4cc8-997d-dce6ad6d6275" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_527c1aa5-c3cc-43f1-9723-bb89b37ba102" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_7d564778-55c5-40b1-9a0a-5e91d5d6301c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_527c1aa5-c3cc-43f1-9723-bb89b37ba102" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_7d564778-55c5-40b1-9a0a-5e91d5d6301c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_e56842ba-197b-470c-ab72-94e1f216312a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_527c1aa5-c3cc-43f1-9723-bb89b37ba102" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_e56842ba-197b-470c-ab72-94e1f216312a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_1982c60b-bd1f-41f7-8e7e-2e07ef893665" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_527c1aa5-c3cc-43f1-9723-bb89b37ba102" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_1982c60b-bd1f-41f7-8e7e-2e07ef893665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_8fe3ea38-920d-432f-b3f5-1964c366420b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_c5a3b573-41aa-4cc8-997d-dce6ad6d6275" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_8fe3ea38-920d-432f-b3f5-1964c366420b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_023a4fc6-f08f-4f49-af97-7c2f8c07c0e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_c5a3b573-41aa-4cc8-997d-dce6ad6d6275" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_023a4fc6-f08f-4f49-af97-7c2f8c07c0e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_29b74dc5-63b5-490f-ad41-90ecf92f5679" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_c5a3b573-41aa-4cc8-997d-dce6ad6d6275" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_29b74dc5-63b5-490f-ad41-90ecf92f5679" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="cah-20230331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_6ce25ef6-1380-43e0-b882-409c1da34495" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_47276095-cca9-4e75-a0e0-1c20a1a75a02" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6ce25ef6-1380-43e0-b882-409c1da34495" xlink:to="loc_us-gaap_AssetsAbstract_47276095-cca9-4e75-a0e0-1c20a1a75a02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_e4071fd6-07c7-4d2f-b5c4-589013c12ba4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_47276095-cca9-4e75-a0e0-1c20a1a75a02" xlink:to="loc_us-gaap_AssetsCurrentAbstract_e4071fd6-07c7-4d2f-b5c4-589013c12ba4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_569b467e-6633-424f-b326-5523184f1089" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e4071fd6-07c7-4d2f-b5c4-589013c12ba4" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_569b467e-6633-424f-b326-5523184f1089" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_8a731ac3-0abd-4a85-aec3-c853421abae4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e4071fd6-07c7-4d2f-b5c4-589013c12ba4" xlink:to="loc_us-gaap_ReceivablesNetCurrent_8a731ac3-0abd-4a85-aec3-c853421abae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_a2c6feac-72c1-47bb-81d0-550aa18952d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e4071fd6-07c7-4d2f-b5c4-589013c12ba4" xlink:to="loc_us-gaap_InventoryNet_a2c6feac-72c1-47bb-81d0-550aa18952d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_20cd8252-a073-41cc-9594-43d7d34237cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e4071fd6-07c7-4d2f-b5c4-589013c12ba4" xlink:to="loc_us-gaap_OtherAssetsCurrent_20cd8252-a073-41cc-9594-43d7d34237cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_6cb0f1db-4982-40e5-8a76-55015d857662" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e4071fd6-07c7-4d2f-b5c4-589013c12ba4" xlink:to="loc_us-gaap_AssetsCurrent_6cb0f1db-4982-40e5-8a76-55015d857662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_95920697-4eb9-4117-87f5-e4b836730d26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_47276095-cca9-4e75-a0e0-1c20a1a75a02" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_95920697-4eb9-4117-87f5-e4b836730d26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_27c1309f-2fa0-46fe-b2ae-8007dde55758" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_47276095-cca9-4e75-a0e0-1c20a1a75a02" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_27c1309f-2fa0-46fe-b2ae-8007dde55758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_13f1a29b-4c46-4cab-8f0e-24b79c445f38" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_47276095-cca9-4e75-a0e0-1c20a1a75a02" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_13f1a29b-4c46-4cab-8f0e-24b79c445f38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_1690829e-8f1d-4672-bb05-6646c1169702" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_47276095-cca9-4e75-a0e0-1c20a1a75a02" xlink:to="loc_us-gaap_Assets_1690829e-8f1d-4672-bb05-6646c1169702" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_54a25610-7f9e-47a1-bae9-167bb8d0493f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6ce25ef6-1380-43e0-b882-409c1da34495" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_54a25610-7f9e-47a1-bae9-167bb8d0493f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_4010e9ae-3fcb-4adb-b5a7-9f600152e504" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_54a25610-7f9e-47a1-bae9-167bb8d0493f" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_4010e9ae-3fcb-4adb-b5a7-9f600152e504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_2b37ee07-e65e-4761-b1c1-ff2685022b54" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4010e9ae-3fcb-4adb-b5a7-9f600152e504" xlink:to="loc_us-gaap_AccountsPayableCurrent_2b37ee07-e65e-4761-b1c1-ff2685022b54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_971218c9-a724-4911-80d1-b39a5b439f25" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4010e9ae-3fcb-4adb-b5a7-9f600152e504" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_971218c9-a724-4911-80d1-b39a5b439f25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_aaa39fd0-6162-423f-9a96-025c6bd188d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4010e9ae-3fcb-4adb-b5a7-9f600152e504" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_aaa39fd0-6162-423f-9a96-025c6bd188d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_a610eadc-185a-4608-a142-c82241efcdd1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4010e9ae-3fcb-4adb-b5a7-9f600152e504" xlink:to="loc_us-gaap_LiabilitiesCurrent_a610eadc-185a-4608-a142-c82241efcdd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_9376ea91-ea94-49c0-b144-5c44d209bd26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_54a25610-7f9e-47a1-bae9-167bb8d0493f" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_9376ea91-ea94-49c0-b144-5c44d209bd26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_b83ae48d-e972-438e-8370-1883d4604cb4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_54a25610-7f9e-47a1-bae9-167bb8d0493f" xlink:to="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_b83ae48d-e972-438e-8370-1883d4604cb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_32a57ad3-f75f-44b4-adc5-ee781de0d03b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_54a25610-7f9e-47a1-bae9-167bb8d0493f" xlink:to="loc_us-gaap_StockholdersEquityAbstract_32a57ad3-f75f-44b4-adc5-ee781de0d03b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_fa040e4a-05e1-4a56-b3ad-54ac3c13e302" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_32a57ad3-f75f-44b4-adc5-ee781de0d03b" xlink:to="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_fa040e4a-05e1-4a56-b3ad-54ac3c13e302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_163a0757-b8f6-4f29-8a9b-98f3cc62ae37" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_fa040e4a-05e1-4a56-b3ad-54ac3c13e302" xlink:to="loc_us-gaap_PreferredStockValue_163a0757-b8f6-4f29-8a9b-98f3cc62ae37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_90ee2b9f-e9c8-49d5-aec6-b8a1d2b4c900" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_32a57ad3-f75f-44b4-adc5-ee781de0d03b" xlink:to="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_90ee2b9f-e9c8-49d5-aec6-b8a1d2b4c900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_3eb07e65-0d30-4ac9-81ef-145ab7f3dfd7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_90ee2b9f-e9c8-49d5-aec6-b8a1d2b4c900" xlink:to="loc_us-gaap_CommonStockValue_3eb07e65-0d30-4ac9-81ef-145ab7f3dfd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7b3cf1d4-d29f-4639-b57a-d068d1cd2bc6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_32a57ad3-f75f-44b4-adc5-ee781de0d03b" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7b3cf1d4-d29f-4639-b57a-d068d1cd2bc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_d82dc3fa-ec36-41a2-ac26-b865f8f74c00" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_32a57ad3-f75f-44b4-adc5-ee781de0d03b" xlink:to="loc_us-gaap_TreasuryStockValue_d82dc3fa-ec36-41a2-ac26-b865f8f74c00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3cdbc00e-57e7-47d1-9ede-f5eaf2a71e2f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_32a57ad3-f75f-44b4-adc5-ee781de0d03b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3cdbc00e-57e7-47d1-9ede-f5eaf2a71e2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d1ad38dc-9bba-45be-b7b4-a90dbb751a73" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_32a57ad3-f75f-44b4-adc5-ee781de0d03b" xlink:to="loc_us-gaap_StockholdersEquity_d1ad38dc-9bba-45be-b7b4-a90dbb751a73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_c9a2c25e-61ac-4374-ad3c-a1ef160b17d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_32a57ad3-f75f-44b4-adc5-ee781de0d03b" xlink:to="loc_us-gaap_MinorityInterest_c9a2c25e-61ac-4374-ad3c-a1ef160b17d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8c0b59c6-ec3e-4e63-83da-c71f431f86f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_32a57ad3-f75f-44b4-adc5-ee781de0d03b" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8c0b59c6-ec3e-4e63-83da-c71f431f86f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_37a74f69-4e18-4a61-93ed-b49ee86b6cd0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_54a25610-7f9e-47a1-bae9-167bb8d0493f" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_37a74f69-4e18-4a61-93ed-b49ee86b6cd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_a445f420-9d17-48bb-9775-c3e339d242a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6ce25ef6-1380-43e0-b882-409c1da34495" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_a445f420-9d17-48bb-9775-c3e339d242a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_487e1953-c6e8-4aee-bdc4-d3647e8484fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6ce25ef6-1380-43e0-b882-409c1da34495" xlink:to="loc_us-gaap_PreferredStockSharesIssued_487e1953-c6e8-4aee-bdc4-d3647e8484fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_329affac-4e96-4ec5-9f45-0dba00ea4491" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6ce25ef6-1380-43e0-b882-409c1da34495" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_329affac-4e96-4ec5-9f45-0dba00ea4491" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_90671232-8082-46e2-b476-fd6313fa8946" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6ce25ef6-1380-43e0-b882-409c1da34495" xlink:to="loc_us-gaap_CommonStockSharesIssued_90671232-8082-46e2-b476-fd6313fa8946" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_fefe38fe-f3ec-4da1-a7b1-0c4baa647780" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6ce25ef6-1380-43e0-b882-409c1da34495" xlink:to="loc_us-gaap_TreasuryStockCommonShares_fefe38fe-f3ec-4da1-a7b1-0c4baa647780" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_3ae62292-25c8-499d-a4a3-0ddd8c1c5f1d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6ce25ef6-1380-43e0-b882-409c1da34495" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_3ae62292-25c8-499d-a4a3-0ddd8c1c5f1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="cah-20230331.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_548e5e99-ba14-453c-8a2c-e53db759f5aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_5d115332-6022-4767-a933-0bd10c5048f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_548e5e99-ba14-453c-8a2c-e53db759f5aa" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_5d115332-6022-4767-a933-0bd10c5048f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_e0ae01be-200a-4d7c-a10f-45c1c588408d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_548e5e99-ba14-453c-8a2c-e53db759f5aa" xlink:to="loc_us-gaap_PreferredStockSharesIssued_e0ae01be-200a-4d7c-a10f-45c1c588408d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_cd6e9c0f-a5a9-4b85-9f23-595b0623d7fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_548e5e99-ba14-453c-8a2c-e53db759f5aa" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_cd6e9c0f-a5a9-4b85-9f23-595b0623d7fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_cdf3f316-9a7f-4aa1-b0aa-a9b9b6ac847d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_548e5e99-ba14-453c-8a2c-e53db759f5aa" xlink:to="loc_us-gaap_CommonStockSharesIssued_cdf3f316-9a7f-4aa1-b0aa-a9b9b6ac847d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_048083d8-faef-45ff-b451-cf1a489bd70a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_548e5e99-ba14-453c-8a2c-e53db759f5aa" xlink:to="loc_us-gaap_TreasuryStockCommonShares_048083d8-faef-45ff-b451-cf1a489bd70a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity" xlink:type="simple" xlink:href="cah-20230331.xsd#CondensedConsolidatedStatementsofShareholdersEquity"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_33bab666-f3d2-44d2-8731-0f7de1e603a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_1f3b3b10-44b0-4af2-8f33-ea70c9552d0b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_33bab666-f3d2-44d2-8731-0f7de1e603a7" xlink:to="loc_us-gaap_StatementTable_1f3b3b10-44b0-4af2-8f33-ea70c9552d0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1df7573c-8084-446a-9847-d0eddc3d5630" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1f3b3b10-44b0-4af2-8f33-ea70c9552d0b" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1df7573c-8084-446a-9847-d0eddc3d5630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_0ca9dbc6-107f-46c3-8df4-ab51a8b9ced7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1df7573c-8084-446a-9847-d0eddc3d5630" xlink:to="loc_us-gaap_EquityComponentDomain_0ca9dbc6-107f-46c3-8df4-ab51a8b9ced7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_60b82a98-c546-42da-9713-8a5d2734426e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0ca9dbc6-107f-46c3-8df4-ab51a8b9ced7" xlink:to="loc_us-gaap_CommonStockMember_60b82a98-c546-42da-9713-8a5d2734426e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_1198105a-ec02-433a-ac9e-a8f33bd7fd71" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0ca9dbc6-107f-46c3-8df4-ab51a8b9ced7" xlink:to="loc_us-gaap_RetainedEarningsMember_1198105a-ec02-433a-ac9e-a8f33bd7fd71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_709b1959-394f-432f-9de1-f0335f0c527e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0ca9dbc6-107f-46c3-8df4-ab51a8b9ced7" xlink:to="loc_us-gaap_TreasuryStockCommonMember_709b1959-394f-432f-9de1-f0335f0c527e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_efbd5168-e067-4f7d-bdd6-6450151eb7da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0ca9dbc6-107f-46c3-8df4-ab51a8b9ced7" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_efbd5168-e067-4f7d-bdd6-6450151eb7da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_d1b8ca76-f128-4bde-b07d-4394891edfee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0ca9dbc6-107f-46c3-8df4-ab51a8b9ced7" xlink:to="loc_us-gaap_NoncontrollingInterestMember_d1b8ca76-f128-4bde-b07d-4394891edfee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_4cbdc49a-f80e-49c0-bae0-5884ee850428" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_85556305-c28a-49e7-9c76-01e7c4587a51" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1f3b3b10-44b0-4af2-8f33-ea70c9552d0b" xlink:to="loc_us-gaap_StatementLineItems_85556305-c28a-49e7-9c76-01e7c4587a51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_eaf19a9e-17c4-4906-b552-5385178df5f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_85556305-c28a-49e7-9c76-01e7c4587a51" xlink:to="loc_us-gaap_CommonStockSharesIssued_eaf19a9e-17c4-4906-b552-5385178df5f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7bb81574-766b-4181-bcd6-61a105dce3f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_85556305-c28a-49e7-9c76-01e7c4587a51" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7bb81574-766b-4181-bcd6-61a105dce3f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_5d3f65bb-2532-4ec3-8c38-bc76eff43602" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_85556305-c28a-49e7-9c76-01e7c4587a51" xlink:to="loc_us-gaap_TreasuryStockCommonShares_5d3f65bb-2532-4ec3-8c38-bc76eff43602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_e9b24256-68fa-47ca-90f0-90ad1b6c4837" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_85556305-c28a-49e7-9c76-01e7c4587a51" xlink:to="loc_us-gaap_TreasuryStockValue_e9b24256-68fa-47ca-90f0-90ad1b6c4837" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_2eb0d1b1-14e4-497c-8c8a-aa37b35a5e08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_85556305-c28a-49e7-9c76-01e7c4587a51" xlink:to="loc_us-gaap_ProfitLoss_2eb0d1b1-14e4-497c-8c8a-aa37b35a5e08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_db4733c9-8448-4b62-a7e6-8f503a083cf2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_85556305-c28a-49e7-9c76-01e7c4587a51" xlink:to="loc_us-gaap_NetIncomeLoss_db4733c9-8448-4b62-a7e6-8f503a083cf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_f53609d6-9c27-4f56-b430-32bdfdf8b5e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_85556305-c28a-49e7-9c76-01e7c4587a51" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_f53609d6-9c27-4f56-b430-32bdfdf8b5e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_1ab772de-b54d-4a7b-8ea1-03ad3879b2ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_85556305-c28a-49e7-9c76-01e7c4587a51" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_1ab772de-b54d-4a7b-8ea1-03ad3879b2ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_dd370e44-1d7b-4327-bdfd-429b455a73d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_85556305-c28a-49e7-9c76-01e7c4587a51" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_dd370e44-1d7b-4327-bdfd-429b455a73d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_28f00124-d3c1-416b-9751-117e8bd05e59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_85556305-c28a-49e7-9c76-01e7c4587a51" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_28f00124-d3c1-416b-9751-117e8bd05e59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_6f1f324c-ad89-4983-97cb-1a86c784bf89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_85556305-c28a-49e7-9c76-01e7c4587a51" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_6f1f324c-ad89-4983-97cb-1a86c784bf89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_9f5753e9-8d0a-46d9-9881-612111f46c9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_85556305-c28a-49e7-9c76-01e7c4587a51" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_9f5753e9-8d0a-46d9-9881-612111f46c9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends_e8f4aac7-223d-4f8e-b437-c070199cde6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Dividends"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_85556305-c28a-49e7-9c76-01e7c4587a51" xlink:to="loc_us-gaap_Dividends_e8f4aac7-223d-4f8e-b437-c070199cde6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOtherShares_39335cd9-4f77-4371-8508-e237ea4f7c87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityOtherShares"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_85556305-c28a-49e7-9c76-01e7c4587a51" xlink:to="loc_us-gaap_StockholdersEquityOtherShares_39335cd9-4f77-4371-8508-e237ea4f7c87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_58e218e9-de6b-430e-a8ca-544a94b87074" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityOther"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_85556305-c28a-49e7-9c76-01e7c4587a51" xlink:to="loc_us-gaap_StockholdersEquityOther_58e218e9-de6b-430e-a8ca-544a94b87074" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_4f40daa6-c1bd-4dcb-99ab-6f2fe7a13f87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_85556305-c28a-49e7-9c76-01e7c4587a51" xlink:to="loc_us-gaap_CommonStockSharesIssued_4f40daa6-c1bd-4dcb-99ab-6f2fe7a13f87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2f673f6a-ecce-4434-9aae-22626e1a53d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_85556305-c28a-49e7-9c76-01e7c4587a51" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2f673f6a-ecce-4434-9aae-22626e1a53d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_f68a8b7c-3fa0-49d3-bd9d-3b6997b96472" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_85556305-c28a-49e7-9c76-01e7c4587a51" xlink:to="loc_us-gaap_TreasuryStockCommonShares_f68a8b7c-3fa0-49d3-bd9d-3b6997b96472" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_8978bf67-8809-4b97-b9ca-fc56e9258d24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_85556305-c28a-49e7-9c76-01e7c4587a51" xlink:to="loc_us-gaap_TreasuryStockValue_8978bf67-8809-4b97-b9ca-fc56e9258d24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_ede57a60-b8b5-429f-81eb-6f3c59e84c55" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_85556305-c28a-49e7-9c76-01e7c4587a51" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_ede57a60-b8b5-429f-81eb-6f3c59e84c55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_45db5373-bca2-4dcd-bf94-b88126d289f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_85556305-c28a-49e7-9c76-01e7c4587a51" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_45db5373-bca2-4dcd-bf94-b88126d289f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_4d616885-e130-4834-8c39-ab8c317a65fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_85556305-c28a-49e7-9c76-01e7c4587a51" xlink:to="loc_us-gaap_TreasuryStockCommonShares_4d616885-e130-4834-8c39-ab8c317a65fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="cah-20230331.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_77445910-c3ce-42f4-9d63-a3937019bbef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9f556e40-09ea-4585-9f72-ef4d8e7b57ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_77445910-c3ce-42f4-9d63-a3937019bbef" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9f556e40-09ea-4585-9f72-ef4d8e7b57ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_b57ed82e-b424-47de-9014-ed04b46ea0e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9f556e40-09ea-4585-9f72-ef4d8e7b57ed" xlink:to="loc_us-gaap_ProfitLoss_b57ed82e-b424-47de-9014-ed04b46ea0e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2617bf03-0820-4cf7-9397-262339060c04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9f556e40-09ea-4585-9f72-ef4d8e7b57ed" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2617bf03-0820-4cf7-9397-262339060c04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_7a464849-7ecb-4749-a11c-0ba2e26e4334" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2617bf03-0820-4cf7-9397-262339060c04" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_7a464849-7ecb-4749-a11c-0ba2e26e4334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_3bc0cf59-f6c2-44f8-b3a3-d29a64e66180" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2617bf03-0820-4cf7-9397-262339060c04" xlink:to="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_3bc0cf59-f6c2-44f8-b3a3-d29a64e66180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherInvestments_156356fb-bb25-44ba-9267-139b699ace41" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfOtherInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2617bf03-0820-4cf7-9397-262339060c04" xlink:to="loc_us-gaap_GainLossOnSaleOfOtherInvestments_156356fb-bb25-44ba-9267-139b699ace41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments_b857bed4-a385-43d2-b10e-7af3cd09c3a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2617bf03-0820-4cf7-9397-262339060c04" xlink:to="loc_us-gaap_GainLossOnSaleOfInvestments_b857bed4-a385-43d2-b10e-7af3cd09c3a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_3a7ca800-6afe-403b-8c9e-ec21943330f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2617bf03-0820-4cf7-9397-262339060c04" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_3a7ca800-6afe-403b-8c9e-ec21943330f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_4df095cc-20d6-4414-98e2-84b9258700cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2617bf03-0820-4cf7-9397-262339060c04" xlink:to="loc_us-gaap_ShareBasedCompensation_4df095cc-20d6-4414-98e2-84b9258700cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_86df3328-7a12-48da-8559-fff259629ae6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2617bf03-0820-4cf7-9397-262339060c04" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_86df3328-7a12-48da-8559-fff259629ae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1c9e19c8-f90c-443b-9137-c5b0f230cbc6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2617bf03-0820-4cf7-9397-262339060c04" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1c9e19c8-f90c-443b-9137-c5b0f230cbc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivables_2f655d07-8319-4fb4-a59f-6c40ca37cd2e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1c9e19c8-f90c-443b-9137-c5b0f230cbc6" xlink:to="loc_us-gaap_IncreaseDecreaseInReceivables_2f655d07-8319-4fb4-a59f-6c40ca37cd2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_00adb3f6-6bd9-4bc8-bfa4-9e0f68646e87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1c9e19c8-f90c-443b-9137-c5b0f230cbc6" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_00adb3f6-6bd9-4bc8-bfa4-9e0f68646e87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_59a55b55-b2da-4185-a1ba-682b6fd60c0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1c9e19c8-f90c-443b-9137-c5b0f230cbc6" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_59a55b55-b2da-4185-a1ba-682b6fd60c0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_c7b5615a-7c63-443e-9187-0c680c841af9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1c9e19c8-f90c-443b-9137-c5b0f230cbc6" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_c7b5615a-7c63-443e-9187-0c680c841af9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2b99eef1-7b0d-465c-919f-b455f1a396da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9f556e40-09ea-4585-9f72-ef4d8e7b57ed" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2b99eef1-7b0d-465c-919f-b455f1a396da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_323e8df1-9224-4104-8fb6-c76554beeede" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_77445910-c3ce-42f4-9d63-a3937019bbef" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_323e8df1-9224-4104-8fb6-c76554beeede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_75f95723-5878-4b14-b4a2-26aaefebb94c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_323e8df1-9224-4104-8fb6-c76554beeede" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_75f95723-5878-4b14-b4a2-26aaefebb94c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_81107fea-916e-46eb-8f08-66e76a4dc7bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_323e8df1-9224-4104-8fb6-c76554beeede" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_81107fea-916e-46eb-8f08-66e76a4dc7bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_c0272e31-c629-4ad2-9481-cd904fd5722d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_323e8df1-9224-4104-8fb6-c76554beeede" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_c0272e31-c629-4ad2-9481-cd904fd5722d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_a497200c-6d10-461d-b5f4-bc236566e160" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_323e8df1-9224-4104-8fb6-c76554beeede" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_a497200c-6d10-461d-b5f4-bc236566e160" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Purchaseofavailableforsalesecuritiesandotherinvestments_213c4966-7b43-4e75-81ae-ad6cf92e5866" xlink:href="cah-20230331.xsd#cah_Purchaseofavailableforsalesecuritiesandotherinvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_323e8df1-9224-4104-8fb6-c76554beeede" xlink:to="loc_cah_Purchaseofavailableforsalesecuritiesandotherinvestments_213c4966-7b43-4e75-81ae-ad6cf92e5866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments_fbb66494-aaae-4c16-bad5-96631f20bcd1" xlink:href="cah-20230331.xsd#cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_323e8df1-9224-4104-8fb6-c76554beeede" xlink:to="loc_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments_fbb66494-aaae-4c16-bad5-96631f20bcd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromHedgeInvestingActivities_69c99dd4-9f4b-4b00-a13e-3d15c7206e3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromHedgeInvestingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_323e8df1-9224-4104-8fb6-c76554beeede" xlink:to="loc_us-gaap_ProceedsFromHedgeInvestingActivities_69c99dd4-9f4b-4b00-a13e-3d15c7206e3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2f56d2b8-f005-489f-bf84-72556328d530" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_323e8df1-9224-4104-8fb6-c76554beeede" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2f56d2b8-f005-489f-bf84-72556328d530" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_f3a46caa-c160-4550-a607-781daa8aab8d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_77445910-c3ce-42f4-9d63-a3937019bbef" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_f3a46caa-c160-4550-a607-781daa8aab8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_3384e509-5ab3-492c-bab7-1b0fb1fa55f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_f3a46caa-c160-4550-a607-781daa8aab8d" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_3384e509-5ab3-492c-bab7-1b0fb1fa55f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Netproceedstaxwithholdingsfromsharebasedcompensation_04c887a5-a413-492d-88af-708d9a10834c" xlink:href="cah-20230331.xsd#cah_Netproceedstaxwithholdingsfromsharebasedcompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_f3a46caa-c160-4550-a607-781daa8aab8d" xlink:to="loc_cah_Netproceedstaxwithholdingsfromsharebasedcompensation_04c887a5-a413-492d-88af-708d9a10834c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock_857da308-fbf4-4808-8826-a943d011a904" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_f3a46caa-c160-4550-a607-781daa8aab8d" xlink:to="loc_us-gaap_PaymentsOfDividendsCommonStock_857da308-fbf4-4808-8826-a943d011a904" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_665f8621-0d9f-4b7e-9ef0-40c1d3c430cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_f3a46caa-c160-4550-a607-781daa8aab8d" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_665f8621-0d9f-4b7e-9ef0-40c1d3c430cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b4515a29-87cf-4885-8e7c-df5ed155c053" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_f3a46caa-c160-4550-a607-781daa8aab8d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b4515a29-87cf-4885-8e7c-df5ed155c053" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5835a173-d4f8-4776-b14a-012fba3fae22" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_77445910-c3ce-42f4-9d63-a3937019bbef" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5835a173-d4f8-4776-b14a-012fba3fae22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CashReclassifiedToAssetHeldForSale_d766e054-2e5c-4076-afa3-cf0663d8300b" xlink:href="cah-20230331.xsd#cah_CashReclassifiedToAssetHeldForSale"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_77445910-c3ce-42f4-9d63-a3937019bbef" xlink:to="loc_cah_CashReclassifiedToAssetHeldForSale_d766e054-2e5c-4076-afa3-cf0663d8300b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_653c89b8-53e8-41e7-ba11-cdc89aa14090" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_77445910-c3ce-42f4-9d63-a3937019bbef" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_653c89b8-53e8-41e7-ba11-cdc89aa14090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d3e0d6b3-b78b-4e1d-ab30-4e48bc116f82" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_77445910-c3ce-42f4-9d63-a3937019bbef" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d3e0d6b3-b78b-4e1d-ab30-4e48bc116f82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fd5be061-c43f-4bf2-a817-a4c0c267609b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_77445910-c3ce-42f4-9d63-a3937019bbef" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fd5be061-c43f-4bf2-a817-a4c0c267609b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="cah-20230331.xsd#BasisofPresentationandSummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_f88faf8d-1ad0-4d66-8197-7ce3b1ac9c7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_5e59eebb-1daa-4371-9af9-369eaed99fea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f88faf8d-1ad0-4d66-8197-7ce3b1ac9c7b" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_5e59eebb-1daa-4371-9af9-369eaed99fea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/Divestitures" xlink:type="simple" xlink:href="cah-20230331.xsd#Divestitures"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/Divestitures" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_9e311d1d-49ec-4ea2-a385-8ea309bc5c83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_16cefcd2-af94-4d82-a6d4-720740a04ba3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_9e311d1d-49ec-4ea2-a385-8ea309bc5c83" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_16cefcd2-af94-4d82-a6d4-720740a04ba3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeverance" xlink:type="simple" xlink:href="cah-20230331.xsd#RestructuringandEmployeeSeverance"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/RestructuringandEmployeeSeverance" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesAbstract_293abd3f-b227-4d46-9c60-268e8eba060d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringChargesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_a9cb7313-b121-45ba-a5e7-6e257c044ab2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_293abd3f-b227-4d46-9c60-268e8eba060d" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_a9cb7313-b121-45ba-a5e7-6e257c044ab2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssets" xlink:type="simple" xlink:href="cah-20230331.xsd#GoodwillandOtherIntangibleAssets"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4698cef8-4b01-4a14-872e-d271dfb141f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_beaca68c-c9ed-4375-99e9-25fd01b84c8d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4698cef8-4b01-4a14-872e-d271dfb141f6" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_beaca68c-c9ed-4375-99e9-25fd01b84c8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowings" xlink:type="simple" xlink:href="cah-20230331.xsd#LongTermObligationsandOtherShortTermBorrowings"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowings" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cah_LongTermObligationsandOtherShortTermBorrowingsAbstract_d23bde25-e66e-432f-9bf6-58976ef0282b" xlink:href="cah-20230331.xsd#cah_LongTermObligationsandOtherShortTermBorrowingsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_da3d795a-929b-4f61-89f5-616f4803d533" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_LongTermObligationsandOtherShortTermBorrowingsAbstract_d23bde25-e66e-432f-9bf6-58976ef0282b" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_da3d795a-929b-4f61-89f5-616f4803d533" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigation" xlink:type="simple" xlink:href="cah-20230331.xsd#CommitmentsContingentLiabilitiesandLitigation"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_bbe2ad83-de63-4281-9284-e923d4c32a99" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_0ac0f826-556a-45fa-ab20-4c3142f6fa26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_bbe2ad83-de63-4281-9284-e923d4c32a99" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_0ac0f826-556a-45fa-ab20-4c3142f6fa26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/IncomeTaxes" xlink:type="simple" xlink:href="cah-20230331.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_61c09ade-b58c-45ce-a408-18de6d88a71b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_c75141a3-7f90-485a-8d76-a7added17c37" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_61c09ade-b58c-45ce-a408-18de6d88a71b" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_c75141a3-7f90-485a-8d76-a7added17c37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="cah-20230331.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_9840b73a-a502-474f-84bd-b475daf743ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_cfc6cbb6-5e12-4ef3-b403-7fd4919a2efc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9840b73a-a502-474f-84bd-b475daf743ee" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_cfc6cbb6-5e12-4ef3-b403-7fd4919a2efc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/FinancialInstruments" xlink:type="simple" xlink:href="cah-20230331.xsd#FinancialInstruments"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/FinancialInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_df862ac5-1111-4504-8c5c-0c2819db9e32" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_ca9dd999-adf3-4703-a201-f67590842325" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_df862ac5-1111-4504-8c5c-0c2819db9e32" xlink:to="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_ca9dd999-adf3-4703-a201-f67590842325" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareholdersEquity" xlink:type="simple" xlink:href="cah-20230331.xsd#ShareholdersEquity"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_7be4343d-fcbd-45f5-8a19-fa86af1390a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_659642dd-e714-485a-be91-1258b63bc428" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_7be4343d-fcbd-45f5-8a19-fa86af1390a2" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_659642dd-e714-485a-be91-1258b63bc428" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthInc" xlink:type="simple" xlink:href="cah-20230331.xsd#EarningsPerShareAttributabletoCardinalHealthInc"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthInc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_5c4ddc61-8fba-4f5c-b972-beee2477c678" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_e142d2fc-33e3-4e2f-a969-2adae6b55646" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_5c4ddc61-8fba-4f5c-b972-beee2477c678" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_e142d2fc-33e3-4e2f-a969-2adae6b55646" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformation" xlink:type="simple" xlink:href="cah-20230331.xsd#SegmentInformation"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/SegmentInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_1cdfef6a-a560-4713-8333-6a9013471e8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_38d2e96d-feca-4844-8950-49edb93c6ea7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_1cdfef6a-a560-4713-8333-6a9013471e8f" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_38d2e96d-feca-4844-8950-49edb93c6ea7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensation" xlink:type="simple" xlink:href="cah-20230331.xsd#ShareBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_626141ff-13ad-410d-93d6-13cea70aa296" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_f45c49a1-4abc-4dbb-8ca6-ea006babe01c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_626141ff-13ad-410d-93d6-13cea70aa296" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_f45c49a1-4abc-4dbb-8ca6-ea006babe01c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="cah-20230331.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_56b97f61-8216-4a6a-a66f-fdd76f77fd6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_8d6185ef-ba5b-41b5-8394-4f8aef169203" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_56b97f61-8216-4a6a-a66f-fdd76f77fd6f" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_8d6185ef-ba5b-41b5-8394-4f8aef169203" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_00e63dd6-2a21-4753-aba0-056dcc23f9d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_56b97f61-8216-4a6a-a66f-fdd76f77fd6f" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_00e63dd6-2a21-4753-aba0-056dcc23f9d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsTables" xlink:type="simple" xlink:href="cah-20230331.xsd#DiscontinuedOperationsandDisposalGroupsTables"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_1746a495-0a27-47c6-a391-02205704fdf0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables" xlink:type="simple" xlink:href="cah-20230331.xsd#RestructuringandEmployeeSeveranceTables"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesAbstract_01cf626f-42f9-4cb1-82bf-5b55d9352003" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringChargesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_5e2acbda-1512-4ac4-a3c9-d37dfe75c5a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_01cf626f-42f9-4cb1-82bf-5b55d9352003" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_5e2acbda-1512-4ac4-a3c9-d37dfe75c5a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_2ce5c736-8a94-46a1-b6d2-e179593d98c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_01cf626f-42f9-4cb1-82bf-5b55d9352003" xlink:to="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_2ce5c736-8a94-46a1-b6d2-e179593d98c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables" xlink:type="simple" xlink:href="cah-20230331.xsd#GoodwillandOtherIntangibleAssetsTables"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_af085d88-af1b-4b3d-a580-19a91c5c1c74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_d56373f3-d08d-4634-953b-70311080b5e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_af085d88-af1b-4b3d-a580-19a91c5c1c74" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_d56373f3-d08d-4634-953b-70311080b5e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_46cba8b5-c2ca-4f2f-8ab9-53c75a63822b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_af085d88-af1b-4b3d-a580-19a91c5c1c74" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_46cba8b5-c2ca-4f2f-8ab9-53c75a63822b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsTables" xlink:type="simple" xlink:href="cah-20230331.xsd#LongTermObligationsandOtherShortTermBorrowingsTables"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cah_LongTermObligationsandOtherShortTermBorrowingsAbstract_d661c19a-7938-4dda-bfdd-aa2bb4493404" xlink:href="cah-20230331.xsd#cah_LongTermObligationsandOtherShortTermBorrowingsAbstract"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="cah-20230331.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_dc62950d-72ac-445a-93b9-b5f772579340" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_08ba6c1a-9a11-404e-aeac-c9f6ae474b69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_dc62950d-72ac-445a-93b9-b5f772579340" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_08ba6c1a-9a11-404e-aeac-c9f6ae474b69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/FinancialInstrumentsTables" xlink:type="simple" xlink:href="cah-20230331.xsd#FinancialInstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/FinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_76fd8f56-03fb-4801-a3dd-1d26d142f5b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_9ea66f38-521e-411d-807a-4c6d4aee8888" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_76fd8f56-03fb-4801-a3dd-1d26d142f5b6" xlink:to="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_9ea66f38-521e-411d-807a-4c6d4aee8888" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareholdersEquityTables" xlink:type="simple" xlink:href="cah-20230331.xsd#ShareholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_cb22dfbf-1e1c-4be6-8ffd-94277e9a9a58" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_370cd9ce-c134-4c4d-805b-04e56f0909e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_cb22dfbf-1e1c-4be6-8ffd-94277e9a9a58" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_370cd9ce-c134-4c4d-805b-04e56f0909e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables" xlink:type="simple" xlink:href="cah-20230331.xsd#EarningsPerShareAttributabletoCardinalHealthIncTables"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_9d1aa5dc-8018-44f7-b598-e4531f765c3a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_8cb12141-06ab-49e8-b878-44c6aee89493" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_9d1aa5dc-8018-44f7-b598-e4531f765c3a" xlink:to="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_8cb12141-06ab-49e8-b878-44c6aee89493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationTables" xlink:type="simple" xlink:href="cah-20230331.xsd#SegmentInformationTables"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/SegmentInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_e3864de9-2104-41c8-b42d-8998e29f85ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_f4b61a3f-2b98-4f3c-9c07-0c26db46d4d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_e3864de9-2104-41c8-b42d-8998e29f85ba" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_f4b61a3f-2b98-4f3c-9c07-0c26db46d4d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_0a957690-97a4-4c98-b645-6fc705944659" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_e3864de9-2104-41c8-b42d-8998e29f85ba" xlink:to="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_0a957690-97a4-4c98-b645-6fc705944659" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_68c5234d-ae04-4564-b6e3-4ede4c7b78f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_e3864de9-2104-41c8-b42d-8998e29f85ba" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_68c5234d-ae04-4564-b6e3-4ede4c7b78f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock_2fe15b5a-31c0-40cb-b73b-815678b87bc2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_e3864de9-2104-41c8-b42d-8998e29f85ba" xlink:to="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock_2fe15b5a-31c0-40cb-b73b-815678b87bc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationTables" xlink:type="simple" xlink:href="cah-20230331.xsd#ShareBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3765ec0a-d494-47d2-a643-c6552dfb64e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_cb4372bf-37c6-4bf9-8a7c-f42a5127661a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3765ec0a-d494-47d2-a643-c6552dfb64e2" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_cb4372bf-37c6-4bf9-8a7c-f42a5127661a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_58006595-6cd8-446f-9e99-425e5bde0674" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3765ec0a-d494-47d2-a643-c6552dfb64e2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_58006595-6cd8-446f-9e99-425e5bde0674" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_e4232449-0a31-4758-8f51-57285705737b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3765ec0a-d494-47d2-a643-c6552dfb64e2" xlink:to="loc_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_e4232449-0a31-4758-8f51-57285705737b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeRecentFinancialAccountingStandardsDetails" xlink:type="simple" xlink:href="cah-20230331.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeRecentFinancialAccountingStandardsDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeRecentFinancialAccountingStandardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_2b0a4ba0-9ac5-4e34-b612-85b277618032" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails" xlink:type="simple" xlink:href="cah-20230331.xsd#DiscontinuedOperationsandDisposalGroupsDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_7fe41c01-bdd9-4e88-95bf-83e9df3af9c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_7693a2f2-27eb-44c8-965d-056cef251dac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_7fe41c01-bdd9-4e88-95bf-83e9df3af9c3" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_7693a2f2-27eb-44c8-965d-056cef251dac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_bc4ebc9b-b5e2-4c4c-8c57-e034a82e1a2e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_7693a2f2-27eb-44c8-965d-056cef251dac" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_bc4ebc9b-b5e2-4c4c-8c57-e034a82e1a2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_f91c99ed-da7e-4b33-a8fd-4d3de2f94d08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_bc4ebc9b-b5e2-4c4c-8c57-e034a82e1a2e" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_f91c99ed-da7e-4b33-a8fd-4d3de2f94d08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureAxis_028d4e6b-a8c1-422a-bbe8-e40f4f5fa731" xlink:href="cah-20230331.xsd#cah_CordisDivestitureAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_7693a2f2-27eb-44c8-965d-056cef251dac" xlink:to="loc_cah_CordisDivestitureAxis_028d4e6b-a8c1-422a-bbe8-e40f4f5fa731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureDomain_94ce987d-f47d-4fd8-83ac-70cccfca1a4e" xlink:href="cah-20230331.xsd#cah_CordisDivestitureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_CordisDivestitureAxis_028d4e6b-a8c1-422a-bbe8-e40f4f5fa731" xlink:to="loc_cah_CordisDivestitureDomain_94ce987d-f47d-4fd8-83ac-70cccfca1a4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureMember_679a9b4c-d600-4ed5-993d-83433c188e0a" xlink:href="cah-20230331.xsd#cah_CordisDivestitureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_CordisDivestitureDomain_94ce987d-f47d-4fd8-83ac-70cccfca1a4e" xlink:to="loc_cah_CordisDivestitureMember_679a9b4c-d600-4ed5-993d-83433c188e0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_6de6b606-d69a-429e-9eeb-e328c8eaee26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_7693a2f2-27eb-44c8-965d-056cef251dac" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_6de6b606-d69a-429e-9eeb-e328c8eaee26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_2dc80c83-be6b-4717-a2cb-dbb3d6e778e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_6de6b606-d69a-429e-9eeb-e328c8eaee26" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_2dc80c83-be6b-4717-a2cb-dbb3d6e778e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails" xlink:type="simple" xlink:href="cah-20230331.xsd#RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesAbstract_26ce7220-d8ec-41b1-9f51-e796eea20ff5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringChargesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_26c5b788-a8fe-4931-82dd-58ac0aa99585" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeveranceCosts1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_26ce7220-d8ec-41b1-9f51-e796eea20ff5" xlink:to="loc_us-gaap_SeveranceCosts1_26c5b788-a8fe-4931-82dd-58ac0aa99585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_FacilityExitAndOtherCosts_5d2115a1-d995-47a2-bb01-8e9b78705f48" xlink:href="cah-20230331.xsd#cah_FacilityExitAndOtherCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_26ce7220-d8ec-41b1-9f51-e796eea20ff5" xlink:to="loc_cah_FacilityExitAndOtherCosts_5d2115a1-d995-47a2-bb01-8e9b78705f48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_d167fbfa-1b59-49b8-ba54-149581cf882b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_26ce7220-d8ec-41b1-9f51-e796eea20ff5" xlink:to="loc_us-gaap_RestructuringCharges_d167fbfa-1b59-49b8-ba54-149581cf882b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails" xlink:type="simple" xlink:href="cah-20230331.xsd#RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesAbstract_b6beb371-719a-49a0-8b97-59d1d14b440a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringChargesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_00406c67-8f82-4a41-b30a-8cbec6765d23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_b6beb371-719a-49a0-8b97-59d1d14b440a" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_00406c67-8f82-4a41-b30a-8cbec6765d23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_977342b7-3030-46d0-b078-1ab4e71d1c39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_00406c67-8f82-4a41-b30a-8cbec6765d23" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_977342b7-3030-46d0-b078-1ab4e71d1c39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_31c1e0b2-703a-4cc9-905c-2ce8d89b874c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_977342b7-3030-46d0-b078-1ab4e71d1c39" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_31c1e0b2-703a-4cc9-905c-2ce8d89b874c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_4079b5e8-35e1-4297-895b-535941c3ae45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_31c1e0b2-703a-4cc9-905c-2ce8d89b874c" xlink:to="loc_us-gaap_EmployeeSeveranceMember_4079b5e8-35e1-4297-895b-535941c3ae45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FacilityClosingMember_7e8ec64c-2082-4a51-868a-6cba268af545" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FacilityClosingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_31c1e0b2-703a-4cc9-905c-2ce8d89b874c" xlink:to="loc_us-gaap_FacilityClosingMember_7e8ec64c-2082-4a51-868a-6cba268af545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_6ce9ad0d-7405-41c5-a956-289784c81585" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_00406c67-8f82-4a41-b30a-8cbec6765d23" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_6ce9ad0d-7405-41c5-a956-289784c81585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_e82cf884-c0a4-4765-9c7f-c34eecb7763f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_6ce9ad0d-7405-41c5-a956-289784c81585" xlink:to="loc_us-gaap_RestructuringReserveRollForward_e82cf884-c0a4-4765-9c7f-c34eecb7763f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_4b500795-ef11-42f2-bf4b-1075b7a56391" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_e82cf884-c0a4-4765-9c7f-c34eecb7763f" xlink:to="loc_us-gaap_RestructuringReserve_4b500795-ef11-42f2-bf4b-1075b7a56391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCosts_a47ecb54-2fcd-4df1-ae47-0ad1fbda28f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_e82cf884-c0a4-4765-9c7f-c34eecb7763f" xlink:to="loc_us-gaap_RestructuringCosts_a47ecb54-2fcd-4df1-ae47-0ad1fbda28f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_666373c6-e435-4818-9777-d1a4e3cd1890" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_e82cf884-c0a4-4765-9c7f-c34eecb7763f" xlink:to="loc_us-gaap_PaymentsForRestructuring_666373c6-e435-4818-9777-d1a4e3cd1890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_f7e71c52-571d-4eab-b6b7-6ca60c180040" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_e82cf884-c0a4-4765-9c7f-c34eecb7763f" xlink:to="loc_us-gaap_RestructuringReserve_f7e71c52-571d-4eab-b6b7-6ca60c180040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails" xlink:type="simple" xlink:href="cah-20230331.xsd#RestructuringandEmployeeSeveranceNarativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cah_NarativeAbstract_5d3c94a2-4956-426b-b246-ab6ebfbdbfa5" xlink:href="cah-20230331.xsd#cah_NarativeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_055e9581-d228-4afe-9b17-5c7dc0aac892" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_NarativeAbstract_5d3c94a2-4956-426b-b246-ab6ebfbdbfa5" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_055e9581-d228-4afe-9b17-5c7dc0aac892" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_0290570a-4adc-47fa-a9a6-3dfed1323d4f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_055e9581-d228-4afe-9b17-5c7dc0aac892" xlink:to="loc_us-gaap_RestructuringPlanAxis_0290570a-4adc-47fa-a9a6-3dfed1323d4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_59cd91c0-a0e5-4ffb-bf41-505ac50b55d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_0290570a-4adc-47fa-a9a6-3dfed1323d4f" xlink:to="loc_us-gaap_RestructuringPlanDomain_59cd91c0-a0e5-4ffb-bf41-505ac50b55d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_c480c69b-6fd0-4db8-b8b2-c408b2cc39cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_055e9581-d228-4afe-9b17-5c7dc0aac892" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_c480c69b-6fd0-4db8-b8b2-c408b2cc39cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_6939a014-429b-429a-b1da-a8a4d8437b6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeveranceCosts1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_c480c69b-6fd0-4db8-b8b2-c408b2cc39cf" xlink:to="loc_us-gaap_SeveranceCosts1_6939a014-429b-429a-b1da-a8a4d8437b6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_FacilityExitAndOtherCosts_ef8698a4-8a40-4a33-aab6-f803b991dcac" xlink:href="cah-20230331.xsd#cah_FacilityExitAndOtherCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_c480c69b-6fd0-4db8-b8b2-c408b2cc39cf" xlink:to="loc_cah_FacilityExitAndOtherCosts_ef8698a4-8a40-4a33-aab6-f803b991dcac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails" xlink:type="simple" xlink:href="cah-20230331.xsd#GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4e38ad1e-b698-40a8-9cfd-90fd3ac57d9d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_5f3e3457-da90-4d69-be38-04f7323b5e05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4e38ad1e-b698-40a8-9cfd-90fd3ac57d9d" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_5f3e3457-da90-4d69-be38-04f7323b5e05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_5581b6f9-d12c-431b-a6d6-91db1995e1e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_5f3e3457-da90-4d69-be38-04f7323b5e05" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_5581b6f9-d12c-431b-a6d6-91db1995e1e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_3b756d27-bb23-4fde-bfb4-cdbb726675b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_5581b6f9-d12c-431b-a6d6-91db1995e1e7" xlink:to="loc_us-gaap_SegmentDomain_3b756d27-bb23-4fde-bfb4-cdbb726675b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalMember_b749739d-4e70-4a69-b6d7-a1c06f83dca0" xlink:href="cah-20230331.xsd#cah_PharmaceuticalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_3b756d27-bb23-4fde-bfb4-cdbb726675b7" xlink:to="loc_cah_PharmaceuticalMember_b749739d-4e70-4a69-b6d7-a1c06f83dca0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember_459dd0a7-d6c7-44dd-ad61-07bc264d5330" xlink:href="cah-20230331.xsd#cah_MedicalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_3b756d27-bb23-4fde-bfb4-cdbb726675b7" xlink:to="loc_cah_MedicalMember_459dd0a7-d6c7-44dd-ad61-07bc264d5330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureAxis_2f10b9f8-64c3-4050-a802-98080b40cb84" xlink:href="cah-20230331.xsd#cah_CordisDivestitureAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_5f3e3457-da90-4d69-be38-04f7323b5e05" xlink:to="loc_cah_CordisDivestitureAxis_2f10b9f8-64c3-4050-a802-98080b40cb84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureDomain_89ce9886-797a-4647-863c-e095d16fda88" xlink:href="cah-20230331.xsd#cah_CordisDivestitureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_CordisDivestitureAxis_2f10b9f8-64c3-4050-a802-98080b40cb84" xlink:to="loc_cah_CordisDivestitureDomain_89ce9886-797a-4647-863c-e095d16fda88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureMember_a500759e-2861-463c-98a5-bd8ac4435933" xlink:href="cah-20230331.xsd#cah_CordisDivestitureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_CordisDivestitureDomain_89ce9886-797a-4647-863c-e095d16fda88" xlink:to="loc_cah_CordisDivestitureMember_a500759e-2861-463c-98a5-bd8ac4435933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_23db62c5-9f53-44c7-9665-dc97ca7b59c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_5f3e3457-da90-4d69-be38-04f7323b5e05" xlink:to="loc_us-gaap_GoodwillLineItems_23db62c5-9f53-44c7-9665-dc97ca7b59c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_95a9b065-8fd9-4b21-a561-ccfba101e328" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_23db62c5-9f53-44c7-9665-dc97ca7b59c2" xlink:to="loc_us-gaap_GoodwillRollForward_95a9b065-8fd9-4b21-a561-ccfba101e328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_38d0dcea-4c0d-4253-98f2-db72c6da0c6d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_95a9b065-8fd9-4b21-a561-ccfba101e328" xlink:to="loc_us-gaap_Goodwill_38d0dcea-4c0d-4253-98f2-db72c6da0c6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_2f88533f-6e23-489d-85fa-59325cf7d0bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_95a9b065-8fd9-4b21-a561-ccfba101e328" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_2f88533f-6e23-489d-85fa-59325cf7d0bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_f3f05aba-ea14-491e-a022-6f676e2b298c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_95a9b065-8fd9-4b21-a561-ccfba101e328" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_f3f05aba-ea14-491e-a022-6f676e2b298c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_c77fe026-08ff-48e3-9d73-5ee46b4e910c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_95a9b065-8fd9-4b21-a561-ccfba101e328" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_c77fe026-08ff-48e3-9d73-5ee46b4e910c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_0ba7df1a-6346-49d0-b908-ee4ecfb08661" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_95a9b065-8fd9-4b21-a561-ccfba101e328" xlink:to="loc_us-gaap_Goodwill_0ba7df1a-6346-49d0-b908-ee4ecfb08661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_72c311b7-e012-4378-ade8-4dc65022805b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_23db62c5-9f53-44c7-9665-dc97ca7b59c2" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_72c311b7-e012-4378-ade8-4dc65022805b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="cah-20230331.xsd#GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c36bd219-fe10-4b73-aa0d-dc6dd5d29fdb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_c22ffae9-594c-4f13-8a44-3567b6173bb1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c36bd219-fe10-4b73-aa0d-dc6dd5d29fdb" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_c22ffae9-594c-4f13-8a44-3567b6173bb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_f3372b8e-7050-4898-a12b-78eeac5e513c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_c22ffae9-594c-4f13-8a44-3567b6173bb1" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_f3372b8e-7050-4898-a12b-78eeac5e513c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_47875f57-183c-4f53-ba6b-8e0b7193934c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_f3372b8e-7050-4898-a12b-78eeac5e513c" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_47875f57-183c-4f53-ba6b-8e0b7193934c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_IPRDTrademarksandOtherMember_71be7658-a7bb-4a51-809a-2dbf99ec3bf4" xlink:href="cah-20230331.xsd#cah_IPRDTrademarksandOtherMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_47875f57-183c-4f53-ba6b-8e0b7193934c" xlink:to="loc_cah_IPRDTrademarksandOtherMember_71be7658-a7bb-4a51-809a-2dbf99ec3bf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_3db197f8-94c5-4e2e-a79d-621a25118318" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_c22ffae9-594c-4f13-8a44-3567b6173bb1" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_3db197f8-94c5-4e2e-a79d-621a25118318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_6f25f955-388b-4f8c-bcd7-b16feedd72ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_3db197f8-94c5-4e2e-a79d-621a25118318" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_6f25f955-388b-4f8c-bcd7-b16feedd72ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_a10843bb-ac5e-4ccb-934c-5d049736f04e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c36bd219-fe10-4b73-aa0d-dc6dd5d29fdb" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_a10843bb-ac5e-4ccb-934c-5d049736f04e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0036e635-b7d2-4c58-a4a4-667903252a07" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_a10843bb-ac5e-4ccb-934c-5d049736f04e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0036e635-b7d2-4c58-a4a4-667903252a07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c1dd52f2-d98b-4e6b-ace3-e19f6e47e6c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0036e635-b7d2-4c58-a4a4-667903252a07" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c1dd52f2-d98b-4e6b-ace3-e19f6e47e6c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_795a8df6-09b4-4877-b6dd-c7d889b24f6d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c1dd52f2-d98b-4e6b-ace3-e19f6e47e6c4" xlink:to="loc_us-gaap_CustomerRelationshipsMember_795a8df6-09b4-4877-b6dd-c7d889b24f6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TrademarksAndPatentsMember_47b4b064-c4ff-445f-ad42-ec75eb4e0d73" xlink:href="cah-20230331.xsd#cah_TrademarksAndPatentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c1dd52f2-d98b-4e6b-ace3-e19f6e47e6c4" xlink:to="loc_cah_TrademarksAndPatentsMember_47b4b064-c4ff-445f-ad42-ec75eb4e0d73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_e4a453ee-d1a2-450f-8b67-fb85c9dcbb21" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c1dd52f2-d98b-4e6b-ace3-e19f6e47e6c4" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_e4a453ee-d1a2-450f-8b67-fb85c9dcbb21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e596331b-9a47-41a6-bef2-3a4c85e14bef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_a10843bb-ac5e-4ccb-934c-5d049736f04e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e596331b-9a47-41a6-bef2-3a4c85e14bef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_ab6bd59b-658e-4ba3-8e5d-a6cd9eacf2ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e596331b-9a47-41a6-bef2-3a4c85e14bef" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_ab6bd59b-658e-4ba3-8e5d-a6cd9eacf2ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_cb568245-fd04-4a4d-8c48-812e966055e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e596331b-9a47-41a6-bef2-3a4c85e14bef" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_cb568245-fd04-4a4d-8c48-812e966055e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_6fb1187e-392a-408e-9e2d-149071ecbdc5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e596331b-9a47-41a6-bef2-3a4c85e14bef" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_6fb1187e-392a-408e-9e2d-149071ecbdc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_35791f35-75ef-4e17-ade3-a410fa139ab2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e596331b-9a47-41a6-bef2-3a4c85e14bef" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_35791f35-75ef-4e17-ade3-a410fa139ab2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_c767be1c-7199-469f-b2c5-30d6137d459d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c36bd219-fe10-4b73-aa0d-dc6dd5d29fdb" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_c767be1c-7199-469f-b2c5-30d6137d459d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_f7f3fe76-024e-447e-987c-cf9a1e82c2e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c36bd219-fe10-4b73-aa0d-dc6dd5d29fdb" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_f7f3fe76-024e-447e-987c-cf9a1e82c2e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" xlink:type="simple" xlink:href="cah-20230331.xsd#GoodwillandOtherIntangibleAssetsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_fb067481-b39d-49c0-ac93-bd13327867e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_87fd3fce-1205-45ca-b273-71fc6881bd4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_fb067481-b39d-49c0-ac93-bd13327867e1" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_87fd3fce-1205-45ca-b273-71fc6881bd4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_655d7d7f-73a6-4c48-b51d-0a178798661d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_fb067481-b39d-49c0-ac93-bd13327867e1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_655d7d7f-73a6-4c48-b51d-0a178798661d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_36eab4bc-efb1-4878-b64b-fe3ead4478e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_fb067481-b39d-49c0-ac93-bd13327867e1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_36eab4bc-efb1-4878-b64b-fe3ead4478e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_9b6e48a9-4076-4eb5-a7a9-ddcf3069b617" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_fb067481-b39d-49c0-ac93-bd13327867e1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_9b6e48a9-4076-4eb5-a7a9-ddcf3069b617" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_fe2a5c9e-0323-4da1-816b-16146be561d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_fb067481-b39d-49c0-ac93-bd13327867e1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_fe2a5c9e-0323-4da1-816b-16146be561d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_1a47a8d1-a750-4087-bb42-b13f09e3e51f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_fb067481-b39d-49c0-ac93-bd13327867e1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_1a47a8d1-a750-4087-bb42-b13f09e3e51f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_bc3665f2-6024-4bef-a332-ef3c1b1b09a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_fb067481-b39d-49c0-ac93-bd13327867e1" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_bc3665f2-6024-4bef-a332-ef3c1b1b09a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis_f7e481a3-40ca-4912-bc87-2bd7dbb7a9f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReportingUnitAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_bc3665f2-6024-4bef-a332-ef3c1b1b09a4" xlink:to="loc_us-gaap_ReportingUnitAxis_f7e481a3-40ca-4912-bc87-2bd7dbb7a9f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_d32e811a-c67c-435f-9a66-bb3be278e3fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReportingUnitDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitAxis_f7e481a3-40ca-4912-bc87-2bd7dbb7a9f3" xlink:to="loc_us-gaap_ReportingUnitDomain_d32e811a-c67c-435f-9a66-bb3be278e3fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalUnitMember_07a4122f-3fc1-441a-aa46-896cafba5edf" xlink:href="cah-20230331.xsd#cah_MedicalUnitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_d32e811a-c67c-435f-9a66-bb3be278e3fc" xlink:to="loc_cah_MedicalUnitMember_07a4122f-3fc1-441a-aa46-896cafba5edf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_fe480157-c365-4169-82d5-ab168da52348" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_bc3665f2-6024-4bef-a332-ef3c1b1b09a4" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_fe480157-c365-4169-82d5-ab168da52348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_1bfc2a90-c134-4080-a3e5-ecb13d036e01" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_fe480157-c365-4169-82d5-ab168da52348" xlink:to="loc_us-gaap_SegmentDomain_1bfc2a90-c134-4080-a3e5-ecb13d036e01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember_9d7108c2-b906-47da-a0f0-aaaf6d2e5c69" xlink:href="cah-20230331.xsd#cah_MedicalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_1bfc2a90-c134-4080-a3e5-ecb13d036e01" xlink:to="loc_cah_MedicalMember_9d7108c2-b906-47da-a0f0-aaaf6d2e5c69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalUnitMember_745699c8-9328-4f9e-a7d6-2bc19928df27" xlink:href="cah-20230331.xsd#cah_MedicalUnitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_1bfc2a90-c134-4080-a3e5-ecb13d036e01" xlink:to="loc_cah_MedicalUnitMember_745699c8-9328-4f9e-a7d6-2bc19928df27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_GoodwillImpairmentAxis_da5677d6-689f-4ae2-bca2-d3d8a75a88cd" xlink:href="cah-20230331.xsd#cah_GoodwillImpairmentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_bc3665f2-6024-4bef-a332-ef3c1b1b09a4" xlink:to="loc_cah_GoodwillImpairmentAxis_da5677d6-689f-4ae2-bca2-d3d8a75a88cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_GoodwillImpairmentDomain_a4d976ae-ff08-47a5-83b3-75376fec16fd" xlink:href="cah-20230331.xsd#cah_GoodwillImpairmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_GoodwillImpairmentAxis_da5677d6-689f-4ae2-bca2-d3d8a75a88cd" xlink:to="loc_cah_GoodwillImpairmentDomain_a4d976ae-ff08-47a5-83b3-75376fec16fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalUnitMember_191141dc-149b-42b3-996d-2f9e20b60824" xlink:href="cah-20230331.xsd#cah_MedicalUnitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_GoodwillImpairmentDomain_a4d976ae-ff08-47a5-83b3-75376fec16fd" xlink:to="loc_cah_MedicalUnitMember_191141dc-149b-42b3-996d-2f9e20b60824" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_238841ef-6c0e-49cf-b899-4bc46b90e2db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_bc3665f2-6024-4bef-a332-ef3c1b1b09a4" xlink:to="loc_us-gaap_GoodwillLineItems_238841ef-6c0e-49cf-b899-4bc46b90e2db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_ed20cf82-606c-4c19-833d-cbb66111f435" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_238841ef-6c0e-49cf-b899-4bc46b90e2db" xlink:to="loc_us-gaap_Goodwill_ed20cf82-606c-4c19-833d-cbb66111f435" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_74015f98-0576-4214-be76-8659bbc18236" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_238841ef-6c0e-49cf-b899-4bc46b90e2db" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_74015f98-0576-4214-be76-8659bbc18236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_DiscountRateFairValueInput_9138c9b8-2ec1-4af7-b941-08cb663582ff" xlink:href="cah-20230331.xsd#cah_DiscountRateFairValueInput"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_238841ef-6c0e-49cf-b899-4bc46b90e2db" xlink:to="loc_cah_DiscountRateFairValueInput_9138c9b8-2ec1-4af7-b941-08cb663582ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TerminalGrowthRateFairValueInput_58822e8b-3bae-4057-8008-fad20aed829a" xlink:href="cah-20230331.xsd#cah_TerminalGrowthRateFairValueInput"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_238841ef-6c0e-49cf-b899-4bc46b90e2db" xlink:to="loc_cah_TerminalGrowthRateFairValueInput_58822e8b-3bae-4057-8008-fad20aed829a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount_000bfecb-2268-41ae-8254-43e8d442e3f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_238841ef-6c0e-49cf-b899-4bc46b90e2db" xlink:to="loc_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount_000bfecb-2268-41ae-8254-43e8d442e3f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails" xlink:type="simple" xlink:href="cah-20230331.xsd#LongTermObligationsandOtherShortTermBorrowingsDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cah_LongTermObligationsandOtherShortTermBorrowingsAbstract_866c3919-988d-4eb6-90e7-be4ff290ea6a" xlink:href="cah-20230331.xsd#cah_LongTermObligationsandOtherShortTermBorrowingsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_9b0f6531-61e0-48a4-ad3b-c2cc73a003cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_LongTermObligationsandOtherShortTermBorrowingsAbstract_866c3919-988d-4eb6-90e7-be4ff290ea6a" xlink:to="loc_us-gaap_DebtInstrumentTable_9b0f6531-61e0-48a4-ad3b-c2cc73a003cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_36e9c428-38b4-48e7-8efc-18ac3bf57ce1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9b0f6531-61e0-48a4-ad3b-c2cc73a003cd" xlink:to="loc_us-gaap_DebtInstrumentAxis_36e9c428-38b4-48e7-8efc-18ac3bf57ce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_82a3c607-0303-406a-9ebe-0560559b2e7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_36e9c428-38b4-48e7-8efc-18ac3bf57ce1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_82a3c607-0303-406a-9ebe-0560559b2e7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A2.616Notesdue2022Member_d558e194-b9b0-4739-a29c-6be5a836e20e" xlink:href="cah-20230331.xsd#cah_A2.616Notesdue2022Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_82a3c607-0303-406a-9ebe-0560559b2e7b" xlink:to="loc_cah_A2.616Notesdue2022Member_d558e194-b9b0-4739-a29c-6be5a836e20e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A32NotesDue2023Member_d8030c8f-c86f-427b-83cd-7bacfc5cb5b0" xlink:href="cah-20230331.xsd#cah_A32NotesDue2023Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_82a3c607-0303-406a-9ebe-0560559b2e7b" xlink:to="loc_cah_A32NotesDue2023Member_d8030c8f-c86f-427b-83cd-7bacfc5cb5b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CommittedReceivablesSalesFacilityProgramMember_8335bdd1-c861-487b-bcec-5d76bf1fab71" xlink:href="cah-20230331.xsd#cah_CommittedReceivablesSalesFacilityProgramMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_82a3c607-0303-406a-9ebe-0560559b2e7b" xlink:to="loc_cah_CommittedReceivablesSalesFacilityProgramMember_8335bdd1-c861-487b-bcec-5d76bf1fab71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_89cc09d6-0918-441f-9927-da48f7567bb0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9b0f6531-61e0-48a4-ad3b-c2cc73a003cd" xlink:to="loc_us-gaap_CreditFacilityAxis_89cc09d6-0918-441f-9927-da48f7567bb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_409329d2-b852-4aba-b8f2-025e3d87e3af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_89cc09d6-0918-441f-9927-da48f7567bb0" xlink:to="loc_us-gaap_CreditFacilityDomain_409329d2-b852-4aba-b8f2-025e3d87e3af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_3432758d-014f-413e-b040-949d4fa83a6d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_409329d2-b852-4aba-b8f2-025e3d87e3af" xlink:to="loc_us-gaap_CommercialPaperMember_3432758d-014f-413e-b040-949d4fa83a6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_7a51752b-595d-401b-a67a-c58f4936059d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_409329d2-b852-4aba-b8f2-025e3d87e3af" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_7a51752b-595d-401b-a67a-c58f4936059d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ShortTermCreditFacilitiesMember_7ec36e8c-083e-4a67-9ba7-9e7236ed1f72" xlink:href="cah-20230331.xsd#cah_ShortTermCreditFacilitiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_409329d2-b852-4aba-b8f2-025e3d87e3af" xlink:to="loc_cah_ShortTermCreditFacilitiesMember_7ec36e8c-083e-4a67-9ba7-9e7236ed1f72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CommittedReceivablesSalesFacilityProgramMember_08df85f5-3ec9-454d-b48d-ec4a353b4008" xlink:href="cah-20230331.xsd#cah_CommittedReceivablesSalesFacilityProgramMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_409329d2-b852-4aba-b8f2-025e3d87e3af" xlink:to="loc_cah_CommittedReceivablesSalesFacilityProgramMember_08df85f5-3ec9-454d-b48d-ec4a353b4008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_48f5c042-5508-4b88-994d-a3bb762d4f03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9b0f6531-61e0-48a4-ad3b-c2cc73a003cd" xlink:to="loc_us-gaap_DebtInstrumentLineItems_48f5c042-5508-4b88-994d-a3bb762d4f03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalLongTermandShortTermObligations_c37d23a3-b99e-43cb-b2ef-f3ebd7711e4b" xlink:href="cah-20230331.xsd#cah_TotalLongTermandShortTermObligations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_48f5c042-5508-4b88-994d-a3bb762d4f03" xlink:to="loc_cah_TotalLongTermandShortTermObligations_c37d23a3-b99e-43cb-b2ef-f3ebd7711e4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_7a30369c-3380-45f7-8559-501655ec169a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_48f5c042-5508-4b88-994d-a3bb762d4f03" xlink:to="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_7a30369c-3380-45f7-8559-501655ec169a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_32c93613-3241-4ea0-8d13-808f5439f228" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_48f5c042-5508-4b88-994d-a3bb762d4f03" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_32c93613-3241-4ea0-8d13-808f5439f228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NotesPayableRepurchased_30da37cf-3ae9-465f-ac26-77253e140b7b" xlink:href="cah-20230331.xsd#cah_NotesPayableRepurchased"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_48f5c042-5508-4b88-994d-a3bb762d4f03" xlink:to="loc_cah_NotesPayableRepurchased_30da37cf-3ae9-465f-ac26-77253e140b7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_c81d5400-7b02-441d-b450-66428cdf15f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_48f5c042-5508-4b88-994d-a3bb762d4f03" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_c81d5400-7b02-441d-b450-66428cdf15f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_986894b5-5802-41fc-8770-65502c557859" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_48f5c042-5508-4b88-994d-a3bb762d4f03" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_986894b5-5802-41fc-8770-65502c557859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherShortTermBorrowings_04d8a791-47fc-4264-8b80-03ac1a51fa3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherShortTermBorrowings"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_48f5c042-5508-4b88-994d-a3bb762d4f03" xlink:to="loc_us-gaap_OtherShortTermBorrowings_04d8a791-47fc-4264-8b80-03ac1a51fa3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails" xlink:type="simple" xlink:href="cah-20230331.xsd#LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_b642e853-fec6-4158-9ffe-5c8d115a3d72" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_0a3b756e-3456-4982-9990-0eaf87e675a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_b642e853-fec6-4158-9ffe-5c8d115a3d72" xlink:to="loc_us-gaap_DebtInstrumentTable_0a3b756e-3456-4982-9990-0eaf87e675a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_64a58b47-ec7f-46ec-b75c-93f3afaeffcd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_0a3b756e-3456-4982-9990-0eaf87e675a0" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_64a58b47-ec7f-46ec-b75c-93f3afaeffcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_a157cce5-9543-4585-b230-ffbccb97d263" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_64a58b47-ec7f-46ec-b75c-93f3afaeffcd" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_a157cce5-9543-4585-b230-ffbccb97d263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_efbbee8c-9d7e-40ff-a18b-430fea46c303" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_0a3b756e-3456-4982-9990-0eaf87e675a0" xlink:to="loc_us-gaap_DebtInstrumentAxis_efbbee8c-9d7e-40ff-a18b-430fea46c303" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b2e0c799-18b3-401a-a15c-a164bfbe78ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_efbbee8c-9d7e-40ff-a18b-430fea46c303" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b2e0c799-18b3-401a-a15c-a164bfbe78ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A2.616Notesdue2022Member_98d7eb97-cf86-4120-9164-1185a94f3d32" xlink:href="cah-20230331.xsd#cah_A2.616Notesdue2022Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b2e0c799-18b3-401a-a15c-a164bfbe78ac" xlink:to="loc_cah_A2.616Notesdue2022Member_98d7eb97-cf86-4120-9164-1185a94f3d32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_844ff826-2260-4f78-b5ea-2bc43b37f5f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_0a3b756e-3456-4982-9990-0eaf87e675a0" xlink:to="loc_us-gaap_CreditFacilityAxis_844ff826-2260-4f78-b5ea-2bc43b37f5f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_de2421cc-8d6d-41b3-9411-2d40dee83203" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_844ff826-2260-4f78-b5ea-2bc43b37f5f2" xlink:to="loc_us-gaap_CreditFacilityDomain_de2421cc-8d6d-41b3-9411-2d40dee83203" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CommittedReceivablesSalesFacilityProgramMember_6c75ae6c-6560-4be2-9b39-7116891506a1" xlink:href="cah-20230331.xsd#cah_CommittedReceivablesSalesFacilityProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_de2421cc-8d6d-41b3-9411-2d40dee83203" xlink:to="loc_cah_CommittedReceivablesSalesFacilityProgramMember_6c75ae6c-6560-4be2-9b39-7116891506a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_033cbc8d-7048-4218-af87-7e5a923356f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_0a3b756e-3456-4982-9990-0eaf87e675a0" xlink:to="loc_us-gaap_DebtInstrumentLineItems_033cbc8d-7048-4218-af87-7e5a923356f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalLongTermandShortTermObligations_f6aefb39-b449-4912-9210-62d44a9e8e17" xlink:href="cah-20230331.xsd#cah_TotalLongTermandShortTermObligations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_033cbc8d-7048-4218-af87-7e5a923356f0" xlink:to="loc_cah_TotalLongTermandShortTermObligations_f6aefb39-b449-4912-9210-62d44a9e8e17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_4cf80141-3ad6-42a3-8216-247e65488d3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_033cbc8d-7048-4218-af87-7e5a923356f0" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_4cf80141-3ad6-42a3-8216-247e65488d3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_fb4c970e-55d1-4bfe-aa57-e7642b03324f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_033cbc8d-7048-4218-af87-7e5a923356f0" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_fb4c970e-55d1-4bfe-aa57-e7642b03324f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod_b8987862-74f7-41fb-b7bf-968a74456612" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_033cbc8d-7048-4218-af87-7e5a923356f0" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod_b8987862-74f7-41fb-b7bf-968a74456612" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAverageOutstandingAmount_3f04e94d-5869-45a7-b8cb-ea99b1b2baeb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityAverageOutstandingAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_033cbc8d-7048-4218-af87-7e5a923356f0" xlink:to="loc_us-gaap_LineOfCreditFacilityAverageOutstandingAmount_3f04e94d-5869-45a7-b8cb-ea99b1b2baeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" xlink:type="simple" xlink:href="cah-20230331.xsd#CommitmentsContingentLiabilitiesandLitigationDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_44d36b57-761c-4202-b7c9-3bc953e364a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_0a560665-de10-476f-8897-04f38de8dfee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_44d36b57-761c-4202-b7c9-3bc953e364a6" xlink:to="loc_us-gaap_LossContingenciesTable_0a560665-de10-476f-8897-04f38de8dfee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_6346ab1f-8331-4371-b5f2-0bf0dac74fe9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_0a560665-de10-476f-8897-04f38de8dfee" xlink:to="loc_srt_MajorCustomersAxis_6346ab1f-8331-4371-b5f2-0bf0dac74fe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_97ab586e-0211-4fe9-934d-947bccceb8b6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_6346ab1f-8331-4371-b5f2-0bf0dac74fe9" xlink:to="loc_srt_NameOfMajorCustomerDomain_97ab586e-0211-4fe9-934d-947bccceb8b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CVSHealthMember_4fa5249b-7141-4d23-8b30-6536b39916eb" xlink:href="cah-20230331.xsd#cah_CVSHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_97ab586e-0211-4fe9-934d-947bccceb8b6" xlink:to="loc_cah_CVSHealthMember_4fa5249b-7141-4d23-8b30-6536b39916eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_0f6cae3c-6a38-44e3-95be-7930555157bb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_0a560665-de10-476f-8897-04f38de8dfee" xlink:to="loc_srt_LitigationCaseAxis_0f6cae3c-6a38-44e3-95be-7930555157bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_329d9136-c25b-43bf-ad93-6b48c5844aae" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_0f6cae3c-6a38-44e3-95be-7930555157bb" xlink:to="loc_srt_LitigationCaseTypeDomain_329d9136-c25b-43bf-ad93-6b48c5844aae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NewYorkOpioidStewardshipActMember_70b1a398-fb8c-4c72-922d-6ce2ebb8aa36" xlink:href="cah-20230331.xsd#cah_NewYorkOpioidStewardshipActMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_329d9136-c25b-43bf-ad93-6b48c5844aae" xlink:to="loc_cah_NewYorkOpioidStewardshipActMember_70b1a398-fb8c-4c72-922d-6ce2ebb8aa36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLawsuitsMember_8082bee4-af78-41af-815f-d9dbdee73ac1" xlink:href="cah-20230331.xsd#cah_OpioidLawsuitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_329d9136-c25b-43bf-ad93-6b48c5844aae" xlink:to="loc_cah_OpioidLawsuitsMember_8082bee4-af78-41af-815f-d9dbdee73ac1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProductLiabilityLawsuitsMember_85c898b3-f951-4251-965e-753560c7efcb" xlink:href="cah-20230331.xsd#cah_ProductLiabilityLawsuitsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_329d9136-c25b-43bf-ad93-6b48c5844aae" xlink:to="loc_cah_ProductLiabilityLawsuitsMember_85c898b3-f951-4251-965e-753560c7efcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ShareholderDerivativeLitigationMember_af3581d0-c831-444d-bc1b-6fc08ae1c2b5" xlink:href="cah-20230331.xsd#cah_ShareholderDerivativeLitigationMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_329d9136-c25b-43bf-ad93-6b48c5844aae" xlink:to="loc_cah_ShareholderDerivativeLitigationMember_af3581d0-c831-444d-bc1b-6fc08ae1c2b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ShareholderSecuritiesLitigationMember_9ed6c8e0-a1f8-478b-b481-23cca563a42b" xlink:href="cah-20230331.xsd#cah_ShareholderSecuritiesLitigationMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_329d9136-c25b-43bf-ad93-6b48c5844aae" xlink:to="loc_cah_ShareholderSecuritiesLitigationMember_9ed6c8e0-a1f8-478b-b481-23cca563a42b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationAxis_37328a44-d026-4b2f-a5a7-f1a5622b17d9" xlink:href="cah-20230331.xsd#cah_OpioidLitigationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_0a560665-de10-476f-8897-04f38de8dfee" xlink:to="loc_cah_OpioidLitigationAxis_37328a44-d026-4b2f-a5a7-f1a5622b17d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationDomain_6ba4ea65-8856-4db2-8243-0ab6790b92e8" xlink:href="cah-20230331.xsd#cah_OpioidLitigationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_OpioidLitigationAxis_37328a44-d026-4b2f-a5a7-f1a5622b17d9" xlink:to="loc_cah_OpioidLitigationDomain_6ba4ea65-8856-4db2-8243-0ab6790b92e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalOpioidLitigationMember_db8a53c4-1476-4c2b-907d-72c80a7a3b74" xlink:href="cah-20230331.xsd#cah_TotalOpioidLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_OpioidLitigationDomain_6ba4ea65-8856-4db2-8243-0ab6790b92e8" xlink:to="loc_cah_TotalOpioidLitigationMember_db8a53c4-1476-4c2b-907d-72c80a7a3b74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LawsuitTypeAxis_1f285b23-0369-49a5-9c4f-490900121e54" xlink:href="cah-20230331.xsd#cah_LawsuitTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_0a560665-de10-476f-8897-04f38de8dfee" xlink:to="loc_cah_LawsuitTypeAxis_1f285b23-0369-49a5-9c4f-490900121e54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LawsuitTypeDomain_29898cf1-205e-4b7d-9077-3d675b2d7cd2" xlink:href="cah-20230331.xsd#cah_LawsuitTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_LawsuitTypeAxis_1f285b23-0369-49a5-9c4f-490900121e54" xlink:to="loc_cah_LawsuitTypeDomain_29898cf1-205e-4b7d-9077-3d675b2d7cd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ClassActionLawsuitsMember_5450f433-ee83-47d6-a696-13288f9414ba" xlink:href="cah-20230331.xsd#cah_ClassActionLawsuitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_LawsuitTypeDomain_29898cf1-205e-4b7d-9077-3d675b2d7cd2" xlink:to="loc_cah_ClassActionLawsuitsMember_5450f433-ee83-47d6-a696-13288f9414ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProductLiabilityLawsuitsMember_c934a177-4c8d-4237-a407-8f106e9cf2d1" xlink:href="cah-20230331.xsd#cah_ProductLiabilityLawsuitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_LawsuitTypeDomain_29898cf1-205e-4b7d-9077-3d675b2d7cd2" xlink:to="loc_cah_ProductLiabilityLawsuitsMember_c934a177-4c8d-4237-a407-8f106e9cf2d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PlaintiffTypeAxis_8ae17632-4365-4c60-9a16-4aad7f83cdaf" xlink:href="cah-20230331.xsd#cah_PlaintiffTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_0a560665-de10-476f-8897-04f38de8dfee" xlink:to="loc_cah_PlaintiffTypeAxis_8ae17632-4365-4c60-9a16-4aad7f83cdaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PlaintiffTypeDomain_5de5e8ab-615c-4dea-a93a-364bfeaf9e05" xlink:href="cah-20230331.xsd#cah_PlaintiffTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_PlaintiffTypeAxis_8ae17632-4365-4c60-9a16-4aad7f83cdaf" xlink:to="loc_cah_PlaintiffTypeDomain_5de5e8ab-615c-4dea-a93a-364bfeaf9e05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PrivatePartiesMember_d6e52a3a-51cc-429d-b53e-e28c4b9584f9" xlink:href="cah-20230331.xsd#cah_PrivatePartiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_PlaintiffTypeDomain_5de5e8ab-615c-4dea-a93a-364bfeaf9e05" xlink:to="loc_cah_PrivatePartiesMember_d6e52a3a-51cc-429d-b53e-e28c4b9584f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_665f3b56-3105-4788-af94-a694560f553b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_0a560665-de10-476f-8897-04f38de8dfee" xlink:to="loc_srt_StatementGeographicalAxis_665f3b56-3105-4788-af94-a694560f553b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_6ede8e74-296b-4b07-930e-86277c848883" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_665f3b56-3105-4788-af94-a694560f553b" xlink:to="loc_srt_SegmentGeographicalDomain_6ede8e74-296b-4b07-930e-86277c848883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_GA_a3873865-100a-47c8-8ae4-0b2b5c3d1e45" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_GA"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_6ede8e74-296b-4b07-930e-86277c848883" xlink:to="loc_stpr_GA_a3873865-100a-47c8-8ae4-0b2b5c3d1e45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WV_781621f6-91ea-426c-adbd-586c0cbb3d44" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_WV"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_6ede8e74-296b-4b07-930e-86277c848883" xlink:to="loc_stpr_WV_781621f6-91ea-426c-adbd-586c0cbb3d44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WA_36fa3d6d-ea2d-4b27-8292-f21be9dba228" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_WA"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_6ede8e74-296b-4b07-930e-86277c848883" xlink:to="loc_stpr_WA_36fa3d6d-ea2d-4b27-8292-f21be9dba228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_AlamedaCountyMember_ed32da73-4b9e-428d-8c54-5813f4b26c43" xlink:href="cah-20230331.xsd#cah_AlamedaCountyMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_6ede8e74-296b-4b07-930e-86277c848883" xlink:to="loc_cah_AlamedaCountyMember_ed32da73-4b9e-428d-8c54-5813f4b26c43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_OK_213cd3e8-e44c-4dce-96ad-d1363ba36222" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_OK"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_6ede8e74-296b-4b07-930e-86277c848883" xlink:to="loc_stpr_OK_213cd3e8-e44c-4dce-96ad-d1363ba36222" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_AL_686552ae-875f-40af-af5c-3004abce534d" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_AL"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_6ede8e74-296b-4b07-930e-86277c848883" xlink:to="loc_stpr_AL_686552ae-875f-40af-af5c-3004abce534d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NativeAmericanTribesMember_e1a514d2-ce81-4f4a-8fcd-e79fe906f2b7" xlink:href="cah-20230331.xsd#cah_NativeAmericanTribesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_6ede8e74-296b-4b07-930e-86277c848883" xlink:to="loc_cah_NativeAmericanTribesMember_e1a514d2-ce81-4f4a-8fcd-e79fe906f2b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c85a83d0-7d1f-4016-bda5-62210ebb960e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_0a560665-de10-476f-8897-04f38de8dfee" xlink:to="loc_srt_RangeAxis_c85a83d0-7d1f-4016-bda5-62210ebb960e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5fa49202-9b62-42fa-bebd-c953ced328db" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_c85a83d0-7d1f-4016-bda5-62210ebb960e" xlink:to="loc_srt_RangeMember_5fa49202-9b62-42fa-bebd-c953ced328db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c21ce6d6-9893-4b44-8224-5e92123d4a3c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5fa49202-9b62-42fa-bebd-c953ced328db" xlink:to="loc_srt_MinimumMember_c21ce6d6-9893-4b44-8224-5e92123d4a3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_514ecc41-edc0-44cf-9a05-8394647d271e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5fa49202-9b62-42fa-bebd-c953ced328db" xlink:to="loc_srt_MaximumMember_514ecc41-edc0-44cf-9a05-8394647d271e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_ab2bf2cc-78a2-4833-98de-4f9fa2749f38" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_0a560665-de10-476f-8897-04f38de8dfee" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_ab2bf2cc-78a2-4833-98de-4f9fa2749f38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_f9dd5b5b-9cac-4828-8d61-a5b7a67abe0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_ab2bf2cc-78a2-4833-98de-4f9fa2749f38" xlink:to="loc_us-gaap_LossContingencyNatureDomain_f9dd5b5b-9cac-4828-8d61-a5b7a67abe0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLawsuitsMember_47fe51d7-8abc-45a7-8894-99dbced94f25" xlink:href="cah-20230331.xsd#cah_OpioidLawsuitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_f9dd5b5b-9cac-4828-8d61-a5b7a67abe0a" xlink:to="loc_cah_OpioidLawsuitsMember_47fe51d7-8abc-45a7-8894-99dbced94f25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProductLiabilityLawsuitsMember_42630b24-2494-4f0f-b408-743806e3968a" xlink:href="cah-20230331.xsd#cah_ProductLiabilityLawsuitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_f9dd5b5b-9cac-4828-8d61-a5b7a67abe0a" xlink:to="loc_cah_ProductLiabilityLawsuitsMember_42630b24-2494-4f0f-b408-743806e3968a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_75aa8c3d-127b-4f16-bd18-b670ad30117e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_0a560665-de10-476f-8897-04f38de8dfee" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_75aa8c3d-127b-4f16-bd18-b670ad30117e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_a91c67f3-c981-49c9-b050-e2dc3a29950d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_75aa8c3d-127b-4f16-bd18-b670ad30117e" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_a91c67f3-c981-49c9-b050-e2dc3a29950d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_ecc2673e-36dc-4131-8284-78e85ce396e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_a91c67f3-c981-49c9-b050-e2dc3a29950d" xlink:to="loc_us-gaap_SubsequentEventMember_ecc2673e-36dc-4131-8284-78e85ce396e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_c3d091b6-9a67-4e08-8e43-988ae34e6867" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_0a560665-de10-476f-8897-04f38de8dfee" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_c3d091b6-9a67-4e08-8e43-988ae34e6867" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_4cd4033a-e478-4b06-86f4-b78723272da0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_c3d091b6-9a67-4e08-8e43-988ae34e6867" xlink:to="loc_us-gaap_SegmentDomain_4cd4033a-e478-4b06-86f4-b78723272da0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalMember_47dcf6de-ebcf-4c0a-bb18-bb27bbc4f70f" xlink:href="cah-20230331.xsd#cah_PharmaceuticalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_4cd4033a-e478-4b06-86f4-b78723272da0" xlink:to="loc_cah_PharmaceuticalMember_47dcf6de-ebcf-4c0a-bb18-bb27bbc4f70f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_AgreementsAxis_5ba67e3f-33e7-4d03-8202-5c80156bbe23" xlink:href="cah-20230331.xsd#cah_AgreementsAxis"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_0a560665-de10-476f-8897-04f38de8dfee" xlink:to="loc_cah_AgreementsAxis_5ba67e3f-33e7-4d03-8202-5c80156bbe23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_AgreementsDomain_fe4d9871-53de-4ac7-8715-9fc67d3de5b7" xlink:href="cah-20230331.xsd#cah_AgreementsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_AgreementsAxis_5ba67e3f-33e7-4d03-8202-5c80156bbe23" xlink:to="loc_cah_AgreementsDomain_fe4d9871-53de-4ac7-8715-9fc67d3de5b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_IVCApril2023AgreementMember_424264c4-513c-47b8-9938-693c95e7f9ed" xlink:href="cah-20230331.xsd#cah_IVCApril2023AgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_AgreementsDomain_fe4d9871-53de-4ac7-8715-9fc67d3de5b7" xlink:to="loc_cah_IVCApril2023AgreementMember_424264c4-513c-47b8-9938-693c95e7f9ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OtherAgreementsMember_8b38fcd1-a49c-4e26-b6de-05d609394983" xlink:href="cah-20230331.xsd#cah_OtherAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_AgreementsDomain_fe4d9871-53de-4ac7-8715-9fc67d3de5b7" xlink:to="loc_cah_OtherAgreementsMember_8b38fcd1-a49c-4e26-b6de-05d609394983" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_57001c87-7177-4af5-b7cd-2a45cee03b99" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_0a560665-de10-476f-8897-04f38de8dfee" xlink:to="loc_us-gaap_LossContingenciesLineItems_57001c87-7177-4af5-b7cd-2a45cee03b99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermPurchaseCommitmentPeriod_ff57b10e-1f0b-4b6d-b8fb-dc230151935d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermPurchaseCommitmentPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_57001c87-7177-4af5-b7cd-2a45cee03b99" xlink:to="loc_us-gaap_LongtermPurchaseCommitmentPeriod_ff57b10e-1f0b-4b6d-b8fb-dc230151935d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_AggregateAnnualAssessment_d35f209f-53df-434d-913b-e37d52deeb70" xlink:href="cah-20230331.xsd#cah_AggregateAnnualAssessment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_57001c87-7177-4af5-b7cd-2a45cee03b99" xlink:to="loc_cah_AggregateAnnualAssessment_d35f209f-53df-434d-913b-e37d52deeb70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualPayments_bff6cb86-975c-4f76-aaf6-967c7756b1e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAccrualPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_57001c87-7177-4af5-b7cd-2a45cee03b99" xlink:to="loc_us-gaap_LossContingencyAccrualPayments_bff6cb86-975c-4f76-aaf6-967c7756b1e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_e29e51e6-eb10-41df-924b-293a0e47dc32" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_57001c87-7177-4af5-b7cd-2a45cee03b99" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_e29e51e6-eb10-41df-924b-293a0e47dc32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease_b7458ac3-be12-489d-a02d-77e8af012ea6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_57001c87-7177-4af5-b7cd-2a45cee03b99" xlink:to="loc_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease_b7458ac3-be12-489d-a02d-77e8af012ea6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_JudgmentForLostProfits_b403ee56-7861-46fc-a5ed-b9de161851e7" xlink:href="cah-20230331.xsd#cah_JudgmentForLostProfits"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_57001c87-7177-4af5-b7cd-2a45cee03b99" xlink:to="loc_cah_JudgmentForLostProfits_b403ee56-7861-46fc-a5ed-b9de161851e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_72a6e379-dc56-4b37-a657-64640e389fdb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_57001c87-7177-4af5-b7cd-2a45cee03b99" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_72a6e379-dc56-4b37-a657-64640e389fdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SettlingStates_fb3f0ae2-839d-4d6b-804f-9ede73f863bc" xlink:href="cah-20230331.xsd#cah_SettlingStates"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_57001c87-7177-4af5-b7cd-2a45cee03b99" xlink:to="loc_cah_SettlingStates_fb3f0ae2-839d-4d6b-804f-9ede73f863bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SettlingUSTerritories_60d7b355-f608-4065-94b2-570b35d0124d" xlink:href="cah-20230331.xsd#cah_SettlingUSTerritories"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_57001c87-7177-4af5-b7cd-2a45cee03b99" xlink:to="loc_cah_SettlingUSTerritories_60d7b355-f608-4065-94b2-570b35d0124d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_dca39be5-c023-4f96-80ae-6678c8bc9150" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_57001c87-7177-4af5-b7cd-2a45cee03b99" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_dca39be5-c023-4f96-80ae-6678c8bc9150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserve_0d46bf59-a1cf-4a4d-b558-990599c60ba4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationReserve"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_57001c87-7177-4af5-b7cd-2a45cee03b99" xlink:to="loc_us-gaap_LitigationReserve_0d46bf59-a1cf-4a4d-b558-990599c60ba4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent_0cd925c6-66ef-4c5f-9a07-8a041d82f5fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_57001c87-7177-4af5-b7cd-2a45cee03b99" xlink:to="loc_us-gaap_LitigationReserveCurrent_0cd925c6-66ef-4c5f-9a07-8a041d82f5fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LossContingencyLawsuitsNumber_79763e6b-6157-41db-91bf-9af556474aa0" xlink:href="cah-20230331.xsd#cah_LossContingencyLawsuitsNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_57001c87-7177-4af5-b7cd-2a45cee03b99" xlink:to="loc_cah_LossContingencyLawsuitsNumber_79763e6b-6157-41db-91bf-9af556474aa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs_dfad94b5-63ad-4e83-90ce-34ac1af25859" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_57001c87-7177-4af5-b7cd-2a45cee03b99" xlink:to="loc_us-gaap_LossContingencyNumberOfPlaintiffs_dfad94b5-63ad-4e83-90ce-34ac1af25859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceRecoveries_38c62994-a9dd-4921-b566-47ad29d449ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InsuranceRecoveries"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_57001c87-7177-4af5-b7cd-2a45cee03b99" xlink:to="loc_us-gaap_InsuranceRecoveries_38c62994-a9dd-4921-b566-47ad29d449ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_23c836a6-f5e5-4c7a-b472-15f91b8655b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_57001c87-7177-4af5-b7cd-2a45cee03b99" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_23c836a6-f5e5-4c7a-b472-15f91b8655b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsSettledNumber_4a1d88a8-a3a6-4782-9813-fa8b4abe8a02" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyClaimsSettledNumber"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_57001c87-7177-4af5-b7cd-2a45cee03b99" xlink:to="loc_us-gaap_LossContingencyClaimsSettledNumber_4a1d88a8-a3a6-4782-9813-fa8b4abe8a02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductLiabilityAccrualPeriodExpense_b4996679-64ee-4f2f-8c82-9597281d54eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductLiabilityAccrualPeriodExpense"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_57001c87-7177-4af5-b7cd-2a45cee03b99" xlink:to="loc_us-gaap_ProductLiabilityAccrualPeriodExpense_b4996679-64ee-4f2f-8c82-9597281d54eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_d63705cd-b6e4-4b2f-9794-0922d9702a6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_57001c87-7177-4af5-b7cd-2a45cee03b99" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_d63705cd-b6e4-4b2f-9794-0922d9702a6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_IncomefromSettlementsofClassActionLawsuits_cc70ded9-3531-4109-b1e0-0afac2e14644" xlink:href="cah-20230331.xsd#cah_IncomefromSettlementsofClassActionLawsuits"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_57001c87-7177-4af5-b7cd-2a45cee03b99" xlink:to="loc_cah_IncomefromSettlementsofClassActionLawsuits_cc70ded9-3531-4109-b1e0-0afac2e14644" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_GrossInsuranceSettlementBeforeAttorneyFees_15c6977a-f302-4fcc-b9c1-8edd54a407aa" xlink:href="cah-20230331.xsd#cah_GrossInsuranceSettlementBeforeAttorneyFees"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_57001c87-7177-4af5-b7cd-2a45cee03b99" xlink:to="loc_cah_GrossInsuranceSettlementBeforeAttorneyFees_15c6977a-f302-4fcc-b9c1-8edd54a407aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalFees_5bd60eaa-7685-45d6-8ee6-60f1e8863d20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalFees"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_57001c87-7177-4af5-b7cd-2a45cee03b99" xlink:to="loc_us-gaap_LegalFees_5bd60eaa-7685-45d6-8ee6-60f1e8863d20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities_c5550fc2-d42e-417a-a914-b6509f8f076b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromInsuranceSettlementOperatingActivities"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_57001c87-7177-4af5-b7cd-2a45cee03b99" xlink:to="loc_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities_c5550fc2-d42e-417a-a914-b6509f8f076b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="cah-20230331.xsd#IncomeTaxesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_333a99be-252c-4354-9270-4cc48d8d77cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_b14d42bf-21c6-4886-a561-21dc88ad8e98" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_333a99be-252c-4354-9270-4cc48d8d77cc" xlink:to="loc_us-gaap_TaxCreditCarryforwardTable_b14d42bf-21c6-4886-a561-21dc88ad8e98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationAxis_77790365-6646-45e4-836c-f7bdee114b78" xlink:href="cah-20230331.xsd#cah_OpioidLitigationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_b14d42bf-21c6-4886-a561-21dc88ad8e98" xlink:to="loc_cah_OpioidLitigationAxis_77790365-6646-45e4-836c-f7bdee114b78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationDomain_da54776c-f2b0-46e8-8f02-bafb31b4fdad" xlink:href="cah-20230331.xsd#cah_OpioidLitigationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_OpioidLitigationAxis_77790365-6646-45e4-836c-f7bdee114b78" xlink:to="loc_cah_OpioidLitigationDomain_da54776c-f2b0-46e8-8f02-bafb31b4fdad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalOpioidLitigationMember_d124c39a-20b9-4757-b764-0e233dad1fcd" xlink:href="cah-20230331.xsd#cah_TotalOpioidLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_OpioidLitigationDomain_da54776c-f2b0-46e8-8f02-bafb31b4fdad" xlink:to="loc_cah_TotalOpioidLitigationMember_d124c39a-20b9-4757-b764-0e233dad1fcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMatterAxis_9bb1d51e-e00d-4489-bfbd-54291f32dbb4" xlink:href="cah-20230331.xsd#cah_TaxMatterAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_b14d42bf-21c6-4886-a561-21dc88ad8e98" xlink:to="loc_cah_TaxMatterAxis_9bb1d51e-e00d-4489-bfbd-54291f32dbb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMatterDomain_cd188419-9a31-4e4f-a983-34decfc12b25" xlink:href="cah-20230331.xsd#cah_TaxMatterDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_TaxMatterAxis_9bb1d51e-e00d-4489-bfbd-54291f32dbb4" xlink:to="loc_cah_TaxMatterDomain_cd188419-9a31-4e4f-a983-34decfc12b25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CareFusionMember_77368f54-4571-44f3-bdf8-b4bc28381f57" xlink:href="cah-20230331.xsd#cah_CareFusionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_TaxMatterDomain_cd188419-9a31-4e4f-a983-34decfc12b25" xlink:to="loc_cah_CareFusionMember_77368f54-4571-44f3-bdf8-b4bc28381f57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_dd53b2ec-ebe2-4e62-97f2-9f42050533d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_b14d42bf-21c6-4886-a561-21dc88ad8e98" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_dd53b2ec-ebe2-4e62-97f2-9f42050533d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1a03a749-7a53-4856-a264-878a6cf1c065" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_dd53b2ec-ebe2-4e62-97f2-9f42050533d0" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1a03a749-7a53-4856-a264-878a6cf1c065" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMattersAgreementAxis_ea9241b4-d4f2-4144-ac7a-7ee1d45db578" xlink:href="cah-20230331.xsd#cah_TaxMattersAgreementAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_b14d42bf-21c6-4886-a561-21dc88ad8e98" xlink:to="loc_cah_TaxMattersAgreementAxis_ea9241b4-d4f2-4144-ac7a-7ee1d45db578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMattersAgreementDomain_0329aea4-288a-4a6c-953c-9ac9cb1454db" xlink:href="cah-20230331.xsd#cah_TaxMattersAgreementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_TaxMattersAgreementAxis_ea9241b4-d4f2-4144-ac7a-7ee1d45db578" xlink:to="loc_cah_TaxMattersAgreementDomain_0329aea4-288a-4a6c-953c-9ac9cb1454db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CareFusionMember_7c22d0ba-ccd1-49fd-a7eb-18e0322d7452" xlink:href="cah-20230331.xsd#cah_CareFusionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_TaxMattersAgreementDomain_0329aea4-288a-4a6c-953c-9ac9cb1454db" xlink:to="loc_cah_CareFusionMember_7c22d0ba-ccd1-49fd-a7eb-18e0322d7452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a7c7992b-8363-46d8-afc9-252870dc8594" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_b14d42bf-21c6-4886-a561-21dc88ad8e98" xlink:to="loc_srt_RangeAxis_a7c7992b-8363-46d8-afc9-252870dc8594" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_766c5327-715f-4b1f-b460-f73bcb4b3afd" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_a7c7992b-8363-46d8-afc9-252870dc8594" xlink:to="loc_srt_RangeMember_766c5327-715f-4b1f-b460-f73bcb4b3afd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4a71940f-769c-4b15-95ff-4b0625692fc2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_766c5327-715f-4b1f-b460-f73bcb4b3afd" xlink:to="loc_srt_MinimumMember_4a71940f-769c-4b15-95ff-4b0625692fc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e0428723-99ec-4616-98dd-9007235061c6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_766c5327-715f-4b1f-b460-f73bcb4b3afd" xlink:to="loc_srt_MaximumMember_e0428723-99ec-4616-98dd-9007235061c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NetOperatingLossCarrybackAxis_3bc57af6-bdd8-46fd-8942-4a2552262d03" xlink:href="cah-20230331.xsd#cah_NetOperatingLossCarrybackAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_b14d42bf-21c6-4886-a561-21dc88ad8e98" xlink:to="loc_cah_NetOperatingLossCarrybackAxis_3bc57af6-bdd8-46fd-8942-4a2552262d03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CARESActDomain_23821944-5bc3-4d28-a384-7070ffd27bf5" xlink:href="cah-20230331.xsd#cah_CARESActDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_NetOperatingLossCarrybackAxis_3bc57af6-bdd8-46fd-8942-4a2552262d03" xlink:to="loc_cah_CARESActDomain_23821944-5bc3-4d28-a384-7070ffd27bf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_55e83f63-3b2e-478d-a12e-14ae2afc93fb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_b14d42bf-21c6-4886-a561-21dc88ad8e98" xlink:to="loc_srt_StatementScenarioAxis_55e83f63-3b2e-478d-a12e-14ae2afc93fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_0f51d318-2a0a-40a0-961b-40d342f04313" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_55e83f63-3b2e-478d-a12e-14ae2afc93fb" xlink:to="loc_srt_ScenarioUnspecifiedDomain_0f51d318-2a0a-40a0-961b-40d342f04313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_4d233b75-1460-4dc1-b15d-bc95413ecbe6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_0f51d318-2a0a-40a0-961b-40d342f04313" xlink:to="loc_srt_ScenarioForecastMember_4d233b75-1460-4dc1-b15d-bc95413ecbe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_GoodwillImpairmentAxis_0966ed8b-7eaf-433c-a2d6-1acaeca09485" xlink:href="cah-20230331.xsd#cah_GoodwillImpairmentAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_b14d42bf-21c6-4886-a561-21dc88ad8e98" xlink:to="loc_cah_GoodwillImpairmentAxis_0966ed8b-7eaf-433c-a2d6-1acaeca09485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_GoodwillImpairmentDomain_7a6c388f-0701-4e15-9e42-6a461fbf5cf4" xlink:href="cah-20230331.xsd#cah_GoodwillImpairmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_GoodwillImpairmentAxis_0966ed8b-7eaf-433c-a2d6-1acaeca09485" xlink:to="loc_cah_GoodwillImpairmentDomain_7a6c388f-0701-4e15-9e42-6a461fbf5cf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalUnitMember_02da21ad-24a0-4df1-8aa6-a73a383c2dc0" xlink:href="cah-20230331.xsd#cah_MedicalUnitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_GoodwillImpairmentDomain_7a6c388f-0701-4e15-9e42-6a461fbf5cf4" xlink:to="loc_cah_MedicalUnitMember_02da21ad-24a0-4df1-8aa6-a73a383c2dc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalUnitGoodwillImpairmentMember_f19c8618-e23e-48b7-9a26-d40e89b268cf" xlink:href="cah-20230331.xsd#cah_MedicalUnitGoodwillImpairmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_GoodwillImpairmentDomain_7a6c388f-0701-4e15-9e42-6a461fbf5cf4" xlink:to="loc_cah_MedicalUnitGoodwillImpairmentMember_f19c8618-e23e-48b7-9a26-d40e89b268cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureAxis_a8dcc43f-ea3b-4d0e-9a0c-e71b891640b3" xlink:href="cah-20230331.xsd#cah_CordisDivestitureAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_b14d42bf-21c6-4886-a561-21dc88ad8e98" xlink:to="loc_cah_CordisDivestitureAxis_a8dcc43f-ea3b-4d0e-9a0c-e71b891640b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureDomain_bce3e53f-5952-4c61-b275-e1482577ed2c" xlink:href="cah-20230331.xsd#cah_CordisDivestitureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_CordisDivestitureAxis_a8dcc43f-ea3b-4d0e-9a0c-e71b891640b3" xlink:to="loc_cah_CordisDivestitureDomain_bce3e53f-5952-4c61-b275-e1482577ed2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureMember_74b403e9-1b10-4061-82b1-50600e79c641" xlink:href="cah-20230331.xsd#cah_CordisDivestitureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_CordisDivestitureDomain_bce3e53f-5952-4c61-b275-e1482577ed2c" xlink:to="loc_cah_CordisDivestitureMember_74b403e9-1b10-4061-82b1-50600e79c641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_92014054-fc2e-4cf8-894f-f01b517d4483" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_b14d42bf-21c6-4886-a561-21dc88ad8e98" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_92014054-fc2e-4cf8-894f-f01b517d4483" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_2204b258-a2ff-4c3d-9b5b-af3ee08b12fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_92014054-fc2e-4cf8-894f-f01b517d4483" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_2204b258-a2ff-4c3d-9b5b-af3ee08b12fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_f44fa03d-5c13-418b-9017-2016199b34f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_2204b258-a2ff-4c3d-9b5b-af3ee08b12fa" xlink:to="loc_us-gaap_SubsequentEventMember_f44fa03d-5c13-418b-9017-2016199b34f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis_3abbe6fa-dfc3-4db8-a835-d0f56bdad8db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReportingUnitAxis"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_b14d42bf-21c6-4886-a561-21dc88ad8e98" xlink:to="loc_us-gaap_ReportingUnitAxis_3abbe6fa-dfc3-4db8-a835-d0f56bdad8db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_546f472a-e0d1-4a73-b9ab-ca880e18482c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReportingUnitDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitAxis_3abbe6fa-dfc3-4db8-a835-d0f56bdad8db" xlink:to="loc_us-gaap_ReportingUnitDomain_546f472a-e0d1-4a73-b9ab-ca880e18482c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalUnitMember_07c6d55d-dbf6-4a55-949c-99963f0a2cae" xlink:href="cah-20230331.xsd#cah_MedicalUnitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_546f472a-e0d1-4a73-b9ab-ca880e18482c" xlink:to="loc_cah_MedicalUnitMember_07c6d55d-dbf6-4a55-949c-99963f0a2cae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_940baa0e-2857-45a0-b8c4-adf73270640f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_b14d42bf-21c6-4886-a561-21dc88ad8e98" xlink:to="loc_us-gaap_TaxCreditCarryforwardLineItems_940baa0e-2857-45a0-b8c4-adf73270640f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_68c75664-afd9-4484-b430-3993b72cdc8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_940baa0e-2857-45a0-b8c4-adf73270640f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_68c75664-afd9-4484-b430-3993b72cdc8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_f3a5e538-31f4-4e74-8a3c-a6c242c8f7ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_940baa0e-2857-45a0-b8c4-adf73270640f" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_f3a5e538-31f4-4e74-8a3c-a6c242c8f7ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_08255c91-1ea6-4a7b-bfa8-cff9957aab80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_940baa0e-2857-45a0-b8c4-adf73270640f" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_08255c91-1ea6-4a7b-bfa8-cff9957aab80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_160df928-b373-491b-a2e7-c1cac280ce20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_940baa0e-2857-45a0-b8c4-adf73270640f" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_160df928-b373-491b-a2e7-c1cac280ce20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_e79fe5e6-5046-40e1-a489-dd06177ff6c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_940baa0e-2857-45a0-b8c4-adf73270640f" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_e79fe5e6-5046-40e1-a489-dd06177ff6c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_f833e07b-8ff6-46d5-b830-8763c41274bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_940baa0e-2857-45a0-b8c4-adf73270640f" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_f833e07b-8ff6-46d5-b830-8763c41274bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_20bf8dfd-ce78-45a4-a4c5-72be4fde3403" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_940baa0e-2857-45a0-b8c4-adf73270640f" xlink:to="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_20bf8dfd-ce78-45a4-a4c5-72be4fde3403" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_IndemnificationReceivable_2e8118df-0897-4c80-a8d3-907dcf18094b" xlink:href="cah-20230331.xsd#cah_IndemnificationReceivable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_940baa0e-2857-45a0-b8c4-adf73270640f" xlink:to="loc_cah_IndemnificationReceivable_2e8118df-0897-4c80-a8d3-907dcf18094b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" xlink:type="simple" xlink:href="cah-20230331.xsd#FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_5a1ab783-c359-4795-8e04-6f5f91c6f857" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_513c3b9a-e525-4961-8e6c-4aae527dae24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_5a1ab783-c359-4795-8e04-6f5f91c6f857" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_513c3b9a-e525-4961-8e6c-4aae527dae24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_410d241e-396a-4854-88b5-a350eb042c7c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_513c3b9a-e525-4961-8e6c-4aae527dae24" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_410d241e-396a-4854-88b5-a350eb042c7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a160c88f-d100-4e00-9ef5-aca3b5634cc0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_410d241e-396a-4854-88b5-a350eb042c7c" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a160c88f-d100-4e00-9ef5-aca3b5634cc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_1800160b-e27b-4f2c-83e5-46c0b1e42490" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a160c88f-d100-4e00-9ef5-aca3b5634cc0" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_1800160b-e27b-4f2c-83e5-46c0b1e42490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_9349c799-755b-4c68-af62-af1cc8024f17" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a160c88f-d100-4e00-9ef5-aca3b5634cc0" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_9349c799-755b-4c68-af62-af1cc8024f17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_e0c1a5da-b0cf-4872-830c-8941a2537a3d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a160c88f-d100-4e00-9ef5-aca3b5634cc0" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_e0c1a5da-b0cf-4872-830c-8941a2537a3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_86fe1960-1c0c-48aa-913d-5ca0c36656bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_513c3b9a-e525-4961-8e6c-4aae527dae24" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_86fe1960-1c0c-48aa-913d-5ca0c36656bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_2dd92eae-b22a-4887-b1bc-86b7c83d9664" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_86fe1960-1c0c-48aa-913d-5ca0c36656bd" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_2dd92eae-b22a-4887-b1bc-86b7c83d9664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_fdfdd0b4-9a6d-431b-bb0c-03dddfc64b1a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_2dd92eae-b22a-4887-b1bc-86b7c83d9664" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_fdfdd0b4-9a6d-431b-bb0c-03dddfc64b1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cafcd035-e418-4e2c-889a-1381cbf9cc4a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_513c3b9a-e525-4961-8e6c-4aae527dae24" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cafcd035-e418-4e2c-889a-1381cbf9cc4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_fc1fd1fb-af0a-4b8a-8c27-655ff5d9d7d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cafcd035-e418-4e2c-889a-1381cbf9cc4a" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_fc1fd1fb-af0a-4b8a-8c27-655ff5d9d7d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_f3049f28-c443-40f3-83e0-31ec44a787ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_fc1fd1fb-af0a-4b8a-8c27-655ff5d9d7d4" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_f3049f28-c443-40f3-83e0-31ec44a787ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_41c3c34b-6fe3-4bf9-8909-476a53a212ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_fc1fd1fb-af0a-4b8a-8c27-655ff5d9d7d4" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_41c3c34b-6fe3-4bf9-8909-476a53a212ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet_94624656-e821-4129-aca7-12f13a15c138" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_fc1fd1fb-af0a-4b8a-8c27-655ff5d9d7d4" xlink:to="loc_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet_94624656-e821-4129-aca7-12f13a15c138" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_616d6584-b9e1-471e-9222-2fd14910f780" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cafcd035-e418-4e2c-889a-1381cbf9cc4a" xlink:to="loc_us-gaap_LiabilitiesAbstract_616d6584-b9e1-471e-9222-2fd14910f780" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet_ae3688ba-6328-4be0-a3e2-4889a1913ba2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_616d6584-b9e1-471e-9222-2fd14910f780" xlink:to="loc_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet_ae3688ba-6328-4be0-a3e2-4889a1913ba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="simple" xlink:href="cah-20230331.xsd#FinancialInstrumentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_ba3519c2-8608-499d-90e8-39ddbbba0bd2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_b9d2e1be-10c4-47c5-8f43-cf3b810b04f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_ba3519c2-8608-499d-90e8-39ddbbba0bd2" xlink:to="loc_us-gaap_DerivativeTable_b9d2e1be-10c4-47c5-8f43-cf3b810b04f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_82d167c3-058f-4033-8d7b-445ed2078302" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_b9d2e1be-10c4-47c5-8f43-cf3b810b04f8" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_82d167c3-058f-4033-8d7b-445ed2078302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_91373d04-faef-45de-bec4-1d863a2bbb4f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_82d167c3-058f-4033-8d7b-445ed2078302" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_91373d04-faef-45de-bec4-1d863a2bbb4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_69ea0439-b0b5-424c-8b12-448b0bf67e20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_91373d04-faef-45de-bec4-1d863a2bbb4f" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_69ea0439-b0b5-424c-8b12-448b0bf67e20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8d7637e7-7a6a-4732-91f1-46b3785bd76f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_b9d2e1be-10c4-47c5-8f43-cf3b810b04f8" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8d7637e7-7a6a-4732-91f1-46b3785bd76f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0ffca032-9362-4939-a04c-ab2376e7afb5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8d7637e7-7a6a-4732-91f1-46b3785bd76f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0ffca032-9362-4939-a04c-ab2376e7afb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_ca024a99-ff53-4339-b8ef-e6b4a08f583c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0ffca032-9362-4939-a04c-ab2376e7afb5" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_ca024a99-ff53-4339-b8ef-e6b4a08f583c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_0deefe9d-d23f-4973-9a14-f4927fb2c8e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_b9d2e1be-10c4-47c5-8f43-cf3b810b04f8" xlink:to="loc_us-gaap_HedgingDesignationAxis_0deefe9d-d23f-4973-9a14-f4927fb2c8e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_ef117b3e-6966-425e-bccc-18f38a249e83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_0deefe9d-d23f-4973-9a14-f4927fb2c8e3" xlink:to="loc_us-gaap_HedgingDesignationDomain_ef117b3e-6966-425e-bccc-18f38a249e83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_38dc4f01-9fbe-4db4-b916-0ce7a2b1e6cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_ef117b3e-6966-425e-bccc-18f38a249e83" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_38dc4f01-9fbe-4db4-b916-0ce7a2b1e6cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_e74d9dd3-fe41-42cd-b2c2-c114f30fb636" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_ef117b3e-6966-425e-bccc-18f38a249e83" xlink:to="loc_us-gaap_NondesignatedMember_e74d9dd3-fe41-42cd-b2c2-c114f30fb636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_85c76ea0-690e-4c5d-81c2-f74c1e68dbb0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_b9d2e1be-10c4-47c5-8f43-cf3b810b04f8" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_85c76ea0-690e-4c5d-81c2-f74c1e68dbb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_b5f757ed-7d21-46ec-8237-5fe558f5a6e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_85c76ea0-690e-4c5d-81c2-f74c1e68dbb0" xlink:to="loc_us-gaap_HedgingRelationshipDomain_b5f757ed-7d21-46ec-8237-5fe558f5a6e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_2407c9be-9fc5-4905-bd3e-a6226e06b814" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_b5f757ed-7d21-46ec-8237-5fe558f5a6e5" xlink:to="loc_us-gaap_FairValueHedgingMember_2407c9be-9fc5-4905-bd3e-a6226e06b814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_4c8dcafa-39d9-4aa9-ae67-20232b67e46b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_b5f757ed-7d21-46ec-8237-5fe558f5a6e5" xlink:to="loc_us-gaap_CashFlowHedgingMember_4c8dcafa-39d9-4aa9-ae67-20232b67e46b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_f5e8bff6-74e0-4940-9ca0-706328ca73f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_b5f757ed-7d21-46ec-8237-5fe558f5a6e5" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_f5e8bff6-74e0-4940-9ca0-706328ca73f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_71d7a26d-4f55-42ad-a2a4-3cc95186c946" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_b9d2e1be-10c4-47c5-8f43-cf3b810b04f8" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_71d7a26d-4f55-42ad-a2a4-3cc95186c946" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_30af096d-3d88-421d-a386-ddec48a6ca9f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_71d7a26d-4f55-42ad-a2a4-3cc95186c946" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_30af096d-3d88-421d-a386-ddec48a6ca9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_e3b8b512-0d9c-46da-93ac-9f6036992f06" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_30af096d-3d88-421d-a386-ddec48a6ca9f" xlink:to="loc_us-gaap_CashFlowHedgingMember_e3b8b512-0d9c-46da-93ac-9f6036992f06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_68cbb5f6-4cf7-40b6-a693-34824eafb868" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_30af096d-3d88-421d-a386-ddec48a6ca9f" xlink:to="loc_us-gaap_ForeignExchangeContractMember_68cbb5f6-4cf7-40b6-a693-34824eafb868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_3cc270b4-367e-4de3-b8ff-836a3f36d2d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_30af096d-3d88-421d-a386-ddec48a6ca9f" xlink:to="loc_us-gaap_InterestRateSwapMember_3cc270b4-367e-4de3-b8ff-836a3f36d2d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_dcafaeba-7bc0-42da-9ffd-14efb0d4e50b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrencySwapMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_30af096d-3d88-421d-a386-ddec48a6ca9f" xlink:to="loc_us-gaap_CurrencySwapMember_dcafaeba-7bc0-42da-9ffd-14efb0d4e50b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MaturityDateAxis_3b51165a-3ad3-4069-9c66-9cc6f2d03267" xlink:href="cah-20230331.xsd#cah_MaturityDateAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_b9d2e1be-10c4-47c5-8f43-cf3b810b04f8" xlink:to="loc_cah_MaturityDateAxis_3b51165a-3ad3-4069-9c66-9cc6f2d03267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MaturityDateDomain_10d419ea-bbd4-48d3-b264-4192146f5ac2" xlink:href="cah-20230331.xsd#cah_MaturityDateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_MaturityDateAxis_3b51165a-3ad3-4069-9c66-9cc6f2d03267" xlink:to="loc_cah_MaturityDateDomain_10d419ea-bbd4-48d3-b264-4192146f5ac2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_September2025Member_d36cbaf8-aec9-4e12-9bbf-ea5b9e536266" xlink:href="cah-20230331.xsd#cah_September2025Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_MaturityDateDomain_10d419ea-bbd4-48d3-b264-4192146f5ac2" xlink:to="loc_cah_September2025Member_d36cbaf8-aec9-4e12-9bbf-ea5b9e536266" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_June2027Member_98be41dd-95f1-47b2-8596-52b02c2024b1" xlink:href="cah-20230331.xsd#cah_June2027Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_MaturityDateDomain_10d419ea-bbd4-48d3-b264-4192146f5ac2" xlink:to="loc_cah_June2027Member_98be41dd-95f1-47b2-8596-52b02c2024b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_March2025Member_dbd90a36-c1b7-430a-9f49-b20d44d97017" xlink:href="cah-20230331.xsd#cah_March2025Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_MaturityDateDomain_10d419ea-bbd4-48d3-b264-4192146f5ac2" xlink:to="loc_cah_March2025Member_dbd90a36-c1b7-430a-9f49-b20d44d97017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_March2026Member_baa3e79d-010e-477f-a958-f70f7d0ea4fe" xlink:href="cah-20230331.xsd#cah_March2026Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_MaturityDateDomain_10d419ea-bbd4-48d3-b264-4192146f5ac2" xlink:to="loc_cah_March2026Member_baa3e79d-010e-477f-a958-f70f7d0ea4fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_20c3940e-04c3-4bba-b837-af8a7af2e542" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_b9d2e1be-10c4-47c5-8f43-cf3b810b04f8" xlink:to="loc_srt_StatementScenarioAxis_20c3940e-04c3-4bba-b837-af8a7af2e542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_3b48a2a7-60b4-4eb0-b5cc-837b201ad998" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_20c3940e-04c3-4bba-b837-af8a7af2e542" xlink:to="loc_srt_ScenarioUnspecifiedDomain_3b48a2a7-60b4-4eb0-b5cc-837b201ad998" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_bb8d9f50-8e63-4339-b4da-18ff47d3826a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_3b48a2a7-60b4-4eb0-b5cc-837b201ad998" xlink:to="loc_srt_ScenarioForecastMember_bb8d9f50-8e63-4339-b4da-18ff47d3826a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_8bade925-f639-4ca4-9e35-332cc6afdab6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_b9d2e1be-10c4-47c5-8f43-cf3b810b04f8" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_8bade925-f639-4ca4-9e35-332cc6afdab6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_ee3411e0-42ce-4dd8-8a82-69da9a98a72d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_8bade925-f639-4ca4-9e35-332cc6afdab6" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_ee3411e0-42ce-4dd8-8a82-69da9a98a72d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_05ca4c67-b097-4e2e-ba1f-7e40bd1d7bab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_ee3411e0-42ce-4dd8-8a82-69da9a98a72d" xlink:to="loc_us-gaap_SubsequentEventMember_05ca4c67-b097-4e2e-ba1f-7e40bd1d7bab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_DateInitiatedAxis_4d373cc2-c8e9-4a42-b47b-65a2bf574e2e" xlink:href="cah-20230331.xsd#cah_DateInitiatedAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_b9d2e1be-10c4-47c5-8f43-cf3b810b04f8" xlink:to="loc_cah_DateInitiatedAxis_4d373cc2-c8e9-4a42-b47b-65a2bf574e2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_DateInitiatedDomain_099896b2-c063-4b9e-aed8-38bb642a64ff" xlink:href="cah-20230331.xsd#cah_DateInitiatedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_DateInitiatedAxis_4d373cc2-c8e9-4a42-b47b-65a2bf574e2e" xlink:to="loc_cah_DateInitiatedDomain_099896b2-c063-4b9e-aed8-38bb642a64ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_March2022Member_32c903ae-2934-415a-b8d6-2a1b3d0fb1d5" xlink:href="cah-20230331.xsd#cah_March2022Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_DateInitiatedDomain_099896b2-c063-4b9e-aed8-38bb642a64ff" xlink:to="loc_cah_March2022Member_32c903ae-2934-415a-b8d6-2a1b3d0fb1d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_September2018Member_cd2b1a69-4d04-4d52-b785-e14206170cd7" xlink:href="cah-20230331.xsd#cah_September2018Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_DateInitiatedDomain_099896b2-c063-4b9e-aed8-38bb642a64ff" xlink:to="loc_cah_September2018Member_cd2b1a69-4d04-4d52-b785-e14206170cd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_1b1a616a-9f94-48d5-89de-593703303123" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_b9d2e1be-10c4-47c5-8f43-cf3b810b04f8" xlink:to="loc_us-gaap_DerivativeLineItems_1b1a616a-9f94-48d5-89de-593703303123" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_67118cef-6d79-42b9-9fde-4ab126451810" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_1b1a616a-9f94-48d5-89de-593703303123" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_67118cef-6d79-42b9-9fde-4ab126451810" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotionalAmount_ab9bf8c0-c094-4f56-954f-b3992e2dbb18" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilityNotionalAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_1b1a616a-9f94-48d5-89de-593703303123" xlink:to="loc_us-gaap_DerivativeLiabilityNotionalAmount_ab9bf8c0-c094-4f56-954f-b3992e2dbb18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotionalAmount_824f9fde-a182-42d7-a19e-3911a07df47f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssetNotionalAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_1b1a616a-9f94-48d5-89de-593703303123" xlink:to="loc_us-gaap_DerivativeAssetNotionalAmount_824f9fde-a182-42d7-a19e-3911a07df47f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_0f1e4001-e6bb-43db-be9c-adf7d995ee80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_1b1a616a-9f94-48d5-89de-593703303123" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_0f1e4001-e6bb-43db-be9c-adf7d995ee80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_2a025b82-598c-41a5-a472-63f93858adc6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_1b1a616a-9f94-48d5-89de-593703303123" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_2a025b82-598c-41a5-a472-63f93858adc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount_d0cf9099-a0b5-4acd-8798-68907a7f3429" xlink:href="cah-20230331.xsd#cah_DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_1b1a616a-9f94-48d5-89de-593703303123" xlink:to="loc_cah_DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount_d0cf9099-a0b5-4acd-8798-68907a7f3429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromHedgeInvestingActivities_aa5c239a-f885-4a56-9c09-9dcdb4393673" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromHedgeInvestingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_1b1a616a-9f94-48d5-89de-593703303123" xlink:to="loc_us-gaap_ProceedsFromHedgeInvestingActivities_aa5c239a-f885-4a56-9c09-9dcdb4393673" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_31a431e2-723d-4b49-a973-9d323f0bbab4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_1b1a616a-9f94-48d5-89de-593703303123" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_31a431e2-723d-4b49-a973-9d323f0bbab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_87b11040-ab89-4ffc-81ad-cbca5da15a56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_1b1a616a-9f94-48d5-89de-593703303123" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_87b11040-ab89-4ffc-81ad-cbca5da15a56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_963849d7-809f-41e3-9057-f92e0f5e5e8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_1b1a616a-9f94-48d5-89de-593703303123" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_963849d7-809f-41e3-9057-f92e0f5e5e8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails" xlink:type="simple" xlink:href="cah-20230331.xsd#FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_6fe953f4-1025-4b6d-b975-a1dcedd7f6bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4a06a8ef-8c71-4bd1-bf66-cb419ec9a950" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_6fe953f4-1025-4b6d-b975-a1dcedd7f6bd" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4a06a8ef-8c71-4bd1-bf66-cb419ec9a950" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2582d78a-2dea-4784-b96e-f70b80521aaa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4a06a8ef-8c71-4bd1-bf66-cb419ec9a950" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2582d78a-2dea-4784-b96e-f70b80521aaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9c4494bc-2b9b-4453-8585-43f04ad62742" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2582d78a-2dea-4784-b96e-f70b80521aaa" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9c4494bc-2b9b-4453-8585-43f04ad62742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_5a560e9d-d01f-4c89-afbc-38b33e0fbb8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9c4494bc-2b9b-4453-8585-43f04ad62742" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_5a560e9d-d01f-4c89-afbc-38b33e0fbb8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7bee449a-7292-4503-baa6-3c5ee3919061" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4a06a8ef-8c71-4bd1-bf66-cb419ec9a950" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7bee449a-7292-4503-baa6-3c5ee3919061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_bce96c52-e8a7-462d-b1e8-da4a3508b5ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7bee449a-7292-4503-baa6-3c5ee3919061" xlink:to="loc_us-gaap_DebtInstrumentFairValue_bce96c52-e8a7-462d-b1e8-da4a3508b5ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CarryingAmountofLongTermandotherShortTermBorrowings_19aa7749-e6fa-474f-abda-42a082b65ec8" xlink:href="cah-20230331.xsd#cah_CarryingAmountofLongTermandotherShortTermBorrowings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7bee449a-7292-4503-baa6-3c5ee3919061" xlink:to="loc_cah_CarryingAmountofLongTermandotherShortTermBorrowings_19aa7749-e6fa-474f-abda-42a082b65ec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="cah-20230331.xsd#ShareholdersEquityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_bc031e12-2c14-47d9-97fb-beb4e2d76eea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_6eded314-592f-4b9a-815a-18bc161adc78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_bc031e12-2c14-47d9-97fb-beb4e2d76eea" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_6eded314-592f-4b9a-815a-18bc161adc78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_8c316b2b-f212-42ba-a23a-d9ee01a2e954" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_6eded314-592f-4b9a-815a-18bc161adc78" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_8c316b2b-f212-42ba-a23a-d9ee01a2e954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6dc58d56-34be-4fd9-9593-c89f95be7a3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8c316b2b-f212-42ba-a23a-d9ee01a2e954" xlink:to="loc_us-gaap_EquityComponentDomain_6dc58d56-34be-4fd9-9593-c89f95be7a3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_2efb182a-293a-4f98-ae5a-c8eae88c719e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6dc58d56-34be-4fd9-9593-c89f95be7a3c" xlink:to="loc_us-gaap_TreasuryStockCommonMember_2efb182a-293a-4f98-ae5a-c8eae88c719e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_204142b6-e711-49da-8eee-9b280f8c7a9a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6dc58d56-34be-4fd9-9593-c89f95be7a3c" xlink:to="loc_us-gaap_TreasuryStockCommonMember_204142b6-e711-49da-8eee-9b280f8c7a9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_262df0e1-1a72-417a-99ab-7cd05d3a77e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_6eded314-592f-4b9a-815a-18bc161adc78" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_262df0e1-1a72-417a-99ab-7cd05d3a77e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_09933b5c-0c04-40b1-8538-d739d22dd536" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_262df0e1-1a72-417a-99ab-7cd05d3a77e4" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_09933b5c-0c04-40b1-8538-d739d22dd536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_922ede20-afb6-46d2-acd0-23532fc7710f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_09933b5c-0c04-40b1-8538-d739d22dd536" xlink:to="loc_us-gaap_SubsequentEventMember_922ede20-afb6-46d2-acd0-23532fc7710f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_b517b836-26c9-4a99-8ff6-607649a6552b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_6eded314-592f-4b9a-815a-18bc161adc78" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_b517b836-26c9-4a99-8ff6-607649a6552b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_b0eb2d70-d053-45e1-92b8-210c6345bb57" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_b517b836-26c9-4a99-8ff6-607649a6552b" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_b0eb2d70-d053-45e1-92b8-210c6345bb57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A250MillionShareRepurchaseProgramMember_d03c64f3-6a4b-4720-9312-4cdb41fcfd0f" xlink:href="cah-20230331.xsd#cah_A250MillionShareRepurchaseProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_b0eb2d70-d053-45e1-92b8-210c6345bb57" xlink:to="loc_cah_A250MillionShareRepurchaseProgramMember_d03c64f3-6a4b-4720-9312-4cdb41fcfd0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A1BillionShareRepurchaseProgramMember_a88fe11d-651f-468d-9a97-17f01936903f" xlink:href="cah-20230331.xsd#cah_A1BillionShareRepurchaseProgramMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_b0eb2d70-d053-45e1-92b8-210c6345bb57" xlink:to="loc_cah_A1BillionShareRepurchaseProgramMember_a88fe11d-651f-468d-9a97-17f01936903f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A300MillionShareRepurchaseProgramMember_44775c6c-32d5-4474-84f8-58ce9135e10a" xlink:href="cah-20230331.xsd#cah_A300MillionShareRepurchaseProgramMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_b0eb2d70-d053-45e1-92b8-210c6345bb57" xlink:to="loc_cah_A300MillionShareRepurchaseProgramMember_44775c6c-32d5-4474-84f8-58ce9135e10a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A500MillionShareRepurchaseProgramMember_e4d8d8eb-42bd-4584-8a09-c11da5e265b8" xlink:href="cah-20230331.xsd#cah_A500MillionShareRepurchaseProgramMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_b0eb2d70-d053-45e1-92b8-210c6345bb57" xlink:to="loc_cah_A500MillionShareRepurchaseProgramMember_e4d8d8eb-42bd-4584-8a09-c11da5e265b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A200MillionShareRepurchaseProgramMember_b69ef862-9997-4f0b-ba41-5a122e94683b" xlink:href="cah-20230331.xsd#cah_A200MillionShareRepurchaseProgramMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_b0eb2d70-d053-45e1-92b8-210c6345bb57" xlink:to="loc_cah_A200MillionShareRepurchaseProgramMember_b69ef862-9997-4f0b-ba41-5a122e94683b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_046c74d5-52ca-4d79-a38e-6482bfab791a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_6eded314-592f-4b9a-815a-18bc161adc78" xlink:to="loc_us-gaap_ClassOfStockLineItems_046c74d5-52ca-4d79-a38e-6482bfab791a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_f9cd2313-a8a6-47fa-b785-8a113c6ff37b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_046c74d5-52ca-4d79-a38e-6482bfab791a" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_f9cd2313-a8a6-47fa-b785-8a113c6ff37b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_6dda974a-5537-444b-871c-19573a8fadc5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_046c74d5-52ca-4d79-a38e-6482bfab791a" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_6dda974a-5537-444b-871c-19573a8fadc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_2adccd76-9881-4f59-a21c-0c7b4fad09f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_046c74d5-52ca-4d79-a38e-6482bfab791a" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_2adccd76-9881-4f59-a21c-0c7b4fad09f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="cah-20230331.xsd#ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_5b670736-5dc7-422e-8090-adc2f4880572" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_0de2f9d9-2106-43e6-aba2-8d7e0f0d53fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_5b670736-5dc7-422e-8090-adc2f4880572" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_0de2f9d9-2106-43e6-aba2-8d7e0f0d53fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2ad4f9fc-3cda-4afc-b083-e61901e24742" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_0de2f9d9-2106-43e6-aba2-8d7e0f0d53fa" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2ad4f9fc-3cda-4afc-b083-e61901e24742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1e2c8b17-e736-402f-850e-80b84b7d56a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2ad4f9fc-3cda-4afc-b083-e61901e24742" xlink:to="loc_us-gaap_EquityComponentDomain_1e2c8b17-e736-402f-850e-80b84b7d56a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_fb27fc97-2ddf-4625-8997-7d3e8d348506" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1e2c8b17-e736-402f-850e-80b84b7d56a2" xlink:to="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_fb27fc97-2ddf-4625-8997-7d3e8d348506" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember_bfec6164-084d-4e42-8e88-d9c6564dac69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1e2c8b17-e736-402f-850e-80b84b7d56a2" xlink:to="loc_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember_bfec6164-084d-4e42-8e88-d9c6564dac69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_b65403de-77d9-4c0a-842f-0df865833c14" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1e2c8b17-e736-402f-850e-80b84b7d56a2" xlink:to="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_b65403de-77d9-4c0a-842f-0df865833c14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5fd541b5-e092-4d9a-b63e-202570fd8a2f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1e2c8b17-e736-402f-850e-80b84b7d56a2" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5fd541b5-e092-4d9a-b63e-202570fd8a2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_5bed25ce-ec70-405f-9c0c-178165a31009" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_0de2f9d9-2106-43e6-aba2-8d7e0f0d53fa" xlink:to="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_5bed25ce-ec70-405f-9c0c-178165a31009" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_fdab17fb-43ec-4c6c-8904-35420e21548d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_5bed25ce-ec70-405f-9c0c-178165a31009" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_fdab17fb-43ec-4c6c-8904-35420e21548d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7427bd2f-0a57-4857-84f4-d95c50a7b802" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_fdab17fb-43ec-4c6c-8904-35420e21548d" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7427bd2f-0a57-4857-84f4-d95c50a7b802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_490bf811-31fc-4d93-9d25-e68ac72dd068" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_fdab17fb-43ec-4c6c-8904-35420e21548d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_490bf811-31fc-4d93-9d25-e68ac72dd068" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_3a63b44a-6eb6-4d16-bf2e-9e689f532fdf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_fdab17fb-43ec-4c6c-8904-35420e21548d" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_3a63b44a-6eb6-4d16-bf2e-9e689f532fdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_2d6f615e-1c56-49ca-b86f-a38bf0875025" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_fdab17fb-43ec-4c6c-8904-35420e21548d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTax_2d6f615e-1c56-49ca-b86f-a38bf0875025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_4b70bfc4-60cf-4ddf-b2cc-8c3cc1a7d995" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_fdab17fb-43ec-4c6c-8904-35420e21548d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_4b70bfc4-60cf-4ddf-b2cc-8c3cc1a7d995" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_42916156-1ac0-42c8-a8a3-0f3597405af3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_fdab17fb-43ec-4c6c-8904-35420e21548d" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_42916156-1ac0-42c8-a8a3-0f3597405af3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails" xlink:type="simple" xlink:href="cah-20230331.xsd#EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_6e4c0d5f-59a6-43c1-a9b3-f82f338224e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_e0089f38-2d53-4987-b939-62b8e928c30e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_6e4c0d5f-59a6-43c1-a9b3-f82f338224e6" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_e0089f38-2d53-4987-b939-62b8e928c30e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SharesThatWouldBeAntidilutiveAsAResultOfNetLoss_6994129d-a292-4936-ba48-86dfd5d21d9c" xlink:href="cah-20230331.xsd#cah_SharesThatWouldBeAntidilutiveAsAResultOfNetLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_6e4c0d5f-59a6-43c1-a9b3-f82f338224e6" xlink:to="loc_cah_SharesThatWouldBeAntidilutiveAsAResultOfNetLoss_6994129d-a292-4936-ba48-86dfd5d21d9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails" xlink:type="simple" xlink:href="cah-20230331.xsd#EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_c1848c4f-6197-425d-a6d0-b4795410a514" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_dae78e1b-cbb8-4d86-95fc-f94ad1107cb7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c1848c4f-6197-425d-a6d0-b4795410a514" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_dae78e1b-cbb8-4d86-95fc-f94ad1107cb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_4c32e5e7-c123-43f7-93b4-c61ff1e27810" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c1848c4f-6197-425d-a6d0-b4795410a514" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_4c32e5e7-c123-43f7-93b4-c61ff1e27810" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_6f4892a0-4405-40e4-84b2-0bbbbdaa1286" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_4c32e5e7-c123-43f7-93b4-c61ff1e27810" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_6f4892a0-4405-40e4-84b2-0bbbbdaa1286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6e076b4e-d0c3-4808-94db-99a1e50b109b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c1848c4f-6197-425d-a6d0-b4795410a514" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6e076b4e-d0c3-4808-94db-99a1e50b109b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationNarrativeDetails" xlink:type="simple" xlink:href="cah-20230331.xsd#SegmentInformationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/SegmentInformationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_a9a07233-05bd-4d1f-90ad-503daa2ceee2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_46851951-b610-400b-a378-c415c538d67d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_a9a07233-05bd-4d1f-90ad-503daa2ceee2" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_46851951-b610-400b-a378-c415c538d67d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationAxis_fbfb82b9-0395-4f9e-9a3d-ff964a3c0327" xlink:href="cah-20230331.xsd#cah_OpioidLitigationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_46851951-b610-400b-a378-c415c538d67d" xlink:to="loc_cah_OpioidLitigationAxis_fbfb82b9-0395-4f9e-9a3d-ff964a3c0327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationDomain_5a11e125-f84b-48ea-bfcd-dfc3c0691ef7" xlink:href="cah-20230331.xsd#cah_OpioidLitigationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_OpioidLitigationAxis_fbfb82b9-0395-4f9e-9a3d-ff964a3c0327" xlink:to="loc_cah_OpioidLitigationDomain_5a11e125-f84b-48ea-bfcd-dfc3c0691ef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalOpioidLitigationMember_0b4d57fe-0640-4b19-bfe5-eec9ec2eb0c3" xlink:href="cah-20230331.xsd#cah_TotalOpioidLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_OpioidLitigationDomain_5a11e125-f84b-48ea-bfcd-dfc3c0691ef7" xlink:to="loc_cah_TotalOpioidLitigationMember_0b4d57fe-0640-4b19-bfe5-eec9ec2eb0c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_56ae9b17-690c-4eb8-9e2c-d060f9312b30" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_46851951-b610-400b-a378-c415c538d67d" xlink:to="loc_srt_LitigationCaseAxis_56ae9b17-690c-4eb8-9e2c-d060f9312b30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_04b2bdac-15aa-4859-89ae-86d86db1bd85" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_56ae9b17-690c-4eb8-9e2c-d060f9312b30" xlink:to="loc_srt_LitigationCaseTypeDomain_04b2bdac-15aa-4859-89ae-86d86db1bd85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NewYorkOpioidStewardshipActMember_dd799755-680d-4583-ad89-f01563668f1f" xlink:href="cah-20230331.xsd#cah_NewYorkOpioidStewardshipActMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_04b2bdac-15aa-4859-89ae-86d86db1bd85" xlink:to="loc_cah_NewYorkOpioidStewardshipActMember_dd799755-680d-4583-ad89-f01563668f1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureAxis_a1e55d8b-0e25-4795-a137-afd62b5b1f63" xlink:href="cah-20230331.xsd#cah_CordisDivestitureAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_46851951-b610-400b-a378-c415c538d67d" xlink:to="loc_cah_CordisDivestitureAxis_a1e55d8b-0e25-4795-a137-afd62b5b1f63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureDomain_88a70068-140c-4a1a-b0af-71e32a64d307" xlink:href="cah-20230331.xsd#cah_CordisDivestitureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_CordisDivestitureAxis_a1e55d8b-0e25-4795-a137-afd62b5b1f63" xlink:to="loc_cah_CordisDivestitureDomain_88a70068-140c-4a1a-b0af-71e32a64d307" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureMember_a1b3be24-b7f0-4e65-b471-496d4f65ea58" xlink:href="cah-20230331.xsd#cah_CordisDivestitureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_CordisDivestitureDomain_88a70068-140c-4a1a-b0af-71e32a64d307" xlink:to="loc_cah_CordisDivestitureMember_a1b3be24-b7f0-4e65-b471-496d4f65ea58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_46a3b41f-64d6-40bf-8c0d-7774a1226b60" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_46851951-b610-400b-a378-c415c538d67d" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_46a3b41f-64d6-40bf-8c0d-7774a1226b60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_1373d489-ee54-4b53-b6d2-5db25dfb0f97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_46a3b41f-64d6-40bf-8c0d-7774a1226b60" xlink:to="loc_us-gaap_SegmentDomain_1373d489-ee54-4b53-b6d2-5db25dfb0f97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember_4fb0d3c8-150e-435e-b2c5-efdca31d47d8" xlink:href="cah-20230331.xsd#cah_MedicalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_1373d489-ee54-4b53-b6d2-5db25dfb0f97" xlink:to="loc_cah_MedicalMember_4fb0d3c8-150e-435e-b2c5-efdca31d47d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis_36030064-fc4f-4caf-a452-bed2f1371b3e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReportingUnitAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_46851951-b610-400b-a378-c415c538d67d" xlink:to="loc_us-gaap_ReportingUnitAxis_36030064-fc4f-4caf-a452-bed2f1371b3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_d2b578ca-f993-4fce-884d-a24e50fef36a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReportingUnitDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitAxis_36030064-fc4f-4caf-a452-bed2f1371b3e" xlink:to="loc_us-gaap_ReportingUnitDomain_d2b578ca-f993-4fce-884d-a24e50fef36a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalUnitMember_96830b82-5b8a-4e42-ae4d-b5a35414f956" xlink:href="cah-20230331.xsd#cah_MedicalUnitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_d2b578ca-f993-4fce-884d-a24e50fef36a" xlink:to="loc_cah_MedicalUnitMember_96830b82-5b8a-4e42-ae4d-b5a35414f956" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_24532173-0c32-487d-8d31-bdd1a3c2374e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_46851951-b610-400b-a378-c415c538d67d" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_24532173-0c32-487d-8d31-bdd1a3c2374e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_00c0e20d-7126-4445-b583-26553587c71f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_24532173-0c32-487d-8d31-bdd1a3c2374e" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_00c0e20d-7126-4445-b583-26553587c71f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProjectCostsOnInvestmentAndOtherSpending_741ed225-0bd9-42b8-b260-ea5c86a88218" xlink:href="cah-20230331.xsd#cah_ProjectCostsOnInvestmentAndOtherSpending"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_24532173-0c32-487d-8d31-bdd1a3c2374e" xlink:to="loc_cah_ProjectCostsOnInvestmentAndOtherSpending_741ed225-0bd9-42b8-b260-ea5c86a88218" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_b9178b8e-72d3-4f21-95b9-7e0e9e8966b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_24532173-0c32-487d-8d31-bdd1a3c2374e" xlink:to="loc_us-gaap_NumberOfReportableSegments_b9178b8e-72d3-4f21-95b9-7e0e9e8966b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_1f0fa068-06c7-4dee-abcf-2898b4b32d81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_24532173-0c32-487d-8d31-bdd1a3c2374e" xlink:to="loc_us-gaap_NumberOfOperatingSegments_1f0fa068-06c7-4dee-abcf-2898b4b32d81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_8861233c-78ae-443d-8c5b-b297088f7ee8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_24532173-0c32-487d-8d31-bdd1a3c2374e" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_8861233c-78ae-443d-8c5b-b297088f7ee8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_238bd9e2-67a4-42ca-a74d-0e39c5758ad7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_a9a07233-05bd-4d1f-90ad-503daa2ceee2" xlink:to="loc_us-gaap_NumberOfOperatingSegments_238bd9e2-67a4-42ca-a74d-0e39c5758ad7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_22f70584-ad06-4cdf-9497-77ccec53e93f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_a9a07233-05bd-4d1f-90ad-503daa2ceee2" xlink:to="loc_us-gaap_NumberOfReportableSegments_22f70584-ad06-4cdf-9497-77ccec53e93f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProjectCostsOnInvestmentAndOtherSpending_d041d891-e5a5-4919-9f61-43b92359dfe2" xlink:href="cah-20230331.xsd#cah_ProjectCostsOnInvestmentAndOtherSpending"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_a9a07233-05bd-4d1f-90ad-503daa2ceee2" xlink:to="loc_cah_ProjectCostsOnInvestmentAndOtherSpending_d041d891-e5a5-4919-9f61-43b92359dfe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails" xlink:type="simple" xlink:href="cah-20230331.xsd#SegmentInformationRevenuebyReportableSegmentDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_3a6572ca-c422-400b-9066-e5c711d8d912" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_b9cb6223-475e-4cc5-bd2a-4ad6399fa6c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_3a6572ca-c422-400b-9066-e5c711d8d912" xlink:to="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_b9cb6223-475e-4cc5-bd2a-4ad6399fa6c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis_615abe97-8573-4a93-9992-049624b3c43b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_b9cb6223-475e-4cc5-bd2a-4ad6399fa6c0" xlink:to="loc_us-gaap_SubsegmentsAxis_615abe97-8573-4a93-9992-049624b3c43b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_6e0fb6bb-f234-4614-83f9-01610ea60891" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsegmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsAxis_615abe97-8573-4a93-9992-049624b3c43b" xlink:to="loc_us-gaap_SubsegmentsDomain_6e0fb6bb-f234-4614-83f9-01610ea60891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalDistributionandSpecialtyMember_fa5829a6-0142-4bc2-af3e-64b106110d89" xlink:href="cah-20230331.xsd#cah_PharmaceuticalDistributionandSpecialtyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_6e0fb6bb-f234-4614-83f9-01610ea60891" xlink:to="loc_cah_PharmaceuticalDistributionandSpecialtyMember_fa5829a6-0142-4bc2-af3e-64b106110d89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NuclearPrecisionHealthSolutionsMember_9cfe9f7d-3cb1-4a0b-a600-9c63e88400af" xlink:href="cah-20230331.xsd#cah_NuclearPrecisionHealthSolutionsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_6e0fb6bb-f234-4614-83f9-01610ea60891" xlink:to="loc_cah_NuclearPrecisionHealthSolutionsMember_9cfe9f7d-3cb1-4a0b-a600-9c63e88400af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicaldistributionandproductsMember_3db2cd0a-e2ba-4a9a-acb4-077782130bde" xlink:href="cah-20230331.xsd#cah_MedicaldistributionandproductsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_6e0fb6bb-f234-4614-83f9-01610ea60891" xlink:to="loc_cah_MedicaldistributionandproductsMember_3db2cd0a-e2ba-4a9a-acb4-077782130bde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CardinalHealthAtHomeMember_e1a1ebcd-cd4e-4252-9177-053ecd04efbe" xlink:href="cah-20230331.xsd#cah_CardinalHealthAtHomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_6e0fb6bb-f234-4614-83f9-01610ea60891" xlink:to="loc_cah_CardinalHealthAtHomeMember_e1a1ebcd-cd4e-4252-9177-053ecd04efbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_c7b20cfe-0b97-4c18-a7d6-e44e8fb4ee87" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_b9cb6223-475e-4cc5-bd2a-4ad6399fa6c0" xlink:to="loc_srt_ConsolidationItemsAxis_c7b20cfe-0b97-4c18-a7d6-e44e8fb4ee87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_70a187f7-adfb-4030-9d90-2df97d27265b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_c7b20cfe-0b97-4c18-a7d6-e44e8fb4ee87" xlink:to="loc_srt_ConsolidationItemsDomain_70a187f7-adfb-4030-9d90-2df97d27265b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_2be83122-27b2-4003-80ba-fd2bb667b2f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_70a187f7-adfb-4030-9d90-2df97d27265b" xlink:to="loc_us-gaap_OperatingSegmentsMember_2be83122-27b2-4003-80ba-fd2bb667b2f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_7b611380-a9b9-48f4-b990-de2f652183f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_70a187f7-adfb-4030-9d90-2df97d27265b" xlink:to="loc_us-gaap_CorporateNonSegmentMember_7b611380-a9b9-48f4-b990-de2f652183f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_3d29f2e5-44a3-4fdf-b581-177bec4fd054" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_b9cb6223-475e-4cc5-bd2a-4ad6399fa6c0" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_3d29f2e5-44a3-4fdf-b581-177bec4fd054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_43bb60df-a81e-4707-bea6-cf162bd861ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_3d29f2e5-44a3-4fdf-b581-177bec4fd054" xlink:to="loc_us-gaap_SegmentDomain_43bb60df-a81e-4707-bea6-cf162bd861ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalMember_04e5a21f-2c66-4cee-8fd5-696512086226" xlink:href="cah-20230331.xsd#cah_PharmaceuticalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_43bb60df-a81e-4707-bea6-cf162bd861ed" xlink:to="loc_cah_PharmaceuticalMember_04e5a21f-2c66-4cee-8fd5-696512086226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember_1b9739f9-b2f0-4d4e-8caf-88967c28d38c" xlink:href="cah-20230331.xsd#cah_MedicalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_43bb60df-a81e-4707-bea6-cf162bd861ed" xlink:to="loc_cah_MedicalMember_1b9739f9-b2f0-4d4e-8caf-88967c28d38c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_39e0716d-84ae-4868-9408-fe1212ef79c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_b9cb6223-475e-4cc5-bd2a-4ad6399fa6c0" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_39e0716d-84ae-4868-9408-fe1212ef79c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_c1287695-8b60-418c-ac4a-d46ac75beeb4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_39e0716d-84ae-4868-9408-fe1212ef79c8" xlink:to="loc_us-gaap_Revenues_c1287695-8b60-418c-ac4a-d46ac75beeb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails" xlink:type="simple" xlink:href="cah-20230331.xsd#SegmentInformationSegmentProfitbyReportableSegmentDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_47c0d0fd-c58a-4f15-bb86-e20e80a2c527" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_4de96dfb-ec50-437c-94e1-c24f836f6a17" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_47c0d0fd-c58a-4f15-bb86-e20e80a2c527" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_4de96dfb-ec50-437c-94e1-c24f836f6a17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_53f98cf3-31e0-4815-98a3-1fab6c526383" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_4de96dfb-ec50-437c-94e1-c24f836f6a17" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_53f98cf3-31e0-4815-98a3-1fab6c526383" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_52eea8b9-d4a4-4ea5-85cc-e9c02b779cb9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_53f98cf3-31e0-4815-98a3-1fab6c526383" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_52eea8b9-d4a4-4ea5-85cc-e9c02b779cb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_62baf2a5-e730-424f-bd2a-786806f8624b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_4de96dfb-ec50-437c-94e1-c24f836f6a17" xlink:to="loc_srt_ConsolidationItemsAxis_62baf2a5-e730-424f-bd2a-786806f8624b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_9b779ac0-de5f-4b19-aab8-914f0827fa1f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_62baf2a5-e730-424f-bd2a-786806f8624b" xlink:to="loc_srt_ConsolidationItemsDomain_9b779ac0-de5f-4b19-aab8-914f0827fa1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_2c399be2-346a-411b-bcff-f66f87c01f23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_9b779ac0-de5f-4b19-aab8-914f0827fa1f" xlink:to="loc_us-gaap_OperatingSegmentsMember_2c399be2-346a-411b-bcff-f66f87c01f23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_a477f636-ab73-485f-b615-0c51f7ac5424" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_9b779ac0-de5f-4b19-aab8-914f0827fa1f" xlink:to="loc_us-gaap_CorporateNonSegmentMember_a477f636-ab73-485f-b615-0c51f7ac5424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_f6d22abb-dd63-4b0f-a106-9b1d5130587a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_4de96dfb-ec50-437c-94e1-c24f836f6a17" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_f6d22abb-dd63-4b0f-a106-9b1d5130587a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_56568c0e-57a0-4891-b167-d5d842457f5f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_f6d22abb-dd63-4b0f-a106-9b1d5130587a" xlink:to="loc_us-gaap_SegmentDomain_56568c0e-57a0-4891-b167-d5d842457f5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalMember_66eebca3-eba2-48e5-b62e-da461c8729cf" xlink:href="cah-20230331.xsd#cah_PharmaceuticalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_56568c0e-57a0-4891-b167-d5d842457f5f" xlink:to="loc_cah_PharmaceuticalMember_66eebca3-eba2-48e5-b62e-da461c8729cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember_2576bc5e-b52b-480b-8227-020aa8f88dcd" xlink:href="cah-20230331.xsd#cah_MedicalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_56568c0e-57a0-4891-b167-d5d842457f5f" xlink:to="loc_cah_MedicalMember_2576bc5e-b52b-480b-8227-020aa8f88dcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_9f26f21d-c4ff-42eb-a2ca-d8ab0773aeea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_4de96dfb-ec50-437c-94e1-c24f836f6a17" xlink:to="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_9f26f21d-c4ff-42eb-a2ca-d8ab0773aeea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_aa45ceb4-e2a9-4993-b803-c73b6922121e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_9f26f21d-c4ff-42eb-a2ca-d8ab0773aeea" xlink:to="loc_us-gaap_OperatingIncomeLoss_aa45ceb4-e2a9-4993-b803-c73b6922121e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_JudgmentForLostProfits_ae7ad4d5-9fb9-47c7-8d83-70f842da8ff3" xlink:href="cah-20230331.xsd#cah_JudgmentForLostProfits"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_9f26f21d-c4ff-42eb-a2ca-d8ab0773aeea" xlink:to="loc_cah_JudgmentForLostProfits_ae7ad4d5-9fb9-47c7-8d83-70f842da8ff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ContingentAttorneyFee_2cf41e6e-c3c0-4328-98ff-0aa9e43da909" xlink:href="cah-20230331.xsd#cah_ContingentAttorneyFee"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_9f26f21d-c4ff-42eb-a2ca-d8ab0773aeea" xlink:to="loc_cah_ContingentAttorneyFee_2cf41e6e-c3c0-4328-98ff-0aa9e43da909" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails" xlink:type="simple" xlink:href="cah-20230331.xsd#SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_8981b891-e175-433a-a376-bbeaf86504ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable_807bafa9-05fa-468a-80d3-4ba776040c3b" xlink:href="cah-20230331.xsd#cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_8981b891-e175-433a-a376-bbeaf86504ad" xlink:to="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable_807bafa9-05fa-468a-80d3-4ba776040c3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_94979fe0-5581-4a1f-ab57-f82e51b82976" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable_807bafa9-05fa-468a-80d3-4ba776040c3b" xlink:to="loc_srt_ConsolidationItemsAxis_94979fe0-5581-4a1f-ab57-f82e51b82976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_21ca1d30-3523-41ab-bcb1-3c9ac2de8ddc" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_94979fe0-5581-4a1f-ab57-f82e51b82976" xlink:to="loc_srt_ConsolidationItemsDomain_21ca1d30-3523-41ab-bcb1-3c9ac2de8ddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_605cd8b5-11a8-4749-8677-3db7cdb3fdf2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_21ca1d30-3523-41ab-bcb1-3c9ac2de8ddc" xlink:to="loc_us-gaap_OperatingSegmentsMember_605cd8b5-11a8-4749-8677-3db7cdb3fdf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_9248cdcb-0e95-4a3c-882e-189a05d0f286" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_21ca1d30-3523-41ab-bcb1-3c9ac2de8ddc" xlink:to="loc_us-gaap_CorporateNonSegmentMember_9248cdcb-0e95-4a3c-882e-189a05d0f286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_a6d1e196-c4b3-4bd5-8183-56d3c71b3a14" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable_807bafa9-05fa-468a-80d3-4ba776040c3b" xlink:to="loc_srt_StatementGeographicalAxis_a6d1e196-c4b3-4bd5-8183-56d3c71b3a14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_b665e707-3945-4882-820e-d94e53a80463" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_a6d1e196-c4b3-4bd5-8183-56d3c71b3a14" xlink:to="loc_srt_SegmentGeographicalDomain_b665e707-3945-4882-820e-d94e53a80463" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_a8ae4d5e-5abc-4d85-bc89-340476d5d221" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_b665e707-3945-4882-820e-d94e53a80463" xlink:to="loc_country_US_a8ae4d5e-5abc-4d85-bc89-340476d5d221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_20b326b3-91da-4968-ae79-f1ce6dd929ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_b665e707-3945-4882-820e-d94e53a80463" xlink:to="loc_us-gaap_NonUsMember_20b326b3-91da-4968-ae79-f1ce6dd929ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems_a24a350e-cc6a-4826-822f-a9c8c3b0b8d8" xlink:href="cah-20230331.xsd#cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable_807bafa9-05fa-468a-80d3-4ba776040c3b" xlink:to="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems_a24a350e-cc6a-4826-822f-a9c8c3b0b8d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_07470280-491b-4425-9361-6ff45bff9e7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems_a24a350e-cc6a-4826-822f-a9c8c3b0b8d8" xlink:to="loc_us-gaap_Revenues_07470280-491b-4425-9361-6ff45bff9e7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails" xlink:type="simple" xlink:href="cah-20230331.xsd#SegmentInformationAssetsbyReportableSegmentDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_840eb5d1-56f6-4923-ae63-4820f95f7666" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_38872a4b-ae15-419a-91bb-efa1c1306193" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_840eb5d1-56f6-4923-ae63-4820f95f7666" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_38872a4b-ae15-419a-91bb-efa1c1306193" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_72f64384-5240-46e7-b240-a44bfd73926a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_38872a4b-ae15-419a-91bb-efa1c1306193" xlink:to="loc_srt_ConsolidationItemsAxis_72f64384-5240-46e7-b240-a44bfd73926a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_ddf1d27f-eeab-4e3a-bca2-6bb6e218ac38" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_72f64384-5240-46e7-b240-a44bfd73926a" xlink:to="loc_srt_ConsolidationItemsDomain_ddf1d27f-eeab-4e3a-bca2-6bb6e218ac38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_9f61157a-b2bb-4765-9f69-38049be4cad1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_ddf1d27f-eeab-4e3a-bca2-6bb6e218ac38" xlink:to="loc_us-gaap_OperatingSegmentsMember_9f61157a-b2bb-4765-9f69-38049be4cad1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_b940e2a2-e092-45e1-9535-a851d9c7b7e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_ddf1d27f-eeab-4e3a-bca2-6bb6e218ac38" xlink:to="loc_us-gaap_CorporateNonSegmentMember_b940e2a2-e092-45e1-9535-a851d9c7b7e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_3f41eb45-dd6f-4ee2-ac11-fa205fb8c283" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_38872a4b-ae15-419a-91bb-efa1c1306193" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_3f41eb45-dd6f-4ee2-ac11-fa205fb8c283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_f2ae4835-5f21-4fc5-a04c-12426479f857" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_3f41eb45-dd6f-4ee2-ac11-fa205fb8c283" xlink:to="loc_us-gaap_SegmentDomain_f2ae4835-5f21-4fc5-a04c-12426479f857" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalMember_a8eb5a79-4039-4298-b16e-52c64abea262" xlink:href="cah-20230331.xsd#cah_PharmaceuticalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_f2ae4835-5f21-4fc5-a04c-12426479f857" xlink:to="loc_cah_PharmaceuticalMember_a8eb5a79-4039-4298-b16e-52c64abea262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember_bb114528-dbba-45cd-81d1-a6b08e182366" xlink:href="cah-20230331.xsd#cah_MedicalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_f2ae4835-5f21-4fc5-a04c-12426479f857" xlink:to="loc_cah_MedicalMember_bb114528-dbba-45cd-81d1-a6b08e182366" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureAxis_abcdda7d-92d0-4efc-b73d-955b53abe3fd" xlink:href="cah-20230331.xsd#cah_CordisDivestitureAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_38872a4b-ae15-419a-91bb-efa1c1306193" xlink:to="loc_cah_CordisDivestitureAxis_abcdda7d-92d0-4efc-b73d-955b53abe3fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureDomain_c377990b-55ad-4d75-acbe-5b66df5fcbf3" xlink:href="cah-20230331.xsd#cah_CordisDivestitureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_CordisDivestitureAxis_abcdda7d-92d0-4efc-b73d-955b53abe3fd" xlink:to="loc_cah_CordisDivestitureDomain_c377990b-55ad-4d75-acbe-5b66df5fcbf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureMember_a5e1e42f-42d0-4508-bd19-086ab57680c7" xlink:href="cah-20230331.xsd#cah_CordisDivestitureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_CordisDivestitureDomain_c377990b-55ad-4d75-acbe-5b66df5fcbf3" xlink:to="loc_cah_CordisDivestitureMember_a5e1e42f-42d0-4508-bd19-086ab57680c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis_4a0ac692-6c0f-468e-bad8-f87805493550" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReportingUnitAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_38872a4b-ae15-419a-91bb-efa1c1306193" xlink:to="loc_us-gaap_ReportingUnitAxis_4a0ac692-6c0f-468e-bad8-f87805493550" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_355ce2a3-5f6e-4cf5-8c01-81a0e1b9282d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReportingUnitDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitAxis_4a0ac692-6c0f-468e-bad8-f87805493550" xlink:to="loc_us-gaap_ReportingUnitDomain_355ce2a3-5f6e-4cf5-8c01-81a0e1b9282d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalUnitMember_9007984c-405b-4339-bd78-60b9de42d155" xlink:href="cah-20230331.xsd#cah_MedicalUnitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_355ce2a3-5f6e-4cf5-8c01-81a0e1b9282d" xlink:to="loc_cah_MedicalUnitMember_9007984c-405b-4339-bd78-60b9de42d155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_d112117d-5cdc-4160-8ee3-3660cca3b5f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_38872a4b-ae15-419a-91bb-efa1c1306193" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_d112117d-5cdc-4160-8ee3-3660cca3b5f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_f2bbeda2-5c70-4414-8bf7-4586c7f4c93e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d112117d-5cdc-4160-8ee3-3660cca3b5f9" xlink:to="loc_us-gaap_Assets_f2bbeda2-5c70-4414-8bf7-4586c7f4c93e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_03d83776-06c4-496e-a3de-74b86901c279" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d112117d-5cdc-4160-8ee3-3660cca3b5f9" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_03d83776-06c4-496e-a3de-74b86901c279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="cah-20230331.xsd#ShareBasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_eda67337-6be4-4eb7-aa83-e2f74783216d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b5e8c14c-7063-42e0-b8be-6758649acaf4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_eda67337-6be4-4eb7-aa83-e2f74783216d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b5e8c14c-7063-42e0-b8be-6758649acaf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b88787cf-07fe-40a2-b1c2-00deb7440808" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b5e8c14c-7063-42e0-b8be-6758649acaf4" xlink:to="loc_us-gaap_AwardTypeAxis_b88787cf-07fe-40a2-b1c2-00deb7440808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1e55df24-37ef-4c87-aca4-800062c09d81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_b88787cf-07fe-40a2-b1c2-00deb7440808" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1e55df24-37ef-4c87-aca4-800062c09d81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_ca08e3e0-3b76-46ac-bf13-00d85fd9adf2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1e55df24-37ef-4c87-aca4-800062c09d81" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_ca08e3e0-3b76-46ac-bf13-00d85fd9adf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_ed933725-22f8-4cf8-b00f-527bf4172ccb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1e55df24-37ef-4c87-aca4-800062c09d81" xlink:to="loc_us-gaap_PerformanceSharesMember_ed933725-22f8-4cf8-b00f-527bf4172ccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7d7e8947-0b35-48eb-9256-3218f270d8ff" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b5e8c14c-7063-42e0-b8be-6758649acaf4" xlink:to="loc_srt_RangeAxis_7d7e8947-0b35-48eb-9256-3218f270d8ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_470f8606-d4be-4694-8004-2f7f65dd40eb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_7d7e8947-0b35-48eb-9256-3218f270d8ff" xlink:to="loc_srt_RangeMember_470f8606-d4be-4694-8004-2f7f65dd40eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_62287ca9-c539-40de-b6fe-136944802e65" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_470f8606-d4be-4694-8004-2f7f65dd40eb" xlink:to="loc_srt_MinimumMember_62287ca9-c539-40de-b6fe-136944802e65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_941b48d2-231d-499d-ba36-1c27913a5a71" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_470f8606-d4be-4694-8004-2f7f65dd40eb" xlink:to="loc_srt_MaximumMember_941b48d2-231d-499d-ba36-1c27913a5a71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_350740c4-9b75-4675-baf6-830da6c310b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b5e8c14c-7063-42e0-b8be-6758649acaf4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_350740c4-9b75-4675-baf6-830da6c310b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_VestingPeriodinyearsforShares_06c1c929-8159-40ee-b069-a1670eee9671" xlink:href="cah-20230331.xsd#cah_VestingPeriodinyearsforShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_350740c4-9b75-4675-baf6-830da6c310b3" xlink:to="loc_cah_VestingPeriodinyearsforShares_06c1c929-8159-40ee-b069-a1670eee9671" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_61dfa077-01c6-42b8-b879-2b6c96b035b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_350740c4-9b75-4675-baf6-830da6c310b3" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_61dfa077-01c6-42b8-b879-2b6c96b035b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_bb7add85-3258-4549-8bf1-c56b636d978e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_350740c4-9b75-4675-baf6-830da6c310b3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_bb7add85-3258-4549-8bf1-c56b636d978e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_9d69f05e-1897-4944-bfcc-89a5baea1346" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_350740c4-9b75-4675-baf6-830da6c310b3" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_9d69f05e-1897-4944-bfcc-89a5baea1346" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_38d0ba70-0e4f-4931-9d3e-fe5ca0b121a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_350740c4-9b75-4675-baf6-830da6c310b3" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_38d0ba70-0e4f-4931-9d3e-fe5ca0b121a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_2af988e5-0287-4bff-b76c-f3e7f016fea1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_350740c4-9b75-4675-baf6-830da6c310b3" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_2af988e5-0287-4bff-b76c-f3e7f016fea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails" xlink:type="simple" xlink:href="cah-20230331.xsd#ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d96318b9-dcef-4d77-b630-3f6e000cd87c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f1e8ae62-0d71-4db0-8f83-66658182c53b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d96318b9-dcef-4d77-b630-3f6e000cd87c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f1e8ae62-0d71-4db0-8f83-66658182c53b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_cc39b8d3-37cd-4285-9318-f6d61a9ae50d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f1e8ae62-0d71-4db0-8f83-66658182c53b" xlink:to="loc_us-gaap_AwardTypeAxis_cc39b8d3-37cd-4285-9318-f6d61a9ae50d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_39fd2f48-d51c-4c07-a5da-58fef30abc25" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_cc39b8d3-37cd-4285-9318-f6d61a9ae50d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_39fd2f48-d51c-4c07-a5da-58fef30abc25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_c386754e-e61f-4d4f-9ea3-eec7ae5e3b7a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_39fd2f48-d51c-4c07-a5da-58fef30abc25" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_c386754e-e61f-4d4f-9ea3-eec7ae5e3b7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_c95c88db-e1b1-4dca-9bd8-a839420341dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_39fd2f48-d51c-4c07-a5da-58fef30abc25" xlink:to="loc_us-gaap_PerformanceSharesMember_c95c88db-e1b1-4dca-9bd8-a839420341dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fd8eb61f-d8ee-4b1c-9e8e-bcdc24c62814" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f1e8ae62-0d71-4db0-8f83-66658182c53b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fd8eb61f-d8ee-4b1c-9e8e-bcdc24c62814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_d5626726-82e2-40a3-bde4-d3299fa3b4e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fd8eb61f-d8ee-4b1c-9e8e-bcdc24c62814" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_d5626726-82e2-40a3-bde4-d3299fa3b4e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails" xlink:type="simple" xlink:href="cah-20230331.xsd#ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_172305dd-4f53-4217-b948-4c98a58ce5fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails" xlink:type="simple" xlink:href="cah-20230331.xsd#ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3af10eef-6bd4-4573-a3a4-24032f0c76c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7aec4ed5-c49d-4bee-8cbf-1888b7d1eedc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3af10eef-6bd4-4573-a3a4-24032f0c76c0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7aec4ed5-c49d-4bee-8cbf-1888b7d1eedc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_342a4943-263f-4307-93d1-d56529edcdf0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7aec4ed5-c49d-4bee-8cbf-1888b7d1eedc" xlink:to="loc_us-gaap_AwardTypeAxis_342a4943-263f-4307-93d1-d56529edcdf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_33bbe54e-f4ed-4041-aeb3-af962a2c86a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_342a4943-263f-4307-93d1-d56529edcdf0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_33bbe54e-f4ed-4041-aeb3-af962a2c86a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0d76841b-04e9-4dcc-ad48-6f55b836f5bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7aec4ed5-c49d-4bee-8cbf-1888b7d1eedc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0d76841b-04e9-4dcc-ad48-6f55b836f5bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_a6de63d9-6b3c-4015-9795-73a469ce6b27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0d76841b-04e9-4dcc-ad48-6f55b836f5bb" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_a6de63d9-6b3c-4015-9795-73a469ce6b27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails" xlink:type="simple" xlink:href="cah-20230331.xsd#ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a2ef9a17-dd6b-40fa-b231-364da9b08332" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fbb93dba-aec2-4384-9343-592b8f472691" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a2ef9a17-dd6b-40fa-b231-364da9b08332" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fbb93dba-aec2-4384-9343-592b8f472691" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_1a0bc289-5fbd-4355-b9f9-2107d5d82174" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fbb93dba-aec2-4384-9343-592b8f472691" xlink:to="loc_us-gaap_AwardTypeAxis_1a0bc289-5fbd-4355-b9f9-2107d5d82174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d9b83166-7eda-42f6-a47a-bc46f01eb336" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1a0bc289-5fbd-4355-b9f9-2107d5d82174" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d9b83166-7eda-42f6-a47a-bc46f01eb336" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_a264840d-ca01-4832-9fbe-dfb1b0e80e05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d9b83166-7eda-42f6-a47a-bc46f01eb336" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_a264840d-ca01-4832-9fbe-dfb1b0e80e05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c5941236-c83d-48be-b7b4-e0fe3f26bcf4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fbb93dba-aec2-4384-9343-592b8f472691" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c5941236-c83d-48be-b7b4-e0fe3f26bcf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_ec35163f-3915-494b-a8a9-c590bc5aaeb9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c5941236-c83d-48be-b7b4-e0fe3f26bcf4" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_ec35163f-3915-494b-a8a9-c590bc5aaeb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_e730adc5-9cf6-4aa0-ae1b-570b7fceed45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c5941236-c83d-48be-b7b4-e0fe3f26bcf4" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_e730adc5-9cf6-4aa0-ae1b-570b7fceed45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2aa5fe4e-ed81-4453-9703-1abbc7b1eb29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c5941236-c83d-48be-b7b4-e0fe3f26bcf4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2aa5fe4e-ed81-4453-9703-1abbc7b1eb29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_dfe3c38c-2645-4b94-a95b-39d43b84e204" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2aa5fe4e-ed81-4453-9703-1abbc7b1eb29" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_dfe3c38c-2645-4b94-a95b-39d43b84e204" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_365f303c-a019-478b-9aaf-6b45e0a119c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2aa5fe4e-ed81-4453-9703-1abbc7b1eb29" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_365f303c-a019-478b-9aaf-6b45e0a119c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_9b08a353-6479-423c-9cd7-5b1577317132" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2aa5fe4e-ed81-4453-9703-1abbc7b1eb29" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_9b08a353-6479-423c-9cd7-5b1577317132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_767eaa9f-6bde-47eb-80bb-c916836efd40" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2aa5fe4e-ed81-4453-9703-1abbc7b1eb29" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_767eaa9f-6bde-47eb-80bb-c916836efd40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4f30094a-dd66-46c5-9137-da359dbcf3a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2aa5fe4e-ed81-4453-9703-1abbc7b1eb29" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4f30094a-dd66-46c5-9137-da359dbcf3a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0bb0d089-5c52-47f1-9f90-62c12736a725" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c5941236-c83d-48be-b7b4-e0fe3f26bcf4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0bb0d089-5c52-47f1-9f90-62c12736a725" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7638a60c-520b-4c6f-ad8f-cc2a2614a00d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0bb0d089-5c52-47f1-9f90-62c12736a725" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7638a60c-520b-4c6f-ad8f-cc2a2614a00d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c08e04a5-3ca3-4216-85b5-229ceb9f4f02" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0bb0d089-5c52-47f1-9f90-62c12736a725" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c08e04a5-3ca3-4216-85b5-229ceb9f4f02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_92b83949-8701-406b-8145-0407ada8db78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0bb0d089-5c52-47f1-9f90-62c12736a725" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_92b83949-8701-406b-8145-0407ada8db78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_d5dea88f-c056-4e99-9599-4147d722da77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0bb0d089-5c52-47f1-9f90-62c12736a725" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_d5dea88f-c056-4e99-9599-4147d722da77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c3fd9ca2-c315-4e7e-bee8-7fb85da4025b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0bb0d089-5c52-47f1-9f90-62c12736a725" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c3fd9ca2-c315-4e7e-bee8-7fb85da4025b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails" xlink:type="simple" xlink:href="cah-20230331.xsd#ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_22b4c562-56fd-4763-84bb-ee9e161bc46a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5d5aca59-3393-4b72-ae91-f32532a314a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_22b4c562-56fd-4763-84bb-ee9e161bc46a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5d5aca59-3393-4b72-ae91-f32532a314a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9309c6bf-7772-4d36-9444-a8c54675e433" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5d5aca59-3393-4b72-ae91-f32532a314a2" xlink:to="loc_us-gaap_AwardTypeAxis_9309c6bf-7772-4d36-9444-a8c54675e433" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2416afb4-686d-495b-9e15-f6e83aee6baf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_9309c6bf-7772-4d36-9444-a8c54675e433" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2416afb4-686d-495b-9e15-f6e83aee6baf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_91df620c-370b-4317-9c02-95c1c05d4d1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2416afb4-686d-495b-9e15-f6e83aee6baf" xlink:to="loc_us-gaap_PerformanceSharesMember_91df620c-370b-4317-9c02-95c1c05d4d1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fb65c2d4-4ba1-4337-884f-c98da59c2283" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5d5aca59-3393-4b72-ae91-f32532a314a2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fb65c2d4-4ba1-4337-884f-c98da59c2283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_ec02c8db-6df7-417d-9f1c-cd7ac7bb0d22" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fb65c2d4-4ba1-4337-884f-c98da59c2283" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_ec02c8db-6df7-417d-9f1c-cd7ac7bb0d22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9d70a7ce-8df5-4988-aa30-d916036aaf5c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fb65c2d4-4ba1-4337-884f-c98da59c2283" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9d70a7ce-8df5-4988-aa30-d916036aaf5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_45502331-e74e-47fe-9f16-2e8e2d9557f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9d70a7ce-8df5-4988-aa30-d916036aaf5c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_45502331-e74e-47fe-9f16-2e8e2d9557f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3067d6ab-3ae0-44f0-a8c0-e560cc42683d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9d70a7ce-8df5-4988-aa30-d916036aaf5c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3067d6ab-3ae0-44f0-a8c0-e560cc42683d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_ac69b541-319b-46c2-82f6-68d0c20e3108" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9d70a7ce-8df5-4988-aa30-d916036aaf5c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_ac69b541-319b-46c2-82f6-68d0c20e3108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_7fa40f2a-2320-4048-b80a-b2ef9796bd00" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9d70a7ce-8df5-4988-aa30-d916036aaf5c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_7fa40f2a-2320-4048-b80a-b2ef9796bd00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9034d7d6-c1ae-4712-998a-4a53486e31ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9d70a7ce-8df5-4988-aa30-d916036aaf5c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9034d7d6-c1ae-4712-998a-4a53486e31ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_03f2b209-4535-48b1-abb4-5517a3e69398" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fb65c2d4-4ba1-4337-884f-c98da59c2283" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_03f2b209-4535-48b1-abb4-5517a3e69398" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f0762474-c201-4abf-af2e-26b8014e2552" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_03f2b209-4535-48b1-abb4-5517a3e69398" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f0762474-c201-4abf-af2e-26b8014e2552" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_12c811ad-6268-4f0d-9372-0dfd7e2426e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_03f2b209-4535-48b1-abb4-5517a3e69398" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_12c811ad-6268-4f0d-9372-0dfd7e2426e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_7ee76213-1bb4-4d46-be5b-2a9dd7e7ac4b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_03f2b209-4535-48b1-abb4-5517a3e69398" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_7ee76213-1bb4-4d46-be5b-2a9dd7e7ac4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_fb640b6e-adfe-49c0-a27e-cc8bb7624165" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_03f2b209-4535-48b1-abb4-5517a3e69398" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_fb640b6e-adfe-49c0-a27e-cc8bb7624165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_bbcb07f8-01b2-4d44-9f69-defb57e89ec1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_03f2b209-4535-48b1-abb4-5517a3e69398" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_bbcb07f8-01b2-4d44-9f69-defb57e89ec1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_8ce902e7-3f7e-4185-a115-61f13d1ba8c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fb65c2d4-4ba1-4337-884f-c98da59c2283" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_8ce902e7-3f7e-4185-a115-61f13d1ba8c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_5a169603-d933-47d3-9c3b-42894d262277" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fb65c2d4-4ba1-4337-884f-c98da59c2283" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_5a169603-d933-47d3-9c3b-42894d262277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_2b241d4a-1dac-492d-b256-b8c7eef85c3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fb65c2d4-4ba1-4337-884f-c98da59c2283" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_2b241d4a-1dac-492d-b256-b8c7eef85c3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>cah-20230331_g1.jpg
<TEXT>
begin 644 cah-20230331_g1.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQ(W@F74'AU.2&W6:,3"X2,;46$[60@;LG(-?HW_P;E_\$AOVX/@;^U!\2_\
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MVF/"OCF?2$#ZI8:/?_Z7:QD[5DDMY LJQD\!RNTG@'-?E?\ \$T/'GCC5?\
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M?\&9/QO\'^/-9GOI_ACXVTSPMI4]U(7D_LY=<T&\MT+'DK']L>)!_"D2*,
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MAXM\-:#XF\!^*+3PUXVU#P[=06$UQ-J^CF%X+ET$<K81Y%",21&Q'0U^V5%
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M&OB[X0WF?'UKX%T-\,US9P+<W]K9Q@L+=+FU!V*"8TF#'Y4=A^SM% '\T/\
MP5Z_;4_X*=_\%O/V'/"5]X;_ ."8/C7P=X'\"^*;2[UZ]@L;W4+CQ!KTEK/
MAL8!:I)]FAC:Z9V D"F:-7=6VA_IK_@Y>_91^/WQ9_X(R?LU>(/AS\*-?UF?
MX?0:/_PENEZ=I4LUWIL,NB)$9I854NJ)+&L;DCY&D7..<?N)10!^!'_!7G]H
M?]JK_@KS_P $ O _Q1T_]ACQOX:\36G[0UE9_P#"&:9H]_J=S-8VVB7ZG4E
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MWCG_ ()3Z[KWQ0L-3U*#X7^-(O#+WL5O)=NQ\U(_L<R:I''.[S1-&Y23>(V
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M1>H:SJOB'Q()'\/^#/"EI%/J-U%&0KW#"62..&%6(7>[@L<A%<JP&'_P2O\
M^"Z_[$?_  5IO=7\'_ FXU_P[XRT*S^V:AX,\8V<,%Y):;E0W4#0RRQSQ*[*
MK$,'0NNY%#*2 ?9]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 ?A#_P?%_\DM_9U_[&#Q)_
MZ(T^OB#_ (+,_P#!'?\ ;%_X)<:7X)\=_'_]K/QA\9?@WXGUF/3]=U+3M0NK
M*XLIQB4VKPW4US%&TD22-#*2ZEH6#*N%W?K;_P '/W_!*G]L7_@J)X%^#VA?
MLB^$M(U6X\':MK-QKBZKKT%B(TN8K18BIE(WY,+YQTP/6OO']NC]CCX;?M[_
M +(GC3]DGXL0J-,\7:(UM#?"(.^FWB8DMKR,'^.&=(Y .C;-IX8B@#\Z_C]H
M?[(W[*__  :G>/\ Q+_P2]GOQX%\4^ HIXM8OK@/J>H2:G?6NGZC)?.@ ^U"
M-Y8)54!8_)\M0%117P9^P=\3?VG=:_X(DWG[$GPK_P"#?KQ%\3O#WQ$T76_,
M^,^FZ^JC4]2FN+A+?5%A_LV0F2R=88T'G];(?,N3C[B_X(P_\$AOV^?@I^QI
M\=/^"7'_  47\'Z4OPD^(.EW3^$]>T'Q1;WLNF7DZ^1<>7%G>H8B"ZBRH5)(
M)"PS+BOG#PA_P35_X.EOV2/V=_$G_!+#]G$^$=8^#NM:A=0:=\1++Q1IUK+I
MMC=2E[A;=IKB.\M4E+.\B+!*RM+)Y;?,6(!V'PX_X)S?M5?$_P#X-2O'O[+7
M[4?P9\0>&?'?PG\0ZKXH\ :+XBLBETEM9,NHDQ(<DB6*XU.! .\F!TQ7RK^T
MK^W3XT_X*4_\$GOV%_\ @F!\/-<-SXV\2>-AX=\51JVYH#IDR:5I1EYRR/;W
MBSN3T-ON)XS7]"W_  3G_9+\??L?_L5>$?V;OCE\;]:^*'B;3].E_P"$I\4>
M)=6N;\WMQ.[/)#$UTS.+6,,(8T./W<8)4%F%?EA_P23_ .#;'X]_L5_\%D-7
M_:=^*N@Z-_PJ/P1>Z]=_"JYBUJ*YN+QYW:VL/-MP=T3):3R2$M]V6%,9X- '
MD_\ P= :-_PJ_P#;2_8G_8V\#?!JZ\<>!O!&@:;!X<^&%O=>3_PD9_M*VLAI
M8<(X5YH;*"W#[&V^<2%.2#@?\%//^'HW_!0#XN_!;X[?"+_@@1X]^#'C#X-Z
MW'=V&OZ->B_DO;>*:WFMK8K'86NQ8)("T?+!?-< +N.?TG_X.#?^"/OQ7_X*
M4?#_ ,!?&G]DSQA::#\:/@_J\E_X1FO;LVT>H0N\4K0"< ^3.DUO#+"[?(&#
MJQ42;T^9/@M^P_\ \')G[?'[9OPN^)O_  4K^)1^"W@3X6RK)>K\._&EM97?
MB*/S(I)XPFC7<N9+DPQ)(\K1I'&&,<>?D8 \^_X+1_"+P)\=_P#@ZO\ V8/A
M5\3?#MKJ^@:GX3\-MJFE7T0D@O(H=5U><PRH>'C8QA64Y#*2""":M_\ !RG\
M.O!'PY_X+)_L/_$+P)X6T_1]5U#Q1I4%Y=Z;9I TJV>O6)M]VP#.SSG"D] 0
M.@%?4G[</_!+?]KWXY?\'"?P&_X*'?#WPII-Q\,? /AO3+/Q'J5QKL,5S%+#
M<ZI)($MV.^0!;J'D#G)]#2?\%Q_^"6W[7O[<_P"WK^RS\??V>O">DW_AOX5>
M(XKSQC<7^NPVLD$2ZI8W),<<A#2GRX)#A>X [T ?._\ P4Q=8_\ @[[_ &6F
M<X!\&Z,.?4W&M@?K2?\ !S9<1-_P6(_80M5<;T\8V#LN>0&\0Z> ?_'3^5>L
M_P#!P%_P23_X* _'S]L_X1_\%-O^"94>G:I\1?AUIUKI\^@7>J6EG*&M+V:[
MM;J,WKI;S(3<S1RQR.N5" !PS!?!OC#_ ,$:?^"[G[9'[9?[/?[??[96K^"M
M7\1^'O&VFS^)O"&AZM:VMIX.T.PU&SN8HXL,5N9Y6:^DD$;2XV1CS&W!4 /+
MO^"C/QL^+-E_P=BZMXHT7]C"_P#VA]0^&6AZ7%X-^%L&H"W,J#P[#>"X5FM[
M@8@N;V>Z \L_. W!&:]"^#O@C_@HU\=?^#@SX1?\%&++_@D#XX_9_P!!E$6C
M?$B,S_;;2\$L-W;3ZC<3+:VP7,$\"%2C?-:J^XD_+],_\%G_ /@D1^W;XD_;
MN\%?\%=/^"2^N:4OQ;\-V$=CX@\+ZI>P6W]J"**2!)HWN2L$@>VE:VFBE>,&
M-8RC;LTG_!+G]A3_ (+;_$O_ (*(WO\ P49_X*O?%ZZ\"V=CI;6>E_"#P=XR
M!T_4I/(:"(7%M87,MK]EB#O, \DDCS;6; 7D _62BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
MR_''C7PK\-?!6L?$7QWKD&F:'H&EW&HZSJ5TV(K2U@C:669SV545F/L*^,M
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MC**6D3R+]NZ72/$'_!X_\!;3X$/#)K]CH>D+XZ.G$&19DMM2DN1-M_B_LHP
MY_@VCIBKO_!*;1].U/\ X.Y_VL+V]M4DET_PMXBN+-V4$Q2'4M&B+#T.R5US
MZ,?6@#W[_@CO_P ' /[1'[8O[;WB;_@G1^W[^RMI_P ,/B;IEC=76EPZ3%=6
MZ[[=5DEL[BVNGD=9/(;SDE5RCHA^494MR_[1/_!P%_P44^+_ .V3\2_V5/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M"[6[Z:;J\L+G>;LW+B;;]B*X\I,^9G(VX/W;10!\)7'_  1BU.?_ (+E0?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O,_P!LK_DUGQU_
MV+T_\A7IE>9_ME?\FL^.O^Q>G_D* /R7HHHH **** "BBB@ K])O^"6G_)K*
M?]C#>?RCK\V:_2;_ ():?\FLI_V,-Y_*.@#Z.HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "O,_VRO\ DUGQU_V+T_\ (5Z97F?[97_)K/CK_L7I_P"0H _)
M>BBB@ HHHH **** "OTF_P""6G_)K*?]C#>?RCK\V:_2;_@EI_R:RG_8PWG\
MHZ /HZBBB@ HHHH R_$'C/PUX6ECAUW4O(:92T8\EVR!U^Z#6?\ \+<^'G_0
MP?\ DI-_\17*?'__ )"6G?\ 7"3_ -"%>?4 >V?\+<^'G_0P?^2DW_Q%'_"W
M/AY_T,'_ )*3?_$5XG10![9_PMSX>?\ 0P?^2DW_ ,11_P +<^'G_0P?^2DW
M_P 17B=% 'MG_"W/AY_T,'_DI-_\13HOBQX FE6&+7\L[!5'V67DG_@%>(U/
MI?\ R$K?_KNG_H0H ^B:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MHZBBB@ HHHH \P^/_P#R$M._ZX2?^A"O/J]!^/\ _P A+3O^N$G_ *$*\^H
M**** "BBB@ J?2_^0E;_ /7=/_0A4%3Z7_R$K?\ Z[I_Z$* /HFBBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M KS/]LK_ )-9\=?]B]/_ "%>F5YG^V5_R:SXZ_[%Z?\ D* /R7HHHH ****
M"BBB@ K])O\ @EI_R:RG_8PWG\HZ_-FOTF_X):?\FLI_V,-Y_*.@#Z.HHHH
M**** /SE_P""ZW_!-'6OVL],N_CK^SQX\USPO\7+;X6ZOX5A71WM?L_BS29P
M\G]C7JW1$8C:9V*2EE\II"^254KO_L6_L6Z)^R)HOB?5=5^)NM^/?'7CW7!K
M'C[Q]XC2)+K6+I8Q%$HBB CMX(HQLBA3Y4!(!YX^K/C_ /\ (2T[_KA)_P"A
M"O/J /+/ W[+6@>!OVM/'O[6EIXJO)]1\>^&]&T>\TB2%!#:II_VC9(C#YF+
M_:#D'@;1BOE/3?\ @B1\6O!_Q#\;_$3X5?\ !4[XO>$;CX@>++KQ#XB@T*TM
M(UN+N=RV6/5@BD(H/"J, "OO^B@#XB^/'_!'SQ_\>K7X1:GK_P#P40^)EKXF
M^$%GJ"Z1XNCM+:2^O+N[E+/>2,W"RB+9"I'18QC!)KT7]F+]A#X[? >^\3W/
MQ%_X**?%+XE0Z_X;FTRRM_%$D2C2)G((O8#&01,H! /O7TQ10!\6_M$?\$A_
M$_[0WPS^"W@G6?V\OB39ZO\ !>6XN]/\8.([S4=6U%RGEW]Q).S$SQ*K*CY)
M7S&((->B_L7?L+_'?]FOXQ-X^^)G_!1'XG_%?3[C3&L8_#?C(P_9(97FA<72
M[.?,41L@[8E:OHVI]+_Y"5O_ -=T_P#0A0!]$T444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% 'R-_P5Y_Y)3X4_P"QAD_]$-7P
M)7WW_P %>?\ DE/A3_L89/\ T0U?AM^T]_P5E/P=^.<GPT^&7P:U+Q3I7A;5
M)+;QUJL*D ,MI--)!;$ @/$(GD=GXVV\JX _>  ^SJ*YSX;_ !6\%?%3X6Z5
M\8O"VJ#^PM7TI-0M[FZQ'Y4)7<?,R<(5Y#<\%3SQ7E_[(O[=7@/]KM/'.K^%
MO#\NEZ-X-U06Z:M?7BE;Z B5A<[=H\E=L>[!)P&Y/% 'N=%?('A[_@L)\*M?
M^(^G:8?@UXNM/ >L:_\ V+I?Q*N[4I83W>=HX*X"?Q'Y]ZK\Q08('UU?WUGI
M=C-J>HW*0V]O$TL\TAPJ(H)9B>P !- $M%?'7AO_ (+$_#G7?&&G3WWP'\8Z
M=\/M8U_^Q],^(]Y;[;*6X+;1E=N O!8@.75024R"!]BT ?LG\(_^24^&/^Q>
MLO\ T0E=#7/?"/\ Y)3X8_[%ZR_]$)70T %%%% !7AGQ,_Y'O4O^NX_]!%>Y
MUX3\4YX+7QIJMU=3)'%')NDDD8!54*"22>@ [T 8M%?)WP@_X+7?\$]?CC^T
MG_PS+X!^,QFU*\>"W\.:Y<:5<PZ7KU[))<1M:6ET\8CD=6@PK$A)BX6%I"K
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M"9%F.$,CS#<%^]G!8;%/[!6]Q!=VZ75K,LD4J!XY$.0RD9!!],5^=D?[!/\
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MKQW_ .$W;?\ R;0!XS17LW_#$GQL_P"B5>.__";MO_DVC_AB3XV?]$J\=_\
MA-VW_P FT >,T5[-_P ,2?&S_HE7CO\ \)NV_P#DVC_AB3XV?]$J\=_^$W;?
M_)M 'C-%>S?\,2?&S_HE7CO_ ,)NV_\ DVC_ (8D^-G_ $2KQW_X3=M_\FT
M?I;\(_\ DE/AC_L7K+_T0E=#7SUX1_:2^-GA7PIIGAC_ (8J\=S_ -FZ=#:^
M?Y]LOF>7&J;MN\XSC.,G'K6C_P -8?&S_HQ_QW_X%6W_ ,50![I17A?_  UA
M\;/^C'_'?_@5;?\ Q5'_  UA\;/^C'_'?_@5;?\ Q5 'NE>&?$S_ )'O4O\
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M3(^M 'YRT5[-_P ,2?&S_HE7CO\ \)NV_P#DVC_AB3XV?]$J\=_^$W;?_)M
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M 'NE%>??!GXQ^/?B;J=[8^+_ ( ^(?!T=K LD-SK4T3+<,6P4783R!SS7H-
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'[C3+^XC\6:S:G:WB;5/(@DCEA5]PM;=CP 6=5RXF]P_X*]?\%N?@MI'P_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!!<:5IEY>V^I7>G02W%H6-I<20JSPEAM;8Q&5R.#CJ*GHHH @N-*TR[
MOK?5+K38)+FT#BUN)(5:2'> &V,1E<@ ''7'-5]=\*^&/%"QIXE\.6&HK"28
M1?6:3!"<9QO!QG Z>E7Z* ,G2/ 7@7P]>C4M \%Z38W 4J+BSTZ*)P#U&Y5!
MP:9'\.?A[%XT?XCQ> ]&7Q%)!Y,FO+I<0O6CQC89]N\K@8QG&*V:* "BBB@
MHHHH **** "H-,TK3-%LDTW1].@M+>,DQV]M"L:*22QPJ@ 9))/N34]% !4&
MF:5IFB6,>EZ-IL%I;1 B*WM85CC3)).%4 #DD_C4]% & _PI^%TCEW^&V@,S
M'))T> DG_OFIKOX<?#R_C@AOO >BSI;1>5;+-I<+"),D[5!7Y5R2<#CDULT4
M 9NA^#O"'AB62?PUX5TW3WE4+*]C8QPEP.@)0#(K2HHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
3 **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>cah-20230331_g2.jpg
<TEXT>
begin 644 cah-20230331_g2.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ K"^*4DD/PR\1RQ2,KKH-X593@@B%\$&MVL#XK?\ )+O$O_8 O/\
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M6:+1-0U O=I$WW9)(HE=H4;G:\@56P<$X-?FY_P;^_\ !;;]L_XF_'SX@?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'X0_\
M!\7_ ,DM_9U_[&#Q)_Z(T^OB#_@LS_P1W_;%_P""7&E^"?'?Q_\ VL_&'QE^
M#?B?68]/UW4M.U"ZLKBRG&)3:O#=37,4;21)(T,I+J6A8,JX7=^MO_!S]_P2
MI_;%_P""HG@7X/:%^R+X2TC5;CP=JVLW&N+JNO06(C2YBM%B*F4C?DPOG'3
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MBC12KM8Y29#P20 #WBBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M3V@'/;R3'CVQ0!]/?\'-'_*8S]@[_L<[#_U(=.H_X*A_\K>7[*7_ &)FA_\
MI;KE'_!S1_RF,_8._P"QSL/_ %(=.H_X*A_\K>7[*7_8F:'_ .ENN4 ?0-K^
MV?\ "1_^#GVY_8W'[#?PW7Q8GAH7!^-PM3_PD;)_PC277E%]N-OEG[/U_P!6
M,5C_ /!4?_@XP^+WP(_;'E_X)V_\$R?V3&^-'Q4TH >)9'M+N]MK.X$8E>TA
MM;(K+</'&0TLGF(D1RI#%7V^+6/_ "N[WO\ V)@_]0R.L?\ X-M9]#T7_@NG
M^VQX?^+$T*_$6?7=;^Q&](%Q+"OB&<W^S/)!<VC''4!3T&: /K#_ ((U?\'
M>N_M[?'SQ!^PO^V;^SN_PA^..@033PZ$R7$,&IK  UQ (+H>=:W,2$2>4Q??
M&'<,-I%>6_&O_@YC_:"^'7_!0/XQ?\$^_AA^PFWQ$\7>&-5FT;X6Z5X7N;F2
M[UN_1XV:2\ 5A#;QV_GRN4&?W:C**6D3R+]NZ72/$'_!X_\  6T^!#PR:_8Z
M'I"^.CIQ!D69+;4I+D3;?XO[*, .?X-HZ8J[_P $IM'T[4_^#N?]K"]O;5))
M=/\ "WB*XLW903%(=2T:(L/0[)77/HQ]: /?O^"._P#P< _M$?MB_MO>)O\
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MU@;5C'TQ_P (UHZ\_P# VB'UH _;2BBB@ HHHH **** "BBB@ HHHH ****
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M^"(=M_P5<^&GPH^%_@?XXV'PPT[X6WUS)8VZ>$CJ$4MO)#!#'!&BW, A6-8
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M/+J:X\5^'].AN5@,L\GFS^1-:W$3"%I,R"W='5'.495"JOZX44 ?#'_!&_\
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M /7=/_0A0!]$T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%'CSX-:?X%:QN/#&G:K<PV\9M-0,S37-U UQ#OCE0*2)!D@!J_1B@ J?2_\
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M''<H%F@D5RDD4B@D!T=64X)!QD$@@GPK]IK_ (*=Z=^S;\9-3^$%Q^SEXO\
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M\$M/^364_P"QAO/Y1T ?1U%%% !1110!YA\?_P#D):=_UPD_]"%>?5Z#\?\
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M^$W;?_)M'_#$GQL_Z)5X[_\ ";MO_DV@#QFBO9O^&)/C9_T2KQW_ .$W;?\
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M<_M;?$JSFN]+\&:,;I=.MG"RZA=/(D-K:(Q!"M-<2Q1!B" 9,D$"O6:^#_\
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MOVROA7XYO_!OQ0^%?C"SL?"GC#1U'VF"RUV>/1K^V))'R/'=+)ZAH%P1N)H
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MP>*Z"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MAF*+4K:.<,NF:7822R2R6S0#[/;VZPR+F3:54$@#0_99_P"";GC7]K[]GO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
3 "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>cah-20230331_g3.jpg
<TEXT>
begin 644 cah-20230331_g3.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** /,OVSOVHO!/[%/[*GC[]JSXAP//I7@7PU<:I+9QR!'
MO)47$-LC$$*\LS1Q*3P#(,\5_/9^RI_P3*_X*8_\'/1\1?MR?M;?MES>!? -
MQKMQ9^$;*729]2M0\3?/#I^FBY@BAM8B1$9C)O>17W>8X=Z_57_@Z?@UZ?\
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M;I^'FL>*;N[^RV&FP:VJ+?3YP(K>9PL5P['A5C=BW\.:_)7_ (.-_@?\-/\
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M%&OV&?VY+K4-._9._:@\)^-[[2H?.U'2])U#%Y;Q;@OFM;R!91'N(7S-NW)
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MJM9>(?'30>"] N8WVM&]_O%RRD<AQ917C*1R&"GM7@WQI_9E_8H_9#_X-AO
M/P0_;ML/'UOX!M?#_AS4O&2?#%;0:S_;%_>Q7S[#=_NBHO+@JQ;GRUP,8 H
M_5+X<_$;P'\7O FD_$_X7>+M/U_P[KMC'>:-K6E7*S6U[;N,I+&Z\.I'((ZU
MM5^?EE_P4[_8'_X)1_\ !'[X!_M!0Z#\3]1^$>MZ9I'A[P)"VG6-UKJQ2V%Q
M<P->KY\,(;RK60.8V(W%0!@DCS3XO_\ !WK_ ,$KOA1\=4^#MGI_Q \3:;!<
M)!J_C;PYHMK+IEG(V ^W=<K+<+&20[Q(RG:3$91@D _4ZO-_V@?VPOV6?V4K
MC0;7]I3]H#PIX&D\47$L'AU/$^LQ6AU*2,QB1(?,(WE3-%D#IYB^M=IX(\:>
M%/B1X+TCXB>!->M]5T/7]+M]1T;4[-]T5Y:3QK+#,A[JZ,K ^A%?B#_P>AWM
MGIOB7]D;4=0NHX+>W\6>(I)YI7"K&BOHI9B3P  "2: /W2KS?]HG]L']EG]D
M>RTG4OVGOC_X4\!6^O7$D&C3>*=9BLUO98PI=(S(1O*AU) Z;A7Y_P#AG_@[
MM_X)1>)/VF$^ 9F\<V.A3ZH-/MOB??Z)!'HCR%]HF8>?]ICMB<?O7A& <LJ*
M"PC_ .#FZ;_@E[<_#WX+W'_!22;XQ2:;)XBU)O!<GP<;32[3F*V,IN3>\&/;
MY6W9SG=GM0!^@GQ@_;!_99_9]\?>&?A9\;_C_P"%/"GB3QG<+!X3T37=9BM[
MG5I6E2%4MXW(,A,DB( /XF [T>,_VP?V6?AW\=M$_9A\=?'_ ,*:3\1/$EO'
M/H'@N_UF*/4M0BD:14>* G>X9H90"!R8V]*_'S_@YH_Y3&?L'?\ 8YV'_J0Z
M=1_P5#_Y6\OV4O\ L3-#_P#2W7* /V#7]L']EE_VBV_9$3X_^%#\4$M_/;P$
M-9B_M41?9Q<[_L^=^/((DSC[ISTKTBORUM?^'8G_ !$_7/E?\+D_X:8_X1H>
M9N_L[_A#OLW_  C2=/\ EZW_ &+'MYV?X:]C_P""HG_!P;^P9_P2K\;6OP@^
M+<_B+Q;X[N+2.ZG\(>";.&>?3H)!F.2[DGEBC@WK\RIN:0J5;8%96(!]ST5\
MA_\ !+?_ (+:?L3?\%:;#5[#]G?6-9T?Q5X?MUN=9\$>+K.*VU&*V+!!=1B*
M22.>#>0I=')0L@=4WIN\V^.7_!R[_P $U_V<?C/\6O@/\7[CQOI.O?"$M%JB
M/H=L\>N78ECB6TTW;=%YI6,F_P#>+$BI&[,RA: /T%HKX7_X)6?\' _[$O\
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MZMD@'[%4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MW@C2_!7PMT2PE\):-X*O]+O+;38TF6]N3;175R9 -QDF^T3&1B<N7).:Z?\
MX*0?\$<OVY/VD_\ @@O^S?\ L#_"OP5HMU\1_AMK&AW'BK3[KQ';PV\,=KI&
MHVLQ2=CLDQ+<Q !3R"3V-?17_!6/_@G_ /M)_M:_\$2;7]B#X+^'=.O/B!%H
M?A.V>PO-6BMX/,L);1KD><YV8 A?!S\V!CK0!ZI_P0]O;K4/^"0O[.D]Y.TC
MK\*-)C#,<D(D(11] J@?A7YE?\'L>EZ=KD_[*FBZO>?9[2\\0^)X+JXR!Y4;
MG1E9LGT!)_"OUC_X)=? /XC_ ++7_!/+X/\ [.WQ?TZWM/$_@[P-9:9KEM:7
M:SQ1W$:X95D3Y7&>XXKXN_X.5/\ @DE^U-_P57U+X Z%^SMH^G3:7X0US6?^
M$UOKS5X+:2QM+PZ:HEB24CSF"V\YVCNH'<4 <C_P=6_L>_LR^ O^",.GW'@;
MX4:!H$OPN\2Z):>!FTW3XX9+.VE?[++:HR@,8VC?>RDD,T*N<LH-?"W_  75
M\8^)O'W_  1/_P""=OBGQA<RSZC/X8\N>XG)+S"+3K"))&)Y9F1%8D\DG/>O
M8?VD/^"1G_!RC^WIJ'@G_@GQ^U[\6?"MY\#? ^LPNGQ2M=1L -3MX$:&*[GM
MT<7UU=);LZHDD:(9&S)(3^^KZ9_X+_\ _!%W]HK]KW]F/]G+]F[]@7P-IEYI
M'P:,M@UKK&OP69M]/CL[.VML-+@2-MMSG'<9[T >.?\ !S1_RF,_8._['.P_
M]2'3J/\ @J'_ ,K>7[*7_8F:'_Z6ZY7T1_P6Q_X);_M>_MN?\%%OV5?VCO@!
MX4TF_P#"WPI\26EYXRN;_78;66WBCU>SNF,<<A#2GRH7.%[@#O1^W'_P2W_:
M]^.?_!PE\!?^"AOP]\*:3<?#+P#X;TRS\2:E<:[#%<PRP7.J22!+=COD 6ZA
MY YR?0T ?.]C_P KN][_ -B8/_4,CKDO^""'PJ^'O[8O_!>']L#]H?\ :?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!R7Q\^"?@+]I+X(^+?V?_ (I:9]L\.^,_#UWHVLP+@,;>XB:)RA(.UP&W
M*W56 (Y%>,_\$F/V*_BI_P $\?V(O#?['_Q4^,-AXY?P??7T>@Z[8Z;):G^S
MIKA[B*&1'=SOC:6100<! @'2OI.B@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH S?&-OXIN_".JVO@;4+2TUN739TT>[OX3)!#=&-A$\B*060/M+ ')
M(KYC_P"".W_!,C3?^"67[*EQ\%]3\>Q^,/&'B/Q1>^(?'7C%;1H?[5OIV"J0
MKLS*B0I$N"QR_F/QO(KZNHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M51]EEY)_X!7B-3Z7_P A*W_Z[I_Z$* /HFBBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ KS/]LK_DUGQU_V+T_\A7IE>9_ME?\ )K/CK_L7
MI_Y"@#\EZ\8^./[??[+_ .SQ\3-)^$_Q+^(L%MJVHSA+Q(1YBZ3&T32)+=%?
M]4KD*H'+?O%8@)EQ[/7Y-?M :9\/?@K^W9XGT3]LOX97,GA;Q9X\O=77Q;]C
M:8S:1<:=>P1PPD*6_<R7,#9C.Y&@S@E$H _3SXA_&[X2_"CP-#\3/B%\0--T
MOP_<-$MOJ\\^8)3*,Q[67.X,.01P1S61\(?VJ/V>?CYK%UH'P<^+&E>(;RQM
MA<7=OI\C%HHMP7><@<9('XU\A?\ !1W3_!5O^RG\#OA%\ ?"VI^,?!U[XLLK
MG3+'2)9KN34+""%@MN),,V7%P% /(( P-N!W7_!-WQO^S7?_ !1\7?#_ ,*?
MLE2_![XCZ/8)_;.@7=Y+/)<6!="'5Y AP&:(D%!Q(A5F!. #[#KEOA5\:_A9
M\;].U+5_A1XRMM;M=(U>73-1N+17"17<85GCRRC=@.IW+E3G@FN/_;$^%GQZ
M^-/PVLOAI\"?B=#X0.J:PD7BG6RI,\>E&*7S5@P,^:S^4!AD.,_.!FO"/^"(
M.CP>'?V?/'GA^UE=XK'XJ7]O&\F-S*EI9J"<=\"@#[0K])O^"6G_ ":RG_8P
MWG\HZ_-FOTF_X):?\FLI_P!C#>?RCH ^CJ*** "BBB@#S#X__P#(2T[_ *X2
M?^A"O/B0!DFO0?C_ /\ (2T[_KA)_P"A"OSQ_P""X_B*/1?V6/!ND^-/$.IZ
M1\-=?^,WAS2OC/JNE3RPM;>%9I9?M7F2Q?/%"\JVT4C+SLE*\[L$ ^M_!7CS
MP5\1]%;Q)X \56&LZ>E[<V;7FFW2S1BXMYG@GBW*2-R2QNC#LRD5K5^>O_!'
M[]AWX6_#;7(OVN?V3/BA:Z3X+UN_\::%XH\&:/,]]INOK;^*+]-(OXI//*0O
M#9QQQJZJ_F0LN"-[,W)?\%.OVC/BA\8_VT/@Q\/?A%X@EM/AM\*_VF_ >D>/
M-0M9&"ZWXFO;^.5-.5E.&CL[1=\PR1YMY&I7,>0 ?IO117Y1?!']F=OVT?V&
M?'7_  5?^)/QW\<Z9\9]0E\4:[X%\0:9XQO+6V\#P:5=WD-IIT-FD@MWM\68
M\Y)8W+K*^2"2Q /U=J?2_P#D)6__ %W3_P!"%>4_L4_'6^_:<_9#^&G[0>K6
ML4%]XQ\$:;JFI00+B..ZEMT:=4_V1+O ]@*]6TO_ )"5O_UW3_T(4 ?1-%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45Y'^
MU[^U1_PRIX4TGQ/_ ,()_;W]J:BUKY']J?9?*Q&7W;O*DW=,8P/K7@/_  ^+
M_P"K=/\ R[O_ +DH ^VJ*^)?^'Q?_5NG_EW?_<E'_#XO_JW3_P N[_[DH ^V
MJ*^)?^'Q?_5NG_EW?_<E'_#XO_JW3_R[O_N2@#[:HKXE_P"'Q?\ U;I_Y=W_
M -R4?\/B_P#JW3_R[O\ [DH ^VJ*S_".O?\ "5>%-,\3_9/(_M+3H;KR/,W>
M7YD:OMW8&<9QG SZ5H4 %%%% !116%J?Q*\%:/?RZ9J6M>7/"VV1/LTAP>O4
M*10!NT5S?_"W/AY_T,'_ )*3?_$4?\+<^'G_ $,'_DI-_P#$4 =)17-_\+<^
M'G_0P?\ DI-_\11_PMSX>?\ 0P?^2DW_ ,10!TE%<W_PMSX>?]#!_P"2DW_Q
M%'_"W/AY_P!#!_Y*3?\ Q% '245C:+\0?"'B&_73-'U?SIV4LJ?9Y%R!R>64
M"MF@ HHHH *\S_;*_P"36?'7_8O3_P A7IE>9_ME?\FL^.O^Q>G_ )"@#\EZ
M_,_]L_\ :"^.6G?'Q_@C^TY\!+OQ?I5CXKU.Z\!QZ3H>Z+6+&YTJ]MK>$  ^
M9(DD\#LR[G0I)@910?TPK'\1> O"7BO7M#\3>(-'6XOO#=])>:).977[-/)!
M);NX"D!LQ2R+A@1\V<9 ( /C;PUXD_:W_P"">_[$WP<6Q^%B^(-,TRYN&^)V
MF0V4EQJ6G6MQ=-<QK#LD"H4222-RRLJN$&5!)JK^S9XM\7?&W]KKXF_\%$])
M^$FOZ5X0TCX>OIOAVPUBV^S7>MSQ1QR$*%WC_E@RY7> 7C&200/NNB@#@OV8
MOC3J7[0_P-T/XQ:O\/[OPM<:Q]I\S0;^9I);7RKF6 ;F:.,G<(PX^4<..O4^
M"?\ !'OP[X@\-_"'XBVWB+0KRPDF^+6I30QWMJ\321FWM0'4,!E3@\CC@U]<
M44 %?I-_P2T_Y-93_L8;S^4=?FS7Z3?\$M/^364_[&&\_E'0!]'4444 %%%%
M 'F'Q_\ ^0EIW_7"3_T(5\H?MQ_M1?"?]F7PGX/M?COX!BUGP=\1/'-GX-UR
M\U%86T[2UO4EVSWRS H;8F/8VX;1O&X@5]7_ !__ .0EIW_7"3_T(5X[\5/A
M/\-/CC\/]3^%7Q@\#:9XD\.:S!Y.IZ-K%HL]O<("&&Y6'4,%96'*LH8$$ T
M?DO^S)\-;7]F?]L;P3I?_!/.YLM)\7_$RU^,L/CCP9%?NVCK#I6K:G#X<OI[
M4$I:HMS';VJNJJ&C5E49,A?F?CI\+?\ @JY^R_\ L_? /X->/?@-\(?+L?VE
MO"^J:?XAM_&-Y<W_ (D\73ZC+.L^H,R !+BX=S+(O*+M5>% 'Z7?L'?\$VOV
M9O\ @GYX=U:R^#'P^T:WUG6]5U";4?$=MIS1W4ME+?3W%K8EY))7\JWADA@
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M)_$?P-_8$^#GPF\8V$EIK&B?#G28-7LY5P]O=&V1YHF![I(S*?\ =KW+2_\
MD)6__7=/_0A4%3Z7_P A*W_Z[I_Z$* /HFBBB@ HHHH **** "BBB@ HHHH
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MM/\ DUE/^QAO/Y1T ?1U%%% !1110!YA\?\ _D):=_UPD_\ 0A7GU>@_'_\
MY"6G?]<)/_0A7GU !1110 4444 %3Z7_ ,A*W_Z[I_Z$*@J?2_\ D)6__7=/
M_0A0!]$T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M9G*-=VO(V.%=&W $KN##*\,&PN/W'_X=[_!/_H;?'?\ X65S_C1_P[W^"?\
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M>:]?_P"'>_P3_P"AM\=_^%E<_P"-'_#O?X)_]#;X[_\ "RN?\: /EG_@E_\
MLT?$W]E_]FB\\-?&VULHO&GB;X@>(O$_B<V%V)XWN+[4II8V\P ;B;<09]#D
M=J^BJW/^'>_P3_Z&WQW_ .%E<_XT?\.]_@G_ -#;X[_\+*Y_QH O_!C_ )'N
M#_KA)_Z#7LM>%_\ #O?X)_\ 0V^._P#PLKG_ !H_X=[_  3_ .AM\=_^%E<_
MXT >Z45X7_P[W^"?_0V^._\ PLKG_&C_ (=[_!/_ *&WQW_X65S_ (T >Z5Y
MG^V5_P FL^.O^Q>G_D*Y?_AWO\$_^AM\=_\ A97/^-'_  [W^"?_ $-OCO\
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M%^,^L_L]?M&?M<Z/X7\9>'_L_P#;&A76CZC+);>?;Q7,66AMG0[H9HGX8\.
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M8X\!>%?VN_\ @M#^T]^U%\9M#MM<N_@??Z%\/OA+::G")H_#L7V'[9J%U"C
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M%,GQ-_: ^%W[0/C/]I3XV:I9Q?$?XB:I\'KN.TM99I$2'2;)F;%II=J650
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MU'_@N1^Q[XKT_P -W\^EZ;X'^(T>HZE#9NUO:O)960C620#:A8@A0Q&<'&:
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MP')>5I(78RAEPNT],9KZ.H **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
#/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>cah-20230331_g4.jpg
<TEXT>
begin 644 cah-20230331_g4.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MX6_\$OOVU_"/Q.^ OC3PYJVO^&;J/0M+U[PM=V=QJ+G1-00+!'+&K3$NRKA
M>6 ZD5]H_P#!O)_P2)^/W_!.CPM\3?CW^V7XMT_5/B]\9M;AOO$5OIUTMPFG
MQ1O<3$/,H"23RSW4TDGEYC&V,*QP:_2.@#\LO^#0[X/_ !:^"?\ P3"\2^$O
MC-\+O$7A'59?C-JMU%IGB?1)["X>!M-TM5E$<Z*Q0LC@-C!*L,\&O*_^#.3X
M#_''X&_#3]H"T^-?P9\5^#Y=2\6Z/)IT7BGP[<Z>UTBPW@9HQ.B%P"RY*Y R
M/6OVAHH ^8_^"S_A+Q5X\_X)2_'WP;X'\,ZAK.KZE\--1@T[2M*LI+BYNI6C
M^6..*,%G8]E4$FOG/_@V+^ WBGPQ_P $8M-^"G[1?P@U326U/Q%XBMM9\+^+
M]#EM9+BSN)F1DE@G16,<D;,.1A@37Z444 ?SZ?\ !.?]G[]K+_@@]_P7B\1_
MLZ:%\&O'_B/]GOXH7L6FQ^)M)\-7M]86]C<NTFE7L\\4;(LMI*[6L[N5VH]Q
M)C:4-<-\!OB5^U!_P1._X+-?M"^+OC3_ ,$U/&OQHU[XG>(M3N/ASXBT+299
M;BZ%SJ,UU#/9W(MY@R7"3(LPCS)&T04@E66OZ1** /PP_P"#</X6_MH?#3_@
ML;^TSXT_;2_9I\3>!_$'Q*T2\\17MS/H<_\ 9*WUSJL-]+:07FTP2,!>'"K(
MQQ$XYV&O*?\ @@]\2?VM/^"9G_!57XK_ + WQ%_8A\5:I9_&#XE6]GJOBN6R
MNXK?0[.SEU(I?*%MGCNK:9+M6$OF1HJ@-N8' _HEHH _F]^ ?BK]JO\ X-E/
MVHOC+\!_B'_P3IUGXS_"[QMJJWOPZ\26%B_E.(C,+5ENA:SH&:&5([B!@)$>
M)67*X\S]/O\ @W\\7_\ !3KXR?!+Q7\??^"D'P_T7PDOB/5H_P#A7?AR+P-;
MZ)J<-@#(\LMS'$B-Y+%XDA651(5A=VW"1&/Z"44 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MXC\4^ OB'J5C:>%=0\"Z=#=272W=C/>P3[;B> +$T,#'.=P+*"O7'GO[&/\
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M>!O@QX6\*Z[\/O%FDV'A.ZT#1H+)ULYRT$M@/*5=T.TB79V: $8YSXK_ ,%
M_P!B[_@I)^VS^P[^PU_P5,_9,\/S>-?B+\,?A?HUWKFA2PPW-[/<1I:W5OJD
M5M<92]+R1,TL0#.V^,JCC=MJ>*?^"4G_  <E_P#!6KQ'X&_9W_X*M^.M*\(?
M"+P9JL5YJ6K0:KHLUQJA13$UPD.F/(UQ>&)G1'N!'&GFNV,EE;[&_P""R?\
MP2<_;?\ B#'\%_CA_P $E?C3>>%_$'P,T^QTW2/AC=>)I;72+^TL75K%XHI&
M^RM/%@Q.MP LT)56<>4%< ^%_P!ES_@N-\,OC5_P40^&>C_\%M/^"7/AS0OB
MWI6J6&D>%_BDF@WNFWN@7)NE-I+=:;>ECM2Y(?SU<&$[F2/&0/3/^"S_ .QW
M_P %8OV,_P#@KS>_\%FO^"=_PB;XBV6L>'[2WU"RL] &LS:2\.GQ6$]O+8J?
MM!ADBMUE$]O@J7D#,G\=E_\ @E]_P7/_ ."OW[:/PA^+?_!7_P"'/@#X7> O
M@_J0O8]/\,7]E-<ZHAGMYYH8EM+N[.^=K:%&>65$B4,R(6)5_9/^"F'_  3V
M_P""S_PC_P""D,?_  4Q_P""3OQ17QS'JFF"TU?X2^-/%86SLF,*0S1P0WMQ
M%;FUE\J.8A)8I(YMQ7((P >5?\$./^"M_P"Q]^V1_P %+-0TG]HC_@G9X9^%
M7[4GBZSN@/'VB0SA-7G@L\W-LUO<DRZ?,;:!F.&?S?+;>P<C?^X%?CS_ ,$V
M/^"47_!3SXV?\%78_P#@L-_P5STGPEX.\2>'M*>T\+^!?"EU;3F28V4EE&TA
MM9IXT@CAFE<;IY97D*YVJN#^PU '\EFA? C_ (7=^R[_ ,%-=2M++S[_ ,"?
M$[P[XHL%VYV^1X@UN"X?VVVMS<G\,=Z]"_98^-FK?\%4OVW]?^/^O)-=P? ?
M_@G]J=E-<72G:]];>%7T^Y;![F_U6\D7UV;ATS7Z)?\ !,S_ ((G_M7_  =N
M/V\?"/[3?A+1M/T+]H_3KVP\&3VFN0W32QSOK/[R18R3"5%] PW<@Y[K7%_\
M$0O^"#7[9O[#_P"S#^U=H_[1/@O0K/QQ\5OAE+X7\!6MAXA@N4(>RU!9!)*A
M*QAYYK4?,1CRB>E '(?\$,/'O[&?PU_X-E?BKXN_X* >'&UOX46WQ-U+_A)=
M!B,GG:H^-*^S6L(CDC8RO<B$+\Z '!9E4,P^<_V^/VL?CE^T5_P1>U7P1^R7
M_P $7M.^#_[)_AJ73;C3OB+XKUC[5J(0ZO D-Q8&<Q2R237,HADE7[7E)9@T
MG)9?LO\ 9U_X(#?M=ZC_ ,&]?Q!_X)J?&-]#\+_$S4_B/-XI\+8UE+JQD>+[
M"\,<TL&[:LOD31DX)0LKD$#!\8N_^"8'_!S!^U=_P3EA_P"":WQW\._#OP%\
M.?AUHT,?AZW?6+&?5/&7V)U:PL))[2ZFBCAC*HPD=8"/*0N)&% '!_\ !6RX
MN+G_ (-0/V,Y+J5G8>,M)0%C_"NE:VJC\% 'X5^@/QT_96^!/[$G_!NIXJ\=
M_LZ_!+PSX>\9K^RO'I>I^+]'T*"#5;Z*_L[8W[S72*)9#)(S3-N8@,H(QM&/
M&?VU?^"-/_!1']HS_@@!^SO^P-X;^&6A)\4/AGXVCN?$FES>*[5;5+&"#5X(
MY8[C=L<LMS;$J.078?PYK]0?$OPE^&4'_!/"Z^!O[66H:?I7A&+X/'1/B)>7
MFH1PVUE8KI?D7LK3M\D:QH)&\T\+MW=J /S[_P"#8/\ 8[_94^)/_!#,6?CW
MX7>']87XHZKX@A^(DM_8Q227*1W4UI%$\C LJQV\4;H,@(SEUPS$GX^_X-A[
M>UM/^"8O[?5K970GAB\'2I#.!CS%&BZN WXCFK_[#G_!(G_@L/X-TWQA^R9^
MPI_P5$^'%_\ LH^,M>G3Q-\0_ OBO3]4'V.2-%G\E$26:SOGM?+#QPS1H25S
M,5P]:7_!I[\*?$_Q/_X)\_MJ?#CP#;+<W?BK3UT+P^T\PC2>ZETG4HHU9S@*
M,S19)X ;- &%_P $K?\ E44_:P_[&WQ!_P"F[1*]^_X(I?LH? /5O^#77XA^
M)=9^%NB7FI?$#P;XZOO$6HW6FQR3W$UH;ZWM&\Q@6'DBUC>/!'EN"ZX8DGI_
MV$O^".7[<GP&_P"#?+X]_P#!/3XB^"]%M_B;X_\ $&K7?AO3;?Q';RVTT5Q9
MZ9%&7N%.R,EK:4$$\8'J*^BO^"9'_!/_ /:3_9A_X(1W'[!OQ;\.Z=:?$:3P
M?XQT]=/M=6BGM_/U&XU![4>>AV8*W$63GY<G/2@#PK_@R^OKJ[_X)2>+(+B=
MG2V^.6KQ0*QX1#I6D/@>VYV/XFOKG_@MY\3_ -@#X2?\$_\ Q#XK_P""DGPZ
MG\8_#TZE:0VWA&QGFBNM8U0EC;00-%-"5D&V23<9%"+&[_P@5YA_P;8?\$\_
MVFO^":7[!_B3X"_M6^'--TOQ'J7Q4O\ 7+2WTO5XKV-K.73]-@1C)$2 V^VE
M&WJ  >XKHO\ @X0_X)E?$S_@JA^P"WP/^">M6-MXR\,^+K3Q1X;M-4N/)MM2
MF@M[FV>U>3!$9:*[E*,1M\Q$#%59F !^+G_!7?\ :?\ VIOVFO\ @E9X'MO"
M7_!(#2?@/^S3X7UC24\!>*M=U);C5YU-O+':"V\P03&*>(O(\OE2B3 8S,6#
M-]<?\%1O^";_ .VY^UW_ ,$XOV%?VQ_V(M!'BOQC\%_A1X?OKKPLRP37$YDT
MW2;F*[@@N/W5R8Y;3$D!#-*'0!'VL#PW[0/_  2__P"#E_\ X*._L&:+^S!^
MU/H'PZ\'Z)\)K;3%\(>$(-7L3J/C*Z@"6<<]W=6MS/;Q""TDN'SNB#L /)9F
M#I]*_MO_ /!)/_@I]\6OV%OV6?%O[*/QFO/!'QN_9^\$:'IFM^ ?^$S9-(UF
MYTZ&W$5Q&58VCSI-;[QYR[)(YMCNOEA6 /CWX.?\%TO!?Q._;?\ AIH'_!>;
M_@EEX>L/'WAG4K?3_#WQ+D\.WNE:AX>=[F,Q7-UIEX2)D295D\Q6!AQ(T49+
M,I_HVK\(O'7_  3 _P""]?\ P6A_:0^%,O\ P5T^&OP^^%WPV^%VIO=W/_"-
MZA8376J12/ URD26EY=L9IA;QIND>**,;G",1L;]W: /QO\ V]_VY/V*/@9_
MP6%U/2/V'O\ @E=J?[0_[8$.C+;>(]>L-5N(K/2U>T@0;U/G1-+%;+ CRB*(
M1(_E^>"TBCYQ_P"")&I?M"WG_!T+\5=4_:=^"/A[X9^/-5^'^IW7BKP/X3DC
M:QTV2:+2YE16BEE1W93%+(P<YE=S\I^4>T?M2_\ !,'_ (+1?L7_ /!9CQQ_
MP4H_X)/^ /!WQ T[XJ6<\6KV/BG6+2!-.2Z^SM=6]U%<W5L[H+BVCGC>W<L
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M_BY8>.+KP6]W;:3X@L-.DM?,T][AYH(G1W<AHQ(8Q@XV(@[&OC/P7_P>+_\
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M,?@K_@RB_8!T;Q';:GXV_:=^*^MZ?#('FTR"33K3[0 <[&D%L[!3T.W#8/#
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M-^'_ !_)&FA>+8M&U+2OL*2.$6XF@U!G\^!6=!*Z.C1 EBC8VUQG_!9N?0]
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MW9P<8H_X+B?\$8=3_P""Q/A?X;>'--_:'@^'Y^'^LWU^\T_A9M3^W"X2!=@
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M;"ZD5 TEI(<-#=1YX\V&98YD)XWQKGBO2J* /SE_X)F_\$$;[]C#]C?XL_L
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M#-$N+T6<JV]U";N[NIRJ2E%M+..XFD 5LM$(]P+AA] :7_R$K?\ Z[I_Z$*
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M (65S_C1_P .]_@G_P!#;X[_ /"RN?\ &@#W2O,_VRO^36?'7_8O3_R%<O\
M\.]_@G_T-OCO_P +*Y_QH_X=[_!/_H;?'?\ X65S_C0!^7]%?J!_P[W^"?\
MT-OCO_PLKG_&C_AWO\$_^AM\=_\ A97/^- 'Y?T5^H'_  [W^"?_ $-OCO\
M\+*Y_P :/^'>_P $_P#H;?'?_A97/^- 'Y?TU885E:98E#L &<+R<=,FOU"_
MX=[_  3_ .AM\=_^%E<_XT?\.]_@G_T-OCO_ ,+*Y_QH _+WRH_,\[RUWE=I
M?'./3-?I1_P2T_Y-93_L8;S^4=;7_#O?X)_]#;X[_P#"RN?\:/\ AWO\$_\
MH;?'?_A97/\ C0![I17A?_#O?X)_]#;X[_\ "RN?\:/^'>_P3_Z&WQW_ .%E
M<_XT >Z45X7_ ,.]_@G_ -#;X[_\+*Y_QH_X=[_!/_H;?'?_ (65S_C0!TOQ
M_P#^0EIW_7"3_P!"%>?5N?\ #O?X)_\ 0V^._P#PLKG_ !H_X=[_  3_ .AM
M\=_^%E<_XT 8=%;G_#O?X)_]#;X[_P#"RN?\:/\ AWO\$_\ H;?'?_A97/\
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M1_\ !0GP_J'B3]CK]HC1?&L6DLHU6SM8Y[6]L@V=C36EU'%<1(Q!"NT85BI
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M4#$*I., D 'TI1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M 'BJ^\:6GBS45^"FB^ _AIJ6HV7Q(\.3H#IT-O+$D\/VO!:&X65T16/&>44
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MLKK]M_P?]ILX+&-(I<V>I@[D PV0 #D=!3O^"^_[)GP=OO\ @G/XX_:8\!^
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MJ2:A\/KRYET+Q'HVH++]GO;1;K,\)22&2*2*0DAMI!()Q]74 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?F?
M_P %MO"_[2/C/_@I#^PQX:_9&^)^A^#/B'<ZO\1?^$>\2^(]'^WV5GM\/PM/
MYD'_ "TWVZS1CT9U;M7TG^PM\(O^"J?PZ\<:UJ/[?G[77P^^(N@W&E+'H>G>
M#_ _]E36MYYJDRR/CYT\L,NWU(-;_P"T;^Q9J?QV_;;_ &=/VN+3X@0:;;_
MN]\53W>AR:<TKZN-7TG^SU"2AP(?*/[PY5MPXXZU[]0!^17_  4J_87N=9_X
M+ ?#O]G?P-\19/#_ ,,/VV89[KX\^%+.)E_M67P?'#J#-&ZD>2;V&6&VE*\D
M+(S%B^*_47XL_$SX+_LS?!K5/BO\6/$&D>%?!7@K23=WVH7:+%;:=;0KM4(J
MC@XPB(@+,65%!) /F/[0/[%>I_&S]O']GG]LJU^($&GVWP/M?&$-UH$FG-))
MJ_\ ;>GV]HI24.!#Y1@+'*MNW8&W&:\\_P""PG_!.?X[_P#!27X<> OAI\(O
MVC]%\!Z=X4\;0^)=;L=?\(?VS::[/; &SAGMS+&DL"2%W:&0/'(=FY?D% '$
M?\$_/#GQ6_;A_:TU3_@LG\??"%YX*\'KX*E\+?L\^"=<417D'AV6=;BZ\07Z
MDXBGO"B>6F<);@9W@I(W)_\ !>KX5_M&>+_@1%^V/X2^/&B>,/@-\,ETCQ=X
MS_9[DTE(+7QM;V%X;J2X;6H)3*5"&&1+;88&:U5FW$@5[/\ LR?LH?\ !4OP
M]\0YHOVX/^"A?@[XK_#F_P!#O-/U;P3IGP>M-&>Z,T1C4FYBD+! "V5 ^8'%
M>'0_\$4OVU+GX'V__!-[6_\ @H183?LIVM\L8T:'P44\8W.@K<_:%T"34O.\
MH0#B+[0L8D,:[=H0^6 #]%_ 'C71?B3X$T3XB^&VD.G:_I%MJ5@9DVN89XEE
M3<.QVL,BM>JVBZ-I7AS1K3P]H5A%:6-A;1V]G:PKM2&)%"HBCL H  ]!5F@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
6444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>cah-20230331_g5.jpg
<TEXT>
begin 644 cah-20230331_g5.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQ(W@F74'AU.2&W6:,3"X2,;46$[60@;LG(-?HW_P;E_\$AOVX/@;^U!\2_\
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MVF/"OCF?2$#ZI8:/?_Z7:QD[5DDMY LJQD\!RNTG@'-?E?\ \$T/'GCC5?\
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M?\&9/QO\'^/-9GOI_ACXVTSPMI4]U(7D_LY=<T&\MT+'DK']L>)!_"D2*,
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MAXM\-:#XF\!^*+3PUXVU#P[=06$UQ-J^CF%X+ET$<K81Y%",21&Q'0U^V5%
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M&OB[X0WF?'UKX%T-\,US9P+<W]K9Q@L+=+FU!V*"8TF#'Y4=A^SM% '\T/\
MP5Z_;4_X*=_\%O/V'/"5]X;_ ."8/C7P=X'\"^*;2[UZ]@L;W4+CQ!KTEK/
MAL8!:I)]FAC:Z9V D"F:-7=6VA_IK_@Y>_91^/WQ9_X(R?LU>(/AS\*-?UF?
MX?0:/_PENEZ=I4LUWIL,NB)$9I854NJ)+&L;DCY&D7..<?N)10!^!'_!7G]H
M?]JK_@KS_P $ O _Q1T_]ACQOX:\36G[0UE9_P#"&:9H]_J=S-8VVB7ZG4E
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MWCG_ ()3Z[KWQ0L-3U*#X7^-(O#+WL5O)=NQ\U(_L<R:I''.[S1-&Y23>(V
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M%&G:KI-]+9ZEI]WXSM4EMKB)RDD3J7RK*RE2#T(-?25?S$_\$FO^"4W[*O\
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M6T[]HSX!Z/XBL=!CU";1F@\46,-O<_:+9(Q(=D,TJ[#O&#NR><@4 ?05%%%
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M!(#M$J1NZJW'(#L/>@#T"BBB@ HHHH ***^<OBS_ ,%+/@]\$/\ @H9\/?\
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MM4-U%XJT""*8K\R1O=Z^SJ#Z$HA/^Z/2@"Y\ /\ @ZU_; _:M^#)^$_[-?\
MP37N_&G[2EM>W+:GX>T2.ZET*STJ!4W:A(F[[0C>:X@^SM( &P?.RZQ'Z^_X
M(/?\%LM;_P""MGPY^('A[XQ?!VR\%?$GX97=O%XDTG37F^QW<%QYXCECCG)E
MA=9+>:.2)V?:0AW?/M7XQ_X-/- TE?\ @HE^VYK"V48N++Q-#:VL@49CADU?
M5F=!Z F&/C_9'I4G_!LM%';?\%8?V];6W0)&GBJ]5(U&  -=U( 8]A0!UO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O,_P!L
MK_DUGQU_V+T_\A7IE>9_ME?\FL^.O^Q>G_D* /R7HHHH **** "BBB@ K])O
M^"6G_)K*?]C#>?RCK\V:_2;_ ():?\FLI_V,-Y_*.@#Z.HHHH **** .8\?_
M !(_X0:YMK?^QOM7VB-FS]HV;<$#^Z<]:Y[_ (:#_P"I1_\ )_\ ^UU!\?\
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M0 4444 %?I-_P2T_Y-93_L8;S^4=?FS7Z3?\$M/^364_[&&\_E'0!]'4444
M%%%% 'F'Q_\ ^0EIW_7"3_T(5Y]7H/Q__P"0EIW_ %PD_P#0A7GU !1110 4
M444 %3Z7_P A*W_Z[I_Z$*@J?2_^0E;_ /7=/_0A0!]$T444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%&*A26'].'_!+3_DUE/^QAO/Y1T ?1U%%% !1110!YA\?_\ D):=_P!<)/\
MT(5Y]76_M:^-_!_PUT0>/OB!XFLM&T32--GNM3U74KA88+6%,%I'=B J@=S7
M(0S0W$*7%O*LD;J&1T;(8'D$$=10 ZBBB@ HHHH *GTO_D)6_P#UW3_T(5!4
M^E_\A*W_ .NZ?^A"@#Z)HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "OB/\ X. ?B/\ MK_![_@GMJGQ1_8I\/6NM76C
MZY:OX_T232OM<]WX=82+<FW4999%D,!9E!*Q>:W\-?;E>9_ME?\ )K/CK_L7
MI_Y"@#^6G_@GMHNK?M!?M;>$/CCX)^#FI>']*\'OXIN?%?B6]LQ"NJ3:A>7S
M6UH''$SPI<H"3RNQ@<!4)]U_;_\ #OB#6/VS?V7M3TG0KRZMK#Q=J+WUQ;6K
MNENIDT[!D900@.T\G'0^E?4/@;P%X2^&V@GPSX)T=;&Q:^NKPP+*[_O[B=[B
M9\N2?FED=L9P-V   !6Q0!X[\3_VDK[P]^U%X6_9*A\!W>WQQX=O;J'Q?'>%
M8["2*&Y;RQ'Y?SMB 'B12-X...?@O]L'_@F5\:OV8_V7IAX>_:B\1^--#378
M"? UEX<FAMWFD8YN=BW<J[EQG.S//45^E>K?"#P[KWQATGXSZQJ6H3WV@Z3/
M9:-IS7 %G:M.?WUR$"Y,S(%CW%B @( !))ZN@#X:_:FEU;]FSX<_"_X;?M3?
M""X^.O@.WCNO^$E\9SZ5+-J]O>EY'BV!K@B+*R1)\TGSK$XR, "G^P_\,?C]
MX(^$WQL_:K^$OP9LO#VO>-;M)_AQX)UK3VC2/3[5I6CB,*-&1OCD\M.5!:)6
M^XPS]XT4 ?F_XV^./Q._X*3^)/@_\#;/X$>)M!U_PKXJMM7^).KZCI36]GI[
M0 +*8B264-^\8))M8-L0;N6K^D;_ ():?\FLI_V,-Y_*.OS9K])O^"6G_)K*
M?]C#>?RCH ^CJ*** "BBB@#\2_\ @Y>O/ASXL_:R'PS_ &K]?DM/ UC^RIXA
MUSX06&HZA):Z;J7CM;N:-P2K*D]U%:"W,,;DC,IVC<X#?2'[+7[+.N?\$]?@
MA\3M)^"&M7OC[PFU]?>)/A+\-4G*/I<;6@D&C6][-+(&BEN$/EE@JQ^<2=Y+
M-7/?\%\_V@_V?_'.F_$K]@OXV?"&PN-9M/V==6\?>!->\1PV\MO=W47VB$I8
M[P62\@,7FDH0X1MP^7)KC?\ @D9X=\-_!W]HO]I[]EGX#^)+S4/@S\/O&.B)
MX!MYM4DOH-'O[K3WFU;3;>>1F)CAG$7[O<=C2,#EBS, 87_!,G5/VPM1_P""
ME?[0$W[:VO:7_P )7=^ /"-]%X9\/W3RZ?X:M)I=1:'3H7/$C1KS)*.'E>0@
ML,$_9?[3/A[XW^+OV?O&'A7]FSQ5I>A>/-3T"XM?"VMZRSBVT^[D0HEPQCCD
M8%,EEPC?,JY4C(KY[_9\_P"4SO[1O_9+? W\]1KV#]HC]M#X1? /X*?$GXQZ
M=>+XVE^%-F+CQGX7\&ZC:W6IZ<"%<K-$91Y#"(F8B0J?+1F ..0#XJ@^ 'PM
M_8,_;A_9Z^''[(7QQ\4>(?B=XI\0SV'QST._\=WFL-KNC#3Y);K6-2MYII%M
M)(YQ$\3JL09I2H#<BM+_ (+C^.?VY[[PK)HW@/1K+P=\&_"_BSPI)X@\3G5-
MVI>,;NZU:SC6PMXDYMK:!I0\LCG,K1JB_*'!L_\ !0G3/V8]#^(?[//[8?['
M;:'9_%[XD?&?P^NC:YX0E6.[\9:)=L!J"7@B.;JT^S!2\D@(BVH-R9P?6?\
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M_P#]KH_X:#_ZE'_R?_\ M= 'I%%>;_\ #0?_ %*/_D__ /:Z/^&@_P#J4?\
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MV]3Z7_R$K?\ Z[I_Z$* /HFBBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M $(4 ?1-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MX,T8W2Z=;.%EU"Z>1(;6T1B"%::XEBB#$$ R9((%>LU\'_\ !Q_I]ZO_  3
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MX."/&7AGP7_P1Q^/-QXGD0C5/!W]DZ= 1E[B^N[B&WMHT7JS^;(A '/RD]J
M/L2SO+34+2*_L+F.:">-9(9HG#+(C#(8$<$$$$&I*XW]G7POK_@?]GWP+X*\
M5AAJFC^#=+LM2#G)%Q%:11R9/<[E-=E0 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %?+O[<_P#P2_\ "G[7/Q-\.?M+_"SX\>,/
M@S\9?"6G2:;HWQ,\!R1^?<::[[VT^^MY08[ZUWDNL;XVN20<$@_45% 'YE_L
MU?\ !O5XH_8Y_:OT#]N_X/\ [9S^(OBI-XC<_$:Z\9?#S38])UO1KHPI?)9V
MEBL3:;?&.-F6ZCD;>Y*R I))GU#XR_\ !&?Q5X@^*/Q%\0_LN_\ !03XC_!;
MP7\9]5EU3XN> ?">E:?=0ZK?S1B.ZO+&ZN8VFTJ>X0#S9(MQ=N>@"C[DHH X
M[]GWX#?"[]E[X)^%_P!GKX*^&TTCPKX/T>'3-$L%<N8X8UQEF/+NQR[.>69F
M8\DUQ'P-_8P\,? []KKXY_M<Z5XTO[[4?CE/X;EU72+BW18-,.CZ9]@C$3#Y
MG\Q?G;=T/ XKVBB@ KQ?]GS]C#PQ^SY^TQ\;_P!I?1O&E_J%]\;M:T?4=5TR
MYMT6+3'T_3Q9(D3+RX=1N.[H>!Q7M%% 'P;^UG_P14\>_M%_MRZW^W?\-O\
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M<J&4KD?G5FO$IO\ @I?_ ,$XK:9[>X_X* _!*.2-BLD;_%;1PRL#@@@W/!H
MO?L$_LA>&_V"OV0_!'[(GA'QA?:_IO@C3I;2UUC4H$BGN5>XEG+.J?*"#*1Q
MV JM^U#^QAX8_:@^+?P9^+6O>-+_ $NY^#/CM_$^F6EG;HZ:C,UI+;>3*6Y1
M<2ELKSD"NQ\ _M,?LX?%;7K+PM\+OV@?!'B35-1T,ZUI^FZ!XKL[R>ZTT3&
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M<,$F@=D;!X.#Q704 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 ?EW_P %Z/$O[(/A#]OS]B'Q%^WI;>&)OA/;
MZO\ $+_A+(_&>DB^TTAM"@6V\Z QR!_]*:WV_*</M/&,CUK]@IO^#??]H[XC
M:WIG_!/?X7? S5/$^G>'+A-<;P=\/8+.YCTRZ7[+.CR&VC)BD60QLH)W!R",
M&LS_ (*9^$_"WCC_ (+ ?L ^%_&OAK3]8TRZUCXF?:=.U2S2X@FV^%PZ[HY
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MX-,C^'/P]B\:/\1XO >C+XBD@\F37ETN(7K1XQL,^W>5P,8SC%;-% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
4% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>cah-20230331_g6.jpg
<TEXT>
begin 644 cah-20230331_g6.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_D
ML_X.*/BS^T)X6_X+<?'J[^&OQ0\3Z=9^%KCP_J!BT[6YXH;)/[)TB-7"*X4
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MM[::=;<:C8ZK&[O<+"SQM)#)(^$RNR-V5J /WO\ VFOVN_V8_P!C/P"GQ/\
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M\$_/#.I^/=&\1_M?>!+"Z^%[%/B!;WNO1Q-H;B;R/+G#$8<R_NP@RS.0H!)
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MM,T#3I+R6X:WMHQA$,DS-(^!_$S$GN: .MHHHH **** "BBB@ HHHH ****
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M!KX=>,["U\.6W_".7%[>SK!?V5W>W;P00!H;;RTBCB.SRV\F3:['<B?TJ44
M?B__ ,%#/@/\<?$__!US^S;\9/#?P:\5ZAX0TKPCI4>J>*K'P[<RZ;9NLNL%
MEEN40Q1D!TR&8$;U]17[0444 ?SH_M#_  ^_X*1?\&Z/_!63XF?MB_LP?LU:
MA\2/@Q\6K^[O)H;33;FXL?(N[DW?V*>2V5FL;FVG9TBD<%7B)P'W.J84DO\
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M;'XO^%;CQ?X<E;@7T\]S:ZBP3UVFXU%2?6W;ZUZUX7_X);_M>Z5_P<X>)/\
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M/21\)+SPXMG!JHUV$W1E'AJ#3\&VSY@'VA&7..G/2@#]1*_ ?_@T/^!_PO\
M'7[7'[7?Q8\9>"=,U36?#NL:=I>BW=_9),UI;WUYK#72IO!V^9]D@!(ZA2.A
M(/[\5^7G_!NC_P $M_VO?^"<?Q,_:6\3_M1^$])TRT^)GB/1[SPF^F:[#>&>
M*WFU=Y2XB)\L@7D& W7<?0T ?'G_  :C?LX_!Z^_X*4?M;>*M0\ Z5<S>!-0
M;1O"Z7-BDBZ?;76J7ZR")6!"$I9QQY&#L++T8@]3_P &N&AZ5X%_X*:_MT_#
MSPI91V.C:9XAFMK'3[=0D4,4&M:G%"BJ. %0E0.P-?37_! __@EO^U[^P'^U
MG^U%\6_VD?"FDZ=HOQ2\26]YX0FT[78;MYXDO]3F8R)&28CLNHCANY([&HO^
M"*7_  2R_; _8E_;^_:N_:!^/OA/2;'PU\6=?NKKP9<V.NPW,EQ$^JWMRIDC
M0EHCY<\9PW<D=J /B#_@V2_Y0U?MT_\ 8K:E_P"H[>T?\$O_ /E4*_:E_P"Q
MIU[_ -)-&KZD_P"")7_!'7]N/]B'_@G%^U)^S=^T!X+T6P\5?%/0KVU\'VMA
MXBM[J*>231[FU4221DK$/-E09;L<]J/V'O\ @CK^W'\#?^#>OXZ?\$\/B%X+
MT6W^)WCO7=5NO#NFV_B*WEMI8Y[?3DC+W"G8A+6TN03Q@>HH ^6M4_Y4?=._
M[&IO_4XEKS__ (+)_$+QGI/_  ;J?L&?"O3=1EM] \1:>+W6MC$))-:6:K;A
M\=0!=3MM/&5!ZJ,?<E]_P1U_;CG_ .#8BS_X)?1^"]%_X6Y#KINI-*/B*W^R
M"/\ X2A]1S]ISY>?L[!L9Z_+UKTGXS_\$,/%W[8?_!!_X5?\$]_BSJVF^%?B
MM\-/#MA<Z!JK3BYL[/6+>*6)X)I(02]O+'*\;,F2I*2!7,81@"+_ (+??\$U
M_P!AWX=?\$(/&O@KP-\%_"^D0?"GPA9ZAX&UZRTN".[M[J"6!/-^T*NZ1[E2
MR2LQ/FF8L<MAA^:?[;GQ+\;?%'_@SY_9FU?QY=SW-SIGQN&CV-W.23)96:>)
M+:V4$_PQQ1I"/:$"O4?$G_!,+_@ZA_;%^#GAW_@FC^U'XQ\/Z'\%]&N+2VOO
M&%[XATBX%[96C(;<3&S=K^\$016CCEC3>Z1F5@5#K]F?\%C_ /@BE\4_BQ_P
M1Q^$O_!-O_@GSX7LM3E^&OC72KM5UO5X;$W%K!IVI17%V[N0AFEN;L2LJ]6E
M8@ "@#R'_@KO^RA\ _A;_P &I/A"S\'_  MT2RN/#'A/P+J^GWMOIT:SC4;N
M:QCO+LR ;C+,+JX+MG+>8<\8KAOVE_\ @FQ^U#_P4F_X-P_V1]9_99LDU[QC
M\,M!M]23PM/=11MJEFT+P,(3,1&\T7EQ%8W(#IY@!+;4;[J_X*=?\$__ -I/
M]J#_ ((36_[!WPC\.Z==_$6/PAX.T]M/N]6B@M_/T^XT][D>>YV8"V\N#GYL
M#'6O"OVC?^"*G[>7Q:_X(O\ P!_9S^"_QSO?A]\:?@MHP%WH6G^,9[;2M<+$
M&2VFEMF\MI4:.)X975D4^8AVB5G4 ^$M6_X+B>(M3^+'@/X0?\'$O_!)+1?$
M2^#KQHM)\1WO@^[T75=+C?8DMP;"?_1[^/Y4)BC\J,[5902!G])O^#KB?PQX
MW_X(>^)O%^E7L-Y:-XC\-ZAH]W$<K*LM[$JR*?0Q2L0?0U\C?M!_\$[O^#E'
M_@LTW@#]F7_@I+\/?AQ\-?ASX1\01ZEJGC+3;W3)KN^D6)X'N1%97ER\DYBD
MEV1JEM"6D!<+M&WW?_@[3O[3X??\$O/A=^QA\*=/EN-2\:_$W1/#_AS14?=-
M/:65K+M5?[S";[$GUD% 'WG_ ,$CM9U7Q!_P2Q_9RU?6W9KJ;X(>%_-D<_-)
MC2K=0Y]20 <^]?0]<7^S?\(K+]G[]G?P%\!=-E22W\$>"]+T""1!A62SM(K=
M2/8B,5VE !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% 'Q_^VE_P2_U?]H+_@H+\ /^"C'P9^)UCX2\:?""_ELO
M$:WFG/,OB/P_-O$MCN1E,3A)[Q4<AE'VMB0=H%?8%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!YA\?_ /D):=_UPD_]"%>?5Z#\?_\ D):=_P!<)/\ T(5Y]0 4
M444 %%%% !4^E_\ (2M_^NZ?^A"H*GTO_D)6_P#UW3_T(4 ?1-%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M)(V#*PRK Y!% "T444 %%%% !1110!YA\?\ _D):=_UPD_\ 0A7GU>@_'_\
MY"6G?]<)/_0A7GU !1110 4444 %3Z7_ ,A*W_Z[I_Z$*@J?2_\ D)6__7=/
M_0A0!]$T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%>):I^U+\9;#4[FPMOV+?&]U'!.\<=S%<VVV90Q <9;H0,CZU!_PUA\;/\
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M%N52\EFAA$=PKJ7S:G=P)%;]?7\5_&F12C_LE^.F5A@@PVQ!'_?VOE_X2?\
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M7?&S_HTWQW_WZMO_ ([0!ZO\&/\ D>X/^N$G_H->RU\L>"_BK\;/"&O)K?\
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M#^MZ%X!EN#K%A<*\*7L\GFL&F2%E*-$DVQU*%H_+W5^A7[&'_!,']H?]G_\
M98\#_"+Q1\)O&B:KH^A1C5XK70;:6*.[D+33HC_;!O599' ; R #@9Q0!D5^
MDW_!+3_DUE/^QAO/Y1U\?_\ #$GQL_Z)5X[_ /";MO\ Y-KZ3_99\8?&S]FG
MX6+\-/\ ADSQWK6W49KK[;Y5M;?ZS;\NSS7Z;>N><]* /KNBO"_^&L/C9_T8
M_P"._P#P*MO_ (JC_AK#XV?]&/\ CO\ \"K;_P"*H ]THKPO_AK#XV?]&/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=Z7X,T8W2Z=;.%EU"Z>1(;6T1B"%::XEBB#$$ R9((%>LU\'_P#!Q_I]ZO\
MP3 U;QP;*6ZTCP?\0_"6O>)[:&,N7TRWUJU,Y*#EE4,'([!">U '&Z-\(/\
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M/0+C0(M&U.[TV*\C@^UZ]I]E*3#,K(^8;B4<C@G(P0#7SW\,/@IXT_X)S?\
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MP=&MSI;W0/WU+7,22+C#); 8RQ8 'JOPA\#_ /!<K]J[]DWP#\=++]M_PO\
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M_8X^(/[-7Q8M2VD^)/#DZ)=1H#+87<8\ZVNXL_\ +2&>..5>Q*8/!(H \?\
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MKKXY_M<Z5XTO[[4?CE/X;EU72+BW18-,.CZ9]@C$3#YG\Q?G;=T/ XKVBB@
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MZ1_P4(_8P\,?\%!_V1?%/[(WC'QI?^'M.\4SZ7+<:OIENDL\!LM3M;]0JO\
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MX9WLVI?#?X4^&O#]S<Q>5<7&B:%;VCRIG.UFB12PR <'C- 'Y)>#?VP/B_\
M\$8?!GQ?_P""0&AZ=>^(O'EKJEN_[$\5V#*^O:9X@NWAMK5F?A_[,NWF:4N0
M&2-@-J*M?3^C?\$.O O_  Q9\%/V*/$OQ-%[X6\'>/[;QI\;+&\TY[@?$_5
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M_7K'P_96^MWP?=]HO$@19I,]]T@8Y]ZZ"@ HHHH **** "OP,_X)$_'#_@W
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*Z;I[RJ%E>QL8X2X'0$H!D5I444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
'%%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139887619136480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Apr. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">1-11373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Cardinal Health, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000721371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--06-30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">OH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">31-0958666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">7000 Cardinal Place<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Dublin<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">OH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">43017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">757-5000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common shares (without par value)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CAH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">254,600,182<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139887617813040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Earnings - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 50,487<span></span>
</td>
<td class="nump">$ 44,836<span></span>
</td>
<td class="nump">$ 151,559<span></span>
</td>
<td class="nump">$ 134,261<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of products sold</a></td>
<td class="nump">48,702<span></span>
</td>
<td class="nump">43,154<span></span>
</td>
<td class="nump">146,497<span></span>
</td>
<td class="nump">129,321<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross margin</a></td>
<td class="nump">1,785<span></span>
</td>
<td class="nump">1,682<span></span>
</td>
<td class="nump">5,062<span></span>
</td>
<td class="nump">4,940<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Distribution, selling, general and administrative expenses</a></td>
<td class="nump">1,179<span></span>
</td>
<td class="nump">1,137<span></span>
</td>
<td class="nump">3,567<span></span>
</td>
<td class="nump">3,402<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring and employee severance</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="nump">62<span></span>
</td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_Amortizationandotheracquisitionrelatedcosts', window );">Amortization and other acquisition-related costs</a></td>
<td class="nump">74<span></span>
</td>
<td class="nump">79<span></span>
</td>
<td class="nump">216<span></span>
</td>
<td class="nump">237<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges', window );">Impairments and (gain)/loss on disposal of assets, net</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">471<span></span>
</td>
<td class="nump">883<span></span>
</td>
<td class="nump">1,764<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Litigation (recoveries)/charges, net</a></td>
<td class="num">(76)<span></span>
</td>
<td class="nump">61<span></span>
</td>
<td class="num">(256)<span></span>
</td>
<td class="nump">113<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating earnings/(loss)</a></td>
<td class="nump">572<span></span>
</td>
<td class="num">(97)<span></span>
</td>
<td class="nump">590<span></span>
</td>
<td class="num">(632)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (income)/expense, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense, net</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">38<span></span>
</td>
<td class="nump">78<span></span>
</td>
<td class="nump">115<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on early extinguishment of debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfInvestments', window );">(Gain)/loss on sale of equity interest in naviHealth</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Earnings/(loss) before income taxes</a></td>
<td class="nump">544<span></span>
</td>
<td class="num">(137)<span></span>
</td>
<td class="nump">517<span></span>
</td>
<td class="num">(741)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">197<span></span>
</td>
<td class="nump">1,253<span></span>
</td>
<td class="nump">189<span></span>
</td>
<td class="nump">328<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net earnings/(loss)</a></td>
<td class="nump">347<span></span>
</td>
<td class="num">(1,390)<span></span>
</td>
<td class="nump">328<span></span>
</td>
<td class="num">(1,069)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Less: Net earnings attributable to noncontrolling interests</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net earnings/(loss) attributable to Cardinal Health, Inc.</a></td>
<td class="nump">$ 345<span></span>
</td>
<td class="num">$ (1,391)<span></span>
</td>
<td class="nump">$ 325<span></span>
</td>
<td class="num">$ (1,071)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Earnings/(Loss) per common share attributable to Cardinal Health, Inc.:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Basic (in shares)</a></td>
<td class="nump">$ 1.35<span></span>
</td>
<td class="num">$ (5.05)<span></span>
</td>
<td class="nump">$ 1.24<span></span>
</td>
<td class="num">$ (3.82)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Diluted (in shares)</a></td>
<td class="nump">$ 1.34<span></span>
</td>
<td class="num">$ (5.05)<span></span>
</td>
<td class="nump">$ 1.23<span></span>
</td>
<td class="num">$ (3.82)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Weighted-average number of common shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">256<span></span>
</td>
<td class="nump">275<span></span>
</td>
<td class="nump">263<span></span>
</td>
<td class="nump">281<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">258<span></span>
</td>
<td class="nump">275<span></span>
</td>
<td class="nump">264<span></span>
</td>
<td class="nump">281<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Cash dividends declared per common share</a></td>
<td class="nump">$ 0.4957<span></span>
</td>
<td class="nump">$ 0.4908<span></span>
</td>
<td class="nump">$ 1.4871<span></span>
</td>
<td class="nump">$ 1.4724<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_Amortizationandotheracquisitionrelatedcosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of acquired intangible assets and changes in the fair value of contingent consideration obligations. This also represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_Amortizationandotheracquisitionrelatedcosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482047/420-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139887619083760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Income - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net earnings/(loss)</a></td>
<td class="nump">$ 347<span></span>
</td>
<td class="num">$ (1,390)<span></span>
</td>
<td class="nump">$ 328<span></span>
</td>
<td class="num">$ (1,069)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income/(loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments and other</a></td>
<td class="nump">4<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="num">(34)<span></span>
</td>
<td class="num">(47)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax', window );">Net unrealized gain on derivative instruments, net of tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive income/(loss), net of tax</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="num">(28)<span></span>
</td>
<td class="num">(43)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Total comprehensive income/(loss)</a></td>
<td class="nump">351<span></span>
</td>
<td class="num">(1,382)<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="num">(1,112)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Less: Net earnings attributable to noncontrolling interests</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive income attributable to Cardinal Health, Inc.</a></td>
<td class="nump">$ 349<span></span>
</td>
<td class="num">$ (1,383)<span></span>
</td>
<td class="nump">$ 297<span></span>
</td>
<td class="num">$ (1,114)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482739/220-10-55-15<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139887617862288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> shares in Thousands, $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and equivalents</a></td>
<td class="nump">$ 3,990<span></span>
</td>
<td class="nump">$ 4,717<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Trade receivables, net</a></td>
<td class="nump">10,992<span></span>
</td>
<td class="nump">10,561<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories, net</a></td>
<td class="nump">16,620<span></span>
</td>
<td class="nump">15,636<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Prepaid expenses and other</a></td>
<td class="nump">1,895<span></span>
</td>
<td class="nump">2,021<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">33,497<span></span>
</td>
<td class="nump">32,935<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">2,362<span></span>
</td>
<td class="nump">2,361<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwill', window );">Goodwill and other intangibles, net</a></td>
<td class="nump">6,567<span></span>
</td>
<td class="nump">7,629<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">951<span></span>
</td>
<td class="nump">953<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">43,377<span></span>
</td>
<td class="nump">43,878<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">29,601<span></span>
</td>
<td class="nump">27,128<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent', window );">Current portion of long-term obligations and other short-term borrowings</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">580<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
<td class="nump">2,876<span></span>
</td>
<td class="nump">2,842<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">32,503<span></span>
</td>
<td class="nump">30,550<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Long-term obligations, less current portion</a></td>
<td class="nump">4,708<span></span>
</td>
<td class="nump">4,735<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent', window );">Deferred income taxes and other liabilities</a></td>
<td class="nump">8,384<span></span>
</td>
<td class="nump">9,299<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Preferred shares, without par value:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Authorized&#8212;500 thousand shares, Issued&#8212;none</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Common shares, without par value:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Authorized&#8212;755 million shares, Issued&#8212;327 million shares at March&#160;31, 2023 and June 30, 2022</a></td>
<td class="nump">2,818<span></span>
</td>
<td class="nump">2,813<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(342)<span></span>
</td>
<td class="num">(280)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Common shares in treasury, at cost: 72 million shares and 54 million shares at March&#160;31, 2023 and June 30, 2022, respectively</a></td>
<td class="num">(4,554)<span></span>
</td>
<td class="num">(3,128)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(142)<span></span>
</td>
<td class="num">(114)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Cardinal Health, Inc. shareholders' deficit</a></td>
<td class="num">(2,220)<span></span>
</td>
<td class="num">(709)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total shareholders&#8217; deficit</a></td>
<td class="num">(2,218)<span></span>
</td>
<td class="num">(706)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders&#8217; deficit</a></td>
<td class="nump">$ 43,377<span></span>
</td>
<td class="nump">$ 43,878<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred shares, authorized</a></td>
<td class="nump">500<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred shares, issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common shares, authorized</a></td>
<td class="nump">755,000<span></span>
</td>
<td class="nump">755,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, issued</a></td>
<td class="nump">327,000<span></span>
</td>
<td class="nump">327,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Common shares in treasury</a></td>
<td class="nump">72,000<span></span>
</td>
<td class="nump">54,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting, and liabilities classified as noncurrent and other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetIncludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetIncludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 41: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-15<br><br>Reference 42: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-16<br><br>Reference 43: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481520/505-30-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139887619139312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - shares<br> shares in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred shares, authorized</a></td>
<td class="nump">500<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred shares, issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common shares, authorized</a></td>
<td class="nump">755,000<span></span>
</td>
<td class="nump">755,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, issued</a></td>
<td class="nump">327,000<span></span>
</td>
<td class="nump">327,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Common shares in treasury</a></td>
<td class="nump">72,000<span></span>
</td>
<td class="nump">54,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139887612531552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Shareholders' Equity - USD ($)<br> shares in Thousands, $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Retained Earnings</div></th>
<th class="th"><div>Treasury Stock, Common</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income/(Loss)</div></th>
<th class="th"><div>Noncontrolling Interest</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Common shares in treasury</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance at beginning of period (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">327,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period at Jun. 30, 2021</a></td>
<td class="nump">$ 1,794<span></span>
</td>
<td class="nump">$ 2,806<span></span>
</td>
<td class="nump">$ 1,205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (34)<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury, balance at beginning of period (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(36,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury, balance at beginning of period at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,186)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</a></td>
<td class="num">(1,069)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss) Attributable to Parent</a></td>
<td class="num">(1,071)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other Comprehensive Income (Loss), Net of Tax</a></td>
<td class="num">(43)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</a></td>
<td class="num">(43)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(43)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</a></td>
<td class="nump">41<span></span>
</td>
<td class="num">$ (5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchase of treasury shares</a></td>
<td class="num">(1,000)<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Treasury shares acquired (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends</a></td>
<td class="num">(415)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(415)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityOtherShares', window );">Stockholders' Equity, Other Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance at end of period (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">327,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period at Mar. 31, 2022</a></td>
<td class="num">(693)<span></span>
</td>
<td class="nump">$ 2,761<span></span>
</td>
<td class="num">(281)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(77)<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury, balance at end of period (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(54,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury, balance at end of period at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Treasury Stock, Value, Acquired, Cost Method</a></td>
<td class="num">(1,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (960)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Common shares in treasury</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance at beginning of period (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">327,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period at Dec. 31, 2021</a></td>
<td class="nump">1,002<span></span>
</td>
<td class="nump">$ 2,721<span></span>
</td>
<td class="nump">1,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(85)<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury, balance at beginning of period (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(50,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury, balance at beginning of period at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,883)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</a></td>
<td class="num">(1,390)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss) Attributable to Parent</a></td>
<td class="num">(1,391)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other Comprehensive Income (Loss), Net of Tax</a></td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</a></td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchase of treasury shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Treasury shares acquired (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends</a></td>
<td class="num">(135)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(135)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityOtherShares', window );">Stockholders' Equity, Other Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="nump">1<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance at end of period (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">327,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period at Mar. 31, 2022</a></td>
<td class="num">(693)<span></span>
</td>
<td class="nump">$ 2,761<span></span>
</td>
<td class="num">(281)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(77)<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury, balance at end of period (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(54,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury, balance at end of period at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Treasury Stock, Value, Acquired, Cost Method</a></td>
<td class="num">$ (200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (220)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Common shares in treasury</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Common shares in treasury</a></td>
<td class="nump">54,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(54,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance at beginning of period (in shares) at Jun. 30, 2022</a></td>
<td class="nump">327,000<span></span>
</td>
<td class="nump">327,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period at Jun. 30, 2022</a></td>
<td class="num">$ (706)<span></span>
</td>
<td class="nump">$ 2,813<span></span>
</td>
<td class="num">(280)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(114)<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury, balance at beginning of period (in shares) at Jun. 30, 2022</a></td>
<td class="num">(54,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury, balance at beginning of period at Jun. 30, 2022</a></td>
<td class="num">$ (3,128)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</a></td>
<td class="nump">328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss) Attributable to Parent</a></td>
<td class="nump">325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other Comprehensive Income (Loss), Net of Tax</a></td>
<td class="num">(28)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</a></td>
<td class="num">$ (28)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</a></td>
<td class="nump">$ 82<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchase of treasury shares</a></td>
<td class="num">(1,500)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Treasury shares acquired (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends</a></td>
<td class="num">(388)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(388)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityOtherShares', window );">Stockholders' Equity, Other Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance at end of period (in shares) at Mar. 31, 2023</a></td>
<td class="nump">327,000<span></span>
</td>
<td class="nump">327,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period at Mar. 31, 2023</a></td>
<td class="num">$ (2,218)<span></span>
</td>
<td class="nump">$ 2,818<span></span>
</td>
<td class="num">(342)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(142)<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury, balance at end of period (in shares) at Mar. 31, 2023</a></td>
<td class="num">(72,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(72,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury, balance at end of period at Mar. 31, 2023</a></td>
<td class="num">$ (4,554)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (4,554)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Treasury Stock, Value, Acquired, Cost Method</a></td>
<td class="num">(1,503)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,503)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromRedemptions', window );">Treasury shares acquired, average price per share (in usd per share)</a></td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Common shares in treasury</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(68,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance at beginning of period (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">327,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period at Dec. 31, 2022</a></td>
<td class="num">(2,212)<span></span>
</td>
<td class="nump">$ 2,747<span></span>
</td>
<td class="num">(560)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(146)<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury, balance at beginning of period (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury, balance at beginning of period at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</a></td>
<td class="nump">347<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss) Attributable to Parent</a></td>
<td class="nump">345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other Comprehensive Income (Loss), Net of Tax</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">$ 21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchase of treasury shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(50)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Treasury shares acquired (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends</a></td>
<td class="num">(128)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(128)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityOtherShares', window );">Stockholders' Equity, Other Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance at end of period (in shares) at Mar. 31, 2023</a></td>
<td class="nump">327,000<span></span>
</td>
<td class="nump">327,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period at Mar. 31, 2023</a></td>
<td class="num">$ (2,218)<span></span>
</td>
<td class="nump">$ 2,818<span></span>
</td>
<td class="num">$ (342)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (142)<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury, balance at end of period (in shares) at Mar. 31, 2023</a></td>
<td class="num">(72,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(72,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury, balance at end of period at Mar. 31, 2023</a></td>
<td class="num">$ (4,554)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (4,554)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Treasury Stock, Value, Acquired, Cost Method</a></td>
<td class="num">$ (253)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (303)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Common shares in treasury</a></td>
<td class="nump">72,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Dividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -SubTopic 405<br> -Topic 942<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481071/942-405-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Dividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromRedemptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-23<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromRedemptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482739/220-10-55-15<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 41: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-15<br><br>Reference 42: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-16<br><br>Reference 43: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityOtherShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of increase (decrease) in shares of stock classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityOtherShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481520/505-30-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139887615742944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net earnings/(loss)</a></td>
<td class="nump">$ 328<span></span>
</td>
<td class="num">$ (1,069)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net earnings/(loss) to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">516<span></span>
</td>
<td class="nump">513<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges', window );">Impairments and (gain)/loss on disposal of assets, net</a></td>
<td class="nump">883<span></span>
</td>
<td class="nump">1,764<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfOtherInvestments', window );">Impairments and loss on sale of other investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfInvestments', window );">(Gain)/loss on sale of equity interest in naviHealth</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on early extinguishment of debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">69<span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for bad debts</a></td>
<td class="nump">79<span></span>
</td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Change in operating assets and liabilities, net of effects from acquisitions and divestitures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInReceivables', window );">Increase in trade receivables</a></td>
<td class="num">(510)<span></span>
</td>
<td class="num">(1,193)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Increase in inventories</a></td>
<td class="num">(1,012)<span></span>
</td>
<td class="num">(922)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Increase in accounts payable</a></td>
<td class="nump">2,473<span></span>
</td>
<td class="nump">1,121<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet', window );">Other accrued liabilities and operating items, net</a></td>
<td class="num">(845)<span></span>
</td>
<td class="num">(206)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">1,981<span></span>
</td>
<td class="nump">130<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinesses', window );">Proceeds from divestitures, net of cash sold</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">923<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisition of subsidiaries, net of cash acquired</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Additions to property and equipment</a></td>
<td class="num">(264)<span></span>
</td>
<td class="num">(223)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from disposal of property and equipment</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_Purchaseofavailableforsalesecuritiesandotherinvestments', window );">Purchases of investments</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(38)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments', window );">Proceeds from investments</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromHedgeInvestingActivities', window );">Proceeds from net investment hedge terminations</a></td>
<td class="nump">29<span></span>
</td>
<td class="nump">71<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by/(used in) investing activities</a></td>
<td class="num">(248)<span></span>
</td>
<td class="nump">771<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Reduction of long-term obligations</a></td>
<td class="num">(571)<span></span>
</td>
<td class="num">(597)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_Netproceedstaxwithholdingsfromsharebasedcompensation', window );">Net tax proceeds/(withholdings) from share-based compensation</a></td>
<td class="nump">11<span></span>
</td>
<td class="num">(26)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDividendsCommonStock', window );">Dividends on common shares</a></td>
<td class="num">(399)<span></span>
</td>
<td class="num">(425)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchase of treasury shares</a></td>
<td class="num">(1,500)<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(2,459)<span></span>
</td>
<td class="num">(2,048)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_CashReclassifiedToAssetHeldForSale', window );">Cash and equivalents reclassified from/(to) assets held for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">109<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash and equivalents</a></td>
<td class="num">(727)<span></span>
</td>
<td class="num">(1,051)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and equivalents at beginning of period</a></td>
<td class="nump">4,717<span></span>
</td>
<td class="nump">3,407<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and equivalents at end of period</a></td>
<td class="nump">$ 3,990<span></span>
</td>
<td class="nump">$ 2,356<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_CashReclassifiedToAssetHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Reclassified to Asset Held for Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_CashReclassifiedToAssetHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_Netproceedstaxwithholdingsfromsharebasedcompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow/(outflow) associated with the amount received from holders exercising their stock options and paid by the company to satisfy an employee's income tax withholding obligation when shares are withheld from settlement of a share-based award to cover taxes. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_Netproceedstaxwithholdingsfromsharebasedcompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of available-for-sale securities and other investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_Purchaseofavailableforsalesecuritiesandotherinvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from purchases of available-for-sale securities and other investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_Purchaseofavailableforsalesecuritiesandotherinvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) included in earnings for investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividendsCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividendsCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromHedgeInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow for a financial contract that meets the hedge criteria as either a cash flow hedge, fair value hedge, or hedge of a net investment in a foreign operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 27<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromHedgeInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139887616997392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation and Summary of Significant Accounting Policies</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">1. Basis of Presentation and Summary of Significant Accounting Policies </span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements include the accounts of all majority-owned or consolidated subsidiaries, and all significant intercompany transactions and amounts have been eliminated. The results of businesses acquired or disposed of are included in the condensed consolidated financial statements from the date of the acquisition or up to the date of disposal, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References to "we," "our," and similar pronouns in this Quarterly Report on Form 10-Q for the quarter ended March&#160;31, 2023 (this "Form 10-Q") refer to Cardinal Health, Inc. and its majority-owned or consolidated subsidiaries unless the context requires otherwise.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our fiscal year ends on June 30. References to fiscal 2023 and 2022 in these condensed consolidated financial statements are to the fiscal years ending or ended June&#160;30, 2023 and June&#160;30, 2022, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements have been prepared in accordance with the U.S. Securities and Exchange Commission ("SEC") instructions to Quarterly Reports on Form 10-Q and include the information and disclosures required by accounting principles generally accepted in the United States ("GAAP") for interim financial reporting. The preparation of financial statements in conformity with GAAP requires us to make estimates, judgments and assumptions that affect amounts reported in the condensed consolidated financial statements and accompanying notes. Actual amounts may differ from these estimated amounts. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our opinion, all adjustments necessary for a fair presentation of the condensed consolidated financial statements have been included. Except as disclosed elsewhere in this Form 10-Q, all such adjustments are of a normal and recurring nature.&#160;In addition, financial results presented for this fiscal 2023 interim period are not necessarily indicative of the results that may be expected for the full fiscal year ending June&#160;30, 2023. These condensed consolidated financial statements are unaudited and, accordingly, should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual Report on Form 10-K for the fiscal year ended June 30, 2022 (our "2022 Form 10-K").</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Recently Issued Financial Accounting Standards</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Not Yet Adopted</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board ("FASB") on our condensed consolidated financial statements as well as material updates to previous assessments, if any, from our fiscal 2022 Form 10-K. There were no accounting standards issued in fiscal 2023 that will have a material impact on our condensed consolidated financial statements.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Recently Adopted Financial Accounting Standards</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new material accounting standards adopted during the nine months ended March 31, 2023.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139887622857616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Divestitures<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">Disposal Groups, Including Discontinued Operations, Disclosure</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">2. Divestitures</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, we sold the Cordis business to Hellman &amp; Friedman for proceeds of $923 million, net of cash transferred, and we retained certain working capital accounts. Cardinal Health also retained product liability associated with lawsuits and claims related to the Cordis OptEase and TrapEase inferior vena cava ("IVC") filter products in the U.S. and Canada, as well as authority for these matters discussed in </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i1d34fc4fc2424fbcb4837cc9f1c0665c_100" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 6</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Cordis business operated within our Medical segment.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205-20/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139887621049840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring and Employee Severance<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringChargesAbstract', window );"><strong>Restructuring Charges [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Restructuring and Employee Severance</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">3. Restructuring and Employee Severance</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes restructuring and employee severance:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.974%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.591%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.592%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee-related</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Facility exit and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">13</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total restructuring and employee severance</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">16</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.974%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.591%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.592%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee-related</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">32</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Facility exit and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">30</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total restructuring and employee severance</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">62</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee-related costs primarily consist of termination benefits provided to employees who have been involuntarily terminated, duplicate payroll costs and retention bonuses incurred during transition periods. Facility exit and other costs primarily consist of project consulting fees, accelerated depreciation, professional, project management and other service fees to support divestitures, costs associated with vacant facilities, and certain other divestiture-related costs.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring and employee severance costs during the three and nine months ended March&#160;31, 2023 and March 31, 2022 were primarily related to the implementation of certain enterprise-wide cost-savings measures and the divestiture of the Cordis business. During the three and nine months ended March 31, 2022, restructuring also included costs related to decreasing our overall office space. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes activity related to liabilities associated with restructuring and employee severance:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:43.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.237%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.237%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.241%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee-<br/>Related Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Facility Exit<br/>and Other Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2022</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">66</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">37</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments and other adjustments</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(51)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at March 31, 2023</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">49</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">52</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//420/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringChargesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringChargesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139887620937728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Other Intangible Assets</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">4. Goodwill and Other Intangible Assets</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the carrying amount of goodwill by segment and in total:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.801%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.517%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.640%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.556%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical (1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2022</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,673&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,182&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,855</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill acquired, net of purchase price adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">13</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustments and other</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(5)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill impairment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(863)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(863)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at March 31, 2023</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,673</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,327</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,000</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">At March 31, 2023 and June 30, 2022, the Medical segment accumulated goodwill impairment loss was $4.4 billion and $3.5&#160;billion, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to changes in our long-term financial plan assumptions made during the three months ended March&#160;31, 2023, we elected to bypass the qualitative assessment and perform quantitative goodwill impairment testing for the Medical Unit. The fair value of the reporting unit was estimated to be approximately 4 percent in excess of its carrying value, primarily driven by a lower discount rate as described below.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We performed quantitative goodwill impairment testing for the Medical Unit at December 31, 2022 and September 30, 2022, which resulted in pre-tax goodwill impairment charges of $709 million and $154 million, respectively. The impairment charge recognized in the second quarter was driven by certain reductions in our long-term financial plan assumptions, and the impairment charge recognized in the first quarter was driven by an increase in the discount rate primarily due to an increase in the risk-free interest rate. The cumulative pre-tax goodwill impairment charges of $863 million were recognized in impairments and (gain)/loss on disposal of assets, net in our condensed consolidated statements of earnings/(loss) for the nine months ended March&#160;31, 2023.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our determinations of the estimated fair value of the Medical Unit at March&#160;31, 2023, December 31, 2022 and September 30, 2022 were based on a combination of the income-based approach (using a terminal growth rate of 2 percent), and the market-based approaches. For the income-based approach, we used discount rates of 10 percent, 10.5 percent and 10.5 percent for each quarter, respectively. The decrease in the discount rate for the interim testing performed at March&#160;31, 2023 was primarily due to a decrease in the risk-free interest rate. Additionally, we assigned a weighting of 80 percent to the discounted cash flow method, 10 percent to the guideline public company method, and 10 percent to the guideline transaction method. Our fair value estimates utilize significant unobservable inputs and thus represent Level 3 fair value measurements.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2022 and December 31, 2021, we performed quantitative goodwill impairment testing for the Medical Unit. This quantitative testing resulted in the carrying </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">amount of the Medical Unit exceeding the fair value, resulting in a pre-tax impairment charges of $474&#160;million and $1.3&#160;billion recorded during the three months ended March 31, 2022 and December 31, 2021, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Other Intangible Assets</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize other intangible assets by class at:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:24.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.070%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.714%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.070%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.409%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted- Average Remaining Amortization Period (Years)</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Indefinite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks and patents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total indefinite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Definite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,235</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,267</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">968</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks, trade names and patents</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">550</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">376</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">174</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed technology and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,037</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">623</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">414</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total definite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,822</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,266</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,556</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total other intangible assets</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,833</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,266</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,567</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:42.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.308%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.643%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.312%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net<br/>Intangible</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Indefinite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks and patents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total indefinite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Definite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,272&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,165&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks, trade names and patents</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">552&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">360&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">192&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed technology and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,038&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">574&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">464&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total definite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,862&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,099&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,763&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total other intangible assets</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,873&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,099&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,774&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>Total amortization of intangible assets was $69 million and $78 million for the three months ended March 31, 2023 and 2022, respectively, and $211 million and $235 million for the nine months ended March&#160;31, 2023 and 2022, respectively. Estimated annual amortization of intangible assets for the remainder of fiscal 2023 through 2027 is as follows: $71 million, $261 million, $236 million, $209 million and $177 million.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//350/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139887621667920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Obligations and Other Short-Term Borrowings<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_LongTermObligationsandOtherShortTermBorrowingsAbstract', window );"><strong>Long-Term Obligations and Other Short-Term Borrowings [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Long-Term Obligations and Other Short-Term Borrowings</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">5. Long-Term Obligations and Other Short-Term Borrowings</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Long-Term Debt</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had total long-term obligations, including the current portion and other short-term borrowings, of $4.7 billion and $5.3 billion for March&#160;31, 2023 and June&#160;30, 2022, respectively. All the notes represent unsecured obligations of Cardinal Health, Inc. and rank equally in right of payment with all of our existing and future unsecured and unsubordinated indebtedness. Interest is paid pursuant to the terms of the obligations. These notes are effectively subordinated to the liabilities of our subsidiaries, including trade payables of $29.6 billion and $27.1 billion at March&#160;31, 2023 and June&#160;30, 2022, respectively.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023, we repaid the full principal of the $550&#160;million 3.2% Notes due 2023 at maturity with available cash.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended March&#160;31, 2022, we redeemed all outstanding $572&#160;million principal amount of 2.616% Notes due June 2022 at a redemption price equal to 100% of the principal amount and accrued but unpaid interest, plus the make-whole premium applicable to the notes. In connection with this redemption, we recorded a $10&#160;million loss on early extinguishment of debt. The early redemption was funded with available cash.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Other Financing Arrangements</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to cash and equivalents and operating cash flow, other sources of liquidity include a&#160;$2.0 billion&#160;commercial paper program backed by a $2.0 billion&#160;revolving credit facility. We also have a&#160;$1.0 billion&#160;committed receivables sales facility. During the nine months ended March&#160;31, 2023, under our commercial paper program and our committed receivables program, we had maximum combined total daily amounts outstanding of $445&#160;million and average combined daily amount outstanding of $4&#160;million. At March&#160;31, 2023, we had no amounts outstanding under our commercial paper program, revolving credit facility or our committed receivables sales facility. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2023, we extended our $2.0 billion revolving credit facility through February 25, 2028. In September 2022, we renewed our committed receivables sales facility program through Cardinal Health Funding, LLC (&#8220;CHF&#8221;) through September 30, 2025. CHF was organized for</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the sole purpose of buying receivables and selling undivided interests in those receivables to third-party purchasers. Although consolidated with Cardinal Health, </span></div>Inc. in accordance with GAAP, CHF is a separate legal entity from Cardinal Health, Inc. and from our subsidiary that sells receivables to CHF. CHF is designed to be a special purpose, bankruptcy-remote entity whose assets are available solely to satisfy the claims of its creditors. Our revolving credit and committed receivables sales facilities require us to maintain a consolidated net leverage ratio of no more than 3.75-to-1. As of March&#160;31, 2023, we were in compliance with this financial covenant.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_LongTermObligationsandOtherShortTermBorrowingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-Term Obligations and Other Short-Term Borrowings [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_LongTermObligationsandOtherShortTermBorrowingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//470/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139887622854096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments, Contingent Liabilities and Litigation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments, Contingent Liabilities and Litigation</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">6. Commitments, Contingent Liabilities and Litigation</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commitments</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Generic Sourcing Venture with CVS Health Corporation ("CVS Health")</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2014, we established Red Oak Sourcing, LLC ("Red Oak Sourcing"), a U.S.-based generic pharmaceutical sourcing venture with CVS Health for an initial term of 10 years. Red Oak Sourcing negotiates generic pharmaceutical supply contracts on behalf of its participants. In August 2021, we amended our agreement to extend the term through June 2029. We are required to make quarterly payments to CVS Health for the term of the arrangement.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Contingencies</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New York Opioid Stewardship Act</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018, the State of New York passed a budget which included the Opioid Stewardship Act (the "OSA"). The OSA created an aggregate $100&#160;million annual assessment on all manufacturers and distributors licensed to sell or distribute opioids in New York. Under the OSA, each licensed manufacturer and distributor would be required to pay a portion of the assessment based on its share of the total morphine milligram equivalents sold or distributed in New York during the applicable calendar year, beginning in 2017. Subsequently, New York passed a new statute that modified the assessment going forward and limited the OSA to two years (2017 and 2018).</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accrue contingencies if it is probable that a liability has been incurred and the amount can be estimated. In the second quarter of fiscal year 2022, we paid the State of New York $20&#160;million, our portion of the assessment for calendar year 2017. At June 30, 2022, we had an accrual of $20&#160;million, which represented our estimate of our portion of the assessment for calendar year 2018. Du</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ring the nine months ended March&#160;31, 2023, we recorded $6&#160;million of income to reduce this accrual to the invoiced amount for the calendar year 2018 assessment and we paid $7&#160;million, resulting in an accrual of $7&#160;million at March 31, 2023.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We become involved from time to time in disputes, litigation and regulatory matters.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we determine that products we source, manufacture or market do not meet our specifications, regulatory requirements, or published standards. When we or a regulatory </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">agency identify a potential quality or regulatory issue, we investigate and take appropriate corrective action. Such actions have led to product recalls, costs to repair or replace affected products, temporary interruptions in product sales, product liability claims and lawsuits and can lead to action by regulators. Even absent an identified regulatory or quality issue or product recall, we can become subject to product liability claims and lawsuits.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we become aware through employees, internal audits or other parties of possible compliance matters, such as complaints or concerns relating to accounting, internal accounting controls, financial reporting, auditing, or other ethical matters or relating to compliance with laws such as healthcare fraud and abuse, anti-corruption or anti-bribery laws. When we become aware of such possible compliance matters, we investigate internally and take appropriate corrective action. In addition, from time to time, we receive subpoenas or requests for information from various federal or state agencies relating to our business or to the business of a customer, supplier or other industry participants. Internal investigations, subpoenas or requests for information could directly or indirectly lead to the assertion of claims or the commencement of legal proceedings against us or result in sanctions.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have been named from time to time in qui tam actions initiated by private third parties. In such actions, the private parties purport to act on behalf of federal or state governments, allege that false claims have been submitted for payment by the government and may receive an award if their claims are successful. After a private party has filed a qui tam action, the government must investigate the private party's claim and determine whether to intervene in and take control over the litigation. These actions may remain under seal while the government makes this determination. If the government declines to intervene, the private party may nonetheless continue to pursue the litigation on his or her own purporting to act on behalf of the government.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accrue for contingencies related to disputes, litigation and regulatory matters if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Because these matters are inherently unpredictable and unfavorable developments or resolutions can occur, assessing contingencies is highly subjective and requires judgments about future events. We regularly review contingencies to determine whether our accruals and related disclosures are adequate. The amount of ultimate loss may differ from these estimates.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize income from the favorable outcome of litigation when we receive the associated cash or assets.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize estimated loss contingencies for certain litigation and regulatory matters and income from favorable resolution of litigation in litigation (recoveries)/charges, net in our condensed consolidated statements of earnings/(loss); however, losses and recoveries of lost profits from disputes that occur in the ordinary course of business are included within segment profit. For example, in the second quarter of fiscal year 2022, our </span></div><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical segment profit was positively impacted by a $16&#160;million judgment for lost profits related to an ordinary course intellectual property rights claim.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opioid Lawsuits and Investigations</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">States &amp; Political Subdivisions</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">National Settlement</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, in February 2022, we along with two other national distributors (collectively, the "Distributors") independently approved a settlement and settlement agreement (the "Settlement Agreement") to settle the vast majority of opioid lawsuits and claims brought by states and political subdivisions. This Settlement Agreement became effective on April 2, 2022. In May and June 2022, the Distributors reached agreements with the States of Washington and Oklahoma, respectively, to resolve the opioid-related claims of those states and their political subdivisions. Under these agreements, Cardinal Health agreed to pay approximately $160&#160;million to the State of Washington and its participating subdivisions and approximately $95&#160;million to the State of Oklahoma and its participating subdivisions. These amounts are consistent with the amounts that would have been allocated to Washington and Oklahoma under the Settlement Agreement. Each of Washington and Oklahoma is now subject to the Settlement Agreement.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the Distributors, parties to the Settlement Agreement include 48 states, the District of Columbia and 5 U.S. territories. Over 99 percent of political subdivisions (by population as calculated under the Settlement Agreement) that had brought opioid-related suits against us have chosen to join the Settlement Agreement or have had their claims addressed by state legislation. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Settlement Agreement, we agreed to pay up to approximately $6.3&#160;billion over 18 years. The Settlement Agreement also includes injunctive relief terms related to distributors&#8217; controlled substance anti-diversion programs. For more information on the terms of the Settlement Agreement, refer to our 2022 Form 10-K. As a result of the Settlement Agreement, most lawsuits brought against us by states and other political subdivisions have been dismissed. We continue to engage in resolution discussions with certain non-participating political subdivisions, including the Attorney General for the State of Alabama, and we intend to defend ourselves vigorously against all remaining lawsuits.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended March 31, 2023, we made our second annual payment of $372&#160;million under the Settlement Agreement. In total, we have $5.85&#160;billion accrued at March&#160;31, 2023, of which $437&#160;million is included in other accrued liabilities and the remainder is included in deferred income taxes and other liabilities in our condensed consolidated balance sheets.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because loss contingencies are inherently unpredictable and unfavorable developments or resolutions can occur, the assessment is highly subjective and requires judgments about future events. We regularly review these opioid litigation matters to determine whether our accrual is adequate. The amount of </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ultimate loss may differ materially from this accrual, whether as a result of settlement discussions, a judicial decision or verdict or otherwise, but we are not able to estimate a range of reasonably possible additional losses for these matters. We continue to strongly dispute the allegations made in these lawsuits and none of these agreements is an admission of liability or wrongdoing.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other Settlements</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">West Virginia subdivisions and Native American tribes were not a part of the national settlement, and we had separate negotiations with these groups. A bench trial before a federal judge in West Virginia in a case brought by Cabell County and City of Huntington against the Distributors concluded in July 2021. In July 2022, a judgment in favor of the Distributors was entered. In July 2022, the Distributors reached an agreement to settle the opioid-related claims of the majority of the remaining West Virginia subdivisions. Under this agreement, we have agreed to pay eligible West Virginia subdivisions up to approximately $124&#160;million over an eleven-year period. This agreement became effective in October 2022 when all participating subdivisions dismissed their cases.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022, we executed a final settlement agreement with the Native American Tribes, pursuant to which we will pay up to approximately $136&#160;million over five years. In connection with this settlement, the court entered dismissals for the Native American tribes' cases.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Department of Justice Investigations</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have received federal grand jury subpoenas issued in connection with investigations being conducted by the U.S. Attorney's Office for the Eastern District of New York and the Fraud Section of the U.S. Department of Justice ("DOJ"). We have also received civil requests for information from other DOJ offices. We believe that these investigations concern operation of our anti-diversion program, our anti-diversion policies and procedures, and distribution of certain controlled substances. We are cooperating with these investigations. We are unable to predict the outcome of any of these investigations. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Private Plaintiffs</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Settlement Agreement does not address claims by private parties, which includes unions and other health and welfare funds, hospital systems and other healthcare providers, businesses and individuals alleging personal injury. Private parties had brought approximately 457 lawsuits as of April 28, 2023. Of these, 107 are purported class actions. The causes of action asserted by these plaintiffs are similar to those asserted by public plaintiffs. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A trial in a case involving 21 plaintiffs began in state court in Georgia in January 2023 and concluded in March 2023 with a verdict for the company and other defendants on all claims. The plaintiffs' motion for a new trial is pending. A trial involving eight hospital plaintiffs is scheduled to begin in Alabama in July 2023. We are vigorously defending ourselves in all of these matters; however, trials are inherently unpredictable and it is possible that an unfavorable outcome in these matters, individually or in the aggregate, could have a negative impact on our financial results.</span></div></div><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Insurance Litigation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in ongoing legal proceedings with insurers related their obligations to reimburse us for defense and indemnity costs in connection with the lawsuits described above. In the nine months ended March 31, 2023, we received approximately $10&#160;million in insurance recoveries related to these matters; however, we have not recorded a receivable for any additional recoveries as of March&#160;31, 2023.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cordis IVC Filter Matters </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Liability Lawsuits</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have been named as a defendant in approximately 453 product liability lawsuits coordinated in Alameda County Superior Court in California involving claims by approximately 5,171 plaintiffs that allege personal injuries associated with the use of IVC filter products. These lawsuits sought a variety of remedies, including unspecified monetary damages. The divestiture of the Cordis business did not include product liability related to the IVC filters in the U.S. and Canada, which we retained.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2023, we executed a settlement agreement that, if certain conditions are satisfied, will resolve approximately 4,376 claims for $275&#160;million. This settlement agreement is subject to certain conditions, including certain opt-in thresholds. Between May and September 2023, we will make settlement payments totaling $275&#160;million into a qualified settlement fund, which will be disbursed to the plaintiffs if required conditions are satisfied. Since July 2021, we have also entered into other agreements to settle approximately 2,881 product liability claims. These settlements will not resolve all IVC filter product liability claims and we will continue to vigorously defend ourselves in the remaining lawsuits.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in August 2021, the Attorney General for the State of New Mexico filed an action against certain IVC filter manufacturers, including us, alleging claims under New Mexico's Unfair Practices Act, Medicaid Fraud Act and Fraud Against Taxpayers Act. The allegations are similar to those made in the product liability lawsuits.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized income of $71&#160;million and $95&#160;million during the three and nine months ended March&#160;31, 2023, respectively, primarily related to a reduction of the reserve for the estimated settlement and defense costs for these matters due to the execution of the settlements noted above. At March&#160;31, 2023, we had a total of $385&#160;million accrued for losses and legal defense costs, related to the IVC filter product liability lawsuits in our condensed consolidated balance sheets. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shareholder Securities Litigation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, the Louisiana Sheriffs' Pension &amp; Relief Fund filed a purported class action complaint against Cardinal Health and certain current and former officers and employees in the United States District Court for the Southern District of Ohio purportedly on behalf of all purchasers of our common shares between March 2015 and May 2018. In June 2020, the court appointed 1199 SEIU Health Care Employees Pension Fund as lead plaintiff and a </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consolidated amended complaint was filed in September 2020. The amended complaint alleges that the defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 by making misrepresentations and omissions related to the acquisition and integration of the Cordis business and inventory and supply chain problems within the Cordis business, and seeks to recover unspecified damages and equitable relief for the alleged misstatements and omissions. The complaint also alleges that one of the individual defendants violated Section 20A of the Exchange Act because he sold shares of Cardinal Health stock during the time period. In February 2023, we reached an agreement in principle with the plaintiffs to settle this matter for $109&#160;million, subject to final approval by the court. The court granted its preliminary approval in April 2023 and will conduct a final hearing in September 2023. If the settlement is approved, our insurance carriers will pay $109&#160;million to the plaintiffs. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Civil Litigation </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Generic Pharmaceutical Pricing Antitrust Litigation </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, pharmaceutical distributors including us were added as defendants in a civil class action lawsuit filed by indirect purchasers of generic drugs, such as hospitals and retail pharmacies. The indirect purchaser case is part of a multidistrict litigation consisting of multiple individual class action matters consolidated in the Eastern District of Pennsylvania. The indirect purchaser plaintiffs allege that pharmaceutical distributors encouraged manufacturers to increase prices, provided anti-competitive pricing information to manufacturers and improperly engaged in customer allocation. In May 2020, the court granted our motion to dismiss. In July 2022, the indirect purchasers filed an amended complaint and in August 2022, we filed a motion to dismiss the intended complaint. We are vigorously defending ourselves in this matter. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Antitrust Litigation Proceeds</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022, we received net cash proceeds resulting from the settlement of a lawsuit in which we were a class member or plaintiff of $66&#160;million, which was recognized in litigation (recoveries)/charges, net, during the nine months ended March 31, 2023. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shareholder Derivative Litigation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Between June 2019 and January 2020, three purported shareholders filed actions on behalf of Cardinal Health, Inc. in the U.S. District Court for the Southern District of Ohio against certain current and former members of our Board of Directors alleging that the defendants breached their fiduciary duties by failing to effectively monitor Cardinal Health's distribution of controlled substances and approving certain payments of executive compensation. In January 2020, the court consolidated these derivative cases under the caption In re Cardinal Health, Inc. Derivative Litigation and in March 2020, plaintiffs filed an amended complaint. </span></div></div>In October 2022, the court entered an order approving the settlement agreement reached between the parties and dismissing the case. The settlement does not include any admission of liability. Under this settlement, in December 2022, Cardinal Health's director and officer liability insurance carriers, on behalf of the defendants, paid Cardinal Health $124&#160;million, less approximately $31&#160;million in attorneys' fees and expenses awarded by the court to plaintiffs' counsel. Cardinal Health received net cash proceeds resulting from this settlement of $93&#160;million, which was recognized in litigation (recoveries)/charges, net, during the nine months ended March 31, 2023.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139887618400960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">7. Income Taxes</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fluctuations in our provision for income taxes as a percentage of pre-tax earnings/(loss) (&#8220;effective tax rate&#8221;) are due to changes in international and U.S. state effective tax rates resulting from our business mix and discrete items. </span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Effective Tax Rate</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended&#160;March&#160;31, 2023, the effective tax rate was&#160;36.3 percent and&#160;36.7 percent, respectively, and reflects any impact of the tax effects of the goodwill impairment charges recognized during the three and nine months ended March&#160;31, 2023. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended&#160;March 31, 2022, the effective tax rate was (916.5) percent and (44.4) percent, respectively, and reflects the impact of the tax effect of the goodwill impairment charges recognized during the three and nine months ended March 31, 2022.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tax Effects of Goodwill Impairment Charges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended March&#160;31, 2023, we recognized pre-tax goodwill impairment charges of $863&#160;million related to the Medical Unit. The net tax benefit related to these charges is $68&#160;million for fiscal 2023. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless an item is considered discrete because it is unusual or infrequent, the tax impact of the item is included in our estimated annual effective tax rate. When items are recognized through our estimated annual effective tax rate, we apply our estimated annual effective tax rate to the earnings/(loss) before income taxes for the year-to-date period to compute our impact from income taxes for the current quarter and year-to-date period. The tax impacts of discrete items are recognized in their entirety in the period in which they occur.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax effect of the goodwill impairment charges during the nine months ended March 31, 2023 was included in our estimated annual effective tax rate because it was not considered unusual or infrequent, given that we recorded goodwill impairments in prior fiscal years. The impact of the non-deductible goodwill increased the estimated annual effective tax rate for fiscal 2023. Applying the higher tax rate to the pre-tax income for the nine months ended March&#160;31, 2023 resulted in recognizing an incremental interim tax expense of approximately $74&#160;million, which impacted the </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">provision for income taxes in the condensed consolidated statements of earnings/(loss) during the three months ended March&#160;31, 2023 and prepaid expenses and other assets in the condensed consolidated balance sheet at March&#160;31, 2023. The incremental interim tax benefit recognized during the nine months ended March&#160;31, 2023 was $66&#160;million and will reverse in the fourth quarter of fiscal 2023.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unrecognized Tax Benefits</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had $1.1 billion and $943 million of unrecognized tax benefits, at March&#160;31, 2023 and June&#160;30, 2022, respectively. The March&#160;31, 2023 and June&#160;30, 2022 balances include $897 million and $858 million of unrecognized tax benefits, respectively, that if recognized, would have an impact on the effective tax rate. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2023 and June&#160;30, 2022, we had $61 million and $48 million, respectively, accrued for the payment of interest and penalties related to unrecognized tax benefits, which we recognize in the provision for income taxes in the condensed consolidated statements of earnings/(loss). These balances are gross amounts before any tax benefits and are included in deferred income taxes and other liabilities in the condensed consolidated balance sheets. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is reasonably possible that there could be a change in the amount of unrecognized tax benefits within the next 12 months due to activities of the U.S. Internal Revenue Service ("IRS") or other taxing authorities, possible settlement of IRS and other audit issues, reassessment of existing unrecognized tax benefits or the expiration of statutes of limitations. We estimate that the range of the possible change in unrecognized tax benefits within the next 12 months is between zero and a net decrease of up to $125 million, exclusive of penalties and interest.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Tax Matters</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions, and various foreign jurisdictions. With few exceptions, we are subject to audit by taxing authorities for fiscal years 2015 through the current fiscal year.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to a tax matters agreement with CareFusion Corporation ("CareFusion"), a subsidiary of Becton, Dickinson and Company. Under the tax matters agreement, CareFusion is obligated to indemnify us for certain tax exposures and transaction taxes prior to our fiscal 2010 spin-off of CareFusion. The indemnification receivable was $80 million and $75&#160;million at </span></div></div>March&#160;31, 2023 and June&#160;30, 2022, respectively, and is included in other assets in the condensed consolidated balance sheets.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139887616991952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Disclosures</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">8. Fair Value Measurements</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the fair values for assets and (liabilities) measured on a recurring basis at:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.938%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,302</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,302</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other investments (1)</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">95</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">95</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contracts (2)</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(52)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(52)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.938%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,425&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,425&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other investments (1)</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contracts (2)</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">The other investments balance includes investments in mutual funds, which offset fluctuations in deferred compensation liabilities. These mutual funds invest in the equity securities of companies with both large and small market capitalization and high quality fixed income debt securities. The fair value of these investments is determined using quoted market prices.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">The fair value of interest rate swaps, foreign currency contracts, and net investment hedges is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in prepaid expenses and other, other assets, other accrued liabilities, and deferred income taxes and other liabilities within the condensed consolidated balance sheets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139887620991536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsDisclosureTextBlock', window );">Financial Instruments</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">9. Financial Instruments </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We utilize derivative financial instruments to manage exposure to certain risks related to our ongoing operations. The primary risks managed through the use of derivative instruments include interest rate risk, currency exchange risk and commodity price risk. We do not use derivative instruments for trading or speculative purposes. While the majority of our derivative instruments are designated as hedging instruments, we also enter into derivative instruments that are designed to hedge a risk but are not designated as hedging instruments. These derivative instruments are adjusted to current fair value through earnings at the end of each period. We are exposed to counterparty credit risk on all of our derivative instruments. Accordingly, we have established and maintain strict counterparty credit guidelines and only enter into derivative instruments with major financial institutions that are rated investment grade or better. We do not have significant exposure to </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">any one counterparty and we believe the risk of loss is remote. Additionally, we do not require collateral under these agreements.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Interest Rate Risk Management</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the impact of interest rate changes. Our objective is to manage the impact of interest rate changes on cash flows and the market value of our borrowings. We utilize a mix of debt maturities on our fixed-rate debt to manage changes in interest rates. In addition, we enter into interest rate swaps to further manage our exposure to interest rate variations related to our borrowings and to lower our overall borrowing costs.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Currency Exchange Risk Management</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conduct business in several major international currencies and are subject to risks associated with changing foreign exchange rates. Our objective is to reduce earnings and cash flow volatility associated with foreign exchange rate changes to allow management to focus its attention on business operations. Accordingly, we enter into various contracts that change in value as foreign exchange rates change to protect the value of existing foreign currency assets and liabilities, commitments and anticipated foreign currency revenue and expenses.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commodity Price Risk Management</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to changes in the price of certain commodities. Our objective is to reduce earnings and cash flow volatility associated with forecasted purchases of these commodities to allow management to focus its attention on business operations. Accordingly, we enter into derivative contracts when possible to manage the price risk associated with certain forecasted purchases.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Fair Value Hedges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into pay-floating interest rate swaps to hedge the changes in the fair value of fixed-rate debt resulting from fluctuations in interest rates. These contracts are designated and qualify as fair value hedges. Accordingly, the gain or loss recorded on the pay-floating interest rate swaps is directly offset by the change in fair value of the underlying debt. Both the derivative instrument and the underlying debt are adjusted to market value at the end of each period with any resulting gain or loss recorded in interest expense, net in the condensed consolidated statements of earnings/(loss). For the three and nine months ended March&#160;31, 2023 and 2022, there was no gain or loss recorded to interest expense as changes in the market value of our derivative instruments offset changes in the market value of the underlying debt.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended March 31, 2023 and 2022, we entered into pay-floating interest rate swaps with total notional amounts of $200 million and $300 million, respectively. These swaps have been designated as fair value hedges of our fixed rate debt and are included in deferred income taxes and other liabilities in the condensed consolidated balance sheets.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Cash Flow Hedges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into derivative instruments to hedge our exposure to changes in cash flows attributable to interest rate, foreign currency and commodity price fluctuations associated with certain forecasted transactions. These derivative instruments are designated and qualify as cash flow hedges. Accordingly, the gain or loss on the derivative instrument is reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same line item associated with the forecasted transaction and in the same period during which the hedged transaction affects earnings.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-tax gains recognized in other comprehensive income/(loss) were $2&#160;million and $1&#160;million for the three months ended March&#160;31, 2023 and 2022, respectively, and $4&#160;million for both the nine months ended March&#160;31, 2023 and 2022. Gains recognized in accumulated other comprehensive loss and reclassified into earnings were $4&#160;million and immaterial for the three months ended March&#160;31, 2023 and 2022, respectively, and were $8&#160;million and immaterial for the nine months ended March&#160;31, 2023 and 2022, respectively. Gains currently included within accumulated other comprehensive loss associated with our cash flow hedges to be reclassified into net earnings within the next 12 months are $7&#160;million.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Net Investment Hedges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We hedge the foreign currency risk associated with certain net investment positions in foreign subsidiaries. To accomplish this, we enter into cross-currency swaps that are designated as hedges of net investments.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended&#160;March 31, 2023, we entered into &#165;19&#160;billion ($150&#160;million) cross-currency swaps maturing in September 2025, &#165;19&#160;billion ($150&#160;million) cross-currency swaps maturing in June 2027, &#8364;100&#160;million ($107&#160;million) cross-currency swaps maturing in March 2025 and &#8364;100&#160;million ($107&#160;million) cross-currency swaps maturing in March 2026.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended&#160;March 31, 2023, we terminated the &#165;48&#160;billion ($400&#160;million) cross-currency swaps entered into in March 2022 and the &#8364;200&#160;million ($233&#160;million) cross-currency swap entered into in September 2018 and received net settlements of $10&#160;million and $19&#160;million in cash, respectively, recorded in proceeds from net investment hedge terminations in our condensed consolidated statements of cash flows.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cross-currency swaps designated as net investment hedges are marked to market using the current spot exchange rate as of the end of the period, with gains and losses included in the foreign currency translation component of accumulated other comprehensive loss until the sale or substantial liquidation of the underlying net investments. To the extent the cross-currency swaps designated as net investment hedges are not highly effective, changes in carrying value attributable to the change in spot rates are recorded in earnings.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-tax gain and loss from net investment hedges recorded in the foreign currency translation component of accumulated other </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">comprehensive loss was an immaterial loss and a $22&#160;million gain during the three months ended March&#160;31, 2023 and 2022, respectively, and a $21&#160;million loss and a $44&#160;million gain during the nine months ended March&#160;31, 2023 and 2022, respectively. Gains recognized in interest expense, net in the condensed consolidated statements of earnings/(loss) for the portion of the net investment hedges excluded from the assessment of hedge effectiveness were $4&#160;million and $5&#160;million during the three months ended March&#160;31, 2023 and 2022, respectively, and $12&#160;million and $16&#160;million during the nine months ended March&#160;31, 2023 and 2022, respectively.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Economic (Non-Designated) Hedges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into foreign currency contracts to manage our foreign exchange exposure related to sales transactions, intercompany financing transactions and other balance sheet items subject to revaluation that do not meet the requirements for hedge accounting treatment. Accordingly, these derivative instruments are adjusted to current market value at the end of each period through earnings. The gain or loss recorded on these instruments is substantially offset by the remeasurement adjustment on the foreign currency denominated asset or liability. The settlement of the derivative instrument and the remeasurement adjustment on the foreign currency denominated asset or liability are both recorded in other (income)/expense, net. We recorded an immaterial loss and a $4 million loss during the three months ended March 31, 2023 and 2022, respectively, and a $3 million loss and an immaterial loss during the nine months ended March&#160;31, 2023 and 2022, respectively. The principal currencies managed through foreign currency contracts are Canadian dollar, Euro, Chinese renminbi, Indian rupee and Thai baht.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of cash and equivalents, trade receivables, accounts payable and other accrued liabilities at March&#160;31, 2023 and June&#160;30, 2022 approximate fair value due to their short-term maturities.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.109%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.986%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.062%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Estimated fair value</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,466</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,049&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying amount</span></td><td colspan="2" style="border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,734</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"/><td colspan="2" style="border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,315&#160;</span></td><td style="border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of our long-term obligations and other short-term borrowings is estimated based on either the quoted market prices for the same or similar issues or other inputs derived from available market information, which represents a Level 2 measurement.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139887617106512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Shareholders' Equity</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">10. Shareholders' Equity/(Deficit)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We repurchased $1.5&#160;billion and $1.0 billion of our common shares, in the aggregate, through share repurchase programs during the nine months ended March&#160;31, 2023 and 2022, </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">respectively. We funded the repurchases with available cash. The common shares repurchased are held in treasury to be used for general corporate purposes.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023, we entered into an accelerated share repurchase ("ASR") program to repurchase common shares for an aggregate purchase price of $250 million. We received an initial delivery of 2.6 million common shares using a reference price of $77.03. The program concluded on February 28, 2023 at a volume weighted average price per common share of $77.27 resulting in a final delivery of 0.6 million common shares.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended December&#160;31, 2022, we entered into an ASR program to repurchase common shares for an aggregate purchase price of $250&#160;million. We received an initial delivery of 2.6 million common shares using a reference price of $76.58. The program concluded on January&#160;13, 2023 at a volume weighted average price per common share of $77.50 resulting in a final delivery of 0.6 million common shares.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2022, we entered into an ASR program to repurchase common shares for an aggregate purchase price of $1.0&#160;billion. We received an initial delivery of 12.0 million common shares using a reference price of $66.74. The program concluded on December 23, 2022 at a volume weighted average price per common share of $73.36 resulting in a final delivery of 1.6 million common shares.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2022, we entered into an ASR program to repurchase common shares for an aggregate purchase price of $200&#160;million. We received an initial delivery of 3.0&#160;million common shares using a reference price of $54.01. The program concluded on April 18, 2022 at a volume weighted average price per common share of $56.02 resulting in a final delivery of 0.6&#160;million common shares. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended December 31, 2021, we entered into an ASR program to repurchase common shares for an aggregate purchase price of $300&#160;million. We received an initial delivery of 4.8&#160;million common shares using a reference price of $50.30. The program concluded on January 31, 2022 at a volume weighted average price per common share of $49.39 resulting in a final delivery of 1.3&#160;million common shares. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2021, we entered into an ASR program to repurchase common shares for an aggregate purchase price of $500&#160;million. We received an initial delivery of 7.8&#160;million common shares using a reference price of $51.53. The program concluded on October 4, 2021 at a volume weighted average price per common share of $51.10 resulting in a final delivery of 2.0&#160;million common shares.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive Loss</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the changes in the balance of accumulated other comprehensive loss by component and in total:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.097%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.492%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.050%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign<br/>Currency<br/>Translation<br/>Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized<br/>Gain/(Loss) on<br/>Derivatives,<br/>net of tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2022</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(102)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(114)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss, before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified to earnings</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(9)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other comprehensive loss attributable to Cardinal Health, Inc. net of tax benefit of $5&#160;million</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(28)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at March 31, 2023</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(136)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(6)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(142)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.097%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.492%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.050%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign<br/>Currency<br/>Translation<br/>Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized<br/>Gain/(Loss) on<br/>Derivatives,<br/>net of tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2021</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss, before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified to earnings</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other comprehensive loss attributable to Cardinal Health, Inc. net of tax benefit of $6&#160;million</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at March 31, 2022</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(93)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(77)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139887616991952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share Attributable to Cardinal Health, Inc.<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings Per Share [Text Block]</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">11. Earnings/(Loss) Per Share Attributable to Cardinal Health, Inc.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the number of common shares used to compute basic and diluted earnings/(loss) per share attributable to Cardinal Health, Inc.:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.406%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.407%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average common shares&#8211;basic</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">256</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock options, restricted share units and performance share units</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average common shares&#8211;diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">258</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.406%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.407%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average common shares&#8211;basic</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">263</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">281&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock options, restricted share units and performance share units</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average common shares&#8211;diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">264</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">281&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The potentially dilutive employee stock options, restricted share units and performance share units that were antidilutive were 2 million for both the three and nine months ended March&#160;31, 2023.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The potentially dilutive employee stock options, restricted share units and performance share units that were antidilutive were 5 million for both the three and nine months ended March 31, 2022. For the three and nine months ended March 31, 2022, there were 2&#160;million and 1&#160;million potentially dilutive employee stock options, restricted share units and performance share units not included in the computation of diluted loss per common share attributable to Cardinal Health, Inc. because their effect would have been antidilutive as a result of the net loss during those periods.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139887620957440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Information</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">12. Segment Information</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations are principally managed on a products and services basis and are comprised of two operating segments, which are the same as our reportable segments: Pharmaceutical and Medical. The factors for determining the reportable segments include the manner in which management evaluates performance for purposes of allocating resources and assessing performance combined with the nature of the individual business activities.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical and over-the-counter healthcare and consumer products in the United States. This segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; provides pharmacy management services to hospitals and operates a limited number of pharmacies, including pharmacies in community health centers; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; and connects pharmacists, payers and pharmaceutical companies and delivers health solutions for medication therapy management, digital patient engagement and telepharmacy; and repackages generic pharmaceuticals and over-the-counter healthcare products.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Medical segment manufactures, sources and distributes Cardinal Health branded medical, surgical and laboratory products, which are sold in the United States, Canada, Europe, Asia and other markets. In addition to distributing Cardinal Health branded products, this segment also distributes a broad range of medical, surgical and laboratory products known as national brand products and provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories and other healthcare providers in the United States and Canada. This </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">segment also distributes medical products to patients' homes in the United States through our Cardinal Health at-Home Solutions division.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present revenue for each reportable segment and disaggregated revenue within our two reportable segments and Corporate:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.591%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.960%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.593%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical Distribution and Specialty Solutions (1) (2)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">46,497</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40,723&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nuclear and Precision Health Solutions (3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">312</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical segment revenue</span></div></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">46,809</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40,957&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical distribution and products (4)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,034</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,283&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cardinal Health at-Home Solutions</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">650</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">601&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical segment revenue</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,684</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,884&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">50,493</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,841&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (5)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">50,487</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,836&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.591%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.960%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.593%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical Distribution and Specialty Solutions (1) (2)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">139,435</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121,501&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nuclear and Precision Health Solutions (3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">875</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">653&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical segment revenue</span></div></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">140,310</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">122,154&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical distribution and products (4)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9,273</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,296&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cardinal Health at-Home Solutions</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,986</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,822&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical segment revenue</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11,259</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,118&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">151,569</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">134,272&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (5)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">151,559</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">134,261&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Products and services offered by our Specialty Solutions division are referred to as &#8220;specialty pharmaceutical products and services."</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Comprised of all Pharmaceutical segment businesses except for Nuclear and Precision Health Solutions division.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Increase from prior year relates to new product launches and changes in revenue recognition presentation from agent to principal for certain customer contracts.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Comprised of all Medical segment businesses except for Cardinal Health at-Home Solutions division.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.</span></div><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present revenue by geographic area:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:43.482%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.215%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.586%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.217%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">49,326</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43,710&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,167</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,131&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">50,493</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,841&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">50,487</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,836&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:43.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.906%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.586%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.217%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">148,136</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">130,933&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,433</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,339&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">151,569</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">134,272&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">151,559</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">134,261&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Profit</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate segment performance based on segment profit, among other measures. Segment profit is segment revenue, less segment cost of products sold, less segment distribution, selling, general and administrative ("SG&amp;A") expenses. Segment SG&amp;A expenses include share-based compensation expense as well as allocated corporate expenses for shared functions, including corporate management, corporate finance, financial and customer care shared services, human resources, information technology and legal and compliance, including certain litigation defense costs. Corporate expenses are allocated to the segments based on headcount, level of benefit provided and other ratable allocation methodologies. The results attributable to noncontrolling interests are recorded within segment profit.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not allocate the following items to our segments: </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">last-in first-out, or ("LIFO"), inventory charges/(credits); </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">surgical gown recall costs/(income);</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">shareholder cooperation agreement costs;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">state opioid assessment related to prior fiscal years;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">restructuring and employee severance;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">amortization and other acquisition-related costs;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">impairments and (gain)/loss on disposal of assets, net; in connection with goodwill impairment testing for the Medical Unit as discussed further in </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i1d34fc4fc2424fbcb4837cc9f1c0665c_88" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 4</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we recognized cumulative goodwill impairment charges of $863&#160;million during the nine months ended March&#160;31, 2023;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">litigation (recoveries)/charges, net;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">other (income)/expense, net;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">interest expense, net;</span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">loss on early extinguishment of debt; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">(gain)/loss on sale of equity interest in naviHealth; or</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">provision for income taxes </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, certain investment spending, certain portions of enterprise-wide incentive compensation and other spending are not allocated to the segments. Investment spending generally includes the first-year spend for certain projects that require incremental investments in the form of additional operating expenses. Because approval for these projects is dependent on executive management, we retain these expenses at Corporate. Investment spending within Corporate was $9 million and $20 million for the three months ended March&#160;31, 2023 and 2022, and $20 million and $38 million for the nine months ended March&#160;31, 2023 and 2022, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present segment profit by reportable segment and Corporate:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:50.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.429%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.122%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical (1)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">600</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">487&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">20</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total segment profit</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">620</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">546&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(48)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(643)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total operating earnings/(loss)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">572</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(97)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.358%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical (1)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,495</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,319&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">29</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total segment profit</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,524</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,551&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(934)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,183)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total operating earnings/(loss)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">590</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(632)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Pharmaceutical segment profit includes opioid-related litigation defense and compliance costs, but does not include a one-time contingent attorney fee of $18&#160;million incurred during the three and nine months ended March 31, 2022 related to the finalization of the Settlement Agreement. Due to the unique nature and significance of the Settlement Agreement, and the one-time, contingent nature of the fee, this related fee was included in litigation (recoveries)/charges, net in the condensed consolidated statements of earnings/(loss). Additionally, pharmaceutical segment profit during the nine months ended March 31, 2022 was positively impacted by a $16&#160;million judgment for lost profits related to an ordinary course intellectual property rights claim.</span></div></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents total assets for each reportable segment and Corporate at: </span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:52.150%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.503%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#d1d1d1;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">27,954</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"/><td style="background-color:#d1d1d1;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,409&#160;</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10,544</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,632&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d1d1d1;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate </span></td><td colspan="2" style="background-color:#d1d1d1;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,879</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d1d1d1;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"/><td colspan="2" style="background-color:#d1d1d1;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,837&#160;</span></td><td style="background-color:#d1d1d1;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total assets</span></td><td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">43,377</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43,878&#160;</span></td><td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>(1)Medical reflects cumulative $863&#160;million goodwill impairment charges recorded in connection with the interim goodwill impairment testing for the Medical Unit during the nine months ended March 31, 2023.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//280/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-26<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-34<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-21<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-21<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139887617083664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Compensation</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">13. Share-Based Compensation</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain stock incentive plans (collectively, the &#8220;Plans&#8221;) for the benefit of certain of our officers, directors and employees. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides total share-based compensation expense by type of award:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.358%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted share unit expense</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">17</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance share unit expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total share-based compensation</span></div></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">21</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.358%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted share unit expense</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">49</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance share unit expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">20</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total share-based compensation</span></div></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">69</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total tax benefit related to share-based compensation was $3 million for both the three months ended March&#160;31, 2023 and 2022, and $9 million for both the nine months ended March&#160;31, 2023 and 2022.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Restricted Share Units</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted share units granted under the Plans generally vest in equal annual installments over three years. Restricted share units accrue cash dividend equivalents that are payable upon vesting of the awards.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes all transactions related to restricted share units under the Plans:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:51.221%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.714%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.218%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Share Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair<br/>Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nonvested at June 30, 2022</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46.03&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70.26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50.03&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58.30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nonvested at March 31, 2023</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2.2</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">57.14</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2023, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested restricted share units </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">not yet recognized was $87 million, which is expected to be recognized over a weighted-average period of two years.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Performance Share Units</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance share units vest over a 3-year performance period based on achievement of specific performance goals. Based on the extent to which the targets are achieved, vested shares may range from zero to 234 percent of the target award amount. Performance share units accrue cash dividend equivalents that are payable upon vesting of the awards.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:49.983%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.023%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.147%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Performance<br/>Share Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair<br/>Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nonvested at June 30, 2022</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54.32&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70.52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59.04&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65.59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nonvested at March 31, 2023</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1.1</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">76.24</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2023, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested performance share units not yet recognized was $39 million, which is expected to be recognized over a weighted-average period of two years if performance goals are achieved.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139887620973360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Financial Accounting Standards</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Recently Issued Financial Accounting Standards</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Not Yet Adopted</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board ("FASB") on our condensed consolidated financial statements as well as material updates to previous assessments, if any, from our fiscal 2022 Form 10-K. There were no accounting standards issued in fiscal 2023 that will have a material impact on our condensed consolidated financial statements.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Recently Adopted Financial Accounting Standards</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new material accounting standards adopted during the nine months ended March 31, 2023.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements include the accounts of all majority-owned or consolidated subsidiaries, and all significant intercompany transactions and amounts have been eliminated. The results of businesses acquired or disposed of are included in the condensed consolidated financial statements from the date of the acquisition or up to the date of disposal, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References to "we," "our," and similar pronouns in this Quarterly Report on Form 10-Q for the quarter ended March&#160;31, 2023 (this "Form 10-Q") refer to Cardinal Health, Inc. and its majority-owned or consolidated subsidiaries unless the context requires otherwise.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our fiscal year ends on June 30. References to fiscal 2023 and 2022 in these condensed consolidated financial statements are to the fiscal years ending or ended June&#160;30, 2023 and June&#160;30, 2022, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements have been prepared in accordance with the U.S. Securities and Exchange Commission ("SEC") instructions to Quarterly Reports on Form 10-Q and include the information and disclosures required by accounting principles generally accepted in the United States ("GAAP") for interim financial reporting. The preparation of financial statements in conformity with GAAP requires us to make estimates, judgments and assumptions that affect amounts reported in the condensed consolidated financial statements and accompanying notes. Actual amounts may differ from these estimated amounts. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our opinion, all adjustments necessary for a fair presentation of the condensed consolidated financial statements have been included. Except as disclosed elsewhere in this Form 10-Q, all such adjustments are of a normal and recurring nature.&#160;In addition, financial results presented for this fiscal 2023 interim period are not necessarily indicative of the results that may be expected for the full fiscal year ending June&#160;30, 2023. These condensed consolidated financial statements are unaudited and, accordingly, should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual Report on Form 10-K for the fiscal year ended June 30, 2022 (our "2022 Form 10-K").</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Recently Issued Financial Accounting Standards</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Not Yet Adopted</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board ("FASB") on our condensed consolidated financial statements as well as material updates to previous assessments, if any, from our fiscal 2022 Form 10-K. There were no accounting standards issued in fiscal 2023 that will have a material impact on our condensed consolidated financial statements.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Recently Adopted Financial Accounting Standards</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new material accounting standards adopted during the nine months ended March 31, 2023.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139887612523040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring and Employee Severance (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringChargesAbstract', window );"><strong>Restructuring Charges [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock', window );">Summary of Restructuring and Employee Severance</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes restructuring and employee severance:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.974%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.591%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.592%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee-related</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Facility exit and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">13</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total restructuring and employee severance</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">16</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.974%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.591%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.592%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee-related</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">32</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Facility exit and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">30</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total restructuring and employee severance</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">62</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock', window );">Schedule of Activity Related to Liabilities Associated with Restructuring and Employee Severance</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes activity related to liabilities associated with restructuring and employee severance:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:43.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.237%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.237%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.241%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee-<br/>Related Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Facility Exit<br/>and Other Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2022</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">66</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">37</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments and other adjustments</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(51)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at March 31, 2023</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">49</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">52</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringChargesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringChargesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139887617077104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of Goodwill by Reportable Segment</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the carrying amount of goodwill by segment and in total:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.801%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.517%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.640%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.556%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical (1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2022</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,673&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,182&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,855</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill acquired, net of purchase price adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">13</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustments and other</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(5)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill impairment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(863)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(863)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at March 31, 2023</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,673</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,327</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,000</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">At March 31, 2023 and June 30, 2022, the Medical segment accumulated goodwill impairment loss was $4.4 billion and $3.5&#160;billion, respectively.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize other intangible assets by class at:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:24.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.070%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.714%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.070%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.409%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted- Average Remaining Amortization Period (Years)</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Indefinite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks and patents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total indefinite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Definite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,235</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,267</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">968</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks, trade names and patents</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">550</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">376</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">174</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed technology and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,037</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">623</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">414</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total definite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,822</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,266</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,556</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total other intangible assets</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,833</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,266</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,567</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:42.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.308%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.643%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.312%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net<br/>Intangible</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Indefinite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks and patents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total indefinite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Definite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,272&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,165&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks, trade names and patents</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">552&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">360&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">192&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed technology and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,038&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">574&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">464&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total definite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,862&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,099&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,763&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total other intangible assets</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,873&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,099&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,774&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139887617083664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Fair Value, Assets and Liabilities Measured on Recurring Basis</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the fair values for assets and (liabilities) measured on a recurring basis at:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.938%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,302</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,302</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other investments (1)</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">95</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">95</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contracts (2)</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(52)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(52)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.938%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,425&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,425&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other investments (1)</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contracts (2)</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">The other investments balance includes investments in mutual funds, which offset fluctuations in deferred compensation liabilities. These mutual funds invest in the equity securities of companies with both large and small market capitalization and high quality fixed income debt securities. The fair value of these investments is determined using quoted market prices.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">The fair value of interest rate swaps, foreign currency contracts, and net investment hedges is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in prepaid expenses and other, other assets, other accrued liabilities, and deferred income taxes and other liabilities within the condensed consolidated balance sheets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139887620889200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock', window );">Schedule of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings Compared to the Respective Carrying Amount</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.109%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.986%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.062%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Estimated fair value</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,466</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,049&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying amount</span></td><td colspan="2" style="border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,734</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"/><td colspan="2" style="border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,315&#160;</span></td><td style="border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139887617021488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of Changes in the Balance of Accumulated Other Comprehensive Loss by Component and in Total</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the changes in the balance of accumulated other comprehensive loss by component and in total:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.097%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.492%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.050%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign<br/>Currency<br/>Translation<br/>Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized<br/>Gain/(Loss) on<br/>Derivatives,<br/>net of tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2022</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(102)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(114)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss, before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified to earnings</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(9)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other comprehensive loss attributable to Cardinal Health, Inc. net of tax benefit of $5&#160;million</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(28)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at March 31, 2023</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(136)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(6)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(142)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.097%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.492%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.050%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign<br/>Currency<br/>Translation<br/>Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized<br/>Gain/(Loss) on<br/>Derivatives,<br/>net of tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2021</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss, before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified to earnings</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other comprehensive loss attributable to Cardinal Health, Inc. net of tax benefit of $6&#160;million</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at March 31, 2022</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(93)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(77)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139887616979856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share Attributable to Cardinal Health, Inc. (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock', window );">Reconciliation of Common Shares Used to Compute Basic and Diluted Earnings Per Share</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the number of common shares used to compute basic and diluted earnings/(loss) per share attributable to Cardinal Health, Inc.:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.406%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.407%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average common shares&#8211;basic</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">256</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock options, restricted share units and performance share units</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average common shares&#8211;diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">258</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.406%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.407%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average common shares&#8211;basic</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">263</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">281&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock options, restricted share units and performance share units</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average common shares&#8211;diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">264</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">281&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139887621622480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Disaggregation of Revenue [Table Text Block]</a></td>
<td class="text"><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.591%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.960%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.593%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical Distribution and Specialty Solutions (1) (2)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">46,497</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40,723&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nuclear and Precision Health Solutions (3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">312</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical segment revenue</span></div></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">46,809</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40,957&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical distribution and products (4)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,034</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,283&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cardinal Health at-Home Solutions</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">650</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">601&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical segment revenue</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,684</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,884&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">50,493</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,841&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (5)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">50,487</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,836&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.591%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.960%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.593%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical Distribution and Specialty Solutions (1) (2)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">139,435</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121,501&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nuclear and Precision Health Solutions (3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">875</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">653&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical segment revenue</span></div></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">140,310</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">122,154&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical distribution and products (4)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9,273</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,296&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cardinal Health at-Home Solutions</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,986</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,822&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical segment revenue</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11,259</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,118&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">151,569</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">134,272&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (5)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">151,559</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">134,261&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Products and services offered by our Specialty Solutions division are referred to as &#8220;specialty pharmaceutical products and services."</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Comprised of all Pharmaceutical segment businesses except for Nuclear and Precision Health Solutions division.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Increase from prior year relates to new product launches and changes in revenue recognition presentation from agent to principal for certain customer contracts.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Comprised of all Medical segment businesses except for Cardinal Health at-Home Solutions division.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock', window );">Revenue from External Customers by Geographic Areas [Table Text Block]</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present revenue by geographic area:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:43.482%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.215%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.586%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.217%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">49,326</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43,710&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,167</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,131&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">50,493</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,841&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">50,487</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,836&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:43.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.906%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.586%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.217%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">148,136</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">130,933&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,433</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,339&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">151,569</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">134,272&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">151,559</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">134,261&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock', window );">Segment Profit by Reportable Segment</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present segment profit by reportable segment and Corporate:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:50.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.429%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.122%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical (1)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">600</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">487&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">20</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total segment profit</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">620</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">546&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(48)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(643)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total operating earnings/(loss)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">572</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(97)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.358%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical (1)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,495</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,319&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">29</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total segment profit</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,524</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,551&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(934)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,183)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total operating earnings/(loss)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">590</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(632)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Pharmaceutical segment profit includes opioid-related litigation defense and compliance costs, but does not include a one-time contingent attorney fee of $18&#160;million incurred during the three and nine months ended March 31, 2022 related to the finalization of the Settlement Agreement. Due to the unique nature and significance of the Settlement Agreement, and the one-time, contingent nature of the fee, this related fee was included in litigation (recoveries)/charges, net in the condensed consolidated statements of earnings/(loss). Additionally, pharmaceutical segment profit during the nine months ended March 31, 2022 was positively impacted by a $16&#160;million judgment for lost profits related to an ordinary course intellectual property rights claim.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock', window );">Assets by Reportable Segment</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents total assets for each reportable segment and Corporate at: </span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:52.150%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.503%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#d1d1d1;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">27,954</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"/><td style="background-color:#d1d1d1;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,409&#160;</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10,544</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,632&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d1d1d1;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate </span></td><td colspan="2" style="background-color:#d1d1d1;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,879</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d1d1d1;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"/><td colspan="2" style="background-color:#d1d1d1;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,837&#160;</span></td><td style="background-color:#d1d1d1;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total assets</span></td><td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">43,377</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43,878&#160;</span></td><td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>(1)Medical reflects cumulative $863&#160;million goodwill impairment charges recorded in connection with the interim goodwill impairment testing for the Medical Unit during the nine months ended March 31, 2023.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph a<br> -SubTopic 10<br> -Topic 280<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139887617868224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of Total Share-based Compensation Expense by Type of Award</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides total share-based compensation expense by type of award:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.358%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted share unit expense</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">17</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance share unit expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total share-based compensation</span></div></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">21</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.358%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted share unit expense</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">49</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance share unit expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">20</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total share-based compensation</span></div></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">69</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of Transactions Related to Restricted Share Units Under the Plans</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes all transactions related to restricted share units under the Plans:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:51.221%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.714%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.218%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Share Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair<br/>Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nonvested at June 30, 2022</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46.03&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70.26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50.03&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58.30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nonvested at March 31, 2023</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2.2</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">57.14</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock', window );">Schedule of Transactions Related to Performance Share Units Under the Plans</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:49.983%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.023%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.147%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Performance<br/>Share Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair<br/>Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nonvested at June 30, 2022</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54.32&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70.52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59.04&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65.59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nonvested at March 31, 2023</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1.1</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">76.24</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested performance-based units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139887615598064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations and Disposal Groups (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinesses', window );">Proceeds from divestitures, net of cash sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 923<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_CordisDivestitureAxis=cah_CordisDivestitureMember', window );">Cordis Divestiture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinesses', window );">Proceeds from divestitures, net of cash sold</a></td>
<td class="nump">$ 923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_CordisDivestitureAxis=cah_CordisDivestitureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_CordisDivestitureAxis=cah_CordisDivestitureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139887610781136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringChargesAbstract', window );"><strong>Restructuring Charges [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Employee-related costs</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">$ 32<span></span>
</td>
<td class="nump">$ 22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_FacilityExitAndOtherCosts', window );">Facility Exit and Other Costs</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Total restructuring and employee severance</a></td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">$ 31<span></span>
</td>
<td class="nump">$ 62<span></span>
</td>
<td class="nump">$ 56<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_FacilityExitAndOtherCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Facility exit and other costs primarily consist of lease termination costs, accelerated depreciation, equipment relocation costs, project consulting fees and costs associated with restructuring our delivery of information technology infrastructure services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_FacilityExitAndOtherCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482047/420-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringChargesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringChargesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139887615679888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning Balance</a></td>
<td class="nump">$ 66<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Additions</a></td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments and other adjustments</a></td>
<td class="num">(51)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending Balance</a></td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Employee- Related Costs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning Balance</a></td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Additions</a></td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments and other adjustments</a></td>
<td class="num">(36)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending Balance</a></td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_FacilityClosingMember', window );">Facility Exit and Other Costs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning Balance</a></td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Additions</a></td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments and other adjustments</a></td>
<td class="num">(15)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending Balance</a></td>
<td class="nump">$ 3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_FacilityClosingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_FacilityClosingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139887621207552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring and Employee Severance Narative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Employee-related costs</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">$ 32<span></span>
</td>
<td class="nump">$ 22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_FacilityExitAndOtherCosts', window );">Facility Exit and Other Costs</a></td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">$ 19<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_FacilityExitAndOtherCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Facility exit and other costs primarily consist of lease termination costs, accelerated depreciation, equipment relocation costs, project consulting fees and costs associated with restructuring our delivery of information technology infrastructure services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_FacilityExitAndOtherCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139887610402528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,855<span></span>
</td>
<td class="nump">$ 5,855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill acquired, net of purchase price adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign currency translation adjustments and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember', window );">Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,673<span></span>
</td>
<td class="nump">2,673<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill acquired, net of purchase price adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign currency translation adjustments and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,673<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember', window );">Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,182<span></span>
</td>
<td class="nump">3,182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill acquired, net of purchase price adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign currency translation adjustments and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="nump">$ 709<span></span>
</td>
<td class="nump">$ 154<span></span>
</td>
<td class="nump">863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Goodwill, Impaired, Accumulated Impairment Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,400<span></span>
</td>
<td class="nump">$ 3,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139887612510160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Net Intangible</a></td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Intangible</a></td>
<td class="nump">4,822<span></span>
</td>
<td class="nump">4,862<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">3,266<span></span>
</td>
<td class="nump">3,099<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Intangible</a></td>
<td class="nump">$ 1,556<span></span>
</td>
<td class="nump">1,763<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Weighted- Average Remaining Amortization Period (Years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Gross Intangible, Total other intangible assets</a></td>
<td class="nump">$ 4,833<span></span>
</td>
<td class="nump">4,873<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net Intangible, Total other intangible assets</a></td>
<td class="nump">1,567<span></span>
</td>
<td class="nump">1,774<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=cah_IPRDTrademarksandOtherMember', window );">Trademarks and patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Net Intangible</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Intangible</a></td>
<td class="nump">3,235<span></span>
</td>
<td class="nump">3,272<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">2,267<span></span>
</td>
<td class="nump">2,165<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Intangible</a></td>
<td class="nump">$ 968<span></span>
</td>
<td class="nump">1,107<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Weighted- Average Remaining Amortization Period (Years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cah_TrademarksAndPatentsMember', window );">Trademarks, trade names and patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Intangible</a></td>
<td class="nump">$ 550<span></span>
</td>
<td class="nump">552<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">376<span></span>
</td>
<td class="nump">360<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Intangible</a></td>
<td class="nump">$ 174<span></span>
</td>
<td class="nump">192<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Weighted- Average Remaining Amortization Period (Years)</a></td>
<td class="text">9 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Intangible</a></td>
<td class="nump">$ 1,037<span></span>
</td>
<td class="nump">1,038<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">623<span></span>
</td>
<td class="nump">574<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Intangible</a></td>
<td class="nump">$ 414<span></span>
</td>
<td class="nump">$ 464<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Weighted- Average Remaining Amortization Period (Years)</a></td>
<td class="text">9 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483147/928-340-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=cah_IPRDTrademarksandOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=cah_IPRDTrademarksandOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cah_TrademarksAndPatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cah_TrademarksAndPatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139887616208624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets (Narrative) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="5">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">$ 69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 211<span></span>
</td>
<td class="nump">$ 235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">Estimated annual amortization of intangible assets - Remainder of Fiscal Year</a></td>
<td class="nump">71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Estimated annual amortization of intangible assets - Year One</a></td>
<td class="nump">261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Estimated annual amortization of intangible assets - Year Two</a></td>
<td class="nump">236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">Estimated annual amortization of intangible assets - Year Three</a></td>
<td class="nump">209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">Estimated annual amortization of intangible assets - Year Four</a></td>
<td class="nump">177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,855<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember', window );">Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 2,327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,182<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 709<span></span>
</td>
<td class="nump">$ 154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cah_MedicalUnitMember', window );">Medical Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 474<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=cah_MedicalUnitMember', window );">Medical Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_DiscountRateFairValueInput', window );">Discount Rate, Fair Value Input</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.50%<span></span>
</td>
<td class="nump">10.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_TerminalGrowthRateFairValueInput', window );">Terminal Growth Rate, Fair Value Input</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount', window );">Reporting Unit, Percentage of Fair Value in Excess of Carrying Amount</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_DiscountRateFairValueInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount Rate, Fair Value Input</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_DiscountRateFairValueInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_TerminalGrowthRateFairValueInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Terminal Growth Rate, Fair Value Input</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_TerminalGrowthRateFairValueInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of fair value of reporting unit in excess of carrying amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_MedicalUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_MedicalUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=cah_MedicalUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=cah_MedicalUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139887618364624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Obligations and Other Short-Term Borrowings (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_TotalLongTermandShortTermObligations', window );">Total Long-Term and Short-Term Obligations</a></td>
<td class="nump">$ 4,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrentAndNoncurrent', window );">Accounts Payable</a></td>
<td class="nump">29,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (Loss) on Extinguishment of Debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of Credit Facility, Maximum Borrowing Capacity</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of Credit Facility, Maximum Borrowing Capacity</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=cah_ShortTermCreditFacilitiesMember', window );">Short Term Credit Facilities Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherShortTermBorrowings', window );">Other Short-term Borrowings</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=cah_A2.616Notesdue2022Member', window );">2.616% Notes due 2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_NotesPayableRepurchased', window );">Notes Payable Repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (Loss) on Extinguishment of Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=cah_A32NotesDue2023Member', window );">3.2% Notes due 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayments of Notes Payable</a></td>
<td class="nump">550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=cah_CommittedReceivablesSalesFacilityProgramMember', window );">Committed Receivables Sales Facility Program [Member] | Short Term Credit Facilities Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of Credit Facility, Maximum Borrowing Capacity</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_NotesPayableRepurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Principal Amount of Notes Payable Repurchased during the quarter</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_NotesPayableRepurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_TotalLongTermandShortTermObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total Long-Term and Short-Term Obligations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_TotalLongTermandShortTermObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowings classified as other, maturing within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(13)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a)(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=cah_ShortTermCreditFacilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=cah_ShortTermCreditFacilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cah_A2.616Notesdue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cah_A2.616Notesdue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cah_A32NotesDue2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cah_A32NotesDue2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cah_CommittedReceivablesSalesFacilityProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cah_CommittedReceivablesSalesFacilityProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139887616407280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Obligations and Other Short-Term Borrowings Summary of Debt (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_TotalLongTermandShortTermObligations', window );">Total Long-Term and Short-Term Obligations</a></td>
<td class="nump">$ 4,700<span></span>
</td>
<td class="nump">$ 5,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent', window );">Long-term Debt and Lease Obligation, Current</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">580<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Long-term Debt and Lease Obligation</a></td>
<td class="nump">4,708<span></span>
</td>
<td class="nump">$ 4,735<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAverageOutstandingAmount', window );">Line of Credit Facility, Average Outstanding Amount</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=cah_CommittedReceivablesSalesFacilityProgramMember', window );">Committed Receivables Sales Facility Program [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod', window );">Line of Credit Facility, Maximum Amount Outstanding During Period</a></td>
<td class="nump">$ 445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_TotalLongTermandShortTermObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total Long-Term and Short-Term Obligations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_TotalLongTermandShortTermObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAverageOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Average amount borrowed under the credit facility during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAverageOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum amount borrowed under the credit facility at any time during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=cah_CommittedReceivablesSalesFacilityProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=cah_CommittedReceivablesSalesFacilityProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139887606997152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments, Contingent Liabilities and Litigation (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="1">5 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">22 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 01, 2023 </div>
<div>plaintiff</div>
</th>
<th class="th">
<div>Apr. 30, 2023 </div>
<div>lawsuit</div>
</th>
<th class="th">
<div>Apr. 28, 2023 </div>
<div>lawsuit </div>
<div>plaintiff</div>
</th>
<th class="th"><div>Jul. 31, 2014</div></th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>plaintiff</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 28, 2023 </div>
<div>lawsuit</div>
</th>
<th class="th">
<div>Jan. 31, 2023 </div>
<div>numberOfUSTerritories </div>
<div>states</div>
</th>
<th class="th">
<div>Oct. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Gain (Loss) Related to Litigation Settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 76,000<span></span>
</td>
<td class="num">$ (61,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 256,000<span></span>
</td>
<td class="num">$ (113,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_IncomefromSettlementsofClassActionLawsuits', window );">Income from Settlements of Class Action Lawsuits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember', window );">Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_JudgmentForLostProfits', window );">Judgment for lost profits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=cah_ProductLiabilityLawsuitsMember', window );">Product Liability Lawsuits | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Loss Contingency, Pending Claims, Number | lawsuit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_LawsuitTypeAxis=cah_ProductLiabilityLawsuitsMember', window );">Product Liability Lawsuits | Subsequent Event | IVC April 2023 Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyClaimsSettledNumber', window );">Loss Contingency, Claims Settled, Number | lawsuit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,376<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_LawsuitTypeAxis=cah_ProductLiabilityLawsuitsMember', window );">Product Liability Lawsuits | Subsequent Event | Other Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyClaimsSettledNumber', window );">Loss Contingency, Claims Settled, Number | lawsuit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_LawsuitTypeAxis=cah_ProductLiabilityLawsuitsMember', window );">Product Liability Lawsuits | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Loss Contingency Accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">385,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">385,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_OpioidLitigationAxis=cah_TotalOpioidLitigationMember', window );">Total Opioid Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Loss Contingency, Estimate of Possible Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_SettlingStates', window );">Settling States | states</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_SettlingUSTerritories', window );">Settling U.S Territories | numberOfUSTerritories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationReserve', window );">Estimated Litigation Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,850,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,850,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationReserveCurrent', window );">Estimated Litigation Liability, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">437,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">437,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=cah_NewYorkOpioidStewardshipActMember', window );">New York Opioid Stewardship Act [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_AggregateAnnualAssessment', window );">Aggregate Annual Assessment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualPayments', window );">Loss Contingency Accrual, Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Loss Contingency Accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease', window );">Loss Contingency Accrual, Period Increase (Decrease)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=cah_OpioidLawsuitsMember', window );">Opioid Lawsuits [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Payments for Legal Settlements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">372,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuranceRecoveries', window );">Insurance Recoveries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=cah_OpioidLawsuitsMember', window );">Opioid Lawsuits [Member] | WEST VIRGINIA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Loss Contingency, Estimate of Possible Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 124,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=cah_OpioidLawsuitsMember', window );">Opioid Lawsuits [Member] | WASHINGTON</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Loss Contingency, Estimate of Possible Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=cah_OpioidLawsuitsMember', window );">Opioid Lawsuits [Member] | OKLAHOMA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Loss Contingency, Estimate of Possible Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 95,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=cah_OpioidLawsuitsMember', window );">Opioid Lawsuits [Member] | Native American tribes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Loss Contingency, Estimate of Possible Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 136,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=cah_OpioidLawsuitsMember', window );">Opioid Lawsuits [Member] | Private Parties [Member] | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_LossContingencyLawsuitsNumber', window );">Loss Contingency, Lawsuits, Number | lawsuit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">457<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">457<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=cah_OpioidLawsuitsMember', window );">Opioid Lawsuits [Member] | Private Parties [Member] | GEORGIA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfPlaintiffs', window );">Loss Contingency, Number of Plaintiffs | plaintiff</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=cah_OpioidLawsuitsMember', window );">Opioid Lawsuits [Member] | Private Parties [Member] | ALABAMA | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfPlaintiffs', window );">Loss Contingency, Number of Plaintiffs | plaintiff</a></td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=cah_OpioidLawsuitsMember', window );">Opioid Lawsuits [Member] | Class Action Lawsuits [Member] | Private Parties [Member] | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_LossContingencyLawsuitsNumber', window );">Loss Contingency, Lawsuits, Number | lawsuit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=cah_ProductLiabilityLawsuitsMember', window );">Product Liability Lawsuits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductLiabilityAccrualPeriodExpense', window );">Product Liability Accrual, Period Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (71,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(95,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=cah_ProductLiabilityLawsuitsMember', window );">Product Liability Lawsuits | IVC April 2023 Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Loss Contingency, Estimate of Possible Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">275,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">275,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=cah_ProductLiabilityLawsuitsMember', window );">Product Liability Lawsuits | Subsequent Event | IVC April 2023 Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Payments for Legal Settlements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 275,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=cah_ProductLiabilityLawsuitsMember', window );">Product Liability Lawsuits | Alameda County [Member] | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfPlaintiffs', window );">Loss Contingency, Number of Plaintiffs | plaintiff</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=cah_ShareholderDerivativeLitigationMember', window );">Shareholder Derivative Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_GrossInsuranceSettlementBeforeAttorneyFees', window );">Gross Insurance Settlement Before Attorney Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities', window );">Proceeds from Insurance Settlement, Operating Activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 93,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=cah_ShareholderSecuritiesLitigationMember', window );">Shareholder Securities Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuranceRecoveries', window );">Insurance Recoveries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">109,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Gain (Loss) Related to Litigation Settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 109,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=cah_CVSHealthMember', window );">CVS Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermPurchaseCommitmentPeriod', window );">Long-term Purchase Commitment, Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_AggregateAnnualAssessment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate Annual Assessment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_AggregateAnnualAssessment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_GrossInsuranceSettlementBeforeAttorneyFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross Insurance Settlement Before Attorney Fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_GrossInsuranceSettlementBeforeAttorneyFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_IncomefromSettlementsofClassActionLawsuits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income from Settlements of Class Action Lawsuits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_IncomefromSettlementsofClassActionLawsuits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_JudgmentForLostProfits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Judgment for lost profits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_JudgmentForLostProfits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_LossContingencyLawsuitsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Lawsuits, Number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_LossContingencyLawsuitsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_SettlingStates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Settling States</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_SettlingStates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_SettlingUSTerritories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Settling U.S Territories</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_SettlingUSTerritories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuranceRecoveries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recovered from insurance. These recoveries reduce costs and losses that are reported as a separate line item under operating expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuranceRecoveries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermPurchaseCommitmentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period covered by the long-term purchase commitment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermPurchaseCommitmentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow reducing loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyClaimsSettledNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of claims settled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyClaimsSettledNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyEstimateOfPossibleLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyEstimateOfPossibleLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNumberOfPlaintiffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of plaintiffs that have filed claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNumberOfPlaintiffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyPendingClaimsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of pending claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyPendingClaimsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLegalSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for the settlement of litigation or for other legal issues during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLegalSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow for proceeds from settlement of insurance claim, classified as operating activities. Excludes insurance settlement classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-21B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromInsuranceSettlementOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductLiabilityAccrualPeriodExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of loss reported during the period pertaining to product liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductLiabilityAccrualPeriodExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=cah_ProductLiabilityLawsuitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=cah_ProductLiabilityLawsuitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_LawsuitTypeAxis=cah_ProductLiabilityLawsuitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_LawsuitTypeAxis=cah_ProductLiabilityLawsuitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_AgreementsAxis=cah_IVCApril2023AgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_AgreementsAxis=cah_IVCApril2023AgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_AgreementsAxis=cah_OtherAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_AgreementsAxis=cah_OtherAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_OpioidLitigationAxis=cah_TotalOpioidLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_OpioidLitigationAxis=cah_TotalOpioidLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=cah_NewYorkOpioidStewardshipActMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=cah_NewYorkOpioidStewardshipActMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=cah_OpioidLawsuitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=cah_OpioidLawsuitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_WV">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_WV</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_WA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_WA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_OK">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_OK</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=cah_NativeAmericanTribesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=cah_NativeAmericanTribesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_PlaintiffTypeAxis=cah_PrivatePartiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_PlaintiffTypeAxis=cah_PrivatePartiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_GA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_GA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_AL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_AL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_LawsuitTypeAxis=cah_ClassActionLawsuitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_LawsuitTypeAxis=cah_ClassActionLawsuitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=cah_ProductLiabilityLawsuitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=cah_ProductLiabilityLawsuitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=cah_AlamedaCountyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=cah_AlamedaCountyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=cah_ShareholderDerivativeLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=cah_ShareholderDerivativeLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=cah_ShareholderSecuritiesLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=cah_ShareholderSecuritiesLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=cah_CVSHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=cah_CVSHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139887610454272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Narrative) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective Income Tax Rate Reconciliation, Percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36.30%<span></span>
</td>
<td class="num">(916.50%)<span></span>
</td>
<td class="nump">36.70%<span></span>
</td>
<td class="num">(44.40%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 197<span></span>
</td>
<td class="nump">$ 1,253<span></span>
</td>
<td class="nump">189<span></span>
</td>
<td class="nump">$ 328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 943<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefits that would impact effective tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">897<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">897<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">858<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Unrecognized tax benefits, interest and penalties accrued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=cah_MedicalUnitMember', window );">Medical Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_GoodwillImpairmentAxis=cah_MedicalUnitGoodwillImpairmentMember', window );">Medical Unit Goodwill Impairment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast [Member] | Medical Unit Goodwill Impairment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (68)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast [Member] | Medical Unit Goodwill Impairment [Member] | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="nump">$ 66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible', window );">Estimated range of decrease in unrecognized tax benefits within the next 12 months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible', window );">Estimated range of decrease in unrecognized tax benefits within the next 12 months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_TaxMatterAxis=cah_CareFusionMember', window );">CareFusion [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_IndemnificationReceivable', window );">Indemnification Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_IndemnificationReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indemnification receivable from Patient recovery related to certain pre-acquisition tax exposures and transaction taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_IndemnificationReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=cah_MedicalUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=cah_MedicalUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_GoodwillImpairmentAxis=cah_MedicalUnitGoodwillImpairmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_GoodwillImpairmentAxis=cah_MedicalUnitGoodwillImpairmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_TaxMatterAxis=cah_CareFusionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_TaxMatterAxis=cah_CareFusionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139887618328384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Fair Value of Assets and Liabilities Measured on a Recurring Basis) (Details) - Recurring - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 1,302<span></span>
</td>
<td class="nump">$ 2,425<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Other investments</a></td>
<td class="nump">95<span></span>
</td>
<td class="nump">97<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet', window );">Forward Contract</a></td>
<td class="num">(52)<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet', window );">Forward Contract</a></td>
<td class="num">(52)<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level&#160;1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">1,302<span></span>
</td>
<td class="nump">2,425<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Other investments</a></td>
<td class="nump">95<span></span>
</td>
<td class="nump">97<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet', window );">Forward Contract</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet', window );">Forward Contract</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level&#160;2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Other investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet', window );">Forward Contract</a></td>
<td class="num">(52)<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet', window );">Forward Contract</a></td>
<td class="num">(52)<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level&#160;3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Other investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet', window );">Forward Contract</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet', window );">Forward Contract</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair values as of the balance sheet date of the net amount of all assets and liabilities resulting from contracts that meet the criteria of being accounted for as derivative instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 10<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480463/815-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139887610941520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Narrative) (Details)<br> &#8364; in Millions, &#165; in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>JPY (&#165;)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1', window );">Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromHedgeInvestingActivities', window );">Proceeds from net investment hedge terminations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="nump">71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_DateInitiatedAxis=cah_March2022Member', window );">Effective March 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromHedgeInvestingActivities', window );">Proceeds from net investment hedge terminations</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_DateInitiatedAxis=cah_September2018Member', window );">Effective September 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromHedgeInvestingActivities', window );">Proceeds from net investment hedge terminations</a></td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax', window );">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign Exchange Contract [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax', window );">Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="nump">44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest Income (Expense), Nonoperating, Net</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging [Member] | Foreign Exchange Contract [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet', window );">Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging [Member] | Foreign Exchange Contract [Member] | Forecast [Member] | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet', window );">Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument | Fair Value Hedging | Interest Rate Swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotionalAmount', window );">Derivative Liability, Notional Amount</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument | Net Investment Hedging [Member] | Currency Swap [Member] | Effective March 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount', window );">Derivatives, Hedge Discontinuances, Termination of Hedging Instrument, Notional Amount</a></td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 48,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument | Net Investment Hedging [Member] | Currency Swap [Member] | Effective September 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount', window );">Derivatives, Hedge Discontinuances, Termination of Hedging Instrument, Notional Amount</a></td>
<td class="nump">233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument | Net Investment Hedging [Member] | Currency Swap [Member] | September 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotionalAmount', window );">Derivative Asset, Notional Amount</a></td>
<td class="nump">150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument | Net Investment Hedging [Member] | Currency Swap [Member] | June 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotionalAmount', window );">Derivative Asset, Notional Amount</a></td>
<td class="nump">150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 19,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument | Net Investment Hedging [Member] | Currency Swap [Member] | March 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotionalAmount', window );">Derivative Liability, Notional Amount</a></td>
<td class="nump">107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument | Net Investment Hedging [Member] | Currency Swap [Member] | March 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotionalAmount', window );">Derivative Liability, Notional Amount</a></td>
<td class="nump">$ 107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember', window );">Other Nonoperating Income (Expense) [Member] | Not Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet', window );">Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (4)<span></span>
</td>
<td class="num">$ (3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivatives, Hedge Discontinuances, Termination of Hedging Instrument, Notional Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 815<br> -SubTopic 25<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480238/815-25-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payments on the derivative asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5C<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column D))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5B<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1B<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1A<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The effective portion of net gain (loss) reclassified from accumulated other comprehensive income into income on derivative instruments designated and qualifying as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4D<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4C<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4CC<br> -SubTopic 10<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4CC<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payments on the derivative liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5C<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column D))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column D))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5B<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1B<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1A<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4C<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480627/815-20-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4CCC<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromHedgeInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow for a financial contract that meets the hedge criteria as either a cash flow hedge, fair value hedge, or hedge of a net investment in a foreign operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 27<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromHedgeInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_DateInitiatedAxis=cah_March2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_DateInitiatedAxis=cah_March2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_DateInitiatedAxis=cah_September2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_DateInitiatedAxis=cah_September2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_MaturityDateAxis=cah_September2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_MaturityDateAxis=cah_September2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_MaturityDateAxis=cah_June2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_MaturityDateAxis=cah_June2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_MaturityDateAxis=cah_March2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_MaturityDateAxis=cah_March2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_MaturityDateAxis=cah_March2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_MaturityDateAxis=cah_March2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139887612500960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_CarryingAmountofLongTermandotherShortTermBorrowings', window );">Carrying Amount of Long-Term and other Short-Term Borrowings</a></td>
<td class="nump">$ 4,734<span></span>
</td>
<td class="nump">$ 5,315<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Estimated fair value</a></td>
<td class="nump">$ 4,466<span></span>
</td>
<td class="nump">$ 5,049<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_CarryingAmountofLongTermandotherShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying Amount of Long-Term and other Short-Term Borrowings</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_CarryingAmountofLongTermandotherShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139887611625216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Narrative) (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="2">4 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2023</div></th>
<th class="th"><div>Jan. 13, 2023</div></th>
<th class="th"><div>Dec. 23, 2022</div></th>
<th class="th"><div>Apr. 18, 2022</div></th>
<th class="th"><div>Jan. 31, 2022</div></th>
<th class="th"><div>Oct. 04, 2021</div></th>
<th class="th"><div>Feb. 28, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Jan. 13, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Oct. 14, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Apr. 18, 2022</div></th>
<th class="th"><div>Jan. 31, 2022</div></th>
<th class="th"><div>Dec. 23, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchase of treasury shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=cah_A250MillionShareRepurchaseProgramMember', window );">$250 million share repurchase program [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchase of treasury shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=cah_A1BillionShareRepurchaseProgramMember', window );">$1 billion share repurchase program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchase of treasury shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=cah_A300MillionShareRepurchaseProgramMember', window );">$300 million share repurchase program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchase of treasury shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=cah_A500MillionShareRepurchaseProgramMember', window );">$500 million share repurchase program [Domain]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchase of treasury shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=cah_A200MillionShareRepurchaseProgramMember', window );">$200 million</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchase of treasury shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockCommonMember', window );">Treasury Stock, Common</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchase of treasury shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Treasury Stock, Shares, Acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20.0)<span></span>
</td>
<td class="num">(19.0)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockCommonMember', window );">Treasury Stock, Common | $250 million share repurchase program [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Treasury Stock, Shares, Acquired</a></td>
<td class="num">(0.6)<span></span>
</td>
<td class="num">(0.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare', window );">Treasury shares acquired, average price per share (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 77.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 77.50<span></span>
</td>
<td class="nump">$ 76.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 77.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockCommonMember', window );">Treasury Stock, Common | $1 billion share repurchase program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Treasury Stock, Shares, Acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare', window );">Treasury shares acquired, average price per share (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 66.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 73.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockCommonMember', window );">Treasury Stock, Common | $300 million share repurchase program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Treasury Stock, Shares, Acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare', window );">Treasury shares acquired, average price per share (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockCommonMember', window );">Treasury Stock, Common | $500 million share repurchase program [Domain]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Treasury Stock, Shares, Acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare', window );">Treasury shares acquired, average price per share (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51.10<span></span>
</td>
<td class="nump">$ 51.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockCommonMember', window );">Treasury Stock, Common | $200 million</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Treasury Stock, Shares, Acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare', window );">Treasury shares acquired, average price per share (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total cost of shares repurchased divided by the total number of shares repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockAcquiredAverageCostPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=cah_A250MillionShareRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=cah_A250MillionShareRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=cah_A1BillionShareRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=cah_A1BillionShareRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=cah_A300MillionShareRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=cah_A300MillionShareRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=cah_A500MillionShareRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=cah_A500MillionShareRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=cah_A200MillionShareRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=cah_A200MillionShareRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockCommonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockCommonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139887605539776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period</a></td>
<td class="num">$ (2,212)<span></span>
</td>
<td class="nump">$ 1,002<span></span>
</td>
<td class="num">$ (706)<span></span>
</td>
<td class="nump">$ 1,794<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTax', window );">Other Comprehensive Income (Loss), Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive income/(loss), net of tax</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="num">(28)<span></span>
</td>
<td class="num">(43)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period</a></td>
<td class="num">(2,218)<span></span>
</td>
<td class="num">(693)<span></span>
</td>
<td class="num">(2,218)<span></span>
</td>
<td class="num">(693)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember', window );">Foreign Currency Translation Adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(102)<span></span>
</td>
<td class="num">(46)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(34)<span></span>
</td>
<td class="num">(47)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive income/(loss), net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(34)<span></span>
</td>
<td class="num">(47)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period</a></td>
<td class="num">(136)<span></span>
</td>
<td class="num">(93)<span></span>
</td>
<td class="num">(136)<span></span>
</td>
<td class="num">(93)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember', window );">Unrealized Gain/(Loss) on Derivatives, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive income/(loss), net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period</a></td>
<td class="num">(6)<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember', window );">Accumulated Other Comprehensive Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(114)<span></span>
</td>
<td class="num">(34)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive income/(loss), net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28)<span></span>
</td>
<td class="num">(43)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period</a></td>
<td class="num">(142)<span></span>
</td>
<td class="num">(77)<span></span>
</td>
<td class="num">(142)<span></span>
</td>
<td class="num">(77)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">AOCI Attributable to Parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period</a></td>
<td class="num">(146)<span></span>
</td>
<td class="num">(85)<span></span>
</td>
<td class="num">(114)<span></span>
</td>
<td class="num">(34)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19)<span></span>
</td>
<td class="num">(38)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period</a></td>
<td class="num">$ (142)<span></span>
</td>
<td class="num">$ (77)<span></span>
</td>
<td class="num">$ (142)<span></span>
</td>
<td class="num">$ (77)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482739/220-10-55-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482739/220-10-55-15<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) allocated to other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482739/220-10-55-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 41: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-15<br><br>Reference 42: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-16<br><br>Reference 43: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139887621553792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share Attributable to Cardinal Health, Inc. (Narrative) (Details)<br> shares in Millions, Reportable_Segments in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>Reportable_Segments </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>Reportable_Segments </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive employee stock options, restricted share units and performance share units that were antidilutive (in shares) | shares</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_SharesThatWouldBeAntidilutiveAsAResultOfNetLoss', window );">Shares that would be antidilutive as a result of net loss | Reportable_Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_SharesThatWouldBeAntidilutiveAsAResultOfNetLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares that would be antidilutive as a result of net loss</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_SharesThatWouldBeAntidilutiveAsAResultOfNetLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139887621296752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details) - shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares&#8211;basic (in shares)</a></td>
<td class="nump">256<span></span>
</td>
<td class="nump">275<span></span>
</td>
<td class="nump">263<span></span>
</td>
<td class="nump">281<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Employee stock options, restricted share units, and performance share units (in shares)</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares&#8211;diluted (in shares)</a></td>
<td class="nump">258<span></span>
</td>
<td class="nump">275<span></span>
</td>
<td class="nump">264<span></span>
</td>
<td class="nump">281<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139887615770896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Narrative) (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Loss Related to Litigation Settlement</a></td>
<td class="num">$ (76)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61<span></span>
</td>
<td class="num">$ (256)<span></span>
</td>
<td class="nump">$ 113<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_ProjectCostsOnInvestmentAndOtherSpending', window );">Project costs on investment and other spending</a></td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_ProjectCostsOnInvestmentAndOtherSpending', window );">Project costs on investment and other spending</a></td>
<td class="nump">$ 9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="nump">$ 38<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=cah_MedicalUnitMember', window );">Medical Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember', window );">Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 709<span></span>
</td>
<td class="nump">$ 154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_ProjectCostsOnInvestmentAndOtherSpending">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment spending at the Corporate level. Investment spending generally includes the first year spend for certain projects that require incremental investments in the form of additional operating expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_ProjectCostsOnInvestmentAndOtherSpending</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=cah_MedicalUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=cah_MedicalUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139887615637984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Revenue by Reportable Segment) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 50,487<span></span>
</td>
<td class="nump">$ 44,836<span></span>
</td>
<td class="nump">$ 151,559<span></span>
</td>
<td class="nump">$ 134,261<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">50,493<span></span>
</td>
<td class="nump">44,841<span></span>
</td>
<td class="nump">151,569<span></span>
</td>
<td class="nump">134,272<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">46,809<span></span>
</td>
<td class="nump">40,957<span></span>
</td>
<td class="nump">140,310<span></span>
</td>
<td class="nump">122,154<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">3,684<span></span>
</td>
<td class="nump">3,884<span></span>
</td>
<td class="nump">11,259<span></span>
</td>
<td class="nump">12,118<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=cah_PharmaceuticalDistributionandSpecialtyMember', window );">Pharmaceutical Distribution and Specialty [Member] | Operating Segments | Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">46,497<span></span>
</td>
<td class="nump">40,723<span></span>
</td>
<td class="nump">139,435<span></span>
</td>
<td class="nump">121,501<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=cah_NuclearPrecisionHealthSolutionsMember', window );">Nuclear Precision Health Services [Member] | Operating Segments | Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">312<span></span>
</td>
<td class="nump">234<span></span>
</td>
<td class="nump">875<span></span>
</td>
<td class="nump">653<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=cah_MedicaldistributionandproductsMember', window );">Medical distribution and products [Member] | Operating Segments | Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">3,034<span></span>
</td>
<td class="nump">3,283<span></span>
</td>
<td class="nump">9,273<span></span>
</td>
<td class="nump">10,296<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=cah_CardinalHealthAtHomeMember', window );">Cardinal Health At Home [Member] | Operating Segments | Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 650<span></span>
</td>
<td class="nump">$ 601<span></span>
</td>
<td class="nump">$ 1,986<span></span>
</td>
<td class="nump">$ 1,822<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=cah_PharmaceuticalDistributionandSpecialtyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=cah_PharmaceuticalDistributionandSpecialtyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=cah_NuclearPrecisionHealthSolutionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=cah_NuclearPrecisionHealthSolutionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=cah_MedicaldistributionandproductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=cah_MedicaldistributionandproductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=cah_CardinalHealthAtHomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=cah_CardinalHealthAtHomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139887618203200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Segment Profit by Reportable Segment) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total operating earnings</a></td>
<td class="nump">$ 572<span></span>
</td>
<td class="num">$ (97)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 590<span></span>
</td>
<td class="num">$ (632)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_ContingentAttorneyFee', window );">Contingent Attorney Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember', window );">Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_JudgmentForLostProfits', window );">Judgment for lost profits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total operating earnings</a></td>
<td class="nump">620<span></span>
</td>
<td class="nump">546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,524<span></span>
</td>
<td class="nump">1,551<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total operating earnings</a></td>
<td class="nump">600<span></span>
</td>
<td class="nump">487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,495<span></span>
</td>
<td class="nump">1,319<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total operating earnings</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="nump">232<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total operating earnings</a></td>
<td class="num">$ (48)<span></span>
</td>
<td class="num">$ (643)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (934)<span></span>
</td>
<td class="num">$ (2,183)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_ContingentAttorneyFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent Attorney Fee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_ContingentAttorneyFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_JudgmentForLostProfits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Judgment for lost profits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_JudgmentForLostProfits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139887605514080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information Revenue From External Customers By Geographic Areas (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems', window );"><strong>Segment Revenue from External Customers by Geographic Area [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 50,487<span></span>
</td>
<td class="nump">$ 44,836<span></span>
</td>
<td class="nump">$ 151,559<span></span>
</td>
<td class="nump">$ 134,261<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">UNITED STATES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems', window );"><strong>Segment Revenue from External Customers by Geographic Area [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">49,326<span></span>
</td>
<td class="nump">43,710<span></span>
</td>
<td class="nump">148,136<span></span>
</td>
<td class="nump">130,933<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems', window );"><strong>Segment Revenue from External Customers by Geographic Area [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">1,167<span></span>
</td>
<td class="nump">1,131<span></span>
</td>
<td class="nump">3,433<span></span>
</td>
<td class="nump">3,339<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems', window );"><strong>Segment Revenue from External Customers by Geographic Area [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">50,493<span></span>
</td>
<td class="nump">44,841<span></span>
</td>
<td class="nump">151,569<span></span>
</td>
<td class="nump">134,272<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems', window );"><strong>Segment Revenue from External Customers by Geographic Area [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="num">$ (6)<span></span>
</td>
<td class="num">$ (5)<span></span>
</td>
<td class="num">$ (10)<span></span>
</td>
<td class="num">$ (11)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Segment Revenue from External Customers by Geographic Area [Table]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139887619059728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Assets by Reportable Segment) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,377<span></span>
</td>
<td class="nump">$ 43,878<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=cah_MedicalUnitMember', window );">Medical Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember', window );">Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember', window );">Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="nump">$ 709<span></span>
</td>
<td class="nump">$ 154<span></span>
</td>
<td class="nump">863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,954<span></span>
</td>
<td class="nump">26,409<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,544<span></span>
</td>
<td class="nump">11,632<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,879<span></span>
</td>
<td class="nump">$ 5,837<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=cah_MedicalUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=cah_MedicalUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139887618207680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Narrative) (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Tax benefit related to share-based compensation</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Share Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</a></td>
<td class="nump">87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Share Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_VestingPeriodinyearsforShares', window );">Vesting Period in years for Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</a></td>
<td class="nump">$ 39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Share Units | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Target performance goal (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Share Units | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Target performance goal (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">234.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_VestingPeriodinyearsforShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Vesting Period in years for Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_VestingPeriodinyearsforShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit for recognition of expense of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139887618197648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation</a></td>
<td class="nump">$ 21<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
<td class="nump">$ 69<span></span>
</td>
<td class="nump">$ 65<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Share Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="nump">49<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Share Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139887618179904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details) - Restricted Share Units<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount | $</a></td>
<td class="nump">$ 87<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Restricted Share Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested at beginning of period (in shares) | shares</a></td>
<td class="nump">2.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">1.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(1.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Canceled and forfeited (in shares) | shares</a></td>
<td class="num">(0.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested at end of period (in shares) | shares</a></td>
<td class="nump">2.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested at beginning of period (in usd per share) | $ / shares</a></td>
<td class="nump">$ 46.03<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in usd per share) | $ / shares</a></td>
<td class="nump">70.26<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in usd per share) | $ / shares</a></td>
<td class="nump">50.03<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Canceled and forfeited (in usd per share) | $ / shares</a></td>
<td class="nump">58.30<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested at end of period (in usd per share) | $ / shares</a></td>
<td class="nump">$ 57.14<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139887618412240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details) - Performance Share Units<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Performance Share Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested at beginning of period (in shares) | shares</a></td>
<td class="nump">1.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">0.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(0.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Canceled and forfeited (in shares) | shares</a></td>
<td class="num">(0.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested at end of period (in shares) | shares</a></td>
<td class="nump">1.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested at beginning of period (in usd per share) | $ / shares</a></td>
<td class="nump">$ 54.32<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in usd per share) | $ / shares</a></td>
<td class="nump">70.52<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in usd per share) | $ / shares</a></td>
<td class="nump">59.04<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Canceled and forfeited (in usd per share) | $ / shares</a></td>
<td class="nump">65.59<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested at end of period (in usd per share) | $ / shares</a></td>
<td class="nump">$ 76.24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount | $</a></td>
<td class="nump">$ 39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>cah-20230331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cah="http://www.cardinal.com/20230331"
  xmlns:country="http://xbrl.sec.gov/country/2023"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="cah-20230331.xsd" xlink:type="simple"/>
    <context id="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ia3e1bc5fa75b4fd38bbf74aaa66b04ed_I20230430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
        </entity>
        <period>
            <instant>2023-04-30</instant>
        </period>
    </context>
    <context id="i7ad6d93eac9d48ab9fec302dd4e88915_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cah:A250MillionShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1023e41d044c49ebb5274f9857d52b5f_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cah:A250MillionShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i00b750b6e2374500a1e8b10702e44d3a_D20221002-20230113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cah:A250MillionShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-02</startDate>
            <endDate>2023-01-13</endDate>
        </period>
    </context>
    <context id="i612fc934cf6040028ee1d4ea22c335da_D20230113-20230113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cah:A250MillionShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-13</startDate>
            <endDate>2023-01-13</endDate>
        </period>
    </context>
    <context id="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ic217743408d440409a59220a0bf14e4c_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i56eab9e952334359a592f758a000f3a5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8b46cf505d1d4c6286a2da8dfd32802a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0e78bc722aef43c4ac908658f754bbe4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7fee7130363347368e48c8a5373ef212_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id91f4a6653dc429ab8550cb153ee63fe_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i08aa4676fa1f412495f0dcda89ef5c61_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6743439f6d344529a1d9776e5a37b6af_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i691c4bcd6648489e9985b2ebac21c4c4_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ic5ce320f275240ee8f228b919198581e_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ibb01906f8808446da382eb7169a9c692_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i3208791586fb4201860768dd298b3bb2_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i69743694027f433b8def521fd90c10b1_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ia191fa3eb5734906a8bf76c6f6496bc1_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="idf64830da37b4122b808db1a1819f451_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i2b78f3c4f51d4889980e7fc07edfec59_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i13c78c23b94549919369f13eef7a33f8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib002348769da4f519bc0a52ddbe725a0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i869ddd309d65479f921f1950d72e9ae7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i400ae55f5bf646e1a4865cfff0502178_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i31325593417c40aea09d306e481d5c1c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1da9880c72714008b4977c3a3f95890e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie41c2a5af47749b785d11deeee809585_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i418f71a8a1cc4ca49f486b30f467dcbc_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia19686236f7848079bbad68bd7c03742_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i49e3f3cae16c423db19dc0526a881118_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if9a10ddae3d841d29503e0ad7359eefa_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iafbe7b9485174b4e8c9f2d802e7dc231_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ifb5d714a0e8b461297b910f807c80a18_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i9330ee3b45ee44a09dbcfeab14ffd40e_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i9f0673078b15401ba450a8f78e2cc590_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i1e1aae70a0da49d484500f615cb3fd5f_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="if9769f07affb42f58d537c7029824f72_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="idb1c4815be35411c8c429c87e4166d03_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i79094c6b94cc48dc906e4841e8ebb7e7_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i7a2aef50edb6408382366ab58c0a5fe5_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i1ab713f43fd740a3981b34442abff7e2_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ic9f0457c7d4d49858c91362f01b0d1db_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="iddb780ecd77a4a539d61e232d9c38a2a_D20220701-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i5339f5e85f3b47c0aa0a7795a0147a83_D20220701-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iada78453d3a64782ab3851803455517a_D20220701-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i8e5c5ae766b74cf6a2409e8a66778fe4_D20220701-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="icafe121606cd4112b5329a3ce5274e9d_D20220701-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="if4a2a8ced444402e984b4c3bc89c5c8d_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="icfec14d9fb124cfe89c5bea933f8e5c2_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i2aece4cef70c4e909ce54489503e648a_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i866c0616d4fa407cb18e678ede1cf44e_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i5ae8d288fa1c40efba1860f8c0297502_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i75b88320c8d34867830cda3167c67779_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i3eb749068f254e87ba6fe7696f1b7ae3_D20210701-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ibf631f27db6a4b97b407bf7c07872ada_D20210701-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i259a6ff3365f4c53ac0b2f2edbb89551_D20210701-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib1adee5e79374a97893072820fddaa0e_D20210701-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i0db8654b67c442ae83277edeaf53cedc_D20210701-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if3c1b25895fb44c59c13bf46018fc577_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:CordisDivestitureAxis">cah:CordisDivestitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ice5ace5e97dc4e54b4c8d923f4a0967c_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="iba8dcdc7b0364befb6c48df592c69089_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i763ae6a550604d44b1d9024df65e87a4_D20220701-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i013227884afa401a8a0fac648dda0a66_D20220701-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ie317acb3d5c44ca0bd1298978e77bb10_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i09619e867c3347d5b88ff001fdae470b_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i043b921434d34afe9a3cdb74397ed704_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i8e6a4d2c754046f2bba40f47b73897d8_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i69ad0b82db074919b5c03d2459c3d06b_D20220701-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ia6e92bcd32f84df9ab392ad9accbdacd_D20220701-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ib4007268cc1f496d86090b7230f7a94b_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i6cd27b73a20c437aa0e84891f2ea5dde_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ic49dbe67bc04485785ead3e50d2ef7b5_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">cah:MedicalUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i984de195edf647df8b5c417d95fb895e_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2c44423c33b44f2b91261015274103c9_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i4173ed46aed24fea930a4ba9e851147e_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">cah:MedicalUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i6f07ddd2def943ba8d68405800839948_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">cah:MedicalUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8537355abc114656ba7b11fcb58c1278_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i31378af16d0d40428cd5734ee81d07a0_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3002eff021944cff84e19dddc37565d6_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">cah:IPRDTrademarksandOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i476e8c3bb99545d29a40a868cf6b4eed_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ief415993dc4a47a1a6841e6902c7341b_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cah:TrademarksAndPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i963e12db354a4503b026e3e3bb6ed1ae_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i173bc20d1a0d49e88d4984456dd1b3e0_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">cah:IPRDTrademarksandOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i70d3a43084b1430ab3dd772e96aa6f88_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ie3d2fdf5757a41fc97c3a3a6ad11d72e_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cah:TrademarksAndPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i85178fe781b44231b4e7afb99223bc34_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i70202e3eb1924e0fb801d98cddcbf880_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cah:A32NotesDue2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i5c0fee9c3dfe482dbe67f839273b347f_D20210701-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cah:A2.616Notesdue2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i08f98bc525534cc2acbd1048c17f5b33_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i075adee0cf414c09a846d45f9d6a66c6_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="if9a5679304ee4538b6bbe0e34a4b5ed6_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">cah:ShortTermCreditFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cah:CommittedReceivablesSalesFacilityProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i78f3cdc10c574a61aeee3a0d9409d753_D20220701-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">cah:CommittedReceivablesSalesFacilityProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i769da3763c9d46579b5dbf1f28eef5e3_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">cah:ShortTermCreditFacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i4e20bef4bcbc46aa8704b4843abc61ed_D20140731-20140731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cah:CVSHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-07-31</startDate>
            <endDate>2014-07-31</endDate>
        </period>
    </context>
    <context id="i5a9e7f91ada745048021249c9ba3bf07_I20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:NewYorkOpioidStewardshipActMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-04-30</instant>
        </period>
    </context>
    <context id="ie6e1b925b14f48bdae321a2a92cddd99_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:NewYorkOpioidStewardshipActMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1ba9cf1bead64efbbe00d2cffc0f7d5f_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:NewYorkOpioidStewardshipActMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i487c1d6cc123481ab174c77df6efc37c_D20220701-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:NewYorkOpioidStewardshipActMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i3177191fb7864f68afd74d62ddd7feeb_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:NewYorkOpioidStewardshipActMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i92600b80cf9f42e68ab2bb551fa5980c_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib507a23581594a42a6beb783c2499b40_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="if44099e3d6fc462fbe010375b43d9efd_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:OK</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="iad6a19c0c20841d5b5851aaeb8d05e17_I20230131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="i92a2e3900c6e4547800cbb60799bcd60_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i2ef2614263ad48d9934f6cc996c22e16_D20220701-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ibd1c21d9101a4eba857ea787640fd22a_I20220731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WV</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="i960566e19fe54aa890cd9defe241cee0_I20221031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cah:NativeAmericanTribesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="i7f5e673a6ff2412f8e6ec60e722680b3_I20230428">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:PlaintiffTypeAxis">cah:PrivatePartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="i584bd35326394834b21f8bff13805226_I20230428">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:LawsuitTypeAxis">cah:ClassActionLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:PlaintiffTypeAxis">cah:PrivatePartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="ie21d9b2ab8b84826b773ef6884028072_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:GA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:PlaintiffTypeAxis">cah:PrivatePartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i39d543d6d5bc4327b0cde155c825cad4_D20230701-20230701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:AL</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:PlaintiffTypeAxis">cah:PrivatePartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-07-01</endDate>
        </period>
    </context>
    <context id="icc7cc411a15e484b83110041666764e1_I20230428">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="i44256b1db02046efa5d29d670a7bcd5d_D20230428-20230428">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cah:AlamedaCountyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-28</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="i9ab800634809483fba34f7f06e7a35fe_D20230430-20230430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:AgreementsAxis">cah:IVCApril2023AgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:LawsuitTypeAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-30</startDate>
            <endDate>2023-04-30</endDate>
        </period>
    </context>
    <context id="i902b5ace502c4edbb1ba6a0998f22efa_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:AgreementsAxis">cah:IVCApril2023AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i5afb309fb1ba4583a4deda7964b8c2cf_D20230501-20230930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:AgreementsAxis">cah:IVCApril2023AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="i80b8e7e7258b478b904b1818e9f2cc0c_D20210701-20230428">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:AgreementsAxis">cah:OtherAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:LawsuitTypeAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="ia3e20dfd93ab46e4866c903c3dfc10cf_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i853c2433b9a24879ba53a4b6f202569b_D20220701-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i9ee8ab07c16a4a6c81486f97137b35dc_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:LawsuitTypeAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iacf755c31715440284f4942dd149ce26_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:ShareholderSecuritiesLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i04e26b0d7e5d4849a52f150680f0c631_D20220701-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:ShareholderDerivativeLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ie12745b4aa3e4e2f8127b2b3aa94621c_D20220701-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">cah:MedicalUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ie5694d08abff46ac90bbee9634d4edd3_D20220701-20230630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:GoodwillImpairmentAxis">cah:MedicalUnitGoodwillImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="i22d8ac48311042cebfc3c15dda5a16fa_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:GoodwillImpairmentAxis">cah:MedicalUnitGoodwillImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ie4fa6e3e07aa461e98a6b82df41d98ce_D20230401-20230630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:GoodwillImpairmentAxis">cah:MedicalUnitGoodwillImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="i0fb653442b8d46c4b1d69a67bca87b29_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ifef254c9824a4dbcbe0e5996b5dcc160_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ia83e033e96e343bda1abf45e39b6de85_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:TaxMatterAxis">cah:CareFusionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i4b473c3f43624d36b0c2c645e60d3c85_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:TaxMatterAxis">cah:CareFusionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i0647080b68e4434fb69d13640e2185be_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i22574d8c00bd4f13ae6ec2c4fcc2f017_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ib308cbc504e54cfea2d4a2a0d5e67181_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ic1d54b1779a94c778dcfd9c480a2851b_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ic019966f86814bbbafa5f64677ed3ae9_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="id3c2602782c94beab41f34560fbefd82_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ic33b3236678d4dba9bb198c5653cc58f_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i590356452cf8465698d99ccf090749ee_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ie7058036db8747708418c4af8c5bbe90_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ib40cb321ed7048c3a2302a1bf22f2f6f_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ifafc390c5b574ce9a766400e79096086_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i9f91dc01d0934f62990f387aff42bfc0_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i324d3cb6fe534b2d935a46f13fe9d0d7_D20220701-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i9ad948cf8f05443b8e4818f18729c732_D20210701-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i580853edf11f49b9b0fd206b92df8e34_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i2cb7ee6cde3b4b9ea40f39a43c463c3f_D20220701-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i70283d29df464fa9bfe3ab000de0526c_D20230401-20240331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="i7ce2d0d359a54a7d863e7717418b0884_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:MaturityDateAxis">cah:September2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i7ca5414a08eb459f8e8d7a93077973ca_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:MaturityDateAxis">cah:June2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i3218ae04c9b1466fb3401cfe9911661b_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:MaturityDateAxis">cah:March2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ibc60a5f6f2fd4df2b6e365b67ce91912_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:MaturityDateAxis">cah:March2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ib1c240be19f544f5b489ee7fbc6ec77d_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:DateInitiatedAxis">cah:March2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ie681b1f27879497aaac9197da201e94c_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:DateInitiatedAxis">cah:September2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i05f897db0bb743d0b9331a8d46baf59a_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:DateInitiatedAxis">cah:March2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="idb235b08598c4a23bff0d5c8e268cb3b_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:DateInitiatedAxis">cah:September2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="if773aecdfcdd4fa1af2b4a92af9fafff_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i286db9ed3e3a475e93934bbb8c001c46_D20220701-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i453169c026a64457a0140b1f759e3178_D20210701-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ieaa5331918d94152a37d35bd4fbf59d1_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ifd36140f852d4fd491f55d7cbb74fc38_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i12151c3f1a7a45f0a2e075e9b264e83b_D20220701-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="if6dc7675fbf84b8eabf826cb41d79193_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ib43a93a1b1cb4e7f9c3a767d383622bd_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i76064daaf24a4ffeb60544ffcf302fab_D20220701-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cah:A250MillionShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i461a6425bd69455b83513a1e59a9776f_D20230101-20230228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cah:A250MillionShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-02-28</endDate>
        </period>
    </context>
    <context id="ib66c40ad89944e97863448aacf257bd4_D20230228-20230228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cah:A250MillionShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-28</startDate>
            <endDate>2023-02-28</endDate>
        </period>
    </context>
    <context id="ica007433189241b2959cc8d752b3303e_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cah:A1BillionShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib99db3d39b2a4d159a049760c79aa4ad_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cah:A1BillionShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="if7a9fd51d7b5402abd517b833b8aa389_D20220701-20221223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cah:A1BillionShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-12-23</endDate>
        </period>
    </context>
    <context id="i3ea1c66ac32f47d58440504438bf12ae_D20221223-20221223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cah:A1BillionShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-23</startDate>
            <endDate>2022-12-23</endDate>
        </period>
    </context>
    <context id="i522fef760d964e82a180d92c34f911f9_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cah:A200MillionShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i62909649d3db4353bc2ea5dbf602e573_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cah:A200MillionShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6a09f6e3558145749952ae7fc79bd2af_D20220101-20220418">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cah:A200MillionShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-18</endDate>
        </period>
    </context>
    <context id="i226477cc1ffc4f0d9d9f5dd33b1e9da1_D20220418-20220418">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cah:A200MillionShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-18</startDate>
            <endDate>2022-04-18</endDate>
        </period>
    </context>
    <context id="i1867aca7ccf1480e9c1ee9dcad7d47ae_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cah:A300MillionShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia9412268ef744658a8712d81ef405c17_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cah:A300MillionShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8be8904a0c5f40cbbebf2f710dcc62b3_D20211001-20220131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cah:A300MillionShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="i2552d9f48bd74eb3a693f3a9fead0a14_D20220131-20220131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cah:A300MillionShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-31</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="ie154fb452e1a418293380c4c4a39a5cd_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cah:A500MillionShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4f140036aee94cfe9d2320e0cd2ce82a_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cah:A500MillionShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4db4d5927cda47f480368591c63e0175_D20210701-20211014">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cah:A500MillionShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-10-14</endDate>
        </period>
    </context>
    <context id="i1cda2ab21b97491cb2163653f2b875c8_D20211004-20211004">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cah:A500MillionShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-04</startDate>
            <endDate>2021-10-04</endDate>
        </period>
    </context>
    <context id="i57bea63d714f4a0dafc21a5f5d7d9581_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i6045190cc1424f8b979c1010722b563f_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i041bf7de7fa94db3b9bf9e7b272751da_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ifc6e3923d3894b44990b34501ac477b5_D20220701-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i44c00bb3d01a45a9b2df0171c33fe41e_D20220701-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ie9df3ae431f2408093261364d8c57572_D20220701-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i5f9b2983d0ee4f86a50ac5496fc9091c_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i7f42aa5a93cc411195bf2bf78d59cde4_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i8d7f6b1c5d2b48eeba8549a518560256_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="icbef955e1ad34a0db8f9c5e948d9cb27_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ibc51bd9677854ac6aaa9f7b93f52a94e_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i63438b89f0184fe2bed728cdd44ae85b_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i515663cfb02c45c09a0fbc66b8fef70c_D20210701-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5450ec0270bb4ceaafa8ee587406b24e_D20210701-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i704ee587ce264884a099492815729252_D20210701-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i8ec1d9ad198a4e43b265abc3a0d32cb8_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="id449ab0597f64cd29ac910cb2816b35b_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i6203134ce90347afaf3c8d39444a0a7d_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="idc26a4e700a342548208bd3adbce0cc3_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:PharmaceuticalDistributionandSpecialtyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i3eeef5beb2e3457385d0a29a55055482_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:PharmaceuticalDistributionandSpecialtyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id1f8c810883d4ff9a38b1a6311b7024a_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:NuclearPrecisionHealthSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i22582fc2d45245928c608e9b04993980_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:NuclearPrecisionHealthSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i16dc5579b6f94e7ca4452bbc7028e7c9_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i45daaa94544f4353a00c894ddf85a502_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i496f651118df4ac294afe39b4aefdc23_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:MedicaldistributionandproductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ieff878faa3b9482d85466ac9bdf16285_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:MedicaldistributionandproductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib56812ccf8264be98f8752c625e2e17a_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:CardinalHealthAtHomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i169b1a322c8c4e52985fff332cb28f47_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:CardinalHealthAtHomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1495b91ae50844b7bd8dee01339cb2ba_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ibc29744d3dd64b99ab33d733a31d8725_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic7c59d976f4b491293536f66988a658a_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i569871ca4d47454f87c9b6023726a3aa_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia03b234276c04aa0af1cf1a16b60bc62_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i0b30b0809298478382f26a051e90bf8a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie54fd2c345514ac293e4ec5b948651d1_D20220701-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:PharmaceuticalDistributionandSpecialtyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i0d7a863829b14c7491f8ae6b2433a880_D20210701-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:PharmaceuticalDistributionandSpecialtyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i92e95db7bd6246ed9c7bac5e8fb213ff_D20220701-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:NuclearPrecisionHealthSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="id8bc9a61c2e44236ab69000fb26a2824_D20210701-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:NuclearPrecisionHealthSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i04924e9230e745fca992f99aa6ace85c_D20220701-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i8b399963940c4fcc875d6ee7b2e2a30c_D20210701-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id19b85c70c834e2788b7091044df235c_D20220701-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:MedicaldistributionandproductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i543467e6acd7440e976c6acaeebc9d47_D20210701-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:MedicaldistributionandproductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i57cd785fabaf4688a3bbe54d4f0ca21d_D20220701-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:CardinalHealthAtHomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="id9e29a915c71426f8011dc3489ec5202_D20210701-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:CardinalHealthAtHomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i44eddf7caae040f987146265a715a28d_D20220701-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ie312826afe694135b31551dc50097180_D20210701-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i09186e53513344a797c14f6874c9c782_D20220701-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i438495dce7084e9eb69ebe58bc06cd29_D20210701-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6ed97f44ba534c3889ad982e9558682c_D20220701-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i9dcc325ed5014b548d6c310c9974f048_D20210701-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i73b99b7f00ef43c3b9264f23015dbdbc_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i4bb3c35435cf4419a78f521a4ab0acc6_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i447a6c019d5146ccb318da808e4fb2f3_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i4060ee92cb7e4a3a973a917c60eb75fc_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if67e0eb500ab42958354df8e59c31390_D20220701-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i5273719c53784b1984b975c2b15073cf_D20210701-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib488e4c93b484184a8e52bee69885132_D20220701-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ib5f105aa532244e0885f2307bc2951ad_D20210701-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5c0c3804d63c4f5fafbb13f1f87b1d95_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ie4a16787e42247d480a65342eeea298b_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ib09896a0291b4dbd9d0deb987d93eb9c_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ibee1c5b1f4f946f18b93d5abfb380e03_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i7f4869e77ac44a00a1348128c89edab9_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iaa15c30af25e4338b4b75b20fdd5cdfd_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i61e443ff0bb041468d351efdad3a60ec_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i7a2edd19ded449568c634ce222c8bf11_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iac5b45b6082b4c20bc77e15c6b0dfe4a_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i6cb3c83f18544d88816e14ee29ce253f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i7de355b6c9f244b0aecf4263ff24158b_D20220701-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ie4307df7bd4b4ddf85fe23923677a14f_D20210701-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9750f858065345b6b71dfdf94a3db05f_D20220701-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ice80dc50332649f4a2e8211087c1473c_D20210701-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia8acc2cf603d4cec94d38cdf7947bf8c_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ia7a3dc6029084cef92896c48e8a19a01_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i34b2dbad9e7648de967669561a47dd81_D20220701-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i2fbe5a679b3841fcb8bbd7dfa64915ad_D20220701-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ifab2ddff45a44bc58da3784419071ae5_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="iace1106122bd40149cc5c5765c33fb32_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="rate">
        <measure>utr:Rate</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="states">
        <measure>cah:states</measure>
    </unit>
    <unit id="numberofusterritories">
        <measure>cah:numberOfUSTerritories</measure>
    </unit>
    <unit id="lawsuit">
        <measure>cah:lawsuit</measure>
    </unit>
    <unit id="plaintiff">
        <measure>cah:plaintiff</measure>
    </unit>
    <unit id="jpy">
        <measure>iso4217:JPY</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="reportable_segments">
        <measure>cah:Reportable_Segments</measure>
    </unit>
    <unit id="segment">
        <measure>cah:segment</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y180L2ZyYWc6MTZlNzFmOWMzZWZmNGIyN2I4ZThkZDJhMWIyNDYwYWQvdGFibGU6OTQxNjVmMjUwOGQ2NGE0NzkxZGUwMWQyOWExZmJmMTgvdGFibGVyYW5nZTo5NDE2NWYyNTA4ZDY0YTQ3OTFkZTAxZDI5YTFmYmYxOF8yLTEtMS0xLTI4Njk0NA_57d81c79-3cb9-4633-bbfb-20d61b0f1952">0000721371</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y180L2ZyYWc6MTZlNzFmOWMzZWZmNGIyN2I4ZThkZDJhMWIyNDYwYWQvdGFibGU6OTQxNjVmMjUwOGQ2NGE0NzkxZGUwMWQyOWExZmJmMTgvdGFibGVyYW5nZTo5NDE2NWYyNTA4ZDY0YTQ3OTFkZTAxZDI5YTFmYmYxOF8zLTEtMS0xLTI4Njk0NA_3b91be8e-71f5-447a-87ab-e2a9ec9ce050">--06-30</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y180L2ZyYWc6MTZlNzFmOWMzZWZmNGIyN2I4ZThkZDJhMWIyNDYwYWQvdGFibGU6OTQxNjVmMjUwOGQ2NGE0NzkxZGUwMWQyOWExZmJmMTgvdGFibGVyYW5nZTo5NDE2NWYyNTA4ZDY0YTQ3OTFkZTAxZDI5YTFmYmYxOF80LTEtMS0xLTI4Njk0NA_6da20d11-20e3-4d39-8e01-25521085be8c">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y180L2ZyYWc6MTZlNzFmOWMzZWZmNGIyN2I4ZThkZDJhMWIyNDYwYWQvdGFibGU6OTQxNjVmMjUwOGQ2NGE0NzkxZGUwMWQyOWExZmJmMTgvdGFibGVyYW5nZTo5NDE2NWYyNTA4ZDY0YTQ3OTFkZTAxZDI5YTFmYmYxOF81LTEtMS0xLTI4Njk0NA_d7b5200d-6a48-43d6-ba27-1f5c2ca0dc87">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y180L2ZyYWc6MTZlNzFmOWMzZWZmNGIyN2I4ZThkZDJhMWIyNDYwYWQvdGFibGU6OTQxNjVmMjUwOGQ2NGE0NzkxZGUwMWQyOWExZmJmMTgvdGFibGVyYW5nZTo5NDE2NWYyNTA4ZDY0YTQ3OTFkZTAxZDI5YTFmYmYxOF82LTEtMS0xLTI4Njk0NA_92106f64-e077-4660-b2a5-0667ff38f2e1">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xL2ZyYWc6MjQ4ZTJhOWJlM2IxNDc1NjhhYTJjZGE1OWYwOGU4ZTYvdGV4dHJlZ2lvbjoyNDhlMmE5YmUzYjE0NzU2OGFhMmNkYTU5ZjA4ZThlNl84NA_4ed707b0-d504-44db-a741-d87f8f51983d">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xL2ZyYWc6MjQ4ZTJhOWJlM2IxNDc1NjhhYTJjZGE1OWYwOGU4ZTYvdGFibGU6YzBhZTVhMzc5MzZjNDUyNDhjM2FiMjIwMzI2N2RkNzAvdGFibGVyYW5nZTpjMGFlNWEzNzkzNmM0NTI0OGMzYWIyMjAzMjY3ZGQ3MF8wLTAtMS0xLTI4Njk0NA_4e7d8e1f-d8d5-4389-ada2-5317b0909db9">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xL2ZyYWc6MjQ4ZTJhOWJlM2IxNDc1NjhhYTJjZGE1OWYwOGU4ZTYvdGV4dHJlZ2lvbjoyNDhlMmE5YmUzYjE0NzU2OGFhMmNkYTU5ZjA4ZThlNl8xMjE_fcb5b694-fbc5-4dff-b95f-5d1bfcd10631">2023-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xL2ZyYWc6MjQ4ZTJhOWJlM2IxNDc1NjhhYTJjZGE1OWYwOGU4ZTYvdGFibGU6OGJlZjVkZTU5MDI2NGIyZDg0NThhM2ZjN2QyMzViMWYvdGFibGVyYW5nZTo4YmVmNWRlNTkwMjY0YjJkODQ1OGEzZmM3ZDIzNWIxZl8wLTAtMS0xLTI4Njk0NA_eefb2d1e-db24-448d-9eee-e1afae87f569">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xL2ZyYWc6MjQ4ZTJhOWJlM2IxNDc1NjhhYTJjZGE1OWYwOGU4ZTYvdGV4dHJlZ2lvbjoyNDhlMmE5YmUzYjE0NzU2OGFhMmNkYTU5ZjA4ZThlNl8xOTA0_17181962-98cf-4e86-acf4-940b4d2dc704">1-11373</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xL2ZyYWc6MjQ4ZTJhOWJlM2IxNDc1NjhhYTJjZGE1OWYwOGU4ZTYvdGV4dHJlZ2lvbjoyNDhlMmE5YmUzYjE0NzU2OGFhMmNkYTU5ZjA4ZThlNl8xOTA1_35c8ee6f-d9ad-4229-8ade-ddcebcee4e99">Cardinal Health, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xL2ZyYWc6MjQ4ZTJhOWJlM2IxNDc1NjhhYTJjZGE1OWYwOGU4ZTYvdGFibGU6YWNjZjFhODcwNDM5NGQ5MTk1MjFiOTViZWI2YjUwOTYvdGFibGVyYW5nZTphY2NmMWE4NzA0Mzk0ZDkxOTUyMWI5NWJlYjZiNTA5Nl8wLTAtMS0xLTI4Njk0NA_eef7738c-09b3-47da-a9c7-4ef61d8485b0">OH</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xL2ZyYWc6MjQ4ZTJhOWJlM2IxNDc1NjhhYTJjZGE1OWYwOGU4ZTYvdGFibGU6YWNjZjFhODcwNDM5NGQ5MTk1MjFiOTViZWI2YjUwOTYvdGFibGVyYW5nZTphY2NmMWE4NzA0Mzk0ZDkxOTUyMWI5NWJlYjZiNTA5Nl8wLTYtMS0xLTI4Njk0NA_e9ce108b-ebe8-4fa6-8c5d-a764da3a24f2">31-0958666</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xL2ZyYWc6MjQ4ZTJhOWJlM2IxNDc1NjhhYTJjZGE1OWYwOGU4ZTYvdGFibGU6YWNjZjFhODcwNDM5NGQ5MTk1MjFiOTViZWI2YjUwOTYvdGFibGVyYW5nZTphY2NmMWE4NzA0Mzk0ZDkxOTUyMWI5NWJlYjZiNTA5Nl8zLTAtMS0xLTI4Njk0NA_2a990dac-23c4-431a-9cc1-897a0dd504f2">7000 Cardinal Place</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xL2ZyYWc6MjQ4ZTJhOWJlM2IxNDc1NjhhYTJjZGE1OWYwOGU4ZTYvdGFibGU6YWNjZjFhODcwNDM5NGQ5MTk1MjFiOTViZWI2YjUwOTYvdGFibGVyYW5nZTphY2NmMWE4NzA0Mzk0ZDkxOTUyMWI5NWJlYjZiNTA5Nl8zLTItMS0xLTI4Njk0NA_de541535-5358-4016-bfe2-157512cff35f">Dublin</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xL2ZyYWc6MjQ4ZTJhOWJlM2IxNDc1NjhhYTJjZGE1OWYwOGU4ZTYvdGFibGU6YWNjZjFhODcwNDM5NGQ5MTk1MjFiOTViZWI2YjUwOTYvdGFibGVyYW5nZTphY2NmMWE4NzA0Mzk0ZDkxOTUyMWI5NWJlYjZiNTA5Nl8zLTQtMS0xLTI4Njk0NA_dd07a187-c5e2-4f15-a019-a287b31513a0">OH</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xL2ZyYWc6MjQ4ZTJhOWJlM2IxNDc1NjhhYTJjZGE1OWYwOGU4ZTYvdGFibGU6YWNjZjFhODcwNDM5NGQ5MTk1MjFiOTViZWI2YjUwOTYvdGFibGVyYW5nZTphY2NmMWE4NzA0Mzk0ZDkxOTUyMWI5NWJlYjZiNTA5Nl8zLTYtMS0xLTI4Njk0NA_61565e01-40e1-4f40-b424-6a27ddce795c">43017</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xL2ZyYWc6MjQ4ZTJhOWJlM2IxNDc1NjhhYTJjZGE1OWYwOGU4ZTYvdGV4dHJlZ2lvbjoyNDhlMmE5YmUzYjE0NzU2OGFhMmNkYTU5ZjA4ZThlNl8yOTY_482647f6-9ed5-4256-8184-6eb789cfaf0f">614</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xL2ZyYWc6MjQ4ZTJhOWJlM2IxNDc1NjhhYTJjZGE1OWYwOGU4ZTYvdGV4dHJlZ2lvbjoyNDhlMmE5YmUzYjE0NzU2OGFhMmNkYTU5ZjA4ZThlNl8xOTAw_fbcc873b-fb9f-4623-bf69-dcf62483ad6e">757-5000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xL2ZyYWc6MjQ4ZTJhOWJlM2IxNDc1NjhhYTJjZGE1OWYwOGU4ZTYvdGFibGU6NDljYzdlNGUxOWVjNDdmNWE4MDQyNjIyZWZlZGRmMmYvdGFibGVyYW5nZTo0OWNjN2U0ZTE5ZWM0N2Y1YTgwNDI2MjJlZmVkZGYyZl8yLTAtMS0xLTI4Njk0NA_84efa336-b035-4826-aab0-03246dd8f2fb">Common shares (without par value)</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xL2ZyYWc6MjQ4ZTJhOWJlM2IxNDc1NjhhYTJjZGE1OWYwOGU4ZTYvdGFibGU6NDljYzdlNGUxOWVjNDdmNWE4MDQyNjIyZWZlZGRmMmYvdGFibGVyYW5nZTo0OWNjN2U0ZTE5ZWM0N2Y1YTgwNDI2MjJlZmVkZGYyZl8yLTEtMS0xLTI4Njk0NA_03707faf-8ed5-4f2f-9be7-71d8e134d631">CAH</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xL2ZyYWc6MjQ4ZTJhOWJlM2IxNDc1NjhhYTJjZGE1OWYwOGU4ZTYvdGFibGU6NDljYzdlNGUxOWVjNDdmNWE4MDQyNjIyZWZlZGRmMmYvdGFibGVyYW5nZTo0OWNjN2U0ZTE5ZWM0N2Y1YTgwNDI2MjJlZmVkZGYyZl8yLTItMS0xLTI4Njk0NA_eb756074-ffe8-451d-8474-03f9b9868aef">NYSE</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xL2ZyYWc6MjQ4ZTJhOWJlM2IxNDc1NjhhYTJjZGE1OWYwOGU4ZTYvdGV4dHJlZ2lvbjoyNDhlMmE5YmUzYjE0NzU2OGFhMmNkYTU5ZjA4ZThlNl8xOTAx_2589a53e-c0f0-43c9-b8b3-0b6fa789f36b">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xL2ZyYWc6MjQ4ZTJhOWJlM2IxNDc1NjhhYTJjZGE1OWYwOGU4ZTYvdGV4dHJlZ2lvbjoyNDhlMmE5YmUzYjE0NzU2OGFhMmNkYTU5ZjA4ZThlNl8xOTAy_9d638c50-fc2c-4fb0-9233-bcbd9fc55ed7">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xL2ZyYWc6MjQ4ZTJhOWJlM2IxNDc1NjhhYTJjZGE1OWYwOGU4ZTYvdGFibGU6N2EzNzRjZTEyOWU3NGNjNWFhOTY4NDM1YWRhYzkyODIvdGFibGVyYW5nZTo3YTM3NGNlMTI5ZTc0Y2M1YWE5Njg0MzVhZGFjOTI4Ml8wLTAtMS0xLTI4Njk0NA_eee726ab-ead8-43d4-ad2f-9ecae828d6e4">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xL2ZyYWc6MjQ4ZTJhOWJlM2IxNDc1NjhhYTJjZGE1OWYwOGU4ZTYvdGFibGU6N2EzNzRjZTEyOWU3NGNjNWFhOTY4NDM1YWRhYzkyODIvdGFibGVyYW5nZTo3YTM3NGNlMTI5ZTc0Y2M1YWE5Njg0MzVhZGFjOTI4Ml8xLTQtMS0xLTI4Njk0NA_69a91947-e711-4fc7-ada0-e8f6f11ea497">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xL2ZyYWc6MjQ4ZTJhOWJlM2IxNDc1NjhhYTJjZGE1OWYwOGU4ZTYvdGFibGU6N2EzNzRjZTEyOWU3NGNjNWFhOTY4NDM1YWRhYzkyODIvdGFibGVyYW5nZTo3YTM3NGNlMTI5ZTc0Y2M1YWE5Njg0MzVhZGFjOTI4Ml8yLTQtMS0xLTI4Njk0NA_f1f39869-0def-4d4b-adb9-f480f405fa03">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xL2ZyYWc6MjQ4ZTJhOWJlM2IxNDc1NjhhYTJjZGE1OWYwOGU4ZTYvdGV4dHJlZ2lvbjoyNDhlMmE5YmUzYjE0NzU2OGFhMmNkYTU5ZjA4ZThlNl8xOTAz_78c876aa-aa43-4561-b4ba-0b8679d79313">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="ia3e1bc5fa75b4fd38bbf74aaa66b04ed_I20230430"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xL2ZyYWc6MjQ4ZTJhOWJlM2IxNDc1NjhhYTJjZGE1OWYwOGU4ZTYvdGV4dHJlZ2lvbjoyNDhlMmE5YmUzYjE0NzU2OGFhMmNkYTU5ZjA4ZThlNl8xODk4_0a84d0bc-181f-439a-963a-2bb253278a92"
      unitRef="shares">254600182</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i7ad6d93eac9d48ab9fec302dd4e88915_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y181NS9mcmFnOjQ1ZjcxODJmYWJiMzRjZWVhMzI0ZTE0OGIxMTEwY2RlL3RleHRyZWdpb246NDVmNzE4MmZhYmIzNGNlZWEzMjRlMTQ4YjExMTBjZGVfNDI1_64d5790a-91d4-4a60-b5e4-f63e7f9964a6"
      unitRef="usd">250000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i1023e41d044c49ebb5274f9857d52b5f_D20221001-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y181NS9mcmFnOjQ1ZjcxODJmYWJiMzRjZWVhMzI0ZTE0OGIxMTEwY2RlL3RleHRyZWdpb246NDVmNzE4MmZhYmIzNGNlZWEzMjRlMTQ4YjExMTBjZGVfNDY0_befe0c17-5788-4e83-82ff-6be63c036597"
      unitRef="shares">2600000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="i1023e41d044c49ebb5274f9857d52b5f_D20221001-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y181NS9mcmFnOjQ1ZjcxODJmYWJiMzRjZWVhMzI0ZTE0OGIxMTEwY2RlL3RleHRyZWdpb246NDVmNzE4MmZhYmIzNGNlZWEzMjRlMTQ4YjExMTBjZGVfNTA4_3c4d1965-d6e1-4226-9f7d-b8f4af72583c"
      unitRef="usdPerShare">76.58</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="i00b750b6e2374500a1e8b10702e44d3a_D20221002-20230113"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y181NS9mcmFnOjQ1ZjcxODJmYWJiMzRjZWVhMzI0ZTE0OGIxMTEwY2RlL3RleHRyZWdpb246NDVmNzE4MmZhYmIzNGNlZWEzMjRlMTQ4YjExMTBjZGVfNTk1_740095a5-5465-4e5d-95dc-6a5c6f2536dc"
      unitRef="usdPerShare">77.50</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i612fc934cf6040028ee1d4ea22c335da_D20230113-20230113"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y181NS9mcmFnOjQ1ZjcxODJmYWJiMzRjZWVhMzI0ZTE0OGIxMTEwY2RlL3RleHRyZWdpb246NDVmNzE4MmZhYmIzNGNlZWEzMjRlMTQ4YjExMTBjZGVfNjMx_1499679e-59cb-421c-8dce-ef1d9f4cad63"
      unitRef="shares">600000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:Revenues
      contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMi0xLTEtMS0yODY5NDQ_f465ea44-24cc-4426-a660-6685dfb42dc7"
      unitRef="usd">50487000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMi0zLTEtMS0yODY5NDQ_2e44fb3d-23dd-43ab-bd72-5376ef3d46a2"
      unitRef="usd">44836000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMi01LTEtMS0yODY5NDQ_732d42d3-1bbe-4bb4-900c-1a3a3afa04ff"
      unitRef="usd">151559000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMi03LTEtMS0yODY5NDQ_6bdddb52-0254-4c48-bbf8-dcaae385fe82"
      unitRef="usd">134261000000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMy0xLTEtMS0yODY5NDQ_559878a9-3af6-47b0-ad2e-3b825471479a"
      unitRef="usd">48702000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMy0zLTEtMS0yODY5NDQ_69c4c24e-981c-43d0-b3c8-56c3d6d99c7d"
      unitRef="usd">43154000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMy01LTEtMS0yODY5NDQ_6b9e8c90-71be-427c-836a-62ee4960b106"
      unitRef="usd">146497000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMy03LTEtMS0yODY5NDQ_f373efa4-f8b6-4199-afdb-95a8ccc4fc17"
      unitRef="usd">129321000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfNC0xLTEtMS0yODY5NDQ_75abda9f-89cf-485a-87b1-df0915f53db9"
      unitRef="usd">1785000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfNC0zLTEtMS0yODY5NDQ_5d1cd0ee-2360-43af-a9c1-b63c778b315c"
      unitRef="usd">1682000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfNC01LTEtMS0yODY5NDQ_90475e66-c866-47aa-b470-f18b2d3ed37c"
      unitRef="usd">5062000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfNC03LTEtMS0yODY5NDQ_ee45a296-cff8-4301-b24f-1d38d36bd136"
      unitRef="usd">4940000000</us-gaap:GrossProfit>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfNy0xLTEtMS0yODY5NDQ_ef93991d-3809-475f-b415-4a3299f87b20"
      unitRef="usd">1179000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfNy0zLTEtMS0yODY5NDQ_3135bffa-b981-43fe-949d-a433473ba3ad"
      unitRef="usd">1137000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfNy01LTEtMS0yODY5NDQ_94860b56-81ab-46da-9889-211d2fa06fc5"
      unitRef="usd">3567000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfNy03LTEtMS0yODY5NDQ_b57126be-9deb-46f3-b0c5-8fb2c7a6bb32"
      unitRef="usd">3402000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:RestructuringCharges
      contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfOC0xLTEtMS0yODY5NDQ_d5c2b286-8fb1-4eb0-89b8-00207baad552"
      unitRef="usd">16000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfOC0zLTEtMS0yODY5NDQ_41b347f7-8733-4c26-83af-c4b5a66c0427"
      unitRef="usd">31000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfOC01LTEtMS0yODY5NDQ_2d06f000-5905-41d7-aa40-697a0033ccb1"
      unitRef="usd">62000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfOC03LTEtMS0yODY5NDQ_76599c3e-f601-4d8a-933e-a34d34e66f22"
      unitRef="usd">56000000</us-gaap:RestructuringCharges>
    <cah:Amortizationandotheracquisitionrelatedcosts
      contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfOS0xLTEtMS0yODY5NDQ_c93cd332-a210-4026-8201-cfe93c90e8e2"
      unitRef="usd">74000000</cah:Amortizationandotheracquisitionrelatedcosts>
    <cah:Amortizationandotheracquisitionrelatedcosts
      contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfOS0zLTEtMS0yODY5NDQ_6d5862b4-d1af-4163-89d6-ecd177ab4404"
      unitRef="usd">79000000</cah:Amortizationandotheracquisitionrelatedcosts>
    <cah:Amortizationandotheracquisitionrelatedcosts
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfOS01LTEtMS0yODY5NDQ_13c4a2c4-fc81-4a3c-8afb-1c0ad1236ea0"
      unitRef="usd">216000000</cah:Amortizationandotheracquisitionrelatedcosts>
    <cah:Amortizationandotheracquisitionrelatedcosts
      contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfOS03LTEtMS0yODY5NDQ_918989ad-a24e-4575-a046-9d7fc5c17974"
      unitRef="usd">237000000</cah:Amortizationandotheracquisitionrelatedcosts>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges
      contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMTAtMS0xLTEtMjg2OTQ0_5b5865e7-17d3-494e-a26f-248d7d4c877f"
      unitRef="usd">-20000000</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges
      contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMTAtMy0xLTEtMjg2OTQ0_d602e7d9-ddae-4a2f-ae35-be0d22fdb36f"
      unitRef="usd">-471000000</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMTAtNS0xLTEtMjg2OTQ0_b33f54a0-e28f-4d84-800e-da7b3dec1734"
      unitRef="usd">-883000000</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges
      contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMTAtNy0xLTEtMjg2OTQ0_115852db-d87a-4857-a6f4-da80ad813355"
      unitRef="usd">-1764000000</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMTEtMS0xLTEtMjg2OTQ0_019bf8f6-add2-4b47-b030-ee6d17785a08"
      unitRef="usd">76000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMTEtMy0xLTEtMjg2OTQ0_06686299-1d87-4c11-8514-99f879d80051"
      unitRef="usd">-61000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMTEtNS0xLTEtMjg2OTQ0_9cd62cf1-3ded-4c41-b09b-5d7b1070f8bc"
      unitRef="usd">256000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMTEtNy0xLTEtMjg2OTQ0_faed8f1e-bfda-4ff1-8541-a81dffabb212"
      unitRef="usd">-113000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:OperatingIncomeLoss
      contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMTItMS0xLTEtMjg2OTQ0_3c8574e7-93d5-4516-b2e3-1d847849dea4"
      unitRef="usd">572000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMTItMy0xLTEtMjg2OTQ0_d5ff7a68-59cb-4bc5-8017-f3d7ab6f4e4a"
      unitRef="usd">-97000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMTItNS0xLTEtMjg2OTQ0_a9409bea-b445-4cef-ac64-8527bbb3e0de"
      unitRef="usd">590000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMTItNy0xLTEtMjg2OTQ0_b35c65f1-6696-4ba1-8b6a-ce08817e8643"
      unitRef="usd">-632000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMTQtMS0xLTEtMjg2OTQ0_4c48ffb9-7c94-4903-b4af-47e2175dc87e"
      unitRef="usd">0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMTQtMy0xLTEtMjg2OTQ0_276abf10-8192-4820-b22a-5c4cae833c8a"
      unitRef="usd">-3000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMTQtNS0xLTEtMjg2OTQ0_fd4f28f3-7e63-49eb-a96e-e967987215cf"
      unitRef="usd">5000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMTQtNy0xLTEtMjg2OTQ0_29d2400d-1efd-4f89-a27f-5d5e5c792188"
      unitRef="usd">14000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:InterestExpense
      contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMTUtMS0xLTEtMjg2OTQ0_583bb06a-90d3-4669-b322-63969015ded9"
      unitRef="usd">28000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMTUtMy0xLTEtMjg2OTQ0_65e58008-4e8a-4681-b3bc-572e92de0d54"
      unitRef="usd">38000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMTUtNS0xLTEtMjg2OTQ0_23a6c153-b429-4dfe-804f-6f0776104f45"
      unitRef="usd">78000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMTUtNy0xLTEtMjg2OTQ0_75b9d5a2-12e4-4069-a1ad-87d782d26564"
      unitRef="usd">115000000</us-gaap:InterestExpense>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMTYtMS0xLTEtMjg2OTQ0_1342af4a-6cce-495b-81ad-95ee7da25dec"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMTYtMy0xLTEtMjg2OTQ0_ca2de022-169c-44cd-b110-81331b60fbe4"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMTYtNS0xLTEtMjg2OTQ0_b6e8f42a-77ed-4f3d-8b4f-df7ae77d61d4"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMTYtNy0xLTEtMjg2OTQ0_3eaa9047-fdd3-4a78-876a-60283b9b9b80"
      unitRef="usd">-10000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainLossOnSaleOfInvestments
      contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMTctMS0xLTEtMjg2OTQ0_822c0dea-eb78-48dc-b658-4f9f6d650ae9"
      unitRef="usd">0</us-gaap:GainLossOnSaleOfInvestments>
    <us-gaap:GainLossOnSaleOfInvestments
      contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMTctMy0xLTEtMjg2OTQ0_3a4c8b31-5176-4102-bd53-9a5b4452de30"
      unitRef="usd">1000000</us-gaap:GainLossOnSaleOfInvestments>
    <us-gaap:GainLossOnSaleOfInvestments
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMTctNS0xLTEtMjg2OTQ0_6aecc8bf-ad07-4d2c-b38f-28d882b4aa91"
      unitRef="usd">0</us-gaap:GainLossOnSaleOfInvestments>
    <us-gaap:GainLossOnSaleOfInvestments
      contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMTctNy0xLTEtMjg2OTQ0_10e6c099-8ead-450c-be48-e060d5bb0ca9"
      unitRef="usd">2000000</us-gaap:GainLossOnSaleOfInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMTgtMS0xLTEtMjg2OTQ0_75e20552-653a-4797-a423-91d5dc0eb6c5"
      unitRef="usd">544000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMTgtMy0xLTEtMjg2OTQ0_e8c523ea-f03e-4895-8fa9-a9b9fe08933c"
      unitRef="usd">-137000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMTgtNS0xLTEtMjg2OTQ0_fe8fdebe-8672-45fa-8454-9d4137a53b58"
      unitRef="usd">517000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMTgtNy0xLTEtMjg2OTQ0_ffb79ac7-b498-42de-9adc-3c136bf64fd4"
      unitRef="usd">-741000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMjAtMS0xLTEtMjg2OTQ0_47770637-67e5-4674-941f-cf34aaa8eea4"
      unitRef="usd">197000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMjAtMy0xLTEtMjg2OTQ0_0a62327a-e528-490d-86e7-4bea388007cc"
      unitRef="usd">1253000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMjAtNS0xLTEtMjg2OTQ0_94b38983-d6ad-4254-a700-6dc52e9f6c0a"
      unitRef="usd">189000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMjAtNy0xLTEtMjg2OTQ0_86c5f02d-c8cb-4037-9ccf-1c03608a9250"
      unitRef="usd">328000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMjEtMS0xLTEtMjg2OTQ0_9d0eb824-fb08-4da3-8055-d270278e2b2e"
      unitRef="usd">347000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMjEtMy0xLTEtMjg2OTQ0_ca70483e-b557-4fc0-b1d6-72d750181642"
      unitRef="usd">-1390000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMjEtNS0xLTEtMjg2OTQ0_806a14e6-3f77-4b43-8f95-1ae5f5f5aeb8"
      unitRef="usd">328000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMjEtNy0xLTEtMjg2OTQ0_8ae2cecf-d05e-4eb9-84a9-f936fc682e3f"
      unitRef="usd">-1069000000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMjYtMS0xLTEtMjg2OTQ0_22b80416-7d2b-4f13-929e-ccce0bd0ef8b"
      unitRef="usd">2000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMjYtMy0xLTEtMjg2OTQ0_23c2f111-3d3b-4511-8a37-77dee76f5632"
      unitRef="usd">1000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMjYtNS0xLTEtMjg2OTQ0_10db0e09-d28a-4fe9-a0a1-b2252a4d48d8"
      unitRef="usd">3000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMjYtNy0xLTEtMjg2OTQ0_980565b8-7d1c-4ecc-af97-4afcf721866e"
      unitRef="usd">2000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMjctMS0xLTEtMjg2OTQ0_85a3bd11-1781-4e7e-b02c-a48a53700384"
      unitRef="usd">345000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMjctMy0xLTEtMjg2OTQ0_f85e46d8-d18a-43db-b7ff-b7d32571c7b4"
      unitRef="usd">-1391000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMjctNS0xLTEtMjg2OTQ0_a6206a32-8720-4c8e-a5b7-b7a1de917b87"
      unitRef="usd">325000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMjctNy0xLTEtMjg2OTQ0_78f36107-a51c-44b2-927c-4d7e4a73eb8b"
      unitRef="usd">-1071000000</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMzAtMS0xLTEtMjg2OTQ0_6a4aa081-291b-4788-a75f-b67a5d60bc41"
      unitRef="usdPerShare">1.35</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMzAtMy0xLTEtMjg2OTQ0_b210b28b-f546-4d9a-8249-8b9031c1b6ba"
      unitRef="usdPerShare">-5.05</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMzAtNS0xLTEtMjg2OTQ0_1ec068b3-cb30-472e-a418-a43c75ef71c3"
      unitRef="usdPerShare">1.24</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMzAtNy0xLTEtMjg2OTQ0_07256555-d1e3-4909-98b3-72c66a33e4dc"
      unitRef="usdPerShare">-3.82</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMzEtMS0xLTEtMjg2OTQ0_7cb92158-3b17-4a29-9e1f-0e22fe3af87f"
      unitRef="usdPerShare">1.34</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMzEtMy0xLTEtMjg2OTQ0_bc232157-3b8b-4b85-84b0-1ad36ba5050c"
      unitRef="usdPerShare">-5.05</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMzEtNS0xLTEtMjg2OTQ0_6bf92272-ea90-4218-865f-d9c61a5e20b7"
      unitRef="usdPerShare">1.23</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMzEtNy0xLTEtMjg2OTQ0_931a37a5-88c7-4484-93ad-5170026fc707"
      unitRef="usdPerShare">-3.82</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMzQtMS0xLTEtMjg2OTQ0_d49e1e23-e255-4886-83b6-d8bad87a76b4"
      unitRef="shares">256000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMzQtMy0xLTEtMjg2OTQ0_b39e1c67-a14d-43d7-aea7-a867cda902fd"
      unitRef="shares">275000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMzQtNS0xLTEtMjg2OTQ0_69613f38-705f-4104-b2de-47efb2c75c34"
      unitRef="shares">263000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMzQtNy0xLTEtMjg2OTQ0_b3d42626-55b2-48d1-952d-37e0105ae49b"
      unitRef="shares">281000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMzUtMS0xLTEtMjg2OTQ0_8af8fe8f-8fa7-4117-a0b7-91f76a24d159"
      unitRef="shares">258000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMzUtMy0xLTEtMjg2OTQ0_5d2b4aac-50bd-4745-91b8-d9589fe9def2"
      unitRef="shares">275000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMzUtNS0xLTEtMjg2OTQ0_bb8d4d89-7271-493c-ab0c-969ecdf49c7f"
      unitRef="shares">264000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMzUtNy0xLTEtMjg2OTQ0_7bc2c11d-e84e-4869-acdf-64e755b5c78d"
      unitRef="shares">281000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMzctMS0xLTEtMjg2OTQ0_9a6ce686-ceae-4c3e-83ba-9ed0faa34233"
      unitRef="usdPerShare">0.4957</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMzctMy0xLTEtMjg2OTQ0_9fe140d7-c2c1-49ed-be9c-36b16ae7cd23"
      unitRef="usdPerShare">0.4908</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMzctNS0xLTEtMjg2OTQ0_23031718-a597-4fbf-b542-c470fd5dba76"
      unitRef="usdPerShare">1.4871</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182MS9mcmFnOmY2MzcxYTU4ZGNlMTQ2ZmQ5M2Y1Mzk1MTFhODFkNDU3L3RhYmxlOjYyZDI2OThjOGY3MDQ5ZTU5ZGMzNzhiNmFlMmViNjUzL3RhYmxlcmFuZ2U6NjJkMjY5OGM4ZjcwNDllNTlkYzM3OGI2YWUyZWI2NTNfMzctNy0xLTEtMjg2OTQ0_4f791a17-edec-4138-b918-e33f3a3e76fd"
      unitRef="usdPerShare">1.4724</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:ProfitLoss
      contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182NC9mcmFnOmI3N2Q3MTQ1NGU4NzRmNjBhZGRkMjU4ZTg4ZDRjMzUwL3RhYmxlOmY0ZWEyZDQ0NTM3NDRmYWJhYjU0MDgxYmIzMWYxYWEzL3RhYmxlcmFuZ2U6ZjRlYTJkNDQ1Mzc0NGZhYmFiNTQwODFiYjMxZjFhYTNfMi0xLTEtMS0yODY5NDQ_06a378ed-d846-4180-bfb7-1951ac1f382b"
      unitRef="usd">347000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182NC9mcmFnOmI3N2Q3MTQ1NGU4NzRmNjBhZGRkMjU4ZTg4ZDRjMzUwL3RhYmxlOmY0ZWEyZDQ0NTM3NDRmYWJhYjU0MDgxYmIzMWYxYWEzL3RhYmxlcmFuZ2U6ZjRlYTJkNDQ1Mzc0NGZhYmFiNTQwODFiYjMxZjFhYTNfMi0zLTEtMS0yODY5NDQ_e2c2de43-375c-4113-8c6f-d98f297b46c6"
      unitRef="usd">-1390000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182NC9mcmFnOmI3N2Q3MTQ1NGU4NzRmNjBhZGRkMjU4ZTg4ZDRjMzUwL3RhYmxlOmY0ZWEyZDQ0NTM3NDRmYWJhYjU0MDgxYmIzMWYxYWEzL3RhYmxlcmFuZ2U6ZjRlYTJkNDQ1Mzc0NGZhYmFiNTQwODFiYjMxZjFhYTNfMi01LTEtMS0yODY5NDQ_a3fd6002-e19a-44ec-8b5f-a0f611d880a4"
      unitRef="usd">328000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182NC9mcmFnOmI3N2Q3MTQ1NGU4NzRmNjBhZGRkMjU4ZTg4ZDRjMzUwL3RhYmxlOmY0ZWEyZDQ0NTM3NDRmYWJhYjU0MDgxYmIzMWYxYWEzL3RhYmxlcmFuZ2U6ZjRlYTJkNDQ1Mzc0NGZhYmFiNTQwODFiYjMxZjFhYTNfMi03LTEtMS0yODY5NDQ_01a5cad9-5c7e-4236-a962-2f26ea32aa16"
      unitRef="usd">-1069000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182NC9mcmFnOmI3N2Q3MTQ1NGU4NzRmNjBhZGRkMjU4ZTg4ZDRjMzUwL3RhYmxlOmY0ZWEyZDQ0NTM3NDRmYWJhYjU0MDgxYmIzMWYxYWEzL3RhYmxlcmFuZ2U6ZjRlYTJkNDQ1Mzc0NGZhYmFiNTQwODFiYjMxZjFhYTNfNS0xLTEtMS0yODY5NDQ_be11c938-63c5-4e03-939f-03219bd95bae"
      unitRef="usd">4000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182NC9mcmFnOmI3N2Q3MTQ1NGU4NzRmNjBhZGRkMjU4ZTg4ZDRjMzUwL3RhYmxlOmY0ZWEyZDQ0NTM3NDRmYWJhYjU0MDgxYmIzMWYxYWEzL3RhYmxlcmFuZ2U6ZjRlYTJkNDQ1Mzc0NGZhYmFiNTQwODFiYjMxZjFhYTNfNS0zLTEtMS0yODY5NDQ_eef751ab-51a9-407a-8b7b-ff03ac4b9821"
      unitRef="usd">-4000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182NC9mcmFnOmI3N2Q3MTQ1NGU4NzRmNjBhZGRkMjU4ZTg4ZDRjMzUwL3RhYmxlOmY0ZWEyZDQ0NTM3NDRmYWJhYjU0MDgxYmIzMWYxYWEzL3RhYmxlcmFuZ2U6ZjRlYTJkNDQ1Mzc0NGZhYmFiNTQwODFiYjMxZjFhYTNfNS01LTEtMS0yODY5NDQ_9259b86f-9aa1-4ed2-bf74-49954f7f1db6"
      unitRef="usd">-34000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182NC9mcmFnOmI3N2Q3MTQ1NGU4NzRmNjBhZGRkMjU4ZTg4ZDRjMzUwL3RhYmxlOmY0ZWEyZDQ0NTM3NDRmYWJhYjU0MDgxYmIzMWYxYWEzL3RhYmxlcmFuZ2U6ZjRlYTJkNDQ1Mzc0NGZhYmFiNTQwODFiYjMxZjFhYTNfNS03LTEtMS0yODY5NDQ_78b7d4bf-5253-4e51-9c89-448473f129cf"
      unitRef="usd">-47000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182NC9mcmFnOmI3N2Q3MTQ1NGU4NzRmNjBhZGRkMjU4ZTg4ZDRjMzUwL3RhYmxlOmY0ZWEyZDQ0NTM3NDRmYWJhYjU0MDgxYmIzMWYxYWEzL3RhYmxlcmFuZ2U6ZjRlYTJkNDQ1Mzc0NGZhYmFiNTQwODFiYjMxZjFhYTNfNy0xLTEtMS0yODY5NDQ_fe43a41d-d24f-411b-ab86-1f5158aa9923"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182NC9mcmFnOmI3N2Q3MTQ1NGU4NzRmNjBhZGRkMjU4ZTg4ZDRjMzUwL3RhYmxlOmY0ZWEyZDQ0NTM3NDRmYWJhYjU0MDgxYmIzMWYxYWEzL3RhYmxlcmFuZ2U6ZjRlYTJkNDQ1Mzc0NGZhYmFiNTQwODFiYjMxZjFhYTNfNy0zLTEtMS0yODY5NDQ_bd201d47-3379-485b-a4f4-f6abb8fd23ef"
      unitRef="usd">12000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182NC9mcmFnOmI3N2Q3MTQ1NGU4NzRmNjBhZGRkMjU4ZTg4ZDRjMzUwL3RhYmxlOmY0ZWEyZDQ0NTM3NDRmYWJhYjU0MDgxYmIzMWYxYWEzL3RhYmxlcmFuZ2U6ZjRlYTJkNDQ1Mzc0NGZhYmFiNTQwODFiYjMxZjFhYTNfNy01LTEtMS0yODY5NDQ_b33d6ec3-3726-41ab-9ef4-38c5ccc084f1"
      unitRef="usd">6000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182NC9mcmFnOmI3N2Q3MTQ1NGU4NzRmNjBhZGRkMjU4ZTg4ZDRjMzUwL3RhYmxlOmY0ZWEyZDQ0NTM3NDRmYWJhYjU0MDgxYmIzMWYxYWEzL3RhYmxlcmFuZ2U6ZjRlYTJkNDQ1Mzc0NGZhYmFiNTQwODFiYjMxZjFhYTNfNy03LTEtMS0yODY5NDQ_e940ca2b-c822-4aff-8666-d69a6aed4b37"
      unitRef="usd">4000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182NC9mcmFnOmI3N2Q3MTQ1NGU4NzRmNjBhZGRkMjU4ZTg4ZDRjMzUwL3RhYmxlOmY0ZWEyZDQ0NTM3NDRmYWJhYjU0MDgxYmIzMWYxYWEzL3RhYmxlcmFuZ2U6ZjRlYTJkNDQ1Mzc0NGZhYmFiNTQwODFiYjMxZjFhYTNfOC0xLTEtMS0yODY5NDQ_d1db4eed-bfb1-45d8-a96c-99e3cce96451"
      unitRef="usd">4000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182NC9mcmFnOmI3N2Q3MTQ1NGU4NzRmNjBhZGRkMjU4ZTg4ZDRjMzUwL3RhYmxlOmY0ZWEyZDQ0NTM3NDRmYWJhYjU0MDgxYmIzMWYxYWEzL3RhYmxlcmFuZ2U6ZjRlYTJkNDQ1Mzc0NGZhYmFiNTQwODFiYjMxZjFhYTNfOC0zLTEtMS0yODY5NDQ_a0db2853-5646-44dd-83f2-a2a67bb7b6c4"
      unitRef="usd">8000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182NC9mcmFnOmI3N2Q3MTQ1NGU4NzRmNjBhZGRkMjU4ZTg4ZDRjMzUwL3RhYmxlOmY0ZWEyZDQ0NTM3NDRmYWJhYjU0MDgxYmIzMWYxYWEzL3RhYmxlcmFuZ2U6ZjRlYTJkNDQ1Mzc0NGZhYmFiNTQwODFiYjMxZjFhYTNfOC01LTEtMS0yODY5NDQ_9671a933-1e1e-47a7-a51a-1b49017372cf"
      unitRef="usd">-28000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182NC9mcmFnOmI3N2Q3MTQ1NGU4NzRmNjBhZGRkMjU4ZTg4ZDRjMzUwL3RhYmxlOmY0ZWEyZDQ0NTM3NDRmYWJhYjU0MDgxYmIzMWYxYWEzL3RhYmxlcmFuZ2U6ZjRlYTJkNDQ1Mzc0NGZhYmFiNTQwODFiYjMxZjFhYTNfOC03LTEtMS0yODY5NDQ_092d6b93-a919-4d14-9fa9-72d7c26e2ed5"
      unitRef="usd">-43000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182NC9mcmFnOmI3N2Q3MTQ1NGU4NzRmNjBhZGRkMjU4ZTg4ZDRjMzUwL3RhYmxlOmY0ZWEyZDQ0NTM3NDRmYWJhYjU0MDgxYmIzMWYxYWEzL3RhYmxlcmFuZ2U6ZjRlYTJkNDQ1Mzc0NGZhYmFiNTQwODFiYjMxZjFhYTNfMTAtMS0xLTEtMjg2OTQ0_ba8bf834-6b82-4b4b-8164-1805e395ac38"
      unitRef="usd">351000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182NC9mcmFnOmI3N2Q3MTQ1NGU4NzRmNjBhZGRkMjU4ZTg4ZDRjMzUwL3RhYmxlOmY0ZWEyZDQ0NTM3NDRmYWJhYjU0MDgxYmIzMWYxYWEzL3RhYmxlcmFuZ2U6ZjRlYTJkNDQ1Mzc0NGZhYmFiNTQwODFiYjMxZjFhYTNfMTAtMy0xLTEtMjg2OTQ0_f9dec262-918c-41c2-87dd-0fcb7758573d"
      unitRef="usd">-1382000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182NC9mcmFnOmI3N2Q3MTQ1NGU4NzRmNjBhZGRkMjU4ZTg4ZDRjMzUwL3RhYmxlOmY0ZWEyZDQ0NTM3NDRmYWJhYjU0MDgxYmIzMWYxYWEzL3RhYmxlcmFuZ2U6ZjRlYTJkNDQ1Mzc0NGZhYmFiNTQwODFiYjMxZjFhYTNfMTAtNS0xLTEtMjg2OTQ0_054b75b3-cac1-4259-aba7-b0e2b9e3ad97"
      unitRef="usd">300000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182NC9mcmFnOmI3N2Q3MTQ1NGU4NzRmNjBhZGRkMjU4ZTg4ZDRjMzUwL3RhYmxlOmY0ZWEyZDQ0NTM3NDRmYWJhYjU0MDgxYmIzMWYxYWEzL3RhYmxlcmFuZ2U6ZjRlYTJkNDQ1Mzc0NGZhYmFiNTQwODFiYjMxZjFhYTNfMTAtNy0xLTEtMjg2OTQ0_6a45bc20-8f6a-4486-b400-a84df78442a8"
      unitRef="usd">-1112000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182NC9mcmFnOmI3N2Q3MTQ1NGU4NzRmNjBhZGRkMjU4ZTg4ZDRjMzUwL3RhYmxlOmY0ZWEyZDQ0NTM3NDRmYWJhYjU0MDgxYmIzMWYxYWEzL3RhYmxlcmFuZ2U6ZjRlYTJkNDQ1Mzc0NGZhYmFiNTQwODFiYjMxZjFhYTNfMTItMS0xLTEtMjg2OTQ0_5445b090-435b-43bc-bcac-0cb461e99adf"
      unitRef="usd">2000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182NC9mcmFnOmI3N2Q3MTQ1NGU4NzRmNjBhZGRkMjU4ZTg4ZDRjMzUwL3RhYmxlOmY0ZWEyZDQ0NTM3NDRmYWJhYjU0MDgxYmIzMWYxYWEzL3RhYmxlcmFuZ2U6ZjRlYTJkNDQ1Mzc0NGZhYmFiNTQwODFiYjMxZjFhYTNfMTItMy0xLTEtMjg2OTQ0_0c52c2bb-68cd-4662-9e2d-5ba1c2dae13c"
      unitRef="usd">1000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182NC9mcmFnOmI3N2Q3MTQ1NGU4NzRmNjBhZGRkMjU4ZTg4ZDRjMzUwL3RhYmxlOmY0ZWEyZDQ0NTM3NDRmYWJhYjU0MDgxYmIzMWYxYWEzL3RhYmxlcmFuZ2U6ZjRlYTJkNDQ1Mzc0NGZhYmFiNTQwODFiYjMxZjFhYTNfMTItNS0xLTEtMjg2OTQ0_a3627142-27ee-4b07-8d8f-c6b12186164d"
      unitRef="usd">3000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182NC9mcmFnOmI3N2Q3MTQ1NGU4NzRmNjBhZGRkMjU4ZTg4ZDRjMzUwL3RhYmxlOmY0ZWEyZDQ0NTM3NDRmYWJhYjU0MDgxYmIzMWYxYWEzL3RhYmxlcmFuZ2U6ZjRlYTJkNDQ1Mzc0NGZhYmFiNTQwODFiYjMxZjFhYTNfMTItNy0xLTEtMjg2OTQ0_3a48471b-b3ca-4574-bd7b-64c7bd6d96f8"
      unitRef="usd">2000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182NC9mcmFnOmI3N2Q3MTQ1NGU4NzRmNjBhZGRkMjU4ZTg4ZDRjMzUwL3RhYmxlOmY0ZWEyZDQ0NTM3NDRmYWJhYjU0MDgxYmIzMWYxYWEzL3RhYmxlcmFuZ2U6ZjRlYTJkNDQ1Mzc0NGZhYmFiNTQwODFiYjMxZjFhYTNfMTQtMS0xLTEtMjg2OTQ0_ffd7aea6-ffe3-4457-b784-8f2c5391c571"
      unitRef="usd">349000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182NC9mcmFnOmI3N2Q3MTQ1NGU4NzRmNjBhZGRkMjU4ZTg4ZDRjMzUwL3RhYmxlOmY0ZWEyZDQ0NTM3NDRmYWJhYjU0MDgxYmIzMWYxYWEzL3RhYmxlcmFuZ2U6ZjRlYTJkNDQ1Mzc0NGZhYmFiNTQwODFiYjMxZjFhYTNfMTQtMy0xLTEtMjg2OTQ0_470f3c86-18c3-4e0c-9eb8-b357f8057627"
      unitRef="usd">-1383000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182NC9mcmFnOmI3N2Q3MTQ1NGU4NzRmNjBhZGRkMjU4ZTg4ZDRjMzUwL3RhYmxlOmY0ZWEyZDQ0NTM3NDRmYWJhYjU0MDgxYmIzMWYxYWEzL3RhYmxlcmFuZ2U6ZjRlYTJkNDQ1Mzc0NGZhYmFiNTQwODFiYjMxZjFhYTNfMTQtNS0xLTEtMjg2OTQ0_32735226-0588-4a6c-a85a-3cd633784c4c"
      unitRef="usd">297000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182NC9mcmFnOmI3N2Q3MTQ1NGU4NzRmNjBhZGRkMjU4ZTg4ZDRjMzUwL3RhYmxlOmY0ZWEyZDQ0NTM3NDRmYWJhYjU0MDgxYmIzMWYxYWEzL3RhYmxlcmFuZ2U6ZjRlYTJkNDQ1Mzc0NGZhYmFiNTQwODFiYjMxZjFhYTNfMTQtNy0xLTEtMjg2OTQ0_b7697901-33fc-452e-920a-220cd175174b"
      unitRef="usd">-1114000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfNC0xLTEtMS0yODY5NDQ_6e351f3e-00a6-4af3-b25d-05c91de272f4"
      unitRef="usd">3990000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ic217743408d440409a59220a0bf14e4c_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfNC0zLTEtMS0yODY5NDQ_1f463960-8f7f-40bc-8e11-ea2c104aff6f"
      unitRef="usd">4717000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ReceivablesNetCurrent
      contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfNS0xLTEtMS0yODY5NDQ_014c88d4-a563-45db-a5ee-ca83d90ac26f"
      unitRef="usd">10992000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="ic217743408d440409a59220a0bf14e4c_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfNS0zLTEtMS0yODY5NDQ_6c677f3c-821f-45cf-98fe-ff85ffe6d3bc"
      unitRef="usd">10561000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:InventoryNet
      contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfNi0xLTEtMS0yODY5NDQ_91ace5b3-6f87-4b0b-bec8-c7e083d128a6"
      unitRef="usd">16620000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="ic217743408d440409a59220a0bf14e4c_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfNi0zLTEtMS0yODY5NDQ_8fe193ff-cfe6-4826-9e5a-ad718114b943"
      unitRef="usd">15636000000</us-gaap:InventoryNet>
    <us-gaap:OtherAssetsCurrent
      contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfNy0xLTEtMS0yODY5NDQ_77f08de4-3862-45ed-a7df-4feff7ca43a4"
      unitRef="usd">1895000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="ic217743408d440409a59220a0bf14e4c_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfNy0zLTEtMS0yODY5NDQ_9a1812a0-5b97-4d32-99d7-8da170040af1"
      unitRef="usd">2021000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfOS0xLTEtMS0yODY5NDQ_bb9cec30-b89b-4ef5-bba1-3ad3b7a50395"
      unitRef="usd">33497000000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ic217743408d440409a59220a0bf14e4c_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfOS0zLTEtMS0yODY5NDQ_6e6a7dc8-ca32-473e-bce3-87e87e70223b"
      unitRef="usd">32935000000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfMTEtMS0xLTEtMjg2OTQ0_cd2f0509-0cd7-40b3-b4d6-339cb4ebb90a"
      unitRef="usd">2362000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ic217743408d440409a59220a0bf14e4c_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfMTEtMy0xLTEtMjg2OTQ0_58cbbd24-c96f-428c-b2be-5c5ac68773d3"
      unitRef="usd">2361000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfMTItMS0xLTEtMjg2OTQ0_f25d438f-f233-4913-b7d6-b2f88bfac58a"
      unitRef="usd">6567000000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="ic217743408d440409a59220a0bf14e4c_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfMTItMy0xLTEtMjg2OTQ0_39d4722d-12f5-49e2-a217-9bd516a1d25e"
      unitRef="usd">7629000000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfMTQtMS0xLTEtMjg2OTQ0_66f8166a-ea93-4859-a333-a0bf328ad502"
      unitRef="usd">951000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ic217743408d440409a59220a0bf14e4c_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfMTQtMy0xLTEtMjg2OTQ0_d1dfb3b5-ba23-4633-b10f-9b9ed2e9871c"
      unitRef="usd">953000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfMTUtMS0xLTEtMjg2OTQ0_e7014d88-c357-4661-8f8a-7f059487a4a7"
      unitRef="usd">43377000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ic217743408d440409a59220a0bf14e4c_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfMTUtMy0xLTEtMjg2OTQ0_3f8d0574-eacd-4464-82bc-ea8e16aa4df1"
      unitRef="usd">43878000000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfMTktMS0xLTEtMjg2OTQ0_3692b8fb-b7a8-4494-9e1c-bbaf46eef2a8"
      unitRef="usd">29601000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="ic217743408d440409a59220a0bf14e4c_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfMTktMy0xLTEtMjg2OTQ0_76462c68-2862-4ec8-946e-8f077912b8e9"
      unitRef="usd">27128000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfMjAtMS0xLTEtMjg2OTQ0_03544af3-782d-487d-9ff0-a59112c69621"
      unitRef="usd">26000000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="ic217743408d440409a59220a0bf14e4c_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfMjAtMy0xLTEtMjg2OTQ0_f2361ca0-033f-450c-89d3-7b5d1da35b46"
      unitRef="usd">580000000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfMjEtMS0xLTEtMjg2OTQ0_ef55d1cb-1918-478c-8216-29ab00a057b6"
      unitRef="usd">2876000000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="ic217743408d440409a59220a0bf14e4c_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfMjEtMy0xLTEtMjg2OTQ0_9ce1b767-7d35-4d26-ad50-1173c87d6f90"
      unitRef="usd">2842000000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfMjMtMS0xLTEtMjg2OTQ0_2f53c6de-3074-4b8b-a1fc-ebca777fb0e7"
      unitRef="usd">32503000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ic217743408d440409a59220a0bf14e4c_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfMjMtMy0xLTEtMjg2OTQ0_71e70a41-4ae4-4fc3-be9a-240453518753"
      unitRef="usd">30550000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfMjUtMS0xLTEtMjg2OTQ0_4306d76e-2f22-4234-b1cf-47b69ff10ac5"
      unitRef="usd">4708000000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="ic217743408d440409a59220a0bf14e4c_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfMjUtMy0xLTEtMjg2OTQ0_95e902c8-8cc8-4096-8f2f-14b2354c0938"
      unitRef="usd">4735000000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent
      contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfMjYtMS0xLTEtMjg2OTQ0_ce5f08fe-7024-409b-a704-00ec0a01e196"
      unitRef="usd">8384000000</us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent>
    <us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent
      contextRef="ic217743408d440409a59220a0bf14e4c_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfMjYtMy0xLTEtMjg2OTQ0_ab4344f9-fc72-440c-aa45-4ad27ccdc258"
      unitRef="usd">9299000000</us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfMzAtMC0xLTEtMjg2OTQ0L3RleHRyZWdpb246NmI5NjM4NWMzOGViNDVkNjhiZGYxYmYzNTcyZTViMWJfMTU_0036531e-a759-4501-a33f-feac3e115836"
      unitRef="shares">500000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ic217743408d440409a59220a0bf14e4c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfMzAtMC0xLTEtMjg2OTQ0L3RleHRyZWdpb246NmI5NjM4NWMzOGViNDVkNjhiZGYxYmYzNTcyZTViMWJfMTU_09dc6687-d72a-4920-9f65-4b0d322c600e"
      unitRef="shares">500000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfMzAtMC0xLTEtMjg2OTQ0L3RleHRyZWdpb246NmI5NjM4NWMzOGViNDVkNjhiZGYxYmYzNTcyZTViMWJfMzM_9ab63c94-7f9e-4c1c-8f66-cdf2f558a7bf"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ic217743408d440409a59220a0bf14e4c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfMzAtMC0xLTEtMjg2OTQ0L3RleHRyZWdpb246NmI5NjM4NWMzOGViNDVkNjhiZGYxYmYzNTcyZTViMWJfMzM_f84bea32-08f7-4398-b0a5-f09a45102e02"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfMzAtMS0xLTEtMjg2OTQ0_9836a14e-a507-4b2a-bb68-430bddb75434"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="ic217743408d440409a59220a0bf14e4c_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfMzAtMy0xLTEtMjg2OTQ0_c068e564-2199-4079-a047-0c534efdf1bd"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfMzItMC0xLTEtMjg2OTQ0L3RleHRyZWdpb246YjhiNjVmY2NlMGRjNDQ2ZjhhNjczYmU2OTRlNGQ1N2NfMTY_8ff38525-bfda-4205-9a82-56d5199595b2"
      unitRef="shares">755000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ic217743408d440409a59220a0bf14e4c_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfMzItMC0xLTEtMjg2OTQ0L3RleHRyZWdpb246YjhiNjVmY2NlMGRjNDQ2ZjhhNjczYmU2OTRlNGQ1N2NfMTY_c85f54c1-c7c7-458b-8892-23598f00e06a"
      unitRef="shares">755000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfMzItMC0xLTEtMjg2OTQ0L3RleHRyZWdpb246YjhiNjVmY2NlMGRjNDQ2ZjhhNjczYmU2OTRlNGQ1N2NfMzQ_1384b21f-4d32-4e90-bb0c-526c7eca8a69"
      unitRef="shares">327000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="ic217743408d440409a59220a0bf14e4c_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfMzItMC0xLTEtMjg2OTQ0L3RleHRyZWdpb246YjhiNjVmY2NlMGRjNDQ2ZjhhNjczYmU2OTRlNGQ1N2NfMzQ_21585e76-3e4a-4f98-bf9a-ed8cc75e2861"
      unitRef="shares">327000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfMzItMS0xLTEtMjg2OTQ0_1a0cfbd8-e0ac-4c9a-a817-ad44920d47f4"
      unitRef="usd">2818000000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="ic217743408d440409a59220a0bf14e4c_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfMzItMy0xLTEtMjg2OTQ0_86dac88d-9c17-4bff-aaae-394cef2638c0"
      unitRef="usd">2813000000</us-gaap:CommonStockValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfMzMtMS0xLTEtMjg2OTQ0_f89c4233-6763-45f8-bdeb-dc22a62224c9"
      unitRef="usd">-342000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ic217743408d440409a59220a0bf14e4c_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfMzMtMy0xLTEtMjg2OTQ0_c281251a-4ee3-437d-9829-6fc3339b03f5"
      unitRef="usd">-280000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:TreasuryStockCommonShares
      contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfMzQtMC0xLTEtMjg2OTQ0L3RleHRyZWdpb246ZjFmZmQ1YzIxYWUwNGQ5Yzg1ZDliY2FkNzJhZDA1YzlfNDE_fff83e81-26b2-4d2f-926b-23f063692df7"
      unitRef="shares">72000000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares
      contextRef="ic217743408d440409a59220a0bf14e4c_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfMzQtMC0xLTEtMjg2OTQ0L3RleHRyZWdpb246ZjFmZmQ1YzIxYWUwNGQ5Yzg1ZDliY2FkNzJhZDA1YzlfNTU_268b9800-77cd-4538-9b3b-c3a130b2f6ec"
      unitRef="shares">54000000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockValue
      contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfMzQtMS0xLTEtMjg2OTQ0_b64bf472-2f6a-441d-b07f-3d8185fcb6ab"
      unitRef="usd">4554000000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="ic217743408d440409a59220a0bf14e4c_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfMzQtMy0xLTEtMjg2OTQ0_9e219953-e4e6-4e16-9dfd-42df1d6f32c1"
      unitRef="usd">3128000000</us-gaap:TreasuryStockValue>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfMzUtMS0xLTEtMjg2OTQ0_f3718a10-f119-4c67-a927-fc9a0e6052ce"
      unitRef="usd">-142000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ic217743408d440409a59220a0bf14e4c_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfMzUtMy0xLTEtMjg2OTQ0_5b28e671-32c1-4a96-8261-1ac1c47cf0ac"
      unitRef="usd">-114000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfMzYtMS0xLTEtMjg2OTQ0_e7311ba6-3b73-41f9-96f1-0cd82ee747c6"
      unitRef="usd">-2220000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic217743408d440409a59220a0bf14e4c_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfMzYtMy0xLTEtMjg2OTQ0_38075cd7-44d6-4081-8658-c9bf1743e4b3"
      unitRef="usd">-709000000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfMzctMS0xLTEtMjg2OTQ0_07f51885-85cd-4bc1-a5d3-1fd4b3897450"
      unitRef="usd">2000000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="ic217743408d440409a59220a0bf14e4c_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfMzctMy0xLTEtMjg2OTQ0_5aa028e7-7278-49d2-8a84-efb223b2fbfd"
      unitRef="usd">3000000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfMzgtMS0xLTEtMjg2OTQ0_0fae8bbe-c363-4db3-9c8d-283de25315ee"
      unitRef="usd">-2218000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic217743408d440409a59220a0bf14e4c_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfMzgtMy0xLTEtMjg2OTQ0_4d8e6a9e-aad4-4de3-9b33-ab8159be9977"
      unitRef="usd">-706000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfMzktMS0xLTEtMjg2OTQ0_946f38ca-ab6d-4f80-bbcf-c3bfebcb68fb"
      unitRef="usd">43377000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ic217743408d440409a59220a0bf14e4c_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y182Ny9mcmFnOjc5NWZhNjVmNjJmMjRiMjk5ODE2MTRjMDFiMTgyZjRhL3RhYmxlOjczZDllNjk2N2U4NTRiMWViNjExYzE1ZDM0YmI0N2JhL3RhYmxlcmFuZ2U6NzNkOWU2OTY3ZTg1NGIxZWI2MTFjMTVkMzRiYjQ3YmFfMzktMy0xLTEtMjg2OTQ0_760364d8-85fd-45cf-83b4-bb34f1671520"
      unitRef="usd">43878000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:CommonStockSharesIssued
      contextRef="i56eab9e952334359a592f758a000f3a5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOmMwMDczMTdhZDBjNDRiNDRiZDAxNWI2MWUxYTcwZmUwL3RhYmxlcmFuZ2U6YzAwNzMxN2FkMGM0NGI0NGJkMDE1YjYxZTFhNzBmZTBfMy0xLTEtMS0yODY5NDQ_2c6cd24a-7906-4f7d-a896-e44d703040b3"
      unitRef="shares">327000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i56eab9e952334359a592f758a000f3a5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOmMwMDczMTdhZDBjNDRiNDRiZDAxNWI2MWUxYTcwZmUwL3RhYmxlcmFuZ2U6YzAwNzMxN2FkMGM0NGI0NGJkMDE1YjYxZTFhNzBmZTBfMy0zLTEtMS0yODY5NDQ_21362cb6-7acd-455b-9c94-390b9959ab1b"
      unitRef="usd">2747000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8b46cf505d1d4c6286a2da8dfd32802a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOmMwMDczMTdhZDBjNDRiNDRiZDAxNWI2MWUxYTcwZmUwL3RhYmxlcmFuZ2U6YzAwNzMxN2FkMGM0NGI0NGJkMDE1YjYxZTFhNzBmZTBfMy01LTEtMS0yODY5NDQ_b5030f87-de68-43c8-bd72-21e84307e378"
      unitRef="usd">-560000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i0e78bc722aef43c4ac908658f754bbe4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOmMwMDczMTdhZDBjNDRiNDRiZDAxNWI2MWUxYTcwZmUwL3RhYmxlcmFuZ2U6YzAwNzMxN2FkMGM0NGI0NGJkMDE1YjYxZTFhNzBmZTBfMy03LTEtMS0yODY5NDQ_b1445a7f-ec9f-42e4-8565-231840f8fbfd"
      unitRef="shares">-68000000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockValue
      contextRef="i0e78bc722aef43c4ac908658f754bbe4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOmMwMDczMTdhZDBjNDRiNDRiZDAxNWI2MWUxYTcwZmUwL3RhYmxlcmFuZ2U6YzAwNzMxN2FkMGM0NGI0NGJkMDE1YjYxZTFhNzBmZTBfMy05LTEtMS0yODY5NDQ_9a6e0956-cf46-452a-9bab-ad55f71cba9f"
      unitRef="usd">-4254000000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7fee7130363347368e48c8a5373ef212_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOmMwMDczMTdhZDBjNDRiNDRiZDAxNWI2MWUxYTcwZmUwL3RhYmxlcmFuZ2U6YzAwNzMxN2FkMGM0NGI0NGJkMDE1YjYxZTFhNzBmZTBfMy0xMS0xLTEtMjg2OTQ0_ad2b4f3d-ee0b-437b-bb7d-972da9fee45f"
      unitRef="usd">-146000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id91f4a6653dc429ab8550cb153ee63fe_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOmMwMDczMTdhZDBjNDRiNDRiZDAxNWI2MWUxYTcwZmUwL3RhYmxlcmFuZ2U6YzAwNzMxN2FkMGM0NGI0NGJkMDE1YjYxZTFhNzBmZTBfMy0xMy0xLTEtMjg2OTQ0_16ae91c5-79cd-496d-a079-83d37f58aa22"
      unitRef="usd">1000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i08aa4676fa1f412495f0dcda89ef5c61_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOmMwMDczMTdhZDBjNDRiNDRiZDAxNWI2MWUxYTcwZmUwL3RhYmxlcmFuZ2U6YzAwNzMxN2FkMGM0NGI0NGJkMDE1YjYxZTFhNzBmZTBfMy0xNS0xLTEtMjg2OTQ0_e0f35c1d-f094-49ff-829c-13548df128cc"
      unitRef="usd">-2212000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOmMwMDczMTdhZDBjNDRiNDRiZDAxNWI2MWUxYTcwZmUwL3RhYmxlcmFuZ2U6YzAwNzMxN2FkMGM0NGI0NGJkMDE1YjYxZTFhNzBmZTBfNC01LTEtMS0yODY5NDQ_85a3bd11-1781-4e7e-b02c-a48a53700384"
      unitRef="usd">345000000</us-gaap:NetIncomeLoss>
    <us-gaap:ProfitLoss
      contextRef="i6743439f6d344529a1d9776e5a37b6af_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOmMwMDczMTdhZDBjNDRiNDRiZDAxNWI2MWUxYTcwZmUwL3RhYmxlcmFuZ2U6YzAwNzMxN2FkMGM0NGI0NGJkMDE1YjYxZTFhNzBmZTBfNC0xMy0xLTEtMjg2OTQ0_7eb08e3f-5994-4f0b-9f98-42e5dbfd957a"
      unitRef="usd">2000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOmMwMDczMTdhZDBjNDRiNDRiZDAxNWI2MWUxYTcwZmUwL3RhYmxlcmFuZ2U6YzAwNzMxN2FkMGM0NGI0NGJkMDE1YjYxZTFhNzBmZTBfNC0xNS0xLTEtMjg2OTQ0_3d56888a-e7b9-42c4-95d1-85788506f609"
      unitRef="usd">347000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOmMwMDczMTdhZDBjNDRiNDRiZDAxNWI2MWUxYTcwZmUwL3RhYmxlcmFuZ2U6YzAwNzMxN2FkMGM0NGI0NGJkMDE1YjYxZTFhNzBmZTBfNS0xMS0xLTEtMjg2OTQ0_d1db4eed-bfb1-45d8-a96c-99e3cce96451"
      unitRef="usd">4000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOmMwMDczMTdhZDBjNDRiNDRiZDAxNWI2MWUxYTcwZmUwL3RhYmxlcmFuZ2U6YzAwNzMxN2FkMGM0NGI0NGJkMDE1YjYxZTFhNzBmZTBfNS0xNS0xLTEtMjg2OTQ0_8a0d8653-4e7f-4fdb-962f-5b8b3465559c"
      unitRef="usd">4000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i691c4bcd6648489e9985b2ebac21c4c4_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOmMwMDczMTdhZDBjNDRiNDRiZDAxNWI2MWUxYTcwZmUwL3RhYmxlcmFuZ2U6YzAwNzMxN2FkMGM0NGI0NGJkMDE1YjYxZTFhNzBmZTBfNy0xLTEtMS0yODY5NDQ_5de2520d-5f25-4b3b-beb4-6d1564a2d8d7"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i691c4bcd6648489e9985b2ebac21c4c4_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOmMwMDczMTdhZDBjNDRiNDRiZDAxNWI2MWUxYTcwZmUwL3RhYmxlcmFuZ2U6YzAwNzMxN2FkMGM0NGI0NGJkMDE1YjYxZTFhNzBmZTBfNy0zLTEtMS0yODY5NDQ_4b0759ec-c3be-4ca5-ad67-e4ca551e4899"
      unitRef="usd">21000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ic5ce320f275240ee8f228b919198581e_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOmMwMDczMTdhZDBjNDRiNDRiZDAxNWI2MWUxYTcwZmUwL3RhYmxlcmFuZ2U6YzAwNzMxN2FkMGM0NGI0NGJkMDE1YjYxZTFhNzBmZTBfNy03LTEtMS0yODY5NDQ_7ea9dc69-58a2-4533-b115-7260e9bde01a"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ic5ce320f275240ee8f228b919198581e_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOmMwMDczMTdhZDBjNDRiNDRiZDAxNWI2MWUxYTcwZmUwL3RhYmxlcmFuZ2U6YzAwNzMxN2FkMGM0NGI0NGJkMDE1YjYxZTFhNzBmZTBfNy05LTEtMS0yODY5NDQ_991c091b-d729-4f7d-9e6f-4c62f5a183a8"
      unitRef="usd">3000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOmMwMDczMTdhZDBjNDRiNDRiZDAxNWI2MWUxYTcwZmUwL3RhYmxlcmFuZ2U6YzAwNzMxN2FkMGM0NGI0NGJkMDE1YjYxZTFhNzBmZTBfNy0xNS0xLTEtMjg2OTQ0_8f528ffa-58af-4872-9fe0-61a7cfb14dc6"
      unitRef="usd">24000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i691c4bcd6648489e9985b2ebac21c4c4_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOmMwMDczMTdhZDBjNDRiNDRiZDAxNWI2MWUxYTcwZmUwL3RhYmxlcmFuZ2U6YzAwNzMxN2FkMGM0NGI0NGJkMDE1YjYxZTFhNzBmZTBfOC0zLTEtMS0yODY5NDQ_d3a126af-81bc-4a92-9a23-4f5bf3522058"
      unitRef="usd">50000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="ic5ce320f275240ee8f228b919198581e_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOmMwMDczMTdhZDBjNDRiNDRiZDAxNWI2MWUxYTcwZmUwL3RhYmxlcmFuZ2U6YzAwNzMxN2FkMGM0NGI0NGJkMDE1YjYxZTFhNzBmZTBfOC03LTEtMS0yODY5NDQ_05caf656-f200-428f-8839-3591d877af1c"
      unitRef="shares">4000000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ic5ce320f275240ee8f228b919198581e_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOmMwMDczMTdhZDBjNDRiNDRiZDAxNWI2MWUxYTcwZmUwL3RhYmxlcmFuZ2U6YzAwNzMxN2FkMGM0NGI0NGJkMDE1YjYxZTFhNzBmZTBfOC05LTEtMS0yODY5NDQ_5fb2b130-7ee3-480a-b6d5-d7fffa22fdda"
      unitRef="usd">303000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOmMwMDczMTdhZDBjNDRiNDRiZDAxNWI2MWUxYTcwZmUwL3RhYmxlcmFuZ2U6YzAwNzMxN2FkMGM0NGI0NGJkMDE1YjYxZTFhNzBmZTBfOC0xNS0xLTEtMjg2OTQ0_719cb846-8c1a-4e8b-829c-6b7540b54506"
      unitRef="usd">253000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:Dividends
      contextRef="ibb01906f8808446da382eb7169a9c692_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOmMwMDczMTdhZDBjNDRiNDRiZDAxNWI2MWUxYTcwZmUwL3RhYmxlcmFuZ2U6YzAwNzMxN2FkMGM0NGI0NGJkMDE1YjYxZTFhNzBmZTBfOS01LTEtMS0yODY5NDQ_b8e02fcd-de0e-4afc-9900-d0a0256d2d6f"
      unitRef="usd">128000000</us-gaap:Dividends>
    <us-gaap:Dividends
      contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOmMwMDczMTdhZDBjNDRiNDRiZDAxNWI2MWUxYTcwZmUwL3RhYmxlcmFuZ2U6YzAwNzMxN2FkMGM0NGI0NGJkMDE1YjYxZTFhNzBmZTBfOS0xNS0xLTEtMjg2OTQ0_2c5ea353-fd38-407e-a0d3-8fc03243f433"
      unitRef="usd">128000000</us-gaap:Dividends>
    <us-gaap:StockholdersEquityOther
      contextRef="i691c4bcd6648489e9985b2ebac21c4c4_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOmMwMDczMTdhZDBjNDRiNDRiZDAxNWI2MWUxYTcwZmUwL3RhYmxlcmFuZ2U6YzAwNzMxN2FkMGM0NGI0NGJkMDE1YjYxZTFhNzBmZTBfMTAtMy0xLTEtMjg2OTQ0_539accdd-3b2d-494f-808d-5d4cb505808c"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityOther
      contextRef="ibb01906f8808446da382eb7169a9c692_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOmMwMDczMTdhZDBjNDRiNDRiZDAxNWI2MWUxYTcwZmUwL3RhYmxlcmFuZ2U6YzAwNzMxN2FkMGM0NGI0NGJkMDE1YjYxZTFhNzBmZTBfMTAtNS0xLTEtMjg2OTQ0_c99a582f-1b96-4c01-84d0-577e334b25fc"
      unitRef="usd">-1000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOtherShares
      contextRef="ic5ce320f275240ee8f228b919198581e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOmMwMDczMTdhZDBjNDRiNDRiZDAxNWI2MWUxYTcwZmUwL3RhYmxlcmFuZ2U6YzAwNzMxN2FkMGM0NGI0NGJkMDE1YjYxZTFhNzBmZTBfMTAtNy0xLTEtMjg2OTQ0_c5be152e-acaf-4eee-a176-3b0bfbab432c"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityOther
      contextRef="i6743439f6d344529a1d9776e5a37b6af_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOmMwMDczMTdhZDBjNDRiNDRiZDAxNWI2MWUxYTcwZmUwL3RhYmxlcmFuZ2U6YzAwNzMxN2FkMGM0NGI0NGJkMDE1YjYxZTFhNzBmZTBfMTAtMTMtMS0xLTI4Njk0NA_ab889506-c96e-47c4-9c8b-91c152698ab8"
      unitRef="usd">1000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOmMwMDczMTdhZDBjNDRiNDRiZDAxNWI2MWUxYTcwZmUwL3RhYmxlcmFuZ2U6YzAwNzMxN2FkMGM0NGI0NGJkMDE1YjYxZTFhNzBmZTBfMTAtMTUtMS0xLTI4Njk0NA_75c45fbf-a79c-4dc8-b5f7-b3625bda9542"
      unitRef="usd">0</us-gaap:StockholdersEquityOther>
    <us-gaap:CommonStockSharesIssued
      contextRef="i3208791586fb4201860768dd298b3bb2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOmMwMDczMTdhZDBjNDRiNDRiZDAxNWI2MWUxYTcwZmUwL3RhYmxlcmFuZ2U6YzAwNzMxN2FkMGM0NGI0NGJkMDE1YjYxZTFhNzBmZTBfMTEtMS0xLTEtMjg2OTQ0_00c07c69-5f55-48da-a7d9-c5299285f4b4"
      unitRef="shares">327000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3208791586fb4201860768dd298b3bb2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOmMwMDczMTdhZDBjNDRiNDRiZDAxNWI2MWUxYTcwZmUwL3RhYmxlcmFuZ2U6YzAwNzMxN2FkMGM0NGI0NGJkMDE1YjYxZTFhNzBmZTBfMTEtMy0xLTEtMjg2OTQ0_10d6aa23-2079-44a5-a8ee-bc8dc6a948a5"
      unitRef="usd">2818000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i69743694027f433b8def521fd90c10b1_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOmMwMDczMTdhZDBjNDRiNDRiZDAxNWI2MWUxYTcwZmUwL3RhYmxlcmFuZ2U6YzAwNzMxN2FkMGM0NGI0NGJkMDE1YjYxZTFhNzBmZTBfMTEtNS0xLTEtMjg2OTQ0_f80c1956-8afd-45c4-80a5-33afff861957"
      unitRef="usd">-342000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares
      contextRef="ia191fa3eb5734906a8bf76c6f6496bc1_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOmMwMDczMTdhZDBjNDRiNDRiZDAxNWI2MWUxYTcwZmUwL3RhYmxlcmFuZ2U6YzAwNzMxN2FkMGM0NGI0NGJkMDE1YjYxZTFhNzBmZTBfMTEtNy0xLTEtMjg2OTQ0_3aa1ca8a-b0fb-40ec-aac8-cd4c5839d9e0"
      unitRef="shares">72000000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockValue
      contextRef="ia191fa3eb5734906a8bf76c6f6496bc1_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOmMwMDczMTdhZDBjNDRiNDRiZDAxNWI2MWUxYTcwZmUwL3RhYmxlcmFuZ2U6YzAwNzMxN2FkMGM0NGI0NGJkMDE1YjYxZTFhNzBmZTBfMTEtOS0xLTEtMjg2OTQ0_345d968b-80ec-4498-812e-5be55e0dc95c"
      unitRef="usd">4554000000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idf64830da37b4122b808db1a1819f451_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOmMwMDczMTdhZDBjNDRiNDRiZDAxNWI2MWUxYTcwZmUwL3RhYmxlcmFuZ2U6YzAwNzMxN2FkMGM0NGI0NGJkMDE1YjYxZTFhNzBmZTBfMTEtMTEtMS0xLTI4Njk0NA_3a1ef906-5bf4-42e5-af17-12521f5e59b4"
      unitRef="usd">-142000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2b78f3c4f51d4889980e7fc07edfec59_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOmMwMDczMTdhZDBjNDRiNDRiZDAxNWI2MWUxYTcwZmUwL3RhYmxlcmFuZ2U6YzAwNzMxN2FkMGM0NGI0NGJkMDE1YjYxZTFhNzBmZTBfMTEtMTMtMS0xLTI4Njk0NA_5a043fd2-ab1c-4707-8bf1-26896ae2d596"
      unitRef="usd">2000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOmMwMDczMTdhZDBjNDRiNDRiZDAxNWI2MWUxYTcwZmUwL3RhYmxlcmFuZ2U6YzAwNzMxN2FkMGM0NGI0NGJkMDE1YjYxZTFhNzBmZTBfMTEtMTUtMS0xLTI4Njk0NA_50de10f4-b95a-4ed7-bc5c-594c7dbdbd9e"
      unitRef="usd">-2218000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesIssued
      contextRef="i13c78c23b94549919369f13eef7a33f8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjE5MmJjMDFkYWYzNTQ0OTA5MDFiYjE1N2M4MTI2MGQ5L3RhYmxlcmFuZ2U6MTkyYmMwMWRhZjM1NDQ5MDkwMWJiMTU3YzgxMjYwZDlfMS0xLTEtMS0yODY5NDQ_e849fe56-aa03-40c1-9be3-0da901dc707c"
      unitRef="shares">327000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i13c78c23b94549919369f13eef7a33f8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjE5MmJjMDFkYWYzNTQ0OTA5MDFiYjE1N2M4MTI2MGQ5L3RhYmxlcmFuZ2U6MTkyYmMwMWRhZjM1NDQ5MDkwMWJiMTU3YzgxMjYwZDlfMS0zLTEtMS0yODY5NDQ_fabbfb60-d9c5-4932-95ac-2ac505c52d74"
      unitRef="usd">2721000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib002348769da4f519bc0a52ddbe725a0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjE5MmJjMDFkYWYzNTQ0OTA5MDFiYjE1N2M4MTI2MGQ5L3RhYmxlcmFuZ2U6MTkyYmMwMWRhZjM1NDQ5MDkwMWJiMTU3YzgxMjYwZDlfMS01LTEtMS0yODY5NDQ_14a89919-5dac-4bde-b626-9d6ea24d0d24"
      unitRef="usd">1245000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i869ddd309d65479f921f1950d72e9ae7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjE5MmJjMDFkYWYzNTQ0OTA5MDFiYjE1N2M4MTI2MGQ5L3RhYmxlcmFuZ2U6MTkyYmMwMWRhZjM1NDQ5MDkwMWJiMTU3YzgxMjYwZDlfMS03LTEtMS0yODY5NDQ_f96cae7f-dcd0-4532-a747-d6eef74db78a"
      unitRef="shares">50000000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockValue
      contextRef="i869ddd309d65479f921f1950d72e9ae7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjE5MmJjMDFkYWYzNTQ0OTA5MDFiYjE1N2M4MTI2MGQ5L3RhYmxlcmFuZ2U6MTkyYmMwMWRhZjM1NDQ5MDkwMWJiMTU3YzgxMjYwZDlfMS05LTEtMS0yODY5NDQ_dbeca2a3-242b-416e-b296-63972bb893d3"
      unitRef="usd">2883000000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i400ae55f5bf646e1a4865cfff0502178_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjE5MmJjMDFkYWYzNTQ0OTA5MDFiYjE1N2M4MTI2MGQ5L3RhYmxlcmFuZ2U6MTkyYmMwMWRhZjM1NDQ5MDkwMWJiMTU3YzgxMjYwZDlfMS0xMS0xLTEtMjg2OTQ0_a70dc501-4eff-4de5-9e67-32673697a9a9"
      unitRef="usd">-85000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i31325593417c40aea09d306e481d5c1c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjE5MmJjMDFkYWYzNTQ0OTA5MDFiYjE1N2M4MTI2MGQ5L3RhYmxlcmFuZ2U6MTkyYmMwMWRhZjM1NDQ5MDkwMWJiMTU3YzgxMjYwZDlfMS0xMy0xLTEtMjg2OTQ0_52695e7a-5090-41ea-9a65-0ad8cc3b1172"
      unitRef="usd">4000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1da9880c72714008b4977c3a3f95890e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjE5MmJjMDFkYWYzNTQ0OTA5MDFiYjE1N2M4MTI2MGQ5L3RhYmxlcmFuZ2U6MTkyYmMwMWRhZjM1NDQ5MDkwMWJiMTU3YzgxMjYwZDlfMS0xNS0xLTEtMjg2OTQ0_3ccc7378-00f5-4f8d-a0cb-5a51c29c8275"
      unitRef="usd">1002000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjE5MmJjMDFkYWYzNTQ0OTA5MDFiYjE1N2M4MTI2MGQ5L3RhYmxlcmFuZ2U6MTkyYmMwMWRhZjM1NDQ5MDkwMWJiMTU3YzgxMjYwZDlfMi01LTEtMS0yODY5NDQ_77ef8dfc-5b96-414c-8c86-ee9f14ac21ca"
      unitRef="usd">-1391000000</us-gaap:NetIncomeLoss>
    <us-gaap:ProfitLoss
      contextRef="ie41c2a5af47749b785d11deeee809585_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjE5MmJjMDFkYWYzNTQ0OTA5MDFiYjE1N2M4MTI2MGQ5L3RhYmxlcmFuZ2U6MTkyYmMwMWRhZjM1NDQ5MDkwMWJiMTU3YzgxMjYwZDlfMi0xMy0xLTEtMjg2OTQ0_6e5f5ce0-6ba9-4093-b17a-0e68742217d6"
      unitRef="usd">1000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjE5MmJjMDFkYWYzNTQ0OTA5MDFiYjE1N2M4MTI2MGQ5L3RhYmxlcmFuZ2U6MTkyYmMwMWRhZjM1NDQ5MDkwMWJiMTU3YzgxMjYwZDlfMi0xNS0xLTEtMjg2OTQ0_f16ab458-2fd9-4b77-a045-7e6e8511f1ad"
      unitRef="usd">-1390000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i418f71a8a1cc4ca49f486b30f467dcbc_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjE5MmJjMDFkYWYzNTQ0OTA5MDFiYjE1N2M4MTI2MGQ5L3RhYmxlcmFuZ2U6MTkyYmMwMWRhZjM1NDQ5MDkwMWJiMTU3YzgxMjYwZDlfMy0xMS0xLTEtMjg2OTQ0_2f7e362e-58f9-4dfb-ba92-cd57a2bf6348"
      unitRef="usd">8000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjE5MmJjMDFkYWYzNTQ0OTA5MDFiYjE1N2M4MTI2MGQ5L3RhYmxlcmFuZ2U6MTkyYmMwMWRhZjM1NDQ5MDkwMWJiMTU3YzgxMjYwZDlfMy0xNS0xLTEtMjg2OTQ0_f7c8fe36-b96b-49a6-bbd2-28104d343a1a"
      unitRef="usd">8000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ia19686236f7848079bbad68bd7c03742_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjE5MmJjMDFkYWYzNTQ0OTA5MDFiYjE1N2M4MTI2MGQ5L3RhYmxlcmFuZ2U6MTkyYmMwMWRhZjM1NDQ5MDkwMWJiMTU3YzgxMjYwZDlfNS0xLTEtMS0yODY5NDQ_9c976a29-8670-4560-9a29-330a47d5b084"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ia19686236f7848079bbad68bd7c03742_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjE5MmJjMDFkYWYzNTQ0OTA5MDFiYjE1N2M4MTI2MGQ5L3RhYmxlcmFuZ2U6MTkyYmMwMWRhZjM1NDQ5MDkwMWJiMTU3YzgxMjYwZDlfNS0zLTEtMS0yODY5NDQ_15ba2bb0-02bc-4200-8cae-b64cea40e3ce"
      unitRef="usd">20000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i49e3f3cae16c423db19dc0526a881118_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjE5MmJjMDFkYWYzNTQ0OTA5MDFiYjE1N2M4MTI2MGQ5L3RhYmxlcmFuZ2U6MTkyYmMwMWRhZjM1NDQ5MDkwMWJiMTU3YzgxMjYwZDlfNS03LTEtMS0yODY5NDQ_76824acf-4888-4589-b0b2-e832607bb770"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i49e3f3cae16c423db19dc0526a881118_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjE5MmJjMDFkYWYzNTQ0OTA5MDFiYjE1N2M4MTI2MGQ5L3RhYmxlcmFuZ2U6MTkyYmMwMWRhZjM1NDQ5MDkwMWJiMTU3YzgxMjYwZDlfNS05LTEtMS0yODY5NDQ_b88040db-1904-46be-a328-01f91101dd63"
      unitRef="usd">3000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjE5MmJjMDFkYWYzNTQ0OTA5MDFiYjE1N2M4MTI2MGQ5L3RhYmxlcmFuZ2U6MTkyYmMwMWRhZjM1NDQ5MDkwMWJiMTU3YzgxMjYwZDlfNS0xNS0xLTEtMjg2OTQ0_bfa19ac0-be77-468d-8a5c-e9978ae32c15"
      unitRef="usd">23000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="ia19686236f7848079bbad68bd7c03742_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjE5MmJjMDFkYWYzNTQ0OTA5MDFiYjE1N2M4MTI2MGQ5L3RhYmxlcmFuZ2U6MTkyYmMwMWRhZjM1NDQ5MDkwMWJiMTU3YzgxMjYwZDlfNi0zLTEtMS0yODY5NDQ_9e964554-06fd-4247-933b-010ccecc5600"
      unitRef="usd">20000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i49e3f3cae16c423db19dc0526a881118_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjE5MmJjMDFkYWYzNTQ0OTA5MDFiYjE1N2M4MTI2MGQ5L3RhYmxlcmFuZ2U6MTkyYmMwMWRhZjM1NDQ5MDkwMWJiMTU3YzgxMjYwZDlfNi03LTEtMS0yODY5NDQ_f5c4c763-e9b3-4091-a9f8-128f6ef31e31"
      unitRef="shares">4000000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i49e3f3cae16c423db19dc0526a881118_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjE5MmJjMDFkYWYzNTQ0OTA5MDFiYjE1N2M4MTI2MGQ5L3RhYmxlcmFuZ2U6MTkyYmMwMWRhZjM1NDQ5MDkwMWJiMTU3YzgxMjYwZDlfNi05LTEtMS0yODY5NDQ_b7c4ce57-8621-40df-916d-3e30967ed089"
      unitRef="usd">220000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjE5MmJjMDFkYWYzNTQ0OTA5MDFiYjE1N2M4MTI2MGQ5L3RhYmxlcmFuZ2U6MTkyYmMwMWRhZjM1NDQ5MDkwMWJiMTU3YzgxMjYwZDlfNi0xNS0xLTEtMjg2OTQ0_3d393ee4-3c07-47f7-9d0b-97dbc87590d8"
      unitRef="usd">200000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:Dividends
      contextRef="if9a10ddae3d841d29503e0ad7359eefa_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjE5MmJjMDFkYWYzNTQ0OTA5MDFiYjE1N2M4MTI2MGQ5L3RhYmxlcmFuZ2U6MTkyYmMwMWRhZjM1NDQ5MDkwMWJiMTU3YzgxMjYwZDlfNy01LTEtMS0yODY5NDQ_b6320e25-fe35-4b32-a0d9-1fe7341f9d10"
      unitRef="usd">135000000</us-gaap:Dividends>
    <us-gaap:Dividends
      contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjE5MmJjMDFkYWYzNTQ0OTA5MDFiYjE1N2M4MTI2MGQ5L3RhYmxlcmFuZ2U6MTkyYmMwMWRhZjM1NDQ5MDkwMWJiMTU3YzgxMjYwZDlfNy0xNS0xLTEtMjg2OTQ0_d5c972a4-3df9-46af-b052-32d84bbaa9e4"
      unitRef="usd">135000000</us-gaap:Dividends>
    <us-gaap:StockholdersEquityOther
      contextRef="ia19686236f7848079bbad68bd7c03742_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjE5MmJjMDFkYWYzNTQ0OTA5MDFiYjE1N2M4MTI2MGQ5L3RhYmxlcmFuZ2U6MTkyYmMwMWRhZjM1NDQ5MDkwMWJiMTU3YzgxMjYwZDlfOC0zLTEtMS0yODY5NDQ_df4e81ec-0f30-48f5-b0c5-73f6467b1473"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityOther
      contextRef="if9a10ddae3d841d29503e0ad7359eefa_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjE5MmJjMDFkYWYzNTQ0OTA5MDFiYjE1N2M4MTI2MGQ5L3RhYmxlcmFuZ2U6MTkyYmMwMWRhZjM1NDQ5MDkwMWJiMTU3YzgxMjYwZDlfOC01LTEtMS0yODY5NDQ_12d11af1-1ee3-4a7c-98c2-27eb762035db"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityOtherShares
      contextRef="i49e3f3cae16c423db19dc0526a881118_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjE5MmJjMDFkYWYzNTQ0OTA5MDFiYjE1N2M4MTI2MGQ5L3RhYmxlcmFuZ2U6MTkyYmMwMWRhZjM1NDQ5MDkwMWJiMTU3YzgxMjYwZDlfOC03LTEtMS0yODY5NDQ_55c36e63-7d80-4b9c-b548-6d3ff5cfa109"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityOther
      contextRef="ie41c2a5af47749b785d11deeee809585_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjE5MmJjMDFkYWYzNTQ0OTA5MDFiYjE1N2M4MTI2MGQ5L3RhYmxlcmFuZ2U6MTkyYmMwMWRhZjM1NDQ5MDkwMWJiMTU3YzgxMjYwZDlfOC0xMy0xLTEtMjg2OTQ0_88fa9e1e-6269-4856-a253-628ad00733d7"
      unitRef="usd">-1000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjE5MmJjMDFkYWYzNTQ0OTA5MDFiYjE1N2M4MTI2MGQ5L3RhYmxlcmFuZ2U6MTkyYmMwMWRhZjM1NDQ5MDkwMWJiMTU3YzgxMjYwZDlfOC0xNS0xLTEtMjg2OTQ0_9f87e3a2-7713-4d70-8eac-921a8f596609"
      unitRef="usd">-1000000</us-gaap:StockholdersEquityOther>
    <us-gaap:CommonStockSharesIssued
      contextRef="iafbe7b9485174b4e8c9f2d802e7dc231_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjE5MmJjMDFkYWYzNTQ0OTA5MDFiYjE1N2M4MTI2MGQ5L3RhYmxlcmFuZ2U6MTkyYmMwMWRhZjM1NDQ5MDkwMWJiMTU3YzgxMjYwZDlfOS0xLTEtMS0yODY5NDQ_ef8bf1ad-3a64-45cd-84bd-fc8605f80d72"
      unitRef="shares">327000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iafbe7b9485174b4e8c9f2d802e7dc231_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjE5MmJjMDFkYWYzNTQ0OTA5MDFiYjE1N2M4MTI2MGQ5L3RhYmxlcmFuZ2U6MTkyYmMwMWRhZjM1NDQ5MDkwMWJiMTU3YzgxMjYwZDlfOS0zLTEtMS0yODY5NDQ_4119fe99-3b60-43fd-a908-4399c51f0c03"
      unitRef="usd">2761000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifb5d714a0e8b461297b910f807c80a18_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjE5MmJjMDFkYWYzNTQ0OTA5MDFiYjE1N2M4MTI2MGQ5L3RhYmxlcmFuZ2U6MTkyYmMwMWRhZjM1NDQ5MDkwMWJiMTU3YzgxMjYwZDlfOS01LTEtMS0yODY5NDQ_7ca8bc5f-5b6e-4fc4-9008-7894763e1679"
      unitRef="usd">-281000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i9330ee3b45ee44a09dbcfeab14ffd40e_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjE5MmJjMDFkYWYzNTQ0OTA5MDFiYjE1N2M4MTI2MGQ5L3RhYmxlcmFuZ2U6MTkyYmMwMWRhZjM1NDQ5MDkwMWJiMTU3YzgxMjYwZDlfOS03LTEtMS0yODY5NDQ_478893bc-e2e1-43b8-a580-65c2b8fe9a96"
      unitRef="shares">54000000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockValue
      contextRef="i9330ee3b45ee44a09dbcfeab14ffd40e_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjE5MmJjMDFkYWYzNTQ0OTA5MDFiYjE1N2M4MTI2MGQ5L3RhYmxlcmFuZ2U6MTkyYmMwMWRhZjM1NDQ5MDkwMWJiMTU3YzgxMjYwZDlfOS05LTEtMS0yODY5NDQ_0b66ee18-5614-493e-be1d-4624a4f8785e"
      unitRef="usd">3100000000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9f0673078b15401ba450a8f78e2cc590_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjE5MmJjMDFkYWYzNTQ0OTA5MDFiYjE1N2M4MTI2MGQ5L3RhYmxlcmFuZ2U6MTkyYmMwMWRhZjM1NDQ5MDkwMWJiMTU3YzgxMjYwZDlfOS0xMS0xLTEtMjg2OTQ0_bc21ccc9-0041-4fff-80c8-d02bd90fd33b"
      unitRef="usd">-77000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1e1aae70a0da49d484500f615cb3fd5f_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjE5MmJjMDFkYWYzNTQ0OTA5MDFiYjE1N2M4MTI2MGQ5L3RhYmxlcmFuZ2U6MTkyYmMwMWRhZjM1NDQ5MDkwMWJiMTU3YzgxMjYwZDlfOS0xMy0xLTEtMjg2OTQ0_1ba4b88a-d70a-4623-9268-3ee9c439f836"
      unitRef="usd">4000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if9769f07affb42f58d537c7029824f72_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjE5MmJjMDFkYWYzNTQ0OTA5MDFiYjE1N2M4MTI2MGQ5L3RhYmxlcmFuZ2U6MTkyYmMwMWRhZjM1NDQ5MDkwMWJiMTU3YzgxMjYwZDlfOS0xNS0xLTEtMjg2OTQ0_2bea77f7-0832-42d6-879c-8def1ccffd62"
      unitRef="usd">-693000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesIssued
      contextRef="idb1c4815be35411c8c429c87e4166d03_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjA5MmVmZGUxZjRmYjQzMjdiNGNlMzAxODU5NWZhY2ZiL3RhYmxlcmFuZ2U6MDkyZWZkZTFmNGZiNDMyN2I0Y2UzMDE4NTk1ZmFjZmJfMy0xLTEtMS0yODY5NDQ_6f941452-91f6-451d-a6d8-7b974e3e06a7"
      unitRef="shares">327000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idb1c4815be35411c8c429c87e4166d03_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjA5MmVmZGUxZjRmYjQzMjdiNGNlMzAxODU5NWZhY2ZiL3RhYmxlcmFuZ2U6MDkyZWZkZTFmNGZiNDMyN2I0Y2UzMDE4NTk1ZmFjZmJfMy0zLTEtMS0yODY5NDQ_50fd0f9c-609d-48c1-8e79-5f07cb0e995b"
      unitRef="usd">2813000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i79094c6b94cc48dc906e4841e8ebb7e7_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjA5MmVmZGUxZjRmYjQzMjdiNGNlMzAxODU5NWZhY2ZiL3RhYmxlcmFuZ2U6MDkyZWZkZTFmNGZiNDMyN2I0Y2UzMDE4NTk1ZmFjZmJfMy01LTEtMS0yODY5NDQ_386fe164-bf98-475c-8546-318dfed61135"
      unitRef="usd">-280000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i7a2aef50edb6408382366ab58c0a5fe5_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjA5MmVmZGUxZjRmYjQzMjdiNGNlMzAxODU5NWZhY2ZiL3RhYmxlcmFuZ2U6MDkyZWZkZTFmNGZiNDMyN2I0Y2UzMDE4NTk1ZmFjZmJfMy03LTEtMS0yODY5NDQ_9a9c90d5-5328-42d7-9cfe-665f41e6c403"
      unitRef="shares">-54000000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockValue
      contextRef="i7a2aef50edb6408382366ab58c0a5fe5_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjA5MmVmZGUxZjRmYjQzMjdiNGNlMzAxODU5NWZhY2ZiL3RhYmxlcmFuZ2U6MDkyZWZkZTFmNGZiNDMyN2I0Y2UzMDE4NTk1ZmFjZmJfMy05LTEtMS0yODY5NDQ_5a2eae1b-1078-4343-ae88-07b42b7af21b"
      unitRef="usd">-3128000000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1ab713f43fd740a3981b34442abff7e2_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjA5MmVmZGUxZjRmYjQzMjdiNGNlMzAxODU5NWZhY2ZiL3RhYmxlcmFuZ2U6MDkyZWZkZTFmNGZiNDMyN2I0Y2UzMDE4NTk1ZmFjZmJfMy0xMS0xLTEtMjg2OTQ0_72ce8a44-1978-4a0f-b176-c591b2fcd266"
      unitRef="usd">-114000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic9f0457c7d4d49858c91362f01b0d1db_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjA5MmVmZGUxZjRmYjQzMjdiNGNlMzAxODU5NWZhY2ZiL3RhYmxlcmFuZ2U6MDkyZWZkZTFmNGZiNDMyN2I0Y2UzMDE4NTk1ZmFjZmJfMy0xMy0xLTEtMjg2OTQ0_25a7c9b5-9c5c-4f54-9771-0d6c683d4f5e"
      unitRef="usd">3000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic217743408d440409a59220a0bf14e4c_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjA5MmVmZGUxZjRmYjQzMjdiNGNlMzAxODU5NWZhY2ZiL3RhYmxlcmFuZ2U6MDkyZWZkZTFmNGZiNDMyN2I0Y2UzMDE4NTk1ZmFjZmJfMy0xNS0xLTEtMjg2OTQ0_b2cdd77d-e40f-4ebe-aebc-7b0365068896"
      unitRef="usd">-706000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjA5MmVmZGUxZjRmYjQzMjdiNGNlMzAxODU5NWZhY2ZiL3RhYmxlcmFuZ2U6MDkyZWZkZTFmNGZiNDMyN2I0Y2UzMDE4NTk1ZmFjZmJfNC01LTEtMS0yODY5NDQ_556bbc86-ddaa-4d5a-9b50-d11a0ede17b2"
      unitRef="usd">325000000</us-gaap:NetIncomeLoss>
    <us-gaap:ProfitLoss
      contextRef="iddb780ecd77a4a539d61e232d9c38a2a_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjA5MmVmZGUxZjRmYjQzMjdiNGNlMzAxODU5NWZhY2ZiL3RhYmxlcmFuZ2U6MDkyZWZkZTFmNGZiNDMyN2I0Y2UzMDE4NTk1ZmFjZmJfNC0xMy0xLTEtMjg2OTQ0_dd3e2016-d336-4a92-bd24-74fc9196d4c5"
      unitRef="usd">3000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjA5MmVmZGUxZjRmYjQzMjdiNGNlMzAxODU5NWZhY2ZiL3RhYmxlcmFuZ2U6MDkyZWZkZTFmNGZiNDMyN2I0Y2UzMDE4NTk1ZmFjZmJfNC0xNS0xLTEtMjg2OTQ0_18993d5d-1e0e-4dd6-9c87-932d096119ed"
      unitRef="usd">328000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i5339f5e85f3b47c0aa0a7795a0147a83_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjA5MmVmZGUxZjRmYjQzMjdiNGNlMzAxODU5NWZhY2ZiL3RhYmxlcmFuZ2U6MDkyZWZkZTFmNGZiNDMyN2I0Y2UzMDE4NTk1ZmFjZmJfNS0xMS0xLTEtMjg2OTQ0_94651b4b-4090-40c9-99cd-cfaddd4f7226"
      unitRef="usd">-28000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjA5MmVmZGUxZjRmYjQzMjdiNGNlMzAxODU5NWZhY2ZiL3RhYmxlcmFuZ2U6MDkyZWZkZTFmNGZiNDMyN2I0Y2UzMDE4NTk1ZmFjZmJfNS0xNS0xLTEtMjg2OTQ0_8cb88a1c-749b-46bd-af99-855361768359"
      unitRef="usd">-28000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="iddb780ecd77a4a539d61e232d9c38a2a_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjA5MmVmZGUxZjRmYjQzMjdiNGNlMzAxODU5NWZhY2ZiL3RhYmxlcmFuZ2U6MDkyZWZkZTFmNGZiNDMyN2I0Y2UzMDE4NTk1ZmFjZmJfNi0xMy0xLTEtMjg2OTQ0_1d846a4a-9071-4015-b220-933bc3214e93"
      unitRef="usd">-2000000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjA5MmVmZGUxZjRmYjQzMjdiNGNlMzAxODU5NWZhY2ZiL3RhYmxlcmFuZ2U6MDkyZWZkZTFmNGZiNDMyN2I0Y2UzMDE4NTk1ZmFjZmJfNi0xNS0xLTEtMjg2OTQ0_e01ee3c7-09c7-4799-8f6b-3dd3bb208400"
      unitRef="usd">-2000000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="iada78453d3a64782ab3851803455517a_D20220701-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjA5MmVmZGUxZjRmYjQzMjdiNGNlMzAxODU5NWZhY2ZiL3RhYmxlcmFuZ2U6MDkyZWZkZTFmNGZiNDMyN2I0Y2UzMDE4NTk1ZmFjZmJfNy0xLTEtMS0yODY5NDQ_43de3074-2b2b-4bf3-837c-b3fc7562df8e"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="iada78453d3a64782ab3851803455517a_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjA5MmVmZGUxZjRmYjQzMjdiNGNlMzAxODU5NWZhY2ZiL3RhYmxlcmFuZ2U6MDkyZWZkZTFmNGZiNDMyN2I0Y2UzMDE4NTk1ZmFjZmJfNy0zLTEtMS0yODY5NDQ_fd11a5dd-fe2e-46f3-8d8b-006855404b01"
      unitRef="usd">5000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjA5MmVmZGUxZjRmYjQzMjdiNGNlMzAxODU5NWZhY2ZiL3RhYmxlcmFuZ2U6MDkyZWZkZTFmNGZiNDMyN2I0Y2UzMDE4NTk1ZmFjZmJfNy03LTEtMS0yODY5NDQ_e3c0b3c6-03a5-4bda-967e-3204b5fd7650"
      unitRef="shares">2000000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i8e5c5ae766b74cf6a2409e8a66778fe4_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjA5MmVmZGUxZjRmYjQzMjdiNGNlMzAxODU5NWZhY2ZiL3RhYmxlcmFuZ2U6MDkyZWZkZTFmNGZiNDMyN2I0Y2UzMDE4NTk1ZmFjZmJfNy05LTEtMS0yODY5NDQ_eaa3e6cc-ce0d-46ba-b10a-afbc16be63bd"
      unitRef="usd">77000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjA5MmVmZGUxZjRmYjQzMjdiNGNlMzAxODU5NWZhY2ZiL3RhYmxlcmFuZ2U6MDkyZWZkZTFmNGZiNDMyN2I0Y2UzMDE4NTk1ZmFjZmJfNy0xNS0xLTEtMjg2OTQ0_5382aaec-85cd-4f91-840d-5f454db1c972"
      unitRef="usd">82000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="iada78453d3a64782ab3851803455517a_D20220701-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjA5MmVmZGUxZjRmYjQzMjdiNGNlMzAxODU5NWZhY2ZiL3RhYmxlcmFuZ2U6MDkyZWZkZTFmNGZiNDMyN2I0Y2UzMDE4NTk1ZmFjZmJfOC0zLTEtMS0yODY5NDQ_e0c67b81-97ca-4416-800b-b8a79fde309b"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i8e5c5ae766b74cf6a2409e8a66778fe4_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjA5MmVmZGUxZjRmYjQzMjdiNGNlMzAxODU5NWZhY2ZiL3RhYmxlcmFuZ2U6MDkyZWZkZTFmNGZiNDMyN2I0Y2UzMDE4NTk1ZmFjZmJfOC03LTEtMS0yODY5NDQ_4ef6f22f-2539-4b27-8b30-b8972393b105"
      unitRef="shares">20000000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i8e5c5ae766b74cf6a2409e8a66778fe4_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjA5MmVmZGUxZjRmYjQzMjdiNGNlMzAxODU5NWZhY2ZiL3RhYmxlcmFuZ2U6MDkyZWZkZTFmNGZiNDMyN2I0Y2UzMDE4NTk1ZmFjZmJfOC05LTEtMS0yODY5NDQ_c5dae461-c117-44d4-85ae-1297337506da"
      unitRef="usd">1503000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjA5MmVmZGUxZjRmYjQzMjdiNGNlMzAxODU5NWZhY2ZiL3RhYmxlcmFuZ2U6MDkyZWZkZTFmNGZiNDMyN2I0Y2UzMDE4NTk1ZmFjZmJfOC0xNS0xLTEtMjg2OTQ0_12e001a9-8222-4d41-b848-41551f164c69"
      unitRef="usd">1503000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:Dividends
      contextRef="icafe121606cd4112b5329a3ce5274e9d_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjA5MmVmZGUxZjRmYjQzMjdiNGNlMzAxODU5NWZhY2ZiL3RhYmxlcmFuZ2U6MDkyZWZkZTFmNGZiNDMyN2I0Y2UzMDE4NTk1ZmFjZmJfOS01LTEtMS0yODY5NDQ_ee0e48bd-2d8a-41c5-a7d4-2ef3ddff98a2"
      unitRef="usd">388000000</us-gaap:Dividends>
    <us-gaap:Dividends
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjA5MmVmZGUxZjRmYjQzMjdiNGNlMzAxODU5NWZhY2ZiL3RhYmxlcmFuZ2U6MDkyZWZkZTFmNGZiNDMyN2I0Y2UzMDE4NTk1ZmFjZmJfOS0xNS0xLTEtMjg2OTQ0_5596df0a-8031-40c4-9112-7c592beaf899"
      unitRef="usd">388000000</us-gaap:Dividends>
    <us-gaap:StockholdersEquityOther
      contextRef="icafe121606cd4112b5329a3ce5274e9d_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjA5MmVmZGUxZjRmYjQzMjdiNGNlMzAxODU5NWZhY2ZiL3RhYmxlcmFuZ2U6MDkyZWZkZTFmNGZiNDMyN2I0Y2UzMDE4NTk1ZmFjZmJfMTAtNS0xLTEtMjg2OTQ0_07e96f63-8a52-4f3b-a2ec-b5375468c314"
      unitRef="usd">1000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOtherShares
      contextRef="i8e5c5ae766b74cf6a2409e8a66778fe4_D20220701-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjA5MmVmZGUxZjRmYjQzMjdiNGNlMzAxODU5NWZhY2ZiL3RhYmxlcmFuZ2U6MDkyZWZkZTFmNGZiNDMyN2I0Y2UzMDE4NTk1ZmFjZmJfMTAtNy0xLTEtMjg2OTQ0_f33e2617-cb11-42e1-ab22-d88cc3402fa3"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityOther
      contextRef="iddb780ecd77a4a539d61e232d9c38a2a_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjA5MmVmZGUxZjRmYjQzMjdiNGNlMzAxODU5NWZhY2ZiL3RhYmxlcmFuZ2U6MDkyZWZkZTFmNGZiNDMyN2I0Y2UzMDE4NTk1ZmFjZmJfMTAtMTMtMS0xLTI4Njk0NA_ef031a40-658b-437e-9ae8-a9cb8f58354c"
      unitRef="usd">-2000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjA5MmVmZGUxZjRmYjQzMjdiNGNlMzAxODU5NWZhY2ZiL3RhYmxlcmFuZ2U6MDkyZWZkZTFmNGZiNDMyN2I0Y2UzMDE4NTk1ZmFjZmJfMTAtMTUtMS0xLTI4Njk0NA_cc93018f-4fa1-4c26-afa9-2ba91a039ecc"
      unitRef="usd">-1000000</us-gaap:StockholdersEquityOther>
    <us-gaap:CommonStockSharesIssued
      contextRef="i3208791586fb4201860768dd298b3bb2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjA5MmVmZGUxZjRmYjQzMjdiNGNlMzAxODU5NWZhY2ZiL3RhYmxlcmFuZ2U6MDkyZWZkZTFmNGZiNDMyN2I0Y2UzMDE4NTk1ZmFjZmJfMTEtMS0xLTEtMjg2OTQ0_0a31b62c-9f71-4744-adfe-df4dc0ee7c47"
      unitRef="shares">327000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3208791586fb4201860768dd298b3bb2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjA5MmVmZGUxZjRmYjQzMjdiNGNlMzAxODU5NWZhY2ZiL3RhYmxlcmFuZ2U6MDkyZWZkZTFmNGZiNDMyN2I0Y2UzMDE4NTk1ZmFjZmJfMTEtMy0xLTEtMjg2OTQ0_492db031-98a2-4bb5-9909-8022bf59d9fa"
      unitRef="usd">2818000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i69743694027f433b8def521fd90c10b1_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjA5MmVmZGUxZjRmYjQzMjdiNGNlMzAxODU5NWZhY2ZiL3RhYmxlcmFuZ2U6MDkyZWZkZTFmNGZiNDMyN2I0Y2UzMDE4NTk1ZmFjZmJfMTEtNS0xLTEtMjg2OTQ0_c2718f4b-7b6e-45f6-a21b-f4f5fd3ab3f7"
      unitRef="usd">-342000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares
      contextRef="ia191fa3eb5734906a8bf76c6f6496bc1_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjA5MmVmZGUxZjRmYjQzMjdiNGNlMzAxODU5NWZhY2ZiL3RhYmxlcmFuZ2U6MDkyZWZkZTFmNGZiNDMyN2I0Y2UzMDE4NTk1ZmFjZmJfMTEtNy0xLTEtMjg2OTQ0_6ac4d55e-f1c2-44d3-8bf5-03b195520bca"
      unitRef="shares">72000000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockValue
      contextRef="ia191fa3eb5734906a8bf76c6f6496bc1_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjA5MmVmZGUxZjRmYjQzMjdiNGNlMzAxODU5NWZhY2ZiL3RhYmxlcmFuZ2U6MDkyZWZkZTFmNGZiNDMyN2I0Y2UzMDE4NTk1ZmFjZmJfMTEtOS0xLTEtMjg2OTQ0_9a23eed8-dbbd-43ea-895b-86483bf7f25a"
      unitRef="usd">4554000000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idf64830da37b4122b808db1a1819f451_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjA5MmVmZGUxZjRmYjQzMjdiNGNlMzAxODU5NWZhY2ZiL3RhYmxlcmFuZ2U6MDkyZWZkZTFmNGZiNDMyN2I0Y2UzMDE4NTk1ZmFjZmJfMTEtMTEtMS0xLTI4Njk0NA_79f83472-b662-46a3-a73d-25574720028d"
      unitRef="usd">-142000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2b78f3c4f51d4889980e7fc07edfec59_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjA5MmVmZGUxZjRmYjQzMjdiNGNlMzAxODU5NWZhY2ZiL3RhYmxlcmFuZ2U6MDkyZWZkZTFmNGZiNDMyN2I0Y2UzMDE4NTk1ZmFjZmJfMTEtMTMtMS0xLTI4Njk0NA_e279e930-895f-4ad0-ba7a-218cc94ab31a"
      unitRef="usd">2000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjA5MmVmZGUxZjRmYjQzMjdiNGNlMzAxODU5NWZhY2ZiL3RhYmxlcmFuZ2U6MDkyZWZkZTFmNGZiNDMyN2I0Y2UzMDE4NTk1ZmFjZmJfMTEtMTUtMS0xLTI4Njk0NA_2cf09a2d-97f6-4e73-a64e-5def4554d7f7"
      unitRef="usd">-2218000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesIssued
      contextRef="if4a2a8ced444402e984b4c3bc89c5c8d_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjM1ODMyMmU3ZDA0MTRjMzViZWI2NDkwNzNjMzI5NTgzL3RhYmxlcmFuZ2U6MzU4MzIyZTdkMDQxNGMzNWJlYjY0OTA3M2MzMjk1ODNfMS0xLTEtMS0yODY5NDQ_e4365db9-f24b-403e-8972-f28c8f5dfc39"
      unitRef="shares">327000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if4a2a8ced444402e984b4c3bc89c5c8d_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjM1ODMyMmU3ZDA0MTRjMzViZWI2NDkwNzNjMzI5NTgzL3RhYmxlcmFuZ2U6MzU4MzIyZTdkMDQxNGMzNWJlYjY0OTA3M2MzMjk1ODNfMS0zLTEtMS0yODY5NDQ_2cbca1ea-85ad-4afc-849c-c3225cfee6aa"
      unitRef="usd">2806000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icfec14d9fb124cfe89c5bea933f8e5c2_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjM1ODMyMmU3ZDA0MTRjMzViZWI2NDkwNzNjMzI5NTgzL3RhYmxlcmFuZ2U6MzU4MzIyZTdkMDQxNGMzNWJlYjY0OTA3M2MzMjk1ODNfMS01LTEtMS0yODY5NDQ_b35942e5-a740-4eae-b356-efdfe94e6752"
      unitRef="usd">1205000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i2aece4cef70c4e909ce54489503e648a_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjM1ODMyMmU3ZDA0MTRjMzViZWI2NDkwNzNjMzI5NTgzL3RhYmxlcmFuZ2U6MzU4MzIyZTdkMDQxNGMzNWJlYjY0OTA3M2MzMjk1ODNfMS03LTEtMS0yODY5NDQ_72c6fd28-9e6d-4f1e-bc4d-8e0b566673a2"
      unitRef="shares">36000000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockValue
      contextRef="i2aece4cef70c4e909ce54489503e648a_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjM1ODMyMmU3ZDA0MTRjMzViZWI2NDkwNzNjMzI5NTgzL3RhYmxlcmFuZ2U6MzU4MzIyZTdkMDQxNGMzNWJlYjY0OTA3M2MzMjk1ODNfMS05LTEtMS0yODY5NDQ_d4209cf4-a513-4e97-9f98-5fc52f3e4b7c"
      unitRef="usd">2186000000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i866c0616d4fa407cb18e678ede1cf44e_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjM1ODMyMmU3ZDA0MTRjMzViZWI2NDkwNzNjMzI5NTgzL3RhYmxlcmFuZ2U6MzU4MzIyZTdkMDQxNGMzNWJlYjY0OTA3M2MzMjk1ODNfMS0xMS0xLTEtMjg2OTQ0_0893dd7f-9877-4d77-8bd6-058b5bc111b0"
      unitRef="usd">-34000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5ae8d288fa1c40efba1860f8c0297502_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjM1ODMyMmU3ZDA0MTRjMzViZWI2NDkwNzNjMzI5NTgzL3RhYmxlcmFuZ2U6MzU4MzIyZTdkMDQxNGMzNWJlYjY0OTA3M2MzMjk1ODNfMS0xMy0xLTEtMjg2OTQ0_1cb3be9e-8aa4-42a1-8052-3b100e585219"
      unitRef="usd">3000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i75b88320c8d34867830cda3167c67779_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjM1ODMyMmU3ZDA0MTRjMzViZWI2NDkwNzNjMzI5NTgzL3RhYmxlcmFuZ2U6MzU4MzIyZTdkMDQxNGMzNWJlYjY0OTA3M2MzMjk1ODNfMS0xNS0xLTEtMjg2OTQ0_e6eb90ea-dcdd-474e-9bd4-bd8c645faad0"
      unitRef="usd">1794000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjM1ODMyMmU3ZDA0MTRjMzViZWI2NDkwNzNjMzI5NTgzL3RhYmxlcmFuZ2U6MzU4MzIyZTdkMDQxNGMzNWJlYjY0OTA3M2MzMjk1ODNfMi01LTEtMS0yODY5NDQ_e4af5ca6-1f58-4572-9ff3-d6278df7c114"
      unitRef="usd">-1071000000</us-gaap:NetIncomeLoss>
    <us-gaap:ProfitLoss
      contextRef="i3eb749068f254e87ba6fe7696f1b7ae3_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjM1ODMyMmU3ZDA0MTRjMzViZWI2NDkwNzNjMzI5NTgzL3RhYmxlcmFuZ2U6MzU4MzIyZTdkMDQxNGMzNWJlYjY0OTA3M2MzMjk1ODNfMi0xMy0xLTEtMjg2OTQ0_c0bc6471-8b40-46d0-8269-1ebd5815f683"
      unitRef="usd">2000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjM1ODMyMmU3ZDA0MTRjMzViZWI2NDkwNzNjMzI5NTgzL3RhYmxlcmFuZ2U6MzU4MzIyZTdkMDQxNGMzNWJlYjY0OTA3M2MzMjk1ODNfMi0xNS0xLTEtMjg2OTQ0_5adecded-f796-45de-af41-d1f97bfa47a6"
      unitRef="usd">-1069000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ibf631f27db6a4b97b407bf7c07872ada_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjM1ODMyMmU3ZDA0MTRjMzViZWI2NDkwNzNjMzI5NTgzL3RhYmxlcmFuZ2U6MzU4MzIyZTdkMDQxNGMzNWJlYjY0OTA3M2MzMjk1ODNfMy0xMS0xLTEtMjg2OTQ0_015d27b4-1b1e-478a-b659-0c7e25ca8e14"
      unitRef="usd">-43000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjM1ODMyMmU3ZDA0MTRjMzViZWI2NDkwNzNjMzI5NTgzL3RhYmxlcmFuZ2U6MzU4MzIyZTdkMDQxNGMzNWJlYjY0OTA3M2MzMjk1ODNfMy0xNS0xLTEtMjg2OTQ0_658e0fab-e6ee-4827-a881-ecac3854f784"
      unitRef="usd">-43000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i259a6ff3365f4c53ac0b2f2edbb89551_D20210701-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjM1ODMyMmU3ZDA0MTRjMzViZWI2NDkwNzNjMzI5NTgzL3RhYmxlcmFuZ2U6MzU4MzIyZTdkMDQxNGMzNWJlYjY0OTA3M2MzMjk1ODNfNS0xLTEtMS0yODY5NDQ_06ab98d5-3da2-4815-9cbb-966febd9370f"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i259a6ff3365f4c53ac0b2f2edbb89551_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjM1ODMyMmU3ZDA0MTRjMzViZWI2NDkwNzNjMzI5NTgzL3RhYmxlcmFuZ2U6MzU4MzIyZTdkMDQxNGMzNWJlYjY0OTA3M2MzMjk1ODNfNS0zLTEtMS0yODY5NDQ_e29d84b3-513d-43cd-a1d6-7a1dbc798f71"
      unitRef="usd">-5000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ib1adee5e79374a97893072820fddaa0e_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjM1ODMyMmU3ZDA0MTRjMzViZWI2NDkwNzNjMzI5NTgzL3RhYmxlcmFuZ2U6MzU4MzIyZTdkMDQxNGMzNWJlYjY0OTA3M2MzMjk1ODNfNS03LTEtMS0yODY5NDQ_d2997bc1-fded-4050-bef5-e7f7fb52c40e"
      unitRef="shares">1000000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ib1adee5e79374a97893072820fddaa0e_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjM1ODMyMmU3ZDA0MTRjMzViZWI2NDkwNzNjMzI5NTgzL3RhYmxlcmFuZ2U6MzU4MzIyZTdkMDQxNGMzNWJlYjY0OTA3M2MzMjk1ODNfNS05LTEtMS0yODY5NDQ_57a2dd1d-b480-473b-9595-34744ee6e63c"
      unitRef="usd">46000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjM1ODMyMmU3ZDA0MTRjMzViZWI2NDkwNzNjMzI5NTgzL3RhYmxlcmFuZ2U6MzU4MzIyZTdkMDQxNGMzNWJlYjY0OTA3M2MzMjk1ODNfNS0xNS0xLTEtMjg2OTQ0_936f353f-5f56-4787-8728-5be3b4c648ea"
      unitRef="usd">41000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i259a6ff3365f4c53ac0b2f2edbb89551_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjM1ODMyMmU3ZDA0MTRjMzViZWI2NDkwNzNjMzI5NTgzL3RhYmxlcmFuZ2U6MzU4MzIyZTdkMDQxNGMzNWJlYjY0OTA3M2MzMjk1ODNfNi0zLTEtMS0yODY5NDQ_2925d187-0757-422b-b16f-d25a6533b58d"
      unitRef="usd">-40000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="ib1adee5e79374a97893072820fddaa0e_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjM1ODMyMmU3ZDA0MTRjMzViZWI2NDkwNzNjMzI5NTgzL3RhYmxlcmFuZ2U6MzU4MzIyZTdkMDQxNGMzNWJlYjY0OTA3M2MzMjk1ODNfNi03LTEtMS0yODY5NDQ_bec5a1e1-5959-4f0c-9992-f636c87876fd"
      unitRef="shares">19000000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ib1adee5e79374a97893072820fddaa0e_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjM1ODMyMmU3ZDA0MTRjMzViZWI2NDkwNzNjMzI5NTgzL3RhYmxlcmFuZ2U6MzU4MzIyZTdkMDQxNGMzNWJlYjY0OTA3M2MzMjk1ODNfNi05LTEtMS0yODY5NDQ_3f2f6548-7cca-4b33-bc3d-58515091b7ab"
      unitRef="usd">960000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjM1ODMyMmU3ZDA0MTRjMzViZWI2NDkwNzNjMzI5NTgzL3RhYmxlcmFuZ2U6MzU4MzIyZTdkMDQxNGMzNWJlYjY0OTA3M2MzMjk1ODNfNi0xNS0xLTEtMjg2OTQ0_e61c655b-a3b2-4728-b53a-b98d72fc5eea"
      unitRef="usd">1000000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:Dividends
      contextRef="i0db8654b67c442ae83277edeaf53cedc_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjM1ODMyMmU3ZDA0MTRjMzViZWI2NDkwNzNjMzI5NTgzL3RhYmxlcmFuZ2U6MzU4MzIyZTdkMDQxNGMzNWJlYjY0OTA3M2MzMjk1ODNfNy01LTEtMS0yODY5NDQ_1a3625eb-0022-42cb-b10e-efaa803c4392"
      unitRef="usd">415000000</us-gaap:Dividends>
    <us-gaap:Dividends
      contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjM1ODMyMmU3ZDA0MTRjMzViZWI2NDkwNzNjMzI5NTgzL3RhYmxlcmFuZ2U6MzU4MzIyZTdkMDQxNGMzNWJlYjY0OTA3M2MzMjk1ODNfNy0xNS0xLTEtMjg2OTQ0_45ec859a-c9ea-4ea2-a4f5-a7a33acbb03e"
      unitRef="usd">415000000</us-gaap:Dividends>
    <us-gaap:StockholdersEquityOther
      contextRef="i0db8654b67c442ae83277edeaf53cedc_D20210701-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjM1ODMyMmU3ZDA0MTRjMzViZWI2NDkwNzNjMzI5NTgzL3RhYmxlcmFuZ2U6MzU4MzIyZTdkMDQxNGMzNWJlYjY0OTA3M2MzMjk1ODNfOC01LTEtMS0yODY5NDQ_46475fb7-8028-4975-91a9-fd91da7717da"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityOtherShares
      contextRef="ib1adee5e79374a97893072820fddaa0e_D20210701-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjM1ODMyMmU3ZDA0MTRjMzViZWI2NDkwNzNjMzI5NTgzL3RhYmxlcmFuZ2U6MzU4MzIyZTdkMDQxNGMzNWJlYjY0OTA3M2MzMjk1ODNfOC03LTEtMS0yODY5NDQ_1d00571f-f3b2-4531-9944-9535d67af4de"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityOther
      contextRef="i3eb749068f254e87ba6fe7696f1b7ae3_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjM1ODMyMmU3ZDA0MTRjMzViZWI2NDkwNzNjMzI5NTgzL3RhYmxlcmFuZ2U6MzU4MzIyZTdkMDQxNGMzNWJlYjY0OTA3M2MzMjk1ODNfOC0xMy0xLTEtMjg2OTQ0_7587a351-0390-4369-9670-003f4679110c"
      unitRef="usd">-1000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjM1ODMyMmU3ZDA0MTRjMzViZWI2NDkwNzNjMzI5NTgzL3RhYmxlcmFuZ2U6MzU4MzIyZTdkMDQxNGMzNWJlYjY0OTA3M2MzMjk1ODNfOC0xNS0xLTEtMjg2OTQ0_8380e6f3-552d-4c15-ba67-1b6ca2c98f7d"
      unitRef="usd">-1000000</us-gaap:StockholdersEquityOther>
    <us-gaap:CommonStockSharesIssued
      contextRef="iafbe7b9485174b4e8c9f2d802e7dc231_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjM1ODMyMmU3ZDA0MTRjMzViZWI2NDkwNzNjMzI5NTgzL3RhYmxlcmFuZ2U6MzU4MzIyZTdkMDQxNGMzNWJlYjY0OTA3M2MzMjk1ODNfOS0xLTEtMS0yODY5NDQ_ff52e299-adbf-49ba-ad71-75a9c496d75b"
      unitRef="shares">327000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iafbe7b9485174b4e8c9f2d802e7dc231_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjM1ODMyMmU3ZDA0MTRjMzViZWI2NDkwNzNjMzI5NTgzL3RhYmxlcmFuZ2U6MzU4MzIyZTdkMDQxNGMzNWJlYjY0OTA3M2MzMjk1ODNfOS0zLTEtMS0yODY5NDQ_b02832c9-a586-4602-9827-7f200df07600"
      unitRef="usd">2761000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifb5d714a0e8b461297b910f807c80a18_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjM1ODMyMmU3ZDA0MTRjMzViZWI2NDkwNzNjMzI5NTgzL3RhYmxlcmFuZ2U6MzU4MzIyZTdkMDQxNGMzNWJlYjY0OTA3M2MzMjk1ODNfOS01LTEtMS0yODY5NDQ_ad577e5c-7c24-419e-868c-ea539dc0759c"
      unitRef="usd">-281000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i9330ee3b45ee44a09dbcfeab14ffd40e_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjM1ODMyMmU3ZDA0MTRjMzViZWI2NDkwNzNjMzI5NTgzL3RhYmxlcmFuZ2U6MzU4MzIyZTdkMDQxNGMzNWJlYjY0OTA3M2MzMjk1ODNfOS03LTEtMS0yODY5NDQ_cec5b7f4-53da-4ff4-832d-9bce394e52d7"
      unitRef="shares">54000000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockValue
      contextRef="i9330ee3b45ee44a09dbcfeab14ffd40e_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjM1ODMyMmU3ZDA0MTRjMzViZWI2NDkwNzNjMzI5NTgzL3RhYmxlcmFuZ2U6MzU4MzIyZTdkMDQxNGMzNWJlYjY0OTA3M2MzMjk1ODNfOS05LTEtMS0yODY5NDQ_48819d01-1844-450b-96ce-c571de2a884a"
      unitRef="usd">3100000000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9f0673078b15401ba450a8f78e2cc590_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjM1ODMyMmU3ZDA0MTRjMzViZWI2NDkwNzNjMzI5NTgzL3RhYmxlcmFuZ2U6MzU4MzIyZTdkMDQxNGMzNWJlYjY0OTA3M2MzMjk1ODNfOS0xMS0xLTEtMjg2OTQ0_31517a67-eff0-4500-b5f1-30cbf3154ea9"
      unitRef="usd">-77000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1e1aae70a0da49d484500f615cb3fd5f_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjM1ODMyMmU3ZDA0MTRjMzViZWI2NDkwNzNjMzI5NTgzL3RhYmxlcmFuZ2U6MzU4MzIyZTdkMDQxNGMzNWJlYjY0OTA3M2MzMjk1ODNfOS0xMy0xLTEtMjg2OTQ0_08f7bd88-a3b9-473f-b5fa-1f955043b2d9"
      unitRef="usd">4000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if9769f07affb42f58d537c7029824f72_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183MC9mcmFnOjczNDAxMzk3OGQwYTQwZmY5MTdmNWI0MTYxMmY5NzdjL3RhYmxlOjM1ODMyMmU3ZDA0MTRjMzViZWI2NDkwNzNjMzI5NTgzL3RhYmxlcmFuZ2U6MzU4MzIyZTdkMDQxNGMzNWJlYjY0OTA3M2MzMjk1ODNfOS0xNS0xLTEtMjg2OTQ0_fa3ba32a-5269-4377-94ab-79eaa2aa3cc6"
      unitRef="usd">-693000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfMy0xLTEtMS0yODY5NDQ_163febd8-dd9a-4c3d-bbbd-9124df675f7f"
      unitRef="usd">328000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfMy0zLTEtMS0yODY5NDQ_202d77f7-bddc-47c0-8de7-077a2fafdf3e"
      unitRef="usd">-1069000000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfNi0xLTEtMS0yODY5NDQ_6c9337b3-ab02-4a08-92be-44b1411a127f"
      unitRef="usd">516000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfNi0zLTEtMS0yODY5NDQ_b5d5a5a7-6766-4be2-be0d-a1feb2e5e05f"
      unitRef="usd">513000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfNy0xLTEtMS0zNzAyMjc_bc7b2822-47d0-4aed-bfab-79f55bb76bea"
      unitRef="usd">-883000000</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges
      contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfNy0zLTEtMS0zNzAyMjc_43f941d8-ff89-493b-8a3a-d74bdc532848"
      unitRef="usd">-1764000000</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <us-gaap:GainLossOnSaleOfOtherInvestments
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfNy0xLTEtMS0yODY5NDQ_de4c708d-5277-4a9c-9ea4-d80b083c8429"
      unitRef="usd">0</us-gaap:GainLossOnSaleOfOtherInvestments>
    <us-gaap:GainLossOnSaleOfOtherInvestments
      contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfNy0zLTEtMS0yODY5NDQ_6dc3df36-2983-47a9-8582-a59e8a9a4c47"
      unitRef="usd">-3000000</us-gaap:GainLossOnSaleOfOtherInvestments>
    <us-gaap:GainLossOnSaleOfInvestments
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfOC0xLTEtMS0yODY5NDQ_81be80d2-2edf-4a5e-9242-12ba59d89dad"
      unitRef="usd">0</us-gaap:GainLossOnSaleOfInvestments>
    <us-gaap:GainLossOnSaleOfInvestments
      contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfOC0zLTEtMS0yODY5NDQ_fca12224-74de-4744-877c-cc79a533e5f0"
      unitRef="usd">2000000</us-gaap:GainLossOnSaleOfInvestments>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfMTAtMS0xLTEtMjg2OTQ0_30aa46e2-161f-4bcc-9204-9a9e39cbbf10"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfMTAtMy0xLTEtMjg2OTQ0_e63d7449-afd0-447c-b5b4-0f0c8cb0d7af"
      unitRef="usd">-10000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ShareBasedCompensation
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfMTEtMS0xLTEtMjg2OTQ0_0223221d-a601-4c68-931a-7cab3537379f"
      unitRef="usd">69000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfMTEtMy0xLTEtMjg2OTQ0_fbd7e70a-57fe-4c30-b6ac-afb752d65ec4"
      unitRef="usd">65000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfMTMtMS0xLTEtMjg2OTQ0_aef6e029-9900-4324-bc6e-0b273dbc09c9"
      unitRef="usd">79000000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfMTMtMy0xLTEtMjg2OTQ0_7c18d82a-be15-4c38-9f92-c846ac8d79b9"
      unitRef="usd">46000000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:IncreaseDecreaseInReceivables
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfMTUtMS0xLTEtMjg2OTQ0_865bb25f-6732-4b0a-92f4-0cf29a5c5388"
      unitRef="usd">510000000</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInReceivables
      contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfMTUtMy0xLTEtMjg2OTQ0_7a389116-c6bd-44c2-9e73-24d0e8ec7a7e"
      unitRef="usd">1193000000</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfMTYtMS0xLTEtMjg2OTQ0_aef1ba4e-3fe6-457f-abd8-5fce012ac3d9"
      unitRef="usd">1012000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfMTYtMy0xLTEtMjg2OTQ0_4c97c433-70f9-4e75-9686-760fb2b13a5f"
      unitRef="usd">922000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfMTctMS0xLTEtMjg2OTQ0_2afe8f8a-678c-4a83-b0d5-bc930fe1a37e"
      unitRef="usd">2473000000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfMTctMy0xLTEtMjg2OTQ0_7a04c180-e10f-4882-8711-d00313744646"
      unitRef="usd">1121000000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfMTgtMS0xLTEtMjg2OTQ0_8bd7f972-ce6f-488e-bb74-a47c40c2e5b5"
      unitRef="usd">845000000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfMTgtMy0xLTEtMjg2OTQ0_0c234768-fee1-4e01-95a2-d122f85d3c76"
      unitRef="usd">206000000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfMTktMS0xLTEtMjg2OTQ0_38d9bb09-c251-43f5-9df5-72e737ca4e98"
      unitRef="usd">1981000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfMTktMy0xLTEtMjg2OTQ0_46bcc13b-3ebc-4b4b-8fde-cbaec4f116e7"
      unitRef="usd">130000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromDivestitureOfBusinesses
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfMjItMS0xLTEtMjg2OTQ0_36d60ceb-1451-47f1-8f25-045ec764d2f3"
      unitRef="usd">0</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <us-gaap:ProceedsFromDivestitureOfBusinesses
      contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfMjItMy0xLTEtMjg2OTQ0_a4872ac6-a0a1-47a8-bc63-76b8cc2822cb"
      unitRef="usd">923000000</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfMjMtMS0xLTEtMjg2OTQ0_c0f9137b-4df9-4170-aadc-22f173f9b4c8"
      unitRef="usd">10000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfMjMtMy0xLTEtMjg2OTQ0_f87eb946-50ed-4950-ac1c-71c4684a03fe"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfMjQtMS0xLTEtMjg2OTQ0_d7b6283a-878b-47af-9029-e67433ad59ab"
      unitRef="usd">264000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfMjQtMy0xLTEtMjg2OTQ0_c867619d-45bb-4a4f-a2f5-8f3b78ee1488"
      unitRef="usd">223000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfMjUtMS0xLTEtMjg2OTQ0_b34bcbca-96fb-4150-bc1b-1ca1e97addcc"
      unitRef="usd">2000000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfMjUtMy0xLTEtMjg2OTQ0_ff48f283-979a-47d7-bb9a-f41f1da6f300"
      unitRef="usd">11000000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <cah:Purchaseofavailableforsalesecuritiesandotherinvestments
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfMjYtMS0xLTEtMjg2OTQ0_de8acc23-36ad-44fe-90e7-e8c65e35c858"
      unitRef="usd">6000000</cah:Purchaseofavailableforsalesecuritiesandotherinvestments>
    <cah:Purchaseofavailableforsalesecuritiesandotherinvestments
      contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfMjYtMy0xLTEtMjg2OTQ0_251d6f36-5655-41a8-82e7-78009a587ce4"
      unitRef="usd">38000000</cah:Purchaseofavailableforsalesecuritiesandotherinvestments>
    <cah:Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfMjctMS0xLTEtMjg2OTQ0_1e804d15-e0f6-4ce0-8276-5489b348fd9f"
      unitRef="usd">1000000</cah:Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments>
    <cah:Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments
      contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfMjctMy0xLTEtMjg2OTQ0_9aa8e8db-c422-408e-921f-7d42a650dfa3"
      unitRef="usd">27000000</cah:Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments>
    <us-gaap:ProceedsFromHedgeInvestingActivities
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfMjgtMS0xLTEtMjg2OTQ0_5f76ed65-6ea9-4ff3-a314-c03a081ebded"
      unitRef="usd">29000000</us-gaap:ProceedsFromHedgeInvestingActivities>
    <us-gaap:ProceedsFromHedgeInvestingActivities
      contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfMjgtMy0xLTEtMjg2OTQ0_2993416f-1309-46c2-857e-4ec3fd0bad03"
      unitRef="usd">71000000</us-gaap:ProceedsFromHedgeInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfMjktMS0xLTEtMjg2OTQ0_720d3f56-e85e-4905-a97b-7a91d2a53965"
      unitRef="usd">-248000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfMjktMy0xLTEtMjg2OTQ0_b6da81e9-b6ca-4d68-b993-148f558823a9"
      unitRef="usd">771000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfMzQtMS0xLTEtMjg2OTQ0_c062f89a-93b4-4955-b87d-191df0163b74"
      unitRef="usd">571000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfMzQtMy0xLTEtMjg2OTQ0_0ca7978f-9066-406c-a075-67389e73493b"
      unitRef="usd">597000000</us-gaap:RepaymentsOfLongTermDebt>
    <cah:Netproceedstaxwithholdingsfromsharebasedcompensation
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfMzUtMS0xLTEtMjg2OTQ0_ff10d6bd-5a79-45e5-9c6b-6f3b0096e937"
      unitRef="usd">11000000</cah:Netproceedstaxwithholdingsfromsharebasedcompensation>
    <cah:Netproceedstaxwithholdingsfromsharebasedcompensation
      contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfMzUtMy0xLTEtMjg2OTQ0_af560d13-a106-4276-8754-d4ab98bd774e"
      unitRef="usd">-26000000</cah:Netproceedstaxwithholdingsfromsharebasedcompensation>
    <us-gaap:PaymentsOfDividendsCommonStock
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfMzctMS0xLTEtMjg2OTQ0_c3721e48-71f0-44c9-8248-3744716ceb89"
      unitRef="usd">399000000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:PaymentsOfDividendsCommonStock
      contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfMzctMy0xLTEtMjg2OTQ0_7ce1ebf9-592f-4566-90c7-02bcf090a647"
      unitRef="usd">425000000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfMzgtMS0xLTEtMjg2OTQ0_319511d2-e690-4bf0-8823-65bb881ced5e"
      unitRef="usd">1500000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfMzgtMy0xLTEtMjg2OTQ0_c3a6682a-46a7-4d3a-98f6-266776247b9c"
      unitRef="usd">1000000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfMzktMS0xLTEtMjg2OTQ0_a1f5aa90-814a-453a-9ea7-0be03c030e0e"
      unitRef="usd">-2459000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfMzktMy0xLTEtMjg2OTQ0_822b3ad8-5b8a-489d-8df2-8afad2640a44"
      unitRef="usd">-2048000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfNDEtMS0xLTEtMjg2OTQ0_36d00775-0ad3-4776-b4e9-b0690786b4e3"
      unitRef="usd">-1000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfNDEtMy0xLTEtMjg2OTQ0_abbb1b4c-d1c0-4cf3-9783-e44bc0c333c2"
      unitRef="usd">-13000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <cah:CashReclassifiedToAssetHeldForSale
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfNDItMS0xLTEtMjg2OTQ0_3c32f349-a613-4866-a51f-4c5d1bbc4879"
      unitRef="usd">0</cah:CashReclassifiedToAssetHeldForSale>
    <cah:CashReclassifiedToAssetHeldForSale
      contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfNDItMy0xLTEtMjg2OTQ0_a659b956-cdae-4cb9-a542-aabbb4e1f26a"
      unitRef="usd">109000000</cah:CashReclassifiedToAssetHeldForSale>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfNDQtMS0xLTEtMjg2OTQ0_996eb76a-b073-4e72-9788-314a5466989b"
      unitRef="usd">-727000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfNDQtMy0xLTEtMjg2OTQ0_59b54d3a-f02b-4fc8-bb64-7128a1c1a592"
      unitRef="usd">-1051000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ic217743408d440409a59220a0bf14e4c_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfNDUtMS0xLTEtMjg2OTQ0_43978c2e-b6d2-4479-8fc1-edd0eed2b085"
      unitRef="usd">4717000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i75b88320c8d34867830cda3167c67779_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfNDUtMy0xLTEtMjg2OTQ0_6698bc56-c9d5-4c90-a56d-e028633c3c37"
      unitRef="usd">3407000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfNDYtMS0xLTEtMjg2OTQ0_abfd1a24-db76-496f-b17b-06fa3e8b1b0e"
      unitRef="usd">3990000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if9769f07affb42f58d537c7029824f72_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183My9mcmFnOjBmMDYzOTk5MmUxYjQxNzZiYThhZjVmMzY2NjFlOTZiL3RhYmxlOmIyN2ViZDI3Y2NkYjQ0NGNhNmFjNjYzYTAzNTJhMzg1L3RhYmxlcmFuZ2U6YjI3ZWJkMjdjY2RiNDQ0Y2E2YWM2NjNhMDM1MmEzODVfNDYtMy0xLTEtMjg2OTQ0_0c64707d-8d15-4913-987c-e8a664f3716e"
      unitRef="usd">2356000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183OS9mcmFnOmNiZjgzZWVmYjI4MDQ3NDA5ODE1ZjJhNjE3YjdjNzkzL3RleHRyZWdpb246Y2JmODNlZWZiMjgwNDc0MDk4MTVmMmE2MTdiN2M3OTNfMjgwNA_b08232ca-2175-4b37-90b5-47f2dbb87443">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;1. Basis of Presentation and Summary of Significant Accounting Policies &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our condensed consolidated financial statements include the accounts of all majority-owned or consolidated subsidiaries, and all significant intercompany transactions and amounts have been eliminated. The results of businesses acquired or disposed of are included in the condensed consolidated financial statements from the date of the acquisition or up to the date of disposal, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;References to "we," "our," and similar pronouns in this Quarterly Report on Form 10-Q for the quarter ended March&#160;31, 2023 (this "Form 10-Q") refer to Cardinal Health, Inc. and its majority-owned or consolidated subsidiaries unless the context requires otherwise.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our fiscal year ends on June 30. References to fiscal 2023 and 2022 in these condensed consolidated financial statements are to the fiscal years ending or ended June&#160;30, 2023 and June&#160;30, 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our condensed consolidated financial statements have been prepared in accordance with the U.S. Securities and Exchange Commission ("SEC") instructions to Quarterly Reports on Form 10-Q and include the information and disclosures required by accounting principles generally accepted in the United States ("GAAP") for interim financial reporting. The preparation of financial statements in conformity with GAAP requires us to make estimates, judgments and assumptions that affect amounts reported in the condensed consolidated financial statements and accompanying notes. Actual amounts may differ from these estimated amounts. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In our opinion, all adjustments necessary for a fair presentation of the condensed consolidated financial statements have been included. Except as disclosed elsewhere in this Form 10-Q, all such adjustments are of a normal and recurring nature.&#160;In addition, financial results presented for this fiscal 2023 interim period are not necessarily indicative of the results that may be expected for the full fiscal year ending June&#160;30, 2023. These condensed consolidated financial statements are unaudited and, accordingly, should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual Report on Form 10-K for the fiscal year ended June 30, 2022 (our "2022 Form 10-K").&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Recently Issued Financial Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We assess the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board ("FASB") on our condensed consolidated financial statements as well as material updates to previous assessments, if any, from our fiscal 2022 Form 10-K. There were no accounting standards issued in fiscal 2023 that will have a material impact on our condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Recently Adopted Financial Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no new material accounting standards adopted during the nine months ended March 31, 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183OS9mcmFnOmNiZjgzZWVmYjI4MDQ3NDA5ODE1ZjJhNjE3YjdjNzkzL3RleHRyZWdpb246Y2JmODNlZWZiMjgwNDc0MDk4MTVmMmE2MTdiN2M3OTNfMjc5OQ_95f0f3ab-9e16-4684-80db-b82880ac9da9">&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our condensed consolidated financial statements include the accounts of all majority-owned or consolidated subsidiaries, and all significant intercompany transactions and amounts have been eliminated. The results of businesses acquired or disposed of are included in the condensed consolidated financial statements from the date of the acquisition or up to the date of disposal, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;References to "we," "our," and similar pronouns in this Quarterly Report on Form 10-Q for the quarter ended March&#160;31, 2023 (this "Form 10-Q") refer to Cardinal Health, Inc. and its majority-owned or consolidated subsidiaries unless the context requires otherwise.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our fiscal year ends on June 30. References to fiscal 2023 and 2022 in these condensed consolidated financial statements are to the fiscal years ending or ended June&#160;30, 2023 and June&#160;30, 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our condensed consolidated financial statements have been prepared in accordance with the U.S. Securities and Exchange Commission ("SEC") instructions to Quarterly Reports on Form 10-Q and include the information and disclosures required by accounting principles generally accepted in the United States ("GAAP") for interim financial reporting. The preparation of financial statements in conformity with GAAP requires us to make estimates, judgments and assumptions that affect amounts reported in the condensed consolidated financial statements and accompanying notes. Actual amounts may differ from these estimated amounts. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In our opinion, all adjustments necessary for a fair presentation of the condensed consolidated financial statements have been included. Except as disclosed elsewhere in this Form 10-Q, all such adjustments are of a normal and recurring nature.&#160;In addition, financial results presented for this fiscal 2023 interim period are not necessarily indicative of the results that may be expected for the full fiscal year ending June&#160;30, 2023. These condensed consolidated financial statements are unaudited and, accordingly, should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual Report on Form 10-K for the fiscal year ended June 30, 2022 (our "2022 Form 10-K").&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Recently Issued Financial Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We assess the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board ("FASB") on our condensed consolidated financial statements as well as material updates to previous assessments, if any, from our fiscal 2022 Form 10-K. There were no accounting standards issued in fiscal 2023 that will have a material impact on our condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Recently Adopted Financial Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no new material accounting standards adopted during the nine months ended March 31, 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y183OS9mcmFnOmNiZjgzZWVmYjI4MDQ3NDA5ODE1ZjJhNjE3YjdjNzkzL3RleHRyZWdpb246Y2JmODNlZWZiMjgwNDc0MDk4MTVmMmE2MTdiN2M3OTNfMjgwMw_8a01b5da-8dd3-4b25-baf1-030e3eb95ca5">&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Recently Issued Financial Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We assess the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board ("FASB") on our condensed consolidated financial statements as well as material updates to previous assessments, if any, from our fiscal 2022 Form 10-K. There were no accounting standards issued in fiscal 2023 that will have a material impact on our condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Recently Adopted Financial Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no new material accounting standards adopted during the nine months ended March 31, 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184Mi9mcmFnOmY0ZDBiYTMzM2M3YzRlZDJhYmIxMWRiY2FmZWQ4MDYzL3RleHRyZWdpb246ZjRkMGJhMzMzYzdjNGVkMmFiYjExZGJjYWZlZDgwNjNfNDgx_ef139275-cd19-425e-a3c7-c359195b1885">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;2. Divestitures&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2021, we sold the Cordis business to Hellman &amp;amp; Friedman for proceeds of $923 million, net of cash transferred, and we retained certain working capital accounts. Cardinal Health also retained product liability associated with lawsuits and claims related to the Cordis OptEase and TrapEase inferior vena cava ("IVC") filter products in the U.S. and Canada, as well as authority for these matters discussed in &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#i1d34fc4fc2424fbcb4837cc9f1c0665c_100" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note 6&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Cordis business operated within our Medical segment.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
    <us-gaap:ProceedsFromDivestitureOfBusinesses
      contextRef="if3c1b25895fb44c59c13bf46018fc577_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184Mi9mcmFnOmY0ZDBiYTMzM2M3YzRlZDJhYmIxMWRiY2FmZWQ4MDYzL3RleHRyZWdpb246ZjRkMGJhMzMzYzdjNGVkMmFiYjExZGJjYWZlZDgwNjNfOTA_b642a1e9-0bbb-4063-b222-9a6cbd879b4f"
      unitRef="usd">923000000</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184NS9mcmFnOjg5OTU5NGU4NGRlYjRlNjViNjQ4YzliODkyMzMxNWRlL3RleHRyZWdpb246ODk5NTk0ZTg0ZGViNGU2NWI2NDhjOWI4OTIzMzE1ZGVfMTA3OA_c29f514c-0ced-491c-a6e9-1333b14bfaf7">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;3. Restructuring and Employee Severance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes restructuring and employee severance:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.974%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.591%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.592%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee-related&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Facility exit and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;13&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total restructuring and employee severance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;16&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.974%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.591%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.592%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee-related&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;32&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Facility exit and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;30&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total restructuring and employee severance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;62&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Employee-related costs primarily consist of termination benefits provided to employees who have been involuntarily terminated, duplicate payroll costs and retention bonuses incurred during transition periods. Facility exit and other costs primarily consist of project consulting fees, accelerated depreciation, professional, project management and other service fees to support divestitures, costs associated with vacant facilities, and certain other divestiture-related costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restructuring and employee severance costs during the three and nine months ended March&#160;31, 2023 and March 31, 2022 were primarily related to the implementation of certain enterprise-wide cost-savings measures and the divestiture of the Cordis business. During the three and nine months ended March 31, 2022, restructuring also included costs related to decreasing our overall office space. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes activity related to liabilities associated with restructuring and employee severance:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.237%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.237%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.241%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee-&lt;br/&gt;Related Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Facility Exit&lt;br/&gt;and Other Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;66&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;37&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payments and other adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(51)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;49&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;52&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184NS9mcmFnOjg5OTU5NGU4NGRlYjRlNjViNjQ4YzliODkyMzMxNWRlL3RleHRyZWdpb246ODk5NTk0ZTg0ZGViNGU2NWI2NDhjOWI4OTIzMzE1ZGVfMTA3Mw_34921057-e925-4a4f-ae12-a23bdb145a1a">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes restructuring and employee severance:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.974%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.591%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.592%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee-related&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Facility exit and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;13&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total restructuring and employee severance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;16&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.974%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.591%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.592%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee-related&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;32&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Facility exit and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;30&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total restructuring and employee severance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;62&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock>
    <us-gaap:SeveranceCosts1
      contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184NS9mcmFnOjg5OTU5NGU4NGRlYjRlNjViNjQ4YzliODkyMzMxNWRlL3RhYmxlOmVjMWZjMDAzMzA2MTRlNDQ4ODU4MGM4MTczYjU4YWMxL3RhYmxlcmFuZ2U6ZWMxZmMwMDMzMDYxNGU0NDg4NTgwYzgxNzNiNThhYzFfMi0xLTEtMS0yODY5NDQ_18e2157c-b67d-47c0-9c43-2868962e89a4"
      unitRef="usd">3000000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184NS9mcmFnOjg5OTU5NGU4NGRlYjRlNjViNjQ4YzliODkyMzMxNWRlL3RhYmxlOmVjMWZjMDAzMzA2MTRlNDQ4ODU4MGM4MTczYjU4YWMxL3RhYmxlcmFuZ2U6ZWMxZmMwMDMzMDYxNGU0NDg4NTgwYzgxNzNiNThhYzFfMi0zLTEtMS0yODY5NDQ_eff99c7a-654f-4ff1-957b-91db50579c54"
      unitRef="usd">12000000</us-gaap:SeveranceCosts1>
    <cah:FacilityExitAndOtherCosts
      contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184NS9mcmFnOjg5OTU5NGU4NGRlYjRlNjViNjQ4YzliODkyMzMxNWRlL3RhYmxlOmVjMWZjMDAzMzA2MTRlNDQ4ODU4MGM4MTczYjU4YWMxL3RhYmxlcmFuZ2U6ZWMxZmMwMDMzMDYxNGU0NDg4NTgwYzgxNzNiNThhYzFfMy0xLTEtMS0yODY5NDQ_045bb275-ff7b-4552-9aca-1683a89e2a0a"
      unitRef="usd">13000000</cah:FacilityExitAndOtherCosts>
    <cah:FacilityExitAndOtherCosts
      contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184NS9mcmFnOjg5OTU5NGU4NGRlYjRlNjViNjQ4YzliODkyMzMxNWRlL3RhYmxlOmVjMWZjMDAzMzA2MTRlNDQ4ODU4MGM4MTczYjU4YWMxL3RhYmxlcmFuZ2U6ZWMxZmMwMDMzMDYxNGU0NDg4NTgwYzgxNzNiNThhYzFfMy0zLTEtMS0yODY5NDQ_451e5757-7153-41c7-948e-0df412a2bff9"
      unitRef="usd">19000000</cah:FacilityExitAndOtherCosts>
    <us-gaap:RestructuringCharges
      contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184NS9mcmFnOjg5OTU5NGU4NGRlYjRlNjViNjQ4YzliODkyMzMxNWRlL3RhYmxlOmVjMWZjMDAzMzA2MTRlNDQ4ODU4MGM4MTczYjU4YWMxL3RhYmxlcmFuZ2U6ZWMxZmMwMDMzMDYxNGU0NDg4NTgwYzgxNzNiNThhYzFfNC0xLTEtMS0yODY5NDQ_9691eb31-1666-491f-8980-b3fd30d429a0"
      unitRef="usd">16000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184NS9mcmFnOjg5OTU5NGU4NGRlYjRlNjViNjQ4YzliODkyMzMxNWRlL3RhYmxlOmVjMWZjMDAzMzA2MTRlNDQ4ODU4MGM4MTczYjU4YWMxL3RhYmxlcmFuZ2U6ZWMxZmMwMDMzMDYxNGU0NDg4NTgwYzgxNzNiNThhYzFfNC0zLTEtMS0yODY5NDQ_dde05ef6-20d9-41f6-8f00-4b8cf98e8344"
      unitRef="usd">31000000</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184NS9mcmFnOjg5OTU5NGU4NGRlYjRlNjViNjQ4YzliODkyMzMxNWRlL3RhYmxlOjVhMTc0MTkxYzJkOTQ1OGViMjY1YjdjNDkyMGViMmNjL3RhYmxlcmFuZ2U6NWExNzQxOTFjMmQ5NDU4ZWIyNjViN2M0OTIwZWIyY2NfMi0xLTEtMS0yODY5NDQ_7681d990-8198-4dcf-9739-91d3124cc082"
      unitRef="usd">32000000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184NS9mcmFnOjg5OTU5NGU4NGRlYjRlNjViNjQ4YzliODkyMzMxNWRlL3RhYmxlOjVhMTc0MTkxYzJkOTQ1OGViMjY1YjdjNDkyMGViMmNjL3RhYmxlcmFuZ2U6NWExNzQxOTFjMmQ5NDU4ZWIyNjViN2M0OTIwZWIyY2NfMi0zLTEtMS0yODY5NDQ_d7552040-5862-4169-b249-e252cce958b5"
      unitRef="usd">22000000</us-gaap:SeveranceCosts1>
    <cah:FacilityExitAndOtherCosts
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184NS9mcmFnOjg5OTU5NGU4NGRlYjRlNjViNjQ4YzliODkyMzMxNWRlL3RhYmxlOjVhMTc0MTkxYzJkOTQ1OGViMjY1YjdjNDkyMGViMmNjL3RhYmxlcmFuZ2U6NWExNzQxOTFjMmQ5NDU4ZWIyNjViN2M0OTIwZWIyY2NfMy0xLTEtMS0yODY5NDQ_59c0807c-9b87-4934-b8d8-ae0901e04c89"
      unitRef="usd">30000000</cah:FacilityExitAndOtherCosts>
    <cah:FacilityExitAndOtherCosts
      contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184NS9mcmFnOjg5OTU5NGU4NGRlYjRlNjViNjQ4YzliODkyMzMxNWRlL3RhYmxlOjVhMTc0MTkxYzJkOTQ1OGViMjY1YjdjNDkyMGViMmNjL3RhYmxlcmFuZ2U6NWExNzQxOTFjMmQ5NDU4ZWIyNjViN2M0OTIwZWIyY2NfMy0zLTEtMS0yODY5NDQ_575e0655-23a5-4333-819a-907fd0bb7329"
      unitRef="usd">34000000</cah:FacilityExitAndOtherCosts>
    <us-gaap:RestructuringCharges
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184NS9mcmFnOjg5OTU5NGU4NGRlYjRlNjViNjQ4YzliODkyMzMxNWRlL3RhYmxlOjVhMTc0MTkxYzJkOTQ1OGViMjY1YjdjNDkyMGViMmNjL3RhYmxlcmFuZ2U6NWExNzQxOTFjMmQ5NDU4ZWIyNjViN2M0OTIwZWIyY2NfNC0xLTEtMS0yODY5NDQ_dc57b4d0-48ef-4098-831d-bb26000ff89f"
      unitRef="usd">62000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184NS9mcmFnOjg5OTU5NGU4NGRlYjRlNjViNjQ4YzliODkyMzMxNWRlL3RhYmxlOjVhMTc0MTkxYzJkOTQ1OGViMjY1YjdjNDkyMGViMmNjL3RhYmxlcmFuZ2U6NWExNzQxOTFjMmQ5NDU4ZWIyNjViN2M0OTIwZWIyY2NfNC0zLTEtMS0yODY5NDQ_d2c210a6-3e41-4759-97b3-99d1ffee5297"
      unitRef="usd">56000000</us-gaap:RestructuringCharges>
    <us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184NS9mcmFnOjg5OTU5NGU4NGRlYjRlNjViNjQ4YzliODkyMzMxNWRlL3RleHRyZWdpb246ODk5NTk0ZTg0ZGViNGU2NWI2NDhjOWI4OTIzMzE1ZGVfMTA1OA_6b6c05e7-911e-4562-af9d-e68d19de534b">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes activity related to liabilities associated with restructuring and employee severance:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.237%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.237%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.241%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee-&lt;br/&gt;Related Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Facility Exit&lt;br/&gt;and Other Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;66&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;37&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payments and other adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(51)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;49&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;52&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock>
    <us-gaap:RestructuringReserve
      contextRef="ice5ace5e97dc4e54b4c8d923f4a0967c_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184NS9mcmFnOjg5OTU5NGU4NGRlYjRlNjViNjQ4YzliODkyMzMxNWRlL3RhYmxlOjA5YWJkOTk2MzkwMzQ3NzRhN2ExM2ViNzA4OTdkMjRlL3RhYmxlcmFuZ2U6MDlhYmQ5OTYzOTAzNDc3NGE3YTEzZWI3MDg5N2QyNGVfMS0xLTEtMS0yODY5NDQ_a1dc553b-823e-468c-b740-66e5dd2ad071"
      unitRef="usd">56000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="iba8dcdc7b0364befb6c48df592c69089_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184NS9mcmFnOjg5OTU5NGU4NGRlYjRlNjViNjQ4YzliODkyMzMxNWRlL3RhYmxlOjA5YWJkOTk2MzkwMzQ3NzRhN2ExM2ViNzA4OTdkMjRlL3RhYmxlcmFuZ2U6MDlhYmQ5OTYzOTAzNDc3NGE3YTEzZWI3MDg5N2QyNGVfMS0zLTEtMS0yODY5NDQ_47508a1e-4eb5-43c0-b34d-2d50819a9013"
      unitRef="usd">10000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="ic217743408d440409a59220a0bf14e4c_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184NS9mcmFnOjg5OTU5NGU4NGRlYjRlNjViNjQ4YzliODkyMzMxNWRlL3RhYmxlOjA5YWJkOTk2MzkwMzQ3NzRhN2ExM2ViNzA4OTdkMjRlL3RhYmxlcmFuZ2U6MDlhYmQ5OTYzOTAzNDc3NGE3YTEzZWI3MDg5N2QyNGVfMS01LTEtMS0yODY5NDQ_0c204b2c-b110-42ba-87e7-fa76456b9091"
      unitRef="usd">66000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringCosts
      contextRef="i763ae6a550604d44b1d9024df65e87a4_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184NS9mcmFnOjg5OTU5NGU4NGRlYjRlNjViNjQ4YzliODkyMzMxNWRlL3RhYmxlOjA5YWJkOTk2MzkwMzQ3NzRhN2ExM2ViNzA4OTdkMjRlL3RhYmxlcmFuZ2U6MDlhYmQ5OTYzOTAzNDc3NGE3YTEzZWI3MDg5N2QyNGVfMi0xLTEtMS0yODY5NDQ_254100d5-aee2-4127-b31b-4d8fec0affe5"
      unitRef="usd">29000000</us-gaap:RestructuringCosts>
    <us-gaap:RestructuringCosts
      contextRef="i013227884afa401a8a0fac648dda0a66_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184NS9mcmFnOjg5OTU5NGU4NGRlYjRlNjViNjQ4YzliODkyMzMxNWRlL3RhYmxlOjA5YWJkOTk2MzkwMzQ3NzRhN2ExM2ViNzA4OTdkMjRlL3RhYmxlcmFuZ2U6MDlhYmQ5OTYzOTAzNDc3NGE3YTEzZWI3MDg5N2QyNGVfMi0zLTEtMS0yODY5NDQ_ecc5ed7c-97f8-499e-bcdb-631cc2d5c7bb"
      unitRef="usd">8000000</us-gaap:RestructuringCosts>
    <us-gaap:RestructuringCosts
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184NS9mcmFnOjg5OTU5NGU4NGRlYjRlNjViNjQ4YzliODkyMzMxNWRlL3RhYmxlOjA5YWJkOTk2MzkwMzQ3NzRhN2ExM2ViNzA4OTdkMjRlL3RhYmxlcmFuZ2U6MDlhYmQ5OTYzOTAzNDc3NGE3YTEzZWI3MDg5N2QyNGVfMi01LTEtMS0yODY5NDQ_a6806b4c-9b1f-48dd-8e4c-11c621e00782"
      unitRef="usd">37000000</us-gaap:RestructuringCosts>
    <us-gaap:PaymentsForRestructuring
      contextRef="i763ae6a550604d44b1d9024df65e87a4_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184NS9mcmFnOjg5OTU5NGU4NGRlYjRlNjViNjQ4YzliODkyMzMxNWRlL3RhYmxlOjA5YWJkOTk2MzkwMzQ3NzRhN2ExM2ViNzA4OTdkMjRlL3RhYmxlcmFuZ2U6MDlhYmQ5OTYzOTAzNDc3NGE3YTEzZWI3MDg5N2QyNGVfMy0xLTEtMS0yODY5NDQ_892d3fa2-16b8-4d0e-8a33-05312dbbf586"
      unitRef="usd">36000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="i013227884afa401a8a0fac648dda0a66_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184NS9mcmFnOjg5OTU5NGU4NGRlYjRlNjViNjQ4YzliODkyMzMxNWRlL3RhYmxlOjA5YWJkOTk2MzkwMzQ3NzRhN2ExM2ViNzA4OTdkMjRlL3RhYmxlcmFuZ2U6MDlhYmQ5OTYzOTAzNDc3NGE3YTEzZWI3MDg5N2QyNGVfMy0zLTEtMS0yODY5NDQ_c2f0d135-f07b-40fa-abc9-ced8f2537267"
      unitRef="usd">15000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184NS9mcmFnOjg5OTU5NGU4NGRlYjRlNjViNjQ4YzliODkyMzMxNWRlL3RhYmxlOjA5YWJkOTk2MzkwMzQ3NzRhN2ExM2ViNzA4OTdkMjRlL3RhYmxlcmFuZ2U6MDlhYmQ5OTYzOTAzNDc3NGE3YTEzZWI3MDg5N2QyNGVfMy01LTEtMS0yODY5NDQ_38b23ca4-b8a8-4afb-ab06-43aefedf2e9b"
      unitRef="usd">51000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserve
      contextRef="ie317acb3d5c44ca0bd1298978e77bb10_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184NS9mcmFnOjg5OTU5NGU4NGRlYjRlNjViNjQ4YzliODkyMzMxNWRlL3RhYmxlOjA5YWJkOTk2MzkwMzQ3NzRhN2ExM2ViNzA4OTdkMjRlL3RhYmxlcmFuZ2U6MDlhYmQ5OTYzOTAzNDc3NGE3YTEzZWI3MDg5N2QyNGVfNC0xLTEtMS0yODY5NDQ_e114c534-fe6c-4f8f-900d-01865fc91bdf"
      unitRef="usd">49000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i09619e867c3347d5b88ff001fdae470b_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184NS9mcmFnOjg5OTU5NGU4NGRlYjRlNjViNjQ4YzliODkyMzMxNWRlL3RhYmxlOjA5YWJkOTk2MzkwMzQ3NzRhN2ExM2ViNzA4OTdkMjRlL3RhYmxlcmFuZ2U6MDlhYmQ5OTYzOTAzNDc3NGE3YTEzZWI3MDg5N2QyNGVfNC0zLTEtMS0yODY5NDQ_cb4759c9-c21d-4afd-a4e7-54137b6bd7b0"
      unitRef="usd">3000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184NS9mcmFnOjg5OTU5NGU4NGRlYjRlNjViNjQ4YzliODkyMzMxNWRlL3RhYmxlOjA5YWJkOTk2MzkwMzQ3NzRhN2ExM2ViNzA4OTdkMjRlL3RhYmxlcmFuZ2U6MDlhYmQ5OTYzOTAzNDc3NGE3YTEzZWI3MDg5N2QyNGVfNC01LTEtMS0yODY5NDQ_bc597167-ed45-41da-a222-49d1d64c3a1d"
      unitRef="usd">52000000</us-gaap:RestructuringReserve>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RleHRyZWdpb246YjY4ZTgyNTRjMTc4NDc2ZWJmZmEzNTI5MzQ3MmQ3MzNfMjg2Nw_5bb01d82-5101-4690-a7f3-e285b813071c">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;4. Goodwill and Other Intangible Assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in the carrying amount of goodwill by segment and in total:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.801%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.517%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,855&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill acquired, net of purchase price adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;13&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustments and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(863)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(863)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,673&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,327&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;At March 31, 2023 and June 30, 2022, the Medical segment accumulated goodwill impairment loss was $4.4 billion and $3.5&#160;billion, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to changes in our long-term financial plan assumptions made during the three months ended March&#160;31, 2023, we elected to bypass the qualitative assessment and perform quantitative goodwill impairment testing for the Medical Unit. The fair value of the reporting unit was estimated to be approximately 4 percent in excess of its carrying value, primarily driven by a lower discount rate as described below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We performed quantitative goodwill impairment testing for the Medical Unit at December 31, 2022 and September 30, 2022, which resulted in pre-tax goodwill impairment charges of $709 million and $154 million, respectively. The impairment charge recognized in the second quarter was driven by certain reductions in our long-term financial plan assumptions, and the impairment charge recognized in the first quarter was driven by an increase in the discount rate primarily due to an increase in the risk-free interest rate. The cumulative pre-tax goodwill impairment charges of $863 million were recognized in impairments and (gain)/loss on disposal of assets, net in our condensed consolidated statements of earnings/(loss) for the nine months ended March&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our determinations of the estimated fair value of the Medical Unit at March&#160;31, 2023, December 31, 2022 and September 30, 2022 were based on a combination of the income-based approach (using a terminal growth rate of 2 percent), and the market-based approaches. For the income-based approach, we used discount rates of 10 percent, 10.5 percent and 10.5 percent for each quarter, respectively. The decrease in the discount rate for the interim testing performed at March&#160;31, 2023 was primarily due to a decrease in the risk-free interest rate. Additionally, we assigned a weighting of 80 percent to the discounted cash flow method, 10 percent to the guideline public company method, and 10 percent to the guideline transaction method. Our fair value estimates utilize significant unobservable inputs and thus represent Level 3 fair value measurements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2022 and December 31, 2021, we performed quantitative goodwill impairment testing for the Medical Unit. This quantitative testing resulted in the carrying &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;amount of the Medical Unit exceeding the fair value, resulting in a pre-tax impairment charges of $474&#160;million and $1.3&#160;billion recorded during the three months ended March 31, 2022 and December 31, 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Other Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize other intangible assets by class at:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.070%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.070%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gross&lt;br/&gt;Intangible&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net&lt;br/&gt;Intangible&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted- Average Remaining Amortization Period (Years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Indefinite-life intangibles:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Trademarks and patents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;11&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;11&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total indefinite-life intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;11&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;11&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Definite-life intangibles:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,235&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,267&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;968&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Trademarks, trade names and patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;550&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;376&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;174&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Developed technology and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,037&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;623&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;414&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total definite-life intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,822&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,266&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,556&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total other intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,833&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,266&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,567&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.308%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.643%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.312%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gross&lt;br/&gt;Intangible&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net&lt;br/&gt;Intangible&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Indefinite-life intangibles:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Trademarks and patents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total indefinite-life intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Definite-life intangibles:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Trademarks, trade names and patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Developed technology and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total definite-life intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total other intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;Total amortization of intangible assets was $69 million and $78 million for the three months ended March 31, 2023 and 2022, respectively, and $211 million and $235 million for the nine months ended March&#160;31, 2023 and 2022, respectively. Estimated annual amortization of intangible assets for the remainder of fiscal 2023 through 2027 is as follows: $71 million, $261 million, $236 million, $209 million and $177 million.</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RleHRyZWdpb246YjY4ZTgyNTRjMTc4NDc2ZWJmZmEzNTI5MzQ3MmQ3MzNfMjg4Mg_f0e5f4b1-3d3e-46c0-824e-63fd7dcaddeb">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in the carrying amount of goodwill by segment and in total:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.801%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.517%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,855&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill acquired, net of purchase price adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;13&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustments and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(863)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(863)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,673&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,327&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;At March 31, 2023 and June 30, 2022, the Medical segment accumulated goodwill impairment loss was $4.4 billion and $3.5&#160;billion, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="i043b921434d34afe9a3cdb74397ed704_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmJlMWI4MDIzZTQ3YTRhNzZhZmRjNTM3ZDgwNzhmYmI3L3RhYmxlcmFuZ2U6YmUxYjgwMjNlNDdhNGE3NmFmZGM1MzdkODA3OGZiYjdfMS0xLTEtMS0yODY5NDQ_a6959a7d-50ff-4ed1-bc09-0b49e3a65012"
      unitRef="usd">2673000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i8e6a4d2c754046f2bba40f47b73897d8_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmJlMWI4MDIzZTQ3YTRhNzZhZmRjNTM3ZDgwNzhmYmI3L3RhYmxlcmFuZ2U6YmUxYjgwMjNlNDdhNGE3NmFmZGM1MzdkODA3OGZiYjdfMS0zLTEtMS0yODY5NDQ_09f29b43-d69e-48a0-b291-fade332deb67"
      unitRef="usd">3182000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ic217743408d440409a59220a0bf14e4c_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmJlMWI4MDIzZTQ3YTRhNzZhZmRjNTM3ZDgwNzhmYmI3L3RhYmxlcmFuZ2U6YmUxYjgwMjNlNDdhNGE3NmFmZGM1MzdkODA3OGZiYjdfMS01LTEtMS0yODY5NDQ_efe90a12-045e-4904-9d53-25c66f7adfb5"
      unitRef="usd">5855000000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i69ad0b82db074919b5c03d2459c3d06b_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmJlMWI4MDIzZTQ3YTRhNzZhZmRjNTM3ZDgwNzhmYmI3L3RhYmxlcmFuZ2U6YmUxYjgwMjNlNDdhNGE3NmFmZGM1MzdkODA3OGZiYjdfMi0xLTEtMS0yODY5NDQ_b253d0c7-0a85-4b88-a68f-b773094ff32c"
      unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="ia6e92bcd32f84df9ab392ad9accbdacd_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmJlMWI4MDIzZTQ3YTRhNzZhZmRjNTM3ZDgwNzhmYmI3L3RhYmxlcmFuZ2U6YmUxYjgwMjNlNDdhNGE3NmFmZGM1MzdkODA3OGZiYjdfMi0zLTEtMS0yODY5NDQ_aae65860-c638-4a32-872a-3f6ed0f96488"
      unitRef="usd">13000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmJlMWI4MDIzZTQ3YTRhNzZhZmRjNTM3ZDgwNzhmYmI3L3RhYmxlcmFuZ2U6YmUxYjgwMjNlNDdhNGE3NmFmZGM1MzdkODA3OGZiYjdfMi01LTEtMS0yODY5NDQ_e90ad1c2-8f36-4ac3-8b15-459c6801eb83"
      unitRef="usd">13000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i69ad0b82db074919b5c03d2459c3d06b_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmJlMWI4MDIzZTQ3YTRhNzZhZmRjNTM3ZDgwNzhmYmI3L3RhYmxlcmFuZ2U6YmUxYjgwMjNlNDdhNGE3NmFmZGM1MzdkODA3OGZiYjdfMy0xLTEtMS0yODY5NDQ_63c85d72-7674-4ebe-9c91-9468998a914f"
      unitRef="usd">0</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="ia6e92bcd32f84df9ab392ad9accbdacd_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmJlMWI4MDIzZTQ3YTRhNzZhZmRjNTM3ZDgwNzhmYmI3L3RhYmxlcmFuZ2U6YmUxYjgwMjNlNDdhNGE3NmFmZGM1MzdkODA3OGZiYjdfMy0zLTEtMS0yODY5NDQ_a4107f1e-ea53-455c-8dce-ed277ea32ee2"
      unitRef="usd">-5000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmJlMWI4MDIzZTQ3YTRhNzZhZmRjNTM3ZDgwNzhmYmI3L3RhYmxlcmFuZ2U6YmUxYjgwMjNlNDdhNGE3NmFmZGM1MzdkODA3OGZiYjdfMy01LTEtMS0yODY5NDQ_7507ca6a-1678-4031-91dd-27f51c96ccd7"
      unitRef="usd">-5000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i69ad0b82db074919b5c03d2459c3d06b_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmJlMWI4MDIzZTQ3YTRhNzZhZmRjNTM3ZDgwNzhmYmI3L3RhYmxlcmFuZ2U6YmUxYjgwMjNlNDdhNGE3NmFmZGM1MzdkODA3OGZiYjdfNC0xLTEtMS0yODY5NDQ_4a206955-6791-4422-995e-a2ad4597d61f"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="ia6e92bcd32f84df9ab392ad9accbdacd_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmJlMWI4MDIzZTQ3YTRhNzZhZmRjNTM3ZDgwNzhmYmI3L3RhYmxlcmFuZ2U6YmUxYjgwMjNlNDdhNGE3NmFmZGM1MzdkODA3OGZiYjdfNC0zLTEtMS0yODY5NDQ_954d80c8-80ff-4960-bcb3-392797821886"
      unitRef="usd">863000000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmJlMWI4MDIzZTQ3YTRhNzZhZmRjNTM3ZDgwNzhmYmI3L3RhYmxlcmFuZ2U6YmUxYjgwMjNlNDdhNGE3NmFmZGM1MzdkODA3OGZiYjdfNC01LTEtMS0yODY5NDQ_cdfd9d97-95a1-4b4c-a9a3-de161c9da387"
      unitRef="usd">863000000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:Goodwill
      contextRef="ib4007268cc1f496d86090b7230f7a94b_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmJlMWI4MDIzZTQ3YTRhNzZhZmRjNTM3ZDgwNzhmYmI3L3RhYmxlcmFuZ2U6YmUxYjgwMjNlNDdhNGE3NmFmZGM1MzdkODA3OGZiYjdfNS0xLTEtMS0yODY5NDQ_7d688352-be3e-4cca-86af-de770f817998"
      unitRef="usd">2673000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i6cd27b73a20c437aa0e84891f2ea5dde_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmJlMWI4MDIzZTQ3YTRhNzZhZmRjNTM3ZDgwNzhmYmI3L3RhYmxlcmFuZ2U6YmUxYjgwMjNlNDdhNGE3NmFmZGM1MzdkODA3OGZiYjdfNS0zLTEtMS0yODY5NDQ_c29e5a86-6015-4245-9322-133a594cdb02"
      unitRef="usd">2327000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmJlMWI4MDIzZTQ3YTRhNzZhZmRjNTM3ZDgwNzhmYmI3L3RhYmxlcmFuZ2U6YmUxYjgwMjNlNDdhNGE3NmFmZGM1MzdkODA3OGZiYjdfNS01LTEtMS0yODY5NDQ_0b047b90-1348-42dd-a2f2-0a1b9b46226c"
      unitRef="usd">5000000000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="i6cd27b73a20c437aa0e84891f2ea5dde_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RleHRyZWdpb246YjY4ZTgyNTRjMTc4NDc2ZWJmZmEzNTI5MzQ3MmQ3MzNfMjI1_f187fac3-8b72-468e-9eed-58e33db084d8"
      unitRef="usd">4400000000</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="i8e6a4d2c754046f2bba40f47b73897d8_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RleHRyZWdpb246YjY4ZTgyNTRjMTc4NDc2ZWJmZmEzNTI5MzQ3MmQ3MzNfMjMy_67051717-e79c-4066-a95a-58ce74ffe812"
      unitRef="usd">3500000000</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount
      contextRef="ic49dbe67bc04485785ead3e50d2ef7b5_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RleHRyZWdpb246YjY4ZTgyNTRjMTc4NDc2ZWJmZmEzNTI5MzQ3MmQ3MzNfMzg0ODI5MDcwMzUxMw_f0df1588-ce64-47c4-a18f-620ae11d79ff"
      unitRef="rate">0.04</us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i984de195edf647df8b5c417d95fb895e_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RleHRyZWdpb246YjY4ZTgyNTRjMTc4NDc2ZWJmZmEzNTI5MzQ3MmQ3MzNfMzg0ODI5MDcwMTY0MQ_4d080f98-4819-4e91-8994-33be604d9d4d"
      unitRef="usd">709000000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i2c44423c33b44f2b91261015274103c9_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RleHRyZWdpb246YjY4ZTgyNTRjMTc4NDc2ZWJmZmEzNTI5MzQ3MmQ3MzNfMzg0ODI5MDcwMTYyNA_9d3e5b1c-bd76-44dd-b501-ac57e2ab19c1"
      unitRef="usd">154000000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="ia6e92bcd32f84df9ab392ad9accbdacd_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RleHRyZWdpb246YjY4ZTgyNTRjMTc4NDc2ZWJmZmEzNTI5MzQ3MmQ3MzNfMTIzNA_954d80c8-80ff-4960-bcb3-392797821886"
      unitRef="usd">863000000</us-gaap:GoodwillImpairmentLoss>
    <cah:TerminalGrowthRateFairValueInput
      contextRef="i4173ed46aed24fea930a4ba9e851147e_I20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RleHRyZWdpb246YjY4ZTgyNTRjMTc4NDc2ZWJmZmEzNTI5MzQ3MmQ3MzNfMTYwMA_825b0ca2-657a-4c57-98b8-bbf70d081b93"
      unitRef="number">0.02</cah:TerminalGrowthRateFairValueInput>
    <cah:TerminalGrowthRateFairValueInput
      contextRef="i6f07ddd2def943ba8d68405800839948_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RleHRyZWdpb246YjY4ZTgyNTRjMTc4NDc2ZWJmZmEzNTI5MzQ3MmQ3MzNfMTYwMA_965b0571-5c62-490e-9082-0a0e4d265534"
      unitRef="number">0.02</cah:TerminalGrowthRateFairValueInput>
    <cah:TerminalGrowthRateFairValueInput
      contextRef="ic49dbe67bc04485785ead3e50d2ef7b5_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RleHRyZWdpb246YjY4ZTgyNTRjMTc4NDc2ZWJmZmEzNTI5MzQ3MmQ3MzNfMTYwMA_c350ead7-2c54-4dbe-b65d-a1ab174a68ee"
      unitRef="number">0.02</cah:TerminalGrowthRateFairValueInput>
    <cah:DiscountRateFairValueInput
      contextRef="ic49dbe67bc04485785ead3e50d2ef7b5_I20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RleHRyZWdpb246YjY4ZTgyNTRjMTc4NDc2ZWJmZmEzNTI5MzQ3MmQ3MzNfMTY0OTI2NzQ0NDk2NQ_672510ff-e347-48f2-aae6-c7b26175547b"
      unitRef="number">0.10</cah:DiscountRateFairValueInput>
    <cah:DiscountRateFairValueInput
      contextRef="i4173ed46aed24fea930a4ba9e851147e_I20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RleHRyZWdpb246YjY4ZTgyNTRjMTc4NDc2ZWJmZmEzNTI5MzQ3MmQ3MzNfMzg0ODI5MDcwMTY2NA_65c77e7e-f80d-49a9-8fd7-9c7945a9f896"
      unitRef="number">0.105</cah:DiscountRateFairValueInput>
    <cah:DiscountRateFairValueInput
      contextRef="i6f07ddd2def943ba8d68405800839948_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RleHRyZWdpb246YjY4ZTgyNTRjMTc4NDc2ZWJmZmEzNTI5MzQ3MmQ3MzNfMzg0ODI5MDcwMTY2NA_bd33a346-219b-4a72-aa1f-8a6272460e3e"
      unitRef="number">0.105</cah:DiscountRateFairValueInput>
    <cah:DiscountRateFairValueInput
      contextRef="i4173ed46aed24fea930a4ba9e851147e_I20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RleHRyZWdpb246YjY4ZTgyNTRjMTc4NDc2ZWJmZmEzNTI5MzQ3MmQ3MzNfMTY5NQ_65c77e7e-f80d-49a9-8fd7-9c7945a9f896"
      unitRef="number">0.105</cah:DiscountRateFairValueInput>
    <cah:DiscountRateFairValueInput
      contextRef="i6f07ddd2def943ba8d68405800839948_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RleHRyZWdpb246YjY4ZTgyNTRjMTc4NDc2ZWJmZmEzNTI5MzQ3MmQ3MzNfMTY5NQ_bd33a346-219b-4a72-aa1f-8a6272460e3e"
      unitRef="number">0.105</cah:DiscountRateFairValueInput>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i8537355abc114656ba7b11fcb58c1278_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RleHRyZWdpb246YjY4ZTgyNTRjMTc4NDc2ZWJmZmEzNTI5MzQ3MmQ3MzNfMzg0ODI5MDcwMTc2Mw_8ea377a7-7ff4-4b82-864d-23af7420e03a"
      unitRef="usd">474000000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i31378af16d0d40428cd5734ee81d07a0_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RleHRyZWdpb246YjY4ZTgyNTRjMTc4NDc2ZWJmZmEzNTI5MzQ3MmQ3MzNfMzg0ODI5MDcwMTc3OA_43aa9ce7-6522-429c-9a4d-a15930c1009f"
      unitRef="usd">1300000000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RleHRyZWdpb246YjY4ZTgyNTRjMTc4NDc2ZWJmZmEzNTI5MzQ3MmQ3MzNfMjg5OA_d72be7e8-93de-44f0-b69a-0386dbd16b8c">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize other intangible assets by class at:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.070%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.070%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gross&lt;br/&gt;Intangible&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net&lt;br/&gt;Intangible&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted- Average Remaining Amortization Period (Years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Indefinite-life intangibles:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Trademarks and patents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;11&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;11&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total indefinite-life intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;11&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;11&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Definite-life intangibles:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,235&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,267&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;968&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Trademarks, trade names and patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;550&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;376&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;174&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Developed technology and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,037&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;623&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;414&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total definite-life intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,822&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,266&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,556&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total other intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,833&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,266&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,567&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.308%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.643%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.312%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gross&lt;br/&gt;Intangible&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net&lt;br/&gt;Intangible&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Indefinite-life intangibles:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Trademarks and patents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total indefinite-life intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Definite-life intangibles:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Trademarks, trade names and patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Developed technology and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total definite-life intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total other intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i3002eff021944cff84e19dddc37565d6_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmQwMDc1ZDRjNzg0ZTQwZjA4Mjk1NTM0NzU1NjgzNmJmL3RhYmxlcmFuZ2U6ZDAwNzVkNGM3ODRlNDBmMDgyOTU1MzQ3NTU2ODM2YmZfMy0xLTEtMS0yODY5NDQ_7716ea35-8d6b-47e0-a0de-f745f89e5e4c"
      unitRef="usd">11000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i3002eff021944cff84e19dddc37565d6_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmQwMDc1ZDRjNzg0ZTQwZjA4Mjk1NTM0NzU1NjgzNmJmL3RhYmxlcmFuZ2U6ZDAwNzVkNGM3ODRlNDBmMDgyOTU1MzQ3NTU2ODM2YmZfMy01LTEtMS0yODY5NDQ_9258a8eb-3ee4-48f9-8faa-74be83df70df"
      unitRef="usd">11000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmQwMDc1ZDRjNzg0ZTQwZjA4Mjk1NTM0NzU1NjgzNmJmL3RhYmxlcmFuZ2U6ZDAwNzVkNGM3ODRlNDBmMDgyOTU1MzQ3NTU2ODM2YmZfNC0xLTEtMS0yODY5NDQ_97dc8a02-b28f-43f9-9e56-094ad981404a"
      unitRef="usd">11000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmQwMDc1ZDRjNzg0ZTQwZjA4Mjk1NTM0NzU1NjgzNmJmL3RhYmxlcmFuZ2U6ZDAwNzVkNGM3ODRlNDBmMDgyOTU1MzQ3NTU2ODM2YmZfNC01LTEtMS0yODY5NDQ_02dfac77-581d-4b5c-bb26-5bfca3b29725"
      unitRef="usd">11000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i476e8c3bb99545d29a40a868cf6b4eed_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmQwMDc1ZDRjNzg0ZTQwZjA4Mjk1NTM0NzU1NjgzNmJmL3RhYmxlcmFuZ2U6ZDAwNzVkNGM3ODRlNDBmMDgyOTU1MzQ3NTU2ODM2YmZfNy0xLTEtMS0yODY5NDQ_9e6658d8-ff12-45d7-ae79-b6ef97e66375"
      unitRef="usd">3235000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i476e8c3bb99545d29a40a868cf6b4eed_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmQwMDc1ZDRjNzg0ZTQwZjA4Mjk1NTM0NzU1NjgzNmJmL3RhYmxlcmFuZ2U6ZDAwNzVkNGM3ODRlNDBmMDgyOTU1MzQ3NTU2ODM2YmZfNy0zLTEtMS0yODY5NDQ_0f94c53f-89d9-4f82-a17d-8f9597bb3526"
      unitRef="usd">2267000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i476e8c3bb99545d29a40a868cf6b4eed_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmQwMDc1ZDRjNzg0ZTQwZjA4Mjk1NTM0NzU1NjgzNmJmL3RhYmxlcmFuZ2U6ZDAwNzVkNGM3ODRlNDBmMDgyOTU1MzQ3NTU2ODM2YmZfNy01LTEtMS0yODY5NDQ_f30875cd-7f32-49bc-82f7-d169aac21990"
      unitRef="usd">968000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="i476e8c3bb99545d29a40a868cf6b4eed_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmQwMDc1ZDRjNzg0ZTQwZjA4Mjk1NTM0NzU1NjgzNmJmL3RhYmxlcmFuZ2U6ZDAwNzVkNGM3ODRlNDBmMDgyOTU1MzQ3NTU2ODM2YmZfNy03LTEtMS0yODY5NDQ_9cda25e1-5fe5-4c7b-b245-1b0b725a1472">P10Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ief415993dc4a47a1a6841e6902c7341b_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmQwMDc1ZDRjNzg0ZTQwZjA4Mjk1NTM0NzU1NjgzNmJmL3RhYmxlcmFuZ2U6ZDAwNzVkNGM3ODRlNDBmMDgyOTU1MzQ3NTU2ODM2YmZfOC0xLTEtMS0yODY5NDQ_6d846297-ea20-4e53-9a4c-1dd6fbd5c8e0"
      unitRef="usd">550000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ief415993dc4a47a1a6841e6902c7341b_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmQwMDc1ZDRjNzg0ZTQwZjA4Mjk1NTM0NzU1NjgzNmJmL3RhYmxlcmFuZ2U6ZDAwNzVkNGM3ODRlNDBmMDgyOTU1MzQ3NTU2ODM2YmZfOC0zLTEtMS0yODY5NDQ_8e262230-35b0-4e8f-94f3-2005734fd354"
      unitRef="usd">376000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ief415993dc4a47a1a6841e6902c7341b_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmQwMDc1ZDRjNzg0ZTQwZjA4Mjk1NTM0NzU1NjgzNmJmL3RhYmxlcmFuZ2U6ZDAwNzVkNGM3ODRlNDBmMDgyOTU1MzQ3NTU2ODM2YmZfOC01LTEtMS0yODY5NDQ_689f8d5e-5bf8-42b8-9cfd-16aa2a04077b"
      unitRef="usd">174000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="ief415993dc4a47a1a6841e6902c7341b_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmQwMDc1ZDRjNzg0ZTQwZjA4Mjk1NTM0NzU1NjgzNmJmL3RhYmxlcmFuZ2U6ZDAwNzVkNGM3ODRlNDBmMDgyOTU1MzQ3NTU2ODM2YmZfOC03LTEtMS0yODY5NDQ_ac791765-c902-406e-aea5-8ba23edcdaff">P9Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i963e12db354a4503b026e3e3bb6ed1ae_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmQwMDc1ZDRjNzg0ZTQwZjA4Mjk1NTM0NzU1NjgzNmJmL3RhYmxlcmFuZ2U6ZDAwNzVkNGM3ODRlNDBmMDgyOTU1MzQ3NTU2ODM2YmZfOS0xLTEtMS0yODY5NDQ_59c464d6-f0ce-4b32-b0ae-3e3136dc8522"
      unitRef="usd">1037000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i963e12db354a4503b026e3e3bb6ed1ae_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmQwMDc1ZDRjNzg0ZTQwZjA4Mjk1NTM0NzU1NjgzNmJmL3RhYmxlcmFuZ2U6ZDAwNzVkNGM3ODRlNDBmMDgyOTU1MzQ3NTU2ODM2YmZfOS0zLTEtMS0yODY5NDQ_320f1fcf-6c48-4acd-8abc-b9757474e814"
      unitRef="usd">623000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i963e12db354a4503b026e3e3bb6ed1ae_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmQwMDc1ZDRjNzg0ZTQwZjA4Mjk1NTM0NzU1NjgzNmJmL3RhYmxlcmFuZ2U6ZDAwNzVkNGM3ODRlNDBmMDgyOTU1MzQ3NTU2ODM2YmZfOS01LTEtMS0yODY5NDQ_e86e4999-480b-4a4f-ab4b-88ce09855733"
      unitRef="usd">414000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="i963e12db354a4503b026e3e3bb6ed1ae_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmQwMDc1ZDRjNzg0ZTQwZjA4Mjk1NTM0NzU1NjgzNmJmL3RhYmxlcmFuZ2U6ZDAwNzVkNGM3ODRlNDBmMDgyOTU1MzQ3NTU2ODM2YmZfOS03LTEtMS0yODY5NDQ_7178b5a2-015f-4b56-9421-78b81d63d48c">P9Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmQwMDc1ZDRjNzg0ZTQwZjA4Mjk1NTM0NzU1NjgzNmJmL3RhYmxlcmFuZ2U6ZDAwNzVkNGM3ODRlNDBmMDgyOTU1MzQ3NTU2ODM2YmZfMTAtMS0xLTEtMjg2OTQ0_11f72dd1-be06-4eb0-b639-1c7543acc538"
      unitRef="usd">4822000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmQwMDc1ZDRjNzg0ZTQwZjA4Mjk1NTM0NzU1NjgzNmJmL3RhYmxlcmFuZ2U6ZDAwNzVkNGM3ODRlNDBmMDgyOTU1MzQ3NTU2ODM2YmZfMTAtMy0xLTEtMjg2OTQ0_217e12e7-c44d-4829-b9ef-39b6a65573f9"
      unitRef="usd">3266000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmQwMDc1ZDRjNzg0ZTQwZjA4Mjk1NTM0NzU1NjgzNmJmL3RhYmxlcmFuZ2U6ZDAwNzVkNGM3ODRlNDBmMDgyOTU1MzQ3NTU2ODM2YmZfMTAtNS0xLTEtMjg2OTQ0_f070d3f4-49ec-4438-ba36-bb5803bc46dd"
      unitRef="usd">1556000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmQwMDc1ZDRjNzg0ZTQwZjA4Mjk1NTM0NzU1NjgzNmJmL3RhYmxlcmFuZ2U6ZDAwNzVkNGM3ODRlNDBmMDgyOTU1MzQ3NTU2ODM2YmZfMTAtNy0xLTEtMjg2OTQ0_49d4d494-0130-4919-8fda-e71116bafe12">P10Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmQwMDc1ZDRjNzg0ZTQwZjA4Mjk1NTM0NzU1NjgzNmJmL3RhYmxlcmFuZ2U6ZDAwNzVkNGM3ODRlNDBmMDgyOTU1MzQ3NTU2ODM2YmZfMTEtMS0xLTEtMjg2OTQ0_14ce0524-6080-43d0-b49c-6c8516a7d29f"
      unitRef="usd">4833000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmQwMDc1ZDRjNzg0ZTQwZjA4Mjk1NTM0NzU1NjgzNmJmL3RhYmxlcmFuZ2U6ZDAwNzVkNGM3ODRlNDBmMDgyOTU1MzQ3NTU2ODM2YmZfMTEtMy0xLTEtMjg2OTQ0_0d457f52-64ad-45e7-b338-b890a7f2343b"
      unitRef="usd">3266000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmQwMDc1ZDRjNzg0ZTQwZjA4Mjk1NTM0NzU1NjgzNmJmL3RhYmxlcmFuZ2U6ZDAwNzVkNGM3ODRlNDBmMDgyOTU1MzQ3NTU2ODM2YmZfMTEtNS0xLTEtMjg2OTQ0_391f2fa6-5b1b-4317-8edf-c96f9a0f6e2a"
      unitRef="usd">1567000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i173bc20d1a0d49e88d4984456dd1b3e0_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmNiNDA4NGY5M2VhMzQ0MTA5ODkxZTRhOWMxNTNhZmQ4L3RhYmxlcmFuZ2U6Y2I0MDg0ZjkzZWEzNDQxMDk4OTFlNGE5YzE1M2FmZDhfMy0xLTEtMS0yODY5NDQ_1febee8f-d5d8-4f3a-8c75-48ce2e2ff2fc"
      unitRef="usd">11000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i173bc20d1a0d49e88d4984456dd1b3e0_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmNiNDA4NGY5M2VhMzQ0MTA5ODkxZTRhOWMxNTNhZmQ4L3RhYmxlcmFuZ2U6Y2I0MDg0ZjkzZWEzNDQxMDk4OTFlNGE5YzE1M2FmZDhfMy01LTEtMS0yODY5NDQ_931f9ac1-689c-4c43-8990-600d15496216"
      unitRef="usd">11000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ic217743408d440409a59220a0bf14e4c_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmNiNDA4NGY5M2VhMzQ0MTA5ODkxZTRhOWMxNTNhZmQ4L3RhYmxlcmFuZ2U6Y2I0MDg0ZjkzZWEzNDQxMDk4OTFlNGE5YzE1M2FmZDhfNC0xLTEtMS0yODY5NDQ_966b1f36-cc50-44af-b649-e653631e917f"
      unitRef="usd">11000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ic217743408d440409a59220a0bf14e4c_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmNiNDA4NGY5M2VhMzQ0MTA5ODkxZTRhOWMxNTNhZmQ4L3RhYmxlcmFuZ2U6Y2I0MDg0ZjkzZWEzNDQxMDk4OTFlNGE5YzE1M2FmZDhfNC01LTEtMS0yODY5NDQ_38736f52-2ea5-4eee-84d4-ecf812fb4e97"
      unitRef="usd">11000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i70d3a43084b1430ab3dd772e96aa6f88_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmNiNDA4NGY5M2VhMzQ0MTA5ODkxZTRhOWMxNTNhZmQ4L3RhYmxlcmFuZ2U6Y2I0MDg0ZjkzZWEzNDQxMDk4OTFlNGE5YzE1M2FmZDhfNy0xLTEtMS0yODY5NDQ_d40ff0d7-b128-4f91-b700-4916c14683d7"
      unitRef="usd">3272000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i70d3a43084b1430ab3dd772e96aa6f88_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmNiNDA4NGY5M2VhMzQ0MTA5ODkxZTRhOWMxNTNhZmQ4L3RhYmxlcmFuZ2U6Y2I0MDg0ZjkzZWEzNDQxMDk4OTFlNGE5YzE1M2FmZDhfNy0zLTEtMS0yODY5NDQ_8b4ea995-7bee-449f-b763-cfcb8ccbea97"
      unitRef="usd">2165000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i70d3a43084b1430ab3dd772e96aa6f88_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmNiNDA4NGY5M2VhMzQ0MTA5ODkxZTRhOWMxNTNhZmQ4L3RhYmxlcmFuZ2U6Y2I0MDg0ZjkzZWEzNDQxMDk4OTFlNGE5YzE1M2FmZDhfNy01LTEtMS0yODY5NDQ_1d3b8697-bb25-44d3-a772-7c3e245af794"
      unitRef="usd">1107000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ie3d2fdf5757a41fc97c3a3a6ad11d72e_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmNiNDA4NGY5M2VhMzQ0MTA5ODkxZTRhOWMxNTNhZmQ4L3RhYmxlcmFuZ2U6Y2I0MDg0ZjkzZWEzNDQxMDk4OTFlNGE5YzE1M2FmZDhfOC0xLTEtMS0yODY5NDQ_3a464291-d01b-4ad5-8e96-1f04676c5a5d"
      unitRef="usd">552000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ie3d2fdf5757a41fc97c3a3a6ad11d72e_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmNiNDA4NGY5M2VhMzQ0MTA5ODkxZTRhOWMxNTNhZmQ4L3RhYmxlcmFuZ2U6Y2I0MDg0ZjkzZWEzNDQxMDk4OTFlNGE5YzE1M2FmZDhfOC0zLTEtMS0yODY5NDQ_149a98c9-3210-4520-8961-8dd4cce08f39"
      unitRef="usd">360000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ie3d2fdf5757a41fc97c3a3a6ad11d72e_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmNiNDA4NGY5M2VhMzQ0MTA5ODkxZTRhOWMxNTNhZmQ4L3RhYmxlcmFuZ2U6Y2I0MDg0ZjkzZWEzNDQxMDk4OTFlNGE5YzE1M2FmZDhfOC01LTEtMS0yODY5NDQ_23d2c241-b3f3-4cc3-8b35-84a6c77591ac"
      unitRef="usd">192000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i85178fe781b44231b4e7afb99223bc34_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmNiNDA4NGY5M2VhMzQ0MTA5ODkxZTRhOWMxNTNhZmQ4L3RhYmxlcmFuZ2U6Y2I0MDg0ZjkzZWEzNDQxMDk4OTFlNGE5YzE1M2FmZDhfOS0xLTEtMS0yODY5NDQ_8b7b9789-82a5-4baa-aa8f-9d766b09303a"
      unitRef="usd">1038000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i85178fe781b44231b4e7afb99223bc34_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmNiNDA4NGY5M2VhMzQ0MTA5ODkxZTRhOWMxNTNhZmQ4L3RhYmxlcmFuZ2U6Y2I0MDg0ZjkzZWEzNDQxMDk4OTFlNGE5YzE1M2FmZDhfOS0zLTEtMS0yODY5NDQ_c49614ef-3561-4e0f-aed9-7517ebf1491f"
      unitRef="usd">574000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i85178fe781b44231b4e7afb99223bc34_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmNiNDA4NGY5M2VhMzQ0MTA5ODkxZTRhOWMxNTNhZmQ4L3RhYmxlcmFuZ2U6Y2I0MDg0ZjkzZWEzNDQxMDk4OTFlNGE5YzE1M2FmZDhfOS01LTEtMS0yODY5NDQ_8eefb0fa-0558-401a-8b94-7c89800ff1e8"
      unitRef="usd">464000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ic217743408d440409a59220a0bf14e4c_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmNiNDA4NGY5M2VhMzQ0MTA5ODkxZTRhOWMxNTNhZmQ4L3RhYmxlcmFuZ2U6Y2I0MDg0ZjkzZWEzNDQxMDk4OTFlNGE5YzE1M2FmZDhfMTAtMS0xLTEtMjg2OTQ0_ddbd384b-de48-460e-b968-a24b8f059542"
      unitRef="usd">4862000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ic217743408d440409a59220a0bf14e4c_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmNiNDA4NGY5M2VhMzQ0MTA5ODkxZTRhOWMxNTNhZmQ4L3RhYmxlcmFuZ2U6Y2I0MDg0ZjkzZWEzNDQxMDk4OTFlNGE5YzE1M2FmZDhfMTAtMy0xLTEtMjg2OTQ0_47d8ef9d-2cfd-4c2f-8705-372b2b7624ea"
      unitRef="usd">3099000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ic217743408d440409a59220a0bf14e4c_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmNiNDA4NGY5M2VhMzQ0MTA5ODkxZTRhOWMxNTNhZmQ4L3RhYmxlcmFuZ2U6Y2I0MDg0ZjkzZWEzNDQxMDk4OTFlNGE5YzE1M2FmZDhfMTAtNS0xLTEtMjg2OTQ0_ed4da037-e8cd-4533-b11c-537b95ef42d7"
      unitRef="usd">1763000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="ic217743408d440409a59220a0bf14e4c_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmNiNDA4NGY5M2VhMzQ0MTA5ODkxZTRhOWMxNTNhZmQ4L3RhYmxlcmFuZ2U6Y2I0MDg0ZjkzZWEzNDQxMDk4OTFlNGE5YzE1M2FmZDhfMTEtMS0xLTEtMjg2OTQ0_158ccc1f-f5cf-4aba-97f2-63f94f4899e0"
      unitRef="usd">4873000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ic217743408d440409a59220a0bf14e4c_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmNiNDA4NGY5M2VhMzQ0MTA5ODkxZTRhOWMxNTNhZmQ4L3RhYmxlcmFuZ2U6Y2I0MDg0ZjkzZWEzNDQxMDk4OTFlNGE5YzE1M2FmZDhfMTEtMy0xLTEtMjg2OTQ0_dd5a10a7-157e-41ea-99b8-83bd2ed74857"
      unitRef="usd">3099000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ic217743408d440409a59220a0bf14e4c_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RhYmxlOmNiNDA4NGY5M2VhMzQ0MTA5ODkxZTRhOWMxNTNhZmQ4L3RhYmxlcmFuZ2U6Y2I0MDg0ZjkzZWEzNDQxMDk4OTFlNGE5YzE1M2FmZDhfMTEtNS0xLTEtMjg2OTQ0_26f8ee57-dab8-4dd5-8423-cf78a6235a8f"
      unitRef="usd">1774000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RleHRyZWdpb246YjY4ZTgyNTRjMTc4NDc2ZWJmZmEzNTI5MzQ3MmQ3MzNfMjYxOQ_eb13f8b7-190b-4fb8-9faa-555fc6e32859"
      unitRef="usd">69000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RleHRyZWdpb246YjY4ZTgyNTRjMTc4NDc2ZWJmZmEzNTI5MzQ3MmQ3MzNfMjYyNg_61bcdafb-2bb9-4765-959b-6761c053b19e"
      unitRef="usd">78000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RleHRyZWdpb246YjY4ZTgyNTRjMTc4NDc2ZWJmZmEzNTI5MzQ3MmQ3MzNfMjY4NQ_08c01fea-f1ce-4c3e-8a6d-11087fa3a361"
      unitRef="usd">211000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RleHRyZWdpb246YjY4ZTgyNTRjMTc4NDc2ZWJmZmEzNTI5MzQ3MmQ3MzNfMjY5Mg_fd666ca8-f576-4dd2-a820-7f6a346edd45"
      unitRef="usd">235000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RleHRyZWdpb246YjY4ZTgyNTRjMTc4NDc2ZWJmZmEzNTI5MzQ3MmQ3MzNfMjgzOQ_84269dcc-390c-4175-afd1-86c42d27c0d3"
      unitRef="usd">71000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RleHRyZWdpb246YjY4ZTgyNTRjMTc4NDc2ZWJmZmEzNTI5MzQ3MmQ3MzNfMjg0Mw_5f1c23c1-5ebc-402a-9ab0-128a533ffaef"
      unitRef="usd">261000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RleHRyZWdpb246YjY4ZTgyNTRjMTc4NDc2ZWJmZmEzNTI5MzQ3MmQ3MzNfMjg0Nw_95cc9da6-042f-4f28-bcee-1fe3b8b79845"
      unitRef="usd">236000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RleHRyZWdpb246YjY4ZTgyNTRjMTc4NDc2ZWJmZmEzNTI5MzQ3MmQ3MzNfMjg1MQ_52a838c3-dd6b-4d57-8449-154b624cf9ba"
      unitRef="usd">209000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y184OC9mcmFnOmI2OGU4MjU0YzE3ODQ3NmViZmZhMzUyOTM0NzJkNzMzL3RleHRyZWdpb246YjY4ZTgyNTRjMTc4NDc2ZWJmZmEzNTI5MzQ3MmQ3MzNfMjg1OQ_f5882ff8-2f3c-4481-97d2-7abddce20be3"
      unitRef="usd">177000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y185Ny9mcmFnOjYyZjA4MTU0NTMzYjQ1MWFhNjJjMmRiMGU3ZDhlMDFmL3RleHRyZWdpb246NjJmMDgxNTQ1MzNiNDUxYWE2MmMyZGIwZTdkOGUwMWZfMTk1NA_ef01f275-5cf6-4f26-9245-d12196798c8d">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;5. Long-Term Obligations and Other Short-Term Borrowings&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Long-Term Debt&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We had total long-term obligations, including the current portion and other short-term borrowings, of $4.7 billion and $5.3 billion for March&#160;31, 2023 and June&#160;30, 2022, respectively. All the notes represent unsecured obligations of Cardinal Health, Inc. and rank equally in right of payment with all of our existing and future unsecured and unsubordinated indebtedness. Interest is paid pursuant to the terms of the obligations. These notes are effectively subordinated to the liabilities of our subsidiaries, including trade payables of $29.6 billion and $27.1 billion at March&#160;31, 2023 and June&#160;30, 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2023, we repaid the full principal of the $550&#160;million 3.2% Notes due 2023 at maturity with available cash.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the nine months ended March&#160;31, 2022, we redeemed all outstanding $572&#160;million principal amount of 2.616% Notes due June 2022 at a redemption price equal to 100% of the principal amount and accrued but unpaid interest, plus the make-whole premium applicable to the notes. In connection with this redemption, we recorded a $10&#160;million loss on early extinguishment of debt. The early redemption was funded with available cash.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Other Financing Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to cash and equivalents and operating cash flow, other sources of liquidity include a&#160;$2.0 billion&#160;commercial paper program backed by a $2.0 billion&#160;revolving credit facility. We also have a&#160;$1.0 billion&#160;committed receivables sales facility. During the nine months ended March&#160;31, 2023, under our commercial paper program and our committed receivables program, we had maximum combined total daily amounts outstanding of $445&#160;million and average combined daily amount outstanding of $4&#160;million. At March&#160;31, 2023, we had no amounts outstanding under our commercial paper program, revolving credit facility or our committed receivables sales facility. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2023, we extended our $2.0 billion revolving credit facility through February 25, 2028. In September 2022, we renewed our committed receivables sales facility program through Cardinal Health Funding, LLC (&#x201c;CHF&#x201d;) through September 30, 2025. CHF was organized for&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the sole purpose of buying receivables and selling undivided interests in those receivables to third-party purchasers. Although consolidated with Cardinal Health, &lt;/span&gt;&lt;/div&gt;Inc. in accordance with GAAP, CHF is a separate legal entity from Cardinal Health, Inc. and from our subsidiary that sells receivables to CHF. CHF is designed to be a special purpose, bankruptcy-remote entity whose assets are available solely to satisfy the claims of its creditors. Our revolving credit and committed receivables sales facilities require us to maintain a consolidated net leverage ratio of no more than 3.75-to-1. As of March&#160;31, 2023, we were in compliance with this financial covenant.</us-gaap:DebtDisclosureTextBlock>
    <cah:TotalLongTermandShortTermObligations
      contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y185Ny9mcmFnOjYyZjA4MTU0NTMzYjQ1MWFhNjJjMmRiMGU3ZDhlMDFmL3RleHRyZWdpb246NjJmMDgxNTQ1MzNiNDUxYWE2MmMyZGIwZTdkOGUwMWZfMTA5OTUxMTYzMDIzNA_a2d35407-fb43-475b-a638-20282e7b71e8"
      unitRef="usd">4700000000</cah:TotalLongTermandShortTermObligations>
    <cah:TotalLongTermandShortTermObligations
      contextRef="ic217743408d440409a59220a0bf14e4c_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y185Ny9mcmFnOjYyZjA4MTU0NTMzYjQ1MWFhNjJjMmRiMGU3ZDhlMDFmL3RleHRyZWdpb246NjJmMDgxNTQ1MzNiNDUxYWE2MmMyZGIwZTdkOGUwMWZfMTY0OTI2NzQ0MzY4OA_c90e5006-0b70-477d-9eda-9531b322b3fb"
      unitRef="usd">5300000000</cah:TotalLongTermandShortTermObligations>
    <us-gaap:AccountsPayableCurrentAndNoncurrent
      contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y185Ny9mcmFnOjYyZjA4MTU0NTMzYjQ1MWFhNjJjMmRiMGU3ZDhlMDFmL3RleHRyZWdpb246NjJmMDgxNTQ1MzNiNDUxYWE2MmMyZGIwZTdkOGUwMWZfNTAy_02827bd0-2c88-4c2e-94ad-fe1a9ee7dfae"
      unitRef="usd">29600000000</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:AccountsPayableCurrentAndNoncurrent
      contextRef="ic217743408d440409a59220a0bf14e4c_I20220630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y185Ny9mcmFnOjYyZjA4MTU0NTMzYjQ1MWFhNjJjMmRiMGU3ZDhlMDFmL3RleHRyZWdpb246NjJmMDgxNTQ1MzNiNDUxYWE2MmMyZGIwZTdkOGUwMWZfNTA5_ed33b5a3-81a0-4d8e-ae37-84918fc2ba96"
      unitRef="usd">27100000000</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="i70202e3eb1924e0fb801d98cddcbf880_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y185Ny9mcmFnOjYyZjA4MTU0NTMzYjQ1MWFhNjJjMmRiMGU3ZDhlMDFmL3RleHRyZWdpb246NjJmMDgxNTQ1MzNiNDUxYWE2MmMyZGIwZTdkOGUwMWZfNTQ5NzU1ODE0MTY3MA_d5901d44-d14d-49d6-9731-18f354bc1367"
      unitRef="usd">550000000</us-gaap:RepaymentsOfNotesPayable>
    <cah:NotesPayableRepurchased
      contextRef="i5c0fee9c3dfe482dbe67f839273b347f_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y185Ny9mcmFnOjYyZjA4MTU0NTMzYjQ1MWFhNjJjMmRiMGU3ZDhlMDFmL3RleHRyZWdpb246NjJmMDgxNTQ1MzNiNDUxYWE2MmMyZGIwZTdkOGUwMWZfNTg2_67bd3202-c701-4a44-b716-0b1b368aca93"
      unitRef="usd">572000000</cah:NotesPayableRepurchased>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i5c0fee9c3dfe482dbe67f839273b347f_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y185Ny9mcmFnOjYyZjA4MTU0NTMzYjQ1MWFhNjJjMmRiMGU3ZDhlMDFmL3RleHRyZWdpb246NjJmMDgxNTQ1MzNiNDUxYWE2MmMyZGIwZTdkOGUwMWZfODMy_8f18e3ab-44c4-42f2-8287-8a821e17d6e7"
      unitRef="usd">-10000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i08f98bc525534cc2acbd1048c17f5b33_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y185Ny9mcmFnOjYyZjA4MTU0NTMzYjQ1MWFhNjJjMmRiMGU3ZDhlMDFmL3RleHRyZWdpb246NjJmMDgxNTQ1MzNiNDUxYWE2MmMyZGIwZTdkOGUwMWZfMTA1Mw_eaec01b1-03f1-4825-af29-f5be18c8d1f1"
      unitRef="usd">2000000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i075adee0cf414c09a846d45f9d6a66c6_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y185Ny9mcmFnOjYyZjA4MTU0NTMzYjQ1MWFhNjJjMmRiMGU3ZDhlMDFmL3RleHRyZWdpb246NjJmMDgxNTQ1MzNiNDUxYWE2MmMyZGIwZTdkOGUwMWZfMTA5Mw_6885719f-66cc-4f4c-b1b3-15689572c802"
      unitRef="usd">2000000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="if9a5679304ee4538b6bbe0e34a4b5ed6_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y185Ny9mcmFnOjYyZjA4MTU0NTMzYjQ1MWFhNjJjMmRiMGU3ZDhlMDFmL3RleHRyZWdpb246NjJmMDgxNTQ1MzNiNDUxYWE2MmMyZGIwZTdkOGUwMWZfMTEzOA_8981b823-7b26-4fce-a336-c10f76796ef3"
      unitRef="usd">1000000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod
      contextRef="i78f3cdc10c574a61aeee3a0d9409d753_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y185Ny9mcmFnOjYyZjA4MTU0NTMzYjQ1MWFhNjJjMmRiMGU3ZDhlMDFmL3RleHRyZWdpb246NjJmMDgxNTQ1MzNiNDUxYWE2MmMyZGIwZTdkOGUwMWZfNTQ5NzU1ODE0MTcxMg_d8f0f0a4-c639-4493-8544-811d07f20665"
      unitRef="usd">445000000</us-gaap:LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod>
    <us-gaap:LineOfCreditFacilityAverageOutstandingAmount
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y185Ny9mcmFnOjYyZjA4MTU0NTMzYjQ1MWFhNjJjMmRiMGU3ZDhlMDFmL3RleHRyZWdpb246NjJmMDgxNTQ1MzNiNDUxYWE2MmMyZGIwZTdkOGUwMWZfNTQ5NzU1ODE0MTcyNg_52995717-1b44-46c5-a577-30096f11e2ca"
      unitRef="usd">4000000</us-gaap:LineOfCreditFacilityAverageOutstandingAmount>
    <us-gaap:OtherShortTermBorrowings
      contextRef="i769da3763c9d46579b5dbf1f28eef5e3_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y185Ny9mcmFnOjYyZjA4MTU0NTMzYjQ1MWFhNjJjMmRiMGU3ZDhlMDFmL3RleHRyZWdpb246NjJmMDgxNTQ1MzNiNDUxYWE2MmMyZGIwZTdkOGUwMWZfMTE5Mw_8355250f-2f5a-4bdd-b586-13d1bb0b43d1"
      unitRef="usd">0</us-gaap:OtherShortTermBorrowings>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i075adee0cf414c09a846d45f9d6a66c6_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y185Ny9mcmFnOjYyZjA4MTU0NTMzYjQ1MWFhNjJjMmRiMGU3ZDhlMDFmL3RleHRyZWdpb246NjJmMDgxNTQ1MzNiNDUxYWE2MmMyZGIwZTdkOGUwMWZfMzg0ODI5MDY5OTYwMQ_6885719f-66cc-4f4c-b1b3-15689572c802"
      unitRef="usd">2000000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDAvZnJhZzo2NGI0MmYwYWIwNTM0MmVmODQyMWRhOGFmZmFiNjU2Mi90ZXh0cmVnaW9uOjY0YjQyZjBhYjA1MzQyZWY4NDIxZGE4YWZmYWI2NTYyXzE3OTUw_3aef8cba-8cf2-4dd0-b5ff-f7ab2f3f04b8">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;6. Commitments, Contingent Liabilities and Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Generic Sourcing Venture with CVS Health Corporation ("CVS Health")&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2014, we established Red Oak Sourcing, LLC ("Red Oak Sourcing"), a U.S.-based generic pharmaceutical sourcing venture with CVS Health for an initial term of 10 years. Red Oak Sourcing negotiates generic pharmaceutical supply contracts on behalf of its participants. In August 2021, we amended our agreement to extend the term through June 2029. We are required to make quarterly payments to CVS Health for the term of the arrangement.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;New York Opioid Stewardship Act&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2018, the State of New York passed a budget which included the Opioid Stewardship Act (the "OSA"). The OSA created an aggregate $100&#160;million annual assessment on all manufacturers and distributors licensed to sell or distribute opioids in New York. Under the OSA, each licensed manufacturer and distributor would be required to pay a portion of the assessment based on its share of the total morphine milligram equivalents sold or distributed in New York during the applicable calendar year, beginning in 2017. Subsequently, New York passed a new statute that modified the assessment going forward and limited the OSA to two years (2017 and 2018).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We accrue contingencies if it is probable that a liability has been incurred and the amount can be estimated. In the second quarter of fiscal year 2022, we paid the State of New York $20&#160;million, our portion of the assessment for calendar year 2017. At June 30, 2022, we had an accrual of $20&#160;million, which represented our estimate of our portion of the assessment for calendar year 2018. Du&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ring the nine months ended March&#160;31, 2023, we recorded $6&#160;million of income to reduce this accrual to the invoiced amount for the calendar year 2018 assessment and we paid $7&#160;million, resulting in an accrual of $7&#160;million at March 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We become involved from time to time in disputes, litigation and regulatory matters.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, we determine that products we source, manufacture or market do not meet our specifications, regulatory requirements, or published standards. When we or a regulatory &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;agency identify a potential quality or regulatory issue, we investigate and take appropriate corrective action. Such actions have led to product recalls, costs to repair or replace affected products, temporary interruptions in product sales, product liability claims and lawsuits and can lead to action by regulators. Even absent an identified regulatory or quality issue or product recall, we can become subject to product liability claims and lawsuits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, we become aware through employees, internal audits or other parties of possible compliance matters, such as complaints or concerns relating to accounting, internal accounting controls, financial reporting, auditing, or other ethical matters or relating to compliance with laws such as healthcare fraud and abuse, anti-corruption or anti-bribery laws. When we become aware of such possible compliance matters, we investigate internally and take appropriate corrective action. In addition, from time to time, we receive subpoenas or requests for information from various federal or state agencies relating to our business or to the business of a customer, supplier or other industry participants. Internal investigations, subpoenas or requests for information could directly or indirectly lead to the assertion of claims or the commencement of legal proceedings against us or result in sanctions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have been named from time to time in qui tam actions initiated by private third parties. In such actions, the private parties purport to act on behalf of federal or state governments, allege that false claims have been submitted for payment by the government and may receive an award if their claims are successful. After a private party has filed a qui tam action, the government must investigate the private party's claim and determine whether to intervene in and take control over the litigation. These actions may remain under seal while the government makes this determination. If the government declines to intervene, the private party may nonetheless continue to pursue the litigation on his or her own purporting to act on behalf of the government.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We accrue for contingencies related to disputes, litigation and regulatory matters if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Because these matters are inherently unpredictable and unfavorable developments or resolutions can occur, assessing contingencies is highly subjective and requires judgments about future events. We regularly review contingencies to determine whether our accruals and related disclosures are adequate. The amount of ultimate loss may differ from these estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize income from the favorable outcome of litigation when we receive the associated cash or assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize estimated loss contingencies for certain litigation and regulatory matters and income from favorable resolution of litigation in litigation (recoveries)/charges, net in our condensed consolidated statements of earnings/(loss); however, losses and recoveries of lost profits from disputes that occur in the ordinary course of business are included within segment profit. For example, in the second quarter of fiscal year 2022, our &lt;/span&gt;&lt;/div&gt;&lt;div style="display:inline-block;vertical-align:top;width:48.214%"&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pharmaceutical segment profit was positively impacted by a $16&#160;million judgment for lost profits related to an ordinary course intellectual property rights claim.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Opioid Lawsuits and Investigations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;States &amp;amp; Political Subdivisions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;National Settlement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As previously disclosed, in February 2022, we along with two other national distributors (collectively, the "Distributors") independently approved a settlement and settlement agreement (the "Settlement Agreement") to settle the vast majority of opioid lawsuits and claims brought by states and political subdivisions. This Settlement Agreement became effective on April 2, 2022. In May and June 2022, the Distributors reached agreements with the States of Washington and Oklahoma, respectively, to resolve the opioid-related claims of those states and their political subdivisions. Under these agreements, Cardinal Health agreed to pay approximately $160&#160;million to the State of Washington and its participating subdivisions and approximately $95&#160;million to the State of Oklahoma and its participating subdivisions. These amounts are consistent with the amounts that would have been allocated to Washington and Oklahoma under the Settlement Agreement. Each of Washington and Oklahoma is now subject to the Settlement Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the Distributors, parties to the Settlement Agreement include 48 states, the District of Columbia and 5 U.S. territories. Over 99 percent of political subdivisions (by population as calculated under the Settlement Agreement) that had brought opioid-related suits against us have chosen to join the Settlement Agreement or have had their claims addressed by state legislation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Settlement Agreement, we agreed to pay up to approximately $6.3&#160;billion over 18 years. The Settlement Agreement also includes injunctive relief terms related to distributors&#x2019; controlled substance anti-diversion programs. For more information on the terms of the Settlement Agreement, refer to our 2022 Form 10-K. As a result of the Settlement Agreement, most lawsuits brought against us by states and other political subdivisions have been dismissed. We continue to engage in resolution discussions with certain non-participating political subdivisions, including the Attorney General for the State of Alabama, and we intend to defend ourselves vigorously against all remaining lawsuits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the nine months ended March 31, 2023, we made our second annual payment of $372&#160;million under the Settlement Agreement. In total, we have $5.85&#160;billion accrued at March&#160;31, 2023, of which $437&#160;million is included in other accrued liabilities and the remainder is included in deferred income taxes and other liabilities in our condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Because loss contingencies are inherently unpredictable and unfavorable developments or resolutions can occur, the assessment is highly subjective and requires judgments about future events. We regularly review these opioid litigation matters to determine whether our accrual is adequate. The amount of &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/&gt;&lt;div style="display:inline-block;vertical-align:top;width:48.215%"&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ultimate loss may differ materially from this accrual, whether as a result of settlement discussions, a judicial decision or verdict or otherwise, but we are not able to estimate a range of reasonably possible additional losses for these matters. We continue to strongly dispute the allegations made in these lawsuits and none of these agreements is an admission of liability or wrongdoing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Other Settlements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;West Virginia subdivisions and Native American tribes were not a part of the national settlement, and we had separate negotiations with these groups. A bench trial before a federal judge in West Virginia in a case brought by Cabell County and City of Huntington against the Distributors concluded in July 2021. In July 2022, a judgment in favor of the Distributors was entered. In July 2022, the Distributors reached an agreement to settle the opioid-related claims of the majority of the remaining West Virginia subdivisions. Under this agreement, we have agreed to pay eligible West Virginia subdivisions up to approximately $124&#160;million over an eleven-year period. This agreement became effective in October 2022 when all participating subdivisions dismissed their cases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2022, we executed a final settlement agreement with the Native American Tribes, pursuant to which we will pay up to approximately $136&#160;million over five years. In connection with this settlement, the court entered dismissals for the Native American tribes' cases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Department of Justice Investigations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have received federal grand jury subpoenas issued in connection with investigations being conducted by the U.S. Attorney's Office for the Eastern District of New York and the Fraud Section of the U.S. Department of Justice ("DOJ"). We have also received civil requests for information from other DOJ offices. We believe that these investigations concern operation of our anti-diversion program, our anti-diversion policies and procedures, and distribution of certain controlled substances. We are cooperating with these investigations. We are unable to predict the outcome of any of these investigations. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Private Plaintiffs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Settlement Agreement does not address claims by private parties, which includes unions and other health and welfare funds, hospital systems and other healthcare providers, businesses and individuals alleging personal injury. Private parties had brought approximately 457 lawsuits as of April 28, 2023. Of these, 107 are purported class actions. The causes of action asserted by these plaintiffs are similar to those asserted by public plaintiffs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A trial in a case involving 21 plaintiffs began in state court in Georgia in January 2023 and concluded in March 2023 with a verdict for the company and other defendants on all claims. The plaintiffs' motion for a new trial is pending. A trial involving eight hospital plaintiffs is scheduled to begin in Alabama in July 2023. We are vigorously defending ourselves in all of these matters; however, trials are inherently unpredictable and it is possible that an unfavorable outcome in these matters, individually or in the aggregate, could have a negative impact on our financial results.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="display:inline-block;vertical-align:top;width:48.214%"&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Insurance Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are involved in ongoing legal proceedings with insurers related their obligations to reimburse us for defense and indemnity costs in connection with the lawsuits described above. In the nine months ended March 31, 2023, we received approximately $10&#160;million in insurance recoveries related to these matters; however, we have not recorded a receivable for any additional recoveries as of March&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cordis IVC Filter Matters &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Liability Lawsuits&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have been named as a defendant in approximately 453 product liability lawsuits coordinated in Alameda County Superior Court in California involving claims by approximately 5,171 plaintiffs that allege personal injuries associated with the use of IVC filter products. These lawsuits sought a variety of remedies, including unspecified monetary damages. The divestiture of the Cordis business did not include product liability related to the IVC filters in the U.S. and Canada, which we retained.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2023, we executed a settlement agreement that, if certain conditions are satisfied, will resolve approximately 4,376 claims for $275&#160;million. This settlement agreement is subject to certain conditions, including certain opt-in thresholds. Between May and September 2023, we will make settlement payments totaling $275&#160;million into a qualified settlement fund, which will be disbursed to the plaintiffs if required conditions are satisfied. Since July 2021, we have also entered into other agreements to settle approximately 2,881 product liability claims. These settlements will not resolve all IVC filter product liability claims and we will continue to vigorously defend ourselves in the remaining lawsuits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, in August 2021, the Attorney General for the State of New Mexico filed an action against certain IVC filter manufacturers, including us, alleging claims under New Mexico's Unfair Practices Act, Medicaid Fraud Act and Fraud Against Taxpayers Act. The allegations are similar to those made in the product liability lawsuits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognized income of $71&#160;million and $95&#160;million during the three and nine months ended March&#160;31, 2023, respectively, primarily related to a reduction of the reserve for the estimated settlement and defense costs for these matters due to the execution of the settlements noted above. At March&#160;31, 2023, we had a total of $385&#160;million accrued for losses and legal defense costs, related to the IVC filter product liability lawsuits in our condensed consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Shareholder Securities Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2019, the Louisiana Sheriffs' Pension &amp;amp; Relief Fund filed a purported class action complaint against Cardinal Health and certain current and former officers and employees in the United States District Court for the Southern District of Ohio purportedly on behalf of all purchasers of our common shares between March 2015 and May 2018. In June 2020, the court appointed 1199 SEIU Health Care Employees Pension Fund as lead plaintiff and a &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/&gt;&lt;div style="display:inline-block;vertical-align:top;width:48.215%"&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;consolidated amended complaint was filed in September 2020. The amended complaint alleges that the defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 by making misrepresentations and omissions related to the acquisition and integration of the Cordis business and inventory and supply chain problems within the Cordis business, and seeks to recover unspecified damages and equitable relief for the alleged misstatements and omissions. The complaint also alleges that one of the individual defendants violated Section 20A of the Exchange Act because he sold shares of Cardinal Health stock during the time period. In February 2023, we reached an agreement in principle with the plaintiffs to settle this matter for $109&#160;million, subject to final approval by the court. The court granted its preliminary approval in April 2023 and will conduct a final hearing in September 2023. If the settlement is approved, our insurance carriers will pay $109&#160;million to the plaintiffs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Civil Litigation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Generic Pharmaceutical Pricing Antitrust Litigation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, pharmaceutical distributors including us were added as defendants in a civil class action lawsuit filed by indirect purchasers of generic drugs, such as hospitals and retail pharmacies. The indirect purchaser case is part of a multidistrict litigation consisting of multiple individual class action matters consolidated in the Eastern District of Pennsylvania. The indirect purchaser plaintiffs allege that pharmaceutical distributors encouraged manufacturers to increase prices, provided anti-competitive pricing information to manufacturers and improperly engaged in customer allocation. In May 2020, the court granted our motion to dismiss. In July 2022, the indirect purchasers filed an amended complaint and in August 2022, we filed a motion to dismiss the intended complaint. We are vigorously defending ourselves in this matter. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Antitrust Litigation Proceeds&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2022, we received net cash proceeds resulting from the settlement of a lawsuit in which we were a class member or plaintiff of $66&#160;million, which was recognized in litigation (recoveries)/charges, net, during the nine months ended March 31, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Shareholder Derivative Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Between June 2019 and January 2020, three purported shareholders filed actions on behalf of Cardinal Health, Inc. in the U.S. District Court for the Southern District of Ohio against certain current and former members of our Board of Directors alleging that the defendants breached their fiduciary duties by failing to effectively monitor Cardinal Health's distribution of controlled substances and approving certain payments of executive compensation. In January 2020, the court consolidated these derivative cases under the caption In re Cardinal Health, Inc. Derivative Litigation and in March 2020, plaintiffs filed an amended complaint. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;In October 2022, the court entered an order approving the settlement agreement reached between the parties and dismissing the case. The settlement does not include any admission of liability. Under this settlement, in December 2022, Cardinal Health's director and officer liability insurance carriers, on behalf of the defendants, paid Cardinal Health $124&#160;million, less approximately $31&#160;million in attorneys' fees and expenses awarded by the court to plaintiffs' counsel. Cardinal Health received net cash proceeds resulting from this settlement of $93&#160;million, which was recognized in litigation (recoveries)/charges, net, during the nine months ended March 31, 2023.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LongtermPurchaseCommitmentPeriod
      contextRef="i4e20bef4bcbc46aa8704b4843abc61ed_D20140731-20140731"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDAvZnJhZzo2NGI0MmYwYWIwNTM0MmVmODQyMWRhOGFmZmFiNjU2Mi90ZXh0cmVnaW9uOjY0YjQyZjBhYjA1MzQyZWY4NDIxZGE4YWZmYWI2NTYyXzI1NA_48cabba9-a75f-46a2-aad0-42271aa122d1">P10Y</us-gaap:LongtermPurchaseCommitmentPeriod>
    <cah:AggregateAnnualAssessment
      contextRef="i5a9e7f91ada745048021249c9ba3bf07_I20180430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDAvZnJhZzo2NGI0MmYwYWIwNTM0MmVmODQyMWRhOGFmZmFiNjU2Mi90ZXh0cmVnaW9uOjY0YjQyZjBhYjA1MzQyZWY4NDIxZGE4YWZmYWI2NTYyXzcwOQ_91a331c3-46de-44ab-93f2-d6253cfa1aff"
      unitRef="usd">100000000</cah:AggregateAnnualAssessment>
    <us-gaap:LossContingencyAccrualPayments
      contextRef="ie6e1b925b14f48bdae321a2a92cddd99_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDAvZnJhZzo2NGI0MmYwYWIwNTM0MmVmODQyMWRhOGFmZmFiNjU2Mi90ZXh0cmVnaW9uOjY0YjQyZjBhYjA1MzQyZWY4NDIxZGE4YWZmYWI2NTYyXzE0MDI_a491d424-4b5a-4e9a-9098-dd5d9062aeae"
      unitRef="usd">20000000</us-gaap:LossContingencyAccrualPayments>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="i1ba9cf1bead64efbbe00d2cffc0f7d5f_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDAvZnJhZzo2NGI0MmYwYWIwNTM0MmVmODQyMWRhOGFmZmFiNjU2Mi90ZXh0cmVnaW9uOjY0YjQyZjBhYjA1MzQyZWY4NDIxZGE4YWZmYWI2NTYyXzE0OTk_6f41c80d-0e63-4a5c-a55d-047cc5bb7da0"
      unitRef="usd">20000000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyAccrualCarryingValuePeriodIncreaseDecrease
      contextRef="i487c1d6cc123481ab174c77df6efc37c_D20220701-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDAvZnJhZzo2NGI0MmYwYWIwNTM0MmVmODQyMWRhOGFmZmFiNjU2Mi90ZXh0cmVnaW9uOjY0YjQyZjBhYjA1MzQyZWY4NDIxZGE4YWZmYWI2NTYyXzE2MzE_6c069275-baed-480f-97bb-a233164f0f7c"
      unitRef="usd">-6000000</us-gaap:LossContingencyAccrualCarryingValuePeriodIncreaseDecrease>
    <us-gaap:LossContingencyAccrualPayments
      contextRef="i487c1d6cc123481ab174c77df6efc37c_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDAvZnJhZzo2NGI0MmYwYWIwNTM0MmVmODQyMWRhOGFmZmFiNjU2Mi90ZXh0cmVnaW9uOjY0YjQyZjBhYjA1MzQyZWY4NDIxZGE4YWZmYWI2NTYyXzQzOTgwNDY1MzYyMTI_c963a491-184d-46fb-a8e4-916a1585fa2a"
      unitRef="usd">7000000</us-gaap:LossContingencyAccrualPayments>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="i3177191fb7864f68afd74d62ddd7feeb_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDAvZnJhZzo2NGI0MmYwYWIwNTM0MmVmODQyMWRhOGFmZmFiNjU2Mi90ZXh0cmVnaW9uOjY0YjQyZjBhYjA1MzQyZWY4NDIxZGE4YWZmYWI2NTYyXzQzOTgwNDY1MzYyODk_defde614-171d-49f0-ae57-8d127332f4b9"
      unitRef="usd">7000000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <cah:JudgmentForLostProfits
      contextRef="i92600b80cf9f42e68ab2bb551fa5980c_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDAvZnJhZzo2NGI0MmYwYWIwNTM0MmVmODQyMWRhOGFmZmFiNjU2Mi90ZXh0cmVnaW9uOjY0YjQyZjBhYjA1MzQyZWY4NDIxZGE4YWZmYWI2NTYyXzUzMTA_9c01752c-b170-4e27-820b-57bd6e842abd"
      unitRef="usd">16000000</cah:JudgmentForLostProfits>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="ib507a23581594a42a6beb783c2499b40_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDAvZnJhZzo2NGI0MmYwYWIwNTM0MmVmODQyMWRhOGFmZmFiNjU2Mi90ZXh0cmVnaW9uOjY0YjQyZjBhYjA1MzQyZWY4NDIxZGE4YWZmYWI2NTYyXzYxNDI_699338ae-c5fd-4973-b05f-1a01cf7b279c"
      unitRef="usd">160000000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="if44099e3d6fc462fbe010375b43d9efd_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDAvZnJhZzo2NGI0MmYwYWIwNTM0MmVmODQyMWRhOGFmZmFiNjU2Mi90ZXh0cmVnaW9uOjY0YjQyZjBhYjA1MzQyZWY4NDIxZGE4YWZmYWI2NTYyXzYyMjU_89f94a4f-ab37-4bcc-8664-c363c02f177f"
      unitRef="usd">95000000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <cah:SettlingStates
      contextRef="iad6a19c0c20841d5b5851aaeb8d05e17_I20230131"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDAvZnJhZzo2NGI0MmYwYWIwNTM0MmVmODQyMWRhOGFmZmFiNjU2Mi90ZXh0cmVnaW9uOjY0YjQyZjBhYjA1MzQyZWY4NDIxZGE4YWZmYWI2NTYyXzE3OTQ0_4c687236-0675-4e18-906c-d6b76b57c38e"
      unitRef="states">48</cah:SettlingStates>
    <cah:SettlingUSTerritories
      contextRef="iad6a19c0c20841d5b5851aaeb8d05e17_I20230131"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDAvZnJhZzo2NGI0MmYwYWIwNTM0MmVmODQyMWRhOGFmZmFiNjU2Mi90ZXh0cmVnaW9uOjY0YjQyZjBhYjA1MzQyZWY4NDIxZGE4YWZmYWI2NTYyXzE3OTQ1_a6d9c3e5-1308-4603-adfd-6680fb8d8273"
      unitRef="numberofusterritories">5</cah:SettlingUSTerritories>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="i92a2e3900c6e4547800cbb60799bcd60_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDAvZnJhZzo2NGI0MmYwYWIwNTM0MmVmODQyMWRhOGFmZmFiNjU2Mi90ZXh0cmVnaW9uOjY0YjQyZjBhYjA1MzQyZWY4NDIxZGE4YWZmYWI2NTYyXzY5NjE_fecb7184-61c5-41a7-993e-5bfff8d1d876"
      unitRef="usd">6300000000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <us-gaap:PaymentsForLegalSettlements
      contextRef="i2ef2614263ad48d9934f6cc996c22e16_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDAvZnJhZzo2NGI0MmYwYWIwNTM0MmVmODQyMWRhOGFmZmFiNjU2Mi90ZXh0cmVnaW9uOjY0YjQyZjBhYjA1MzQyZWY4NDIxZGE4YWZmYWI2NTYyXzc3MjM_8306fb37-d460-4226-8df8-fa4b6c07eac0"
      unitRef="usd">372000000</us-gaap:PaymentsForLegalSettlements>
    <us-gaap:LitigationReserve
      contextRef="i92a2e3900c6e4547800cbb60799bcd60_I20230331"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDAvZnJhZzo2NGI0MmYwYWIwNTM0MmVmODQyMWRhOGFmZmFiNjU2Mi90ZXh0cmVnaW9uOjY0YjQyZjBhYjA1MzQyZWY4NDIxZGE4YWZmYWI2NTYyXzc3NzY_f802714c-86a5-4962-9ac9-4a4590e4e901"
      unitRef="usd">5850000000</us-gaap:LitigationReserve>
    <us-gaap:LitigationReserveCurrent
      contextRef="i92a2e3900c6e4547800cbb60799bcd60_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDAvZnJhZzo2NGI0MmYwYWIwNTM0MmVmODQyMWRhOGFmZmFiNjU2Mi90ZXh0cmVnaW9uOjY0YjQyZjBhYjA1MzQyZWY4NDIxZGE4YWZmYWI2NTYyXzc4MDM_71540c2f-2d5e-458a-8440-535a2c7d1e60"
      unitRef="usd">437000000</us-gaap:LitigationReserveCurrent>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="ibd1c21d9101a4eba857ea787640fd22a_I20220731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDAvZnJhZzo2NGI0MmYwYWIwNTM0MmVmODQyMWRhOGFmZmFiNjU2Mi90ZXh0cmVnaW9uOjY0YjQyZjBhYjA1MzQyZWY4NDIxZGE4YWZmYWI2NTYyXzg2MTY_55dc2501-a25f-49d2-b101-f2ce17b97ddb"
      unitRef="usd">124000000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="i960566e19fe54aa890cd9defe241cee0_I20221031"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDAvZnJhZzo2NGI0MmYwYWIwNTM0MmVmODQyMWRhOGFmZmFiNjU2Mi90ZXh0cmVnaW9uOjY0YjQyZjBhYjA1MzQyZWY4NDIxZGE4YWZmYWI2NTYyXzkwMTU_8138b431-0fe9-40b4-a5a6-fa1e90146bf9"
      unitRef="usd">136000000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <cah:LossContingencyLawsuitsNumber
      contextRef="i7f5e673a6ff2412f8e6ec60e722680b3_I20230428"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDAvZnJhZzo2NGI0MmYwYWIwNTM0MmVmODQyMWRhOGFmZmFiNjU2Mi90ZXh0cmVnaW9uOjY0YjQyZjBhYjA1MzQyZWY4NDIxZGE4YWZmYWI2NTYyXzEwNzY5_389544b4-37c2-4247-aac6-395b50dd91fb"
      unitRef="lawsuit">457</cah:LossContingencyLawsuitsNumber>
    <cah:LossContingencyLawsuitsNumber
      contextRef="i584bd35326394834b21f8bff13805226_I20230428"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDAvZnJhZzo2NGI0MmYwYWIwNTM0MmVmODQyMWRhOGFmZmFiNjU2Mi90ZXh0cmVnaW9uOjY0YjQyZjBhYjA1MzQyZWY4NDIxZGE4YWZmYWI2NTYyXzEwODE1_d02fcf7b-855b-4af2-adab-907430b37fe4"
      unitRef="lawsuit">107</cah:LossContingencyLawsuitsNumber>
    <us-gaap:LossContingencyNumberOfPlaintiffs
      contextRef="ie21d9b2ab8b84826b773ef6884028072_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDAvZnJhZzo2NGI0MmYwYWIwNTM0MmVmODQyMWRhOGFmZmFiNjU2Mi90ZXh0cmVnaW9uOjY0YjQyZjBhYjA1MzQyZWY4NDIxZGE4YWZmYWI2NTYyXzEwOTc4_472e4e88-d6ae-463a-be5e-ed3fc33cb380"
      unitRef="plaintiff">21</us-gaap:LossContingencyNumberOfPlaintiffs>
    <us-gaap:LossContingencyNumberOfPlaintiffs
      contextRef="i39d543d6d5bc4327b0cde155c825cad4_D20230701-20230701"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDAvZnJhZzo2NGI0MmYwYWIwNTM0MmVmODQyMWRhOGFmZmFiNjU2Mi90ZXh0cmVnaW9uOjY0YjQyZjBhYjA1MzQyZWY4NDIxZGE4YWZmYWI2NTYyXzExMTY3_a7f46e58-a2ca-495f-894f-9aad27bb0bea"
      unitRef="plaintiff">8</us-gaap:LossContingencyNumberOfPlaintiffs>
    <us-gaap:InsuranceRecoveries
      contextRef="i2ef2614263ad48d9934f6cc996c22e16_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDAvZnJhZzo2NGI0MmYwYWIwNTM0MmVmODQyMWRhOGFmZmFiNjU2Mi90ZXh0cmVnaW9uOjY0YjQyZjBhYjA1MzQyZWY4NDIxZGE4YWZmYWI2NTYyXzExNzcz_de16c384-ca76-4f67-98cb-ea74971f17fb"
      unitRef="usd">10000000</us-gaap:InsuranceRecoveries>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="icc7cc411a15e484b83110041666764e1_I20230428"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDAvZnJhZzo2NGI0MmYwYWIwNTM0MmVmODQyMWRhOGFmZmFiNjU2Mi90ZXh0cmVnaW9uOjY0YjQyZjBhYjA1MzQyZWY4NDIxZGE4YWZmYWI2NTYyXzEyMDMy_5ed521d7-147e-4f46-82b7-8aa8f955737d"
      unitRef="lawsuit">453</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyNumberOfPlaintiffs
      contextRef="i44256b1db02046efa5d29d670a7bcd5d_D20230428-20230428"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDAvZnJhZzo2NGI0MmYwYWIwNTM0MmVmODQyMWRhOGFmZmFiNjU2Mi90ZXh0cmVnaW9uOjY0YjQyZjBhYjA1MzQyZWY4NDIxZGE4YWZmYWI2NTYyXzEyMTU1_e273fff6-f50f-4bae-b3d4-80632d6c75bf"
      unitRef="plaintiff">5171</us-gaap:LossContingencyNumberOfPlaintiffs>
    <us-gaap:LossContingencyClaimsSettledNumber
      contextRef="i9ab800634809483fba34f7f06e7a35fe_D20230430-20230430"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDAvZnJhZzo2NGI0MmYwYWIwNTM0MmVmODQyMWRhOGFmZmFiNjU2Mi90ZXh0cmVnaW9uOjY0YjQyZjBhYjA1MzQyZWY4NDIxZGE4YWZmYWI2NTYyXzM4NDgyOTA3MjM2OTg_310cb90b-dae9-4932-bb06-a8e996fb9527"
      unitRef="lawsuit">4376</us-gaap:LossContingencyClaimsSettledNumber>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="i902b5ace502c4edbb1ba6a0998f22efa_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDAvZnJhZzo2NGI0MmYwYWIwNTM0MmVmODQyMWRhOGFmZmFiNjU2Mi90ZXh0cmVnaW9uOjY0YjQyZjBhYjA1MzQyZWY4NDIxZGE4YWZmYWI2NTYyXzM4NDgyOTA3MjM3MzI_df08946b-57e7-4cd0-bf50-cd3dd387c3bb"
      unitRef="usd">275000000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <us-gaap:PaymentsForLegalSettlements
      contextRef="i5afb309fb1ba4583a4deda7964b8c2cf_D20230501-20230930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDAvZnJhZzo2NGI0MmYwYWIwNTM0MmVmODQyMWRhOGFmZmFiNjU2Mi90ZXh0cmVnaW9uOjY0YjQyZjBhYjA1MzQyZWY4NDIxZGE4YWZmYWI2NTYyXzU0OTc1NTgxNjU0Mzg_2c463f19-8ddd-44d7-8398-5cf9b99cdd53"
      unitRef="usd">275000000</us-gaap:PaymentsForLegalSettlements>
    <us-gaap:LossContingencyClaimsSettledNumber
      contextRef="i80b8e7e7258b478b904b1818e9f2cc0c_D20210701-20230428"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDAvZnJhZzo2NGI0MmYwYWIwNTM0MmVmODQyMWRhOGFmZmFiNjU2Mi90ZXh0cmVnaW9uOjY0YjQyZjBhYjA1MzQyZWY4NDIxZGE4YWZmYWI2NTYyXzEyODM4_f3a862c7-d4c4-4c54-a81b-b872a6b6e8a9"
      unitRef="lawsuit">2881</us-gaap:LossContingencyClaimsSettledNumber>
    <us-gaap:ProductLiabilityAccrualPeriodExpense
      contextRef="ia3e20dfd93ab46e4866c903c3dfc10cf_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDAvZnJhZzo2NGI0MmYwYWIwNTM0MmVmODQyMWRhOGFmZmFiNjU2Mi90ZXh0cmVnaW9uOjY0YjQyZjBhYjA1MzQyZWY4NDIxZGE4YWZmYWI2NTYyXzEzMTYz_17ed36e4-fe0a-487d-af99-7f19a8f3537b"
      unitRef="usd">-71000000</us-gaap:ProductLiabilityAccrualPeriodExpense>
    <us-gaap:ProductLiabilityAccrualPeriodExpense
      contextRef="i853c2433b9a24879ba53a4b6f202569b_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDAvZnJhZzo2NGI0MmYwYWIwNTM0MmVmODQyMWRhOGFmZmFiNjU2Mi90ZXh0cmVnaW9uOjY0YjQyZjBhYjA1MzQyZWY4NDIxZGE4YWZmYWI2NTYyXzEzMTcw_c6b4c76a-f8c6-4e70-a660-a0ce4a505414"
      unitRef="usd">-95000000</us-gaap:ProductLiabilityAccrualPeriodExpense>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="i9ee8ab07c16a4a6c81486f97137b35dc_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDAvZnJhZzo2NGI0MmYwYWIwNTM0MmVmODQyMWRhOGFmZmFiNjU2Mi90ZXh0cmVnaW9uOjY0YjQyZjBhYjA1MzQyZWY4NDIxZGE4YWZmYWI2NTYyXzEzNDM1_7d4a35af-51c6-4a86-a76c-e71ab74216e5"
      unitRef="usd">385000000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="iacf755c31715440284f4942dd149ce26_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDAvZnJhZzo2NGI0MmYwYWIwNTM0MmVmODQyMWRhOGFmZmFiNjU2Mi90ZXh0cmVnaW9uOjY0YjQyZjBhYjA1MzQyZWY4NDIxZGE4YWZmYWI2NTYyXzM4NDgyOTA3MjM3NDY_d0cd28e0-a8bf-4e07-a2c7-4001c586c96e"
      unitRef="usd">109000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:InsuranceRecoveries
      contextRef="iacf755c31715440284f4942dd149ce26_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDAvZnJhZzo2NGI0MmYwYWIwNTM0MmVmODQyMWRhOGFmZmFiNjU2Mi90ZXh0cmVnaW9uOjY0YjQyZjBhYjA1MzQyZWY4NDIxZGE4YWZmYWI2NTYyXzM4NDgyOTA3MjM3NjA_e2157eb6-716c-4cb2-8b38-5213a3548d25"
      unitRef="usd">109000000</us-gaap:InsuranceRecoveries>
    <cah:IncomefromSettlementsofClassActionLawsuits
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDAvZnJhZzo2NGI0MmYwYWIwNTM0MmVmODQyMWRhOGFmZmFiNjU2Mi90ZXh0cmVnaW9uOjY0YjQyZjBhYjA1MzQyZWY4NDIxZGE4YWZmYWI2NTYyXzE2NDY5_70ff50e8-4b2b-4c49-bc5b-e9133552e95b"
      unitRef="usd">66000000</cah:IncomefromSettlementsofClassActionLawsuits>
    <cah:GrossInsuranceSettlementBeforeAttorneyFees
      contextRef="i04e26b0d7e5d4849a52f150680f0c631_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDAvZnJhZzo2NGI0MmYwYWIwNTM0MmVmODQyMWRhOGFmZmFiNjU2Mi90ZXh0cmVnaW9uOjY0YjQyZjBhYjA1MzQyZWY4NDIxZGE4YWZmYWI2NTYyXzE3NjU2_bd8c6a34-6f82-4a03-9891-edb4221df4d2"
      unitRef="usd">124000000</cah:GrossInsuranceSettlementBeforeAttorneyFees>
    <us-gaap:LegalFees
      contextRef="i04e26b0d7e5d4849a52f150680f0c631_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDAvZnJhZzo2NGI0MmYwYWIwNTM0MmVmODQyMWRhOGFmZmFiNjU2Mi90ZXh0cmVnaW9uOjY0YjQyZjBhYjA1MzQyZWY4NDIxZGE4YWZmYWI2NTYyXzE3Njc5_f47a8064-a5dc-40e1-af30-375cf6db8131"
      unitRef="usd">31000000</us-gaap:LegalFees>
    <us-gaap:ProceedsFromInsuranceSettlementOperatingActivities
      contextRef="i04e26b0d7e5d4849a52f150680f0c631_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDAvZnJhZzo2NGI0MmYwYWIwNTM0MmVmODQyMWRhOGFmZmFiNjU2Mi90ZXh0cmVnaW9uOjY0YjQyZjBhYjA1MzQyZWY4NDIxZGE4YWZmYWI2NTYyXzE3ODI5_2629ac01-e949-44f6-80cd-0da1405253ff"
      unitRef="usd">93000000</us-gaap:ProceedsFromInsuranceSettlementOperatingActivities>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDMvZnJhZzphZGIwZjc3ODQ5Yzk0OGRiYWRkN2JkZGVlYTgwZDU3ZC90ZXh0cmVnaW9uOmFkYjBmNzc4NDljOTQ4ZGJhZGQ3YmRkZWVhODBkNTdkXzQzMTc_fc3f5a8b-af8f-4d57-956e-8479d3ef0ad8">&lt;div style="display:inline-block;vertical-align:top;width:48.214%"&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;7. Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fluctuations in our provision for income taxes as a percentage of pre-tax earnings/(loss) (&#x201c;effective tax rate&#x201d;) are due to changes in international and U.S. state effective tax rates resulting from our business mix and discrete items. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Effective Tax Rate&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and nine months ended&#160;March&#160;31, 2023, the effective tax rate was&#160;36.3 percent and&#160;36.7 percent, respectively, and reflects any impact of the tax effects of the goodwill impairment charges recognized during the three and nine months ended March&#160;31, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and nine months ended&#160;March 31, 2022, the effective tax rate was (916.5) percent and (44.4) percent, respectively, and reflects the impact of the tax effect of the goodwill impairment charges recognized during the three and nine months ended March 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Tax Effects of Goodwill Impairment Charges&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the nine months ended March&#160;31, 2023, we recognized pre-tax goodwill impairment charges of $863&#160;million related to the Medical Unit. The net tax benefit related to these charges is $68&#160;million for fiscal 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unless an item is considered discrete because it is unusual or infrequent, the tax impact of the item is included in our estimated annual effective tax rate. When items are recognized through our estimated annual effective tax rate, we apply our estimated annual effective tax rate to the earnings/(loss) before income taxes for the year-to-date period to compute our impact from income taxes for the current quarter and year-to-date period. The tax impacts of discrete items are recognized in their entirety in the period in which they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The tax effect of the goodwill impairment charges during the nine months ended March 31, 2023 was included in our estimated annual effective tax rate because it was not considered unusual or infrequent, given that we recorded goodwill impairments in prior fiscal years. The impact of the non-deductible goodwill increased the estimated annual effective tax rate for fiscal 2023. Applying the higher tax rate to the pre-tax income for the nine months ended March&#160;31, 2023 resulted in recognizing an incremental interim tax expense of approximately $74&#160;million, which impacted the &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/&gt;&lt;div style="display:inline-block;vertical-align:top;width:48.215%"&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;provision for income taxes in the condensed consolidated statements of earnings/(loss) during the three months ended March&#160;31, 2023 and prepaid expenses and other assets in the condensed consolidated balance sheet at March&#160;31, 2023. The incremental interim tax benefit recognized during the nine months ended March&#160;31, 2023 was $66&#160;million and will reverse in the fourth quarter of fiscal 2023.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Unrecognized Tax Benefits&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We had $1.1 billion and $943 million of unrecognized tax benefits, at March&#160;31, 2023 and June&#160;30, 2022, respectively. The March&#160;31, 2023 and June&#160;30, 2022 balances include $897 million and $858 million of unrecognized tax benefits, respectively, that if recognized, would have an impact on the effective tax rate. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At March&#160;31, 2023 and June&#160;30, 2022, we had $61 million and $48 million, respectively, accrued for the payment of interest and penalties related to unrecognized tax benefits, which we recognize in the provision for income taxes in the condensed consolidated statements of earnings/(loss). These balances are gross amounts before any tax benefits and are included in deferred income taxes and other liabilities in the condensed consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;It is reasonably possible that there could be a change in the amount of unrecognized tax benefits within the next 12 months due to activities of the U.S. Internal Revenue Service ("IRS") or other taxing authorities, possible settlement of IRS and other audit issues, reassessment of existing unrecognized tax benefits or the expiration of statutes of limitations. We estimate that the range of the possible change in unrecognized tax benefits within the next 12 months is between zero and a net decrease of up to $125 million, exclusive of penalties and interest.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Tax Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions, and various foreign jurisdictions. With few exceptions, we are subject to audit by taxing authorities for fiscal years 2015 through the current fiscal year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are a party to a tax matters agreement with CareFusion Corporation ("CareFusion"), a subsidiary of Becton, Dickinson and Company. Under the tax matters agreement, CareFusion is obligated to indemnify us for certain tax exposures and transaction taxes prior to our fiscal 2010 spin-off of CareFusion. The indemnification receivable was $80 million and $75&#160;million at &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;March&#160;31, 2023 and June&#160;30, 2022, respectively, and is included in other assets in the condensed consolidated balance sheets.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDMvZnJhZzphZGIwZjc3ODQ5Yzk0OGRiYWRkN2JkZGVlYTgwZDU3ZC90ZXh0cmVnaW9uOmFkYjBmNzc4NDljOTQ4ZGJhZGQ3YmRkZWVhODBkNTdkXzM0OQ_b908f30a-d1cb-48e0-832a-1944d6afb4a8"
      unitRef="number">0.363</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDMvZnJhZzphZGIwZjc3ODQ5Yzk0OGRiYWRkN2JkZGVlYTgwZDU3ZC90ZXh0cmVnaW9uOmFkYjBmNzc4NDljOTQ4ZGJhZGQ3YmRkZWVhODBkNTdkXzM1Ng_fd3419c9-554c-4638-b070-7eb64e713ce7"
      unitRef="number">0.367</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDMvZnJhZzphZGIwZjc3ODQ5Yzk0OGRiYWRkN2JkZGVlYTgwZDU3ZC90ZXh0cmVnaW9uOmFkYjBmNzc4NDljOTQ4ZGJhZGQ3YmRkZWVhODBkNTdkXzU2MQ_417c57df-6afc-4489-be95-94a586dee2a6"
      unitRef="number">-9.165</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDMvZnJhZzphZGIwZjc3ODQ5Yzk0OGRiYWRkN2JkZGVlYTgwZDU3ZC90ZXh0cmVnaW9uOmFkYjBmNzc4NDljOTQ4ZGJhZGQ3YmRkZWVhODBkNTdkXzU2OA_45824f02-9c65-406e-b6b3-2af4f8ae07d1"
      unitRef="number">-0.444</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="ie12745b4aa3e4e2f8127b2b3aa94621c_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDMvZnJhZzphZGIwZjc3ODQ5Yzk0OGRiYWRkN2JkZGVlYTgwZDU3ZC90ZXh0cmVnaW9uOmFkYjBmNzc4NDljOTQ4ZGJhZGQ3YmRkZWVhODBkNTdkXzg0Mw_81d80d54-799e-4fdb-8938-1abf1e264da3"
      unitRef="usd">863000000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ie5694d08abff46ac90bbee9634d4edd3_D20220701-20230630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDMvZnJhZzphZGIwZjc3ODQ5Yzk0OGRiYWRkN2JkZGVlYTgwZDU3ZC90ZXh0cmVnaW9uOmFkYjBmNzc4NDljOTQ4ZGJhZGQ3YmRkZWVhODBkNTdkXzkyMQ_e02dc733-d382-4589-8795-f28314e59f55"
      unitRef="usd">-68000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i22d8ac48311042cebfc3c15dda5a16fa_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDMvZnJhZzphZGIwZjc3ODQ5Yzk0OGRiYWRkN2JkZGVlYTgwZDU3ZC90ZXh0cmVnaW9uOmFkYjBmNzc4NDljOTQ4ZGJhZGQ3YmRkZWVhODBkNTdkXzIwMzQ_0c7ffd07-eeca-4a90-8f33-84570b7fb693"
      unitRef="usd">74000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ie4fa6e3e07aa461e98a6b82df41d98ce_D20230401-20230630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDMvZnJhZzphZGIwZjc3ODQ5Yzk0OGRiYWRkN2JkZGVlYTgwZDU3ZC90ZXh0cmVnaW9uOmFkYjBmNzc4NDljOTQ4ZGJhZGQ3YmRkZWVhODBkNTdkXzU0OTc1NTgxNDM3Njc_41923bf4-257e-442d-815b-1dc425a99c0e"
      unitRef="usd">66000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDMvZnJhZzphZGIwZjc3ODQ5Yzk0OGRiYWRkN2JkZGVlYTgwZDU3ZC90ZXh0cmVnaW9uOmFkYjBmNzc4NDljOTQ4ZGJhZGQ3YmRkZWVhODBkNTdkXzIzODU_0ae59b1a-c97b-42e6-ab9b-b817a2e67afc"
      unitRef="usd">1100000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ic217743408d440409a59220a0bf14e4c_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDMvZnJhZzphZGIwZjc3ODQ5Yzk0OGRiYWRkN2JkZGVlYTgwZDU3ZC90ZXh0cmVnaW9uOmFkYjBmNzc4NDljOTQ4ZGJhZGQ3YmRkZWVhODBkNTdkXzIzOTI_cbc11d84-76e9-4eae-88a0-42b30d5657aa"
      unitRef="usd">943000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDMvZnJhZzphZGIwZjc3ODQ5Yzk0OGRiYWRkN2JkZGVlYTgwZDU3ZC90ZXh0cmVnaW9uOmFkYjBmNzc4NDljOTQ4ZGJhZGQ3YmRkZWVhODBkNTdkXzI0ODQ_f4e88101-5117-44da-a4b9-1b7279ea605d"
      unitRef="usd">897000000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="ic217743408d440409a59220a0bf14e4c_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDMvZnJhZzphZGIwZjc3ODQ5Yzk0OGRiYWRkN2JkZGVlYTgwZDU3ZC90ZXh0cmVnaW9uOmFkYjBmNzc4NDljOTQ4ZGJhZGQ3YmRkZWVhODBkNTdkXzI0OTE_c0535ce1-5e47-49ba-9614-eb5cebff5e9a"
      unitRef="usd">858000000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDMvZnJhZzphZGIwZjc3ODQ5Yzk0OGRiYWRkN2JkZGVlYTgwZDU3ZC90ZXh0cmVnaW9uOmFkYjBmNzc4NDljOTQ4ZGJhZGQ3YmRkZWVhODBkNTdkXzI2Mjg_3da589e2-950b-4ad3-a7e9-e1201c3125f1"
      unitRef="usd">61000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="ic217743408d440409a59220a0bf14e4c_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDMvZnJhZzphZGIwZjc3ODQ5Yzk0OGRiYWRkN2JkZGVlYTgwZDU3ZC90ZXh0cmVnaW9uOmFkYjBmNzc4NDljOTQ4ZGJhZGQ3YmRkZWVhODBkNTdkXzI2MzU_0c297ded-eb53-40fc-aaef-518d9d41c01c"
      unitRef="usd">48000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible
      contextRef="i0fb653442b8d46c4b1d69a67bca87b29_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDMvZnJhZzphZGIwZjc3ODQ5Yzk0OGRiYWRkN2JkZGVlYTgwZDU3ZC90ZXh0cmVnaW9uOmFkYjBmNzc4NDljOTQ4ZGJhZGQ3YmRkZWVhODBkNTdkXzM1MTg_4ee93fa3-1f67-4d18-b339-c902c028f19a"
      unitRef="usd">0</us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible>
    <us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible
      contextRef="ifef254c9824a4dbcbe0e5996b5dcc160_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDMvZnJhZzphZGIwZjc3ODQ5Yzk0OGRiYWRkN2JkZGVlYTgwZDU3ZC90ZXh0cmVnaW9uOmFkYjBmNzc4NDljOTQ4ZGJhZGQ3YmRkZWVhODBkNTdkXzM1NDk_5769d669-6139-4f47-abd0-39d6ab0faad2"
      unitRef="usd">125000000</us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible>
    <cah:IndemnificationReceivable
      contextRef="ia83e033e96e343bda1abf45e39b6de85_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDMvZnJhZzphZGIwZjc3ODQ5Yzk0OGRiYWRkN2JkZGVlYTgwZDU3ZC90ZXh0cmVnaW9uOmFkYjBmNzc4NDljOTQ4ZGJhZGQ3YmRkZWVhODBkNTdkXzQxOTg_0a75d12c-d0d5-4126-a309-f16fa26c0708"
      unitRef="usd">80000000</cah:IndemnificationReceivable>
    <cah:IndemnificationReceivable
      contextRef="i4b473c3f43624d36b0c2c645e60d3c85_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDMvZnJhZzphZGIwZjc3ODQ5Yzk0OGRiYWRkN2JkZGVlYTgwZDU3ZC90ZXh0cmVnaW9uOmFkYjBmNzc4NDljOTQ4ZGJhZGQ3YmRkZWVhODBkNTdkXzQyMDU_cda7e9b3-663f-435b-8af8-cdc7fe5f306d"
      unitRef="usd">75000000</cah:IndemnificationReceivable>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDYvZnJhZzo5ZDA4MzdmNjYxMjU0M2E0ODc0ZjM3OWFlZjc3MjY2Mi90ZXh0cmVnaW9uOjlkMDgzN2Y2NjEyNTQzYTQ4NzRmMzc5YWVmNzcyNjYyXzEyMjI_f775b671-2d7f-47be-a991-c89870c2d471">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;8. Fair Value Measurements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present the fair values for assets and (liabilities) measured on a recurring basis at:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.938%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,302&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,302&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other investments (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;95&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;95&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forward contracts (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.938%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other investments (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forward contracts (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;The other investments balance includes investments in mutual funds, which offset fluctuations in deferred compensation liabilities. These mutual funds invest in the equity securities of companies with both large and small market capitalization and high quality fixed income debt securities. The fair value of these investments is determined using quoted market prices.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;The fair value of interest rate swaps, foreign currency contracts, and net investment hedges is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in prepaid expenses and other, other assets, other accrued liabilities, and deferred income taxes and other liabilities within the condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDYvZnJhZzo5ZDA4MzdmNjYxMjU0M2E0ODc0ZjM3OWFlZjc3MjY2Mi90ZXh0cmVnaW9uOjlkMDgzN2Y2NjEyNTQzYTQ4NzRmMzc5YWVmNzcyNjYyXzEyMDg_d0511be6-05df-4080-9533-22cc8c02a236">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present the fair values for assets and (liabilities) measured on a recurring basis at:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.938%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,302&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,302&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other investments (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;95&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;95&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forward contracts (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.938%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other investments (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forward contracts (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;The other investments balance includes investments in mutual funds, which offset fluctuations in deferred compensation liabilities. These mutual funds invest in the equity securities of companies with both large and small market capitalization and high quality fixed income debt securities. The fair value of these investments is determined using quoted market prices.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;The fair value of interest rate swaps, foreign currency contracts, and net investment hedges is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in prepaid expenses and other, other assets, other accrued liabilities, and deferred income taxes and other liabilities within the condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i0647080b68e4434fb69d13640e2185be_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDYvZnJhZzo5ZDA4MzdmNjYxMjU0M2E0ODc0ZjM3OWFlZjc3MjY2Mi90YWJsZTo2ZmI3Njg5ODc1NjE0MjJlYWYyZDdiMDFkNGEyNTc4Yy90YWJsZXJhbmdlOjZmYjc2ODk4NzU2MTQyMmVhZjJkN2IwMWQ0YTI1NzhjXzMtMS0xLTEtMjg2OTQ0_46b609ad-53f9-4e8e-9795-ecc0f1b40469"
      unitRef="usd">1302000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i22574d8c00bd4f13ae6ec2c4fcc2f017_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDYvZnJhZzo5ZDA4MzdmNjYxMjU0M2E0ODc0ZjM3OWFlZjc3MjY2Mi90YWJsZTo2ZmI3Njg5ODc1NjE0MjJlYWYyZDdiMDFkNGEyNTc4Yy90YWJsZXJhbmdlOjZmYjc2ODk4NzU2MTQyMmVhZjJkN2IwMWQ0YTI1NzhjXzMtMy0xLTEtMjg2OTQ0_23784e5a-c381-460a-92f4-d1f9828c6a7a"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ib308cbc504e54cfea2d4a2a0d5e67181_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDYvZnJhZzo5ZDA4MzdmNjYxMjU0M2E0ODc0ZjM3OWFlZjc3MjY2Mi90YWJsZTo2ZmI3Njg5ODc1NjE0MjJlYWYyZDdiMDFkNGEyNTc4Yy90YWJsZXJhbmdlOjZmYjc2ODk4NzU2MTQyMmVhZjJkN2IwMWQ0YTI1NzhjXzMtNS0xLTEtMjg2OTQ0_4aad3254-e892-41e5-a30d-b4c738732194"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ic1d54b1779a94c778dcfd9c480a2851b_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDYvZnJhZzo5ZDA4MzdmNjYxMjU0M2E0ODc0ZjM3OWFlZjc3MjY2Mi90YWJsZTo2ZmI3Njg5ODc1NjE0MjJlYWYyZDdiMDFkNGEyNTc4Yy90YWJsZXJhbmdlOjZmYjc2ODk4NzU2MTQyMmVhZjJkN2IwMWQ0YTI1NzhjXzMtNy0xLTEtMjg2OTQ0_4b720a6f-8b63-4194-a98b-500f700fd213"
      unitRef="usd">1302000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i0647080b68e4434fb69d13640e2185be_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDYvZnJhZzo5ZDA4MzdmNjYxMjU0M2E0ODc0ZjM3OWFlZjc3MjY2Mi90YWJsZTo2ZmI3Njg5ODc1NjE0MjJlYWYyZDdiMDFkNGEyNTc4Yy90YWJsZXJhbmdlOjZmYjc2ODk4NzU2MTQyMmVhZjJkN2IwMWQ0YTI1NzhjXzUtMS0xLTEtMjg2OTQ0_903f1b45-097c-474e-9d9b-7adc1172a4ab"
      unitRef="usd">95000000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i22574d8c00bd4f13ae6ec2c4fcc2f017_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDYvZnJhZzo5ZDA4MzdmNjYxMjU0M2E0ODc0ZjM3OWFlZjc3MjY2Mi90YWJsZTo2ZmI3Njg5ODc1NjE0MjJlYWYyZDdiMDFkNGEyNTc4Yy90YWJsZXJhbmdlOjZmYjc2ODk4NzU2MTQyMmVhZjJkN2IwMWQ0YTI1NzhjXzUtMy0xLTEtMjg2OTQ0_8d5d038b-90d6-4e82-b87e-a6bfb5a7836c"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ib308cbc504e54cfea2d4a2a0d5e67181_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDYvZnJhZzo5ZDA4MzdmNjYxMjU0M2E0ODc0ZjM3OWFlZjc3MjY2Mi90YWJsZTo2ZmI3Njg5ODc1NjE0MjJlYWYyZDdiMDFkNGEyNTc4Yy90YWJsZXJhbmdlOjZmYjc2ODk4NzU2MTQyMmVhZjJkN2IwMWQ0YTI1NzhjXzUtNS0xLTEtMjg2OTQ0_1aeb4d69-2064-46b5-84b9-2b702aef6b7c"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ic1d54b1779a94c778dcfd9c480a2851b_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDYvZnJhZzo5ZDA4MzdmNjYxMjU0M2E0ODc0ZjM3OWFlZjc3MjY2Mi90YWJsZTo2ZmI3Njg5ODc1NjE0MjJlYWYyZDdiMDFkNGEyNTc4Yy90YWJsZXJhbmdlOjZmYjc2ODk4NzU2MTQyMmVhZjJkN2IwMWQ0YTI1NzhjXzUtNy0xLTEtMjg2OTQ0_4bebf854-25cb-485f-b965-672c302e7603"
      unitRef="usd">95000000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet
      contextRef="i0647080b68e4434fb69d13640e2185be_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDYvZnJhZzo5ZDA4MzdmNjYxMjU0M2E0ODc0ZjM3OWFlZjc3MjY2Mi90YWJsZTo2ZmI3Njg5ODc1NjE0MjJlYWYyZDdiMDFkNGEyNTc4Yy90YWJsZXJhbmdlOjZmYjc2ODk4NzU2MTQyMmVhZjJkN2IwMWQ0YTI1NzhjXzgtMS0xLTEtMjg2OTQ0_39981380-d816-470a-8409-859dd01e63f1"
      unitRef="usd">0</us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet>
    <us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet
      contextRef="i22574d8c00bd4f13ae6ec2c4fcc2f017_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDYvZnJhZzo5ZDA4MzdmNjYxMjU0M2E0ODc0ZjM3OWFlZjc3MjY2Mi90YWJsZTo2ZmI3Njg5ODc1NjE0MjJlYWYyZDdiMDFkNGEyNTc4Yy90YWJsZXJhbmdlOjZmYjc2ODk4NzU2MTQyMmVhZjJkN2IwMWQ0YTI1NzhjXzgtMy0xLTEtMjg2OTQ0_413970cf-feb1-4338-9a4b-1f23a460bdda"
      unitRef="usd">-52000000</us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet>
    <us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet
      contextRef="ib308cbc504e54cfea2d4a2a0d5e67181_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDYvZnJhZzo5ZDA4MzdmNjYxMjU0M2E0ODc0ZjM3OWFlZjc3MjY2Mi90YWJsZTo2ZmI3Njg5ODc1NjE0MjJlYWYyZDdiMDFkNGEyNTc4Yy90YWJsZXJhbmdlOjZmYjc2ODk4NzU2MTQyMmVhZjJkN2IwMWQ0YTI1NzhjXzgtNS0xLTEtMjg2OTQ0_d40fd569-8641-46e0-a4e7-a7cbe3c0c646"
      unitRef="usd">0</us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet>
    <us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet
      contextRef="ic1d54b1779a94c778dcfd9c480a2851b_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDYvZnJhZzo5ZDA4MzdmNjYxMjU0M2E0ODc0ZjM3OWFlZjc3MjY2Mi90YWJsZTo2ZmI3Njg5ODc1NjE0MjJlYWYyZDdiMDFkNGEyNTc4Yy90YWJsZXJhbmdlOjZmYjc2ODk4NzU2MTQyMmVhZjJkN2IwMWQ0YTI1NzhjXzgtNy0xLTEtMjg2OTQ0_c66a4834-31b5-406d-ba46-3b67550246da"
      unitRef="usd">-52000000</us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ic019966f86814bbbafa5f64677ed3ae9_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDYvZnJhZzo5ZDA4MzdmNjYxMjU0M2E0ODc0ZjM3OWFlZjc3MjY2Mi90YWJsZTo3YzRmM2E4OWJmNDE0NTRhOGU1MGJkOTI0NDEyMjE5MC90YWJsZXJhbmdlOjdjNGYzYTg5YmY0MTQ1NGE4ZTUwYmQ5MjQ0MTIyMTkwXzMtMS0xLTEtMjg2OTQ0_c6638f5c-4ec4-4efd-aff8-a26ebb8bb74b"
      unitRef="usd">2425000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="id3c2602782c94beab41f34560fbefd82_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDYvZnJhZzo5ZDA4MzdmNjYxMjU0M2E0ODc0ZjM3OWFlZjc3MjY2Mi90YWJsZTo3YzRmM2E4OWJmNDE0NTRhOGU1MGJkOTI0NDEyMjE5MC90YWJsZXJhbmdlOjdjNGYzYTg5YmY0MTQ1NGE4ZTUwYmQ5MjQ0MTIyMTkwXzMtMy0xLTEtMjg2OTQ0_723b2f18-0db5-4b03-8788-1a2f23576222"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ic33b3236678d4dba9bb198c5653cc58f_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDYvZnJhZzo5ZDA4MzdmNjYxMjU0M2E0ODc0ZjM3OWFlZjc3MjY2Mi90YWJsZTo3YzRmM2E4OWJmNDE0NTRhOGU1MGJkOTI0NDEyMjE5MC90YWJsZXJhbmdlOjdjNGYzYTg5YmY0MTQ1NGE4ZTUwYmQ5MjQ0MTIyMTkwXzMtNS0xLTEtMjg2OTQ0_90ef35dc-08c9-412e-bc9d-72e2cb3f0266"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i590356452cf8465698d99ccf090749ee_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDYvZnJhZzo5ZDA4MzdmNjYxMjU0M2E0ODc0ZjM3OWFlZjc3MjY2Mi90YWJsZTo3YzRmM2E4OWJmNDE0NTRhOGU1MGJkOTI0NDEyMjE5MC90YWJsZXJhbmdlOjdjNGYzYTg5YmY0MTQ1NGE4ZTUwYmQ5MjQ0MTIyMTkwXzMtNy0xLTEtMjg2OTQ0_ae7b7d13-1888-4c23-8b39-6146cdbba85d"
      unitRef="usd">2425000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ic019966f86814bbbafa5f64677ed3ae9_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDYvZnJhZzo5ZDA4MzdmNjYxMjU0M2E0ODc0ZjM3OWFlZjc3MjY2Mi90YWJsZTo3YzRmM2E4OWJmNDE0NTRhOGU1MGJkOTI0NDEyMjE5MC90YWJsZXJhbmdlOjdjNGYzYTg5YmY0MTQ1NGE4ZTUwYmQ5MjQ0MTIyMTkwXzUtMS0xLTEtMjg2OTQ0_5138fe7e-8832-4270-b89e-05f7a7bd0e3f"
      unitRef="usd">97000000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="id3c2602782c94beab41f34560fbefd82_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDYvZnJhZzo5ZDA4MzdmNjYxMjU0M2E0ODc0ZjM3OWFlZjc3MjY2Mi90YWJsZTo3YzRmM2E4OWJmNDE0NTRhOGU1MGJkOTI0NDEyMjE5MC90YWJsZXJhbmdlOjdjNGYzYTg5YmY0MTQ1NGE4ZTUwYmQ5MjQ0MTIyMTkwXzUtMy0xLTEtMjg2OTQ0_4c7782c4-103f-44ef-85ec-adbea767618b"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ic33b3236678d4dba9bb198c5653cc58f_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDYvZnJhZzo5ZDA4MzdmNjYxMjU0M2E0ODc0ZjM3OWFlZjc3MjY2Mi90YWJsZTo3YzRmM2E4OWJmNDE0NTRhOGU1MGJkOTI0NDEyMjE5MC90YWJsZXJhbmdlOjdjNGYzYTg5YmY0MTQ1NGE4ZTUwYmQ5MjQ0MTIyMTkwXzUtNS0xLTEtMjg2OTQ0_13d410f3-962b-4dab-bb5f-9285b387cdd0"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i590356452cf8465698d99ccf090749ee_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDYvZnJhZzo5ZDA4MzdmNjYxMjU0M2E0ODc0ZjM3OWFlZjc3MjY2Mi90YWJsZTo3YzRmM2E4OWJmNDE0NTRhOGU1MGJkOTI0NDEyMjE5MC90YWJsZXJhbmdlOjdjNGYzYTg5YmY0MTQ1NGE4ZTUwYmQ5MjQ0MTIyMTkwXzUtNy0xLTEtMjg2OTQ0_baef2075-b855-4ee8-b13d-7ebbc539deaa"
      unitRef="usd">97000000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet
      contextRef="ic019966f86814bbbafa5f64677ed3ae9_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDYvZnJhZzo5ZDA4MzdmNjYxMjU0M2E0ODc0ZjM3OWFlZjc3MjY2Mi90YWJsZTo3YzRmM2E4OWJmNDE0NTRhOGU1MGJkOTI0NDEyMjE5MC90YWJsZXJhbmdlOjdjNGYzYTg5YmY0MTQ1NGE4ZTUwYmQ5MjQ0MTIyMTkwXzYtMS0xLTEtMjg2OTQ0_3afb4693-13b0-41aa-898d-674b43e2267a"
      unitRef="usd">0</us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet>
    <us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet
      contextRef="id3c2602782c94beab41f34560fbefd82_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDYvZnJhZzo5ZDA4MzdmNjYxMjU0M2E0ODc0ZjM3OWFlZjc3MjY2Mi90YWJsZTo3YzRmM2E4OWJmNDE0NTRhOGU1MGJkOTI0NDEyMjE5MC90YWJsZXJhbmdlOjdjNGYzYTg5YmY0MTQ1NGE4ZTUwYmQ5MjQ0MTIyMTkwXzYtMy0xLTEtMjg2OTQ0_a1758862-1591-4abd-94f1-92eab4204df2"
      unitRef="usd">15000000</us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet>
    <us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet
      contextRef="ic33b3236678d4dba9bb198c5653cc58f_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDYvZnJhZzo5ZDA4MzdmNjYxMjU0M2E0ODc0ZjM3OWFlZjc3MjY2Mi90YWJsZTo3YzRmM2E4OWJmNDE0NTRhOGU1MGJkOTI0NDEyMjE5MC90YWJsZXJhbmdlOjdjNGYzYTg5YmY0MTQ1NGE4ZTUwYmQ5MjQ0MTIyMTkwXzYtNS0xLTEtMjg2OTQ0_419fbff5-a16e-4cc3-acfb-ebdaa9411a14"
      unitRef="usd">0</us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet>
    <us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet
      contextRef="i590356452cf8465698d99ccf090749ee_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDYvZnJhZzo5ZDA4MzdmNjYxMjU0M2E0ODc0ZjM3OWFlZjc3MjY2Mi90YWJsZTo3YzRmM2E4OWJmNDE0NTRhOGU1MGJkOTI0NDEyMjE5MC90YWJsZXJhbmdlOjdjNGYzYTg5YmY0MTQ1NGE4ZTUwYmQ5MjQ0MTIyMTkwXzYtNy0xLTEtMjg2OTQ0_065b93fd-6604-4192-aacb-052a2e457c37"
      unitRef="usd">15000000</us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet>
    <us-gaap:FinancialInstrumentsDisclosureTextBlock
      contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDkvZnJhZzoyNWNlMTUzYjg0YzY0ZTc2OTNhY2U2MmNjZjgxYzk2MS90ZXh0cmVnaW9uOjI1Y2UxNTNiODRjNjRlNzY5M2FjZTYyY2NmODFjOTYxXzgwMTc_0b70712a-d0d9-490b-8fc5-8b7b7913fe60">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;9. Financial Instruments &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We utilize derivative financial instruments to manage exposure to certain risks related to our ongoing operations. The primary risks managed through the use of derivative instruments include interest rate risk, currency exchange risk and commodity price risk. We do not use derivative instruments for trading or speculative purposes. While the majority of our derivative instruments are designated as hedging instruments, we also enter into derivative instruments that are designed to hedge a risk but are not designated as hedging instruments. These derivative instruments are adjusted to current fair value through earnings at the end of each period. We are exposed to counterparty credit risk on all of our derivative instruments. Accordingly, we have established and maintain strict counterparty credit guidelines and only enter into derivative instruments with major financial institutions that are rated investment grade or better. We do not have significant exposure to &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;any one counterparty and we believe the risk of loss is remote. Additionally, we do not require collateral under these agreements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Interest Rate Risk Management&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are exposed to the impact of interest rate changes. Our objective is to manage the impact of interest rate changes on cash flows and the market value of our borrowings. We utilize a mix of debt maturities on our fixed-rate debt to manage changes in interest rates. In addition, we enter into interest rate swaps to further manage our exposure to interest rate variations related to our borrowings and to lower our overall borrowing costs.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Currency Exchange Risk Management&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We conduct business in several major international currencies and are subject to risks associated with changing foreign exchange rates. Our objective is to reduce earnings and cash flow volatility associated with foreign exchange rate changes to allow management to focus its attention on business operations. Accordingly, we enter into various contracts that change in value as foreign exchange rates change to protect the value of existing foreign currency assets and liabilities, commitments and anticipated foreign currency revenue and expenses.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Commodity Price Risk Management&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are exposed to changes in the price of certain commodities. Our objective is to reduce earnings and cash flow volatility associated with forecasted purchases of these commodities to allow management to focus its attention on business operations. Accordingly, we enter into derivative contracts when possible to manage the price risk associated with certain forecasted purchases.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Fair Value Hedges&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We enter into pay-floating interest rate swaps to hedge the changes in the fair value of fixed-rate debt resulting from fluctuations in interest rates. These contracts are designated and qualify as fair value hedges. Accordingly, the gain or loss recorded on the pay-floating interest rate swaps is directly offset by the change in fair value of the underlying debt. Both the derivative instrument and the underlying debt are adjusted to market value at the end of each period with any resulting gain or loss recorded in interest expense, net in the condensed consolidated statements of earnings/(loss). For the three and nine months ended March&#160;31, 2023 and 2022, there was no gain or loss recorded to interest expense as changes in the market value of our derivative instruments offset changes in the market value of the underlying debt.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the nine months ended March 31, 2023 and 2022, we entered into pay-floating interest rate swaps with total notional amounts of $200 million and $300 million, respectively. These swaps have been designated as fair value hedges of our fixed rate debt and are included in deferred income taxes and other liabilities in the condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Cash Flow Hedges&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We enter into derivative instruments to hedge our exposure to changes in cash flows attributable to interest rate, foreign currency and commodity price fluctuations associated with certain forecasted transactions. These derivative instruments are designated and qualify as cash flow hedges. Accordingly, the gain or loss on the derivative instrument is reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same line item associated with the forecasted transaction and in the same period during which the hedged transaction affects earnings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pre-tax gains recognized in other comprehensive income/(loss) were $2&#160;million and $1&#160;million for the three months ended March&#160;31, 2023 and 2022, respectively, and $4&#160;million for both the nine months ended March&#160;31, 2023 and 2022. Gains recognized in accumulated other comprehensive loss and reclassified into earnings were $4&#160;million and immaterial for the three months ended March&#160;31, 2023 and 2022, respectively, and were $8&#160;million and immaterial for the nine months ended March&#160;31, 2023 and 2022, respectively. Gains currently included within accumulated other comprehensive loss associated with our cash flow hedges to be reclassified into net earnings within the next 12 months are $7&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Net Investment Hedges&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We hedge the foreign currency risk associated with certain net investment positions in foreign subsidiaries. To accomplish this, we enter into cross-currency swaps that are designated as hedges of net investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended&#160;March 31, 2023, we entered into &#xa5;19&#160;billion ($150&#160;million) cross-currency swaps maturing in September 2025, &#xa5;19&#160;billion ($150&#160;million) cross-currency swaps maturing in June 2027, &#x20ac;100&#160;million ($107&#160;million) cross-currency swaps maturing in March 2025 and &#x20ac;100&#160;million ($107&#160;million) cross-currency swaps maturing in March 2026.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended&#160;March 31, 2023, we terminated the &#xa5;48&#160;billion ($400&#160;million) cross-currency swaps entered into in March 2022 and the &#x20ac;200&#160;million ($233&#160;million) cross-currency swap entered into in September 2018 and received net settlements of $10&#160;million and $19&#160;million in cash, respectively, recorded in proceeds from net investment hedge terminations in our condensed consolidated statements of cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cross-currency swaps designated as net investment hedges are marked to market using the current spot exchange rate as of the end of the period, with gains and losses included in the foreign currency translation component of accumulated other comprehensive loss until the sale or substantial liquidation of the underlying net investments. To the extent the cross-currency swaps designated as net investment hedges are not highly effective, changes in carrying value attributable to the change in spot rates are recorded in earnings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pre-tax gain and loss from net investment hedges recorded in the foreign currency translation component of accumulated other &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;comprehensive loss was an immaterial loss and a $22&#160;million gain during the three months ended March&#160;31, 2023 and 2022, respectively, and a $21&#160;million loss and a $44&#160;million gain during the nine months ended March&#160;31, 2023 and 2022, respectively. Gains recognized in interest expense, net in the condensed consolidated statements of earnings/(loss) for the portion of the net investment hedges excluded from the assessment of hedge effectiveness were $4&#160;million and $5&#160;million during the three months ended March&#160;31, 2023 and 2022, respectively, and $12&#160;million and $16&#160;million during the nine months ended March&#160;31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Economic (Non-Designated) Hedges&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We enter into foreign currency contracts to manage our foreign exchange exposure related to sales transactions, intercompany financing transactions and other balance sheet items subject to revaluation that do not meet the requirements for hedge accounting treatment. Accordingly, these derivative instruments are adjusted to current market value at the end of each period through earnings. The gain or loss recorded on these instruments is substantially offset by the remeasurement adjustment on the foreign currency denominated asset or liability. The settlement of the derivative instrument and the remeasurement adjustment on the foreign currency denominated asset or liability are both recorded in other (income)/expense, net. We recorded an immaterial loss and a $4 million loss during the three months ended March 31, 2023 and 2022, respectively, and a $3 million loss and an immaterial loss during the nine months ended March&#160;31, 2023 and 2022, respectively. The principal currencies managed through foreign currency contracts are Canadian dollar, Euro, Chinese renminbi, Indian rupee and Thai baht.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts of cash and equivalents, trade receivables, accounts payable and other accrued liabilities at March&#160;31, 2023 and June&#160;30, 2022 approximate fair value due to their short-term maturities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.109%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.986%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.062%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Estimated fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,466&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,734&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of our long-term obligations and other short-term borrowings is estimated based on either the quoted market prices for the same or similar issues or other inputs derived from available market information, which represents a Level 2 measurement.&lt;/span&gt;&lt;/div&gt;</us-gaap:FinancialInstrumentsDisclosureTextBlock>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDkvZnJhZzoyNWNlMTUzYjg0YzY0ZTc2OTNhY2U2MmNjZjgxYzk2MS90ZXh0cmVnaW9uOjI1Y2UxNTNiODRjNjRlNzY5M2FjZTYyY2NmODFjOTYxXzMyNTI_741382ce-00a8-4b5e-922c-2efaee48ddc8"
      unitRef="usd">0</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDkvZnJhZzoyNWNlMTUzYjg0YzY0ZTc2OTNhY2U2MmNjZjgxYzk2MS90ZXh0cmVnaW9uOjI1Y2UxNTNiODRjNjRlNzY5M2FjZTYyY2NmODFjOTYxXzMyNTI_b0ee285c-f109-4110-8c84-5ce87cc00c2e"
      unitRef="usd">0</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDkvZnJhZzoyNWNlMTUzYjg0YzY0ZTc2OTNhY2U2MmNjZjgxYzk2MS90ZXh0cmVnaW9uOjI1Y2UxNTNiODRjNjRlNzY5M2FjZTYyY2NmODFjOTYxXzMyNTI_bb7d4d06-96e2-47d5-a0c7-2b97c4ad667b"
      unitRef="usd">0</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDkvZnJhZzoyNWNlMTUzYjg0YzY0ZTc2OTNhY2U2MmNjZjgxYzk2MS90ZXh0cmVnaW9uOjI1Y2UxNTNiODRjNjRlNzY5M2FjZTYyY2NmODFjOTYxXzMyNTI_d7de8f97-a1ff-490b-8d4f-95e66fa6f681"
      unitRef="usd">0</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="ie7058036db8747708418c4af8c5bbe90_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDkvZnJhZzoyNWNlMTUzYjg0YzY0ZTc2OTNhY2U2MmNjZjgxYzk2MS90ZXh0cmVnaW9uOjI1Y2UxNTNiODRjNjRlNzY5M2FjZTYyY2NmODFjOTYxXzM1MjQ_f25d6a08-132f-4b6c-ae6c-d73772122590"
      unitRef="usd">200000000</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="ib40cb321ed7048c3a2302a1bf22f2f6f_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDkvZnJhZzoyNWNlMTUzYjg0YzY0ZTc2OTNhY2U2MmNjZjgxYzk2MS90ZXh0cmVnaW9uOjI1Y2UxNTNiODRjNjRlNzY5M2FjZTYyY2NmODFjOTYxXzM1MzE_c2b09c12-44d7-49af-a768-8eb982ed8e97"
      unitRef="usd">300000000</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="ifafc390c5b574ce9a766400e79096086_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDkvZnJhZzoyNWNlMTUzYjg0YzY0ZTc2OTNhY2U2MmNjZjgxYzk2MS90ZXh0cmVnaW9uOjI1Y2UxNTNiODRjNjRlNzY5M2FjZTYyY2NmODFjOTYxXzQ0MjU_699a51d2-141b-4825-8e57-3a240493974c"
      unitRef="usd">2000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i9f91dc01d0934f62990f387aff42bfc0_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDkvZnJhZzoyNWNlMTUzYjg0YzY0ZTc2OTNhY2U2MmNjZjgxYzk2MS90ZXh0cmVnaW9uOjI1Y2UxNTNiODRjNjRlNzY5M2FjZTYyY2NmODFjOTYxXzQ0Mzk_3bd766d0-c83c-42cf-929a-481c89d600f4"
      unitRef="usd">1000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i324d3cb6fe534b2d935a46f13fe9d0d7_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDkvZnJhZzoyNWNlMTUzYjg0YzY0ZTc2OTNhY2U2MmNjZjgxYzk2MS90ZXh0cmVnaW9uOjI1Y2UxNTNiODRjNjRlNzY5M2FjZTYyY2NmODFjOTYxXzQ1MDc_6bbffcdc-7232-4ead-bb38-1d4a8a9217d5"
      unitRef="usd">4000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i9ad948cf8f05443b8e4818f18729c732_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDkvZnJhZzoyNWNlMTUzYjg0YzY0ZTc2OTNhY2U2MmNjZjgxYzk2MS90ZXh0cmVnaW9uOjI1Y2UxNTNiODRjNjRlNzY5M2FjZTYyY2NmODFjOTYxXzQ1MDc_d760d865-f292-49b7-b8fb-13372d758846"
      unitRef="usd">4000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet
      contextRef="i580853edf11f49b9b0fd206b92df8e34_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDkvZnJhZzoyNWNlMTUzYjg0YzY0ZTc2OTNhY2U2MmNjZjgxYzk2MS90ZXh0cmVnaW9uOjI1Y2UxNTNiODRjNjRlNzY5M2FjZTYyY2NmODFjOTYxXzEwOTk1MTE2Mzg1MTU_6b1cd0a3-91f4-4599-b2ff-023a2512e360"
      unitRef="usd">4000000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet
      contextRef="i2cb7ee6cde3b4b9ea40f39a43c463c3f_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDkvZnJhZzoyNWNlMTUzYjg0YzY0ZTc2OTNhY2U2MmNjZjgxYzk2MS90ZXh0cmVnaW9uOjI1Y2UxNTNiODRjNjRlNzY5M2FjZTYyY2NmODFjOTYxXzEwOTk1MTE2Mjg5MDEy_3c74551f-1770-4ad3-9f91-b457f6d0ac86"
      unitRef="usd">8000000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet
      contextRef="i70283d29df464fa9bfe3ab000de0526c_D20230401-20240331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDkvZnJhZzoyNWNlMTUzYjg0YzY0ZTc2OTNhY2U2MmNjZjgxYzk2MS90ZXh0cmVnaW9uOjI1Y2UxNTNiODRjNjRlNzY5M2FjZTYyY2NmODFjOTYxXzEwOTk1MTE2Mzg3MjU_47f34235-70fa-4f08-90d4-4c7b4a51fce1"
      unitRef="usd">7000000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeAssetNotionalAmount
      contextRef="i7ce2d0d359a54a7d863e7717418b0884_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDkvZnJhZzoyNWNlMTUzYjg0YzY0ZTc2OTNhY2U2MmNjZjgxYzk2MS90ZXh0cmVnaW9uOjI1Y2UxNTNiODRjNjRlNzY5M2FjZTYyY2NmODFjOTYxXzU0OTc1NTgxNTA1Njg_72bf928a-f5ac-4c3b-a1b2-f447a40a3f08"
      unitRef="jpy">19000000000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeAssetNotionalAmount
      contextRef="i7ce2d0d359a54a7d863e7717418b0884_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDkvZnJhZzoyNWNlMTUzYjg0YzY0ZTc2OTNhY2U2MmNjZjgxYzk2MS90ZXh0cmVnaW9uOjI1Y2UxNTNiODRjNjRlNzY5M2FjZTYyY2NmODFjOTYxXzU0OTc1NTgxNTA1ODE_21046e09-4f2f-4350-8935-3679a208374e"
      unitRef="usd">150000000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeAssetNotionalAmount
      contextRef="i7ca5414a08eb459f8e8d7a93077973ca_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDkvZnJhZzoyNWNlMTUzYjg0YzY0ZTc2OTNhY2U2MmNjZjgxYzk2MS90ZXh0cmVnaW9uOjI1Y2UxNTNiODRjNjRlNzY5M2FjZTYyY2NmODFjOTYxXzU0OTc1NTgxNTA1OTU_55456095-783b-4fb0-9563-9e9c758816ce"
      unitRef="jpy">19000000000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeAssetNotionalAmount
      contextRef="i7ca5414a08eb459f8e8d7a93077973ca_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDkvZnJhZzoyNWNlMTUzYjg0YzY0ZTc2OTNhY2U2MmNjZjgxYzk2MS90ZXh0cmVnaW9uOjI1Y2UxNTNiODRjNjRlNzY5M2FjZTYyY2NmODFjOTYxXzU0OTc1NTgxNTA2MDg_2c82e744-d162-43f6-aba4-0b65688cf4e2"
      unitRef="usd">150000000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="i3218ae04c9b1466fb3401cfe9911661b_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDkvZnJhZzoyNWNlMTUzYjg0YzY0ZTc2OTNhY2U2MmNjZjgxYzk2MS90ZXh0cmVnaW9uOjI1Y2UxNTNiODRjNjRlNzY5M2FjZTYyY2NmODFjOTYxXzU0OTc1NTgxNTA2MjI_257c9f5b-1100-488f-86af-dd484ddd73e5"
      unitRef="eur">100000000</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="i3218ae04c9b1466fb3401cfe9911661b_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDkvZnJhZzoyNWNlMTUzYjg0YzY0ZTc2OTNhY2U2MmNjZjgxYzk2MS90ZXh0cmVnaW9uOjI1Y2UxNTNiODRjNjRlNzY5M2FjZTYyY2NmODFjOTYxXzU0OTc1NTgxNTA2MzY_4fc748be-3aef-440c-b109-97e029ab11b1"
      unitRef="usd">107000000</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="ibc60a5f6f2fd4df2b6e365b67ce91912_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDkvZnJhZzoyNWNlMTUzYjg0YzY0ZTc2OTNhY2U2MmNjZjgxYzk2MS90ZXh0cmVnaW9uOjI1Y2UxNTNiODRjNjRlNzY5M2FjZTYyY2NmODFjOTYxXzU0OTc1NTgxNTA2NTA_18f27b20-6ae8-4ebb-9433-1b72efb2ed45"
      unitRef="eur">100000000</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="ibc60a5f6f2fd4df2b6e365b67ce91912_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDkvZnJhZzoyNWNlMTUzYjg0YzY0ZTc2OTNhY2U2MmNjZjgxYzk2MS90ZXh0cmVnaW9uOjI1Y2UxNTNiODRjNjRlNzY5M2FjZTYyY2NmODFjOTYxXzU0OTc1NTgxNTA2NjQ_776a1584-5b7d-4515-8f3a-fc73014b6fb5"
      unitRef="usd">107000000</us-gaap:DerivativeLiabilityNotionalAmount>
    <cah:DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount
      contextRef="ib1c240be19f544f5b489ee7fbc6ec77d_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDkvZnJhZzoyNWNlMTUzYjg0YzY0ZTc2OTNhY2U2MmNjZjgxYzk2MS90ZXh0cmVnaW9uOjI1Y2UxNTNiODRjNjRlNzY5M2FjZTYyY2NmODFjOTYxXzU0OTc1NTgxNTA2Nzg_8098993a-8bf0-488e-87e0-4eda24d4a471"
      unitRef="jpy">48000000000</cah:DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount>
    <cah:DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount
      contextRef="ib1c240be19f544f5b489ee7fbc6ec77d_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDkvZnJhZzoyNWNlMTUzYjg0YzY0ZTc2OTNhY2U2MmNjZjgxYzk2MS90ZXh0cmVnaW9uOjI1Y2UxNTNiODRjNjRlNzY5M2FjZTYyY2NmODFjOTYxXzU0OTc1NTgxNTA2OTE_c93ee9f4-72ce-4cf8-917a-b15835b2d8d2"
      unitRef="usd">400000000</cah:DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount>
    <cah:DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount
      contextRef="ie681b1f27879497aaac9197da201e94c_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDkvZnJhZzoyNWNlMTUzYjg0YzY0ZTc2OTNhY2U2MmNjZjgxYzk2MS90ZXh0cmVnaW9uOjI1Y2UxNTNiODRjNjRlNzY5M2FjZTYyY2NmODFjOTYxXzU0OTc1NTgxNTA3MDU_b41e1ae6-8b13-42ab-a3ab-dc6b43cf0372"
      unitRef="eur">200000000</cah:DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount>
    <cah:DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount
      contextRef="ie681b1f27879497aaac9197da201e94c_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDkvZnJhZzoyNWNlMTUzYjg0YzY0ZTc2OTNhY2U2MmNjZjgxYzk2MS90ZXh0cmVnaW9uOjI1Y2UxNTNiODRjNjRlNzY5M2FjZTYyY2NmODFjOTYxXzU0OTc1NTgxNTA3MTk_5821ad9c-2531-4ddf-b09f-6c3fd923e4e6"
      unitRef="usd">233000000</cah:DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount>
    <us-gaap:ProceedsFromHedgeInvestingActivities
      contextRef="i05f897db0bb743d0b9331a8d46baf59a_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDkvZnJhZzoyNWNlMTUzYjg0YzY0ZTc2OTNhY2U2MmNjZjgxYzk2MS90ZXh0cmVnaW9uOjI1Y2UxNTNiODRjNjRlNzY5M2FjZTYyY2NmODFjOTYxXzU0OTc1NTgxNTA3MzM_22411494-d91d-44ca-aae3-233bfc73cf67"
      unitRef="usd">10000000</us-gaap:ProceedsFromHedgeInvestingActivities>
    <us-gaap:ProceedsFromHedgeInvestingActivities
      contextRef="idb235b08598c4a23bff0d5c8e268cb3b_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDkvZnJhZzoyNWNlMTUzYjg0YzY0ZTc2OTNhY2U2MmNjZjgxYzk2MS90ZXh0cmVnaW9uOjI1Y2UxNTNiODRjNjRlNzY5M2FjZTYyY2NmODFjOTYxXzU0OTc1NTgxNTA3NDY_440975f3-daf1-4c29-a8e2-ebe51cef9318"
      unitRef="usd">19000000</us-gaap:ProceedsFromHedgeInvestingActivities>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="if773aecdfcdd4fa1af2b4a92af9fafff_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDkvZnJhZzoyNWNlMTUzYjg0YzY0ZTc2OTNhY2U2MmNjZjgxYzk2MS90ZXh0cmVnaW9uOjI1Y2UxNTNiODRjNjRlNzY5M2FjZTYyY2NmODFjOTYxXzU4NDY_f11402e0-30bf-4b16-8cc7-714b07db8531"
      unitRef="usd">22000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i286db9ed3e3a475e93934bbb8c001c46_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDkvZnJhZzoyNWNlMTUzYjg0YzY0ZTc2OTNhY2U2MmNjZjgxYzk2MS90ZXh0cmVnaW9uOjI1Y2UxNTNiODRjNjRlNzY5M2FjZTYyY2NmODFjOTYxXzU5MTU_85ee580a-4558-472e-97c1-0b8d2317bb16"
      unitRef="usd">21000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i453169c026a64457a0140b1f759e3178_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDkvZnJhZzoyNWNlMTUzYjg0YzY0ZTc2OTNhY2U2MmNjZjgxYzk2MS90ZXh0cmVnaW9uOjI1Y2UxNTNiODRjNjRlNzY5M2FjZTYyY2NmODFjOTYxXzU5Mjk_5c0faee8-7ac7-4c2d-98ca-8beb12f026e9"
      unitRef="usd">44000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="ieaa5331918d94152a37d35bd4fbf59d1_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDkvZnJhZzoyNWNlMTUzYjg0YzY0ZTc2OTNhY2U2MmNjZjgxYzk2MS90ZXh0cmVnaW9uOjI1Y2UxNTNiODRjNjRlNzY5M2FjZTYyY2NmODFjOTYxXzYxODA_11154d8b-ca1a-49ba-aa11-297dc4bfa5d6"
      unitRef="usd">4000000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="if773aecdfcdd4fa1af2b4a92af9fafff_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDkvZnJhZzoyNWNlMTUzYjg0YzY0ZTc2OTNhY2U2MmNjZjgxYzk2MS90ZXh0cmVnaW9uOjI1Y2UxNTNiODRjNjRlNzY5M2FjZTYyY2NmODFjOTYxXzYxODc_b1d7daf2-98b8-4a04-bce2-19619713a3a6"
      unitRef="usd">5000000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="i286db9ed3e3a475e93934bbb8c001c46_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDkvZnJhZzoyNWNlMTUzYjg0YzY0ZTc2OTNhY2U2MmNjZjgxYzk2MS90ZXh0cmVnaW9uOjI1Y2UxNTNiODRjNjRlNzY5M2FjZTYyY2NmODFjOTYxXzYyNDk_40dcb75e-1422-4a84-978c-c2623877f29e"
      unitRef="usd">12000000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="i453169c026a64457a0140b1f759e3178_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDkvZnJhZzoyNWNlMTUzYjg0YzY0ZTc2OTNhY2U2MmNjZjgxYzk2MS90ZXh0cmVnaW9uOjI1Y2UxNTNiODRjNjRlNzY5M2FjZTYyY2NmODFjOTYxXzYyNTY_e2eb69b3-d618-409e-a467-1b8720a2dc53"
      unitRef="usd">16000000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="ifd36140f852d4fd491f55d7cbb74fc38_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDkvZnJhZzoyNWNlMTUzYjg0YzY0ZTc2OTNhY2U2MmNjZjgxYzk2MS90ZXh0cmVnaW9uOjI1Y2UxNTNiODRjNjRlNzY5M2FjZTYyY2NmODFjOTYxXzcwOTA_8c8c7958-3ddb-4997-9422-334f52054440"
      unitRef="usd">-4000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i12151c3f1a7a45f0a2e075e9b264e83b_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDkvZnJhZzoyNWNlMTUzYjg0YzY0ZTc2OTNhY2U2MmNjZjgxYzk2MS90ZXh0cmVnaW9uOjI1Y2UxNTNiODRjNjRlNzY5M2FjZTYyY2NmODFjOTYxXzcxNTk_18f7fded-880c-41be-820d-85f55eac5587"
      unitRef="usd">-3000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDkvZnJhZzoyNWNlMTUzYjg0YzY0ZTc2OTNhY2U2MmNjZjgxYzk2MS90ZXh0cmVnaW9uOjI1Y2UxNTNiODRjNjRlNzY5M2FjZTYyY2NmODFjOTYxXzgwMTk_3bef790d-7150-468a-8d81-852636c7129c">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.109%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.986%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.062%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Estimated fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,466&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,734&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock>
    <us-gaap:DebtInstrumentFairValue
      contextRef="if6dc7675fbf84b8eabf826cb41d79193_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDkvZnJhZzoyNWNlMTUzYjg0YzY0ZTc2OTNhY2U2MmNjZjgxYzk2MS90YWJsZTo5ZjU5NDM0ZjUzNzE0YWM5OGRhNzMzYzEyZmU4Mzc4Yi90YWJsZXJhbmdlOjlmNTk0MzRmNTM3MTRhYzk4ZGE3MzNjMTJmZTgzNzhiXzEtMS0xLTEtMjg2OTQ0_205f7965-8d32-4479-a564-1e3d45a2b1c9"
      unitRef="usd">4466000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="ib43a93a1b1cb4e7f9c3a767d383622bd_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDkvZnJhZzoyNWNlMTUzYjg0YzY0ZTc2OTNhY2U2MmNjZjgxYzk2MS90YWJsZTo5ZjU5NDM0ZjUzNzE0YWM5OGRhNzMzYzEyZmU4Mzc4Yi90YWJsZXJhbmdlOjlmNTk0MzRmNTM3MTRhYzk4ZGE3MzNjMTJmZTgzNzhiXzEtMy0xLTEtMjg2OTQ0_ce698e45-9605-4082-a493-5964318a08c7"
      unitRef="usd">5049000000</us-gaap:DebtInstrumentFairValue>
    <cah:CarryingAmountofLongTermandotherShortTermBorrowings
      contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDkvZnJhZzoyNWNlMTUzYjg0YzY0ZTc2OTNhY2U2MmNjZjgxYzk2MS90YWJsZTo5ZjU5NDM0ZjUzNzE0YWM5OGRhNzMzYzEyZmU4Mzc4Yi90YWJsZXJhbmdlOjlmNTk0MzRmNTM3MTRhYzk4ZGE3MzNjMTJmZTgzNzhiXzItMS0xLTEtMjg2OTQ0_383f8d54-f1b8-4c97-ae0d-bb15b5076ed3"
      unitRef="usd">4734000000</cah:CarryingAmountofLongTermandotherShortTermBorrowings>
    <cah:CarryingAmountofLongTermandotherShortTermBorrowings
      contextRef="ic217743408d440409a59220a0bf14e4c_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMDkvZnJhZzoyNWNlMTUzYjg0YzY0ZTc2OTNhY2U2MmNjZjgxYzk2MS90YWJsZTo5ZjU5NDM0ZjUzNzE0YWM5OGRhNzMzYzEyZmU4Mzc4Yi90YWJsZXJhbmdlOjlmNTk0MzRmNTM3MTRhYzk4ZGE3MzNjMTJmZTgzNzhiXzItMy0xLTEtMjg2OTQ0_924ecb78-1414-4a2a-9d3d-3cad8500b204"
      unitRef="usd">5315000000</cah:CarryingAmountofLongTermandotherShortTermBorrowings>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90ZXh0cmVnaW9uOjg3MTUwZDI5NjZmYTQ4OTk5ZWU5Yjg2MTk5NGFkM2ViXzU0OTc1NTgxNDMwNDU_cf439e00-4f7c-44c6-8ed1-e77d670f241f">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;10. Shareholders' Equity/(Deficit)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We repurchased $1.5&#160;billion and $1.0 billion of our common shares, in the aggregate, through share repurchase programs during the nine months ended March&#160;31, 2023 and 2022, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;respectively. We funded the repurchases with available cash. The common shares repurchased are held in treasury to be used for general corporate purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2023, we entered into an accelerated share repurchase ("ASR") program to repurchase common shares for an aggregate purchase price of $250 million. We received an initial delivery of 2.6 million common shares using a reference price of $77.03. The program concluded on February 28, 2023 at a volume weighted average price per common share of $77.27 resulting in a final delivery of 0.6 million common shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended December&#160;31, 2022, we entered into an ASR program to repurchase common shares for an aggregate purchase price of $250&#160;million. We received an initial delivery of 2.6 million common shares using a reference price of $76.58. The program concluded on January&#160;13, 2023 at a volume weighted average price per common share of $77.50 resulting in a final delivery of 0.6 million common shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended September 30, 2022, we entered into an ASR program to repurchase common shares for an aggregate purchase price of $1.0&#160;billion. We received an initial delivery of 12.0 million common shares using a reference price of $66.74. The program concluded on December 23, 2022 at a volume weighted average price per common share of $73.36 resulting in a final delivery of 1.6 million common shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2022, we entered into an ASR program to repurchase common shares for an aggregate purchase price of $200&#160;million. We received an initial delivery of 3.0&#160;million common shares using a reference price of $54.01. The program concluded on April 18, 2022 at a volume weighted average price per common share of $56.02 resulting in a final delivery of 0.6&#160;million common shares. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended December 31, 2021, we entered into an ASR program to repurchase common shares for an aggregate purchase price of $300&#160;million. We received an initial delivery of 4.8&#160;million common shares using a reference price of $50.30. The program concluded on January 31, 2022 at a volume weighted average price per common share of $49.39 resulting in a final delivery of 1.3&#160;million common shares. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended September 30, 2021, we entered into an ASR program to repurchase common shares for an aggregate purchase price of $500&#160;million. We received an initial delivery of 7.8&#160;million common shares using a reference price of $51.53. The program concluded on October 4, 2021 at a volume weighted average price per common share of $51.10 resulting in a final delivery of 2.0&#160;million common shares.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Accumulated Other Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the changes in the balance of accumulated other comprehensive loss by component and in total:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.097%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.492%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.050%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign&lt;br/&gt;Currency&lt;br/&gt;Translation&lt;br/&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unrealized&lt;br/&gt;Gain/(Loss) on&lt;br/&gt;Derivatives,&lt;br/&gt;net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated Other&lt;br/&gt;Comprehensive&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(102)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(114)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive loss, before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amounts reclassified to earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other comprehensive loss attributable to Cardinal Health, Inc. net of tax benefit of $5&#160;million&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(136)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(142)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.097%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.492%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.050%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign&lt;br/&gt;Currency&lt;br/&gt;Translation&lt;br/&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unrealized&lt;br/&gt;Gain/(Loss) on&lt;br/&gt;Derivatives,&lt;br/&gt;net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated Other&lt;br/&gt;Comprehensive&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(46)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive loss, before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(47)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amounts reclassified to earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other comprehensive loss attributable to Cardinal Health, Inc. net of tax benefit of $6&#160;million&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(47)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(93)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(77)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i8e5c5ae766b74cf6a2409e8a66778fe4_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90ZXh0cmVnaW9uOjg3MTUwZDI5NjZmYTQ4OTk5ZWU5Yjg2MTk5NGFkM2ViXzI0_38d6ffc2-2033-4ab3-b0f4-69839941e302"
      unitRef="usd">1500000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="ib1adee5e79374a97893072820fddaa0e_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90ZXh0cmVnaW9uOjg3MTUwZDI5NjZmYTQ4OTk5ZWU5Yjg2MTk5NGFkM2ViXzMx_9b10397b-fd0c-4182-b0b7-9ee740face84"
      unitRef="usd">1000000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i7ad6d93eac9d48ab9fec302dd4e88915_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90ZXh0cmVnaW9uOjg3MTUwZDI5NjZmYTQ4OTk5ZWU5Yjg2MTk5NGFkM2ViXzQ2NQ_64d5790a-91d4-4a60-b5e4-f63e7f9964a6"
      unitRef="usd">250000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i76064daaf24a4ffeb60544ffcf302fab_D20220701-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90ZXh0cmVnaW9uOjg3MTUwZDI5NjZmYTQ4OTk5ZWU5Yjg2MTk5NGFkM2ViXzU0OTc1NTgxNDI4MTg_e02fd90b-740d-4c4f-9bcf-39c1eb57fe25"
      unitRef="shares">2600000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="i76064daaf24a4ffeb60544ffcf302fab_D20220701-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90ZXh0cmVnaW9uOjg3MTUwZDI5NjZmYTQ4OTk5ZWU5Yjg2MTk5NGFkM2ViXzE2NDkyNjc0NDQxNDI_b23205a1-a59d-4031-ba6e-3b0af8a1ae4b"
      unitRef="usdPerShare">77.03</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="i461a6425bd69455b83513a1e59a9776f_D20230101-20230228"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90ZXh0cmVnaW9uOjg3MTUwZDI5NjZmYTQ4OTk5ZWU5Yjg2MTk5NGFkM2ViXzE2NDkyNjc0NDQxMjU_84d25392-bfce-4928-a77d-65f7458b47d1"
      unitRef="usdPerShare">77.27</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="ib66c40ad89944e97863448aacf257bd4_D20230228-20230228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90ZXh0cmVnaW9uOjg3MTUwZDI5NjZmYTQ4OTk5ZWU5Yjg2MTk5NGFkM2ViXzE2NDkyNjc0NDQxMTk_2a344e0b-b753-43bb-9451-571b88ea656c"
      unitRef="shares">600000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i7ad6d93eac9d48ab9fec302dd4e88915_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90ZXh0cmVnaW9uOjg3MTUwZDI5NjZmYTQ4OTk5ZWU5Yjg2MTk5NGFkM2ViXzU0OTc1NTgxNDI5MjI_f6df533e-b90c-46b6-bd4b-e9770d51cb91"
      unitRef="usd">250000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i1023e41d044c49ebb5274f9857d52b5f_D20221001-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90ZXh0cmVnaW9uOjg3MTUwZDI5NjZmYTQ4OTk5ZWU5Yjg2MTk5NGFkM2ViXzE2NDkyNjc0NDQwOTk_befe0c17-5788-4e83-82ff-6be63c036597"
      unitRef="shares">2600000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="i1023e41d044c49ebb5274f9857d52b5f_D20221001-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90ZXh0cmVnaW9uOjg3MTUwZDI5NjZmYTQ4OTk5ZWU5Yjg2MTk5NGFkM2ViXzE2NDkyNjc0NDQxMDU_3c4d1965-d6e1-4226-9f7d-b8f4af72583c"
      unitRef="usdPerShare">76.58</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="i00b750b6e2374500a1e8b10702e44d3a_D20221002-20230113"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90ZXh0cmVnaW9uOjg3MTUwZDI5NjZmYTQ4OTk5ZWU5Yjg2MTk5NGFkM2ViXzE2NDkyNjc0NDQxMDk_740095a5-5465-4e5d-95dc-6a5c6f2536dc"
      unitRef="usdPerShare">77.50</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i612fc934cf6040028ee1d4ea22c335da_D20230113-20230113"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90ZXh0cmVnaW9uOjg3MTUwZDI5NjZmYTQ4OTk5ZWU5Yjg2MTk5NGFkM2ViXzE2NDkyNjc0NDQxMTM_1499679e-59cb-421c-8dce-ef1d9f4cad63"
      unitRef="shares">600000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="ica007433189241b2959cc8d752b3303e_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90ZXh0cmVnaW9uOjg3MTUwZDI5NjZmYTQ4OTk5ZWU5Yjg2MTk5NGFkM2ViXzgzMw_507388bd-1174-4743-a988-73cb172bbfb1"
      unitRef="usd">1000000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="ib99db3d39b2a4d159a049760c79aa4ad_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90ZXh0cmVnaW9uOjg3MTUwZDI5NjZmYTQ4OTk5ZWU5Yjg2MTk5NGFkM2ViXzE2NDkyNjc0NDQxMzA_43d58a0c-5c47-4110-993c-286c1dea9c80"
      unitRef="shares">12000000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="ib99db3d39b2a4d159a049760c79aa4ad_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90ZXh0cmVnaW9uOjg3MTUwZDI5NjZmYTQ4OTk5ZWU5Yjg2MTk5NGFkM2ViXzE2NDkyNjc0NDQ2ODc_aec13b63-df56-43bd-b48f-7699a0dcdd79"
      unitRef="usdPerShare">66.74</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="if7a9fd51d7b5402abd517b833b8aa389_D20220701-20221223"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90ZXh0cmVnaW9uOjg3MTUwZDI5NjZmYTQ4OTk5ZWU5Yjg2MTk5NGFkM2ViXzEwMTg_2aa58be1-c8e9-46e1-9780-9c739316afbe"
      unitRef="usdPerShare">73.36</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i3ea1c66ac32f47d58440504438bf12ae_D20221223-20221223"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90ZXh0cmVnaW9uOjg3MTUwZDI5NjZmYTQ4OTk5ZWU5Yjg2MTk5NGFkM2ViXzEwNTQ_68524cd8-c5c1-40eb-9da5-12c3e4080198"
      unitRef="shares">1600000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i522fef760d964e82a180d92c34f911f9_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90ZXh0cmVnaW9uOjg3MTUwZDI5NjZmYTQ4OTk5ZWU5Yjg2MTk5NGFkM2ViXzEyMTU_3da53880-46c7-451b-87f0-f2fc4d368d7f"
      unitRef="usd">200000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i62909649d3db4353bc2ea5dbf602e573_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90ZXh0cmVnaW9uOjg3MTUwZDI5NjZmYTQ4OTk5ZWU5Yjg2MTk5NGFkM2ViXzEyNTQ_2efcda0d-d724-45b6-8397-d643862b4694"
      unitRef="shares">3000000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="i62909649d3db4353bc2ea5dbf602e573_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90ZXh0cmVnaW9uOjg3MTUwZDI5NjZmYTQ4OTk5ZWU5Yjg2MTk5NGFkM2ViXzEyOTg_c03aae3b-8289-45a2-be8a-8bd90f94ee71"
      unitRef="usdPerShare">54.01</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="i6a09f6e3558145749952ae7fc79bd2af_D20220101-20220418"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90ZXh0cmVnaW9uOjg3MTUwZDI5NjZmYTQ4OTk5ZWU5Yjg2MTk5NGFkM2ViXzEzOTk_9b9043cb-26c8-4937-88b5-4207a77e6a0c"
      unitRef="usdPerShare">56.02</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i226477cc1ffc4f0d9d9f5dd33b1e9da1_D20220418-20220418"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90ZXh0cmVnaW9uOjg3MTUwZDI5NjZmYTQ4OTk5ZWU5Yjg2MTk5NGFkM2ViXzE0MzU_c8f6aa68-51a3-42c0-8224-c0953e6168da"
      unitRef="shares">600000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i1867aca7ccf1480e9c1ee9dcad7d47ae_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90ZXh0cmVnaW9uOjg3MTUwZDI5NjZmYTQ4OTk5ZWU5Yjg2MTk5NGFkM2ViXzU0OTc1NTgxNDI4MjM_e0f2cd57-58a2-4c61-897b-3fe786f483dd"
      unitRef="usd">300000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="ia9412268ef744658a8712d81ef405c17_D20211001-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90ZXh0cmVnaW9uOjg3MTUwZDI5NjZmYTQ4OTk5ZWU5Yjg2MTk5NGFkM2ViXzU0OTc1NTgxNDI4Mzc_51cec397-96aa-411c-b913-eedca43250f6"
      unitRef="shares">4800000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="ia9412268ef744658a8712d81ef405c17_D20211001-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90ZXh0cmVnaW9uOjg3MTUwZDI5NjZmYTQ4OTk5ZWU5Yjg2MTk5NGFkM2ViXzU0OTc1NTgxNDI4NTA_84942d60-7d09-48f2-b463-221159a1ed24"
      unitRef="usdPerShare">50.30</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="i8be8904a0c5f40cbbebf2f710dcc62b3_D20211001-20220131"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90ZXh0cmVnaW9uOjg3MTUwZDI5NjZmYTQ4OTk5ZWU5Yjg2MTk5NGFkM2ViXzU0OTc1NTgxNDI4NTg_151bc7cc-0c0c-440c-a0e3-88e9aaccdb7f"
      unitRef="usdPerShare">49.39</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i2552d9f48bd74eb3a693f3a9fead0a14_D20220131-20220131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90ZXh0cmVnaW9uOjg3MTUwZDI5NjZmYTQ4OTk5ZWU5Yjg2MTk5NGFkM2ViXzU0OTc1NTgxNDI4NjY_feac5664-0757-4dc0-9013-debaa9b72235"
      unitRef="shares">1300000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="ie154fb452e1a418293380c4c4a39a5cd_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90ZXh0cmVnaW9uOjg3MTUwZDI5NjZmYTQ4OTk5ZWU5Yjg2MTk5NGFkM2ViXzU0OTc1NTgxNDI4Nzk_3b1908eb-476c-4b0b-8571-d1170d1d9f37"
      unitRef="usd">500000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i4f140036aee94cfe9d2320e0cd2ce82a_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90ZXh0cmVnaW9uOjg3MTUwZDI5NjZmYTQ4OTk5ZWU5Yjg2MTk5NGFkM2ViXzU0OTc1NTgxNDI4OTM_99837f95-8481-4e9d-8add-c25e154212b5"
      unitRef="shares">7800000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="i4f140036aee94cfe9d2320e0cd2ce82a_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90ZXh0cmVnaW9uOjg3MTUwZDI5NjZmYTQ4OTk5ZWU5Yjg2MTk5NGFkM2ViXzU0OTc1NTgxNDI5MDY_83e51958-dcfc-4c8f-864b-9b45c0419d3b"
      unitRef="usdPerShare">51.53</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="i4db4d5927cda47f480368591c63e0175_D20210701-20211014"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90ZXh0cmVnaW9uOjg3MTUwZDI5NjZmYTQ4OTk5ZWU5Yjg2MTk5NGFkM2ViXzU0OTc1NTgxNDI5MTQ_f35b8c07-7962-4574-8baf-57c3194f3ac2"
      unitRef="usdPerShare">51.10</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i1cda2ab21b97491cb2163653f2b875c8_D20211004-20211004"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90ZXh0cmVnaW9uOjg3MTUwZDI5NjZmYTQ4OTk5ZWU5Yjg2MTk5NGFkM2ViXzU0OTc1NTgxNDI5MzY_7806d958-aeb3-468f-9cbc-15916af557e4"
      unitRef="shares">2000000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90ZXh0cmVnaW9uOjg3MTUwZDI5NjZmYTQ4OTk5ZWU5Yjg2MTk5NGFkM2ViXzIwMTI_0981c231-505d-45a7-9b5e-0ecbf7c1139b">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the changes in the balance of accumulated other comprehensive loss by component and in total:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.097%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.492%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.050%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign&lt;br/&gt;Currency&lt;br/&gt;Translation&lt;br/&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unrealized&lt;br/&gt;Gain/(Loss) on&lt;br/&gt;Derivatives,&lt;br/&gt;net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated Other&lt;br/&gt;Comprehensive&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(102)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(114)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive loss, before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amounts reclassified to earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other comprehensive loss attributable to Cardinal Health, Inc. net of tax benefit of $5&#160;million&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(136)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(142)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.097%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.492%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.050%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign&lt;br/&gt;Currency&lt;br/&gt;Translation&lt;br/&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unrealized&lt;br/&gt;Gain/(Loss) on&lt;br/&gt;Derivatives,&lt;br/&gt;net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated Other&lt;br/&gt;Comprehensive&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(46)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive loss, before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(47)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amounts reclassified to earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other comprehensive loss attributable to Cardinal Health, Inc. net of tax benefit of $6&#160;million&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(47)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(93)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(77)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i57bea63d714f4a0dafc21a5f5d7d9581_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90YWJsZTpiMGJhNTBmZTM5NjQ0ZGNlOWUwOWIzZmFmYTg1NWMxNy90YWJsZXJhbmdlOmIwYmE1MGZlMzk2NDRkY2U5ZTA5YjNmYWZhODU1YzE3XzEtMS0xLTEtMjg2OTQ0_84569150-46ee-47c3-bec5-3785720324a1"
      unitRef="usd">-102000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6045190cc1424f8b979c1010722b563f_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90YWJsZTpiMGJhNTBmZTM5NjQ0ZGNlOWUwOWIzZmFmYTg1NWMxNy90YWJsZXJhbmdlOmIwYmE1MGZlMzk2NDRkY2U5ZTA5YjNmYWZhODU1YzE3XzEtMy0xLTEtMjg2OTQ0_f5ad6fb9-81d9-486c-a729-11c82e5ac578"
      unitRef="usd">-12000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i041bf7de7fa94db3b9bf9e7b272751da_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90YWJsZTpiMGJhNTBmZTM5NjQ0ZGNlOWUwOWIzZmFmYTg1NWMxNy90YWJsZXJhbmdlOmIwYmE1MGZlMzk2NDRkY2U5ZTA5YjNmYWZhODU1YzE3XzEtNS0xLTEtMjg2OTQ0_bafaa009-5074-4dec-8558-4837632395bf"
      unitRef="usd">-114000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="ifc6e3923d3894b44990b34501ac477b5_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90YWJsZTpiMGJhNTBmZTM5NjQ0ZGNlOWUwOWIzZmFmYTg1NWMxNy90YWJsZXJhbmdlOmIwYmE1MGZlMzk2NDRkY2U5ZTA5YjNmYWZhODU1YzE3XzItMS0xLTEtMjg2OTQ0_560aab5d-0179-4157-8d7e-11f62fcd90f7"
      unitRef="usd">-34000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i44c00bb3d01a45a9b2df0171c33fe41e_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90YWJsZTpiMGJhNTBmZTM5NjQ0ZGNlOWUwOWIzZmFmYTg1NWMxNy90YWJsZXJhbmdlOmIwYmE1MGZlMzk2NDRkY2U5ZTA5YjNmYWZhODU1YzE3XzItMy0xLTEtMjg2OTQ0_f9905c2e-79f7-468e-a5c1-fbcf2efe81a0"
      unitRef="usd">15000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i5339f5e85f3b47c0aa0a7795a0147a83_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90YWJsZTpiMGJhNTBmZTM5NjQ0ZGNlOWUwOWIzZmFmYTg1NWMxNy90YWJsZXJhbmdlOmIwYmE1MGZlMzk2NDRkY2U5ZTA5YjNmYWZhODU1YzE3XzItNS0xLTEtMjg2OTQ0_eac17f89-1e64-48bf-8353-6c22db66572f"
      unitRef="usd">-19000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="ifc6e3923d3894b44990b34501ac477b5_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90YWJsZTpiMGJhNTBmZTM5NjQ0ZGNlOWUwOWIzZmFmYTg1NWMxNy90YWJsZXJhbmdlOmIwYmE1MGZlMzk2NDRkY2U5ZTA5YjNmYWZhODU1YzE3XzMtMS0xLTEtMjg2OTQ0_720fa8b7-0034-49a1-b394-19b7b230816f"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i44c00bb3d01a45a9b2df0171c33fe41e_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90YWJsZTpiMGJhNTBmZTM5NjQ0ZGNlOWUwOWIzZmFmYTg1NWMxNy90YWJsZXJhbmdlOmIwYmE1MGZlMzk2NDRkY2U5ZTA5YjNmYWZhODU1YzE3XzMtMy0xLTEtMjg2OTQ0_af710ddf-8f12-4f99-a523-fc0caecd973d"
      unitRef="usd">9000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i5339f5e85f3b47c0aa0a7795a0147a83_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90YWJsZTpiMGJhNTBmZTM5NjQ0ZGNlOWUwOWIzZmFmYTg1NWMxNy90YWJsZXJhbmdlOmIwYmE1MGZlMzk2NDRkY2U5ZTA5YjNmYWZhODU1YzE3XzMtNS0xLTEtMjg2OTQ0_847e4ea2-606b-438d-a1a8-d1f391b3088d"
      unitRef="usd">9000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90YWJsZTpiMGJhNTBmZTM5NjQ0ZGNlOWUwOWIzZmFmYTg1NWMxNy90YWJsZXJhbmdlOmIwYmE1MGZlMzk2NDRkY2U5ZTA5YjNmYWZhODU1YzE3XzQtMC0xLTEtMjg2OTQ0L3RleHRyZWdpb246NTRjZTM4ZjJkOTQwNDI4NGE1MGRlMGI2MDRhNjM3YWFfOTU_ae4bf9e3-7daf-4084-a1cb-147eed546e48"
      unitRef="usd">5000000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ifc6e3923d3894b44990b34501ac477b5_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90YWJsZTpiMGJhNTBmZTM5NjQ0ZGNlOWUwOWIzZmFmYTg1NWMxNy90YWJsZXJhbmdlOmIwYmE1MGZlMzk2NDRkY2U5ZTA5YjNmYWZhODU1YzE3XzQtMS0xLTEtMjg2OTQ0_94b1aa6c-efd5-4b0f-a050-829d431e55b3"
      unitRef="usd">-34000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i44c00bb3d01a45a9b2df0171c33fe41e_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90YWJsZTpiMGJhNTBmZTM5NjQ0ZGNlOWUwOWIzZmFmYTg1NWMxNy90YWJsZXJhbmdlOmIwYmE1MGZlMzk2NDRkY2U5ZTA5YjNmYWZhODU1YzE3XzQtMy0xLTEtMjg2OTQ0_16d8290d-8439-453f-8bde-5d82ca8d7e82"
      unitRef="usd">6000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ie9df3ae431f2408093261364d8c57572_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90YWJsZTpiMGJhNTBmZTM5NjQ0ZGNlOWUwOWIzZmFmYTg1NWMxNy90YWJsZXJhbmdlOmIwYmE1MGZlMzk2NDRkY2U5ZTA5YjNmYWZhODU1YzE3XzQtNS0xLTEtMjg2OTQ0_3b899454-1ebf-49fc-86e4-da7fed5f11f3"
      unitRef="usd">-28000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5f9b2983d0ee4f86a50ac5496fc9091c_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90YWJsZTpiMGJhNTBmZTM5NjQ0ZGNlOWUwOWIzZmFmYTg1NWMxNy90YWJsZXJhbmdlOmIwYmE1MGZlMzk2NDRkY2U5ZTA5YjNmYWZhODU1YzE3XzUtMS0xLTEtMjg2OTQ0_bb22f156-6337-4f5c-8ad8-343456c915be"
      unitRef="usd">-136000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7f42aa5a93cc411195bf2bf78d59cde4_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90YWJsZTpiMGJhNTBmZTM5NjQ0ZGNlOWUwOWIzZmFmYTg1NWMxNy90YWJsZXJhbmdlOmIwYmE1MGZlMzk2NDRkY2U5ZTA5YjNmYWZhODU1YzE3XzUtMy0xLTEtMjg2OTQ0_b2d092d0-d3a2-420f-998a-bd0ca8b199a1"
      unitRef="usd">-6000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8d7f6b1c5d2b48eeba8549a518560256_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90YWJsZTpiMGJhNTBmZTM5NjQ0ZGNlOWUwOWIzZmFmYTg1NWMxNy90YWJsZXJhbmdlOmIwYmE1MGZlMzk2NDRkY2U5ZTA5YjNmYWZhODU1YzE3XzUtNS0xLTEtMjg2OTQ0_afeb4ec4-9031-47ae-a0e3-b136ab5b0a29"
      unitRef="usd">-142000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icbef955e1ad34a0db8f9c5e948d9cb27_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90YWJsZToxYTc1NTQ5MjhkNGI0ZDI0YmQ3NjYwZWU4MDAxYjVkNS90YWJsZXJhbmdlOjFhNzU1NDkyOGQ0YjRkMjRiZDc2NjBlZTgwMDFiNWQ1XzEtMS0xLTEtMjg2OTQ0_cf118745-e6eb-429b-8ceb-0a52904029e3"
      unitRef="usd">-46000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibc51bd9677854ac6aaa9f7b93f52a94e_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90YWJsZToxYTc1NTQ5MjhkNGI0ZDI0YmQ3NjYwZWU4MDAxYjVkNS90YWJsZXJhbmdlOjFhNzU1NDkyOGQ0YjRkMjRiZDc2NjBlZTgwMDFiNWQ1XzEtMy0xLTEtMjg2OTQ0_3438fd5b-ce1f-4528-af93-2daea89e986d"
      unitRef="usd">12000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i63438b89f0184fe2bed728cdd44ae85b_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90YWJsZToxYTc1NTQ5MjhkNGI0ZDI0YmQ3NjYwZWU4MDAxYjVkNS90YWJsZXJhbmdlOjFhNzU1NDkyOGQ0YjRkMjRiZDc2NjBlZTgwMDFiNWQ1XzEtNS0xLTEtMjg2OTQ0_8dffc69d-43ec-4da4-b7e1-46dd964c6c29"
      unitRef="usd">-34000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i515663cfb02c45c09a0fbc66b8fef70c_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90YWJsZToxYTc1NTQ5MjhkNGI0ZDI0YmQ3NjYwZWU4MDAxYjVkNS90YWJsZXJhbmdlOjFhNzU1NDkyOGQ0YjRkMjRiZDc2NjBlZTgwMDFiNWQ1XzItMS0xLTEtMjg2OTQ0_bdba8793-83cb-48a6-91de-0b669db3dbcc"
      unitRef="usd">-47000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i5450ec0270bb4ceaafa8ee587406b24e_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90YWJsZToxYTc1NTQ5MjhkNGI0ZDI0YmQ3NjYwZWU4MDAxYjVkNS90YWJsZXJhbmdlOjFhNzU1NDkyOGQ0YjRkMjRiZDc2NjBlZTgwMDFiNWQ1XzItMy0xLTEtMjg2OTQ0_ea12aed6-ad98-45b5-88c8-7c822613c896"
      unitRef="usd">9000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="ibf631f27db6a4b97b407bf7c07872ada_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90YWJsZToxYTc1NTQ5MjhkNGI0ZDI0YmQ3NjYwZWU4MDAxYjVkNS90YWJsZXJhbmdlOjFhNzU1NDkyOGQ0YjRkMjRiZDc2NjBlZTgwMDFiNWQ1XzItNS0xLTEtMjg2OTQ0_3d2dd55a-9d64-4efc-82ae-56fa5e233e54"
      unitRef="usd">-38000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i515663cfb02c45c09a0fbc66b8fef70c_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90YWJsZToxYTc1NTQ5MjhkNGI0ZDI0YmQ3NjYwZWU4MDAxYjVkNS90YWJsZXJhbmdlOjFhNzU1NDkyOGQ0YjRkMjRiZDc2NjBlZTgwMDFiNWQ1XzMtMS0xLTEtMjg2OTQ0_fc0a9d50-2f7b-4570-9af9-39a2abb2bc78"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i5450ec0270bb4ceaafa8ee587406b24e_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90YWJsZToxYTc1NTQ5MjhkNGI0ZDI0YmQ3NjYwZWU4MDAxYjVkNS90YWJsZXJhbmdlOjFhNzU1NDkyOGQ0YjRkMjRiZDc2NjBlZTgwMDFiNWQ1XzMtMy0xLTEtMjg2OTQ0_6169a393-c339-4dc9-9fb2-656d87490dfc"
      unitRef="usd">5000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="ibf631f27db6a4b97b407bf7c07872ada_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90YWJsZToxYTc1NTQ5MjhkNGI0ZDI0YmQ3NjYwZWU4MDAxYjVkNS90YWJsZXJhbmdlOjFhNzU1NDkyOGQ0YjRkMjRiZDc2NjBlZTgwMDFiNWQ1XzMtNS0xLTEtMjg2OTQ0_e61a6747-f994-48b9-9ebd-57090e920c6f"
      unitRef="usd">5000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90YWJsZToxYTc1NTQ5MjhkNGI0ZDI0YmQ3NjYwZWU4MDAxYjVkNS90YWJsZXJhbmdlOjFhNzU1NDkyOGQ0YjRkMjRiZDc2NjBlZTgwMDFiNWQ1XzQtMC0xLTEtMjg2OTQ0L3RleHRyZWdpb246MTgxM2IzNjc4ODNkNGQ5MDljYmJkNmQ0NDc0ODZlYTBfOTU_017d1bce-4bee-4e97-beaa-77e892150cb1"
      unitRef="usd">6000000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i515663cfb02c45c09a0fbc66b8fef70c_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90YWJsZToxYTc1NTQ5MjhkNGI0ZDI0YmQ3NjYwZWU4MDAxYjVkNS90YWJsZXJhbmdlOjFhNzU1NDkyOGQ0YjRkMjRiZDc2NjBlZTgwMDFiNWQ1XzQtMS0xLTEtMjg2OTQ0_ce601dd9-c14b-4513-a39a-b9b05987ef8c"
      unitRef="usd">-47000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i5450ec0270bb4ceaafa8ee587406b24e_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90YWJsZToxYTc1NTQ5MjhkNGI0ZDI0YmQ3NjYwZWU4MDAxYjVkNS90YWJsZXJhbmdlOjFhNzU1NDkyOGQ0YjRkMjRiZDc2NjBlZTgwMDFiNWQ1XzQtMy0xLTEtMjg2OTQ0_a8dfa241-1e7c-4fd3-8669-32a1032c7fce"
      unitRef="usd">4000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i704ee587ce264884a099492815729252_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90YWJsZToxYTc1NTQ5MjhkNGI0ZDI0YmQ3NjYwZWU4MDAxYjVkNS90YWJsZXJhbmdlOjFhNzU1NDkyOGQ0YjRkMjRiZDc2NjBlZTgwMDFiNWQ1XzQtNS0xLTEtMjg2OTQ0_7ece7d3d-aa81-4023-a0ef-3e5045169588"
      unitRef="usd">-43000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8ec1d9ad198a4e43b265abc3a0d32cb8_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90YWJsZToxYTc1NTQ5MjhkNGI0ZDI0YmQ3NjYwZWU4MDAxYjVkNS90YWJsZXJhbmdlOjFhNzU1NDkyOGQ0YjRkMjRiZDc2NjBlZTgwMDFiNWQ1XzUtMS0xLTEtMjg2OTQ0_c45db010-9f6f-4d8c-89d9-3ccfc46c2d7a"
      unitRef="usd">-93000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id449ab0597f64cd29ac910cb2816b35b_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90YWJsZToxYTc1NTQ5MjhkNGI0ZDI0YmQ3NjYwZWU4MDAxYjVkNS90YWJsZXJhbmdlOjFhNzU1NDkyOGQ0YjRkMjRiZDc2NjBlZTgwMDFiNWQ1XzUtMy0xLTEtMjg2OTQ0_7b4459ab-74ea-4a6a-975d-5a7b1d7a97b8"
      unitRef="usd">16000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6203134ce90347afaf3c8d39444a0a7d_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTIvZnJhZzo4NzE1MGQyOTY2ZmE0ODk5OWVlOWI4NjE5OTRhZDNlYi90YWJsZToxYTc1NTQ5MjhkNGI0ZDI0YmQ3NjYwZWU4MDAxYjVkNS90YWJsZXJhbmdlOjFhNzU1NDkyOGQ0YjRkMjRiZDc2NjBlZTgwMDFiNWQ1XzUtNS0xLTEtMjg2OTQ0_75d80f22-a7de-44c4-a821-86f1069889fc"
      unitRef="usd">-77000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTUvZnJhZzoxYzYzZDA1YTlmYTk0MjhmODhkZjhiZjQ2NjI3ZjQ4Yi90ZXh0cmVnaW9uOjFjNjNkMDVhOWZhOTQyOGY4OGRmOGJmNDY2MjdmNDhiXzk0NQ_8ecacc64-8105-4fec-9c63-7d6e7256c2dd">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;11. Earnings/(Loss) Per Share Attributable to Cardinal Health, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reconciles the number of common shares used to compute basic and diluted earnings/(loss) per share attributable to Cardinal Health, Inc.:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares&#x2013;basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;256&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee stock options, restricted share units and performance share units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-average common shares&#x2013;diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;258&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares&#x2013;basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;263&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee stock options, restricted share units and performance share units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-average common shares&#x2013;diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;264&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The potentially dilutive employee stock options, restricted share units and performance share units that were antidilutive were 2 million for both the three and nine months ended March&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The potentially dilutive employee stock options, restricted share units and performance share units that were antidilutive were 5 million for both the three and nine months ended March 31, 2022. For the three and nine months ended March 31, 2022, there were 2&#160;million and 1&#160;million potentially dilutive employee stock options, restricted share units and performance share units not included in the computation of diluted loss per common share attributable to Cardinal Health, Inc. because their effect would have been antidilutive as a result of the net loss during those periods.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTUvZnJhZzoxYzYzZDA1YTlmYTk0MjhmODhkZjhiZjQ2NjI3ZjQ4Yi90ZXh0cmVnaW9uOjFjNjNkMDVhOWZhOTQyOGY4OGRmOGJmNDY2MjdmNDhiXzk0MQ_1839ceb7-68ab-45f6-8c52-af6f18f6f4be">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reconciles the number of common shares used to compute basic and diluted earnings/(loss) per share attributable to Cardinal Health, Inc.:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares&#x2013;basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;256&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee stock options, restricted share units and performance share units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-average common shares&#x2013;diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;258&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares&#x2013;basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;263&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee stock options, restricted share units and performance share units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-average common shares&#x2013;diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;264&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTUvZnJhZzoxYzYzZDA1YTlmYTk0MjhmODhkZjhiZjQ2NjI3ZjQ4Yi90YWJsZToxY2U3YmIxZjc4YTA0MjA0OTkzNzBkNjBkOWZhOGZmYi90YWJsZXJhbmdlOjFjZTdiYjFmNzhhMDQyMDQ5OTM3MGQ2MGQ5ZmE4ZmZiXzItMS0xLTEtMjg2OTQ0_4e89ed84-7b07-4285-b7af-8caf23941308"
      unitRef="shares">256000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTUvZnJhZzoxYzYzZDA1YTlmYTk0MjhmODhkZjhiZjQ2NjI3ZjQ4Yi90YWJsZToxY2U3YmIxZjc4YTA0MjA0OTkzNzBkNjBkOWZhOGZmYi90YWJsZXJhbmdlOjFjZTdiYjFmNzhhMDQyMDQ5OTM3MGQ2MGQ5ZmE4ZmZiXzItMy0xLTEtMjg2OTQ0_33456497-04e3-41c5-923b-7333742756f4"
      unitRef="shares">275000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTUvZnJhZzoxYzYzZDA1YTlmYTk0MjhmODhkZjhiZjQ2NjI3ZjQ4Yi90YWJsZToxY2U3YmIxZjc4YTA0MjA0OTkzNzBkNjBkOWZhOGZmYi90YWJsZXJhbmdlOjFjZTdiYjFmNzhhMDQyMDQ5OTM3MGQ2MGQ5ZmE4ZmZiXzQtMS0xLTEtMjg2OTQ0_30547a20-c32b-437c-a7f0-6349cdbfb69e"
      unitRef="shares">2000000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTUvZnJhZzoxYzYzZDA1YTlmYTk0MjhmODhkZjhiZjQ2NjI3ZjQ4Yi90YWJsZToxY2U3YmIxZjc4YTA0MjA0OTkzNzBkNjBkOWZhOGZmYi90YWJsZXJhbmdlOjFjZTdiYjFmNzhhMDQyMDQ5OTM3MGQ2MGQ5ZmE4ZmZiXzQtMy0xLTEtMjg2OTQ0_cf43625e-87b4-48e4-b927-0810e5d49523"
      unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTUvZnJhZzoxYzYzZDA1YTlmYTk0MjhmODhkZjhiZjQ2NjI3ZjQ4Yi90YWJsZToxY2U3YmIxZjc4YTA0MjA0OTkzNzBkNjBkOWZhOGZmYi90YWJsZXJhbmdlOjFjZTdiYjFmNzhhMDQyMDQ5OTM3MGQ2MGQ5ZmE4ZmZiXzUtMS0xLTEtMjg2OTQ0_0fb08b0f-d988-4cfd-a95c-8f9077797303"
      unitRef="shares">258000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTUvZnJhZzoxYzYzZDA1YTlmYTk0MjhmODhkZjhiZjQ2NjI3ZjQ4Yi90YWJsZToxY2U3YmIxZjc4YTA0MjA0OTkzNzBkNjBkOWZhOGZmYi90YWJsZXJhbmdlOjFjZTdiYjFmNzhhMDQyMDQ5OTM3MGQ2MGQ5ZmE4ZmZiXzUtMy0xLTEtMjg2OTQ0_9b63ab52-7820-4abb-84c8-58e82a4a8eb7"
      unitRef="shares">275000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTUvZnJhZzoxYzYzZDA1YTlmYTk0MjhmODhkZjhiZjQ2NjI3ZjQ4Yi90YWJsZTo0ZmNiMjk0ZTFhNGY0MTI4OWFkZjk0MjcxNTkwYmVhYy90YWJsZXJhbmdlOjRmY2IyOTRlMWE0ZjQxMjg5YWRmOTQyNzE1OTBiZWFjXzItMS0xLTEtMjg2OTQ0_c182c5ec-2d99-481d-b6a4-ee0246807c8e"
      unitRef="shares">263000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTUvZnJhZzoxYzYzZDA1YTlmYTk0MjhmODhkZjhiZjQ2NjI3ZjQ4Yi90YWJsZTo0ZmNiMjk0ZTFhNGY0MTI4OWFkZjk0MjcxNTkwYmVhYy90YWJsZXJhbmdlOjRmY2IyOTRlMWE0ZjQxMjg5YWRmOTQyNzE1OTBiZWFjXzItMy0xLTEtMjg2OTQ0_9ab39adf-7e77-4294-811b-f2a04dd9ec58"
      unitRef="shares">281000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTUvZnJhZzoxYzYzZDA1YTlmYTk0MjhmODhkZjhiZjQ2NjI3ZjQ4Yi90YWJsZTo0ZmNiMjk0ZTFhNGY0MTI4OWFkZjk0MjcxNTkwYmVhYy90YWJsZXJhbmdlOjRmY2IyOTRlMWE0ZjQxMjg5YWRmOTQyNzE1OTBiZWFjXzQtMS0xLTEtMjg2OTQ0_8001003d-5dfc-42a9-a03d-126197d95ea8"
      unitRef="shares">1000000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTUvZnJhZzoxYzYzZDA1YTlmYTk0MjhmODhkZjhiZjQ2NjI3ZjQ4Yi90YWJsZTo0ZmNiMjk0ZTFhNGY0MTI4OWFkZjk0MjcxNTkwYmVhYy90YWJsZXJhbmdlOjRmY2IyOTRlMWE0ZjQxMjg5YWRmOTQyNzE1OTBiZWFjXzQtMy0xLTEtMjg2OTQ0_9be59836-31a8-43e1-a6f6-e0550e52631a"
      unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTUvZnJhZzoxYzYzZDA1YTlmYTk0MjhmODhkZjhiZjQ2NjI3ZjQ4Yi90YWJsZTo0ZmNiMjk0ZTFhNGY0MTI4OWFkZjk0MjcxNTkwYmVhYy90YWJsZXJhbmdlOjRmY2IyOTRlMWE0ZjQxMjg5YWRmOTQyNzE1OTBiZWFjXzUtMS0xLTEtMjg2OTQ0_ac51f02c-b540-40d3-b955-f463e153a4a6"
      unitRef="shares">264000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTUvZnJhZzoxYzYzZDA1YTlmYTk0MjhmODhkZjhiZjQ2NjI3ZjQ4Yi90YWJsZTo0ZmNiMjk0ZTFhNGY0MTI4OWFkZjk0MjcxNTkwYmVhYy90YWJsZXJhbmdlOjRmY2IyOTRlMWE0ZjQxMjg5YWRmOTQyNzE1OTBiZWFjXzUtMy0xLTEtMjg2OTQ0_3eb69860-b78a-4bcb-b7fa-5b647c2c8890"
      unitRef="shares">281000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTUvZnJhZzoxYzYzZDA1YTlmYTk0MjhmODhkZjhiZjQ2NjI3ZjQ4Yi90ZXh0cmVnaW9uOjFjNjNkMDVhOWZhOTQyOGY4OGRmOGJmNDY2MjdmNDhiXzU0OTc1NTgxNTI5Nw_26b0f308-7bfb-4736-8b93-14d21b640848"
      unitRef="shares">2000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTUvZnJhZzoxYzYzZDA1YTlmYTk0MjhmODhkZjhiZjQ2NjI3ZjQ4Yi90ZXh0cmVnaW9uOjFjNjNkMDVhOWZhOTQyOGY4OGRmOGJmNDY2MjdmNDhiXzU0OTc1NTgxNTI5Nw_de747c67-db71-4636-8c01-82188705a408"
      unitRef="shares">2000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTUvZnJhZzoxYzYzZDA1YTlmYTk0MjhmODhkZjhiZjQ2NjI3ZjQ4Yi90ZXh0cmVnaW9uOjFjNjNkMDVhOWZhOTQyOGY4OGRmOGJmNDY2MjdmNDhiXzU0OTc1NTgxNTQ3Mw_3c411e0b-70a8-4f9f-9846-e73041a01537"
      unitRef="shares">5000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTUvZnJhZzoxYzYzZDA1YTlmYTk0MjhmODhkZjhiZjQ2NjI3ZjQ4Yi90ZXh0cmVnaW9uOjFjNjNkMDVhOWZhOTQyOGY4OGRmOGJmNDY2MjdmNDhiXzU0OTc1NTgxNTQ3Mw_ebf12571-0d30-41d0-9359-d21c865633e8"
      unitRef="shares">5000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <cah:SharesThatWouldBeAntidilutiveAsAResultOfNetLoss
      contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTUvZnJhZzoxYzYzZDA1YTlmYTk0MjhmODhkZjhiZjQ2NjI3ZjQ4Yi90ZXh0cmVnaW9uOjFjNjNkMDVhOWZhOTQyOGY4OGRmOGJmNDY2MjdmNDhiXzU0OTc1NTgxNDA5ODc_2a4f7c9c-78f7-4d10-8d15-dc7b53a502d0"
      unitRef="reportable_segments">2000000</cah:SharesThatWouldBeAntidilutiveAsAResultOfNetLoss>
    <cah:SharesThatWouldBeAntidilutiveAsAResultOfNetLoss
      contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTUvZnJhZzoxYzYzZDA1YTlmYTk0MjhmODhkZjhiZjQ2NjI3ZjQ4Yi90ZXh0cmVnaW9uOjFjNjNkMDVhOWZhOTQyOGY4OGRmOGJmNDY2MjdmNDhiXzU0OTc1NTgxNDEwMDA_5e457c93-1140-47e1-b665-c7e098348e03"
      unitRef="reportable_segments">1000000</cah:SharesThatWouldBeAntidilutiveAsAResultOfNetLoss>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90ZXh0cmVnaW9uOjZmYzA0ZmQwYjc5NTQ1MTBiZDFkNWU0YTZmYzJlNGFiXzU3MTU_b3aab43d-a051-4088-b031-3e36f71fca1c">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;12. Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our operations are principally managed on a products and services basis and are comprised of two operating segments, which are the same as our reportable segments: Pharmaceutical and Medical. The factors for determining the reportable segments include the manner in which management evaluates performance for purposes of allocating resources and assessing performance combined with the nature of the individual business activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical and over-the-counter healthcare and consumer products in the United States. This segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; provides pharmacy management services to hospitals and operates a limited number of pharmacies, including pharmacies in community health centers; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; and connects pharmacists, payers and pharmaceutical companies and delivers health solutions for medication therapy management, digital patient engagement and telepharmacy; and repackages generic pharmaceuticals and over-the-counter healthcare products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Medical segment manufactures, sources and distributes Cardinal Health branded medical, surgical and laboratory products, which are sold in the United States, Canada, Europe, Asia and other markets. In addition to distributing Cardinal Health branded products, this segment also distributes a broad range of medical, surgical and laboratory products known as national brand products and provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories and other healthcare providers in the United States and Canada. This &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;segment also distributes medical products to patients' homes in the United States through our Cardinal Health at-Home Solutions division.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present revenue for each reportable segment and disaggregated revenue within our two reportable segments and Corporate:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.591%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical Distribution and Specialty Solutions (1) (2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;46,497&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nuclear and Precision Health Solutions (3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;312&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical segment revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;46,809&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical distribution and products (4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,034&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cardinal Health at-Home Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;650&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical segment revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,684&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Total segment revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;50,493&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate (5)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;50,487&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.591%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical Distribution and Specialty Solutions (1) (2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;139,435&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;121,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nuclear and Precision Health Solutions (3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;875&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical segment revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;140,310&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;122,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical distribution and products (4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;9,273&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cardinal Health at-Home Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,986&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical segment revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;11,259&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Total segment revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;151,569&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;134,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate (5)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;151,559&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;134,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Products and services offered by our Specialty Solutions division are referred to as &#x201c;specialty pharmaceutical products and services."&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Comprised of all Pharmaceutical segment businesses except for Nuclear and Precision Health Solutions division.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Increase from prior year relates to new product launches and changes in revenue recognition presentation from agent to principal for certain customer contracts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Comprised of all Medical segment businesses except for Cardinal Health at-Home Solutions division.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(5)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.&lt;/span&gt;&lt;/div&gt;&lt;div style="display:inline-block;vertical-align:top;width:48.214%"&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present revenue by geographic area:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.482%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.215%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.586%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.217%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;49,326&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,167&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Total segment revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;50,493&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;50,487&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.906%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.586%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.217%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;148,136&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;130,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,433&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Total segment revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;151,569&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;134,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;151,559&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;134,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Segment Profit&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We evaluate segment performance based on segment profit, among other measures. Segment profit is segment revenue, less segment cost of products sold, less segment distribution, selling, general and administrative ("SG&amp;amp;A") expenses. Segment SG&amp;amp;A expenses include share-based compensation expense as well as allocated corporate expenses for shared functions, including corporate management, corporate finance, financial and customer care shared services, human resources, information technology and legal and compliance, including certain litigation defense costs. Corporate expenses are allocated to the segments based on headcount, level of benefit provided and other ratable allocation methodologies. The results attributable to noncontrolling interests are recorded within segment profit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We do not allocate the following items to our segments: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt"&gt;last-in first-out, or ("LIFO"), inventory charges/(credits); &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt"&gt;surgical gown recall costs/(income);&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt"&gt;shareholder cooperation agreement costs;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt"&gt;state opioid assessment related to prior fiscal years;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt"&gt;restructuring and employee severance;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt"&gt;amortization and other acquisition-related costs;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt"&gt;impairments and (gain)/loss on disposal of assets, net; in connection with goodwill impairment testing for the Medical Unit as discussed further in &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#i1d34fc4fc2424fbcb4837cc9f1c0665c_88" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note 4&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, we recognized cumulative goodwill impairment charges of $863&#160;million during the nine months ended March&#160;31, 2023;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt"&gt;litigation (recoveries)/charges, net;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt"&gt;other (income)/expense, net;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt"&gt;interest expense, net;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/&gt;&lt;div style="display:inline-block;vertical-align:top;width:48.215%"&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt"&gt;loss on early extinguishment of debt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt"&gt;(gain)/loss on sale of equity interest in naviHealth; or&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt"&gt;provision for income taxes &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, certain investment spending, certain portions of enterprise-wide incentive compensation and other spending are not allocated to the segments. Investment spending generally includes the first-year spend for certain projects that require incremental investments in the form of additional operating expenses. Because approval for these projects is dependent on executive management, we retain these expenses at Corporate. Investment spending within Corporate was $9 million and $20 million for the three months ended March&#160;31, 2023 and 2022, and $20 million and $38 million for the nine months ended March&#160;31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present segment profit by reportable segment and Corporate:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.429%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical (1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;600&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;20&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total segment profit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;620&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(643)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total operating earnings/(loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;572&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(97)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical (1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,495&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;29&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total segment profit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,524&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(934)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,183)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total operating earnings/(loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;590&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(632)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Pharmaceutical segment profit includes opioid-related litigation defense and compliance costs, but does not include a one-time contingent attorney fee of $18&#160;million incurred during the three and nine months ended March 31, 2022 related to the finalization of the Settlement Agreement. Due to the unique nature and significance of the Settlement Agreement, and the one-time, contingent nature of the fee, this related fee was included in litigation (recoveries)/charges, net in the condensed consolidated statements of earnings/(loss). Additionally, pharmaceutical segment profit during the nine months ended March 31, 2022 was positively impacted by a $16&#160;million judgment for lost profits related to an ordinary course intellectual property rights claim.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents total assets for each reportable segment and Corporate at: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.500%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.503%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d1d1d1;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;27,954&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"/&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10,544&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d1d1d1;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d1d1d1;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,879&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d1d1d1;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;43,377&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;(1)Medical reflects cumulative $863&#160;million goodwill impairment charges recorded in connection with the interim goodwill impairment testing for the Medical Unit during the nine months ended March 31, 2023.</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90ZXh0cmVnaW9uOjZmYzA0ZmQwYjc5NTQ1MTBiZDFkNWU0YTZmYzJlNGFiXzEwMQ_b6e3f197-a086-46d0-afe1-513b7b8c63cb"
      unitRef="segment">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90ZXh0cmVnaW9uOjZmYzA0ZmQwYjc5NTQ1MTBiZDFkNWU0YTZmYzJlNGFiXzEwMQ_f0d9d156-1de4-4b34-b1f0-32d65e4d3f4e"
      unitRef="segment">2</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90ZXh0cmVnaW9uOjZmYzA0ZmQwYjc5NTQ1MTBiZDFkNWU0YTZmYzJlNGFiXzIwNDA_b6e3f197-a086-46d0-afe1-513b7b8c63cb"
      unitRef="segment">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90ZXh0cmVnaW9uOjZmYzA0ZmQwYjc5NTQ1MTBiZDFkNWU0YTZmYzJlNGFiXzIwNDA_f0d9d156-1de4-4b34-b1f0-32d65e4d3f4e"
      unitRef="segment">2</us-gaap:NumberOfReportableSegments>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90ZXh0cmVnaW9uOjZmYzA0ZmQwYjc5NTQ1MTBiZDFkNWU0YTZmYzJlNGFiXzU3Mjk_696ea255-63ee-4be3-b9e7-2359a2b04497">&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.591%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical Distribution and Specialty Solutions (1) (2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;46,497&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nuclear and Precision Health Solutions (3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;312&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical segment revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;46,809&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical distribution and products (4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,034&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cardinal Health at-Home Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;650&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical segment revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,684&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Total segment revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;50,493&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate (5)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;50,487&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.591%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical Distribution and Specialty Solutions (1) (2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;139,435&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;121,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nuclear and Precision Health Solutions (3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;875&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical segment revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;140,310&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;122,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical distribution and products (4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;9,273&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cardinal Health at-Home Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,986&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical segment revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;11,259&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Total segment revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;151,569&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;134,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate (5)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;151,559&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;134,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Products and services offered by our Specialty Solutions division are referred to as &#x201c;specialty pharmaceutical products and services."&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Comprised of all Pharmaceutical segment businesses except for Nuclear and Precision Health Solutions division.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Increase from prior year relates to new product launches and changes in revenue recognition presentation from agent to principal for certain customer contracts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Comprised of all Medical segment businesses except for Cardinal Health at-Home Solutions division.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(5)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:Revenues
      contextRef="idc26a4e700a342548208bd3adbce0cc3_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpjN2M4NWJkM2U0ODY0MTdlYjM3OTU2YjI2MTE1MzFhMS90YWJsZXJhbmdlOmM3Yzg1YmQzZTQ4NjQxN2ViMzc5NTZiMjYxMTUzMWExXzItMS0xLTEtMjg2OTQ0_18574e7b-b7b3-4cea-ac91-249d6a9251a4"
      unitRef="usd">46497000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3eeef5beb2e3457385d0a29a55055482_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpjN2M4NWJkM2U0ODY0MTdlYjM3OTU2YjI2MTE1MzFhMS90YWJsZXJhbmdlOmM3Yzg1YmQzZTQ4NjQxN2ViMzc5NTZiMjYxMTUzMWExXzItMy0xLTEtMjg2OTQ0_5914dadc-b40c-4e66-8c1e-1741344adec1"
      unitRef="usd">40723000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id1f8c810883d4ff9a38b1a6311b7024a_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpjN2M4NWJkM2U0ODY0MTdlYjM3OTU2YjI2MTE1MzFhMS90YWJsZXJhbmdlOmM3Yzg1YmQzZTQ4NjQxN2ViMzc5NTZiMjYxMTUzMWExXzMtMS0xLTEtMjg2OTQ0_3e580059-56b4-449f-9a6a-d7e67005646b"
      unitRef="usd">312000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i22582fc2d45245928c608e9b04993980_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpjN2M4NWJkM2U0ODY0MTdlYjM3OTU2YjI2MTE1MzFhMS90YWJsZXJhbmdlOmM3Yzg1YmQzZTQ4NjQxN2ViMzc5NTZiMjYxMTUzMWExXzMtMy0xLTEtMjg2OTQ0_897cf184-516e-4116-8690-80cd0b520895"
      unitRef="usd">234000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i16dc5579b6f94e7ca4452bbc7028e7c9_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpjN2M4NWJkM2U0ODY0MTdlYjM3OTU2YjI2MTE1MzFhMS90YWJsZXJhbmdlOmM3Yzg1YmQzZTQ4NjQxN2ViMzc5NTZiMjYxMTUzMWExXzQtMS0xLTEtMjg2OTQ0_b41e1e5b-55ad-44bf-8c7c-bc08ac7c3a20"
      unitRef="usd">46809000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i45daaa94544f4353a00c894ddf85a502_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpjN2M4NWJkM2U0ODY0MTdlYjM3OTU2YjI2MTE1MzFhMS90YWJsZXJhbmdlOmM3Yzg1YmQzZTQ4NjQxN2ViMzc5NTZiMjYxMTUzMWExXzQtMy0xLTEtMjg2OTQ0_b63e13b4-8ba6-43ff-a74a-489fb80ff6e3"
      unitRef="usd">40957000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i496f651118df4ac294afe39b4aefdc23_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpjN2M4NWJkM2U0ODY0MTdlYjM3OTU2YjI2MTE1MzFhMS90YWJsZXJhbmdlOmM3Yzg1YmQzZTQ4NjQxN2ViMzc5NTZiMjYxMTUzMWExXzUtMS0xLTEtMjg2OTQ0_d20863a7-0e7f-4bfd-9bf3-2459011a6a84"
      unitRef="usd">3034000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ieff878faa3b9482d85466ac9bdf16285_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpjN2M4NWJkM2U0ODY0MTdlYjM3OTU2YjI2MTE1MzFhMS90YWJsZXJhbmdlOmM3Yzg1YmQzZTQ4NjQxN2ViMzc5NTZiMjYxMTUzMWExXzUtMy0xLTEtMjg2OTQ0_5e8c9561-b8b3-4c80-b5b4-3dfa5863831d"
      unitRef="usd">3283000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib56812ccf8264be98f8752c625e2e17a_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpjN2M4NWJkM2U0ODY0MTdlYjM3OTU2YjI2MTE1MzFhMS90YWJsZXJhbmdlOmM3Yzg1YmQzZTQ4NjQxN2ViMzc5NTZiMjYxMTUzMWExXzYtMS0xLTEtMjg2OTQ0_0c8e26ea-b2c6-45f6-846f-08d683f30fa3"
      unitRef="usd">650000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i169b1a322c8c4e52985fff332cb28f47_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpjN2M4NWJkM2U0ODY0MTdlYjM3OTU2YjI2MTE1MzFhMS90YWJsZXJhbmdlOmM3Yzg1YmQzZTQ4NjQxN2ViMzc5NTZiMjYxMTUzMWExXzYtMy0xLTEtMjg2OTQ0_1fee6fa9-25ba-4df3-8f3d-d81a21d15ac7"
      unitRef="usd">601000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1495b91ae50844b7bd8dee01339cb2ba_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpjN2M4NWJkM2U0ODY0MTdlYjM3OTU2YjI2MTE1MzFhMS90YWJsZXJhbmdlOmM3Yzg1YmQzZTQ4NjQxN2ViMzc5NTZiMjYxMTUzMWExXzctMS0xLTEtMjg2OTQ0_c3b8ed98-bfe4-4bdc-99b1-cfb2e399a961"
      unitRef="usd">3684000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibc29744d3dd64b99ab33d733a31d8725_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpjN2M4NWJkM2U0ODY0MTdlYjM3OTU2YjI2MTE1MzFhMS90YWJsZXJhbmdlOmM3Yzg1YmQzZTQ4NjQxN2ViMzc5NTZiMjYxMTUzMWExXzctMy0xLTEtMjg2OTQ0_1116a13d-fa6f-47a3-9cc3-7c843b04db92"
      unitRef="usd">3884000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic7c59d976f4b491293536f66988a658a_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpjN2M4NWJkM2U0ODY0MTdlYjM3OTU2YjI2MTE1MzFhMS90YWJsZXJhbmdlOmM3Yzg1YmQzZTQ4NjQxN2ViMzc5NTZiMjYxMTUzMWExXzgtMS0xLTEtMjg2OTQ0_d2d9aad5-eb2c-417d-88c2-57a417b9056c"
      unitRef="usd">50493000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i569871ca4d47454f87c9b6023726a3aa_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpjN2M4NWJkM2U0ODY0MTdlYjM3OTU2YjI2MTE1MzFhMS90YWJsZXJhbmdlOmM3Yzg1YmQzZTQ4NjQxN2ViMzc5NTZiMjYxMTUzMWExXzgtMy0xLTEtMjg2OTQ0_de246105-4b53-4a16-939f-3efbf48e6a9e"
      unitRef="usd">44841000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia03b234276c04aa0af1cf1a16b60bc62_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpjN2M4NWJkM2U0ODY0MTdlYjM3OTU2YjI2MTE1MzFhMS90YWJsZXJhbmdlOmM3Yzg1YmQzZTQ4NjQxN2ViMzc5NTZiMjYxMTUzMWExXzktMS0xLTEtMjg2OTQ0_cb27356b-ce76-4150-b31a-88fdd5513bc9"
      unitRef="usd">-6000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0b30b0809298478382f26a051e90bf8a_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpjN2M4NWJkM2U0ODY0MTdlYjM3OTU2YjI2MTE1MzFhMS90YWJsZXJhbmdlOmM3Yzg1YmQzZTQ4NjQxN2ViMzc5NTZiMjYxMTUzMWExXzktMy0xLTEtMjg2OTQ0_fc273ded-b0f7-4cd7-b0a0-85e8566076e2"
      unitRef="usd">-5000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpjN2M4NWJkM2U0ODY0MTdlYjM3OTU2YjI2MTE1MzFhMS90YWJsZXJhbmdlOmM3Yzg1YmQzZTQ4NjQxN2ViMzc5NTZiMjYxMTUzMWExXzEwLTEtMS0xLTI4Njk0NA_8b929348-2156-43a9-910b-a07b130945a8"
      unitRef="usd">50487000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpjN2M4NWJkM2U0ODY0MTdlYjM3OTU2YjI2MTE1MzFhMS90YWJsZXJhbmdlOmM3Yzg1YmQzZTQ4NjQxN2ViMzc5NTZiMjYxMTUzMWExXzEwLTMtMS0xLTI4Njk0NA_7eb0407c-964b-4e7b-bf4d-02116ae17161"
      unitRef="usd">44836000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie54fd2c345514ac293e4ec5b948651d1_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpmNGJjYjczNDEwNTE0YjBmYjkyNzU4ZmY2OTViM2JkZS90YWJsZXJhbmdlOmY0YmNiNzM0MTA1MTRiMGZiOTI3NThmZjY5NWIzYmRlXzItMS0xLTEtMjg2OTQ0_e9c41963-12ca-4a16-8232-7bea86fba633"
      unitRef="usd">139435000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0d7a863829b14c7491f8ae6b2433a880_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpmNGJjYjczNDEwNTE0YjBmYjkyNzU4ZmY2OTViM2JkZS90YWJsZXJhbmdlOmY0YmNiNzM0MTA1MTRiMGZiOTI3NThmZjY5NWIzYmRlXzItMy0xLTEtMjg2OTQ0_ee9b67c9-536c-47c5-aa9a-d1fdabb3ffb0"
      unitRef="usd">121501000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i92e95db7bd6246ed9c7bac5e8fb213ff_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpmNGJjYjczNDEwNTE0YjBmYjkyNzU4ZmY2OTViM2JkZS90YWJsZXJhbmdlOmY0YmNiNzM0MTA1MTRiMGZiOTI3NThmZjY5NWIzYmRlXzMtMS0xLTEtMjg2OTQ0_09d7a20d-753c-43ce-989c-037a3c1a9b9a"
      unitRef="usd">875000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id8bc9a61c2e44236ab69000fb26a2824_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpmNGJjYjczNDEwNTE0YjBmYjkyNzU4ZmY2OTViM2JkZS90YWJsZXJhbmdlOmY0YmNiNzM0MTA1MTRiMGZiOTI3NThmZjY5NWIzYmRlXzMtMy0xLTEtMjg2OTQ0_fc5fb015-74d4-4166-922d-34f45a0f23fd"
      unitRef="usd">653000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i04924e9230e745fca992f99aa6ace85c_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpmNGJjYjczNDEwNTE0YjBmYjkyNzU4ZmY2OTViM2JkZS90YWJsZXJhbmdlOmY0YmNiNzM0MTA1MTRiMGZiOTI3NThmZjY5NWIzYmRlXzQtMS0xLTEtMjg2OTQ0_dcdce57e-dff8-4894-bb4d-0aec0f00a083"
      unitRef="usd">140310000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8b399963940c4fcc875d6ee7b2e2a30c_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpmNGJjYjczNDEwNTE0YjBmYjkyNzU4ZmY2OTViM2JkZS90YWJsZXJhbmdlOmY0YmNiNzM0MTA1MTRiMGZiOTI3NThmZjY5NWIzYmRlXzQtMy0xLTEtMjg2OTQ0_d3b828b7-6385-48c2-afce-142fdd863bbd"
      unitRef="usd">122154000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id19b85c70c834e2788b7091044df235c_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpmNGJjYjczNDEwNTE0YjBmYjkyNzU4ZmY2OTViM2JkZS90YWJsZXJhbmdlOmY0YmNiNzM0MTA1MTRiMGZiOTI3NThmZjY5NWIzYmRlXzUtMS0xLTEtMjg2OTQ0_9d834dc3-35be-4bd0-8ec4-f101000a2297"
      unitRef="usd">9273000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i543467e6acd7440e976c6acaeebc9d47_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpmNGJjYjczNDEwNTE0YjBmYjkyNzU4ZmY2OTViM2JkZS90YWJsZXJhbmdlOmY0YmNiNzM0MTA1MTRiMGZiOTI3NThmZjY5NWIzYmRlXzUtMy0xLTEtMjg2OTQ0_9e4c2a36-9aa8-40d7-a6df-5714319d9ec7"
      unitRef="usd">10296000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i57cd785fabaf4688a3bbe54d4f0ca21d_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpmNGJjYjczNDEwNTE0YjBmYjkyNzU4ZmY2OTViM2JkZS90YWJsZXJhbmdlOmY0YmNiNzM0MTA1MTRiMGZiOTI3NThmZjY5NWIzYmRlXzYtMS0xLTEtMjg2OTQ0_a8f25338-cc67-487a-89ab-1c0d94b96f66"
      unitRef="usd">1986000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id9e29a915c71426f8011dc3489ec5202_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpmNGJjYjczNDEwNTE0YjBmYjkyNzU4ZmY2OTViM2JkZS90YWJsZXJhbmdlOmY0YmNiNzM0MTA1MTRiMGZiOTI3NThmZjY5NWIzYmRlXzYtMy0xLTEtMjg2OTQ0_b2cdf083-f7b4-4081-ad34-985bb1821400"
      unitRef="usd">1822000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i44eddf7caae040f987146265a715a28d_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpmNGJjYjczNDEwNTE0YjBmYjkyNzU4ZmY2OTViM2JkZS90YWJsZXJhbmdlOmY0YmNiNzM0MTA1MTRiMGZiOTI3NThmZjY5NWIzYmRlXzctMS0xLTEtMjg2OTQ0_1cc16b83-49f9-49b8-bf03-5991099e3142"
      unitRef="usd">11259000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie312826afe694135b31551dc50097180_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpmNGJjYjczNDEwNTE0YjBmYjkyNzU4ZmY2OTViM2JkZS90YWJsZXJhbmdlOmY0YmNiNzM0MTA1MTRiMGZiOTI3NThmZjY5NWIzYmRlXzctMy0xLTEtMjg2OTQ0_e18328cb-be47-4830-add4-d6e34c0d4ce2"
      unitRef="usd">12118000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i09186e53513344a797c14f6874c9c782_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpmNGJjYjczNDEwNTE0YjBmYjkyNzU4ZmY2OTViM2JkZS90YWJsZXJhbmdlOmY0YmNiNzM0MTA1MTRiMGZiOTI3NThmZjY5NWIzYmRlXzgtMS0xLTEtMjg2OTQ0_cc9c9394-0622-44ef-b1fc-74d8a1b2e62e"
      unitRef="usd">151569000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i438495dce7084e9eb69ebe58bc06cd29_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpmNGJjYjczNDEwNTE0YjBmYjkyNzU4ZmY2OTViM2JkZS90YWJsZXJhbmdlOmY0YmNiNzM0MTA1MTRiMGZiOTI3NThmZjY5NWIzYmRlXzgtMy0xLTEtMjg2OTQ0_12ff11cf-26b5-4c28-adb8-120fb431c8bb"
      unitRef="usd">134272000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6ed97f44ba534c3889ad982e9558682c_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpmNGJjYjczNDEwNTE0YjBmYjkyNzU4ZmY2OTViM2JkZS90YWJsZXJhbmdlOmY0YmNiNzM0MTA1MTRiMGZiOTI3NThmZjY5NWIzYmRlXzktMS0xLTEtMjg2OTQ0_14de0a77-df94-4a52-a248-dfa383656e71"
      unitRef="usd">-10000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9dcc325ed5014b548d6c310c9974f048_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpmNGJjYjczNDEwNTE0YjBmYjkyNzU4ZmY2OTViM2JkZS90YWJsZXJhbmdlOmY0YmNiNzM0MTA1MTRiMGZiOTI3NThmZjY5NWIzYmRlXzktMy0xLTEtMjg2OTQ0_70137c91-6127-4a86-b2ba-db9aced9c03f"
      unitRef="usd">-11000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpmNGJjYjczNDEwNTE0YjBmYjkyNzU4ZmY2OTViM2JkZS90YWJsZXJhbmdlOmY0YmNiNzM0MTA1MTRiMGZiOTI3NThmZjY5NWIzYmRlXzEwLTEtMS0xLTI4Njk0NA_9083c730-0881-4afc-8694-a3402b330b4c"
      unitRef="usd">151559000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpmNGJjYjczNDEwNTE0YjBmYjkyNzU4ZmY2OTViM2JkZS90YWJsZXJhbmdlOmY0YmNiNzM0MTA1MTRiMGZiOTI3NThmZjY5NWIzYmRlXzEwLTMtMS0xLTI4Njk0NA_6bdddb52-0254-4c48-bbf8-dcaae385fe82"
      unitRef="usd">134261000000</us-gaap:Revenues>
    <us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90ZXh0cmVnaW9uOjZmYzA0ZmQwYjc5NTQ1MTBiZDFkNWU0YTZmYzJlNGFiXzU3MjU_1a9a70cd-1827-4078-9328-3a2718650aa9">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present revenue by geographic area:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.482%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.215%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.586%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.217%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;49,326&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,167&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Total segment revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;50,493&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;50,487&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.906%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.586%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.217%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;148,136&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;130,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,433&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Total segment revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;151,569&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;134,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;151,559&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;134,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock>
    <us-gaap:Revenues
      contextRef="i73b99b7f00ef43c3b9264f23015dbdbc_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpiODliZDJiMjMwYmE0ZjVmYTY1MjI2MGZkZDQ1ZDhiMS90YWJsZXJhbmdlOmI4OWJkMmIyMzBiYTRmNWZhNjUyMjYwZmRkNDVkOGIxXzItMS0xLTEtMjg2OTQ0_c4c43d26-e86b-41f7-9b7d-8b8f9d463921"
      unitRef="usd">49326000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4bb3c35435cf4419a78f521a4ab0acc6_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpiODliZDJiMjMwYmE0ZjVmYTY1MjI2MGZkZDQ1ZDhiMS90YWJsZXJhbmdlOmI4OWJkMmIyMzBiYTRmNWZhNjUyMjYwZmRkNDVkOGIxXzItMy0xLTEtMjg2OTQ0_fb436046-4834-4559-850e-fc0dbf1b0555"
      unitRef="usd">43710000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i447a6c019d5146ccb318da808e4fb2f3_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpiODliZDJiMjMwYmE0ZjVmYTY1MjI2MGZkZDQ1ZDhiMS90YWJsZXJhbmdlOmI4OWJkMmIyMzBiYTRmNWZhNjUyMjYwZmRkNDVkOGIxXzMtMS0xLTEtMjg2OTQ0_fbd501e4-ce39-4618-99d5-15a5951751e8"
      unitRef="usd">1167000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4060ee92cb7e4a3a973a917c60eb75fc_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpiODliZDJiMjMwYmE0ZjVmYTY1MjI2MGZkZDQ1ZDhiMS90YWJsZXJhbmdlOmI4OWJkMmIyMzBiYTRmNWZhNjUyMjYwZmRkNDVkOGIxXzMtMy0xLTEtMjg2OTQ0_bed4ec58-68ad-4960-ab1c-85607377cbc2"
      unitRef="usd">1131000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic7c59d976f4b491293536f66988a658a_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpiODliZDJiMjMwYmE0ZjVmYTY1MjI2MGZkZDQ1ZDhiMS90YWJsZXJhbmdlOmI4OWJkMmIyMzBiYTRmNWZhNjUyMjYwZmRkNDVkOGIxXzQtMS0xLTEtMjg2OTQ0_9b564c76-ea0a-4bfc-bfcc-5d5c1b93ffbf"
      unitRef="usd">50493000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i569871ca4d47454f87c9b6023726a3aa_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpiODliZDJiMjMwYmE0ZjVmYTY1MjI2MGZkZDQ1ZDhiMS90YWJsZXJhbmdlOmI4OWJkMmIyMzBiYTRmNWZhNjUyMjYwZmRkNDVkOGIxXzQtMy0xLTEtMjg2OTQ0_80e65f17-72a6-4f3e-a46f-25b8d79360f4"
      unitRef="usd">44841000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia03b234276c04aa0af1cf1a16b60bc62_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpiODliZDJiMjMwYmE0ZjVmYTY1MjI2MGZkZDQ1ZDhiMS90YWJsZXJhbmdlOmI4OWJkMmIyMzBiYTRmNWZhNjUyMjYwZmRkNDVkOGIxXzUtMS0xLTEtMjg2OTQ0_e9630610-0a44-4f33-a7b7-0e9e5a2e709a"
      unitRef="usd">-6000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0b30b0809298478382f26a051e90bf8a_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpiODliZDJiMjMwYmE0ZjVmYTY1MjI2MGZkZDQ1ZDhiMS90YWJsZXJhbmdlOmI4OWJkMmIyMzBiYTRmNWZhNjUyMjYwZmRkNDVkOGIxXzUtMy0xLTEtMjg2OTQ0_caa74134-df1f-47fa-a962-0eb2d2d2ce88"
      unitRef="usd">-5000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpiODliZDJiMjMwYmE0ZjVmYTY1MjI2MGZkZDQ1ZDhiMS90YWJsZXJhbmdlOmI4OWJkMmIyMzBiYTRmNWZhNjUyMjYwZmRkNDVkOGIxXzYtMS0xLTEtMjg2OTQ0_6f540ad5-6aed-4dcc-820c-4f9b0f8634d7"
      unitRef="usd">50487000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpiODliZDJiMjMwYmE0ZjVmYTY1MjI2MGZkZDQ1ZDhiMS90YWJsZXJhbmdlOmI4OWJkMmIyMzBiYTRmNWZhNjUyMjYwZmRkNDVkOGIxXzYtMy0xLTEtMjg2OTQ0_3e60792d-f1e7-45f7-808c-f817028029fa"
      unitRef="usd">44836000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if67e0eb500ab42958354df8e59c31390_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpkM2E4ODdlZTI2MDM0OGU0OWUwZDJlMGE2NTkxYzc2ZC90YWJsZXJhbmdlOmQzYTg4N2VlMjYwMzQ4ZTQ5ZTBkMmUwYTY1OTFjNzZkXzItMS0xLTEtMjg2OTQ0_9e3f9545-d67d-4a52-8221-3af7797830a9"
      unitRef="usd">148136000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5273719c53784b1984b975c2b15073cf_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpkM2E4ODdlZTI2MDM0OGU0OWUwZDJlMGE2NTkxYzc2ZC90YWJsZXJhbmdlOmQzYTg4N2VlMjYwMzQ4ZTQ5ZTBkMmUwYTY1OTFjNzZkXzItMy0xLTEtMjg2OTQ0_c5d7e4eb-fb8c-4f79-a0a9-90cdac7c1be2"
      unitRef="usd">130933000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib488e4c93b484184a8e52bee69885132_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpkM2E4ODdlZTI2MDM0OGU0OWUwZDJlMGE2NTkxYzc2ZC90YWJsZXJhbmdlOmQzYTg4N2VlMjYwMzQ4ZTQ5ZTBkMmUwYTY1OTFjNzZkXzMtMS0xLTEtMjg2OTQ0_1b897c48-7407-4265-9a4e-9327756b0f8f"
      unitRef="usd">3433000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib5f105aa532244e0885f2307bc2951ad_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpkM2E4ODdlZTI2MDM0OGU0OWUwZDJlMGE2NTkxYzc2ZC90YWJsZXJhbmdlOmQzYTg4N2VlMjYwMzQ4ZTQ5ZTBkMmUwYTY1OTFjNzZkXzMtMy0xLTEtMjg2OTQ0_6a0f9187-e9ba-436b-a8b1-641bf4c62b19"
      unitRef="usd">3339000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i09186e53513344a797c14f6874c9c782_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpkM2E4ODdlZTI2MDM0OGU0OWUwZDJlMGE2NTkxYzc2ZC90YWJsZXJhbmdlOmQzYTg4N2VlMjYwMzQ4ZTQ5ZTBkMmUwYTY1OTFjNzZkXzQtMS0xLTEtMjg2OTQ0_41b0adca-8c45-4ae6-82dc-c354f5a6bbef"
      unitRef="usd">151569000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i438495dce7084e9eb69ebe58bc06cd29_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpkM2E4ODdlZTI2MDM0OGU0OWUwZDJlMGE2NTkxYzc2ZC90YWJsZXJhbmdlOmQzYTg4N2VlMjYwMzQ4ZTQ5ZTBkMmUwYTY1OTFjNzZkXzQtMy0xLTEtMjg2OTQ0_40acc133-33ca-41b2-b433-626f9e108e0f"
      unitRef="usd">134272000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6ed97f44ba534c3889ad982e9558682c_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpkM2E4ODdlZTI2MDM0OGU0OWUwZDJlMGE2NTkxYzc2ZC90YWJsZXJhbmdlOmQzYTg4N2VlMjYwMzQ4ZTQ5ZTBkMmUwYTY1OTFjNzZkXzUtMS0xLTEtMjg2OTQ0_be44dea1-713b-4a9b-bc0c-2de176b8cd5b"
      unitRef="usd">-10000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9dcc325ed5014b548d6c310c9974f048_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpkM2E4ODdlZTI2MDM0OGU0OWUwZDJlMGE2NTkxYzc2ZC90YWJsZXJhbmdlOmQzYTg4N2VlMjYwMzQ4ZTQ5ZTBkMmUwYTY1OTFjNzZkXzUtMy0xLTEtMjg2OTQ0_c4d9dd92-6635-4845-a8f1-22db78e63153"
      unitRef="usd">-11000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpkM2E4ODdlZTI2MDM0OGU0OWUwZDJlMGE2NTkxYzc2ZC90YWJsZXJhbmdlOmQzYTg4N2VlMjYwMzQ4ZTQ5ZTBkMmUwYTY1OTFjNzZkXzYtMS0xLTEtMjg2OTQ0_1172e5fe-1d49-42ed-9caa-d6a7e7f5384d"
      unitRef="usd">151559000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpkM2E4ODdlZTI2MDM0OGU0OWUwZDJlMGE2NTkxYzc2ZC90YWJsZXJhbmdlOmQzYTg4N2VlMjYwMzQ4ZTQ5ZTBkMmUwYTY1OTFjNzZkXzYtMy0xLTEtMjg2OTQ0_174ebb52-c628-44a3-8af0-f2d35b5ded97"
      unitRef="usd">134261000000</us-gaap:Revenues>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="ie12745b4aa3e4e2f8127b2b3aa94621c_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90ZXh0cmVnaW9uOjZmYzA0ZmQwYjc5NTQ1MTBiZDFkNWU0YTZmYzJlNGFiXzQyNDY_81d80d54-799e-4fdb-8938-1abf1e264da3"
      unitRef="usd">863000000</us-gaap:GoodwillImpairmentLoss>
    <cah:ProjectCostsOnInvestmentAndOtherSpending
      contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90ZXh0cmVnaW9uOjZmYzA0ZmQwYjc5NTQ1MTBiZDFkNWU0YTZmYzJlNGFiXzUwMDc_1abb8290-9c18-4627-b786-4ef0e436dea3"
      unitRef="usd">9000000</cah:ProjectCostsOnInvestmentAndOtherSpending>
    <cah:ProjectCostsOnInvestmentAndOtherSpending
      contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90ZXh0cmVnaW9uOjZmYzA0ZmQwYjc5NTQ1MTBiZDFkNWU0YTZmYzJlNGFiXzUwMTQ_cf2d9214-0581-45c5-9128-b29d743ff233"
      unitRef="usd">20000000</cah:ProjectCostsOnInvestmentAndOtherSpending>
    <cah:ProjectCostsOnInvestmentAndOtherSpending
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90ZXh0cmVnaW9uOjZmYzA0ZmQwYjc5NTQ1MTBiZDFkNWU0YTZmYzJlNGFiXzUwNTk_86d80263-64d1-4530-a47e-2520a5501922"
      unitRef="usd">20000000</cah:ProjectCostsOnInvestmentAndOtherSpending>
    <cah:ProjectCostsOnInvestmentAndOtherSpending
      contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90ZXh0cmVnaW9uOjZmYzA0ZmQwYjc5NTQ1MTBiZDFkNWU0YTZmYzJlNGFiXzUwNjY_f62b9231-ea4c-412c-b1d5-607cd49011d2"
      unitRef="usd">38000000</cah:ProjectCostsOnInvestmentAndOtherSpending>
    <us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90ZXh0cmVnaW9uOjZmYzA0ZmQwYjc5NTQ1MTBiZDFkNWU0YTZmYzJlNGFiXzU3MTk_d3ef53de-0f28-42e6-bbf7-574d732b0b97">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present segment profit by reportable segment and Corporate:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.429%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical (1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;600&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;20&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total segment profit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;620&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(643)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total operating earnings/(loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;572&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(97)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical (1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,495&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;29&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total segment profit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,524&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(934)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,183)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total operating earnings/(loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;590&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(632)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Pharmaceutical segment profit includes opioid-related litigation defense and compliance costs, but does not include a one-time contingent attorney fee of $18&#160;million incurred during the three and nine months ended March 31, 2022 related to the finalization of the Settlement Agreement. Due to the unique nature and significance of the Settlement Agreement, and the one-time, contingent nature of the fee, this related fee was included in litigation (recoveries)/charges, net in the condensed consolidated statements of earnings/(loss). Additionally, pharmaceutical segment profit during the nine months ended March 31, 2022 was positively impacted by a $16&#160;million judgment for lost profits related to an ordinary course intellectual property rights claim.&lt;/span&gt;&lt;/div&gt;</us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock>
    <us-gaap:OperatingIncomeLoss
      contextRef="i16dc5579b6f94e7ca4452bbc7028e7c9_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTo3MzQ0YzQwMTBhN2I0MzY4YmMwNWJiNzRlZDI3MjEzOC90YWJsZXJhbmdlOjczNDRjNDAxMGE3YjQzNjhiYzA1YmI3NGVkMjcyMTM4XzItMS0xLTEtMjg2OTQ0_b6bf9dbe-3728-47dd-a9cb-1e414f9b2fd7"
      unitRef="usd">600000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i45daaa94544f4353a00c894ddf85a502_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTo3MzQ0YzQwMTBhN2I0MzY4YmMwNWJiNzRlZDI3MjEzOC90YWJsZXJhbmdlOjczNDRjNDAxMGE3YjQzNjhiYzA1YmI3NGVkMjcyMTM4XzItMy0xLTEtMjg2OTQ0_29343a32-c189-439d-8c90-09094b594370"
      unitRef="usd">487000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i1495b91ae50844b7bd8dee01339cb2ba_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTo3MzQ0YzQwMTBhN2I0MzY4YmMwNWJiNzRlZDI3MjEzOC90YWJsZXJhbmdlOjczNDRjNDAxMGE3YjQzNjhiYzA1YmI3NGVkMjcyMTM4XzMtMS0xLTEtMjg2OTQ0_4976030d-c059-4f61-b535-8f2500c851cc"
      unitRef="usd">20000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ibc29744d3dd64b99ab33d733a31d8725_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTo3MzQ0YzQwMTBhN2I0MzY4YmMwNWJiNzRlZDI3MjEzOC90YWJsZXJhbmdlOjczNDRjNDAxMGE3YjQzNjhiYzA1YmI3NGVkMjcyMTM4XzMtMy0xLTEtMjg2OTQ0_15591908-dccc-4757-b696-965913526fab"
      unitRef="usd">59000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ic7c59d976f4b491293536f66988a658a_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTo3MzQ0YzQwMTBhN2I0MzY4YmMwNWJiNzRlZDI3MjEzOC90YWJsZXJhbmdlOjczNDRjNDAxMGE3YjQzNjhiYzA1YmI3NGVkMjcyMTM4XzQtMS0xLTEtMjg2OTQ0_6fbeb105-4497-4ac1-841c-590f4872346d"
      unitRef="usd">620000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i569871ca4d47454f87c9b6023726a3aa_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTo3MzQ0YzQwMTBhN2I0MzY4YmMwNWJiNzRlZDI3MjEzOC90YWJsZXJhbmdlOjczNDRjNDAxMGE3YjQzNjhiYzA1YmI3NGVkMjcyMTM4XzQtMy0xLTEtMjg2OTQ0_8d647f6c-3595-46d8-a227-a2bfde83fcf6"
      unitRef="usd">546000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ia03b234276c04aa0af1cf1a16b60bc62_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTo3MzQ0YzQwMTBhN2I0MzY4YmMwNWJiNzRlZDI3MjEzOC90YWJsZXJhbmdlOjczNDRjNDAxMGE3YjQzNjhiYzA1YmI3NGVkMjcyMTM4XzUtMS0xLTEtMjg2OTQ0_73197045-9b70-40a5-8b08-5730ac7515db"
      unitRef="usd">-48000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i0b30b0809298478382f26a051e90bf8a_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTo3MzQ0YzQwMTBhN2I0MzY4YmMwNWJiNzRlZDI3MjEzOC90YWJsZXJhbmdlOjczNDRjNDAxMGE3YjQzNjhiYzA1YmI3NGVkMjcyMTM4XzUtMy0xLTEtMjg2OTQ0_d9285fb6-4716-4cbf-b505-432ec51eb304"
      unitRef="usd">-643000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTo3MzQ0YzQwMTBhN2I0MzY4YmMwNWJiNzRlZDI3MjEzOC90YWJsZXJhbmdlOjczNDRjNDAxMGE3YjQzNjhiYzA1YmI3NGVkMjcyMTM4XzYtMS0xLTEtMjg2OTQ0_a2e83a9e-29d4-45ea-b36f-3bad389ed8d9"
      unitRef="usd">572000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTo3MzQ0YzQwMTBhN2I0MzY4YmMwNWJiNzRlZDI3MjEzOC90YWJsZXJhbmdlOjczNDRjNDAxMGE3YjQzNjhiYzA1YmI3NGVkMjcyMTM4XzYtMy0xLTEtMjg2OTQ0_d926b019-9a54-42ae-a59f-5990d6dd2541"
      unitRef="usd">-97000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i04924e9230e745fca992f99aa6ace85c_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpkNDEzNjgxYjM1ODE0ODA4ODU1NDYzZmJkNTA5NDM1YS90YWJsZXJhbmdlOmQ0MTM2ODFiMzU4MTQ4MDg4NTU0NjNmYmQ1MDk0MzVhXzItMS0xLTEtMjg2OTQ0_d5d35543-2aeb-4996-a0f3-cedaef97ad96"
      unitRef="usd">1495000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i8b399963940c4fcc875d6ee7b2e2a30c_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpkNDEzNjgxYjM1ODE0ODA4ODU1NDYzZmJkNTA5NDM1YS90YWJsZXJhbmdlOmQ0MTM2ODFiMzU4MTQ4MDg4NTU0NjNmYmQ1MDk0MzVhXzItMy0xLTEtMjg2OTQ0_abe19c98-e0d0-4919-8603-30326f5bbe96"
      unitRef="usd">1319000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i44eddf7caae040f987146265a715a28d_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpkNDEzNjgxYjM1ODE0ODA4ODU1NDYzZmJkNTA5NDM1YS90YWJsZXJhbmdlOmQ0MTM2ODFiMzU4MTQ4MDg4NTU0NjNmYmQ1MDk0MzVhXzMtMS0xLTEtMjg2OTQ0_31267205-03ee-41f2-8a5b-8369a94e91e1"
      unitRef="usd">29000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ie312826afe694135b31551dc50097180_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpkNDEzNjgxYjM1ODE0ODA4ODU1NDYzZmJkNTA5NDM1YS90YWJsZXJhbmdlOmQ0MTM2ODFiMzU4MTQ4MDg4NTU0NjNmYmQ1MDk0MzVhXzMtMy0xLTEtMjg2OTQ0_8df6aacf-4ccb-425e-85a9-bd079e061d8e"
      unitRef="usd">232000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i09186e53513344a797c14f6874c9c782_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpkNDEzNjgxYjM1ODE0ODA4ODU1NDYzZmJkNTA5NDM1YS90YWJsZXJhbmdlOmQ0MTM2ODFiMzU4MTQ4MDg4NTU0NjNmYmQ1MDk0MzVhXzQtMS0xLTEtMjg2OTQ0_3c7454ac-5042-4040-9b44-e092717fc417"
      unitRef="usd">1524000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i438495dce7084e9eb69ebe58bc06cd29_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpkNDEzNjgxYjM1ODE0ODA4ODU1NDYzZmJkNTA5NDM1YS90YWJsZXJhbmdlOmQ0MTM2ODFiMzU4MTQ4MDg4NTU0NjNmYmQ1MDk0MzVhXzQtMy0xLTEtMjg2OTQ0_7c4dcd8c-4b99-45af-aa11-02e5d66ee63b"
      unitRef="usd">1551000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i6ed97f44ba534c3889ad982e9558682c_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpkNDEzNjgxYjM1ODE0ODA4ODU1NDYzZmJkNTA5NDM1YS90YWJsZXJhbmdlOmQ0MTM2ODFiMzU4MTQ4MDg4NTU0NjNmYmQ1MDk0MzVhXzUtMS0xLTEtMjg2OTQ0_f400714b-aa96-44fb-9dd8-00c5a5384089"
      unitRef="usd">-934000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i9dcc325ed5014b548d6c310c9974f048_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpkNDEzNjgxYjM1ODE0ODA4ODU1NDYzZmJkNTA5NDM1YS90YWJsZXJhbmdlOmQ0MTM2ODFiMzU4MTQ4MDg4NTU0NjNmYmQ1MDk0MzVhXzUtMy0xLTEtMjg2OTQ0_d03fa483-101e-41f9-ae57-7e16a26f2df3"
      unitRef="usd">-2183000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpkNDEzNjgxYjM1ODE0ODA4ODU1NDYzZmJkNTA5NDM1YS90YWJsZXJhbmdlOmQ0MTM2ODFiMzU4MTQ4MDg4NTU0NjNmYmQ1MDk0MzVhXzYtMS0xLTEtMjg2OTQ0_9e4d5a53-e719-4579-b538-d44b8c048515"
      unitRef="usd">590000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTpkNDEzNjgxYjM1ODE0ODA4ODU1NDYzZmJkNTA5NDM1YS90YWJsZXJhbmdlOmQ0MTM2ODFiMzU4MTQ4MDg4NTU0NjNmYmQ1MDk0MzVhXzYtMy0xLTEtMjg2OTQ0_3c0e7754-5ddf-40d3-b03d-479ff44a7e2d"
      unitRef="usd">-632000000</us-gaap:OperatingIncomeLoss>
    <cah:ContingentAttorneyFee
      contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90ZXh0cmVnaW9uOjZmYzA0ZmQwYjc5NTQ1MTBiZDFkNWU0YTZmYzJlNGFiXzU0OTc1NTgxNTU4NzE_d6b953ba-9cd8-4124-92dd-99302cbd903d"
      unitRef="usd">18000000</cah:ContingentAttorneyFee>
    <cah:ContingentAttorneyFee
      contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90ZXh0cmVnaW9uOjZmYzA0ZmQwYjc5NTQ1MTBiZDFkNWU0YTZmYzJlNGFiXzU0OTc1NTgxNTU4NzE_d7825190-f000-42b3-8df7-469b93990b70"
      unitRef="usd">18000000</cah:ContingentAttorneyFee>
    <cah:JudgmentForLostProfits
      contextRef="i92600b80cf9f42e68ab2bb551fa5980c_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90ZXh0cmVnaW9uOjZmYzA0ZmQwYjc5NTQ1MTBiZDFkNWU0YTZmYzJlNGFiXzUzMDc_9c01752c-b170-4e27-820b-57bd6e842abd"
      unitRef="usd">16000000</cah:JudgmentForLostProfits>
    <us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90ZXh0cmVnaW9uOjZmYzA0ZmQwYjc5NTQ1MTBiZDFkNWU0YTZmYzJlNGFiXzU3MTQ_99ef0df9-62b9-478f-a329-5ebf2848a695">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents total assets for each reportable segment and Corporate at: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.500%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.503%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d1d1d1;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;27,954&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"/&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10,544&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d1d1d1;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d1d1d1;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,879&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d1d1d1;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;43,377&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;(1)Medical reflects cumulative $863&#160;million goodwill impairment charges recorded in connection with the interim goodwill impairment testing for the Medical Unit during the nine months ended March 31, 2023.</us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock>
    <us-gaap:Assets
      contextRef="i5c0c3804d63c4f5fafbb13f1f87b1d95_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTphZWRkNjI1ZTM1M2I0NjA0ODNlMjU1OGMyYzA3OGVlNS90YWJsZXJhbmdlOmFlZGQ2MjVlMzUzYjQ2MDQ4M2UyNTU4YzJjMDc4ZWU1XzEtMS0xLTEtMjg2OTQ0_c4d9a72a-8e92-409c-bb33-f38c6c30935b"
      unitRef="usd">27954000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ie4a16787e42247d480a65342eeea298b_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTphZWRkNjI1ZTM1M2I0NjA0ODNlMjU1OGMyYzA3OGVlNS90YWJsZXJhbmdlOmFlZGQ2MjVlMzUzYjQ2MDQ4M2UyNTU4YzJjMDc4ZWU1XzEtMy0xLTEtMjg2OTQ0_f154bb84-7a83-41ab-9f72-18de252c01eb"
      unitRef="usd">26409000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ib09896a0291b4dbd9d0deb987d93eb9c_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTphZWRkNjI1ZTM1M2I0NjA0ODNlMjU1OGMyYzA3OGVlNS90YWJsZXJhbmdlOmFlZGQ2MjVlMzUzYjQ2MDQ4M2UyNTU4YzJjMDc4ZWU1XzItMS0xLTEtMjg2OTQ0_b9b760ca-2494-40a6-8068-932ec9d180f0"
      unitRef="usd">10544000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ibee1c5b1f4f946f18b93d5abfb380e03_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTphZWRkNjI1ZTM1M2I0NjA0ODNlMjU1OGMyYzA3OGVlNS90YWJsZXJhbmdlOmFlZGQ2MjVlMzUzYjQ2MDQ4M2UyNTU4YzJjMDc4ZWU1XzItMy0xLTEtMjg2OTQ0_bbf9108c-5915-4be8-ab2b-3fa96d4eb2d1"
      unitRef="usd">11632000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i7f4869e77ac44a00a1348128c89edab9_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTphZWRkNjI1ZTM1M2I0NjA0ODNlMjU1OGMyYzA3OGVlNS90YWJsZXJhbmdlOmFlZGQ2MjVlMzUzYjQ2MDQ4M2UyNTU4YzJjMDc4ZWU1XzMtMS0xLTEtMjg2OTQ0_05e31436-d6aa-48a3-a329-f7e2e38d8804"
      unitRef="usd">4879000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="iaa15c30af25e4338b4b75b20fdd5cdfd_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTphZWRkNjI1ZTM1M2I0NjA0ODNlMjU1OGMyYzA3OGVlNS90YWJsZXJhbmdlOmFlZGQ2MjVlMzUzYjQ2MDQ4M2UyNTU4YzJjMDc4ZWU1XzMtMy0xLTEtMjg2OTQ0_33f331f7-49bb-40b3-a3ee-18c572b972d1"
      unitRef="usd">5837000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ia417c574587a496b8f3ac8b2f1e28b1a_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTphZWRkNjI1ZTM1M2I0NjA0ODNlMjU1OGMyYzA3OGVlNS90YWJsZXJhbmdlOmFlZGQ2MjVlMzUzYjQ2MDQ4M2UyNTU4YzJjMDc4ZWU1XzQtMS0xLTEtMjg2OTQ0_18fde7c2-a807-448a-88a2-96c84665e885"
      unitRef="usd">43377000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ic217743408d440409a59220a0bf14e4c_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90YWJsZTphZWRkNjI1ZTM1M2I0NjA0ODNlMjU1OGMyYzA3OGVlNS90YWJsZXJhbmdlOmFlZGQ2MjVlMzUzYjQ2MDQ4M2UyNTU4YzJjMDc4ZWU1XzQtMy0xLTEtMjg2OTQ0_16514b21-dc88-430c-97db-c7715d821b17"
      unitRef="usd">43878000000</us-gaap:Assets>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="ie12745b4aa3e4e2f8127b2b3aa94621c_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMTgvZnJhZzo2ZmMwNGZkMGI3OTU0NTEwYmQxZDVlNGE2ZmMyZTRhYi90ZXh0cmVnaW9uOjZmYzA0ZmQwYjc5NTQ1MTBiZDFkNWU0YTZmYzJlNGFiXzU1MjI_81d80d54-799e-4fdb-8938-1abf1e264da3"
      unitRef="usd">863000000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMjEvZnJhZzo3NGQ2NzRmYTY0NTQ0YWQzYWVkMGE5MDM4ZTA3OTkwZS90ZXh0cmVnaW9uOjc0ZDY3NGZhNjQ1NDRhZDNhZWQwYTkwMzhlMDc5OTBlXzE4MDk_d2a19e3c-9f25-4a3f-a52c-7daca739fa8b">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;13. Share-Based Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We maintain stock incentive plans (collectively, the &#x201c;Plans&#x201d;) for the benefit of certain of our officers, directors and employees. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides total share-based compensation expense by type of award:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restricted share unit expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;17&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance share unit expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total share-based compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;21&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restricted share unit expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;49&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance share unit expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;20&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total share-based compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;69&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total tax benefit related to share-based compensation was $3 million for both the three months ended March&#160;31, 2023 and 2022, and $9 million for both the nine months ended March&#160;31, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Restricted Share Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted share units granted under the Plans generally vest in equal annual installments over three years. Restricted share units accrue cash dividend equivalents that are payable upon vesting of the awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes all transactions related to restricted share units under the Plans:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.221%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.218%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restricted Share Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Grant Date Fair&lt;br/&gt;Value per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nonvested at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;46.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;70.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Canceled and forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nonvested at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;57.14&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At March&#160;31, 2023, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested restricted share units &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;not yet recognized was $87 million, which is expected to be recognized over a weighted-average period of two years.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Performance Share Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Performance share units vest over a 3-year performance period based on achievement of specific performance goals. Based on the extent to which the targets are achieved, vested shares may range from zero to 234 percent of the target award amount. Performance share units accrue cash dividend equivalents that are payable upon vesting of the awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.023%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.147%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Performance&lt;br/&gt;Share Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Grant Date Fair&lt;br/&gt;Value per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nonvested at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;70.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Canceled and forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;65.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nonvested at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;76.24&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At March&#160;31, 2023, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested performance share units not yet recognized was $39 million, which is expected to be recognized over a weighted-average period of two years if performance goals are achieved.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMjEvZnJhZzo3NGQ2NzRmYTY0NTQ0YWQzYWVkMGE5MDM4ZTA3OTkwZS90ZXh0cmVnaW9uOjc0ZDY3NGZhNjQ1NDRhZDNhZWQwYTkwMzhlMDc5OTBlXzE4MTA_cb72ab6f-fbd2-4906-8ab2-becc502f7d02">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides total share-based compensation expense by type of award:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restricted share unit expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;17&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance share unit expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total share-based compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;21&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restricted share unit expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;49&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance share unit expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;20&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total share-based compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;69&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i61e443ff0bb041468d351efdad3a60ec_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMjEvZnJhZzo3NGQ2NzRmYTY0NTQ0YWQzYWVkMGE5MDM4ZTA3OTkwZS90YWJsZTpmM2M4OWNkZjUzNmU0YzVhODZiYzc2YmQ0OWE4OWJkNy90YWJsZXJhbmdlOmYzYzg5Y2RmNTM2ZTRjNWE4NmJjNzZiZDQ5YTg5YmQ3XzItMS0xLTEtMjg2OTQ0_3b999e5b-0090-42f6-a190-b8abd1c81a37"
      unitRef="usd">17000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7a2edd19ded449568c634ce222c8bf11_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMjEvZnJhZzo3NGQ2NzRmYTY0NTQ0YWQzYWVkMGE5MDM4ZTA3OTkwZS90YWJsZTpmM2M4OWNkZjUzNmU0YzVhODZiYzc2YmQ0OWE4OWJkNy90YWJsZXJhbmdlOmYzYzg5Y2RmNTM2ZTRjNWE4NmJjNzZiZDQ5YTg5YmQ3XzItMy0xLTEtMjg2OTQ0_f8aba577-1e92-4eb5-a9bd-775b3cc85534"
      unitRef="usd">18000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iac5b45b6082b4c20bc77e15c6b0dfe4a_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMjEvZnJhZzo3NGQ2NzRmYTY0NTQ0YWQzYWVkMGE5MDM4ZTA3OTkwZS90YWJsZTpmM2M4OWNkZjUzNmU0YzVhODZiYzc2YmQ0OWE4OWJkNy90YWJsZXJhbmdlOmYzYzg5Y2RmNTM2ZTRjNWE4NmJjNzZiZDQ5YTg5YmQ3XzQtMS0xLTEtMjg2OTQ0_4d81e1a7-f241-471e-b92a-f5aeff4634f5"
      unitRef="usd">4000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6cb3c83f18544d88816e14ee29ce253f_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMjEvZnJhZzo3NGQ2NzRmYTY0NTQ0YWQzYWVkMGE5MDM4ZTA3OTkwZS90YWJsZTpmM2M4OWNkZjUzNmU0YzVhODZiYzc2YmQ0OWE4OWJkNy90YWJsZXJhbmdlOmYzYzg5Y2RmNTM2ZTRjNWE4NmJjNzZiZDQ5YTg5YmQ3XzQtMy0xLTEtMjg2OTQ0_e987d088-0fea-4b52-86f5-01b27d0c3808"
      unitRef="usd">5000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMjEvZnJhZzo3NGQ2NzRmYTY0NTQ0YWQzYWVkMGE5MDM4ZTA3OTkwZS90YWJsZTpmM2M4OWNkZjUzNmU0YzVhODZiYzc2YmQ0OWE4OWJkNy90YWJsZXJhbmdlOmYzYzg5Y2RmNTM2ZTRjNWE4NmJjNzZiZDQ5YTg5YmQ3XzUtMS0xLTEtMjg2OTQ0_9fc700da-1ef8-4eb1-9b72-b879ce3c95f4"
      unitRef="usd">21000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMjEvZnJhZzo3NGQ2NzRmYTY0NTQ0YWQzYWVkMGE5MDM4ZTA3OTkwZS90YWJsZTpmM2M4OWNkZjUzNmU0YzVhODZiYzc2YmQ0OWE4OWJkNy90YWJsZXJhbmdlOmYzYzg5Y2RmNTM2ZTRjNWE4NmJjNzZiZDQ5YTg5YmQ3XzUtMy0xLTEtMjg2OTQ0_cd895d7f-bfce-488f-b254-38e3660445ea"
      unitRef="usd">23000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7de355b6c9f244b0aecf4263ff24158b_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMjEvZnJhZzo3NGQ2NzRmYTY0NTQ0YWQzYWVkMGE5MDM4ZTA3OTkwZS90YWJsZTpmNTM5NDI1N2ZiODg0MTM5OTk2ZmI5NjgwMzEzODQ3NS90YWJsZXJhbmdlOmY1Mzk0MjU3ZmI4ODQxMzk5OTZmYjk2ODAzMTM4NDc1XzItMS0xLTEtMjg2OTQ0_c524c61d-0a3d-4963-9929-7114bcaf54de"
      unitRef="usd">49000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie4307df7bd4b4ddf85fe23923677a14f_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMjEvZnJhZzo3NGQ2NzRmYTY0NTQ0YWQzYWVkMGE5MDM4ZTA3OTkwZS90YWJsZTpmNTM5NDI1N2ZiODg0MTM5OTk2ZmI5NjgwMzEzODQ3NS90YWJsZXJhbmdlOmY1Mzk0MjU3ZmI4ODQxMzk5OTZmYjk2ODAzMTM4NDc1XzItMy0xLTEtMjg2OTQ0_d0339608-531b-4c77-b049-636ef3456507"
      unitRef="usd">53000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9750f858065345b6b71dfdf94a3db05f_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMjEvZnJhZzo3NGQ2NzRmYTY0NTQ0YWQzYWVkMGE5MDM4ZTA3OTkwZS90YWJsZTpmNTM5NDI1N2ZiODg0MTM5OTk2ZmI5NjgwMzEzODQ3NS90YWJsZXJhbmdlOmY1Mzk0MjU3ZmI4ODQxMzk5OTZmYjk2ODAzMTM4NDc1XzQtMS0xLTEtMjg2OTQ0_8b233a1f-6f1e-44e7-8166-90dee03165b8"
      unitRef="usd">20000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ice80dc50332649f4a2e8211087c1473c_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMjEvZnJhZzo3NGQ2NzRmYTY0NTQ0YWQzYWVkMGE5MDM4ZTA3OTkwZS90YWJsZTpmNTM5NDI1N2ZiODg0MTM5OTk2ZmI5NjgwMzEzODQ3NS90YWJsZXJhbmdlOmY1Mzk0MjU3ZmI4ODQxMzk5OTZmYjk2ODAzMTM4NDc1XzQtMy0xLTEtMjg2OTQ0_b968dbb1-1be9-4247-aa36-404385377148"
      unitRef="usd">12000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMjEvZnJhZzo3NGQ2NzRmYTY0NTQ0YWQzYWVkMGE5MDM4ZTA3OTkwZS90YWJsZTpmNTM5NDI1N2ZiODg0MTM5OTk2ZmI5NjgwMzEzODQ3NS90YWJsZXJhbmdlOmY1Mzk0MjU3ZmI4ODQxMzk5OTZmYjk2ODAzMTM4NDc1XzUtMS0xLTEtMjg2OTQ0_52508af8-116c-484f-a219-b75d0ae07ff3"
      unitRef="usd">69000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMjEvZnJhZzo3NGQ2NzRmYTY0NTQ0YWQzYWVkMGE5MDM4ZTA3OTkwZS90YWJsZTpmNTM5NDI1N2ZiODg0MTM5OTk2ZmI5NjgwMzEzODQ3NS90YWJsZXJhbmdlOmY1Mzk0MjU3ZmI4ODQxMzk5OTZmYjk2ODAzMTM4NDc1XzUtMy0xLTEtMjg2OTQ0_b3e5fde3-f2bd-4836-bf88-726027c454a7"
      unitRef="usd">65000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMjEvZnJhZzo3NGQ2NzRmYTY0NTQ0YWQzYWVkMGE5MDM4ZTA3OTkwZS90ZXh0cmVnaW9uOjc0ZDY3NGZhNjQ1NDRhZDNhZWQwYTkwMzhlMDc5OTBlXzI5Mw_33e36649-b168-43d6-b5f8-405db208cb44"
      unitRef="usd">3000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMjEvZnJhZzo3NGQ2NzRmYTY0NTQ0YWQzYWVkMGE5MDM4ZTA3OTkwZS90ZXh0cmVnaW9uOjc0ZDY3NGZhNjQ1NDRhZDNhZWQwYTkwMzhlMDc5OTBlXzI5Mw_67fe6db2-127d-4552-94c5-8f89698406ce"
      unitRef="usd">3000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMjEvZnJhZzo3NGQ2NzRmYTY0NTQ0YWQzYWVkMGE5MDM4ZTA3OTkwZS90ZXh0cmVnaW9uOjc0ZDY3NGZhNjQ1NDRhZDNhZWQwYTkwMzhlMDc5OTBlXzM1OQ_78c71c2a-ba1e-467c-8570-f2b42b745f52"
      unitRef="usd">9000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMjEvZnJhZzo3NGQ2NzRmYTY0NTQ0YWQzYWVkMGE5MDM4ZTA3OTkwZS90ZXh0cmVnaW9uOjc0ZDY3NGZhNjQ1NDRhZDNhZWQwYTkwMzhlMDc5OTBlXzM1OQ_8f0b4362-118f-4719-bf20-f6b89b7f4254"
      unitRef="usd">9000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i7de355b6c9f244b0aecf4263ff24158b_D20220701-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMjEvZnJhZzo3NGQ2NzRmYTY0NTQ0YWQzYWVkMGE5MDM4ZTA3OTkwZS90ZXh0cmVnaW9uOjc0ZDY3NGZhNjQ1NDRhZDNhZWQwYTkwMzhlMDc5OTBlXzUwOA_d49b26a3-a0d6-496f-ac57-e594a26b488f">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMjEvZnJhZzo3NGQ2NzRmYTY0NTQ0YWQzYWVkMGE5MDM4ZTA3OTkwZS90ZXh0cmVnaW9uOjc0ZDY3NGZhNjQ1NDRhZDNhZWQwYTkwMzhlMDc5OTBlXzE4MDA_5fb509aa-de5a-4117-a655-eee3bf130a80">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes all transactions related to restricted share units under the Plans:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.221%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.218%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restricted Share Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Grant Date Fair&lt;br/&gt;Value per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nonvested at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;46.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;70.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Canceled and forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nonvested at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;57.14&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ia8acc2cf603d4cec94d38cdf7947bf8c_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMjEvZnJhZzo3NGQ2NzRmYTY0NTQ0YWQzYWVkMGE5MDM4ZTA3OTkwZS90YWJsZTpjOTUzODQ1YTdhN2Y0ZDJkOTc1N2Q1NGQzOTU0ZDA4ZS90YWJsZXJhbmdlOmM5NTM4NDVhN2E3ZjRkMmQ5NzU3ZDU0ZDM5NTRkMDhlXzEtMS0xLTEtMjg2OTQ0_282d2bd2-fb8a-4052-92d7-3b6c3ba21fc2"
      unitRef="shares">2700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ia8acc2cf603d4cec94d38cdf7947bf8c_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMjEvZnJhZzo3NGQ2NzRmYTY0NTQ0YWQzYWVkMGE5MDM4ZTA3OTkwZS90YWJsZTpjOTUzODQ1YTdhN2Y0ZDJkOTc1N2Q1NGQzOTU0ZDA4ZS90YWJsZXJhbmdlOmM5NTM4NDVhN2E3ZjRkMmQ5NzU3ZDU0ZDM5NTRkMDhlXzEtMy0xLTEtMjg2OTQ0_f17a48d7-48bc-4317-9e09-05b186819900"
      unitRef="usdPerShare">46.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i7de355b6c9f244b0aecf4263ff24158b_D20220701-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMjEvZnJhZzo3NGQ2NzRmYTY0NTQ0YWQzYWVkMGE5MDM4ZTA3OTkwZS90YWJsZTpjOTUzODQ1YTdhN2Y0ZDJkOTc1N2Q1NGQzOTU0ZDA4ZS90YWJsZXJhbmdlOmM5NTM4NDVhN2E3ZjRkMmQ5NzU3ZDU0ZDM5NTRkMDhlXzItMS0xLTEtMjg2OTQ0_3b8e4c4f-d6b9-4c96-b126-78b34abbc19d"
      unitRef="shares">1300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i7de355b6c9f244b0aecf4263ff24158b_D20220701-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMjEvZnJhZzo3NGQ2NzRmYTY0NTQ0YWQzYWVkMGE5MDM4ZTA3OTkwZS90YWJsZTpjOTUzODQ1YTdhN2Y0ZDJkOTc1N2Q1NGQzOTU0ZDA4ZS90YWJsZXJhbmdlOmM5NTM4NDVhN2E3ZjRkMmQ5NzU3ZDU0ZDM5NTRkMDhlXzItMy0xLTEtMjg2OTQ0_5278f09a-a808-4f0d-8621-4b9215a5c437"
      unitRef="usdPerShare">70.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i7de355b6c9f244b0aecf4263ff24158b_D20220701-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMjEvZnJhZzo3NGQ2NzRmYTY0NTQ0YWQzYWVkMGE5MDM4ZTA3OTkwZS90YWJsZTpjOTUzODQ1YTdhN2Y0ZDJkOTc1N2Q1NGQzOTU0ZDA4ZS90YWJsZXJhbmdlOmM5NTM4NDVhN2E3ZjRkMmQ5NzU3ZDU0ZDM5NTRkMDhlXzMtMS0xLTEtMjg2OTQ0_2934a99b-0c8c-4688-9f6b-5fd56f2bbb90"
      unitRef="shares">1300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i7de355b6c9f244b0aecf4263ff24158b_D20220701-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMjEvZnJhZzo3NGQ2NzRmYTY0NTQ0YWQzYWVkMGE5MDM4ZTA3OTkwZS90YWJsZTpjOTUzODQ1YTdhN2Y0ZDJkOTc1N2Q1NGQzOTU0ZDA4ZS90YWJsZXJhbmdlOmM5NTM4NDVhN2E3ZjRkMmQ5NzU3ZDU0ZDM5NTRkMDhlXzMtMy0xLTEtMjg2OTQ0_5893dbf6-e2c4-4535-893f-516a3ed091fb"
      unitRef="usdPerShare">50.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i7de355b6c9f244b0aecf4263ff24158b_D20220701-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMjEvZnJhZzo3NGQ2NzRmYTY0NTQ0YWQzYWVkMGE5MDM4ZTA3OTkwZS90YWJsZTpjOTUzODQ1YTdhN2Y0ZDJkOTc1N2Q1NGQzOTU0ZDA4ZS90YWJsZXJhbmdlOmM5NTM4NDVhN2E3ZjRkMmQ5NzU3ZDU0ZDM5NTRkMDhlXzQtMS0xLTEtMjg2OTQ0_de91d07d-05eb-4c76-83ac-cf4ea8296e70"
      unitRef="shares">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i7de355b6c9f244b0aecf4263ff24158b_D20220701-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMjEvZnJhZzo3NGQ2NzRmYTY0NTQ0YWQzYWVkMGE5MDM4ZTA3OTkwZS90YWJsZTpjOTUzODQ1YTdhN2Y0ZDJkOTc1N2Q1NGQzOTU0ZDA4ZS90YWJsZXJhbmdlOmM5NTM4NDVhN2E3ZjRkMmQ5NzU3ZDU0ZDM5NTRkMDhlXzQtMy0xLTEtMjg2OTQ0_48fcf82a-384b-4a15-93e1-e2cbd3d2de23"
      unitRef="usdPerShare">58.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ia7a3dc6029084cef92896c48e8a19a01_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMjEvZnJhZzo3NGQ2NzRmYTY0NTQ0YWQzYWVkMGE5MDM4ZTA3OTkwZS90YWJsZTpjOTUzODQ1YTdhN2Y0ZDJkOTc1N2Q1NGQzOTU0ZDA4ZS90YWJsZXJhbmdlOmM5NTM4NDVhN2E3ZjRkMmQ5NzU3ZDU0ZDM5NTRkMDhlXzUtMS0xLTEtMjg2OTQ0_06388dcd-5daa-4a25-88fc-3395cc2d34a5"
      unitRef="shares">2200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ia7a3dc6029084cef92896c48e8a19a01_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMjEvZnJhZzo3NGQ2NzRmYTY0NTQ0YWQzYWVkMGE5MDM4ZTA3OTkwZS90YWJsZTpjOTUzODQ1YTdhN2Y0ZDJkOTc1N2Q1NGQzOTU0ZDA4ZS90YWJsZXJhbmdlOmM5NTM4NDVhN2E3ZjRkMmQ5NzU3ZDU0ZDM5NTRkMDhlXzUtMy0xLTEtMjg2OTQ0_c8a9e106-3b9a-45ed-b60b-c3259caaac87"
      unitRef="usdPerShare">57.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="ia7a3dc6029084cef92896c48e8a19a01_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMjEvZnJhZzo3NGQ2NzRmYTY0NTQ0YWQzYWVkMGE5MDM4ZTA3OTkwZS90ZXh0cmVnaW9uOjc0ZDY3NGZhNjQ1NDRhZDNhZWQwYTkwMzhlMDc5OTBlXzg1NQ_3bbc5362-f753-4829-9d4e-334f77146ff3"
      unitRef="usd">87000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i7de355b6c9f244b0aecf4263ff24158b_D20220701-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMjEvZnJhZzo3NGQ2NzRmYTY0NTQ0YWQzYWVkMGE5MDM4ZTA3OTkwZS90ZXh0cmVnaW9uOjc0ZDY3NGZhNjQ1NDRhZDNhZWQwYTkwMzhlMDc5OTBlXzkyOA_deb70b92-5964-49b8-bc37-fe53b4a24fc1">P2Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <cah:VestingPeriodinyearsforShares
      contextRef="i9750f858065345b6b71dfdf94a3db05f_D20220701-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMjEvZnJhZzo3NGQ2NzRmYTY0NTQ0YWQzYWVkMGE5MDM4ZTA3OTkwZS90ZXh0cmVnaW9uOjc0ZDY3NGZhNjQ1NDRhZDNhZWQwYTkwMzhlMDc5OTBlXzk5Mg_822a0039-3f79-43e2-826d-259099b9c1c4"
      unitRef="number">3</cah:VestingPeriodinyearsforShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i34b2dbad9e7648de967669561a47dd81_D20220701-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMjEvZnJhZzo3NGQ2NzRmYTY0NTQ0YWQzYWVkMGE5MDM4ZTA3OTkwZS90ZXh0cmVnaW9uOjc0ZDY3NGZhNjQ1NDRhZDNhZWQwYTkwMzhlMDc5OTBlXzEyMzE_32eb6414-bd07-4d9d-9354-e27e5a5ec693"
      unitRef="number">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i2fbe5a679b3841fcb8bbd7dfa64915ad_D20220701-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMjEvZnJhZzo3NGQ2NzRmYTY0NTQ0YWQzYWVkMGE5MDM4ZTA3OTkwZS90ZXh0cmVnaW9uOjc0ZDY3NGZhNjQ1NDRhZDNhZWQwYTkwMzhlMDc5OTBlXzEyMzc_7bd8b84a-9621-4e7b-80f4-a54d66c8cefc"
      unitRef="number">2.34</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock
      contextRef="ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMjEvZnJhZzo3NGQ2NzRmYTY0NTQ0YWQzYWVkMGE5MDM4ZTA3OTkwZS90ZXh0cmVnaW9uOjc0ZDY3NGZhNjQ1NDRhZDNhZWQwYTkwMzhlMDc5OTBlXzE3ODM_f42fad25-93b8-4605-8afb-d107ec93a02c">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.023%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.147%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Performance&lt;br/&gt;Share Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Grant Date Fair&lt;br/&gt;Value per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nonvested at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;70.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Canceled and forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;65.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nonvested at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;76.24&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ifab2ddff45a44bc58da3784419071ae5_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMjEvZnJhZzo3NGQ2NzRmYTY0NTQ0YWQzYWVkMGE5MDM4ZTA3OTkwZS90YWJsZToxMWNlZjRhY2Q3YjE0M2VkOTdkMTRiYWU5NmVhYmYwMC90YWJsZXJhbmdlOjExY2VmNGFjZDdiMTQzZWQ5N2QxNGJhZTk2ZWFiZjAwXzEtMS0xLTEtMjg2OTQ0_1b3839bd-aaa4-4c00-b41e-a1de266a72c5"
      unitRef="shares">1200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ifab2ddff45a44bc58da3784419071ae5_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMjEvZnJhZzo3NGQ2NzRmYTY0NTQ0YWQzYWVkMGE5MDM4ZTA3OTkwZS90YWJsZToxMWNlZjRhY2Q3YjE0M2VkOTdkMTRiYWU5NmVhYmYwMC90YWJsZXJhbmdlOjExY2VmNGFjZDdiMTQzZWQ5N2QxNGJhZTk2ZWFiZjAwXzEtMy0xLTEtMjg2OTQ0_4bcabfd9-2b64-43c8-b51d-5c4c6234b316"
      unitRef="usdPerShare">54.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i9750f858065345b6b71dfdf94a3db05f_D20220701-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMjEvZnJhZzo3NGQ2NzRmYTY0NTQ0YWQzYWVkMGE5MDM4ZTA3OTkwZS90YWJsZToxMWNlZjRhY2Q3YjE0M2VkOTdkMTRiYWU5NmVhYmYwMC90YWJsZXJhbmdlOjExY2VmNGFjZDdiMTQzZWQ5N2QxNGJhZTk2ZWFiZjAwXzItMS0xLTEtMjg2OTQ0_b7dc104e-2976-46b5-b03b-4e0e55e270b6"
      unitRef="shares">600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i9750f858065345b6b71dfdf94a3db05f_D20220701-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMjEvZnJhZzo3NGQ2NzRmYTY0NTQ0YWQzYWVkMGE5MDM4ZTA3OTkwZS90YWJsZToxMWNlZjRhY2Q3YjE0M2VkOTdkMTRiYWU5NmVhYmYwMC90YWJsZXJhbmdlOjExY2VmNGFjZDdiMTQzZWQ5N2QxNGJhZTk2ZWFiZjAwXzItMy0xLTEtMjg2OTQ0_5cfc93ec-12b1-4ff6-bcd1-7dd7f640440b"
      unitRef="usdPerShare">70.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i9750f858065345b6b71dfdf94a3db05f_D20220701-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMjEvZnJhZzo3NGQ2NzRmYTY0NTQ0YWQzYWVkMGE5MDM4ZTA3OTkwZS90YWJsZToxMWNlZjRhY2Q3YjE0M2VkOTdkMTRiYWU5NmVhYmYwMC90YWJsZXJhbmdlOjExY2VmNGFjZDdiMTQzZWQ5N2QxNGJhZTk2ZWFiZjAwXzMtMS0xLTEtMjg2OTQ0_76451eb2-b8dd-4c85-bcde-f6f3253c18ff"
      unitRef="shares">400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i9750f858065345b6b71dfdf94a3db05f_D20220701-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMjEvZnJhZzo3NGQ2NzRmYTY0NTQ0YWQzYWVkMGE5MDM4ZTA3OTkwZS90YWJsZToxMWNlZjRhY2Q3YjE0M2VkOTdkMTRiYWU5NmVhYmYwMC90YWJsZXJhbmdlOjExY2VmNGFjZDdiMTQzZWQ5N2QxNGJhZTk2ZWFiZjAwXzMtMy0xLTEtMjg2OTQ0_585db14e-8816-417d-ba3c-e3d0af852a0d"
      unitRef="usdPerShare">59.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i9750f858065345b6b71dfdf94a3db05f_D20220701-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMjEvZnJhZzo3NGQ2NzRmYTY0NTQ0YWQzYWVkMGE5MDM4ZTA3OTkwZS90YWJsZToxMWNlZjRhY2Q3YjE0M2VkOTdkMTRiYWU5NmVhYmYwMC90YWJsZXJhbmdlOjExY2VmNGFjZDdiMTQzZWQ5N2QxNGJhZTk2ZWFiZjAwXzQtMS0xLTEtMjg2OTQ0_4c02c5f8-3226-4995-8438-aa158ab18574"
      unitRef="shares">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i9750f858065345b6b71dfdf94a3db05f_D20220701-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMjEvZnJhZzo3NGQ2NzRmYTY0NTQ0YWQzYWVkMGE5MDM4ZTA3OTkwZS90YWJsZToxMWNlZjRhY2Q3YjE0M2VkOTdkMTRiYWU5NmVhYmYwMC90YWJsZXJhbmdlOjExY2VmNGFjZDdiMTQzZWQ5N2QxNGJhZTk2ZWFiZjAwXzQtMy0xLTEtMjg2OTQ0_d3be355a-af53-4b09-ad6f-d39ef2ecbfb7"
      unitRef="usdPerShare">65.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="iace1106122bd40149cc5c5765c33fb32_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMjEvZnJhZzo3NGQ2NzRmYTY0NTQ0YWQzYWVkMGE5MDM4ZTA3OTkwZS90YWJsZToxMWNlZjRhY2Q3YjE0M2VkOTdkMTRiYWU5NmVhYmYwMC90YWJsZXJhbmdlOjExY2VmNGFjZDdiMTQzZWQ5N2QxNGJhZTk2ZWFiZjAwXzUtMS0xLTEtMjg2OTQ0_94673bf5-8918-4d4c-8fb8-9f121f7a07ac"
      unitRef="shares">1100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="iace1106122bd40149cc5c5765c33fb32_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMjEvZnJhZzo3NGQ2NzRmYTY0NTQ0YWQzYWVkMGE5MDM4ZTA3OTkwZS90YWJsZToxMWNlZjRhY2Q3YjE0M2VkOTdkMTRiYWU5NmVhYmYwMC90YWJsZXJhbmdlOjExY2VmNGFjZDdiMTQzZWQ5N2QxNGJhZTk2ZWFiZjAwXzUtMy0xLTEtMjg2OTQ0_2e647015-3a7c-4644-9b2d-c478d35eaed7"
      unitRef="usdPerShare">76.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="iace1106122bd40149cc5c5765c33fb32_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMjEvZnJhZzo3NGQ2NzRmYTY0NTQ0YWQzYWVkMGE5MDM4ZTA3OTkwZS90ZXh0cmVnaW9uOjc0ZDY3NGZhNjQ1NDRhZDNhZWQwYTkwMzhlMDc5OTBlXzE2NTU_a3c307af-980b-4fe7-993e-67f3dbaf9667"
      unitRef="usd">39000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i9750f858065345b6b71dfdf94a3db05f_D20220701-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMzRmYzRmYzI0MjRmYmNiNDgzN2NjOWYxYzA2NjVjL3NlYzoxZDM0ZmM0ZmMyNDI0ZmJjYjQ4MzdjYzlmMWMwNjY1Y18xMjEvZnJhZzo3NGQ2NzRmYTY0NTQ0YWQzYWVkMGE5MDM4ZTA3OTkwZS90ZXh0cmVnaW9uOjc0ZDY3NGZhNjQ1NDRhZDNhZWQwYTkwMzhlMDc5OTBlXzE3Mjg_17baa54e-f600-4020-a4c4-1609a7d67302">P2Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>74
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( #F#I%8'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    "  Y@Z16</I9 N\    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9)1
M2\,P$,>_BN2]O31U(J'+BV-/"H(#Q;>0W+9@TX3DI-VWMZU;A^@'\#%W__SN
M=W"-B=*$A,\I1$SD,-\,ONVR-''-CD11 F1S1*]S.2:ZL;D/R6L:G^D 49L/
M?4 0G-^!1])6DX8)6,2%R%1CC30)-85TQENSX.-G:F>8-8 M>NPH0U56P-0T
M,9Z&MH$K8((1)I^_"V@7XES]$SMW@)V30W9+JN_[LJ_GW+A#!6]/CR_SNH7K
M,NG.X/@K.TFGB&MVF?Q:/VQV6Z8$%W7!5P6_W0DNQ4J*^_?)]8??5=@'Z_;N
M'QM?!%4#O^Y"?0%02P,$%     @ .8.D5IE<G",0!@  G"<  !,   !X;"]T
M:&5M92]T:&5M93$N>&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M
M3A^%$5B-;'EDD81_OT<V$,N6#>V23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R
M>&#9+]O6N[<OWN!7,B0103 9IZ_PP JE3%ZU6FD PSA]R1,2P]R"BPA+>!3+
MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,!
M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K
MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2
MBW <!.!1NY["G?1LOZ1!";2C:=!DV/;:KI&FJHU33]/W?=_KFVB<"HU;3]-K
M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$
MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7<K_WUE[O)I#-ZG7TZSFN4
M?VFK :?MNYO/D_QSZ.2?IY/734+.<+PL"?'[(UMAAR=N.Q-R.AQG0GS/]O:1
MI24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG LR+7E$8D19_(
M+;KD$3BU20TR$S\(G8:8:E < J0),9:AAOBTQJP1X!-]M[X(R-^-B/>K;YH]
M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M
MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZ<TT#PE"\D^DJ1CVFS(Z=T)LWH
M,QK!1J\;=8=HTCQZ_@7YG#4*')$;'0)G&[-&(81IN_ >KR2.FJW"$2M"/F(9
M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+
MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T
M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MN&(59QNVAY6VA]7^' 0&'JS 6BK[%(3K?. *^OK4\P0(@8R?2UJ)VS! K#1
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MHE=[X68-^ZQ;I]#U&!R3Y7(K)&0%+$>IE%R!XJVX0IU![?&YIC-LC!^9 8&
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MNOV4H;U18MN\JU\*I4397&YXFO%: ^#_+T*HMQO=P?&#DME_ %!+ P04
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M&EUE*5VE6:J@"!DYRWU1TGHI:Z=.=[3EVGGK;1SS$K@*[>A#10M&AXF^LZ+
MT1:-02QT\5A>.N)R[<SUF)<=%W7#RM<HX\7F4C&1([[*T@VMGO>J,317(-L(
MK+B -Z;%QKSD=!K#P= O7<:?.2->=4SGVJGNN$_C6)30)O;6G!&F3F=X%FI
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MC$(UJ 3@]S7GZO&F^J+3?L%;_ ]02P,$%     @ .8.D5K/RJ1:E @  Q <
M !@   !X;"]W;W)K<VAE971S+W-H965T-2YX;6RME5UOFS 4AO^*Q:1ID[I
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M@LU(* R)1N6#.ICM-KI+9N@U],Z:0I/OS[/E &4=3DEH]+4"KC#M<HLM\OB
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MA-CR&M@OE6E,KT%[W1H)=I6UC6C?NYZ/1ZZ>YR7Q3-'1BEC&L>)DR#3=^3@
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M^;R$2OK$UF#PR]RZ2@9\=8N1KQW(@I4J/4K'XX-1)949G![SVB=W>FQCT,K
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M)F]^[A2W8-K- $\L*,?MC?<;:=3?B(2V?BI7SS,INMKB_H:9S>*:XN\#I>K
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MHY>1)S$K$;QBV%407Q8-UF9VZGGGP3@@0_N05%=TB$V&?IHC,AO(DQ;J#6K
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M9  R%P5(&>*GKA:G!8Y8L^"NT1A=)_7XX6_GI[.G/\6TI6(&SJDT2)4T*FQ
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M^-,&O,^L#<T#*6B_1E_^!5!+ P04    "  Y@Z16>F;MXJD$   8"P  &0
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M^9%;]J^WTINKT'?ZFKA>T[TSF_:;+=WCGGUW\ERL8@X].CXY:[OEXW$EP^4
M=V?QL]H!I58P"@><3?Z\P'_6R%;(>DJRGIV>+[\[2?HYI,V??H.T8#^IQEG^
MD!+/_X#OX?E2AZC2IN"LY;/$6<OY7<[JQ2]5:-%2YVCFHF?FXO3T5LE[@M/0
MGCQK$$^ALG-.0]!$7W34%WX<P/WS]G,D%4,02[DWQO=,J=R%T6A0<+%NH_>:
MRF,HN0\K[P@-:-.83_O5-G9X !FFP>GT05-N2(#F:MCMC!]<I<AFHF[F$YZV
MN#E/ LZ$)LMW$=!..9%2R%&XXN9=L"_^ !,!5]9%) H%W\(2>GFZZT#C*/37
MFOS(H_P>U]]#H,_AAA.0S%<"Y(L_XV.^ =:;+=U ,RN!UI,^/;66-6E&OSY%
M[<^C'(YP5<37T$G&C7.=-@J'$[$_-/X%X:&)3U9I+V\YAP2KZF@5*YQ_ PK=
MRB=(=L?1TB.7RX-'_DEVT:=>#SZ MR2(F'N2S^-A1=F&JN/0TSJZ)72NC,$+
M,-1F)=]OC3&]X[/VXX,%Y_ADR*;/QP[YP^%X#Z>:4F?BT4^F>O*N+=;'X^/E
M7L8G-[@FO;W?N[=MA\[DRIY0R/4&OTG(!2H.NKR)CY?(R&11,D?WIF.>G%SO
MGET16(1Z9(X5G_J4M)H?%X7'/]VST/A,,>/G3.%@)3E;]L?(;W^ >,_+J^'#
MQ?!P^;9;/#=XCNQ29-^[MR.#)04CW+RQHB'9#^ :"M T#(9OT%F/>(<1[E,2
M7M!4V^T7?0^L!/N<9\$4I4.6/ I3ZN-9BB_\&*Q=>QAWEWUH?$C8/1U!W7T]
M'J+,X\L)%3W2Z#V<&KZC<$N!DX/?8CF&'6 //2^U$_&^MF8BWF[IUI_<62%"
M*SW!',;+;+V+]Y^?MU*C7+>^=Q6/3!E_@8,4;CM^<LW'G(Z?NZ!P44?A10+/
M3Y4#325"@*]B"3NZ6&2.T($&?K*UZCT HF(<<25/):?S2>39.[#5:TW126\'
M\[HA(/C*;=%QGA!E31ZF!O^O#3U'X5"R0N%=,O1 %W# >1:=#R[3"4T+4VV"
M4+,J]$8.83 Y-7D$RBAJNX?174KLNU;Z%U0F34*BA0[<T7?%^S%EC\5RLCP_
MQ[]GD_GR.9*E=PA^?7JZQ&^G)V?!(0]D)]"N<QZ]YL:HJ#1O(<._UH9^BNC+
MUY.NI0A\9T946,-VB3[G7$U#MXUGZFI7>Q? K.$(\E)B+04QRM15>,<P//'F
M*S>K^+TI=J[XET(="K3R#O*F8Z]1S9*WX4IE-_S.GPMO/807X]IOV]<*7X>W
MZ;KEX9U$Q&]#5*M0:VR=3Y^>'0D;WO,+'[S9\;MU $UO2OYSJU!'EA;@][6!
MU^('.J!]V?+B_U!+ P04    "  Y@Z16Y]>80U<%  !:$P  &0   'AL+W=O
M<FMS:&5E=',O<VAE970Q-RYX;6S56-MNVS@0_96!6G1MP)!U\R5I8L!)6K3%
M%BV:=ONPV =:&DM"*=(EJ3C9K]\A)3MV&[N)VQ38!ULDQ3DS<PY)D3Q92O5%
M%X@&KBLN]*E7&+,X[O=U6F#%M"\7*.C-7*J*&:JJO*\7"EGFC"K>CX)@V*]8
M*;S)B6M[KR8GLC:\%/A>@:ZKBJF;,^1R>>J%WJKA0YD7QC;T)R<+EN,EFD^+
M]XIJ_35*5E8H="D%*)R?>M/P^"RQ_5V'OTI<ZHTRV$QF4GZQE=?9J1?8@)!C
M:BP"H\<5GB/G%HC"^-IB>FN7UG"SO$)_Z7*G7&9,X[GDG\O,%*?>V(,,YZSF
MYH-<OL(VGX'%2R77[A^63=^(/*:U-K)JC:E>E:)YLNN6APV#<;##(&H-(A=W
MX\A%><$,FYPHN01E>Q.:+;A4G34%5PHKRJ51]+8D.S.Y+)C"0O(,E?X#7GRM
M2W-STC>$;-_WTQ;EK$&)=J <P5LI3*'AA<@PV[;O4T3KL*)56&?17L"W3/D0
MASV(@BC>@Q>OTXP=7KP#KTD,_I[.M%$T$OZY*\<&(KD;PLZ.8[U@*9YZ-/PU
MJBOT)L^>A,/@^9X DW6 R3[T>^NP'R4,?+@+J=^YP'F9EJ8+GY'FTJ)6:4%C
M.8.GH3^ 6<FYFR+"-03K!CD'62M(955135MDW8-2@"D06)XKS)G!'E65K/.B
MZ;&!#PLE<\4J#5FM2I$[.T%!0]6,%[3C!4CMM%C+[<*@0M0C)+U -V_YC6]#
MG]?.P,+<>M$T9TP![(J5G,TX0LITX<-'ZK05^5;B-M ">>:RH>5,U^H&C(09
M0FW?TWH'.0I4C!.*6DA%F0+9+R1Y].'B-B'*'O=FU(,ET@N#"JT_\L+L>I32
MVF11L^]YZWC3RP]>=\6?#6SC[796-E*+MY(#-M@O4[0B/HT& :T>3E2_&0(I
M$JN9-2Q%:4K*,D-.3<0"&43^<-7_&V^UMFDSNR!3.B+=]#(:^4'<$+\*/)4B
MY;6EA"!>XDS5M/1#-%Y);0CJ2O*Z0N+(KJ V)HJ"/@@M\ *W!^#*4S2RPX,6
M7QL/B<A@7HIOT@AVI?$C_2Z(GVI&GEL)HSLE)(W^;PH-_<%XCT)OF' "A?'/
M"T0)/9Y E[@PK4+!;U)H8V&\ET)AY <'2#0<^J-DCT3KH1DU&D6':Q3[\?#'
M&H6':K2U"/Z&&10\; ;%!\DS2/P@W"//E+IR",<_J<U@Z ?1;US@PD>7)WZ@
M/(D_/D2>P(^#>RQPJU%YL$#)D1\?W6?RQ+]H@7M\A08/5&ATF$*TX]RW27B7
M&FG33IJL#Y]!H1_>XPNT<Y'V89JF=55SMT-[1S(I.)<5[?T+>R:]0OA3:NWR
MF$M.AULGIMU_ZO:(6_Z+3EWB6>34VNZ;9XPST9#!-CQ(YR'=\L"MA]F-:Y6"
MM'=[8XLC#>/'T*%B&[SN AU3B1\!GP3M9SEYS^Y(X:SU3K2^J6DCOOI\PE/H
MA$'4=<_V$2;=UNK[L'JT4Z9!Y48)9UJ7=+Y@]J"MH1.373@@@*,N3"M9"Z,W
MNMG]NP1DB@X"N89G3\91&#V'#G6VOX\VM=UL,&-4.:L=T1;GG*G,B?J*<C9%
M#UZ+U >!QO)KV#6%*>CL8YHQL9;:Q3B$3C3N;E+RS4G$DA /'1G-?Y@0-;^.
M]=!B)@XZ= K$!S*>C+IP1.;CAQ ^Z+K?8Q)^^W5R(2;TB'<3[B@XBAT=0UL>
MC;IWG:W[&_<=%:K<W>IH"IX2;ZX^UJWKBZ-I<U]RV[VY=2+_>4D,<IR3:>"/
M!AZHYB:GJ1BY<+<G,VF,K%RQ0$:':]N!WL^E-*N*=;"^3IO\!U!+ P04
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MP,4\6IU=MDS::7%-0R%$)HQC)PQ1_> ^U5],0;%!%C%.MJ>,P%: 09MS58^
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M([D+OJ0921E:@.<KC4ZS^4$;M*\07?T;4$L#!!0    ( #F#I%:6XO._104
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M,9X&'8?:RHS1>#N>(DI-QJS8"H_@MJ*FN%(YTD&D@2L-=7;_L*FCH$&C'Y"
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MEA?0?&&H"KL!.^BOR*M_ 5!+ P04    "  Y@Z16V17>0-P"  !9!@  &0
M 'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6R-56UOVC 0_BNG;)I:J6M""'1E
M@ 1]43NM:E6Z[L.T#R8YB%7'SFP'VOWZG1T(M*)H7_#;W7//<[D[^DNEGTR.
M:.&Y$-(,@MS:LA>&)LVQ8.98E2CI9:9TP2P=]3PTI4:6>:="A'$4=<."<1D,
M^_[N3@_[JK*"2[S38*JB8/IEC$(M!T$K6%_<\WENW44X[)=LCA.T/\H[3:>P
M0<EX@=)P)4'C;!",6KUQXNR]P2/'I=G:@U,R5>K)':ZS01 Y0B@PM0Z!T;+
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M1L<GG0!T/<CJ@U6E'QY396D4^6U.LQ^U,Z#WF5)V?7 !FG^3X3]02P,$%
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M@6I[J%;!NCU,>S#)0:PZ=F8;:/_[V4E((;@(;7U);.>^S_?=.>?K;[AXE!F
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M?LMC3J(S0-4ZK0I>EO-PH]8BD/$X) !'?ZNRK&M=9R4S>NE+K4VPH 0;[H0
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M.$GET2GX<G\%CMX=@W<@R<&-M"R3Q<>ND%B+%=U9B>O]%A=JP76#V1GPX0E
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M?/=L@MV&2-?%C>L/J1!I7+Q<,;I@/!\@WW],4_&\D3O8/R%B^C]02P,$%
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M]86$!9 P @FC0+":OF>%OF?.BS>5TW2XF>3+4"/*%F$4ZL>WZ(H]A/&V\BR
M9LR,PGS7)OM9<R;P&G./<R3'RGE(1@*9D0+!:C+Y7OGTYCF%NN$[$>U2'>I2
M.=NM&WKL]0A*"T!I!)1&H6AUL2N/ZCYHU\UQ4#)#T@)0&@&E42A:769<RHS_
MC^:;9WFF^[K'<K2JA^0DH#DI%*VN5NEL^,X'ZTGZF(O2Q]RZ8"%7*.O!K>J
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MOK4=S9HKW1_9RU2WL"A,@'Z^X5P=!N8%=5,<_@=02P,$%     @ .8.D5NC
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MNW#S#.;%XNG_V1_;-V)G 7-P8 %SNX#Y>@'SP +][0+]5POT#RTPV"XP>+5
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MF@^0W\^21+POY ZJN8HF_P%02P,$%     @ .8.D5B%D?CXB!   @Q<  !D
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ML!+M^E#PV9%&6<#5F-$9L8>B@/ )7.D<)8QR(745T!/29$7Y3,'^.6I"F3J
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MT')Z5%-0344U#=5T5#,J[7SGA#X_'TCGS3/:1!NUVAL=-]NTV_8Z&XPO]G,
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M ;>_']C?^]@IEB4S.%'B"T]M-@K>!)#BBI7"WJC-%=;Q> <3)8S_A4V]MQ-
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M,4MDMO%OP^FU)BWP<+QG_]/Y;GQ9$85SP;[23.=3[\&##->D8OI9[#YAX\_
M\J6"*?<+NT:WYT%:*2V*!FQV4%!>?\FW)@X' ,/3#0@;0'@*Z/\$$#6 Z*T6
M^@V@_U8+@P;@7/=KWUW@%D23>"+%#J35-FQVX*+OT"9>E-L\>='2K%*#TW%"
M)*=\HV")$EYR(A$>M99T56FR8@A:P)S(C'+"X!,2IO,[^,S3>[AYQE3PE#)*
MW(F+-<Q%49B18U'P16'FX*(H*XTP(XJF0'@&"\J,((-D^7(+-PO4A#)U"Q]
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M*7N\W3W8'HARVVR/6Y5"E'GS=<-HPG@=('^_+4OQ<% WT._A7/P/4$L#!!0
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M\8RLI>P"W&9ETBGQ[LF.9%L"/C.:@NA)$);A!$R*S1#&P<T/\!NA:X;S3;P
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M0+__S+EZO2@F:(X*S;\"4$L#!!0    ( #F#I%8OK#QJY 0   TB   9
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M$M-$G*(/B&;HEB:)FB*&ME06:!P[*K5-"FW> 6T^NF697 H49C&).^0#L_S
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MZ_+<-1:.W^<P4-K0JNWV2K>IV<ZC _^ZQA!*8SOR=4WMFHOJ=SD2F&TZ>K-
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M$ZXGJ/MSQN3N0BNHO@ 9_P-02P,$%     @ .8.D5IANT)]V P  O1   !D
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M-^((Y@ \8$@4F??@SOLH6+^G@N:WV^%?4$L#!!0    ( #F#I%:7BKL<P
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M_.4!  !_(0  &@   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSS=H[3L-
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M][G$Y!-02P$"% ,4    "  Y@Z16!T%-8H$   "Q    $
M@ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( #F#I%9P^ED"[P
M "L"   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4
M Q0    ( #F#I%:97)PC$ 8  )PG   3              "  <T!  !X;"]T
M:&5M92]T:&5M93$N>&UL4$L! A0#%     @ .8.D5KJ-4+.]!0  P1X  !@
M             ("!#@@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4
M Q0    ( #F#I%9:(S+-8 <  %PB   8              " @0$.  !X;"]W
M;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    "  Y@Z16VA:WWQ $  "O
M#P  &               @(&7%0  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL
M4$L! A0#%     @ .8.D5N[DQ[=9!@  S1L  !@              ("!W1D
M 'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( #F#I%:S\JD6
MI0(  ,0'   8              " @6P@  !X;"]W;W)K<VAE971S+W-H965T
M-2YX;6Q02P$"% ,4    "  Y@Z16Q,2![YP/  !!L@  &
M@(%'(P  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ .8.D
M5O B\_UP!P  T1\  !@              ("!&3,  'AL+W=O<FMS:&5E=',O
M<VAE970W+GAM;%!+ 0(4 Q0    ( #F#I%;>NDZG+@8  &<0   8
M      " @;\Z  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4
M"  Y@Z16Y=T;M#D#  #$!@  &               @($C00  >&PO=V]R:W-H
M965T<R]S:&5E=#DN>&UL4$L! A0#%     @ .8.D5AS/ZCI3!   $@L  !D
M             ("!DD0  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"
M% ,4    "  Y@Z16.)?LFX@'  #?%   &0              @($<20  >&PO
M=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( #F#I%:K+(9JP04
M 'L.   9              " @=M0  !X;"]W;W)K<VAE971S+W-H965T,3(N
M>&UL4$L! A0#%     @ .8.D5D.CYNM,&0  A4D  !D              ("!
MTU8  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    "  Y@Z16
MNS-,JNP'  "9%@  &0              @(%6<   >&PO=V]R:W-H965T<R]S
M:&5E=#$T+GAM;%!+ 0(4 Q0    ( #F#I%9Z9NWBJ00  !@+   9
M      " @7EX  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%
M  @ .8.D5JB^ 6!*#   >"D  !D              ("!67T  'AL+W=O<FMS
M:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    "  Y@Z16Y]>80U<%  !:$P
M&0              @(':B0  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+
M 0(4 Q0    ( #F#I%:$71YBJP,  ,P*   9              " @6B/  !X
M;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ .8.D5B_,.[*Z
M#   3B0  !D              ("!2I,  'AL+W=O<FMS:&5E=',O<VAE970Q
M.2YX;6Q02P$"% ,4    "  Y@Z16EN+SOT4%  #;#@  &0
M@($[H   >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( #F#
MI%9I'A\]2@8   (3   9              " @;>E  !X;"]W;W)K<VAE971S
M+W-H965T,C$N>&UL4$L! A0#%     @ .8.D5N%R,IHL P  @P@  !D
M         ("!.*P  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4
M    "  Y@Z16;X&O!90$  "]"P  &0              @(&;KP  >&PO=V]R
M:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( #F#I%:__/Q*N00  "X+
M   9              " @6:T  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL
M4$L! A0#%     @ .8.D5MD5WD#< @  608  !D              ("!5KD
M 'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4    "  Y@Z16-&H#
M75,#  ! "   &0              @(%IO   >&PO=V]R:W-H965T<R]S:&5E
M=#(V+GAM;%!+ 0(4 Q0    ( #F#I%8C^+*/#P,  -0'   9
M  " @?._  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @
M.8.D5AE<*"<X!P  SA0  !D              ("!.<,  'AL+W=O<FMS:&5E
M=',O<VAE970R."YX;6Q02P$"% ,4    "  Y@Z16<^/LULP#  #M"@  &0
M            @(&HR@  >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4
M Q0    ( #F#I%9GSW P#@,  (<+   9              " @:O.  !X;"]W
M;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ .8.D5EMG1K,' P
M\ D  !D              ("!\-$  'AL+W=O<FMS:&5E=',O<VAE970S,2YX
M;6Q02P$"% ,4    "  Y@Z16MF]8>VH#   %#0  &0              @($N
MU0  >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( #F#I%;V
M@<CGS0(  ,H(   9              " @<_8  !X;"]W;W)K<VAE971S+W-H
M965T,S,N>&UL4$L! A0#%     @ .8.D5IRA3!HM!0  1B,  !D
M     ("!T]L  'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( #F#I%;HP.OOQ!<  %R[ 0 9              "
M@4/W  !X;"]W;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ .8.D
M5F*IH+LY!P  MT@  !D              ("!/@\! 'AL+W=O<FMS:&5E=',O
M<VAE970T,"YX;6Q02P$"% ,4    "  Y@Z16(61^/B($  "#%P  &0
M        @(&N%@$ >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0
M   ( #F#I%8?&AW^2PH  !MX   9              " @0<; 0!X;"]W;W)K
M<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @ .8.D5@[2*6?A @  ?0@
M !D              ("!B24! 'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q0
M2P$"% ,4    "  Y@Z16C%!HBKD.  #_$0$ &0              @(&A* $
M>&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( #F#I%;"1:<@
M808  +HM   9              " @9$W 0!X;"]W;W)K<VAE971S+W-H965T
M-#4N>&UL4$L! A0#%     @ .8.D5GZE_]\J P  *0H  !D
M ("!*3X! 'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q02P$"% ,4    "  Y
M@Z16<I![E'D#   .#   &0              @(&*00$ >&PO=V]R:W-H965T
M<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( #F#I%:G0QRPWP0   XD   9
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M970U,BYX;6Q02P$"% ,4    "  Y@Z16+ZP\:N0$   -(@  &0
M    @('K7@$ >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    (
M #F#I%:8;M"?=@,  +T0   9              " @09D 0!X;"]W;W)K<VAE
M971S+W-H965T-30N>&UL4$L! A0#%     @ .8.D5@DYTXO^ P   PX  !D
M             ("!LV<! 'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6Q02P$"
M% ,4    "  Y@Z16@T(1D=@#   F#0  &0              @('H:P$ >&PO
M=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4 Q0    ( #F#I%:JK@T'8P,
M ,@5   -              "  ?=O 0!X;"]S='EL97,N>&UL4$L! A0#%
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K 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !  $  =Q$  $I] 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>266</ContextCount>
  <ElementCount>253</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>87</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>13</UnitCount>
  <MyReports>
    <Report instance="cah-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="cah-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - Condensed Consolidated Statements of Earnings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings</Role>
      <ShortName>Condensed Consolidated Statements of Earnings</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="cah-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Condensed Consolidated Statements of Comprehensive Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="cah-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="cah-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="cah-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Condensed Consolidated Statements of Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Shareholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="cah-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="cah-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="cah-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Divestitures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/Divestitures</Role>
      <ShortName>Divestitures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="cah-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Restructuring and Employee Severance</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/RestructuringandEmployeeSeverance</Role>
      <ShortName>Restructuring and Employee Severance</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="cah-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Goodwill and Other Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/GoodwillandOtherIntangibleAssets</Role>
      <ShortName>Goodwill and Other Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="cah-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowings</Role>
      <ShortName>Long-Term Obligations and Other Short-Term Borrowings</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="cah-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Commitments, Contingent Liabilities and Litigation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigation</Role>
      <ShortName>Commitments, Contingent Liabilities and Litigation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="cah-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="cah-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="cah-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/FinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="cah-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareholdersEquity</Role>
      <ShortName>Shareholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="cah-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc.</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthInc</Role>
      <ShortName>Earnings Per Share Attributable to Cardinal Health, Inc.</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="cah-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/SegmentInformation</Role>
      <ShortName>Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="cah-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Share-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareBasedCompensation</Role>
      <ShortName>Share-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="cah-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="cah-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Restructuring and Employee Severance (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables</Role>
      <ShortName>Restructuring and Employee Severance (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/RestructuringandEmployeeSeverance</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="cah-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Goodwill and Other Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables</Role>
      <ShortName>Goodwill and Other Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/GoodwillandOtherIntangibleAssets</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="cah-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/FairValueMeasurements</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="cah-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/FinancialInstrumentsTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/FinancialInstruments</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="cah-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Shareholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareholdersEquityTables</Role>
      <ShortName>Shareholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/ShareholdersEquity</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="cah-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables</Role>
      <ShortName>Earnings Per Share Attributable to Cardinal Health, Inc. (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthInc</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="cah-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/SegmentInformationTables</Role>
      <ShortName>Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/SegmentInformation</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="cah-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Share-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareBasedCompensationTables</Role>
      <ShortName>Share-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/ShareBasedCompensation</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="cah-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Discontinued Operations and Disposal Groups (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails</Role>
      <ShortName>Discontinued Operations and Disposal Groups (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="cah-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails</Role>
      <ShortName>Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="cah-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails</Role>
      <ShortName>Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="cah-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Restructuring and Employee Severance Narative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails</Role>
      <ShortName>Restructuring and Employee Severance Narative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="cah-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails</Role>
      <ShortName>Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="cah-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="cah-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Goodwill and Other Intangible Assets (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails</Role>
      <ShortName>Goodwill and Other Intangible Assets (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="cah-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails</Role>
      <ShortName>Long-Term Obligations and Other Short-Term Borrowings (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowings</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="cah-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings Summary of Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails</Role>
      <ShortName>Long-Term Obligations and Other Short-Term Borrowings Summary of Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="cah-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Commitments, Contingent Liabilities and Litigation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails</Role>
      <ShortName>Commitments, Contingent Liabilities and Litigation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigation</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="cah-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - Income Taxes (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/IncomeTaxes</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="cah-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - Fair Value Measurements (Fair Value of Assets and Liabilities Measured on a Recurring Basis) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements (Fair Value of Assets and Liabilities Measured on a Recurring Basis) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="cah-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - Financial Instruments (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails</Role>
      <ShortName>Financial Instruments (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="cah-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - Financial Instruments Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails</Role>
      <ShortName>Financial Instruments Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="cah-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - Shareholders' Equity (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails</Role>
      <ShortName>Shareholders' Equity (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/ShareholdersEquityTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="cah-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails</Role>
      <ShortName>Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/ShareholdersEquityTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="cah-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails</Role>
      <ShortName>Earnings Per Share Attributable to Cardinal Health, Inc. (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="cah-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails</Role>
      <ShortName>Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="cah-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000051 - Disclosure - Segment Information (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/SegmentInformationNarrativeDetails</Role>
      <ShortName>Segment Information (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/SegmentInformationTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="cah-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000052 - Disclosure - Segment Information (Revenue by Reportable Segment) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails</Role>
      <ShortName>Segment Information (Revenue by Reportable Segment) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/SegmentInformationTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="cah-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000053 - Disclosure - Segment Information (Segment Profit by Reportable Segment) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails</Role>
      <ShortName>Segment Information (Segment Profit by Reportable Segment) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/SegmentInformationTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="cah-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0000054 - Disclosure - Segment Information Revenue From External Customers By Geographic Areas (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails</Role>
      <ShortName>Segment Information Revenue From External Customers By Geographic Areas (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="cah-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0000055 - Disclosure - Segment Information (Assets by Reportable Segment) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails</Role>
      <ShortName>Segment Information (Assets by Reportable Segment) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/SegmentInformationTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="cah-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0000056 - Disclosure - Share-Based Compensation (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails</Role>
      <ShortName>Share-Based Compensation (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/ShareBasedCompensationTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="cah-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>0000057 - Disclosure - Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails</Role>
      <ShortName>Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/ShareBasedCompensationTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="cah-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>0000060 - Disclosure - Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails</Role>
      <ShortName>Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/ShareBasedCompensationTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="cah-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>0000061 - Disclosure - Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails</Role>
      <ShortName>Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/ShareBasedCompensationTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="cah-20230331.htm">cah-20230331.htm</File>
    <File>a23q3_10qx33123xexhibit311.htm</File>
    <File>a23q3_10qx33123xexhibit312.htm</File>
    <File>a23q3_10qx33123xexhibit321.htm</File>
    <File>a23q3_10qx33123xexhibit991.htm</File>
    <File>cah-20230331.xsd</File>
    <File>cah-20230331_cal.xml</File>
    <File>cah-20230331_def.xml</File>
    <File>cah-20230331_lab.xml</File>
    <File>cah-20230331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>cah-20230331_g1.jpg</File>
    <File>cah-20230331_g2.jpg</File>
    <File>cah-20230331_g3.jpg</File>
    <File>cah-20230331_g4.jpg</File>
    <File>cah-20230331_g5.jpg</File>
    <File>cah-20230331_g6.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="834">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>79
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "cah-20230331.htm": {
   "axisCustom": 9,
   "axisStandard": 25,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 834,
    "http://xbrl.sec.gov/dei/2023": 29
   },
   "contextCount": 266,
   "dts": {
    "calculationLink": {
     "local": [
      "cah-20230331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "cah-20230331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "cah-20230331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "cah-20230331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cah-20230331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "cah-20230331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"
     ]
    }
   },
   "elementCount": 496,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2023": 5,
    "total": 5
   },
   "keyCustom": 24,
   "keyStandard": 229,
   "memberCustom": 40,
   "memberStandard": 42,
   "nsprefix": "cah",
   "nsuri": "http://www.cardinal.com/20230331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover Page",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.cardinal.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Restructuring and Employee Severance",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.cardinal.com/role/RestructuringandEmployeeSeverance",
     "shortName": "Restructuring and Employee Severance",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Goodwill and Other Intangible Assets",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssets",
     "shortName": "Goodwill and Other Intangible Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowings",
     "shortName": "Long-Term Obligations and Other Short-Term Borrowings",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Commitments, Contingent Liabilities and Litigation",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigation",
     "shortName": "Commitments, Contingent Liabilities and Litigation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.cardinal.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Fair Value Measurements",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.cardinal.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Financial Instruments",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.cardinal.com/role/FinancialInstruments",
     "shortName": "Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "i0cd8fe77970644be9137a7d83eeb7054_D20210701-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Shareholders' Equity",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.cardinal.com/role/ShareholdersEquity",
     "shortName": "Shareholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc.",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthInc",
     "shortName": "Earnings Per Share Attributable to Cardinal Health, Inc.",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Segment Information",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.cardinal.com/role/SegmentInformation",
     "shortName": "Segment Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000002 - Statement - Condensed Consolidated Statements of Earnings",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings",
     "shortName": "Condensed Consolidated Statements of Earnings",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Share-Based Compensation",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.cardinal.com/role/ShareBasedCompensation",
     "shortName": "Share-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "21",
     "role": "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Restructuring and Employee Severance (Tables)",
     "menuCat": "Tables",
     "order": "22",
     "role": "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables",
     "shortName": "Restructuring and Employee Severance (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Goodwill and Other Intangible Assets (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables",
     "shortName": "Goodwill and Other Intangible Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Fair Value Measurements (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://www.cardinal.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Financial Instruments (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://www.cardinal.com/role/FinancialInstrumentsTables",
     "shortName": "Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Shareholders' Equity (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://www.cardinal.com/role/ShareholdersEquityTables",
     "shortName": "Shareholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables",
     "shortName": "Earnings Per Share Attributable to Cardinal Health, Inc. (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Segment Information (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://www.cardinal.com/role/SegmentInformationTables",
     "shortName": "Segment Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Share-Based Compensation (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://www.cardinal.com/role/ShareBasedCompensationTables",
     "shortName": "Share-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - Condensed Consolidated Statements of Comprehensive Income",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome",
     "shortName": "Condensed Consolidated Statements of Comprehensive Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromDivestitureOfBusinesses",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Discontinued Operations and Disposal Groups (Details)",
     "menuCat": "Details",
     "order": "30",
     "role": "http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails",
     "shortName": "Discontinued Operations and Disposal Groups (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "if3c1b25895fb44c59c13bf46018fc577_D20210701-20210930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromDivestitureOfBusinesses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SeveranceCosts1",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails",
     "shortName": "Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "ic217743408d440409a59220a0bf14e4c_I20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails",
     "shortName": "Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "ic217743408d440409a59220a0bf14e4c_I20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SeveranceCosts1",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Restructuring and Employee Severance Narative (Details)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails",
     "shortName": "Restructuring and Employee Severance Narative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "ic217743408d440409a59220a0bf14e4c_I20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails",
     "shortName": "Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:GoodwillAcquiredDuringPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "ia417c574587a496b8f3ac8b2f1e28b1a_I20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails",
     "shortName": "Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "ia417c574587a496b8f3ac8b2f1e28b1a_I20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Goodwill and Other Intangible Assets (Narrative) (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
     "shortName": "Goodwill and Other Intangible Assets (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "ia417c574587a496b8f3ac8b2f1e28b1a_I20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "cah:TotalLongTermandShortTermObligations",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails",
     "shortName": "Long-Term Obligations and Other Short-Term Borrowings (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "ic217743408d440409a59220a0bf14e4c_I20220630",
      "decimals": "-8",
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableCurrentAndNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "ia417c574587a496b8f3ac8b2f1e28b1a_I20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "cah:TotalLongTermandShortTermObligations",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings Summary of Debt (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails",
     "shortName": "Long-Term Obligations and Other Short-Term Borrowings Summary of Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:LineOfCreditFacilityAverageOutstandingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainLossRelatedToLitigationSettlement",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Commitments, Contingent Liabilities and Litigation (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
     "shortName": "Commitments, Contingent Liabilities and Litigation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "cah:IncomefromSettlementsofClassActionLawsuits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "ia417c574587a496b8f3ac8b2f1e28b1a_I20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - Condensed Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "ia417c574587a496b8f3ac8b2f1e28b1a_I20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - Income Taxes (Narrative) (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
     "shortName": "Income Taxes (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "ic1d54b1779a94c778dcfd9c480a2851b_I20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - Fair Value Measurements (Fair Value of Assets and Liabilities Measured on a Recurring Basis) (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails",
     "shortName": "Fair Value Measurements (Fair Value of Assets and Liabilities Measured on a Recurring Basis) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "ic1d54b1779a94c778dcfd9c480a2851b_I20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1",
       "us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1",
       "us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1",
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - Financial Instruments (Narrative) (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails",
     "shortName": "Financial Instruments (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1",
       "us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1",
       "us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1",
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "ia417c574587a496b8f3ac8b2f1e28b1a_I20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "cah:CarryingAmountofLongTermandotherShortTermBorrowings",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - Financial Instruments Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails",
     "shortName": "Financial Instruments Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "ia417c574587a496b8f3ac8b2f1e28b1a_I20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "cah:CarryingAmountofLongTermandotherShortTermBorrowings",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsForRepurchaseOfCommonStock",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - Shareholders' Equity (Narrative) (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails",
     "shortName": "Shareholders' Equity (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "i7ad6d93eac9d48ab9fec302dd4e88915_D20221001-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:PaymentsForRepurchaseOfCommonStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "i08aa4676fa1f412495f0dcda89ef5c61_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails",
     "shortName": "Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Narrative) (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails",
     "shortName": "Earnings Per Share Attributable to Cardinal Health, Inc. (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails",
     "shortName": "Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainLossRelatedToLitigationSettlement",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000051 - Disclosure - Segment Information (Narrative) (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.cardinal.com/role/SegmentInformationNarrativeDetails",
     "shortName": "Segment Information (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000052 - Disclosure - Segment Information (Revenue by Reportable Segment) (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
     "shortName": "Segment Information (Revenue by Reportable Segment) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "i16dc5579b6f94e7ca4452bbc7028e7c9_D20230101-20230331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "ia417c574587a496b8f3ac8b2f1e28b1a_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000053 - Disclosure - Segment Information (Segment Profit by Reportable Segment) (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails",
     "shortName": "Segment Information (Segment Profit by Reportable Segment) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "i5dd2e5fc3ed54f20bfab2ed85428f964_D20220101-20220331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "cah:ContingentAttorneyFee",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000054 - Disclosure - Segment Information Revenue From External Customers By Geographic Areas (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails",
     "shortName": "Segment Information Revenue From External Customers By Geographic Areas (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "i73b99b7f00ef43c3b9264f23015dbdbc_D20230101-20230331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "ia417c574587a496b8f3ac8b2f1e28b1a_I20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Assets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000055 - Disclosure - Segment Information (Assets by Reportable Segment) (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
     "shortName": "Segment Information (Assets by Reportable Segment) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "i5c0c3804d63c4f5fafbb13f1f87b1d95_I20230331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:Assets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000056 - Disclosure - Share-Based Compensation (Narrative) (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
     "shortName": "Share-Based Compensation (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000057 - Disclosure - Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails",
     "shortName": "Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "i67d106a8bf4e4cea845ce9596a23f17e_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "i7de355b6c9f244b0aecf4263ff24158b_D20220701-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000060 - Disclosure - Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails",
     "shortName": "Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "ia8acc2cf603d4cec94d38cdf7947bf8c_I20220630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "ifab2ddff45a44bc58da3784419071ae5_I20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000061 - Disclosure - Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
     "shortName": "Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "ifab2ddff45a44bc58da3784419071ae5_I20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "i2aece4cef70c4e909ce54489503e648a_I20210630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TreasuryStockCommonShares",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - Condensed Consolidated Statements of Shareholders' Equity",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
     "shortName": "Condensed Consolidated Statements of Shareholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "if4a2a8ced444402e984b4c3bc89c5c8d_I20210630",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - Condensed Consolidated Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000008 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - Divestitures",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.cardinal.com/role/Divestitures",
     "shortName": "Divestitures",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20230331.htm",
      "contextRef": "ieaff16b2548b4780b3eb61d841b44435_D20220701-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 87,
   "tag": {
    "cah_A1BillionShareRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "$1 billion share repurchase program",
        "label": "$1 billion share repurchase program [Member]",
        "terseLabel": "$1 billion share repurchase program"
       }
      }
     },
     "localname": "A1BillionShareRepurchaseProgramMember",
     "nsuri": "http://www.cardinal.com/20230331",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_A2.616Notesdue2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.616% Notes due 2022",
        "label": "2.616% Notes due 2022 [Member]",
        "terseLabel": "2.616% Notes due 2022 [Member]"
       }
      }
     },
     "localname": "A2.616Notesdue2022Member",
     "nsuri": "http://www.cardinal.com/20230331",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails",
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_A200MillionShareRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "$200 million share repurchase program",
        "label": "$200 million share repurchase program [Member]",
        "terseLabel": "$200 million"
       }
      }
     },
     "localname": "A200MillionShareRepurchaseProgramMember",
     "nsuri": "http://www.cardinal.com/20230331",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_A250MillionShareRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "$250 million share repurchase program",
        "label": "$250 million share repurchase program [Member]",
        "terseLabel": "$250 million share repurchase program [Member]"
       }
      }
     },
     "localname": "A250MillionShareRepurchaseProgramMember",
     "nsuri": "http://www.cardinal.com/20230331",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_A300MillionShareRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "$300 million share repurchase program",
        "label": "$300 million share repurchase program [Member]",
        "terseLabel": "$300 million share repurchase program"
       }
      }
     },
     "localname": "A300MillionShareRepurchaseProgramMember",
     "nsuri": "http://www.cardinal.com/20230331",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_A32NotesDue2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.2% Notes due 2023",
        "label": "3.2% Notes due 2023 [Member]",
        "terseLabel": "3.2% Notes due 2023"
       }
      }
     },
     "localname": "A32NotesDue2023Member",
     "nsuri": "http://www.cardinal.com/20230331",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_A500MillionShareRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "$500 million share repurchase program [Domain]",
        "label": "$500 million share repurchase program [Member]",
        "terseLabel": "$500 million share repurchase program [Domain]"
       }
      }
     },
     "localname": "A500MillionShareRepurchaseProgramMember",
     "nsuri": "http://www.cardinal.com/20230331",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_AggregateAnnualAssessment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate Annual Assessment",
        "label": "Aggregate Annual Assessment",
        "terseLabel": "Aggregate Annual Assessment"
       }
      }
     },
     "localname": "AggregateAnnualAssessment",
     "nsuri": "http://www.cardinal.com/20230331",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_AgreementsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement",
        "label": "Agreements [Axis]",
        "terseLabel": "Agreements [Axis]"
       }
      }
     },
     "localname": "AgreementsAxis",
     "nsuri": "http://www.cardinal.com/20230331",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cah_AgreementsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreements [Domain]",
        "label": "Agreements [Domain]",
        "terseLabel": "Agreements [Domain]"
       }
      }
     },
     "localname": "AgreementsDomain",
     "nsuri": "http://www.cardinal.com/20230331",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_AlamedaCountyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Alameda County [Member]",
        "label": "Alameda County [Member]",
        "terseLabel": "Alameda County [Member]"
       }
      }
     },
     "localname": "AlamedaCountyMember",
     "nsuri": "http://www.cardinal.com/20230331",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_Amortizationandotheracquisitionrelatedcosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of acquired intangible assets and changes in the fair value of contingent consideration obligations. This also represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.",
        "label": "Amortization and other acquisition-related costs",
        "terseLabel": "Amortization and other acquisition-related costs"
       }
      }
     },
     "localname": "Amortizationandotheracquisitionrelatedcosts",
     "nsuri": "http://www.cardinal.com/20230331",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_CARESActDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CARES Act",
        "label": "CARES Act [Domain]",
        "terseLabel": "Net Operating Loss Carryback [Domain]"
       }
      }
     },
     "localname": "CARESActDomain",
     "nsuri": "http://www.cardinal.com/20230331",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_CVSHealthMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CVS Health [Member]",
        "label": "CVS Health [Member]",
        "terseLabel": "CVS Health"
       }
      }
     },
     "localname": "CVSHealthMember",
     "nsuri": "http://www.cardinal.com/20230331",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_CardinalHealthAtHomeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cardinal Health At Home [Member]",
        "label": "Cardinal Health At Home [Member]",
        "terseLabel": "Cardinal Health At Home [Member]"
       }
      }
     },
     "localname": "CardinalHealthAtHomeMember",
     "nsuri": "http://www.cardinal.com/20230331",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_CareFusionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CareFusion [Member]",
        "label": "CareFusion [Member]",
        "terseLabel": "CareFusion [Member]"
       }
      }
     },
     "localname": "CareFusionMember",
     "nsuri": "http://www.cardinal.com/20230331",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_CarryingAmountofLongTermandotherShortTermBorrowings": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying Amount of Long-Term and other Short-Term Borrowings",
        "label": "Carrying Amount of Long-Term and other Short-Term Borrowings",
        "terseLabel": "Carrying Amount of Long-Term and other Short-Term Borrowings"
       }
      }
     },
     "localname": "CarryingAmountofLongTermandotherShortTermBorrowings",
     "nsuri": "http://www.cardinal.com/20230331",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_CashReclassifiedToAssetHeldForSale": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Reclassified to Asset Held for Sale",
        "label": "Cash Reclassified to Asset Held for Sale",
        "terseLabel": "Cash and equivalents reclassified from/(to) assets held for sale"
       }
      }
     },
     "localname": "CashReclassifiedToAssetHeldForSale",
     "nsuri": "http://www.cardinal.com/20230331",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_ClassActionLawsuitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Action Lawsuits [Member]",
        "label": "Class Action Lawsuits [Member]",
        "terseLabel": "Class Action Lawsuits [Member]"
       }
      }
     },
     "localname": "ClassActionLawsuitsMember",
     "nsuri": "http://www.cardinal.com/20230331",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_CommittedReceivablesSalesFacilityProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Committed receivables sales facility program that exists largely to provide liquidity by selling interests in trade receivables.",
        "label": "Committed Receivables Sales Facility Program [Member]",
        "terseLabel": "Committed Receivables Sales Facility Program [Member]"
       }
      }
     },
     "localname": "CommittedReceivablesSalesFacilityProgramMember",
     "nsuri": "http://www.cardinal.com/20230331",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails",
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_ContingentAttorneyFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent Attorney Fee",
        "label": "Contingent Attorney Fee",
        "terseLabel": "Contingent Attorney Fee"
       }
      }
     },
     "localname": "ContingentAttorneyFee",
     "nsuri": "http://www.cardinal.com/20230331",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_CordisDivestitureAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cordis Divestiture",
        "label": "Cordis Divestiture [Axis]",
        "terseLabel": "Cordis Divestiture [Axis]"
       }
      }
     },
     "localname": "CordisDivestitureAxis",
     "nsuri": "http://www.cardinal.com/20230331",
     "presentation": [
      "http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails",
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cah_CordisDivestitureDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cordis Divestiture [Domain]",
        "label": "Cordis Divestiture [Domain]",
        "terseLabel": "Cordis Divestiture [Domain]"
       }
      }
     },
     "localname": "CordisDivestitureDomain",
     "nsuri": "http://www.cardinal.com/20230331",
     "presentation": [
      "http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails",
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_CordisDivestitureMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cordis Divestiture",
        "label": "Cordis Divestiture [Member]",
        "terseLabel": "Cordis Divestiture"
       }
      }
     },
     "localname": "CordisDivestitureMember",
     "nsuri": "http://www.cardinal.com/20230331",
     "presentation": [
      "http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails",
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_DateInitiatedAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date Initiated",
        "label": "Date Initiated [Axis]",
        "terseLabel": "Effective Date [Axis]"
       }
      }
     },
     "localname": "DateInitiatedAxis",
     "nsuri": "http://www.cardinal.com/20230331",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cah_DateInitiatedDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date Initiated [Domain]",
        "label": "Date Initiated [Domain]",
        "terseLabel": "Date Initiated [Domain]"
       }
      }
     },
     "localname": "DateInitiatedDomain",
     "nsuri": "http://www.cardinal.com/20230331",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivatives, Hedge Discontinuances, Termination of Hedging Instrument, Notional Amount",
        "label": "Derivatives, Hedge Discontinuances, Termination of Hedging Instrument, Notional Amount",
        "terseLabel": "Derivatives, Hedge Discontinuances, Termination of Hedging Instrument, Notional Amount"
       }
      }
     },
     "localname": "DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount",
     "nsuri": "http://www.cardinal.com/20230331",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_DiscountRateFairValueInput": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount Rate, Fair Value Input",
        "label": "Discount Rate, Fair Value Input",
        "terseLabel": "Discount Rate, Fair Value Input"
       }
      }
     },
     "localname": "DiscountRateFairValueInput",
     "nsuri": "http://www.cardinal.com/20230331",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cah_FacilityExitAndOtherCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_RestructuringCharges",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility exit and other costs primarily consist of lease termination costs, accelerated depreciation, equipment relocation costs, project consulting fees and costs associated with restructuring our delivery of information technology infrastructure services.",
        "label": "Facility Exit and Other Costs",
        "terseLabel": "Facility Exit and Other Costs"
       }
      }
     },
     "localname": "FacilityExitAndOtherCosts",
     "nsuri": "http://www.cardinal.com/20230331",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails",
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_GoodwillImpairmentAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Goodwill Impairment",
        "label": "Goodwill Impairment [Axis]",
        "terseLabel": "Goodwill Impairment [Axis]"
       }
      }
     },
     "localname": "GoodwillImpairmentAxis",
     "nsuri": "http://www.cardinal.com/20230331",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cah_GoodwillImpairmentDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Goodwill Impairment [Domain]",
        "label": "Goodwill Impairment [Domain]",
        "terseLabel": "Goodwill Impairment [Domain]"
       }
      }
     },
     "localname": "GoodwillImpairmentDomain",
     "nsuri": "http://www.cardinal.com/20230331",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_GrossInsuranceSettlementBeforeAttorneyFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross Insurance Settlement Before Attorney Fees",
        "label": "Gross Insurance Settlement Before Attorney Fees",
        "terseLabel": "Gross Insurance Settlement Before Attorney Fees"
       }
      }
     },
     "localname": "GrossInsuranceSettlementBeforeAttorneyFees",
     "nsuri": "http://www.cardinal.com/20230331",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_IPRDTrademarksandOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Includes in process investigation of new knowledge useful in developing new product or service or new process or techniques or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for the improvements to existing product or process and rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style.",
        "label": "IPR&amp;D,TrademarksandOther [Member]",
        "terseLabel": "Trademarks and patents"
       }
      }
     },
     "localname": "IPRDTrademarksandOtherMember",
     "nsuri": "http://www.cardinal.com/20230331",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_IVCApril2023AgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "IVC April 2023 Agreement",
        "label": "IVC April 2023 Agreement [Member]",
        "terseLabel": "IVC April 2023 Agreement"
       }
      }
     },
     "localname": "IVCApril2023AgreementMember",
     "nsuri": "http://www.cardinal.com/20230331",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_IncomefromSettlementsofClassActionLawsuits": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income from Settlements of Class Action Lawsuits",
        "label": "Income from Settlements of Class Action Lawsuits",
        "terseLabel": "Income from Settlements of Class Action Lawsuits"
       }
      }
     },
     "localname": "IncomefromSettlementsofClassActionLawsuits",
     "nsuri": "http://www.cardinal.com/20230331",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_IndemnificationReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indemnification receivable from Patient recovery related to certain pre-acquisition tax exposures and transaction taxes.",
        "label": "Indemnification Receivable",
        "terseLabel": "Indemnification Receivable"
       }
      }
     },
     "localname": "IndemnificationReceivable",
     "nsuri": "http://www.cardinal.com/20230331",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_JudgmentForLostProfits": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Judgment for lost profits",
        "label": "Judgment for lost profits",
        "terseLabel": "Judgment for lost profits"
       }
      }
     },
     "localname": "JudgmentForLostProfits",
     "nsuri": "http://www.cardinal.com/20230331",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_June2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "June 2027",
        "label": "June 2027 [Member]",
        "terseLabel": "June 2027"
       }
      }
     },
     "localname": "June2027Member",
     "nsuri": "http://www.cardinal.com/20230331",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_LawsuitTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lawsuit Type [Axis]",
        "label": "Lawsuit Type [Axis]",
        "terseLabel": "Lawsuit Type [Axis]"
       }
      }
     },
     "localname": "LawsuitTypeAxis",
     "nsuri": "http://www.cardinal.com/20230331",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cah_LawsuitTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Lawsuit Type [Axis]",
        "label": "Lawsuit Type [Domain]",
        "terseLabel": "Lawsuit Type [Domain]"
       }
      }
     },
     "localname": "LawsuitTypeDomain",
     "nsuri": "http://www.cardinal.com/20230331",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_LongTermObligationsandOtherShortTermBorrowingsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-Term Obligations and Other Short-Term Borrowings [Abstract]",
        "label": "Long-Term Obligations and Other Short-Term Borrowings [Abstract]",
        "terseLabel": "Long-Term Obligations and Other Short-Term Borrowings [Abstract]"
       }
      }
     },
     "localname": "LongTermObligationsandOtherShortTermBorrowingsAbstract",
     "nsuri": "http://www.cardinal.com/20230331",
     "xbrltype": "stringItemType"
    },
    "cah_LossContingencyLawsuitsNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Lawsuits, Number",
        "label": "Loss Contingency, Lawsuits, Number",
        "verboseLabel": "Loss Contingency, Lawsuits, Number"
       }
      }
     },
     "localname": "LossContingencyLawsuitsNumber",
     "nsuri": "http://www.cardinal.com/20230331",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cah_March2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "March 2022",
        "label": "March 2022 [Member]",
        "terseLabel": "Effective March 2022"
       }
      }
     },
     "localname": "March2022Member",
     "nsuri": "http://www.cardinal.com/20230331",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_March2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "March 2025",
        "label": "March 2025 [Member]",
        "terseLabel": "March 2025"
       }
      }
     },
     "localname": "March2025Member",
     "nsuri": "http://www.cardinal.com/20230331",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_March2026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "March 2026",
        "label": "March 2026 [Member]",
        "terseLabel": "March 2026"
       }
      }
     },
     "localname": "March2026Member",
     "nsuri": "http://www.cardinal.com/20230331",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_MaturityDateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maturity Date",
        "label": "Maturity Date [Axis]",
        "terseLabel": "Maturity Date"
       }
      }
     },
     "localname": "MaturityDateAxis",
     "nsuri": "http://www.cardinal.com/20230331",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cah_MaturityDateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maturity Date [Domain]",
        "label": "Maturity Date [Domain]",
        "terseLabel": "Maturity Date [Domain]"
       }
      }
     },
     "localname": "MaturityDateDomain",
     "nsuri": "http://www.cardinal.com/20230331",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_MedicalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medical [Member]",
        "label": "Medical Member",
        "terseLabel": "Medical"
       }
      }
     },
     "localname": "MedicalMember",
     "nsuri": "http://www.cardinal.com/20230331",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_MedicalUnitGoodwillImpairmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medical Unit Goodwill Impairment",
        "label": "Medical Unit Goodwill Impairment [Member]",
        "terseLabel": "Medical Unit Goodwill Impairment [Member]"
       }
      }
     },
     "localname": "MedicalUnitGoodwillImpairmentMember",
     "nsuri": "http://www.cardinal.com/20230331",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_MedicalUnitMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medical Unit",
        "label": "Medical Unit [Member]",
        "terseLabel": "Medical Unit"
       }
      }
     },
     "localname": "MedicalUnitMember",
     "nsuri": "http://www.cardinal.com/20230331",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_MedicaldistributionandproductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medical distribution and products [Member]",
        "label": "Medical distribution and products [Member]",
        "terseLabel": "Medical distribution and products [Member]"
       }
      }
     },
     "localname": "MedicaldistributionandproductsMember",
     "nsuri": "http://www.cardinal.com/20230331",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_NarativeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Narative [Abstract]",
        "label": "Narative [Abstract]",
        "terseLabel": "Narative [Abstract]"
       }
      }
     },
     "localname": "NarativeAbstract",
     "nsuri": "http://www.cardinal.com/20230331",
     "xbrltype": "stringItemType"
    },
    "cah_NativeAmericanTribesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Native American tribes",
        "label": "Native American tribes [Member]",
        "terseLabel": "Native American tribes"
       }
      }
     },
     "localname": "NativeAmericanTribesMember",
     "nsuri": "http://www.cardinal.com/20230331",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_NetOperatingLossCarrybackAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Operating Loss Carryback",
        "label": "Net Operating Loss Carryback [Axis]",
        "terseLabel": "Net Operating Loss Carryback [Axis]"
       }
      }
     },
     "localname": "NetOperatingLossCarrybackAxis",
     "nsuri": "http://www.cardinal.com/20230331",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cah_Netproceedstaxwithholdingsfromsharebasedcompensation": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net cash inflow/(outflow) associated with the amount received from holders exercising their stock options and paid by the company to satisfy an employee's income tax withholding obligation when shares are withheld from settlement of a share-based award to cover taxes. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.",
        "label": "Net proceeds/(tax withholdings) from share-based compensation",
        "terseLabel": "Net tax proceeds/(withholdings) from share-based compensation"
       }
      }
     },
     "localname": "Netproceedstaxwithholdingsfromsharebasedcompensation",
     "nsuri": "http://www.cardinal.com/20230331",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_NewYorkOpioidStewardshipActMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "New York Opioid Stewardship Act",
        "label": "New York Opioid Stewardship Act [Member]",
        "terseLabel": "New York Opioid Stewardship Act [Member]"
       }
      }
     },
     "localname": "NewYorkOpioidStewardshipActMember",
     "nsuri": "http://www.cardinal.com/20230331",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_NotesPayableRepurchased": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Principal Amount of Notes Payable Repurchased during the quarter",
        "label": "Notes Payable Repurchased",
        "terseLabel": "Notes Payable Repurchased"
       }
      }
     },
     "localname": "NotesPayableRepurchased",
     "nsuri": "http://www.cardinal.com/20230331",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_NuclearPrecisionHealthSolutionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nuclear Precision Health Solutions",
        "label": "Nuclear Precision Health Solutions [Member]",
        "terseLabel": "Nuclear Precision Health Services [Member]"
       }
      }
     },
     "localname": "NuclearPrecisionHealthSolutionsMember",
     "nsuri": "http://www.cardinal.com/20230331",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_OpioidLawsuitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Opioid Lawsuits [Member]",
        "label": "Opioid Lawsuits [Member]",
        "terseLabel": "Opioid Lawsuits [Member]"
       }
      }
     },
     "localname": "OpioidLawsuitsMember",
     "nsuri": "http://www.cardinal.com/20230331",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_OpioidLitigationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Opioid Litigation",
        "label": "Opioid Litigation [Axis]",
        "terseLabel": "Opioid Litigation [Axis]"
       }
      }
     },
     "localname": "OpioidLitigationAxis",
     "nsuri": "http://www.cardinal.com/20230331",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cah_OpioidLitigationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Opioid Litigation [Domain]",
        "label": "Opioid Litigation [Domain]",
        "terseLabel": "Opioid Litigation [Domain]"
       }
      }
     },
     "localname": "OpioidLitigationDomain",
     "nsuri": "http://www.cardinal.com/20230331",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_OtherAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Agreements",
        "label": "Other Agreements [Member]",
        "terseLabel": "Other Agreements [Member]"
       }
      }
     },
     "localname": "OtherAgreementsMember",
     "nsuri": "http://www.cardinal.com/20230331",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_PharmaceuticalDistributionandSpecialtyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pharmaceutical Distribution and Specialty [Member]",
        "label": "Pharmaceutical Distribution and Specialty [Member]",
        "terseLabel": "Pharmaceutical Distribution and Specialty [Member]"
       }
      }
     },
     "localname": "PharmaceuticalDistributionandSpecialtyMember",
     "nsuri": "http://www.cardinal.com/20230331",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_PharmaceuticalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pharmaceutical [Member]",
        "label": "Pharmaceutical Member",
        "terseLabel": "Pharmaceutical"
       }
      }
     },
     "localname": "PharmaceuticalMember",
     "nsuri": "http://www.cardinal.com/20230331",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_PlaintiffTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plaintiff Type [Axis]",
        "label": "Plaintiff Type [Axis]",
        "terseLabel": "Plaintiff Type [Axis]"
       }
      }
     },
     "localname": "PlaintiffTypeAxis",
     "nsuri": "http://www.cardinal.com/20230331",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cah_PlaintiffTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Plaintiff Type [Axis]",
        "label": "Plaintiff Type [Domain]",
        "terseLabel": "Plaintiff Type [Domain]"
       }
      }
     },
     "localname": "PlaintiffTypeDomain",
     "nsuri": "http://www.cardinal.com/20230331",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_PrivatePartiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Private Parties [Member]",
        "label": "Private Parties [Member]",
        "terseLabel": "Private Parties [Member]"
       }
      }
     },
     "localname": "PrivatePartiesMember",
     "nsuri": "http://www.cardinal.com/20230331",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from sales of available-for-sale securities and other investments.",
        "label": "Proceeds from sale of available-for-sale securities and other investments",
        "terseLabel": "Proceeds from investments"
       }
      }
     },
     "localname": "Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments",
     "nsuri": "http://www.cardinal.com/20230331",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_ProductLiabilityLawsuitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product Liability Lawsuits [Member]",
        "label": "Product Liability Lawsuits [Member]",
        "terseLabel": "Product Liability Lawsuits"
       }
      }
     },
     "localname": "ProductLiabilityLawsuitsMember",
     "nsuri": "http://www.cardinal.com/20230331",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_ProjectCostsOnInvestmentAndOtherSpending": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment spending at the Corporate level. Investment spending generally includes the first year spend for certain projects that require incremental investments in the form of additional operating expenses.",
        "label": "Project Costs On Investment And Other Spending",
        "terseLabel": "Project costs on investment and other spending"
       }
      }
     },
     "localname": "ProjectCostsOnInvestmentAndOtherSpending",
     "nsuri": "http://www.cardinal.com/20230331",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_Purchaseofavailableforsalesecuritiesandotherinvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow from purchases of available-for-sale securities and other investments.",
        "label": "Purchase of available-for-sale securities and other investments",
        "negatedLabel": "Purchases of investments"
       }
      }
     },
     "localname": "Purchaseofavailableforsalesecuritiesandotherinvestments",
     "nsuri": "http://www.cardinal.com/20230331",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Line Items] for Segment Revenue from External Customers by Geographic Area [Table]",
        "label": "Segment Revenue from External Customers by Geographic Area [Line Items]",
        "terseLabel": "Segment Revenue from External Customers by Geographic Area [Line Items]"
       }
      }
     },
     "localname": "SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems",
     "nsuri": "http://www.cardinal.com/20230331",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Segment Revenue from External Customers by Geographic Area [Table]",
        "label": "Segment Revenue from External Customers by Geographic Area [Table]",
        "terseLabel": "Segment Revenue from External Customers by Geographic Area [Table]"
       }
      }
     },
     "localname": "SegmentRevenuefromExternalCustomersbyGeographicAreaTable",
     "nsuri": "http://www.cardinal.com/20230331",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cah_September2018Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "September 2018",
        "label": "September 2018 [Member]",
        "terseLabel": "Effective September 2018"
       }
      }
     },
     "localname": "September2018Member",
     "nsuri": "http://www.cardinal.com/20230331",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_September2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "September 2025",
        "label": "September 2025 [Member]",
        "terseLabel": "September 2025"
       }
      }
     },
     "localname": "September2025Member",
     "nsuri": "http://www.cardinal.com/20230331",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_SettlingStates": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Settling States",
        "label": "Settling States",
        "terseLabel": "Settling States"
       }
      }
     },
     "localname": "SettlingStates",
     "nsuri": "http://www.cardinal.com/20230331",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cah_SettlingUSTerritories": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Settling U.S Territories",
        "label": "Settling U.S Territories",
        "terseLabel": "Settling U.S Territories"
       }
      }
     },
     "localname": "SettlingUSTerritories",
     "nsuri": "http://www.cardinal.com/20230331",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cah_ShareholderDerivativeLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shareholder Derivative Litigation",
        "label": "Shareholder Derivative Litigation [Member]",
        "terseLabel": "Shareholder Derivative Litigation [Member]"
       }
      }
     },
     "localname": "ShareholderDerivativeLitigationMember",
     "nsuri": "http://www.cardinal.com/20230331",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_ShareholderSecuritiesLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shareholder Securities Litigation",
        "label": "Shareholder Securities Litigation [Member]",
        "terseLabel": "Shareholder Securities Litigation [Member]"
       }
      }
     },
     "localname": "ShareholderSecuritiesLitigationMember",
     "nsuri": "http://www.cardinal.com/20230331",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_SharesThatWouldBeAntidilutiveAsAResultOfNetLoss": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares that would be antidilutive as a result of net loss",
        "label": "Shares that would be antidilutive as a result of net loss",
        "terseLabel": "Shares that would be antidilutive as a result of net loss"
       }
      }
     },
     "localname": "SharesThatWouldBeAntidilutiveAsAResultOfNetLoss",
     "nsuri": "http://www.cardinal.com/20230331",
     "presentation": [
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cah_ShortTermCreditFacilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other short-term credit facilities and an unsecured line of credit",
        "label": "Short Term Credit Facilities Member",
        "terseLabel": "Short Term Credit Facilities Member"
       }
      }
     },
     "localname": "ShortTermCreditFacilitiesMember",
     "nsuri": "http://www.cardinal.com/20230331",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_TaxMatterAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Matter [Axis]",
        "label": "Tax Matter [Axis]",
        "terseLabel": "Tax Matter [Axis]"
       }
      }
     },
     "localname": "TaxMatterAxis",
     "nsuri": "http://www.cardinal.com/20230331",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cah_TaxMatterDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Tax Matter [Axis]",
        "label": "Tax Matter [Domain]",
        "terseLabel": "Tax Matter [Domain]"
       }
      }
     },
     "localname": "TaxMatterDomain",
     "nsuri": "http://www.cardinal.com/20230331",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_TaxMattersAgreementAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Matters Agreement [Axis]",
        "label": "Tax Matters Agreement [Axis]",
        "terseLabel": "Tax Matters Agreement [Axis]"
       }
      }
     },
     "localname": "TaxMattersAgreementAxis",
     "nsuri": "http://www.cardinal.com/20230331",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cah_TaxMattersAgreementDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Tax Matters Agreement [Axis]",
        "label": "Tax Matters Agreement [Domain]",
        "terseLabel": "Tax Matters Agreement [Domain]"
       }
      }
     },
     "localname": "TaxMattersAgreementDomain",
     "nsuri": "http://www.cardinal.com/20230331",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_TerminalGrowthRateFairValueInput": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Terminal Growth Rate, Fair Value Input",
        "label": "Terminal Growth Rate, Fair Value Input",
        "terseLabel": "Terminal Growth Rate, Fair Value Input"
       }
      }
     },
     "localname": "TerminalGrowthRateFairValueInput",
     "nsuri": "http://www.cardinal.com/20230331",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cah_TotalLongTermandShortTermObligations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total Long-Term and Short-Term Obligations",
        "label": "Total Long-Term and Short-Term Obligations",
        "terseLabel": "Total Long-Term and Short-Term Obligations"
       }
      }
     },
     "localname": "TotalLongTermandShortTermObligations",
     "nsuri": "http://www.cardinal.com/20230331",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails",
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_TotalOpioidLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total Opioid Litigation",
        "label": "Total Opioid Litigation [Member]",
        "terseLabel": "Total Opioid Litigation [Member]"
       }
      }
     },
     "localname": "TotalOpioidLitigationMember",
     "nsuri": "http://www.cardinal.com/20230331",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_TrademarksAndPatentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, and the exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.",
        "label": "Trademarks And Patents Member",
        "terseLabel": "Trademarks, trade names and patents"
       }
      }
     },
     "localname": "TrademarksAndPatentsMember",
     "nsuri": "http://www.cardinal.com/20230331",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_VestingPeriodinyearsforShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting Period in years for Shares",
        "label": "Vesting Period in years for Shares",
        "terseLabel": "Vesting Period in years for Shares"
       }
      }
     },
     "localname": "VestingPeriodinyearsforShares",
     "nsuri": "http://www.cardinal.com/20230331",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "UNITED STATES"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r697"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r698"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r695"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r695"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r695"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r699"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r695"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r695"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r695"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r695"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r694"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r696"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_ConsolidationItemsAxis": {
     "auth_ref": [
      "r224",
      "r257",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r274",
      "r278",
      "r332",
      "r333",
      "r334",
      "r335",
      "r337",
      "r338",
      "r340",
      "r342",
      "r343",
      "r739",
      "r740"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]",
        "terseLabel": "Consolidation Items [Axis]"
       }
      }
     },
     "localname": "ConsolidationItemsAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsDomain": {
     "auth_ref": [
      "r224",
      "r257",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r274",
      "r278",
      "r332",
      "r333",
      "r334",
      "r335",
      "r337",
      "r338",
      "r340",
      "r342",
      "r343",
      "r739",
      "r740"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Domain]",
        "terseLabel": "Consolidation Items [Domain]"
       }
      }
     },
     "localname": "ConsolidationItemsDomain",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r284",
      "r668",
      "r742",
      "r761",
      "r762"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r326",
      "r327",
      "r328",
      "r329",
      "r396",
      "r505",
      "r544",
      "r566",
      "r567",
      "r619",
      "r621",
      "r623",
      "r624",
      "r635",
      "r650",
      "r651",
      "r659",
      "r666",
      "r674",
      "r680",
      "r741",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r326",
      "r327",
      "r328",
      "r329",
      "r396",
      "r505",
      "r544",
      "r566",
      "r567",
      "r619",
      "r621",
      "r623",
      "r624",
      "r635",
      "r650",
      "r651",
      "r659",
      "r666",
      "r674",
      "r680",
      "r741",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r284",
      "r668",
      "r742",
      "r761",
      "r762"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r326",
      "r327",
      "r328",
      "r329",
      "r389",
      "r396",
      "r424",
      "r425",
      "r426",
      "r504",
      "r505",
      "r544",
      "r566",
      "r567",
      "r619",
      "r621",
      "r623",
      "r624",
      "r635",
      "r650",
      "r651",
      "r659",
      "r666",
      "r674",
      "r680",
      "r683",
      "r733",
      "r741",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r326",
      "r327",
      "r328",
      "r329",
      "r389",
      "r396",
      "r424",
      "r425",
      "r426",
      "r504",
      "r505",
      "r544",
      "r566",
      "r567",
      "r619",
      "r621",
      "r623",
      "r624",
      "r635",
      "r650",
      "r651",
      "r659",
      "r666",
      "r674",
      "r680",
      "r683",
      "r733",
      "r741",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r397",
      "r717"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast [Member]"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r237",
      "r397",
      "r701",
      "r717"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r282",
      "r283",
      "r562",
      "r563",
      "r564",
      "r620",
      "r622",
      "r625",
      "r636",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r654",
      "r667",
      "r683",
      "r742",
      "r761"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r282",
      "r283",
      "r562",
      "r563",
      "r564",
      "r620",
      "r622",
      "r625",
      "r636",
      "r639",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r654",
      "r667",
      "r683",
      "r742",
      "r761"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r237",
      "r397",
      "r701",
      "r702",
      "r717"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "stpr_AL": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ALABAMA",
        "terseLabel": "ALABAMA"
       }
      }
     },
     "localname": "AL",
     "nsuri": "http://xbrl.sec.gov/stpr/2023",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_GA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "GEORGIA",
        "terseLabel": "GEORGIA"
       }
      }
     },
     "localname": "GA",
     "nsuri": "http://xbrl.sec.gov/stpr/2023",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_OK": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "OKLAHOMA",
        "terseLabel": "OKLAHOMA"
       }
      }
     },
     "localname": "OK",
     "nsuri": "http://xbrl.sec.gov/stpr/2023",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_WA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "WASHINGTON",
        "terseLabel": "WASHINGTON"
       }
      }
     },
     "localname": "WA",
     "nsuri": "http://xbrl.sec.gov/stpr/2023",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_WV": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "WEST VIRGINIA",
        "terseLabel": "WEST VIRGINIA"
       }
      }
     },
     "localname": "WV",
     "nsuri": "http://xbrl.sec.gov/stpr/2023",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r28",
      "r679"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableCurrentAndNoncurrent": {
     "auth_ref": [
      "r114",
      "r759"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Accounts Payable",
        "terseLabel": "Accounts Payable"
       }
      }
     },
     "localname": "AccountsPayableCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r4",
      "r16",
      "r38",
      "r205",
      "r707",
      "r708"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, including the portion attributable to the noncontrolling interest.",
        "label": "Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Foreign Currency Translation Adjustments"
       }
      }
     },
     "localname": "AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r5",
      "r16",
      "r38"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges, including the portion attributable to the noncontrolling interest.",
        "label": "Accumulated Net Gain (Loss) from Cash Flow Hedges Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Unrealized Gain/(Loss) on Derivatives, net of tax"
       }
      }
     },
     "localname": "AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r37",
      "r38",
      "r134",
      "r194",
      "r520",
      "r549",
      "r550"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r2",
      "r16",
      "r38",
      "r470",
      "r473",
      "r499",
      "r545",
      "r546",
      "r706",
      "r707",
      "r708",
      "r714",
      "r715",
      "r716"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income/(Loss)",
        "verboseLabel": "AOCI Attributable to Parent"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net earnings/(loss) to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r428",
      "r436"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Total share-based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r11",
      "r55",
      "r60"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Potentially dilutive employee stock options, restricted share units and performance share units that were antidilutive (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r2",
      "r16",
      "r38",
      "r706",
      "r707",
      "r708"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, including the portion attributable to the noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AociIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r168",
      "r190",
      "r222",
      "r255",
      "r270",
      "r276",
      "r285",
      "r332",
      "r333",
      "r335",
      "r336",
      "r337",
      "r339",
      "r341",
      "r343",
      "r344",
      "r458",
      "r462",
      "r487",
      "r516",
      "r587",
      "r679",
      "r693",
      "r739",
      "r740",
      "r751"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "terseLabel": "Total assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r184",
      "r197",
      "r222",
      "r285",
      "r332",
      "r333",
      "r335",
      "r336",
      "r337",
      "r339",
      "r341",
      "r343",
      "r344",
      "r458",
      "r462",
      "r487",
      "r679",
      "r739",
      "r740",
      "r751"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "verboseLabel": "Basis of Presentation and Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r456",
      "r672",
      "r673"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r84",
      "r85",
      "r456",
      "r672",
      "r673"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r44",
      "r186",
      "r655"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r44",
      "r145",
      "r219"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and equivalents at end of period",
        "periodStartLabel": "Cash and equivalents at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r1",
      "r145"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net decrease in cash and equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowHedgingMember": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.",
        "label": "Cash Flow Hedging [Member]",
        "terseLabel": "Cash Flow Hedging [Member]"
       }
      }
     },
     "localname": "CashFlowHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1": {
     "auth_ref": [
      "r167"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement.",
        "label": "Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments",
        "terseLabel": "Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments"
       }
      }
     },
     "localname": "ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [
      "r191",
      "r192",
      "r193",
      "r250",
      "r373",
      "r374",
      "r375",
      "r377",
      "r380",
      "r385",
      "r387",
      "r552",
      "r553",
      "r554",
      "r555",
      "r666",
      "r700",
      "r711"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r158",
      "r685",
      "r686",
      "r687",
      "r690"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial Paper [Member]"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r156",
      "r323",
      "r324",
      "r640",
      "r735"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments, Contingent Liabilities and Litigation"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Declared",
        "terseLabel": "Cash dividends declared per common share"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareDeclared",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r681",
      "r682",
      "r683",
      "r685",
      "r686",
      "r687",
      "r690",
      "r714",
      "r715",
      "r747",
      "r763",
      "r765"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Number of Shares, Par Value and Other Disclosure [Abstract]",
        "terseLabel": "Common shares, without par value:"
       }
      }
     },
     "localname": "CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r129",
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common shares, authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "periodEndLabel": "Balance at end of period (in shares)",
        "periodStartLabel": "Balance at beginning of period (in shares)",
        "terseLabel": "Common shares, issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r129",
      "r519",
      "r679"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Authorized\u2014755 million shares, Issued\u2014327 million shares at March\u00a031, 2023 and June 30, 2022"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r39",
      "r202",
      "r204",
      "r212",
      "r512",
      "r531"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Total comprehensive income attributable to Cardinal Health, Inc."
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r92",
      "r164",
      "r202",
      "r204",
      "r211",
      "r511",
      "r530"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Total comprehensive income/(loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateNonSegmentMember": {
     "auth_ref": [
      "r21",
      "r269",
      "r270",
      "r271",
      "r272",
      "r278",
      "r720"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.",
        "label": "Corporate, Non-Segment [Member]",
        "terseLabel": "Corporate"
       }
      }
     },
     "localname": "CorporateNonSegmentMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r139",
      "r506"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of products sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails",
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails",
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrencySwapMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Swap involving the exchange of principal and interest in one currency for another currency.",
        "label": "Currency Swap [Member]",
        "terseLabel": "Currency Swap [Member]"
       }
      }
     },
     "localname": "CurrencySwapMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerRelationshipsMember": {
     "auth_ref": [
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.",
        "label": "Customer Relationships [Member]",
        "terseLabel": "Customer relationships"
       }
      }
     },
     "localname": "CustomerRelationshipsMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r157",
      "r220",
      "r345",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r361",
      "r368",
      "r369",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Long-Term Obligations and Other Short-Term Borrowings"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowings"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r25",
      "r126",
      "r127",
      "r169",
      "r170",
      "r224",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r352",
      "r357",
      "r358",
      "r359",
      "r360",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r498",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r712"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails",
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFairValue": {
     "auth_ref": [
      "r359",
      "r486",
      "r662",
      "r663"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.",
        "label": "Debt Instrument, Fair Value Disclosure",
        "terseLabel": "Estimated fair value"
       }
      }
     },
     "localname": "DebtInstrumentFairValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [
      "r224",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r352",
      "r357",
      "r358",
      "r359",
      "r360",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r370",
      "r498",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r712"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails",
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r32",
      "r224",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r352",
      "r357",
      "r358",
      "r359",
      "r360",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r498",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r712"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails",
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r32",
      "r72",
      "r75",
      "r110",
      "r111",
      "r113",
      "r115",
      "r160",
      "r161",
      "r224",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r352",
      "r357",
      "r358",
      "r359",
      "r360",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r370",
      "r498",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r712"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails",
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible": {
     "auth_ref": [
      "r82"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.",
        "label": "Decrease in Unrecognized Tax Benefits is Reasonably Possible",
        "terseLabel": "Estimated range of decrease in unrecognized tax benefits within the next 12 months"
       }
      }
     },
     "localname": "DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting, and liabilities classified as noncurrent and other.",
        "label": "Deferred Tax and Other Liabilities, Noncurrent",
        "terseLabel": "Deferred income taxes and other liabilities"
       }
      }
     },
     "localname": "DeferredTaxAndOtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r11",
      "r260"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetNotionalAmount": {
     "auth_ref": [
      "r626",
      "r629",
      "r631",
      "r633",
      "r744",
      "r745",
      "r746"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payments on the derivative asset.",
        "label": "Derivative Asset, Notional Amount",
        "terseLabel": "Derivative Asset, Notional Amount"
       }
      }
     },
     "localname": "DerivativeAssetNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet": {
     "auth_ref": [
      "r12"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair values as of the balance sheet date of the net amount of all assets and liabilities resulting from contracts that meet the criteria of being accounted for as derivative instruments.",
        "label": "Derivative Assets (Liabilities), at Fair Value, Net",
        "terseLabel": "Forward Contract"
       }
      }
     },
     "localname": "DerivativeAssetsLiabilitiesAtFairValueNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [
      "r565",
      "r567",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r588",
      "r589",
      "r590",
      "r591",
      "r602",
      "r603",
      "r604",
      "r605",
      "r608",
      "r609",
      "r610",
      "r611",
      "r626",
      "r628",
      "r632",
      "r634",
      "r681",
      "r683"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative, Name [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r100",
      "r102",
      "r103",
      "r106",
      "r565",
      "r567",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r588",
      "r589",
      "r590",
      "r591",
      "r602",
      "r603",
      "r604",
      "r605",
      "r608",
      "r609",
      "r610",
      "r611",
      "r626",
      "r628",
      "r632",
      "r634",
      "r657",
      "r681",
      "r683"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "auth_ref": [
      "r18",
      "r100",
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of hedging relationship.",
        "label": "Hedging Relationship [Axis]",
        "terseLabel": "Hedging Relationship [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet": {
     "auth_ref": [
      "r23",
      "r104"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The effective portion of net gain (loss) reclassified from accumulated other comprehensive income into income on derivative instruments designated and qualifying as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net",
        "terseLabel": "Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet": {
     "auth_ref": [
      "r105",
      "r704"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.",
        "label": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net",
        "terseLabel": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net"
       }
      }
     },
     "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilityNotionalAmount": {
     "auth_ref": [
      "r627",
      "r629",
      "r630",
      "r633",
      "r744",
      "r745",
      "r746"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payments on the derivative liability.",
        "label": "Derivative Liability, Notional Amount",
        "terseLabel": "Derivative Liability, Notional Amount"
       }
      }
     },
     "localname": "DerivativeLiabilityNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLineItems": {
     "auth_ref": [
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative [Line Items]",
        "terseLabel": "Derivative [Line Items]"
       }
      }
     },
     "localname": "DerivativeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeTable": {
     "auth_ref": [
      "r18",
      "r93",
      "r94",
      "r95",
      "r99",
      "r101",
      "r103",
      "r107",
      "r108",
      "r109",
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
        "label": "Derivative [Table]",
        "terseLabel": "Derivative [Table]"
       }
      }
     },
     "localname": "DerivativeTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Designated as Hedging Instrument [Member]",
        "terseLabel": "Designated as Hedging Instrument"
       }
      }
     },
     "localname": "DesignatedAsHedgingInstrumentMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.",
        "label": "Developed Technology Rights [Member]",
        "verboseLabel": "Developed technology and other"
       }
      }
     },
     "localname": "DevelopedTechnologyRightsMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r742"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Disaggregation of Revenue [Table Text Block]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r398",
      "r401",
      "r429",
      "r430",
      "r432",
      "r675"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "verboseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinued Operations and Disposal Groups [Abstract]"
       }
      }
     },
     "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": {
     "auth_ref": [
      "r116",
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]",
        "terseLabel": "Disposal Groups, Including Discontinued Operations, Disclosure"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/Divestitures"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "auth_ref": [
      "r672",
      "r673"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of disposal group.",
        "label": "Disposal Group Name [Domain]",
        "terseLabel": "Disposal Group Name [Domain]"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Dividends": {
     "auth_ref": [
      "r7",
      "r162"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.",
        "label": "Dividends",
        "negatedTerseLabel": "Dividends"
       }
      }
     },
     "localname": "Dividends",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic [Abstract]",
        "terseLabel": "Earnings/(Loss) per common share attributable to Cardinal Health, Inc.:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r238",
      "r246",
      "r247",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Earnings Per Share [Text Block]"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthInc"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r488"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "terseLabel": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective Income Tax Rate Reconciliation, Percent"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r431"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": {
     "auth_ref": [
      "r428"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Expense, Tax Benefit",
        "terseLabel": "Tax benefit related to share-based compensation"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeSeveranceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan.",
        "label": "Employee Severance [Member]",
        "terseLabel": "Employee- Related Costs"
       }
      }
     },
     "localname": "EmployeeSeveranceMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r17",
      "r180",
      "r205",
      "r206",
      "r207",
      "r225",
      "r226",
      "r227",
      "r229",
      "r234",
      "r236",
      "r249",
      "r286",
      "r287",
      "r388",
      "r433",
      "r434",
      "r435",
      "r447",
      "r448",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r477",
      "r489",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r499",
      "r545",
      "r546",
      "r547",
      "r560",
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FacilityClosingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Closing of a facility associated with exit from or disposal of business activities or restructurings pursuant to a plan.",
        "label": "Facility Closing [Member]",
        "terseLabel": "Facility Exit and Other Costs"
       }
      }
     },
     "localname": "FacilityClosingMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [
      "r480",
      "r481",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails",
      "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r480",
      "r481",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring",
        "verboseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails",
      "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r359",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r481",
      "r501",
      "r502",
      "r503",
      "r662",
      "r663",
      "r669",
      "r670",
      "r671"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails",
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r480",
      "r481",
      "r482",
      "r483",
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Disclosures"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueHedgingMember": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A hedge of the exposure to changes in the fair value of a recognized asset or liability, or of an unrecognized firm commitment, that are attributable to a particular risk.",
        "label": "Fair Value Hedging [Member]",
        "terseLabel": "Fair Value Hedging"
       }
      }
     },
     "localname": "FairValueHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r359",
      "r390",
      "r395",
      "r481",
      "r501",
      "r669",
      "r670",
      "r671"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level\u00a01"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r359",
      "r390",
      "r395",
      "r481",
      "r502",
      "r662",
      "r663",
      "r669",
      "r670",
      "r671"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2",
        "verboseLabel": "Level\u00a02"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails",
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r359",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r481",
      "r503",
      "r662",
      "r663",
      "r669",
      "r670",
      "r671"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level\u00a03"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r359",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r501",
      "r502",
      "r503",
      "r662",
      "r663",
      "r669",
      "r670",
      "r671"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails",
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r479",
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.",
        "label": "Financial Instruments Disclosure [Text Block]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "FinancialInstrumentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r188",
      "r305"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "terseLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r152"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "Estimated annual amortization of intangible assets - Year One"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year",
        "terseLabel": "Estimated annual amortization of intangible assets - Remainder of Fiscal Year"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r152"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "Estimated annual amortization of intangible assets - Year Four"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r152"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "Estimated annual amortization of intangible assets - Year Three"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r152"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "Estimated annual amortization of intangible assets - Year Two"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r302",
      "r304",
      "r305",
      "r307",
      "r507",
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r151",
      "r508"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Gross Intangible"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r56",
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "verboseLabel": "Finite-Lived Intangible Assets, Major Class Name"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r151",
      "r507"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "terseLabel": "Net Intangible"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Assets, Remaining Amortization Period",
        "terseLabel": "Weighted- Average Remaining Amortization Period (Years)"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ForeignExchangeContractMember": {
     "auth_ref": [
      "r657",
      "r669",
      "r678"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.",
        "label": "Foreign Exchange Contract [Member]",
        "terseLabel": "Foreign Exchange Contract [Member]"
       }
      }
     },
     "localname": "ForeignExchangeContractMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnSaleOfInvestments": {
     "auth_ref": [
      "r11"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities.",
        "label": "Gain (Loss) on Sale of Investments",
        "negatedTerseLabel": "(Gain)/loss on sale of equity interest in naviHealth"
       }
      }
     },
     "localname": "GainLossOnSaleOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfOtherInvestments": {
     "auth_ref": [
      "r11"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) included in earnings for investments classified as other.",
        "label": "Gain (Loss) on Sale of Other Investments",
        "negatedTerseLabel": "Impairments and loss on sale of other investments"
       }
      }
     },
     "localname": "GainLossOnSaleOfOtherInvestments",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges": {
     "auth_ref": [
      "r710"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 5.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value.",
        "label": "Gain (Loss) on Sale of Assets and Asset Impairment Charges",
        "negatedTerseLabel": "Impairments and (gain)/loss on disposal of assets, net"
       }
      }
     },
     "localname": "GainLossOnSalesOfAssetsAndAssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossRelatedToLitigationSettlement": {
     "auth_ref": [
      "r736"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 6.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.",
        "label": "Gain (Loss) Related to Litigation Settlement",
        "negatedLabel": "Loss Related to Litigation Settlement",
        "negatedTerseLabel": "Litigation (recoveries)/charges, net",
        "terseLabel": "Gain (Loss) Related to Litigation Settlement"
       }
      }
     },
     "localname": "GainLossRelatedToLitigationSettlement",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r11",
      "r67",
      "r68"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedLabel": "Gain (Loss) on Extinguishment of Debt",
        "negatedTerseLabel": "Loss on early extinguishment of debt"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings",
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r187",
      "r289",
      "r509",
      "r660",
      "r679",
      "r723",
      "r730"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "auth_ref": [
      "r293",
      "r660"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.",
        "label": "Goodwill, Acquired During Period",
        "terseLabel": "Goodwill acquired, net of purchase price adjustments"
       }
      }
     },
     "localname": "GoodwillAcquiredDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Goodwill and Other Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": {
     "auth_ref": [
      "r297"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Foreign Currency Translation Gain (Loss)",
        "negatedTerseLabel": "Foreign currency translation adjustments and other"
       }
      }
     },
     "localname": "GoodwillForeignCurrencyTranslationGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": {
     "auth_ref": [
      "r292",
      "r299",
      "r660"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impaired, Accumulated Impairment Loss",
        "terseLabel": "Goodwill, Impaired, Accumulated Impairment Loss"
       }
      }
     },
     "localname": "GoodwillImpairedAccumulatedImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r11",
      "r290",
      "r296",
      "r301",
      "r660"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "terseLabel": "Goodwill impairment"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillLineItems": {
     "auth_ref": [
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Goodwill [Line Items]",
        "terseLabel": "Goodwill [Line Items]"
       }
      }
     },
     "localname": "GoodwillLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Goodwill [Roll Forward]"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r138",
      "r222",
      "r255",
      "r269",
      "r275",
      "r278",
      "r285",
      "r332",
      "r333",
      "r335",
      "r336",
      "r337",
      "r339",
      "r341",
      "r343",
      "r344",
      "r487",
      "r658",
      "r739"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "Gross margin"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r18",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgingRelationshipDomain": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature or intent of a hedge.",
        "label": "Hedging Relationship [Domain]",
        "terseLabel": "Hedging Relationship [Domain]"
       }
      }
     },
     "localname": "HedgingRelationshipDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r0",
      "r136",
      "r174",
      "r255",
      "r269",
      "r275",
      "r278",
      "r514",
      "r525",
      "r658"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Earnings/(loss) before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": {
     "auth_ref": [
      "r135",
      "r173",
      "r175",
      "r213",
      "r228",
      "r230",
      "r231",
      "r232",
      "r233",
      "r241",
      "r243",
      "r244",
      "r478",
      "r513",
      "r760"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Basic Share",
        "terseLabel": "Basic (in shares)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": {
     "auth_ref": [
      "r135",
      "r213",
      "r228",
      "r230",
      "r231",
      "r232",
      "r233",
      "r241",
      "r243",
      "r244",
      "r245",
      "r478",
      "r513",
      "r760"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Diluted Share",
        "terseLabel": "Diluted (in shares)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "auth_ref": [
      "r672",
      "r673"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of disposal group.",
        "label": "Disposal Group Name [Axis]",
        "terseLabel": "Disposal Group Name [Axis]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "auth_ref": [
      "r14",
      "r19",
      "r26",
      "r117",
      "r118",
      "r119",
      "r120",
      "r121",
      "r122",
      "r123",
      "r124",
      "r125",
      "r155"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table]",
        "terseLabel": "Schedule of Assets and Liabilities Held for Sale [Table]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r308",
      "r314",
      "r598"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r314",
      "r598"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r223",
      "r437",
      "r441",
      "r445",
      "r446",
      "r449",
      "r451",
      "r454",
      "r455",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r178",
      "r179",
      "r235",
      "r236",
      "r263",
      "r439",
      "r450",
      "r532"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income Tax Expense (Benefit)",
        "verboseLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r10"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Increase in accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r10"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "Increase in inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Change in operating assets and liabilities, net of effects from acquisitions and divestitures:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": {
     "auth_ref": [
      "r10"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net",
        "negatedTerseLabel": "Other accrued liabilities and operating items, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingCapitalNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInReceivables": {
     "auth_ref": [
      "r10"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Receivables",
        "negatedTerseLabel": "Increase in trade receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInReceivables",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r303",
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-Lived Intangible Assets [Axis]",
        "terseLabel": "Indefinite-lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Indefinite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Indefinite-lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r153"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Net Intangible"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r57",
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InsuranceRecoveries": {
     "auth_ref": [
      "r140"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount recovered from insurance. These recoveries reduce costs and losses that are reported as a separate line item under operating expenses.",
        "label": "Insurance Recoveries",
        "terseLabel": "Insurance Recoveries"
       }
      }
     },
     "localname": "InsuranceRecoveries",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "auth_ref": [
      "r187"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "terseLabel": "Gross Intangible, Total other intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r54",
      "r58"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Net Intangible, Total other intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetIncludingGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.",
        "label": "Intangible Assets, Net (Including Goodwill)",
        "terseLabel": "Goodwill and other intangibles, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetIncludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r112",
      "r177",
      "r208",
      "r259",
      "r497",
      "r599",
      "r691",
      "r764"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "terseLabel": "Interest expense, net"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of nonoperating interest income (expense).",
        "label": "Interest Income (Expense), Nonoperating, Net",
        "terseLabel": "Interest Income (Expense), Nonoperating, Net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateSwapMember": {
     "auth_ref": [
      "r653",
      "r688",
      "r689"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.",
        "label": "Interest Rate Swap [Member]",
        "terseLabel": "Interest Rate Swap"
       }
      }
     },
     "localname": "InterestRateSwapMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r195",
      "r656",
      "r679"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories, net"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r480"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.",
        "label": "Investments, Fair Value Disclosure",
        "terseLabel": "Other investments"
       }
      }
     },
     "localname": "InvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LegalFees": {
     "auth_ref": [
      "r140"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.",
        "label": "Legal Fees",
        "terseLabel": "Legal Fees"
       }
      }
     },
     "localname": "LegalFees",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r133",
      "r172",
      "r523",
      "r679",
      "r713",
      "r721",
      "r748"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and shareholders\u2019 deficit"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Shareholders\u2019 Deficit"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r31",
      "r185",
      "r222",
      "r285",
      "r332",
      "r333",
      "r335",
      "r336",
      "r337",
      "r339",
      "r341",
      "r343",
      "r344",
      "r459",
      "r462",
      "r463",
      "r487",
      "r679",
      "r739",
      "r751",
      "r752"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityAverageOutstandingAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average amount borrowed under the credit facility during the period.",
        "label": "Line of Credit Facility, Average Outstanding Amount",
        "terseLabel": "Line of Credit Facility, Average Outstanding Amount"
       }
      }
     },
     "localname": "LineOfCreditFacilityAverageOutstandingAmount",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount borrowed under the credit facility at any time during the period.",
        "label": "Line of Credit Facility, Maximum Amount Outstanding During Period",
        "terseLabel": "Line of Credit Facility, Maximum Amount Outstanding During Period"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r29"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Line of Credit Facility, Maximum Borrowing Capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationReserve": {
     "auth_ref": [
      "r33",
      "r736"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs.",
        "label": "Estimated Litigation Liability",
        "terseLabel": "Estimated Litigation Liability"
       }
      }
     },
     "localname": "LitigationReserve",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationReserveCurrent": {
     "auth_ref": [
      "r33",
      "r736"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position.",
        "label": "Estimated Litigation Liability, Current",
        "terseLabel": "Estimated Litigation Liability, Current"
       }
      }
     },
     "localname": "LitigationReserveCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligations": {
     "auth_ref": [
      "r25",
      "r517"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent.",
        "label": "Long-Term Debt and Lease Obligation",
        "terseLabel": "Long-term obligations, less current portion",
        "verboseLabel": "Long-term Debt and Lease Obligation"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligations",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt and lease obligation, classified as current.",
        "label": "Long-Term Debt and Lease Obligation, Current",
        "terseLabel": "Current portion of long-term obligations and other short-term borrowings",
        "verboseLabel": "Long-term Debt and Lease Obligation, Current"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligationsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r32",
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-Term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongtermPurchaseCommitmentPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period covered by the long-term purchase commitment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Long-Term Purchase Commitment, Period",
        "terseLabel": "Long-term Purchase Commitment, Period"
       }
      }
     },
     "localname": "LongtermPurchaseCommitmentPeriod",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LossContingenciesByNatureOfContingencyAxis": {
     "auth_ref": [
      "r325",
      "r326",
      "r327",
      "r331",
      "r737",
      "r738"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.",
        "label": "Loss Contingency Nature [Axis]",
        "terseLabel": "Loss Contingency Nature [Axis]"
       }
      }
     },
     "localname": "LossContingenciesByNatureOfContingencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [
      "r325",
      "r326",
      "r327",
      "r331",
      "r737",
      "r738"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r325",
      "r326",
      "r327",
      "r331",
      "r737",
      "r738"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "auth_ref": [
      "r325",
      "r701"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss contingency liability.",
        "label": "Loss Contingency Accrual",
        "terseLabel": "Loss Contingency Accrual"
       }
      }
     },
     "localname": "LossContingencyAccrualAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease": {
     "auth_ref": [
      "r736"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in loss contingency liability.",
        "label": "Loss Contingency Accrual, Period Increase (Decrease)",
        "negatedTerseLabel": "Loss Contingency Accrual, Period Increase (Decrease)"
       }
      }
     },
     "localname": "LossContingencyAccrualCarryingValuePeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyAccrualPayments": {
     "auth_ref": [
      "r736"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow reducing loss contingency liability.",
        "label": "Loss Contingency Accrual, Payments",
        "terseLabel": "Loss Contingency Accrual, Payments"
       }
      }
     },
     "localname": "LossContingencyAccrualPayments",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyClaimsSettledNumber": {
     "auth_ref": [
      "r737",
      "r738"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of claims settled.",
        "label": "Loss Contingency, Claims Settled, Number",
        "terseLabel": "Loss Contingency, Claims Settled, Number"
       }
      }
     },
     "localname": "LossContingencyClaimsSettledNumber",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LossContingencyEstimateOfPossibleLoss": {
     "auth_ref": [
      "r326",
      "r327",
      "r330",
      "r331"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.",
        "label": "Loss Contingency, Estimate of Possible Loss",
        "terseLabel": "Loss Contingency, Estimate of Possible Loss"
       }
      }
     },
     "localname": "LossContingencyEstimateOfPossibleLoss",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyNatureDomain": {
     "auth_ref": [
      "r325",
      "r326",
      "r327",
      "r331",
      "r737",
      "r738"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.",
        "label": "Loss Contingency, Nature [Domain]",
        "terseLabel": "Loss Contingency, Nature [Domain]"
       }
      }
     },
     "localname": "LossContingencyNatureDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencyNumberOfPlaintiffs": {
     "auth_ref": [
      "r737",
      "r738"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of plaintiffs that have filed claims pertaining to a loss contingency.",
        "label": "Loss Contingency, Number of Plaintiffs",
        "terseLabel": "Loss Contingency, Number of Plaintiffs"
       }
      }
     },
     "localname": "LossContingencyNumberOfPlaintiffs",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LossContingencyPendingClaimsNumber": {
     "auth_ref": [
      "r737",
      "r738"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of pending claims pertaining to a loss contingency.",
        "label": "Loss Contingency, Pending Claims, Number",
        "terseLabel": "Loss Contingency, Pending Claims, Number"
       }
      }
     },
     "localname": "LossContingencyPendingClaimsNumber",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r36",
      "r171",
      "r222",
      "r285",
      "r332",
      "r335",
      "r336",
      "r337",
      "r343",
      "r344",
      "r487",
      "r522",
      "r577"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity.",
        "label": "Equity, Attributable to Noncontrolling Interest",
        "terseLabel": "Noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDecreaseFromRedemptions": {
     "auth_ref": [
      "r89",
      "r162",
      "r165"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).",
        "label": "Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests",
        "terseLabel": "Treasury shares acquired, average price per share (in usd per share)"
       }
      }
     },
     "localname": "MinorityInterestDecreaseFromRedemptions",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r217"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash used in financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r217"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by/(used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r145",
      "r146",
      "r147"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r137",
      "r147",
      "r176",
      "r183",
      "r200",
      "r203",
      "r207",
      "r222",
      "r228",
      "r230",
      "r231",
      "r232",
      "r233",
      "r235",
      "r236",
      "r242",
      "r255",
      "r269",
      "r275",
      "r278",
      "r285",
      "r332",
      "r333",
      "r335",
      "r336",
      "r337",
      "r339",
      "r341",
      "r343",
      "r344",
      "r478",
      "r487",
      "r528",
      "r595",
      "r612",
      "r613",
      "r658",
      "r691",
      "r739"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net earnings/(loss) attributable to Cardinal Health, Inc."
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r91",
      "r166",
      "r200",
      "r203",
      "r235",
      "r236",
      "r527",
      "r708"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      },
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "negatedTerseLabel": "Less: Net earnings attributable to noncontrolling interests"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetInvestmentHedgingMember": {
     "auth_ref": [
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedges of a net investment in a foreign operation.",
        "label": "Net Investment Hedging [Member]",
        "terseLabel": "Net Investment Hedging [Member]"
       }
      }
     },
     "localname": "NetInvestmentHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Financial Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [
      "r766",
      "r767",
      "r768",
      "r769"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "Non-US [Member]"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r87",
      "r388",
      "r714",
      "r715",
      "r716",
      "r765"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Noncontrolling Interest"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NondesignatedMember": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Not Designated as Hedging Instrument [Member]",
        "terseLabel": "Not Designated as Hedging Instrument [Member]"
       }
      }
     },
     "localname": "NondesignatedMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r719"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r719"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r255",
      "r269",
      "r275",
      "r278",
      "r658"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "terseLabel": "Total operating earnings",
        "totalLabel": "Operating earnings/(loss)"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingSegmentsMember": {
     "auth_ref": [
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Operating Segments [Member]",
        "terseLabel": "Operating Segments"
       }
      }
     },
     "localname": "OperatingSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other accrued liabilities"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r196",
      "r679"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Prepaid expenses and other"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r189"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": {
     "auth_ref": [
      "r24",
      "r38",
      "r206",
      "r489",
      "r492",
      "r495",
      "r706"
     ],
     "calculation": {
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax",
        "verboseLabel": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": {
     "auth_ref": [
      "r198",
      "r199"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax",
        "terseLabel": "Net unrealized gain on derivative instruments, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": {
     "auth_ref": [
      "r198",
      "r199",
      "r464",
      "r465",
      "r468"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax",
        "terseLabel": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r3"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Foreign currency translation adjustments and other"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax": {
     "auth_ref": [
      "r466"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.",
        "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax",
        "terseLabel": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r17",
      "r24",
      "r201",
      "r204",
      "r210",
      "r489",
      "r490",
      "r495",
      "r510",
      "r529",
      "r706",
      "r707"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other Comprehensive Income (Loss), Net of Tax",
        "totalLabel": "Total other comprehensive income/(loss), net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive income/(loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r8",
      "r15",
      "r164",
      "r201",
      "r204"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossTax": {
     "auth_ref": [
      "r6",
      "r205",
      "r210",
      "r439",
      "r452",
      "r453",
      "r489",
      "r493",
      "r495",
      "r510",
      "r529"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Tax",
        "terseLabel": "Other Comprehensive Income (Loss), Tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r142"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "negatedLabel": "Other (income)/expense, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other nonoperating income (expense).",
        "label": "Other Nonoperating Income (Expense) [Member]",
        "terseLabel": "Other Nonoperating Income (Expense) [Member]"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherShortTermBorrowings": {
     "auth_ref": [
      "r27",
      "r574"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of borrowings classified as other, maturing within one year or the normal operating cycle, if longer.",
        "label": "Other Short-Term Borrowings",
        "terseLabel": "Other Short-term Borrowings"
       }
      }
     },
     "localname": "OtherShortTermBorrowings",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForLegalSettlements": {
     "auth_ref": [
      "r9"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid for the settlement of litigation or for other legal issues during the period.",
        "label": "Payments for Legal Settlements",
        "terseLabel": "Payments for Legal Settlements"
       }
      }
     },
     "localname": "PaymentsForLegalSettlements",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedTerseLabel": "Purchase of treasury shares",
        "terseLabel": "Purchase of treasury shares"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRestructuring": {
     "auth_ref": [
      "r313",
      "r709"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.",
        "label": "Payments for Restructuring",
        "negatedLabel": "Payments and other adjustments"
       }
      }
     },
     "localname": "PaymentsForRestructuring",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDividendsCommonStock": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.",
        "label": "Payments of Ordinary Dividends, Common Stock",
        "negatedLabel": "Dividends on common shares"
       }
      }
     },
     "localname": "PaymentsOfDividendsCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "terseLabel": "Acquisition of subsidiaries, net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r144"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Additions to property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance Share Units",
        "verboseLabel": "Performance Share Unit"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Number of Shares, Par Value and Other Disclosure [Abstract]",
        "terseLabel": "Preferred shares, without par value:"
       }
      }
     },
     "localname": "PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r128",
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred shares, authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r128",
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred shares, issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r128",
      "r518",
      "r679"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Authorized\u2014500 thousand shares, Issued\u2014none"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromDivestitureOfBusinesses": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.",
        "label": "Proceeds from Divestiture of Businesses",
        "terseLabel": "Proceeds from divestitures, net of cash sold"
       }
      }
     },
     "localname": "ProceedsFromDivestitureOfBusinesses",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromHedgeInvestingActivities": {
     "auth_ref": [
      "r218",
      "r703"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow for a financial contract that meets the hedge criteria as either a cash flow hedge, fair value hedge, or hedge of a net investment in a foreign operation.",
        "label": "Proceeds from Hedge, Investing Activities",
        "terseLabel": "Proceeds from net investment hedge terminations"
       }
      }
     },
     "localname": "ProceedsFromHedgeInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromInsuranceSettlementOperatingActivities": {
     "auth_ref": [
      "r216",
      "r652"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow for proceeds from settlement of insurance claim, classified as operating activities. Excludes insurance settlement classified as investing activities.",
        "label": "Proceeds from Insurance Settlement, Operating Activities",
        "terseLabel": "Proceeds from Insurance Settlement, Operating Activities"
       }
      }
     },
     "localname": "ProceedsFromInsuranceSettlementOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "auth_ref": [
      "r143"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "terseLabel": "Proceeds from disposal of property and equipment"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductLiabilityAccrualPeriodExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of loss reported during the period pertaining to product liability.",
        "label": "Product Liability Accrual, Period Expense",
        "terseLabel": "Product Liability Accrual, Period Expense"
       }
      }
     },
     "localname": "ProductLiabilityAccrualPeriodExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r183",
      "r200",
      "r203",
      "r215",
      "r222",
      "r228",
      "r235",
      "r236",
      "r255",
      "r269",
      "r275",
      "r278",
      "r285",
      "r332",
      "r333",
      "r335",
      "r336",
      "r337",
      "r339",
      "r341",
      "r343",
      "r344",
      "r457",
      "r460",
      "r461",
      "r478",
      "r487",
      "r514",
      "r526",
      "r559",
      "r595",
      "r612",
      "r613",
      "r658",
      "r676",
      "r677",
      "r692",
      "r708",
      "r739"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net earnings/(loss)",
        "totalLabel": "Net earnings/(loss)",
        "verboseLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r13",
      "r515",
      "r524",
      "r679"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r214",
      "r288"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "terseLabel": "Provision for bad debts"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesNetCurrent": {
     "auth_ref": [
      "r679"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.",
        "label": "Receivables, Net, Current",
        "terseLabel": "Trade receivables, net"
       }
      }
     },
     "localname": "ReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]",
        "terseLabel": "Reclassification Adjustment out of Accumulated Other Comprehensive Loss [Rollforward]"
       }
      }
     },
     "localname": "ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": {
     "auth_ref": [
      "r24",
      "r38",
      "r206",
      "r489",
      "r494",
      "r495",
      "r706"
     ],
     "calculation": {
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).",
        "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax",
        "negatedTerseLabel": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]",
        "terseLabel": "AOCI, Net of Tax [Roll Forward]"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about items reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Table]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Loss [Table]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock": {
     "auth_ref": [
      "r51",
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets.",
        "label": "Reconciliation of Assets from Segment to Consolidated [Table Text Block]",
        "terseLabel": "Assets by Reportable Segment"
       }
      }
     },
     "localname": "ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable": {
     "auth_ref": [
      "r50",
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.",
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]",
        "terseLabel": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]"
       }
      }
     },
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": {
     "auth_ref": [
      "r50",
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.",
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]",
        "terseLabel": "Segment Profit by Reportable Segment"
       }
      }
     },
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable": {
     "auth_ref": [
      "r49",
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification, description, and amounts of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues.",
        "label": "Reconciliation of Revenue from Segments to Consolidated [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ReconciliationOfRevenueFromSegmentsToConsolidatedTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r43",
      "r555"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-Term Debt",
        "negatedTerseLabel": "Reduction of long-term obligations"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "auth_ref": [
      "r43"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.",
        "label": "Repayments of Notes Payable",
        "terseLabel": "Repayments of Notes Payable"
       }
      }
     },
     "localname": "RepaymentsOfNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReportingUnitAxis": {
     "auth_ref": [
      "r300",
      "r301",
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by reporting unit.",
        "label": "Reporting Unit [Axis]",
        "terseLabel": "Reporting Unit [Axis]"
       }
      }
     },
     "localname": "ReportingUnitAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReportingUnitDomain": {
     "auth_ref": [
      "r300",
      "r301",
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Level of reporting at which goodwill is tested for impairment.",
        "label": "Reporting Unit [Domain]",
        "terseLabel": "Reporting Unit [Domain]"
       }
      }
     },
     "localname": "ReportingUnitDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of fair value of reporting unit in excess of carrying amount.",
        "label": "Reporting Unit, Percentage of Fair Value in Excess of Carrying Amount",
        "terseLabel": "Reporting Unit, Percentage of Fair Value in Excess of Carrying Amount"
       }
      }
     },
     "localname": "ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Share Units",
        "verboseLabel": "Restricted Share Unit"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r310",
      "r311",
      "r313",
      "r316",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "terseLabel": "Restructuring and Employee Severance"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeverance"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r11",
      "r317",
      "r319",
      "r734"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      },
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Charges",
        "terseLabel": "Restructuring and employee severance",
        "totalLabel": "Total restructuring and employee severance"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings",
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringChargesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Charges [Abstract]",
        "terseLabel": "Restructuring Charges [Abstract]"
       }
      }
     },
     "localname": "RestructuringChargesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "auth_ref": [
      "r312",
      "r313",
      "r319",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of restructuring cost.",
        "label": "Restructuring Type [Axis]",
        "terseLabel": "Restructuring Type [Axis]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "auth_ref": [
      "r312",
      "r313",
      "r314",
      "r315",
      "r319",
      "r320",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "terseLabel": "Restructuring Cost and Reserve [Line Items]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails",
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCosts": {
     "auth_ref": [
      "r11"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Costs",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "RestructuringCosts",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringPlanAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by individual restructuring plan.",
        "label": "Restructuring Plan [Axis]",
        "terseLabel": "Restructuring Plan [Axis]"
       }
      }
     },
     "localname": "RestructuringPlanAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringPlanDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the individual restructuring plans.",
        "label": "Restructuring Plan [Domain]",
        "terseLabel": "Restructuring Plan [Domain]"
       }
      }
     },
     "localname": "RestructuringPlanDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringReserve": {
     "auth_ref": [
      "r313",
      "r318"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.",
        "label": "Restructuring Reserve",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance"
       }
      }
     },
     "localname": "RestructuringReserve",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringReserveRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Restructuring Reserve [Roll Forward]",
        "terseLabel": "Restructuring Reserve [Roll Forward]"
       }
      }
     },
     "localname": "RestructuringReserveRollForward",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r130",
      "r162",
      "r521",
      "r548",
      "r550",
      "r556",
      "r576",
      "r679"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated undistributed earnings (deficit).",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r180",
      "r225",
      "r226",
      "r227",
      "r229",
      "r234",
      "r236",
      "r286",
      "r287",
      "r433",
      "r434",
      "r435",
      "r447",
      "r448",
      "r469",
      "r471",
      "r472",
      "r474",
      "r477",
      "r545",
      "r547",
      "r560",
      "r765"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated undistributed earnings (deficit).",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.",
        "label": "Revenue from External Customers by Geographic Areas [Table Text Block]",
        "terseLabel": "Revenue from External Customers by Geographic Areas [Table Text Block]"
       }
      }
     },
     "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r209",
      "r222",
      "r256",
      "r257",
      "r268",
      "r273",
      "r274",
      "r280",
      "r282",
      "r284",
      "r285",
      "r332",
      "r333",
      "r335",
      "r336",
      "r337",
      "r339",
      "r341",
      "r343",
      "r344",
      "r487",
      "r514",
      "r739"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Revenue",
        "verboseLabel": "Total revenue"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings",
      "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Revolving Credit Facility [Member]"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r38",
      "r749",
      "r750"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of Changes in the Balance of Accumulated Other Comprehensive Loss by Component and in Total"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.",
        "label": "Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]",
        "terseLabel": "Schedule of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings Compared to the Respective Carrying Amount"
       }
      }
     },
     "localname": "ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]",
        "terseLabel": "Schedule of Total Share-based Compensation Expense by Type of Award"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r480",
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r56",
      "r59",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r56",
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "auth_ref": [
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.",
        "label": "Schedule of Goodwill [Table]",
        "terseLabel": "Goodwill [Table]"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r660",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Schedule of Goodwill by Reportable Segment"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r20",
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity.",
        "label": "Schedule of Indefinite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Indefinite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested performance-based units.",
        "label": "Schedule of Nonvested Performance-Based Units Activity [Table Text Block]",
        "terseLabel": "Schedule of Transactions Related to Performance Share Units Under the Plans"
       }
      }
     },
     "localname": "ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r312",
      "r313",
      "r314",
      "r315",
      "r319",
      "r320",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "terseLabel": "Schedule of Restructuring and Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails",
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": {
     "auth_ref": [
      "r61",
      "r63",
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.",
        "label": "Restructuring and Related Costs [Table Text Block]",
        "terseLabel": "Summary of Restructuring and Employee Severance"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": {
     "auth_ref": [
      "r62",
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.",
        "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]",
        "terseLabel": "Schedule of Activity Related to Liabilities Associated with Restructuring and Employee Severance"
       }
      }
     },
     "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r46",
      "r47",
      "r48",
      "r53"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r399",
      "r400",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Schedule of Transactions Related to Restricted Share Units Under the Plans"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r69",
      "r70",
      "r71",
      "r72",
      "r73",
      "r74",
      "r75",
      "r160",
      "r161",
      "r162",
      "r191",
      "r192",
      "r193",
      "r250",
      "r373",
      "r374",
      "r375",
      "r377",
      "r380",
      "r385",
      "r387",
      "r552",
      "r553",
      "r554",
      "r555",
      "r666",
      "r700",
      "r711"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).",
        "label": "Schedule of Weighted Average Number of Shares [Table Text Block]",
        "terseLabel": "Reconciliation of Common Shares Used to Compute Basic and Diluted Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r252",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r278",
      "r284",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r315",
      "r321",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r660",
      "r705",
      "r761"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r267",
      "r272",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]",
        "terseLabel": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r141"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Distribution, selling, general and administrative expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SeveranceCosts1": {
     "auth_ref": [
      "r11"
     ],
     "calculation": {
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_RestructuringCharges",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.",
        "label": "Severance Costs",
        "verboseLabel": "Employee-related costs"
       }
      }
     },
     "localname": "SeveranceCosts1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails",
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r10"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r675"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Award vesting period (in years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedTerseLabel": "Canceled and forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Canceled and forfeited (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r413",
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Nonvested at end of period (in shares)",
        "periodStartLabel": "Nonvested at beginning of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Restricted Share Units",
        "verboseLabel": "Performance Share Units"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r413",
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Nonvested at end of period (in usd per share)",
        "periodStartLabel": "Nonvested at beginning of period (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted-Average Grant Date Fair Value per Share",
        "verboseLabel": "Weighted-Average Grant Date Fair Value per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedTerseLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [
      "r399",
      "r400",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareRepurchaseProgramAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by share repurchase program.",
        "label": "Share Repurchase Program [Axis]",
        "terseLabel": "Share Repurchase Program [Axis]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareRepurchaseProgramDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the share repurchase program.",
        "label": "Share Repurchase Program [Domain]",
        "terseLabel": "Share Repurchase Program [Domain]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r743"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Target performance goal (as a percent)",
        "verboseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r182",
      "r252",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r278",
      "r284",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r309",
      "r315",
      "r321",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r660",
      "r705",
      "r761"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]",
        "verboseLabel": "Operating and Reportable Segment"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r17",
      "r35",
      "r180",
      "r205",
      "r206",
      "r207",
      "r225",
      "r226",
      "r227",
      "r229",
      "r234",
      "r236",
      "r249",
      "r286",
      "r287",
      "r388",
      "r433",
      "r434",
      "r435",
      "r447",
      "r448",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r477",
      "r489",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r499",
      "r545",
      "r546",
      "r547",
      "r560",
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [
      "r225",
      "r226",
      "r227",
      "r249",
      "r506",
      "r551",
      "r561",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r575",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r594",
      "r596",
      "r597",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r614",
      "r684"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "verboseLabel": "Statement of Stockholders' Equity"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r225",
      "r226",
      "r227",
      "r249",
      "r506",
      "r551",
      "r561",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r575",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r594",
      "r596",
      "r597",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r614",
      "r684"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r17",
      "r128",
      "r129",
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r80",
      "r128",
      "r129",
      "r162"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r129",
      "r131",
      "r132",
      "r149",
      "r577",
      "r593",
      "r615",
      "r616",
      "r679",
      "r693",
      "r713",
      "r721",
      "r748",
      "r765"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.",
        "label": "Equity, Attributable to Parent",
        "totalLabel": "Total Cardinal Health, Inc. shareholders' deficit"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent [Abstract]",
        "terseLabel": "Shareholders\u2019 deficit:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r87",
      "r88",
      "r90",
      "r180",
      "r181",
      "r206",
      "r225",
      "r226",
      "r227",
      "r229",
      "r234",
      "r286",
      "r287",
      "r388",
      "r433",
      "r434",
      "r435",
      "r447",
      "r448",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r477",
      "r489",
      "r491",
      "r495",
      "r499",
      "r546",
      "r547",
      "r558",
      "r577",
      "r593",
      "r615",
      "r616",
      "r637",
      "r692",
      "r713",
      "r721",
      "r748",
      "r765"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.",
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at beginning of period",
        "totalLabel": "Total shareholders\u2019 deficit"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r159",
      "r221",
      "r372",
      "r374",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r386",
      "r388",
      "r476",
      "r617",
      "r618",
      "r638"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for equity.",
        "label": "Equity [Text Block]",
        "terseLabel": "Shareholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityOther": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.",
        "label": "Stockholders' Equity, Other",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "StockholdersEquityOther",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityOtherShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of increase (decrease) in shares of stock classified as other.",
        "label": "Stockholders' Equity, Other Shares",
        "terseLabel": "Stockholders' Equity, Other Shares"
       }
      }
     },
     "localname": "StockholdersEquityOtherShares",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SubsegmentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business subsegments.",
        "label": "Subsegments [Axis]",
        "terseLabel": "Subsegments [Axis]"
       }
      }
     },
     "localname": "SubsegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsegmentsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Divisions of a component of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Subsegments [Domain]",
        "terseLabel": "Subsegments [Domain]"
       }
      }
     },
     "localname": "SubsegmentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r496",
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r496",
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r496",
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxCreditCarryforwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Tax Credit Carryforward [Line Items]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "TaxCreditCarryforwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardTable": {
     "auth_ref": [
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A listing of tax credit carryforwards available to reduce future taxable income including descriptions, amounts, expiration dates, limitations on use and the related deferred tax assets and valuation allowances.",
        "label": "Tax Credit Carryforward [Table]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "TaxCreditCarryforwardTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TreasuryStockAcquiredAverageCostPerShare": {
     "auth_ref": [
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased.",
        "label": "Shares Acquired, Average Cost Per Share",
        "terseLabel": "Treasury shares acquired, average price per share (in usd per share)"
       }
      }
     },
     "localname": "TreasuryStockAcquiredAverageCostPerShare",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_TreasuryStockCommonMember": {
     "auth_ref": [
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common [Member]",
        "terseLabel": "Treasury Stock, Common",
        "verboseLabel": "Treasury Shares"
       }
      }
     },
     "localname": "TreasuryStockCommonMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockCommonShares": {
     "auth_ref": [
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common, Shares",
        "negatedPeriodEndLabel": "Treasury, balance at end of period (in shares)",
        "negatedPeriodStartLabel": "Treasury, balance at beginning of period (in shares)",
        "terseLabel": "Common shares in treasury"
       }
      }
     },
     "localname": "TreasuryStockCommonShares",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "auth_ref": [
      "r17",
      "r129",
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.",
        "label": "Treasury Stock, Shares, Acquired",
        "negatedLabel": "Treasury shares acquired (in shares)",
        "negatedTerseLabel": "Treasury Stock, Shares, Acquired"
       }
      }
     },
     "localname": "TreasuryStockSharesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r34",
      "r76",
      "r77"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedLabel": "Common shares in treasury, at cost: 72 million shares and 54 million shares at March\u00a031, 2023 and June 30, 2022, respectively",
        "negatedPeriodEndLabel": "Treasury, balance at end of period",
        "negatedPeriodStartLabel": "Treasury, balance at beginning of period"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "auth_ref": [
      "r17",
      "r76",
      "r162"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "negatedTerseLabel": "Treasury Stock, Value, Acquired, Cost Method"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "auth_ref": [
      "r312",
      "r313",
      "r319",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the types of restructuring costs.",
        "label": "Type of Restructuring [Domain]",
        "terseLabel": "Type of Restructuring [Domain]"
       }
      }
     },
     "localname": "TypeOfRestructuringDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r438",
      "r443"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r442"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Unrecognized tax benefits, interest and penalties accrued"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "auth_ref": [
      "r444"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "terseLabel": "Unrecognized tax benefits that would impact effective tax rate"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r718"
     ],
     "calculation": {
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment",
        "terseLabel": "Employee stock options, restricted share units, and performance share units (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment [Abstract]",
        "terseLabel": "Effect of dilutive securities:"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r240",
      "r245"
     ],
     "calculation": {
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (in shares)",
        "totalLabel": "Weighted-average common shares\u2013diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings",
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r239",
      "r245"
     ],
     "calculation": {
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (in shares)",
        "verboseLabel": "Weighted-average common shares\u2013basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings",
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]",
        "terseLabel": "Weighted-average number of common shares outstanding:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 13
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-5",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-8",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480238/815-25-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org//205-20/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-11",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-3A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-4A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480463/815-10-45-5",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-4B",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5D",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(13))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org//235/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "https://asc.fasb.org//350/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org//360/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org//440/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org//470/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481573/470-10-45-12A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org//505/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-38",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-23",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480238/815-25-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(20))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b),(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-21B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "27",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-27",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "a",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org//260/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "https://asc.fasb.org//280/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-26",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a)(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-34",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "420",
   "URI": "https://asc.fasb.org//420/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "420",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "420",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(e))",
   "Topic": "420",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org//718/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b),(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org//740/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4CCC",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4E",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480627/815-20-45-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)(iii)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)(iv)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(i)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(11))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(17))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "205",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "205",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "205",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(b)(2)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(a)(2)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(a)(4)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(e)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(f)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13)(a)(4))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(17))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(19))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(8))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-05(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-05(4))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Subparagraph": "(b)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-12",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(9))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(d)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(Column D))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13A(Column D))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.3)",
   "Topic": "420",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13B(Column A))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13B(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13C(Column E))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4)",
   "Topic": "420",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-16",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(b)(1)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(a)(1)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(d)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13C(Column A)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13C(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "830",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "830",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "830",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r694": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r695": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r696": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r697": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r698": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r699": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147481071/942-405-45-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4CC",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1A",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "https://asc.fasb.org//1943274/2147482047/420-10-45-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r735": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org//450/tableOfContent",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r739": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r740": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r741": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r742": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r743": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r744": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r745": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r746": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1B",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r747": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r748": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r749": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r750": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r751": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r752": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r753": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r754": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r755": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r756": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r757": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r758": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r759": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481549/505-30-45-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r760": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r761": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r762": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r763": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "205",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r764": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Subparagraph": "(i)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r765": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r766": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r767": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r768": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r769": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-20",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-15",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-16",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-24",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4I",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1B",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(i)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(ii)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(iii)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>80
<FILENAME>0001628280-23-015775-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-23-015775-xbrl.zip
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M[YA*SG(\^7A3'N.583H'[S@=[.X8%"(6UG(S)Y.<7PJTN^33XEV"8-"D\N(
M;9!!+ W$ ,P*5$<DR+=LELDX8[:BGYOZ,V%$[80ZD$NKH!I(@,RDR]!!6XK8
M!TA^2X2FB>O!W!B4\7QY&%XN)'M_%T@*EH(IBIA:OYGD!O (<Q2;I7)9I& 9
M3AH6?\>J2N 30%J:T09 *(V:LQ(X( @3M)6ZP6@-#WNK:2R#Q(OC!EE4"@8
MI@9Z?'/6QQ-SF[%4Z9E=H-:(B;0.RMHQ3B]#W(BRL00^NPCF3K0O%W_]#</?
MQ<IDO=H>=J.] ULCK)811"$Z324>=^QK/Y/GC!OA,0,,2-H18&Z9L"2OI,VH
M!IGE8%!B47K&EB!6VE:H1]QJ(#*]36ET+!*\MFP'6$D$P!< <7859[R8"'8,
MVOI4*5A$/=Z,!CLB1!$-DO 4'B5M48H 6O+/B-N6L!RP1;&LW5"ZTE"*AJB?
MMQ$."\K\3U):>]T-1NT.?[T1L/7=/Q46 X29\PGPZ[!J4&Z.>677KT))<BP
MD;JED'9U9>  W#65UC,BK$3A_9#0ON'293XV0G&/N3KOWN"F47,U%4KP*F*Q
M6LG$GQS8:FQE(KF1U $9U('/$ 5YJBQE;+]*K4_OGC^U%0C(@:^I4LEI2U9A
M0P#:1[=\$#>9'S6"CEB6/_AK+,@0S(SZ(GD2$V\VIL<;B^FUB>P.M->GP+41
MCE4QE0D!EW:9_O2'6X">!"FAV6]I)C6VE>1CJ:2;DQ"XKUE:9QZ$'E]AB:R8
M+@E:GU*NZ@Z5E2F!;^N%2QQKD_@ O+2=B )Z1 'F*!$EK1\R@6P/4,8ZDR58
M_06#.=X0,+?Z7E:<3;FJ/)'19(LTA;244TR3O4<B7JN.-8@Y/-ZO&CU\41&D
M:H,V'>O*/1S!.JF#7UL+$M[IU_=.;+R0]'Y%BC 2B,>CCQIXF0A,-@2!GD[#
MS-Y%".WF:ZWG2^Z%X2-(E-*^CN/*$ Z6<NP]7G-M'=[303I\V1B.?JV0HN%Z
MYX$J*0 ->KME70>.39?P!Q%T1E%4UW&]#E%EW%X+$B)&OP!$XC.&'X^:S>=,
MR4NAZE.)6_:-)P_1DT&_T;NYP4O9S?F#RV2Q:AHW'$:4NHS<&SHC[#U"J-R1
MO]?1<4A@IXV]U@;^!5SFN71.B"\DC+&&^J#R1"(^[V0'^ 8_6^)__$M"?+$H
MQ:^51/A^ 59%[,\O7O]_T_8LC'RL(.TP1!+ HSTS[;YC*0"3.JE?;YYF@E]2
ME@Y2S^=I+U+]">OBW.E1X*OW.>'$XA[:XPDJ6G'->@\"M9:VJ *T08$V@E2P
MT FVRH$5C)#O3)UM[CVA>^$R8)-V5<?(]JD!G30  >%)$"#RA^,UVAHA6<IB
MJM544,8L^*0^XS<U;XJ\5'HN4#K+=&!*OH)E8.]/D1.MKR'"Z7*T_VWF]10#
MYJF2O>?S5]O1;N>@WP@7&-:)>N"C?MZ[ _V]3JM;-WS_Y8&5K]ZKA?V]1=V'
MON7_P<)>M-_JK%NY_M:_L%C,2-VIQWZIIX7Q+3[4WT&4_U#_:KN/U>%_V4_'
M__[XP7_ _OCNW?&GE>_VC[B[\ >&JT8A812.F#^ 8XN>/W(L<YDD2GR+L;QU
M > 9Q^^10X1Q_A;C<Y))D;*S*Q%7= C /@;]^Z1Q6O\JR1(EWKIX5>IP\VP4
M3HFGXL&K6#7Q=6ZJ\#' 6KF[5;YRI:7^#7?)_*VVH]\!4$L#!!0    ( #F#
MI%9A N1X[P<  "0G   >    83(S<3-?,3!Q>#,S,3(S>&5X:&EB:70S,3(N
M:'1M[5II;R,W$OV>7\'(R,0#Z&H=/B2/ <=V$ .3F>S B\%^6E#-:C5C=K-#
MLB5K?_U6D:W+\B&O$X_62(!HW,UBL4@^OGID\^3[B\_GU__Z[9*E+E/LMW_^
M]/'JG-4:K=;7[GFK=7%]P7ZY_O4CZS7;$;LV/+?229USU6I=?JJQ6NI<,6BU
MIM-I<]IM:C-N77]ID:M>2VEMH2F<J)V>T!O\!2Y.OSOYOM%@%SHN,\@=BPUP
M!X*55N9C]E6 O6&-1F5UKHN9D>/4L4Z[TV5?M;F1$Q[*G70*3N=^3EKA^:3E
M&SD9:3$[/1%RPJ3X4).B+:#3Z[8/>P=)KQOW1P<0'1\=0_?@H!<=1?U_1QAD
M"\U#'>MF"C[4,IDW4J#V![U.\[!?N.%4"I<.HG;[A]J:J8-;U^!*CO-!C.&
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MV'!G"31$$[#5MZJEGYNE!N!NE#" QA*IMB?PQ@):T+_^?0#ITPFDQP+ID,J
MJ0/O1,EB"*8!6,#_D"0+M<)_4/(M5 VKR$6SE,"E<M610CL!\ZC =+!-N@1
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M/]!1*(2\X/=T2P$M=T_'%7X]QVY(**#Z4J!QA7%LJEZ9!1;NY4[PV<VS,/E
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M+,Z,S6SQ1):*>;M"D$\D=G02VREP'*@02:,A%NU42UX%-4(@(@R:Z@>C%^5
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MI@VQ-L!Y3*GS]4)T=N2PJ=IA\CF9$N[SS!1;^&?9KJH7_P-02P,$%     @
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M5S4#!(FZQ1#(=&'BAV> BP"./FAG0BFCO)J *+DRT%M@!SZ>@05PW\9VOX(
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M(S\X7H/GCKJ=KF*=M;]8\!))B]J>(]9FS-NVD0RWO9)118ZUHG[E-4;M/RH
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M[>)#D7\!K+L,.LQ$2/_X1D@]D@8KV78<1)-%S-L&8=TV1,E42A%3LPPZS$<
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M;J>WU?OF2 /:!A^^0SZB@[T-?O!I"W4(]&?O$/SY3;)U#"BL]^?G@W?[9P>
M?6]8EE$L1$.I:%M$ 0H#,&X;8U$;4<*$]RJ2:,?[NH%IRRJQ4>N7DVQXE(^&
MK8$I6E],=Y20QR)'B9^0BR<:<:P0ERQ\#Q;>N,[""&"D!)^MK2IO#CBVK6V0
M;8G3X6*:*N-A8.&U?RZ9] =5[<;$@(UWQ%^/^B?SUOB __/Q\3>K<JG8M$"2
MM6-,F[ X]FW%X"NB45NMA#(A J(()ZW]O/C<JA*ZMJ8DN3M(^KC3W\>C<IC%
MLWD<)MKLIW)>P]"R9RUW%&"PT-//@)Q"M?4J^0N7MN'_@B?!F2-3MF+6!7?#
M=+MP1SH-F;R0?X^RY(. ZV'#Y 9H>.*&C!_%-&W7&I]9FW@DEQR9Z50G+R5=
M3F?66AZN J!-MPZ*X$(%;S$9MU<=#P=["8V"L+3*$4"^\BA/1P.F)\&&1V9X
M?2@GYFI_4V?'#T]&\^N+ENG[UB_DTI MR!W<9(]A0.FAZGYX,O5GTEA5J*SJ
M2=5=4PY;&HU;\.:L7!U__/;O)U]6>3,J"NC;^.1JLH9#,QR5C=0B/Q3Z.OV+
M<*4-IZ'M4$1M1IUN6V5I&UD1C50Z4@%P;#^4U^7]"KTFLC^K0\[W$]?_^ALP
MP4/?/3MM<1OS=O+Y3TW^N,!<8W1OTC^@>GK9< @:*W1!!15Y/Z&B[EDK $(Z
M:VTFL&1<M6ZU;H9F?#[TFE:^:.-RI&AG!'<RQ)/.W0F'H^YX=^AN>Z_U2Z*J
M_(U0LCJY87B45<>O!NGXU;-HYW&GS_5M*'^=GR*]-,MIDB=Z]>=3I&=_:4#]
MRG'4CHXX< K I=6$TK9UUNOH. ]>?D>1/E!/[&4]  @)FNWD/=.?A29;*O&&
M*G':4"4.>M.TNC"4T#+.@1)/!3M]I=**A#=O_+4%DM.^\4+9 ^T/;RFFH [4
M70]FX.Q%PMC0',#1-&V'K4,8Z/!H>GD5('>H^N9#S/I5VH1J!T1:"R,PS%MZ
M6%W&OTUON_.&6_LWO2\A[)5;.KF2#OHFNS3Q&XAMDZG'<-E-6+WOP>?OGP"^
MX*'&9 W"<I7SQYVK_>X:W2J33[#R)U8YX[,_KMNP.5#X!Y8I?SQ+^'/JQ^?9
M+I@P;O$&=-!A7IS=$#"K;JJTDYO<U.S8&4F9('>.#_8VSK8_?:2==YWCSJ>W
M1]M[^ZRSOH7W/^T<[7_]?+:]OGD]=D;W][;2_=VMO4U^L.?0/DGW;_#.\2':
M^OKGT<&[M\?;>YMLZ[83ND$286P[&*_ ;_:L;7P*! =G@B+*B\!67K^_V78\
M?::FQ_'X1W"A<A]:6[L_EG[L/('F,VT3K)>4KWU+[@4D+WLT>1=%FW=N0J)+
M6B^2*.^.,?L8=)\#]_'7"3)?-((_.4:IYO0?HQ+>7):+FS7RF;#)Z0T'>80V
M&FLFVT'B=-3!R93E&K6#BB)B' S3<A99(Q^CU>=^++WV.F?C:@1@J6Q^1-E,
M)_-=-9=OIL&4I=+Y(:5S=H/2B3A2K81N(Q]BFWEF0>E8W8Y,H<@0CP;1IU$Z
MCSMG,\\P:?Q..#)MM+\QBIK%FU;!JK4O )_]O%JZ&I7C4":,<YRS_H94L'E1
MO:M[EEZ>=M9!;\Y:_7"2XJ1%^)*5%9CMF[Y+(P:(F_)]I9M3S3]O"E^VTEG;
MS-^VPYK^8GZ]*3K9:K4>%>F?@;HA-X'9Q5P<K>+JY5'H=J<\U?H%.*6*;H\S
M1MXCD/SK:NO;59']4/[ LLAL:?GT.#7-X );C!]:[_SZEU1.26%,VQA&VXP+
MW+;,FC:R2DCMI:;X;GT_O]7.'^#@6:\[3M<:YS\I=5@"OD,IX]HHY;VCZ=FX
MJ?XLOCU&YR[O8W_1^F8?^XL6?*W,:G6PKEIW7!L467=,$(K&I4M>5)M TCMB
M#CKG) &A:3F:M]7^"WC)J)^-]=_X;2M7=:*A 5L',$QRRZ*GRMHHF3%&"(M8
M\),ZR(RB%3 5+@,OO?S["KIA[UPUI&HSZ+CN\/;%"*Y6K('9:?N\*D::F@,H
M!WY'J!K]N?3E^F?V%S**>61=&RL,^)AJT]:"FC:Q8*<HD<IHLO(:).&%0.@%
M5F2J,Z?T?;UZJXA,^)*0J@+R(!\#OE=%2#N7OH1;:R)/9 I=/&)LF7='P]L?
M>0"F?EVEV+M6,O9:*=?[E7Z6*]-GCHH+?^ PM&T1S.>VB<-0O#+=$W-6KKR\
MK3ZT)(.'58>^;0R+4E3ZX05G9UI&Y+8:S2$02=B#M38A]SJT<"U[_'<LWF/[
M<;_#$]]SA![Y9GR]//0=;S[GYID:S_N1X0_:>ILE<U"9MU95'S45Z&S-_[\;
M:EP_JAKU;#')_>K,WE"T^_N::[+WY_G/XLM5(6I;)OM:&>R)/#XB E6#I =R
ME1!R::)O&/7T70 VPF-V\FBXJ&:_[4BL2C(3\W3+^)XY:]%SK"C<K&P_F'1<
MZ_['O1\^7P]=;/B>T8GQ:596QIT#7V22*/O5J ^BE^Z"#IEZ=*1U5"1G[6]W
M0^(47-DR?:!L.F3UWV5K'<SI:%P)*VTD70.,<U9FE4/Y]CR6"V;!CX/!Z9Z=
M4(ZZP^J6[4$8=P8LAKF.V6^G_\WZ<L+-/\ <W].?3\@V-XG/7-CF@1UY&-N0
M6TB\U J-UPJ4K;S>. 4R]<TE*7<Y2'\WFY0'B*VT<>G=VMJ'2XIA*YAR5(2'
M2?]2P.LGX(D#L%A*^*)*. ,%_D=:<,V&56RO$G'XH3O]GG! -Z^$N65L"C9O
MF>)S&+9VLO+S4KP;+MZ)_ 0OQ7MAQ5NDW$?]80%$J43[0Y&[X)>F>1%D5RQE
MMP;T?3K9U2NOWX?#5$8F"6UU]G\IM8V76J J6;K,\Z;ODTDM)RNO$S1NO35N
MF!=+@6VZP":"$OK4 OMC=R[U1O/U!E]Y_;%_*=?TKNF&*I:^\>]1-CR[G,@M
M ?F/9;4P.X$&2S73>#7#TVZM)2Y85/D6>.7U17R\JD#6"_U$[^N[*I:"6X..
M/(RP9!DAGS=]GVYEG%2+8$>9S89+,]MT::VHR=A27!=77"48VO/]GV^*O"Q;
M.R$"INZ[T-J$)D^74MQX*08BLR5:GC>!GW [&EIYO0N3:H;+M:I%$-A$3_9=
ME#R+8_>/.%[S['OJUZI-%+><&[EC7WT=JMZI53).-;G0.^WKFNOA&M^\ $#C
M5JOLMJF0-LQ,,9C(:75T<GP^'VNI7XS/\1]V<UME-<^ >P['B<:.JJ:<*8"+
M0O$EE>2M0HR#(O<C-RS/C_V/LS14J69A!O(>]-NWJ@-^58[;E GB*"\'J;A8
M^>)*LV?E,/3@M\&1*7K&9>GPJNG9E H]+\Y:Y:@X3$G6QSP-UQR,/+%AJVML
M&D]>5(\,CL[*S&6F/RT=/.XGC+>J# %#36=:C_)>6&U]"M.L$M.WAE'%VN.'
M8&JJ%YP/,OWH\G+8#C&&<9[WBZ%5>=1#_\@D#%F.!H-NRIQ@X(4A=01>[\ZJ
M5[J\WT\%+*9]>C'M1!K5P)R-_YW,0CEY;<_T1]&X9.J*\31>HDXU@2[/*[J?
M[\*T85BE>1^_)K4PV;I=]6+\M96/BI:=9,:JGAJG'*M^OTC(44RV;:?9.\F!
M!0ZK.ANO6A^N3%O5P-9XUE9;:V7*#>+'4YZ5DY9?3),3GX3KZ8KAG==_&I4O
M+N<J+C,0%E.D">OGHWYJ,Z9L%/EU93EF^NH9<,EAL,=Y*N[3SD]2/HHQ'?N5
M!J@FL!S9$KC6C%EHU.^FV4A\,CG//$V&7[;RE/[B)"N!>[:K*:I.E)T%Z%3H
M^S*5O?O7J!]:%*W>>-[.&O?YL("^^_9$&<3JO]^>136<.SGEN.;*Q7&X-"47
MWTGU'6YYNS^Y!A](JL*:?JP.A5\,O$PC3Q*?5W, TYEFX.II\JJ-R<14OY 7
MB:D&8RGJGMU^T/CYM>S];#3XCR? <^WW>?ZY*O<X"=?>^P#<TE#_[(9Z+VG%
M/T8F5>, 8[$ST;S]2V=3IX6,_CV^:R)?6Z9PDRQM%$\$[)=*QZZ</[KR:^N7
MB_K)67^<)2'9!OAU @'&Y:&*J5+X=5)P&;3#2IRP=W?"WN4Y>Z^T@ (@NV7Z
M.9PF$1X?XZGL6"72\#' K,+[)N:WTIJ@A9-!FEC*I$M\&*0!@7$:#1(:&27S
MEHJI)$L-(_?PL9L/JM>NPJ@!7]S>KY89#)(:!G-S<4KI/"O&K,XJM7Y9V5K_
M+],;_+:V\NL+,)U5[13H=1I/-<SRW."=T^+%I!1JSYRE$C!9&G(6L_'TG^0I
MNU556L7 Q(]G],5*:R7MN'89F.^0OB5SW_?I4SIKD?ZUH9O!!*6/)UFWF_XM
MC_)1M[K)33^<3#\ <8XG+2>KEO5'U:/=[#/H7_ATV;Y")RH*5U2MC.B8,2Y/
M-[!-2@26B# AW!0E .4.1V!9@:5>7'X")A+\FD2YJLTTTGY9Y:HN1H"Y5EM[
M1Z$,YVQ2H<*+8E]%5GX><],(&BZ&@*RJE>Z*FZKA @X:5>T-1Y<P"SSJLQC'
M_!>2\(*LQ2+OP9-Y]3H?*M8]'J<U2]"J-X"I]56'6CT ?# QAWV@F$O)KL:I
M5^#)VWHT9NW2%9F]!'\N<<.%7$X6#5I:K^+I3+=6+F\.JLHP)#2VUN^G87VK
M)?[G7$M<0R/AFLEM_9+:F2"KZH?S)B8@Z]?5UMO;!>R;D;1 VLUGZ O,Z#B1
M3%73(J4-FY8I\KD;C3'GQJD+@^$4/U39XH87189 $$!^NS##R0!VS0G(3&A5
M<82A^1Q:_;R56U#88Q66TLX-QN^9YH]K?5<[- ]??/?$U!)@+ '&/0#&YMC9
M7=G^DGSVE&VQ2M-PX?=,3!Q,S"2/(MPP-6]C 2S#)3>P-V' RQ:\ /SNQ_HT
M:9<K;M7%DSZ50TO&,CV4$D<F^Y)XTD_5&SSHDSGPMS5Q21'!PP-3C)]-N2*+
MRM:,$TM^7-U=;1V&/ACLI.A3MO1!:NA23LE! 0HX&Z2]4[^L)!E;^?7<]DQ'
M./:H^V5RR^'IE?Y4'+^=C96QFJJF^F,_2R^KG('R^GZL\V2'*9]5-@8COZSL
M;KP!K%:,H#MC@U- NPEI3*9_;&N^\_ZQKU8]>/G893E1M5DQ-F$>]*P;IJ!$
M"M44E1ZXM448_<3D^VG(9&(W?NBLY]27G[+;>6JQ<Z[[ULA\I[[0A-FY>OHD
M5+>%^Q\:3JZ#4M:KBM/'*&5*5C&=?0VA5-F0J*=H%E/Y R:$S]2$U*V=)ZJ)
M,>OD3O?+8/YLN35O3G>":[KR^'03?BW>^A2YQ>XW]?_?X_([SV(._J!S&_7\
M!GUC#K4'L__MX/J> YII*MK[5C!\IMR3*6/*CR>?Y&P1DT^"7ZC(H[*X$7;O
MY%X/:9:C5:WTS)LET*R^7P7$.PSYMRM.@>%(^6\36EUD.3Y'#>/K,RSK,5GC
M>B)E./4=[E'2X:G&?',01LQZ^\C]YF/J[C\TI]:=LW)72.2QNVF>+.]I)>]/
ME+/L%A59C\A/BB/XJT,UTZ%>A%YL .\[;?I(+GPHTM)X%4.9!LI;XWA%%?F]
MB!*X*[-37,Q.?CX[ET/<II?B+I/-$Y,H^5FZW9GRJ!6A!^4D?'2QR%*M1H]#
M2L,4@@%^'!4NK<W;,#P)81R1&%<7*5,4VHV74[X?2[*F.]Z<<11"ZM#PQH6T
MZ4KUE05L<AZ<_T[[5Y<Z@BGZZ3C^RU^Z>5G^>AZD'QX589Q#!RZGY87^\*C\
MSL)>NC/U8+6U-BVO4615@.B"D"E>4U%NLJ8^C;(/8(**=K4>,)ZL\\T-55_]
MY>T,U6KD;3PS7EA*BU> 0*IY@)$?C_KC,$[UZO2^2U&<B^!1FK&KJPTSB<;?
M 54NHZ!E9&@9&5I&AI:1H3E@,;*,#"TC0\O(T#(R-)O(D)A%9.AA94ENQ"6-
MB!7]0*&29;!H&2QZLF#1_ -"]0T%Q?BXB9#W"@7=M1'F:>O4L'OU<2?M?QV%
M>V[R:I)2;?">+E&;/5WKHR)%U1X124HG+BK62M&9M,D(;L,T!8:264\AH_\$
M^\1;-NMVIP&@_\0<KXKI3U?/;*1-LQE,$PRPY4?5R1!;F.KMU5[B%)4##^#L
MVMFJ5EEEK9J4(*ZB?.$T*X<79\9"4:ZV+HWSGJ.[\S7],*QJ#I^_I66Z95Z=
M\2DR.TIZ ,9P,3F3Z;HS6I5X;N8G1>^G+*I]5FFVSS==34+4:6_Q>0#R?0I
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M.X)-$> ]&D^$1M*,Y=7,R)*\$_O) 8)%$B,0X.#H%AWOQV]F5A4.$B !-@^
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M:L@NJ*U]!B*X>>/;)/BUUY8%DH?@\!&.#\MF7&!]9BZF)#ZP]!OO ,]+F"J
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MY,^$)/*%#YQP5L3+5T0!"5F-[PE^,+%6V)PAOQO#O@;0<:1$,$9Z_#<(;M@
MGR5HP3S!"J21_<"<=4M[7-BP&_;-<J(I"[25%P(Q 'R=-=\3O*8%S(I\.[3A
M>;P1H!EO"10; L2F$=$P_&S[&LJ_^_A3+OD"G#1R,)Z/CQ!+.Y2?E$PZ$Y '
M>-C>%,Z/0U#AYKDC05:7!N)P XA&%2#:[DX@TI?7R<+=&K'P@1G+ GE3/.WO
M\<R>>][T$9!/+,P'U$1V2[KQ!Y+H+VR*FBCPR5R&JKX8#;HQ[2!G^SCVE%?\
MPV_V$'.7,X!H*((_M.@S!EA?TMRX:%SGA+EL9H>;:[)38  .>#$894C;#I(=
M"ZW"=-T(YN(<BQ2+H_LP9EM[#: 4+,R782Y!YPMC]>;;BKD!EV!S%Y"'8UH^
MZ!O(7ZN5[WVC10,[3-8P#W^*:X/Y7@Q[\<I2\.%LOQ- J+&E1[*Q1[*]W(!*
MO*0*P-<>3039( ,R(@8?ZS,&3,)L!H(L7*#6Y\/<4H%.M8$Y-K]?@+O?;B*E
MG"RVS\"'R&B]%/W@/"_T]DB;\!\VY?1NOMUD.>-@EN/THQL;!&2>F.FVV*<,
MIJJPJMXV)&@%K$<=N<5-6.-SQWMD/N/:$ S]8 ?X)1[U,*RWI-T"&E/KWF:H
M%#YH29DUIA=0A=7$+VA].,,%% ^F$HRVI;D@P9A3$CBP5ZY*PB.  H+J\ -*
M*BP+$W"NO;@UVL-!YG(R0]@CD0GU=;_HY$8B*3\Y]E_<#MH=_2[^]V!8=I*]
MU)N9SLB2'K^(W[Q!C14W_=JRD&]P[(^>8UNHQN+0GX%];.*YU!OO!+,'-ZCU
MQG=XO/#_\O9_S.7JU6N^N3T*SVQV&BKAI#I%A8+N^M]% !2?![)];]9C(1I@
M;_;WF[_8^K3;FUGP7Z-G]&83:](;=8>6-9[I5F<PZ%O_&8TPA#!D6N_[E^8/
MQ]<A2S*>0NBQ$*IWN@*CP\MB5&AB-[B6@ PL'MZ1\)2#?Y&UF01D8AZC)G^D
MKMS0"87*&,(!'DU9:-I.F]]843 ?+*JZFND$7G)3I"//? "0HQU("$)8NY.D
MUR?9]: GP5("R[<G,/@,#TKFQS;!3Z0ID$[TFVR:LD.**9H_'LUW!,T/+D[S
M!]%[)8-P+36GK2O*?@4EWU04J\)&!U45"W4J .8+#/A-Z2["X+6 )<!O\5"B
M61&L1!I^B<M,K@>+;TG5:+RN^K:R1K@'X(,,O#$*9AO>.8#DQ@R\^,,U3=Z)
M6MH*K@_<_N;-9G"Y1)V9?[L#6=M(.2I@>_O<B038-V:PH$V]^S.R'TR'[L\E
MJ:6?I1:>$L)=#-)=R[VNL!/'7 7L._F/5S(OQG9I2?31J^W1-YRN1(O\\:M'
M>QHNT"?:[I!?5&;4B)G%XS8]VG B\V?C47O<*7[<:>OQ,Y&Q(U\0 .SR_>9'
M+^2ZFQDSAD9O1UI8?3RY)?GRM\C7+$E"+$5"$]/!MB+<,M%K=Y)[?)BKIZ"W
MU_3Y%1+>'Z;?_V?D,O%ZA]_ VMH! @'8DI9*EH$IO]@F7&GB=8X['6C-1K+F
M+8.[M+YPY0F="P$Z4Z;2O+(RU[%AMCLT^$H2ZVSFKISTF8,?0'2$Z*"#WQ],
M$#!+\P\/[I5KJ5^*GM".^1A$-D!Y9CM\'P&>KH$P@N M=(Y*G"L,*>@=H)W=
MDNKVF6:A.5_+V6_NVMI[-]9"6P?<P1_12T-]9<@JUH]1B.JM]#FM(O@2)'#0
MTE[TAXG3"-_!>@OX"H<>OM$=CS-O$/Z +0!][I1O]X4QZ&V\L[)ITRB<83?1
M3C>(H.8A)GQMYW/%0N:OV6PXP8>=Y!-S CP.YTSA)RE^Q6.'^8)=?_A^XK_\
MX;#HA7B@\PK=\;@]ZG</D;E=HZUW^Z5D;L5A>\;H%,/JW>$33HC^44^(NHVS
M)X^U8M(II[#CUQW>?Y#E1)V=</J",.P]]8"/ M9]HNBL -^(0-EE&Q!$>"+0
M_^\)$HA+PN!?W8OM^G*;_BGQ,:,#;*GIG?M_52;_8MVYY(:^V$M0B'YEC]HG
M;VFZ3[2%'"/Z,$\32/_OPD^ ,&?W$[C)?KTGM\9WIO-HKH.;E]FI8=ZT>E.D
MF913,0[159IT'33@TF&4NPY6&;;?:8]'XZ,/:\"PX^)/<U23\G'VK*?/NOV-
MB.JT3L"?'WH0Y?"G*)=R(E$G3=!E4O+.M^?3ZA._P4H>;/9XQ#WOLU8<T68Q
MFQT&FV$ID]=GF)]"IN'^^Y8],,=;B;@E5TL?3GB[_.+C1;,.AKKW[LPAIX'I
MK[7W9'PH;:@;;!GJ\E'1&&&M;'='L-W]R&!9+H7_NMDPI,T PY7O8?P1VL5<
M-C=YW(-F4A 1MS]EX^)2E,K-9$$+QK !$+"%C ',A_6O/#\4I;VYA0V7Y%G,
MY$$_4V^)(5&6-O-I]7<M'AP[Y28M,GF9@#,>)S%WO FN/%JM8"IKP3-)W !F
MLBE/Y+.-9LEP889:""H@F:T6)D5"?65NG'UB6CP% A:YY,Y1,LL%+-E1LECX
MB=O3\ \Y FS88K''@2^4/7C. VTO\ND%6S1DQATQGQQEL%I8K$5C > M%@3<
MQ2;LEEH44&*(-H>!,:9%CC-SV#=[8CMVN-ZPY<DE39E<#/P18$ 4C#F-K##;
MLI "P2<Q=<#4DTS<E\DMH-P==8^?P'@/L'T/$1YH2^^!FPY!K9@ON'TTA8^-
M4+,209B;ED:!B%PZ$QDR..DR\6H+=):B$1&G%#A(;?#"ML/<+>(0G(GB,._1
M_'J/_](F9F 'AQBL^2YYD.+V3G,YL?*RZI,U55)H_<[(L M8V ,>H%KD)-L5
MOCR>$E4 H(P Y"?_A*T]=]K2)E$H?('(B#Z6"29C_8*"%9'Y/#_)(OBR39D)
M2TWM&:@=0/2<FW$IW*&(V6W 8I*A:>S'>*-HTY8[<3QW+M] $K<BW\?E\%=Y
M$ ;PE[M.QY/(^%&8M6#_E"0A(SPR4H)#.5],4#3@!*W^H Y@K@,LTMDA&A8F
MR08*T"P2#>A02LE>*3ZY-$T)4<:WGY*5R+XA""W&@1U$DS^(3"0=S)D;Q^)%
MKA")\1&"1("9%$%@4XH4G@\X@Y^$N7AQF$N\\YQH2:(5B<DTL0!"!;:08V%F
MRU[AJ4)Y)S ;/$<Z<+V01A:)6NG#)V9Y*8B$"TG, @-Y/#@'#S9D'1PSF:EY
MS/YEB^]:5;2+Q-N_H6?$.@,GY!:/DDJ0&<O3CPO37YH6B\(\KGE*6!8V#BZ2
MRI5];YG3Y>F'* BJ*=$AZ46FM@15#$:?14[J!-P-FM.>. 5VJ O<RCY^? =W
MR"6%W<#_?>2JV%/WJ.YAS^D>]A&D#IW3P#NA2,O 4 JR2FBW-T!C-W>8_0[O
MB7N ?,UR/,P0G[> 1_G!#KKM SK79\":6K"PF3.5?RW-X&N0:EF>S#%E <"
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M6Q2Z^^'#&PU39"*?:;<WF\^EMOOF_WZ6IMHWGK\2GF3X('EPPVM?%ZQ8YLK
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MA"DK9(2]])^0G. $TY7]4U/M0C]^?"=;@HI^HKR))_:3M5W9PI8_FP+1$MT
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M,Y,+HD1KLV#KWI+Y6L*(B'67""G%O_(QBB!X/,412?]+*;[2$^>S>>280+E
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MB'L,;&J;!(26=*1'^#;0=/K>C>T7/&S<=-;_E1F%<1VD.-XW@5&JLC8:;E8
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M3<2X4]L*9:$5)D4H#E!$&ER8I 0)5VX ;C:E/U,@2KK^"JTD\JGDV/8Y)SR
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MM%][K(DJP-_X&C+#FA0B5Q5^ZHR=ZX-LY1JV"K)E"_#7A&:51%$%^-/JFRK
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M<P FL#]OQ7S1O&;N,T8:ZC-H5+.-L@;P8^6J9+F$>0X3V=.JQBGDG"A>N)&
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M00K/; >6!3P4A+! P:"\K3F T!5,CBHUWD':VMOXOJ%%KOTG_ 7WD,CG7P9
M)/8,",:UF%Q!WMI;\3U-HJ&5QH,841Z<C*&HLQ,-"]&S*3>=$OAO%UN<E31X
MBC3H-U(:R&OO7N:=>B R7"^6'R ^7NC),?Y'-)US L<109<)\5R;V6'F3@
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MV9S,!?,$3@E.=O@#ZRK<WB1GYWLTP* =1,@U[3=0CU+A^9\(8[#U&FVRBO)
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MD) &P ,4@J/X(V5;NR+OW1D9ZG;9*"/#2I%A>N\6S"C'- 8(>PHHC*Q>(^V
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M3_;__$_T!?%O38TYS0:VQTS<V C(65SX;]V%Y%8+.1E:%H&62GS)N#AUC@I
MB(CD4[((+310$+@V1@:'B8\T%.%E10&S==>34*P\D3-;]^-9=R6B9 AQW-N4
MQH[3)2%M@/+1NHFT+*YK*&E 6[L\4X8,*JND#"NOZI=!Y?% I1*Y\HI"J[$!
M5F(,:-Q @.2< \>5YMH[:HB8=23U>,9]W^R=A=,OQ8Y@-0[&'/:&L:'>76EM
M2X=A%AV^6J%?LV(T.1Y_#U1[\[P:8W'(&>I3I9Y@$*#,R937;8%2GM@X?YRR
MF0?M#:%*]T6T-9\*+J='LK$8U*R@3<:@^V%0)1BCH3-8,@(83YH.U#D@2<!
M8\V%,<)P2[=VERX9EK&@25C0U$2BC KW0X5J6A 72"M" /+( QH]:: 9TB#.
MGH)($(%3IL",Z[P+9PID1&@$(C0UVR@CPOT0H7H'56''C2+10T$*4(<H4$$K
M(+ 3%G,?F1Z+O@II "*LY )J$VZ0Y3;J<RMO,^-ZMT3T<A3O\:-X,S;%\888
M_]8Y3^/X5Z]?'%0,A_VV.2_4\0][![UNZEF_UXD/=/PZ":CZP3!OHHL(.1P^
M2QOH]9J()DVN)!1P(S&@AAH@$:< 2<@\44Q;(K=V"6ML5=K,ZIN$6'6^'+AR
M[,H*-2L$MNEBKT'%H<0< X5D$B^T&$CA'(#!&B&89(*X0KQ05M.ZZN<A9'2I
M!1]:>:)8YD./"QL'TWP(,FH$,P18;1&@F"F@C1; 0(^-\D0[)2(?@E7%T\R'
M,F+5D ^M+\J9^5"=@6V:#W%-F;$8 AEX$D25')BXND#TZ5T0DE*L9>)#:$::
M>_WX4(Z8YC:RCMD-V\.??C!X.C,2VM(30-P:]EK=:U <WU5B\<WU49LL4+!\
M$L'*XZ%QP[PZ&LP,?^4;X>MJQ)/1N!%"!4'TUTS\PUA@(MD'T!K*D5=*NY1)
M4 _)@:PO4K/88#;?!S;?:1X++<,6&P.XM Y0GB)\'CO C$86.^T1L9''9O.M
MF_G6(H4OF^_#FF\EOJ8)QP)1#+#P'E #!9!.!F"Y01A)CCAU6[LK2-K)YENW
MW7?E%R*S^:[=?*=W7Z*3,A<RP!"K 66" N-$W(RI%<9QIWB0M2'/6:^K9GI=
MH[!@.4MQ:J<C@\U-29M-;NY,2:O$8Y[K?GS(^*'_>-T9GFRW(L#MW+-@RO+#
M7*=:2ZLM4;>"L:G#IMRH!+^\^RZT^[ZMAJY"<$)[S4$(G@ :MU]@A*1 !FP9
M4<@R@9(V;K7H4D,.I]>U3ZQ9"&4E_;UGQ;S-0OG55M3;$)2O1>!S\22 ?*"_
MTLU@VA6C @9BDP"FM$D[&5J@O)'1,V,B2,@$QZ),<%PFFI(1^2='Y,R[FYY(
MFJ%V0:BM!*T)%H1AS %D4@*JN05:,@V(=9R0R, MM5N[6%5UZC/OSBC?!)3/
MO+NN1QZ9=S_R9C#-NXW@2J@X8X0$"RC#'B@,-8C39QT2# EJRD3:96H4U061
MBU#_KT5\.O[7M;_N_CO^,>[WF>X?M[OC[I'K4&9].G9;J84B>)>)XF2B[[UO
M=7M#/T@A]6B0+IJ)3UM+MQ@@/8Q_">VN[MKTC8-A_$51>N,JTG[_!]W]M^G_
MNGMC0Z-^BCB5OWWI#=II63SM^TY1!N2W;VTW/!FSR8E/C;X77GU$F_@HY\.;
M/W+/_LWWH.5YQ67GBC489[:COPS\T_$/OXV/CMK=8HJ*#_UV_0O2Z<W4^BN^
MKWQY]'!*[4A&TO.-SIQ&7SQZ])WBT:<LJGR-X!U$V(TOPQUTXVMW-$NQ7$>S
M<7^8J]G9^>_LMO3WF4CA/1:8+I1J_6CMW''J>-_L[,("'A*B9A#T-7[];%<5
MB^L(<,M$+3&N=V'1@X[XU-%JZY:Q'ZW"-8W]_[OMJ]<[!F_)HSWUXSWTRW:B
MO*T41VF]C,RXA2!XN_#RKT+1F!7-^4"'[;-(2 [\M]:[WIGN+L=P6O?;P%,!
MPW:XN(4*3/Z96BU\!.0(#3;^'U-,@[&&2B*L50%9R#FS_W"Q-?[02?]JY(X]
M,'VO/P.=E.B?ZLXW?3'8^O5Z?V-G)TG137QF90RLTM"#\YGX<#NP?,!%"0VF
M.USBE3,/!G<4NOFC]VT6HYWHW"Y":.8/ 7F* F%3#M(DDRA?7^&=K5%FVIKP
M\>6E/_+^TA^Y\196A4;=^?SS,[+%FIKA'\YE<:O;?_"=XUL@YO-+-_#YI!OX
MN^[$8?>M]R?>7PUX8_! 1)<!T94;+L([3-W\\FW-WOX:HVOH+-K!;#Y,7),+
M\; AR+);SMM>OZCH\C2BHN^G=VWM/FEW6_'+.O'7MPC>S?7$Y9Y:F\.U?=VW
M)RV"M@LBM\"CS8%\=1R%V5SVC_.N;Q%8# *^-@C+7FJ^URWK>USWK\7@WG 7
MZ4-7G[MVW!;F,9W'']'E+K5/W9"O__0\&PS\?)PHJQ+4,&7D^7F_'Q=42Q?3
M^/2Q+6QM;6QZ,?-4:JZENZ[E_WO>_JH[LQR519ZU3L?@*TIVJMU)]M+Y2IHB
M89F@3 I-%3<R$&VEP0%Y+ W2_[R>,TTI+IYG79?^\^)J^3P;/H]/<Q&'[&_=
M.?<-.<"^&!U@GUIV\/'326SG[.#TC[/X/>W]T\_LS=X+O'_X[G1_[V5[__#X
MXM/INY/+ ^Q3^^/37J=S</H9'^ /]. P?N;CW^V#TQ>Q3R]0ZL?1V6MX@/\X
MF3[ /OAQ\/G-QP_XS>$1^71XC Y>O?[^Z>/K^%TO3_</_T[/W(Y])D=G+\/!
MC!I?W!,6_7D/(-0\52XDP&#F &16(9=\\$"W=LFV4HW5N)N-J(]9$K6I@+BB
MO*#: >+2M<4L1D)00J%TE$(*E68*8ZBA"2A=I2H $4-.8 ;$>@%BI> 8"I03
MQ9,RG@B 0F.!] @!K[%%,)5VY6%KEVX+5,WO;%XYUZ;0S,.^=K[5]]9'HS =
M/R@*LOY$NF2/P,[>78WV@1^.'+8,/BL#G_=5-@81M3+N(4 S3E+%51-_\AY8
M+8E34%N<P ?!2,>JJ@H-H6-9D66S.4R&C77#1H6S<,N%""0R%8PB9V$V "6#
M!R%(%H+GCAA;P ;C52FTQS/?38^-O>Y^C4N_UV\O0U?F=0E_>KHR'NV+B#H9
M;E8&-^TJ2U%(6Y^J(O @15)M,\!X*X$5'D:>@K#4/,(-W^8X!XU6?Z349+2H
M#4O):+$FM*B0DTA$D"(A !N9"* 2<Z \TT [@21"U"A*(EJP;4YXCJ@\F,W]
MU?=?=-NU_/<O*1%N4!SB]5*IXAQ562=-*:I!E\D+V3=:-?Q<5,E*=(SB7N$I
M()+CZ!MY![1PT4L*/@1A-26:I@N:4K&F<I4<4=ELKI(A8ZV046$L2D=B@C4$
MS*CHWSB"@5(N25-K%/<1"G5 6[MX&^(&15,V3C>VF@U9;U'86^N47\N&6R9.
M--_@U IG:T/-,L2N!6+?S#CH,D99;PD$1BH#J \,&*,1(-H1(S2#1+&M74*V
MZ:;(*,T)5P^CD71+9Y8).S40?&I#\C+XK M\JL=EGD<7, 6L=:1V5! /C/4$
M2.'C_T6<+F(B^.!M1:H^81U!8"7U+YN039\S\N<)[/6^Q*Y<7&;E?TFWA_,!
MY-KIXWC@_^KH[O!9U[T8CWT^8E@AH.^78'Y=A<TZ'""#"D ;_70*#0&&.@X(
M4=90']DFU,EC)[RQ:5/Y0'*S^5]&CP=#CVD-1R:M,0Y38!4/@&)I@<'& V:9
MMEP*01PIT6/I>%\^H)S;!E_U>NY;N].Y.IA,!:EU][B=\[\?**%J/-JE;UH6
MV.N<IV$;3TY&IM4ATXSJU $S1XD,(&!" %4H\AH1>4V<3"E-T);)R&OX-N.-
MC9+EP\O-YC4911X<12IE.I6C F,'$ XLHHC'0,?9!<HXAKA&#C._M2NV.:Z6
M"LOGF6L_SVP*(2O2$%9P1%E;S*P-\YI(^$BEB\=G AD'%\#!&043.0\2<:Z!
MURJR*<D4T"3RJK2G$2RU8Q!O[2I6]?(:PJ5RC&BSN53&A97@PC0_<L@%0PP#
M1N.("SQ"@D$P1'ZDO,->28%LPH5JY;SF17\VLZCV;%*RLK&HDP;+LJ)4"S][
M'1"X-LRL!-_LKZX.CS]4>9H7$%$G);"$B8C'' $9I 8B0*9HFD$MMG8IV2:B
MZ6&OVM30N[?2Z*;B[+):5XW$V=HPW8RS:\#92EPP2 ?CIAC]8>L I9P"B8V-
M?Y4><:VI2_<<(LY*(5<4&'R8"G7+IL)5D_:JM?96H?S[,W[!&HZM:Z9,_6=;
MFW:G/6R/+M6^/]%]?]+KQ($:_)__D1$A?VOM^="V[9L/L'.295UXP.WRU9VK
MN;Z?AO6\\;.L1;X^?O/,VMC[X:#U15\DW:IE3KOJ1&%7%"JH'4NM3S1@M'#^
M*M=-OKRQ<M;ZN1H=(%SA.&,&&*%E9*V* N613??' N7>!ZSEUBY6VQPV]B"G
M?DDQ3<7 %;GQM</ ^GCJ&0/7CX'3GKO@E&/+)<"%J$D27U,1^X ,4 B%(CYZ
ME<KZ;B.\*L\]"S[>;7YCK^!+KU^87R^T.KWN,8C>Z5FK9V+GBA)M$UI+K<%)
M?&_YANA+QP[$Y\S9-6ME;7_&*3F, [[GS; 0V__2'NK.GUX/_)NK.7J>3]<7
MQZK39U6^!@FC15T1(;$#5 H'5 @0Q/T&H0ABBN.DIE+5?FL(5\M)-YM-<#)<
MK!4NIJE-P(0CJR&(0)ZTK*$%4KF('H8YY#1AAO*M72:KRK+-2\9I"J\99?Y:
MVS_W;C+FF2]@K3\-N!SUB4.%[&*M'(=F7"GW@47 L08@A22@0A;J^AQ@I0V,
MNP@3AJ=+H5(TEKG4+\JT$?A1&^:2\>,!\6.:QRCKD1%< .$( ]1A#M(% X"0
M(#8Z03PH6. 'K4I2U#9"LSF7KC981')9?K;0"-4*>6O#W#+:KA-M]ZML#0=&
M+'<>$"@HH$8:H%&PP!NKA1#!0"\*23<&J[<X&D+7[H5<64^R#@#]&&&K#$'K
MA:#*F1SR L8-!%#M(P0%2X#Q2@,<9Y$1AJ1@)$(0W&9L5;&KK"I9FS8V_6CS
MSUGGF-NMCA\,+HGGZ-@SGUX^_NEEQOK58?V,&VJ40.X$]P 'C '%A *#; !4
M&*Y"0%!;5A0)A]7TBV:QS7RLN:G\,./(P^-()4C(O(+82B!M_"-.)@<RX  0
M-9@P:J$BLL"1E0F1Y^/.NZUQSP<?&8UKM;NV=^9;0_U]LCY>/@!]**XSGHA#
M_3U"5'&<,>'63DJ@9)1:%4H=S5#7]BS 5$]<0$P32AF@!:0 0F_CQH,\4GQK
M5VX329O*=O)1Z&:SG8PDCX(DTWQ'FSB7-"@0K(A^$X46:$T9H-IA8:VSF$6^
MH[:QJJ$2Y4KNE-?ZHF>^+'HW#9IUF]N5M[GO=P,X1S<??T?ZJS^F_(,TO8/M
MUK?V\*1W/FQ]T?W65]TY]_EZ]ZHLUK6_CML>-0'2^Y_R(LGB,>Y_G\>Y[L?W
MN\*@\6_K)ZT+NECEJER-ET6JE4=&B__]L&<_%_@VN!J2^1@1R8SH;D;TX]EP
M__EU1A3;Z_C_O+OX]-%],9CR@[/7[.!TGQY\W/_QYE7LP][?GP].3]J?7L7Q
MB2-W<&@O/AW^'?OW1]+T^0="PAE!/CID3*5L>90D;0,(7EOB$6*2\$77U3TY
M=UY7F[2NE+.<2P&<P!I0A2%0@4>B;J C&%L>??^M70:K)]F57[321AI!T3U6
M*.!R3W\]&)Q?87QML+;LUG5[".WOWH$?OM_+IO"8IO!C_Q^E#2=642""\H!:
M9($,G /K @Z,22U,J!/$YN54Z^44)#4^U9V%,@A B9+ 0,U B(N ,@2Q3R+T
M*<7Y;FB]=$DBI=ZPR&%MSB"NF]C?R16\T[9R?'!.VYH^:5"1KNJ(@$ S&(W#
M1.YA#)?13*!QS@@6,3/%]D=>6CYKR&<-]3MKR(BQ1L28/E&PD$O/. 48J>@
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M$Q%I)B[4D.K,PH5L^HN9_C2;(1(*9IT E#H.XEPA(#F3P*HX2W'V/#5D:U?
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MDG&]"XL>=,2G<IMONP\^6H5K&OO_MX:KZ'..P=O;]'#7^]2/]] OVXGXEB(
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MB@T8\SDVX'KGM)3=<M[V^KHX3SWOQN%+[XI.;+L[EK(=S#-P]]5_J9DQEMO
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MD0DR6LH##C3[A3RC7!2$?+):XYS!#AJ0(P2&81$)KDPRE"1B! Z*1F.CNBV
MK'FPP\.)?:V 6C+2PT0D%'S B L@1E9QA4#J@0?SX)2V,RLOSIUV:L7%O1"B
M=25$\YS4WPN@/96X@X>#N5K9.6"LWE++$.74(4XDL!MJ))+,*.J<-BRP*BV
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MA'R26N.<P0O41A^YCTEASZ/!QD?!N38"%!3)M;TM@*Q[\,*#B7VM5)2B7J9
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MSJ< RM3Y81,A<MU+4>W&42O:00_Z.OSE']W^<%ACZ4M-7K].;:QR(O[%]7L
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M,:=TC(3G;!QTAM5BI1S&5H4_7#V'&1[UA]!R/RV33#1=Z6GV6<RX[%*!I.5
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MSUO<@J79K6P+O5B5!ZA2JU7G+BD.!C&,3VF^9T5[H@Y[4/[@M];W_N!KWIQ
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MPEBU -WC:M,HOGQ>QC;%+7G9?(]DG-U/9^DR2.2-%,C<QL0Q7D6-2::Y?S
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M+9ZW>-[B^3<G)&WQ_ O@^6K/>9MQ:74& ,X5X+GWQ+#(2&:HU987C!4."]5
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MJD@*EIE J9<Z8ANMU?/AHEH/W#TAK0%*5G=<SHAUD[SM8DD_TO"""/D12/
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M]%C_'1X&7S@$^)DCW;931POW+=RW[LGO'_J75?/,<R&C8*3@QA,N@B0V1Z^
MTIF1D>4\MP_</=E"?PO]+?1_<^A?X^QM]?PO"O8KWM]<T\BB01YS:D'/IY*H
MX"-QNHC:9+$(S"3O[X,G._MAP?[K>\;N+\BM)4S_96P @N"_OOO^T7_!/\V(
MYA[C[:0<=^,5TJCCEZ<364T)#+UG+LKP:_/';[Y;7O3,U:_=01I$^M%O?3,Z
MZPZ:V46_X=*\I!M6'_]VV?7C\U^UWBLT17BN_9SUC:M/Z5Y"[J4M4'W&V1[C
M^<:/LSVZ\;/K+DO%7IZI3[KL];?,N;S[P<+L?>(<?(/!PLQ2=JO+WN#XOA$)
MJ%CY[IJMZP*<^:-[D^[X^V00.GFVVP'E@FT3!W@8U:C5L$"Q&8Z2E?LKH',8
MX;=V'OW4'73@9CUD]/[Y-FSUFY#Z!K"^9RN>/+__94>_/)IIBG?U]+<Y);^/
M69SSHJ2YG'>EM+.Y[6R"C7*=1'X_A'WK%:CGFUM>?E8;C2^;#O%U4BH>V B_
M=W*'&;?D=722GUU3>:^>^>'W*U__7%LXIZC,K6.9IR;S7 >EX%_%N2B\IS8/
M67).L:S(L[;#WAI?%(YCGQ\]>RT.V=_PO1?9X<F^.#YX]^'-R<OSXW\./QR=
M')V_Z;_@R[ZHUPR>Y> L>_/VW<<W_SSY>'3PXL/AP3M^?/*T=_3LB8 QT$/V
MM/_FX#P>KFGE06.P ;GNO/"*\)@;HIP4A"L76& QLNC6=MA[\#6<+08]! RJ
MV\FVTM9*6WOBM2?>]B?>"EV"SFG4QE%2*.T(=SPG2NN,%!DLIN"Z8+2X9R=>
M6W@]S:KM;C:%?[#2Z\]&,,>HE#SG&4 7SWBFC=" 6":SD?+ 78M@]P#!CM:P
MV^NBL#3F!7%.9(1S$XDMN":A$'F1TZ"IC'>!8-]9!<^/! .?IC:W"_Y@%[S%
M_>\.]U<TUUS)O, <48:4PCR$0!3WG 07%671\J#E@\']6J=M1M$(,TM;^;YT
M9V^OT7:K;[O5?Y5K?.^!L1^H2_QG:RC(C6!XGBEN*?S'V-Q[*5G0A3%%5.JV
M&DI+"O;5U)4UH27/LQ@S+XFE#$-+FA(+L(MUYX6CO%"YEZFD1:YR@CUX?W^[
MD;_21OZ!R]6^VM9>[94&MH;16A!IP0CA7$?8VD5.7'16.6?A0XG=VFDAVJW=
M;NV6ANI>;.,5AP+UN56%AA/:,@';V.?$P!H2Z?+ N#!1:HYU2#1;K4-Z>-&P
MAV(I_*CMF3\;DD+N6?112"$-I]%ID&.3F\)X2CU T]V9#2WNW!IWUK5GAH.C
MX SL 9]A_:/Q@B@X. B-&2]DX801'MLS?[9=L'[GWXN6ANU._;([]?ON1O35
M]NZ*ZD^Y-EHY37)&P987+"-*%Y0H[[ES(5,Q1Q[=8K6U>KMWV[V[A>+?[M-M
M]NF*;L]@F1SCE-@\Y@2V9DZ4S>&@Y:9P4@I-#29VZ_MTQG[O,8 ?L//I9\.-
M$E2J&*2BEG.6P[]!FFBU9BRW+N=M+.#>H=&:SJ?*2JNETD0Q3%VPQA!C5"3:
MRZ*PF<ZSW%2=3]4]\C2T#L.'M9%;G?].=N^*SN\X:/@<FV4(T/1YR"(QP6LB
M84D#9HUI&L%>EZL=!MN]V^[=5N?_0OMT1>=7(42;14,R(13A&36@\VM.I%-:
M95F,-& 7KN(^[=.VMJ5M*GA?,YQ;F^&K%>JM:RKHO?6YXA9F%!N?%UD@5A>*
M&,:MBIG0@K-$AU[<E1.CK7QH<:%-1[K_2+'2V$9Z%:+VA+GH"7<L$B4S07+)
M++.R8#P83#7,M&Z1HD6*>X$4;7;3':/""LUR\-R;+)<D*(><^GE.+*6.B%Q:
M+4+D#!.0Z:XL5MNIW$=4:#MOW52_TW;>^N),+M\+'_^].2+:SEM?^ZA8UWE+
M*,!O&DD4+A)NK"%:1D:*/&H>N=(Z9,G4E)]]5-P]*#\L9OP6=EO8O0>PV]KP
MWQB"EVUX[X6AF9&$"AD(IP$@6%M%5&X]"UYR)>0=V? M!+<0W$+P-X?@MA/5
MUP;=%1<)*Z(*04CB#4 M]UB)P1D6<DIE"I8+HV)RD=Q9;L<W!-TU?8=6&IW#
M:Y3U[F!BZG9;R_V)EIH,V=[0O?NM;SZ0JF-,OB<D_3^_];N#^@U6O;'<=&AX
ML7/;BZ_^M.Y3Q-4>HP(W[]PE%OL=Y8L(/.NH='?X0K.; (8U #,_M=6.!>B0
M#AWT,<MX094URN8TD]0I;5PN&Y^.F5/$.L.XZMWI7)JR\[^W0+%">IH5<+N(
MF!6,XL(%+71A6!ZI#*<'J9\>S2BY76.]>5WQ."Z#VW<-9+WPWR^OWOSC+RSC
MQ>NWK_F;D[.KHY.7;P]/'#\Z<.S-/[_WW_0!H$Z>"VR1=]B'_W\\BH=O7W\X
M?G$:+,VCLJ#[Z<P2'@&+=#2&""&B*T+.E- [CXI5Q:]IT).RJ+=9?>%!J82+
MY\$+'AD<7<:"EJD$9RKJ@J?59\WJLW;UO]#J7QV=G1;4.F^B)<Q:3;@L!(%]
M:$DA"^HRD5NJP\XCN9H9/%U]F-S.^#S _T<A=/JPT.=E)PQ\\)U#,W+GG9RF
M#E9YDA-<T-W.*)07 :[S/O2N=K>6GV!BI(5E@BO+I<IL'FQ!O>*8(<=S4<N/
M;-'CR\H//WIQFBF7T0CV8J0.+$?8TP24%T\HS92,)C=Y07<>L37$>)\,'YGS
MF \IM<P*SFW0-)=&>I6'8&4F*OB@S?*W\/&EEE\<GIU&7Q2%,XI$(0O481DQ
MBF5$QL+DO C><P'+GZ]2D:S@QP"TEC7P46FZ-V#(7N<)Z%9]]!K!-T#)N8W2
MTMQX%/H&J:U'^+78Q06M[@6(-IR<G>,+V>F6\#OX3:\WO"Q_W4I@OT;C^+FG
M??+A(@S*\+)YK./X-#W4ZV!&K3"O%^:SCZ )@?55:.\<R77F""R:("9Z2E3A
M./-,NLSG<!9NAK+=!R 61W#_D\O0>Q\.TUYK)6*#1&2'EZ<"3C66.TI$L" 1
M&3-$&YL1RI01>1ZC"6"BL^)ABP0"P\GEL)6$39)P='FJA7/:FX)DG$6PDI@B
MUH5 0/?)+5A/6E4'7?'P)0'U^%86-L@"/7QQ*IA1N7(Y\;X B]D+213GFE#!
M;<&XB]H:D(7L#DWF;R<.3X>35FO8* V@-42A%(M1$19S.".XHD1+T(.EL=Z[
MP#(;0&N@<I7&JY&&O76NS]JS.W52IJFE/N?1P?\89SQ:9[G*)0 3'%-940AW
MBM1_]8\6O*MW8$ O"M)!L.,#4"M[PW(R"B=PZ7^CO_3;BH XNJI%X.WKJS=O
M]_GAR:OLZ.3P(WR?'O[S]/SH[>]O#_LONX?/7N5O#LY[AP=/^\LB -_I'QZ<
M?3@Z@=]\Q+&]^O#ZGR?L$.[_YMGSRS<G_AV(U^7A/V_BX<D[>K1_&B+8P S4
M1>%B@8=#033C@GC*J"[@;'"JWM"PP,'OXT8R.89MJ.0T9)Q2;5AT&G:W%U$J
M;OE.)\"^NH I'X\FX3HW<[&%FSD$)AG?WLV<WY0"F-S,8J_SQW!P1D["J-\Y
MMC"<BFTYP=UQR@S\ZQQ0IOK"OX=XQ^[@K%R1]CMUD;-;C7TV<!3MU?UWSSW\
M_X3.N?&=<7+8]_!9QO@LP]DB[(()7 ?XDMGK)J-1&(P[%PC[]9%496^6:8W2
M[^UTC7;1.OZ:1Y8SY[^F^ .N#"X,##!)#_X])URW.YST#X=,^^+XY-6'PY/7
M'P\/GG\$E#+,YX)GDD3+<\*EL,04N4*(5RQ(*ZL*U;TU!Y7]1+7E<Z/5K0Q\
MG@R\SHY/GK,CC&I_?,V/]T^=SH+(,C!CK,Q !J0G.GBP:D5.+9Q(-H\6<7PU
MTW(J ^@VV^29^WTR"/7;V>Y:/]U^KU=Y^X;C4,)G%_ QHM $U$U I.#G(0LA
MY[$9 60!J/UW,+WQ^6[G^<#MI9N-S.!=)_QG8GJ]*\"V3HI"XT\NS%4?KWG9
M'9]WX%-\#[383OC0!7P&^,-?Q\D8;C=W7WP37DTP#@XW1%<BNL\L_#$(9;D'
M-P9(#.4878$7INL[%Y-1.3%PH_&PBH" 4*8QXXNYQ]CKG)S#4];/;."N(<9F
M2CH+=ZROU.L:F.[NN!O*9O#PM;+KNV8$[RU >6(IA4?&T'KYE4!:K;C0G1M.
M!N/RSVH<CZNS97_@CX:#^J!I]^BZ/7ITLG]UB@ LK<\(<TIA"5T@FAM/8J!&
MAR!]-* !,KVWQKOPE:&Y7?D[7'EQ&GR>6V%RHJ@!//8J$!-R]"=HJL#,LT87
ML/)R;XV'<;KRXT_'XUOJN=N8&%]6SSV8C!H%=E/ >7$>=CN7&.))@(V_BA,X
M$"[@(JY[87H-6F^S<V0&UPU@,E,P\D(6K<JH!QL/K'T;E<JV3EYY&>H3JSR.
M1WA&U'OI0;A=OL&^>2&./KZBQP=/,M!P\L/]4R\T+ 'G8'!S3[CV8'_+G!+8
M0J#Q6D?S0B*G\29>U,8KE^^Q_]-)*]#QDU!OHW$'E@"D;GQ5*Q3O3;>'R]-Q
MICQ_T#OH-B%75F\@'T(?M214IR;C<@SP@I?9*N_'93$$[7(? U?,VU#(J'+-
M9&YS+N.M _=H%LQO%-A $QBW*8-O]\SZ/7/&3@M0,7*86.)PAKF!_0(V'YH"
MH/H7RCBC<V02VT3HT>R2&7B:/A[]B*%LKZ#%_-[!DR>)#VX@D^2G?S&N?^Y"
MI;>CNHL9T T*KUP9SS#CW&@"DF<G:"4D'._6FOANYZ(W*=-/^^9=()?GPQY>
M)?2[DW['7%STNB[MU%JM3@HX*O(HEX-0"6S:U./S;CDWR%KF':;$P@B^MI27
M !'PU_(Y\<QT!^4?P[(,Y?'@R0<T92;=\AQ/CN.(7JM6^-<)__'!X=6IBE2%
MW%C"N>.$L\B(8@H4+:,8#53Z(F ]^DTG1 ]FOP/_#68$IEM86 .48K07D[E7
M?V-.[C%'-DX2RM[J'/D&/M#*1?L4;%'8A@#N^R.PL<]"?Z'MQ4/QB,(NQ[SU
M-/>P_W&2$YX \G3?PT: 9ZI\GA=A9));('TE]H:7NXTC% QO5QG5O2[\S*,2
M4)G>H6,JR=@J<TU%K:P33(B<.\>,LYYF7#DJH[!Y?MLHWA_PL,?Q,0A7=_S4
M./047!V:#]W^I#]UJC\V%_#)^*HUOC:X1^GAY6DPP6744I+E$8Y$Q3#CAVD"
MJQ$H1FUHQ.S%O558:*RO2@C<L-\/(X>B>V% GN ,&IZ-3+^#I1AX=EUM>8AD
M4AC0N#(7.>4.C'/%"\]%!-76%(4K6DGYFHYTD)1"*2&IC@1FWQ$>N2.H-A$J
M"J5!9W(J8[>1E%%X/^R]3VB3%J43ZU79Z_P#F-(KAYUS\_Z3T"5J(PJI\XR'
MP$6N;&%MR$(.FIX5P;<R\Q5EYLG'X_U3I16UBN5$6H9A81>(R?.".)I%"2M5
MA(B9 ;="E^X8W<.@D@8XO)*GMS3X[TQ\MK3K\MW.I$IZG8PZ&_$K'9#U%U:'
M4'\K:<L8?>Q74H+?MC"$)ASI0=&YJE7Z<L%ZW-);+<&>=QZF#UW6IJ F!-#I
M,J]YIKT4^=:)_]>(^GX:[O%LL-7\_@G*R+"U,F_AF7$?#L].O8I9S PGKL@U
M-JO,B1)@>"I*?28CPZR5G4><;VI5.9\O!; X,F=A)EWS<O4Y8G7G]23KQ&J_
M&OV<0%42UHK2+40)*Y4$TW#04DEP50@O'.AJ0DJ29YDN(J6!.0.B=+T@[77V
MUWK+IQ"V#1H5VIM<%KG3GA=":BN\C30RI((6X=;:?+*ZIE'M65;,HF3$[H?@
MR<<P&OZP0@''*JIB*A=@0661L"@,X=9[8H4J",T]M3:S'/Z[\V@P7#U5UQU!
M-Q^"&#+9H+1UAJ-KCL?E$_HAFM!/@QU-S.AJMDM@9)5.@0_>VC0/<B-]/,N.
M#YZ+PX/7XOCD]>7ABSNP;Z[9)4TAU4R81()=E7RQ?X6+<>A;V'!SX89!N S7
MJ9Z+>VNJKS9W6LH:Z3R=I-V^V_GCC\>=G_[O_U)PGO_V^+^?IK_H;S]/?S@;
M3!TQ%7L=^%[RW@U'9V8 V\>C4#6;^9:;\J2+;62/PF7GY;!O!I^W+SM;WOSN
M$ &MBS(YV2>CBV$94-6RDRM<]/G5076M#" 6%<!VWW=]F+GM2\S6&9_CS^=_
ME)STW9$G%V:$2UJ'=$8E9@W!UW%Y % 2,45*EDENU)7\H$6472&9J-Y=1N#Z
M(27Z2>&YDM?PUU'H&8R3UXP/-5?+W*]JP,YF/S$6AC<9;_[)'+"[@/-1X_JC
M_[*C7]:D?=_FA)A>*-%KS :7^#Q +'KFH@R_-G_\ML1SD7[TV^(-D&=TF?D"
M[U=]7#^<UGM*Y/A\-2]J?>/ZT??2HR]1D]0\'6R/YF+CQ]D>W?C9#9?E3'V)
MR])<WNJR-4OLDE2)1 "U@79J+>M*G:9](X/T?;C.#<RXG]H?\*XC(#?B6]JJ
MB[PZ7_#VZSET\WP)O38OU&?,ZTU8]%5G?/FDOF;N/[5XX79S__^^R:F:;OTB
M_V9/_>T>^NE<I?U34-([-",OMA;_52AJ2*:^J6+V.2;>.E5@_M_ST6P2S@*Q
MHV#>$1-A__YJ>I?FJMSY9?'6<-]Y_6:3:K(RQ$]43;ZZ(@*/LI=5C[.M)L+X
MGF2;/_Y4E4%D>UKI.[\L@\OJS3]=HXG<GNTR<!ISL401-Z\"5)_?8;O?FI3N
M"P%;E8H$-D6=S@"7_6L,9L-B,L.-BM"-$W%[G6J[2ZTAS+MK.)F[WLI&^CQ>
M//ZP>?%N+,U<+.4L+)>YR7)CX"_/8(L:KIFC1A@A'2O0D>;VT.@U#E/*0!Q#
M9;P^V]__<S?Y%Y!>!DQF,'U!1CN]< 9/")**OHTX&O:O*8-)'R]4B*##Q8R3
M 5XN6]APK[WFACY@HEE5=6(#WO\B5.[/RKC?[5@S>#>:7(S=%1F%/NRH9DR7
MR7JOB72PHF66S83N@=X57K.$.2WC555MV#/=JCBF"[^H'$1#-.UO4_O\(*7H
M9JDXAD5;<9KADM["Y=5-U5/_F72QABFM+++]C T*V:*79!#&($]U[ PSG8:X
M"@/XP7"$2?0&\YZE )./T+W.?EJC31&2RS#"YH@XP(M>=R;'*7TR3H'6#=\'
M^'N\IK!]C89TN\IVP*:O5-K^.,U^.B?V!_YQ&OU9@"<+Y;VK>/]P>+#__LW@
M]_,W'X?LZ!E<O__Z\O4_SR^/3@[A[[_[QP<OK@[_>7E^_.QI_TW_:??H[2MV
MV-79F_\YSUS_[X'Y1T^.W[[.X/I7;][^^_SUVWUZ^!'^_N<UAWM_>//L"7_]
MSYL^7),=G;R^^A\D5#AY=7F:FQ"5LX8H%QDR?V7$BAA)E,:RF,>,6[4,E )C
M]IEW0EL 5I_9X%E&<VJ]M$5!U4.L>2\ 3F<" V#>R,NX\\=<%1]NZS_@SZHD
M\ L87<6M1KNZ_;Y!FNG<?&W$^J^-[.M'^BP,$L3\A8F@"-)_PZ"Q;+1R/?_]
M5^.U>#R$$W-4H?]/.[,/=GY^<*?9\T'G]TD/ WZ45P&_$K70;GD.A\E+^/^Q
M>3>=D#J@LK/\_L[/NW .O=K[:X]8+,OHG-4S>7%N1GWCPB1ICU6&+4[L^PT3
MB]7&, %(6X,/6)$:Q,YU1P!/G"N1PR'B>&&,DH!%7/'<6%?0X/$(H#S# J'F
MCY40XW!PAK?ZLXY!S"1V3?X/3+3[U4]&5XE?[P<[#9XC_PE7SEAK-#%21 )S
MSH@Q<"!PQB0UAC*&$?E9<GT3C>G@E($.N"P]H+.<#6&]T8+;)#B3BPL04EQX
M#$2FI'P;SDTO-CHF1I&Z6$T",)/BC/N3,]A5J,S0)->PXM,XMCD;A60:HB95
M1;BG)=W3V&!3TZ*K7,U1:#0P7^E?[T+G/Q.X:\#,_Z:D+RG=B_(\O7!=]F)F
M:?;WH@Q@0>6YYPB-CKO7P]&[SO%%=P@V]5_C< FF4GG>O>CLNX?'XX)R>C'J
MHE^4JMTD'LEM@;(R?=8+-+RP+LE._!FH]Y?G77?>%"94@KM^.CH_X6<[QW_M
M[_Q<E:G GVAYU,RIL ]@(YSA_;8J>3(ZR @&CC>2BXPKV&*,:Z>MR6W,)&9V
M4)7QZV@^]IL[[R?^5N0D*\O^K:O'OW$NU#= 7G=Y_.(4YAPL&)<#Z/I .#>6
MZ!ST<5\PD;MH*)A#B+PWU34UI+G364<\Q5K/OAE,P.3$LWE4:;&^6XY'73M!
M\[W3ZSHDBDL B/X&3(B:?@&$-DEABO<WPKO7>94RKL:5\.UV@@'9G5YG_G[+
MM^M<#B<]CZZ*>=P%H(6=T+ 8-9 Z>Y!*_T"K',"X/$?8KK]492>#&7QQGA*F
M<2Y2%LE\B1 8TG[QJ?S\XW3\+.UZKN 0A7+@S2B=<+LP9 "; 7X/?@I[0>YU
M_IK8$NX#]T *]-6M/8!W0/$:XS0F=TY_Z+NQ6V_ON><[&^)U88_@1D]3UNN"
MLM+@ .QO3*RX'%:';><GO'U-HTS5S[>M7[X50FYL//*U*+"J6M':ZJP/L$X7
M]8%$VC(:VJH<]#P5I38L*U<=T/%@C0+JF8FSHIK'--%5=K$SJ%Z@*ERQ3">%
M(B7#!+B9;\[].09IG.U90M.4?F 5S+?*5"X"M9H)2[$QHO4FY(P:9C1SWGNM
MJ]I2V.[)NT$INS&7;EB6L^/^:A_GS_3^K'67%GHWN$"RPX/GIX9KZCGCA%O,
M0PW:$)UI1;P77F<%,R&QMMP O;M)_]P,7Z@P+J!)C1_[XTH?G1%[U!G,9E!M
M@XK<8AOIHJ#"NTAM,+[@(6+U4.:9B]%E47H1;]M;:KU0[8\?PR;'5+&_36_R
M,,@MOHEL'9^\.RTBITYEGF2A@,/="$>,$/"22^>$M=*;[#:R56F&4YJMVMII
M8*SAEMI2^A06&WVS%,1MJYSF*_FWV0U<24=]X1R@*%?46"JYD]+'(D272W=3
M54B^L8Y__?Y8V!V5F^'Y %7S,AR$ZK_MGMFP9]CAQR>GA<L*C2RLU@1/P B)
M1$MKB6&P- 6/ &)NY]$JA=:B)IQ:1;AA/Y%&@"8P<:$*;S2@6G-)= ?OAZ"T
M^D9#: S[U=TROY]0K6C4@:\IC.W!?R>"]N+C\<G9Y='!:_C>ZZO#D^>G3A<Y
M*@*$*J0>*B+(FPJ<:%H8*I2(H)WM/%JEU%S":8#G26]<&PB??H+G5$JJ:;12
M@< 7RD0O.=B"H!S*&(*]=8E%>X+?E9 <'[P[]2'Z4%!.J*3(3Q4S8K#QH_*4
MR3QGD5M]HY!,>=ZF#;7NU';[*MZZ/U)>PY^CH0O!KV5^OC]/L-'(M"$=#W@
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M7V2?6-#Y.=K:-VZ6]2VT-7'T]LDI&+=64L5)01T@/#62@#D0B+ Q1N6I5[)
M.M!\@[K6M,E*J<%4-=QW)YMV5>H%7)_JF/K]=C*HK&O8M-T0$X/<<AKJ5&?
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M%S6-\-PE-B=$#!9;%,QE?%R3UQ 6,D%F2@I:V)N7?);B@-MYP;F9#*1%#V<
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MS^B&#(OL!GNPVB)@#4XG_,?>+B>.GW+) @]*$5^80'B1&V*#""3X/+H\=Q:
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M3")\+<4!%DPLK.1JBESJ5:KHSV8W^E?9>36(ICOJ_)G$Q<&J[#LP!0XQU="
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M9,WG4G4U0_5X'5/V.E&9!=)6C9N!7PS45?2YC7M@Y9;U/<9+U]F"]V-.C7V
M*+X6S/ZL*I(>7CK^.N;D:772((P1$LZ;@JNRIC?!%:U;02SH= DQ&NB"A9[Q
M)2?\JQ&A7T'H<&[_;NOC#B9&6E@&^@,F9F0V!Q6#>L6IY9SGXM;%3T@K]SP%
M*?%YYC*,AO$Q#G8_#:4IMFC5O@W>;@86C#B568PB"XIPRRSH>EP3ZX0E0=,\
M%X(%+>S.H^(& N5I)I$I%T/)\Z?/3[,BII]_ 9 ;G2%>@[SNSEOD-]7B/4#T
MF?=D'X3$T(GGT0/V9#?9BK7'E>IT(LVQIJ73$,.!,T]U.9N%Z=E6>]\6O,%+
M/IM=."W=WD+*^]:>Y^44E#6>[PK@IL[G?P]A%/CB(!W+J(5,\U'6>11MXR:J
MBE@C:%.NF^H")LE["-I@!'TN_7PXX_^'\Q9$'5LH+S_VO\I5&N/A&OKBRBV=
MC/+Y#--I6BC\K@YNOJ_<<6%0SG27Y15K])<%C:^*FOJ9X";N\KEVA,Y<I#$^
MQ[ZC&]9OK=PW>LR44 \&,:<?;E: ED&@Y>IJN;I:KJZ6J^O!<'45+5=7R]75
M<G6U7%TM5U?+U=5R=;5<7=MQ=7US#JVOXF583TEV,\78BG]TM5,7=E;&Q9HS
MG9?\HK-DC\:T;U+04DRS[J]2MQM*62_U-= ZKJ(?\_UTFQXS3;U_Q>^SKKGL
M0L_*^7YCW858%C[7.I]!Y:ZHDG&J;+ZYW-'5>/WNHO-ET:T!UCC6T2RK;MMX
M?3,>6&$S+X/P7'%M!(M49(7*8N:*G&[E]7TV&I;E-+0_\_S^._53;:J4GH8V
MV+_1ZYOC-4ZM5ZXP.2=%5(QPV$M$*TU)\)8S1GWDGMVB]>5NIY<2TSZ9$.W.
MI&.: (_9U:T 7"\ 3IQ&+HW*"FR7Z!WA6:"@6>89R:5PL?!649CI1_E-%4$8
M"J]W7?FO3@Q-XF!5@0,O+DVB-YO/8DH]T^;Z7<";\-W>W@K,;!/26JS.WS(R
M=>=2V$06G\+@UL#5<=-G#B-5[U-Z:2NNF\3U^."Y.&4%T\;!_ ?-->$\%D1E
MSI/,&\HSP40>X\XCO4I9]<VB5*O.Z >9.KYAK)]IY>*5*EW.@Q+GX'^,,]#E
MG.4JE\[I2%U6%,*=TBQ?]SCKR&MAV8\FJ<WJ'<2=E[,),=I\8CX<=$O7&R)O
MZ0E<_]\XB]]\2Q[66_+B_,VSYY=OWCK8,B_$ZX_OLN-G+[NO_WGY[HC]_N[-
ML[][KT_.+M\<O,K?/%[:DOVG[UZ__7?_Z*.#;=A[>WSR@K]Y!M=\]B)_W7_Y
M[LT_?Y\?'_S[W=&)?_<_'U]@_>!I='D41EDX-E0DW M)M"@"45QJGX>8&:^6
MR8$MTQ[F'Q0,JK@-UIHLY$(+ 7,NI<AV.@& [@(]EJ-)^,)F3K&%F?.IKKG\
M5N%AB:&X5',-$A;*+^"H*VXUCOL<6%]O(#[M3=QX4I=;U.5PR9PKFPY:=3'[
M&">VXJR$LQ>=X.8L51]<C- ?]:$3S A9',I??L)2O9\[/_W?_Z4 %'Z;=6K'
M;\&I'=(']+>?4]Y474):U2*4%2LLIL69FK85E:$4LJY:C:U>;465P4>85GST
MNQ\:"].- ER@BYU#UV1 ?(.DAB?39P&I[;R$9WEPXG-PJ]KE2H586_2;2H=7
MUA3UBSJ^M$D''=3$,0L'52$]S0HL)>"!NV 4%RYHH0O#\DAEN"$)/E\^M:8K
M-#V^<)6J\N )//AQTW_YEMHG83_<67>8';\XM3I38!L9XJFSA&.]A\J9(51S
M[@L3+3<*0WI[ZQA3*[1!R?H4D?C,G+E6)+Z 2-"CL],(>BO53A,AN,,^E(I8
M6 6"51,\2)J[()-(K.G;6HO$,OU!E?0=>_!.F;R#3;>ZRBF7#JFT>F7SUMEP
MZ%.U#7ZS.TJ6;VVPS)LWG\[0<*]3[>X(TAN+C5V'YIV?MMNVPGL6!*C(P0L>
M66:CL2QX)3A341>\WK8UDK,UVW8#[\DV^_?'W:*OV.&+4TZE$])' @@-6Y0K
M32R<ID1S(U3A0:4WQ<XC38N]52*'G^=Q>]O%SYQ7,4BI959P,',TS:617N4A
M6)D)ODA UR[^G2_^\?XI%XKQF#&B72$(S\ PM87-"3.11V5"!JK6SB/.]U8=
MW#_?"J!3/<4&@/Z"^#Q%J_M,,K;>7D KX<GL 'O63,[SV>0\KB;G'C_:C8?.
M+9F/+A<8UQHC]#J!V;;8@C+)!6BF)@\\L*C@M64V-T;S@E&WM4N[6:_9<CTD
M)N*O#4)GV>'EJ0)%/0,%@$BML=&"MT1IT!2IL9$&5G!O\IU'JKC!:[W,'%'1
M&_82&TL59\;X",J/#8,0N^/5)C2-$'7+[81(%)K[3,%X(R^,TYFU(>@BYYX'
M[_-E(2I6V8$W'&73$ZSF:OMW-?)6G-:+T[LK4&A"QKR3>4Y\CC%; 0J-DJ#0
M1*9RRH/048B=1\7_S]Z[-K619&NC?T7!V?N<[@@GD_=+]PE'N!O;0\< 8[?<
M'OA"Y!4$NC"Z-(9X?_R[LDH2N@$2"!!V[=CCMJ5255;FRF<]:^6ZZ'ND*7O%
MTDU(WBOD^%_:Y:ESNW"'9:$N\EI#$=@Q=I6-BH*4G<8'[4$OY[<6+L&4*QD7
M&GZDN*=5^>BVPUB-,'(MWE2:L^UVOMN\M;!=^WH:RX&5140G8!ZT>^XPL>RM
M"BUABP(O2_YB7,UNQIGIBO"(:5_H*&GF"BY&_0[*J1[#0BB%1[/3NACDTJZY
MR$,Y.85[<N$]1NDT_QW8;BYSD@G,@ON68'4SW852FW9MSDY9F?73Z.:XG48W
M%A$L9?Q-.=)QOB)\!M/D822;S(P6RW-]9?:XPD%D8;X^0) G]T^^18Y=FMAF
MM^RG$[A%NTR0&E*<XOA_P;OTAC5T;M H2\PHRWUJ.P*6@0XHJD#F:-.;FPU3
MO\-,&<C;WVD.^][E[36:RE-8DQQW-;.;1NQL*/HCH5^*Z0V]^^7,C^0Z/R^#
M5QY^GHJB6 OLFT:K%(-2)1:)N0_O-$B#MIX7;;0X]=$ESSP1(5AAB4SV 055
M*HV]@L;>O=R[_G2,O4HI8(4B;";$K<%()]#@F@N%G4I.&F" ZMXHJQ+CRETQ
M%/?7&$SP"K#XCM/#H>:YI=SF1!VTG'(YHX'G;/Q[@2/K4$">(O[R)IPJ!W66
M?1-ZO=B_;TQ3)4!K=F'EVE&=CL58=&-1+')7+ >!67NL9'7P9&5D$2MKN231
M:"N=IB%Q$HSVX]9*=U@=%70]QH%VTX]D)]>#\L><&,I<XHB*W#&0TX T$0Z1
MX#D5UAB/X_TU FYJD'5S(]3>N)1^RE&!IV/V"-MG4D=OPEGWE_;$!LB.K*$(
MO3Y7U=>R3/5*M=E*3SH8G,IR ULQ,>NUH]F'H1U9NK75Y"3"'(ZF<+EM:'ZX
M;;A[?;#SY1A;,.QADI$WRB%.HT36F=P\A2@+_U(V^:VW9'M!ZQ3WP*K]GA*E
M..-8!\X!9HT5AE)LL4LD!R84ZTWOA]U'K?>/![NPWO7=8^\\R>?[2,G<NR[:
MB+2V&%;>,1R$%* 4M]X:OB#48 2S@)^#2;R:T..Y .Q"%E"6[QBTX_!C/#H3
MG3P"*:G"\K\>\8^Q_;E)L%,'&_5K9] ,NP6K'I^M#4_5*BF]14HQW/\X\:AU
MMAT%(2HW*+/(<F<0<8HJ$ZW$(FR]U69!],-#>XD\,2I5XO!0<:B_/_98,.$C
MB$/D( [&660DX2@ZD3T/240#H*7%O&MZ2=":/H@MW$M%/[K1Y6 AY[4;MIIK
MC_U'[5MB.EZATWMQWY%;<?MRXWC>V K[=VS;9LYY>=<.NT4Z9J__KNR546VS
M6[89W3L[.6;!"FTB149@X((V,&05L(0($D(\(U0D F;8 BJXH:!;B<2C1.(:
MS -/C0HQ9*AEB./DD;4QMZ[1P01./ C&UEM^._#.!;E,-*TI\YRO1AEUC>'"
ME*ZIT8I-'C;?@> 3G<F'5TPTTGL"C]NH/^28@N:#I9.</ERSK<Z@*-E6GHKE
M4,O)L98%U<KCLO&A24Z)[G9OFN,-\PG&[KA1AG7CWE&_HK8\MQ0?+<Y3\\%+
MIVU=\ZIV,>Q,/:Z+URT2/9LY83[7#RW[- QGI9S\.]7]9/^*-KQRC="1DW&8
M;F'':9.C(Z(BQV*W3+UHUC['OV-NX?EG[/[=@+G^:6OW\Y];/^?#JG*YX''%
M(<R@?]HIVWN\N7F-Z3Q2^.6DVW40BO/DWB 6M"2[87N]T;7QV["X\NWO-NI9
M]NVB<=/L(TORH%^^32[D/VP@4E3G'1UKW50=[!;S.7SQ\:AOIODA$]NX:;"S
M2MYL<E(P#K8IZ ?IN2-!&BN5\U8K1\VRC&$GE@=YN^W;%$7O\UC>1HW0IQ5#
M:GP#%+R.W<X/K!/VR%[]Y)C':%BR#)$D@8T'HI%CS"!O,/68ZMSS<>MMGJIY
MK5#V.,KQ1&&X)L56O<B[;A7BD&*B@GNC*;<\..\BCL( J13!>V"JSR@9%668
MR%S8.3\62IH@I4&2@%#P!!:;=0$C!I]:AY.U9>F'^:CH&\X0OX%J[&6+*J?0
MC:G J(]19@D;X;<OFS=DA_U>6<K^U6G;KV51]PG>D3L##+KMFZ9L6?6E&(J^
MS&>#;J,7&L5ZO:G];;N-SJ WF8$X><&P'=3HJLR&X&VG+P$=E+L;I7B9%SU>
M#']W69:-GVA;4VI&=[5 MTZ&711!'F7[ME$XU&0$T<15KR^.9UA+WQ;%@:[*
M[J5YP49M%&XJ"A4=HW+WN0^#@OG^WLE%DH?U![9NOMCZ&9:H*/;;"$4U8=AN
MO^7Z/K"X.PU_W@!B65IUOW=:\+H3M8/BXD>_F7PL:/V.:^;"!R5_;\!O6VV8
MO5HI#N-JPL.PE"+QO=SF?6 AO:$>*,EP&<L#=\D!1N,#/()KO0M8K$X:U78>
M/GS<'Z)X8J/LIS L^5$4E5OUV-AJ%D&A1",CX\P%F\-LN8C,.!FB%O>IG+*J
M_-1P/H]'4ZF46VH!?#L QH&M$H%0CP(. G%");(,&Y1RI!&5'BNLM]YJO#['
M!'=<,<\29Y+RP*0#0]A+6&V) _/#Q;[#,5$M]D,6^VIOY\NQ#]GIY!B2DB7$
MF7!(VZ21#UZE*!+#,FR]5?=VQ^W?6L+[II!'5<"[*N!=%?"N"GAO8 %O517P
MK@IX5P6\JP+>50'OJH!W5<"[*N!=%?!>MH#WO64 WSXT0K%T:,YF;CXP8:*W
MH(;G4VF-50IBRG%*SM,6O?Q@&]V_;',0;XI>]C:GZN7AJ!"M.-IYEZ]IP7??
M]LZ^X#WZ'A_L>'QTML<.OGYH9L?(WMGA@D*TS?.]8CR',([W5_OU3]>']4]\
M'\:\=^W%X=>_LF/D"NZ;"]%>[9WM'B>03R<53%I0"7'E(K+&$.2UT0I[&K@B
M=U6QW-02E'J[EI>[5JQW;2_:O-I3 /S2U2B?5M;_S 7^!\UXD,92_ZX C'?M
M\*^;V([AQ(2#["T<=',BU&^VU^C5,_C_T'MCY^0X8$&(BQ)A$6!O8(V1$8PA
M2KW7'E-+F5Q^;VR.$JL7*4K-9N>RR'O+2YU/.V(OG^04^4MYY_R=9:8\-1FJ
MFJ)TU$1@T,^UUE!\<F"JS6<=I0B!V@$9JMG^+_>IE^SL$;=-S*NA\EQN$[I^
M*D^ RB_I_5OMD8RS:K"O:[#+^9:7=(C>:CA0LHR3K_38K6)O/1#/]%+FUG1Y
MB"G[ZHD<Q$_WAHO\5>6P0BX]47#V7XH^M?FJK;<_ ?T?'D#U?E[>M)SQL>>1
M;^)Z+_;>_2N"950:360MK_S@LXE7.V^TFK<'S1NKYFWY>:MW^K:Y"AS/>P9]
M\7_K]/P]J28J+:Q?EA&2VUYU/=)SWT0^YA[5")]]A"OOFZ%_>_/VS6T'L;W3
M6OSOH $VYR(?^2KOB6N;\[:+4>)_'O5ZDZ_5S7?=F/=:)<]"<H4U=E)'SAG/
M9:,"89+C2(D6+BX;39\%YUT[Y/^\OQ&?!7[>UQ(!]S!'U^'7/WI']0X]:NVR
M_;,3 =>1_;/W,+X_FH=?#Z^.=D)C;^?#^?['[/CR_/!J^)O__''J6J%Y<';4
M.CSS]&#GG._G8N/U3U=[K;].C\[^.-^GNY=[7S_AP_HNV;\^/?O/]5Y_[T_\
M[5_U]_V]LQ-Z4/^$C[ET$AL;D& I%WG0$9E<R3-ZCQ-Q''-IMMZ2-PS3N2BZ
M]?MCEP.=Z7B;A^S%#-TK[LF5E,7,(V<53H6*WQDJ4BH4#]IC[ )/A-DHHZ?Y
M[,S3A(EZ8E3<R(RS5P*(5S. 2)G2/ J+/-,$<8DM,C1Q%$@RFN96M<IF"-*4
MT%\K2*P@L8+$A9#H&-;>>8%A,W&?HJ6!6VIQ$%$JHDD%B9L*B?MS'-':P*C@
M*&I#$2=1Y)R:@!SWBFG%*#&\@L0*$BM(O*>$#0F".Z*4L0:VCM+!IV \U]A2
M+8BK;.?-QL59JLB=HMC*A+23#'#1<&2-=DA@G$!84J"$5;;SDJ[043 (3%*\
M&TBK*Z>O_'[.9A:+;%DYH='^._;Z98VEG\CM)^9TM1=?J#A?K899EW=V]V:R
M%ZJ52G.LH#F^S'M=#6;9N2H0-LHCKGA$)AB'E V>$$4MMV[KK9E/7'XE:F,Q
MPCPIF5[VC.^'QH=U^2GOPX?*$E\/;LPR3AU$P PHIL%!YM,:BIQ6$5GIDA-6
M:2;]J[?$*_#83/!8ET>O H]G 8\Y-QZQT?$@#:) $Q&73B"=*Z53IS"U,4FG
M*O"HP&.S?5^59;)>D)CW:467M,C]E;Q#7(N$G)$"244]PS0JB5EEF50.K8UR
M:&ULT.1BV)S(XGQ8Q/$]!T?5/3;P'@_UTD[7@:!+IQ1LE OW0Z=[:;M%A8-^
MMVBW_!-]E MWZ5GYOEC4NOR[.S#0OXLRA67BPP0BO>N/>=5^[%?6V%J(ULF\
M"Y@9HPG3& 5-)()EM6"-88.T,"%@$B7+'52^#VML%0Q[#E-MJ?$\QH[[GN#I
MIV?Q+_?@'>%OCP"J"I!6 Z0YRX\PH[!/*$5'$&=,(V.Y0R119KF$%0UVZZV8
M#V684^05''S'</ "#N.*K3PW.,SYC@/'*0@)]$3R'!4?,;(\*F25=Y%Y["67
M%5NIX.G%X6D5MO)PGW3%5IX;D&;9BI?2<LTX8L0)Q+$,R %+0<Q))02F7+X:
MME+YD5_&C[QY WXM5U83^Y03.UV_=W'I_:K4WNLM"%<-MBJU]^RF4"Y771M5
MJJXJ[=UIB'T'%;RJ2GM5I;T7FK>JTEY5::^JM%>-L*JT5U7:>_#;OOYJ 8O?
M:Q7O-";&2)FTU(0[YVRR(DDNE8J!V6CNZRM;50M8Y+%F>5QP'3_X^D=K?^<]
MWJ]_/CWX^(7L??SC_*"^B^&SJ[VS]V+O]UF/=3C;_WAX?5@_$8>M0[Q7_T3V
M/[[G1_4OEX>M3V+O[!-\MGNU5S^_7%AISTO)=!(>\>@Y_)$"LBEI9*F,SFGG
M%'=;;^D;OJ#=?57+I$*GS4*GP#R5F"I-O>$N6I>[DG$A<7(@V9H^,3I]?V?[
MSP=,LT=IBC)'$]$(AWR4YC!#6FF-B*6),J$DI?3VL_T*FBIHVBQH\HPY1IF4
M2@<>G#7.$:.]D()Y+W2JH&E3H6DN[,C@F)@('F'M#>*$1N2\"4C12+UC"5-Y
M1]A1!4T5-&T6- F#F9!<4)\TET(:'8SQ/F&#%3<Q5C;=9N/3+'6R43D5"$-$
M V'BG@)U<LP@2;CT 6QV+<+FV715^,:F)*YNK._^1Z_$MC'>NQ^CWL$S(?B"
M2FR",)VBBDAK1A&G"B.G3418)&65"SBRM/76J,?"]QKK#E1U23;0C_5C%S5Z
MOOT[E[66X_:IYXA@EA#G,2$MHD<VP&(JJ231;FT68K6)-W,3K\OC4VWB9]G$
M\Y7)6. $)X:,I [Q8!UR3B1DJ!:.:>5#P-4F_LXW\;I\(Q5C7N]FG=6XSL9$
ML1+ DX5 /$:-'&Q@I*)S7C 3HK4;QI@?&AM4U=YYU*Q\7_BT+HN^RF9_7@@[
M7%![QR;'I6&(,(<1)]8B#>H&2<4=9Y%2>5>/MX<Y;C<FJWR5\3R(J?S8,+$N
MA\(/ETO^?' P=XI#E-!:4D2$(8A;%Y#AB8#YD9>/8AX2W7I+UG6$4R'!CX$$
MZ_)*5(3AN1%BO@,B,<FE)) E,B+N/4/6)X>B"]8:3H@E=W1 K&"B@HFG]WM4
MA.')X&"6,& IG&$)# :)>6[\1Y&UWB$LJ*61"^69>DV$H0H(J0JEO*XKJXE]
MD0HTTQ5C&*C"(?R@[/+\A>AIG3RL4E-^U&B'V.[_@O)%SZN1:5$8[B92Z7D?
M/3-%.+]]_336.G/!5,XV;=M'^,PW!R'VIK[,12P&_0&,*(&&Z+VI79XV_&FM
MDQ(H^UIJ#CQ\F95,<6F(*7:[,2][ZR*V>\4WM>8-)=BNP1AZ<>J>P^?EW\/8
MBF33_E6M%_V@6_P&'E;<S[;S/RX;_=,:2,)IK0E2$6NV#9H,R$FS!E)R#F/R
M]J+1!T&X+A^>OS^%6:G]%QZ8;UP8*/EE.ZT( W;]B4<5PZLE8"VUOS-MR8_N
M%P.>FI,>_*X?NRV8\E ;]&"6X>Z=/OQC.(:+;L/#W<8:]WL2:+IA CV]6HU<
M9R%+4]?V8ZUW:2] 9L$^A?NT:[#,W=CV5S>'$F\*^6C'_L0"UTYC.(FSR^QL
M#_[LE#)Z 8_(5XX?&[]=1)\%((%@=R,(8>\4=D?GLI>?U6L D<I2DG_;;?3.
M"YGO-/^.X<UPV^5O 1#11>P6UG3>D/G*<H"EC %P>N!IY;OU:O;BHML!2<LO
M"K\I;QY[>2# QD$4^V.I/G PXW\7);N*DADU"H^]&( L6QCL(+]9OW/SMJN^
MX^W;)HRM@\DY+S$D/[HW<&=PT_STENW!X_-:]//+@KC8]DDL=UQ15J?F@4Q:
M0 G?Z/I!J]?/DP1W@W4:CK5<(%L#.MO+N-9K%*@$WUY8(*[Y!=J]/',PI04.
MOAG"H2U,E_&_O.\.X%X3N%4NPQC>ANC1M]\F[S;Y@P*GAH@&;Q[R@XO#L()#
MVWXA427N]DXC/'P&+(84?G_0@AGT\_^^$TP65FPK[^ZZ_W@[#TN%/48"XRD7
M3:><\N2\XYHI[TTB'DLI_#'!9FOTJZGAS'2+\"''-BJCL.3<14.8LBIH%J-3
M6/#C'; L"5:8H,+$+ J=3AN5'QIMF!J C=UVK]\=%$)P<YA>AT?]UNSX\Q<W
M),]'AN35_M?]YE[]R_7AV0D&$P\?U3T8;?NGA_0+W0/S\NCL!)YU3O?^-/CH
M/Z?8M_YJVZ]F<'"V2^":;_OU_<;!SN>S_;//S?WK0[%'/YP=U0^O#NE^ZV#G
MP]E!_?#;?ZY/+O?J_AC#-"I"+0HX&,0-=D@G+Y!VRBF8[10E+JW]1AOD^%WV
MS 6?F%'>1!,MQUH8$EV,L [6*!L5L+,(YOD%K ',=Z9EMPJ8O$O 9M1!C%11
MOK(Z(.R^FBZ%*C+;M;&@U"8DI;:"WEWV31ZHV+*:6D*I?@40[@-R7$\A9AJ_
M7&/BY0JH;%N@/H!GQ7[('XVPL=0NW=@L( :^Z RZ (HGG8RI'= N)5DK$1N4
M!\S(U?!'Y5WA1Z?=S@ (4X8N4 T9S"<&-3F4(6.<4;JEVAKKVOC-GV8D+SXO
MP!*PL]4)F8L5/*GX8KL&<Q ZH /[Q4-O>6*AY[JV4)?PUZSL!LWRLHM!%Z8C
M:[NOIXUFJ<-:]JS3S0^"=\@3<<M=LR8"X@M"4,R:[144(#]CXBI06\ VF[U.
MK:CEE%^Z<]L-^Z>V/W'7<B4*6@':J9@'-R@OR.][[Z-'K/F.X=N0Q;=\4#GU
M_4F%/%K3:+MMN#G\IE^2[:R[0+5;T,<@'(U.*!8BW[&0KN$-,^N(W0O;A:GT
MH  ;_?(MLK8%YGWG[&[7WGG?Z>8E:UX5DWAJX0H0%^ C#5!^H1"*%DAO(<'P
MPP8P@D7//!D D<J[9ZATV\VK)1:CL!@*29C948W^H+1<QLO5+19A@@J>@*S%
M+&D.:$GL3DII\19YX1JIX2U<.[D=[U'FL[@T4R?59>7V:\M^0V492;8M%/G?
M7X&:#3^@Y0>S=5,[%UO+WGS^I\-2JUQO4R*&ON2A#BDMJ5+7WJM'IO6.U#A)
MY3BESO%$M:$">(5/$3LLA+I3TVP./MLV0$@[3@ME%D&09@<2"9QZS.WS;FAF
M_MG(.-P"LQ!V %@N>0YALY1;8"A#W6SL9BJ="^;"C6&X)=4MV;,]Z<:2 <^;
MDFN=!;J4OMT=P?SG#/.?\[ON%3HC#_$UZMP9F,LKV&A=@(TR;TF6.BR;4EF?
M%D9+@3.3^GB)WV?$G+ -LPB5>JIP&XR-IXRFKI/?,8-U@3HC?F!KK<:W4B>[
M_H21E^^<?U:>OQ;/+*ZX&=YH"("Q4V.#^^\"C@]%M!#/"5!=8%#G>Z9!MS!Y
MAO?.3Y[$O^E?_6VSE5I [0PSN7G)<BXZL'4NX;8%:_D[;XCFS36P37H;LA5^
M'[&;]R-V\QULAVRG#D!X778WQ%XA*;U8K,)0?Q;+VK8EE(TH7F.HCF?L^9)4
M@F7=\8UBR0L]7,Q67LN13^:&'I:BN&A_@?8? $^\(2^91(YV4>WO3F: A6]O
M]FD+'S+>"'!GD"^X0VN\;(5H=_P WCT3*]#Y[4+WP?^/9V621<]2FXF-DX6^
M,^A-!, 6-&,X$)C:<K?;WBU3,;H2;G71!2WB2\8VX8YI]/J3,SEFW*4WHYBE
M*1=&YMV-H0^S6#!X-]^X**9K[B9=6/CVH/2OCAPGF['UQM;#OPOKX3O8>+-T
M^P:H2T=<?LWL!!_YOX8ST'B2_>)M84> .07CZ)7N]Y*.3#SWB??.(K=A[?(T
MMFLP2;U&]F-.J]T;0W(><8:SMNC=-D*@<Y!$K8B2J/VS\#R_1A&>6+P+>X5
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M8:;HXL(6CV!]E;2\1FFIGQ\+38D-QB,J&$$\A(0<-@E)SU(PE$4>)4@+8P]
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MOO[5//BZR_?/WHL#P(ZC'7A&8_;T]P1PY<OET<ZN /1J'=8_\8/ZN3CZ^D4
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M*7(Q5_9WP>!D>(R*;+T5?!O/=WN^@^^_ VEHUHA^?K(O+39)1B:$)EPH;HP
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MJOW6X=>CTX.=+^3P^CTK.I_/MA'67$A#1,[^B!%QY1ERT0O$E!:*8@9V?<X
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M()4SMF1[T$*A4P2TY,>^>E1Y>$WQ+_B@Z&!Q HBS*_8OCZET.#&LD7+)(:[
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M\+R_&S[VBGYJY4?YQQGMNHW<<@U@YG:[HYRY]3J.\.PN'ATO')3OUS[Y<\P
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MYCAEF38NJ116$6&IKEC0/$#:".EMXCV1#B"-FV3@7RZ+<&.&A#$$&Q,9;%
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MADX"3(616"/!B$/<*X4<Y@9))F-B7$B!U<J:F''HI,I/J_+3JORTT5!JE,"
MGQKG-CA 3ITB(85D.%"=K")0D=)Y@-(1^6G:4<8L24@F$A'G42%-I$0&AQ@Q
M(U(XG=WR126E58+:?'(O'S4.7@ 04,E-XI9&30G!6GG"%?,5]YH3P!CJ4F&D
M#LX11%PTB%.ND+5,(HXYTX(I13@ !EGH#A55AEJ5H59EJ#TWAWR46D^U)3SS
MEC B0TU0@;5-&A$B/>*:)V0I,<@I$;"-6*7$5M;DD@0VJPRU)<?U*D-MME0?
M^Z!35,HH+#D'UDB8LBIH%J-36/"*ZL\)K@]1?19%"I&A1%T 7 >6[Y+62%&)
MJ?)<<*L UZ<N1GEY?!U#&'M!=.9Z<G)=^^-*8K'=4TJ%O]RM,G=F.Q.)(L^\
MF.!=7]WQ<VQ_K_LXVK!W[(_?>@_UOMTZ'FGR"R&B_.SRBA_$YMDWQG)>*0=:
M1F16M ]@S2)7%& 1',7: \M^V<SC:A$\^2*0*D4)TXT(50#I0E!DN!=()VVD
MT1Q+'U?6A@_.AEZXS.0K%5T!"7L:V=U2C&]8X+JW(5RJ7)=ZKGE)K)8_30(\
M,^<2U9I[RC6W2;8_?E/:*^*IA8TG'S%(Y9$6"F=6P:E37"1!7S904"V")U\$
M.F''F03@(3IE'038AV#/0$DZ;9Q*'&9S96U4B& LX+E#6/\.W*D-B>?.E*W1
ML63 ;V1^E@NN;!;0&;JS>2>=(Q-8.\5^VS;S:V7^=SE%I1!XL0\FU+:-QGGQ
M'3Z8>RW$_Y[F7H7-9OY/O=D!_MHH!;2+%G#VXCY][T>E0@[H>X^T]1LZWK^=
M#ZM\9P'F\E]_]_H^_ 6WU@KD%@# >/I?PFG[#!R73FR^.JO_<K:]_BUPXZC,
M388QT$UN9$+6"X6B,-Q2Z7+5T\I:CS6<1]ON#+I=M>*.]66];Y_&PMO.00%6
M4@\Q:\3_][3^'5 V+Y[N@>T6^?TG]KRL)CH] =#XWF_4T4KEFBREM#L#</!<
M@O*CE][U\W[.2OLE*/067%;7KW?/*ZGXC?5O(CF!C;6PO0J+."$*62D$BC$R
MEPC#5N-ED8KOG![#[<)%8-4WP+<':.KT-L/.3>>^/=I0!@#X0=WX&ST\[E:2
MOQZAYZW4,Z8F#7E4H1ZI4?K8JKF[+TMT31'^)(5Z:O:%>J)&R4P+]>8[:#]N
M,=IJ$7_X>-(M3L!2>K9CCUNGL(N,4Z8VC\55H\]B'V"<#S_B&$5HBS,:7\M?
M8D#K<$=V/Y8-L7[/M+78 $PMWMMZNWSM;]L II'71CEJKZH\;:O5S)0)5@RP
MJ3].P<EBN'2FZ*/R8*>OKEB04[ 213J#(HX:6"OU26(6N(_>\,"T#TD9KES2
M=S6 %3/S6=X!/^Z>?P ?JWU:NEC;P O:.P>VN7U2\HFKZ0;VZV)[X8,6_2.T
MP^V=+_F(C.SNA(,MN@MT\X^C[1U/MBC0S=\_7N3^A7L;ZWQOZ AM4VR51V1_
MP^?>L;W#3T>;QQ_%UL47MK>1/Y/_#J]M'&1J.IP:034--'<S2D[;'&JGR-"@
M$ .GE3E+2?)T98W6AD7)Y[%4H2J^JHJO'IT5\%?L]4N;"2C2%\#$2\+0YPLE
M5<A,(1.%DB-<P26NX'(\N!P2'B?*<@WXR+7SB#-PZTW$!F'AB)::&(/QRAJ7
M-;P4M5T+7RKU>R_*NY0U4;-@?-/6ZC\C]2NGLO.AV8ME5\QO(B@;V8U&1^YY
M0D$Z@[@W$CE")5+:,6Z=\\2$E352FQK(J@JG>3#_NPG.E!CPC$SG-@14=&?F
M&#%(=P15.F%CD=58(YYP0%I2@K@SE @K/,\=JQ2N43E'*+'L,:^_2[8_37QK
MP4#MIZ4E-;VIK$C-HP!K<T0XRP!W,<8A[#7X9U)K9))T2*0@9*+..8-'DYJA
MDY0)T>(EXU5+;/I+S6=N6W_%9V8.#T-\1AL67)(H4L\1%TP@>"4A0:1E,6!#
MDEM9$WAVX9LJ2/.PC;_-2C:-?(37##E#+<7ZZXK9+"^_>7\YFQ7%>12&C1#$
M"=&0@%5 6,126TPBS:Q'L :BU=3(J(#BX-IPU=OX%*<*V5049Z8 < HH5O&;
MF6/#(+_A.OFDJ45,<\ &2P0R+)),=UQ@@89(&? ;76/#>EF+%Z]Y9OF;9]?E
MOYG:="7)7]RKV#Y^;M/,Q1 61-9E=.*3LBQXB:G!FON8#-5&>JZCML183,HS
M_A<E4E7BTS10.4(3!DNF=? !B6 M0"4%5Q#0$S%FA/<T,&Y%3GP:U@FK1&%>
M0!3F2:1?YC5;ZSF$N^8N86MR>:Z[$K8>!>95PM92P/Q0$S-M3218(N8,P+R(
M 3F)'?*,"N.MM5YG)6Y5(PO;XGQ2:W_=&C3KW5&5UZL]=8A2F^:DG0O ?MP6
MH/&M3G>U:,9NKLS,-9K'95E;NG9O5V_6NC6ON/L=56\# I4#XSA4^S90G^9R
M9>6OQ_8'ZE5&L9I0Y)^_'L. ]RNI>B\,UJNU3E;&O?CP1_LE;ES7*!%]:,[
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M@B>81T2-DHA+)Y##S"$><10B4H6=S'5R\Z1<4A7+/0'!F1(#*GVCY<&((3T
MG[QAT2-"'4$\)8F<#P2I$%22''..7:EO)):A7?RBD)I*WVAI2,U2ZAL]%V"-
MT#=2D@L2'45.AX"XUR(#5D1))D8%\T2GE$G-\'E_I6\TEZ:_U'SF=>H;/2,\
M#.L;B> (^#Q:$_!YB K(6>919 %;6#/4XK"R)DP-#P-$I6]4Z1M5_*;2-WI6
M#!NA;\0]IC[W_6:4YI:,1B#-F4;6$J&M(UHHGBG.-!*.5<BFHCB5OM'\8\,@
MOPG,Y9(WBVS*57D.&V2#3"@P$Q.-WB6G5M:DJ(GA1LV+%Z^I](TJ?:,9Z1OY
M2 B6A%(7.";<>"^\4%)XQI)CM-(W6FRH'*%O9+A4S*4L<$LTXH%[I)/+<MB$
MDJ0L5M;GQ">RS+(7<Y6-5>D;5?I&,]$W>A285PE;2P'S@XR81LG!#1*(694;
M'G".C*-@*5SIP$2T,>0.+;)&*WVC2M_H"?2-[JJ$FX6"SN-8:Z6@\^)EHW1K
MY\LWRSP#EIF0T=@AGJ)"QK"(I$HL.)N,E !-;-A3?T8)G4<%FBH)G7E99PSV
MP6]$.6L%SX?@&"..*4:6>XX _XQ5 =P@3._1T"GJ:5C+XY9"1VU8K.VF[MG5
MZX,UO'U<5EE&YZ35*2?PEQ)$Z]]COZJVSP)O?*J_H^#KCU@'.]UI]^Z/#-7X
M]3>>M;)\[G%"/%<7>O8J8RW88ZJ,&:T1)F9>N N7Y50_Q64)FZ@>>&!5B=)-
MO,,%'>GVQD@5Y0^?0,S#=9ZH!GK6 ED/4K(1?/<)OWZTB\G9 'X]JGCXH7%]
M"(N>=<3?PB9;;\+%_AUMHWM0W#/V_57X1&/_?_=]]=..P4?V8D_]<@_]OIY)
M=^GR%,"<C@N"T<>)E_\P%%VZA6,^T$[].':*K7A6?&H!JYC.HRL>MX'?]D%'
M48%!VE*R1Q(83Q[^3SGER7G'-5/>FT0\EN!Z?2.47XG('K2OAVX_(M>.]@C9
M!%;_BVV<V?/.RIO;-PQW>Y,5W45HAAYL/$*3^3""$<B.Q"\])9?S7T==ZWDY
M#3Q?#?>><5)20WE-XMF3&H%K2CR!R FI,38>5YKX3#1RDI@8B +=9!.]O\_P
M\+-_ OQ$&/GNQT'=C:?^,>XSC\_$)KO4J,#8HTUO=IL1?7"@Z<B!OE]J:9'0
M0=3X$T@5&5IC8CQ=I<?3]/[N-"?G,/>I%?773[GS] ZGIQ,F6K@G+S9BQ[?K
MY=G.)-H[$T)Q3YS^N<\B6#X GV8Z[WZ4T4[1@T<#C]ARIA7D^E\[$L9C;_Y_
M?=&;*P[:.5)[T.V>_/+FS=G960UNL;;?^OYFO>T/ZM]CYTT,^[;])MBN?:,H
M88J\@3LEQ#!"!=:4Y5_>A/B#D=I!%TQL_3C"Y7OIV)]BIUL>:JSG&6P :V^E
MXD,3;N2D?R_YA0%_<C6_H[9:V$YA^]?ZJ7[U&?C-G1=PU[$=<T"QVRHN+0E6
M6_YUX'+_^H>F1/W:*3Z>VC9PY\8YW!9<JIMU Z^\F!SX+4]Q_MM[5]'[XL_Q
MI!LS*O6%H;!>+=[78?_::M4*@@B,!_OY?]_80>Z_/ 9\MQ)69<#S9<"=B2P8
M]WZDI+1F^:;=-U7?"K&5VG'_M%%^5Z?9,^N11GIMX&_A8]F6/UU_\)8%CVW"
M= H3KC=Z:J!;K>\]HS7E^2QY739+<+7K+KG1LOPSX6]L>6P*VQ+J/Q?!_5UX
MYZ#>AFUWU%[\'JZ/=K,P_]MV#&!TZ_OM6.8DK1:A?(<M]^GWT;7!WLX+JGII
M#F/:<%Y_(XSX?SK%V]-V.XMB#QBO1O_?M>WV4I7I96+%:S)<1BK#70C#M93]
MEWTC^+\_&+!@]J-_;XSTC>]MGH$$<W#%< _J,8&!1'^:3Z>+[01_A?WIY+3=
M.;6]/A:?8R]E!^SY4L+]LVT[VXP=M/VC$<^+=5_F#X&YT^6V@B?@G \<IE6&
M,%M#H/<:PGO8%IH^WV-E"/<8 JVV@X6V GK7=I"7]%U;0J9JUW^_WU*(+K[4
M/M?>UJYLAC"!>WY7:)V4":0C#,M@^:H-RYC*L!;9L(SI&];G[- <]SR*_=+;
MV,\>14X"17^V6D?Y]P_-7DIG&5Y_S)*^/(EJMLI1NV?!C'KG,MA+=BH_O_WW
MDQS,O,P3?2A/%8O__/;ISV+'_F@U6\?G@,7=V.QD@,Q]C(YML='R90G.TAW+
MY E]N_[GZYG0M[;A^V')XL]Z\RCW#5KNZ=UX]W[9IW<CIGHO;_^5S.F?Z[\M
M^YQ>F^R?UL7&*YG8OSZ]>ST3^U<[=G+WR5=CN'R)YO9M61#V5RX!^Y#3SW--
M&3BO&[9K>Z%ZU*^@RKYGO5G<7 OY]*!Q&GKG"]>'!>3GX3F_G0XWD[K0E!Z7
M&<W&2H,;3(G_&EVGWHT/9<7-77WKT,%KKJTX[<1.D:M.SWI/5<87"G]@FTV
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ME-4QY3W'E&]<*YS#?PZZQXVU_Q]02P,$%     @ .8.D5I^FV>5/$@  Q,P
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M8J#.A@JA*,K/ I=S.!H>D_S:*@EWR2GS99:J;*:,VIVLIGMPUCG3IP!\?0K
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MQE ZBN?:D_0M,,8T6X^%C]<?YVVU5^V!W5\<0HL#;*X".K.E)CX(0%LY$03
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M8ZIJV=4*6%E9@[!H%>7\_MJL77!:QTA4J5*0@282(L_$X11K:<S<L]I;] ^
M-Z8:E4=@54WE#<*N7R$=P&T24 8RS\H0YTIEE7#(^^0CR<:*Y'@2G%8/GZR!
MZPFDEPW)IRKJJAY)N? @OLV;?:_3ONYK]9<TX<G:1(,D+)<>+\Z4KH8Z$2$R
ML\P+97GM#8"'X'M@,MJ3MMT'U]^@#77Z,L)EQ)4:)8&&WYNCXUES"O )3J#U
M\PAGTCG]"'TSS45S[R=>-=VB>UWZ<<XVZ<(S-*(:K7MV*K5*_7ZN(#BO\F"4
M<O XTP5;8A'.EGB?I$0+GB.^I%+6KG^\#<?6>=Q7I,@F.%$SJTH-0G\8ALZ:
M>&T5"2"83Z!EY+6=@FL0QE3SN+7F;^1H;R'N*B&(MSZ6IF>G;[Y.%^='6/58
M)B:&($00.!B7<%B +JH+F?!$J>(LLWC]F+I;@PO?O<&8-C"KZ;6>2 ==J_K2
M@"L=8U_UI>RXS"+:-?O&;[XP5;U]C55H.'E46G+6ZM_/K&.&JT04E9I(7TZS
MB<H3K2 ST%G(Z^' .MT^'W3"0MVQORPQ-_C6.B&N>K)>B$3FI*V/F:AB&,H@
M'#[-Z(F 29%I(Y)(@QRULAG<,2UUU1EW:[_4':BUYF%=5^ 4QW>-J>&L\^>J
MF<C%",![HYTQ)(5RW%A0@5CJ,Q$Y4AJ-"=G6S@2NB7]46TJ#4_71-#^H$7!^
MP /BZ]>_RV=$+II79]?_"GZV.,0!H1":>;%L^ALWY\D.Y9-=B0/@1U $RT4I
M.40YS=/KZ0Q?I3<?/FUN*>P>8PUSXI$E6\GF^'O_\$)Z45R4 _AM>12@+1E3
M_<U7\/:7BVZ!B'"T$Y%9TMI#,9 ]D3DJ8D62)(;L7(DAUZ^O>B#$;5> []SN
MQGUZ/4W .'"I%+[EA-:^-1$?=&"$X2/.8TY1Q-JAZ@<!').U,237KL_FPVFQ
MFJEQ*\3O">-%^N=RM;D\D9I:P:4D-.E2JHL"\D8 X<9D1T$[]%IW0;G[H8[)
M^W]T\E76[)I6P]G[Y4=)G?[EA_\#4$L#!!0    ( #F#I%;'*E$*:7   -/Y
M!  4    8V%H+3(P,C,P,S,Q7V1E9BYX;6SLO5EW6T>2+OK>O\+7Y_5&.>>A
M5E>?1<MV'9UC2UJ2J^K<)ZP<(B5TD8 * &6K?_V-! D.( !N8.<&2+H?3'.
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MN>3BHD;9F.5=<#U[26A._(<"8HXA(!LMT7=D>$P6(QZBM2(CN3TJ@PHV@L/
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MLH4..!\,R%PP<RED5H-JS!609Q%1VX?KNR)J!U%_Z)O,"NHFF?%Q6 -%T;9
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M^\Q[!@PK"=!8'88U[I]$2F8?">A+U:>2DEEU[.):Q_Y*_V9YQV%4T"XJ6^?
M%% &$YUW.H&7189"IGUIGK&["<=3NNW=B[<;[)A>-![(PKV+Z3H$U@750#>^
MFQ&=YLZW/\<>$8$>Y#Z>, 2N;4JHP6LE27$Y#5%(!J7$E**W69C65>W'%()'
M[GZ/)0/[4'GPA-SE)K'$B/6VPF=;._N7 H'785*2%0S*)#EP-X.7=/CWI.\
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MOL-E/>4KDLN+U=$E9'+2! -%DUFJD@T0E17 =:$CS!FMX\ !W VH7HQ0-&;
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M U (IJ+0CCS[FN%3!^7Y.E,U%(G(7.2BM)X._3SF!@XC#_N0>W@Y6#E]2I7
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MR((QV-+V[?4E&R2P49HH\]?"]LX*+K)^?!^1^F[ 3#!LZ\MJS"'$O-82\E%
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MT5&V3@!$%<\=B$D5 .N;>+G5@3K\ +<B;*2E809UFGHF[8CFS)"UN\NU<Y%
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M!V+?2%9PN^76>E$4BNI@R'[PZL/GS9/V#2Z!@4%&*HR1\;/+QQ6H&S?.#0@
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M8HI+_/P&\U.BU+D#"]W,7/@.Q=KQ8C!>)&I]2XO1LP.#!*E<O,_I01ENF_>
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MFR?#+77#K-, ]<BVL19?F>[NZZHV35XS=M;@(_FD"'&Q+U7.G23H+!DV^+&
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MOKXJ_VKG2_5"UBDN%J_%I"Y\!IBSBIT(N3.@)2',6J'J85A+E&?7+%]#W].
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M(1N7X8ML",Y6/R&=8% ^WGI1>M]2^?N+2]J:ZN[=<"52AS<U'#/ASJ!"6A"
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MAV'SG_6:8/'IP5="'WK:D/PNJ@TXJ_1M'MP7F*<4L%LK24PS^:2[*G<_B,$
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MD.[[N8=T;B6Z:?+S;&"$9*X)J<.P/7#&><+A,+^&%$Z>Q/5B$(2(F?CM/QQ
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MQ\9GOW:M($3Q!6.GDI2CR,BYYKP1+T2G4U@3F67"-0M#*W[A%R^OP2;@+Y?
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M/)274!)FY0C)XP'[!-!<B :/HOGA#[ IE$#'JA(.@:5/'N(1NGFJ<G!53_[
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MA*JB, R]1-WBRD?@8$LU#S5LFIN3]/3&D7-F?7/S.V"P5>>YS^:-A+97S1/
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M+8@\:TY0IEB8'R)/J\E]TFMP8HA^JW[5%SCYNK$N:Y_G#:-="R%?MVN!Y$\
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MS$/T56Y8:JC?_R3T\;=6!P72QLU%,A!W2E&"TU,L!)DY<40=?&-K"[P5_)Y
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M0QLW>;_>:&!1)<0Q3NCH^:V/5!*DH#C7( #"4FWM%PB1?R8QHME%'JI7'/L
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M^P+O,? 1)P&9=HJ6X)_L*FTQ^9HOF.(OQ6Z]OEV#.M[XG8>ZH0D-(77T92<
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M2/8.AQI;I[<Y=DSK-;SG)GD%#ES=_N"R:Q^06U05*'*F#$[2>OZR MNPP@3
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M3RYL[XIC:]+>_=_RUOK_U_]SU]+$?P%02P,$%     @ .8.D5F.YG9ZS30
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M39NNSHZO[+R8Q;;VU'_UR/M3YI0&04DD>(=?U,X)&9>^I/RA*V8WP-K]K_F
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M:V6>:X>KG'>WW0UJ(_>\X2_3/49J#HXIZR)>G4\XLG[#_8E!$A)%_9K^^U#
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M&<!6\I'HA9L\C66&*R^!HL$':/[A/ N!;VB&._ZWGIW"FE2N7)E/OY=G4(C
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M="F%PMNMC__):7Q:\7"(FSFH8&;2J>5X[?AN#_JQ6+$Y*:1XLQ''%J(Q1O=
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M""'!(JP=Y!Q4WJ:?WEX5DTC/BQ\V;'GF:MGQ6A[0.!8F&!>\8DVRXFV!%KM
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M^.R]X[=",Q[+*0J[&IS\@ NHG)_HXVJR('QEJIVZZP?Z,V6>98G)&2<O6;;
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MBUV1#N?;?^DCZ/_=_F?MM%5FASFA\W^T]]Y!3<7?OF@0$.D*8J0&!46E*5U
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M;02C-E?H0@XJ*KZI8 .7MWPQ:YE5Q1(5;[>Q@_U=3U*GI>_<W&!ERQ:#(YY
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M>;#X>YM-2,6$7ASH=I$'2X7=F6#+S$.@-A9R'=D\V'%]C##J!0)8PT7C?AF
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M [6;Z.=("K8$<F/GWANK\V#;&JO%/WDNW:ZUR=(8FDQ(_=)6:W/A44__DKS
M?<]Y"#($2DZ6]I+K*)P*-H(QT;%!%L?5?A^]RFAQ[[(ZG432['!3?9QP@5W[
MNDI>4/;D&X$=YDHQUNB\E>3-G1Y.' \6?+ A&3D)9SX$YE-76Y#UR[N,K]?:
MAEY/N?WZN6RFZA'IMHR#ENB9?"8)=J DVC+Z\TTAY\UI+:83. H1LAY;;7&,
M/R[*>("^3 '9UHH;7[^'1:\[Z!PE!!TBY9M?=Q6*/D414\A$G6:? @> /,I
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M?;&DN][ZO\+_#V@Z_?^O_R]>.-[D?P-02P,$%     @ .8.D5CU4UY,%9P
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M*$D,'@_U,(PMZ-\C?W?XS30R4$]QQ9Z; ]]OW5M[YZI?R(Z4\ZG"07](TSR
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M3(-#OG?ZL7QA-?5GIE*Z*[$W8$FST!6>BS+/0 H%4X-,^J,;2]"FE]Z='$=
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M%F5I\B%1!LIB?C"K>T*-^;;LY"BX]23]:=<&6ZVRB'?G-4=!+ \0AZ(N<BI
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MLRV";3/0>,"K4;RBFF$;OZ"C7=7MKX\*^O:VF@=L-S2B",^@#G+5+AE2P*%
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M@!.]?V>T<9>2#U.K,[9P4D[6WL6@\#">-BLCW"DZ##9"MB$-KN*SQ@9?B50
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MMLIARG@U$MS*F.%Q<7&8U41(/:U,S',*V(H+:28]P\\_8CW\-8&D?,K5PLV
M]/3/_/([-SJ?/FW^E1:AZS3W\G9N1/T3=!!< PR0R*_\]$B[0EQ#L+S*HLW\
M%.[QVD)K:]B2\DS7@%_VX]EQ_W/1\#$?^4@]N@-SZ\4_IH853!8.33VW":8"
MF<4YYW?RL8)3IS=A#/;3<7G5VE=#>1=V9)IPR>"N(V_[>B1K(P%3EG>71D%
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M-^7=(IJ'XSNO>\?.BA3JQ3P1TWB9&;TCNRU(0S-*\]"S>2 S$]?SG:LXP'[
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M@VD:0QXF9?8J(7720W\F1&_^W!JT[*063]$K(YP*6FT[$<]5]B08BJ5]1\B
M%SDAU\ OIRPX<*4QLWEC_U15RZR]/6DE?C.L%HEJH3+G,% 2IXV$P'$=.%D,
M3JID<*P_PA_Y0*SI')69YC+5W;F" ,>+:V[AOVM!Z6V"2SN2N;^A803+#9$
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M@8L!>)MZYW+R.7R#QI7MFV^QMU"0UM<+*6N>5"AFMA7-1'@LDP2V(( 3F[S
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M[8UOIZ^X;*'IOP^?CC*/?]1$@) (%799731!_ "J7N(#/J1T:@WJ!G?75,3
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MN#!L8E(D:UW@E6YLE9;XUNI<B5"O$%J8XH>%MNG/J7,N0!+L7:LK?;D^S-4
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M:&%8@//;PK>6CY285QI.:#Q:CB4ZXTN]VS!@)%KX&,@ %KB.MU9AQ8]+9#J
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M,GS]NG%72U#<#AWY,A@[J&K_$KUW3)V-6%1_]A&;Q\=#'/8J;'-H'4G?>;*
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MATI!!IL59X[?BOL;(N1#:"?*.+_[&K.)J:5U^9*=WN><!]K&=XE[G?3>>Z-
M%I?5UIN>JU(/Q8/A7$RBT#_?O]JLJ)&3'JP@V)?R=+=;_HW#=#:;Y__'OWT&
M$.\O@4*THX=@"W2(+Q0EX9P%T7[8<Y%Q_!4:TP+R,.#E$BUJ!O0.WHV@?E&\
M"E^%N8?'T'8R%AT##89H9XLDG#YF%79A*6EL\O':$"WD#^[]BX?,X73%#>O1
MIU3.5C<2CC1A*#V$K75ICU[X*%[,SZ&_,9"M1K&+\.I@?0:*_0KQ2B5>&,ZI
M0)T>-*\E).>%#M9Z6#7<BVC15FXNN*]YT;)<,4,^]KWWN/YZ:"\(<'(6QD@,
M(!ZI"XJZWP5XM7<D/_,;<RQ]NAB<K/'J#1R>U@>?(<4"%U52)5 YC)#%K;D$
M.UV(OKZ41+T57N9'6T!KCEBVO"["WEODU-4&XQ$"R\7/H1[W-QJ<M7E>$8,J
M .C*5(55F*(/>)*_@V?![+_-B81CQ>,=>7JFD5:S#0CU7TZ4[LLDXN/CU,<6
M06XI;RC?/+"!!C.*!J(6JYAMLV*% H$TYF/HC0&TZ#'/;[E7FB2:3#QWDKCW
M.^GJ?@4;^^Q)R37- O1C*D+UD_S@?@0]UZB_!M 7'N7I8B/I8TM)SV]9K<)4
M$F 3X;9[GCMX:+Z\J-?E=77 ,3 P_:V3XV K2AZI(%PS4!)[@K-\61"9R'X2
ML9=_C8HAJ&)-7.\-N]=1<_GJS^06GWG="9-?-U"RRS#\QGQ-]F^66%Y)8"5N
M!5Y-T=<<G8ZB8W5;,E_BQY#;H'C.E"IDS$T7I]7Y"E=R.E[/GIDGK50+2_58
M2C,!AXXNL+J\TCBG8]8<Q>)%I0#[08 \>+108(:G(VHK"!V(]%RCFO>.Q[G=
M@#_E_9;WU(A*T\-N9/-OYF:M&98SNXJXV])XC?756-;BVOR:O^B?_S(K<R5L
M$/?JVX+=]4(K6EH!6LD'WWO9Q\,V*2I2EQ6U%6T./V 8JE@2K T/^WVV<I%9
M",,SCI^1D/0(1+M8'_+FY,APE2OXHF@6@W]J90*,F;I ==T0G+5_V55G=K))
M_G^Z+;A7+*?.8XB56D%@ 2XIXLKB*5V+UN064[^OXJVKL+@R]$;A_@S!B:VU
MX_S:'\4V1.U5F+,DZ?>T16P*E%GNH=E)J,6$RN@2&Y$!L F2-'$\/AUY5ZPZ
M9.U0$=B>%_K^.D;)]R/:?$HCK*3Y!=&R.][K>%;K,7MY6*I8/E)@!_FQO5OS
M8B5W_9>D<VU?9L1L>_N#?ZE>]P,I ;>UJ#"G. DG%=T27%YLN*>LC)QI,L'*
M%%"VG_?_M@L]RF@7ZTB"WBV![>$%5 1"<:*N7(#$]YQR"P<KW<Z9P),=PV/"
M-8:S<QG+#]LF72OZ=K\]L]?>YI"\2-W>/"/;6&A0^F)<R=%7].ATDG:GZN+X
MIX6.B2?8\;3 %"A0K)1572,1P_?T<0HV#ZO:/X_,7_7XE.__[?J$B^F5]T^5
M8TID,D4%*+8$[*\B%VH%.OA!H(8DU'#P!$G,[LB.X<FM/(G2V09E,?8XE_JY
MV)T?M&J6,R+ZF&5+\6_?OI[@_.Z)>XFAU#.!Z=J;0\=P 0;?"U2QVBV@'<B:
M7*-JR!M\Y/D2MX.'C^>7U)K=^#HPZ>!_4-BUU:>XKNY$[E]]C6IOEAILV/CC
M/+10LUXLURBX@9]:Z<V0!"4?J.6G<@BQ"&EJN%%Q&SIV6?>\B(DW'8HX.L2S
M*9TY8'BUC=S@.U[%ENXI)ZG?EJCF>;'"-=#/%0+ 5#9J84+@/Y<K-0A<V&\?
M@SX!S6[/N6DLW#:ID9Z[\]+BEM/4SZ\;,XWN?5S0V[@Y.6TQT\EA"3(BQXNU
M(6^Q_#,!YD)>56_\@A4F5M</"D%_B)+@U^G5E_+I"^RG7P]V[&A-,7;UG3 _
MM1L5K7VYQ^0GLL5>\J0/B@=0H-N2*LXPE7]0LL;@_A[$.1<)40,#\Z?JZUY1
M/4H5!U27AT^>.8#(<QSX%H)W,[Y3IJ%2=>'?_1\&:85TDR/4U_7O*W]^,6JH
M,8TP-XSWX9C:U'48F&326<=/]CO##EPI#"7='%HI''JRCF1SM[V">;_<31F4
MN7C.LA$FD]'PN7R^11-DI6A9\2P23:TUX[+6MU2[W5-/F\;:]<#1[C1G6-"<
MOC1HD4@^7)B/M7"K:I#_ZXS/7/^?;/V"JR5V5F_$FX3[4SL(/'T+J2]=W)U;
MO@<-DSR2 FJP'0SDQ*?+>]*F-:O_=T_3E'U<&)IM1@QM0N;\44@->K2X^.QT
MOYM1AJ:3C"$QIK/T2[YT_J!5Q=X_JP@>_34C9F;/USE'ALNS=(.(E\M@FXB
M;FX*K!6(1RF\N+H$CCL%!Q*/$J0,5V%3UM93#$(BB4=76K[STV=@S&+7:/
MYV^UH)PR>6$Y\2A\4_;H\SM[HU!P["&&6B<J@6I2-+>T*_[!PL7 N(;-4CMD
MG4/_+TW[___C__T#6!W]#U!+ P04    "  Y@Z16%(.1(HSH   +>@D %
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MYB-]-K^[_9UFHOSC3DN]78F/^E-[KS^^:L]R$1#J"<Q#[;8E"*(DE/HG&L-
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M*"EIXBV>#D([KY]^A]+?92P<6C%B9$ZC)* %8/(^79G8*+,75ND ODM7(#<
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M:D4'^Q5I[B8@_4;GDX>BKD&:79C;,?#U$$X5DEG#]EVCZ?<&P4\6V/6(P[3
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M;[C6A1ZT%^TH[%OUS=@K?Z,S+)4&;<- RS)SZZ3]7&T=*"V[J?X"M86@,G'
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MY3[CG2;_#T^FB?S]N@PBE\(<0;RICB 62G+*6$BA%"B&*&88LH &D,<X\$C
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M*G6GWVUH(5!4A)H' I1$$''$((N4A"P,&>4$"9]:70 \T_[<R&"K(C Z.M+
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MBF!!.8((Q7HY'R7:8>=1"&.&E-23IQ*A4R5#&Z%SF^(:O4IB6I>E;':A^YJ
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MM'/^.?..YOBS#_8;T/4.]>-3)A_D*B^C\DRM5N-&E!4-FYRQ90*L)C/6"Y/
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M^[TL%HPI'$>,0DZE!Y%9:5#L2>C%G OE)3B)G"I7=8N;&]U45SP:-0<+JC;
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M ]%"95:UI/LYSS?F9Y-)L/R%K(KFY-LZAP,E\^XQO#K2>[NT-EG"[QXFME.
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M9^?1$Y]OGCMU?J!YX1J/$\SUEBWWRN_ZTWA0>N^HP"]RB2&7"(&8)-*<94I
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M80_ :6SA<*=GW[+UUZ]EHV]WO](K+E,"\:!6HE2=XH>#''FAA,@R$8-8DP]
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MF1O-[*V,C)F1L=-5G/LBF'8D<CM$(Q/'.3H!E?OL4 BFF7UQD(FEL?L</5?
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M=><#Q7<7!I@TCKONX&F\UG.EWZMM4;'0?L\$Y!3&1:'?\S@'2-9O/(IUB%9
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M D@@ 1C".OJ#"<UU5(ARZM0E[_(P<Z.J@X)8>3#3K]_G"9IVO',[1B-SS-[
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M Y85*4@2E7,5IUP3C%O)A;<M<XLK6E>:8L^],]'!&Z.M<O0GJAUJ958BF[J
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M  FIWV<=M "2%XG905=<"9>CU>.CYW: :HZ/5-N=HCTL=:Z.WZ,6%SG)"B1
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MY&[SW,HA1TS\<U=NE+R+6%O6^+0IA?Y?M6DNJ;63=Y4\_A?'FD;;";*+&D:
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M&$B'^R']\(KEGP1*G]9OZ0?-E3_3\S/AI;5.)6W>;+[SY7H!-3.2Y 60)-,
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MHX8RTJ,0<9.\'A<[4U0-_M52HSQ,QY75%UA*_IYLQ&KYM=KPA#)@ ]R^'#<
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MF=N4KC1-#JHF^U+7D"R]1D#;9W4\F$:>VK<1ZE[80Z *26V, =ED28Y!/Z[
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MN?P:RPT[7C6SJ)KQ+D]VA+%WYVCX,7(4<*=A6:=J\I-3]F\.Q\\UCA6UOO/
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M^[6Z_(.S)ZNC'[NK<DWE]!M=_=W^^^I1E86(Y#=WS/0KW^NJ/,1"X]RH3"I
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M0/4JI<7Y?+UZ%[[7V.55U*&.KT9F 8VNS#'$')XXE%JOJID043=_M'J0DF[
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M9%MKBL>I.59I;AC_]A;CZ80]R>^/Q.*?9C6H5P? (\8(-2BSG8_J0_$@C<>
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M?S<+\SLV3XI*VII$+FO%E8K%@PLV05$B:"ZL(<M]N%>[TVWT17=;V.<L//'
MURFL.K! KIGT\$8W-1/31*+:-#+\E_F4V/,GZ=B+=]GO=[:O'6/D+)#KD'(-
MKID"'KT')33JF)&9YGGPC;<PKFO8Q7DY/12Z.@E_+.9UHCBQ%Y>; .8\;;FQ
MW?+#N\7:\%<I#RS(33FX _(U.&@KG"8GVDH[7#[Z(12/ZT1V@?/!!=VK#7],
M!YH_PG*Y2=<A+XC^\56.V_5O?EC3A]&:JS>X#M/9J9OU'$#@Z&U]CF7J\ V
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ME"U$;@IBSE9@ZS>N?6GL6F4V0,U^,#U.A!U ]/K$__+<:0^<.45'&JK14OO
M1JBW#>C,:JZR*>SN"-V&#O5SU/41=3RE,]U47AT@\8G]W#.I:7F#1FJ(-M>I
MZM5T44&!,=8S*;0(K'7=R1[D]>) MT7(W<[. XFK;R0^:),G3L>V-NW,OJK\
MS=SMA!*0^V)0631)G0Z-_3G,@T%E=T@>+;<NBN]>GZ_6B\^XW/09J4-</TV_
MK"Y].*^#R\4 \U&!<M;6@J$,R6;G?!2J-$^A>X*<;@%W/! 6P\ADY$C,=6R
M;)AW85W+&"]KE6Q4D1D%2=6<"J4+A*P$8+(:HT*6[2YI_H^O,*[M=@JP-.1P
M!_?C&_R*L\67FCR5/LT7L\79]_?3LT]7VT%2V%HBUOZQI,,U*^"BL5"BT\GG
M%*-H_?+V#$GCIM*=4AVUE$T7=]X3S+OV\%%[(VN%M0_*@N+!0$1BH PJ.8U<
MT9].9X%U%\P;RQ$X3$ =:+@G]O3KLJ;[A$@NO*[-E[0CAL4@P:'.$$S*'D,J
M(K2.A3Q'4[<FUX$HV!UF^XND;XC=R#)[]7FQ7$__:R/&28K:.*$T%#J6=4).
M!I>4 \<%>F-JK\'6#<[WI[);8VYP&+806]_ _ /7$U,BY\XB2"\"*$9GS:/(
M==PTLQQ3S*GYM+0G*>K6MAL<</N*HV]PO<=J_-9&JC<.S[8"B4^DMIX7J8$<
M(O*0D-N:7BLA*,Y*X-*'V+K2^$!2QRVS&!..S038 4X?-#'N/_8E:VQ$GNI0
M:0_*^ *QIII+E@V7-M<V+\W?:W>AK(_:L>&?PP:04X?H(T5_?T_%%EG0&F!"
MD;VKZ [PSB9(Q0=>Q[P(;*T2=Z&KCS*STR/O:!F]U*J0/\+RV,$X>R]QDIJ/
MIS<V2HE'B<Q8Y>IDU-H:SM=I \E+B)E+*:PS%H<J$SQ)B<=-R^'MO5*;B;,E
MRY(0N*C3.W4*I,;IT%I>DG&.Q]P\._EIBEY2"<<^V+FK[!K*I8/K]2D?_L9&
M?_[V!><KW)JU),D:1UVE,/L_&)83HW6VV1:PDLQG5?WYJ'D&%KAUUM?JTM:6
M7P.R7U*6U#%X/;6$7QRH_Z#KZ^.?./N*?UO,UY]6$VDP1!438(F\/E73;HV*
M9!E)#)DL%X=^5#S?I?@E>3BG@_)1<GUQ**[G]..?BXF/!I4+Y-DQLK451@W!
MTA]S3D4RXVLN^JC@O2#T)?E&I\/L(5)\F5 E[.&DH @Z>00F:S>E'#@X;B)P
MPY6)J.E::5V(<B"I?70&Z1*N>TOR10+VE\7Y<L*#LL%E3H>QEB\R5UM?*P&1
MR\(\72.:GS"WX@E*=X*K^?\C7/>68P=H?:RS:DS2&%T$&"84U*<*",0RLF]D
MXI%'YD/K9.MC!N'8EX^W%I+H %#;H5;3^=F_T/'9%F9;LC=XJ-V\4ZA]YN@P
M)#H6(I+C%R/9'D4VAM(](GJI%3E"M/?&5A[#Y]Z <I&2F:5 QWF 9&P=YJ(+
M^& ,:5 9D<X/RM(Z\O@ &6//JCQ*L$_!Y  N]S'TI!)_D5G+;%!<B )$)'G:
MBK81@C+@O$FAQ* QW[&3GAI\<OW!'0G]$#'='X%R(,\ZT Q/#WPJ=!@8UQ9(
M>6I0W'AP(I,3&[EQ.6@A56O'[OA9:B<?HW+,U=*._SV Z=98(1Y+$G560.)2
M5>N<##0RR0$3V>>Y%L6QYMW*7LHDM;T$^^0DM7VXW,<%<Z$H?;:<N21J#U,#
MRM:)S:P0]2$4DP7J9/SNETL/%\L1@GETJM8^7.I#O#?N0JNT\3XY\+*.BB^^
M=JG(AHRIQ+T7+A=A![,?3C0\[4@Q'\BMD45]OU7U1JN1XC*VDFR<+Z "5N,Y
M",@RNV!U<"[E'>3]\*?W.17GD+N_$0>[P\#%B0@J>VL"0BF,<&R#!B>C!*NE
M-053'2MU$ K&GJ+60F9/0N  !G:G\[GG7/&<:KI^!"6(;N]-!D'Z3+!HF!.[
MM+CKQ&=L)Z<G5?\^3.O SG^H([ESBI/R,XEA#<86B*[F)<>D#)DN* 9KU/S[
M7J6I@SU%#^$<'L?GCH RP2Q8*JYRP2109-#049$94HS&<,Z+DJU+K/KH[G:D
M"!\;!;$//SO"P=T) XI\X.(=,%W3(P174+MV@C/:1[)ZG9!F(%3T/N#A>(P<
MP>N1C8KZV+<XGZ_?AS7^0GOXUS [Q]_F7\[7$\^E2SXZ$%BCJZ%8<HP5!W*1
M"?A2.U%VB4@_OD(?.7C'(:$A#\=NX8/+S[7"X=?EXL_UIP?VHIT3 ET$&<D.
M4X1M<(R,L1)(00;,3OBP QZ>6Z>/++?C4=&4GQW<*[>><M[A,E6QG-7V(-?;
M^OE;PM7J;7D=ELOOVU)..A<3QE@D&SV"$,;5BE$$)S19:!)=5DJ@+*VCTX=3
MVT?:6IO[Z40RZ[7V[/?%_*P>P[=Q-CW;ME>[K-;Z\(D84__NI\62#BCM^X@I
M1(>MTZ0*K<$6CRQ%J[IN/RJNTHJ<,4EZLJ>]<[FF[!H@/-,5B:H40=\&L\N-
M<MCJQ[<QB^O?YO19Y]7NVSJ@/K)BM.1@.-99#4%!R#)"$BE9&0CW=X.R#5J7
MW2-CO/#-"7!POV/9<6+HX&:]O85-G%,:]$D)!])M6C\2,QR6!-R%.DY!V]2\
M4O,^%>-Z\T<+]DF@[,WE[G!RH^.?$T$FPRPP4HQD29H 'B.2^UG; _DHT+:.
M"#Y&2T^8V5_&3T+F0(:/[-:]$G\UW/RQ6.,JGR/)45S$P;/6#KE7Y)!&.DM6
M>@C")ZBE!\$1VP1[SNYYZO-[ L*ADELT9N/84)!BLX$WFPW(RPTX8D5R!9(S
M!92P$1RI4; QI))TBCJR77#PT(>/&^MK#X*C&3@R EXO/G^>KM>8WV/"Z==Z
MIZX^!/KR2TC3V73]_=UR<;8,GR]VYJ34,6=>=[:I_HP0$]:^GM;$PDN(EN\
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M<AWMSHB!2OHB1.LZ]L=HZ>D6:P.D)EP?^2J[23?MYWR9/H45YHED.4B;"LB
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M=ME1B_GJPKADM3&TE))]K;U6$)5D(+V7T8I$K,/&^!I.78?M:([$Q.(L NH
M>E]?3FPF/A89-&KI0/*B0*%5X$*]"C5)*)%<L3BHQN"0UL1[*>FPQT4;2#5@
M? ?PN=D/NT;=W^$<RVQ]P9S0.GD.'&M7^& CQ!(<I%*\US:$Z%I[XP^0TF&U
M?!L M6!]!PCZ;;[$M'@WG_TODEWPQVX5JPMN6"Y>.(B2;$OE>80@T$+B*23A
M6,+F?60?(*7#0N@V"&K!^GX1]/9]6/]S<769ZPF;UC<J?*>\+]#Z@AH-:%;[
ME)'3 J&VLLF9&6YM*2:UOJXXCM(.*S!'Q5]+P?4+SYOC^U><A\O:3O?%//\T
MI_?B:KV9@8'YHC@ID=$)[DKUC<E/)NZ2,>FLD4EQ855L;8:=0&Z']4.C K6Y
M"#M Z_>8EAA6Y.@\M.C5:_K[8DXN_.?K(?$7@L7B<LF0T+K*7.*K2AJLB*A*
M1JGN5Z>=C-.C".VPCJ4-0L<7V^3#3C)^F,_*+.UFOB:<?=J$D00ZSFD5P)PG
MMB7'(+A<!R_:G IWS*LAG4\>?$&'R>JG8:8=.WOMZ?XC>=3_")=7^'?"_-5R
M.ZOEYI>+\F*UPO4JS//UT"DZNG<?S;1%B!M7R^5L_NZ[L)JMCF\&/PH93;K(
MC\^@1NWG;VBZ;3>^NNDWK@,/T3H)2>K:#-9K<,@4F%)G&R93W/T>C"=KG<?H
M.57UWCQ[R_T7>[G_:G[#?/K +XMZVG\ABVUD77.99/0!4 M-#EQ-*$.30(5
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MV\2!HT_1B%I;;S79@2EILBI%'5*:C?2^!)-:9P@=1VE?(<ZC$+2G/_?8(NO
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M[=$Q"<G*:+P07/#6[<CWD-&%FIP6'@\%$8Z4U<0Z][^O\H8UQ#LB?9=*02M
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MJ.1EZUXYVS=W$>1J*-'%R>SM !1_6RSR[[/+RY\^? RS9>70IDD/D]F1*V"
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MCKOQLP!02P$"% ,4    "  Y@Z16M"J3W?L'   P)P  '@
M@ $     83(S<3-?,3!Q>#,S,3(S>&5X:&EB:70S,3$N:'1M4$L! A0#%
M  @ .8.D5F$"Y'CO!P  )"<  !X              ( !-P@  &$R,W$S7S$P
M<7@S,S$R,WAE>&AI8FET,S$R+FAT;5!+ 0(4 Q0    ( #F#I%;WG"GWY@0
M %D7   >              "  6(0  !A,C-Q,U\Q,'%X,S,Q,C-X97AH:6)I
M=#,R,2YH=&U02P$"% ,4    "  Y@Z16>6E6VO4;  !IK@  '@
M    @ &$%0  83(S<3-?,3!Q>#,S,3(S>&5X:&EB:70Y.3$N:'1M4$L! A0#
M%     @ .8.D5CNL?NOU4@( E>X< !               ( !M3$  &-A:"TR
M,#(S,#,S,2YH=&U02P$"% ,4    "  Y@Z16GZ;9Y4\2  #$S   $
M        @ '8A ( 8V%H+3(P,C,P,S,Q+GAS9%!+ 0(4 Q0    ( #F#I%9
MY%F-51<  ,O;   4              "  567 @!C86@M,C R,S S,S%?8V%L
M+GAM;%!+ 0(4 Q0    ( #F#I%;'*E$*:7   -/Y!  4              "
M =RN @!C86@M,C R,S S,S%?9&5F+GAM;%!+ 0(4 Q0    ( #F#I%;%\-N5
M;&H  !Q^   3              "  7<? P!C86@M,C R,S S,S%?9S$N:G!G
M4$L! A0#%     @ .8.D5GR4T!@Q7@  [7   !,              ( !%(H#
M &-A:"TR,#(S,#,S,5]G,BYJ<&=02P$"% ,4    "  Y@Z168[F=GK--  "'
M70  $P              @ %VZ , 8V%H+3(P,C,P,S,Q7V<S+FIP9U!+ 0(4
M Q0    ( #F#I%832O\>%W8  (&%   3              "  5HV! !C86@M
M,C R,S S,S%?9S0N:G!G4$L! A0#%     @ .8.D5CU4UY,%9P  /WH  !,
M             ( !HJP$ &-A:"TR,#(S,#,S,5]G-2YJ<&=02P$"% ,4
M"  Y@Z16\8TX0_]7  #9:0  $P              @ '8$P4 8V%H+3(P,C,P
M,S,Q7V<V+FIP9U!+ 0(4 Q0    ( #F#I%84@Y$BC.@   MZ"0 4
M      "  0AL!0!C86@M,C R,S S,S%?;&%B+GAM;%!+ 0(4 Q0    ( #F#
MI%9/U^:_?)X  'PO!P 4              "  <94!@!C86@M,C R,S S,S%?
=<')E+GAM;%!+!08     $  0 #H$  !T\P8    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
